{"version": "v2.0", "data": [{"id": "10907391_3_0", "context": "Physicians should be aware that PLP can occur after initiation of paclitaxel.", "question": "Treatment.Drug in paclitaxel", "question_type": "Adverse_event.Treatment.Drug", "answers": "paclitaxel"}, {"id": "10907391_3_1", "context": "Physicians should be aware that PLP can occur after initiation of paclitaxel.", "question": "Treatment.Dosage in paclitaxel", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10907391_3_2", "context": "Physicians should be aware that PLP can occur after initiation of paclitaxel.", "question": "Treatment.Freq in paclitaxel", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10907391_3_3", "context": "Physicians should be aware that PLP can occur after initiation of paclitaxel.", "question": "Treatment.Route in paclitaxel", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10907391_3_4", "context": "Physicians should be aware that PLP can occur after initiation of paclitaxel.", "question": "Treatment.Time_elapsed in paclitaxel", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10907391_3_5", "context": "Physicians should be aware that PLP can occur after initiation of paclitaxel.", "question": "Treatment.Duration in paclitaxel", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10907391_3_6", "context": "Physicians should be aware that PLP can occur after initiation of paclitaxel.", "question": "Treatment.Disorder in paclitaxel", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10907391_3_7", "context": "Physicians should be aware that PLP can occur after initiation of paclitaxel.", "question": "Combination.Drug in paclitaxel", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18957000_3_8", "context": "Heparin-dependent antibodies and thrombosis without heparin-induced thrombocytopenia.", "question": "Treatment.Drug in heparin", "question_type": "Adverse_event.Treatment.Drug", "answers": "heparin"}, {"id": "18957000_3_9", "context": "Heparin-dependent antibodies and thrombosis without heparin-induced thrombocytopenia.", "question": "Treatment.Dosage in heparin", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18957000_3_10", "context": "Heparin-dependent antibodies and thrombosis without heparin-induced thrombocytopenia.", "question": "Treatment.Freq in heparin", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18957000_3_11", "context": "Heparin-dependent antibodies and thrombosis without heparin-induced thrombocytopenia.", "question": "Treatment.Route in heparin", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18957000_3_12", "context": "Heparin-dependent antibodies and thrombosis without heparin-induced thrombocytopenia.", "question": "Treatment.Time_elapsed in heparin", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18957000_3_13", "context": "Heparin-dependent antibodies and thrombosis without heparin-induced thrombocytopenia.", "question": "Treatment.Duration in heparin", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18957000_3_14", "context": "Heparin-dependent antibodies and thrombosis without heparin-induced thrombocytopenia.", "question": "Treatment.Disorder in heparin", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18957000_3_15", "context": "Heparin-dependent antibodies and thrombosis without heparin-induced thrombocytopenia.", "question": "Combination.Drug in heparin", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6405633_1_16", "context": "Treatment of lithium tremor with metoprolol.", "question": "Treatment.Drug in metoprolol", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "lithium; metoprolol"}, {"id": "6405633_1_17", "context": "Treatment of lithium tremor with metoprolol.", "question": "Treatment.Dosage in metoprolol", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "6405633_1_18", "context": "Treatment of lithium tremor with metoprolol.", "question": "Treatment.Freq in metoprolol", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "6405633_1_19", "context": "Treatment of lithium tremor with metoprolol.", "question": "Treatment.Route in metoprolol", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "6405633_1_20", "context": "Treatment of lithium tremor with metoprolol.", "question": "Treatment.Time_elapsed in metoprolol", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6405633_1_21", "context": "Treatment of lithium tremor with metoprolol.", "question": "Treatment.Duration in metoprolol", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "6405633_1_22", "context": "Treatment of lithium tremor with metoprolol.", "question": "Treatment.Disorder in metoprolol", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "lithium tremor"}, {"id": "6405633_1_23", "context": "Treatment of lithium tremor with metoprolol.", "question": "Combination.Drug in metoprolol", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "4044222_1_24", "context": "A 54-year-old man, treated with amiodarone, developed thyrotoxicosis.", "question": "Subject.Age in A 54-year-old man", "question_type": "Adverse_event.Subject.Age", "answers": "54-year-old"}, {"id": "4044222_1_25", "context": "A 54-year-old man, treated with amiodarone, developed thyrotoxicosis.", "question": "Subject.Gender in A 54-year-old man", "question_type": "Adverse_event.Subject.Gender", "answers": "man"}, {"id": "4044222_1_26", "context": "A 54-year-old man, treated with amiodarone, developed thyrotoxicosis.", "question": "Subject.Population in A 54-year-old man", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "4044222_1_27", "context": "A 54-year-old man, treated with amiodarone, developed thyrotoxicosis.", "question": "Subject.Race in A 54-year-old man", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "4044222_1_28", "context": "A 54-year-old man, treated with amiodarone, developed thyrotoxicosis.", "question": "Subject.Disorder in A 54-year-old man", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "4044222_1_29", "context": "A 54-year-old man, treated with amiodarone, developed thyrotoxicosis.", "question": "Treatment.Drug in amiodarone", "question_type": "Adverse_event.Treatment.Drug", "answers": "amiodarone"}, {"id": "4044222_1_30", "context": "A 54-year-old man, treated with amiodarone, developed thyrotoxicosis.", "question": "Treatment.Dosage in amiodarone", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "4044222_1_31", "context": "A 54-year-old man, treated with amiodarone, developed thyrotoxicosis.", "question": "Treatment.Freq in amiodarone", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "4044222_1_32", "context": "A 54-year-old man, treated with amiodarone, developed thyrotoxicosis.", "question": "Treatment.Route in amiodarone", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "4044222_1_33", "context": "A 54-year-old man, treated with amiodarone, developed thyrotoxicosis.", "question": "Treatment.Time_elapsed in amiodarone", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "4044222_1_34", "context": "A 54-year-old man, treated with amiodarone, developed thyrotoxicosis.", "question": "Treatment.Duration in amiodarone", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "4044222_1_35", "context": "A 54-year-old man, treated with amiodarone, developed thyrotoxicosis.", "question": "Treatment.Disorder in amiodarone", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "4044222_1_36", "context": "A 54-year-old man, treated with amiodarone, developed thyrotoxicosis.", "question": "Combination.Drug in amiodarone", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12962465_2_37", "context": "Gynaecomastia is a rarely reported adverse drug reaction due to isoniazid therapy.", "question": "Treatment.Drug in isoniazid therapy", "question_type": "Adverse_event.Treatment.Drug", "answers": "isoniazid"}, {"id": "12962465_2_38", "context": "Gynaecomastia is a rarely reported adverse drug reaction due to isoniazid therapy.", "question": "Treatment.Dosage in isoniazid therapy", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12962465_2_39", "context": "Gynaecomastia is a rarely reported adverse drug reaction due to isoniazid therapy.", "question": "Treatment.Freq in isoniazid therapy", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12962465_2_40", "context": "Gynaecomastia is a rarely reported adverse drug reaction due to isoniazid therapy.", "question": "Treatment.Route in isoniazid therapy", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12962465_2_41", "context": "Gynaecomastia is a rarely reported adverse drug reaction due to isoniazid therapy.", "question": "Treatment.Time_elapsed in isoniazid therapy", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12962465_2_42", "context": "Gynaecomastia is a rarely reported adverse drug reaction due to isoniazid therapy.", "question": "Treatment.Duration in isoniazid therapy", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12962465_2_43", "context": "Gynaecomastia is a rarely reported adverse drug reaction due to isoniazid therapy.", "question": "Treatment.Disorder in isoniazid therapy", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12962465_2_44", "context": "Gynaecomastia is a rarely reported adverse drug reaction due to isoniazid therapy.", "question": "Combination.Drug in isoniazid therapy", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15112258_6_45", "context": "The authors performed a literature search using PubMed and the search terms \"gemcitabine\" and \"radiation recall\" to find prior cases of radiation recall attributed to gemcitabine.", "question": "Subject.Age in prior cases", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "15112258_6_46", "context": "The authors performed a literature search using PubMed and the search terms \"gemcitabine\" and \"radiation recall\" to find prior cases of radiation recall attributed to gemcitabine.", "question": "Subject.Gender in prior cases", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15112258_6_47", "context": "The authors performed a literature search using PubMed and the search terms \"gemcitabine\" and \"radiation recall\" to find prior cases of radiation recall attributed to gemcitabine.", "question": "Subject.Population in prior cases", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "15112258_6_48", "context": "The authors performed a literature search using PubMed and the search terms \"gemcitabine\" and \"radiation recall\" to find prior cases of radiation recall attributed to gemcitabine.", "question": "Subject.Race in prior cases", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15112258_6_49", "context": "The authors performed a literature search using PubMed and the search terms \"gemcitabine\" and \"radiation recall\" to find prior cases of radiation recall attributed to gemcitabine.", "question": "Subject.Disorder in prior cases", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15112258_6_50", "context": "The authors performed a literature search using PubMed and the search terms \"gemcitabine\" and \"radiation recall\" to find prior cases of radiation recall attributed to gemcitabine.", "question": "Treatment.Drug in gemcitabine", "question_type": "Adverse_event.Treatment.Drug", "answers": "gemcitabine"}, {"id": "15112258_6_51", "context": "The authors performed a literature search using PubMed and the search terms \"gemcitabine\" and \"radiation recall\" to find prior cases of radiation recall attributed to gemcitabine.", "question": "Treatment.Dosage in gemcitabine", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15112258_6_52", "context": "The authors performed a literature search using PubMed and the search terms \"gemcitabine\" and \"radiation recall\" to find prior cases of radiation recall attributed to gemcitabine.", "question": "Treatment.Freq in gemcitabine", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15112258_6_53", "context": "The authors performed a literature search using PubMed and the search terms \"gemcitabine\" and \"radiation recall\" to find prior cases of radiation recall attributed to gemcitabine.", "question": "Treatment.Route in gemcitabine", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15112258_6_54", "context": "The authors performed a literature search using PubMed and the search terms \"gemcitabine\" and \"radiation recall\" to find prior cases of radiation recall attributed to gemcitabine.", "question": "Treatment.Time_elapsed in gemcitabine", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15112258_6_55", "context": "The authors performed a literature search using PubMed and the search terms \"gemcitabine\" and \"radiation recall\" to find prior cases of radiation recall attributed to gemcitabine.", "question": "Treatment.Duration in gemcitabine", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15112258_6_56", "context": "The authors performed a literature search using PubMed and the search terms \"gemcitabine\" and \"radiation recall\" to find prior cases of radiation recall attributed to gemcitabine.", "question": "Treatment.Disorder in gemcitabine", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15112258_6_57", "context": "The authors performed a literature search using PubMed and the search terms \"gemcitabine\" and \"radiation recall\" to find prior cases of radiation recall attributed to gemcitabine.", "question": "Combination.Drug in gemcitabine", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "1893404_1_58", "context": "Carbamazepine-induced Diabetes mellitus.", "question": "Treatment.Drug in Carbamazepine", "question_type": "Adverse_event.Treatment.Drug", "answers": "Carbamazepine"}, {"id": "1893404_1_59", "context": "Carbamazepine-induced Diabetes mellitus.", "question": "Treatment.Dosage in Carbamazepine", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "1893404_1_60", "context": "Carbamazepine-induced Diabetes mellitus.", "question": "Treatment.Freq in Carbamazepine", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "1893404_1_61", "context": "Carbamazepine-induced Diabetes mellitus.", "question": "Treatment.Route in Carbamazepine", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "1893404_1_62", "context": "Carbamazepine-induced Diabetes mellitus.", "question": "Treatment.Time_elapsed in Carbamazepine", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "1893404_1_63", "context": "Carbamazepine-induced Diabetes mellitus.", "question": "Treatment.Duration in Carbamazepine", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "1893404_1_64", "context": "Carbamazepine-induced Diabetes mellitus.", "question": "Treatment.Disorder in Carbamazepine", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "1893404_1_65", "context": "Carbamazepine-induced Diabetes mellitus.", "question": "Combination.Drug in Carbamazepine", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15827071_5_66", "context": "She displayed symptoms of ST 8 days after the introduction of linezolid.", "question": "Subject.Age in She", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "15827071_5_67", "context": "She displayed symptoms of ST 8 days after the introduction of linezolid.", "question": "Subject.Gender in She", "question_type": "Adverse_event.Subject.Gender", "answers": "She"}, {"id": "15827071_5_68", "context": "She displayed symptoms of ST 8 days after the introduction of linezolid.", "question": "Subject.Population in She", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "15827071_5_69", "context": "She displayed symptoms of ST 8 days after the introduction of linezolid.", "question": "Subject.Race in She", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15827071_5_70", "context": "She displayed symptoms of ST 8 days after the introduction of linezolid.", "question": "Subject.Disorder in She", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15827071_5_71", "context": "She displayed symptoms of ST 8 days after the introduction of linezolid.", "question": "Treatment.Drug in 8 days after the introduction of linezolid", "question_type": "Adverse_event.Treatment.Drug", "answers": "linezolid"}, {"id": "15827071_5_72", "context": "She displayed symptoms of ST 8 days after the introduction of linezolid.", "question": "Treatment.Dosage in 8 days after the introduction of linezolid", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15827071_5_73", "context": "She displayed symptoms of ST 8 days after the introduction of linezolid.", "question": "Treatment.Freq in 8 days after the introduction of linezolid", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15827071_5_74", "context": "She displayed symptoms of ST 8 days after the introduction of linezolid.", "question": "Treatment.Route in 8 days after the introduction of linezolid", "question_type": "Adverse_event.Treatment.Route", "answers": "introduction"}, {"id": "15827071_5_75", "context": "She displayed symptoms of ST 8 days after the introduction of linezolid.", "question": "Treatment.Time_elapsed in 8 days after the introduction of linezolid", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "8 days"}, {"id": "15827071_5_76", "context": "She displayed symptoms of ST 8 days after the introduction of linezolid.", "question": "Treatment.Duration in 8 days after the introduction of linezolid", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15827071_5_77", "context": "She displayed symptoms of ST 8 days after the introduction of linezolid.", "question": "Treatment.Disorder in 8 days after the introduction of linezolid", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15827071_5_78", "context": "She displayed symptoms of ST 8 days after the introduction of linezolid.", "question": "Combination.Drug in 8 days after the introduction of linezolid", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9819544_2_79", "context": "Naproxen is a commonly used nonsteroidal anti-inflammatory drug (NSAID) whose side effects include tinnitus and transient hearing loss.", "question": "Treatment.Drug in Naproxen", "question_type": "Adverse_event.Treatment.Drug", "answers": "Naproxen"}, {"id": "9819544_2_80", "context": "Naproxen is a commonly used nonsteroidal anti-inflammatory drug (NSAID) whose side effects include tinnitus and transient hearing loss.", "question": "Treatment.Dosage in Naproxen", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9819544_2_81", "context": "Naproxen is a commonly used nonsteroidal anti-inflammatory drug (NSAID) whose side effects include tinnitus and transient hearing loss.", "question": "Treatment.Freq in Naproxen", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9819544_2_82", "context": "Naproxen is a commonly used nonsteroidal anti-inflammatory drug (NSAID) whose side effects include tinnitus and transient hearing loss.", "question": "Treatment.Route in Naproxen", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9819544_2_83", "context": "Naproxen is a commonly used nonsteroidal anti-inflammatory drug (NSAID) whose side effects include tinnitus and transient hearing loss.", "question": "Treatment.Time_elapsed in Naproxen", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9819544_2_84", "context": "Naproxen is a commonly used nonsteroidal anti-inflammatory drug (NSAID) whose side effects include tinnitus and transient hearing loss.", "question": "Treatment.Duration in Naproxen", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9819544_2_85", "context": "Naproxen is a commonly used nonsteroidal anti-inflammatory drug (NSAID) whose side effects include tinnitus and transient hearing loss.", "question": "Treatment.Disorder in Naproxen", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9819544_2_86", "context": "Naproxen is a commonly used nonsteroidal anti-inflammatory drug (NSAID) whose side effects include tinnitus and transient hearing loss.", "question": "Combination.Drug in Naproxen", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3159106_3_87", "context": "The allopurinol hypersensitivity syndrome is a rare adverse drug reaction.", "question": "Treatment.Drug in allopurinol", "question_type": "Adverse_event.Treatment.Drug", "answers": "allopurinol"}, {"id": "3159106_3_88", "context": "The allopurinol hypersensitivity syndrome is a rare adverse drug reaction.", "question": "Treatment.Dosage in allopurinol", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3159106_3_89", "context": "The allopurinol hypersensitivity syndrome is a rare adverse drug reaction.", "question": "Treatment.Freq in allopurinol", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3159106_3_90", "context": "The allopurinol hypersensitivity syndrome is a rare adverse drug reaction.", "question": "Treatment.Route in allopurinol", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3159106_3_91", "context": "The allopurinol hypersensitivity syndrome is a rare adverse drug reaction.", "question": "Treatment.Time_elapsed in allopurinol", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3159106_3_92", "context": "The allopurinol hypersensitivity syndrome is a rare adverse drug reaction.", "question": "Treatment.Duration in allopurinol", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3159106_3_93", "context": "The allopurinol hypersensitivity syndrome is a rare adverse drug reaction.", "question": "Treatment.Disorder in allopurinol", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3159106_3_94", "context": "The allopurinol hypersensitivity syndrome is a rare adverse drug reaction.", "question": "Combination.Drug in allopurinol", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8452107_2_95", "context": "The pulmonary toxicity is probably induced by piritrexim.", "question": "Treatment.Drug in piritrexim", "question_type": "Adverse_event.Treatment.Drug", "answers": "piritrexim"}, {"id": "8452107_2_96", "context": "The pulmonary toxicity is probably induced by piritrexim.", "question": "Treatment.Dosage in piritrexim", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8452107_2_97", "context": "The pulmonary toxicity is probably induced by piritrexim.", "question": "Treatment.Freq in piritrexim", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8452107_2_98", "context": "The pulmonary toxicity is probably induced by piritrexim.", "question": "Treatment.Route in piritrexim", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8452107_2_99", "context": "The pulmonary toxicity is probably induced by piritrexim.", "question": "Treatment.Time_elapsed in piritrexim", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8452107_2_100", "context": "The pulmonary toxicity is probably induced by piritrexim.", "question": "Treatment.Duration in piritrexim", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8452107_2_101", "context": "The pulmonary toxicity is probably induced by piritrexim.", "question": "Treatment.Disorder in piritrexim", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8452107_2_102", "context": "The pulmonary toxicity is probably induced by piritrexim.", "question": "Combination.Drug in piritrexim", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15944830_1_103", "context": "BACKGROUND: Interferon (IFN)-associated retinopathy is typically characterized by retinal hemorrhages and cotton wool spots at the posterior fundus, but visual function is usually maintained.", "question": "Treatment.Drug in Interferon (IFN)", "question_type": "Adverse_event.Treatment.Drug", "answers": "Interferon"}, {"id": "15944830_1_104", "context": "BACKGROUND: Interferon (IFN)-associated retinopathy is typically characterized by retinal hemorrhages and cotton wool spots at the posterior fundus, but visual function is usually maintained.", "question": "Treatment.Dosage in Interferon (IFN)", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15944830_1_105", "context": "BACKGROUND: Interferon (IFN)-associated retinopathy is typically characterized by retinal hemorrhages and cotton wool spots at the posterior fundus, but visual function is usually maintained.", "question": "Treatment.Freq in Interferon (IFN)", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15944830_1_106", "context": "BACKGROUND: Interferon (IFN)-associated retinopathy is typically characterized by retinal hemorrhages and cotton wool spots at the posterior fundus, but visual function is usually maintained.", "question": "Treatment.Route in Interferon (IFN)", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15944830_1_107", "context": "BACKGROUND: Interferon (IFN)-associated retinopathy is typically characterized by retinal hemorrhages and cotton wool spots at the posterior fundus, but visual function is usually maintained.", "question": "Treatment.Time_elapsed in Interferon (IFN)", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15944830_1_108", "context": "BACKGROUND: Interferon (IFN)-associated retinopathy is typically characterized by retinal hemorrhages and cotton wool spots at the posterior fundus, but visual function is usually maintained.", "question": "Treatment.Duration in Interferon (IFN)", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15944830_1_109", "context": "BACKGROUND: Interferon (IFN)-associated retinopathy is typically characterized by retinal hemorrhages and cotton wool spots at the posterior fundus, but visual function is usually maintained.", "question": "Treatment.Disorder in Interferon (IFN)", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15944830_1_110", "context": "BACKGROUND: Interferon (IFN)-associated retinopathy is typically characterized by retinal hemorrhages and cotton wool spots at the posterior fundus, but visual function is usually maintained.", "question": "Combination.Drug in Interferon (IFN)", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7986915_2_111", "context": "We describe a patient with a liver abscess due to Entamoeba histolytica, in whom metronidazole therapy (total dose, 21 g over 14 days) was complicated by reversible deafness, tinnitus, and ataxia and who relapsed 5 months later with a splenic abscess.", "question": "Subject.Age in a patient with a liver abscess due to Entamoeba histolytica", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "7986915_2_112", "context": "We describe a patient with a liver abscess due to Entamoeba histolytica, in whom metronidazole therapy (total dose, 21 g over 14 days) was complicated by reversible deafness, tinnitus, and ataxia and who relapsed 5 months later with a splenic abscess.", "question": "Subject.Gender in a patient with a liver abscess due to Entamoeba histolytica", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "7986915_2_113", "context": "We describe a patient with a liver abscess due to Entamoeba histolytica, in whom metronidazole therapy (total dose, 21 g over 14 days) was complicated by reversible deafness, tinnitus, and ataxia and who relapsed 5 months later with a splenic abscess.", "question": "Subject.Population in a patient with a liver abscess due to Entamoeba histolytica", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "7986915_2_114", "context": "We describe a patient with a liver abscess due to Entamoeba histolytica, in whom metronidazole therapy (total dose, 21 g over 14 days) was complicated by reversible deafness, tinnitus, and ataxia and who relapsed 5 months later with a splenic abscess.", "question": "Subject.Race in a patient with a liver abscess due to Entamoeba histolytica", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "7986915_2_115", "context": "We describe a patient with a liver abscess due to Entamoeba histolytica, in whom metronidazole therapy (total dose, 21 g over 14 days) was complicated by reversible deafness, tinnitus, and ataxia and who relapsed 5 months later with a splenic abscess.", "question": "Subject.Disorder in a patient with a liver abscess due to Entamoeba histolytica", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "7986915_2_116", "context": "We describe a patient with a liver abscess due to Entamoeba histolytica, in whom metronidazole therapy (total dose, 21 g over 14 days) was complicated by reversible deafness, tinnitus, and ataxia and who relapsed 5 months later with a splenic abscess.", "question": "Treatment.Drug in metronidazole therapy (total dose, 21 g over 14 days)", "question_type": "Adverse_event.Treatment.Drug", "answers": "metronidazole"}, {"id": "7986915_2_117", "context": "We describe a patient with a liver abscess due to Entamoeba histolytica, in whom metronidazole therapy (total dose, 21 g over 14 days) was complicated by reversible deafness, tinnitus, and ataxia and who relapsed 5 months later with a splenic abscess.", "question": "Treatment.Dosage in metronidazole therapy (total dose, 21 g over 14 days)", "question_type": "Adverse_event.Treatment.Dosage", "answers": "21 g"}, {"id": "7986915_2_118", "context": "We describe a patient with a liver abscess due to Entamoeba histolytica, in whom metronidazole therapy (total dose, 21 g over 14 days) was complicated by reversible deafness, tinnitus, and ataxia and who relapsed 5 months later with a splenic abscess.", "question": "Treatment.Freq in metronidazole therapy (total dose, 21 g over 14 days)", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7986915_2_119", "context": "We describe a patient with a liver abscess due to Entamoeba histolytica, in whom metronidazole therapy (total dose, 21 g over 14 days) was complicated by reversible deafness, tinnitus, and ataxia and who relapsed 5 months later with a splenic abscess.", "question": "Treatment.Route in metronidazole therapy (total dose, 21 g over 14 days)", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7986915_2_120", "context": "We describe a patient with a liver abscess due to Entamoeba histolytica, in whom metronidazole therapy (total dose, 21 g over 14 days) was complicated by reversible deafness, tinnitus, and ataxia and who relapsed 5 months later with a splenic abscess.", "question": "Treatment.Time_elapsed in metronidazole therapy (total dose, 21 g over 14 days)", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7986915_2_121", "context": "We describe a patient with a liver abscess due to Entamoeba histolytica, in whom metronidazole therapy (total dose, 21 g over 14 days) was complicated by reversible deafness, tinnitus, and ataxia and who relapsed 5 months later with a splenic abscess.", "question": "Treatment.Duration in metronidazole therapy (total dose, 21 g over 14 days)", "question_type": "Adverse_event.Treatment.Duration", "answers": "14 days"}, {"id": "7986915_2_122", "context": "We describe a patient with a liver abscess due to Entamoeba histolytica, in whom metronidazole therapy (total dose, 21 g over 14 days) was complicated by reversible deafness, tinnitus, and ataxia and who relapsed 5 months later with a splenic abscess.", "question": "Treatment.Disorder in metronidazole therapy (total dose, 21 g over 14 days)", "question_type": "Adverse_event.Treatment.Disorder", "answers": "liver abscess; Entamoeba histolytica"}, {"id": "7986915_2_123", "context": "We describe a patient with a liver abscess due to Entamoeba histolytica, in whom metronidazole therapy (total dose, 21 g over 14 days) was complicated by reversible deafness, tinnitus, and ataxia and who relapsed 5 months later with a splenic abscess.", "question": "Combination.Drug in metronidazole therapy (total dose, 21 g over 14 days)", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18159131_4_124", "context": "We present a Japanese male patient who underwent a living-donor kidney transplantation having received tacrolimus, mycophenolate mofetil, and prednisolone for immunosuppression.", "question": "Subject.Age in a Japanese male patient who underwent a living-donor kidney transplantation; immunosuppression", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "18159131_4_125", "context": "We present a Japanese male patient who underwent a living-donor kidney transplantation having received tacrolimus, mycophenolate mofetil, and prednisolone for immunosuppression.", "question": "Subject.Gender in a Japanese male patient who underwent a living-donor kidney transplantation; immunosuppression", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": "male"}, {"id": "18159131_4_126", "context": "We present a Japanese male patient who underwent a living-donor kidney transplantation having received tacrolimus, mycophenolate mofetil, and prednisolone for immunosuppression.", "question": "Subject.Population in a Japanese male patient who underwent a living-donor kidney transplantation; immunosuppression", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "18159131_4_127", "context": "We present a Japanese male patient who underwent a living-donor kidney transplantation having received tacrolimus, mycophenolate mofetil, and prednisolone for immunosuppression.", "question": "Subject.Race in a Japanese male patient who underwent a living-donor kidney transplantation; immunosuppression", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": "Japanese"}, {"id": "18159131_4_128", "context": "We present a Japanese male patient who underwent a living-donor kidney transplantation having received tacrolimus, mycophenolate mofetil, and prednisolone for immunosuppression.", "question": "Subject.Disorder in a Japanese male patient who underwent a living-donor kidney transplantation; immunosuppression", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": "kidney transplantation"}, {"id": "18159131_4_129", "context": "We present a Japanese male patient who underwent a living-donor kidney transplantation having received tacrolimus, mycophenolate mofetil, and prednisolone for immunosuppression.", "question": "Treatment.Drug in tacrolimus, mycophenolate mofetil, and prednisolone", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "tacrolimus; mycophenolate mofeti; prednisolone"}, {"id": "18159131_4_130", "context": "We present a Japanese male patient who underwent a living-donor kidney transplantation having received tacrolimus, mycophenolate mofetil, and prednisolone for immunosuppression.", "question": "Treatment.Dosage in tacrolimus, mycophenolate mofetil, and prednisolone", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "18159131_4_131", "context": "We present a Japanese male patient who underwent a living-donor kidney transplantation having received tacrolimus, mycophenolate mofetil, and prednisolone for immunosuppression.", "question": "Treatment.Freq in tacrolimus, mycophenolate mofetil, and prednisolone", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "18159131_4_132", "context": "We present a Japanese male patient who underwent a living-donor kidney transplantation having received tacrolimus, mycophenolate mofetil, and prednisolone for immunosuppression.", "question": "Treatment.Route in tacrolimus, mycophenolate mofetil, and prednisolone", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "18159131_4_133", "context": "We present a Japanese male patient who underwent a living-donor kidney transplantation having received tacrolimus, mycophenolate mofetil, and prednisolone for immunosuppression.", "question": "Treatment.Time_elapsed in tacrolimus, mycophenolate mofetil, and prednisolone", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18159131_4_134", "context": "We present a Japanese male patient who underwent a living-donor kidney transplantation having received tacrolimus, mycophenolate mofetil, and prednisolone for immunosuppression.", "question": "Treatment.Duration in tacrolimus, mycophenolate mofetil, and prednisolone", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "18159131_4_135", "context": "We present a Japanese male patient who underwent a living-donor kidney transplantation having received tacrolimus, mycophenolate mofetil, and prednisolone for immunosuppression.", "question": "Treatment.Disorder in tacrolimus, mycophenolate mofetil, and prednisolone", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "immunosuppression"}, {"id": "18159131_4_136", "context": "We present a Japanese male patient who underwent a living-donor kidney transplantation having received tacrolimus, mycophenolate mofetil, and prednisolone for immunosuppression.", "question": "Combination.Drug in tacrolimus, mycophenolate mofetil, and prednisolone", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": "tacrolimus; mycophenolate mofeti; prednisolone"}, {"id": "6430252_1_137", "context": "Gold nephropathy due to auranofin obscured by tolmetin pseudoproteinuria.", "question": "Treatment.Drug in auranofin", "question_type": "Adverse_event.Treatment.Drug", "answers": "Gold; auranofin; tolmetin"}, {"id": "6430252_1_138", "context": "Gold nephropathy due to auranofin obscured by tolmetin pseudoproteinuria.", "question": "Treatment.Dosage in auranofin", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6430252_1_139", "context": "Gold nephropathy due to auranofin obscured by tolmetin pseudoproteinuria.", "question": "Treatment.Freq in auranofin", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6430252_1_140", "context": "Gold nephropathy due to auranofin obscured by tolmetin pseudoproteinuria.", "question": "Treatment.Route in auranofin", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6430252_1_141", "context": "Gold nephropathy due to auranofin obscured by tolmetin pseudoproteinuria.", "question": "Treatment.Time_elapsed in auranofin", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6430252_1_142", "context": "Gold nephropathy due to auranofin obscured by tolmetin pseudoproteinuria.", "question": "Treatment.Duration in auranofin", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6430252_1_143", "context": "Gold nephropathy due to auranofin obscured by tolmetin pseudoproteinuria.", "question": "Treatment.Disorder in auranofin", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6430252_1_144", "context": "Gold nephropathy due to auranofin obscured by tolmetin pseudoproteinuria.", "question": "Combination.Drug in auranofin", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "2690546_3_145", "context": "We report three cases of amiodarone-induced torsades de pointe.", "question": "Subject.Age in three cases", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "2690546_3_146", "context": "We report three cases of amiodarone-induced torsades de pointe.", "question": "Subject.Gender in three cases", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "2690546_3_147", "context": "We report three cases of amiodarone-induced torsades de pointe.", "question": "Subject.Population in three cases", "question_type": "Adverse_event.Subject.Population", "answers": "three"}, {"id": "2690546_3_148", "context": "We report three cases of amiodarone-induced torsades de pointe.", "question": "Subject.Race in three cases", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "2690546_3_149", "context": "We report three cases of amiodarone-induced torsades de pointe.", "question": "Subject.Disorder in three cases", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "2690546_3_150", "context": "We report three cases of amiodarone-induced torsades de pointe.", "question": "Treatment.Drug in amiodarone", "question_type": "Adverse_event.Treatment.Drug", "answers": "amiodarone"}, {"id": "2690546_3_151", "context": "We report three cases of amiodarone-induced torsades de pointe.", "question": "Treatment.Dosage in amiodarone", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "2690546_3_152", "context": "We report three cases of amiodarone-induced torsades de pointe.", "question": "Treatment.Freq in amiodarone", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2690546_3_153", "context": "We report three cases of amiodarone-induced torsades de pointe.", "question": "Treatment.Route in amiodarone", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "2690546_3_154", "context": "We report three cases of amiodarone-induced torsades de pointe.", "question": "Treatment.Time_elapsed in amiodarone", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2690546_3_155", "context": "We report three cases of amiodarone-induced torsades de pointe.", "question": "Treatment.Duration in amiodarone", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2690546_3_156", "context": "We report three cases of amiodarone-induced torsades de pointe.", "question": "Treatment.Disorder in amiodarone", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "2690546_3_157", "context": "We report three cases of amiodarone-induced torsades de pointe.", "question": "Combination.Drug in amiodarone", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11720625_1_158", "context": "Torsades de pointes due to drug interaction between disopyramide and clarithromycin.", "question": "Treatment.Drug in drug interaction between disopyramide and clarithromycin", "question_type": "Adverse_event.Treatment.Drug", "answers": "disopyramide; clarithromycin"}, {"id": "11720625_1_159", "context": "Torsades de pointes due to drug interaction between disopyramide and clarithromycin.", "question": "Treatment.Dosage in drug interaction between disopyramide and clarithromycin", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11720625_1_160", "context": "Torsades de pointes due to drug interaction between disopyramide and clarithromycin.", "question": "Treatment.Freq in drug interaction between disopyramide and clarithromycin", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11720625_1_161", "context": "Torsades de pointes due to drug interaction between disopyramide and clarithromycin.", "question": "Treatment.Route in drug interaction between disopyramide and clarithromycin", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11720625_1_162", "context": "Torsades de pointes due to drug interaction between disopyramide and clarithromycin.", "question": "Treatment.Time_elapsed in drug interaction between disopyramide and clarithromycin", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11720625_1_163", "context": "Torsades de pointes due to drug interaction between disopyramide and clarithromycin.", "question": "Treatment.Duration in drug interaction between disopyramide and clarithromycin", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11720625_1_164", "context": "Torsades de pointes due to drug interaction between disopyramide and clarithromycin.", "question": "Treatment.Disorder in drug interaction between disopyramide and clarithromycin", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11720625_1_165", "context": "Torsades de pointes due to drug interaction between disopyramide and clarithromycin.", "question": "Combination.Drug in drug interaction between disopyramide and clarithromycin", "question_type": "Adverse_event.Combination.Drug", "answers": "disopyramide; clarithromycin"}, {"id": "12053072_2_166", "context": "We describe a patient who developed HUS after treatment with mitomycin C (total dose 144 mg/m2) due to a carcinoma of the ascending colon.", "question": "Subject.Age in a patient", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "12053072_2_167", "context": "We describe a patient who developed HUS after treatment with mitomycin C (total dose 144 mg/m2) due to a carcinoma of the ascending colon.", "question": "Subject.Gender in a patient", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "12053072_2_168", "context": "We describe a patient who developed HUS after treatment with mitomycin C (total dose 144 mg/m2) due to a carcinoma of the ascending colon.", "question": "Subject.Population in a patient", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "12053072_2_169", "context": "We describe a patient who developed HUS after treatment with mitomycin C (total dose 144 mg/m2) due to a carcinoma of the ascending colon.", "question": "Subject.Race in a patient", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "12053072_2_170", "context": "We describe a patient who developed HUS after treatment with mitomycin C (total dose 144 mg/m2) due to a carcinoma of the ascending colon.", "question": "Subject.Disorder in a patient", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "12053072_2_171", "context": "We describe a patient who developed HUS after treatment with mitomycin C (total dose 144 mg/m2) due to a carcinoma of the ascending colon.", "question": "Treatment.Drug in mitomycin C (total dose 144 mg/m2)", "question_type": "Adverse_event.Treatment.Drug", "answers": "mitomycin C"}, {"id": "12053072_2_172", "context": "We describe a patient who developed HUS after treatment with mitomycin C (total dose 144 mg/m2) due to a carcinoma of the ascending colon.", "question": "Treatment.Dosage in mitomycin C (total dose 144 mg/m2)", "question_type": "Adverse_event.Treatment.Dosage", "answers": "144 mg/m2"}, {"id": "12053072_2_173", "context": "We describe a patient who developed HUS after treatment with mitomycin C (total dose 144 mg/m2) due to a carcinoma of the ascending colon.", "question": "Treatment.Freq in mitomycin C (total dose 144 mg/m2)", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12053072_2_174", "context": "We describe a patient who developed HUS after treatment with mitomycin C (total dose 144 mg/m2) due to a carcinoma of the ascending colon.", "question": "Treatment.Route in mitomycin C (total dose 144 mg/m2)", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12053072_2_175", "context": "We describe a patient who developed HUS after treatment with mitomycin C (total dose 144 mg/m2) due to a carcinoma of the ascending colon.", "question": "Treatment.Time_elapsed in mitomycin C (total dose 144 mg/m2)", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12053072_2_176", "context": "We describe a patient who developed HUS after treatment with mitomycin C (total dose 144 mg/m2) due to a carcinoma of the ascending colon.", "question": "Treatment.Duration in mitomycin C (total dose 144 mg/m2)", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12053072_2_177", "context": "We describe a patient who developed HUS after treatment with mitomycin C (total dose 144 mg/m2) due to a carcinoma of the ascending colon.", "question": "Treatment.Disorder in mitomycin C (total dose 144 mg/m2)", "question_type": "Adverse_event.Treatment.Disorder", "answers": "carcinoma of the ascending colon"}, {"id": "12053072_2_178", "context": "We describe a patient who developed HUS after treatment with mitomycin C (total dose 144 mg/m2) due to a carcinoma of the ascending colon.", "question": "Combination.Drug in mitomycin C (total dose 144 mg/m2)", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "23006440_5_179", "context": "In this case, 5-FU increased PHT, which in turn may have increased the PB concentration, suggesting that when fluoropyrimidine antitumor agents are administered to patients receiving PHT in combination with other drugs, some measures should be taken in consideration of secondary effects of antitumor agents on other drugs that may possibly interact with PHT, including frequent monitoring of blood drug concentration.", "question": "Subject.Age in patients", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "23006440_5_180", "context": "In this case, 5-FU increased PHT, which in turn may have increased the PB concentration, suggesting that when fluoropyrimidine antitumor agents are administered to patients receiving PHT in combination with other drugs, some measures should be taken in consideration of secondary effects of antitumor agents on other drugs that may possibly interact with PHT, including frequent monitoring of blood drug concentration.", "question": "Subject.Gender in patients", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "23006440_5_181", "context": "In this case, 5-FU increased PHT, which in turn may have increased the PB concentration, suggesting that when fluoropyrimidine antitumor agents are administered to patients receiving PHT in combination with other drugs, some measures should be taken in consideration of secondary effects of antitumor agents on other drugs that may possibly interact with PHT, including frequent monitoring of blood drug concentration.", "question": "Subject.Population in patients", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "23006440_5_182", "context": "In this case, 5-FU increased PHT, which in turn may have increased the PB concentration, suggesting that when fluoropyrimidine antitumor agents are administered to patients receiving PHT in combination with other drugs, some measures should be taken in consideration of secondary effects of antitumor agents on other drugs that may possibly interact with PHT, including frequent monitoring of blood drug concentration.", "question": "Subject.Race in patients", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "23006440_5_183", "context": "In this case, 5-FU increased PHT, which in turn may have increased the PB concentration, suggesting that when fluoropyrimidine antitumor agents are administered to patients receiving PHT in combination with other drugs, some measures should be taken in consideration of secondary effects of antitumor agents on other drugs that may possibly interact with PHT, including frequent monitoring of blood drug concentration.", "question": "Subject.Disorder in patients", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "23006440_5_184", "context": "In this case, 5-FU increased PHT, which in turn may have increased the PB concentration, suggesting that when fluoropyrimidine antitumor agents are administered to patients receiving PHT in combination with other drugs, some measures should be taken in consideration of secondary effects of antitumor agents on other drugs that may possibly interact with PHT, including frequent monitoring of blood drug concentration.", "question": "Treatment.Drug in 5-FU increased PHT, which in turn may have increased the PB concentration", "question_type": "Adverse_event.Treatment.Drug", "answers": "5-FU; PHT"}, {"id": "23006440_5_185", "context": "In this case, 5-FU increased PHT, which in turn may have increased the PB concentration, suggesting that when fluoropyrimidine antitumor agents are administered to patients receiving PHT in combination with other drugs, some measures should be taken in consideration of secondary effects of antitumor agents on other drugs that may possibly interact with PHT, including frequent monitoring of blood drug concentration.", "question": "Treatment.Dosage in 5-FU increased PHT, which in turn may have increased the PB concentration", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "23006440_5_186", "context": "In this case, 5-FU increased PHT, which in turn may have increased the PB concentration, suggesting that when fluoropyrimidine antitumor agents are administered to patients receiving PHT in combination with other drugs, some measures should be taken in consideration of secondary effects of antitumor agents on other drugs that may possibly interact with PHT, including frequent monitoring of blood drug concentration.", "question": "Treatment.Freq in 5-FU increased PHT, which in turn may have increased the PB concentration", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "23006440_5_187", "context": "In this case, 5-FU increased PHT, which in turn may have increased the PB concentration, suggesting that when fluoropyrimidine antitumor agents are administered to patients receiving PHT in combination with other drugs, some measures should be taken in consideration of secondary effects of antitumor agents on other drugs that may possibly interact with PHT, including frequent monitoring of blood drug concentration.", "question": "Treatment.Route in 5-FU increased PHT, which in turn may have increased the PB concentration", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "23006440_5_188", "context": "In this case, 5-FU increased PHT, which in turn may have increased the PB concentration, suggesting that when fluoropyrimidine antitumor agents are administered to patients receiving PHT in combination with other drugs, some measures should be taken in consideration of secondary effects of antitumor agents on other drugs that may possibly interact with PHT, including frequent monitoring of blood drug concentration.", "question": "Treatment.Time_elapsed in 5-FU increased PHT, which in turn may have increased the PB concentration", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "23006440_5_189", "context": "In this case, 5-FU increased PHT, which in turn may have increased the PB concentration, suggesting that when fluoropyrimidine antitumor agents are administered to patients receiving PHT in combination with other drugs, some measures should be taken in consideration of secondary effects of antitumor agents on other drugs that may possibly interact with PHT, including frequent monitoring of blood drug concentration.", "question": "Treatment.Duration in 5-FU increased PHT, which in turn may have increased the PB concentration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "23006440_5_190", "context": "In this case, 5-FU increased PHT, which in turn may have increased the PB concentration, suggesting that when fluoropyrimidine antitumor agents are administered to patients receiving PHT in combination with other drugs, some measures should be taken in consideration of secondary effects of antitumor agents on other drugs that may possibly interact with PHT, including frequent monitoring of blood drug concentration.", "question": "Treatment.Disorder in 5-FU increased PHT, which in turn may have increased the PB concentration", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "23006440_5_191", "context": "In this case, 5-FU increased PHT, which in turn may have increased the PB concentration, suggesting that when fluoropyrimidine antitumor agents are administered to patients receiving PHT in combination with other drugs, some measures should be taken in consideration of secondary effects of antitumor agents on other drugs that may possibly interact with PHT, including frequent monitoring of blood drug concentration.", "question": "Combination.Drug in 5-FU increased PHT, which in turn may have increased the PB concentration", "question_type": "Adverse_event.Combination.Drug", "answers": "5-FU; PHT"}, {"id": "16181292_2_192", "context": "Severe loss of vision after removal of cataract caused by intravitreal triamcinolone in combination with photodynamic therapy for exudative age-related macular degeneration.", "question": "Treatment.Drug in intravitreal triamcinolone; photodynamic", "question_type": "Adverse_event.Treatment.Drug", "answers": "triamcinolone; photodynamic"}, {"id": "16181292_2_193", "context": "Severe loss of vision after removal of cataract caused by intravitreal triamcinolone in combination with photodynamic therapy for exudative age-related macular degeneration.", "question": "Treatment.Dosage in intravitreal triamcinolone; photodynamic", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16181292_2_194", "context": "Severe loss of vision after removal of cataract caused by intravitreal triamcinolone in combination with photodynamic therapy for exudative age-related macular degeneration.", "question": "Treatment.Freq in intravitreal triamcinolone; photodynamic", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16181292_2_195", "context": "Severe loss of vision after removal of cataract caused by intravitreal triamcinolone in combination with photodynamic therapy for exudative age-related macular degeneration.", "question": "Treatment.Route in intravitreal triamcinolone; photodynamic", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16181292_2_196", "context": "Severe loss of vision after removal of cataract caused by intravitreal triamcinolone in combination with photodynamic therapy for exudative age-related macular degeneration.", "question": "Treatment.Time_elapsed in intravitreal triamcinolone; photodynamic", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16181292_2_197", "context": "Severe loss of vision after removal of cataract caused by intravitreal triamcinolone in combination with photodynamic therapy for exudative age-related macular degeneration.", "question": "Treatment.Duration in intravitreal triamcinolone; photodynamic", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16181292_2_198", "context": "Severe loss of vision after removal of cataract caused by intravitreal triamcinolone in combination with photodynamic therapy for exudative age-related macular degeneration.", "question": "Treatment.Disorder in intravitreal triamcinolone; photodynamic", "question_type": "Adverse_event.Treatment.Disorder", "answers": "exudative age-related macular degeneration"}, {"id": "16181292_2_199", "context": "Severe loss of vision after removal of cataract caused by intravitreal triamcinolone in combination with photodynamic therapy for exudative age-related macular degeneration.", "question": "Combination.Drug in intravitreal triamcinolone; photodynamic", "question_type": "Adverse_event.Combination.Drug", "answers": "triamcinolone; photodynamic"}, {"id": "10715308_12_200", "context": "The CATAPULT I study shows that tirapazamine enhances the activity of cisplatin in patients with advanced NSCLC and confirms that hypoxia is an exploitable therapeutic target in human malignancies.", "question": "Subject.Age in patients with advanced NSCLC", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "10715308_12_201", "context": "The CATAPULT I study shows that tirapazamine enhances the activity of cisplatin in patients with advanced NSCLC and confirms that hypoxia is an exploitable therapeutic target in human malignancies.", "question": "Subject.Gender in patients with advanced NSCLC", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "10715308_12_202", "context": "The CATAPULT I study shows that tirapazamine enhances the activity of cisplatin in patients with advanced NSCLC and confirms that hypoxia is an exploitable therapeutic target in human malignancies.", "question": "Subject.Population in patients with advanced NSCLC", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "10715308_12_203", "context": "The CATAPULT I study shows that tirapazamine enhances the activity of cisplatin in patients with advanced NSCLC and confirms that hypoxia is an exploitable therapeutic target in human malignancies.", "question": "Subject.Race in patients with advanced NSCLC", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "10715308_12_204", "context": "The CATAPULT I study shows that tirapazamine enhances the activity of cisplatin in patients with advanced NSCLC and confirms that hypoxia is an exploitable therapeutic target in human malignancies.", "question": "Subject.Disorder in patients with advanced NSCLC", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "10715308_12_205", "context": "The CATAPULT I study shows that tirapazamine enhances the activity of cisplatin in patients with advanced NSCLC and confirms that hypoxia is an exploitable therapeutic target in human malignancies.", "question": "Treatment.Drug in tirapazamine", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "tirapazamine"}, {"id": "10715308_12_206", "context": "The CATAPULT I study shows that tirapazamine enhances the activity of cisplatin in patients with advanced NSCLC and confirms that hypoxia is an exploitable therapeutic target in human malignancies.", "question": "Treatment.Dosage in tirapazamine", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "10715308_12_207", "context": "The CATAPULT I study shows that tirapazamine enhances the activity of cisplatin in patients with advanced NSCLC and confirms that hypoxia is an exploitable therapeutic target in human malignancies.", "question": "Treatment.Freq in tirapazamine", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "10715308_12_208", "context": "The CATAPULT I study shows that tirapazamine enhances the activity of cisplatin in patients with advanced NSCLC and confirms that hypoxia is an exploitable therapeutic target in human malignancies.", "question": "Treatment.Route in tirapazamine", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "10715308_12_209", "context": "The CATAPULT I study shows that tirapazamine enhances the activity of cisplatin in patients with advanced NSCLC and confirms that hypoxia is an exploitable therapeutic target in human malignancies.", "question": "Treatment.Time_elapsed in tirapazamine", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10715308_12_210", "context": "The CATAPULT I study shows that tirapazamine enhances the activity of cisplatin in patients with advanced NSCLC and confirms that hypoxia is an exploitable therapeutic target in human malignancies.", "question": "Treatment.Duration in tirapazamine", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "10715308_12_211", "context": "The CATAPULT I study shows that tirapazamine enhances the activity of cisplatin in patients with advanced NSCLC and confirms that hypoxia is an exploitable therapeutic target in human malignancies.", "question": "Treatment.Disorder in tirapazamine", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "advanced NSCLC"}, {"id": "10715308_12_212", "context": "The CATAPULT I study shows that tirapazamine enhances the activity of cisplatin in patients with advanced NSCLC and confirms that hypoxia is an exploitable therapeutic target in human malignancies.", "question": "Combination.Drug in tirapazamine", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "9619226_1_213", "context": "Cardiac arrest associated with sulprostone use during caesarean section.", "question": "Treatment.Drug in sulprostone", "question_type": "Adverse_event.Treatment.Drug", "answers": "sulprostone"}, {"id": "9619226_1_214", "context": "Cardiac arrest associated with sulprostone use during caesarean section.", "question": "Treatment.Dosage in sulprostone", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9619226_1_215", "context": "Cardiac arrest associated with sulprostone use during caesarean section.", "question": "Treatment.Freq in sulprostone", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9619226_1_216", "context": "Cardiac arrest associated with sulprostone use during caesarean section.", "question": "Treatment.Route in sulprostone", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9619226_1_217", "context": "Cardiac arrest associated with sulprostone use during caesarean section.", "question": "Treatment.Time_elapsed in sulprostone", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9619226_1_218", "context": "Cardiac arrest associated with sulprostone use during caesarean section.", "question": "Treatment.Duration in sulprostone", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9619226_1_219", "context": "Cardiac arrest associated with sulprostone use during caesarean section.", "question": "Treatment.Disorder in sulprostone", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9619226_1_220", "context": "Cardiac arrest associated with sulprostone use during caesarean section.", "question": "Combination.Drug in sulprostone", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11807466_1_221", "context": "Linear IgA bullous dermatosis occurring after carbamazepine.", "question": "Treatment.Drug in carbamazepine", "question_type": "Adverse_event.Treatment.Drug", "answers": "carbamazepine"}, {"id": "11807466_1_222", "context": "Linear IgA bullous dermatosis occurring after carbamazepine.", "question": "Treatment.Dosage in carbamazepine", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11807466_1_223", "context": "Linear IgA bullous dermatosis occurring after carbamazepine.", "question": "Treatment.Freq in carbamazepine", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11807466_1_224", "context": "Linear IgA bullous dermatosis occurring after carbamazepine.", "question": "Treatment.Route in carbamazepine", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11807466_1_225", "context": "Linear IgA bullous dermatosis occurring after carbamazepine.", "question": "Treatment.Time_elapsed in carbamazepine", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11807466_1_226", "context": "Linear IgA bullous dermatosis occurring after carbamazepine.", "question": "Treatment.Duration in carbamazepine", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11807466_1_227", "context": "Linear IgA bullous dermatosis occurring after carbamazepine.", "question": "Treatment.Disorder in carbamazepine", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11807466_1_228", "context": "Linear IgA bullous dermatosis occurring after carbamazepine.", "question": "Combination.Drug in carbamazepine", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12053072_1_229", "context": "Erythropoietin is beneficial in mitomycin-induced hemolytic-uremic syndrome.", "question": "Treatment.Drug in Erythropoietin", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "Erythropoietin"}, {"id": "12053072_1_230", "context": "Erythropoietin is beneficial in mitomycin-induced hemolytic-uremic syndrome.", "question": "Treatment.Dosage in Erythropoietin", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "12053072_1_231", "context": "Erythropoietin is beneficial in mitomycin-induced hemolytic-uremic syndrome.", "question": "Treatment.Freq in Erythropoietin", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "12053072_1_232", "context": "Erythropoietin is beneficial in mitomycin-induced hemolytic-uremic syndrome.", "question": "Treatment.Route in Erythropoietin", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "12053072_1_233", "context": "Erythropoietin is beneficial in mitomycin-induced hemolytic-uremic syndrome.", "question": "Treatment.Time_elapsed in Erythropoietin", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12053072_1_234", "context": "Erythropoietin is beneficial in mitomycin-induced hemolytic-uremic syndrome.", "question": "Treatment.Duration in Erythropoietin", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "12053072_1_235", "context": "Erythropoietin is beneficial in mitomycin-induced hemolytic-uremic syndrome.", "question": "Treatment.Disorder in Erythropoietin", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "mitomycin-induced hemolytic-uremic syndrome"}, {"id": "12053072_1_236", "context": "Erythropoietin is beneficial in mitomycin-induced hemolytic-uremic syndrome.", "question": "Combination.Drug in Erythropoietin", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "12053072_1_237", "context": "Erythropoietin is beneficial in mitomycin-induced hemolytic-uremic syndrome.", "question": "Treatment.Drug in mitomycin", "question_type": "Adverse_event.Treatment.Drug", "answers": "mitomycin"}, {"id": "12053072_1_238", "context": "Erythropoietin is beneficial in mitomycin-induced hemolytic-uremic syndrome.", "question": "Treatment.Dosage in mitomycin", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12053072_1_239", "context": "Erythropoietin is beneficial in mitomycin-induced hemolytic-uremic syndrome.", "question": "Treatment.Freq in mitomycin", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12053072_1_240", "context": "Erythropoietin is beneficial in mitomycin-induced hemolytic-uremic syndrome.", "question": "Treatment.Route in mitomycin", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12053072_1_241", "context": "Erythropoietin is beneficial in mitomycin-induced hemolytic-uremic syndrome.", "question": "Treatment.Time_elapsed in mitomycin", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12053072_1_242", "context": "Erythropoietin is beneficial in mitomycin-induced hemolytic-uremic syndrome.", "question": "Treatment.Duration in mitomycin", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12053072_1_243", "context": "Erythropoietin is beneficial in mitomycin-induced hemolytic-uremic syndrome.", "question": "Treatment.Disorder in mitomycin", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12053072_1_244", "context": "Erythropoietin is beneficial in mitomycin-induced hemolytic-uremic syndrome.", "question": "Combination.Drug in mitomycin", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8305778_9_245", "context": "Hypothyroidism, occurring in up to 11 percent of patients treated with amiodarone, can also alter drug metabolism and sensitize the central nervous system, thus increasing the potential for toxicity.", "question": "Subject.Age in 11 percent of patients", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "8305778_9_246", "context": "Hypothyroidism, occurring in up to 11 percent of patients treated with amiodarone, can also alter drug metabolism and sensitize the central nervous system, thus increasing the potential for toxicity.", "question": "Subject.Gender in 11 percent of patients", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "8305778_9_247", "context": "Hypothyroidism, occurring in up to 11 percent of patients treated with amiodarone, can also alter drug metabolism and sensitize the central nervous system, thus increasing the potential for toxicity.", "question": "Subject.Population in 11 percent of patients", "question_type": "Adverse_event.Subject.Population", "answers": "11 percent"}, {"id": "8305778_9_248", "context": "Hypothyroidism, occurring in up to 11 percent of patients treated with amiodarone, can also alter drug metabolism and sensitize the central nervous system, thus increasing the potential for toxicity.", "question": "Subject.Race in 11 percent of patients", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "8305778_9_249", "context": "Hypothyroidism, occurring in up to 11 percent of patients treated with amiodarone, can also alter drug metabolism and sensitize the central nervous system, thus increasing the potential for toxicity.", "question": "Subject.Disorder in 11 percent of patients", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "8305778_9_250", "context": "Hypothyroidism, occurring in up to 11 percent of patients treated with amiodarone, can also alter drug metabolism and sensitize the central nervous system, thus increasing the potential for toxicity.", "question": "Treatment.Drug in amiodarone", "question_type": "Adverse_event.Treatment.Drug", "answers": "amiodarone"}, {"id": "8305778_9_251", "context": "Hypothyroidism, occurring in up to 11 percent of patients treated with amiodarone, can also alter drug metabolism and sensitize the central nervous system, thus increasing the potential for toxicity.", "question": "Treatment.Dosage in amiodarone", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8305778_9_252", "context": "Hypothyroidism, occurring in up to 11 percent of patients treated with amiodarone, can also alter drug metabolism and sensitize the central nervous system, thus increasing the potential for toxicity.", "question": "Treatment.Freq in amiodarone", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8305778_9_253", "context": "Hypothyroidism, occurring in up to 11 percent of patients treated with amiodarone, can also alter drug metabolism and sensitize the central nervous system, thus increasing the potential for toxicity.", "question": "Treatment.Route in amiodarone", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8305778_9_254", "context": "Hypothyroidism, occurring in up to 11 percent of patients treated with amiodarone, can also alter drug metabolism and sensitize the central nervous system, thus increasing the potential for toxicity.", "question": "Treatment.Time_elapsed in amiodarone", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8305778_9_255", "context": "Hypothyroidism, occurring in up to 11 percent of patients treated with amiodarone, can also alter drug metabolism and sensitize the central nervous system, thus increasing the potential for toxicity.", "question": "Treatment.Duration in amiodarone", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8305778_9_256", "context": "Hypothyroidism, occurring in up to 11 percent of patients treated with amiodarone, can also alter drug metabolism and sensitize the central nervous system, thus increasing the potential for toxicity.", "question": "Treatment.Disorder in amiodarone", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8305778_9_257", "context": "Hypothyroidism, occurring in up to 11 percent of patients treated with amiodarone, can also alter drug metabolism and sensitize the central nervous system, thus increasing the potential for toxicity.", "question": "Combination.Drug in amiodarone", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3513544_2_258", "context": "We report the first case of herpes esophagitis in a renal transplant patient treated with Cyclosporine A while on chronic steroid therapy.", "question": "Subject.Age in a renal transplant patient", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "3513544_2_259", "context": "We report the first case of herpes esophagitis in a renal transplant patient treated with Cyclosporine A while on chronic steroid therapy.", "question": "Subject.Gender in a renal transplant patient", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "3513544_2_260", "context": "We report the first case of herpes esophagitis in a renal transplant patient treated with Cyclosporine A while on chronic steroid therapy.", "question": "Subject.Population in a renal transplant patient", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "3513544_2_261", "context": "We report the first case of herpes esophagitis in a renal transplant patient treated with Cyclosporine A while on chronic steroid therapy.", "question": "Subject.Race in a renal transplant patient", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "3513544_2_262", "context": "We report the first case of herpes esophagitis in a renal transplant patient treated with Cyclosporine A while on chronic steroid therapy.", "question": "Subject.Disorder in a renal transplant patient", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "3513544_2_263", "context": "We report the first case of herpes esophagitis in a renal transplant patient treated with Cyclosporine A while on chronic steroid therapy.", "question": "Treatment.Drug in Cyclosporine A while on chronic steroid therapy", "question_type": "Adverse_event.Treatment.Drug", "answers": "Cyclosporine A; chronic steroid"}, {"id": "3513544_2_264", "context": "We report the first case of herpes esophagitis in a renal transplant patient treated with Cyclosporine A while on chronic steroid therapy.", "question": "Treatment.Dosage in Cyclosporine A while on chronic steroid therapy", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3513544_2_265", "context": "We report the first case of herpes esophagitis in a renal transplant patient treated with Cyclosporine A while on chronic steroid therapy.", "question": "Treatment.Freq in Cyclosporine A while on chronic steroid therapy", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3513544_2_266", "context": "We report the first case of herpes esophagitis in a renal transplant patient treated with Cyclosporine A while on chronic steroid therapy.", "question": "Treatment.Route in Cyclosporine A while on chronic steroid therapy", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3513544_2_267", "context": "We report the first case of herpes esophagitis in a renal transplant patient treated with Cyclosporine A while on chronic steroid therapy.", "question": "Treatment.Time_elapsed in Cyclosporine A while on chronic steroid therapy", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3513544_2_268", "context": "We report the first case of herpes esophagitis in a renal transplant patient treated with Cyclosporine A while on chronic steroid therapy.", "question": "Treatment.Duration in Cyclosporine A while on chronic steroid therapy", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3513544_2_269", "context": "We report the first case of herpes esophagitis in a renal transplant patient treated with Cyclosporine A while on chronic steroid therapy.", "question": "Treatment.Disorder in Cyclosporine A while on chronic steroid therapy", "question_type": "Adverse_event.Treatment.Disorder", "answers": "renal transplant"}, {"id": "3513544_2_270", "context": "We report the first case of herpes esophagitis in a renal transplant patient treated with Cyclosporine A while on chronic steroid therapy.", "question": "Combination.Drug in Cyclosporine A while on chronic steroid therapy", "question_type": "Adverse_event.Combination.Drug", "answers": "Cyclosporine A; chronic steroid"}, {"id": "1827039_1_271", "context": "Severe hepatocellular dysfunction following cyproterone acetate therapy.", "question": "Treatment.Drug in cyproterone acetate", "question_type": "Adverse_event.Treatment.Drug", "answers": "cyproterone acetate"}, {"id": "1827039_1_272", "context": "Severe hepatocellular dysfunction following cyproterone acetate therapy.", "question": "Treatment.Dosage in cyproterone acetate", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "1827039_1_273", "context": "Severe hepatocellular dysfunction following cyproterone acetate therapy.", "question": "Treatment.Freq in cyproterone acetate", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "1827039_1_274", "context": "Severe hepatocellular dysfunction following cyproterone acetate therapy.", "question": "Treatment.Route in cyproterone acetate", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "1827039_1_275", "context": "Severe hepatocellular dysfunction following cyproterone acetate therapy.", "question": "Treatment.Time_elapsed in cyproterone acetate", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "1827039_1_276", "context": "Severe hepatocellular dysfunction following cyproterone acetate therapy.", "question": "Treatment.Duration in cyproterone acetate", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "1827039_1_277", "context": "Severe hepatocellular dysfunction following cyproterone acetate therapy.", "question": "Treatment.Disorder in cyproterone acetate", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "1827039_1_278", "context": "Severe hepatocellular dysfunction following cyproterone acetate therapy.", "question": "Combination.Drug in cyproterone acetate", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11672959_2_279", "context": "It is thought that the clinico-pathological features and chronology of this case bore the hallmarks of the so-called \"3-week sulphasalazine syndrome\", a rare, but often fatal, immunoallergic reaction to sulphasalazine.", "question": "Treatment.Drug in sulphasalazine", "question_type": "Adverse_event.Treatment.Drug", "answers": "sulphasalazine"}, {"id": "11672959_2_280", "context": "It is thought that the clinico-pathological features and chronology of this case bore the hallmarks of the so-called \"3-week sulphasalazine syndrome\", a rare, but often fatal, immunoallergic reaction to sulphasalazine.", "question": "Treatment.Dosage in sulphasalazine", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11672959_2_281", "context": "It is thought that the clinico-pathological features and chronology of this case bore the hallmarks of the so-called \"3-week sulphasalazine syndrome\", a rare, but often fatal, immunoallergic reaction to sulphasalazine.", "question": "Treatment.Freq in sulphasalazine", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11672959_2_282", "context": "It is thought that the clinico-pathological features and chronology of this case bore the hallmarks of the so-called \"3-week sulphasalazine syndrome\", a rare, but often fatal, immunoallergic reaction to sulphasalazine.", "question": "Treatment.Route in sulphasalazine", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11672959_2_283", "context": "It is thought that the clinico-pathological features and chronology of this case bore the hallmarks of the so-called \"3-week sulphasalazine syndrome\", a rare, but often fatal, immunoallergic reaction to sulphasalazine.", "question": "Treatment.Time_elapsed in sulphasalazine", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11672959_2_284", "context": "It is thought that the clinico-pathological features and chronology of this case bore the hallmarks of the so-called \"3-week sulphasalazine syndrome\", a rare, but often fatal, immunoallergic reaction to sulphasalazine.", "question": "Treatment.Duration in sulphasalazine", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11672959_2_285", "context": "It is thought that the clinico-pathological features and chronology of this case bore the hallmarks of the so-called \"3-week sulphasalazine syndrome\", a rare, but often fatal, immunoallergic reaction to sulphasalazine.", "question": "Treatment.Disorder in sulphasalazine", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11672959_2_286", "context": "It is thought that the clinico-pathological features and chronology of this case bore the hallmarks of the so-called \"3-week sulphasalazine syndrome\", a rare, but often fatal, immunoallergic reaction to sulphasalazine.", "question": "Combination.Drug in sulphasalazine", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6405633_2_287", "context": "Two patients with bipolar affective disorder and a history of bronchospastic phenomena experienced tremor during lithium carbonate therapy.", "question": "Subject.Age in Two patients with bipolar affective disorder and a history of bronchospastic phenomena", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "6405633_2_288", "context": "Two patients with bipolar affective disorder and a history of bronchospastic phenomena experienced tremor during lithium carbonate therapy.", "question": "Subject.Gender in Two patients with bipolar affective disorder and a history of bronchospastic phenomena", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "6405633_2_289", "context": "Two patients with bipolar affective disorder and a history of bronchospastic phenomena experienced tremor during lithium carbonate therapy.", "question": "Subject.Population in Two patients with bipolar affective disorder and a history of bronchospastic phenomena", "question_type": "Adverse_event.Subject.Population", "answers": "Two"}, {"id": "6405633_2_290", "context": "Two patients with bipolar affective disorder and a history of bronchospastic phenomena experienced tremor during lithium carbonate therapy.", "question": "Subject.Race in Two patients with bipolar affective disorder and a history of bronchospastic phenomena", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "6405633_2_291", "context": "Two patients with bipolar affective disorder and a history of bronchospastic phenomena experienced tremor during lithium carbonate therapy.", "question": "Subject.Disorder in Two patients with bipolar affective disorder and a history of bronchospastic phenomena", "question_type": "Adverse_event.Subject.Disorder", "answers": "a history of bronchospastic phenomena"}, {"id": "6405633_2_292", "context": "Two patients with bipolar affective disorder and a history of bronchospastic phenomena experienced tremor during lithium carbonate therapy.", "question": "Treatment.Drug in lithium carbonate therapy", "question_type": "Adverse_event.Treatment.Drug", "answers": "lithium carbonate"}, {"id": "6405633_2_293", "context": "Two patients with bipolar affective disorder and a history of bronchospastic phenomena experienced tremor during lithium carbonate therapy.", "question": "Treatment.Dosage in lithium carbonate therapy", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6405633_2_294", "context": "Two patients with bipolar affective disorder and a history of bronchospastic phenomena experienced tremor during lithium carbonate therapy.", "question": "Treatment.Freq in lithium carbonate therapy", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6405633_2_295", "context": "Two patients with bipolar affective disorder and a history of bronchospastic phenomena experienced tremor during lithium carbonate therapy.", "question": "Treatment.Route in lithium carbonate therapy", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6405633_2_296", "context": "Two patients with bipolar affective disorder and a history of bronchospastic phenomena experienced tremor during lithium carbonate therapy.", "question": "Treatment.Time_elapsed in lithium carbonate therapy", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6405633_2_297", "context": "Two patients with bipolar affective disorder and a history of bronchospastic phenomena experienced tremor during lithium carbonate therapy.", "question": "Treatment.Duration in lithium carbonate therapy", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6405633_2_298", "context": "Two patients with bipolar affective disorder and a history of bronchospastic phenomena experienced tremor during lithium carbonate therapy.", "question": "Treatment.Disorder in lithium carbonate therapy", "question_type": "Adverse_event.Treatment.Disorder", "answers": "bipolar affective disorder"}, {"id": "6405633_2_299", "context": "Two patients with bipolar affective disorder and a history of bronchospastic phenomena experienced tremor during lithium carbonate therapy.", "question": "Combination.Drug in lithium carbonate therapy", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6344831_1_300", "context": "Acute renal failure most likely was secondary to the nephrotoxic effect of captopril on chronically hypoperfused kidneys.", "question": "Subject.Age in chronically hypoperfused kidneys", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "6344831_1_301", "context": "Acute renal failure most likely was secondary to the nephrotoxic effect of captopril on chronically hypoperfused kidneys.", "question": "Subject.Gender in chronically hypoperfused kidneys", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "6344831_1_302", "context": "Acute renal failure most likely was secondary to the nephrotoxic effect of captopril on chronically hypoperfused kidneys.", "question": "Subject.Population in chronically hypoperfused kidneys", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "6344831_1_303", "context": "Acute renal failure most likely was secondary to the nephrotoxic effect of captopril on chronically hypoperfused kidneys.", "question": "Subject.Race in chronically hypoperfused kidneys", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "6344831_1_304", "context": "Acute renal failure most likely was secondary to the nephrotoxic effect of captopril on chronically hypoperfused kidneys.", "question": "Subject.Disorder in chronically hypoperfused kidneys", "question_type": "Adverse_event.Subject.Disorder", "answers": "chronically hypoperfused kidneys"}, {"id": "6344831_1_305", "context": "Acute renal failure most likely was secondary to the nephrotoxic effect of captopril on chronically hypoperfused kidneys.", "question": "Treatment.Drug in captopril", "question_type": "Adverse_event.Treatment.Drug", "answers": "captopril"}, {"id": "6344831_1_306", "context": "Acute renal failure most likely was secondary to the nephrotoxic effect of captopril on chronically hypoperfused kidneys.", "question": "Treatment.Dosage in captopril", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6344831_1_307", "context": "Acute renal failure most likely was secondary to the nephrotoxic effect of captopril on chronically hypoperfused kidneys.", "question": "Treatment.Freq in captopril", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6344831_1_308", "context": "Acute renal failure most likely was secondary to the nephrotoxic effect of captopril on chronically hypoperfused kidneys.", "question": "Treatment.Route in captopril", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6344831_1_309", "context": "Acute renal failure most likely was secondary to the nephrotoxic effect of captopril on chronically hypoperfused kidneys.", "question": "Treatment.Time_elapsed in captopril", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6344831_1_310", "context": "Acute renal failure most likely was secondary to the nephrotoxic effect of captopril on chronically hypoperfused kidneys.", "question": "Treatment.Duration in captopril", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6344831_1_311", "context": "Acute renal failure most likely was secondary to the nephrotoxic effect of captopril on chronically hypoperfused kidneys.", "question": "Treatment.Disorder in captopril", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6344831_1_312", "context": "Acute renal failure most likely was secondary to the nephrotoxic effect of captopril on chronically hypoperfused kidneys.", "question": "Combination.Drug in captopril", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "2154663_3_313", "context": "We report a case of radiotherapy-enhanced aminoglutethimide skin toxicity in a patient with metastatic breast cancer.", "question": "Subject.Age in a patient with metastatic breast cancer", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "2154663_3_314", "context": "We report a case of radiotherapy-enhanced aminoglutethimide skin toxicity in a patient with metastatic breast cancer.", "question": "Subject.Gender in a patient with metastatic breast cancer", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "2154663_3_315", "context": "We report a case of radiotherapy-enhanced aminoglutethimide skin toxicity in a patient with metastatic breast cancer.", "question": "Subject.Population in a patient with metastatic breast cancer", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "2154663_3_316", "context": "We report a case of radiotherapy-enhanced aminoglutethimide skin toxicity in a patient with metastatic breast cancer.", "question": "Subject.Race in a patient with metastatic breast cancer", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "2154663_3_317", "context": "We report a case of radiotherapy-enhanced aminoglutethimide skin toxicity in a patient with metastatic breast cancer.", "question": "Subject.Disorder in a patient with metastatic breast cancer", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "2154663_3_318", "context": "We report a case of radiotherapy-enhanced aminoglutethimide skin toxicity in a patient with metastatic breast cancer.", "question": "Treatment.Drug in radiotherapy-enhanced aminoglutethimide", "question_type": "Adverse_event.Treatment.Drug", "answers": "aminoglutethimide"}, {"id": "2154663_3_319", "context": "We report a case of radiotherapy-enhanced aminoglutethimide skin toxicity in a patient with metastatic breast cancer.", "question": "Treatment.Dosage in radiotherapy-enhanced aminoglutethimide", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "2154663_3_320", "context": "We report a case of radiotherapy-enhanced aminoglutethimide skin toxicity in a patient with metastatic breast cancer.", "question": "Treatment.Freq in radiotherapy-enhanced aminoglutethimide", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2154663_3_321", "context": "We report a case of radiotherapy-enhanced aminoglutethimide skin toxicity in a patient with metastatic breast cancer.", "question": "Treatment.Route in radiotherapy-enhanced aminoglutethimide", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "2154663_3_322", "context": "We report a case of radiotherapy-enhanced aminoglutethimide skin toxicity in a patient with metastatic breast cancer.", "question": "Treatment.Time_elapsed in radiotherapy-enhanced aminoglutethimide", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2154663_3_323", "context": "We report a case of radiotherapy-enhanced aminoglutethimide skin toxicity in a patient with metastatic breast cancer.", "question": "Treatment.Duration in radiotherapy-enhanced aminoglutethimide", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2154663_3_324", "context": "We report a case of radiotherapy-enhanced aminoglutethimide skin toxicity in a patient with metastatic breast cancer.", "question": "Treatment.Disorder in radiotherapy-enhanced aminoglutethimide", "question_type": "Adverse_event.Treatment.Disorder", "answers": "metastatic breast cancer"}, {"id": "2154663_3_325", "context": "We report a case of radiotherapy-enhanced aminoglutethimide skin toxicity in a patient with metastatic breast cancer.", "question": "Combination.Drug in radiotherapy-enhanced aminoglutethimide", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "25540831_8_326", "context": "Clinicians should also be aware of the possibility of serotonin syndrome when encountering a patient taking serotonergic drugs who presents with characteristic symptoms of serotonin syndrome.", "question": "Subject.Age in a patient", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "25540831_8_327", "context": "Clinicians should also be aware of the possibility of serotonin syndrome when encountering a patient taking serotonergic drugs who presents with characteristic symptoms of serotonin syndrome.", "question": "Subject.Gender in a patient", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "25540831_8_328", "context": "Clinicians should also be aware of the possibility of serotonin syndrome when encountering a patient taking serotonergic drugs who presents with characteristic symptoms of serotonin syndrome.", "question": "Subject.Population in a patient", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "25540831_8_329", "context": "Clinicians should also be aware of the possibility of serotonin syndrome when encountering a patient taking serotonergic drugs who presents with characteristic symptoms of serotonin syndrome.", "question": "Subject.Race in a patient", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "25540831_8_330", "context": "Clinicians should also be aware of the possibility of serotonin syndrome when encountering a patient taking serotonergic drugs who presents with characteristic symptoms of serotonin syndrome.", "question": "Subject.Disorder in a patient", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "25540831_8_331", "context": "Clinicians should also be aware of the possibility of serotonin syndrome when encountering a patient taking serotonergic drugs who presents with characteristic symptoms of serotonin syndrome.", "question": "Treatment.Drug in serotonergic drugs", "question_type": "Adverse_event.Treatment.Drug", "answers": "serotonergic drugs"}, {"id": "25540831_8_332", "context": "Clinicians should also be aware of the possibility of serotonin syndrome when encountering a patient taking serotonergic drugs who presents with characteristic symptoms of serotonin syndrome.", "question": "Treatment.Dosage in serotonergic drugs", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "25540831_8_333", "context": "Clinicians should also be aware of the possibility of serotonin syndrome when encountering a patient taking serotonergic drugs who presents with characteristic symptoms of serotonin syndrome.", "question": "Treatment.Freq in serotonergic drugs", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "25540831_8_334", "context": "Clinicians should also be aware of the possibility of serotonin syndrome when encountering a patient taking serotonergic drugs who presents with characteristic symptoms of serotonin syndrome.", "question": "Treatment.Route in serotonergic drugs", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "25540831_8_335", "context": "Clinicians should also be aware of the possibility of serotonin syndrome when encountering a patient taking serotonergic drugs who presents with characteristic symptoms of serotonin syndrome.", "question": "Treatment.Time_elapsed in serotonergic drugs", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "25540831_8_336", "context": "Clinicians should also be aware of the possibility of serotonin syndrome when encountering a patient taking serotonergic drugs who presents with characteristic symptoms of serotonin syndrome.", "question": "Treatment.Duration in serotonergic drugs", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "25540831_8_337", "context": "Clinicians should also be aware of the possibility of serotonin syndrome when encountering a patient taking serotonergic drugs who presents with characteristic symptoms of serotonin syndrome.", "question": "Treatment.Disorder in serotonergic drugs", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "25540831_8_338", "context": "Clinicians should also be aware of the possibility of serotonin syndrome when encountering a patient taking serotonergic drugs who presents with characteristic symptoms of serotonin syndrome.", "question": "Combination.Drug in serotonergic drugs", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "946400_3_339", "context": "Such a rapid and relentless progression of methyldopa-induced liver injury is undoubtedly rare, but it may be prevented by careful supervision of patients who exhibit liver function abnormalities early in the course of therapy.", "question": "Treatment.Drug in methyldopa", "question_type": "Adverse_event.Treatment.Drug", "answers": "methyldopa"}, {"id": "946400_3_340", "context": "Such a rapid and relentless progression of methyldopa-induced liver injury is undoubtedly rare, but it may be prevented by careful supervision of patients who exhibit liver function abnormalities early in the course of therapy.", "question": "Treatment.Dosage in methyldopa", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "946400_3_341", "context": "Such a rapid and relentless progression of methyldopa-induced liver injury is undoubtedly rare, but it may be prevented by careful supervision of patients who exhibit liver function abnormalities early in the course of therapy.", "question": "Treatment.Freq in methyldopa", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "946400_3_342", "context": "Such a rapid and relentless progression of methyldopa-induced liver injury is undoubtedly rare, but it may be prevented by careful supervision of patients who exhibit liver function abnormalities early in the course of therapy.", "question": "Treatment.Route in methyldopa", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "946400_3_343", "context": "Such a rapid and relentless progression of methyldopa-induced liver injury is undoubtedly rare, but it may be prevented by careful supervision of patients who exhibit liver function abnormalities early in the course of therapy.", "question": "Treatment.Time_elapsed in methyldopa", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "946400_3_344", "context": "Such a rapid and relentless progression of methyldopa-induced liver injury is undoubtedly rare, but it may be prevented by careful supervision of patients who exhibit liver function abnormalities early in the course of therapy.", "question": "Treatment.Duration in methyldopa", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "946400_3_345", "context": "Such a rapid and relentless progression of methyldopa-induced liver injury is undoubtedly rare, but it may be prevented by careful supervision of patients who exhibit liver function abnormalities early in the course of therapy.", "question": "Treatment.Disorder in methyldopa", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "946400_3_346", "context": "Such a rapid and relentless progression of methyldopa-induced liver injury is undoubtedly rare, but it may be prevented by careful supervision of patients who exhibit liver function abnormalities early in the course of therapy.", "question": "Combination.Drug in methyldopa", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6507240_2_347", "context": "In eight patients, a mean decrease in serum Na+ of 8.25 +/- 3.2 mEq/L was observed after a single 200 mg intravenous dose of lorcainide.", "question": "Subject.Age in eight patients", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "6507240_2_348", "context": "In eight patients, a mean decrease in serum Na+ of 8.25 +/- 3.2 mEq/L was observed after a single 200 mg intravenous dose of lorcainide.", "question": "Subject.Gender in eight patients", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "6507240_2_349", "context": "In eight patients, a mean decrease in serum Na+ of 8.25 +/- 3.2 mEq/L was observed after a single 200 mg intravenous dose of lorcainide.", "question": "Subject.Population in eight patients", "question_type": "Adverse_event.Subject.Population", "answers": "eight"}, {"id": "6507240_2_350", "context": "In eight patients, a mean decrease in serum Na+ of 8.25 +/- 3.2 mEq/L was observed after a single 200 mg intravenous dose of lorcainide.", "question": "Subject.Race in eight patients", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "6507240_2_351", "context": "In eight patients, a mean decrease in serum Na+ of 8.25 +/- 3.2 mEq/L was observed after a single 200 mg intravenous dose of lorcainide.", "question": "Subject.Disorder in eight patients", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "6507240_2_352", "context": "In eight patients, a mean decrease in serum Na+ of 8.25 +/- 3.2 mEq/L was observed after a single 200 mg intravenous dose of lorcainide.", "question": "Treatment.Drug in a single 200 mg intravenous dose of lorcainide", "question_type": "Adverse_event.Treatment.Drug", "answers": "lorcainide"}, {"id": "6507240_2_353", "context": "In eight patients, a mean decrease in serum Na+ of 8.25 +/- 3.2 mEq/L was observed after a single 200 mg intravenous dose of lorcainide.", "question": "Treatment.Dosage in a single 200 mg intravenous dose of lorcainide", "question_type": "Adverse_event.Treatment.Dosage", "answers": "a single 200 mg"}, {"id": "6507240_2_354", "context": "In eight patients, a mean decrease in serum Na+ of 8.25 +/- 3.2 mEq/L was observed after a single 200 mg intravenous dose of lorcainide.", "question": "Treatment.Freq in a single 200 mg intravenous dose of lorcainide", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6507240_2_355", "context": "In eight patients, a mean decrease in serum Na+ of 8.25 +/- 3.2 mEq/L was observed after a single 200 mg intravenous dose of lorcainide.", "question": "Treatment.Route in a single 200 mg intravenous dose of lorcainide", "question_type": "Adverse_event.Treatment.Route", "answers": "intravenous"}, {"id": "6507240_2_356", "context": "In eight patients, a mean decrease in serum Na+ of 8.25 +/- 3.2 mEq/L was observed after a single 200 mg intravenous dose of lorcainide.", "question": "Treatment.Time_elapsed in a single 200 mg intravenous dose of lorcainide", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6507240_2_357", "context": "In eight patients, a mean decrease in serum Na+ of 8.25 +/- 3.2 mEq/L was observed after a single 200 mg intravenous dose of lorcainide.", "question": "Treatment.Duration in a single 200 mg intravenous dose of lorcainide", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6507240_2_358", "context": "In eight patients, a mean decrease in serum Na+ of 8.25 +/- 3.2 mEq/L was observed after a single 200 mg intravenous dose of lorcainide.", "question": "Treatment.Disorder in a single 200 mg intravenous dose of lorcainide", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6507240_2_359", "context": "In eight patients, a mean decrease in serum Na+ of 8.25 +/- 3.2 mEq/L was observed after a single 200 mg intravenous dose of lorcainide.", "question": "Combination.Drug in a single 200 mg intravenous dose of lorcainide", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "2234880_1_360", "context": "Nitrendipine-induced gingival hyperplasia.", "question": "Treatment.Drug in Nitrendipine", "question_type": "Adverse_event.Treatment.Drug", "answers": "Nitrendipine"}, {"id": "2234880_1_361", "context": "Nitrendipine-induced gingival hyperplasia.", "question": "Treatment.Dosage in Nitrendipine", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "2234880_1_362", "context": "Nitrendipine-induced gingival hyperplasia.", "question": "Treatment.Freq in Nitrendipine", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2234880_1_363", "context": "Nitrendipine-induced gingival hyperplasia.", "question": "Treatment.Route in Nitrendipine", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "2234880_1_364", "context": "Nitrendipine-induced gingival hyperplasia.", "question": "Treatment.Time_elapsed in Nitrendipine", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2234880_1_365", "context": "Nitrendipine-induced gingival hyperplasia.", "question": "Treatment.Duration in Nitrendipine", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2234880_1_366", "context": "Nitrendipine-induced gingival hyperplasia.", "question": "Treatment.Disorder in Nitrendipine", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "2234880_1_367", "context": "Nitrendipine-induced gingival hyperplasia.", "question": "Combination.Drug in Nitrendipine", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3501467_1_368", "context": "Extensive immunological investigations were performed in a patient with definite seronegative rheumatoid arthritis who developed hypogammaglobulinemia in the course of gold therapy.", "question": "Subject.Age in a patient with definite seronegative rheumatoid arthritis", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "3501467_1_369", "context": "Extensive immunological investigations were performed in a patient with definite seronegative rheumatoid arthritis who developed hypogammaglobulinemia in the course of gold therapy.", "question": "Subject.Gender in a patient with definite seronegative rheumatoid arthritis", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "3501467_1_370", "context": "Extensive immunological investigations were performed in a patient with definite seronegative rheumatoid arthritis who developed hypogammaglobulinemia in the course of gold therapy.", "question": "Subject.Population in a patient with definite seronegative rheumatoid arthritis", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "3501467_1_371", "context": "Extensive immunological investigations were performed in a patient with definite seronegative rheumatoid arthritis who developed hypogammaglobulinemia in the course of gold therapy.", "question": "Subject.Race in a patient with definite seronegative rheumatoid arthritis", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "3501467_1_372", "context": "Extensive immunological investigations were performed in a patient with definite seronegative rheumatoid arthritis who developed hypogammaglobulinemia in the course of gold therapy.", "question": "Subject.Disorder in a patient with definite seronegative rheumatoid arthritis", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "3501467_1_373", "context": "Extensive immunological investigations were performed in a patient with definite seronegative rheumatoid arthritis who developed hypogammaglobulinemia in the course of gold therapy.", "question": "Treatment.Drug in gold therapy", "question_type": "Adverse_event.Treatment.Drug", "answers": "gold"}, {"id": "3501467_1_374", "context": "Extensive immunological investigations were performed in a patient with definite seronegative rheumatoid arthritis who developed hypogammaglobulinemia in the course of gold therapy.", "question": "Treatment.Dosage in gold therapy", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3501467_1_375", "context": "Extensive immunological investigations were performed in a patient with definite seronegative rheumatoid arthritis who developed hypogammaglobulinemia in the course of gold therapy.", "question": "Treatment.Freq in gold therapy", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3501467_1_376", "context": "Extensive immunological investigations were performed in a patient with definite seronegative rheumatoid arthritis who developed hypogammaglobulinemia in the course of gold therapy.", "question": "Treatment.Route in gold therapy", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3501467_1_377", "context": "Extensive immunological investigations were performed in a patient with definite seronegative rheumatoid arthritis who developed hypogammaglobulinemia in the course of gold therapy.", "question": "Treatment.Time_elapsed in gold therapy", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3501467_1_378", "context": "Extensive immunological investigations were performed in a patient with definite seronegative rheumatoid arthritis who developed hypogammaglobulinemia in the course of gold therapy.", "question": "Treatment.Duration in gold therapy", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3501467_1_379", "context": "Extensive immunological investigations were performed in a patient with definite seronegative rheumatoid arthritis who developed hypogammaglobulinemia in the course of gold therapy.", "question": "Treatment.Disorder in gold therapy", "question_type": "Adverse_event.Treatment.Disorder", "answers": "rheumatoid arthritis"}, {"id": "3501467_1_380", "context": "Extensive immunological investigations were performed in a patient with definite seronegative rheumatoid arthritis who developed hypogammaglobulinemia in the course of gold therapy.", "question": "Combination.Drug in gold therapy", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12763355_4_381", "context": "When SASP was changed to 5-aminosalicylic acid (5-ASA), his skin eruptions were resolved, however, he developed weakness and atrophy in his right arm as well as progressive worsening of the dysesthesia in his legs and gait disturbance.", "question": "Subject.Age in he", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "12763355_4_382", "context": "When SASP was changed to 5-aminosalicylic acid (5-ASA), his skin eruptions were resolved, however, he developed weakness and atrophy in his right arm as well as progressive worsening of the dysesthesia in his legs and gait disturbance.", "question": "Subject.Gender in he", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "12763355_4_383", "context": "When SASP was changed to 5-aminosalicylic acid (5-ASA), his skin eruptions were resolved, however, he developed weakness and atrophy in his right arm as well as progressive worsening of the dysesthesia in his legs and gait disturbance.", "question": "Subject.Population in he", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "12763355_4_384", "context": "When SASP was changed to 5-aminosalicylic acid (5-ASA), his skin eruptions were resolved, however, he developed weakness and atrophy in his right arm as well as progressive worsening of the dysesthesia in his legs and gait disturbance.", "question": "Subject.Race in he", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "12763355_4_385", "context": "When SASP was changed to 5-aminosalicylic acid (5-ASA), his skin eruptions were resolved, however, he developed weakness and atrophy in his right arm as well as progressive worsening of the dysesthesia in his legs and gait disturbance.", "question": "Subject.Disorder in he", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "12763355_4_386", "context": "When SASP was changed to 5-aminosalicylic acid (5-ASA), his skin eruptions were resolved, however, he developed weakness and atrophy in his right arm as well as progressive worsening of the dysesthesia in his legs and gait disturbance.", "question": "Treatment.Drug in SASP was changed to 5-aminosalicylic acid (5-ASA)", "question_type": "Adverse_event.Treatment.Drug", "answers": "SASP; 5-aminosalicylic acid"}, {"id": "12763355_4_387", "context": "When SASP was changed to 5-aminosalicylic acid (5-ASA), his skin eruptions were resolved, however, he developed weakness and atrophy in his right arm as well as progressive worsening of the dysesthesia in his legs and gait disturbance.", "question": "Treatment.Dosage in SASP was changed to 5-aminosalicylic acid (5-ASA)", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12763355_4_388", "context": "When SASP was changed to 5-aminosalicylic acid (5-ASA), his skin eruptions were resolved, however, he developed weakness and atrophy in his right arm as well as progressive worsening of the dysesthesia in his legs and gait disturbance.", "question": "Treatment.Freq in SASP was changed to 5-aminosalicylic acid (5-ASA)", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12763355_4_389", "context": "When SASP was changed to 5-aminosalicylic acid (5-ASA), his skin eruptions were resolved, however, he developed weakness and atrophy in his right arm as well as progressive worsening of the dysesthesia in his legs and gait disturbance.", "question": "Treatment.Route in SASP was changed to 5-aminosalicylic acid (5-ASA)", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12763355_4_390", "context": "When SASP was changed to 5-aminosalicylic acid (5-ASA), his skin eruptions were resolved, however, he developed weakness and atrophy in his right arm as well as progressive worsening of the dysesthesia in his legs and gait disturbance.", "question": "Treatment.Time_elapsed in SASP was changed to 5-aminosalicylic acid (5-ASA)", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12763355_4_391", "context": "When SASP was changed to 5-aminosalicylic acid (5-ASA), his skin eruptions were resolved, however, he developed weakness and atrophy in his right arm as well as progressive worsening of the dysesthesia in his legs and gait disturbance.", "question": "Treatment.Duration in SASP was changed to 5-aminosalicylic acid (5-ASA)", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12763355_4_392", "context": "When SASP was changed to 5-aminosalicylic acid (5-ASA), his skin eruptions were resolved, however, he developed weakness and atrophy in his right arm as well as progressive worsening of the dysesthesia in his legs and gait disturbance.", "question": "Treatment.Disorder in SASP was changed to 5-aminosalicylic acid (5-ASA)", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12763355_4_393", "context": "When SASP was changed to 5-aminosalicylic acid (5-ASA), his skin eruptions were resolved, however, he developed weakness and atrophy in his right arm as well as progressive worsening of the dysesthesia in his legs and gait disturbance.", "question": "Combination.Drug in SASP was changed to 5-aminosalicylic acid (5-ASA)", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12763355_4_394", "context": "When SASP was changed to 5-aminosalicylic acid (5-ASA), his skin eruptions were resolved, however, he developed weakness and atrophy in his right arm as well as progressive worsening of the dysesthesia in his legs and gait disturbance.", "question": "Treatment.Drug in SASP was changed to 5-aminosalicylic acid (5-ASA)", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "5-aminosalicylic acid; SASP"}, {"id": "12763355_4_395", "context": "When SASP was changed to 5-aminosalicylic acid (5-ASA), his skin eruptions were resolved, however, he developed weakness and atrophy in his right arm as well as progressive worsening of the dysesthesia in his legs and gait disturbance.", "question": "Treatment.Dosage in SASP was changed to 5-aminosalicylic acid (5-ASA)", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "12763355_4_396", "context": "When SASP was changed to 5-aminosalicylic acid (5-ASA), his skin eruptions were resolved, however, he developed weakness and atrophy in his right arm as well as progressive worsening of the dysesthesia in his legs and gait disturbance.", "question": "Treatment.Freq in SASP was changed to 5-aminosalicylic acid (5-ASA)", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "12763355_4_397", "context": "When SASP was changed to 5-aminosalicylic acid (5-ASA), his skin eruptions were resolved, however, he developed weakness and atrophy in his right arm as well as progressive worsening of the dysesthesia in his legs and gait disturbance.", "question": "Treatment.Route in SASP was changed to 5-aminosalicylic acid (5-ASA)", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "12763355_4_398", "context": "When SASP was changed to 5-aminosalicylic acid (5-ASA), his skin eruptions were resolved, however, he developed weakness and atrophy in his right arm as well as progressive worsening of the dysesthesia in his legs and gait disturbance.", "question": "Treatment.Time_elapsed in SASP was changed to 5-aminosalicylic acid (5-ASA)", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12763355_4_399", "context": "When SASP was changed to 5-aminosalicylic acid (5-ASA), his skin eruptions were resolved, however, he developed weakness and atrophy in his right arm as well as progressive worsening of the dysesthesia in his legs and gait disturbance.", "question": "Treatment.Duration in SASP was changed to 5-aminosalicylic acid (5-ASA)", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "12763355_4_400", "context": "When SASP was changed to 5-aminosalicylic acid (5-ASA), his skin eruptions were resolved, however, he developed weakness and atrophy in his right arm as well as progressive worsening of the dysesthesia in his legs and gait disturbance.", "question": "Treatment.Disorder in SASP was changed to 5-aminosalicylic acid (5-ASA)", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "skin eruptions"}, {"id": "12763355_4_401", "context": "When SASP was changed to 5-aminosalicylic acid (5-ASA), his skin eruptions were resolved, however, he developed weakness and atrophy in his right arm as well as progressive worsening of the dysesthesia in his legs and gait disturbance.", "question": "Combination.Drug in SASP was changed to 5-aminosalicylic acid (5-ASA)", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "17697264_2_402", "context": "One case of tacrolimus-induced hepatic VOD developing after lung transplantation (LT) has been recently reported.", "question": "Treatment.Drug in tacrolimus; after lung transplantation (LT)", "question_type": "Adverse_event.Treatment.Drug", "answers": "tacrolimus"}, {"id": "17697264_2_403", "context": "One case of tacrolimus-induced hepatic VOD developing after lung transplantation (LT) has been recently reported.", "question": "Treatment.Dosage in tacrolimus; after lung transplantation (LT)", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17697264_2_404", "context": "One case of tacrolimus-induced hepatic VOD developing after lung transplantation (LT) has been recently reported.", "question": "Treatment.Freq in tacrolimus; after lung transplantation (LT)", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17697264_2_405", "context": "One case of tacrolimus-induced hepatic VOD developing after lung transplantation (LT) has been recently reported.", "question": "Treatment.Route in tacrolimus; after lung transplantation (LT)", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17697264_2_406", "context": "One case of tacrolimus-induced hepatic VOD developing after lung transplantation (LT) has been recently reported.", "question": "Treatment.Time_elapsed in tacrolimus; after lung transplantation (LT)", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17697264_2_407", "context": "One case of tacrolimus-induced hepatic VOD developing after lung transplantation (LT) has been recently reported.", "question": "Treatment.Duration in tacrolimus; after lung transplantation (LT)", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17697264_2_408", "context": "One case of tacrolimus-induced hepatic VOD developing after lung transplantation (LT) has been recently reported.", "question": "Treatment.Disorder in tacrolimus; after lung transplantation (LT)", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17697264_2_409", "context": "One case of tacrolimus-induced hepatic VOD developing after lung transplantation (LT) has been recently reported.", "question": "Combination.Drug in tacrolimus; after lung transplantation (LT)", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16948177_4_410", "context": "We describe a case of an NHL patient who received rituximab and developed symptomatic, biopsy-proven multinodular bronchiolitis obliterans with organizing pneumonia (BOOP).", "question": "Subject.Age in an NHL patient", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "16948177_4_411", "context": "We describe a case of an NHL patient who received rituximab and developed symptomatic, biopsy-proven multinodular bronchiolitis obliterans with organizing pneumonia (BOOP).", "question": "Subject.Gender in an NHL patient", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "16948177_4_412", "context": "We describe a case of an NHL patient who received rituximab and developed symptomatic, biopsy-proven multinodular bronchiolitis obliterans with organizing pneumonia (BOOP).", "question": "Subject.Population in an NHL patient", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "16948177_4_413", "context": "We describe a case of an NHL patient who received rituximab and developed symptomatic, biopsy-proven multinodular bronchiolitis obliterans with organizing pneumonia (BOOP).", "question": "Subject.Race in an NHL patient", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16948177_4_414", "context": "We describe a case of an NHL patient who received rituximab and developed symptomatic, biopsy-proven multinodular bronchiolitis obliterans with organizing pneumonia (BOOP).", "question": "Subject.Disorder in an NHL patient", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "16948177_4_415", "context": "We describe a case of an NHL patient who received rituximab and developed symptomatic, biopsy-proven multinodular bronchiolitis obliterans with organizing pneumonia (BOOP).", "question": "Treatment.Drug in rituximab", "question_type": "Adverse_event.Treatment.Drug", "answers": "rituximab"}, {"id": "16948177_4_416", "context": "We describe a case of an NHL patient who received rituximab and developed symptomatic, biopsy-proven multinodular bronchiolitis obliterans with organizing pneumonia (BOOP).", "question": "Treatment.Dosage in rituximab", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16948177_4_417", "context": "We describe a case of an NHL patient who received rituximab and developed symptomatic, biopsy-proven multinodular bronchiolitis obliterans with organizing pneumonia (BOOP).", "question": "Treatment.Freq in rituximab", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16948177_4_418", "context": "We describe a case of an NHL patient who received rituximab and developed symptomatic, biopsy-proven multinodular bronchiolitis obliterans with organizing pneumonia (BOOP).", "question": "Treatment.Route in rituximab", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16948177_4_419", "context": "We describe a case of an NHL patient who received rituximab and developed symptomatic, biopsy-proven multinodular bronchiolitis obliterans with organizing pneumonia (BOOP).", "question": "Treatment.Time_elapsed in rituximab", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16948177_4_420", "context": "We describe a case of an NHL patient who received rituximab and developed symptomatic, biopsy-proven multinodular bronchiolitis obliterans with organizing pneumonia (BOOP).", "question": "Treatment.Duration in rituximab", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16948177_4_421", "context": "We describe a case of an NHL patient who received rituximab and developed symptomatic, biopsy-proven multinodular bronchiolitis obliterans with organizing pneumonia (BOOP).", "question": "Treatment.Disorder in rituximab", "question_type": "Adverse_event.Treatment.Disorder", "answers": "NHL"}, {"id": "16948177_4_422", "context": "We describe a case of an NHL patient who received rituximab and developed symptomatic, biopsy-proven multinodular bronchiolitis obliterans with organizing pneumonia (BOOP).", "question": "Combination.Drug in rituximab", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11720625_4_423", "context": "We describe a case of TdP caused by a drug interaction in a 76-year-old woman taking long-term disopyramide after she was given clarithromycin concomitantly for chronic bronchitis.", "question": "Subject.Age in 76-year-old woman", "question_type": "Adverse_event.Subject.Age", "answers": "76-year-old"}, {"id": "11720625_4_424", "context": "We describe a case of TdP caused by a drug interaction in a 76-year-old woman taking long-term disopyramide after she was given clarithromycin concomitantly for chronic bronchitis.", "question": "Subject.Gender in 76-year-old woman", "question_type": "Adverse_event.Subject.Gender", "answers": "woman"}, {"id": "11720625_4_425", "context": "We describe a case of TdP caused by a drug interaction in a 76-year-old woman taking long-term disopyramide after she was given clarithromycin concomitantly for chronic bronchitis.", "question": "Subject.Population in 76-year-old woman", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "11720625_4_426", "context": "We describe a case of TdP caused by a drug interaction in a 76-year-old woman taking long-term disopyramide after she was given clarithromycin concomitantly for chronic bronchitis.", "question": "Subject.Race in 76-year-old woman", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "11720625_4_427", "context": "We describe a case of TdP caused by a drug interaction in a 76-year-old woman taking long-term disopyramide after she was given clarithromycin concomitantly for chronic bronchitis.", "question": "Subject.Disorder in 76-year-old woman", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "11720625_4_428", "context": "We describe a case of TdP caused by a drug interaction in a 76-year-old woman taking long-term disopyramide after she was given clarithromycin concomitantly for chronic bronchitis.", "question": "Treatment.Drug in long-term disopyramide; clarithromycin", "question_type": "Adverse_event.Treatment.Drug", "answers": "long-term disopyramide; clarithromycin"}, {"id": "11720625_4_429", "context": "We describe a case of TdP caused by a drug interaction in a 76-year-old woman taking long-term disopyramide after she was given clarithromycin concomitantly for chronic bronchitis.", "question": "Treatment.Dosage in long-term disopyramide; clarithromycin", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11720625_4_430", "context": "We describe a case of TdP caused by a drug interaction in a 76-year-old woman taking long-term disopyramide after she was given clarithromycin concomitantly for chronic bronchitis.", "question": "Treatment.Freq in long-term disopyramide; clarithromycin", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11720625_4_431", "context": "We describe a case of TdP caused by a drug interaction in a 76-year-old woman taking long-term disopyramide after she was given clarithromycin concomitantly for chronic bronchitis.", "question": "Treatment.Route in long-term disopyramide; clarithromycin", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11720625_4_432", "context": "We describe a case of TdP caused by a drug interaction in a 76-year-old woman taking long-term disopyramide after she was given clarithromycin concomitantly for chronic bronchitis.", "question": "Treatment.Time_elapsed in long-term disopyramide; clarithromycin", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11720625_4_433", "context": "We describe a case of TdP caused by a drug interaction in a 76-year-old woman taking long-term disopyramide after she was given clarithromycin concomitantly for chronic bronchitis.", "question": "Treatment.Duration in long-term disopyramide; clarithromycin", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11720625_4_434", "context": "We describe a case of TdP caused by a drug interaction in a 76-year-old woman taking long-term disopyramide after she was given clarithromycin concomitantly for chronic bronchitis.", "question": "Treatment.Disorder in long-term disopyramide; clarithromycin", "question_type": "Adverse_event.Treatment.Disorder", "answers": "chronic bronchitis"}, {"id": "11720625_4_435", "context": "We describe a case of TdP caused by a drug interaction in a 76-year-old woman taking long-term disopyramide after she was given clarithromycin concomitantly for chronic bronchitis.", "question": "Combination.Drug in long-term disopyramide; clarithromycin", "question_type": "Adverse_event.Combination.Drug", "answers": "long-term disopyramide; clarithromycin"}, {"id": "14971874_2_436", "context": "Thus, clinical recognition of sleep disordered breathing should be taken into account when rheumatoid arthritis patients are to be treated with infliximab.", "question": "Subject.Age in rheumatoid arthritis patients", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "14971874_2_437", "context": "Thus, clinical recognition of sleep disordered breathing should be taken into account when rheumatoid arthritis patients are to be treated with infliximab.", "question": "Subject.Gender in rheumatoid arthritis patients", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "14971874_2_438", "context": "Thus, clinical recognition of sleep disordered breathing should be taken into account when rheumatoid arthritis patients are to be treated with infliximab.", "question": "Subject.Population in rheumatoid arthritis patients", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "14971874_2_439", "context": "Thus, clinical recognition of sleep disordered breathing should be taken into account when rheumatoid arthritis patients are to be treated with infliximab.", "question": "Subject.Race in rheumatoid arthritis patients", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "14971874_2_440", "context": "Thus, clinical recognition of sleep disordered breathing should be taken into account when rheumatoid arthritis patients are to be treated with infliximab.", "question": "Subject.Disorder in rheumatoid arthritis patients", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "14971874_2_441", "context": "Thus, clinical recognition of sleep disordered breathing should be taken into account when rheumatoid arthritis patients are to be treated with infliximab.", "question": "Treatment.Drug in infliximab", "question_type": "Adverse_event.Treatment.Drug", "answers": "infliximab"}, {"id": "14971874_2_442", "context": "Thus, clinical recognition of sleep disordered breathing should be taken into account when rheumatoid arthritis patients are to be treated with infliximab.", "question": "Treatment.Dosage in infliximab", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "14971874_2_443", "context": "Thus, clinical recognition of sleep disordered breathing should be taken into account when rheumatoid arthritis patients are to be treated with infliximab.", "question": "Treatment.Freq in infliximab", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "14971874_2_444", "context": "Thus, clinical recognition of sleep disordered breathing should be taken into account when rheumatoid arthritis patients are to be treated with infliximab.", "question": "Treatment.Route in infliximab", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "14971874_2_445", "context": "Thus, clinical recognition of sleep disordered breathing should be taken into account when rheumatoid arthritis patients are to be treated with infliximab.", "question": "Treatment.Time_elapsed in infliximab", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "14971874_2_446", "context": "Thus, clinical recognition of sleep disordered breathing should be taken into account when rheumatoid arthritis patients are to be treated with infliximab.", "question": "Treatment.Duration in infliximab", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "14971874_2_447", "context": "Thus, clinical recognition of sleep disordered breathing should be taken into account when rheumatoid arthritis patients are to be treated with infliximab.", "question": "Treatment.Disorder in infliximab", "question_type": "Adverse_event.Treatment.Disorder", "answers": "rheumatoid arthritis"}, {"id": "14971874_2_448", "context": "Thus, clinical recognition of sleep disordered breathing should be taken into account when rheumatoid arthritis patients are to be treated with infliximab.", "question": "Combination.Drug in infliximab", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18006091_2_449", "context": "We present a case of a sustained monomorphic ventricular tachycardia following adenosine infusion.", "question": "Treatment.Drug in adenosine infusion", "question_type": "Adverse_event.Treatment.Drug", "answers": "adenosine"}, {"id": "18006091_2_450", "context": "We present a case of a sustained monomorphic ventricular tachycardia following adenosine infusion.", "question": "Treatment.Dosage in adenosine infusion", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18006091_2_451", "context": "We present a case of a sustained monomorphic ventricular tachycardia following adenosine infusion.", "question": "Treatment.Freq in adenosine infusion", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18006091_2_452", "context": "We present a case of a sustained monomorphic ventricular tachycardia following adenosine infusion.", "question": "Treatment.Route in adenosine infusion", "question_type": "Adverse_event.Treatment.Route", "answers": "infusion"}, {"id": "18006091_2_453", "context": "We present a case of a sustained monomorphic ventricular tachycardia following adenosine infusion.", "question": "Treatment.Time_elapsed in adenosine infusion", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18006091_2_454", "context": "We present a case of a sustained monomorphic ventricular tachycardia following adenosine infusion.", "question": "Treatment.Duration in adenosine infusion", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18006091_2_455", "context": "We present a case of a sustained monomorphic ventricular tachycardia following adenosine infusion.", "question": "Treatment.Disorder in adenosine infusion", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18006091_2_456", "context": "We present a case of a sustained monomorphic ventricular tachycardia following adenosine infusion.", "question": "Combination.Drug in adenosine infusion", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11008259_1_457", "context": "Provocation of non-convulsive status epilepticus by tiagabine in three adolescent patients.", "question": "Subject.Age in three adolescent patients", "question_type": "Adverse_event.Subject.Age", "answers": "adolescent"}, {"id": "11008259_1_458", "context": "Provocation of non-convulsive status epilepticus by tiagabine in three adolescent patients.", "question": "Subject.Gender in three adolescent patients", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "11008259_1_459", "context": "Provocation of non-convulsive status epilepticus by tiagabine in three adolescent patients.", "question": "Subject.Population in three adolescent patients", "question_type": "Adverse_event.Subject.Population", "answers": "three"}, {"id": "11008259_1_460", "context": "Provocation of non-convulsive status epilepticus by tiagabine in three adolescent patients.", "question": "Subject.Race in three adolescent patients", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "11008259_1_461", "context": "Provocation of non-convulsive status epilepticus by tiagabine in three adolescent patients.", "question": "Subject.Disorder in three adolescent patients", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "11008259_1_462", "context": "Provocation of non-convulsive status epilepticus by tiagabine in three adolescent patients.", "question": "Treatment.Drug in tiagabine", "question_type": "Adverse_event.Treatment.Drug", "answers": "tiagabine"}, {"id": "11008259_1_463", "context": "Provocation of non-convulsive status epilepticus by tiagabine in three adolescent patients.", "question": "Treatment.Dosage in tiagabine", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11008259_1_464", "context": "Provocation of non-convulsive status epilepticus by tiagabine in three adolescent patients.", "question": "Treatment.Freq in tiagabine", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11008259_1_465", "context": "Provocation of non-convulsive status epilepticus by tiagabine in three adolescent patients.", "question": "Treatment.Route in tiagabine", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11008259_1_466", "context": "Provocation of non-convulsive status epilepticus by tiagabine in three adolescent patients.", "question": "Treatment.Time_elapsed in tiagabine", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11008259_1_467", "context": "Provocation of non-convulsive status epilepticus by tiagabine in three adolescent patients.", "question": "Treatment.Duration in tiagabine", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11008259_1_468", "context": "Provocation of non-convulsive status epilepticus by tiagabine in three adolescent patients.", "question": "Treatment.Disorder in tiagabine", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11008259_1_469", "context": "Provocation of non-convulsive status epilepticus by tiagabine in three adolescent patients.", "question": "Combination.Drug in tiagabine", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "19260037_5_470", "context": "We recommend that a TMA in association with quinine be consistently referred to as quinine-associated thrombotic microangiopathy (quinine-TMA) to better distinguish this entity from idiopathic TTP.", "question": "Treatment.Drug in quinine", "question_type": "Adverse_event.Treatment.Drug", "answers": "quinine"}, {"id": "19260037_5_471", "context": "We recommend that a TMA in association with quinine be consistently referred to as quinine-associated thrombotic microangiopathy (quinine-TMA) to better distinguish this entity from idiopathic TTP.", "question": "Treatment.Dosage in quinine", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "19260037_5_472", "context": "We recommend that a TMA in association with quinine be consistently referred to as quinine-associated thrombotic microangiopathy (quinine-TMA) to better distinguish this entity from idiopathic TTP.", "question": "Treatment.Freq in quinine", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "19260037_5_473", "context": "We recommend that a TMA in association with quinine be consistently referred to as quinine-associated thrombotic microangiopathy (quinine-TMA) to better distinguish this entity from idiopathic TTP.", "question": "Treatment.Route in quinine", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "19260037_5_474", "context": "We recommend that a TMA in association with quinine be consistently referred to as quinine-associated thrombotic microangiopathy (quinine-TMA) to better distinguish this entity from idiopathic TTP.", "question": "Treatment.Time_elapsed in quinine", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19260037_5_475", "context": "We recommend that a TMA in association with quinine be consistently referred to as quinine-associated thrombotic microangiopathy (quinine-TMA) to better distinguish this entity from idiopathic TTP.", "question": "Treatment.Duration in quinine", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "19260037_5_476", "context": "We recommend that a TMA in association with quinine be consistently referred to as quinine-associated thrombotic microangiopathy (quinine-TMA) to better distinguish this entity from idiopathic TTP.", "question": "Treatment.Disorder in quinine", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "19260037_5_477", "context": "We recommend that a TMA in association with quinine be consistently referred to as quinine-associated thrombotic microangiopathy (quinine-TMA) to better distinguish this entity from idiopathic TTP.", "question": "Combination.Drug in quinine", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6625005_3_478", "context": "The authors describe a case of oral-facial dyskinesia that occurred after discontinuation of amoxapine, and antidepressant which may also have neuroleptic effects.", "question": "Treatment.Drug in discontinuation of amoxapine, and antidepressant which may also have neuroleptic effects", "question_type": "Adverse_event.Treatment.Drug", "answers": "antidepressant; amoxapine"}, {"id": "6625005_3_479", "context": "The authors describe a case of oral-facial dyskinesia that occurred after discontinuation of amoxapine, and antidepressant which may also have neuroleptic effects.", "question": "Treatment.Dosage in discontinuation of amoxapine, and antidepressant which may also have neuroleptic effects", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6625005_3_480", "context": "The authors describe a case of oral-facial dyskinesia that occurred after discontinuation of amoxapine, and antidepressant which may also have neuroleptic effects.", "question": "Treatment.Freq in discontinuation of amoxapine, and antidepressant which may also have neuroleptic effects", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6625005_3_481", "context": "The authors describe a case of oral-facial dyskinesia that occurred after discontinuation of amoxapine, and antidepressant which may also have neuroleptic effects.", "question": "Treatment.Route in discontinuation of amoxapine, and antidepressant which may also have neuroleptic effects", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6625005_3_482", "context": "The authors describe a case of oral-facial dyskinesia that occurred after discontinuation of amoxapine, and antidepressant which may also have neuroleptic effects.", "question": "Treatment.Time_elapsed in discontinuation of amoxapine, and antidepressant which may also have neuroleptic effects", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6625005_3_483", "context": "The authors describe a case of oral-facial dyskinesia that occurred after discontinuation of amoxapine, and antidepressant which may also have neuroleptic effects.", "question": "Treatment.Duration in discontinuation of amoxapine, and antidepressant which may also have neuroleptic effects", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6625005_3_484", "context": "The authors describe a case of oral-facial dyskinesia that occurred after discontinuation of amoxapine, and antidepressant which may also have neuroleptic effects.", "question": "Treatment.Disorder in discontinuation of amoxapine, and antidepressant which may also have neuroleptic effects", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6625005_3_485", "context": "The authors describe a case of oral-facial dyskinesia that occurred after discontinuation of amoxapine, and antidepressant which may also have neuroleptic effects.", "question": "Combination.Drug in discontinuation of amoxapine, and antidepressant which may also have neuroleptic effects", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "19934385_3_486", "context": "A 34-year-old HIV-infected man who had recently initiated efavirenz-based antiretroviral therapy was diagnosed with disseminated Histoplasma capsulatum infection.", "question": "Subject.Age in A 34-year-old HIV-infected man", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": "34-year-old"}, {"id": "19934385_3_487", "context": "A 34-year-old HIV-infected man who had recently initiated efavirenz-based antiretroviral therapy was diagnosed with disseminated Histoplasma capsulatum infection.", "question": "Subject.Gender in A 34-year-old HIV-infected man", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": "man"}, {"id": "19934385_3_488", "context": "A 34-year-old HIV-infected man who had recently initiated efavirenz-based antiretroviral therapy was diagnosed with disseminated Histoplasma capsulatum infection.", "question": "Subject.Population in A 34-year-old HIV-infected man", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "19934385_3_489", "context": "A 34-year-old HIV-infected man who had recently initiated efavirenz-based antiretroviral therapy was diagnosed with disseminated Histoplasma capsulatum infection.", "question": "Subject.Race in A 34-year-old HIV-infected man", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "19934385_3_490", "context": "A 34-year-old HIV-infected man who had recently initiated efavirenz-based antiretroviral therapy was diagnosed with disseminated Histoplasma capsulatum infection.", "question": "Subject.Disorder in A 34-year-old HIV-infected man", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": "disseminated Histoplasma capsulatum infection"}, {"id": "19934385_3_491", "context": "A 34-year-old HIV-infected man who had recently initiated efavirenz-based antiretroviral therapy was diagnosed with disseminated Histoplasma capsulatum infection.", "question": "Treatment.Drug in initiated efavirenz-based antiretroviral therapy", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "efavirenz; antiretroviral"}, {"id": "19934385_3_492", "context": "A 34-year-old HIV-infected man who had recently initiated efavirenz-based antiretroviral therapy was diagnosed with disseminated Histoplasma capsulatum infection.", "question": "Treatment.Dosage in initiated efavirenz-based antiretroviral therapy", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "19934385_3_493", "context": "A 34-year-old HIV-infected man who had recently initiated efavirenz-based antiretroviral therapy was diagnosed with disseminated Histoplasma capsulatum infection.", "question": "Treatment.Freq in initiated efavirenz-based antiretroviral therapy", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "19934385_3_494", "context": "A 34-year-old HIV-infected man who had recently initiated efavirenz-based antiretroviral therapy was diagnosed with disseminated Histoplasma capsulatum infection.", "question": "Treatment.Route in initiated efavirenz-based antiretroviral therapy", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "19934385_3_495", "context": "A 34-year-old HIV-infected man who had recently initiated efavirenz-based antiretroviral therapy was diagnosed with disseminated Histoplasma capsulatum infection.", "question": "Treatment.Time_elapsed in initiated efavirenz-based antiretroviral therapy", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19934385_3_496", "context": "A 34-year-old HIV-infected man who had recently initiated efavirenz-based antiretroviral therapy was diagnosed with disseminated Histoplasma capsulatum infection.", "question": "Treatment.Duration in initiated efavirenz-based antiretroviral therapy", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "19934385_3_497", "context": "A 34-year-old HIV-infected man who had recently initiated efavirenz-based antiretroviral therapy was diagnosed with disseminated Histoplasma capsulatum infection.", "question": "Treatment.Disorder in initiated efavirenz-based antiretroviral therapy", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "HIV"}, {"id": "19934385_3_498", "context": "A 34-year-old HIV-infected man who had recently initiated efavirenz-based antiretroviral therapy was diagnosed with disseminated Histoplasma capsulatum infection.", "question": "Combination.Drug in initiated efavirenz-based antiretroviral therapy", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": "efavirenz; antiretroviral"}, {"id": "2154663_1_499", "context": "Aminoglutethimide was discontinued until completion of radiotherapy, and the rash resolved.", "question": "Treatment.Drug in Aminoglutethimide was discontinued until completion of radiotherapy", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "Aminoglutethimide"}, {"id": "2154663_1_500", "context": "Aminoglutethimide was discontinued until completion of radiotherapy, and the rash resolved.", "question": "Treatment.Dosage in Aminoglutethimide was discontinued until completion of radiotherapy", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "2154663_1_501", "context": "Aminoglutethimide was discontinued until completion of radiotherapy, and the rash resolved.", "question": "Treatment.Freq in Aminoglutethimide was discontinued until completion of radiotherapy", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "2154663_1_502", "context": "Aminoglutethimide was discontinued until completion of radiotherapy, and the rash resolved.", "question": "Treatment.Route in Aminoglutethimide was discontinued until completion of radiotherapy", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "2154663_1_503", "context": "Aminoglutethimide was discontinued until completion of radiotherapy, and the rash resolved.", "question": "Treatment.Time_elapsed in Aminoglutethimide was discontinued until completion of radiotherapy", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2154663_1_504", "context": "Aminoglutethimide was discontinued until completion of radiotherapy, and the rash resolved.", "question": "Treatment.Duration in Aminoglutethimide was discontinued until completion of radiotherapy", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "2154663_1_505", "context": "Aminoglutethimide was discontinued until completion of radiotherapy, and the rash resolved.", "question": "Treatment.Disorder in Aminoglutethimide was discontinued until completion of radiotherapy", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "2154663_1_506", "context": "Aminoglutethimide was discontinued until completion of radiotherapy, and the rash resolved.", "question": "Combination.Drug in Aminoglutethimide was discontinued until completion of radiotherapy", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "15941649_4_507", "context": "We explored ophthalmic and neurologic findings in two children who have been exposed prenatally to VGB.", "question": "Subject.Age in two children", "question_type": "Adverse_event.Subject.Age", "answers": "children"}, {"id": "15941649_4_508", "context": "We explored ophthalmic and neurologic findings in two children who have been exposed prenatally to VGB.", "question": "Subject.Gender in two children", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15941649_4_509", "context": "We explored ophthalmic and neurologic findings in two children who have been exposed prenatally to VGB.", "question": "Subject.Population in two children", "question_type": "Adverse_event.Subject.Population", "answers": "two"}, {"id": "15941649_4_510", "context": "We explored ophthalmic and neurologic findings in two children who have been exposed prenatally to VGB.", "question": "Subject.Race in two children", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15941649_4_511", "context": "We explored ophthalmic and neurologic findings in two children who have been exposed prenatally to VGB.", "question": "Subject.Disorder in two children", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15941649_4_512", "context": "We explored ophthalmic and neurologic findings in two children who have been exposed prenatally to VGB.", "question": "Treatment.Drug in exposed prenatally to VGB; VGB", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "15941649_4_513", "context": "We explored ophthalmic and neurologic findings in two children who have been exposed prenatally to VGB.", "question": "Treatment.Dosage in exposed prenatally to VGB; VGB", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15941649_4_514", "context": "We explored ophthalmic and neurologic findings in two children who have been exposed prenatally to VGB.", "question": "Treatment.Freq in exposed prenatally to VGB; VGB", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15941649_4_515", "context": "We explored ophthalmic and neurologic findings in two children who have been exposed prenatally to VGB.", "question": "Treatment.Route in exposed prenatally to VGB; VGB", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15941649_4_516", "context": "We explored ophthalmic and neurologic findings in two children who have been exposed prenatally to VGB.", "question": "Treatment.Time_elapsed in exposed prenatally to VGB; VGB", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15941649_4_517", "context": "We explored ophthalmic and neurologic findings in two children who have been exposed prenatally to VGB.", "question": "Treatment.Duration in exposed prenatally to VGB; VGB", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15941649_4_518", "context": "We explored ophthalmic and neurologic findings in two children who have been exposed prenatally to VGB.", "question": "Treatment.Disorder in exposed prenatally to VGB; VGB", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15941649_4_519", "context": "We explored ophthalmic and neurologic findings in two children who have been exposed prenatally to VGB.", "question": "Combination.Drug in exposed prenatally to VGB; VGB", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "2572964_2_520", "context": "Two cases are described of chronic schizophrenic patients maintained on depot neuroleptics, who developed severe extrapyramidal symptoms following a period of heavy betel nut consumption.", "question": "Subject.Age in Two cases", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "2572964_2_521", "context": "Two cases are described of chronic schizophrenic patients maintained on depot neuroleptics, who developed severe extrapyramidal symptoms following a period of heavy betel nut consumption.", "question": "Subject.Gender in Two cases", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "2572964_2_522", "context": "Two cases are described of chronic schizophrenic patients maintained on depot neuroleptics, who developed severe extrapyramidal symptoms following a period of heavy betel nut consumption.", "question": "Subject.Population in Two cases", "question_type": "Adverse_event.Subject.Population", "answers": "Two"}, {"id": "2572964_2_523", "context": "Two cases are described of chronic schizophrenic patients maintained on depot neuroleptics, who developed severe extrapyramidal symptoms following a period of heavy betel nut consumption.", "question": "Subject.Race in Two cases", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "2572964_2_524", "context": "Two cases are described of chronic schizophrenic patients maintained on depot neuroleptics, who developed severe extrapyramidal symptoms following a period of heavy betel nut consumption.", "question": "Subject.Disorder in Two cases", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "2572964_2_525", "context": "Two cases are described of chronic schizophrenic patients maintained on depot neuroleptics, who developed severe extrapyramidal symptoms following a period of heavy betel nut consumption.", "question": "Treatment.Drug in heavy betel nut consumption; depot neuroleptics", "question_type": "Adverse_event.Treatment.Drug", "answers": "depot neuroleptics; betel nut"}, {"id": "2572964_2_526", "context": "Two cases are described of chronic schizophrenic patients maintained on depot neuroleptics, who developed severe extrapyramidal symptoms following a period of heavy betel nut consumption.", "question": "Treatment.Dosage in heavy betel nut consumption; depot neuroleptics", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "2572964_2_527", "context": "Two cases are described of chronic schizophrenic patients maintained on depot neuroleptics, who developed severe extrapyramidal symptoms following a period of heavy betel nut consumption.", "question": "Treatment.Freq in heavy betel nut consumption; depot neuroleptics", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2572964_2_528", "context": "Two cases are described of chronic schizophrenic patients maintained on depot neuroleptics, who developed severe extrapyramidal symptoms following a period of heavy betel nut consumption.", "question": "Treatment.Route in heavy betel nut consumption; depot neuroleptics", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "2572964_2_529", "context": "Two cases are described of chronic schizophrenic patients maintained on depot neuroleptics, who developed severe extrapyramidal symptoms following a period of heavy betel nut consumption.", "question": "Treatment.Time_elapsed in heavy betel nut consumption; depot neuroleptics", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2572964_2_530", "context": "Two cases are described of chronic schizophrenic patients maintained on depot neuroleptics, who developed severe extrapyramidal symptoms following a period of heavy betel nut consumption.", "question": "Treatment.Duration in heavy betel nut consumption; depot neuroleptics", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2572964_2_531", "context": "Two cases are described of chronic schizophrenic patients maintained on depot neuroleptics, who developed severe extrapyramidal symptoms following a period of heavy betel nut consumption.", "question": "Treatment.Disorder in heavy betel nut consumption; depot neuroleptics", "question_type": "Adverse_event.Treatment.Disorder", "answers": "chronic schizophrenic"}, {"id": "2572964_2_532", "context": "Two cases are described of chronic schizophrenic patients maintained on depot neuroleptics, who developed severe extrapyramidal symptoms following a period of heavy betel nut consumption.", "question": "Combination.Drug in heavy betel nut consumption; depot neuroleptics", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "160443_1_533", "context": "Five personal observations of an acute amnestic episode in younger individuals after intake of clioquinol are described together with three observations from the medical literature.", "question": "Subject.Age in younger individuals", "question_type": "Adverse_event.Subject.Age", "answers": "younger"}, {"id": "160443_1_534", "context": "Five personal observations of an acute amnestic episode in younger individuals after intake of clioquinol are described together with three observations from the medical literature.", "question": "Subject.Gender in younger individuals", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "160443_1_535", "context": "Five personal observations of an acute amnestic episode in younger individuals after intake of clioquinol are described together with three observations from the medical literature.", "question": "Subject.Population in younger individuals", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "160443_1_536", "context": "Five personal observations of an acute amnestic episode in younger individuals after intake of clioquinol are described together with three observations from the medical literature.", "question": "Subject.Race in younger individuals", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "160443_1_537", "context": "Five personal observations of an acute amnestic episode in younger individuals after intake of clioquinol are described together with three observations from the medical literature.", "question": "Subject.Disorder in younger individuals", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "160443_1_538", "context": "Five personal observations of an acute amnestic episode in younger individuals after intake of clioquinol are described together with three observations from the medical literature.", "question": "Treatment.Drug in intake of clioquinol", "question_type": "Adverse_event.Treatment.Drug", "answers": "clioquinol"}, {"id": "160443_1_539", "context": "Five personal observations of an acute amnestic episode in younger individuals after intake of clioquinol are described together with three observations from the medical literature.", "question": "Treatment.Dosage in intake of clioquinol", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "160443_1_540", "context": "Five personal observations of an acute amnestic episode in younger individuals after intake of clioquinol are described together with three observations from the medical literature.", "question": "Treatment.Freq in intake of clioquinol", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "160443_1_541", "context": "Five personal observations of an acute amnestic episode in younger individuals after intake of clioquinol are described together with three observations from the medical literature.", "question": "Treatment.Route in intake of clioquinol", "question_type": "Adverse_event.Treatment.Route", "answers": "intake"}, {"id": "160443_1_542", "context": "Five personal observations of an acute amnestic episode in younger individuals after intake of clioquinol are described together with three observations from the medical literature.", "question": "Treatment.Time_elapsed in intake of clioquinol", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "160443_1_543", "context": "Five personal observations of an acute amnestic episode in younger individuals after intake of clioquinol are described together with three observations from the medical literature.", "question": "Treatment.Duration in intake of clioquinol", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "160443_1_544", "context": "Five personal observations of an acute amnestic episode in younger individuals after intake of clioquinol are described together with three observations from the medical literature.", "question": "Treatment.Disorder in intake of clioquinol", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "160443_1_545", "context": "Five personal observations of an acute amnestic episode in younger individuals after intake of clioquinol are described together with three observations from the medical literature.", "question": "Combination.Drug in intake of clioquinol", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6344831_2_546", "context": "In a patient with severe renovascular hypertension, nonoliguric acute renal failure developed after she received captopril treatment.", "question": "Subject.Age in a patient with severe renovascular hypertension", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "6344831_2_547", "context": "In a patient with severe renovascular hypertension, nonoliguric acute renal failure developed after she received captopril treatment.", "question": "Subject.Gender in a patient with severe renovascular hypertension", "question_type": "Adverse_event.Subject.Gender", "answers": "she"}, {"id": "6344831_2_548", "context": "In a patient with severe renovascular hypertension, nonoliguric acute renal failure developed after she received captopril treatment.", "question": "Subject.Population in a patient with severe renovascular hypertension", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "6344831_2_549", "context": "In a patient with severe renovascular hypertension, nonoliguric acute renal failure developed after she received captopril treatment.", "question": "Subject.Race in a patient with severe renovascular hypertension", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "6344831_2_550", "context": "In a patient with severe renovascular hypertension, nonoliguric acute renal failure developed after she received captopril treatment.", "question": "Subject.Disorder in a patient with severe renovascular hypertension", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "6344831_2_551", "context": "In a patient with severe renovascular hypertension, nonoliguric acute renal failure developed after she received captopril treatment.", "question": "Treatment.Drug in captopril", "question_type": "Adverse_event.Treatment.Drug", "answers": "captopril"}, {"id": "6344831_2_552", "context": "In a patient with severe renovascular hypertension, nonoliguric acute renal failure developed after she received captopril treatment.", "question": "Treatment.Dosage in captopril", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6344831_2_553", "context": "In a patient with severe renovascular hypertension, nonoliguric acute renal failure developed after she received captopril treatment.", "question": "Treatment.Freq in captopril", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6344831_2_554", "context": "In a patient with severe renovascular hypertension, nonoliguric acute renal failure developed after she received captopril treatment.", "question": "Treatment.Route in captopril", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6344831_2_555", "context": "In a patient with severe renovascular hypertension, nonoliguric acute renal failure developed after she received captopril treatment.", "question": "Treatment.Time_elapsed in captopril", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6344831_2_556", "context": "In a patient with severe renovascular hypertension, nonoliguric acute renal failure developed after she received captopril treatment.", "question": "Treatment.Duration in captopril", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6344831_2_557", "context": "In a patient with severe renovascular hypertension, nonoliguric acute renal failure developed after she received captopril treatment.", "question": "Treatment.Disorder in captopril", "question_type": "Adverse_event.Treatment.Disorder", "answers": "renovascular hypertension"}, {"id": "6344831_2_558", "context": "In a patient with severe renovascular hypertension, nonoliguric acute renal failure developed after she received captopril treatment.", "question": "Combination.Drug in captopril", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "1834424_1_559", "context": "A 30-year-old pharmacist suffered from acute allergic contact dermatitis due to 4-chloro-7-nitrobenzofurazan (NBD-Cl).", "question": "Subject.Age in A 30-year-old pharmacist", "question_type": "Adverse_event.Subject.Age", "answers": "30-year-old"}, {"id": "1834424_1_560", "context": "A 30-year-old pharmacist suffered from acute allergic contact dermatitis due to 4-chloro-7-nitrobenzofurazan (NBD-Cl).", "question": "Subject.Gender in A 30-year-old pharmacist", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "1834424_1_561", "context": "A 30-year-old pharmacist suffered from acute allergic contact dermatitis due to 4-chloro-7-nitrobenzofurazan (NBD-Cl).", "question": "Subject.Population in A 30-year-old pharmacist", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "1834424_1_562", "context": "A 30-year-old pharmacist suffered from acute allergic contact dermatitis due to 4-chloro-7-nitrobenzofurazan (NBD-Cl).", "question": "Subject.Race in A 30-year-old pharmacist", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "1834424_1_563", "context": "A 30-year-old pharmacist suffered from acute allergic contact dermatitis due to 4-chloro-7-nitrobenzofurazan (NBD-Cl).", "question": "Subject.Disorder in A 30-year-old pharmacist", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "1834424_1_564", "context": "A 30-year-old pharmacist suffered from acute allergic contact dermatitis due to 4-chloro-7-nitrobenzofurazan (NBD-Cl).", "question": "Treatment.Drug in 4-chloro-7-nitrobenzofurazan (NBD-Cl)", "question_type": "Adverse_event.Treatment.Drug", "answers": "4-chloro-7-nitrobenzofurazan"}, {"id": "1834424_1_565", "context": "A 30-year-old pharmacist suffered from acute allergic contact dermatitis due to 4-chloro-7-nitrobenzofurazan (NBD-Cl).", "question": "Treatment.Dosage in 4-chloro-7-nitrobenzofurazan (NBD-Cl)", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "1834424_1_566", "context": "A 30-year-old pharmacist suffered from acute allergic contact dermatitis due to 4-chloro-7-nitrobenzofurazan (NBD-Cl).", "question": "Treatment.Freq in 4-chloro-7-nitrobenzofurazan (NBD-Cl)", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "1834424_1_567", "context": "A 30-year-old pharmacist suffered from acute allergic contact dermatitis due to 4-chloro-7-nitrobenzofurazan (NBD-Cl).", "question": "Treatment.Route in 4-chloro-7-nitrobenzofurazan (NBD-Cl)", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "1834424_1_568", "context": "A 30-year-old pharmacist suffered from acute allergic contact dermatitis due to 4-chloro-7-nitrobenzofurazan (NBD-Cl).", "question": "Treatment.Time_elapsed in 4-chloro-7-nitrobenzofurazan (NBD-Cl)", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "1834424_1_569", "context": "A 30-year-old pharmacist suffered from acute allergic contact dermatitis due to 4-chloro-7-nitrobenzofurazan (NBD-Cl).", "question": "Treatment.Duration in 4-chloro-7-nitrobenzofurazan (NBD-Cl)", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "1834424_1_570", "context": "A 30-year-old pharmacist suffered from acute allergic contact dermatitis due to 4-chloro-7-nitrobenzofurazan (NBD-Cl).", "question": "Treatment.Disorder in 4-chloro-7-nitrobenzofurazan (NBD-Cl)", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "1834424_1_571", "context": "A 30-year-old pharmacist suffered from acute allergic contact dermatitis due to 4-chloro-7-nitrobenzofurazan (NBD-Cl).", "question": "Combination.Drug in 4-chloro-7-nitrobenzofurazan (NBD-Cl)", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15760792_1_572", "context": "CONCLUSION: This rare case of PTU-induced ANCA-associated vasculitis manifested with ototoxicity in combination with systemic involvement.", "question": "Treatment.Drug in PTU", "question_type": "Adverse_event.Treatment.Drug", "answers": "PTU"}, {"id": "15760792_1_573", "context": "CONCLUSION: This rare case of PTU-induced ANCA-associated vasculitis manifested with ototoxicity in combination with systemic involvement.", "question": "Treatment.Dosage in PTU", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15760792_1_574", "context": "CONCLUSION: This rare case of PTU-induced ANCA-associated vasculitis manifested with ototoxicity in combination with systemic involvement.", "question": "Treatment.Freq in PTU", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15760792_1_575", "context": "CONCLUSION: This rare case of PTU-induced ANCA-associated vasculitis manifested with ototoxicity in combination with systemic involvement.", "question": "Treatment.Route in PTU", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15760792_1_576", "context": "CONCLUSION: This rare case of PTU-induced ANCA-associated vasculitis manifested with ototoxicity in combination with systemic involvement.", "question": "Treatment.Time_elapsed in PTU", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15760792_1_577", "context": "CONCLUSION: This rare case of PTU-induced ANCA-associated vasculitis manifested with ototoxicity in combination with systemic involvement.", "question": "Treatment.Duration in PTU", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15760792_1_578", "context": "CONCLUSION: This rare case of PTU-induced ANCA-associated vasculitis manifested with ototoxicity in combination with systemic involvement.", "question": "Treatment.Disorder in PTU", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15760792_1_579", "context": "CONCLUSION: This rare case of PTU-induced ANCA-associated vasculitis manifested with ototoxicity in combination with systemic involvement.", "question": "Combination.Drug in PTU", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7887138_1_580", "context": "A 15-year follow-up of phenytoin-induced unilateral gingival hyperplasia: a case report.", "question": "Treatment.Drug in phenytoin", "question_type": "Adverse_event.Treatment.Drug", "answers": "phenytoin"}, {"id": "7887138_1_581", "context": "A 15-year follow-up of phenytoin-induced unilateral gingival hyperplasia: a case report.", "question": "Treatment.Dosage in phenytoin", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7887138_1_582", "context": "A 15-year follow-up of phenytoin-induced unilateral gingival hyperplasia: a case report.", "question": "Treatment.Freq in phenytoin", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7887138_1_583", "context": "A 15-year follow-up of phenytoin-induced unilateral gingival hyperplasia: a case report.", "question": "Treatment.Route in phenytoin", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7887138_1_584", "context": "A 15-year follow-up of phenytoin-induced unilateral gingival hyperplasia: a case report.", "question": "Treatment.Time_elapsed in phenytoin", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "15-year"}, {"id": "7887138_1_585", "context": "A 15-year follow-up of phenytoin-induced unilateral gingival hyperplasia: a case report.", "question": "Treatment.Duration in phenytoin", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7887138_1_586", "context": "A 15-year follow-up of phenytoin-induced unilateral gingival hyperplasia: a case report.", "question": "Treatment.Disorder in phenytoin", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7887138_1_587", "context": "A 15-year follow-up of phenytoin-induced unilateral gingival hyperplasia: a case report.", "question": "Combination.Drug in phenytoin", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8627446_2_588", "context": "We describe two patients with rheumatoid factor-positive, polyarticular-onset juvenile rheumatoid arthritis in whom accelerated nodulosis developed during methotrexate therapy.", "question": "Subject.Age in two patients with rheumatoid factor-positive, polyarticular-onset juvenile rheumatoid arthritis", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "8627446_2_589", "context": "We describe two patients with rheumatoid factor-positive, polyarticular-onset juvenile rheumatoid arthritis in whom accelerated nodulosis developed during methotrexate therapy.", "question": "Subject.Gender in two patients with rheumatoid factor-positive, polyarticular-onset juvenile rheumatoid arthritis", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "8627446_2_590", "context": "We describe two patients with rheumatoid factor-positive, polyarticular-onset juvenile rheumatoid arthritis in whom accelerated nodulosis developed during methotrexate therapy.", "question": "Subject.Population in two patients with rheumatoid factor-positive, polyarticular-onset juvenile rheumatoid arthritis", "question_type": "Adverse_event.Subject.Population", "answers": "two"}, {"id": "8627446_2_591", "context": "We describe two patients with rheumatoid factor-positive, polyarticular-onset juvenile rheumatoid arthritis in whom accelerated nodulosis developed during methotrexate therapy.", "question": "Subject.Race in two patients with rheumatoid factor-positive, polyarticular-onset juvenile rheumatoid arthritis", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "8627446_2_592", "context": "We describe two patients with rheumatoid factor-positive, polyarticular-onset juvenile rheumatoid arthritis in whom accelerated nodulosis developed during methotrexate therapy.", "question": "Subject.Disorder in two patients with rheumatoid factor-positive, polyarticular-onset juvenile rheumatoid arthritis", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "8627446_2_593", "context": "We describe two patients with rheumatoid factor-positive, polyarticular-onset juvenile rheumatoid arthritis in whom accelerated nodulosis developed during methotrexate therapy.", "question": "Treatment.Drug in methotrexate therapy", "question_type": "Adverse_event.Treatment.Drug", "answers": "methotrexate"}, {"id": "8627446_2_594", "context": "We describe two patients with rheumatoid factor-positive, polyarticular-onset juvenile rheumatoid arthritis in whom accelerated nodulosis developed during methotrexate therapy.", "question": "Treatment.Dosage in methotrexate therapy", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8627446_2_595", "context": "We describe two patients with rheumatoid factor-positive, polyarticular-onset juvenile rheumatoid arthritis in whom accelerated nodulosis developed during methotrexate therapy.", "question": "Treatment.Freq in methotrexate therapy", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8627446_2_596", "context": "We describe two patients with rheumatoid factor-positive, polyarticular-onset juvenile rheumatoid arthritis in whom accelerated nodulosis developed during methotrexate therapy.", "question": "Treatment.Route in methotrexate therapy", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8627446_2_597", "context": "We describe two patients with rheumatoid factor-positive, polyarticular-onset juvenile rheumatoid arthritis in whom accelerated nodulosis developed during methotrexate therapy.", "question": "Treatment.Time_elapsed in methotrexate therapy", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8627446_2_598", "context": "We describe two patients with rheumatoid factor-positive, polyarticular-onset juvenile rheumatoid arthritis in whom accelerated nodulosis developed during methotrexate therapy.", "question": "Treatment.Duration in methotrexate therapy", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8627446_2_599", "context": "We describe two patients with rheumatoid factor-positive, polyarticular-onset juvenile rheumatoid arthritis in whom accelerated nodulosis developed during methotrexate therapy.", "question": "Treatment.Disorder in methotrexate therapy", "question_type": "Adverse_event.Treatment.Disorder", "answers": "rheumatoid factor-positive, polyarticular-onset juvenile rheumatoid arthritis"}, {"id": "8627446_2_600", "context": "We describe two patients with rheumatoid factor-positive, polyarticular-onset juvenile rheumatoid arthritis in whom accelerated nodulosis developed during methotrexate therapy.", "question": "Combination.Drug in methotrexate therapy", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10465148_6_601", "context": "The clinical data suggest that anterior lumbosacral radiculopathy is also a type of neurologic complication associated with intrathecal methotrexate treatment.", "question": "Treatment.Drug in intrathecal methotrexate", "question_type": "Adverse_event.Treatment.Drug", "answers": "methotrexate"}, {"id": "10465148_6_602", "context": "The clinical data suggest that anterior lumbosacral radiculopathy is also a type of neurologic complication associated with intrathecal methotrexate treatment.", "question": "Treatment.Dosage in intrathecal methotrexate", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10465148_6_603", "context": "The clinical data suggest that anterior lumbosacral radiculopathy is also a type of neurologic complication associated with intrathecal methotrexate treatment.", "question": "Treatment.Freq in intrathecal methotrexate", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10465148_6_604", "context": "The clinical data suggest that anterior lumbosacral radiculopathy is also a type of neurologic complication associated with intrathecal methotrexate treatment.", "question": "Treatment.Route in intrathecal methotrexate", "question_type": "Adverse_event.Treatment.Route", "answers": "intrathecal"}, {"id": "10465148_6_605", "context": "The clinical data suggest that anterior lumbosacral radiculopathy is also a type of neurologic complication associated with intrathecal methotrexate treatment.", "question": "Treatment.Time_elapsed in intrathecal methotrexate", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10465148_6_606", "context": "The clinical data suggest that anterior lumbosacral radiculopathy is also a type of neurologic complication associated with intrathecal methotrexate treatment.", "question": "Treatment.Duration in intrathecal methotrexate", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10465148_6_607", "context": "The clinical data suggest that anterior lumbosacral radiculopathy is also a type of neurologic complication associated with intrathecal methotrexate treatment.", "question": "Treatment.Disorder in intrathecal methotrexate", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10465148_6_608", "context": "The clinical data suggest that anterior lumbosacral radiculopathy is also a type of neurologic complication associated with intrathecal methotrexate treatment.", "question": "Combination.Drug in intrathecal methotrexate", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "24927617_5_609", "context": "At admission simvastatin and all antiviral drugs were discontinued because toxicity due to a drug-drug interaction was suspected.", "question": "Treatment.Drug in simvastatin and all antiviral drugs", "question_type": "Adverse_event.Treatment.Drug", "answers": "simvastatin"}, {"id": "24927617_5_610", "context": "At admission simvastatin and all antiviral drugs were discontinued because toxicity due to a drug-drug interaction was suspected.", "question": "Treatment.Dosage in simvastatin and all antiviral drugs", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "24927617_5_611", "context": "At admission simvastatin and all antiviral drugs were discontinued because toxicity due to a drug-drug interaction was suspected.", "question": "Treatment.Freq in simvastatin and all antiviral drugs", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "24927617_5_612", "context": "At admission simvastatin and all antiviral drugs were discontinued because toxicity due to a drug-drug interaction was suspected.", "question": "Treatment.Route in simvastatin and all antiviral drugs", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "24927617_5_613", "context": "At admission simvastatin and all antiviral drugs were discontinued because toxicity due to a drug-drug interaction was suspected.", "question": "Treatment.Time_elapsed in simvastatin and all antiviral drugs", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "24927617_5_614", "context": "At admission simvastatin and all antiviral drugs were discontinued because toxicity due to a drug-drug interaction was suspected.", "question": "Treatment.Duration in simvastatin and all antiviral drugs", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "24927617_5_615", "context": "At admission simvastatin and all antiviral drugs were discontinued because toxicity due to a drug-drug interaction was suspected.", "question": "Treatment.Disorder in simvastatin and all antiviral drugs", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "24927617_5_616", "context": "At admission simvastatin and all antiviral drugs were discontinued because toxicity due to a drug-drug interaction was suspected.", "question": "Combination.Drug in simvastatin and all antiviral drugs", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6614033_1_617", "context": "A major limitation in the use of amphotericin B is its potential to cause nephrotoxicity.", "question": "Treatment.Drug in amphotericin B", "question_type": "Adverse_event.Treatment.Drug", "answers": "amphotericin B"}, {"id": "6614033_1_618", "context": "A major limitation in the use of amphotericin B is its potential to cause nephrotoxicity.", "question": "Treatment.Dosage in amphotericin B", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6614033_1_619", "context": "A major limitation in the use of amphotericin B is its potential to cause nephrotoxicity.", "question": "Treatment.Freq in amphotericin B", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6614033_1_620", "context": "A major limitation in the use of amphotericin B is its potential to cause nephrotoxicity.", "question": "Treatment.Route in amphotericin B", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6614033_1_621", "context": "A major limitation in the use of amphotericin B is its potential to cause nephrotoxicity.", "question": "Treatment.Time_elapsed in amphotericin B", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6614033_1_622", "context": "A major limitation in the use of amphotericin B is its potential to cause nephrotoxicity.", "question": "Treatment.Duration in amphotericin B", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6614033_1_623", "context": "A major limitation in the use of amphotericin B is its potential to cause nephrotoxicity.", "question": "Treatment.Disorder in amphotericin B", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6614033_1_624", "context": "A major limitation in the use of amphotericin B is its potential to cause nephrotoxicity.", "question": "Combination.Drug in amphotericin B", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "2461837_2_625", "context": "We report a case of hyperpigmentation due to bleomycin treatment in a patient with acquired immune deficiency syndrome (AIDS).", "question": "Subject.Age in a patient with acquired immune deficiency syndrome (AIDS)", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "2461837_2_626", "context": "We report a case of hyperpigmentation due to bleomycin treatment in a patient with acquired immune deficiency syndrome (AIDS).", "question": "Subject.Gender in a patient with acquired immune deficiency syndrome (AIDS)", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "2461837_2_627", "context": "We report a case of hyperpigmentation due to bleomycin treatment in a patient with acquired immune deficiency syndrome (AIDS).", "question": "Subject.Population in a patient with acquired immune deficiency syndrome (AIDS)", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "2461837_2_628", "context": "We report a case of hyperpigmentation due to bleomycin treatment in a patient with acquired immune deficiency syndrome (AIDS).", "question": "Subject.Race in a patient with acquired immune deficiency syndrome (AIDS)", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "2461837_2_629", "context": "We report a case of hyperpigmentation due to bleomycin treatment in a patient with acquired immune deficiency syndrome (AIDS).", "question": "Subject.Disorder in a patient with acquired immune deficiency syndrome (AIDS)", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "2461837_2_630", "context": "We report a case of hyperpigmentation due to bleomycin treatment in a patient with acquired immune deficiency syndrome (AIDS).", "question": "Treatment.Drug in bleomycin", "question_type": "Adverse_event.Treatment.Drug", "answers": "bleomycin"}, {"id": "2461837_2_631", "context": "We report a case of hyperpigmentation due to bleomycin treatment in a patient with acquired immune deficiency syndrome (AIDS).", "question": "Treatment.Dosage in bleomycin", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "2461837_2_632", "context": "We report a case of hyperpigmentation due to bleomycin treatment in a patient with acquired immune deficiency syndrome (AIDS).", "question": "Treatment.Freq in bleomycin", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2461837_2_633", "context": "We report a case of hyperpigmentation due to bleomycin treatment in a patient with acquired immune deficiency syndrome (AIDS).", "question": "Treatment.Route in bleomycin", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "2461837_2_634", "context": "We report a case of hyperpigmentation due to bleomycin treatment in a patient with acquired immune deficiency syndrome (AIDS).", "question": "Treatment.Time_elapsed in bleomycin", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2461837_2_635", "context": "We report a case of hyperpigmentation due to bleomycin treatment in a patient with acquired immune deficiency syndrome (AIDS).", "question": "Treatment.Duration in bleomycin", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2461837_2_636", "context": "We report a case of hyperpigmentation due to bleomycin treatment in a patient with acquired immune deficiency syndrome (AIDS).", "question": "Treatment.Disorder in bleomycin", "question_type": "Adverse_event.Treatment.Disorder", "answers": "acquired immune deficiency syndrome"}, {"id": "2461837_2_637", "context": "We report a case of hyperpigmentation due to bleomycin treatment in a patient with acquired immune deficiency syndrome (AIDS).", "question": "Combination.Drug in bleomycin", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8551001_2_638", "context": "Azathioprine-induced myelosuppression due to thiopurine methyltransferase deficiency in a patient with autoimmune hepatitis.", "question": "Subject.Age in a patient with autoimmune hepatitis", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "8551001_2_639", "context": "Azathioprine-induced myelosuppression due to thiopurine methyltransferase deficiency in a patient with autoimmune hepatitis.", "question": "Subject.Gender in a patient with autoimmune hepatitis", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "8551001_2_640", "context": "Azathioprine-induced myelosuppression due to thiopurine methyltransferase deficiency in a patient with autoimmune hepatitis.", "question": "Subject.Population in a patient with autoimmune hepatitis", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "8551001_2_641", "context": "Azathioprine-induced myelosuppression due to thiopurine methyltransferase deficiency in a patient with autoimmune hepatitis.", "question": "Subject.Race in a patient with autoimmune hepatitis", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "8551001_2_642", "context": "Azathioprine-induced myelosuppression due to thiopurine methyltransferase deficiency in a patient with autoimmune hepatitis.", "question": "Subject.Disorder in a patient with autoimmune hepatitis", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "8551001_2_643", "context": "Azathioprine-induced myelosuppression due to thiopurine methyltransferase deficiency in a patient with autoimmune hepatitis.", "question": "Treatment.Drug in Azathioprine", "question_type": "Adverse_event.Treatment.Drug", "answers": "Azathioprine"}, {"id": "8551001_2_644", "context": "Azathioprine-induced myelosuppression due to thiopurine methyltransferase deficiency in a patient with autoimmune hepatitis.", "question": "Treatment.Dosage in Azathioprine", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8551001_2_645", "context": "Azathioprine-induced myelosuppression due to thiopurine methyltransferase deficiency in a patient with autoimmune hepatitis.", "question": "Treatment.Freq in Azathioprine", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8551001_2_646", "context": "Azathioprine-induced myelosuppression due to thiopurine methyltransferase deficiency in a patient with autoimmune hepatitis.", "question": "Treatment.Route in Azathioprine", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8551001_2_647", "context": "Azathioprine-induced myelosuppression due to thiopurine methyltransferase deficiency in a patient with autoimmune hepatitis.", "question": "Treatment.Time_elapsed in Azathioprine", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8551001_2_648", "context": "Azathioprine-induced myelosuppression due to thiopurine methyltransferase deficiency in a patient with autoimmune hepatitis.", "question": "Treatment.Duration in Azathioprine", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8551001_2_649", "context": "Azathioprine-induced myelosuppression due to thiopurine methyltransferase deficiency in a patient with autoimmune hepatitis.", "question": "Treatment.Disorder in Azathioprine", "question_type": "Adverse_event.Treatment.Disorder", "answers": "thiopurine methyltransferase deficiency; autoimmune hepatitis"}, {"id": "8551001_2_650", "context": "Azathioprine-induced myelosuppression due to thiopurine methyltransferase deficiency in a patient with autoimmune hepatitis.", "question": "Combination.Drug in Azathioprine", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8645078_2_651", "context": "Captopril-associated \"pseudocholangitis'.", "question": "Treatment.Drug in Captopril", "question_type": "Adverse_event.Treatment.Drug", "answers": "Captopril"}, {"id": "8645078_2_652", "context": "Captopril-associated \"pseudocholangitis'.", "question": "Treatment.Dosage in Captopril", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8645078_2_653", "context": "Captopril-associated \"pseudocholangitis'.", "question": "Treatment.Freq in Captopril", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8645078_2_654", "context": "Captopril-associated \"pseudocholangitis'.", "question": "Treatment.Route in Captopril", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8645078_2_655", "context": "Captopril-associated \"pseudocholangitis'.", "question": "Treatment.Time_elapsed in Captopril", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8645078_2_656", "context": "Captopril-associated \"pseudocholangitis'.", "question": "Treatment.Duration in Captopril", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8645078_2_657", "context": "Captopril-associated \"pseudocholangitis'.", "question": "Treatment.Disorder in Captopril", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8645078_2_658", "context": "Captopril-associated \"pseudocholangitis'.", "question": "Combination.Drug in Captopril", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6628806_1_659", "context": "A case of toxic hepatitis caused by combination therapy with methotrexate and etretinate in the treatment of severe psoriasis is presented in a 47-year-old woman.", "question": "Subject.Age in psoriasis; a 47-year-old woman", "question_type": "Adverse_event.Subject.Age", "answers": "47-year-old"}, {"id": "6628806_1_660", "context": "A case of toxic hepatitis caused by combination therapy with methotrexate and etretinate in the treatment of severe psoriasis is presented in a 47-year-old woman.", "question": "Subject.Gender in psoriasis; a 47-year-old woman", "question_type": "Adverse_event.Subject.Gender", "answers": "woman"}, {"id": "6628806_1_661", "context": "A case of toxic hepatitis caused by combination therapy with methotrexate and etretinate in the treatment of severe psoriasis is presented in a 47-year-old woman.", "question": "Subject.Population in psoriasis; a 47-year-old woman", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "6628806_1_662", "context": "A case of toxic hepatitis caused by combination therapy with methotrexate and etretinate in the treatment of severe psoriasis is presented in a 47-year-old woman.", "question": "Subject.Race in psoriasis; a 47-year-old woman", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "6628806_1_663", "context": "A case of toxic hepatitis caused by combination therapy with methotrexate and etretinate in the treatment of severe psoriasis is presented in a 47-year-old woman.", "question": "Subject.Disorder in psoriasis; a 47-year-old woman", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "6628806_1_664", "context": "A case of toxic hepatitis caused by combination therapy with methotrexate and etretinate in the treatment of severe psoriasis is presented in a 47-year-old woman.", "question": "Treatment.Drug in combination therapy with methotrexate and etretinate", "question_type": "Adverse_event.Treatment.Drug", "answers": "etretinate; methotrexate"}, {"id": "6628806_1_665", "context": "A case of toxic hepatitis caused by combination therapy with methotrexate and etretinate in the treatment of severe psoriasis is presented in a 47-year-old woman.", "question": "Treatment.Dosage in combination therapy with methotrexate and etretinate", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6628806_1_666", "context": "A case of toxic hepatitis caused by combination therapy with methotrexate and etretinate in the treatment of severe psoriasis is presented in a 47-year-old woman.", "question": "Treatment.Freq in combination therapy with methotrexate and etretinate", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6628806_1_667", "context": "A case of toxic hepatitis caused by combination therapy with methotrexate and etretinate in the treatment of severe psoriasis is presented in a 47-year-old woman.", "question": "Treatment.Route in combination therapy with methotrexate and etretinate", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6628806_1_668", "context": "A case of toxic hepatitis caused by combination therapy with methotrexate and etretinate in the treatment of severe psoriasis is presented in a 47-year-old woman.", "question": "Treatment.Time_elapsed in combination therapy with methotrexate and etretinate", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6628806_1_669", "context": "A case of toxic hepatitis caused by combination therapy with methotrexate and etretinate in the treatment of severe psoriasis is presented in a 47-year-old woman.", "question": "Treatment.Duration in combination therapy with methotrexate and etretinate", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6628806_1_670", "context": "A case of toxic hepatitis caused by combination therapy with methotrexate and etretinate in the treatment of severe psoriasis is presented in a 47-year-old woman.", "question": "Treatment.Disorder in combination therapy with methotrexate and etretinate", "question_type": "Adverse_event.Treatment.Disorder", "answers": "severe psoriasis"}, {"id": "6628806_1_671", "context": "A case of toxic hepatitis caused by combination therapy with methotrexate and etretinate in the treatment of severe psoriasis is presented in a 47-year-old woman.", "question": "Combination.Drug in combination therapy with methotrexate and etretinate", "question_type": "Adverse_event.Combination.Drug", "answers": "methotrexate; etretinate"}, {"id": "1988604_2_672", "context": "Thrombin is highly effective for stopping intractable arterial hemorrhage during stereotactic brain biopsy; however, it is a vasospastic agent and may have been responsible for the cerebral infarctions in one patient.", "question": "Treatment.Drug in Thrombin", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "Thrombin"}, {"id": "1988604_2_673", "context": "Thrombin is highly effective for stopping intractable arterial hemorrhage during stereotactic brain biopsy; however, it is a vasospastic agent and may have been responsible for the cerebral infarctions in one patient.", "question": "Treatment.Dosage in Thrombin", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "1988604_2_674", "context": "Thrombin is highly effective for stopping intractable arterial hemorrhage during stereotactic brain biopsy; however, it is a vasospastic agent and may have been responsible for the cerebral infarctions in one patient.", "question": "Treatment.Freq in Thrombin", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "1988604_2_675", "context": "Thrombin is highly effective for stopping intractable arterial hemorrhage during stereotactic brain biopsy; however, it is a vasospastic agent and may have been responsible for the cerebral infarctions in one patient.", "question": "Treatment.Route in Thrombin", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "1988604_2_676", "context": "Thrombin is highly effective for stopping intractable arterial hemorrhage during stereotactic brain biopsy; however, it is a vasospastic agent and may have been responsible for the cerebral infarctions in one patient.", "question": "Treatment.Time_elapsed in Thrombin", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "1988604_2_677", "context": "Thrombin is highly effective for stopping intractable arterial hemorrhage during stereotactic brain biopsy; however, it is a vasospastic agent and may have been responsible for the cerebral infarctions in one patient.", "question": "Treatment.Duration in Thrombin", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "1988604_2_678", "context": "Thrombin is highly effective for stopping intractable arterial hemorrhage during stereotactic brain biopsy; however, it is a vasospastic agent and may have been responsible for the cerebral infarctions in one patient.", "question": "Treatment.Disorder in Thrombin", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "intractable arterial hemorrhage"}, {"id": "1988604_2_679", "context": "Thrombin is highly effective for stopping intractable arterial hemorrhage during stereotactic brain biopsy; however, it is a vasospastic agent and may have been responsible for the cerebral infarctions in one patient.", "question": "Combination.Drug in Thrombin", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "1988604_2_680", "context": "Thrombin is highly effective for stopping intractable arterial hemorrhage during stereotactic brain biopsy; however, it is a vasospastic agent and may have been responsible for the cerebral infarctions in one patient.", "question": "Subject.Age in one patient", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "1988604_2_681", "context": "Thrombin is highly effective for stopping intractable arterial hemorrhage during stereotactic brain biopsy; however, it is a vasospastic agent and may have been responsible for the cerebral infarctions in one patient.", "question": "Subject.Gender in one patient", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "1988604_2_682", "context": "Thrombin is highly effective for stopping intractable arterial hemorrhage during stereotactic brain biopsy; however, it is a vasospastic agent and may have been responsible for the cerebral infarctions in one patient.", "question": "Subject.Population in one patient", "question_type": "Adverse_event.Subject.Population", "answers": "one"}, {"id": "1988604_2_683", "context": "Thrombin is highly effective for stopping intractable arterial hemorrhage during stereotactic brain biopsy; however, it is a vasospastic agent and may have been responsible for the cerebral infarctions in one patient.", "question": "Subject.Race in one patient", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "1988604_2_684", "context": "Thrombin is highly effective for stopping intractable arterial hemorrhage during stereotactic brain biopsy; however, it is a vasospastic agent and may have been responsible for the cerebral infarctions in one patient.", "question": "Subject.Disorder in one patient", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "1988604_2_685", "context": "Thrombin is highly effective for stopping intractable arterial hemorrhage during stereotactic brain biopsy; however, it is a vasospastic agent and may have been responsible for the cerebral infarctions in one patient.", "question": "Treatment.Drug in Thrombin", "question_type": "Adverse_event.Treatment.Drug", "answers": "Thrombin"}, {"id": "1988604_2_686", "context": "Thrombin is highly effective for stopping intractable arterial hemorrhage during stereotactic brain biopsy; however, it is a vasospastic agent and may have been responsible for the cerebral infarctions in one patient.", "question": "Treatment.Dosage in Thrombin", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "1988604_2_687", "context": "Thrombin is highly effective for stopping intractable arterial hemorrhage during stereotactic brain biopsy; however, it is a vasospastic agent and may have been responsible for the cerebral infarctions in one patient.", "question": "Treatment.Freq in Thrombin", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "1988604_2_688", "context": "Thrombin is highly effective for stopping intractable arterial hemorrhage during stereotactic brain biopsy; however, it is a vasospastic agent and may have been responsible for the cerebral infarctions in one patient.", "question": "Treatment.Route in Thrombin", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "1988604_2_689", "context": "Thrombin is highly effective for stopping intractable arterial hemorrhage during stereotactic brain biopsy; however, it is a vasospastic agent and may have been responsible for the cerebral infarctions in one patient.", "question": "Treatment.Time_elapsed in Thrombin", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "1988604_2_690", "context": "Thrombin is highly effective for stopping intractable arterial hemorrhage during stereotactic brain biopsy; however, it is a vasospastic agent and may have been responsible for the cerebral infarctions in one patient.", "question": "Treatment.Duration in Thrombin", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "1988604_2_691", "context": "Thrombin is highly effective for stopping intractable arterial hemorrhage during stereotactic brain biopsy; however, it is a vasospastic agent and may have been responsible for the cerebral infarctions in one patient.", "question": "Treatment.Disorder in Thrombin", "question_type": "Adverse_event.Treatment.Disorder", "answers": "intractable arterial hemorrhage"}, {"id": "1988604_2_692", "context": "Thrombin is highly effective for stopping intractable arterial hemorrhage during stereotactic brain biopsy; however, it is a vasospastic agent and may have been responsible for the cerebral infarctions in one patient.", "question": "Combination.Drug in Thrombin", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12439602_2_693", "context": "Carboplatin hypersensitivity presenting as coronary vasospasm - a case report.", "question": "Treatment.Drug in Carboplatin", "question_type": "Adverse_event.Treatment.Drug", "answers": "Carboplatin"}, {"id": "12439602_2_694", "context": "Carboplatin hypersensitivity presenting as coronary vasospasm - a case report.", "question": "Treatment.Dosage in Carboplatin", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12439602_2_695", "context": "Carboplatin hypersensitivity presenting as coronary vasospasm - a case report.", "question": "Treatment.Freq in Carboplatin", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12439602_2_696", "context": "Carboplatin hypersensitivity presenting as coronary vasospasm - a case report.", "question": "Treatment.Route in Carboplatin", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12439602_2_697", "context": "Carboplatin hypersensitivity presenting as coronary vasospasm - a case report.", "question": "Treatment.Time_elapsed in Carboplatin", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12439602_2_698", "context": "Carboplatin hypersensitivity presenting as coronary vasospasm - a case report.", "question": "Treatment.Duration in Carboplatin", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12439602_2_699", "context": "Carboplatin hypersensitivity presenting as coronary vasospasm - a case report.", "question": "Treatment.Disorder in Carboplatin", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12439602_2_700", "context": "Carboplatin hypersensitivity presenting as coronary vasospasm - a case report.", "question": "Combination.Drug in Carboplatin", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "23471710_1_701", "context": "Severe hypoglycemia from Helicobacter pylori triple-drug therapy and insulin detemir drug interaction.", "question": "Treatment.Drug in Helicobacter pylori triple-drug therapy and insulin detemir drug interaction", "question_type": "Adverse_event.Treatment.Drug", "answers": "Helicobacter pylori triple-drug; insulin detemir drug"}, {"id": "23471710_1_702", "context": "Severe hypoglycemia from Helicobacter pylori triple-drug therapy and insulin detemir drug interaction.", "question": "Treatment.Dosage in Helicobacter pylori triple-drug therapy and insulin detemir drug interaction", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "23471710_1_703", "context": "Severe hypoglycemia from Helicobacter pylori triple-drug therapy and insulin detemir drug interaction.", "question": "Treatment.Freq in Helicobacter pylori triple-drug therapy and insulin detemir drug interaction", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "23471710_1_704", "context": "Severe hypoglycemia from Helicobacter pylori triple-drug therapy and insulin detemir drug interaction.", "question": "Treatment.Route in Helicobacter pylori triple-drug therapy and insulin detemir drug interaction", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "23471710_1_705", "context": "Severe hypoglycemia from Helicobacter pylori triple-drug therapy and insulin detemir drug interaction.", "question": "Treatment.Time_elapsed in Helicobacter pylori triple-drug therapy and insulin detemir drug interaction", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "23471710_1_706", "context": "Severe hypoglycemia from Helicobacter pylori triple-drug therapy and insulin detemir drug interaction.", "question": "Treatment.Duration in Helicobacter pylori triple-drug therapy and insulin detemir drug interaction", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "23471710_1_707", "context": "Severe hypoglycemia from Helicobacter pylori triple-drug therapy and insulin detemir drug interaction.", "question": "Treatment.Disorder in Helicobacter pylori triple-drug therapy and insulin detemir drug interaction", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "23471710_1_708", "context": "Severe hypoglycemia from Helicobacter pylori triple-drug therapy and insulin detemir drug interaction.", "question": "Combination.Drug in Helicobacter pylori triple-drug therapy and insulin detemir drug interaction", "question_type": "Adverse_event.Combination.Drug", "answers": "insulin detemir drug; Helicobacter pylori triple-drug"}, {"id": "18765315_3_709", "context": "The aim of this study was to describe the occurrence of acute coronary syndromes in 3 cases of rituximab infusions.", "question": "Treatment.Drug in rituximab infusions", "question_type": "Adverse_event.Treatment.Drug", "answers": "rituximab"}, {"id": "18765315_3_710", "context": "The aim of this study was to describe the occurrence of acute coronary syndromes in 3 cases of rituximab infusions.", "question": "Treatment.Dosage in rituximab infusions", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18765315_3_711", "context": "The aim of this study was to describe the occurrence of acute coronary syndromes in 3 cases of rituximab infusions.", "question": "Treatment.Freq in rituximab infusions", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18765315_3_712", "context": "The aim of this study was to describe the occurrence of acute coronary syndromes in 3 cases of rituximab infusions.", "question": "Treatment.Route in rituximab infusions", "question_type": "Adverse_event.Treatment.Route", "answers": "infusions"}, {"id": "18765315_3_713", "context": "The aim of this study was to describe the occurrence of acute coronary syndromes in 3 cases of rituximab infusions.", "question": "Treatment.Time_elapsed in rituximab infusions", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18765315_3_714", "context": "The aim of this study was to describe the occurrence of acute coronary syndromes in 3 cases of rituximab infusions.", "question": "Treatment.Duration in rituximab infusions", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18765315_3_715", "context": "The aim of this study was to describe the occurrence of acute coronary syndromes in 3 cases of rituximab infusions.", "question": "Treatment.Disorder in rituximab infusions", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18765315_3_716", "context": "The aim of this study was to describe the occurrence of acute coronary syndromes in 3 cases of rituximab infusions.", "question": "Combination.Drug in rituximab infusions", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12196060_12_717", "context": "Acute pharmacokinetic and pharmacodynamic interactions between phenytoin and isradipine were probably responsible for the lethargy, dysarthria, ataxia, and weakness our patient developed.", "question": "Treatment.Drug in Acute pharmacokinetic and pharmacodynamic interactions between phenytoin and isradipine", "question_type": "Adverse_event.Treatment.Drug", "answers": "phenytoin; isradipine"}, {"id": "12196060_12_718", "context": "Acute pharmacokinetic and pharmacodynamic interactions between phenytoin and isradipine were probably responsible for the lethargy, dysarthria, ataxia, and weakness our patient developed.", "question": "Treatment.Dosage in Acute pharmacokinetic and pharmacodynamic interactions between phenytoin and isradipine", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12196060_12_719", "context": "Acute pharmacokinetic and pharmacodynamic interactions between phenytoin and isradipine were probably responsible for the lethargy, dysarthria, ataxia, and weakness our patient developed.", "question": "Treatment.Freq in Acute pharmacokinetic and pharmacodynamic interactions between phenytoin and isradipine", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12196060_12_720", "context": "Acute pharmacokinetic and pharmacodynamic interactions between phenytoin and isradipine were probably responsible for the lethargy, dysarthria, ataxia, and weakness our patient developed.", "question": "Treatment.Route in Acute pharmacokinetic and pharmacodynamic interactions between phenytoin and isradipine", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12196060_12_721", "context": "Acute pharmacokinetic and pharmacodynamic interactions between phenytoin and isradipine were probably responsible for the lethargy, dysarthria, ataxia, and weakness our patient developed.", "question": "Treatment.Time_elapsed in Acute pharmacokinetic and pharmacodynamic interactions between phenytoin and isradipine", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12196060_12_722", "context": "Acute pharmacokinetic and pharmacodynamic interactions between phenytoin and isradipine were probably responsible for the lethargy, dysarthria, ataxia, and weakness our patient developed.", "question": "Treatment.Duration in Acute pharmacokinetic and pharmacodynamic interactions between phenytoin and isradipine", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12196060_12_723", "context": "Acute pharmacokinetic and pharmacodynamic interactions between phenytoin and isradipine were probably responsible for the lethargy, dysarthria, ataxia, and weakness our patient developed.", "question": "Treatment.Disorder in Acute pharmacokinetic and pharmacodynamic interactions between phenytoin and isradipine", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12196060_12_724", "context": "Acute pharmacokinetic and pharmacodynamic interactions between phenytoin and isradipine were probably responsible for the lethargy, dysarthria, ataxia, and weakness our patient developed.", "question": "Combination.Drug in Acute pharmacokinetic and pharmacodynamic interactions between phenytoin and isradipine", "question_type": "Adverse_event.Combination.Drug", "answers": "phenytoin; isradipine"}, {"id": "11819156_2_725", "context": "A patient suffering from a rare enzyme deficiency developed a malignant neuroleptic syndrome after having been treated with one single dose of haloperidol.", "question": "Subject.Age in A patient suffering from a rare enzyme deficiency", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "11819156_2_726", "context": "A patient suffering from a rare enzyme deficiency developed a malignant neuroleptic syndrome after having been treated with one single dose of haloperidol.", "question": "Subject.Gender in A patient suffering from a rare enzyme deficiency", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "11819156_2_727", "context": "A patient suffering from a rare enzyme deficiency developed a malignant neuroleptic syndrome after having been treated with one single dose of haloperidol.", "question": "Subject.Population in A patient suffering from a rare enzyme deficiency", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "11819156_2_728", "context": "A patient suffering from a rare enzyme deficiency developed a malignant neuroleptic syndrome after having been treated with one single dose of haloperidol.", "question": "Subject.Race in A patient suffering from a rare enzyme deficiency", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "11819156_2_729", "context": "A patient suffering from a rare enzyme deficiency developed a malignant neuroleptic syndrome after having been treated with one single dose of haloperidol.", "question": "Subject.Disorder in A patient suffering from a rare enzyme deficiency", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "11819156_2_730", "context": "A patient suffering from a rare enzyme deficiency developed a malignant neuroleptic syndrome after having been treated with one single dose of haloperidol.", "question": "Treatment.Drug in one single dose of haloperidol", "question_type": "Adverse_event.Treatment.Drug", "answers": "haloperidol"}, {"id": "11819156_2_731", "context": "A patient suffering from a rare enzyme deficiency developed a malignant neuroleptic syndrome after having been treated with one single dose of haloperidol.", "question": "Treatment.Dosage in one single dose of haloperidol", "question_type": "Adverse_event.Treatment.Dosage", "answers": "one single dose"}, {"id": "11819156_2_732", "context": "A patient suffering from a rare enzyme deficiency developed a malignant neuroleptic syndrome after having been treated with one single dose of haloperidol.", "question": "Treatment.Freq in one single dose of haloperidol", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11819156_2_733", "context": "A patient suffering from a rare enzyme deficiency developed a malignant neuroleptic syndrome after having been treated with one single dose of haloperidol.", "question": "Treatment.Route in one single dose of haloperidol", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11819156_2_734", "context": "A patient suffering from a rare enzyme deficiency developed a malignant neuroleptic syndrome after having been treated with one single dose of haloperidol.", "question": "Treatment.Time_elapsed in one single dose of haloperidol", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11819156_2_735", "context": "A patient suffering from a rare enzyme deficiency developed a malignant neuroleptic syndrome after having been treated with one single dose of haloperidol.", "question": "Treatment.Duration in one single dose of haloperidol", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11819156_2_736", "context": "A patient suffering from a rare enzyme deficiency developed a malignant neuroleptic syndrome after having been treated with one single dose of haloperidol.", "question": "Treatment.Disorder in one single dose of haloperidol", "question_type": "Adverse_event.Treatment.Disorder", "answers": "enzyme deficiency"}, {"id": "11819156_2_737", "context": "A patient suffering from a rare enzyme deficiency developed a malignant neuroleptic syndrome after having been treated with one single dose of haloperidol.", "question": "Combination.Drug in one single dose of haloperidol", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8645078_3_738", "context": "Captopril is known to be associated with dermatologic, hematologic, and pulmonary adverse effects.", "question": "Treatment.Drug in Captopril", "question_type": "Adverse_event.Treatment.Drug", "answers": "Captopril"}, {"id": "8645078_3_739", "context": "Captopril is known to be associated with dermatologic, hematologic, and pulmonary adverse effects.", "question": "Treatment.Dosage in Captopril", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8645078_3_740", "context": "Captopril is known to be associated with dermatologic, hematologic, and pulmonary adverse effects.", "question": "Treatment.Freq in Captopril", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8645078_3_741", "context": "Captopril is known to be associated with dermatologic, hematologic, and pulmonary adverse effects.", "question": "Treatment.Route in Captopril", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8645078_3_742", "context": "Captopril is known to be associated with dermatologic, hematologic, and pulmonary adverse effects.", "question": "Treatment.Time_elapsed in Captopril", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8645078_3_743", "context": "Captopril is known to be associated with dermatologic, hematologic, and pulmonary adverse effects.", "question": "Treatment.Duration in Captopril", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8645078_3_744", "context": "Captopril is known to be associated with dermatologic, hematologic, and pulmonary adverse effects.", "question": "Treatment.Disorder in Captopril", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8645078_3_745", "context": "Captopril is known to be associated with dermatologic, hematologic, and pulmonary adverse effects.", "question": "Combination.Drug in Captopril", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16446228_1_746", "context": "Here, we present a case of sirolimus-associated interstitial pneumonitis in a cardiac transplant recipient that resolved completely with withdrawal of the drug and treatment with corticosteroids.", "question": "Subject.Age in a case of sirolimus-associated interstitial pneumonitis in a cardiac transplant recipient", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "16446228_1_747", "context": "Here, we present a case of sirolimus-associated interstitial pneumonitis in a cardiac transplant recipient that resolved completely with withdrawal of the drug and treatment with corticosteroids.", "question": "Subject.Gender in a case of sirolimus-associated interstitial pneumonitis in a cardiac transplant recipient", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "16446228_1_748", "context": "Here, we present a case of sirolimus-associated interstitial pneumonitis in a cardiac transplant recipient that resolved completely with withdrawal of the drug and treatment with corticosteroids.", "question": "Subject.Population in a case of sirolimus-associated interstitial pneumonitis in a cardiac transplant recipient", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "16446228_1_749", "context": "Here, we present a case of sirolimus-associated interstitial pneumonitis in a cardiac transplant recipient that resolved completely with withdrawal of the drug and treatment with corticosteroids.", "question": "Subject.Race in a case of sirolimus-associated interstitial pneumonitis in a cardiac transplant recipient", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "16446228_1_750", "context": "Here, we present a case of sirolimus-associated interstitial pneumonitis in a cardiac transplant recipient that resolved completely with withdrawal of the drug and treatment with corticosteroids.", "question": "Subject.Disorder in a case of sirolimus-associated interstitial pneumonitis in a cardiac transplant recipient", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "16446228_1_751", "context": "Here, we present a case of sirolimus-associated interstitial pneumonitis in a cardiac transplant recipient that resolved completely with withdrawal of the drug and treatment with corticosteroids.", "question": "Treatment.Drug in withdrawal of the drug and treatment with corticosteroids", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "corticosteroids"}, {"id": "16446228_1_752", "context": "Here, we present a case of sirolimus-associated interstitial pneumonitis in a cardiac transplant recipient that resolved completely with withdrawal of the drug and treatment with corticosteroids.", "question": "Treatment.Dosage in withdrawal of the drug and treatment with corticosteroids", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "16446228_1_753", "context": "Here, we present a case of sirolimus-associated interstitial pneumonitis in a cardiac transplant recipient that resolved completely with withdrawal of the drug and treatment with corticosteroids.", "question": "Treatment.Freq in withdrawal of the drug and treatment with corticosteroids", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "16446228_1_754", "context": "Here, we present a case of sirolimus-associated interstitial pneumonitis in a cardiac transplant recipient that resolved completely with withdrawal of the drug and treatment with corticosteroids.", "question": "Treatment.Route in withdrawal of the drug and treatment with corticosteroids", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "16446228_1_755", "context": "Here, we present a case of sirolimus-associated interstitial pneumonitis in a cardiac transplant recipient that resolved completely with withdrawal of the drug and treatment with corticosteroids.", "question": "Treatment.Time_elapsed in withdrawal of the drug and treatment with corticosteroids", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16446228_1_756", "context": "Here, we present a case of sirolimus-associated interstitial pneumonitis in a cardiac transplant recipient that resolved completely with withdrawal of the drug and treatment with corticosteroids.", "question": "Treatment.Duration in withdrawal of the drug and treatment with corticosteroids", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "16446228_1_757", "context": "Here, we present a case of sirolimus-associated interstitial pneumonitis in a cardiac transplant recipient that resolved completely with withdrawal of the drug and treatment with corticosteroids.", "question": "Treatment.Disorder in withdrawal of the drug and treatment with corticosteroids", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "16446228_1_758", "context": "Here, we present a case of sirolimus-associated interstitial pneumonitis in a cardiac transplant recipient that resolved completely with withdrawal of the drug and treatment with corticosteroids.", "question": "Combination.Drug in withdrawal of the drug and treatment with corticosteroids", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "16446228_1_759", "context": "Here, we present a case of sirolimus-associated interstitial pneumonitis in a cardiac transplant recipient that resolved completely with withdrawal of the drug and treatment with corticosteroids.", "question": "Treatment.Drug in sirolimus", "question_type": "Adverse_event.Treatment.Drug", "answers": "sirolimus"}, {"id": "16446228_1_760", "context": "Here, we present a case of sirolimus-associated interstitial pneumonitis in a cardiac transplant recipient that resolved completely with withdrawal of the drug and treatment with corticosteroids.", "question": "Treatment.Dosage in sirolimus", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16446228_1_761", "context": "Here, we present a case of sirolimus-associated interstitial pneumonitis in a cardiac transplant recipient that resolved completely with withdrawal of the drug and treatment with corticosteroids.", "question": "Treatment.Freq in sirolimus", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16446228_1_762", "context": "Here, we present a case of sirolimus-associated interstitial pneumonitis in a cardiac transplant recipient that resolved completely with withdrawal of the drug and treatment with corticosteroids.", "question": "Treatment.Route in sirolimus", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16446228_1_763", "context": "Here, we present a case of sirolimus-associated interstitial pneumonitis in a cardiac transplant recipient that resolved completely with withdrawal of the drug and treatment with corticosteroids.", "question": "Treatment.Time_elapsed in sirolimus", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16446228_1_764", "context": "Here, we present a case of sirolimus-associated interstitial pneumonitis in a cardiac transplant recipient that resolved completely with withdrawal of the drug and treatment with corticosteroids.", "question": "Treatment.Duration in sirolimus", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16446228_1_765", "context": "Here, we present a case of sirolimus-associated interstitial pneumonitis in a cardiac transplant recipient that resolved completely with withdrawal of the drug and treatment with corticosteroids.", "question": "Treatment.Disorder in sirolimus", "question_type": "Adverse_event.Treatment.Disorder", "answers": "sirolimus-associated interstitial pneumonitis"}, {"id": "16446228_1_766", "context": "Here, we present a case of sirolimus-associated interstitial pneumonitis in a cardiac transplant recipient that resolved completely with withdrawal of the drug and treatment with corticosteroids.", "question": "Combination.Drug in sirolimus", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3586163_1_767", "context": "Other upper tract neoplasms after cyclophosphamide are reviewed.", "question": "Treatment.Drug in cyclophosphamide", "question_type": "Adverse_event.Treatment.Drug", "answers": "cyclophosphamide"}, {"id": "3586163_1_768", "context": "Other upper tract neoplasms after cyclophosphamide are reviewed.", "question": "Treatment.Dosage in cyclophosphamide", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3586163_1_769", "context": "Other upper tract neoplasms after cyclophosphamide are reviewed.", "question": "Treatment.Freq in cyclophosphamide", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3586163_1_770", "context": "Other upper tract neoplasms after cyclophosphamide are reviewed.", "question": "Treatment.Route in cyclophosphamide", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3586163_1_771", "context": "Other upper tract neoplasms after cyclophosphamide are reviewed.", "question": "Treatment.Time_elapsed in cyclophosphamide", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3586163_1_772", "context": "Other upper tract neoplasms after cyclophosphamide are reviewed.", "question": "Treatment.Duration in cyclophosphamide", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3586163_1_773", "context": "Other upper tract neoplasms after cyclophosphamide are reviewed.", "question": "Treatment.Disorder in cyclophosphamide", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3586163_1_774", "context": "Other upper tract neoplasms after cyclophosphamide are reviewed.", "question": "Combination.Drug in cyclophosphamide", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "647693_1_775", "context": "Four patients receiving high-dose tamoxifen for greater than 1 year have demonstrated similar retinal changes.", "question": "Subject.Age in Four patients", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "647693_1_776", "context": "Four patients receiving high-dose tamoxifen for greater than 1 year have demonstrated similar retinal changes.", "question": "Subject.Gender in Four patients", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "647693_1_777", "context": "Four patients receiving high-dose tamoxifen for greater than 1 year have demonstrated similar retinal changes.", "question": "Subject.Population in Four patients", "question_type": "Adverse_event.Subject.Population", "answers": "Four"}, {"id": "647693_1_778", "context": "Four patients receiving high-dose tamoxifen for greater than 1 year have demonstrated similar retinal changes.", "question": "Subject.Race in Four patients", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "647693_1_779", "context": "Four patients receiving high-dose tamoxifen for greater than 1 year have demonstrated similar retinal changes.", "question": "Subject.Disorder in Four patients", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "647693_1_780", "context": "Four patients receiving high-dose tamoxifen for greater than 1 year have demonstrated similar retinal changes.", "question": "Treatment.Drug in high-dose tamoxifen for greater than 1 year", "question_type": "Adverse_event.Treatment.Drug", "answers": "tamoxifen"}, {"id": "647693_1_781", "context": "Four patients receiving high-dose tamoxifen for greater than 1 year have demonstrated similar retinal changes.", "question": "Treatment.Dosage in high-dose tamoxifen for greater than 1 year", "question_type": "Adverse_event.Treatment.Dosage", "answers": "high-dose"}, {"id": "647693_1_782", "context": "Four patients receiving high-dose tamoxifen for greater than 1 year have demonstrated similar retinal changes.", "question": "Treatment.Freq in high-dose tamoxifen for greater than 1 year", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "647693_1_783", "context": "Four patients receiving high-dose tamoxifen for greater than 1 year have demonstrated similar retinal changes.", "question": "Treatment.Route in high-dose tamoxifen for greater than 1 year", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "647693_1_784", "context": "Four patients receiving high-dose tamoxifen for greater than 1 year have demonstrated similar retinal changes.", "question": "Treatment.Time_elapsed in high-dose tamoxifen for greater than 1 year", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "647693_1_785", "context": "Four patients receiving high-dose tamoxifen for greater than 1 year have demonstrated similar retinal changes.", "question": "Treatment.Duration in high-dose tamoxifen for greater than 1 year", "question_type": "Adverse_event.Treatment.Duration", "answers": "1 year"}, {"id": "647693_1_786", "context": "Four patients receiving high-dose tamoxifen for greater than 1 year have demonstrated similar retinal changes.", "question": "Treatment.Disorder in high-dose tamoxifen for greater than 1 year", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "647693_1_787", "context": "Four patients receiving high-dose tamoxifen for greater than 1 year have demonstrated similar retinal changes.", "question": "Combination.Drug in high-dose tamoxifen for greater than 1 year", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12390172_3_788", "context": "Retinal dysfunction and anterior segment deposits in a patient treated with rifabutin.", "question": "Subject.Age in patient", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "12390172_3_789", "context": "Retinal dysfunction and anterior segment deposits in a patient treated with rifabutin.", "question": "Subject.Gender in patient", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "12390172_3_790", "context": "Retinal dysfunction and anterior segment deposits in a patient treated with rifabutin.", "question": "Subject.Population in patient", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "12390172_3_791", "context": "Retinal dysfunction and anterior segment deposits in a patient treated with rifabutin.", "question": "Subject.Race in patient", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "12390172_3_792", "context": "Retinal dysfunction and anterior segment deposits in a patient treated with rifabutin.", "question": "Subject.Disorder in patient", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "12390172_3_793", "context": "Retinal dysfunction and anterior segment deposits in a patient treated with rifabutin.", "question": "Treatment.Drug in rifabutin", "question_type": "Adverse_event.Treatment.Drug", "answers": "rifabutin"}, {"id": "12390172_3_794", "context": "Retinal dysfunction and anterior segment deposits in a patient treated with rifabutin.", "question": "Treatment.Dosage in rifabutin", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12390172_3_795", "context": "Retinal dysfunction and anterior segment deposits in a patient treated with rifabutin.", "question": "Treatment.Freq in rifabutin", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12390172_3_796", "context": "Retinal dysfunction and anterior segment deposits in a patient treated with rifabutin.", "question": "Treatment.Route in rifabutin", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12390172_3_797", "context": "Retinal dysfunction and anterior segment deposits in a patient treated with rifabutin.", "question": "Treatment.Time_elapsed in rifabutin", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12390172_3_798", "context": "Retinal dysfunction and anterior segment deposits in a patient treated with rifabutin.", "question": "Treatment.Duration in rifabutin", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12390172_3_799", "context": "Retinal dysfunction and anterior segment deposits in a patient treated with rifabutin.", "question": "Treatment.Disorder in rifabutin", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12390172_3_800", "context": "Retinal dysfunction and anterior segment deposits in a patient treated with rifabutin.", "question": "Combination.Drug in rifabutin", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11590881_1_801", "context": "Carbamazepine induced right bundle branch block in a Greenlandic patient.", "question": "Subject.Age in Greenlandic patient", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "11590881_1_802", "context": "Carbamazepine induced right bundle branch block in a Greenlandic patient.", "question": "Subject.Gender in Greenlandic patient", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "11590881_1_803", "context": "Carbamazepine induced right bundle branch block in a Greenlandic patient.", "question": "Subject.Population in Greenlandic patient", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "11590881_1_804", "context": "Carbamazepine induced right bundle branch block in a Greenlandic patient.", "question": "Subject.Race in Greenlandic patient", "question_type": "Adverse_event.Subject.Race", "answers": "Greenlandic"}, {"id": "11590881_1_805", "context": "Carbamazepine induced right bundle branch block in a Greenlandic patient.", "question": "Subject.Disorder in Greenlandic patient", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "11590881_1_806", "context": "Carbamazepine induced right bundle branch block in a Greenlandic patient.", "question": "Treatment.Drug in Carbamazepine", "question_type": "Adverse_event.Treatment.Drug", "answers": "Carbamazepine"}, {"id": "11590881_1_807", "context": "Carbamazepine induced right bundle branch block in a Greenlandic patient.", "question": "Treatment.Dosage in Carbamazepine", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11590881_1_808", "context": "Carbamazepine induced right bundle branch block in a Greenlandic patient.", "question": "Treatment.Freq in Carbamazepine", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11590881_1_809", "context": "Carbamazepine induced right bundle branch block in a Greenlandic patient.", "question": "Treatment.Route in Carbamazepine", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11590881_1_810", "context": "Carbamazepine induced right bundle branch block in a Greenlandic patient.", "question": "Treatment.Time_elapsed in Carbamazepine", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11590881_1_811", "context": "Carbamazepine induced right bundle branch block in a Greenlandic patient.", "question": "Treatment.Duration in Carbamazepine", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11590881_1_812", "context": "Carbamazepine induced right bundle branch block in a Greenlandic patient.", "question": "Treatment.Disorder in Carbamazepine", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11590881_1_813", "context": "Carbamazepine induced right bundle branch block in a Greenlandic patient.", "question": "Combination.Drug in Carbamazepine", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17068466_2_814", "context": "RESULTS: Both cases presented here describe corneal ulcers that persisted and showed signs of worsening during weeks of frequent topical dosing with moxifloxacin.", "question": "Subject.Age in Both cases", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "17068466_2_815", "context": "RESULTS: Both cases presented here describe corneal ulcers that persisted and showed signs of worsening during weeks of frequent topical dosing with moxifloxacin.", "question": "Subject.Gender in Both cases", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "17068466_2_816", "context": "RESULTS: Both cases presented here describe corneal ulcers that persisted and showed signs of worsening during weeks of frequent topical dosing with moxifloxacin.", "question": "Subject.Population in Both cases", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "17068466_2_817", "context": "RESULTS: Both cases presented here describe corneal ulcers that persisted and showed signs of worsening during weeks of frequent topical dosing with moxifloxacin.", "question": "Subject.Race in Both cases", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "17068466_2_818", "context": "RESULTS: Both cases presented here describe corneal ulcers that persisted and showed signs of worsening during weeks of frequent topical dosing with moxifloxacin.", "question": "Subject.Disorder in Both cases", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "17068466_2_819", "context": "RESULTS: Both cases presented here describe corneal ulcers that persisted and showed signs of worsening during weeks of frequent topical dosing with moxifloxacin.", "question": "Treatment.Drug in weeks of frequent topical dosing with moxifloxacin", "question_type": "Adverse_event.Treatment.Drug", "answers": "moxifloxacin"}, {"id": "17068466_2_820", "context": "RESULTS: Both cases presented here describe corneal ulcers that persisted and showed signs of worsening during weeks of frequent topical dosing with moxifloxacin.", "question": "Treatment.Dosage in weeks of frequent topical dosing with moxifloxacin", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17068466_2_821", "context": "RESULTS: Both cases presented here describe corneal ulcers that persisted and showed signs of worsening during weeks of frequent topical dosing with moxifloxacin.", "question": "Treatment.Freq in weeks of frequent topical dosing with moxifloxacin", "question_type": "Adverse_event.Treatment.Freq", "answers": "frequent"}, {"id": "17068466_2_822", "context": "RESULTS: Both cases presented here describe corneal ulcers that persisted and showed signs of worsening during weeks of frequent topical dosing with moxifloxacin.", "question": "Treatment.Route in weeks of frequent topical dosing with moxifloxacin", "question_type": "Adverse_event.Treatment.Route", "answers": "topical"}, {"id": "17068466_2_823", "context": "RESULTS: Both cases presented here describe corneal ulcers that persisted and showed signs of worsening during weeks of frequent topical dosing with moxifloxacin.", "question": "Treatment.Time_elapsed in weeks of frequent topical dosing with moxifloxacin", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17068466_2_824", "context": "RESULTS: Both cases presented here describe corneal ulcers that persisted and showed signs of worsening during weeks of frequent topical dosing with moxifloxacin.", "question": "Treatment.Duration in weeks of frequent topical dosing with moxifloxacin", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17068466_2_825", "context": "RESULTS: Both cases presented here describe corneal ulcers that persisted and showed signs of worsening during weeks of frequent topical dosing with moxifloxacin.", "question": "Treatment.Disorder in weeks of frequent topical dosing with moxifloxacin", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17068466_2_826", "context": "RESULTS: Both cases presented here describe corneal ulcers that persisted and showed signs of worsening during weeks of frequent topical dosing with moxifloxacin.", "question": "Combination.Drug in weeks of frequent topical dosing with moxifloxacin", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8844232_2_827", "context": "We describe a case of poisoning with 3,4-methylenedioxymet-amphetamine Ecstasy that presented with all the features suggestive of a fatal outcome, including a creatinine phosphokinase level markedly higher than any previously reported.", "question": "Subject.Age in a case", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "8844232_2_828", "context": "We describe a case of poisoning with 3,4-methylenedioxymet-amphetamine Ecstasy that presented with all the features suggestive of a fatal outcome, including a creatinine phosphokinase level markedly higher than any previously reported.", "question": "Subject.Gender in a case", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "8844232_2_829", "context": "We describe a case of poisoning with 3,4-methylenedioxymet-amphetamine Ecstasy that presented with all the features suggestive of a fatal outcome, including a creatinine phosphokinase level markedly higher than any previously reported.", "question": "Subject.Population in a case", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "8844232_2_830", "context": "We describe a case of poisoning with 3,4-methylenedioxymet-amphetamine Ecstasy that presented with all the features suggestive of a fatal outcome, including a creatinine phosphokinase level markedly higher than any previously reported.", "question": "Subject.Race in a case", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "8844232_2_831", "context": "We describe a case of poisoning with 3,4-methylenedioxymet-amphetamine Ecstasy that presented with all the features suggestive of a fatal outcome, including a creatinine phosphokinase level markedly higher than any previously reported.", "question": "Subject.Disorder in a case", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "8844232_2_832", "context": "We describe a case of poisoning with 3,4-methylenedioxymet-amphetamine Ecstasy that presented with all the features suggestive of a fatal outcome, including a creatinine phosphokinase level markedly higher than any previously reported.", "question": "Treatment.Drug in 3,4-methylenedioxymet-amphetamine Ecstasy", "question_type": "Adverse_event.Treatment.Drug", "answers": "3,4-methylenedioxymet-amphetamine"}, {"id": "8844232_2_833", "context": "We describe a case of poisoning with 3,4-methylenedioxymet-amphetamine Ecstasy that presented with all the features suggestive of a fatal outcome, including a creatinine phosphokinase level markedly higher than any previously reported.", "question": "Treatment.Dosage in 3,4-methylenedioxymet-amphetamine Ecstasy", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8844232_2_834", "context": "We describe a case of poisoning with 3,4-methylenedioxymet-amphetamine Ecstasy that presented with all the features suggestive of a fatal outcome, including a creatinine phosphokinase level markedly higher than any previously reported.", "question": "Treatment.Freq in 3,4-methylenedioxymet-amphetamine Ecstasy", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8844232_2_835", "context": "We describe a case of poisoning with 3,4-methylenedioxymet-amphetamine Ecstasy that presented with all the features suggestive of a fatal outcome, including a creatinine phosphokinase level markedly higher than any previously reported.", "question": "Treatment.Route in 3,4-methylenedioxymet-amphetamine Ecstasy", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8844232_2_836", "context": "We describe a case of poisoning with 3,4-methylenedioxymet-amphetamine Ecstasy that presented with all the features suggestive of a fatal outcome, including a creatinine phosphokinase level markedly higher than any previously reported.", "question": "Treatment.Time_elapsed in 3,4-methylenedioxymet-amphetamine Ecstasy", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8844232_2_837", "context": "We describe a case of poisoning with 3,4-methylenedioxymet-amphetamine Ecstasy that presented with all the features suggestive of a fatal outcome, including a creatinine phosphokinase level markedly higher than any previously reported.", "question": "Treatment.Duration in 3,4-methylenedioxymet-amphetamine Ecstasy", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8844232_2_838", "context": "We describe a case of poisoning with 3,4-methylenedioxymet-amphetamine Ecstasy that presented with all the features suggestive of a fatal outcome, including a creatinine phosphokinase level markedly higher than any previously reported.", "question": "Treatment.Disorder in 3,4-methylenedioxymet-amphetamine Ecstasy", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8844232_2_839", "context": "We describe a case of poisoning with 3,4-methylenedioxymet-amphetamine Ecstasy that presented with all the features suggestive of a fatal outcome, including a creatinine phosphokinase level markedly higher than any previously reported.", "question": "Combination.Drug in 3,4-methylenedioxymet-amphetamine Ecstasy", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "14964753_7_840", "context": "Ramipril-induced cutaneous vasculitis is particularly rare and our case was atypical because the patient had tolerated lisinopril before.", "question": "Subject.Age in the patient had tolerated lisinopril before", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "14964753_7_841", "context": "Ramipril-induced cutaneous vasculitis is particularly rare and our case was atypical because the patient had tolerated lisinopril before.", "question": "Subject.Gender in the patient had tolerated lisinopril before", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "14964753_7_842", "context": "Ramipril-induced cutaneous vasculitis is particularly rare and our case was atypical because the patient had tolerated lisinopril before.", "question": "Subject.Population in the patient had tolerated lisinopril before", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "14964753_7_843", "context": "Ramipril-induced cutaneous vasculitis is particularly rare and our case was atypical because the patient had tolerated lisinopril before.", "question": "Subject.Race in the patient had tolerated lisinopril before", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "14964753_7_844", "context": "Ramipril-induced cutaneous vasculitis is particularly rare and our case was atypical because the patient had tolerated lisinopril before.", "question": "Subject.Disorder in the patient had tolerated lisinopril before", "question_type": "Adverse_event.Subject.Disorder", "answers": "tolerated lisinopril"}, {"id": "14964753_7_845", "context": "Ramipril-induced cutaneous vasculitis is particularly rare and our case was atypical because the patient had tolerated lisinopril before.", "question": "Treatment.Drug in Ramipril", "question_type": "Adverse_event.Treatment.Drug", "answers": "Ramipril"}, {"id": "14964753_7_846", "context": "Ramipril-induced cutaneous vasculitis is particularly rare and our case was atypical because the patient had tolerated lisinopril before.", "question": "Treatment.Dosage in Ramipril", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "14964753_7_847", "context": "Ramipril-induced cutaneous vasculitis is particularly rare and our case was atypical because the patient had tolerated lisinopril before.", "question": "Treatment.Freq in Ramipril", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "14964753_7_848", "context": "Ramipril-induced cutaneous vasculitis is particularly rare and our case was atypical because the patient had tolerated lisinopril before.", "question": "Treatment.Route in Ramipril", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "14964753_7_849", "context": "Ramipril-induced cutaneous vasculitis is particularly rare and our case was atypical because the patient had tolerated lisinopril before.", "question": "Treatment.Time_elapsed in Ramipril", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "14964753_7_850", "context": "Ramipril-induced cutaneous vasculitis is particularly rare and our case was atypical because the patient had tolerated lisinopril before.", "question": "Treatment.Duration in Ramipril", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "14964753_7_851", "context": "Ramipril-induced cutaneous vasculitis is particularly rare and our case was atypical because the patient had tolerated lisinopril before.", "question": "Treatment.Disorder in Ramipril", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "14964753_7_852", "context": "Ramipril-induced cutaneous vasculitis is particularly rare and our case was atypical because the patient had tolerated lisinopril before.", "question": "Combination.Drug in Ramipril", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11978156_6_853", "context": "To date, this is the first reported case of what appears to be isolated thrombocytopenia associated with lansoprazole.", "question": "Treatment.Drug in lansoprazole", "question_type": "Adverse_event.Treatment.Drug", "answers": "lansoprazole"}, {"id": "11978156_6_854", "context": "To date, this is the first reported case of what appears to be isolated thrombocytopenia associated with lansoprazole.", "question": "Treatment.Dosage in lansoprazole", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11978156_6_855", "context": "To date, this is the first reported case of what appears to be isolated thrombocytopenia associated with lansoprazole.", "question": "Treatment.Freq in lansoprazole", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11978156_6_856", "context": "To date, this is the first reported case of what appears to be isolated thrombocytopenia associated with lansoprazole.", "question": "Treatment.Route in lansoprazole", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11978156_6_857", "context": "To date, this is the first reported case of what appears to be isolated thrombocytopenia associated with lansoprazole.", "question": "Treatment.Time_elapsed in lansoprazole", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11978156_6_858", "context": "To date, this is the first reported case of what appears to be isolated thrombocytopenia associated with lansoprazole.", "question": "Treatment.Duration in lansoprazole", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11978156_6_859", "context": "To date, this is the first reported case of what appears to be isolated thrombocytopenia associated with lansoprazole.", "question": "Treatment.Disorder in lansoprazole", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11978156_6_860", "context": "To date, this is the first reported case of what appears to be isolated thrombocytopenia associated with lansoprazole.", "question": "Combination.Drug in lansoprazole", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "1628669_1_861", "context": "A 7-year-old girl developed diabetes mellitus and exocrine pancreatic insufficiency after 3.5 years of almost continuous treatment with azathioprine and/or prednisone for idiopathic auto-immune haemolytic anaemia.", "question": "Subject.Age in A 7-year-old girl", "question_type": "Adverse_event.Subject.Age", "answers": "7-year-old"}, {"id": "1628669_1_862", "context": "A 7-year-old girl developed diabetes mellitus and exocrine pancreatic insufficiency after 3.5 years of almost continuous treatment with azathioprine and/or prednisone for idiopathic auto-immune haemolytic anaemia.", "question": "Subject.Gender in A 7-year-old girl", "question_type": "Adverse_event.Subject.Gender", "answers": "girl"}, {"id": "1628669_1_863", "context": "A 7-year-old girl developed diabetes mellitus and exocrine pancreatic insufficiency after 3.5 years of almost continuous treatment with azathioprine and/or prednisone for idiopathic auto-immune haemolytic anaemia.", "question": "Subject.Population in A 7-year-old girl", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "1628669_1_864", "context": "A 7-year-old girl developed diabetes mellitus and exocrine pancreatic insufficiency after 3.5 years of almost continuous treatment with azathioprine and/or prednisone for idiopathic auto-immune haemolytic anaemia.", "question": "Subject.Race in A 7-year-old girl", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "1628669_1_865", "context": "A 7-year-old girl developed diabetes mellitus and exocrine pancreatic insufficiency after 3.5 years of almost continuous treatment with azathioprine and/or prednisone for idiopathic auto-immune haemolytic anaemia.", "question": "Subject.Disorder in A 7-year-old girl", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "1628669_1_866", "context": "A 7-year-old girl developed diabetes mellitus and exocrine pancreatic insufficiency after 3.5 years of almost continuous treatment with azathioprine and/or prednisone for idiopathic auto-immune haemolytic anaemia.", "question": "Treatment.Drug in 3.5 years of almost continuous treatment with azathioprine and/or prednisone", "question_type": "Adverse_event.Treatment.Drug", "answers": "azathioprine; prednisone; azathioprine; prednisone"}, {"id": "1628669_1_867", "context": "A 7-year-old girl developed diabetes mellitus and exocrine pancreatic insufficiency after 3.5 years of almost continuous treatment with azathioprine and/or prednisone for idiopathic auto-immune haemolytic anaemia.", "question": "Treatment.Dosage in 3.5 years of almost continuous treatment with azathioprine and/or prednisone", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "1628669_1_868", "context": "A 7-year-old girl developed diabetes mellitus and exocrine pancreatic insufficiency after 3.5 years of almost continuous treatment with azathioprine and/or prednisone for idiopathic auto-immune haemolytic anaemia.", "question": "Treatment.Freq in 3.5 years of almost continuous treatment with azathioprine and/or prednisone", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "1628669_1_869", "context": "A 7-year-old girl developed diabetes mellitus and exocrine pancreatic insufficiency after 3.5 years of almost continuous treatment with azathioprine and/or prednisone for idiopathic auto-immune haemolytic anaemia.", "question": "Treatment.Route in 3.5 years of almost continuous treatment with azathioprine and/or prednisone", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "1628669_1_870", "context": "A 7-year-old girl developed diabetes mellitus and exocrine pancreatic insufficiency after 3.5 years of almost continuous treatment with azathioprine and/or prednisone for idiopathic auto-immune haemolytic anaemia.", "question": "Treatment.Time_elapsed in 3.5 years of almost continuous treatment with azathioprine and/or prednisone", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "1628669_1_871", "context": "A 7-year-old girl developed diabetes mellitus and exocrine pancreatic insufficiency after 3.5 years of almost continuous treatment with azathioprine and/or prednisone for idiopathic auto-immune haemolytic anaemia.", "question": "Treatment.Duration in 3.5 years of almost continuous treatment with azathioprine and/or prednisone", "question_type": "Adverse_event.Treatment.Duration", "answers": "3.5 years"}, {"id": "1628669_1_872", "context": "A 7-year-old girl developed diabetes mellitus and exocrine pancreatic insufficiency after 3.5 years of almost continuous treatment with azathioprine and/or prednisone for idiopathic auto-immune haemolytic anaemia.", "question": "Treatment.Disorder in 3.5 years of almost continuous treatment with azathioprine and/or prednisone", "question_type": "Adverse_event.Treatment.Disorder", "answers": "idiopathic auto-immune haemolytic anaemia"}, {"id": "1628669_1_873", "context": "A 7-year-old girl developed diabetes mellitus and exocrine pancreatic insufficiency after 3.5 years of almost continuous treatment with azathioprine and/or prednisone for idiopathic auto-immune haemolytic anaemia.", "question": "Combination.Drug in 3.5 years of almost continuous treatment with azathioprine and/or prednisone", "question_type": "Adverse_event.Combination.Drug", "answers": "azathioprine; prednisone"}, {"id": "10485779_2_874", "context": "The human immunodeficiency virus protease inhibitor ritonavir is a potent inhibitor of the cytochrome P450 3A4 enzyme, and ritonavir's concomitant administration with the substrates of this enzyme may lead to dangerous drug interactions.", "question": "Treatment.Drug in ritonavir's concomitant administration with the substrates of this enzyme", "question_type": "Adverse_event.Treatment.Drug", "answers": "ritonavir; substrates of this enzyme"}, {"id": "10485779_2_875", "context": "The human immunodeficiency virus protease inhibitor ritonavir is a potent inhibitor of the cytochrome P450 3A4 enzyme, and ritonavir's concomitant administration with the substrates of this enzyme may lead to dangerous drug interactions.", "question": "Treatment.Dosage in ritonavir's concomitant administration with the substrates of this enzyme", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10485779_2_876", "context": "The human immunodeficiency virus protease inhibitor ritonavir is a potent inhibitor of the cytochrome P450 3A4 enzyme, and ritonavir's concomitant administration with the substrates of this enzyme may lead to dangerous drug interactions.", "question": "Treatment.Freq in ritonavir's concomitant administration with the substrates of this enzyme", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10485779_2_877", "context": "The human immunodeficiency virus protease inhibitor ritonavir is a potent inhibitor of the cytochrome P450 3A4 enzyme, and ritonavir's concomitant administration with the substrates of this enzyme may lead to dangerous drug interactions.", "question": "Treatment.Route in ritonavir's concomitant administration with the substrates of this enzyme", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10485779_2_878", "context": "The human immunodeficiency virus protease inhibitor ritonavir is a potent inhibitor of the cytochrome P450 3A4 enzyme, and ritonavir's concomitant administration with the substrates of this enzyme may lead to dangerous drug interactions.", "question": "Treatment.Time_elapsed in ritonavir's concomitant administration with the substrates of this enzyme", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10485779_2_879", "context": "The human immunodeficiency virus protease inhibitor ritonavir is a potent inhibitor of the cytochrome P450 3A4 enzyme, and ritonavir's concomitant administration with the substrates of this enzyme may lead to dangerous drug interactions.", "question": "Treatment.Duration in ritonavir's concomitant administration with the substrates of this enzyme", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10485779_2_880", "context": "The human immunodeficiency virus protease inhibitor ritonavir is a potent inhibitor of the cytochrome P450 3A4 enzyme, and ritonavir's concomitant administration with the substrates of this enzyme may lead to dangerous drug interactions.", "question": "Treatment.Disorder in ritonavir's concomitant administration with the substrates of this enzyme", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10485779_2_881", "context": "The human immunodeficiency virus protease inhibitor ritonavir is a potent inhibitor of the cytochrome P450 3A4 enzyme, and ritonavir's concomitant administration with the substrates of this enzyme may lead to dangerous drug interactions.", "question": "Combination.Drug in ritonavir's concomitant administration with the substrates of this enzyme", "question_type": "Adverse_event.Combination.Drug", "answers": "substrates of this enzyme; ritonavir"}, {"id": "10510017_3_882", "context": "There remains a paucity of information pertaining to alternative anticoagulation strategies for use during cardiopulmonary bypass concomitant with heparin-induced thrombocytopenia, especially in children.", "question": "Subject.Age in children", "question_type": "Adverse_event.Subject.Age", "answers": "children"}, {"id": "10510017_3_883", "context": "There remains a paucity of information pertaining to alternative anticoagulation strategies for use during cardiopulmonary bypass concomitant with heparin-induced thrombocytopenia, especially in children.", "question": "Subject.Gender in children", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "10510017_3_884", "context": "There remains a paucity of information pertaining to alternative anticoagulation strategies for use during cardiopulmonary bypass concomitant with heparin-induced thrombocytopenia, especially in children.", "question": "Subject.Population in children", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "10510017_3_885", "context": "There remains a paucity of information pertaining to alternative anticoagulation strategies for use during cardiopulmonary bypass concomitant with heparin-induced thrombocytopenia, especially in children.", "question": "Subject.Race in children", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "10510017_3_886", "context": "There remains a paucity of information pertaining to alternative anticoagulation strategies for use during cardiopulmonary bypass concomitant with heparin-induced thrombocytopenia, especially in children.", "question": "Subject.Disorder in children", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "10510017_3_887", "context": "There remains a paucity of information pertaining to alternative anticoagulation strategies for use during cardiopulmonary bypass concomitant with heparin-induced thrombocytopenia, especially in children.", "question": "Treatment.Drug in heparin", "question_type": "Adverse_event.Treatment.Drug", "answers": "heparin"}, {"id": "10510017_3_888", "context": "There remains a paucity of information pertaining to alternative anticoagulation strategies for use during cardiopulmonary bypass concomitant with heparin-induced thrombocytopenia, especially in children.", "question": "Treatment.Dosage in heparin", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10510017_3_889", "context": "There remains a paucity of information pertaining to alternative anticoagulation strategies for use during cardiopulmonary bypass concomitant with heparin-induced thrombocytopenia, especially in children.", "question": "Treatment.Freq in heparin", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10510017_3_890", "context": "There remains a paucity of information pertaining to alternative anticoagulation strategies for use during cardiopulmonary bypass concomitant with heparin-induced thrombocytopenia, especially in children.", "question": "Treatment.Route in heparin", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10510017_3_891", "context": "There remains a paucity of information pertaining to alternative anticoagulation strategies for use during cardiopulmonary bypass concomitant with heparin-induced thrombocytopenia, especially in children.", "question": "Treatment.Time_elapsed in heparin", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10510017_3_892", "context": "There remains a paucity of information pertaining to alternative anticoagulation strategies for use during cardiopulmonary bypass concomitant with heparin-induced thrombocytopenia, especially in children.", "question": "Treatment.Duration in heparin", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10510017_3_893", "context": "There remains a paucity of information pertaining to alternative anticoagulation strategies for use during cardiopulmonary bypass concomitant with heparin-induced thrombocytopenia, especially in children.", "question": "Treatment.Disorder in heparin", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10510017_3_894", "context": "There remains a paucity of information pertaining to alternative anticoagulation strategies for use during cardiopulmonary bypass concomitant with heparin-induced thrombocytopenia, especially in children.", "question": "Combination.Drug in heparin", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8308511_1_895", "context": "Unintended exposure to acyclovir early in pregnancy, which is not uncommon, may cause excessive maternal and physician anxiety.", "question": "Treatment.Drug in Unintended exposure to acyclovir", "question_type": "Adverse_event.Treatment.Drug", "answers": "acyclovir"}, {"id": "8308511_1_896", "context": "Unintended exposure to acyclovir early in pregnancy, which is not uncommon, may cause excessive maternal and physician anxiety.", "question": "Treatment.Dosage in Unintended exposure to acyclovir", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8308511_1_897", "context": "Unintended exposure to acyclovir early in pregnancy, which is not uncommon, may cause excessive maternal and physician anxiety.", "question": "Treatment.Freq in Unintended exposure to acyclovir", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8308511_1_898", "context": "Unintended exposure to acyclovir early in pregnancy, which is not uncommon, may cause excessive maternal and physician anxiety.", "question": "Treatment.Route in Unintended exposure to acyclovir", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8308511_1_899", "context": "Unintended exposure to acyclovir early in pregnancy, which is not uncommon, may cause excessive maternal and physician anxiety.", "question": "Treatment.Time_elapsed in Unintended exposure to acyclovir", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8308511_1_900", "context": "Unintended exposure to acyclovir early in pregnancy, which is not uncommon, may cause excessive maternal and physician anxiety.", "question": "Treatment.Duration in Unintended exposure to acyclovir", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8308511_1_901", "context": "Unintended exposure to acyclovir early in pregnancy, which is not uncommon, may cause excessive maternal and physician anxiety.", "question": "Treatment.Disorder in Unintended exposure to acyclovir", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8308511_1_902", "context": "Unintended exposure to acyclovir early in pregnancy, which is not uncommon, may cause excessive maternal and physician anxiety.", "question": "Combination.Drug in Unintended exposure to acyclovir", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "14964753_6_903", "context": "The ACE inhibitors can cause various skin side effects; however, it rarely causes cutaneous vasculitis.", "question": "Treatment.Drug in ACE inhibitors", "question_type": "Adverse_event.Treatment.Drug", "answers": "ACE inhibitors"}, {"id": "14964753_6_904", "context": "The ACE inhibitors can cause various skin side effects; however, it rarely causes cutaneous vasculitis.", "question": "Treatment.Dosage in ACE inhibitors", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "14964753_6_905", "context": "The ACE inhibitors can cause various skin side effects; however, it rarely causes cutaneous vasculitis.", "question": "Treatment.Freq in ACE inhibitors", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "14964753_6_906", "context": "The ACE inhibitors can cause various skin side effects; however, it rarely causes cutaneous vasculitis.", "question": "Treatment.Route in ACE inhibitors", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "14964753_6_907", "context": "The ACE inhibitors can cause various skin side effects; however, it rarely causes cutaneous vasculitis.", "question": "Treatment.Time_elapsed in ACE inhibitors", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "14964753_6_908", "context": "The ACE inhibitors can cause various skin side effects; however, it rarely causes cutaneous vasculitis.", "question": "Treatment.Duration in ACE inhibitors", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "14964753_6_909", "context": "The ACE inhibitors can cause various skin side effects; however, it rarely causes cutaneous vasculitis.", "question": "Treatment.Disorder in ACE inhibitors", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "14964753_6_910", "context": "The ACE inhibitors can cause various skin side effects; however, it rarely causes cutaneous vasculitis.", "question": "Combination.Drug in ACE inhibitors", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10633877_2_911", "context": "Salicylate intoxication was excluded, and theophylline was finally incriminated.", "question": "Treatment.Drug in theophylline", "question_type": "Adverse_event.Treatment.Drug", "answers": "theophylline"}, {"id": "10633877_2_912", "context": "Salicylate intoxication was excluded, and theophylline was finally incriminated.", "question": "Treatment.Dosage in theophylline", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10633877_2_913", "context": "Salicylate intoxication was excluded, and theophylline was finally incriminated.", "question": "Treatment.Freq in theophylline", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10633877_2_914", "context": "Salicylate intoxication was excluded, and theophylline was finally incriminated.", "question": "Treatment.Route in theophylline", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10633877_2_915", "context": "Salicylate intoxication was excluded, and theophylline was finally incriminated.", "question": "Treatment.Time_elapsed in theophylline", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10633877_2_916", "context": "Salicylate intoxication was excluded, and theophylline was finally incriminated.", "question": "Treatment.Duration in theophylline", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10633877_2_917", "context": "Salicylate intoxication was excluded, and theophylline was finally incriminated.", "question": "Treatment.Disorder in theophylline", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10633877_2_918", "context": "Salicylate intoxication was excluded, and theophylline was finally incriminated.", "question": "Combination.Drug in theophylline", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15028328_4_919", "context": "We present a case of stroke after PPA ingestion that occurred 4 months after the recall in an 8-year-old boy on chronic peritoneal dialysis.", "question": "Subject.Age in an 8-year-old boy on chronic peritoneal dialysis", "question_type": "Adverse_event.Subject.Age", "answers": "8-year-old"}, {"id": "15028328_4_920", "context": "We present a case of stroke after PPA ingestion that occurred 4 months after the recall in an 8-year-old boy on chronic peritoneal dialysis.", "question": "Subject.Gender in an 8-year-old boy on chronic peritoneal dialysis", "question_type": "Adverse_event.Subject.Gender", "answers": "boy"}, {"id": "15028328_4_921", "context": "We present a case of stroke after PPA ingestion that occurred 4 months after the recall in an 8-year-old boy on chronic peritoneal dialysis.", "question": "Subject.Population in an 8-year-old boy on chronic peritoneal dialysis", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "15028328_4_922", "context": "We present a case of stroke after PPA ingestion that occurred 4 months after the recall in an 8-year-old boy on chronic peritoneal dialysis.", "question": "Subject.Race in an 8-year-old boy on chronic peritoneal dialysis", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15028328_4_923", "context": "We present a case of stroke after PPA ingestion that occurred 4 months after the recall in an 8-year-old boy on chronic peritoneal dialysis.", "question": "Subject.Disorder in an 8-year-old boy on chronic peritoneal dialysis", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15028328_4_924", "context": "We present a case of stroke after PPA ingestion that occurred 4 months after the recall in an 8-year-old boy on chronic peritoneal dialysis.", "question": "Treatment.Drug in PPA", "question_type": "Adverse_event.Treatment.Drug", "answers": "PPA"}, {"id": "15028328_4_925", "context": "We present a case of stroke after PPA ingestion that occurred 4 months after the recall in an 8-year-old boy on chronic peritoneal dialysis.", "question": "Treatment.Dosage in PPA", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15028328_4_926", "context": "We present a case of stroke after PPA ingestion that occurred 4 months after the recall in an 8-year-old boy on chronic peritoneal dialysis.", "question": "Treatment.Freq in PPA", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15028328_4_927", "context": "We present a case of stroke after PPA ingestion that occurred 4 months after the recall in an 8-year-old boy on chronic peritoneal dialysis.", "question": "Treatment.Route in PPA", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15028328_4_928", "context": "We present a case of stroke after PPA ingestion that occurred 4 months after the recall in an 8-year-old boy on chronic peritoneal dialysis.", "question": "Treatment.Time_elapsed in PPA", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "4 months"}, {"id": "15028328_4_929", "context": "We present a case of stroke after PPA ingestion that occurred 4 months after the recall in an 8-year-old boy on chronic peritoneal dialysis.", "question": "Treatment.Duration in PPA", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15028328_4_930", "context": "We present a case of stroke after PPA ingestion that occurred 4 months after the recall in an 8-year-old boy on chronic peritoneal dialysis.", "question": "Treatment.Disorder in PPA", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15028328_4_931", "context": "We present a case of stroke after PPA ingestion that occurred 4 months after the recall in an 8-year-old boy on chronic peritoneal dialysis.", "question": "Combination.Drug in PPA", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15028328_1_932", "context": "Cerebral infarcts in a pediatric patient secondary to phenylpropanolamine, a recalled medication.", "question": "Subject.Age in pediatric patient", "question_type": "Adverse_event.Subject.Age", "answers": "pediatric"}, {"id": "15028328_1_933", "context": "Cerebral infarcts in a pediatric patient secondary to phenylpropanolamine, a recalled medication.", "question": "Subject.Gender in pediatric patient", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15028328_1_934", "context": "Cerebral infarcts in a pediatric patient secondary to phenylpropanolamine, a recalled medication.", "question": "Subject.Population in pediatric patient", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "15028328_1_935", "context": "Cerebral infarcts in a pediatric patient secondary to phenylpropanolamine, a recalled medication.", "question": "Subject.Race in pediatric patient", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15028328_1_936", "context": "Cerebral infarcts in a pediatric patient secondary to phenylpropanolamine, a recalled medication.", "question": "Subject.Disorder in pediatric patient", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15028328_1_937", "context": "Cerebral infarcts in a pediatric patient secondary to phenylpropanolamine, a recalled medication.", "question": "Treatment.Drug in phenylpropanolamine", "question_type": "Adverse_event.Treatment.Drug", "answers": "phenylpropanolamine"}, {"id": "15028328_1_938", "context": "Cerebral infarcts in a pediatric patient secondary to phenylpropanolamine, a recalled medication.", "question": "Treatment.Dosage in phenylpropanolamine", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15028328_1_939", "context": "Cerebral infarcts in a pediatric patient secondary to phenylpropanolamine, a recalled medication.", "question": "Treatment.Freq in phenylpropanolamine", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15028328_1_940", "context": "Cerebral infarcts in a pediatric patient secondary to phenylpropanolamine, a recalled medication.", "question": "Treatment.Route in phenylpropanolamine", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15028328_1_941", "context": "Cerebral infarcts in a pediatric patient secondary to phenylpropanolamine, a recalled medication.", "question": "Treatment.Time_elapsed in phenylpropanolamine", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15028328_1_942", "context": "Cerebral infarcts in a pediatric patient secondary to phenylpropanolamine, a recalled medication.", "question": "Treatment.Duration in phenylpropanolamine", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15028328_1_943", "context": "Cerebral infarcts in a pediatric patient secondary to phenylpropanolamine, a recalled medication.", "question": "Treatment.Disorder in phenylpropanolamine", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15028328_1_944", "context": "Cerebral infarcts in a pediatric patient secondary to phenylpropanolamine, a recalled medication.", "question": "Combination.Drug in phenylpropanolamine", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16164579_2_945", "context": "To our knowledge, our report is one of the first on shock and angio-oedema from irbesartan.", "question": "Treatment.Drug in irbesartan", "question_type": "Adverse_event.Treatment.Drug", "answers": "irbesartan"}, {"id": "16164579_2_946", "context": "To our knowledge, our report is one of the first on shock and angio-oedema from irbesartan.", "question": "Treatment.Dosage in irbesartan", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16164579_2_947", "context": "To our knowledge, our report is one of the first on shock and angio-oedema from irbesartan.", "question": "Treatment.Freq in irbesartan", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16164579_2_948", "context": "To our knowledge, our report is one of the first on shock and angio-oedema from irbesartan.", "question": "Treatment.Route in irbesartan", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16164579_2_949", "context": "To our knowledge, our report is one of the first on shock and angio-oedema from irbesartan.", "question": "Treatment.Time_elapsed in irbesartan", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16164579_2_950", "context": "To our knowledge, our report is one of the first on shock and angio-oedema from irbesartan.", "question": "Treatment.Duration in irbesartan", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16164579_2_951", "context": "To our knowledge, our report is one of the first on shock and angio-oedema from irbesartan.", "question": "Treatment.Disorder in irbesartan", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16164579_2_952", "context": "To our knowledge, our report is one of the first on shock and angio-oedema from irbesartan.", "question": "Combination.Drug in irbesartan", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15944830_2_953", "context": "Clinical course of macular edema in two cases of interferon-associated retinopathy observed by optical coherence tomography.", "question": "Subject.Age in two cases", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "15944830_2_954", "context": "Clinical course of macular edema in two cases of interferon-associated retinopathy observed by optical coherence tomography.", "question": "Subject.Gender in two cases", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15944830_2_955", "context": "Clinical course of macular edema in two cases of interferon-associated retinopathy observed by optical coherence tomography.", "question": "Subject.Population in two cases", "question_type": "Adverse_event.Subject.Population", "answers": "two"}, {"id": "15944830_2_956", "context": "Clinical course of macular edema in two cases of interferon-associated retinopathy observed by optical coherence tomography.", "question": "Subject.Race in two cases", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15944830_2_957", "context": "Clinical course of macular edema in two cases of interferon-associated retinopathy observed by optical coherence tomography.", "question": "Subject.Disorder in two cases", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15944830_2_958", "context": "Clinical course of macular edema in two cases of interferon-associated retinopathy observed by optical coherence tomography.", "question": "Treatment.Drug in interferon", "question_type": "Adverse_event.Treatment.Drug", "answers": "interferon"}, {"id": "15944830_2_959", "context": "Clinical course of macular edema in two cases of interferon-associated retinopathy observed by optical coherence tomography.", "question": "Treatment.Dosage in interferon", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15944830_2_960", "context": "Clinical course of macular edema in two cases of interferon-associated retinopathy observed by optical coherence tomography.", "question": "Treatment.Freq in interferon", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15944830_2_961", "context": "Clinical course of macular edema in two cases of interferon-associated retinopathy observed by optical coherence tomography.", "question": "Treatment.Route in interferon", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15944830_2_962", "context": "Clinical course of macular edema in two cases of interferon-associated retinopathy observed by optical coherence tomography.", "question": "Treatment.Time_elapsed in interferon", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15944830_2_963", "context": "Clinical course of macular edema in two cases of interferon-associated retinopathy observed by optical coherence tomography.", "question": "Treatment.Duration in interferon", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15944830_2_964", "context": "Clinical course of macular edema in two cases of interferon-associated retinopathy observed by optical coherence tomography.", "question": "Treatment.Disorder in interferon", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15944830_2_965", "context": "Clinical course of macular edema in two cases of interferon-associated retinopathy observed by optical coherence tomography.", "question": "Combination.Drug in interferon", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16939867_3_966", "context": "This report describes a 13-year-old female with a right frontal high-grade glioma and complex partial seizures who developed localized purpura after 23 months of lamotrigine monotherapy.", "question": "Subject.Age in a 13-year-old female with a right frontal high-grade glioma and complex partial seizures", "question_type": "Adverse_event.Subject.Age", "answers": "13-year-old"}, {"id": "16939867_3_967", "context": "This report describes a 13-year-old female with a right frontal high-grade glioma and complex partial seizures who developed localized purpura after 23 months of lamotrigine monotherapy.", "question": "Subject.Gender in a 13-year-old female with a right frontal high-grade glioma and complex partial seizures", "question_type": "Adverse_event.Subject.Gender", "answers": "female"}, {"id": "16939867_3_968", "context": "This report describes a 13-year-old female with a right frontal high-grade glioma and complex partial seizures who developed localized purpura after 23 months of lamotrigine monotherapy.", "question": "Subject.Population in a 13-year-old female with a right frontal high-grade glioma and complex partial seizures", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "16939867_3_969", "context": "This report describes a 13-year-old female with a right frontal high-grade glioma and complex partial seizures who developed localized purpura after 23 months of lamotrigine monotherapy.", "question": "Subject.Race in a 13-year-old female with a right frontal high-grade glioma and complex partial seizures", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16939867_3_970", "context": "This report describes a 13-year-old female with a right frontal high-grade glioma and complex partial seizures who developed localized purpura after 23 months of lamotrigine monotherapy.", "question": "Subject.Disorder in a 13-year-old female with a right frontal high-grade glioma and complex partial seizures", "question_type": "Adverse_event.Subject.Disorder", "answers": "right frontal high-grade glioma"}, {"id": "16939867_3_971", "context": "This report describes a 13-year-old female with a right frontal high-grade glioma and complex partial seizures who developed localized purpura after 23 months of lamotrigine monotherapy.", "question": "Treatment.Drug in 23 months of lamotrigine monotherapy", "question_type": "Adverse_event.Treatment.Drug", "answers": "lamotrigine"}, {"id": "16939867_3_972", "context": "This report describes a 13-year-old female with a right frontal high-grade glioma and complex partial seizures who developed localized purpura after 23 months of lamotrigine monotherapy.", "question": "Treatment.Dosage in 23 months of lamotrigine monotherapy", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16939867_3_973", "context": "This report describes a 13-year-old female with a right frontal high-grade glioma and complex partial seizures who developed localized purpura after 23 months of lamotrigine monotherapy.", "question": "Treatment.Freq in 23 months of lamotrigine monotherapy", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16939867_3_974", "context": "This report describes a 13-year-old female with a right frontal high-grade glioma and complex partial seizures who developed localized purpura after 23 months of lamotrigine monotherapy.", "question": "Treatment.Route in 23 months of lamotrigine monotherapy", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16939867_3_975", "context": "This report describes a 13-year-old female with a right frontal high-grade glioma and complex partial seizures who developed localized purpura after 23 months of lamotrigine monotherapy.", "question": "Treatment.Time_elapsed in 23 months of lamotrigine monotherapy", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16939867_3_976", "context": "This report describes a 13-year-old female with a right frontal high-grade glioma and complex partial seizures who developed localized purpura after 23 months of lamotrigine monotherapy.", "question": "Treatment.Duration in 23 months of lamotrigine monotherapy", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16939867_3_977", "context": "This report describes a 13-year-old female with a right frontal high-grade glioma and complex partial seizures who developed localized purpura after 23 months of lamotrigine monotherapy.", "question": "Treatment.Disorder in 23 months of lamotrigine monotherapy", "question_type": "Adverse_event.Treatment.Disorder", "answers": "23 months; complex partial seizures"}, {"id": "16939867_3_978", "context": "This report describes a 13-year-old female with a right frontal high-grade glioma and complex partial seizures who developed localized purpura after 23 months of lamotrigine monotherapy.", "question": "Combination.Drug in 23 months of lamotrigine monotherapy", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9491301_2_979", "context": "Patient 1 presented bilateral ballism 1 week after intravenous heroin injection.", "question": "Subject.Age in Patient 1", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "9491301_2_980", "context": "Patient 1 presented bilateral ballism 1 week after intravenous heroin injection.", "question": "Subject.Gender in Patient 1", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "9491301_2_981", "context": "Patient 1 presented bilateral ballism 1 week after intravenous heroin injection.", "question": "Subject.Population in Patient 1", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "9491301_2_982", "context": "Patient 1 presented bilateral ballism 1 week after intravenous heroin injection.", "question": "Subject.Race in Patient 1", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "9491301_2_983", "context": "Patient 1 presented bilateral ballism 1 week after intravenous heroin injection.", "question": "Subject.Disorder in Patient 1", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "9491301_2_984", "context": "Patient 1 presented bilateral ballism 1 week after intravenous heroin injection.", "question": "Treatment.Drug in intravenous heroin injection", "question_type": "Adverse_event.Treatment.Drug", "answers": "heroin"}, {"id": "9491301_2_985", "context": "Patient 1 presented bilateral ballism 1 week after intravenous heroin injection.", "question": "Treatment.Dosage in intravenous heroin injection", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9491301_2_986", "context": "Patient 1 presented bilateral ballism 1 week after intravenous heroin injection.", "question": "Treatment.Freq in intravenous heroin injection", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9491301_2_987", "context": "Patient 1 presented bilateral ballism 1 week after intravenous heroin injection.", "question": "Treatment.Route in intravenous heroin injection", "question_type": "Adverse_event.Treatment.Route", "answers": "intravenous; injection"}, {"id": "9491301_2_988", "context": "Patient 1 presented bilateral ballism 1 week after intravenous heroin injection.", "question": "Treatment.Time_elapsed in intravenous heroin injection", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9491301_2_989", "context": "Patient 1 presented bilateral ballism 1 week after intravenous heroin injection.", "question": "Treatment.Duration in intravenous heroin injection", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9491301_2_990", "context": "Patient 1 presented bilateral ballism 1 week after intravenous heroin injection.", "question": "Treatment.Disorder in intravenous heroin injection", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9491301_2_991", "context": "Patient 1 presented bilateral ballism 1 week after intravenous heroin injection.", "question": "Combination.Drug in intravenous heroin injection", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3718111_1_992", "context": "He became hyperkalemic on rechallenge with timolol and normokalemic following its withdrawal.", "question": "Subject.Age in He", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "3718111_1_993", "context": "He became hyperkalemic on rechallenge with timolol and normokalemic following its withdrawal.", "question": "Subject.Gender in He", "question_type": "Adverse_event.Subject.Gender", "answers": "He"}, {"id": "3718111_1_994", "context": "He became hyperkalemic on rechallenge with timolol and normokalemic following its withdrawal.", "question": "Subject.Population in He", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "3718111_1_995", "context": "He became hyperkalemic on rechallenge with timolol and normokalemic following its withdrawal.", "question": "Subject.Race in He", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "3718111_1_996", "context": "He became hyperkalemic on rechallenge with timolol and normokalemic following its withdrawal.", "question": "Subject.Disorder in He", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "3718111_1_997", "context": "He became hyperkalemic on rechallenge with timolol and normokalemic following its withdrawal.", "question": "Treatment.Drug in timolol", "question_type": "Adverse_event.Treatment.Drug", "answers": "timolol"}, {"id": "3718111_1_998", "context": "He became hyperkalemic on rechallenge with timolol and normokalemic following its withdrawal.", "question": "Treatment.Dosage in timolol", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3718111_1_999", "context": "He became hyperkalemic on rechallenge with timolol and normokalemic following its withdrawal.", "question": "Treatment.Freq in timolol", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3718111_1_1000", "context": "He became hyperkalemic on rechallenge with timolol and normokalemic following its withdrawal.", "question": "Treatment.Route in timolol", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3718111_1_1001", "context": "He became hyperkalemic on rechallenge with timolol and normokalemic following its withdrawal.", "question": "Treatment.Time_elapsed in timolol", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3718111_1_1002", "context": "He became hyperkalemic on rechallenge with timolol and normokalemic following its withdrawal.", "question": "Treatment.Duration in timolol", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3718111_1_1003", "context": "He became hyperkalemic on rechallenge with timolol and normokalemic following its withdrawal.", "question": "Treatment.Disorder in timolol", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3718111_1_1004", "context": "He became hyperkalemic on rechallenge with timolol and normokalemic following its withdrawal.", "question": "Combination.Drug in timolol", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11247558_1_1005", "context": "Ischaemic colitis in a patient taking meloxicam.", "question": "Subject.Age in a patient", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "11247558_1_1006", "context": "Ischaemic colitis in a patient taking meloxicam.", "question": "Subject.Gender in a patient", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "11247558_1_1007", "context": "Ischaemic colitis in a patient taking meloxicam.", "question": "Subject.Population in a patient", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "11247558_1_1008", "context": "Ischaemic colitis in a patient taking meloxicam.", "question": "Subject.Race in a patient", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "11247558_1_1009", "context": "Ischaemic colitis in a patient taking meloxicam.", "question": "Subject.Disorder in a patient", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "11247558_1_1010", "context": "Ischaemic colitis in a patient taking meloxicam.", "question": "Treatment.Drug in meloxicam", "question_type": "Adverse_event.Treatment.Drug", "answers": "meloxicam"}, {"id": "11247558_1_1011", "context": "Ischaemic colitis in a patient taking meloxicam.", "question": "Treatment.Dosage in meloxicam", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11247558_1_1012", "context": "Ischaemic colitis in a patient taking meloxicam.", "question": "Treatment.Freq in meloxicam", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11247558_1_1013", "context": "Ischaemic colitis in a patient taking meloxicam.", "question": "Treatment.Route in meloxicam", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11247558_1_1014", "context": "Ischaemic colitis in a patient taking meloxicam.", "question": "Treatment.Time_elapsed in meloxicam", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11247558_1_1015", "context": "Ischaemic colitis in a patient taking meloxicam.", "question": "Treatment.Duration in meloxicam", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11247558_1_1016", "context": "Ischaemic colitis in a patient taking meloxicam.", "question": "Treatment.Disorder in meloxicam", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11247558_1_1017", "context": "Ischaemic colitis in a patient taking meloxicam.", "question": "Combination.Drug in meloxicam", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17937473_2_1018", "context": "Leflunomide-associated infections in rheumatoid arthritis.", "question": "Treatment.Drug in Leflunomide", "question_type": "Adverse_event.Treatment.Drug", "answers": "Leflunomide"}, {"id": "17937473_2_1019", "context": "Leflunomide-associated infections in rheumatoid arthritis.", "question": "Treatment.Dosage in Leflunomide", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17937473_2_1020", "context": "Leflunomide-associated infections in rheumatoid arthritis.", "question": "Treatment.Freq in Leflunomide", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17937473_2_1021", "context": "Leflunomide-associated infections in rheumatoid arthritis.", "question": "Treatment.Route in Leflunomide", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17937473_2_1022", "context": "Leflunomide-associated infections in rheumatoid arthritis.", "question": "Treatment.Time_elapsed in Leflunomide", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17937473_2_1023", "context": "Leflunomide-associated infections in rheumatoid arthritis.", "question": "Treatment.Duration in Leflunomide", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17937473_2_1024", "context": "Leflunomide-associated infections in rheumatoid arthritis.", "question": "Treatment.Disorder in Leflunomide", "question_type": "Adverse_event.Treatment.Disorder", "answers": "rheumatoid arthritis"}, {"id": "17937473_2_1025", "context": "Leflunomide-associated infections in rheumatoid arthritis.", "question": "Combination.Drug in Leflunomide", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11903249_1_1026", "context": "Cutaneous sarcoidosis during interferon alfa and ribavirin treatment of hepatitis C virus infection: two cases.", "question": "Subject.Age in two cases", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "11903249_1_1027", "context": "Cutaneous sarcoidosis during interferon alfa and ribavirin treatment of hepatitis C virus infection: two cases.", "question": "Subject.Gender in two cases", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "11903249_1_1028", "context": "Cutaneous sarcoidosis during interferon alfa and ribavirin treatment of hepatitis C virus infection: two cases.", "question": "Subject.Population in two cases", "question_type": "Adverse_event.Subject.Population", "answers": "two"}, {"id": "11903249_1_1029", "context": "Cutaneous sarcoidosis during interferon alfa and ribavirin treatment of hepatitis C virus infection: two cases.", "question": "Subject.Race in two cases", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "11903249_1_1030", "context": "Cutaneous sarcoidosis during interferon alfa and ribavirin treatment of hepatitis C virus infection: two cases.", "question": "Subject.Disorder in two cases", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "11903249_1_1031", "context": "Cutaneous sarcoidosis during interferon alfa and ribavirin treatment of hepatitis C virus infection: two cases.", "question": "Treatment.Drug in interferon alfa and ribavirin treatment of hepatitis C virus infection", "question_type": "Adverse_event.Treatment.Drug", "answers": "alfa; ribavirin"}, {"id": "11903249_1_1032", "context": "Cutaneous sarcoidosis during interferon alfa and ribavirin treatment of hepatitis C virus infection: two cases.", "question": "Treatment.Dosage in interferon alfa and ribavirin treatment of hepatitis C virus infection", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11903249_1_1033", "context": "Cutaneous sarcoidosis during interferon alfa and ribavirin treatment of hepatitis C virus infection: two cases.", "question": "Treatment.Freq in interferon alfa and ribavirin treatment of hepatitis C virus infection", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11903249_1_1034", "context": "Cutaneous sarcoidosis during interferon alfa and ribavirin treatment of hepatitis C virus infection: two cases.", "question": "Treatment.Route in interferon alfa and ribavirin treatment of hepatitis C virus infection", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11903249_1_1035", "context": "Cutaneous sarcoidosis during interferon alfa and ribavirin treatment of hepatitis C virus infection: two cases.", "question": "Treatment.Time_elapsed in interferon alfa and ribavirin treatment of hepatitis C virus infection", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11903249_1_1036", "context": "Cutaneous sarcoidosis during interferon alfa and ribavirin treatment of hepatitis C virus infection: two cases.", "question": "Treatment.Duration in interferon alfa and ribavirin treatment of hepatitis C virus infection", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11903249_1_1037", "context": "Cutaneous sarcoidosis during interferon alfa and ribavirin treatment of hepatitis C virus infection: two cases.", "question": "Treatment.Disorder in interferon alfa and ribavirin treatment of hepatitis C virus infection", "question_type": "Adverse_event.Treatment.Disorder", "answers": "hepatitis C virus infection"}, {"id": "11903249_1_1038", "context": "Cutaneous sarcoidosis during interferon alfa and ribavirin treatment of hepatitis C virus infection: two cases.", "question": "Combination.Drug in interferon alfa and ribavirin treatment of hepatitis C virus infection", "question_type": "Adverse_event.Combination.Drug", "answers": "alfa; ribavirin"}, {"id": "7632529_2_1039", "context": "Acute renal failure in a child associated with acyclovir.", "question": "Subject.Age in a child", "question_type": "Adverse_event.Subject.Age", "answers": "child"}, {"id": "7632529_2_1040", "context": "Acute renal failure in a child associated with acyclovir.", "question": "Subject.Gender in a child", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "7632529_2_1041", "context": "Acute renal failure in a child associated with acyclovir.", "question": "Subject.Population in a child", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "7632529_2_1042", "context": "Acute renal failure in a child associated with acyclovir.", "question": "Subject.Race in a child", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "7632529_2_1043", "context": "Acute renal failure in a child associated with acyclovir.", "question": "Subject.Disorder in a child", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "7632529_2_1044", "context": "Acute renal failure in a child associated with acyclovir.", "question": "Treatment.Drug in acyclovir", "question_type": "Adverse_event.Treatment.Drug", "answers": "acyclovir"}, {"id": "7632529_2_1045", "context": "Acute renal failure in a child associated with acyclovir.", "question": "Treatment.Dosage in acyclovir", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7632529_2_1046", "context": "Acute renal failure in a child associated with acyclovir.", "question": "Treatment.Freq in acyclovir", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7632529_2_1047", "context": "Acute renal failure in a child associated with acyclovir.", "question": "Treatment.Route in acyclovir", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7632529_2_1048", "context": "Acute renal failure in a child associated with acyclovir.", "question": "Treatment.Time_elapsed in acyclovir", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7632529_2_1049", "context": "Acute renal failure in a child associated with acyclovir.", "question": "Treatment.Duration in acyclovir", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7632529_2_1050", "context": "Acute renal failure in a child associated with acyclovir.", "question": "Treatment.Disorder in acyclovir", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7632529_2_1051", "context": "Acute renal failure in a child associated with acyclovir.", "question": "Combination.Drug in acyclovir", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18622319_4_1052", "context": "Bevacizumab is a recently developed monoclonal antibody against vascular endothelial growth factor receptor used to inhibit angiogenesis.", "question": "Treatment.Drug in Bevacizumab is a recently developed monoclonal antibody", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "Bevacizumab"}, {"id": "18622319_4_1053", "context": "Bevacizumab is a recently developed monoclonal antibody against vascular endothelial growth factor receptor used to inhibit angiogenesis.", "question": "Treatment.Dosage in Bevacizumab is a recently developed monoclonal antibody", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "18622319_4_1054", "context": "Bevacizumab is a recently developed monoclonal antibody against vascular endothelial growth factor receptor used to inhibit angiogenesis.", "question": "Treatment.Freq in Bevacizumab is a recently developed monoclonal antibody", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "18622319_4_1055", "context": "Bevacizumab is a recently developed monoclonal antibody against vascular endothelial growth factor receptor used to inhibit angiogenesis.", "question": "Treatment.Route in Bevacizumab is a recently developed monoclonal antibody", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "18622319_4_1056", "context": "Bevacizumab is a recently developed monoclonal antibody against vascular endothelial growth factor receptor used to inhibit angiogenesis.", "question": "Treatment.Time_elapsed in Bevacizumab is a recently developed monoclonal antibody", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18622319_4_1057", "context": "Bevacizumab is a recently developed monoclonal antibody against vascular endothelial growth factor receptor used to inhibit angiogenesis.", "question": "Treatment.Duration in Bevacizumab is a recently developed monoclonal antibody", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "18622319_4_1058", "context": "Bevacizumab is a recently developed monoclonal antibody against vascular endothelial growth factor receptor used to inhibit angiogenesis.", "question": "Treatment.Disorder in Bevacizumab is a recently developed monoclonal antibody", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "angiogenesis"}, {"id": "18622319_4_1059", "context": "Bevacizumab is a recently developed monoclonal antibody against vascular endothelial growth factor receptor used to inhibit angiogenesis.", "question": "Combination.Drug in Bevacizumab is a recently developed monoclonal antibody", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "7387219_3_1060", "context": "Two patients with rheumatoid arthritis developed evidence of hepatotoxicity while receiving D-penicillamine.", "question": "Subject.Age in Two patients with rheumatoid arthritis", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "7387219_3_1061", "context": "Two patients with rheumatoid arthritis developed evidence of hepatotoxicity while receiving D-penicillamine.", "question": "Subject.Gender in Two patients with rheumatoid arthritis", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "7387219_3_1062", "context": "Two patients with rheumatoid arthritis developed evidence of hepatotoxicity while receiving D-penicillamine.", "question": "Subject.Population in Two patients with rheumatoid arthritis", "question_type": "Adverse_event.Subject.Population", "answers": "Two"}, {"id": "7387219_3_1063", "context": "Two patients with rheumatoid arthritis developed evidence of hepatotoxicity while receiving D-penicillamine.", "question": "Subject.Race in Two patients with rheumatoid arthritis", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "7387219_3_1064", "context": "Two patients with rheumatoid arthritis developed evidence of hepatotoxicity while receiving D-penicillamine.", "question": "Subject.Disorder in Two patients with rheumatoid arthritis", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "7387219_3_1065", "context": "Two patients with rheumatoid arthritis developed evidence of hepatotoxicity while receiving D-penicillamine.", "question": "Treatment.Drug in D-penicillamine", "question_type": "Adverse_event.Treatment.Drug", "answers": "D-penicillamine"}, {"id": "7387219_3_1066", "context": "Two patients with rheumatoid arthritis developed evidence of hepatotoxicity while receiving D-penicillamine.", "question": "Treatment.Dosage in D-penicillamine", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7387219_3_1067", "context": "Two patients with rheumatoid arthritis developed evidence of hepatotoxicity while receiving D-penicillamine.", "question": "Treatment.Freq in D-penicillamine", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7387219_3_1068", "context": "Two patients with rheumatoid arthritis developed evidence of hepatotoxicity while receiving D-penicillamine.", "question": "Treatment.Route in D-penicillamine", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7387219_3_1069", "context": "Two patients with rheumatoid arthritis developed evidence of hepatotoxicity while receiving D-penicillamine.", "question": "Treatment.Time_elapsed in D-penicillamine", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7387219_3_1070", "context": "Two patients with rheumatoid arthritis developed evidence of hepatotoxicity while receiving D-penicillamine.", "question": "Treatment.Duration in D-penicillamine", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7387219_3_1071", "context": "Two patients with rheumatoid arthritis developed evidence of hepatotoxicity while receiving D-penicillamine.", "question": "Treatment.Disorder in D-penicillamine", "question_type": "Adverse_event.Treatment.Disorder", "answers": "rheumatoid arthritis"}, {"id": "7387219_3_1072", "context": "Two patients with rheumatoid arthritis developed evidence of hepatotoxicity while receiving D-penicillamine.", "question": "Combination.Drug in D-penicillamine", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17310853_1_1073", "context": "Fatal venous thrombembolism complicating imatinib therapy in a patient with metastatic gastrointestinal stromal tumor.", "question": "Subject.Age in a patient with metastatic gastrointestinal stromal tumor", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "17310853_1_1074", "context": "Fatal venous thrombembolism complicating imatinib therapy in a patient with metastatic gastrointestinal stromal tumor.", "question": "Subject.Gender in a patient with metastatic gastrointestinal stromal tumor", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "17310853_1_1075", "context": "Fatal venous thrombembolism complicating imatinib therapy in a patient with metastatic gastrointestinal stromal tumor.", "question": "Subject.Population in a patient with metastatic gastrointestinal stromal tumor", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "17310853_1_1076", "context": "Fatal venous thrombembolism complicating imatinib therapy in a patient with metastatic gastrointestinal stromal tumor.", "question": "Subject.Race in a patient with metastatic gastrointestinal stromal tumor", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "17310853_1_1077", "context": "Fatal venous thrombembolism complicating imatinib therapy in a patient with metastatic gastrointestinal stromal tumor.", "question": "Subject.Disorder in a patient with metastatic gastrointestinal stromal tumor", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "17310853_1_1078", "context": "Fatal venous thrombembolism complicating imatinib therapy in a patient with metastatic gastrointestinal stromal tumor.", "question": "Treatment.Drug in imatinib", "question_type": "Adverse_event.Treatment.Drug", "answers": "imatinib"}, {"id": "17310853_1_1079", "context": "Fatal venous thrombembolism complicating imatinib therapy in a patient with metastatic gastrointestinal stromal tumor.", "question": "Treatment.Dosage in imatinib", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17310853_1_1080", "context": "Fatal venous thrombembolism complicating imatinib therapy in a patient with metastatic gastrointestinal stromal tumor.", "question": "Treatment.Freq in imatinib", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17310853_1_1081", "context": "Fatal venous thrombembolism complicating imatinib therapy in a patient with metastatic gastrointestinal stromal tumor.", "question": "Treatment.Route in imatinib", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17310853_1_1082", "context": "Fatal venous thrombembolism complicating imatinib therapy in a patient with metastatic gastrointestinal stromal tumor.", "question": "Treatment.Time_elapsed in imatinib", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17310853_1_1083", "context": "Fatal venous thrombembolism complicating imatinib therapy in a patient with metastatic gastrointestinal stromal tumor.", "question": "Treatment.Duration in imatinib", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17310853_1_1084", "context": "Fatal venous thrombembolism complicating imatinib therapy in a patient with metastatic gastrointestinal stromal tumor.", "question": "Treatment.Disorder in imatinib", "question_type": "Adverse_event.Treatment.Disorder", "answers": "metastatic gastrointestinal stromal tumor"}, {"id": "17310853_1_1085", "context": "Fatal venous thrombembolism complicating imatinib therapy in a patient with metastatic gastrointestinal stromal tumor.", "question": "Combination.Drug in imatinib", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "19296063_2_1086", "context": "However, acute cardiomyopathy and pericarditis secondary to methylphenidate use has been rarely reported.", "question": "Treatment.Drug in methylphenidate", "question_type": "Adverse_event.Treatment.Drug", "answers": "methylphenidate"}, {"id": "19296063_2_1087", "context": "However, acute cardiomyopathy and pericarditis secondary to methylphenidate use has been rarely reported.", "question": "Treatment.Dosage in methylphenidate", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "19296063_2_1088", "context": "However, acute cardiomyopathy and pericarditis secondary to methylphenidate use has been rarely reported.", "question": "Treatment.Freq in methylphenidate", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "19296063_2_1089", "context": "However, acute cardiomyopathy and pericarditis secondary to methylphenidate use has been rarely reported.", "question": "Treatment.Route in methylphenidate", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "19296063_2_1090", "context": "However, acute cardiomyopathy and pericarditis secondary to methylphenidate use has been rarely reported.", "question": "Treatment.Time_elapsed in methylphenidate", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19296063_2_1091", "context": "However, acute cardiomyopathy and pericarditis secondary to methylphenidate use has been rarely reported.", "question": "Treatment.Duration in methylphenidate", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "19296063_2_1092", "context": "However, acute cardiomyopathy and pericarditis secondary to methylphenidate use has been rarely reported.", "question": "Treatment.Disorder in methylphenidate", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "19296063_2_1093", "context": "However, acute cardiomyopathy and pericarditis secondary to methylphenidate use has been rarely reported.", "question": "Combination.Drug in methylphenidate", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7897759_2_1094", "context": "Propoxyphene-induced wide QRS complex dysrhythmia responsive to sodium bicarbonate--a case report.", "question": "Treatment.Drug in Propoxyphene", "question_type": "Adverse_event.Treatment.Drug", "answers": "Propoxyphene"}, {"id": "7897759_2_1095", "context": "Propoxyphene-induced wide QRS complex dysrhythmia responsive to sodium bicarbonate--a case report.", "question": "Treatment.Dosage in Propoxyphene", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7897759_2_1096", "context": "Propoxyphene-induced wide QRS complex dysrhythmia responsive to sodium bicarbonate--a case report.", "question": "Treatment.Freq in Propoxyphene", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7897759_2_1097", "context": "Propoxyphene-induced wide QRS complex dysrhythmia responsive to sodium bicarbonate--a case report.", "question": "Treatment.Route in Propoxyphene", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7897759_2_1098", "context": "Propoxyphene-induced wide QRS complex dysrhythmia responsive to sodium bicarbonate--a case report.", "question": "Treatment.Time_elapsed in Propoxyphene", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7897759_2_1099", "context": "Propoxyphene-induced wide QRS complex dysrhythmia responsive to sodium bicarbonate--a case report.", "question": "Treatment.Duration in Propoxyphene", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7897759_2_1100", "context": "Propoxyphene-induced wide QRS complex dysrhythmia responsive to sodium bicarbonate--a case report.", "question": "Treatment.Disorder in Propoxyphene", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7897759_2_1101", "context": "Propoxyphene-induced wide QRS complex dysrhythmia responsive to sodium bicarbonate--a case report.", "question": "Combination.Drug in Propoxyphene", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "24927617_11_1102", "context": "Simvastatin plasma concentration increased 30 times in this patient and statin induced muscle toxicity is related to the concentration of the statin in blood.", "question": "Subject.Age in Simvastatin plasma concentration increased 30 times in this patient", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "24927617_11_1103", "context": "Simvastatin plasma concentration increased 30 times in this patient and statin induced muscle toxicity is related to the concentration of the statin in blood.", "question": "Subject.Gender in Simvastatin plasma concentration increased 30 times in this patient", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "24927617_11_1104", "context": "Simvastatin plasma concentration increased 30 times in this patient and statin induced muscle toxicity is related to the concentration of the statin in blood.", "question": "Subject.Population in Simvastatin plasma concentration increased 30 times in this patient", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "24927617_11_1105", "context": "Simvastatin plasma concentration increased 30 times in this patient and statin induced muscle toxicity is related to the concentration of the statin in blood.", "question": "Subject.Race in Simvastatin plasma concentration increased 30 times in this patient", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "24927617_11_1106", "context": "Simvastatin plasma concentration increased 30 times in this patient and statin induced muscle toxicity is related to the concentration of the statin in blood.", "question": "Subject.Disorder in Simvastatin plasma concentration increased 30 times in this patient", "question_type": "Adverse_event.Subject.Disorder", "answers": "Simvastatin plasma concentration increased 30 times"}, {"id": "24927617_11_1107", "context": "Simvastatin plasma concentration increased 30 times in this patient and statin induced muscle toxicity is related to the concentration of the statin in blood.", "question": "Treatment.Drug in statin", "question_type": "Adverse_event.Treatment.Drug", "answers": "statin"}, {"id": "24927617_11_1108", "context": "Simvastatin plasma concentration increased 30 times in this patient and statin induced muscle toxicity is related to the concentration of the statin in blood.", "question": "Treatment.Dosage in statin", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "24927617_11_1109", "context": "Simvastatin plasma concentration increased 30 times in this patient and statin induced muscle toxicity is related to the concentration of the statin in blood.", "question": "Treatment.Freq in statin", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "24927617_11_1110", "context": "Simvastatin plasma concentration increased 30 times in this patient and statin induced muscle toxicity is related to the concentration of the statin in blood.", "question": "Treatment.Route in statin", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "24927617_11_1111", "context": "Simvastatin plasma concentration increased 30 times in this patient and statin induced muscle toxicity is related to the concentration of the statin in blood.", "question": "Treatment.Time_elapsed in statin", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "24927617_11_1112", "context": "Simvastatin plasma concentration increased 30 times in this patient and statin induced muscle toxicity is related to the concentration of the statin in blood.", "question": "Treatment.Duration in statin", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "24927617_11_1113", "context": "Simvastatin plasma concentration increased 30 times in this patient and statin induced muscle toxicity is related to the concentration of the statin in blood.", "question": "Treatment.Disorder in statin", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "24927617_11_1114", "context": "Simvastatin plasma concentration increased 30 times in this patient and statin induced muscle toxicity is related to the concentration of the statin in blood.", "question": "Combination.Drug in statin", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11171531_3_1115", "context": "Poorly controlled hypertension in a painter with chronic lead toxicity.", "question": "Subject.Age in a painter", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "11171531_3_1116", "context": "Poorly controlled hypertension in a painter with chronic lead toxicity.", "question": "Subject.Gender in a painter", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "11171531_3_1117", "context": "Poorly controlled hypertension in a painter with chronic lead toxicity.", "question": "Subject.Population in a painter", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "11171531_3_1118", "context": "Poorly controlled hypertension in a painter with chronic lead toxicity.", "question": "Subject.Race in a painter", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "11171531_3_1119", "context": "Poorly controlled hypertension in a painter with chronic lead toxicity.", "question": "Subject.Disorder in a painter", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "11171531_3_1120", "context": "Poorly controlled hypertension in a painter with chronic lead toxicity.", "question": "Treatment.Drug in lead", "question_type": "Adverse_event.Treatment.Drug", "answers": "lead"}, {"id": "11171531_3_1121", "context": "Poorly controlled hypertension in a painter with chronic lead toxicity.", "question": "Treatment.Dosage in lead", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11171531_3_1122", "context": "Poorly controlled hypertension in a painter with chronic lead toxicity.", "question": "Treatment.Freq in lead", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11171531_3_1123", "context": "Poorly controlled hypertension in a painter with chronic lead toxicity.", "question": "Treatment.Route in lead", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11171531_3_1124", "context": "Poorly controlled hypertension in a painter with chronic lead toxicity.", "question": "Treatment.Time_elapsed in lead", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11171531_3_1125", "context": "Poorly controlled hypertension in a painter with chronic lead toxicity.", "question": "Treatment.Duration in lead", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11171531_3_1126", "context": "Poorly controlled hypertension in a painter with chronic lead toxicity.", "question": "Treatment.Disorder in lead", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11171531_3_1127", "context": "Poorly controlled hypertension in a painter with chronic lead toxicity.", "question": "Combination.Drug in lead", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9695308_4_1128", "context": "It was concluded that ANCA is closely related to the pathogenesis of crescentic glomerulonephritis and that treatment with PTU appeared to induce ANCA.", "question": "Treatment.Drug in PTU", "question_type": "Adverse_event.Treatment.Drug", "answers": "PTU"}, {"id": "9695308_4_1129", "context": "It was concluded that ANCA is closely related to the pathogenesis of crescentic glomerulonephritis and that treatment with PTU appeared to induce ANCA.", "question": "Treatment.Dosage in PTU", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9695308_4_1130", "context": "It was concluded that ANCA is closely related to the pathogenesis of crescentic glomerulonephritis and that treatment with PTU appeared to induce ANCA.", "question": "Treatment.Freq in PTU", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9695308_4_1131", "context": "It was concluded that ANCA is closely related to the pathogenesis of crescentic glomerulonephritis and that treatment with PTU appeared to induce ANCA.", "question": "Treatment.Route in PTU", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9695308_4_1132", "context": "It was concluded that ANCA is closely related to the pathogenesis of crescentic glomerulonephritis and that treatment with PTU appeared to induce ANCA.", "question": "Treatment.Time_elapsed in PTU", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9695308_4_1133", "context": "It was concluded that ANCA is closely related to the pathogenesis of crescentic glomerulonephritis and that treatment with PTU appeared to induce ANCA.", "question": "Treatment.Duration in PTU", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9695308_4_1134", "context": "It was concluded that ANCA is closely related to the pathogenesis of crescentic glomerulonephritis and that treatment with PTU appeared to induce ANCA.", "question": "Treatment.Disorder in PTU", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9695308_4_1135", "context": "It was concluded that ANCA is closely related to the pathogenesis of crescentic glomerulonephritis and that treatment with PTU appeared to induce ANCA.", "question": "Combination.Drug in PTU", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12561997_1_1136", "context": "Gelatinous transformation of bone marrow following chemotherapy for myeloma.", "question": "Treatment.Drug in chemotherapy", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "12561997_1_1137", "context": "Gelatinous transformation of bone marrow following chemotherapy for myeloma.", "question": "Treatment.Dosage in chemotherapy", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12561997_1_1138", "context": "Gelatinous transformation of bone marrow following chemotherapy for myeloma.", "question": "Treatment.Freq in chemotherapy", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12561997_1_1139", "context": "Gelatinous transformation of bone marrow following chemotherapy for myeloma.", "question": "Treatment.Route in chemotherapy", "question_type": "Adverse_event.Treatment.Route", "answers": "chemotherapy"}, {"id": "12561997_1_1140", "context": "Gelatinous transformation of bone marrow following chemotherapy for myeloma.", "question": "Treatment.Time_elapsed in chemotherapy", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12561997_1_1141", "context": "Gelatinous transformation of bone marrow following chemotherapy for myeloma.", "question": "Treatment.Duration in chemotherapy", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12561997_1_1142", "context": "Gelatinous transformation of bone marrow following chemotherapy for myeloma.", "question": "Treatment.Disorder in chemotherapy", "question_type": "Adverse_event.Treatment.Disorder", "answers": "myeloma"}, {"id": "12561997_1_1143", "context": "Gelatinous transformation of bone marrow following chemotherapy for myeloma.", "question": "Combination.Drug in chemotherapy", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15279668_2_1144", "context": "We discuss a case with significant progressive peripheral neurological deterioration following administration of both fludarabine and cytarabine as part of the FLA (fludarabine and cytarabine) regime.", "question": "Subject.Age in a case", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "15279668_2_1145", "context": "We discuss a case with significant progressive peripheral neurological deterioration following administration of both fludarabine and cytarabine as part of the FLA (fludarabine and cytarabine) regime.", "question": "Subject.Gender in a case", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15279668_2_1146", "context": "We discuss a case with significant progressive peripheral neurological deterioration following administration of both fludarabine and cytarabine as part of the FLA (fludarabine and cytarabine) regime.", "question": "Subject.Population in a case", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "15279668_2_1147", "context": "We discuss a case with significant progressive peripheral neurological deterioration following administration of both fludarabine and cytarabine as part of the FLA (fludarabine and cytarabine) regime.", "question": "Subject.Race in a case", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15279668_2_1148", "context": "We discuss a case with significant progressive peripheral neurological deterioration following administration of both fludarabine and cytarabine as part of the FLA (fludarabine and cytarabine) regime.", "question": "Subject.Disorder in a case", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15279668_2_1149", "context": "We discuss a case with significant progressive peripheral neurological deterioration following administration of both fludarabine and cytarabine as part of the FLA (fludarabine and cytarabine) regime.", "question": "Treatment.Drug in fludarabine and cytarabine; FLA (fludarabine and cytarabine) regime", "question_type": "Adverse_event.Treatment.Drug", "answers": "fludarabine; cytarabine; FLA (fludarabine and cytarabine)"}, {"id": "15279668_2_1150", "context": "We discuss a case with significant progressive peripheral neurological deterioration following administration of both fludarabine and cytarabine as part of the FLA (fludarabine and cytarabine) regime.", "question": "Treatment.Dosage in fludarabine and cytarabine; FLA (fludarabine and cytarabine) regime", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15279668_2_1151", "context": "We discuss a case with significant progressive peripheral neurological deterioration following administration of both fludarabine and cytarabine as part of the FLA (fludarabine and cytarabine) regime.", "question": "Treatment.Freq in fludarabine and cytarabine; FLA (fludarabine and cytarabine) regime", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15279668_2_1152", "context": "We discuss a case with significant progressive peripheral neurological deterioration following administration of both fludarabine and cytarabine as part of the FLA (fludarabine and cytarabine) regime.", "question": "Treatment.Route in fludarabine and cytarabine; FLA (fludarabine and cytarabine) regime", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15279668_2_1153", "context": "We discuss a case with significant progressive peripheral neurological deterioration following administration of both fludarabine and cytarabine as part of the FLA (fludarabine and cytarabine) regime.", "question": "Treatment.Time_elapsed in fludarabine and cytarabine; FLA (fludarabine and cytarabine) regime", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15279668_2_1154", "context": "We discuss a case with significant progressive peripheral neurological deterioration following administration of both fludarabine and cytarabine as part of the FLA (fludarabine and cytarabine) regime.", "question": "Treatment.Duration in fludarabine and cytarabine; FLA (fludarabine and cytarabine) regime", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15279668_2_1155", "context": "We discuss a case with significant progressive peripheral neurological deterioration following administration of both fludarabine and cytarabine as part of the FLA (fludarabine and cytarabine) regime.", "question": "Treatment.Disorder in fludarabine and cytarabine; FLA (fludarabine and cytarabine) regime", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15279668_2_1156", "context": "We discuss a case with significant progressive peripheral neurological deterioration following administration of both fludarabine and cytarabine as part of the FLA (fludarabine and cytarabine) regime.", "question": "Combination.Drug in fludarabine and cytarabine; FLA (fludarabine and cytarabine) regime", "question_type": "Adverse_event.Combination.Drug", "answers": "fludarabine; cytarabine"}, {"id": "7174620_2_1157", "context": "The course of delirium due to lithium intoxication.", "question": "Treatment.Drug in lithium intoxication", "question_type": "Adverse_event.Treatment.Drug", "answers": "lithium"}, {"id": "7174620_2_1158", "context": "The course of delirium due to lithium intoxication.", "question": "Treatment.Dosage in lithium intoxication", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7174620_2_1159", "context": "The course of delirium due to lithium intoxication.", "question": "Treatment.Freq in lithium intoxication", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7174620_2_1160", "context": "The course of delirium due to lithium intoxication.", "question": "Treatment.Route in lithium intoxication", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7174620_2_1161", "context": "The course of delirium due to lithium intoxication.", "question": "Treatment.Time_elapsed in lithium intoxication", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7174620_2_1162", "context": "The course of delirium due to lithium intoxication.", "question": "Treatment.Duration in lithium intoxication", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7174620_2_1163", "context": "The course of delirium due to lithium intoxication.", "question": "Treatment.Disorder in lithium intoxication", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7174620_2_1164", "context": "The course of delirium due to lithium intoxication.", "question": "Combination.Drug in lithium intoxication", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "21350204_10_1165", "context": "Preadmission warfarin use was not associated with any secondary intracerebral hemorrhage (OR, 1.2; 95% CI, 0.7 to 2.2), symptomatic intracerebral hemorrhage (OR, 1.1; 95% CI, 0.5 to 2.3), or gastrointestinal hemorrhage (OR, 1.1; 95% CI, 0.2 to 5.6).", "question": "Treatment.Drug in Preadmission warfarin", "question_type": "Adverse_event.Treatment.Drug", "answers": "warfarin"}, {"id": "21350204_10_1166", "context": "Preadmission warfarin use was not associated with any secondary intracerebral hemorrhage (OR, 1.2; 95% CI, 0.7 to 2.2), symptomatic intracerebral hemorrhage (OR, 1.1; 95% CI, 0.5 to 2.3), or gastrointestinal hemorrhage (OR, 1.1; 95% CI, 0.2 to 5.6).", "question": "Treatment.Dosage in Preadmission warfarin", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "21350204_10_1167", "context": "Preadmission warfarin use was not associated with any secondary intracerebral hemorrhage (OR, 1.2; 95% CI, 0.7 to 2.2), symptomatic intracerebral hemorrhage (OR, 1.1; 95% CI, 0.5 to 2.3), or gastrointestinal hemorrhage (OR, 1.1; 95% CI, 0.2 to 5.6).", "question": "Treatment.Freq in Preadmission warfarin", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "21350204_10_1168", "context": "Preadmission warfarin use was not associated with any secondary intracerebral hemorrhage (OR, 1.2; 95% CI, 0.7 to 2.2), symptomatic intracerebral hemorrhage (OR, 1.1; 95% CI, 0.5 to 2.3), or gastrointestinal hemorrhage (OR, 1.1; 95% CI, 0.2 to 5.6).", "question": "Treatment.Route in Preadmission warfarin", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "21350204_10_1169", "context": "Preadmission warfarin use was not associated with any secondary intracerebral hemorrhage (OR, 1.2; 95% CI, 0.7 to 2.2), symptomatic intracerebral hemorrhage (OR, 1.1; 95% CI, 0.5 to 2.3), or gastrointestinal hemorrhage (OR, 1.1; 95% CI, 0.2 to 5.6).", "question": "Treatment.Time_elapsed in Preadmission warfarin", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "21350204_10_1170", "context": "Preadmission warfarin use was not associated with any secondary intracerebral hemorrhage (OR, 1.2; 95% CI, 0.7 to 2.2), symptomatic intracerebral hemorrhage (OR, 1.1; 95% CI, 0.5 to 2.3), or gastrointestinal hemorrhage (OR, 1.1; 95% CI, 0.2 to 5.6).", "question": "Treatment.Duration in Preadmission warfarin", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "21350204_10_1171", "context": "Preadmission warfarin use was not associated with any secondary intracerebral hemorrhage (OR, 1.2; 95% CI, 0.7 to 2.2), symptomatic intracerebral hemorrhage (OR, 1.1; 95% CI, 0.5 to 2.3), or gastrointestinal hemorrhage (OR, 1.1; 95% CI, 0.2 to 5.6).", "question": "Treatment.Disorder in Preadmission warfarin", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "21350204_10_1172", "context": "Preadmission warfarin use was not associated with any secondary intracerebral hemorrhage (OR, 1.2; 95% CI, 0.7 to 2.2), symptomatic intracerebral hemorrhage (OR, 1.1; 95% CI, 0.5 to 2.3), or gastrointestinal hemorrhage (OR, 1.1; 95% CI, 0.2 to 5.6).", "question": "Combination.Drug in Preadmission warfarin", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16507380_11_1173", "context": "In this case of a possible drug-drug interaction between IFN alfa 11 MU TIW and gemfibrozil 600 mg BID in a patient undergoing treatment for IFN-induced hypertriglyceridemia, the Naranjo Adverse Drug Reactions (ADR) Probability Scale score was 7 (ie, ADR possibly related to treatment).", "question": "Subject.Age in a patient undergoing treatment for IFN-induced hypertriglyceridemia", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "16507380_11_1174", "context": "In this case of a possible drug-drug interaction between IFN alfa 11 MU TIW and gemfibrozil 600 mg BID in a patient undergoing treatment for IFN-induced hypertriglyceridemia, the Naranjo Adverse Drug Reactions (ADR) Probability Scale score was 7 (ie, ADR possibly related to treatment).", "question": "Subject.Gender in a patient undergoing treatment for IFN-induced hypertriglyceridemia", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "16507380_11_1175", "context": "In this case of a possible drug-drug interaction between IFN alfa 11 MU TIW and gemfibrozil 600 mg BID in a patient undergoing treatment for IFN-induced hypertriglyceridemia, the Naranjo Adverse Drug Reactions (ADR) Probability Scale score was 7 (ie, ADR possibly related to treatment).", "question": "Subject.Population in a patient undergoing treatment for IFN-induced hypertriglyceridemia", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "16507380_11_1176", "context": "In this case of a possible drug-drug interaction between IFN alfa 11 MU TIW and gemfibrozil 600 mg BID in a patient undergoing treatment for IFN-induced hypertriglyceridemia, the Naranjo Adverse Drug Reactions (ADR) Probability Scale score was 7 (ie, ADR possibly related to treatment).", "question": "Subject.Race in a patient undergoing treatment for IFN-induced hypertriglyceridemia", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16507380_11_1177", "context": "In this case of a possible drug-drug interaction between IFN alfa 11 MU TIW and gemfibrozil 600 mg BID in a patient undergoing treatment for IFN-induced hypertriglyceridemia, the Naranjo Adverse Drug Reactions (ADR) Probability Scale score was 7 (ie, ADR possibly related to treatment).", "question": "Subject.Disorder in a patient undergoing treatment for IFN-induced hypertriglyceridemia", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "16507380_11_1178", "context": "In this case of a possible drug-drug interaction between IFN alfa 11 MU TIW and gemfibrozil 600 mg BID in a patient undergoing treatment for IFN-induced hypertriglyceridemia, the Naranjo Adverse Drug Reactions (ADR) Probability Scale score was 7 (ie, ADR possibly related to treatment).", "question": "Treatment.Drug in IFN alfa 11 MU TIW; gemfibrozil 600 mg BID", "question_type": "Adverse_event.Treatment.Drug", "answers": "IFN alfa 11; gemfibrozil"}, {"id": "16507380_11_1179", "context": "In this case of a possible drug-drug interaction between IFN alfa 11 MU TIW and gemfibrozil 600 mg BID in a patient undergoing treatment for IFN-induced hypertriglyceridemia, the Naranjo Adverse Drug Reactions (ADR) Probability Scale score was 7 (ie, ADR possibly related to treatment).", "question": "Treatment.Dosage in IFN alfa 11 MU TIW; gemfibrozil 600 mg BID", "question_type": "Adverse_event.Treatment.Dosage", "answers": "600 mg"}, {"id": "16507380_11_1180", "context": "In this case of a possible drug-drug interaction between IFN alfa 11 MU TIW and gemfibrozil 600 mg BID in a patient undergoing treatment for IFN-induced hypertriglyceridemia, the Naranjo Adverse Drug Reactions (ADR) Probability Scale score was 7 (ie, ADR possibly related to treatment).", "question": "Treatment.Freq in IFN alfa 11 MU TIW; gemfibrozil 600 mg BID", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16507380_11_1181", "context": "In this case of a possible drug-drug interaction between IFN alfa 11 MU TIW and gemfibrozil 600 mg BID in a patient undergoing treatment for IFN-induced hypertriglyceridemia, the Naranjo Adverse Drug Reactions (ADR) Probability Scale score was 7 (ie, ADR possibly related to treatment).", "question": "Treatment.Route in IFN alfa 11 MU TIW; gemfibrozil 600 mg BID", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16507380_11_1182", "context": "In this case of a possible drug-drug interaction between IFN alfa 11 MU TIW and gemfibrozil 600 mg BID in a patient undergoing treatment for IFN-induced hypertriglyceridemia, the Naranjo Adverse Drug Reactions (ADR) Probability Scale score was 7 (ie, ADR possibly related to treatment).", "question": "Treatment.Time_elapsed in IFN alfa 11 MU TIW; gemfibrozil 600 mg BID", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16507380_11_1183", "context": "In this case of a possible drug-drug interaction between IFN alfa 11 MU TIW and gemfibrozil 600 mg BID in a patient undergoing treatment for IFN-induced hypertriglyceridemia, the Naranjo Adverse Drug Reactions (ADR) Probability Scale score was 7 (ie, ADR possibly related to treatment).", "question": "Treatment.Duration in IFN alfa 11 MU TIW; gemfibrozil 600 mg BID", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16507380_11_1184", "context": "In this case of a possible drug-drug interaction between IFN alfa 11 MU TIW and gemfibrozil 600 mg BID in a patient undergoing treatment for IFN-induced hypertriglyceridemia, the Naranjo Adverse Drug Reactions (ADR) Probability Scale score was 7 (ie, ADR possibly related to treatment).", "question": "Treatment.Disorder in IFN alfa 11 MU TIW; gemfibrozil 600 mg BID", "question_type": "Adverse_event.Treatment.Disorder", "answers": "IFN-induced hypertriglyceridemia"}, {"id": "16507380_11_1185", "context": "In this case of a possible drug-drug interaction between IFN alfa 11 MU TIW and gemfibrozil 600 mg BID in a patient undergoing treatment for IFN-induced hypertriglyceridemia, the Naranjo Adverse Drug Reactions (ADR) Probability Scale score was 7 (ie, ADR possibly related to treatment).", "question": "Combination.Drug in IFN alfa 11 MU TIW; gemfibrozil 600 mg BID", "question_type": "Adverse_event.Combination.Drug", "answers": "IFN alfa 11; gemfibrozil"}, {"id": "11554897_5_1186", "context": "Stupor from lamotrigine toxicity.", "question": "Treatment.Drug in lamotrigine", "question_type": "Adverse_event.Treatment.Drug", "answers": "lamotrigine"}, {"id": "11554897_5_1187", "context": "Stupor from lamotrigine toxicity.", "question": "Treatment.Dosage in lamotrigine", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11554897_5_1188", "context": "Stupor from lamotrigine toxicity.", "question": "Treatment.Freq in lamotrigine", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11554897_5_1189", "context": "Stupor from lamotrigine toxicity.", "question": "Treatment.Route in lamotrigine", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11554897_5_1190", "context": "Stupor from lamotrigine toxicity.", "question": "Treatment.Time_elapsed in lamotrigine", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11554897_5_1191", "context": "Stupor from lamotrigine toxicity.", "question": "Treatment.Duration in lamotrigine", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11554897_5_1192", "context": "Stupor from lamotrigine toxicity.", "question": "Treatment.Disorder in lamotrigine", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11554897_5_1193", "context": "Stupor from lamotrigine toxicity.", "question": "Combination.Drug in lamotrigine", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "2417800_2_1194", "context": "Autopsy findings were consistent with bleomycin and oxygen-induced pulmonary damage.", "question": "Treatment.Drug in bleomycin and oxygen", "question_type": "Adverse_event.Treatment.Drug", "answers": "oxygen; bleomycin"}, {"id": "2417800_2_1195", "context": "Autopsy findings were consistent with bleomycin and oxygen-induced pulmonary damage.", "question": "Treatment.Dosage in bleomycin and oxygen", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "2417800_2_1196", "context": "Autopsy findings were consistent with bleomycin and oxygen-induced pulmonary damage.", "question": "Treatment.Freq in bleomycin and oxygen", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2417800_2_1197", "context": "Autopsy findings were consistent with bleomycin and oxygen-induced pulmonary damage.", "question": "Treatment.Route in bleomycin and oxygen", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "2417800_2_1198", "context": "Autopsy findings were consistent with bleomycin and oxygen-induced pulmonary damage.", "question": "Treatment.Time_elapsed in bleomycin and oxygen", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2417800_2_1199", "context": "Autopsy findings were consistent with bleomycin and oxygen-induced pulmonary damage.", "question": "Treatment.Duration in bleomycin and oxygen", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2417800_2_1200", "context": "Autopsy findings were consistent with bleomycin and oxygen-induced pulmonary damage.", "question": "Treatment.Disorder in bleomycin and oxygen", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "2417800_2_1201", "context": "Autopsy findings were consistent with bleomycin and oxygen-induced pulmonary damage.", "question": "Combination.Drug in bleomycin and oxygen", "question_type": "Adverse_event.Combination.Drug", "answers": "oxygen; bleomycin"}, {"id": "9426968_2_1202", "context": "We report a case of vitiligo that occurred during the second month of interferon alpha 2a therapy for chronic active hepatitis C.", "question": "Treatment.Drug in during the second month of interferon alpha 2a therapy", "question_type": "Adverse_event.Treatment.Drug", "answers": "interferon alpha 2a"}, {"id": "9426968_2_1203", "context": "We report a case of vitiligo that occurred during the second month of interferon alpha 2a therapy for chronic active hepatitis C.", "question": "Treatment.Dosage in during the second month of interferon alpha 2a therapy", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9426968_2_1204", "context": "We report a case of vitiligo that occurred during the second month of interferon alpha 2a therapy for chronic active hepatitis C.", "question": "Treatment.Freq in during the second month of interferon alpha 2a therapy", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9426968_2_1205", "context": "We report a case of vitiligo that occurred during the second month of interferon alpha 2a therapy for chronic active hepatitis C.", "question": "Treatment.Route in during the second month of interferon alpha 2a therapy", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9426968_2_1206", "context": "We report a case of vitiligo that occurred during the second month of interferon alpha 2a therapy for chronic active hepatitis C.", "question": "Treatment.Time_elapsed in during the second month of interferon alpha 2a therapy", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9426968_2_1207", "context": "We report a case of vitiligo that occurred during the second month of interferon alpha 2a therapy for chronic active hepatitis C.", "question": "Treatment.Duration in during the second month of interferon alpha 2a therapy", "question_type": "Adverse_event.Treatment.Duration", "answers": "the second month"}, {"id": "9426968_2_1208", "context": "We report a case of vitiligo that occurred during the second month of interferon alpha 2a therapy for chronic active hepatitis C.", "question": "Treatment.Disorder in during the second month of interferon alpha 2a therapy", "question_type": "Adverse_event.Treatment.Disorder", "answers": "chronic active hepatitis C"}, {"id": "9426968_2_1209", "context": "We report a case of vitiligo that occurred during the second month of interferon alpha 2a therapy for chronic active hepatitis C.", "question": "Combination.Drug in during the second month of interferon alpha 2a therapy", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16244351_2_1210", "context": "Vardenafil is a new oral phosphodiesterase inhibitor used for erectile dysfunction.", "question": "Treatment.Drug in Vardenafil is a new oral phosphodiesterase inhibitor", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "Vardenafil"}, {"id": "16244351_2_1211", "context": "Vardenafil is a new oral phosphodiesterase inhibitor used for erectile dysfunction.", "question": "Treatment.Dosage in Vardenafil is a new oral phosphodiesterase inhibitor", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "16244351_2_1212", "context": "Vardenafil is a new oral phosphodiesterase inhibitor used for erectile dysfunction.", "question": "Treatment.Freq in Vardenafil is a new oral phosphodiesterase inhibitor", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "16244351_2_1213", "context": "Vardenafil is a new oral phosphodiesterase inhibitor used for erectile dysfunction.", "question": "Treatment.Route in Vardenafil is a new oral phosphodiesterase inhibitor", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": "oral"}, {"id": "16244351_2_1214", "context": "Vardenafil is a new oral phosphodiesterase inhibitor used for erectile dysfunction.", "question": "Treatment.Time_elapsed in Vardenafil is a new oral phosphodiesterase inhibitor", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16244351_2_1215", "context": "Vardenafil is a new oral phosphodiesterase inhibitor used for erectile dysfunction.", "question": "Treatment.Duration in Vardenafil is a new oral phosphodiesterase inhibitor", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "16244351_2_1216", "context": "Vardenafil is a new oral phosphodiesterase inhibitor used for erectile dysfunction.", "question": "Treatment.Disorder in Vardenafil is a new oral phosphodiesterase inhibitor", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "erectile dysfunction"}, {"id": "16244351_2_1217", "context": "Vardenafil is a new oral phosphodiesterase inhibitor used for erectile dysfunction.", "question": "Combination.Drug in Vardenafil is a new oral phosphodiesterase inhibitor", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "17959575_16_1218", "context": "CONCLUSION: A patient with CHF and ESRD developed myoclonic muscle spasms after receiving dobutamine by continuous i.v.", "question": "Subject.Age in A patient with CHF and ESRD", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "17959575_16_1219", "context": "CONCLUSION: A patient with CHF and ESRD developed myoclonic muscle spasms after receiving dobutamine by continuous i.v.", "question": "Subject.Gender in A patient with CHF and ESRD", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "17959575_16_1220", "context": "CONCLUSION: A patient with CHF and ESRD developed myoclonic muscle spasms after receiving dobutamine by continuous i.v.", "question": "Subject.Population in A patient with CHF and ESRD", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "17959575_16_1221", "context": "CONCLUSION: A patient with CHF and ESRD developed myoclonic muscle spasms after receiving dobutamine by continuous i.v.", "question": "Subject.Race in A patient with CHF and ESRD", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "17959575_16_1222", "context": "CONCLUSION: A patient with CHF and ESRD developed myoclonic muscle spasms after receiving dobutamine by continuous i.v.", "question": "Subject.Disorder in A patient with CHF and ESRD", "question_type": "Adverse_event.Subject.Disorder", "answers": "ESRD"}, {"id": "17959575_16_1223", "context": "CONCLUSION: A patient with CHF and ESRD developed myoclonic muscle spasms after receiving dobutamine by continuous i.v.", "question": "Treatment.Drug in dobutamine by continuous i.v", "question_type": "Adverse_event.Treatment.Drug", "answers": "dobutamine"}, {"id": "17959575_16_1224", "context": "CONCLUSION: A patient with CHF and ESRD developed myoclonic muscle spasms after receiving dobutamine by continuous i.v.", "question": "Treatment.Dosage in dobutamine by continuous i.v", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17959575_16_1225", "context": "CONCLUSION: A patient with CHF and ESRD developed myoclonic muscle spasms after receiving dobutamine by continuous i.v.", "question": "Treatment.Freq in dobutamine by continuous i.v", "question_type": "Adverse_event.Treatment.Freq", "answers": "continuous"}, {"id": "17959575_16_1226", "context": "CONCLUSION: A patient with CHF and ESRD developed myoclonic muscle spasms after receiving dobutamine by continuous i.v.", "question": "Treatment.Route in dobutamine by continuous i.v", "question_type": "Adverse_event.Treatment.Route", "answers": "i.v"}, {"id": "17959575_16_1227", "context": "CONCLUSION: A patient with CHF and ESRD developed myoclonic muscle spasms after receiving dobutamine by continuous i.v.", "question": "Treatment.Time_elapsed in dobutamine by continuous i.v", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17959575_16_1228", "context": "CONCLUSION: A patient with CHF and ESRD developed myoclonic muscle spasms after receiving dobutamine by continuous i.v.", "question": "Treatment.Duration in dobutamine by continuous i.v", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17959575_16_1229", "context": "CONCLUSION: A patient with CHF and ESRD developed myoclonic muscle spasms after receiving dobutamine by continuous i.v.", "question": "Treatment.Disorder in dobutamine by continuous i.v", "question_type": "Adverse_event.Treatment.Disorder", "answers": "CHF"}, {"id": "17959575_16_1230", "context": "CONCLUSION: A patient with CHF and ESRD developed myoclonic muscle spasms after receiving dobutamine by continuous i.v.", "question": "Combination.Drug in dobutamine by continuous i.v", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "2568058_1_1231", "context": "Nail-changes induced by penicillamine.", "question": "Treatment.Drug in penicillamine", "question_type": "Adverse_event.Treatment.Drug", "answers": "penicillamine"}, {"id": "2568058_1_1232", "context": "Nail-changes induced by penicillamine.", "question": "Treatment.Dosage in penicillamine", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "2568058_1_1233", "context": "Nail-changes induced by penicillamine.", "question": "Treatment.Freq in penicillamine", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2568058_1_1234", "context": "Nail-changes induced by penicillamine.", "question": "Treatment.Route in penicillamine", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "2568058_1_1235", "context": "Nail-changes induced by penicillamine.", "question": "Treatment.Time_elapsed in penicillamine", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2568058_1_1236", "context": "Nail-changes induced by penicillamine.", "question": "Treatment.Duration in penicillamine", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2568058_1_1237", "context": "Nail-changes induced by penicillamine.", "question": "Treatment.Disorder in penicillamine", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "2568058_1_1238", "context": "Nail-changes induced by penicillamine.", "question": "Combination.Drug in penicillamine", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18562412_4_1239", "context": "The fourth patient showed RLS symptoms that were initially caused by a 20-mg daily olanzapine dosage and were later mitigated when olanzapine was reduced and ropinirole was administered.", "question": "Subject.Age in The fourth patient", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "18562412_4_1240", "context": "The fourth patient showed RLS symptoms that were initially caused by a 20-mg daily olanzapine dosage and were later mitigated when olanzapine was reduced and ropinirole was administered.", "question": "Subject.Gender in The fourth patient", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "18562412_4_1241", "context": "The fourth patient showed RLS symptoms that were initially caused by a 20-mg daily olanzapine dosage and were later mitigated when olanzapine was reduced and ropinirole was administered.", "question": "Subject.Population in The fourth patient", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "18562412_4_1242", "context": "The fourth patient showed RLS symptoms that were initially caused by a 20-mg daily olanzapine dosage and were later mitigated when olanzapine was reduced and ropinirole was administered.", "question": "Subject.Race in The fourth patient", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "18562412_4_1243", "context": "The fourth patient showed RLS symptoms that were initially caused by a 20-mg daily olanzapine dosage and were later mitigated when olanzapine was reduced and ropinirole was administered.", "question": "Subject.Disorder in The fourth patient", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "18562412_4_1244", "context": "The fourth patient showed RLS symptoms that were initially caused by a 20-mg daily olanzapine dosage and were later mitigated when olanzapine was reduced and ropinirole was administered.", "question": "Treatment.Drug in 20-mg daily olanzapine dosage", "question_type": "Adverse_event.Treatment.Drug", "answers": "olanzapine"}, {"id": "18562412_4_1245", "context": "The fourth patient showed RLS symptoms that were initially caused by a 20-mg daily olanzapine dosage and were later mitigated when olanzapine was reduced and ropinirole was administered.", "question": "Treatment.Dosage in 20-mg daily olanzapine dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": "20-mg"}, {"id": "18562412_4_1246", "context": "The fourth patient showed RLS symptoms that were initially caused by a 20-mg daily olanzapine dosage and were later mitigated when olanzapine was reduced and ropinirole was administered.", "question": "Treatment.Freq in 20-mg daily olanzapine dosage", "question_type": "Adverse_event.Treatment.Freq", "answers": "daily"}, {"id": "18562412_4_1247", "context": "The fourth patient showed RLS symptoms that were initially caused by a 20-mg daily olanzapine dosage and were later mitigated when olanzapine was reduced and ropinirole was administered.", "question": "Treatment.Route in 20-mg daily olanzapine dosage", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18562412_4_1248", "context": "The fourth patient showed RLS symptoms that were initially caused by a 20-mg daily olanzapine dosage and were later mitigated when olanzapine was reduced and ropinirole was administered.", "question": "Treatment.Time_elapsed in 20-mg daily olanzapine dosage", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18562412_4_1249", "context": "The fourth patient showed RLS symptoms that were initially caused by a 20-mg daily olanzapine dosage and were later mitigated when olanzapine was reduced and ropinirole was administered.", "question": "Treatment.Duration in 20-mg daily olanzapine dosage", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18562412_4_1250", "context": "The fourth patient showed RLS symptoms that were initially caused by a 20-mg daily olanzapine dosage and were later mitigated when olanzapine was reduced and ropinirole was administered.", "question": "Treatment.Disorder in 20-mg daily olanzapine dosage", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18562412_4_1251", "context": "The fourth patient showed RLS symptoms that were initially caused by a 20-mg daily olanzapine dosage and were later mitigated when olanzapine was reduced and ropinirole was administered.", "question": "Combination.Drug in 20-mg daily olanzapine dosage", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9819544_1_1252", "context": "Naproxen-associated sudden sensorineural hearing loss.", "question": "Treatment.Drug in Naproxen", "question_type": "Adverse_event.Treatment.Drug", "answers": "Naproxen"}, {"id": "9819544_1_1253", "context": "Naproxen-associated sudden sensorineural hearing loss.", "question": "Treatment.Dosage in Naproxen", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9819544_1_1254", "context": "Naproxen-associated sudden sensorineural hearing loss.", "question": "Treatment.Freq in Naproxen", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9819544_1_1255", "context": "Naproxen-associated sudden sensorineural hearing loss.", "question": "Treatment.Route in Naproxen", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9819544_1_1256", "context": "Naproxen-associated sudden sensorineural hearing loss.", "question": "Treatment.Time_elapsed in Naproxen", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9819544_1_1257", "context": "Naproxen-associated sudden sensorineural hearing loss.", "question": "Treatment.Duration in Naproxen", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9819544_1_1258", "context": "Naproxen-associated sudden sensorineural hearing loss.", "question": "Treatment.Disorder in Naproxen", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9819544_1_1259", "context": "Naproxen-associated sudden sensorineural hearing loss.", "question": "Combination.Drug in Naproxen", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15719254_3_1260", "context": "Retinoic acid may increase the risk of bone marrow transplant nephropathy.", "question": "Treatment.Drug in Retinoic acid", "question_type": "Adverse_event.Treatment.Drug", "answers": "Retinoic acid"}, {"id": "15719254_3_1261", "context": "Retinoic acid may increase the risk of bone marrow transplant nephropathy.", "question": "Treatment.Dosage in Retinoic acid", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15719254_3_1262", "context": "Retinoic acid may increase the risk of bone marrow transplant nephropathy.", "question": "Treatment.Freq in Retinoic acid", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15719254_3_1263", "context": "Retinoic acid may increase the risk of bone marrow transplant nephropathy.", "question": "Treatment.Route in Retinoic acid", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15719254_3_1264", "context": "Retinoic acid may increase the risk of bone marrow transplant nephropathy.", "question": "Treatment.Time_elapsed in Retinoic acid", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15719254_3_1265", "context": "Retinoic acid may increase the risk of bone marrow transplant nephropathy.", "question": "Treatment.Duration in Retinoic acid", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15719254_3_1266", "context": "Retinoic acid may increase the risk of bone marrow transplant nephropathy.", "question": "Treatment.Disorder in Retinoic acid", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15719254_3_1267", "context": "Retinoic acid may increase the risk of bone marrow transplant nephropathy.", "question": "Combination.Drug in Retinoic acid", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15827071_13_1268", "context": "A review of published case reports showed a short time to onset of symptoms following the introduction of linezolid, generally within 1-3 days.", "question": "Treatment.Drug in introduction of linezolid, generally within 1-3 days", "question_type": "Adverse_event.Treatment.Drug", "answers": "linezolid"}, {"id": "15827071_13_1269", "context": "A review of published case reports showed a short time to onset of symptoms following the introduction of linezolid, generally within 1-3 days.", "question": "Treatment.Dosage in introduction of linezolid, generally within 1-3 days", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15827071_13_1270", "context": "A review of published case reports showed a short time to onset of symptoms following the introduction of linezolid, generally within 1-3 days.", "question": "Treatment.Freq in introduction of linezolid, generally within 1-3 days", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15827071_13_1271", "context": "A review of published case reports showed a short time to onset of symptoms following the introduction of linezolid, generally within 1-3 days.", "question": "Treatment.Route in introduction of linezolid, generally within 1-3 days", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15827071_13_1272", "context": "A review of published case reports showed a short time to onset of symptoms following the introduction of linezolid, generally within 1-3 days.", "question": "Treatment.Time_elapsed in introduction of linezolid, generally within 1-3 days", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "within 1-3 days"}, {"id": "15827071_13_1273", "context": "A review of published case reports showed a short time to onset of symptoms following the introduction of linezolid, generally within 1-3 days.", "question": "Treatment.Duration in introduction of linezolid, generally within 1-3 days", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15827071_13_1274", "context": "A review of published case reports showed a short time to onset of symptoms following the introduction of linezolid, generally within 1-3 days.", "question": "Treatment.Disorder in introduction of linezolid, generally within 1-3 days", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15827071_13_1275", "context": "A review of published case reports showed a short time to onset of symptoms following the introduction of linezolid, generally within 1-3 days.", "question": "Combination.Drug in introduction of linezolid, generally within 1-3 days", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10465148_2_1276", "context": "Intrathecal chemotherapy with methotrexate or cytosine arabinoside is the standard approach to prophylaxis and treatment of central nervous system leukemia in children.", "question": "Subject.Age in children", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": "children"}, {"id": "10465148_2_1277", "context": "Intrathecal chemotherapy with methotrexate or cytosine arabinoside is the standard approach to prophylaxis and treatment of central nervous system leukemia in children.", "question": "Subject.Gender in children", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "10465148_2_1278", "context": "Intrathecal chemotherapy with methotrexate or cytosine arabinoside is the standard approach to prophylaxis and treatment of central nervous system leukemia in children.", "question": "Subject.Population in children", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "10465148_2_1279", "context": "Intrathecal chemotherapy with methotrexate or cytosine arabinoside is the standard approach to prophylaxis and treatment of central nervous system leukemia in children.", "question": "Subject.Race in children", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "10465148_2_1280", "context": "Intrathecal chemotherapy with methotrexate or cytosine arabinoside is the standard approach to prophylaxis and treatment of central nervous system leukemia in children.", "question": "Subject.Disorder in children", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "10465148_2_1281", "context": "Intrathecal chemotherapy with methotrexate or cytosine arabinoside is the standard approach to prophylaxis and treatment of central nervous system leukemia in children.", "question": "Treatment.Drug in Intrathecal chemotherapy with methotrexate or cytosine arabinoside", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "methotrexate; cytosine arabinoside"}, {"id": "10465148_2_1282", "context": "Intrathecal chemotherapy with methotrexate or cytosine arabinoside is the standard approach to prophylaxis and treatment of central nervous system leukemia in children.", "question": "Treatment.Dosage in Intrathecal chemotherapy with methotrexate or cytosine arabinoside", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "10465148_2_1283", "context": "Intrathecal chemotherapy with methotrexate or cytosine arabinoside is the standard approach to prophylaxis and treatment of central nervous system leukemia in children.", "question": "Treatment.Freq in Intrathecal chemotherapy with methotrexate or cytosine arabinoside", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "10465148_2_1284", "context": "Intrathecal chemotherapy with methotrexate or cytosine arabinoside is the standard approach to prophylaxis and treatment of central nervous system leukemia in children.", "question": "Treatment.Route in Intrathecal chemotherapy with methotrexate or cytosine arabinoside", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": "Intrathecal chemotherapy"}, {"id": "10465148_2_1285", "context": "Intrathecal chemotherapy with methotrexate or cytosine arabinoside is the standard approach to prophylaxis and treatment of central nervous system leukemia in children.", "question": "Treatment.Time_elapsed in Intrathecal chemotherapy with methotrexate or cytosine arabinoside", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10465148_2_1286", "context": "Intrathecal chemotherapy with methotrexate or cytosine arabinoside is the standard approach to prophylaxis and treatment of central nervous system leukemia in children.", "question": "Treatment.Duration in Intrathecal chemotherapy with methotrexate or cytosine arabinoside", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "10465148_2_1287", "context": "Intrathecal chemotherapy with methotrexate or cytosine arabinoside is the standard approach to prophylaxis and treatment of central nervous system leukemia in children.", "question": "Treatment.Disorder in Intrathecal chemotherapy with methotrexate or cytosine arabinoside", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "central nervous system leukemia"}, {"id": "10465148_2_1288", "context": "Intrathecal chemotherapy with methotrexate or cytosine arabinoside is the standard approach to prophylaxis and treatment of central nervous system leukemia in children.", "question": "Combination.Drug in Intrathecal chemotherapy with methotrexate or cytosine arabinoside", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "15827071_10_1289", "context": "The following day, the patient developed anxiety, panic attacks, tremors, tachycardia, and hypertension that persisted throughout linezolid treatment.", "question": "Subject.Age in patient", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "15827071_10_1290", "context": "The following day, the patient developed anxiety, panic attacks, tremors, tachycardia, and hypertension that persisted throughout linezolid treatment.", "question": "Subject.Gender in patient", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15827071_10_1291", "context": "The following day, the patient developed anxiety, panic attacks, tremors, tachycardia, and hypertension that persisted throughout linezolid treatment.", "question": "Subject.Population in patient", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "15827071_10_1292", "context": "The following day, the patient developed anxiety, panic attacks, tremors, tachycardia, and hypertension that persisted throughout linezolid treatment.", "question": "Subject.Race in patient", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15827071_10_1293", "context": "The following day, the patient developed anxiety, panic attacks, tremors, tachycardia, and hypertension that persisted throughout linezolid treatment.", "question": "Subject.Disorder in patient", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15827071_10_1294", "context": "The following day, the patient developed anxiety, panic attacks, tremors, tachycardia, and hypertension that persisted throughout linezolid treatment.", "question": "Treatment.Drug in linezolid", "question_type": "Adverse_event.Treatment.Drug", "answers": "linezolid"}, {"id": "15827071_10_1295", "context": "The following day, the patient developed anxiety, panic attacks, tremors, tachycardia, and hypertension that persisted throughout linezolid treatment.", "question": "Treatment.Dosage in linezolid", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15827071_10_1296", "context": "The following day, the patient developed anxiety, panic attacks, tremors, tachycardia, and hypertension that persisted throughout linezolid treatment.", "question": "Treatment.Freq in linezolid", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15827071_10_1297", "context": "The following day, the patient developed anxiety, panic attacks, tremors, tachycardia, and hypertension that persisted throughout linezolid treatment.", "question": "Treatment.Route in linezolid", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15827071_10_1298", "context": "The following day, the patient developed anxiety, panic attacks, tremors, tachycardia, and hypertension that persisted throughout linezolid treatment.", "question": "Treatment.Time_elapsed in linezolid", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15827071_10_1299", "context": "The following day, the patient developed anxiety, panic attacks, tremors, tachycardia, and hypertension that persisted throughout linezolid treatment.", "question": "Treatment.Duration in linezolid", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15827071_10_1300", "context": "The following day, the patient developed anxiety, panic attacks, tremors, tachycardia, and hypertension that persisted throughout linezolid treatment.", "question": "Treatment.Disorder in linezolid", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15827071_10_1301", "context": "The following day, the patient developed anxiety, panic attacks, tremors, tachycardia, and hypertension that persisted throughout linezolid treatment.", "question": "Combination.Drug in linezolid", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9527943_1_1302", "context": "Effect of beta-blockade on symptomatic dexamethasone-induced hypertrophic obstructive cardiomyopathy in premature infants: three case reports and literature review.", "question": "Subject.Age in premature infants", "question_type": "Adverse_event.Subject.Age", "answers": "infants"}, {"id": "9527943_1_1303", "context": "Effect of beta-blockade on symptomatic dexamethasone-induced hypertrophic obstructive cardiomyopathy in premature infants: three case reports and literature review.", "question": "Subject.Gender in premature infants", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "9527943_1_1304", "context": "Effect of beta-blockade on symptomatic dexamethasone-induced hypertrophic obstructive cardiomyopathy in premature infants: three case reports and literature review.", "question": "Subject.Population in premature infants", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "9527943_1_1305", "context": "Effect of beta-blockade on symptomatic dexamethasone-induced hypertrophic obstructive cardiomyopathy in premature infants: three case reports and literature review.", "question": "Subject.Race in premature infants", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "9527943_1_1306", "context": "Effect of beta-blockade on symptomatic dexamethasone-induced hypertrophic obstructive cardiomyopathy in premature infants: three case reports and literature review.", "question": "Subject.Disorder in premature infants", "question_type": "Adverse_event.Subject.Disorder", "answers": "premature"}, {"id": "9527943_1_1307", "context": "Effect of beta-blockade on symptomatic dexamethasone-induced hypertrophic obstructive cardiomyopathy in premature infants: three case reports and literature review.", "question": "Treatment.Drug in dexamethasone", "question_type": "Adverse_event.Treatment.Drug", "answers": "dexamethasone"}, {"id": "9527943_1_1308", "context": "Effect of beta-blockade on symptomatic dexamethasone-induced hypertrophic obstructive cardiomyopathy in premature infants: three case reports and literature review.", "question": "Treatment.Dosage in dexamethasone", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9527943_1_1309", "context": "Effect of beta-blockade on symptomatic dexamethasone-induced hypertrophic obstructive cardiomyopathy in premature infants: three case reports and literature review.", "question": "Treatment.Freq in dexamethasone", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9527943_1_1310", "context": "Effect of beta-blockade on symptomatic dexamethasone-induced hypertrophic obstructive cardiomyopathy in premature infants: three case reports and literature review.", "question": "Treatment.Route in dexamethasone", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9527943_1_1311", "context": "Effect of beta-blockade on symptomatic dexamethasone-induced hypertrophic obstructive cardiomyopathy in premature infants: three case reports and literature review.", "question": "Treatment.Time_elapsed in dexamethasone", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9527943_1_1312", "context": "Effect of beta-blockade on symptomatic dexamethasone-induced hypertrophic obstructive cardiomyopathy in premature infants: three case reports and literature review.", "question": "Treatment.Duration in dexamethasone", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9527943_1_1313", "context": "Effect of beta-blockade on symptomatic dexamethasone-induced hypertrophic obstructive cardiomyopathy in premature infants: three case reports and literature review.", "question": "Treatment.Disorder in dexamethasone", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9527943_1_1314", "context": "Effect of beta-blockade on symptomatic dexamethasone-induced hypertrophic obstructive cardiomyopathy in premature infants: three case reports and literature review.", "question": "Combination.Drug in dexamethasone", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9527943_1_1315", "context": "Effect of beta-blockade on symptomatic dexamethasone-induced hypertrophic obstructive cardiomyopathy in premature infants: three case reports and literature review.", "question": "Subject.Age in premature infants", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": "infants"}, {"id": "9527943_1_1316", "context": "Effect of beta-blockade on symptomatic dexamethasone-induced hypertrophic obstructive cardiomyopathy in premature infants: three case reports and literature review.", "question": "Subject.Gender in premature infants", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "9527943_1_1317", "context": "Effect of beta-blockade on symptomatic dexamethasone-induced hypertrophic obstructive cardiomyopathy in premature infants: three case reports and literature review.", "question": "Subject.Population in premature infants", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "9527943_1_1318", "context": "Effect of beta-blockade on symptomatic dexamethasone-induced hypertrophic obstructive cardiomyopathy in premature infants: three case reports and literature review.", "question": "Subject.Race in premature infants", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "9527943_1_1319", "context": "Effect of beta-blockade on symptomatic dexamethasone-induced hypertrophic obstructive cardiomyopathy in premature infants: three case reports and literature review.", "question": "Subject.Disorder in premature infants", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": "premature"}, {"id": "9527943_1_1320", "context": "Effect of beta-blockade on symptomatic dexamethasone-induced hypertrophic obstructive cardiomyopathy in premature infants: three case reports and literature review.", "question": "Treatment.Drug in beta-blockade", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "beta-blockade"}, {"id": "9527943_1_1321", "context": "Effect of beta-blockade on symptomatic dexamethasone-induced hypertrophic obstructive cardiomyopathy in premature infants: three case reports and literature review.", "question": "Treatment.Dosage in beta-blockade", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "9527943_1_1322", "context": "Effect of beta-blockade on symptomatic dexamethasone-induced hypertrophic obstructive cardiomyopathy in premature infants: three case reports and literature review.", "question": "Treatment.Freq in beta-blockade", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "9527943_1_1323", "context": "Effect of beta-blockade on symptomatic dexamethasone-induced hypertrophic obstructive cardiomyopathy in premature infants: three case reports and literature review.", "question": "Treatment.Route in beta-blockade", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "9527943_1_1324", "context": "Effect of beta-blockade on symptomatic dexamethasone-induced hypertrophic obstructive cardiomyopathy in premature infants: three case reports and literature review.", "question": "Treatment.Time_elapsed in beta-blockade", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9527943_1_1325", "context": "Effect of beta-blockade on symptomatic dexamethasone-induced hypertrophic obstructive cardiomyopathy in premature infants: three case reports and literature review.", "question": "Treatment.Duration in beta-blockade", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "9527943_1_1326", "context": "Effect of beta-blockade on symptomatic dexamethasone-induced hypertrophic obstructive cardiomyopathy in premature infants: three case reports and literature review.", "question": "Treatment.Disorder in beta-blockade", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "symptomatic dexamethasone-induced hypertrophic obstructive cardiomyopathy"}, {"id": "9527943_1_1327", "context": "Effect of beta-blockade on symptomatic dexamethasone-induced hypertrophic obstructive cardiomyopathy in premature infants: three case reports and literature review.", "question": "Combination.Drug in beta-blockade", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "7235792_1_1328", "context": "Although transient increases in ectopy after bretylium therapy have been described, presumably due to catecholamine release, the occurrence of life-threatening ventricular arrhythmia leading to cardiac arrest has not previously been emphasized.", "question": "Treatment.Drug in bretylium", "question_type": "Adverse_event.Treatment.Drug", "answers": "bretylium"}, {"id": "7235792_1_1329", "context": "Although transient increases in ectopy after bretylium therapy have been described, presumably due to catecholamine release, the occurrence of life-threatening ventricular arrhythmia leading to cardiac arrest has not previously been emphasized.", "question": "Treatment.Dosage in bretylium", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7235792_1_1330", "context": "Although transient increases in ectopy after bretylium therapy have been described, presumably due to catecholamine release, the occurrence of life-threatening ventricular arrhythmia leading to cardiac arrest has not previously been emphasized.", "question": "Treatment.Freq in bretylium", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7235792_1_1331", "context": "Although transient increases in ectopy after bretylium therapy have been described, presumably due to catecholamine release, the occurrence of life-threatening ventricular arrhythmia leading to cardiac arrest has not previously been emphasized.", "question": "Treatment.Route in bretylium", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7235792_1_1332", "context": "Although transient increases in ectopy after bretylium therapy have been described, presumably due to catecholamine release, the occurrence of life-threatening ventricular arrhythmia leading to cardiac arrest has not previously been emphasized.", "question": "Treatment.Time_elapsed in bretylium", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7235792_1_1333", "context": "Although transient increases in ectopy after bretylium therapy have been described, presumably due to catecholamine release, the occurrence of life-threatening ventricular arrhythmia leading to cardiac arrest has not previously been emphasized.", "question": "Treatment.Duration in bretylium", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7235792_1_1334", "context": "Although transient increases in ectopy after bretylium therapy have been described, presumably due to catecholamine release, the occurrence of life-threatening ventricular arrhythmia leading to cardiac arrest has not previously been emphasized.", "question": "Treatment.Disorder in bretylium", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7235792_1_1335", "context": "Although transient increases in ectopy after bretylium therapy have been described, presumably due to catecholamine release, the occurrence of life-threatening ventricular arrhythmia leading to cardiac arrest has not previously been emphasized.", "question": "Combination.Drug in bretylium", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16531969_4_1336", "context": "We report three cases of IFN beta induced hepatitis in MS and discuss the pathology findings and possible mechanisms of drug-induced liver injury.", "question": "Subject.Age in three cases", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "16531969_4_1337", "context": "We report three cases of IFN beta induced hepatitis in MS and discuss the pathology findings and possible mechanisms of drug-induced liver injury.", "question": "Subject.Gender in three cases", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "16531969_4_1338", "context": "We report three cases of IFN beta induced hepatitis in MS and discuss the pathology findings and possible mechanisms of drug-induced liver injury.", "question": "Subject.Population in three cases", "question_type": "Adverse_event.Subject.Population", "answers": "three"}, {"id": "16531969_4_1339", "context": "We report three cases of IFN beta induced hepatitis in MS and discuss the pathology findings and possible mechanisms of drug-induced liver injury.", "question": "Subject.Race in three cases", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16531969_4_1340", "context": "We report three cases of IFN beta induced hepatitis in MS and discuss the pathology findings and possible mechanisms of drug-induced liver injury.", "question": "Subject.Disorder in three cases", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "16531969_4_1341", "context": "We report three cases of IFN beta induced hepatitis in MS and discuss the pathology findings and possible mechanisms of drug-induced liver injury.", "question": "Treatment.Drug in IFN beta", "question_type": "Adverse_event.Treatment.Drug", "answers": "IFN beta"}, {"id": "16531969_4_1342", "context": "We report three cases of IFN beta induced hepatitis in MS and discuss the pathology findings and possible mechanisms of drug-induced liver injury.", "question": "Treatment.Dosage in IFN beta", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16531969_4_1343", "context": "We report three cases of IFN beta induced hepatitis in MS and discuss the pathology findings and possible mechanisms of drug-induced liver injury.", "question": "Treatment.Freq in IFN beta", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16531969_4_1344", "context": "We report three cases of IFN beta induced hepatitis in MS and discuss the pathology findings and possible mechanisms of drug-induced liver injury.", "question": "Treatment.Route in IFN beta", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16531969_4_1345", "context": "We report three cases of IFN beta induced hepatitis in MS and discuss the pathology findings and possible mechanisms of drug-induced liver injury.", "question": "Treatment.Time_elapsed in IFN beta", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16531969_4_1346", "context": "We report three cases of IFN beta induced hepatitis in MS and discuss the pathology findings and possible mechanisms of drug-induced liver injury.", "question": "Treatment.Duration in IFN beta", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16531969_4_1347", "context": "We report three cases of IFN beta induced hepatitis in MS and discuss the pathology findings and possible mechanisms of drug-induced liver injury.", "question": "Treatment.Disorder in IFN beta", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16531969_4_1348", "context": "We report three cases of IFN beta induced hepatitis in MS and discuss the pathology findings and possible mechanisms of drug-induced liver injury.", "question": "Combination.Drug in IFN beta", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "14530108_2_1349", "context": "RTA is one type of nephrotoxicity induced by FK506, and it is reversible in mild cases when appropriately treated.", "question": "Treatment.Drug in FK506", "question_type": "Adverse_event.Treatment.Drug", "answers": "FK506"}, {"id": "14530108_2_1350", "context": "RTA is one type of nephrotoxicity induced by FK506, and it is reversible in mild cases when appropriately treated.", "question": "Treatment.Dosage in FK506", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "14530108_2_1351", "context": "RTA is one type of nephrotoxicity induced by FK506, and it is reversible in mild cases when appropriately treated.", "question": "Treatment.Freq in FK506", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "14530108_2_1352", "context": "RTA is one type of nephrotoxicity induced by FK506, and it is reversible in mild cases when appropriately treated.", "question": "Treatment.Route in FK506", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "14530108_2_1353", "context": "RTA is one type of nephrotoxicity induced by FK506, and it is reversible in mild cases when appropriately treated.", "question": "Treatment.Time_elapsed in FK506", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "14530108_2_1354", "context": "RTA is one type of nephrotoxicity induced by FK506, and it is reversible in mild cases when appropriately treated.", "question": "Treatment.Duration in FK506", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "14530108_2_1355", "context": "RTA is one type of nephrotoxicity induced by FK506, and it is reversible in mild cases when appropriately treated.", "question": "Treatment.Disorder in FK506", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "14530108_2_1356", "context": "RTA is one type of nephrotoxicity induced by FK506, and it is reversible in mild cases when appropriately treated.", "question": "Combination.Drug in FK506", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11984077_2_1357", "context": "The most common side effects associated with amifostine are nausea, vomiting, hypotension, hypocalcemia and allergic reactions.", "question": "Treatment.Drug in amifostine", "question_type": "Adverse_event.Treatment.Drug", "answers": "amifostine"}, {"id": "11984077_2_1358", "context": "The most common side effects associated with amifostine are nausea, vomiting, hypotension, hypocalcemia and allergic reactions.", "question": "Treatment.Dosage in amifostine", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11984077_2_1359", "context": "The most common side effects associated with amifostine are nausea, vomiting, hypotension, hypocalcemia and allergic reactions.", "question": "Treatment.Freq in amifostine", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11984077_2_1360", "context": "The most common side effects associated with amifostine are nausea, vomiting, hypotension, hypocalcemia and allergic reactions.", "question": "Treatment.Route in amifostine", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11984077_2_1361", "context": "The most common side effects associated with amifostine are nausea, vomiting, hypotension, hypocalcemia and allergic reactions.", "question": "Treatment.Time_elapsed in amifostine", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11984077_2_1362", "context": "The most common side effects associated with amifostine are nausea, vomiting, hypotension, hypocalcemia and allergic reactions.", "question": "Treatment.Duration in amifostine", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11984077_2_1363", "context": "The most common side effects associated with amifostine are nausea, vomiting, hypotension, hypocalcemia and allergic reactions.", "question": "Treatment.Disorder in amifostine", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11984077_2_1364", "context": "The most common side effects associated with amifostine are nausea, vomiting, hypotension, hypocalcemia and allergic reactions.", "question": "Combination.Drug in amifostine", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16449538_5_1365", "context": "Nonconvulsive status epilepticus due to ifosfamide.", "question": "Treatment.Drug in ifosfamide", "question_type": "Adverse_event.Treatment.Drug", "answers": "ifosfamide"}, {"id": "16449538_5_1366", "context": "Nonconvulsive status epilepticus due to ifosfamide.", "question": "Treatment.Dosage in ifosfamide", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16449538_5_1367", "context": "Nonconvulsive status epilepticus due to ifosfamide.", "question": "Treatment.Freq in ifosfamide", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16449538_5_1368", "context": "Nonconvulsive status epilepticus due to ifosfamide.", "question": "Treatment.Route in ifosfamide", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16449538_5_1369", "context": "Nonconvulsive status epilepticus due to ifosfamide.", "question": "Treatment.Time_elapsed in ifosfamide", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16449538_5_1370", "context": "Nonconvulsive status epilepticus due to ifosfamide.", "question": "Treatment.Duration in ifosfamide", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16449538_5_1371", "context": "Nonconvulsive status epilepticus due to ifosfamide.", "question": "Treatment.Disorder in ifosfamide", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16449538_5_1372", "context": "Nonconvulsive status epilepticus due to ifosfamide.", "question": "Combination.Drug in ifosfamide", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16122280_3_1373", "context": "Clinical experience in infectious patients has shown that oral telithromycin 800mg once daily for 5-10 days is effective for the treatment of community-acquired upper and lower respiratory tract infections.", "question": "Subject.Age in infectious patients", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "16122280_3_1374", "context": "Clinical experience in infectious patients has shown that oral telithromycin 800mg once daily for 5-10 days is effective for the treatment of community-acquired upper and lower respiratory tract infections.", "question": "Subject.Gender in infectious patients", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "16122280_3_1375", "context": "Clinical experience in infectious patients has shown that oral telithromycin 800mg once daily for 5-10 days is effective for the treatment of community-acquired upper and lower respiratory tract infections.", "question": "Subject.Population in infectious patients", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "16122280_3_1376", "context": "Clinical experience in infectious patients has shown that oral telithromycin 800mg once daily for 5-10 days is effective for the treatment of community-acquired upper and lower respiratory tract infections.", "question": "Subject.Race in infectious patients", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "16122280_3_1377", "context": "Clinical experience in infectious patients has shown that oral telithromycin 800mg once daily for 5-10 days is effective for the treatment of community-acquired upper and lower respiratory tract infections.", "question": "Subject.Disorder in infectious patients", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": "infectious"}, {"id": "16122280_3_1378", "context": "Clinical experience in infectious patients has shown that oral telithromycin 800mg once daily for 5-10 days is effective for the treatment of community-acquired upper and lower respiratory tract infections.", "question": "Treatment.Drug in oral telithromycin 800mg once daily for 5-10 days", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "telithromycin"}, {"id": "16122280_3_1379", "context": "Clinical experience in infectious patients has shown that oral telithromycin 800mg once daily for 5-10 days is effective for the treatment of community-acquired upper and lower respiratory tract infections.", "question": "Treatment.Dosage in oral telithromycin 800mg once daily for 5-10 days", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": "800mg"}, {"id": "16122280_3_1380", "context": "Clinical experience in infectious patients has shown that oral telithromycin 800mg once daily for 5-10 days is effective for the treatment of community-acquired upper and lower respiratory tract infections.", "question": "Treatment.Freq in oral telithromycin 800mg once daily for 5-10 days", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": "once daily"}, {"id": "16122280_3_1381", "context": "Clinical experience in infectious patients has shown that oral telithromycin 800mg once daily for 5-10 days is effective for the treatment of community-acquired upper and lower respiratory tract infections.", "question": "Treatment.Route in oral telithromycin 800mg once daily for 5-10 days", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": "oral"}, {"id": "16122280_3_1382", "context": "Clinical experience in infectious patients has shown that oral telithromycin 800mg once daily for 5-10 days is effective for the treatment of community-acquired upper and lower respiratory tract infections.", "question": "Treatment.Time_elapsed in oral telithromycin 800mg once daily for 5-10 days", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16122280_3_1383", "context": "Clinical experience in infectious patients has shown that oral telithromycin 800mg once daily for 5-10 days is effective for the treatment of community-acquired upper and lower respiratory tract infections.", "question": "Treatment.Duration in oral telithromycin 800mg once daily for 5-10 days", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": "5-10 days"}, {"id": "16122280_3_1384", "context": "Clinical experience in infectious patients has shown that oral telithromycin 800mg once daily for 5-10 days is effective for the treatment of community-acquired upper and lower respiratory tract infections.", "question": "Treatment.Disorder in oral telithromycin 800mg once daily for 5-10 days", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "community-acquired upper and lower respiratory tract infections"}, {"id": "16122280_3_1385", "context": "Clinical experience in infectious patients has shown that oral telithromycin 800mg once daily for 5-10 days is effective for the treatment of community-acquired upper and lower respiratory tract infections.", "question": "Combination.Drug in oral telithromycin 800mg once daily for 5-10 days", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "2549018_2_1386", "context": "Five patients receiving fluoxetine for the treatment of obsessive compulsive disorder or major depression developed akathisia.", "question": "Subject.Age in Five patients", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "2549018_2_1387", "context": "Five patients receiving fluoxetine for the treatment of obsessive compulsive disorder or major depression developed akathisia.", "question": "Subject.Gender in Five patients", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "2549018_2_1388", "context": "Five patients receiving fluoxetine for the treatment of obsessive compulsive disorder or major depression developed akathisia.", "question": "Subject.Population in Five patients", "question_type": "Adverse_event.Subject.Population", "answers": "Five"}, {"id": "2549018_2_1389", "context": "Five patients receiving fluoxetine for the treatment of obsessive compulsive disorder or major depression developed akathisia.", "question": "Subject.Race in Five patients", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "2549018_2_1390", "context": "Five patients receiving fluoxetine for the treatment of obsessive compulsive disorder or major depression developed akathisia.", "question": "Subject.Disorder in Five patients", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "2549018_2_1391", "context": "Five patients receiving fluoxetine for the treatment of obsessive compulsive disorder or major depression developed akathisia.", "question": "Treatment.Drug in fluoxetine", "question_type": "Adverse_event.Treatment.Drug", "answers": "fluoxetine"}, {"id": "2549018_2_1392", "context": "Five patients receiving fluoxetine for the treatment of obsessive compulsive disorder or major depression developed akathisia.", "question": "Treatment.Dosage in fluoxetine", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "2549018_2_1393", "context": "Five patients receiving fluoxetine for the treatment of obsessive compulsive disorder or major depression developed akathisia.", "question": "Treatment.Freq in fluoxetine", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2549018_2_1394", "context": "Five patients receiving fluoxetine for the treatment of obsessive compulsive disorder or major depression developed akathisia.", "question": "Treatment.Route in fluoxetine", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "2549018_2_1395", "context": "Five patients receiving fluoxetine for the treatment of obsessive compulsive disorder or major depression developed akathisia.", "question": "Treatment.Time_elapsed in fluoxetine", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2549018_2_1396", "context": "Five patients receiving fluoxetine for the treatment of obsessive compulsive disorder or major depression developed akathisia.", "question": "Treatment.Duration in fluoxetine", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2549018_2_1397", "context": "Five patients receiving fluoxetine for the treatment of obsessive compulsive disorder or major depression developed akathisia.", "question": "Treatment.Disorder in fluoxetine", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "2549018_2_1398", "context": "Five patients receiving fluoxetine for the treatment of obsessive compulsive disorder or major depression developed akathisia.", "question": "Combination.Drug in fluoxetine", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "14723711_6_1399", "context": "This fourth type of cutaneous minocycline hyperpigmentation may be a variant of Type I, but based on clinical, pathological and microanalytical differences, appears to be a new entity.", "question": "Treatment.Drug in minocycline", "question_type": "Adverse_event.Treatment.Drug", "answers": "minocycline"}, {"id": "14723711_6_1400", "context": "This fourth type of cutaneous minocycline hyperpigmentation may be a variant of Type I, but based on clinical, pathological and microanalytical differences, appears to be a new entity.", "question": "Treatment.Dosage in minocycline", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "14723711_6_1401", "context": "This fourth type of cutaneous minocycline hyperpigmentation may be a variant of Type I, but based on clinical, pathological and microanalytical differences, appears to be a new entity.", "question": "Treatment.Freq in minocycline", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "14723711_6_1402", "context": "This fourth type of cutaneous minocycline hyperpigmentation may be a variant of Type I, but based on clinical, pathological and microanalytical differences, appears to be a new entity.", "question": "Treatment.Route in minocycline", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "14723711_6_1403", "context": "This fourth type of cutaneous minocycline hyperpigmentation may be a variant of Type I, but based on clinical, pathological and microanalytical differences, appears to be a new entity.", "question": "Treatment.Time_elapsed in minocycline", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "14723711_6_1404", "context": "This fourth type of cutaneous minocycline hyperpigmentation may be a variant of Type I, but based on clinical, pathological and microanalytical differences, appears to be a new entity.", "question": "Treatment.Duration in minocycline", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "14723711_6_1405", "context": "This fourth type of cutaneous minocycline hyperpigmentation may be a variant of Type I, but based on clinical, pathological and microanalytical differences, appears to be a new entity.", "question": "Treatment.Disorder in minocycline", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "14723711_6_1406", "context": "This fourth type of cutaneous minocycline hyperpigmentation may be a variant of Type I, but based on clinical, pathological and microanalytical differences, appears to be a new entity.", "question": "Combination.Drug in minocycline", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12196060_1_1407", "context": "Phenytoin/isradipine interaction causing severe neurologic toxicity.", "question": "Treatment.Drug in Phenytoin/isradipine interaction", "question_type": "Adverse_event.Treatment.Drug", "answers": "Phenytoin; isradipine"}, {"id": "12196060_1_1408", "context": "Phenytoin/isradipine interaction causing severe neurologic toxicity.", "question": "Treatment.Dosage in Phenytoin/isradipine interaction", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12196060_1_1409", "context": "Phenytoin/isradipine interaction causing severe neurologic toxicity.", "question": "Treatment.Freq in Phenytoin/isradipine interaction", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12196060_1_1410", "context": "Phenytoin/isradipine interaction causing severe neurologic toxicity.", "question": "Treatment.Route in Phenytoin/isradipine interaction", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12196060_1_1411", "context": "Phenytoin/isradipine interaction causing severe neurologic toxicity.", "question": "Treatment.Time_elapsed in Phenytoin/isradipine interaction", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12196060_1_1412", "context": "Phenytoin/isradipine interaction causing severe neurologic toxicity.", "question": "Treatment.Duration in Phenytoin/isradipine interaction", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12196060_1_1413", "context": "Phenytoin/isradipine interaction causing severe neurologic toxicity.", "question": "Treatment.Disorder in Phenytoin/isradipine interaction", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12196060_1_1414", "context": "Phenytoin/isradipine interaction causing severe neurologic toxicity.", "question": "Combination.Drug in Phenytoin/isradipine interaction", "question_type": "Adverse_event.Combination.Drug", "answers": "isradipine; Phenytoin"}, {"id": "3609047_3_1415", "context": "We report a case of torsade de pointes following a single oral dose of amiodarone (1400 mg or 30 mg kg-1) administered after short intravenous loading for prevention of paroxysmal atrial flutter.", "question": "Treatment.Drug in a single oral dose of amiodarone (1400 mg or 30 mg kg-1)", "question_type": "Adverse_event.Treatment.Drug", "answers": "amiodarone"}, {"id": "3609047_3_1416", "context": "We report a case of torsade de pointes following a single oral dose of amiodarone (1400 mg or 30 mg kg-1) administered after short intravenous loading for prevention of paroxysmal atrial flutter.", "question": "Treatment.Dosage in a single oral dose of amiodarone (1400 mg or 30 mg kg-1)", "question_type": "Adverse_event.Treatment.Dosage", "answers": "single oral dose; 1400 mg; 30 mg kg-1"}, {"id": "3609047_3_1417", "context": "We report a case of torsade de pointes following a single oral dose of amiodarone (1400 mg or 30 mg kg-1) administered after short intravenous loading for prevention of paroxysmal atrial flutter.", "question": "Treatment.Freq in a single oral dose of amiodarone (1400 mg or 30 mg kg-1)", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3609047_3_1418", "context": "We report a case of torsade de pointes following a single oral dose of amiodarone (1400 mg or 30 mg kg-1) administered after short intravenous loading for prevention of paroxysmal atrial flutter.", "question": "Treatment.Route in a single oral dose of amiodarone (1400 mg or 30 mg kg-1)", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3609047_3_1419", "context": "We report a case of torsade de pointes following a single oral dose of amiodarone (1400 mg or 30 mg kg-1) administered after short intravenous loading for prevention of paroxysmal atrial flutter.", "question": "Treatment.Time_elapsed in a single oral dose of amiodarone (1400 mg or 30 mg kg-1)", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3609047_3_1420", "context": "We report a case of torsade de pointes following a single oral dose of amiodarone (1400 mg or 30 mg kg-1) administered after short intravenous loading for prevention of paroxysmal atrial flutter.", "question": "Treatment.Duration in a single oral dose of amiodarone (1400 mg or 30 mg kg-1)", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3609047_3_1421", "context": "We report a case of torsade de pointes following a single oral dose of amiodarone (1400 mg or 30 mg kg-1) administered after short intravenous loading for prevention of paroxysmal atrial flutter.", "question": "Treatment.Disorder in a single oral dose of amiodarone (1400 mg or 30 mg kg-1)", "question_type": "Adverse_event.Treatment.Disorder", "answers": "prevention of paroxysmal atrial flutter"}, {"id": "3609047_3_1422", "context": "We report a case of torsade de pointes following a single oral dose of amiodarone (1400 mg or 30 mg kg-1) administered after short intravenous loading for prevention of paroxysmal atrial flutter.", "question": "Combination.Drug in a single oral dose of amiodarone (1400 mg or 30 mg kg-1)", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "14660304_2_1423", "context": "Traditionally, children with acute lymphoblastic leukemia receive prednisone, as part of multiagent remission-induction chemotherapy.", "question": "Subject.Age in children with acute lymphoblastic leukemia", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": "children"}, {"id": "14660304_2_1424", "context": "Traditionally, children with acute lymphoblastic leukemia receive prednisone, as part of multiagent remission-induction chemotherapy.", "question": "Subject.Gender in children with acute lymphoblastic leukemia", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "14660304_2_1425", "context": "Traditionally, children with acute lymphoblastic leukemia receive prednisone, as part of multiagent remission-induction chemotherapy.", "question": "Subject.Population in children with acute lymphoblastic leukemia", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "14660304_2_1426", "context": "Traditionally, children with acute lymphoblastic leukemia receive prednisone, as part of multiagent remission-induction chemotherapy.", "question": "Subject.Race in children with acute lymphoblastic leukemia", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "14660304_2_1427", "context": "Traditionally, children with acute lymphoblastic leukemia receive prednisone, as part of multiagent remission-induction chemotherapy.", "question": "Subject.Disorder in children with acute lymphoblastic leukemia", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "14660304_2_1428", "context": "Traditionally, children with acute lymphoblastic leukemia receive prednisone, as part of multiagent remission-induction chemotherapy.", "question": "Treatment.Drug in prednisone", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "prednisone"}, {"id": "14660304_2_1429", "context": "Traditionally, children with acute lymphoblastic leukemia receive prednisone, as part of multiagent remission-induction chemotherapy.", "question": "Treatment.Dosage in prednisone", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "14660304_2_1430", "context": "Traditionally, children with acute lymphoblastic leukemia receive prednisone, as part of multiagent remission-induction chemotherapy.", "question": "Treatment.Freq in prednisone", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "14660304_2_1431", "context": "Traditionally, children with acute lymphoblastic leukemia receive prednisone, as part of multiagent remission-induction chemotherapy.", "question": "Treatment.Route in prednisone", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "14660304_2_1432", "context": "Traditionally, children with acute lymphoblastic leukemia receive prednisone, as part of multiagent remission-induction chemotherapy.", "question": "Treatment.Time_elapsed in prednisone", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "14660304_2_1433", "context": "Traditionally, children with acute lymphoblastic leukemia receive prednisone, as part of multiagent remission-induction chemotherapy.", "question": "Treatment.Duration in prednisone", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "14660304_2_1434", "context": "Traditionally, children with acute lymphoblastic leukemia receive prednisone, as part of multiagent remission-induction chemotherapy.", "question": "Treatment.Disorder in prednisone", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "acute lymphoblastic leukemia"}, {"id": "14660304_2_1435", "context": "Traditionally, children with acute lymphoblastic leukemia receive prednisone, as part of multiagent remission-induction chemotherapy.", "question": "Combination.Drug in prednisone", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "15760792_3_1436", "context": "Propylthiouracil-induced sensorineural hearing loss associated with antineutrophil cytoplasmic antibodies.", "question": "Treatment.Drug in Propylthiouracil", "question_type": "Adverse_event.Treatment.Drug", "answers": "Propylthiouracil"}, {"id": "15760792_3_1437", "context": "Propylthiouracil-induced sensorineural hearing loss associated with antineutrophil cytoplasmic antibodies.", "question": "Treatment.Dosage in Propylthiouracil", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15760792_3_1438", "context": "Propylthiouracil-induced sensorineural hearing loss associated with antineutrophil cytoplasmic antibodies.", "question": "Treatment.Freq in Propylthiouracil", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15760792_3_1439", "context": "Propylthiouracil-induced sensorineural hearing loss associated with antineutrophil cytoplasmic antibodies.", "question": "Treatment.Route in Propylthiouracil", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15760792_3_1440", "context": "Propylthiouracil-induced sensorineural hearing loss associated with antineutrophil cytoplasmic antibodies.", "question": "Treatment.Time_elapsed in Propylthiouracil", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15760792_3_1441", "context": "Propylthiouracil-induced sensorineural hearing loss associated with antineutrophil cytoplasmic antibodies.", "question": "Treatment.Duration in Propylthiouracil", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15760792_3_1442", "context": "Propylthiouracil-induced sensorineural hearing loss associated with antineutrophil cytoplasmic antibodies.", "question": "Treatment.Disorder in Propylthiouracil", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15760792_3_1443", "context": "Propylthiouracil-induced sensorineural hearing loss associated with antineutrophil cytoplasmic antibodies.", "question": "Combination.Drug in Propylthiouracil", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9466030_1_1444", "context": "Acute respiratory depression as a complication of nebulised morphine.", "question": "Treatment.Drug in nebulised morphine", "question_type": "Adverse_event.Treatment.Drug", "answers": "morphine"}, {"id": "9466030_1_1445", "context": "Acute respiratory depression as a complication of nebulised morphine.", "question": "Treatment.Dosage in nebulised morphine", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9466030_1_1446", "context": "Acute respiratory depression as a complication of nebulised morphine.", "question": "Treatment.Freq in nebulised morphine", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9466030_1_1447", "context": "Acute respiratory depression as a complication of nebulised morphine.", "question": "Treatment.Route in nebulised morphine", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9466030_1_1448", "context": "Acute respiratory depression as a complication of nebulised morphine.", "question": "Treatment.Time_elapsed in nebulised morphine", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9466030_1_1449", "context": "Acute respiratory depression as a complication of nebulised morphine.", "question": "Treatment.Duration in nebulised morphine", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9466030_1_1450", "context": "Acute respiratory depression as a complication of nebulised morphine.", "question": "Treatment.Disorder in nebulised morphine", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9466030_1_1451", "context": "Acute respiratory depression as a complication of nebulised morphine.", "question": "Combination.Drug in nebulised morphine", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7420580_2_1452", "context": "We report on a patient with an embryonal teratocarcinoma of the testicle who had the syndrome of inappropriate secretion of antidiuretic hormone after receiving a high dose of vinblastine.", "question": "Subject.Age in a patient with an embryonal teratocarcinoma of the testicle", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "7420580_2_1453", "context": "We report on a patient with an embryonal teratocarcinoma of the testicle who had the syndrome of inappropriate secretion of antidiuretic hormone after receiving a high dose of vinblastine.", "question": "Subject.Gender in a patient with an embryonal teratocarcinoma of the testicle", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "7420580_2_1454", "context": "We report on a patient with an embryonal teratocarcinoma of the testicle who had the syndrome of inappropriate secretion of antidiuretic hormone after receiving a high dose of vinblastine.", "question": "Subject.Population in a patient with an embryonal teratocarcinoma of the testicle", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "7420580_2_1455", "context": "We report on a patient with an embryonal teratocarcinoma of the testicle who had the syndrome of inappropriate secretion of antidiuretic hormone after receiving a high dose of vinblastine.", "question": "Subject.Race in a patient with an embryonal teratocarcinoma of the testicle", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "7420580_2_1456", "context": "We report on a patient with an embryonal teratocarcinoma of the testicle who had the syndrome of inappropriate secretion of antidiuretic hormone after receiving a high dose of vinblastine.", "question": "Subject.Disorder in a patient with an embryonal teratocarcinoma of the testicle", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "7420580_2_1457", "context": "We report on a patient with an embryonal teratocarcinoma of the testicle who had the syndrome of inappropriate secretion of antidiuretic hormone after receiving a high dose of vinblastine.", "question": "Treatment.Drug in a high dose of vinblastine", "question_type": "Adverse_event.Treatment.Drug", "answers": "vinblastine"}, {"id": "7420580_2_1458", "context": "We report on a patient with an embryonal teratocarcinoma of the testicle who had the syndrome of inappropriate secretion of antidiuretic hormone after receiving a high dose of vinblastine.", "question": "Treatment.Dosage in a high dose of vinblastine", "question_type": "Adverse_event.Treatment.Dosage", "answers": "high dose"}, {"id": "7420580_2_1459", "context": "We report on a patient with an embryonal teratocarcinoma of the testicle who had the syndrome of inappropriate secretion of antidiuretic hormone after receiving a high dose of vinblastine.", "question": "Treatment.Freq in a high dose of vinblastine", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7420580_2_1460", "context": "We report on a patient with an embryonal teratocarcinoma of the testicle who had the syndrome of inappropriate secretion of antidiuretic hormone after receiving a high dose of vinblastine.", "question": "Treatment.Route in a high dose of vinblastine", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7420580_2_1461", "context": "We report on a patient with an embryonal teratocarcinoma of the testicle who had the syndrome of inappropriate secretion of antidiuretic hormone after receiving a high dose of vinblastine.", "question": "Treatment.Time_elapsed in a high dose of vinblastine", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7420580_2_1462", "context": "We report on a patient with an embryonal teratocarcinoma of the testicle who had the syndrome of inappropriate secretion of antidiuretic hormone after receiving a high dose of vinblastine.", "question": "Treatment.Duration in a high dose of vinblastine", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7420580_2_1463", "context": "We report on a patient with an embryonal teratocarcinoma of the testicle who had the syndrome of inappropriate secretion of antidiuretic hormone after receiving a high dose of vinblastine.", "question": "Treatment.Disorder in a high dose of vinblastine", "question_type": "Adverse_event.Treatment.Disorder", "answers": "embryonal teratocarcinoma of the testicle"}, {"id": "7420580_2_1464", "context": "We report on a patient with an embryonal teratocarcinoma of the testicle who had the syndrome of inappropriate secretion of antidiuretic hormone after receiving a high dose of vinblastine.", "question": "Combination.Drug in a high dose of vinblastine", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8864370_4_1465", "context": "Methotrexate-induced liver cirrhosis.", "question": "Treatment.Drug in Methotrexate", "question_type": "Adverse_event.Treatment.Drug", "answers": "Methotrexate"}, {"id": "8864370_4_1466", "context": "Methotrexate-induced liver cirrhosis.", "question": "Treatment.Dosage in Methotrexate", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8864370_4_1467", "context": "Methotrexate-induced liver cirrhosis.", "question": "Treatment.Freq in Methotrexate", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8864370_4_1468", "context": "Methotrexate-induced liver cirrhosis.", "question": "Treatment.Route in Methotrexate", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8864370_4_1469", "context": "Methotrexate-induced liver cirrhosis.", "question": "Treatment.Time_elapsed in Methotrexate", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8864370_4_1470", "context": "Methotrexate-induced liver cirrhosis.", "question": "Treatment.Duration in Methotrexate", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8864370_4_1471", "context": "Methotrexate-induced liver cirrhosis.", "question": "Treatment.Disorder in Methotrexate", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8864370_4_1472", "context": "Methotrexate-induced liver cirrhosis.", "question": "Combination.Drug in Methotrexate", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17195428_2_1473", "context": "A case of oculogyric crisis induced by metoclopramide is described in this paper.", "question": "Treatment.Drug in metoclopramide", "question_type": "Adverse_event.Treatment.Drug", "answers": "metoclopramide"}, {"id": "17195428_2_1474", "context": "A case of oculogyric crisis induced by metoclopramide is described in this paper.", "question": "Treatment.Dosage in metoclopramide", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17195428_2_1475", "context": "A case of oculogyric crisis induced by metoclopramide is described in this paper.", "question": "Treatment.Freq in metoclopramide", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17195428_2_1476", "context": "A case of oculogyric crisis induced by metoclopramide is described in this paper.", "question": "Treatment.Route in metoclopramide", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17195428_2_1477", "context": "A case of oculogyric crisis induced by metoclopramide is described in this paper.", "question": "Treatment.Time_elapsed in metoclopramide", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17195428_2_1478", "context": "A case of oculogyric crisis induced by metoclopramide is described in this paper.", "question": "Treatment.Duration in metoclopramide", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17195428_2_1479", "context": "A case of oculogyric crisis induced by metoclopramide is described in this paper.", "question": "Treatment.Disorder in metoclopramide", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17195428_2_1480", "context": "A case of oculogyric crisis induced by metoclopramide is described in this paper.", "question": "Combination.Drug in metoclopramide", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12806509_1_1481", "context": "Early-onset acute transverse myelitis following hepatitis B vaccination and respiratory infection: case report.", "question": "Subject.Age in case", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "12806509_1_1482", "context": "Early-onset acute transverse myelitis following hepatitis B vaccination and respiratory infection: case report.", "question": "Subject.Gender in case", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "12806509_1_1483", "context": "Early-onset acute transverse myelitis following hepatitis B vaccination and respiratory infection: case report.", "question": "Subject.Population in case", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "12806509_1_1484", "context": "Early-onset acute transverse myelitis following hepatitis B vaccination and respiratory infection: case report.", "question": "Subject.Race in case", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "12806509_1_1485", "context": "Early-onset acute transverse myelitis following hepatitis B vaccination and respiratory infection: case report.", "question": "Subject.Disorder in case", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "12806509_1_1486", "context": "Early-onset acute transverse myelitis following hepatitis B vaccination and respiratory infection: case report.", "question": "Treatment.Drug in hepatitis B vaccination", "question_type": "Adverse_event.Treatment.Drug", "answers": "hepatitis B vaccination"}, {"id": "12806509_1_1487", "context": "Early-onset acute transverse myelitis following hepatitis B vaccination and respiratory infection: case report.", "question": "Treatment.Dosage in hepatitis B vaccination", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12806509_1_1488", "context": "Early-onset acute transverse myelitis following hepatitis B vaccination and respiratory infection: case report.", "question": "Treatment.Freq in hepatitis B vaccination", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12806509_1_1489", "context": "Early-onset acute transverse myelitis following hepatitis B vaccination and respiratory infection: case report.", "question": "Treatment.Route in hepatitis B vaccination", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12806509_1_1490", "context": "Early-onset acute transverse myelitis following hepatitis B vaccination and respiratory infection: case report.", "question": "Treatment.Time_elapsed in hepatitis B vaccination", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12806509_1_1491", "context": "Early-onset acute transverse myelitis following hepatitis B vaccination and respiratory infection: case report.", "question": "Treatment.Duration in hepatitis B vaccination", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12806509_1_1492", "context": "Early-onset acute transverse myelitis following hepatitis B vaccination and respiratory infection: case report.", "question": "Treatment.Disorder in hepatitis B vaccination", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12806509_1_1493", "context": "Early-onset acute transverse myelitis following hepatitis B vaccination and respiratory infection: case report.", "question": "Combination.Drug in hepatitis B vaccination", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "2429270_5_1494", "context": "The pro-arrhythmic effects of procainamide may be explained on the basis of both its vagolytic action on the atrioventricular node as well as by prolongation of refractoriness in the accessory pathway.", "question": "Treatment.Drug in procainamide", "question_type": "Adverse_event.Treatment.Drug", "answers": "procainamide"}, {"id": "2429270_5_1495", "context": "The pro-arrhythmic effects of procainamide may be explained on the basis of both its vagolytic action on the atrioventricular node as well as by prolongation of refractoriness in the accessory pathway.", "question": "Treatment.Dosage in procainamide", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "2429270_5_1496", "context": "The pro-arrhythmic effects of procainamide may be explained on the basis of both its vagolytic action on the atrioventricular node as well as by prolongation of refractoriness in the accessory pathway.", "question": "Treatment.Freq in procainamide", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2429270_5_1497", "context": "The pro-arrhythmic effects of procainamide may be explained on the basis of both its vagolytic action on the atrioventricular node as well as by prolongation of refractoriness in the accessory pathway.", "question": "Treatment.Route in procainamide", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "2429270_5_1498", "context": "The pro-arrhythmic effects of procainamide may be explained on the basis of both its vagolytic action on the atrioventricular node as well as by prolongation of refractoriness in the accessory pathway.", "question": "Treatment.Time_elapsed in procainamide", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2429270_5_1499", "context": "The pro-arrhythmic effects of procainamide may be explained on the basis of both its vagolytic action on the atrioventricular node as well as by prolongation of refractoriness in the accessory pathway.", "question": "Treatment.Duration in procainamide", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2429270_5_1500", "context": "The pro-arrhythmic effects of procainamide may be explained on the basis of both its vagolytic action on the atrioventricular node as well as by prolongation of refractoriness in the accessory pathway.", "question": "Treatment.Disorder in procainamide", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "2429270_5_1501", "context": "The pro-arrhythmic effects of procainamide may be explained on the basis of both its vagolytic action on the atrioventricular node as well as by prolongation of refractoriness in the accessory pathway.", "question": "Combination.Drug in procainamide", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12661801_3_1502", "context": "We present the management of agranulocytosis and neutropenic sepsis secondary to carbimazole with recombinant human granulocyte colony stimulating factor (G-CSF).", "question": "Treatment.Drug in carbimazole with recombinant human granulocyte colony stimulating factor (G-CSF)", "question_type": "Adverse_event.Treatment.Drug", "answers": "carbimazole; recombinant human granulocyte colony stimulating factor"}, {"id": "12661801_3_1503", "context": "We present the management of agranulocytosis and neutropenic sepsis secondary to carbimazole with recombinant human granulocyte colony stimulating factor (G-CSF).", "question": "Treatment.Dosage in carbimazole with recombinant human granulocyte colony stimulating factor (G-CSF)", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12661801_3_1504", "context": "We present the management of agranulocytosis and neutropenic sepsis secondary to carbimazole with recombinant human granulocyte colony stimulating factor (G-CSF).", "question": "Treatment.Freq in carbimazole with recombinant human granulocyte colony stimulating factor (G-CSF)", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12661801_3_1505", "context": "We present the management of agranulocytosis and neutropenic sepsis secondary to carbimazole with recombinant human granulocyte colony stimulating factor (G-CSF).", "question": "Treatment.Route in carbimazole with recombinant human granulocyte colony stimulating factor (G-CSF)", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12661801_3_1506", "context": "We present the management of agranulocytosis and neutropenic sepsis secondary to carbimazole with recombinant human granulocyte colony stimulating factor (G-CSF).", "question": "Treatment.Time_elapsed in carbimazole with recombinant human granulocyte colony stimulating factor (G-CSF)", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12661801_3_1507", "context": "We present the management of agranulocytosis and neutropenic sepsis secondary to carbimazole with recombinant human granulocyte colony stimulating factor (G-CSF).", "question": "Treatment.Duration in carbimazole with recombinant human granulocyte colony stimulating factor (G-CSF)", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12661801_3_1508", "context": "We present the management of agranulocytosis and neutropenic sepsis secondary to carbimazole with recombinant human granulocyte colony stimulating factor (G-CSF).", "question": "Treatment.Disorder in carbimazole with recombinant human granulocyte colony stimulating factor (G-CSF)", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12661801_3_1509", "context": "We present the management of agranulocytosis and neutropenic sepsis secondary to carbimazole with recombinant human granulocyte colony stimulating factor (G-CSF).", "question": "Combination.Drug in carbimazole with recombinant human granulocyte colony stimulating factor (G-CSF)", "question_type": "Adverse_event.Combination.Drug", "answers": "recombinant human granulocyte colony stimulating factor; carbimazole"}, {"id": "16459502_1_1510", "context": "Cutaneous mycobacterial infection post intravesical BCG installation.", "question": "Treatment.Drug in intravesical BCG installation", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16459502_1_1511", "context": "Cutaneous mycobacterial infection post intravesical BCG installation.", "question": "Treatment.Dosage in intravesical BCG installation", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16459502_1_1512", "context": "Cutaneous mycobacterial infection post intravesical BCG installation.", "question": "Treatment.Freq in intravesical BCG installation", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16459502_1_1513", "context": "Cutaneous mycobacterial infection post intravesical BCG installation.", "question": "Treatment.Route in intravesical BCG installation", "question_type": "Adverse_event.Treatment.Route", "answers": "intravesical"}, {"id": "16459502_1_1514", "context": "Cutaneous mycobacterial infection post intravesical BCG installation.", "question": "Treatment.Time_elapsed in intravesical BCG installation", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16459502_1_1515", "context": "Cutaneous mycobacterial infection post intravesical BCG installation.", "question": "Treatment.Duration in intravesical BCG installation", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16459502_1_1516", "context": "Cutaneous mycobacterial infection post intravesical BCG installation.", "question": "Treatment.Disorder in intravesical BCG installation", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16459502_1_1517", "context": "Cutaneous mycobacterial infection post intravesical BCG installation.", "question": "Combination.Drug in intravesical BCG installation", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "19690222_2_1518", "context": "On day 4, following 3 doses of dalteparin, the patient developed acute respiratory distress attributable to a massive right hemothorax confirmed by computed tomography pulmonary angiography (CTPA) and intercostal drainage of 1500 mL of frank blood.", "question": "Subject.Age in the patient", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "19690222_2_1519", "context": "On day 4, following 3 doses of dalteparin, the patient developed acute respiratory distress attributable to a massive right hemothorax confirmed by computed tomography pulmonary angiography (CTPA) and intercostal drainage of 1500 mL of frank blood.", "question": "Subject.Gender in the patient", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "19690222_2_1520", "context": "On day 4, following 3 doses of dalteparin, the patient developed acute respiratory distress attributable to a massive right hemothorax confirmed by computed tomography pulmonary angiography (CTPA) and intercostal drainage of 1500 mL of frank blood.", "question": "Subject.Population in the patient", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "19690222_2_1521", "context": "On day 4, following 3 doses of dalteparin, the patient developed acute respiratory distress attributable to a massive right hemothorax confirmed by computed tomography pulmonary angiography (CTPA) and intercostal drainage of 1500 mL of frank blood.", "question": "Subject.Race in the patient", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "19690222_2_1522", "context": "On day 4, following 3 doses of dalteparin, the patient developed acute respiratory distress attributable to a massive right hemothorax confirmed by computed tomography pulmonary angiography (CTPA) and intercostal drainage of 1500 mL of frank blood.", "question": "Subject.Disorder in the patient", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "19690222_2_1523", "context": "On day 4, following 3 doses of dalteparin, the patient developed acute respiratory distress attributable to a massive right hemothorax confirmed by computed tomography pulmonary angiography (CTPA) and intercostal drainage of 1500 mL of frank blood.", "question": "Treatment.Drug in 3 doses of dalteparin", "question_type": "Adverse_event.Treatment.Drug", "answers": "dalteparin"}, {"id": "19690222_2_1524", "context": "On day 4, following 3 doses of dalteparin, the patient developed acute respiratory distress attributable to a massive right hemothorax confirmed by computed tomography pulmonary angiography (CTPA) and intercostal drainage of 1500 mL of frank blood.", "question": "Treatment.Dosage in 3 doses of dalteparin", "question_type": "Adverse_event.Treatment.Dosage", "answers": "3 doses"}, {"id": "19690222_2_1525", "context": "On day 4, following 3 doses of dalteparin, the patient developed acute respiratory distress attributable to a massive right hemothorax confirmed by computed tomography pulmonary angiography (CTPA) and intercostal drainage of 1500 mL of frank blood.", "question": "Treatment.Freq in 3 doses of dalteparin", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "19690222_2_1526", "context": "On day 4, following 3 doses of dalteparin, the patient developed acute respiratory distress attributable to a massive right hemothorax confirmed by computed tomography pulmonary angiography (CTPA) and intercostal drainage of 1500 mL of frank blood.", "question": "Treatment.Route in 3 doses of dalteparin", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "19690222_2_1527", "context": "On day 4, following 3 doses of dalteparin, the patient developed acute respiratory distress attributable to a massive right hemothorax confirmed by computed tomography pulmonary angiography (CTPA) and intercostal drainage of 1500 mL of frank blood.", "question": "Treatment.Time_elapsed in 3 doses of dalteparin", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19690222_2_1528", "context": "On day 4, following 3 doses of dalteparin, the patient developed acute respiratory distress attributable to a massive right hemothorax confirmed by computed tomography pulmonary angiography (CTPA) and intercostal drainage of 1500 mL of frank blood.", "question": "Treatment.Duration in 3 doses of dalteparin", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "19690222_2_1529", "context": "On day 4, following 3 doses of dalteparin, the patient developed acute respiratory distress attributable to a massive right hemothorax confirmed by computed tomography pulmonary angiography (CTPA) and intercostal drainage of 1500 mL of frank blood.", "question": "Treatment.Disorder in 3 doses of dalteparin", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "19690222_2_1530", "context": "On day 4, following 3 doses of dalteparin, the patient developed acute respiratory distress attributable to a massive right hemothorax confirmed by computed tomography pulmonary angiography (CTPA) and intercostal drainage of 1500 mL of frank blood.", "question": "Combination.Drug in 3 doses of dalteparin", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "23774436_2_1531", "context": "A 4-month regimen of gatifloxacin with rifampin, isoniazid, and pyrazinamide is being evaluated for the treatment of tuberculosis in a phase 3 randomized controlled trial (OFLOTUB).", "question": "Treatment.Drug in gatifloxacin; rifampin; isoniazid; pyrazinamide", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "gatifloxacin; rifampin; isoniazid; pyrazinamide"}, {"id": "23774436_2_1532", "context": "A 4-month regimen of gatifloxacin with rifampin, isoniazid, and pyrazinamide is being evaluated for the treatment of tuberculosis in a phase 3 randomized controlled trial (OFLOTUB).", "question": "Treatment.Dosage in gatifloxacin; rifampin; isoniazid; pyrazinamide", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "23774436_2_1533", "context": "A 4-month regimen of gatifloxacin with rifampin, isoniazid, and pyrazinamide is being evaluated for the treatment of tuberculosis in a phase 3 randomized controlled trial (OFLOTUB).", "question": "Treatment.Freq in gatifloxacin; rifampin; isoniazid; pyrazinamide", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "23774436_2_1534", "context": "A 4-month regimen of gatifloxacin with rifampin, isoniazid, and pyrazinamide is being evaluated for the treatment of tuberculosis in a phase 3 randomized controlled trial (OFLOTUB).", "question": "Treatment.Route in gatifloxacin; rifampin; isoniazid; pyrazinamide", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "23774436_2_1535", "context": "A 4-month regimen of gatifloxacin with rifampin, isoniazid, and pyrazinamide is being evaluated for the treatment of tuberculosis in a phase 3 randomized controlled trial (OFLOTUB).", "question": "Treatment.Time_elapsed in gatifloxacin; rifampin; isoniazid; pyrazinamide", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "23774436_2_1536", "context": "A 4-month regimen of gatifloxacin with rifampin, isoniazid, and pyrazinamide is being evaluated for the treatment of tuberculosis in a phase 3 randomized controlled trial (OFLOTUB).", "question": "Treatment.Duration in gatifloxacin; rifampin; isoniazid; pyrazinamide", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "23774436_2_1537", "context": "A 4-month regimen of gatifloxacin with rifampin, isoniazid, and pyrazinamide is being evaluated for the treatment of tuberculosis in a phase 3 randomized controlled trial (OFLOTUB).", "question": "Treatment.Disorder in gatifloxacin; rifampin; isoniazid; pyrazinamide", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "tuberculosis"}, {"id": "23774436_2_1538", "context": "A 4-month regimen of gatifloxacin with rifampin, isoniazid, and pyrazinamide is being evaluated for the treatment of tuberculosis in a phase 3 randomized controlled trial (OFLOTUB).", "question": "Combination.Drug in gatifloxacin; rifampin; isoniazid; pyrazinamide", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": "isoniazid; pyrazinamide"}, {"id": "9619226_2_1539", "context": "We postulate that the bolus of sulprostone resulted in possible coronary spasm that resulted in cardiac arrest.", "question": "Treatment.Drug in sulprostone", "question_type": "Adverse_event.Treatment.Drug", "answers": "sulprostone"}, {"id": "9619226_2_1540", "context": "We postulate that the bolus of sulprostone resulted in possible coronary spasm that resulted in cardiac arrest.", "question": "Treatment.Dosage in sulprostone", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9619226_2_1541", "context": "We postulate that the bolus of sulprostone resulted in possible coronary spasm that resulted in cardiac arrest.", "question": "Treatment.Freq in sulprostone", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9619226_2_1542", "context": "We postulate that the bolus of sulprostone resulted in possible coronary spasm that resulted in cardiac arrest.", "question": "Treatment.Route in sulprostone", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9619226_2_1543", "context": "We postulate that the bolus of sulprostone resulted in possible coronary spasm that resulted in cardiac arrest.", "question": "Treatment.Time_elapsed in sulprostone", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9619226_2_1544", "context": "We postulate that the bolus of sulprostone resulted in possible coronary spasm that resulted in cardiac arrest.", "question": "Treatment.Duration in sulprostone", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9619226_2_1545", "context": "We postulate that the bolus of sulprostone resulted in possible coronary spasm that resulted in cardiac arrest.", "question": "Treatment.Disorder in sulprostone", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9619226_2_1546", "context": "We postulate that the bolus of sulprostone resulted in possible coronary spasm that resulted in cardiac arrest.", "question": "Combination.Drug in sulprostone", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12661801_1_1547", "context": "A 72-year-old woman with a history of thyrotoxicosis presented with sore throat and fever two weeks after starting carbimazole.", "question": "Subject.Age in 72-year-old woman with a history of thyrotoxicosis", "question_type": "Adverse_event.Subject.Age", "answers": "72-year-old"}, {"id": "12661801_1_1548", "context": "A 72-year-old woman with a history of thyrotoxicosis presented with sore throat and fever two weeks after starting carbimazole.", "question": "Subject.Gender in 72-year-old woman with a history of thyrotoxicosis", "question_type": "Adverse_event.Subject.Gender", "answers": "woman"}, {"id": "12661801_1_1549", "context": "A 72-year-old woman with a history of thyrotoxicosis presented with sore throat and fever two weeks after starting carbimazole.", "question": "Subject.Population in 72-year-old woman with a history of thyrotoxicosis", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "12661801_1_1550", "context": "A 72-year-old woman with a history of thyrotoxicosis presented with sore throat and fever two weeks after starting carbimazole.", "question": "Subject.Race in 72-year-old woman with a history of thyrotoxicosis", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "12661801_1_1551", "context": "A 72-year-old woman with a history of thyrotoxicosis presented with sore throat and fever two weeks after starting carbimazole.", "question": "Subject.Disorder in 72-year-old woman with a history of thyrotoxicosis", "question_type": "Adverse_event.Subject.Disorder", "answers": "thyrotoxicosis"}, {"id": "12661801_1_1552", "context": "A 72-year-old woman with a history of thyrotoxicosis presented with sore throat and fever two weeks after starting carbimazole.", "question": "Treatment.Drug in two weeks after starting carbimazole", "question_type": "Adverse_event.Treatment.Drug", "answers": "carbimazole"}, {"id": "12661801_1_1553", "context": "A 72-year-old woman with a history of thyrotoxicosis presented with sore throat and fever two weeks after starting carbimazole.", "question": "Treatment.Dosage in two weeks after starting carbimazole", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12661801_1_1554", "context": "A 72-year-old woman with a history of thyrotoxicosis presented with sore throat and fever two weeks after starting carbimazole.", "question": "Treatment.Freq in two weeks after starting carbimazole", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12661801_1_1555", "context": "A 72-year-old woman with a history of thyrotoxicosis presented with sore throat and fever two weeks after starting carbimazole.", "question": "Treatment.Route in two weeks after starting carbimazole", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12661801_1_1556", "context": "A 72-year-old woman with a history of thyrotoxicosis presented with sore throat and fever two weeks after starting carbimazole.", "question": "Treatment.Time_elapsed in two weeks after starting carbimazole", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "two weeks"}, {"id": "12661801_1_1557", "context": "A 72-year-old woman with a history of thyrotoxicosis presented with sore throat and fever two weeks after starting carbimazole.", "question": "Treatment.Duration in two weeks after starting carbimazole", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12661801_1_1558", "context": "A 72-year-old woman with a history of thyrotoxicosis presented with sore throat and fever two weeks after starting carbimazole.", "question": "Treatment.Disorder in two weeks after starting carbimazole", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12661801_1_1559", "context": "A 72-year-old woman with a history of thyrotoxicosis presented with sore throat and fever two weeks after starting carbimazole.", "question": "Combination.Drug in two weeks after starting carbimazole", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8700794_5_1560", "context": "Without other causes for the hyponatremia, she was diagnosed with the syndrome of inappropriate antidiuretic hormone, presumably caused by desmopressin.", "question": "Subject.Age in she", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "8700794_5_1561", "context": "Without other causes for the hyponatremia, she was diagnosed with the syndrome of inappropriate antidiuretic hormone, presumably caused by desmopressin.", "question": "Subject.Gender in she", "question_type": "Adverse_event.Subject.Gender", "answers": "she"}, {"id": "8700794_5_1562", "context": "Without other causes for the hyponatremia, she was diagnosed with the syndrome of inappropriate antidiuretic hormone, presumably caused by desmopressin.", "question": "Subject.Population in she", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "8700794_5_1563", "context": "Without other causes for the hyponatremia, she was diagnosed with the syndrome of inappropriate antidiuretic hormone, presumably caused by desmopressin.", "question": "Subject.Race in she", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "8700794_5_1564", "context": "Without other causes for the hyponatremia, she was diagnosed with the syndrome of inappropriate antidiuretic hormone, presumably caused by desmopressin.", "question": "Subject.Disorder in she", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "8700794_5_1565", "context": "Without other causes for the hyponatremia, she was diagnosed with the syndrome of inappropriate antidiuretic hormone, presumably caused by desmopressin.", "question": "Treatment.Drug in desmopressin", "question_type": "Adverse_event.Treatment.Drug", "answers": "desmopressin"}, {"id": "8700794_5_1566", "context": "Without other causes for the hyponatremia, she was diagnosed with the syndrome of inappropriate antidiuretic hormone, presumably caused by desmopressin.", "question": "Treatment.Dosage in desmopressin", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8700794_5_1567", "context": "Without other causes for the hyponatremia, she was diagnosed with the syndrome of inappropriate antidiuretic hormone, presumably caused by desmopressin.", "question": "Treatment.Freq in desmopressin", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8700794_5_1568", "context": "Without other causes for the hyponatremia, she was diagnosed with the syndrome of inappropriate antidiuretic hormone, presumably caused by desmopressin.", "question": "Treatment.Route in desmopressin", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8700794_5_1569", "context": "Without other causes for the hyponatremia, she was diagnosed with the syndrome of inappropriate antidiuretic hormone, presumably caused by desmopressin.", "question": "Treatment.Time_elapsed in desmopressin", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8700794_5_1570", "context": "Without other causes for the hyponatremia, she was diagnosed with the syndrome of inappropriate antidiuretic hormone, presumably caused by desmopressin.", "question": "Treatment.Duration in desmopressin", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8700794_5_1571", "context": "Without other causes for the hyponatremia, she was diagnosed with the syndrome of inappropriate antidiuretic hormone, presumably caused by desmopressin.", "question": "Treatment.Disorder in desmopressin", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8700794_5_1572", "context": "Without other causes for the hyponatremia, she was diagnosed with the syndrome of inappropriate antidiuretic hormone, presumably caused by desmopressin.", "question": "Combination.Drug in desmopressin", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15279668_1_1573", "context": "Fatal peripheral neuropathy following FLA chemotherapy.", "question": "Treatment.Drug in FLA chemotherapy", "question_type": "Adverse_event.Treatment.Drug", "answers": "FLA"}, {"id": "15279668_1_1574", "context": "Fatal peripheral neuropathy following FLA chemotherapy.", "question": "Treatment.Dosage in FLA chemotherapy", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15279668_1_1575", "context": "Fatal peripheral neuropathy following FLA chemotherapy.", "question": "Treatment.Freq in FLA chemotherapy", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15279668_1_1576", "context": "Fatal peripheral neuropathy following FLA chemotherapy.", "question": "Treatment.Route in FLA chemotherapy", "question_type": "Adverse_event.Treatment.Route", "answers": "chemotherapy"}, {"id": "15279668_1_1577", "context": "Fatal peripheral neuropathy following FLA chemotherapy.", "question": "Treatment.Time_elapsed in FLA chemotherapy", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15279668_1_1578", "context": "Fatal peripheral neuropathy following FLA chemotherapy.", "question": "Treatment.Duration in FLA chemotherapy", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15279668_1_1579", "context": "Fatal peripheral neuropathy following FLA chemotherapy.", "question": "Treatment.Disorder in FLA chemotherapy", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15279668_1_1580", "context": "Fatal peripheral neuropathy following FLA chemotherapy.", "question": "Combination.Drug in FLA chemotherapy", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "19249953_1_1581", "context": "Rhabdomyolysis caused by a potential sitagliptin-lovastatin interaction.", "question": "Treatment.Drug in potential sitagliptin-lovastatin interaction", "question_type": "Adverse_event.Treatment.Drug", "answers": "sitagliptin; lovastatin"}, {"id": "19249953_1_1582", "context": "Rhabdomyolysis caused by a potential sitagliptin-lovastatin interaction.", "question": "Treatment.Dosage in potential sitagliptin-lovastatin interaction", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "19249953_1_1583", "context": "Rhabdomyolysis caused by a potential sitagliptin-lovastatin interaction.", "question": "Treatment.Freq in potential sitagliptin-lovastatin interaction", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "19249953_1_1584", "context": "Rhabdomyolysis caused by a potential sitagliptin-lovastatin interaction.", "question": "Treatment.Route in potential sitagliptin-lovastatin interaction", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "19249953_1_1585", "context": "Rhabdomyolysis caused by a potential sitagliptin-lovastatin interaction.", "question": "Treatment.Time_elapsed in potential sitagliptin-lovastatin interaction", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19249953_1_1586", "context": "Rhabdomyolysis caused by a potential sitagliptin-lovastatin interaction.", "question": "Treatment.Duration in potential sitagliptin-lovastatin interaction", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "19249953_1_1587", "context": "Rhabdomyolysis caused by a potential sitagliptin-lovastatin interaction.", "question": "Treatment.Disorder in potential sitagliptin-lovastatin interaction", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "19249953_1_1588", "context": "Rhabdomyolysis caused by a potential sitagliptin-lovastatin interaction.", "question": "Combination.Drug in potential sitagliptin-lovastatin interaction", "question_type": "Adverse_event.Combination.Drug", "answers": "lovastatin; sitagliptin"}, {"id": "8305778_3_1589", "context": "A 78-year-old man with a history of congestive heart failure and coronary artery disease began taking amiodarone to suppress sustained ventricular tachycardia.", "question": "Subject.Age in A 78-year-old man with a history of congestive heart failure and coronary artery disease", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": "78-year-old"}, {"id": "8305778_3_1590", "context": "A 78-year-old man with a history of congestive heart failure and coronary artery disease began taking amiodarone to suppress sustained ventricular tachycardia.", "question": "Subject.Gender in A 78-year-old man with a history of congestive heart failure and coronary artery disease", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": "man"}, {"id": "8305778_3_1591", "context": "A 78-year-old man with a history of congestive heart failure and coronary artery disease began taking amiodarone to suppress sustained ventricular tachycardia.", "question": "Subject.Population in A 78-year-old man with a history of congestive heart failure and coronary artery disease", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "8305778_3_1592", "context": "A 78-year-old man with a history of congestive heart failure and coronary artery disease began taking amiodarone to suppress sustained ventricular tachycardia.", "question": "Subject.Race in A 78-year-old man with a history of congestive heart failure and coronary artery disease", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "8305778_3_1593", "context": "A 78-year-old man with a history of congestive heart failure and coronary artery disease began taking amiodarone to suppress sustained ventricular tachycardia.", "question": "Subject.Disorder in A 78-year-old man with a history of congestive heart failure and coronary artery disease", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": "congestive heart failure; coronary artery disease"}, {"id": "8305778_3_1594", "context": "A 78-year-old man with a history of congestive heart failure and coronary artery disease began taking amiodarone to suppress sustained ventricular tachycardia.", "question": "Treatment.Drug in amiodarone", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "amiodarone"}, {"id": "8305778_3_1595", "context": "A 78-year-old man with a history of congestive heart failure and coronary artery disease began taking amiodarone to suppress sustained ventricular tachycardia.", "question": "Treatment.Dosage in amiodarone", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "8305778_3_1596", "context": "A 78-year-old man with a history of congestive heart failure and coronary artery disease began taking amiodarone to suppress sustained ventricular tachycardia.", "question": "Treatment.Freq in amiodarone", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "8305778_3_1597", "context": "A 78-year-old man with a history of congestive heart failure and coronary artery disease began taking amiodarone to suppress sustained ventricular tachycardia.", "question": "Treatment.Route in amiodarone", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "8305778_3_1598", "context": "A 78-year-old man with a history of congestive heart failure and coronary artery disease began taking amiodarone to suppress sustained ventricular tachycardia.", "question": "Treatment.Time_elapsed in amiodarone", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8305778_3_1599", "context": "A 78-year-old man with a history of congestive heart failure and coronary artery disease began taking amiodarone to suppress sustained ventricular tachycardia.", "question": "Treatment.Duration in amiodarone", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "8305778_3_1600", "context": "A 78-year-old man with a history of congestive heart failure and coronary artery disease began taking amiodarone to suppress sustained ventricular tachycardia.", "question": "Treatment.Disorder in amiodarone", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "sustained ventricular tachycardia"}, {"id": "8305778_3_1601", "context": "A 78-year-old man with a history of congestive heart failure and coronary artery disease began taking amiodarone to suppress sustained ventricular tachycardia.", "question": "Combination.Drug in amiodarone", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "8645078_1_1602", "context": "A patient with severe cholestatic jaundice induced by captopril is presented.", "question": "Subject.Age in A patient", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "8645078_1_1603", "context": "A patient with severe cholestatic jaundice induced by captopril is presented.", "question": "Subject.Gender in A patient", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "8645078_1_1604", "context": "A patient with severe cholestatic jaundice induced by captopril is presented.", "question": "Subject.Population in A patient", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "8645078_1_1605", "context": "A patient with severe cholestatic jaundice induced by captopril is presented.", "question": "Subject.Race in A patient", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "8645078_1_1606", "context": "A patient with severe cholestatic jaundice induced by captopril is presented.", "question": "Subject.Disorder in A patient", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "8645078_1_1607", "context": "A patient with severe cholestatic jaundice induced by captopril is presented.", "question": "Treatment.Drug in captopril", "question_type": "Adverse_event.Treatment.Drug", "answers": "captopril"}, {"id": "8645078_1_1608", "context": "A patient with severe cholestatic jaundice induced by captopril is presented.", "question": "Treatment.Dosage in captopril", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8645078_1_1609", "context": "A patient with severe cholestatic jaundice induced by captopril is presented.", "question": "Treatment.Freq in captopril", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8645078_1_1610", "context": "A patient with severe cholestatic jaundice induced by captopril is presented.", "question": "Treatment.Route in captopril", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8645078_1_1611", "context": "A patient with severe cholestatic jaundice induced by captopril is presented.", "question": "Treatment.Time_elapsed in captopril", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8645078_1_1612", "context": "A patient with severe cholestatic jaundice induced by captopril is presented.", "question": "Treatment.Duration in captopril", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8645078_1_1613", "context": "A patient with severe cholestatic jaundice induced by captopril is presented.", "question": "Treatment.Disorder in captopril", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8645078_1_1614", "context": "A patient with severe cholestatic jaundice induced by captopril is presented.", "question": "Combination.Drug in captopril", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "14723711_3_1615", "context": "Three distinct types of minocycline-induced cutaneous pigmentation have been described.", "question": "Treatment.Drug in minocycline", "question_type": "Adverse_event.Treatment.Drug", "answers": "minocycline"}, {"id": "14723711_3_1616", "context": "Three distinct types of minocycline-induced cutaneous pigmentation have been described.", "question": "Treatment.Dosage in minocycline", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "14723711_3_1617", "context": "Three distinct types of minocycline-induced cutaneous pigmentation have been described.", "question": "Treatment.Freq in minocycline", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "14723711_3_1618", "context": "Three distinct types of minocycline-induced cutaneous pigmentation have been described.", "question": "Treatment.Route in minocycline", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "14723711_3_1619", "context": "Three distinct types of minocycline-induced cutaneous pigmentation have been described.", "question": "Treatment.Time_elapsed in minocycline", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "14723711_3_1620", "context": "Three distinct types of minocycline-induced cutaneous pigmentation have been described.", "question": "Treatment.Duration in minocycline", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "14723711_3_1621", "context": "Three distinct types of minocycline-induced cutaneous pigmentation have been described.", "question": "Treatment.Disorder in minocycline", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "14723711_3_1622", "context": "Three distinct types of minocycline-induced cutaneous pigmentation have been described.", "question": "Combination.Drug in minocycline", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18765315_4_1623", "context": "The occurrence of symptoms that could be ascribed to an acute coronary syndrome should always be taken seriously during the first rituximab infusion and investigated aggressively.", "question": "Treatment.Drug in first rituximab infusion", "question_type": "Adverse_event.Treatment.Drug", "answers": "rituximab"}, {"id": "18765315_4_1624", "context": "The occurrence of symptoms that could be ascribed to an acute coronary syndrome should always be taken seriously during the first rituximab infusion and investigated aggressively.", "question": "Treatment.Dosage in first rituximab infusion", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18765315_4_1625", "context": "The occurrence of symptoms that could be ascribed to an acute coronary syndrome should always be taken seriously during the first rituximab infusion and investigated aggressively.", "question": "Treatment.Freq in first rituximab infusion", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18765315_4_1626", "context": "The occurrence of symptoms that could be ascribed to an acute coronary syndrome should always be taken seriously during the first rituximab infusion and investigated aggressively.", "question": "Treatment.Route in first rituximab infusion", "question_type": "Adverse_event.Treatment.Route", "answers": "infusion"}, {"id": "18765315_4_1627", "context": "The occurrence of symptoms that could be ascribed to an acute coronary syndrome should always be taken seriously during the first rituximab infusion and investigated aggressively.", "question": "Treatment.Time_elapsed in first rituximab infusion", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18765315_4_1628", "context": "The occurrence of symptoms that could be ascribed to an acute coronary syndrome should always be taken seriously during the first rituximab infusion and investigated aggressively.", "question": "Treatment.Duration in first rituximab infusion", "question_type": "Adverse_event.Treatment.Duration", "answers": "first"}, {"id": "18765315_4_1629", "context": "The occurrence of symptoms that could be ascribed to an acute coronary syndrome should always be taken seriously during the first rituximab infusion and investigated aggressively.", "question": "Treatment.Disorder in first rituximab infusion", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18765315_4_1630", "context": "The occurrence of symptoms that could be ascribed to an acute coronary syndrome should always be taken seriously during the first rituximab infusion and investigated aggressively.", "question": "Combination.Drug in first rituximab infusion", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12635752_1_1631", "context": "Antithyroid treatment with propylthiouracil (PTU) resulted in elevated hepatic enzymes and after the 12th week of pregnancy treatment was changed to carbimazole (CBZ).", "question": "Subject.Age in 12th week of pregnancy", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "12635752_1_1632", "context": "Antithyroid treatment with propylthiouracil (PTU) resulted in elevated hepatic enzymes and after the 12th week of pregnancy treatment was changed to carbimazole (CBZ).", "question": "Subject.Gender in 12th week of pregnancy", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "12635752_1_1633", "context": "Antithyroid treatment with propylthiouracil (PTU) resulted in elevated hepatic enzymes and after the 12th week of pregnancy treatment was changed to carbimazole (CBZ).", "question": "Subject.Population in 12th week of pregnancy", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "12635752_1_1634", "context": "Antithyroid treatment with propylthiouracil (PTU) resulted in elevated hepatic enzymes and after the 12th week of pregnancy treatment was changed to carbimazole (CBZ).", "question": "Subject.Race in 12th week of pregnancy", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "12635752_1_1635", "context": "Antithyroid treatment with propylthiouracil (PTU) resulted in elevated hepatic enzymes and after the 12th week of pregnancy treatment was changed to carbimazole (CBZ).", "question": "Subject.Disorder in 12th week of pregnancy", "question_type": "Adverse_event.Subject.Disorder", "answers": "pregnancy"}, {"id": "12635752_1_1636", "context": "Antithyroid treatment with propylthiouracil (PTU) resulted in elevated hepatic enzymes and after the 12th week of pregnancy treatment was changed to carbimazole (CBZ).", "question": "Treatment.Drug in propylthiouracil (PTU)", "question_type": "Adverse_event.Treatment.Drug", "answers": "propylthiouracil"}, {"id": "12635752_1_1637", "context": "Antithyroid treatment with propylthiouracil (PTU) resulted in elevated hepatic enzymes and after the 12th week of pregnancy treatment was changed to carbimazole (CBZ).", "question": "Treatment.Dosage in propylthiouracil (PTU)", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12635752_1_1638", "context": "Antithyroid treatment with propylthiouracil (PTU) resulted in elevated hepatic enzymes and after the 12th week of pregnancy treatment was changed to carbimazole (CBZ).", "question": "Treatment.Freq in propylthiouracil (PTU)", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12635752_1_1639", "context": "Antithyroid treatment with propylthiouracil (PTU) resulted in elevated hepatic enzymes and after the 12th week of pregnancy treatment was changed to carbimazole (CBZ).", "question": "Treatment.Route in propylthiouracil (PTU)", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12635752_1_1640", "context": "Antithyroid treatment with propylthiouracil (PTU) resulted in elevated hepatic enzymes and after the 12th week of pregnancy treatment was changed to carbimazole (CBZ).", "question": "Treatment.Time_elapsed in propylthiouracil (PTU)", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12635752_1_1641", "context": "Antithyroid treatment with propylthiouracil (PTU) resulted in elevated hepatic enzymes and after the 12th week of pregnancy treatment was changed to carbimazole (CBZ).", "question": "Treatment.Duration in propylthiouracil (PTU)", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12635752_1_1642", "context": "Antithyroid treatment with propylthiouracil (PTU) resulted in elevated hepatic enzymes and after the 12th week of pregnancy treatment was changed to carbimazole (CBZ).", "question": "Treatment.Disorder in propylthiouracil (PTU)", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12635752_1_1643", "context": "Antithyroid treatment with propylthiouracil (PTU) resulted in elevated hepatic enzymes and after the 12th week of pregnancy treatment was changed to carbimazole (CBZ).", "question": "Combination.Drug in propylthiouracil (PTU)", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12635752_1_1644", "context": "Antithyroid treatment with propylthiouracil (PTU) resulted in elevated hepatic enzymes and after the 12th week of pregnancy treatment was changed to carbimazole (CBZ).", "question": "Subject.Age in 12th week of pregnancy", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "12635752_1_1645", "context": "Antithyroid treatment with propylthiouracil (PTU) resulted in elevated hepatic enzymes and after the 12th week of pregnancy treatment was changed to carbimazole (CBZ).", "question": "Subject.Gender in 12th week of pregnancy", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "12635752_1_1646", "context": "Antithyroid treatment with propylthiouracil (PTU) resulted in elevated hepatic enzymes and after the 12th week of pregnancy treatment was changed to carbimazole (CBZ).", "question": "Subject.Population in 12th week of pregnancy", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "12635752_1_1647", "context": "Antithyroid treatment with propylthiouracil (PTU) resulted in elevated hepatic enzymes and after the 12th week of pregnancy treatment was changed to carbimazole (CBZ).", "question": "Subject.Race in 12th week of pregnancy", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "12635752_1_1648", "context": "Antithyroid treatment with propylthiouracil (PTU) resulted in elevated hepatic enzymes and after the 12th week of pregnancy treatment was changed to carbimazole (CBZ).", "question": "Subject.Disorder in 12th week of pregnancy", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": "pregnancy"}, {"id": "12635752_1_1649", "context": "Antithyroid treatment with propylthiouracil (PTU) resulted in elevated hepatic enzymes and after the 12th week of pregnancy treatment was changed to carbimazole (CBZ).", "question": "Treatment.Drug in carbimazole (CBZ)", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "carbimazole"}, {"id": "12635752_1_1650", "context": "Antithyroid treatment with propylthiouracil (PTU) resulted in elevated hepatic enzymes and after the 12th week of pregnancy treatment was changed to carbimazole (CBZ).", "question": "Treatment.Dosage in carbimazole (CBZ)", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "12635752_1_1651", "context": "Antithyroid treatment with propylthiouracil (PTU) resulted in elevated hepatic enzymes and after the 12th week of pregnancy treatment was changed to carbimazole (CBZ).", "question": "Treatment.Freq in carbimazole (CBZ)", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "12635752_1_1652", "context": "Antithyroid treatment with propylthiouracil (PTU) resulted in elevated hepatic enzymes and after the 12th week of pregnancy treatment was changed to carbimazole (CBZ).", "question": "Treatment.Route in carbimazole (CBZ)", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "12635752_1_1653", "context": "Antithyroid treatment with propylthiouracil (PTU) resulted in elevated hepatic enzymes and after the 12th week of pregnancy treatment was changed to carbimazole (CBZ).", "question": "Treatment.Time_elapsed in carbimazole (CBZ)", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12635752_1_1654", "context": "Antithyroid treatment with propylthiouracil (PTU) resulted in elevated hepatic enzymes and after the 12th week of pregnancy treatment was changed to carbimazole (CBZ).", "question": "Treatment.Duration in carbimazole (CBZ)", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "12635752_1_1655", "context": "Antithyroid treatment with propylthiouracil (PTU) resulted in elevated hepatic enzymes and after the 12th week of pregnancy treatment was changed to carbimazole (CBZ).", "question": "Treatment.Disorder in carbimazole (CBZ)", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "Antithyroid"}, {"id": "12635752_1_1656", "context": "Antithyroid treatment with propylthiouracil (PTU) resulted in elevated hepatic enzymes and after the 12th week of pregnancy treatment was changed to carbimazole (CBZ).", "question": "Combination.Drug in carbimazole (CBZ)", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "9695308_2_1657", "context": "Antineutrophil cytoplasmic antibody-positive crescentic glomerulonephritis associated with propylthiouracil therapy.", "question": "Treatment.Drug in propylthiouracil therapy", "question_type": "Adverse_event.Treatment.Drug", "answers": "propylthiouracil"}, {"id": "9695308_2_1658", "context": "Antineutrophil cytoplasmic antibody-positive crescentic glomerulonephritis associated with propylthiouracil therapy.", "question": "Treatment.Dosage in propylthiouracil therapy", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9695308_2_1659", "context": "Antineutrophil cytoplasmic antibody-positive crescentic glomerulonephritis associated with propylthiouracil therapy.", "question": "Treatment.Freq in propylthiouracil therapy", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9695308_2_1660", "context": "Antineutrophil cytoplasmic antibody-positive crescentic glomerulonephritis associated with propylthiouracil therapy.", "question": "Treatment.Route in propylthiouracil therapy", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9695308_2_1661", "context": "Antineutrophil cytoplasmic antibody-positive crescentic glomerulonephritis associated with propylthiouracil therapy.", "question": "Treatment.Time_elapsed in propylthiouracil therapy", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9695308_2_1662", "context": "Antineutrophil cytoplasmic antibody-positive crescentic glomerulonephritis associated with propylthiouracil therapy.", "question": "Treatment.Duration in propylthiouracil therapy", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9695308_2_1663", "context": "Antineutrophil cytoplasmic antibody-positive crescentic glomerulonephritis associated with propylthiouracil therapy.", "question": "Treatment.Disorder in propylthiouracil therapy", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9695308_2_1664", "context": "Antineutrophil cytoplasmic antibody-positive crescentic glomerulonephritis associated with propylthiouracil therapy.", "question": "Combination.Drug in propylthiouracil therapy", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12399645_2_1665", "context": "ADH hypersecretion in relation to plasma osmolality was reversed by mizoribin withdrawal, suggesting that bredinin might adversely induce SIADH.", "question": "Subject.Age in plasma osmolality", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "12399645_2_1666", "context": "ADH hypersecretion in relation to plasma osmolality was reversed by mizoribin withdrawal, suggesting that bredinin might adversely induce SIADH.", "question": "Subject.Gender in plasma osmolality", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "12399645_2_1667", "context": "ADH hypersecretion in relation to plasma osmolality was reversed by mizoribin withdrawal, suggesting that bredinin might adversely induce SIADH.", "question": "Subject.Population in plasma osmolality", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "12399645_2_1668", "context": "ADH hypersecretion in relation to plasma osmolality was reversed by mizoribin withdrawal, suggesting that bredinin might adversely induce SIADH.", "question": "Subject.Race in plasma osmolality", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "12399645_2_1669", "context": "ADH hypersecretion in relation to plasma osmolality was reversed by mizoribin withdrawal, suggesting that bredinin might adversely induce SIADH.", "question": "Subject.Disorder in plasma osmolality", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": "plasma osmolality"}, {"id": "12399645_2_1670", "context": "ADH hypersecretion in relation to plasma osmolality was reversed by mizoribin withdrawal, suggesting that bredinin might adversely induce SIADH.", "question": "Treatment.Drug in mizoribin withdrawal", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "mizoribin"}, {"id": "12399645_2_1671", "context": "ADH hypersecretion in relation to plasma osmolality was reversed by mizoribin withdrawal, suggesting that bredinin might adversely induce SIADH.", "question": "Treatment.Dosage in mizoribin withdrawal", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "12399645_2_1672", "context": "ADH hypersecretion in relation to plasma osmolality was reversed by mizoribin withdrawal, suggesting that bredinin might adversely induce SIADH.", "question": "Treatment.Freq in mizoribin withdrawal", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "12399645_2_1673", "context": "ADH hypersecretion in relation to plasma osmolality was reversed by mizoribin withdrawal, suggesting that bredinin might adversely induce SIADH.", "question": "Treatment.Route in mizoribin withdrawal", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "12399645_2_1674", "context": "ADH hypersecretion in relation to plasma osmolality was reversed by mizoribin withdrawal, suggesting that bredinin might adversely induce SIADH.", "question": "Treatment.Time_elapsed in mizoribin withdrawal", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12399645_2_1675", "context": "ADH hypersecretion in relation to plasma osmolality was reversed by mizoribin withdrawal, suggesting that bredinin might adversely induce SIADH.", "question": "Treatment.Duration in mizoribin withdrawal", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "12399645_2_1676", "context": "ADH hypersecretion in relation to plasma osmolality was reversed by mizoribin withdrawal, suggesting that bredinin might adversely induce SIADH.", "question": "Treatment.Disorder in mizoribin withdrawal", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "ADH hypersecretion"}, {"id": "12399645_2_1677", "context": "ADH hypersecretion in relation to plasma osmolality was reversed by mizoribin withdrawal, suggesting that bredinin might adversely induce SIADH.", "question": "Combination.Drug in mizoribin withdrawal", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "12399645_2_1678", "context": "ADH hypersecretion in relation to plasma osmolality was reversed by mizoribin withdrawal, suggesting that bredinin might adversely induce SIADH.", "question": "Treatment.Drug in bredinin", "question_type": "Adverse_event.Treatment.Drug", "answers": "bredinin"}, {"id": "12399645_2_1679", "context": "ADH hypersecretion in relation to plasma osmolality was reversed by mizoribin withdrawal, suggesting that bredinin might adversely induce SIADH.", "question": "Treatment.Dosage in bredinin", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12399645_2_1680", "context": "ADH hypersecretion in relation to plasma osmolality was reversed by mizoribin withdrawal, suggesting that bredinin might adversely induce SIADH.", "question": "Treatment.Freq in bredinin", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12399645_2_1681", "context": "ADH hypersecretion in relation to plasma osmolality was reversed by mizoribin withdrawal, suggesting that bredinin might adversely induce SIADH.", "question": "Treatment.Route in bredinin", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12399645_2_1682", "context": "ADH hypersecretion in relation to plasma osmolality was reversed by mizoribin withdrawal, suggesting that bredinin might adversely induce SIADH.", "question": "Treatment.Time_elapsed in bredinin", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12399645_2_1683", "context": "ADH hypersecretion in relation to plasma osmolality was reversed by mizoribin withdrawal, suggesting that bredinin might adversely induce SIADH.", "question": "Treatment.Duration in bredinin", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12399645_2_1684", "context": "ADH hypersecretion in relation to plasma osmolality was reversed by mizoribin withdrawal, suggesting that bredinin might adversely induce SIADH.", "question": "Treatment.Disorder in bredinin", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12399645_2_1685", "context": "ADH hypersecretion in relation to plasma osmolality was reversed by mizoribin withdrawal, suggesting that bredinin might adversely induce SIADH.", "question": "Combination.Drug in bredinin", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10510017_1_1686", "context": "Heparin-induced thrombocytopenia is a rare and serious complication of anticoagulation therapy.", "question": "Treatment.Drug in anticoagulation therapy", "question_type": "Adverse_event.Treatment.Drug", "answers": "Heparin"}, {"id": "10510017_1_1687", "context": "Heparin-induced thrombocytopenia is a rare and serious complication of anticoagulation therapy.", "question": "Treatment.Dosage in anticoagulation therapy", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10510017_1_1688", "context": "Heparin-induced thrombocytopenia is a rare and serious complication of anticoagulation therapy.", "question": "Treatment.Freq in anticoagulation therapy", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10510017_1_1689", "context": "Heparin-induced thrombocytopenia is a rare and serious complication of anticoagulation therapy.", "question": "Treatment.Route in anticoagulation therapy", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10510017_1_1690", "context": "Heparin-induced thrombocytopenia is a rare and serious complication of anticoagulation therapy.", "question": "Treatment.Time_elapsed in anticoagulation therapy", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10510017_1_1691", "context": "Heparin-induced thrombocytopenia is a rare and serious complication of anticoagulation therapy.", "question": "Treatment.Duration in anticoagulation therapy", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10510017_1_1692", "context": "Heparin-induced thrombocytopenia is a rare and serious complication of anticoagulation therapy.", "question": "Treatment.Disorder in anticoagulation therapy", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10510017_1_1693", "context": "Heparin-induced thrombocytopenia is a rare and serious complication of anticoagulation therapy.", "question": "Combination.Drug in anticoagulation therapy", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18991509_1_1694", "context": "Iatrogenic Cushing syndrome after epidural triamcinolone injections in an HIV type 1-infected patient receiving therapy with ritonavir-lopinavir.", "question": "Subject.Age in an HIV type 1-infected patient", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "18991509_1_1695", "context": "Iatrogenic Cushing syndrome after epidural triamcinolone injections in an HIV type 1-infected patient receiving therapy with ritonavir-lopinavir.", "question": "Subject.Gender in an HIV type 1-infected patient", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "18991509_1_1696", "context": "Iatrogenic Cushing syndrome after epidural triamcinolone injections in an HIV type 1-infected patient receiving therapy with ritonavir-lopinavir.", "question": "Subject.Population in an HIV type 1-infected patient", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "18991509_1_1697", "context": "Iatrogenic Cushing syndrome after epidural triamcinolone injections in an HIV type 1-infected patient receiving therapy with ritonavir-lopinavir.", "question": "Subject.Race in an HIV type 1-infected patient", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "18991509_1_1698", "context": "Iatrogenic Cushing syndrome after epidural triamcinolone injections in an HIV type 1-infected patient receiving therapy with ritonavir-lopinavir.", "question": "Subject.Disorder in an HIV type 1-infected patient", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "18991509_1_1699", "context": "Iatrogenic Cushing syndrome after epidural triamcinolone injections in an HIV type 1-infected patient receiving therapy with ritonavir-lopinavir.", "question": "Treatment.Drug in receiving therapy with ritonavir-lopinavir; epidural triamcinolone injections", "question_type": "Adverse_event.Treatment.Drug", "answers": "epidural triamcinolone; ritonavir-lopinavir"}, {"id": "18991509_1_1700", "context": "Iatrogenic Cushing syndrome after epidural triamcinolone injections in an HIV type 1-infected patient receiving therapy with ritonavir-lopinavir.", "question": "Treatment.Dosage in receiving therapy with ritonavir-lopinavir; epidural triamcinolone injections", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18991509_1_1701", "context": "Iatrogenic Cushing syndrome after epidural triamcinolone injections in an HIV type 1-infected patient receiving therapy with ritonavir-lopinavir.", "question": "Treatment.Freq in receiving therapy with ritonavir-lopinavir; epidural triamcinolone injections", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18991509_1_1702", "context": "Iatrogenic Cushing syndrome after epidural triamcinolone injections in an HIV type 1-infected patient receiving therapy with ritonavir-lopinavir.", "question": "Treatment.Route in receiving therapy with ritonavir-lopinavir; epidural triamcinolone injections", "question_type": "Adverse_event.Treatment.Route", "answers": "injections"}, {"id": "18991509_1_1703", "context": "Iatrogenic Cushing syndrome after epidural triamcinolone injections in an HIV type 1-infected patient receiving therapy with ritonavir-lopinavir.", "question": "Treatment.Time_elapsed in receiving therapy with ritonavir-lopinavir; epidural triamcinolone injections", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18991509_1_1704", "context": "Iatrogenic Cushing syndrome after epidural triamcinolone injections in an HIV type 1-infected patient receiving therapy with ritonavir-lopinavir.", "question": "Treatment.Duration in receiving therapy with ritonavir-lopinavir; epidural triamcinolone injections", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18991509_1_1705", "context": "Iatrogenic Cushing syndrome after epidural triamcinolone injections in an HIV type 1-infected patient receiving therapy with ritonavir-lopinavir.", "question": "Treatment.Disorder in receiving therapy with ritonavir-lopinavir; epidural triamcinolone injections", "question_type": "Adverse_event.Treatment.Disorder", "answers": "HIV type 1"}, {"id": "18991509_1_1706", "context": "Iatrogenic Cushing syndrome after epidural triamcinolone injections in an HIV type 1-infected patient receiving therapy with ritonavir-lopinavir.", "question": "Combination.Drug in receiving therapy with ritonavir-lopinavir; epidural triamcinolone injections", "question_type": "Adverse_event.Combination.Drug", "answers": "epidural triamcinolone; ritonavir-lopinavir"}, {"id": "18622319_2_1707", "context": "Otolaryngologists should be made aware of a newer cause of nasal septal perforations resulting from the more recent antiangiogenic therapy used to treat malignancies.", "question": "Treatment.Drug in the more recent antiangiogenic therapy", "question_type": "Adverse_event.Treatment.Drug", "answers": "the more recent antiangiogenic therapy"}, {"id": "18622319_2_1708", "context": "Otolaryngologists should be made aware of a newer cause of nasal septal perforations resulting from the more recent antiangiogenic therapy used to treat malignancies.", "question": "Treatment.Dosage in the more recent antiangiogenic therapy", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18622319_2_1709", "context": "Otolaryngologists should be made aware of a newer cause of nasal septal perforations resulting from the more recent antiangiogenic therapy used to treat malignancies.", "question": "Treatment.Freq in the more recent antiangiogenic therapy", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18622319_2_1710", "context": "Otolaryngologists should be made aware of a newer cause of nasal septal perforations resulting from the more recent antiangiogenic therapy used to treat malignancies.", "question": "Treatment.Route in the more recent antiangiogenic therapy", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18622319_2_1711", "context": "Otolaryngologists should be made aware of a newer cause of nasal septal perforations resulting from the more recent antiangiogenic therapy used to treat malignancies.", "question": "Treatment.Time_elapsed in the more recent antiangiogenic therapy", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18622319_2_1712", "context": "Otolaryngologists should be made aware of a newer cause of nasal septal perforations resulting from the more recent antiangiogenic therapy used to treat malignancies.", "question": "Treatment.Duration in the more recent antiangiogenic therapy", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18622319_2_1713", "context": "Otolaryngologists should be made aware of a newer cause of nasal septal perforations resulting from the more recent antiangiogenic therapy used to treat malignancies.", "question": "Treatment.Disorder in the more recent antiangiogenic therapy", "question_type": "Adverse_event.Treatment.Disorder", "answers": "malignancies"}, {"id": "18622319_2_1714", "context": "Otolaryngologists should be made aware of a newer cause of nasal septal perforations resulting from the more recent antiangiogenic therapy used to treat malignancies.", "question": "Combination.Drug in the more recent antiangiogenic therapy", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7459812_2_1715", "context": "Following several of these courses of therapy, respiratory distress occurred 9 to 12 days after the chlorambucil was given.", "question": "Treatment.Drug in the chlorambucil", "question_type": "Adverse_event.Treatment.Drug", "answers": "chlorambucil"}, {"id": "7459812_2_1716", "context": "Following several of these courses of therapy, respiratory distress occurred 9 to 12 days after the chlorambucil was given.", "question": "Treatment.Dosage in the chlorambucil", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7459812_2_1717", "context": "Following several of these courses of therapy, respiratory distress occurred 9 to 12 days after the chlorambucil was given.", "question": "Treatment.Freq in the chlorambucil", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7459812_2_1718", "context": "Following several of these courses of therapy, respiratory distress occurred 9 to 12 days after the chlorambucil was given.", "question": "Treatment.Route in the chlorambucil", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7459812_2_1719", "context": "Following several of these courses of therapy, respiratory distress occurred 9 to 12 days after the chlorambucil was given.", "question": "Treatment.Time_elapsed in the chlorambucil", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "9 to 12 days"}, {"id": "7459812_2_1720", "context": "Following several of these courses of therapy, respiratory distress occurred 9 to 12 days after the chlorambucil was given.", "question": "Treatment.Duration in the chlorambucil", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7459812_2_1721", "context": "Following several of these courses of therapy, respiratory distress occurred 9 to 12 days after the chlorambucil was given.", "question": "Treatment.Disorder in the chlorambucil", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7459812_2_1722", "context": "Following several of these courses of therapy, respiratory distress occurred 9 to 12 days after the chlorambucil was given.", "question": "Combination.Drug in the chlorambucil", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "19648225_2_1723", "context": "Possible mechanisms for damage to the urothelium by ketamine are suggested.", "question": "Treatment.Drug in ketamine", "question_type": "Adverse_event.Treatment.Drug", "answers": "ketamine"}, {"id": "19648225_2_1724", "context": "Possible mechanisms for damage to the urothelium by ketamine are suggested.", "question": "Treatment.Dosage in ketamine", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "19648225_2_1725", "context": "Possible mechanisms for damage to the urothelium by ketamine are suggested.", "question": "Treatment.Freq in ketamine", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "19648225_2_1726", "context": "Possible mechanisms for damage to the urothelium by ketamine are suggested.", "question": "Treatment.Route in ketamine", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "19648225_2_1727", "context": "Possible mechanisms for damage to the urothelium by ketamine are suggested.", "question": "Treatment.Time_elapsed in ketamine", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19648225_2_1728", "context": "Possible mechanisms for damage to the urothelium by ketamine are suggested.", "question": "Treatment.Duration in ketamine", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "19648225_2_1729", "context": "Possible mechanisms for damage to the urothelium by ketamine are suggested.", "question": "Treatment.Disorder in ketamine", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "19648225_2_1730", "context": "Possible mechanisms for damage to the urothelium by ketamine are suggested.", "question": "Combination.Drug in ketamine", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "19217693_2_1731", "context": "Persistent hypoglycemia in a patient with diabetes taking etanercept for the treatment of psoriasis.", "question": "Subject.Age in a patient with diabetes", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "19217693_2_1732", "context": "Persistent hypoglycemia in a patient with diabetes taking etanercept for the treatment of psoriasis.", "question": "Subject.Gender in a patient with diabetes", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "19217693_2_1733", "context": "Persistent hypoglycemia in a patient with diabetes taking etanercept for the treatment of psoriasis.", "question": "Subject.Population in a patient with diabetes", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "19217693_2_1734", "context": "Persistent hypoglycemia in a patient with diabetes taking etanercept for the treatment of psoriasis.", "question": "Subject.Race in a patient with diabetes", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "19217693_2_1735", "context": "Persistent hypoglycemia in a patient with diabetes taking etanercept for the treatment of psoriasis.", "question": "Subject.Disorder in a patient with diabetes", "question_type": "Adverse_event.Subject.Disorder", "answers": "diabetes"}, {"id": "19217693_2_1736", "context": "Persistent hypoglycemia in a patient with diabetes taking etanercept for the treatment of psoriasis.", "question": "Treatment.Drug in etanercept", "question_type": "Adverse_event.Treatment.Drug", "answers": "etanercept"}, {"id": "19217693_2_1737", "context": "Persistent hypoglycemia in a patient with diabetes taking etanercept for the treatment of psoriasis.", "question": "Treatment.Dosage in etanercept", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "19217693_2_1738", "context": "Persistent hypoglycemia in a patient with diabetes taking etanercept for the treatment of psoriasis.", "question": "Treatment.Freq in etanercept", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "19217693_2_1739", "context": "Persistent hypoglycemia in a patient with diabetes taking etanercept for the treatment of psoriasis.", "question": "Treatment.Route in etanercept", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "19217693_2_1740", "context": "Persistent hypoglycemia in a patient with diabetes taking etanercept for the treatment of psoriasis.", "question": "Treatment.Time_elapsed in etanercept", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19217693_2_1741", "context": "Persistent hypoglycemia in a patient with diabetes taking etanercept for the treatment of psoriasis.", "question": "Treatment.Duration in etanercept", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "19217693_2_1742", "context": "Persistent hypoglycemia in a patient with diabetes taking etanercept for the treatment of psoriasis.", "question": "Treatment.Disorder in etanercept", "question_type": "Adverse_event.Treatment.Disorder", "answers": "psoriasis"}, {"id": "19217693_2_1743", "context": "Persistent hypoglycemia in a patient with diabetes taking etanercept for the treatment of psoriasis.", "question": "Combination.Drug in etanercept", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15965422_1_1744", "context": "Cutaneous necrosis after injection of polyethylene glycol-modified interferon alfa.", "question": "Treatment.Drug in injection of polyethylene glycol-modified interferon alfa", "question_type": "Adverse_event.Treatment.Drug", "answers": "polyethylene glycol-modified interferon alfa."}, {"id": "15965422_1_1745", "context": "Cutaneous necrosis after injection of polyethylene glycol-modified interferon alfa.", "question": "Treatment.Dosage in injection of polyethylene glycol-modified interferon alfa", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15965422_1_1746", "context": "Cutaneous necrosis after injection of polyethylene glycol-modified interferon alfa.", "question": "Treatment.Freq in injection of polyethylene glycol-modified interferon alfa", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15965422_1_1747", "context": "Cutaneous necrosis after injection of polyethylene glycol-modified interferon alfa.", "question": "Treatment.Route in injection of polyethylene glycol-modified interferon alfa", "question_type": "Adverse_event.Treatment.Route", "answers": "injection"}, {"id": "15965422_1_1748", "context": "Cutaneous necrosis after injection of polyethylene glycol-modified interferon alfa.", "question": "Treatment.Time_elapsed in injection of polyethylene glycol-modified interferon alfa", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15965422_1_1749", "context": "Cutaneous necrosis after injection of polyethylene glycol-modified interferon alfa.", "question": "Treatment.Duration in injection of polyethylene glycol-modified interferon alfa", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15965422_1_1750", "context": "Cutaneous necrosis after injection of polyethylene glycol-modified interferon alfa.", "question": "Treatment.Disorder in injection of polyethylene glycol-modified interferon alfa", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15965422_1_1751", "context": "Cutaneous necrosis after injection of polyethylene glycol-modified interferon alfa.", "question": "Combination.Drug in injection of polyethylene glycol-modified interferon alfa", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3586163_3_1752", "context": "We report an unusual case of simultaneous transitional cell carcinoma of the renal pelvis and distal ureter without transitional cell carcinoma of the bladder occurring after chronic cyclophosphamide therapy for nonHodgkin's lymphoma.", "question": "Treatment.Drug in chronic cyclophosphamide therapy", "question_type": "Adverse_event.Treatment.Drug", "answers": "cyclophosphamide"}, {"id": "3586163_3_1753", "context": "We report an unusual case of simultaneous transitional cell carcinoma of the renal pelvis and distal ureter without transitional cell carcinoma of the bladder occurring after chronic cyclophosphamide therapy for nonHodgkin's lymphoma.", "question": "Treatment.Dosage in chronic cyclophosphamide therapy", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3586163_3_1754", "context": "We report an unusual case of simultaneous transitional cell carcinoma of the renal pelvis and distal ureter without transitional cell carcinoma of the bladder occurring after chronic cyclophosphamide therapy for nonHodgkin's lymphoma.", "question": "Treatment.Freq in chronic cyclophosphamide therapy", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3586163_3_1755", "context": "We report an unusual case of simultaneous transitional cell carcinoma of the renal pelvis and distal ureter without transitional cell carcinoma of the bladder occurring after chronic cyclophosphamide therapy for nonHodgkin's lymphoma.", "question": "Treatment.Route in chronic cyclophosphamide therapy", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3586163_3_1756", "context": "We report an unusual case of simultaneous transitional cell carcinoma of the renal pelvis and distal ureter without transitional cell carcinoma of the bladder occurring after chronic cyclophosphamide therapy for nonHodgkin's lymphoma.", "question": "Treatment.Time_elapsed in chronic cyclophosphamide therapy", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3586163_3_1757", "context": "We report an unusual case of simultaneous transitional cell carcinoma of the renal pelvis and distal ureter without transitional cell carcinoma of the bladder occurring after chronic cyclophosphamide therapy for nonHodgkin's lymphoma.", "question": "Treatment.Duration in chronic cyclophosphamide therapy", "question_type": "Adverse_event.Treatment.Duration", "answers": "chronic"}, {"id": "3586163_3_1758", "context": "We report an unusual case of simultaneous transitional cell carcinoma of the renal pelvis and distal ureter without transitional cell carcinoma of the bladder occurring after chronic cyclophosphamide therapy for nonHodgkin's lymphoma.", "question": "Treatment.Disorder in chronic cyclophosphamide therapy", "question_type": "Adverse_event.Treatment.Disorder", "answers": "nonHodgkin's lymphoma"}, {"id": "3586163_3_1759", "context": "We report an unusual case of simultaneous transitional cell carcinoma of the renal pelvis and distal ureter without transitional cell carcinoma of the bladder occurring after chronic cyclophosphamide therapy for nonHodgkin's lymphoma.", "question": "Combination.Drug in chronic cyclophosphamide therapy", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18359591_1_1760", "context": "In the present paper, we describe two patients with active UC who developed a severe systemic CMV infection during a treatment with an oral microemulsion form of cyclosporine.", "question": "Subject.Age in two patients with active UC", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "18359591_1_1761", "context": "In the present paper, we describe two patients with active UC who developed a severe systemic CMV infection during a treatment with an oral microemulsion form of cyclosporine.", "question": "Subject.Gender in two patients with active UC", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "18359591_1_1762", "context": "In the present paper, we describe two patients with active UC who developed a severe systemic CMV infection during a treatment with an oral microemulsion form of cyclosporine.", "question": "Subject.Population in two patients with active UC", "question_type": "Adverse_event.Subject.Population", "answers": "two"}, {"id": "18359591_1_1763", "context": "In the present paper, we describe two patients with active UC who developed a severe systemic CMV infection during a treatment with an oral microemulsion form of cyclosporine.", "question": "Subject.Race in two patients with active UC", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "18359591_1_1764", "context": "In the present paper, we describe two patients with active UC who developed a severe systemic CMV infection during a treatment with an oral microemulsion form of cyclosporine.", "question": "Subject.Disorder in two patients with active UC", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "18359591_1_1765", "context": "In the present paper, we describe two patients with active UC who developed a severe systemic CMV infection during a treatment with an oral microemulsion form of cyclosporine.", "question": "Treatment.Drug in oral microemulsion form of cyclosporine", "question_type": "Adverse_event.Treatment.Drug", "answers": "cyclosporine"}, {"id": "18359591_1_1766", "context": "In the present paper, we describe two patients with active UC who developed a severe systemic CMV infection during a treatment with an oral microemulsion form of cyclosporine.", "question": "Treatment.Dosage in oral microemulsion form of cyclosporine", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18359591_1_1767", "context": "In the present paper, we describe two patients with active UC who developed a severe systemic CMV infection during a treatment with an oral microemulsion form of cyclosporine.", "question": "Treatment.Freq in oral microemulsion form of cyclosporine", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18359591_1_1768", "context": "In the present paper, we describe two patients with active UC who developed a severe systemic CMV infection during a treatment with an oral microemulsion form of cyclosporine.", "question": "Treatment.Route in oral microemulsion form of cyclosporine", "question_type": "Adverse_event.Treatment.Route", "answers": "oral"}, {"id": "18359591_1_1769", "context": "In the present paper, we describe two patients with active UC who developed a severe systemic CMV infection during a treatment with an oral microemulsion form of cyclosporine.", "question": "Treatment.Time_elapsed in oral microemulsion form of cyclosporine", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18359591_1_1770", "context": "In the present paper, we describe two patients with active UC who developed a severe systemic CMV infection during a treatment with an oral microemulsion form of cyclosporine.", "question": "Treatment.Duration in oral microemulsion form of cyclosporine", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18359591_1_1771", "context": "In the present paper, we describe two patients with active UC who developed a severe systemic CMV infection during a treatment with an oral microemulsion form of cyclosporine.", "question": "Treatment.Disorder in oral microemulsion form of cyclosporine", "question_type": "Adverse_event.Treatment.Disorder", "answers": "active UC"}, {"id": "18359591_1_1772", "context": "In the present paper, we describe two patients with active UC who developed a severe systemic CMV infection during a treatment with an oral microemulsion form of cyclosporine.", "question": "Combination.Drug in oral microemulsion form of cyclosporine", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9681092_5_1773", "context": "Prior to surgery, the patient received droperidol, an agent known to prolong the QT interval.", "question": "Subject.Age in the patient", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "9681092_5_1774", "context": "Prior to surgery, the patient received droperidol, an agent known to prolong the QT interval.", "question": "Subject.Gender in the patient", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "9681092_5_1775", "context": "Prior to surgery, the patient received droperidol, an agent known to prolong the QT interval.", "question": "Subject.Population in the patient", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "9681092_5_1776", "context": "Prior to surgery, the patient received droperidol, an agent known to prolong the QT interval.", "question": "Subject.Race in the patient", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "9681092_5_1777", "context": "Prior to surgery, the patient received droperidol, an agent known to prolong the QT interval.", "question": "Subject.Disorder in the patient", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "9681092_5_1778", "context": "Prior to surgery, the patient received droperidol, an agent known to prolong the QT interval.", "question": "Treatment.Drug in droperidol; Prior to surgery", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "droperidol"}, {"id": "9681092_5_1779", "context": "Prior to surgery, the patient received droperidol, an agent known to prolong the QT interval.", "question": "Treatment.Dosage in droperidol; Prior to surgery", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "9681092_5_1780", "context": "Prior to surgery, the patient received droperidol, an agent known to prolong the QT interval.", "question": "Treatment.Freq in droperidol; Prior to surgery", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "9681092_5_1781", "context": "Prior to surgery, the patient received droperidol, an agent known to prolong the QT interval.", "question": "Treatment.Route in droperidol; Prior to surgery", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "9681092_5_1782", "context": "Prior to surgery, the patient received droperidol, an agent known to prolong the QT interval.", "question": "Treatment.Time_elapsed in droperidol; Prior to surgery", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9681092_5_1783", "context": "Prior to surgery, the patient received droperidol, an agent known to prolong the QT interval.", "question": "Treatment.Duration in droperidol; Prior to surgery", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "9681092_5_1784", "context": "Prior to surgery, the patient received droperidol, an agent known to prolong the QT interval.", "question": "Treatment.Disorder in droperidol; Prior to surgery", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "9681092_5_1785", "context": "Prior to surgery, the patient received droperidol, an agent known to prolong the QT interval.", "question": "Combination.Drug in droperidol; Prior to surgery", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "20110001_4_1786", "context": "OBJECTIVE: We report a case of cutaneous KS lesions in a patient affected by CML treated with imatinib.", "question": "Subject.Age in a patient affected by CML", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "20110001_4_1787", "context": "OBJECTIVE: We report a case of cutaneous KS lesions in a patient affected by CML treated with imatinib.", "question": "Subject.Gender in a patient affected by CML", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "20110001_4_1788", "context": "OBJECTIVE: We report a case of cutaneous KS lesions in a patient affected by CML treated with imatinib.", "question": "Subject.Population in a patient affected by CML", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "20110001_4_1789", "context": "OBJECTIVE: We report a case of cutaneous KS lesions in a patient affected by CML treated with imatinib.", "question": "Subject.Race in a patient affected by CML", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "20110001_4_1790", "context": "OBJECTIVE: We report a case of cutaneous KS lesions in a patient affected by CML treated with imatinib.", "question": "Subject.Disorder in a patient affected by CML", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "20110001_4_1791", "context": "OBJECTIVE: We report a case of cutaneous KS lesions in a patient affected by CML treated with imatinib.", "question": "Treatment.Drug in imatinib", "question_type": "Adverse_event.Treatment.Drug", "answers": "imatinib"}, {"id": "20110001_4_1792", "context": "OBJECTIVE: We report a case of cutaneous KS lesions in a patient affected by CML treated with imatinib.", "question": "Treatment.Dosage in imatinib", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "20110001_4_1793", "context": "OBJECTIVE: We report a case of cutaneous KS lesions in a patient affected by CML treated with imatinib.", "question": "Treatment.Freq in imatinib", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "20110001_4_1794", "context": "OBJECTIVE: We report a case of cutaneous KS lesions in a patient affected by CML treated with imatinib.", "question": "Treatment.Route in imatinib", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "20110001_4_1795", "context": "OBJECTIVE: We report a case of cutaneous KS lesions in a patient affected by CML treated with imatinib.", "question": "Treatment.Time_elapsed in imatinib", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "20110001_4_1796", "context": "OBJECTIVE: We report a case of cutaneous KS lesions in a patient affected by CML treated with imatinib.", "question": "Treatment.Duration in imatinib", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "20110001_4_1797", "context": "OBJECTIVE: We report a case of cutaneous KS lesions in a patient affected by CML treated with imatinib.", "question": "Treatment.Disorder in imatinib", "question_type": "Adverse_event.Treatment.Disorder", "answers": "CML"}, {"id": "20110001_4_1798", "context": "OBJECTIVE: We report a case of cutaneous KS lesions in a patient affected by CML treated with imatinib.", "question": "Combination.Drug in imatinib", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17907595_6_1799", "context": "The FK 506 dose was constant within 21 days after discontinuing phenytoin in Patient 1 who had 36 days of phenytoin therapy.", "question": "Subject.Age in Patient 1", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "17907595_6_1800", "context": "The FK 506 dose was constant within 21 days after discontinuing phenytoin in Patient 1 who had 36 days of phenytoin therapy.", "question": "Subject.Gender in Patient 1", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "17907595_6_1801", "context": "The FK 506 dose was constant within 21 days after discontinuing phenytoin in Patient 1 who had 36 days of phenytoin therapy.", "question": "Subject.Population in Patient 1", "question_type": "Adverse_event.Subject.Population", "answers": "1"}, {"id": "17907595_6_1802", "context": "The FK 506 dose was constant within 21 days after discontinuing phenytoin in Patient 1 who had 36 days of phenytoin therapy.", "question": "Subject.Race in Patient 1", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "17907595_6_1803", "context": "The FK 506 dose was constant within 21 days after discontinuing phenytoin in Patient 1 who had 36 days of phenytoin therapy.", "question": "Subject.Disorder in Patient 1", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "17907595_6_1804", "context": "The FK 506 dose was constant within 21 days after discontinuing phenytoin in Patient 1 who had 36 days of phenytoin therapy.", "question": "Treatment.Drug in phenytoin", "question_type": "Adverse_event.Treatment.Drug", "answers": "phenytoin; phenytoin therapy"}, {"id": "17907595_6_1805", "context": "The FK 506 dose was constant within 21 days after discontinuing phenytoin in Patient 1 who had 36 days of phenytoin therapy.", "question": "Treatment.Dosage in phenytoin", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17907595_6_1806", "context": "The FK 506 dose was constant within 21 days after discontinuing phenytoin in Patient 1 who had 36 days of phenytoin therapy.", "question": "Treatment.Freq in phenytoin", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17907595_6_1807", "context": "The FK 506 dose was constant within 21 days after discontinuing phenytoin in Patient 1 who had 36 days of phenytoin therapy.", "question": "Treatment.Route in phenytoin", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17907595_6_1808", "context": "The FK 506 dose was constant within 21 days after discontinuing phenytoin in Patient 1 who had 36 days of phenytoin therapy.", "question": "Treatment.Time_elapsed in phenytoin", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "36 days"}, {"id": "17907595_6_1809", "context": "The FK 506 dose was constant within 21 days after discontinuing phenytoin in Patient 1 who had 36 days of phenytoin therapy.", "question": "Treatment.Duration in phenytoin", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17907595_6_1810", "context": "The FK 506 dose was constant within 21 days after discontinuing phenytoin in Patient 1 who had 36 days of phenytoin therapy.", "question": "Treatment.Disorder in phenytoin", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17907595_6_1811", "context": "The FK 506 dose was constant within 21 days after discontinuing phenytoin in Patient 1 who had 36 days of phenytoin therapy.", "question": "Combination.Drug in phenytoin", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11597289_14_1812", "context": "In patients receiving antithrombin III and concomitant heparin, a significantly increased bleeding incidence was observed (23.8% for antithrombin III group vs 13.5% for placebo group; P<.001).", "question": "Subject.Age in patients", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "11597289_14_1813", "context": "In patients receiving antithrombin III and concomitant heparin, a significantly increased bleeding incidence was observed (23.8% for antithrombin III group vs 13.5% for placebo group; P<.001).", "question": "Subject.Gender in patients", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "11597289_14_1814", "context": "In patients receiving antithrombin III and concomitant heparin, a significantly increased bleeding incidence was observed (23.8% for antithrombin III group vs 13.5% for placebo group; P<.001).", "question": "Subject.Population in patients", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "11597289_14_1815", "context": "In patients receiving antithrombin III and concomitant heparin, a significantly increased bleeding incidence was observed (23.8% for antithrombin III group vs 13.5% for placebo group; P<.001).", "question": "Subject.Race in patients", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "11597289_14_1816", "context": "In patients receiving antithrombin III and concomitant heparin, a significantly increased bleeding incidence was observed (23.8% for antithrombin III group vs 13.5% for placebo group; P<.001).", "question": "Subject.Disorder in patients", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "11597289_14_1817", "context": "In patients receiving antithrombin III and concomitant heparin, a significantly increased bleeding incidence was observed (23.8% for antithrombin III group vs 13.5% for placebo group; P<.001).", "question": "Treatment.Drug in antithrombin III and concomitant heparin", "question_type": "Adverse_event.Treatment.Drug", "answers": "concomitant heparin; antithrombin III"}, {"id": "11597289_14_1818", "context": "In patients receiving antithrombin III and concomitant heparin, a significantly increased bleeding incidence was observed (23.8% for antithrombin III group vs 13.5% for placebo group; P<.001).", "question": "Treatment.Dosage in antithrombin III and concomitant heparin", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11597289_14_1819", "context": "In patients receiving antithrombin III and concomitant heparin, a significantly increased bleeding incidence was observed (23.8% for antithrombin III group vs 13.5% for placebo group; P<.001).", "question": "Treatment.Freq in antithrombin III and concomitant heparin", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11597289_14_1820", "context": "In patients receiving antithrombin III and concomitant heparin, a significantly increased bleeding incidence was observed (23.8% for antithrombin III group vs 13.5% for placebo group; P<.001).", "question": "Treatment.Route in antithrombin III and concomitant heparin", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11597289_14_1821", "context": "In patients receiving antithrombin III and concomitant heparin, a significantly increased bleeding incidence was observed (23.8% for antithrombin III group vs 13.5% for placebo group; P<.001).", "question": "Treatment.Time_elapsed in antithrombin III and concomitant heparin", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11597289_14_1822", "context": "In patients receiving antithrombin III and concomitant heparin, a significantly increased bleeding incidence was observed (23.8% for antithrombin III group vs 13.5% for placebo group; P<.001).", "question": "Treatment.Duration in antithrombin III and concomitant heparin", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11597289_14_1823", "context": "In patients receiving antithrombin III and concomitant heparin, a significantly increased bleeding incidence was observed (23.8% for antithrombin III group vs 13.5% for placebo group; P<.001).", "question": "Treatment.Disorder in antithrombin III and concomitant heparin", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11597289_14_1824", "context": "In patients receiving antithrombin III and concomitant heparin, a significantly increased bleeding incidence was observed (23.8% for antithrombin III group vs 13.5% for placebo group; P<.001).", "question": "Combination.Drug in antithrombin III and concomitant heparin", "question_type": "Adverse_event.Combination.Drug", "answers": "antithrombin III; concomitant heparin"}, {"id": "968449_2_1825", "context": "Bone marrow chromosomes were studied in 2 patients with polycythaemia vera (PV) at the time of diagnosis and several times subsequently during therapy with chlorambucil.", "question": "Subject.Age in 2 patients with polycythaemia vera (PV)", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "968449_2_1826", "context": "Bone marrow chromosomes were studied in 2 patients with polycythaemia vera (PV) at the time of diagnosis and several times subsequently during therapy with chlorambucil.", "question": "Subject.Gender in 2 patients with polycythaemia vera (PV)", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "968449_2_1827", "context": "Bone marrow chromosomes were studied in 2 patients with polycythaemia vera (PV) at the time of diagnosis and several times subsequently during therapy with chlorambucil.", "question": "Subject.Population in 2 patients with polycythaemia vera (PV)", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": "2"}, {"id": "968449_2_1828", "context": "Bone marrow chromosomes were studied in 2 patients with polycythaemia vera (PV) at the time of diagnosis and several times subsequently during therapy with chlorambucil.", "question": "Subject.Race in 2 patients with polycythaemia vera (PV)", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "968449_2_1829", "context": "Bone marrow chromosomes were studied in 2 patients with polycythaemia vera (PV) at the time of diagnosis and several times subsequently during therapy with chlorambucil.", "question": "Subject.Disorder in 2 patients with polycythaemia vera (PV)", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "968449_2_1830", "context": "Bone marrow chromosomes were studied in 2 patients with polycythaemia vera (PV) at the time of diagnosis and several times subsequently during therapy with chlorambucil.", "question": "Treatment.Drug in chlorambucil", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "chlorambucil"}, {"id": "968449_2_1831", "context": "Bone marrow chromosomes were studied in 2 patients with polycythaemia vera (PV) at the time of diagnosis and several times subsequently during therapy with chlorambucil.", "question": "Treatment.Dosage in chlorambucil", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "968449_2_1832", "context": "Bone marrow chromosomes were studied in 2 patients with polycythaemia vera (PV) at the time of diagnosis and several times subsequently during therapy with chlorambucil.", "question": "Treatment.Freq in chlorambucil", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "968449_2_1833", "context": "Bone marrow chromosomes were studied in 2 patients with polycythaemia vera (PV) at the time of diagnosis and several times subsequently during therapy with chlorambucil.", "question": "Treatment.Route in chlorambucil", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "968449_2_1834", "context": "Bone marrow chromosomes were studied in 2 patients with polycythaemia vera (PV) at the time of diagnosis and several times subsequently during therapy with chlorambucil.", "question": "Treatment.Time_elapsed in chlorambucil", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "968449_2_1835", "context": "Bone marrow chromosomes were studied in 2 patients with polycythaemia vera (PV) at the time of diagnosis and several times subsequently during therapy with chlorambucil.", "question": "Treatment.Duration in chlorambucil", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "968449_2_1836", "context": "Bone marrow chromosomes were studied in 2 patients with polycythaemia vera (PV) at the time of diagnosis and several times subsequently during therapy with chlorambucil.", "question": "Treatment.Disorder in chlorambucil", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "polycythaemia vera (PV)"}, {"id": "968449_2_1837", "context": "Bone marrow chromosomes were studied in 2 patients with polycythaemia vera (PV) at the time of diagnosis and several times subsequently during therapy with chlorambucil.", "question": "Combination.Drug in chlorambucil", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "2429270_4_1838", "context": "Procainamide-induced incessant supraventricular tachycardia in the Wolff-Parkinson-White syndrome.", "question": "Treatment.Drug in Procainamide", "question_type": "Adverse_event.Treatment.Drug", "answers": "Procainamide"}, {"id": "2429270_4_1839", "context": "Procainamide-induced incessant supraventricular tachycardia in the Wolff-Parkinson-White syndrome.", "question": "Treatment.Dosage in Procainamide", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "2429270_4_1840", "context": "Procainamide-induced incessant supraventricular tachycardia in the Wolff-Parkinson-White syndrome.", "question": "Treatment.Freq in Procainamide", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2429270_4_1841", "context": "Procainamide-induced incessant supraventricular tachycardia in the Wolff-Parkinson-White syndrome.", "question": "Treatment.Route in Procainamide", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "2429270_4_1842", "context": "Procainamide-induced incessant supraventricular tachycardia in the Wolff-Parkinson-White syndrome.", "question": "Treatment.Time_elapsed in Procainamide", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2429270_4_1843", "context": "Procainamide-induced incessant supraventricular tachycardia in the Wolff-Parkinson-White syndrome.", "question": "Treatment.Duration in Procainamide", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2429270_4_1844", "context": "Procainamide-induced incessant supraventricular tachycardia in the Wolff-Parkinson-White syndrome.", "question": "Treatment.Disorder in Procainamide", "question_type": "Adverse_event.Treatment.Disorder", "answers": "Wolff-Parkinson-White syndrome"}, {"id": "2429270_4_1845", "context": "Procainamide-induced incessant supraventricular tachycardia in the Wolff-Parkinson-White syndrome.", "question": "Combination.Drug in Procainamide", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "19249953_10_1846", "context": "To our knowledge, however, this is the first case report of a possible sitagliptin-lovastatin interaction that may have caused rhabdomyolysis.", "question": "Treatment.Drug in sitagliptin-lovastatin interaction", "question_type": "Adverse_event.Treatment.Drug", "answers": "sitagliptin; lovastatin"}, {"id": "19249953_10_1847", "context": "To our knowledge, however, this is the first case report of a possible sitagliptin-lovastatin interaction that may have caused rhabdomyolysis.", "question": "Treatment.Dosage in sitagliptin-lovastatin interaction", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "19249953_10_1848", "context": "To our knowledge, however, this is the first case report of a possible sitagliptin-lovastatin interaction that may have caused rhabdomyolysis.", "question": "Treatment.Freq in sitagliptin-lovastatin interaction", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "19249953_10_1849", "context": "To our knowledge, however, this is the first case report of a possible sitagliptin-lovastatin interaction that may have caused rhabdomyolysis.", "question": "Treatment.Route in sitagliptin-lovastatin interaction", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "19249953_10_1850", "context": "To our knowledge, however, this is the first case report of a possible sitagliptin-lovastatin interaction that may have caused rhabdomyolysis.", "question": "Treatment.Time_elapsed in sitagliptin-lovastatin interaction", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19249953_10_1851", "context": "To our knowledge, however, this is the first case report of a possible sitagliptin-lovastatin interaction that may have caused rhabdomyolysis.", "question": "Treatment.Duration in sitagliptin-lovastatin interaction", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "19249953_10_1852", "context": "To our knowledge, however, this is the first case report of a possible sitagliptin-lovastatin interaction that may have caused rhabdomyolysis.", "question": "Treatment.Disorder in sitagliptin-lovastatin interaction", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "19249953_10_1853", "context": "To our knowledge, however, this is the first case report of a possible sitagliptin-lovastatin interaction that may have caused rhabdomyolysis.", "question": "Combination.Drug in sitagliptin-lovastatin interaction", "question_type": "Adverse_event.Combination.Drug", "answers": "lovastatin; sitagliptin"}, {"id": "897744_2_1854", "context": "A drug addict with staphylococcal endocarditis treated with methicillin, who developed massive proteinuria and acute nephritic syndrome is described.", "question": "Subject.Age in A drug addict", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "897744_2_1855", "context": "A drug addict with staphylococcal endocarditis treated with methicillin, who developed massive proteinuria and acute nephritic syndrome is described.", "question": "Subject.Gender in A drug addict", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "897744_2_1856", "context": "A drug addict with staphylococcal endocarditis treated with methicillin, who developed massive proteinuria and acute nephritic syndrome is described.", "question": "Subject.Population in A drug addict", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "897744_2_1857", "context": "A drug addict with staphylococcal endocarditis treated with methicillin, who developed massive proteinuria and acute nephritic syndrome is described.", "question": "Subject.Race in A drug addict", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "897744_2_1858", "context": "A drug addict with staphylococcal endocarditis treated with methicillin, who developed massive proteinuria and acute nephritic syndrome is described.", "question": "Subject.Disorder in A drug addict", "question_type": "Adverse_event.Subject.Disorder", "answers": "drug addict"}, {"id": "897744_2_1859", "context": "A drug addict with staphylococcal endocarditis treated with methicillin, who developed massive proteinuria and acute nephritic syndrome is described.", "question": "Treatment.Drug in methicillin", "question_type": "Adverse_event.Treatment.Drug", "answers": "methicillin"}, {"id": "897744_2_1860", "context": "A drug addict with staphylococcal endocarditis treated with methicillin, who developed massive proteinuria and acute nephritic syndrome is described.", "question": "Treatment.Dosage in methicillin", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "897744_2_1861", "context": "A drug addict with staphylococcal endocarditis treated with methicillin, who developed massive proteinuria and acute nephritic syndrome is described.", "question": "Treatment.Freq in methicillin", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "897744_2_1862", "context": "A drug addict with staphylococcal endocarditis treated with methicillin, who developed massive proteinuria and acute nephritic syndrome is described.", "question": "Treatment.Route in methicillin", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "897744_2_1863", "context": "A drug addict with staphylococcal endocarditis treated with methicillin, who developed massive proteinuria and acute nephritic syndrome is described.", "question": "Treatment.Time_elapsed in methicillin", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "897744_2_1864", "context": "A drug addict with staphylococcal endocarditis treated with methicillin, who developed massive proteinuria and acute nephritic syndrome is described.", "question": "Treatment.Duration in methicillin", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "897744_2_1865", "context": "A drug addict with staphylococcal endocarditis treated with methicillin, who developed massive proteinuria and acute nephritic syndrome is described.", "question": "Treatment.Disorder in methicillin", "question_type": "Adverse_event.Treatment.Disorder", "answers": "staphylococcal endocarditis"}, {"id": "897744_2_1866", "context": "A drug addict with staphylococcal endocarditis treated with methicillin, who developed massive proteinuria and acute nephritic syndrome is described.", "question": "Combination.Drug in methicillin", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7035691_3_1867", "context": "Although inhibition of the angiotensin-converting enzyme is considered to be efficient treatment for hypertension associated with chronic renal failure, care should be taken when captopril is administered initially to a patient with decreased renal function, under the conditions of sodium and water depletion.", "question": "Subject.Age in a patient with decreased renal function", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "7035691_3_1868", "context": "Although inhibition of the angiotensin-converting enzyme is considered to be efficient treatment for hypertension associated with chronic renal failure, care should be taken when captopril is administered initially to a patient with decreased renal function, under the conditions of sodium and water depletion.", "question": "Subject.Gender in a patient with decreased renal function", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "7035691_3_1869", "context": "Although inhibition of the angiotensin-converting enzyme is considered to be efficient treatment for hypertension associated with chronic renal failure, care should be taken when captopril is administered initially to a patient with decreased renal function, under the conditions of sodium and water depletion.", "question": "Subject.Population in a patient with decreased renal function", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "7035691_3_1870", "context": "Although inhibition of the angiotensin-converting enzyme is considered to be efficient treatment for hypertension associated with chronic renal failure, care should be taken when captopril is administered initially to a patient with decreased renal function, under the conditions of sodium and water depletion.", "question": "Subject.Race in a patient with decreased renal function", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "7035691_3_1871", "context": "Although inhibition of the angiotensin-converting enzyme is considered to be efficient treatment for hypertension associated with chronic renal failure, care should be taken when captopril is administered initially to a patient with decreased renal function, under the conditions of sodium and water depletion.", "question": "Subject.Disorder in a patient with decreased renal function", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": "decreased renal function"}, {"id": "7035691_3_1872", "context": "Although inhibition of the angiotensin-converting enzyme is considered to be efficient treatment for hypertension associated with chronic renal failure, care should be taken when captopril is administered initially to a patient with decreased renal function, under the conditions of sodium and water depletion.", "question": "Treatment.Drug in captopril", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "captopril"}, {"id": "7035691_3_1873", "context": "Although inhibition of the angiotensin-converting enzyme is considered to be efficient treatment for hypertension associated with chronic renal failure, care should be taken when captopril is administered initially to a patient with decreased renal function, under the conditions of sodium and water depletion.", "question": "Treatment.Dosage in captopril", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "7035691_3_1874", "context": "Although inhibition of the angiotensin-converting enzyme is considered to be efficient treatment for hypertension associated with chronic renal failure, care should be taken when captopril is administered initially to a patient with decreased renal function, under the conditions of sodium and water depletion.", "question": "Treatment.Freq in captopril", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "7035691_3_1875", "context": "Although inhibition of the angiotensin-converting enzyme is considered to be efficient treatment for hypertension associated with chronic renal failure, care should be taken when captopril is administered initially to a patient with decreased renal function, under the conditions of sodium and water depletion.", "question": "Treatment.Route in captopril", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "7035691_3_1876", "context": "Although inhibition of the angiotensin-converting enzyme is considered to be efficient treatment for hypertension associated with chronic renal failure, care should be taken when captopril is administered initially to a patient with decreased renal function, under the conditions of sodium and water depletion.", "question": "Treatment.Time_elapsed in captopril", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7035691_3_1877", "context": "Although inhibition of the angiotensin-converting enzyme is considered to be efficient treatment for hypertension associated with chronic renal failure, care should be taken when captopril is administered initially to a patient with decreased renal function, under the conditions of sodium and water depletion.", "question": "Treatment.Duration in captopril", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "7035691_3_1878", "context": "Although inhibition of the angiotensin-converting enzyme is considered to be efficient treatment for hypertension associated with chronic renal failure, care should be taken when captopril is administered initially to a patient with decreased renal function, under the conditions of sodium and water depletion.", "question": "Treatment.Disorder in captopril", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "hypertension associated with chronic renal failure"}, {"id": "7035691_3_1879", "context": "Although inhibition of the angiotensin-converting enzyme is considered to be efficient treatment for hypertension associated with chronic renal failure, care should be taken when captopril is administered initially to a patient with decreased renal function, under the conditions of sodium and water depletion.", "question": "Combination.Drug in captopril", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "7907218_1_1880", "context": "Two patients with extrapyramidal side effects after the use of fluphenazine decanoate were evaluated by means of IBZM-SPECT.", "question": "Subject.Age in Two patients", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "7907218_1_1881", "context": "Two patients with extrapyramidal side effects after the use of fluphenazine decanoate were evaluated by means of IBZM-SPECT.", "question": "Subject.Gender in Two patients", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "7907218_1_1882", "context": "Two patients with extrapyramidal side effects after the use of fluphenazine decanoate were evaluated by means of IBZM-SPECT.", "question": "Subject.Population in Two patients", "question_type": "Adverse_event.Subject.Population", "answers": "Two"}, {"id": "7907218_1_1883", "context": "Two patients with extrapyramidal side effects after the use of fluphenazine decanoate were evaluated by means of IBZM-SPECT.", "question": "Subject.Race in Two patients", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "7907218_1_1884", "context": "Two patients with extrapyramidal side effects after the use of fluphenazine decanoate were evaluated by means of IBZM-SPECT.", "question": "Subject.Disorder in Two patients", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "7907218_1_1885", "context": "Two patients with extrapyramidal side effects after the use of fluphenazine decanoate were evaluated by means of IBZM-SPECT.", "question": "Treatment.Drug in fluphenazine decanoate", "question_type": "Adverse_event.Treatment.Drug", "answers": "fluphenazine decanoate"}, {"id": "7907218_1_1886", "context": "Two patients with extrapyramidal side effects after the use of fluphenazine decanoate were evaluated by means of IBZM-SPECT.", "question": "Treatment.Dosage in fluphenazine decanoate", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7907218_1_1887", "context": "Two patients with extrapyramidal side effects after the use of fluphenazine decanoate were evaluated by means of IBZM-SPECT.", "question": "Treatment.Freq in fluphenazine decanoate", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7907218_1_1888", "context": "Two patients with extrapyramidal side effects after the use of fluphenazine decanoate were evaluated by means of IBZM-SPECT.", "question": "Treatment.Route in fluphenazine decanoate", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7907218_1_1889", "context": "Two patients with extrapyramidal side effects after the use of fluphenazine decanoate were evaluated by means of IBZM-SPECT.", "question": "Treatment.Time_elapsed in fluphenazine decanoate", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7907218_1_1890", "context": "Two patients with extrapyramidal side effects after the use of fluphenazine decanoate were evaluated by means of IBZM-SPECT.", "question": "Treatment.Duration in fluphenazine decanoate", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7907218_1_1891", "context": "Two patients with extrapyramidal side effects after the use of fluphenazine decanoate were evaluated by means of IBZM-SPECT.", "question": "Treatment.Disorder in fluphenazine decanoate", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7907218_1_1892", "context": "Two patients with extrapyramidal side effects after the use of fluphenazine decanoate were evaluated by means of IBZM-SPECT.", "question": "Combination.Drug in fluphenazine decanoate", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10348150_2_1893", "context": "The clinical course suggests that the interstitial pneumonitis was induced by hydroxyurea.", "question": "Treatment.Drug in hydroxyurea", "question_type": "Adverse_event.Treatment.Drug", "answers": "hydroxyurea"}, {"id": "10348150_2_1894", "context": "The clinical course suggests that the interstitial pneumonitis was induced by hydroxyurea.", "question": "Treatment.Dosage in hydroxyurea", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10348150_2_1895", "context": "The clinical course suggests that the interstitial pneumonitis was induced by hydroxyurea.", "question": "Treatment.Freq in hydroxyurea", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10348150_2_1896", "context": "The clinical course suggests that the interstitial pneumonitis was induced by hydroxyurea.", "question": "Treatment.Route in hydroxyurea", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10348150_2_1897", "context": "The clinical course suggests that the interstitial pneumonitis was induced by hydroxyurea.", "question": "Treatment.Time_elapsed in hydroxyurea", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10348150_2_1898", "context": "The clinical course suggests that the interstitial pneumonitis was induced by hydroxyurea.", "question": "Treatment.Duration in hydroxyurea", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10348150_2_1899", "context": "The clinical course suggests that the interstitial pneumonitis was induced by hydroxyurea.", "question": "Treatment.Disorder in hydroxyurea", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10348150_2_1900", "context": "The clinical course suggests that the interstitial pneumonitis was induced by hydroxyurea.", "question": "Combination.Drug in hydroxyurea", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "2196696_1_1901", "context": "Disulfiram-induced hepatitis.", "question": "Treatment.Drug in Disulfiram", "question_type": "Adverse_event.Treatment.Drug", "answers": "Disulfiram"}, {"id": "2196696_1_1902", "context": "Disulfiram-induced hepatitis.", "question": "Treatment.Dosage in Disulfiram", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "2196696_1_1903", "context": "Disulfiram-induced hepatitis.", "question": "Treatment.Freq in Disulfiram", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2196696_1_1904", "context": "Disulfiram-induced hepatitis.", "question": "Treatment.Route in Disulfiram", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "2196696_1_1905", "context": "Disulfiram-induced hepatitis.", "question": "Treatment.Time_elapsed in Disulfiram", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2196696_1_1906", "context": "Disulfiram-induced hepatitis.", "question": "Treatment.Duration in Disulfiram", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2196696_1_1907", "context": "Disulfiram-induced hepatitis.", "question": "Treatment.Disorder in Disulfiram", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "2196696_1_1908", "context": "Disulfiram-induced hepatitis.", "question": "Combination.Drug in Disulfiram", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15112258_13_1909", "context": "The majority of radiation recall reactions attributed to gemcitabine are reported to affect internal tissue or organs.", "question": "Treatment.Drug in gemcitabine", "question_type": "Adverse_event.Treatment.Drug", "answers": "gemcitabine"}, {"id": "15112258_13_1910", "context": "The majority of radiation recall reactions attributed to gemcitabine are reported to affect internal tissue or organs.", "question": "Treatment.Dosage in gemcitabine", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15112258_13_1911", "context": "The majority of radiation recall reactions attributed to gemcitabine are reported to affect internal tissue or organs.", "question": "Treatment.Freq in gemcitabine", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15112258_13_1912", "context": "The majority of radiation recall reactions attributed to gemcitabine are reported to affect internal tissue or organs.", "question": "Treatment.Route in gemcitabine", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15112258_13_1913", "context": "The majority of radiation recall reactions attributed to gemcitabine are reported to affect internal tissue or organs.", "question": "Treatment.Time_elapsed in gemcitabine", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15112258_13_1914", "context": "The majority of radiation recall reactions attributed to gemcitabine are reported to affect internal tissue or organs.", "question": "Treatment.Duration in gemcitabine", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15112258_13_1915", "context": "The majority of radiation recall reactions attributed to gemcitabine are reported to affect internal tissue or organs.", "question": "Treatment.Disorder in gemcitabine", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15112258_13_1916", "context": "The majority of radiation recall reactions attributed to gemcitabine are reported to affect internal tissue or organs.", "question": "Combination.Drug in gemcitabine", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18487000_2_1917", "context": "The known side effects of sibutramine, ie, hypertension and tachycardia, depend on its adrenergic and serotoninergic effects.", "question": "Treatment.Drug in sibutramine", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18487000_2_1918", "context": "The known side effects of sibutramine, ie, hypertension and tachycardia, depend on its adrenergic and serotoninergic effects.", "question": "Treatment.Dosage in sibutramine", "question_type": "Adverse_event.Treatment.Dosage", "answers": "sibutramine"}, {"id": "18487000_2_1919", "context": "The known side effects of sibutramine, ie, hypertension and tachycardia, depend on its adrenergic and serotoninergic effects.", "question": "Treatment.Freq in sibutramine", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18487000_2_1920", "context": "The known side effects of sibutramine, ie, hypertension and tachycardia, depend on its adrenergic and serotoninergic effects.", "question": "Treatment.Route in sibutramine", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18487000_2_1921", "context": "The known side effects of sibutramine, ie, hypertension and tachycardia, depend on its adrenergic and serotoninergic effects.", "question": "Treatment.Time_elapsed in sibutramine", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18487000_2_1922", "context": "The known side effects of sibutramine, ie, hypertension and tachycardia, depend on its adrenergic and serotoninergic effects.", "question": "Treatment.Duration in sibutramine", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18487000_2_1923", "context": "The known side effects of sibutramine, ie, hypertension and tachycardia, depend on its adrenergic and serotoninergic effects.", "question": "Treatment.Disorder in sibutramine", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18487000_2_1924", "context": "The known side effects of sibutramine, ie, hypertension and tachycardia, depend on its adrenergic and serotoninergic effects.", "question": "Combination.Drug in sibutramine", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "20979526_8_1925", "context": "Because at the end of the first month the patient's platelet counts were normal and the thrombocytopenia developed after the co-medication with conventional drugs, it was suspected that the thrombocytopenia might not be attributed to the use of FHP.", "question": "Treatment.Drug in FHP", "question_type": "Adverse_event.Treatment.Drug", "answers": "FHP"}, {"id": "20979526_8_1926", "context": "Because at the end of the first month the patient's platelet counts were normal and the thrombocytopenia developed after the co-medication with conventional drugs, it was suspected that the thrombocytopenia might not be attributed to the use of FHP.", "question": "Treatment.Dosage in FHP", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "20979526_8_1927", "context": "Because at the end of the first month the patient's platelet counts were normal and the thrombocytopenia developed after the co-medication with conventional drugs, it was suspected that the thrombocytopenia might not be attributed to the use of FHP.", "question": "Treatment.Freq in FHP", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "20979526_8_1928", "context": "Because at the end of the first month the patient's platelet counts were normal and the thrombocytopenia developed after the co-medication with conventional drugs, it was suspected that the thrombocytopenia might not be attributed to the use of FHP.", "question": "Treatment.Route in FHP", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "20979526_8_1929", "context": "Because at the end of the first month the patient's platelet counts were normal and the thrombocytopenia developed after the co-medication with conventional drugs, it was suspected that the thrombocytopenia might not be attributed to the use of FHP.", "question": "Treatment.Time_elapsed in FHP", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "20979526_8_1930", "context": "Because at the end of the first month the patient's platelet counts were normal and the thrombocytopenia developed after the co-medication with conventional drugs, it was suspected that the thrombocytopenia might not be attributed to the use of FHP.", "question": "Treatment.Duration in FHP", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "20979526_8_1931", "context": "Because at the end of the first month the patient's platelet counts were normal and the thrombocytopenia developed after the co-medication with conventional drugs, it was suspected that the thrombocytopenia might not be attributed to the use of FHP.", "question": "Treatment.Disorder in FHP", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "20979526_8_1932", "context": "Because at the end of the first month the patient's platelet counts were normal and the thrombocytopenia developed after the co-medication with conventional drugs, it was suspected that the thrombocytopenia might not be attributed to the use of FHP.", "question": "Combination.Drug in FHP", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12625995_3_1933", "context": "Two cases of childhood-onset schizophrenia associated with clozapine-induced akathisia responsive to beta-blocker treatment are described.", "question": "Subject.Age in Two cases of childhood-onset schizophrenia", "question_type": "Adverse_event.Subject.Age", "answers": "childhood"}, {"id": "12625995_3_1934", "context": "Two cases of childhood-onset schizophrenia associated with clozapine-induced akathisia responsive to beta-blocker treatment are described.", "question": "Subject.Gender in Two cases of childhood-onset schizophrenia", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "12625995_3_1935", "context": "Two cases of childhood-onset schizophrenia associated with clozapine-induced akathisia responsive to beta-blocker treatment are described.", "question": "Subject.Population in Two cases of childhood-onset schizophrenia", "question_type": "Adverse_event.Subject.Population", "answers": "Two"}, {"id": "12625995_3_1936", "context": "Two cases of childhood-onset schizophrenia associated with clozapine-induced akathisia responsive to beta-blocker treatment are described.", "question": "Subject.Race in Two cases of childhood-onset schizophrenia", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "12625995_3_1937", "context": "Two cases of childhood-onset schizophrenia associated with clozapine-induced akathisia responsive to beta-blocker treatment are described.", "question": "Subject.Disorder in Two cases of childhood-onset schizophrenia", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "12625995_3_1938", "context": "Two cases of childhood-onset schizophrenia associated with clozapine-induced akathisia responsive to beta-blocker treatment are described.", "question": "Treatment.Drug in clozapine", "question_type": "Adverse_event.Treatment.Drug", "answers": "clozapine"}, {"id": "12625995_3_1939", "context": "Two cases of childhood-onset schizophrenia associated with clozapine-induced akathisia responsive to beta-blocker treatment are described.", "question": "Treatment.Dosage in clozapine", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12625995_3_1940", "context": "Two cases of childhood-onset schizophrenia associated with clozapine-induced akathisia responsive to beta-blocker treatment are described.", "question": "Treatment.Freq in clozapine", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12625995_3_1941", "context": "Two cases of childhood-onset schizophrenia associated with clozapine-induced akathisia responsive to beta-blocker treatment are described.", "question": "Treatment.Route in clozapine", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12625995_3_1942", "context": "Two cases of childhood-onset schizophrenia associated with clozapine-induced akathisia responsive to beta-blocker treatment are described.", "question": "Treatment.Time_elapsed in clozapine", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12625995_3_1943", "context": "Two cases of childhood-onset schizophrenia associated with clozapine-induced akathisia responsive to beta-blocker treatment are described.", "question": "Treatment.Duration in clozapine", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12625995_3_1944", "context": "Two cases of childhood-onset schizophrenia associated with clozapine-induced akathisia responsive to beta-blocker treatment are described.", "question": "Treatment.Disorder in clozapine", "question_type": "Adverse_event.Treatment.Disorder", "answers": "schizophrenia"}, {"id": "12625995_3_1945", "context": "Two cases of childhood-onset schizophrenia associated with clozapine-induced akathisia responsive to beta-blocker treatment are described.", "question": "Combination.Drug in clozapine", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12625995_3_1946", "context": "Two cases of childhood-onset schizophrenia associated with clozapine-induced akathisia responsive to beta-blocker treatment are described.", "question": "Subject.Age in Two cases of childhood-onset schizophrenia", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": "childhood"}, {"id": "12625995_3_1947", "context": "Two cases of childhood-onset schizophrenia associated with clozapine-induced akathisia responsive to beta-blocker treatment are described.", "question": "Subject.Gender in Two cases of childhood-onset schizophrenia", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "12625995_3_1948", "context": "Two cases of childhood-onset schizophrenia associated with clozapine-induced akathisia responsive to beta-blocker treatment are described.", "question": "Subject.Population in Two cases of childhood-onset schizophrenia", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": "Two"}, {"id": "12625995_3_1949", "context": "Two cases of childhood-onset schizophrenia associated with clozapine-induced akathisia responsive to beta-blocker treatment are described.", "question": "Subject.Race in Two cases of childhood-onset schizophrenia", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "12625995_3_1950", "context": "Two cases of childhood-onset schizophrenia associated with clozapine-induced akathisia responsive to beta-blocker treatment are described.", "question": "Subject.Disorder in Two cases of childhood-onset schizophrenia", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "12625995_3_1951", "context": "Two cases of childhood-onset schizophrenia associated with clozapine-induced akathisia responsive to beta-blocker treatment are described.", "question": "Treatment.Drug in beta-blocker treatment", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "beta-blocker"}, {"id": "12625995_3_1952", "context": "Two cases of childhood-onset schizophrenia associated with clozapine-induced akathisia responsive to beta-blocker treatment are described.", "question": "Treatment.Dosage in beta-blocker treatment", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "12625995_3_1953", "context": "Two cases of childhood-onset schizophrenia associated with clozapine-induced akathisia responsive to beta-blocker treatment are described.", "question": "Treatment.Freq in beta-blocker treatment", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "12625995_3_1954", "context": "Two cases of childhood-onset schizophrenia associated with clozapine-induced akathisia responsive to beta-blocker treatment are described.", "question": "Treatment.Route in beta-blocker treatment", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "12625995_3_1955", "context": "Two cases of childhood-onset schizophrenia associated with clozapine-induced akathisia responsive to beta-blocker treatment are described.", "question": "Treatment.Time_elapsed in beta-blocker treatment", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12625995_3_1956", "context": "Two cases of childhood-onset schizophrenia associated with clozapine-induced akathisia responsive to beta-blocker treatment are described.", "question": "Treatment.Duration in beta-blocker treatment", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "12625995_3_1957", "context": "Two cases of childhood-onset schizophrenia associated with clozapine-induced akathisia responsive to beta-blocker treatment are described.", "question": "Treatment.Disorder in beta-blocker treatment", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "clozapine-induced akathisia responsive"}, {"id": "12625995_3_1958", "context": "Two cases of childhood-onset schizophrenia associated with clozapine-induced akathisia responsive to beta-blocker treatment are described.", "question": "Combination.Drug in beta-blocker treatment", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "11688826_2_1959", "context": "Syndrome of inappropriate secretion of ADH (SIADH) following cisplatin administration in a pulmonary adenocarcinoma patient with a malignant pleural effusion.", "question": "Subject.Age in a pulmonary adenocarcinoma patient with a malignant pleural effusion", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "11688826_2_1960", "context": "Syndrome of inappropriate secretion of ADH (SIADH) following cisplatin administration in a pulmonary adenocarcinoma patient with a malignant pleural effusion.", "question": "Subject.Gender in a pulmonary adenocarcinoma patient with a malignant pleural effusion", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "11688826_2_1961", "context": "Syndrome of inappropriate secretion of ADH (SIADH) following cisplatin administration in a pulmonary adenocarcinoma patient with a malignant pleural effusion.", "question": "Subject.Population in a pulmonary adenocarcinoma patient with a malignant pleural effusion", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "11688826_2_1962", "context": "Syndrome of inappropriate secretion of ADH (SIADH) following cisplatin administration in a pulmonary adenocarcinoma patient with a malignant pleural effusion.", "question": "Subject.Race in a pulmonary adenocarcinoma patient with a malignant pleural effusion", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "11688826_2_1963", "context": "Syndrome of inappropriate secretion of ADH (SIADH) following cisplatin administration in a pulmonary adenocarcinoma patient with a malignant pleural effusion.", "question": "Subject.Disorder in a pulmonary adenocarcinoma patient with a malignant pleural effusion", "question_type": "Adverse_event.Subject.Disorder", "answers": "malignant pleural effusion"}, {"id": "11688826_2_1964", "context": "Syndrome of inappropriate secretion of ADH (SIADH) following cisplatin administration in a pulmonary adenocarcinoma patient with a malignant pleural effusion.", "question": "Treatment.Drug in cisplatin", "question_type": "Adverse_event.Treatment.Drug", "answers": "cisplatin"}, {"id": "11688826_2_1965", "context": "Syndrome of inappropriate secretion of ADH (SIADH) following cisplatin administration in a pulmonary adenocarcinoma patient with a malignant pleural effusion.", "question": "Treatment.Dosage in cisplatin", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11688826_2_1966", "context": "Syndrome of inappropriate secretion of ADH (SIADH) following cisplatin administration in a pulmonary adenocarcinoma patient with a malignant pleural effusion.", "question": "Treatment.Freq in cisplatin", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11688826_2_1967", "context": "Syndrome of inappropriate secretion of ADH (SIADH) following cisplatin administration in a pulmonary adenocarcinoma patient with a malignant pleural effusion.", "question": "Treatment.Route in cisplatin", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11688826_2_1968", "context": "Syndrome of inappropriate secretion of ADH (SIADH) following cisplatin administration in a pulmonary adenocarcinoma patient with a malignant pleural effusion.", "question": "Treatment.Time_elapsed in cisplatin", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11688826_2_1969", "context": "Syndrome of inappropriate secretion of ADH (SIADH) following cisplatin administration in a pulmonary adenocarcinoma patient with a malignant pleural effusion.", "question": "Treatment.Duration in cisplatin", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11688826_2_1970", "context": "Syndrome of inappropriate secretion of ADH (SIADH) following cisplatin administration in a pulmonary adenocarcinoma patient with a malignant pleural effusion.", "question": "Treatment.Disorder in cisplatin", "question_type": "Adverse_event.Treatment.Disorder", "answers": "pulmonary adenocarcinoma"}, {"id": "11688826_2_1971", "context": "Syndrome of inappropriate secretion of ADH (SIADH) following cisplatin administration in a pulmonary adenocarcinoma patient with a malignant pleural effusion.", "question": "Combination.Drug in cisplatin", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12546343_2_1972", "context": "He had an immediate hypersensitivity reaction during the initiation of the MTX infusion with diffuse urticaria, facial swelling, cough, and chest tightness.", "question": "Treatment.Drug in MTX infusion", "question_type": "Adverse_event.Treatment.Drug", "answers": "MTX"}, {"id": "12546343_2_1973", "context": "He had an immediate hypersensitivity reaction during the initiation of the MTX infusion with diffuse urticaria, facial swelling, cough, and chest tightness.", "question": "Treatment.Dosage in MTX infusion", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12546343_2_1974", "context": "He had an immediate hypersensitivity reaction during the initiation of the MTX infusion with diffuse urticaria, facial swelling, cough, and chest tightness.", "question": "Treatment.Freq in MTX infusion", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12546343_2_1975", "context": "He had an immediate hypersensitivity reaction during the initiation of the MTX infusion with diffuse urticaria, facial swelling, cough, and chest tightness.", "question": "Treatment.Route in MTX infusion", "question_type": "Adverse_event.Treatment.Route", "answers": "infusion"}, {"id": "12546343_2_1976", "context": "He had an immediate hypersensitivity reaction during the initiation of the MTX infusion with diffuse urticaria, facial swelling, cough, and chest tightness.", "question": "Treatment.Time_elapsed in MTX infusion", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "immediate"}, {"id": "12546343_2_1977", "context": "He had an immediate hypersensitivity reaction during the initiation of the MTX infusion with diffuse urticaria, facial swelling, cough, and chest tightness.", "question": "Treatment.Duration in MTX infusion", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12546343_2_1978", "context": "He had an immediate hypersensitivity reaction during the initiation of the MTX infusion with diffuse urticaria, facial swelling, cough, and chest tightness.", "question": "Treatment.Disorder in MTX infusion", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12546343_2_1979", "context": "He had an immediate hypersensitivity reaction during the initiation of the MTX infusion with diffuse urticaria, facial swelling, cough, and chest tightness.", "question": "Combination.Drug in MTX infusion", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "20110001_1_1980", "context": "CONCLUSIONS: We present a case of a patient with CML who developed KS 12 months after starting treatment with imatinib 400 mg/d.", "question": "Subject.Age in a patient", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "20110001_1_1981", "context": "CONCLUSIONS: We present a case of a patient with CML who developed KS 12 months after starting treatment with imatinib 400 mg/d.", "question": "Subject.Gender in a patient", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "20110001_1_1982", "context": "CONCLUSIONS: We present a case of a patient with CML who developed KS 12 months after starting treatment with imatinib 400 mg/d.", "question": "Subject.Population in a patient", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "20110001_1_1983", "context": "CONCLUSIONS: We present a case of a patient with CML who developed KS 12 months after starting treatment with imatinib 400 mg/d.", "question": "Subject.Race in a patient", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "20110001_1_1984", "context": "CONCLUSIONS: We present a case of a patient with CML who developed KS 12 months after starting treatment with imatinib 400 mg/d.", "question": "Subject.Disorder in a patient", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "20110001_1_1985", "context": "CONCLUSIONS: We present a case of a patient with CML who developed KS 12 months after starting treatment with imatinib 400 mg/d.", "question": "Treatment.Drug in 12 months; imatinib 400 mg/d", "question_type": "Adverse_event.Treatment.Drug", "answers": "imatinib"}, {"id": "20110001_1_1986", "context": "CONCLUSIONS: We present a case of a patient with CML who developed KS 12 months after starting treatment with imatinib 400 mg/d.", "question": "Treatment.Dosage in 12 months; imatinib 400 mg/d", "question_type": "Adverse_event.Treatment.Dosage", "answers": "400 mg/d"}, {"id": "20110001_1_1987", "context": "CONCLUSIONS: We present a case of a patient with CML who developed KS 12 months after starting treatment with imatinib 400 mg/d.", "question": "Treatment.Freq in 12 months; imatinib 400 mg/d", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "20110001_1_1988", "context": "CONCLUSIONS: We present a case of a patient with CML who developed KS 12 months after starting treatment with imatinib 400 mg/d.", "question": "Treatment.Route in 12 months; imatinib 400 mg/d", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "20110001_1_1989", "context": "CONCLUSIONS: We present a case of a patient with CML who developed KS 12 months after starting treatment with imatinib 400 mg/d.", "question": "Treatment.Time_elapsed in 12 months; imatinib 400 mg/d", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "12 months"}, {"id": "20110001_1_1990", "context": "CONCLUSIONS: We present a case of a patient with CML who developed KS 12 months after starting treatment with imatinib 400 mg/d.", "question": "Treatment.Duration in 12 months; imatinib 400 mg/d", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "20110001_1_1991", "context": "CONCLUSIONS: We present a case of a patient with CML who developed KS 12 months after starting treatment with imatinib 400 mg/d.", "question": "Treatment.Disorder in 12 months; imatinib 400 mg/d", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "20110001_1_1992", "context": "CONCLUSIONS: We present a case of a patient with CML who developed KS 12 months after starting treatment with imatinib 400 mg/d.", "question": "Combination.Drug in 12 months; imatinib 400 mg/d", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16531969_2_1993", "context": "Grade 3 hepatotoxicity (AST and ALT > 5 to 20 upper limit normal) or higher has been observed in as many as 1.4% of MS patients on IFN beta.", "question": "Subject.Age in 1.4% of MS patients", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "16531969_2_1994", "context": "Grade 3 hepatotoxicity (AST and ALT > 5 to 20 upper limit normal) or higher has been observed in as many as 1.4% of MS patients on IFN beta.", "question": "Subject.Gender in 1.4% of MS patients", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "16531969_2_1995", "context": "Grade 3 hepatotoxicity (AST and ALT > 5 to 20 upper limit normal) or higher has been observed in as many as 1.4% of MS patients on IFN beta.", "question": "Subject.Population in 1.4% of MS patients", "question_type": "Adverse_event.Subject.Population", "answers": "1.4%"}, {"id": "16531969_2_1996", "context": "Grade 3 hepatotoxicity (AST and ALT > 5 to 20 upper limit normal) or higher has been observed in as many as 1.4% of MS patients on IFN beta.", "question": "Subject.Race in 1.4% of MS patients", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16531969_2_1997", "context": "Grade 3 hepatotoxicity (AST and ALT > 5 to 20 upper limit normal) or higher has been observed in as many as 1.4% of MS patients on IFN beta.", "question": "Subject.Disorder in 1.4% of MS patients", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "16531969_2_1998", "context": "Grade 3 hepatotoxicity (AST and ALT > 5 to 20 upper limit normal) or higher has been observed in as many as 1.4% of MS patients on IFN beta.", "question": "Treatment.Drug in IFN beta", "question_type": "Adverse_event.Treatment.Drug", "answers": "IFN beta"}, {"id": "16531969_2_1999", "context": "Grade 3 hepatotoxicity (AST and ALT > 5 to 20 upper limit normal) or higher has been observed in as many as 1.4% of MS patients on IFN beta.", "question": "Treatment.Dosage in IFN beta", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16531969_2_2000", "context": "Grade 3 hepatotoxicity (AST and ALT > 5 to 20 upper limit normal) or higher has been observed in as many as 1.4% of MS patients on IFN beta.", "question": "Treatment.Freq in IFN beta", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16531969_2_2001", "context": "Grade 3 hepatotoxicity (AST and ALT > 5 to 20 upper limit normal) or higher has been observed in as many as 1.4% of MS patients on IFN beta.", "question": "Treatment.Route in IFN beta", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16531969_2_2002", "context": "Grade 3 hepatotoxicity (AST and ALT > 5 to 20 upper limit normal) or higher has been observed in as many as 1.4% of MS patients on IFN beta.", "question": "Treatment.Time_elapsed in IFN beta", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16531969_2_2003", "context": "Grade 3 hepatotoxicity (AST and ALT > 5 to 20 upper limit normal) or higher has been observed in as many as 1.4% of MS patients on IFN beta.", "question": "Treatment.Duration in IFN beta", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16531969_2_2004", "context": "Grade 3 hepatotoxicity (AST and ALT > 5 to 20 upper limit normal) or higher has been observed in as many as 1.4% of MS patients on IFN beta.", "question": "Treatment.Disorder in IFN beta", "question_type": "Adverse_event.Treatment.Disorder", "answers": "MS"}, {"id": "16531969_2_2005", "context": "Grade 3 hepatotoxicity (AST and ALT > 5 to 20 upper limit normal) or higher has been observed in as many as 1.4% of MS patients on IFN beta.", "question": "Combination.Drug in IFN beta", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17329303_6_2006", "context": "The second patient was a girl of 6, already on risperidone for ADHD and borderline intellectual functioning when referred.", "question": "Subject.Age in a girl of 6", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": "6"}, {"id": "17329303_6_2007", "context": "The second patient was a girl of 6, already on risperidone for ADHD and borderline intellectual functioning when referred.", "question": "Subject.Gender in a girl of 6", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": "girl"}, {"id": "17329303_6_2008", "context": "The second patient was a girl of 6, already on risperidone for ADHD and borderline intellectual functioning when referred.", "question": "Subject.Population in a girl of 6", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "17329303_6_2009", "context": "The second patient was a girl of 6, already on risperidone for ADHD and borderline intellectual functioning when referred.", "question": "Subject.Race in a girl of 6", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "17329303_6_2010", "context": "The second patient was a girl of 6, already on risperidone for ADHD and borderline intellectual functioning when referred.", "question": "Subject.Disorder in a girl of 6", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "17329303_6_2011", "context": "The second patient was a girl of 6, already on risperidone for ADHD and borderline intellectual functioning when referred.", "question": "Treatment.Drug in risperidone", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "risperidone"}, {"id": "17329303_6_2012", "context": "The second patient was a girl of 6, already on risperidone for ADHD and borderline intellectual functioning when referred.", "question": "Treatment.Dosage in risperidone", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "17329303_6_2013", "context": "The second patient was a girl of 6, already on risperidone for ADHD and borderline intellectual functioning when referred.", "question": "Treatment.Freq in risperidone", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "17329303_6_2014", "context": "The second patient was a girl of 6, already on risperidone for ADHD and borderline intellectual functioning when referred.", "question": "Treatment.Route in risperidone", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "17329303_6_2015", "context": "The second patient was a girl of 6, already on risperidone for ADHD and borderline intellectual functioning when referred.", "question": "Treatment.Time_elapsed in risperidone", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17329303_6_2016", "context": "The second patient was a girl of 6, already on risperidone for ADHD and borderline intellectual functioning when referred.", "question": "Treatment.Duration in risperidone", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "17329303_6_2017", "context": "The second patient was a girl of 6, already on risperidone for ADHD and borderline intellectual functioning when referred.", "question": "Treatment.Disorder in risperidone", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "ADHD; borderline intellectual functioning"}, {"id": "17329303_6_2018", "context": "The second patient was a girl of 6, already on risperidone for ADHD and borderline intellectual functioning when referred.", "question": "Combination.Drug in risperidone", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "12196060_2_2019", "context": "To report a young man on phenytoin who developed acute neurologic symptoms after isradipine was introduced to his treatment regimen and discuss the possible causes of this drug interaction.", "question": "Subject.Age in a young man", "question_type": "Adverse_event.Subject.Age", "answers": "young"}, {"id": "12196060_2_2020", "context": "To report a young man on phenytoin who developed acute neurologic symptoms after isradipine was introduced to his treatment regimen and discuss the possible causes of this drug interaction.", "question": "Subject.Gender in a young man", "question_type": "Adverse_event.Subject.Gender", "answers": "man"}, {"id": "12196060_2_2021", "context": "To report a young man on phenytoin who developed acute neurologic symptoms after isradipine was introduced to his treatment regimen and discuss the possible causes of this drug interaction.", "question": "Subject.Population in a young man", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "12196060_2_2022", "context": "To report a young man on phenytoin who developed acute neurologic symptoms after isradipine was introduced to his treatment regimen and discuss the possible causes of this drug interaction.", "question": "Subject.Race in a young man", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "12196060_2_2023", "context": "To report a young man on phenytoin who developed acute neurologic symptoms after isradipine was introduced to his treatment regimen and discuss the possible causes of this drug interaction.", "question": "Subject.Disorder in a young man", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "12196060_2_2024", "context": "To report a young man on phenytoin who developed acute neurologic symptoms after isradipine was introduced to his treatment regimen and discuss the possible causes of this drug interaction.", "question": "Treatment.Drug in phenytoin; isradipine", "question_type": "Adverse_event.Treatment.Drug", "answers": "isradipine; phenytoin"}, {"id": "12196060_2_2025", "context": "To report a young man on phenytoin who developed acute neurologic symptoms after isradipine was introduced to his treatment regimen and discuss the possible causes of this drug interaction.", "question": "Treatment.Dosage in phenytoin; isradipine", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12196060_2_2026", "context": "To report a young man on phenytoin who developed acute neurologic symptoms after isradipine was introduced to his treatment regimen and discuss the possible causes of this drug interaction.", "question": "Treatment.Freq in phenytoin; isradipine", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12196060_2_2027", "context": "To report a young man on phenytoin who developed acute neurologic symptoms after isradipine was introduced to his treatment regimen and discuss the possible causes of this drug interaction.", "question": "Treatment.Route in phenytoin; isradipine", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12196060_2_2028", "context": "To report a young man on phenytoin who developed acute neurologic symptoms after isradipine was introduced to his treatment regimen and discuss the possible causes of this drug interaction.", "question": "Treatment.Time_elapsed in phenytoin; isradipine", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12196060_2_2029", "context": "To report a young man on phenytoin who developed acute neurologic symptoms after isradipine was introduced to his treatment regimen and discuss the possible causes of this drug interaction.", "question": "Treatment.Duration in phenytoin; isradipine", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12196060_2_2030", "context": "To report a young man on phenytoin who developed acute neurologic symptoms after isradipine was introduced to his treatment regimen and discuss the possible causes of this drug interaction.", "question": "Treatment.Disorder in phenytoin; isradipine", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12196060_2_2031", "context": "To report a young man on phenytoin who developed acute neurologic symptoms after isradipine was introduced to his treatment regimen and discuss the possible causes of this drug interaction.", "question": "Combination.Drug in phenytoin; isradipine", "question_type": "Adverse_event.Combination.Drug", "answers": "phenytoin; isradipine"}, {"id": "16446228_2_2032", "context": "Reversible sirolimus-associated pneumonitis after heart transplantation.", "question": "Treatment.Drug in sirolimus", "question_type": "Adverse_event.Treatment.Drug", "answers": "sirolimus"}, {"id": "16446228_2_2033", "context": "Reversible sirolimus-associated pneumonitis after heart transplantation.", "question": "Treatment.Dosage in sirolimus", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16446228_2_2034", "context": "Reversible sirolimus-associated pneumonitis after heart transplantation.", "question": "Treatment.Freq in sirolimus", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16446228_2_2035", "context": "Reversible sirolimus-associated pneumonitis after heart transplantation.", "question": "Treatment.Route in sirolimus", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16446228_2_2036", "context": "Reversible sirolimus-associated pneumonitis after heart transplantation.", "question": "Treatment.Time_elapsed in sirolimus", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16446228_2_2037", "context": "Reversible sirolimus-associated pneumonitis after heart transplantation.", "question": "Treatment.Duration in sirolimus", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16446228_2_2038", "context": "Reversible sirolimus-associated pneumonitis after heart transplantation.", "question": "Treatment.Disorder in sirolimus", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16446228_2_2039", "context": "Reversible sirolimus-associated pneumonitis after heart transplantation.", "question": "Combination.Drug in sirolimus", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "2063999_2_2040", "context": "We report a girl with the Rett syndrome who had acute encephalopathy probably induced by calcium hopantenate (HOPA).", "question": "Subject.Age in a girl", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "2063999_2_2041", "context": "We report a girl with the Rett syndrome who had acute encephalopathy probably induced by calcium hopantenate (HOPA).", "question": "Subject.Gender in a girl", "question_type": "Adverse_event.Subject.Gender", "answers": "girl"}, {"id": "2063999_2_2042", "context": "We report a girl with the Rett syndrome who had acute encephalopathy probably induced by calcium hopantenate (HOPA).", "question": "Subject.Population in a girl", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "2063999_2_2043", "context": "We report a girl with the Rett syndrome who had acute encephalopathy probably induced by calcium hopantenate (HOPA).", "question": "Subject.Race in a girl", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "2063999_2_2044", "context": "We report a girl with the Rett syndrome who had acute encephalopathy probably induced by calcium hopantenate (HOPA).", "question": "Subject.Disorder in a girl", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "2063999_2_2045", "context": "We report a girl with the Rett syndrome who had acute encephalopathy probably induced by calcium hopantenate (HOPA).", "question": "Treatment.Drug in calcium hopantenate (HOPA)", "question_type": "Adverse_event.Treatment.Drug", "answers": "calcium hopantenate"}, {"id": "2063999_2_2046", "context": "We report a girl with the Rett syndrome who had acute encephalopathy probably induced by calcium hopantenate (HOPA).", "question": "Treatment.Dosage in calcium hopantenate (HOPA)", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "2063999_2_2047", "context": "We report a girl with the Rett syndrome who had acute encephalopathy probably induced by calcium hopantenate (HOPA).", "question": "Treatment.Freq in calcium hopantenate (HOPA)", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2063999_2_2048", "context": "We report a girl with the Rett syndrome who had acute encephalopathy probably induced by calcium hopantenate (HOPA).", "question": "Treatment.Route in calcium hopantenate (HOPA)", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "2063999_2_2049", "context": "We report a girl with the Rett syndrome who had acute encephalopathy probably induced by calcium hopantenate (HOPA).", "question": "Treatment.Time_elapsed in calcium hopantenate (HOPA)", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2063999_2_2050", "context": "We report a girl with the Rett syndrome who had acute encephalopathy probably induced by calcium hopantenate (HOPA).", "question": "Treatment.Duration in calcium hopantenate (HOPA)", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2063999_2_2051", "context": "We report a girl with the Rett syndrome who had acute encephalopathy probably induced by calcium hopantenate (HOPA).", "question": "Treatment.Disorder in calcium hopantenate (HOPA)", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "2063999_2_2052", "context": "We report a girl with the Rett syndrome who had acute encephalopathy probably induced by calcium hopantenate (HOPA).", "question": "Combination.Drug in calcium hopantenate (HOPA)", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11126885_7_2053", "context": "Only after three subsequent episodes of severe, symptomatic thrombocytopenia over the next four weeks did he say, upon repeat questioning, that he had continued to take quinine for night leg cramps.", "question": "Subject.Age in he; night leg cramps", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "11126885_7_2054", "context": "Only after three subsequent episodes of severe, symptomatic thrombocytopenia over the next four weeks did he say, upon repeat questioning, that he had continued to take quinine for night leg cramps.", "question": "Subject.Gender in he; night leg cramps", "question_type": "Adverse_event.Subject.Gender", "answers": "he"}, {"id": "11126885_7_2055", "context": "Only after three subsequent episodes of severe, symptomatic thrombocytopenia over the next four weeks did he say, upon repeat questioning, that he had continued to take quinine for night leg cramps.", "question": "Subject.Population in he; night leg cramps", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "11126885_7_2056", "context": "Only after three subsequent episodes of severe, symptomatic thrombocytopenia over the next four weeks did he say, upon repeat questioning, that he had continued to take quinine for night leg cramps.", "question": "Subject.Race in he; night leg cramps", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "11126885_7_2057", "context": "Only after three subsequent episodes of severe, symptomatic thrombocytopenia over the next four weeks did he say, upon repeat questioning, that he had continued to take quinine for night leg cramps.", "question": "Subject.Disorder in he; night leg cramps", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "11126885_7_2058", "context": "Only after three subsequent episodes of severe, symptomatic thrombocytopenia over the next four weeks did he say, upon repeat questioning, that he had continued to take quinine for night leg cramps.", "question": "Treatment.Drug in continued to take quinine", "question_type": "Adverse_event.Treatment.Drug", "answers": "quinine"}, {"id": "11126885_7_2059", "context": "Only after three subsequent episodes of severe, symptomatic thrombocytopenia over the next four weeks did he say, upon repeat questioning, that he had continued to take quinine for night leg cramps.", "question": "Treatment.Dosage in continued to take quinine", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11126885_7_2060", "context": "Only after three subsequent episodes of severe, symptomatic thrombocytopenia over the next four weeks did he say, upon repeat questioning, that he had continued to take quinine for night leg cramps.", "question": "Treatment.Freq in continued to take quinine", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11126885_7_2061", "context": "Only after three subsequent episodes of severe, symptomatic thrombocytopenia over the next four weeks did he say, upon repeat questioning, that he had continued to take quinine for night leg cramps.", "question": "Treatment.Route in continued to take quinine", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11126885_7_2062", "context": "Only after three subsequent episodes of severe, symptomatic thrombocytopenia over the next four weeks did he say, upon repeat questioning, that he had continued to take quinine for night leg cramps.", "question": "Treatment.Time_elapsed in continued to take quinine", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "over the next four weeks"}, {"id": "11126885_7_2063", "context": "Only after three subsequent episodes of severe, symptomatic thrombocytopenia over the next four weeks did he say, upon repeat questioning, that he had continued to take quinine for night leg cramps.", "question": "Treatment.Duration in continued to take quinine", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11126885_7_2064", "context": "Only after three subsequent episodes of severe, symptomatic thrombocytopenia over the next four weeks did he say, upon repeat questioning, that he had continued to take quinine for night leg cramps.", "question": "Treatment.Disorder in continued to take quinine", "question_type": "Adverse_event.Treatment.Disorder", "answers": "night leg cramps"}, {"id": "11126885_7_2065", "context": "Only after three subsequent episodes of severe, symptomatic thrombocytopenia over the next four weeks did he say, upon repeat questioning, that he had continued to take quinine for night leg cramps.", "question": "Combination.Drug in continued to take quinine", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10327035_1_2066", "context": "An episode of subacute encephalopathy after the infusion of a moderate dose of methotrexate (1500 mg/m2) (MTX) is reported in a young adult with metastastic gastric cancer.", "question": "Subject.Age in a young adult with metastastic gastric cancer", "question_type": "Adverse_event.Subject.Age", "answers": "young adult"}, {"id": "10327035_1_2067", "context": "An episode of subacute encephalopathy after the infusion of a moderate dose of methotrexate (1500 mg/m2) (MTX) is reported in a young adult with metastastic gastric cancer.", "question": "Subject.Gender in a young adult with metastastic gastric cancer", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "10327035_1_2068", "context": "An episode of subacute encephalopathy after the infusion of a moderate dose of methotrexate (1500 mg/m2) (MTX) is reported in a young adult with metastastic gastric cancer.", "question": "Subject.Population in a young adult with metastastic gastric cancer", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "10327035_1_2069", "context": "An episode of subacute encephalopathy after the infusion of a moderate dose of methotrexate (1500 mg/m2) (MTX) is reported in a young adult with metastastic gastric cancer.", "question": "Subject.Race in a young adult with metastastic gastric cancer", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "10327035_1_2070", "context": "An episode of subacute encephalopathy after the infusion of a moderate dose of methotrexate (1500 mg/m2) (MTX) is reported in a young adult with metastastic gastric cancer.", "question": "Subject.Disorder in a young adult with metastastic gastric cancer", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "10327035_1_2071", "context": "An episode of subacute encephalopathy after the infusion of a moderate dose of methotrexate (1500 mg/m2) (MTX) is reported in a young adult with metastastic gastric cancer.", "question": "Treatment.Drug in a moderate dose of methotrexate (1500 mg/m2) (MTX)", "question_type": "Adverse_event.Treatment.Drug", "answers": "methotrexate"}, {"id": "10327035_1_2072", "context": "An episode of subacute encephalopathy after the infusion of a moderate dose of methotrexate (1500 mg/m2) (MTX) is reported in a young adult with metastastic gastric cancer.", "question": "Treatment.Dosage in a moderate dose of methotrexate (1500 mg/m2) (MTX)", "question_type": "Adverse_event.Treatment.Dosage", "answers": "1500 mg/m2"}, {"id": "10327035_1_2073", "context": "An episode of subacute encephalopathy after the infusion of a moderate dose of methotrexate (1500 mg/m2) (MTX) is reported in a young adult with metastastic gastric cancer.", "question": "Treatment.Freq in a moderate dose of methotrexate (1500 mg/m2) (MTX)", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10327035_1_2074", "context": "An episode of subacute encephalopathy after the infusion of a moderate dose of methotrexate (1500 mg/m2) (MTX) is reported in a young adult with metastastic gastric cancer.", "question": "Treatment.Route in a moderate dose of methotrexate (1500 mg/m2) (MTX)", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10327035_1_2075", "context": "An episode of subacute encephalopathy after the infusion of a moderate dose of methotrexate (1500 mg/m2) (MTX) is reported in a young adult with metastastic gastric cancer.", "question": "Treatment.Time_elapsed in a moderate dose of methotrexate (1500 mg/m2) (MTX)", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10327035_1_2076", "context": "An episode of subacute encephalopathy after the infusion of a moderate dose of methotrexate (1500 mg/m2) (MTX) is reported in a young adult with metastastic gastric cancer.", "question": "Treatment.Duration in a moderate dose of methotrexate (1500 mg/m2) (MTX)", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10327035_1_2077", "context": "An episode of subacute encephalopathy after the infusion of a moderate dose of methotrexate (1500 mg/m2) (MTX) is reported in a young adult with metastastic gastric cancer.", "question": "Treatment.Disorder in a moderate dose of methotrexate (1500 mg/m2) (MTX)", "question_type": "Adverse_event.Treatment.Disorder", "answers": "metastastic gastric cancer"}, {"id": "10327035_1_2078", "context": "An episode of subacute encephalopathy after the infusion of a moderate dose of methotrexate (1500 mg/m2) (MTX) is reported in a young adult with metastastic gastric cancer.", "question": "Combination.Drug in a moderate dose of methotrexate (1500 mg/m2) (MTX)", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "24927617_1_2079", "context": "Rhabdomyolysis in a hepatitis C virus infected patient treated with telaprevir and simvastatin.", "question": "Subject.Age in hepatitis C virus infected patient", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "24927617_1_2080", "context": "Rhabdomyolysis in a hepatitis C virus infected patient treated with telaprevir and simvastatin.", "question": "Subject.Gender in hepatitis C virus infected patient", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "24927617_1_2081", "context": "Rhabdomyolysis in a hepatitis C virus infected patient treated with telaprevir and simvastatin.", "question": "Subject.Population in hepatitis C virus infected patient", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "24927617_1_2082", "context": "Rhabdomyolysis in a hepatitis C virus infected patient treated with telaprevir and simvastatin.", "question": "Subject.Race in hepatitis C virus infected patient", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "24927617_1_2083", "context": "Rhabdomyolysis in a hepatitis C virus infected patient treated with telaprevir and simvastatin.", "question": "Subject.Disorder in hepatitis C virus infected patient", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "24927617_1_2084", "context": "Rhabdomyolysis in a hepatitis C virus infected patient treated with telaprevir and simvastatin.", "question": "Treatment.Drug in telaprevir and simvastatin", "question_type": "Adverse_event.Treatment.Drug", "answers": "telaprevir; simvastatin"}, {"id": "24927617_1_2085", "context": "Rhabdomyolysis in a hepatitis C virus infected patient treated with telaprevir and simvastatin.", "question": "Treatment.Dosage in telaprevir and simvastatin", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "24927617_1_2086", "context": "Rhabdomyolysis in a hepatitis C virus infected patient treated with telaprevir and simvastatin.", "question": "Treatment.Freq in telaprevir and simvastatin", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "24927617_1_2087", "context": "Rhabdomyolysis in a hepatitis C virus infected patient treated with telaprevir and simvastatin.", "question": "Treatment.Route in telaprevir and simvastatin", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "24927617_1_2088", "context": "Rhabdomyolysis in a hepatitis C virus infected patient treated with telaprevir and simvastatin.", "question": "Treatment.Time_elapsed in telaprevir and simvastatin", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "24927617_1_2089", "context": "Rhabdomyolysis in a hepatitis C virus infected patient treated with telaprevir and simvastatin.", "question": "Treatment.Duration in telaprevir and simvastatin", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "24927617_1_2090", "context": "Rhabdomyolysis in a hepatitis C virus infected patient treated with telaprevir and simvastatin.", "question": "Treatment.Disorder in telaprevir and simvastatin", "question_type": "Adverse_event.Treatment.Disorder", "answers": "hepatitis C virus"}, {"id": "24927617_1_2091", "context": "Rhabdomyolysis in a hepatitis C virus infected patient treated with telaprevir and simvastatin.", "question": "Combination.Drug in telaprevir and simvastatin", "question_type": "Adverse_event.Combination.Drug", "answers": "telaprevir; simvastatin"}, {"id": "15779196_1_2092", "context": "Four days after intravenous Zoledronic acid, the patient presented to emergency room with complaints of carpopedal spasm and bronchospasm.", "question": "Subject.Age in patient", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "15779196_1_2093", "context": "Four days after intravenous Zoledronic acid, the patient presented to emergency room with complaints of carpopedal spasm and bronchospasm.", "question": "Subject.Gender in patient", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15779196_1_2094", "context": "Four days after intravenous Zoledronic acid, the patient presented to emergency room with complaints of carpopedal spasm and bronchospasm.", "question": "Subject.Population in patient", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "15779196_1_2095", "context": "Four days after intravenous Zoledronic acid, the patient presented to emergency room with complaints of carpopedal spasm and bronchospasm.", "question": "Subject.Race in patient", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15779196_1_2096", "context": "Four days after intravenous Zoledronic acid, the patient presented to emergency room with complaints of carpopedal spasm and bronchospasm.", "question": "Subject.Disorder in patient", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15779196_1_2097", "context": "Four days after intravenous Zoledronic acid, the patient presented to emergency room with complaints of carpopedal spasm and bronchospasm.", "question": "Treatment.Drug in Four days after intravenous Zoledronic acid", "question_type": "Adverse_event.Treatment.Drug", "answers": "Zoledronic acid"}, {"id": "15779196_1_2098", "context": "Four days after intravenous Zoledronic acid, the patient presented to emergency room with complaints of carpopedal spasm and bronchospasm.", "question": "Treatment.Dosage in Four days after intravenous Zoledronic acid", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15779196_1_2099", "context": "Four days after intravenous Zoledronic acid, the patient presented to emergency room with complaints of carpopedal spasm and bronchospasm.", "question": "Treatment.Freq in Four days after intravenous Zoledronic acid", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15779196_1_2100", "context": "Four days after intravenous Zoledronic acid, the patient presented to emergency room with complaints of carpopedal spasm and bronchospasm.", "question": "Treatment.Route in Four days after intravenous Zoledronic acid", "question_type": "Adverse_event.Treatment.Route", "answers": "intravenous"}, {"id": "15779196_1_2101", "context": "Four days after intravenous Zoledronic acid, the patient presented to emergency room with complaints of carpopedal spasm and bronchospasm.", "question": "Treatment.Time_elapsed in Four days after intravenous Zoledronic acid", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "Four days after"}, {"id": "15779196_1_2102", "context": "Four days after intravenous Zoledronic acid, the patient presented to emergency room with complaints of carpopedal spasm and bronchospasm.", "question": "Treatment.Duration in Four days after intravenous Zoledronic acid", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15779196_1_2103", "context": "Four days after intravenous Zoledronic acid, the patient presented to emergency room with complaints of carpopedal spasm and bronchospasm.", "question": "Treatment.Disorder in Four days after intravenous Zoledronic acid", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15779196_1_2104", "context": "Four days after intravenous Zoledronic acid, the patient presented to emergency room with complaints of carpopedal spasm and bronchospasm.", "question": "Combination.Drug in Four days after intravenous Zoledronic acid", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7117795_3_2105", "context": "Ulcerating enteritis associated with flucytosine therapy.", "question": "Treatment.Drug in flucytosine therapy", "question_type": "Adverse_event.Treatment.Drug", "answers": "flucytosine"}, {"id": "7117795_3_2106", "context": "Ulcerating enteritis associated with flucytosine therapy.", "question": "Treatment.Dosage in flucytosine therapy", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7117795_3_2107", "context": "Ulcerating enteritis associated with flucytosine therapy.", "question": "Treatment.Freq in flucytosine therapy", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7117795_3_2108", "context": "Ulcerating enteritis associated with flucytosine therapy.", "question": "Treatment.Route in flucytosine therapy", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7117795_3_2109", "context": "Ulcerating enteritis associated with flucytosine therapy.", "question": "Treatment.Time_elapsed in flucytosine therapy", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7117795_3_2110", "context": "Ulcerating enteritis associated with flucytosine therapy.", "question": "Treatment.Duration in flucytosine therapy", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7117795_3_2111", "context": "Ulcerating enteritis associated with flucytosine therapy.", "question": "Treatment.Disorder in flucytosine therapy", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7117795_3_2112", "context": "Ulcerating enteritis associated with flucytosine therapy.", "question": "Combination.Drug in flucytosine therapy", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15681911_2_2113", "context": "OBJECTIVES: To describe clinical and pathologic findings in patients noted to develop lower gastrointestinal symptoms when exposed to rofecoxib.", "question": "Subject.Age in patients", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "15681911_2_2114", "context": "OBJECTIVES: To describe clinical and pathologic findings in patients noted to develop lower gastrointestinal symptoms when exposed to rofecoxib.", "question": "Subject.Gender in patients", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15681911_2_2115", "context": "OBJECTIVES: To describe clinical and pathologic findings in patients noted to develop lower gastrointestinal symptoms when exposed to rofecoxib.", "question": "Subject.Population in patients", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "15681911_2_2116", "context": "OBJECTIVES: To describe clinical and pathologic findings in patients noted to develop lower gastrointestinal symptoms when exposed to rofecoxib.", "question": "Subject.Race in patients", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15681911_2_2117", "context": "OBJECTIVES: To describe clinical and pathologic findings in patients noted to develop lower gastrointestinal symptoms when exposed to rofecoxib.", "question": "Subject.Disorder in patients", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15681911_2_2118", "context": "OBJECTIVES: To describe clinical and pathologic findings in patients noted to develop lower gastrointestinal symptoms when exposed to rofecoxib.", "question": "Treatment.Drug in rofecoxib", "question_type": "Adverse_event.Treatment.Drug", "answers": "rofecoxib"}, {"id": "15681911_2_2119", "context": "OBJECTIVES: To describe clinical and pathologic findings in patients noted to develop lower gastrointestinal symptoms when exposed to rofecoxib.", "question": "Treatment.Dosage in rofecoxib", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15681911_2_2120", "context": "OBJECTIVES: To describe clinical and pathologic findings in patients noted to develop lower gastrointestinal symptoms when exposed to rofecoxib.", "question": "Treatment.Freq in rofecoxib", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15681911_2_2121", "context": "OBJECTIVES: To describe clinical and pathologic findings in patients noted to develop lower gastrointestinal symptoms when exposed to rofecoxib.", "question": "Treatment.Route in rofecoxib", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15681911_2_2122", "context": "OBJECTIVES: To describe clinical and pathologic findings in patients noted to develop lower gastrointestinal symptoms when exposed to rofecoxib.", "question": "Treatment.Time_elapsed in rofecoxib", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15681911_2_2123", "context": "OBJECTIVES: To describe clinical and pathologic findings in patients noted to develop lower gastrointestinal symptoms when exposed to rofecoxib.", "question": "Treatment.Duration in rofecoxib", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15681911_2_2124", "context": "OBJECTIVES: To describe clinical and pathologic findings in patients noted to develop lower gastrointestinal symptoms when exposed to rofecoxib.", "question": "Treatment.Disorder in rofecoxib", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15681911_2_2125", "context": "OBJECTIVES: To describe clinical and pathologic findings in patients noted to develop lower gastrointestinal symptoms when exposed to rofecoxib.", "question": "Combination.Drug in rofecoxib", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15338554_5_2126", "context": "Our findings suggest that significant progression of marrow reticulin fibrosis during imatinib therapy can be an indicator for a return or progression of CML and, in some patients with CML, imatinib may promote cytogenetic clonal evolution, resulting in a poor response to treatment.", "question": "Treatment.Drug in imatinib", "question_type": "Adverse_event.Treatment.Drug", "answers": "imatinib"}, {"id": "15338554_5_2127", "context": "Our findings suggest that significant progression of marrow reticulin fibrosis during imatinib therapy can be an indicator for a return or progression of CML and, in some patients with CML, imatinib may promote cytogenetic clonal evolution, resulting in a poor response to treatment.", "question": "Treatment.Dosage in imatinib", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15338554_5_2128", "context": "Our findings suggest that significant progression of marrow reticulin fibrosis during imatinib therapy can be an indicator for a return or progression of CML and, in some patients with CML, imatinib may promote cytogenetic clonal evolution, resulting in a poor response to treatment.", "question": "Treatment.Freq in imatinib", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15338554_5_2129", "context": "Our findings suggest that significant progression of marrow reticulin fibrosis during imatinib therapy can be an indicator for a return or progression of CML and, in some patients with CML, imatinib may promote cytogenetic clonal evolution, resulting in a poor response to treatment.", "question": "Treatment.Route in imatinib", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15338554_5_2130", "context": "Our findings suggest that significant progression of marrow reticulin fibrosis during imatinib therapy can be an indicator for a return or progression of CML and, in some patients with CML, imatinib may promote cytogenetic clonal evolution, resulting in a poor response to treatment.", "question": "Treatment.Time_elapsed in imatinib", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15338554_5_2131", "context": "Our findings suggest that significant progression of marrow reticulin fibrosis during imatinib therapy can be an indicator for a return or progression of CML and, in some patients with CML, imatinib may promote cytogenetic clonal evolution, resulting in a poor response to treatment.", "question": "Treatment.Duration in imatinib", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15338554_5_2132", "context": "Our findings suggest that significant progression of marrow reticulin fibrosis during imatinib therapy can be an indicator for a return or progression of CML and, in some patients with CML, imatinib may promote cytogenetic clonal evolution, resulting in a poor response to treatment.", "question": "Treatment.Disorder in imatinib", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15338554_5_2133", "context": "Our findings suggest that significant progression of marrow reticulin fibrosis during imatinib therapy can be an indicator for a return or progression of CML and, in some patients with CML, imatinib may promote cytogenetic clonal evolution, resulting in a poor response to treatment.", "question": "Combination.Drug in imatinib", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8840640_2_2134", "context": "Metabolic acidosis induced by cetrimide-chlorhexidine solution in hydatid cyst surgery.", "question": "Treatment.Drug in cetrimide-chlorhexidine solution", "question_type": "Adverse_event.Treatment.Drug", "answers": "cetrimide; chlorhexidine"}, {"id": "8840640_2_2135", "context": "Metabolic acidosis induced by cetrimide-chlorhexidine solution in hydatid cyst surgery.", "question": "Treatment.Dosage in cetrimide-chlorhexidine solution", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8840640_2_2136", "context": "Metabolic acidosis induced by cetrimide-chlorhexidine solution in hydatid cyst surgery.", "question": "Treatment.Freq in cetrimide-chlorhexidine solution", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8840640_2_2137", "context": "Metabolic acidosis induced by cetrimide-chlorhexidine solution in hydatid cyst surgery.", "question": "Treatment.Route in cetrimide-chlorhexidine solution", "question_type": "Adverse_event.Treatment.Route", "answers": "solution"}, {"id": "8840640_2_2138", "context": "Metabolic acidosis induced by cetrimide-chlorhexidine solution in hydatid cyst surgery.", "question": "Treatment.Time_elapsed in cetrimide-chlorhexidine solution", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8840640_2_2139", "context": "Metabolic acidosis induced by cetrimide-chlorhexidine solution in hydatid cyst surgery.", "question": "Treatment.Duration in cetrimide-chlorhexidine solution", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8840640_2_2140", "context": "Metabolic acidosis induced by cetrimide-chlorhexidine solution in hydatid cyst surgery.", "question": "Treatment.Disorder in cetrimide-chlorhexidine solution", "question_type": "Adverse_event.Treatment.Disorder", "answers": "hydatid cyst"}, {"id": "8840640_2_2141", "context": "Metabolic acidosis induced by cetrimide-chlorhexidine solution in hydatid cyst surgery.", "question": "Combination.Drug in cetrimide-chlorhexidine solution", "question_type": "Adverse_event.Combination.Drug", "answers": "chlorhexidine; cetrimide"}, {"id": "7685228_1_2142", "context": "Reversal of gold-induced neutropenia with granulocyte colony-stimulating factor (G-CSF).", "question": "Subject.Age in granulocyte colony-stimulating factor", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "7685228_1_2143", "context": "Reversal of gold-induced neutropenia with granulocyte colony-stimulating factor (G-CSF).", "question": "Subject.Gender in granulocyte colony-stimulating factor", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "7685228_1_2144", "context": "Reversal of gold-induced neutropenia with granulocyte colony-stimulating factor (G-CSF).", "question": "Subject.Population in granulocyte colony-stimulating factor", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "7685228_1_2145", "context": "Reversal of gold-induced neutropenia with granulocyte colony-stimulating factor (G-CSF).", "question": "Subject.Race in granulocyte colony-stimulating factor", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "7685228_1_2146", "context": "Reversal of gold-induced neutropenia with granulocyte colony-stimulating factor (G-CSF).", "question": "Subject.Disorder in granulocyte colony-stimulating factor", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "7685228_1_2147", "context": "Reversal of gold-induced neutropenia with granulocyte colony-stimulating factor (G-CSF).", "question": "Treatment.Drug in gold; granulocyte colony-stimulating factor (G-CSF)", "question_type": "Adverse_event.Treatment.Drug", "answers": "gold"}, {"id": "7685228_1_2148", "context": "Reversal of gold-induced neutropenia with granulocyte colony-stimulating factor (G-CSF).", "question": "Treatment.Dosage in gold; granulocyte colony-stimulating factor (G-CSF)", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7685228_1_2149", "context": "Reversal of gold-induced neutropenia with granulocyte colony-stimulating factor (G-CSF).", "question": "Treatment.Freq in gold; granulocyte colony-stimulating factor (G-CSF)", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7685228_1_2150", "context": "Reversal of gold-induced neutropenia with granulocyte colony-stimulating factor (G-CSF).", "question": "Treatment.Route in gold; granulocyte colony-stimulating factor (G-CSF)", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7685228_1_2151", "context": "Reversal of gold-induced neutropenia with granulocyte colony-stimulating factor (G-CSF).", "question": "Treatment.Time_elapsed in gold; granulocyte colony-stimulating factor (G-CSF)", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7685228_1_2152", "context": "Reversal of gold-induced neutropenia with granulocyte colony-stimulating factor (G-CSF).", "question": "Treatment.Duration in gold; granulocyte colony-stimulating factor (G-CSF)", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7685228_1_2153", "context": "Reversal of gold-induced neutropenia with granulocyte colony-stimulating factor (G-CSF).", "question": "Treatment.Disorder in gold; granulocyte colony-stimulating factor (G-CSF)", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7685228_1_2154", "context": "Reversal of gold-induced neutropenia with granulocyte colony-stimulating factor (G-CSF).", "question": "Combination.Drug in gold; granulocyte colony-stimulating factor (G-CSF)", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "946400_2_2155", "context": "Methyldopa-induced liver injury.", "question": "Treatment.Drug in Methyldopa", "question_type": "Adverse_event.Treatment.Drug", "answers": "Methyldopa"}, {"id": "946400_2_2156", "context": "Methyldopa-induced liver injury.", "question": "Treatment.Dosage in Methyldopa", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "946400_2_2157", "context": "Methyldopa-induced liver injury.", "question": "Treatment.Freq in Methyldopa", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "946400_2_2158", "context": "Methyldopa-induced liver injury.", "question": "Treatment.Route in Methyldopa", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "946400_2_2159", "context": "Methyldopa-induced liver injury.", "question": "Treatment.Time_elapsed in Methyldopa", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "946400_2_2160", "context": "Methyldopa-induced liver injury.", "question": "Treatment.Duration in Methyldopa", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "946400_2_2161", "context": "Methyldopa-induced liver injury.", "question": "Treatment.Disorder in Methyldopa", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "946400_2_2162", "context": "Methyldopa-induced liver injury.", "question": "Combination.Drug in Methyldopa", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "14971874_1_2163", "context": "After infliximab treatment, additional sleep studies revealed an increase in the number of apneic events and SaO2 dips suggesting that TNFalpha plays an important role in the pathophysiology of sleep apnea.", "question": "Treatment.Drug in infliximab", "question_type": "Adverse_event.Treatment.Drug", "answers": "infliximab"}, {"id": "14971874_1_2164", "context": "After infliximab treatment, additional sleep studies revealed an increase in the number of apneic events and SaO2 dips suggesting that TNFalpha plays an important role in the pathophysiology of sleep apnea.", "question": "Treatment.Dosage in infliximab", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "14971874_1_2165", "context": "After infliximab treatment, additional sleep studies revealed an increase in the number of apneic events and SaO2 dips suggesting that TNFalpha plays an important role in the pathophysiology of sleep apnea.", "question": "Treatment.Freq in infliximab", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "14971874_1_2166", "context": "After infliximab treatment, additional sleep studies revealed an increase in the number of apneic events and SaO2 dips suggesting that TNFalpha plays an important role in the pathophysiology of sleep apnea.", "question": "Treatment.Route in infliximab", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "14971874_1_2167", "context": "After infliximab treatment, additional sleep studies revealed an increase in the number of apneic events and SaO2 dips suggesting that TNFalpha plays an important role in the pathophysiology of sleep apnea.", "question": "Treatment.Time_elapsed in infliximab", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "14971874_1_2168", "context": "After infliximab treatment, additional sleep studies revealed an increase in the number of apneic events and SaO2 dips suggesting that TNFalpha plays an important role in the pathophysiology of sleep apnea.", "question": "Treatment.Duration in infliximab", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "14971874_1_2169", "context": "After infliximab treatment, additional sleep studies revealed an increase in the number of apneic events and SaO2 dips suggesting that TNFalpha plays an important role in the pathophysiology of sleep apnea.", "question": "Treatment.Disorder in infliximab", "question_type": "Adverse_event.Treatment.Disorder", "answers": "pathophysiology of sleep apnea"}, {"id": "14971874_1_2170", "context": "After infliximab treatment, additional sleep studies revealed an increase in the number of apneic events and SaO2 dips suggesting that TNFalpha plays an important role in the pathophysiology of sleep apnea.", "question": "Combination.Drug in infliximab", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6507240_4_2171", "context": "One patient developed severe hyponatremia with serum Na+ of 108 mEq/L when hydrochlorothiazide was given to control hypertension.", "question": "Subject.Age in One patient", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "6507240_4_2172", "context": "One patient developed severe hyponatremia with serum Na+ of 108 mEq/L when hydrochlorothiazide was given to control hypertension.", "question": "Subject.Gender in One patient", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "6507240_4_2173", "context": "One patient developed severe hyponatremia with serum Na+ of 108 mEq/L when hydrochlorothiazide was given to control hypertension.", "question": "Subject.Population in One patient", "question_type": "Adverse_event.Subject.Population", "answers": "One"}, {"id": "6507240_4_2174", "context": "One patient developed severe hyponatremia with serum Na+ of 108 mEq/L when hydrochlorothiazide was given to control hypertension.", "question": "Subject.Race in One patient", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "6507240_4_2175", "context": "One patient developed severe hyponatremia with serum Na+ of 108 mEq/L when hydrochlorothiazide was given to control hypertension.", "question": "Subject.Disorder in One patient", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "6507240_4_2176", "context": "One patient developed severe hyponatremia with serum Na+ of 108 mEq/L when hydrochlorothiazide was given to control hypertension.", "question": "Treatment.Drug in hydrochlorothiazide", "question_type": "Adverse_event.Treatment.Drug", "answers": "hydrochlorothiazide"}, {"id": "6507240_4_2177", "context": "One patient developed severe hyponatremia with serum Na+ of 108 mEq/L when hydrochlorothiazide was given to control hypertension.", "question": "Treatment.Dosage in hydrochlorothiazide", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6507240_4_2178", "context": "One patient developed severe hyponatremia with serum Na+ of 108 mEq/L when hydrochlorothiazide was given to control hypertension.", "question": "Treatment.Freq in hydrochlorothiazide", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6507240_4_2179", "context": "One patient developed severe hyponatremia with serum Na+ of 108 mEq/L when hydrochlorothiazide was given to control hypertension.", "question": "Treatment.Route in hydrochlorothiazide", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6507240_4_2180", "context": "One patient developed severe hyponatremia with serum Na+ of 108 mEq/L when hydrochlorothiazide was given to control hypertension.", "question": "Treatment.Time_elapsed in hydrochlorothiazide", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6507240_4_2181", "context": "One patient developed severe hyponatremia with serum Na+ of 108 mEq/L when hydrochlorothiazide was given to control hypertension.", "question": "Treatment.Duration in hydrochlorothiazide", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6507240_4_2182", "context": "One patient developed severe hyponatremia with serum Na+ of 108 mEq/L when hydrochlorothiazide was given to control hypertension.", "question": "Treatment.Disorder in hydrochlorothiazide", "question_type": "Adverse_event.Treatment.Disorder", "answers": "hypertension"}, {"id": "6507240_4_2183", "context": "One patient developed severe hyponatremia with serum Na+ of 108 mEq/L when hydrochlorothiazide was given to control hypertension.", "question": "Combination.Drug in hydrochlorothiazide", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "1624172_3_2184", "context": "Thyroid dysfunction has been reported in patients with malignant disease treated with recombinant alpha interferon.", "question": "Subject.Age in patients with malignant disease", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "1624172_3_2185", "context": "Thyroid dysfunction has been reported in patients with malignant disease treated with recombinant alpha interferon.", "question": "Subject.Gender in patients with malignant disease", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "1624172_3_2186", "context": "Thyroid dysfunction has been reported in patients with malignant disease treated with recombinant alpha interferon.", "question": "Subject.Population in patients with malignant disease", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "1624172_3_2187", "context": "Thyroid dysfunction has been reported in patients with malignant disease treated with recombinant alpha interferon.", "question": "Subject.Race in patients with malignant disease", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "1624172_3_2188", "context": "Thyroid dysfunction has been reported in patients with malignant disease treated with recombinant alpha interferon.", "question": "Subject.Disorder in patients with malignant disease", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "1624172_3_2189", "context": "Thyroid dysfunction has been reported in patients with malignant disease treated with recombinant alpha interferon.", "question": "Treatment.Drug in recombinant alpha interferon", "question_type": "Adverse_event.Treatment.Drug", "answers": "recombinant alpha interferon"}, {"id": "1624172_3_2190", "context": "Thyroid dysfunction has been reported in patients with malignant disease treated with recombinant alpha interferon.", "question": "Treatment.Dosage in recombinant alpha interferon", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "1624172_3_2191", "context": "Thyroid dysfunction has been reported in patients with malignant disease treated with recombinant alpha interferon.", "question": "Treatment.Freq in recombinant alpha interferon", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "1624172_3_2192", "context": "Thyroid dysfunction has been reported in patients with malignant disease treated with recombinant alpha interferon.", "question": "Treatment.Route in recombinant alpha interferon", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "1624172_3_2193", "context": "Thyroid dysfunction has been reported in patients with malignant disease treated with recombinant alpha interferon.", "question": "Treatment.Time_elapsed in recombinant alpha interferon", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "1624172_3_2194", "context": "Thyroid dysfunction has been reported in patients with malignant disease treated with recombinant alpha interferon.", "question": "Treatment.Duration in recombinant alpha interferon", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "1624172_3_2195", "context": "Thyroid dysfunction has been reported in patients with malignant disease treated with recombinant alpha interferon.", "question": "Treatment.Disorder in recombinant alpha interferon", "question_type": "Adverse_event.Treatment.Disorder", "answers": "malignant disease"}, {"id": "1624172_3_2196", "context": "Thyroid dysfunction has been reported in patients with malignant disease treated with recombinant alpha interferon.", "question": "Combination.Drug in recombinant alpha interferon", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15112258_9_2197", "context": "The authors also determined that their case of myositis developing in the rectus abdominus muscle of a patient with pancreatic adenocarcinoma was the manifestation of radiation recall, thereby bringing the number of patients who developed radiation recall to gemcitabine and were discussed in the current study to 13.", "question": "Subject.Age in a patient with pancreatic adenocarcinoma", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "15112258_9_2198", "context": "The authors also determined that their case of myositis developing in the rectus abdominus muscle of a patient with pancreatic adenocarcinoma was the manifestation of radiation recall, thereby bringing the number of patients who developed radiation recall to gemcitabine and were discussed in the current study to 13.", "question": "Subject.Gender in a patient with pancreatic adenocarcinoma", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15112258_9_2199", "context": "The authors also determined that their case of myositis developing in the rectus abdominus muscle of a patient with pancreatic adenocarcinoma was the manifestation of radiation recall, thereby bringing the number of patients who developed radiation recall to gemcitabine and were discussed in the current study to 13.", "question": "Subject.Population in a patient with pancreatic adenocarcinoma", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "15112258_9_2200", "context": "The authors also determined that their case of myositis developing in the rectus abdominus muscle of a patient with pancreatic adenocarcinoma was the manifestation of radiation recall, thereby bringing the number of patients who developed radiation recall to gemcitabine and were discussed in the current study to 13.", "question": "Subject.Race in a patient with pancreatic adenocarcinoma", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15112258_9_2201", "context": "The authors also determined that their case of myositis developing in the rectus abdominus muscle of a patient with pancreatic adenocarcinoma was the manifestation of radiation recall, thereby bringing the number of patients who developed radiation recall to gemcitabine and were discussed in the current study to 13.", "question": "Subject.Disorder in a patient with pancreatic adenocarcinoma", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15112258_9_2202", "context": "The authors also determined that their case of myositis developing in the rectus abdominus muscle of a patient with pancreatic adenocarcinoma was the manifestation of radiation recall, thereby bringing the number of patients who developed radiation recall to gemcitabine and were discussed in the current study to 13.", "question": "Treatment.Drug in gemcitabine", "question_type": "Adverse_event.Treatment.Drug", "answers": "gemcitabine"}, {"id": "15112258_9_2203", "context": "The authors also determined that their case of myositis developing in the rectus abdominus muscle of a patient with pancreatic adenocarcinoma was the manifestation of radiation recall, thereby bringing the number of patients who developed radiation recall to gemcitabine and were discussed in the current study to 13.", "question": "Treatment.Dosage in gemcitabine", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15112258_9_2204", "context": "The authors also determined that their case of myositis developing in the rectus abdominus muscle of a patient with pancreatic adenocarcinoma was the manifestation of radiation recall, thereby bringing the number of patients who developed radiation recall to gemcitabine and were discussed in the current study to 13.", "question": "Treatment.Freq in gemcitabine", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15112258_9_2205", "context": "The authors also determined that their case of myositis developing in the rectus abdominus muscle of a patient with pancreatic adenocarcinoma was the manifestation of radiation recall, thereby bringing the number of patients who developed radiation recall to gemcitabine and were discussed in the current study to 13.", "question": "Treatment.Route in gemcitabine", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15112258_9_2206", "context": "The authors also determined that their case of myositis developing in the rectus abdominus muscle of a patient with pancreatic adenocarcinoma was the manifestation of radiation recall, thereby bringing the number of patients who developed radiation recall to gemcitabine and were discussed in the current study to 13.", "question": "Treatment.Time_elapsed in gemcitabine", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15112258_9_2207", "context": "The authors also determined that their case of myositis developing in the rectus abdominus muscle of a patient with pancreatic adenocarcinoma was the manifestation of radiation recall, thereby bringing the number of patients who developed radiation recall to gemcitabine and were discussed in the current study to 13.", "question": "Treatment.Duration in gemcitabine", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15112258_9_2208", "context": "The authors also determined that their case of myositis developing in the rectus abdominus muscle of a patient with pancreatic adenocarcinoma was the manifestation of radiation recall, thereby bringing the number of patients who developed radiation recall to gemcitabine and were discussed in the current study to 13.", "question": "Treatment.Disorder in gemcitabine", "question_type": "Adverse_event.Treatment.Disorder", "answers": "pancreatic adenocarcinoma"}, {"id": "15112258_9_2209", "context": "The authors also determined that their case of myositis developing in the rectus abdominus muscle of a patient with pancreatic adenocarcinoma was the manifestation of radiation recall, thereby bringing the number of patients who developed radiation recall to gemcitabine and were discussed in the current study to 13.", "question": "Combination.Drug in gemcitabine", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11126885_8_2210", "context": "Even after a strict warning, he took another quinine tablet that evening, which triggered his fifth episode of severe thrombocytopenia, and confirmed the etiology of quinine-induced thrombocytopenia.", "question": "Treatment.Drug in quinine tablet", "question_type": "Adverse_event.Treatment.Drug", "answers": "quinine"}, {"id": "11126885_8_2211", "context": "Even after a strict warning, he took another quinine tablet that evening, which triggered his fifth episode of severe thrombocytopenia, and confirmed the etiology of quinine-induced thrombocytopenia.", "question": "Treatment.Dosage in quinine tablet", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11126885_8_2212", "context": "Even after a strict warning, he took another quinine tablet that evening, which triggered his fifth episode of severe thrombocytopenia, and confirmed the etiology of quinine-induced thrombocytopenia.", "question": "Treatment.Freq in quinine tablet", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11126885_8_2213", "context": "Even after a strict warning, he took another quinine tablet that evening, which triggered his fifth episode of severe thrombocytopenia, and confirmed the etiology of quinine-induced thrombocytopenia.", "question": "Treatment.Route in quinine tablet", "question_type": "Adverse_event.Treatment.Route", "answers": "tablet"}, {"id": "11126885_8_2214", "context": "Even after a strict warning, he took another quinine tablet that evening, which triggered his fifth episode of severe thrombocytopenia, and confirmed the etiology of quinine-induced thrombocytopenia.", "question": "Treatment.Time_elapsed in quinine tablet", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11126885_8_2215", "context": "Even after a strict warning, he took another quinine tablet that evening, which triggered his fifth episode of severe thrombocytopenia, and confirmed the etiology of quinine-induced thrombocytopenia.", "question": "Treatment.Duration in quinine tablet", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11126885_8_2216", "context": "Even after a strict warning, he took another quinine tablet that evening, which triggered his fifth episode of severe thrombocytopenia, and confirmed the etiology of quinine-induced thrombocytopenia.", "question": "Treatment.Disorder in quinine tablet", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11126885_8_2217", "context": "Even after a strict warning, he took another quinine tablet that evening, which triggered his fifth episode of severe thrombocytopenia, and confirmed the etiology of quinine-induced thrombocytopenia.", "question": "Combination.Drug in quinine tablet", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "968449_4_2218", "context": "Case 1 presented after 25 months of myelosuppressive therapy a deletion of chromosome no. 12, del (12) (p11), in 60% of the diploid cells.", "question": "Subject.Age in Case 1", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "968449_4_2219", "context": "Case 1 presented after 25 months of myelosuppressive therapy a deletion of chromosome no. 12, del (12) (p11), in 60% of the diploid cells.", "question": "Subject.Gender in Case 1", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "968449_4_2220", "context": "Case 1 presented after 25 months of myelosuppressive therapy a deletion of chromosome no. 12, del (12) (p11), in 60% of the diploid cells.", "question": "Subject.Population in Case 1", "question_type": "Adverse_event.Subject.Population", "answers": "1"}, {"id": "968449_4_2221", "context": "Case 1 presented after 25 months of myelosuppressive therapy a deletion of chromosome no. 12, del (12) (p11), in 60% of the diploid cells.", "question": "Subject.Race in Case 1", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "968449_4_2222", "context": "Case 1 presented after 25 months of myelosuppressive therapy a deletion of chromosome no. 12, del (12) (p11), in 60% of the diploid cells.", "question": "Subject.Disorder in Case 1", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "968449_4_2223", "context": "Case 1 presented after 25 months of myelosuppressive therapy a deletion of chromosome no. 12, del (12) (p11), in 60% of the diploid cells.", "question": "Treatment.Drug in 25 months of myelosuppressive therapy", "question_type": "Adverse_event.Treatment.Drug", "answers": "myelosuppressive"}, {"id": "968449_4_2224", "context": "Case 1 presented after 25 months of myelosuppressive therapy a deletion of chromosome no. 12, del (12) (p11), in 60% of the diploid cells.", "question": "Treatment.Dosage in 25 months of myelosuppressive therapy", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "968449_4_2225", "context": "Case 1 presented after 25 months of myelosuppressive therapy a deletion of chromosome no. 12, del (12) (p11), in 60% of the diploid cells.", "question": "Treatment.Freq in 25 months of myelosuppressive therapy", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "968449_4_2226", "context": "Case 1 presented after 25 months of myelosuppressive therapy a deletion of chromosome no. 12, del (12) (p11), in 60% of the diploid cells.", "question": "Treatment.Route in 25 months of myelosuppressive therapy", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "968449_4_2227", "context": "Case 1 presented after 25 months of myelosuppressive therapy a deletion of chromosome no. 12, del (12) (p11), in 60% of the diploid cells.", "question": "Treatment.Time_elapsed in 25 months of myelosuppressive therapy", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "25 months"}, {"id": "968449_4_2228", "context": "Case 1 presented after 25 months of myelosuppressive therapy a deletion of chromosome no. 12, del (12) (p11), in 60% of the diploid cells.", "question": "Treatment.Duration in 25 months of myelosuppressive therapy", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "968449_4_2229", "context": "Case 1 presented after 25 months of myelosuppressive therapy a deletion of chromosome no. 12, del (12) (p11), in 60% of the diploid cells.", "question": "Treatment.Disorder in 25 months of myelosuppressive therapy", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "968449_4_2230", "context": "Case 1 presented after 25 months of myelosuppressive therapy a deletion of chromosome no. 12, del (12) (p11), in 60% of the diploid cells.", "question": "Combination.Drug in 25 months of myelosuppressive therapy", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "1893404_2_2231", "context": "Diabetes Mellitus was observed in a patient given carbamazepine.", "question": "Subject.Age in a patient", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "1893404_2_2232", "context": "Diabetes Mellitus was observed in a patient given carbamazepine.", "question": "Subject.Gender in a patient", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "1893404_2_2233", "context": "Diabetes Mellitus was observed in a patient given carbamazepine.", "question": "Subject.Population in a patient", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "1893404_2_2234", "context": "Diabetes Mellitus was observed in a patient given carbamazepine.", "question": "Subject.Race in a patient", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "1893404_2_2235", "context": "Diabetes Mellitus was observed in a patient given carbamazepine.", "question": "Subject.Disorder in a patient", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "1893404_2_2236", "context": "Diabetes Mellitus was observed in a patient given carbamazepine.", "question": "Treatment.Drug in carbamazepine", "question_type": "Adverse_event.Treatment.Drug", "answers": "carbamazepine"}, {"id": "1893404_2_2237", "context": "Diabetes Mellitus was observed in a patient given carbamazepine.", "question": "Treatment.Dosage in carbamazepine", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "1893404_2_2238", "context": "Diabetes Mellitus was observed in a patient given carbamazepine.", "question": "Treatment.Freq in carbamazepine", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "1893404_2_2239", "context": "Diabetes Mellitus was observed in a patient given carbamazepine.", "question": "Treatment.Route in carbamazepine", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "1893404_2_2240", "context": "Diabetes Mellitus was observed in a patient given carbamazepine.", "question": "Treatment.Time_elapsed in carbamazepine", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "1893404_2_2241", "context": "Diabetes Mellitus was observed in a patient given carbamazepine.", "question": "Treatment.Duration in carbamazepine", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "1893404_2_2242", "context": "Diabetes Mellitus was observed in a patient given carbamazepine.", "question": "Treatment.Disorder in carbamazepine", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "1893404_2_2243", "context": "Diabetes Mellitus was observed in a patient given carbamazepine.", "question": "Combination.Drug in carbamazepine", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "25295553_3_2244", "context": "Anxiety is common in patients with schizophrenia and pregabalin has been suggested as an off-label add-on treatment.", "question": "Subject.Age in patients with schizophrenia", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "25295553_3_2245", "context": "Anxiety is common in patients with schizophrenia and pregabalin has been suggested as an off-label add-on treatment.", "question": "Subject.Gender in patients with schizophrenia", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "25295553_3_2246", "context": "Anxiety is common in patients with schizophrenia and pregabalin has been suggested as an off-label add-on treatment.", "question": "Subject.Population in patients with schizophrenia", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "25295553_3_2247", "context": "Anxiety is common in patients with schizophrenia and pregabalin has been suggested as an off-label add-on treatment.", "question": "Subject.Race in patients with schizophrenia", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "25295553_3_2248", "context": "Anxiety is common in patients with schizophrenia and pregabalin has been suggested as an off-label add-on treatment.", "question": "Subject.Disorder in patients with schizophrenia", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": "schizophrenia"}, {"id": "25295553_3_2249", "context": "Anxiety is common in patients with schizophrenia and pregabalin has been suggested as an off-label add-on treatment.", "question": "Treatment.Drug in pregabalin has been suggested as an off-label add-on treatment", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "pregabalin"}, {"id": "25295553_3_2250", "context": "Anxiety is common in patients with schizophrenia and pregabalin has been suggested as an off-label add-on treatment.", "question": "Treatment.Dosage in pregabalin has been suggested as an off-label add-on treatment", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "25295553_3_2251", "context": "Anxiety is common in patients with schizophrenia and pregabalin has been suggested as an off-label add-on treatment.", "question": "Treatment.Freq in pregabalin has been suggested as an off-label add-on treatment", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "25295553_3_2252", "context": "Anxiety is common in patients with schizophrenia and pregabalin has been suggested as an off-label add-on treatment.", "question": "Treatment.Route in pregabalin has been suggested as an off-label add-on treatment", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "25295553_3_2253", "context": "Anxiety is common in patients with schizophrenia and pregabalin has been suggested as an off-label add-on treatment.", "question": "Treatment.Time_elapsed in pregabalin has been suggested as an off-label add-on treatment", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "25295553_3_2254", "context": "Anxiety is common in patients with schizophrenia and pregabalin has been suggested as an off-label add-on treatment.", "question": "Treatment.Duration in pregabalin has been suggested as an off-label add-on treatment", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "25295553_3_2255", "context": "Anxiety is common in patients with schizophrenia and pregabalin has been suggested as an off-label add-on treatment.", "question": "Treatment.Disorder in pregabalin has been suggested as an off-label add-on treatment", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "Anxiety"}, {"id": "25295553_3_2256", "context": "Anxiety is common in patients with schizophrenia and pregabalin has been suggested as an off-label add-on treatment.", "question": "Combination.Drug in pregabalin has been suggested as an off-label add-on treatment", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "8996514_2_2257", "context": "Large cerebral infarction during praziquantel therapy in neurocysticercosis.", "question": "Treatment.Drug in praziquantel", "question_type": "Adverse_event.Treatment.Drug", "answers": "praziquantel"}, {"id": "8996514_2_2258", "context": "Large cerebral infarction during praziquantel therapy in neurocysticercosis.", "question": "Treatment.Dosage in praziquantel", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8996514_2_2259", "context": "Large cerebral infarction during praziquantel therapy in neurocysticercosis.", "question": "Treatment.Freq in praziquantel", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8996514_2_2260", "context": "Large cerebral infarction during praziquantel therapy in neurocysticercosis.", "question": "Treatment.Route in praziquantel", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8996514_2_2261", "context": "Large cerebral infarction during praziquantel therapy in neurocysticercosis.", "question": "Treatment.Time_elapsed in praziquantel", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8996514_2_2262", "context": "Large cerebral infarction during praziquantel therapy in neurocysticercosis.", "question": "Treatment.Duration in praziquantel", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8996514_2_2263", "context": "Large cerebral infarction during praziquantel therapy in neurocysticercosis.", "question": "Treatment.Disorder in praziquantel", "question_type": "Adverse_event.Treatment.Disorder", "answers": "neurocysticercosis"}, {"id": "8996514_2_2264", "context": "Large cerebral infarction during praziquantel therapy in neurocysticercosis.", "question": "Combination.Drug in praziquantel", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18556970_2_2265", "context": "We report a 13 year-old male who developed life-threatening anaphylaxis early in the course of Increlex therapy.", "question": "Subject.Age in a 13 year-old male", "question_type": "Adverse_event.Subject.Age", "answers": "13 year-old"}, {"id": "18556970_2_2266", "context": "We report a 13 year-old male who developed life-threatening anaphylaxis early in the course of Increlex therapy.", "question": "Subject.Gender in a 13 year-old male", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "18556970_2_2267", "context": "We report a 13 year-old male who developed life-threatening anaphylaxis early in the course of Increlex therapy.", "question": "Subject.Population in a 13 year-old male", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "18556970_2_2268", "context": "We report a 13 year-old male who developed life-threatening anaphylaxis early in the course of Increlex therapy.", "question": "Subject.Race in a 13 year-old male", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "18556970_2_2269", "context": "We report a 13 year-old male who developed life-threatening anaphylaxis early in the course of Increlex therapy.", "question": "Subject.Disorder in a 13 year-old male", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "18556970_2_2270", "context": "We report a 13 year-old male who developed life-threatening anaphylaxis early in the course of Increlex therapy.", "question": "Treatment.Drug in Increlex", "question_type": "Adverse_event.Treatment.Drug", "answers": "Increlex"}, {"id": "18556970_2_2271", "context": "We report a 13 year-old male who developed life-threatening anaphylaxis early in the course of Increlex therapy.", "question": "Treatment.Dosage in Increlex", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18556970_2_2272", "context": "We report a 13 year-old male who developed life-threatening anaphylaxis early in the course of Increlex therapy.", "question": "Treatment.Freq in Increlex", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18556970_2_2273", "context": "We report a 13 year-old male who developed life-threatening anaphylaxis early in the course of Increlex therapy.", "question": "Treatment.Route in Increlex", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18556970_2_2274", "context": "We report a 13 year-old male who developed life-threatening anaphylaxis early in the course of Increlex therapy.", "question": "Treatment.Time_elapsed in Increlex", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18556970_2_2275", "context": "We report a 13 year-old male who developed life-threatening anaphylaxis early in the course of Increlex therapy.", "question": "Treatment.Duration in Increlex", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18556970_2_2276", "context": "We report a 13 year-old male who developed life-threatening anaphylaxis early in the course of Increlex therapy.", "question": "Treatment.Disorder in Increlex", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18556970_2_2277", "context": "We report a 13 year-old male who developed life-threatening anaphylaxis early in the course of Increlex therapy.", "question": "Combination.Drug in Increlex", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16531969_1_2278", "context": "Drug induced liver injury secondary to interferon-beta (IFN-beta) in multiple sclerosis.", "question": "Treatment.Drug in interferon-beta (IFN-beta)", "question_type": "Adverse_event.Treatment.Drug", "answers": "interferon-beta"}, {"id": "16531969_1_2279", "context": "Drug induced liver injury secondary to interferon-beta (IFN-beta) in multiple sclerosis.", "question": "Treatment.Dosage in interferon-beta (IFN-beta)", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16531969_1_2280", "context": "Drug induced liver injury secondary to interferon-beta (IFN-beta) in multiple sclerosis.", "question": "Treatment.Freq in interferon-beta (IFN-beta)", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16531969_1_2281", "context": "Drug induced liver injury secondary to interferon-beta (IFN-beta) in multiple sclerosis.", "question": "Treatment.Route in interferon-beta (IFN-beta)", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16531969_1_2282", "context": "Drug induced liver injury secondary to interferon-beta (IFN-beta) in multiple sclerosis.", "question": "Treatment.Time_elapsed in interferon-beta (IFN-beta)", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16531969_1_2283", "context": "Drug induced liver injury secondary to interferon-beta (IFN-beta) in multiple sclerosis.", "question": "Treatment.Duration in interferon-beta (IFN-beta)", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16531969_1_2284", "context": "Drug induced liver injury secondary to interferon-beta (IFN-beta) in multiple sclerosis.", "question": "Treatment.Disorder in interferon-beta (IFN-beta)", "question_type": "Adverse_event.Treatment.Disorder", "answers": "multiple sclerosis"}, {"id": "16531969_1_2285", "context": "Drug induced liver injury secondary to interferon-beta (IFN-beta) in multiple sclerosis.", "question": "Combination.Drug in interferon-beta (IFN-beta)", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9925865_1_2286", "context": "CONCLUSION: Lipoid pneumonia as a result of mineral oil aspiration still occurs in the pediatric population.", "question": "Subject.Age in pediatric", "question_type": "Adverse_event.Subject.Age", "answers": "pediatric"}, {"id": "9925865_1_2287", "context": "CONCLUSION: Lipoid pneumonia as a result of mineral oil aspiration still occurs in the pediatric population.", "question": "Subject.Gender in pediatric", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "9925865_1_2288", "context": "CONCLUSION: Lipoid pneumonia as a result of mineral oil aspiration still occurs in the pediatric population.", "question": "Subject.Population in pediatric", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "9925865_1_2289", "context": "CONCLUSION: Lipoid pneumonia as a result of mineral oil aspiration still occurs in the pediatric population.", "question": "Subject.Race in pediatric", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "9925865_1_2290", "context": "CONCLUSION: Lipoid pneumonia as a result of mineral oil aspiration still occurs in the pediatric population.", "question": "Subject.Disorder in pediatric", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "9925865_1_2291", "context": "CONCLUSION: Lipoid pneumonia as a result of mineral oil aspiration still occurs in the pediatric population.", "question": "Treatment.Drug in mineral oil aspiration", "question_type": "Adverse_event.Treatment.Drug", "answers": "mineral oil"}, {"id": "9925865_1_2292", "context": "CONCLUSION: Lipoid pneumonia as a result of mineral oil aspiration still occurs in the pediatric population.", "question": "Treatment.Dosage in mineral oil aspiration", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9925865_1_2293", "context": "CONCLUSION: Lipoid pneumonia as a result of mineral oil aspiration still occurs in the pediatric population.", "question": "Treatment.Freq in mineral oil aspiration", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9925865_1_2294", "context": "CONCLUSION: Lipoid pneumonia as a result of mineral oil aspiration still occurs in the pediatric population.", "question": "Treatment.Route in mineral oil aspiration", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9925865_1_2295", "context": "CONCLUSION: Lipoid pneumonia as a result of mineral oil aspiration still occurs in the pediatric population.", "question": "Treatment.Time_elapsed in mineral oil aspiration", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9925865_1_2296", "context": "CONCLUSION: Lipoid pneumonia as a result of mineral oil aspiration still occurs in the pediatric population.", "question": "Treatment.Duration in mineral oil aspiration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9925865_1_2297", "context": "CONCLUSION: Lipoid pneumonia as a result of mineral oil aspiration still occurs in the pediatric population.", "question": "Treatment.Disorder in mineral oil aspiration", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9925865_1_2298", "context": "CONCLUSION: Lipoid pneumonia as a result of mineral oil aspiration still occurs in the pediatric population.", "question": "Combination.Drug in mineral oil aspiration", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "21350204_12_2299", "context": "The results from the present study suggest that tissue plasminogen activator treatment appears to be safe in patients with acute ischemic stroke taking warfarin with an international normalized ratio <1.7 and may reduce the risk of poor functional outcome.", "question": "Subject.Age in patients with acute ischemic stroke", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "21350204_12_2300", "context": "The results from the present study suggest that tissue plasminogen activator treatment appears to be safe in patients with acute ischemic stroke taking warfarin with an international normalized ratio <1.7 and may reduce the risk of poor functional outcome.", "question": "Subject.Gender in patients with acute ischemic stroke", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "21350204_12_2301", "context": "The results from the present study suggest that tissue plasminogen activator treatment appears to be safe in patients with acute ischemic stroke taking warfarin with an international normalized ratio <1.7 and may reduce the risk of poor functional outcome.", "question": "Subject.Population in patients with acute ischemic stroke", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "21350204_12_2302", "context": "The results from the present study suggest that tissue plasminogen activator treatment appears to be safe in patients with acute ischemic stroke taking warfarin with an international normalized ratio <1.7 and may reduce the risk of poor functional outcome.", "question": "Subject.Race in patients with acute ischemic stroke", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "21350204_12_2303", "context": "The results from the present study suggest that tissue plasminogen activator treatment appears to be safe in patients with acute ischemic stroke taking warfarin with an international normalized ratio <1.7 and may reduce the risk of poor functional outcome.", "question": "Subject.Disorder in patients with acute ischemic stroke", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "21350204_12_2304", "context": "The results from the present study suggest that tissue plasminogen activator treatment appears to be safe in patients with acute ischemic stroke taking warfarin with an international normalized ratio <1.7 and may reduce the risk of poor functional outcome.", "question": "Treatment.Drug in taking warfarin with an international normalized ratio <1.7; tissue plasminogen activator treatment", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "tissue plasminogen activator; warfarin"}, {"id": "21350204_12_2305", "context": "The results from the present study suggest that tissue plasminogen activator treatment appears to be safe in patients with acute ischemic stroke taking warfarin with an international normalized ratio <1.7 and may reduce the risk of poor functional outcome.", "question": "Treatment.Dosage in taking warfarin with an international normalized ratio <1.7; tissue plasminogen activator treatment", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "21350204_12_2306", "context": "The results from the present study suggest that tissue plasminogen activator treatment appears to be safe in patients with acute ischemic stroke taking warfarin with an international normalized ratio <1.7 and may reduce the risk of poor functional outcome.", "question": "Treatment.Freq in taking warfarin with an international normalized ratio <1.7; tissue plasminogen activator treatment", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "21350204_12_2307", "context": "The results from the present study suggest that tissue plasminogen activator treatment appears to be safe in patients with acute ischemic stroke taking warfarin with an international normalized ratio <1.7 and may reduce the risk of poor functional outcome.", "question": "Treatment.Route in taking warfarin with an international normalized ratio <1.7; tissue plasminogen activator treatment", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "21350204_12_2308", "context": "The results from the present study suggest that tissue plasminogen activator treatment appears to be safe in patients with acute ischemic stroke taking warfarin with an international normalized ratio <1.7 and may reduce the risk of poor functional outcome.", "question": "Treatment.Time_elapsed in taking warfarin with an international normalized ratio <1.7; tissue plasminogen activator treatment", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "21350204_12_2309", "context": "The results from the present study suggest that tissue plasminogen activator treatment appears to be safe in patients with acute ischemic stroke taking warfarin with an international normalized ratio <1.7 and may reduce the risk of poor functional outcome.", "question": "Treatment.Duration in taking warfarin with an international normalized ratio <1.7; tissue plasminogen activator treatment", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "21350204_12_2310", "context": "The results from the present study suggest that tissue plasminogen activator treatment appears to be safe in patients with acute ischemic stroke taking warfarin with an international normalized ratio <1.7 and may reduce the risk of poor functional outcome.", "question": "Treatment.Disorder in taking warfarin with an international normalized ratio <1.7; tissue plasminogen activator treatment", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "acute ischemic stroke"}, {"id": "21350204_12_2311", "context": "The results from the present study suggest that tissue plasminogen activator treatment appears to be safe in patients with acute ischemic stroke taking warfarin with an international normalized ratio <1.7 and may reduce the risk of poor functional outcome.", "question": "Combination.Drug in taking warfarin with an international normalized ratio <1.7; tissue plasminogen activator treatment", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": "tissue plasminogen activator; warfarin"}, {"id": "17157086_4_2312", "context": "Because of chronic asthma, she had been receiving a leukotriene receptor antagonist (montelukast) for 5 years before the current presentation; 1 week before onset she had had 1 week of treatment with two dietary supplements for weight control; one of these included Garcinia Cambogia, a possible cause of two recent cases of hepatitis in the USA; in addition, both formulas contained a citrus derivative that interferes cytochrome functions.", "question": "Subject.Age in she", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "17157086_4_2313", "context": "Because of chronic asthma, she had been receiving a leukotriene receptor antagonist (montelukast) for 5 years before the current presentation; 1 week before onset she had had 1 week of treatment with two dietary supplements for weight control; one of these included Garcinia Cambogia, a possible cause of two recent cases of hepatitis in the USA; in addition, both formulas contained a citrus derivative that interferes cytochrome functions.", "question": "Subject.Gender in she", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "17157086_4_2314", "context": "Because of chronic asthma, she had been receiving a leukotriene receptor antagonist (montelukast) for 5 years before the current presentation; 1 week before onset she had had 1 week of treatment with two dietary supplements for weight control; one of these included Garcinia Cambogia, a possible cause of two recent cases of hepatitis in the USA; in addition, both formulas contained a citrus derivative that interferes cytochrome functions.", "question": "Subject.Population in she", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "17157086_4_2315", "context": "Because of chronic asthma, she had been receiving a leukotriene receptor antagonist (montelukast) for 5 years before the current presentation; 1 week before onset she had had 1 week of treatment with two dietary supplements for weight control; one of these included Garcinia Cambogia, a possible cause of two recent cases of hepatitis in the USA; in addition, both formulas contained a citrus derivative that interferes cytochrome functions.", "question": "Subject.Race in she", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "17157086_4_2316", "context": "Because of chronic asthma, she had been receiving a leukotriene receptor antagonist (montelukast) for 5 years before the current presentation; 1 week before onset she had had 1 week of treatment with two dietary supplements for weight control; one of these included Garcinia Cambogia, a possible cause of two recent cases of hepatitis in the USA; in addition, both formulas contained a citrus derivative that interferes cytochrome functions.", "question": "Subject.Disorder in she", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "17157086_4_2317", "context": "Because of chronic asthma, she had been receiving a leukotriene receptor antagonist (montelukast) for 5 years before the current presentation; 1 week before onset she had had 1 week of treatment with two dietary supplements for weight control; one of these included Garcinia Cambogia, a possible cause of two recent cases of hepatitis in the USA; in addition, both formulas contained a citrus derivative that interferes cytochrome functions.", "question": "Treatment.Drug in a leukotriene receptor antagonist (montelukast) for 5 years", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "montelukast"}, {"id": "17157086_4_2318", "context": "Because of chronic asthma, she had been receiving a leukotriene receptor antagonist (montelukast) for 5 years before the current presentation; 1 week before onset she had had 1 week of treatment with two dietary supplements for weight control; one of these included Garcinia Cambogia, a possible cause of two recent cases of hepatitis in the USA; in addition, both formulas contained a citrus derivative that interferes cytochrome functions.", "question": "Treatment.Dosage in a leukotriene receptor antagonist (montelukast) for 5 years", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "17157086_4_2319", "context": "Because of chronic asthma, she had been receiving a leukotriene receptor antagonist (montelukast) for 5 years before the current presentation; 1 week before onset she had had 1 week of treatment with two dietary supplements for weight control; one of these included Garcinia Cambogia, a possible cause of two recent cases of hepatitis in the USA; in addition, both formulas contained a citrus derivative that interferes cytochrome functions.", "question": "Treatment.Freq in a leukotriene receptor antagonist (montelukast) for 5 years", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "17157086_4_2320", "context": "Because of chronic asthma, she had been receiving a leukotriene receptor antagonist (montelukast) for 5 years before the current presentation; 1 week before onset she had had 1 week of treatment with two dietary supplements for weight control; one of these included Garcinia Cambogia, a possible cause of two recent cases of hepatitis in the USA; in addition, both formulas contained a citrus derivative that interferes cytochrome functions.", "question": "Treatment.Route in a leukotriene receptor antagonist (montelukast) for 5 years", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "17157086_4_2321", "context": "Because of chronic asthma, she had been receiving a leukotriene receptor antagonist (montelukast) for 5 years before the current presentation; 1 week before onset she had had 1 week of treatment with two dietary supplements for weight control; one of these included Garcinia Cambogia, a possible cause of two recent cases of hepatitis in the USA; in addition, both formulas contained a citrus derivative that interferes cytochrome functions.", "question": "Treatment.Time_elapsed in a leukotriene receptor antagonist (montelukast) for 5 years", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": "5 years"}, {"id": "17157086_4_2322", "context": "Because of chronic asthma, she had been receiving a leukotriene receptor antagonist (montelukast) for 5 years before the current presentation; 1 week before onset she had had 1 week of treatment with two dietary supplements for weight control; one of these included Garcinia Cambogia, a possible cause of two recent cases of hepatitis in the USA; in addition, both formulas contained a citrus derivative that interferes cytochrome functions.", "question": "Treatment.Duration in a leukotriene receptor antagonist (montelukast) for 5 years", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "17157086_4_2323", "context": "Because of chronic asthma, she had been receiving a leukotriene receptor antagonist (montelukast) for 5 years before the current presentation; 1 week before onset she had had 1 week of treatment with two dietary supplements for weight control; one of these included Garcinia Cambogia, a possible cause of two recent cases of hepatitis in the USA; in addition, both formulas contained a citrus derivative that interferes cytochrome functions.", "question": "Treatment.Disorder in a leukotriene receptor antagonist (montelukast) for 5 years", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "chronic asthma"}, {"id": "17157086_4_2324", "context": "Because of chronic asthma, she had been receiving a leukotriene receptor antagonist (montelukast) for 5 years before the current presentation; 1 week before onset she had had 1 week of treatment with two dietary supplements for weight control; one of these included Garcinia Cambogia, a possible cause of two recent cases of hepatitis in the USA; in addition, both formulas contained a citrus derivative that interferes cytochrome functions.", "question": "Combination.Drug in a leukotriene receptor antagonist (montelukast) for 5 years", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "17157086_4_2325", "context": "Because of chronic asthma, she had been receiving a leukotriene receptor antagonist (montelukast) for 5 years before the current presentation; 1 week before onset she had had 1 week of treatment with two dietary supplements for weight control; one of these included Garcinia Cambogia, a possible cause of two recent cases of hepatitis in the USA; in addition, both formulas contained a citrus derivative that interferes cytochrome functions.", "question": "Subject.Age in two recent cases", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "17157086_4_2326", "context": "Because of chronic asthma, she had been receiving a leukotriene receptor antagonist (montelukast) for 5 years before the current presentation; 1 week before onset she had had 1 week of treatment with two dietary supplements for weight control; one of these included Garcinia Cambogia, a possible cause of two recent cases of hepatitis in the USA; in addition, both formulas contained a citrus derivative that interferes cytochrome functions.", "question": "Subject.Gender in two recent cases", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "17157086_4_2327", "context": "Because of chronic asthma, she had been receiving a leukotriene receptor antagonist (montelukast) for 5 years before the current presentation; 1 week before onset she had had 1 week of treatment with two dietary supplements for weight control; one of these included Garcinia Cambogia, a possible cause of two recent cases of hepatitis in the USA; in addition, both formulas contained a citrus derivative that interferes cytochrome functions.", "question": "Subject.Population in two recent cases", "question_type": "Adverse_event.Subject.Population", "answers": "two"}, {"id": "17157086_4_2328", "context": "Because of chronic asthma, she had been receiving a leukotriene receptor antagonist (montelukast) for 5 years before the current presentation; 1 week before onset she had had 1 week of treatment with two dietary supplements for weight control; one of these included Garcinia Cambogia, a possible cause of two recent cases of hepatitis in the USA; in addition, both formulas contained a citrus derivative that interferes cytochrome functions.", "question": "Subject.Race in two recent cases", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "17157086_4_2329", "context": "Because of chronic asthma, she had been receiving a leukotriene receptor antagonist (montelukast) for 5 years before the current presentation; 1 week before onset she had had 1 week of treatment with two dietary supplements for weight control; one of these included Garcinia Cambogia, a possible cause of two recent cases of hepatitis in the USA; in addition, both formulas contained a citrus derivative that interferes cytochrome functions.", "question": "Subject.Disorder in two recent cases", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "17157086_4_2330", "context": "Because of chronic asthma, she had been receiving a leukotriene receptor antagonist (montelukast) for 5 years before the current presentation; 1 week before onset she had had 1 week of treatment with two dietary supplements for weight control; one of these included Garcinia Cambogia, a possible cause of two recent cases of hepatitis in the USA; in addition, both formulas contained a citrus derivative that interferes cytochrome functions.", "question": "Treatment.Drug in Garcinia Cambogia", "question_type": "Adverse_event.Treatment.Drug", "answers": "Garcinia Cambogia"}, {"id": "17157086_4_2331", "context": "Because of chronic asthma, she had been receiving a leukotriene receptor antagonist (montelukast) for 5 years before the current presentation; 1 week before onset she had had 1 week of treatment with two dietary supplements for weight control; one of these included Garcinia Cambogia, a possible cause of two recent cases of hepatitis in the USA; in addition, both formulas contained a citrus derivative that interferes cytochrome functions.", "question": "Treatment.Dosage in Garcinia Cambogia", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17157086_4_2332", "context": "Because of chronic asthma, she had been receiving a leukotriene receptor antagonist (montelukast) for 5 years before the current presentation; 1 week before onset she had had 1 week of treatment with two dietary supplements for weight control; one of these included Garcinia Cambogia, a possible cause of two recent cases of hepatitis in the USA; in addition, both formulas contained a citrus derivative that interferes cytochrome functions.", "question": "Treatment.Freq in Garcinia Cambogia", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17157086_4_2333", "context": "Because of chronic asthma, she had been receiving a leukotriene receptor antagonist (montelukast) for 5 years before the current presentation; 1 week before onset she had had 1 week of treatment with two dietary supplements for weight control; one of these included Garcinia Cambogia, a possible cause of two recent cases of hepatitis in the USA; in addition, both formulas contained a citrus derivative that interferes cytochrome functions.", "question": "Treatment.Route in Garcinia Cambogia", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17157086_4_2334", "context": "Because of chronic asthma, she had been receiving a leukotriene receptor antagonist (montelukast) for 5 years before the current presentation; 1 week before onset she had had 1 week of treatment with two dietary supplements for weight control; one of these included Garcinia Cambogia, a possible cause of two recent cases of hepatitis in the USA; in addition, both formulas contained a citrus derivative that interferes cytochrome functions.", "question": "Treatment.Time_elapsed in Garcinia Cambogia", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17157086_4_2335", "context": "Because of chronic asthma, she had been receiving a leukotriene receptor antagonist (montelukast) for 5 years before the current presentation; 1 week before onset she had had 1 week of treatment with two dietary supplements for weight control; one of these included Garcinia Cambogia, a possible cause of two recent cases of hepatitis in the USA; in addition, both formulas contained a citrus derivative that interferes cytochrome functions.", "question": "Treatment.Duration in Garcinia Cambogia", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17157086_4_2336", "context": "Because of chronic asthma, she had been receiving a leukotriene receptor antagonist (montelukast) for 5 years before the current presentation; 1 week before onset she had had 1 week of treatment with two dietary supplements for weight control; one of these included Garcinia Cambogia, a possible cause of two recent cases of hepatitis in the USA; in addition, both formulas contained a citrus derivative that interferes cytochrome functions.", "question": "Treatment.Disorder in Garcinia Cambogia", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17157086_4_2337", "context": "Because of chronic asthma, she had been receiving a leukotriene receptor antagonist (montelukast) for 5 years before the current presentation; 1 week before onset she had had 1 week of treatment with two dietary supplements for weight control; one of these included Garcinia Cambogia, a possible cause of two recent cases of hepatitis in the USA; in addition, both formulas contained a citrus derivative that interferes cytochrome functions.", "question": "Combination.Drug in Garcinia Cambogia", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "2204409_1_2338", "context": "An episode of leukoencephalopathy is reported in a 13-year-old girl who, after standard radiotherapy for a posterior fossa medulloblastoma, received 8 treatments with a protocol containing a 4-hour infusion of 500 mg/m2 methotrexate and 12 mg intrathecal methotrexate.", "question": "Subject.Age in 13-year-old girl who", "question_type": "Adverse_event.Subject.Age", "answers": "13-year-old"}, {"id": "2204409_1_2339", "context": "An episode of leukoencephalopathy is reported in a 13-year-old girl who, after standard radiotherapy for a posterior fossa medulloblastoma, received 8 treatments with a protocol containing a 4-hour infusion of 500 mg/m2 methotrexate and 12 mg intrathecal methotrexate.", "question": "Subject.Gender in 13-year-old girl who", "question_type": "Adverse_event.Subject.Gender", "answers": "girl"}, {"id": "2204409_1_2340", "context": "An episode of leukoencephalopathy is reported in a 13-year-old girl who, after standard radiotherapy for a posterior fossa medulloblastoma, received 8 treatments with a protocol containing a 4-hour infusion of 500 mg/m2 methotrexate and 12 mg intrathecal methotrexate.", "question": "Subject.Population in 13-year-old girl who", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "2204409_1_2341", "context": "An episode of leukoencephalopathy is reported in a 13-year-old girl who, after standard radiotherapy for a posterior fossa medulloblastoma, received 8 treatments with a protocol containing a 4-hour infusion of 500 mg/m2 methotrexate and 12 mg intrathecal methotrexate.", "question": "Subject.Race in 13-year-old girl who", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "2204409_1_2342", "context": "An episode of leukoencephalopathy is reported in a 13-year-old girl who, after standard radiotherapy for a posterior fossa medulloblastoma, received 8 treatments with a protocol containing a 4-hour infusion of 500 mg/m2 methotrexate and 12 mg intrathecal methotrexate.", "question": "Subject.Disorder in 13-year-old girl who", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "2204409_1_2343", "context": "An episode of leukoencephalopathy is reported in a 13-year-old girl who, after standard radiotherapy for a posterior fossa medulloblastoma, received 8 treatments with a protocol containing a 4-hour infusion of 500 mg/m2 methotrexate and 12 mg intrathecal methotrexate.", "question": "Treatment.Drug in standard radiotherapy for a posterior fossa medulloblastoma, received 8 treatments with a protocol containing a 4-hour infusion of 500 mg/m2 methotrexate and 12 mg intrathecal methotrexate", "question_type": "Adverse_event.Treatment.Drug", "answers": "radiotherapy; methotrexate; intrathecal methotrexate"}, {"id": "2204409_1_2344", "context": "An episode of leukoencephalopathy is reported in a 13-year-old girl who, after standard radiotherapy for a posterior fossa medulloblastoma, received 8 treatments with a protocol containing a 4-hour infusion of 500 mg/m2 methotrexate and 12 mg intrathecal methotrexate.", "question": "Treatment.Dosage in standard radiotherapy for a posterior fossa medulloblastoma, received 8 treatments with a protocol containing a 4-hour infusion of 500 mg/m2 methotrexate and 12 mg intrathecal methotrexate", "question_type": "Adverse_event.Treatment.Dosage", "answers": "500 mg/m2; 12 mg"}, {"id": "2204409_1_2345", "context": "An episode of leukoencephalopathy is reported in a 13-year-old girl who, after standard radiotherapy for a posterior fossa medulloblastoma, received 8 treatments with a protocol containing a 4-hour infusion of 500 mg/m2 methotrexate and 12 mg intrathecal methotrexate.", "question": "Treatment.Freq in standard radiotherapy for a posterior fossa medulloblastoma, received 8 treatments with a protocol containing a 4-hour infusion of 500 mg/m2 methotrexate and 12 mg intrathecal methotrexate", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2204409_1_2346", "context": "An episode of leukoencephalopathy is reported in a 13-year-old girl who, after standard radiotherapy for a posterior fossa medulloblastoma, received 8 treatments with a protocol containing a 4-hour infusion of 500 mg/m2 methotrexate and 12 mg intrathecal methotrexate.", "question": "Treatment.Route in standard radiotherapy for a posterior fossa medulloblastoma, received 8 treatments with a protocol containing a 4-hour infusion of 500 mg/m2 methotrexate and 12 mg intrathecal methotrexate", "question_type": "Adverse_event.Treatment.Route", "answers": "infusion"}, {"id": "2204409_1_2347", "context": "An episode of leukoencephalopathy is reported in a 13-year-old girl who, after standard radiotherapy for a posterior fossa medulloblastoma, received 8 treatments with a protocol containing a 4-hour infusion of 500 mg/m2 methotrexate and 12 mg intrathecal methotrexate.", "question": "Treatment.Time_elapsed in standard radiotherapy for a posterior fossa medulloblastoma, received 8 treatments with a protocol containing a 4-hour infusion of 500 mg/m2 methotrexate and 12 mg intrathecal methotrexate", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2204409_1_2348", "context": "An episode of leukoencephalopathy is reported in a 13-year-old girl who, after standard radiotherapy for a posterior fossa medulloblastoma, received 8 treatments with a protocol containing a 4-hour infusion of 500 mg/m2 methotrexate and 12 mg intrathecal methotrexate.", "question": "Treatment.Duration in standard radiotherapy for a posterior fossa medulloblastoma, received 8 treatments with a protocol containing a 4-hour infusion of 500 mg/m2 methotrexate and 12 mg intrathecal methotrexate", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2204409_1_2349", "context": "An episode of leukoencephalopathy is reported in a 13-year-old girl who, after standard radiotherapy for a posterior fossa medulloblastoma, received 8 treatments with a protocol containing a 4-hour infusion of 500 mg/m2 methotrexate and 12 mg intrathecal methotrexate.", "question": "Treatment.Disorder in standard radiotherapy for a posterior fossa medulloblastoma, received 8 treatments with a protocol containing a 4-hour infusion of 500 mg/m2 methotrexate and 12 mg intrathecal methotrexate", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "2204409_1_2350", "context": "An episode of leukoencephalopathy is reported in a 13-year-old girl who, after standard radiotherapy for a posterior fossa medulloblastoma, received 8 treatments with a protocol containing a 4-hour infusion of 500 mg/m2 methotrexate and 12 mg intrathecal methotrexate.", "question": "Combination.Drug in standard radiotherapy for a posterior fossa medulloblastoma, received 8 treatments with a protocol containing a 4-hour infusion of 500 mg/m2 methotrexate and 12 mg intrathecal methotrexate", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11514944_1_2351", "context": "BACKGROUND: Accutane a teratogenic prescription drug licensed to treat severe, recalcitrant nodular acne.", "question": "Treatment.Drug in Accutane", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "Accutane"}, {"id": "11514944_1_2352", "context": "BACKGROUND: Accutane a teratogenic prescription drug licensed to treat severe, recalcitrant nodular acne.", "question": "Treatment.Dosage in Accutane", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "11514944_1_2353", "context": "BACKGROUND: Accutane a teratogenic prescription drug licensed to treat severe, recalcitrant nodular acne.", "question": "Treatment.Freq in Accutane", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "11514944_1_2354", "context": "BACKGROUND: Accutane a teratogenic prescription drug licensed to treat severe, recalcitrant nodular acne.", "question": "Treatment.Route in Accutane", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "11514944_1_2355", "context": "BACKGROUND: Accutane a teratogenic prescription drug licensed to treat severe, recalcitrant nodular acne.", "question": "Treatment.Time_elapsed in Accutane", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11514944_1_2356", "context": "BACKGROUND: Accutane a teratogenic prescription drug licensed to treat severe, recalcitrant nodular acne.", "question": "Treatment.Duration in Accutane", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "11514944_1_2357", "context": "BACKGROUND: Accutane a teratogenic prescription drug licensed to treat severe, recalcitrant nodular acne.", "question": "Treatment.Disorder in Accutane", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "severe, recalcitrant nodular acne"}, {"id": "11514944_1_2358", "context": "BACKGROUND: Accutane a teratogenic prescription drug licensed to treat severe, recalcitrant nodular acne.", "question": "Combination.Drug in Accutane", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "12452753_5_2359", "context": "OBJECTIVE: To report the safe use of fluorouracil in a patient with breast cancer who had allergic reactions to capecitabine.", "question": "Subject.Age in a patient with breast cancer who had allergic reactions to capecitabine", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "12452753_5_2360", "context": "OBJECTIVE: To report the safe use of fluorouracil in a patient with breast cancer who had allergic reactions to capecitabine.", "question": "Subject.Gender in a patient with breast cancer who had allergic reactions to capecitabine", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "12452753_5_2361", "context": "OBJECTIVE: To report the safe use of fluorouracil in a patient with breast cancer who had allergic reactions to capecitabine.", "question": "Subject.Population in a patient with breast cancer who had allergic reactions to capecitabine", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "12452753_5_2362", "context": "OBJECTIVE: To report the safe use of fluorouracil in a patient with breast cancer who had allergic reactions to capecitabine.", "question": "Subject.Race in a patient with breast cancer who had allergic reactions to capecitabine", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "12452753_5_2363", "context": "OBJECTIVE: To report the safe use of fluorouracil in a patient with breast cancer who had allergic reactions to capecitabine.", "question": "Subject.Disorder in a patient with breast cancer who had allergic reactions to capecitabine", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": "allergic reactions to capecitabine"}, {"id": "12452753_5_2364", "context": "OBJECTIVE: To report the safe use of fluorouracil in a patient with breast cancer who had allergic reactions to capecitabine.", "question": "Treatment.Drug in fluorouracil", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "fluorouracil"}, {"id": "12452753_5_2365", "context": "OBJECTIVE: To report the safe use of fluorouracil in a patient with breast cancer who had allergic reactions to capecitabine.", "question": "Treatment.Dosage in fluorouracil", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "12452753_5_2366", "context": "OBJECTIVE: To report the safe use of fluorouracil in a patient with breast cancer who had allergic reactions to capecitabine.", "question": "Treatment.Freq in fluorouracil", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "12452753_5_2367", "context": "OBJECTIVE: To report the safe use of fluorouracil in a patient with breast cancer who had allergic reactions to capecitabine.", "question": "Treatment.Route in fluorouracil", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "12452753_5_2368", "context": "OBJECTIVE: To report the safe use of fluorouracil in a patient with breast cancer who had allergic reactions to capecitabine.", "question": "Treatment.Time_elapsed in fluorouracil", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12452753_5_2369", "context": "OBJECTIVE: To report the safe use of fluorouracil in a patient with breast cancer who had allergic reactions to capecitabine.", "question": "Treatment.Duration in fluorouracil", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "12452753_5_2370", "context": "OBJECTIVE: To report the safe use of fluorouracil in a patient with breast cancer who had allergic reactions to capecitabine.", "question": "Treatment.Disorder in fluorouracil", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "breast cancer"}, {"id": "12452753_5_2371", "context": "OBJECTIVE: To report the safe use of fluorouracil in a patient with breast cancer who had allergic reactions to capecitabine.", "question": "Combination.Drug in fluorouracil", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "7797283_1_2372", "context": "Esophageal candidiasis following omeprazole therapy: a report of two cases.", "question": "Subject.Age in two cases", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "7797283_1_2373", "context": "Esophageal candidiasis following omeprazole therapy: a report of two cases.", "question": "Subject.Gender in two cases", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "7797283_1_2374", "context": "Esophageal candidiasis following omeprazole therapy: a report of two cases.", "question": "Subject.Population in two cases", "question_type": "Adverse_event.Subject.Population", "answers": "two"}, {"id": "7797283_1_2375", "context": "Esophageal candidiasis following omeprazole therapy: a report of two cases.", "question": "Subject.Race in two cases", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "7797283_1_2376", "context": "Esophageal candidiasis following omeprazole therapy: a report of two cases.", "question": "Subject.Disorder in two cases", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "7797283_1_2377", "context": "Esophageal candidiasis following omeprazole therapy: a report of two cases.", "question": "Treatment.Drug in omeprazole", "question_type": "Adverse_event.Treatment.Drug", "answers": "omeprazole"}, {"id": "7797283_1_2378", "context": "Esophageal candidiasis following omeprazole therapy: a report of two cases.", "question": "Treatment.Dosage in omeprazole", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7797283_1_2379", "context": "Esophageal candidiasis following omeprazole therapy: a report of two cases.", "question": "Treatment.Freq in omeprazole", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7797283_1_2380", "context": "Esophageal candidiasis following omeprazole therapy: a report of two cases.", "question": "Treatment.Route in omeprazole", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7797283_1_2381", "context": "Esophageal candidiasis following omeprazole therapy: a report of two cases.", "question": "Treatment.Time_elapsed in omeprazole", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7797283_1_2382", "context": "Esophageal candidiasis following omeprazole therapy: a report of two cases.", "question": "Treatment.Duration in omeprazole", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7797283_1_2383", "context": "Esophageal candidiasis following omeprazole therapy: a report of two cases.", "question": "Treatment.Disorder in omeprazole", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7797283_1_2384", "context": "Esophageal candidiasis following omeprazole therapy: a report of two cases.", "question": "Combination.Drug in omeprazole", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11059196_2_2385", "context": "We describe a 10-year-old boy with ulcerative colitis who developed acute pancreatitis while on long-term treatment with 5-aminosalicylic acid.", "question": "Subject.Age in a 10-year-old boy with ulcerative colitis", "question_type": "Adverse_event.Subject.Age", "answers": "10-year-old"}, {"id": "11059196_2_2386", "context": "We describe a 10-year-old boy with ulcerative colitis who developed acute pancreatitis while on long-term treatment with 5-aminosalicylic acid.", "question": "Subject.Gender in a 10-year-old boy with ulcerative colitis", "question_type": "Adverse_event.Subject.Gender", "answers": "boy"}, {"id": "11059196_2_2387", "context": "We describe a 10-year-old boy with ulcerative colitis who developed acute pancreatitis while on long-term treatment with 5-aminosalicylic acid.", "question": "Subject.Population in a 10-year-old boy with ulcerative colitis", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "11059196_2_2388", "context": "We describe a 10-year-old boy with ulcerative colitis who developed acute pancreatitis while on long-term treatment with 5-aminosalicylic acid.", "question": "Subject.Race in a 10-year-old boy with ulcerative colitis", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "11059196_2_2389", "context": "We describe a 10-year-old boy with ulcerative colitis who developed acute pancreatitis while on long-term treatment with 5-aminosalicylic acid.", "question": "Subject.Disorder in a 10-year-old boy with ulcerative colitis", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "11059196_2_2390", "context": "We describe a 10-year-old boy with ulcerative colitis who developed acute pancreatitis while on long-term treatment with 5-aminosalicylic acid.", "question": "Treatment.Drug in long-term treatment with 5-aminosalicylic acid", "question_type": "Adverse_event.Treatment.Drug", "answers": "5-aminosalicylic acid"}, {"id": "11059196_2_2391", "context": "We describe a 10-year-old boy with ulcerative colitis who developed acute pancreatitis while on long-term treatment with 5-aminosalicylic acid.", "question": "Treatment.Dosage in long-term treatment with 5-aminosalicylic acid", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11059196_2_2392", "context": "We describe a 10-year-old boy with ulcerative colitis who developed acute pancreatitis while on long-term treatment with 5-aminosalicylic acid.", "question": "Treatment.Freq in long-term treatment with 5-aminosalicylic acid", "question_type": "Adverse_event.Treatment.Freq", "answers": "long-term treatment"}, {"id": "11059196_2_2393", "context": "We describe a 10-year-old boy with ulcerative colitis who developed acute pancreatitis while on long-term treatment with 5-aminosalicylic acid.", "question": "Treatment.Route in long-term treatment with 5-aminosalicylic acid", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11059196_2_2394", "context": "We describe a 10-year-old boy with ulcerative colitis who developed acute pancreatitis while on long-term treatment with 5-aminosalicylic acid.", "question": "Treatment.Time_elapsed in long-term treatment with 5-aminosalicylic acid", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11059196_2_2395", "context": "We describe a 10-year-old boy with ulcerative colitis who developed acute pancreatitis while on long-term treatment with 5-aminosalicylic acid.", "question": "Treatment.Duration in long-term treatment with 5-aminosalicylic acid", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11059196_2_2396", "context": "We describe a 10-year-old boy with ulcerative colitis who developed acute pancreatitis while on long-term treatment with 5-aminosalicylic acid.", "question": "Treatment.Disorder in long-term treatment with 5-aminosalicylic acid", "question_type": "Adverse_event.Treatment.Disorder", "answers": "ulcerative colitis"}, {"id": "11059196_2_2397", "context": "We describe a 10-year-old boy with ulcerative colitis who developed acute pancreatitis while on long-term treatment with 5-aminosalicylic acid.", "question": "Combination.Drug in long-term treatment with 5-aminosalicylic acid", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "22010004_8_2398", "context": "The mechanism of niacin-induced coagulopathy is theorized to be related to diminished coagulation factors, and limited data suggest that this may be more pronounced with extended-release niacin.", "question": "Treatment.Drug in niacin", "question_type": "Adverse_event.Treatment.Drug", "answers": "niacin; extended-release niacin"}, {"id": "22010004_8_2399", "context": "The mechanism of niacin-induced coagulopathy is theorized to be related to diminished coagulation factors, and limited data suggest that this may be more pronounced with extended-release niacin.", "question": "Treatment.Dosage in niacin", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "22010004_8_2400", "context": "The mechanism of niacin-induced coagulopathy is theorized to be related to diminished coagulation factors, and limited data suggest that this may be more pronounced with extended-release niacin.", "question": "Treatment.Freq in niacin", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "22010004_8_2401", "context": "The mechanism of niacin-induced coagulopathy is theorized to be related to diminished coagulation factors, and limited data suggest that this may be more pronounced with extended-release niacin.", "question": "Treatment.Route in niacin", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "22010004_8_2402", "context": "The mechanism of niacin-induced coagulopathy is theorized to be related to diminished coagulation factors, and limited data suggest that this may be more pronounced with extended-release niacin.", "question": "Treatment.Time_elapsed in niacin", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "22010004_8_2403", "context": "The mechanism of niacin-induced coagulopathy is theorized to be related to diminished coagulation factors, and limited data suggest that this may be more pronounced with extended-release niacin.", "question": "Treatment.Duration in niacin", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "22010004_8_2404", "context": "The mechanism of niacin-induced coagulopathy is theorized to be related to diminished coagulation factors, and limited data suggest that this may be more pronounced with extended-release niacin.", "question": "Treatment.Disorder in niacin", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "22010004_8_2405", "context": "The mechanism of niacin-induced coagulopathy is theorized to be related to diminished coagulation factors, and limited data suggest that this may be more pronounced with extended-release niacin.", "question": "Combination.Drug in niacin", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16449538_6_2406", "context": "OBJECTIVE: To report 2 cases of nonconvulsive status epilepticus (NCSE) following infusion of ifosfamide.", "question": "Treatment.Drug in infusion of ifosfamide", "question_type": "Adverse_event.Treatment.Drug", "answers": "ifosfamide"}, {"id": "16449538_6_2407", "context": "OBJECTIVE: To report 2 cases of nonconvulsive status epilepticus (NCSE) following infusion of ifosfamide.", "question": "Treatment.Dosage in infusion of ifosfamide", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16449538_6_2408", "context": "OBJECTIVE: To report 2 cases of nonconvulsive status epilepticus (NCSE) following infusion of ifosfamide.", "question": "Treatment.Freq in infusion of ifosfamide", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16449538_6_2409", "context": "OBJECTIVE: To report 2 cases of nonconvulsive status epilepticus (NCSE) following infusion of ifosfamide.", "question": "Treatment.Route in infusion of ifosfamide", "question_type": "Adverse_event.Treatment.Route", "answers": "infusion"}, {"id": "16449538_6_2410", "context": "OBJECTIVE: To report 2 cases of nonconvulsive status epilepticus (NCSE) following infusion of ifosfamide.", "question": "Treatment.Time_elapsed in infusion of ifosfamide", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16449538_6_2411", "context": "OBJECTIVE: To report 2 cases of nonconvulsive status epilepticus (NCSE) following infusion of ifosfamide.", "question": "Treatment.Duration in infusion of ifosfamide", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16449538_6_2412", "context": "OBJECTIVE: To report 2 cases of nonconvulsive status epilepticus (NCSE) following infusion of ifosfamide.", "question": "Treatment.Disorder in infusion of ifosfamide", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16449538_6_2413", "context": "OBJECTIVE: To report 2 cases of nonconvulsive status epilepticus (NCSE) following infusion of ifosfamide.", "question": "Combination.Drug in infusion of ifosfamide", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "24679099_8_2414", "context": "We conclude that the observed toxicity with jaundice was probably caused by an interaction of this popular Chinese formula and temozolomide.", "question": "Treatment.Drug in temozolomide", "question_type": "Adverse_event.Treatment.Drug", "answers": "temozolomide"}, {"id": "24679099_8_2415", "context": "We conclude that the observed toxicity with jaundice was probably caused by an interaction of this popular Chinese formula and temozolomide.", "question": "Treatment.Dosage in temozolomide", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "24679099_8_2416", "context": "We conclude that the observed toxicity with jaundice was probably caused by an interaction of this popular Chinese formula and temozolomide.", "question": "Treatment.Freq in temozolomide", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "24679099_8_2417", "context": "We conclude that the observed toxicity with jaundice was probably caused by an interaction of this popular Chinese formula and temozolomide.", "question": "Treatment.Route in temozolomide", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "24679099_8_2418", "context": "We conclude that the observed toxicity with jaundice was probably caused by an interaction of this popular Chinese formula and temozolomide.", "question": "Treatment.Time_elapsed in temozolomide", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "24679099_8_2419", "context": "We conclude that the observed toxicity with jaundice was probably caused by an interaction of this popular Chinese formula and temozolomide.", "question": "Treatment.Duration in temozolomide", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "24679099_8_2420", "context": "We conclude that the observed toxicity with jaundice was probably caused by an interaction of this popular Chinese formula and temozolomide.", "question": "Treatment.Disorder in temozolomide", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "24679099_8_2421", "context": "We conclude that the observed toxicity with jaundice was probably caused by an interaction of this popular Chinese formula and temozolomide.", "question": "Combination.Drug in temozolomide", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "14723711_2_2422", "context": "Pigmentary disorders are recognized adverse effects of the semi-synthetic tetracycline derivative antibiotic, minocycline.", "question": "Treatment.Drug in semi-synthetic tetracycline derivative antibiotic, minocycline", "question_type": "Adverse_event.Treatment.Drug", "answers": "minocycline"}, {"id": "14723711_2_2423", "context": "Pigmentary disorders are recognized adverse effects of the semi-synthetic tetracycline derivative antibiotic, minocycline.", "question": "Treatment.Dosage in semi-synthetic tetracycline derivative antibiotic, minocycline", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "14723711_2_2424", "context": "Pigmentary disorders are recognized adverse effects of the semi-synthetic tetracycline derivative antibiotic, minocycline.", "question": "Treatment.Freq in semi-synthetic tetracycline derivative antibiotic, minocycline", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "14723711_2_2425", "context": "Pigmentary disorders are recognized adverse effects of the semi-synthetic tetracycline derivative antibiotic, minocycline.", "question": "Treatment.Route in semi-synthetic tetracycline derivative antibiotic, minocycline", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "14723711_2_2426", "context": "Pigmentary disorders are recognized adverse effects of the semi-synthetic tetracycline derivative antibiotic, minocycline.", "question": "Treatment.Time_elapsed in semi-synthetic tetracycline derivative antibiotic, minocycline", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "14723711_2_2427", "context": "Pigmentary disorders are recognized adverse effects of the semi-synthetic tetracycline derivative antibiotic, minocycline.", "question": "Treatment.Duration in semi-synthetic tetracycline derivative antibiotic, minocycline", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "14723711_2_2428", "context": "Pigmentary disorders are recognized adverse effects of the semi-synthetic tetracycline derivative antibiotic, minocycline.", "question": "Treatment.Disorder in semi-synthetic tetracycline derivative antibiotic, minocycline", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "14723711_2_2429", "context": "Pigmentary disorders are recognized adverse effects of the semi-synthetic tetracycline derivative antibiotic, minocycline.", "question": "Combination.Drug in semi-synthetic tetracycline derivative antibiotic, minocycline", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "25295553_2_2430", "context": "Pregabalin is an antiepileptic drug with anti-anxiety properties and is approved for treatment of generalized anxiety disorder.", "question": "Treatment.Drug in Pregabalin is an antiepileptic drug with anti-anxiety properties", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "Pregabalin"}, {"id": "25295553_2_2431", "context": "Pregabalin is an antiepileptic drug with anti-anxiety properties and is approved for treatment of generalized anxiety disorder.", "question": "Treatment.Dosage in Pregabalin is an antiepileptic drug with anti-anxiety properties", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "25295553_2_2432", "context": "Pregabalin is an antiepileptic drug with anti-anxiety properties and is approved for treatment of generalized anxiety disorder.", "question": "Treatment.Freq in Pregabalin is an antiepileptic drug with anti-anxiety properties", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "25295553_2_2433", "context": "Pregabalin is an antiepileptic drug with anti-anxiety properties and is approved for treatment of generalized anxiety disorder.", "question": "Treatment.Route in Pregabalin is an antiepileptic drug with anti-anxiety properties", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "25295553_2_2434", "context": "Pregabalin is an antiepileptic drug with anti-anxiety properties and is approved for treatment of generalized anxiety disorder.", "question": "Treatment.Time_elapsed in Pregabalin is an antiepileptic drug with anti-anxiety properties", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "25295553_2_2435", "context": "Pregabalin is an antiepileptic drug with anti-anxiety properties and is approved for treatment of generalized anxiety disorder.", "question": "Treatment.Duration in Pregabalin is an antiepileptic drug with anti-anxiety properties", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "25295553_2_2436", "context": "Pregabalin is an antiepileptic drug with anti-anxiety properties and is approved for treatment of generalized anxiety disorder.", "question": "Treatment.Disorder in Pregabalin is an antiepileptic drug with anti-anxiety properties", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "generalized anxiety disorder"}, {"id": "25295553_2_2437", "context": "Pregabalin is an antiepileptic drug with anti-anxiety properties and is approved for treatment of generalized anxiety disorder.", "question": "Combination.Drug in Pregabalin is an antiepileptic drug with anti-anxiety properties", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "16615675_4_2438", "context": "We report a case of chronic use of HCQ associated with torsade de pointes.", "question": "Treatment.Drug in chronic use of HCQ", "question_type": "Adverse_event.Treatment.Drug", "answers": "HCQ"}, {"id": "16615675_4_2439", "context": "We report a case of chronic use of HCQ associated with torsade de pointes.", "question": "Treatment.Dosage in chronic use of HCQ", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16615675_4_2440", "context": "We report a case of chronic use of HCQ associated with torsade de pointes.", "question": "Treatment.Freq in chronic use of HCQ", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16615675_4_2441", "context": "We report a case of chronic use of HCQ associated with torsade de pointes.", "question": "Treatment.Route in chronic use of HCQ", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16615675_4_2442", "context": "We report a case of chronic use of HCQ associated with torsade de pointes.", "question": "Treatment.Time_elapsed in chronic use of HCQ", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16615675_4_2443", "context": "We report a case of chronic use of HCQ associated with torsade de pointes.", "question": "Treatment.Duration in chronic use of HCQ", "question_type": "Adverse_event.Treatment.Duration", "answers": "chronic"}, {"id": "16615675_4_2444", "context": "We report a case of chronic use of HCQ associated with torsade de pointes.", "question": "Treatment.Disorder in chronic use of HCQ", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16615675_4_2445", "context": "We report a case of chronic use of HCQ associated with torsade de pointes.", "question": "Combination.Drug in chronic use of HCQ", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17959575_18_2446", "context": "PURPOSE: The occurrence of myoclonus associated with continuous i.v. infusion of dobutamine in a patient with end-stage renal disease (ESRD) is described.", "question": "Subject.Age in a patient with end-stage renal disease (ESRD)", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "17959575_18_2447", "context": "PURPOSE: The occurrence of myoclonus associated with continuous i.v. infusion of dobutamine in a patient with end-stage renal disease (ESRD) is described.", "question": "Subject.Gender in a patient with end-stage renal disease (ESRD)", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "17959575_18_2448", "context": "PURPOSE: The occurrence of myoclonus associated with continuous i.v. infusion of dobutamine in a patient with end-stage renal disease (ESRD) is described.", "question": "Subject.Population in a patient with end-stage renal disease (ESRD)", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "17959575_18_2449", "context": "PURPOSE: The occurrence of myoclonus associated with continuous i.v. infusion of dobutamine in a patient with end-stage renal disease (ESRD) is described.", "question": "Subject.Race in a patient with end-stage renal disease (ESRD)", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "17959575_18_2450", "context": "PURPOSE: The occurrence of myoclonus associated with continuous i.v. infusion of dobutamine in a patient with end-stage renal disease (ESRD) is described.", "question": "Subject.Disorder in a patient with end-stage renal disease (ESRD)", "question_type": "Adverse_event.Subject.Disorder", "answers": "end-stage renal disease (ESRD)"}, {"id": "17959575_18_2451", "context": "PURPOSE: The occurrence of myoclonus associated with continuous i.v. infusion of dobutamine in a patient with end-stage renal disease (ESRD) is described.", "question": "Treatment.Drug in continuous i.v. infusion of dobutamine", "question_type": "Adverse_event.Treatment.Drug", "answers": "dobutamine"}, {"id": "17959575_18_2452", "context": "PURPOSE: The occurrence of myoclonus associated with continuous i.v. infusion of dobutamine in a patient with end-stage renal disease (ESRD) is described.", "question": "Treatment.Dosage in continuous i.v. infusion of dobutamine", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17959575_18_2453", "context": "PURPOSE: The occurrence of myoclonus associated with continuous i.v. infusion of dobutamine in a patient with end-stage renal disease (ESRD) is described.", "question": "Treatment.Freq in continuous i.v. infusion of dobutamine", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17959575_18_2454", "context": "PURPOSE: The occurrence of myoclonus associated with continuous i.v. infusion of dobutamine in a patient with end-stage renal disease (ESRD) is described.", "question": "Treatment.Route in continuous i.v. infusion of dobutamine", "question_type": "Adverse_event.Treatment.Route", "answers": "infusion"}, {"id": "17959575_18_2455", "context": "PURPOSE: The occurrence of myoclonus associated with continuous i.v. infusion of dobutamine in a patient with end-stage renal disease (ESRD) is described.", "question": "Treatment.Time_elapsed in continuous i.v. infusion of dobutamine", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17959575_18_2456", "context": "PURPOSE: The occurrence of myoclonus associated with continuous i.v. infusion of dobutamine in a patient with end-stage renal disease (ESRD) is described.", "question": "Treatment.Duration in continuous i.v. infusion of dobutamine", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17959575_18_2457", "context": "PURPOSE: The occurrence of myoclonus associated with continuous i.v. infusion of dobutamine in a patient with end-stage renal disease (ESRD) is described.", "question": "Treatment.Disorder in continuous i.v. infusion of dobutamine", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17959575_18_2458", "context": "PURPOSE: The occurrence of myoclonus associated with continuous i.v. infusion of dobutamine in a patient with end-stage renal disease (ESRD) is described.", "question": "Combination.Drug in continuous i.v. infusion of dobutamine", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15235919_3_2459", "context": "The case concerns the sudden death of a 29-year-old male during clozapine therapy started 2 weeks before.", "question": "Subject.Age in a 29-year-old male", "question_type": "Adverse_event.Subject.Age", "answers": "29-year-old"}, {"id": "15235919_3_2460", "context": "The case concerns the sudden death of a 29-year-old male during clozapine therapy started 2 weeks before.", "question": "Subject.Gender in a 29-year-old male", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15235919_3_2461", "context": "The case concerns the sudden death of a 29-year-old male during clozapine therapy started 2 weeks before.", "question": "Subject.Population in a 29-year-old male", "question_type": "Adverse_event.Subject.Population", "answers": "male"}, {"id": "15235919_3_2462", "context": "The case concerns the sudden death of a 29-year-old male during clozapine therapy started 2 weeks before.", "question": "Subject.Race in a 29-year-old male", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15235919_3_2463", "context": "The case concerns the sudden death of a 29-year-old male during clozapine therapy started 2 weeks before.", "question": "Subject.Disorder in a 29-year-old male", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15235919_3_2464", "context": "The case concerns the sudden death of a 29-year-old male during clozapine therapy started 2 weeks before.", "question": "Treatment.Drug in clozapine", "question_type": "Adverse_event.Treatment.Drug", "answers": "clozapine"}, {"id": "15235919_3_2465", "context": "The case concerns the sudden death of a 29-year-old male during clozapine therapy started 2 weeks before.", "question": "Treatment.Dosage in clozapine", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15235919_3_2466", "context": "The case concerns the sudden death of a 29-year-old male during clozapine therapy started 2 weeks before.", "question": "Treatment.Freq in clozapine", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15235919_3_2467", "context": "The case concerns the sudden death of a 29-year-old male during clozapine therapy started 2 weeks before.", "question": "Treatment.Route in clozapine", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15235919_3_2468", "context": "The case concerns the sudden death of a 29-year-old male during clozapine therapy started 2 weeks before.", "question": "Treatment.Time_elapsed in clozapine", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "2 weeks before"}, {"id": "15235919_3_2469", "context": "The case concerns the sudden death of a 29-year-old male during clozapine therapy started 2 weeks before.", "question": "Treatment.Duration in clozapine", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15235919_3_2470", "context": "The case concerns the sudden death of a 29-year-old male during clozapine therapy started 2 weeks before.", "question": "Treatment.Disorder in clozapine", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15235919_3_2471", "context": "The case concerns the sudden death of a 29-year-old male during clozapine therapy started 2 weeks before.", "question": "Combination.Drug in clozapine", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12806509_2_2472", "context": "In this paper, we report a case of 3 years-old boy who developed acute onset tetraparesia following a viral respiratory infecction and hepatitis B vaccination.", "question": "Subject.Age in 3 years-old boy", "question_type": "Adverse_event.Subject.Age", "answers": "3 years-old"}, {"id": "12806509_2_2473", "context": "In this paper, we report a case of 3 years-old boy who developed acute onset tetraparesia following a viral respiratory infecction and hepatitis B vaccination.", "question": "Subject.Gender in 3 years-old boy", "question_type": "Adverse_event.Subject.Gender", "answers": "boy"}, {"id": "12806509_2_2474", "context": "In this paper, we report a case of 3 years-old boy who developed acute onset tetraparesia following a viral respiratory infecction and hepatitis B vaccination.", "question": "Subject.Population in 3 years-old boy", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "12806509_2_2475", "context": "In this paper, we report a case of 3 years-old boy who developed acute onset tetraparesia following a viral respiratory infecction and hepatitis B vaccination.", "question": "Subject.Race in 3 years-old boy", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "12806509_2_2476", "context": "In this paper, we report a case of 3 years-old boy who developed acute onset tetraparesia following a viral respiratory infecction and hepatitis B vaccination.", "question": "Subject.Disorder in 3 years-old boy", "question_type": "Adverse_event.Subject.Disorder", "answers": "a viral respiratory infecction"}, {"id": "12806509_2_2477", "context": "In this paper, we report a case of 3 years-old boy who developed acute onset tetraparesia following a viral respiratory infecction and hepatitis B vaccination.", "question": "Treatment.Drug in hepatitis B vaccination", "question_type": "Adverse_event.Treatment.Drug", "answers": "hepatitis B vaccination"}, {"id": "12806509_2_2478", "context": "In this paper, we report a case of 3 years-old boy who developed acute onset tetraparesia following a viral respiratory infecction and hepatitis B vaccination.", "question": "Treatment.Dosage in hepatitis B vaccination", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12806509_2_2479", "context": "In this paper, we report a case of 3 years-old boy who developed acute onset tetraparesia following a viral respiratory infecction and hepatitis B vaccination.", "question": "Treatment.Freq in hepatitis B vaccination", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12806509_2_2480", "context": "In this paper, we report a case of 3 years-old boy who developed acute onset tetraparesia following a viral respiratory infecction and hepatitis B vaccination.", "question": "Treatment.Route in hepatitis B vaccination", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12806509_2_2481", "context": "In this paper, we report a case of 3 years-old boy who developed acute onset tetraparesia following a viral respiratory infecction and hepatitis B vaccination.", "question": "Treatment.Time_elapsed in hepatitis B vaccination", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12806509_2_2482", "context": "In this paper, we report a case of 3 years-old boy who developed acute onset tetraparesia following a viral respiratory infecction and hepatitis B vaccination.", "question": "Treatment.Duration in hepatitis B vaccination", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12806509_2_2483", "context": "In this paper, we report a case of 3 years-old boy who developed acute onset tetraparesia following a viral respiratory infecction and hepatitis B vaccination.", "question": "Treatment.Disorder in hepatitis B vaccination", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12806509_2_2484", "context": "In this paper, we report a case of 3 years-old boy who developed acute onset tetraparesia following a viral respiratory infecction and hepatitis B vaccination.", "question": "Combination.Drug in hepatitis B vaccination", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9925865_6_2485", "context": "Treatment of ELP in children is generally supportive, with the symptoms and roentgenographic abnormalities resolving within months after stopping the use of mineral oil.", "question": "Treatment.Drug in stopping the use of mineral oil", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "mineral oil"}, {"id": "9925865_6_2486", "context": "Treatment of ELP in children is generally supportive, with the symptoms and roentgenographic abnormalities resolving within months after stopping the use of mineral oil.", "question": "Treatment.Dosage in stopping the use of mineral oil", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "9925865_6_2487", "context": "Treatment of ELP in children is generally supportive, with the symptoms and roentgenographic abnormalities resolving within months after stopping the use of mineral oil.", "question": "Treatment.Freq in stopping the use of mineral oil", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "9925865_6_2488", "context": "Treatment of ELP in children is generally supportive, with the symptoms and roentgenographic abnormalities resolving within months after stopping the use of mineral oil.", "question": "Treatment.Route in stopping the use of mineral oil", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "9925865_6_2489", "context": "Treatment of ELP in children is generally supportive, with the symptoms and roentgenographic abnormalities resolving within months after stopping the use of mineral oil.", "question": "Treatment.Time_elapsed in stopping the use of mineral oil", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9925865_6_2490", "context": "Treatment of ELP in children is generally supportive, with the symptoms and roentgenographic abnormalities resolving within months after stopping the use of mineral oil.", "question": "Treatment.Duration in stopping the use of mineral oil", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "9925865_6_2491", "context": "Treatment of ELP in children is generally supportive, with the symptoms and roentgenographic abnormalities resolving within months after stopping the use of mineral oil.", "question": "Treatment.Disorder in stopping the use of mineral oil", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "ELP"}, {"id": "9925865_6_2492", "context": "Treatment of ELP in children is generally supportive, with the symptoms and roentgenographic abnormalities resolving within months after stopping the use of mineral oil.", "question": "Combination.Drug in stopping the use of mineral oil", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "17710018_3_2493", "context": "PET scintigraphy of etoposide-induced pulmonary toxicity.", "question": "Treatment.Drug in etoposide", "question_type": "Adverse_event.Treatment.Drug", "answers": "etoposide"}, {"id": "17710018_3_2494", "context": "PET scintigraphy of etoposide-induced pulmonary toxicity.", "question": "Treatment.Dosage in etoposide", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17710018_3_2495", "context": "PET scintigraphy of etoposide-induced pulmonary toxicity.", "question": "Treatment.Freq in etoposide", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17710018_3_2496", "context": "PET scintigraphy of etoposide-induced pulmonary toxicity.", "question": "Treatment.Route in etoposide", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17710018_3_2497", "context": "PET scintigraphy of etoposide-induced pulmonary toxicity.", "question": "Treatment.Time_elapsed in etoposide", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17710018_3_2498", "context": "PET scintigraphy of etoposide-induced pulmonary toxicity.", "question": "Treatment.Duration in etoposide", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17710018_3_2499", "context": "PET scintigraphy of etoposide-induced pulmonary toxicity.", "question": "Treatment.Disorder in etoposide", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17710018_3_2500", "context": "PET scintigraphy of etoposide-induced pulmonary toxicity.", "question": "Combination.Drug in etoposide", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11807466_2_2501", "context": "We report a patient who experienced LABD shortly after starting carbamazepine therapy.", "question": "Subject.Age in a patient", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "11807466_2_2502", "context": "We report a patient who experienced LABD shortly after starting carbamazepine therapy.", "question": "Subject.Gender in a patient", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "11807466_2_2503", "context": "We report a patient who experienced LABD shortly after starting carbamazepine therapy.", "question": "Subject.Population in a patient", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "11807466_2_2504", "context": "We report a patient who experienced LABD shortly after starting carbamazepine therapy.", "question": "Subject.Race in a patient", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "11807466_2_2505", "context": "We report a patient who experienced LABD shortly after starting carbamazepine therapy.", "question": "Subject.Disorder in a patient", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "11807466_2_2506", "context": "We report a patient who experienced LABD shortly after starting carbamazepine therapy.", "question": "Treatment.Drug in starting carbamazepine therapy", "question_type": "Adverse_event.Treatment.Drug", "answers": "carbamazepine"}, {"id": "11807466_2_2507", "context": "We report a patient who experienced LABD shortly after starting carbamazepine therapy.", "question": "Treatment.Dosage in starting carbamazepine therapy", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11807466_2_2508", "context": "We report a patient who experienced LABD shortly after starting carbamazepine therapy.", "question": "Treatment.Freq in starting carbamazepine therapy", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11807466_2_2509", "context": "We report a patient who experienced LABD shortly after starting carbamazepine therapy.", "question": "Treatment.Route in starting carbamazepine therapy", "question_type": "Adverse_event.Treatment.Route", "answers": "starting"}, {"id": "11807466_2_2510", "context": "We report a patient who experienced LABD shortly after starting carbamazepine therapy.", "question": "Treatment.Time_elapsed in starting carbamazepine therapy", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11807466_2_2511", "context": "We report a patient who experienced LABD shortly after starting carbamazepine therapy.", "question": "Treatment.Duration in starting carbamazepine therapy", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11807466_2_2512", "context": "We report a patient who experienced LABD shortly after starting carbamazepine therapy.", "question": "Treatment.Disorder in starting carbamazepine therapy", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11807466_2_2513", "context": "We report a patient who experienced LABD shortly after starting carbamazepine therapy.", "question": "Combination.Drug in starting carbamazepine therapy", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "1759924_1_2514", "context": "Fulminant metoclopramide induced neuroleptic malignant syndrome rapidly responsive to intravenous dantrolene.", "question": "Treatment.Drug in Fulminant metoclopramide", "question_type": "Adverse_event.Treatment.Drug", "answers": "metoclopramide"}, {"id": "1759924_1_2515", "context": "Fulminant metoclopramide induced neuroleptic malignant syndrome rapidly responsive to intravenous dantrolene.", "question": "Treatment.Dosage in Fulminant metoclopramide", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "1759924_1_2516", "context": "Fulminant metoclopramide induced neuroleptic malignant syndrome rapidly responsive to intravenous dantrolene.", "question": "Treatment.Freq in Fulminant metoclopramide", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "1759924_1_2517", "context": "Fulminant metoclopramide induced neuroleptic malignant syndrome rapidly responsive to intravenous dantrolene.", "question": "Treatment.Route in Fulminant metoclopramide", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "1759924_1_2518", "context": "Fulminant metoclopramide induced neuroleptic malignant syndrome rapidly responsive to intravenous dantrolene.", "question": "Treatment.Time_elapsed in Fulminant metoclopramide", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "1759924_1_2519", "context": "Fulminant metoclopramide induced neuroleptic malignant syndrome rapidly responsive to intravenous dantrolene.", "question": "Treatment.Duration in Fulminant metoclopramide", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "1759924_1_2520", "context": "Fulminant metoclopramide induced neuroleptic malignant syndrome rapidly responsive to intravenous dantrolene.", "question": "Treatment.Disorder in Fulminant metoclopramide", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "1759924_1_2521", "context": "Fulminant metoclopramide induced neuroleptic malignant syndrome rapidly responsive to intravenous dantrolene.", "question": "Combination.Drug in Fulminant metoclopramide", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "19648225_1_2522", "context": "Can ketamine prescribed for pain cause damage to the urinary tract?", "question": "Treatment.Drug in ketamine", "question_type": "Adverse_event.Treatment.Drug", "answers": "ketamine"}, {"id": "19648225_1_2523", "context": "Can ketamine prescribed for pain cause damage to the urinary tract?", "question": "Treatment.Dosage in ketamine", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "19648225_1_2524", "context": "Can ketamine prescribed for pain cause damage to the urinary tract?", "question": "Treatment.Freq in ketamine", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "19648225_1_2525", "context": "Can ketamine prescribed for pain cause damage to the urinary tract?", "question": "Treatment.Route in ketamine", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "19648225_1_2526", "context": "Can ketamine prescribed for pain cause damage to the urinary tract?", "question": "Treatment.Time_elapsed in ketamine", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19648225_1_2527", "context": "Can ketamine prescribed for pain cause damage to the urinary tract?", "question": "Treatment.Duration in ketamine", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "19648225_1_2528", "context": "Can ketamine prescribed for pain cause damage to the urinary tract?", "question": "Treatment.Disorder in ketamine", "question_type": "Adverse_event.Treatment.Disorder", "answers": "pain"}, {"id": "19648225_1_2529", "context": "Can ketamine prescribed for pain cause damage to the urinary tract?", "question": "Combination.Drug in ketamine", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "1450506_3_2530", "context": "Sixteen hours after the first administration of IFN, IFN was suspended by the symptoms of congestive heart failure (CHF).", "question": "Treatment.Drug in IFN", "question_type": "Adverse_event.Treatment.Drug", "answers": "IFN"}, {"id": "1450506_3_2531", "context": "Sixteen hours after the first administration of IFN, IFN was suspended by the symptoms of congestive heart failure (CHF).", "question": "Treatment.Dosage in IFN", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "1450506_3_2532", "context": "Sixteen hours after the first administration of IFN, IFN was suspended by the symptoms of congestive heart failure (CHF).", "question": "Treatment.Freq in IFN", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "1450506_3_2533", "context": "Sixteen hours after the first administration of IFN, IFN was suspended by the symptoms of congestive heart failure (CHF).", "question": "Treatment.Route in IFN", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "1450506_3_2534", "context": "Sixteen hours after the first administration of IFN, IFN was suspended by the symptoms of congestive heart failure (CHF).", "question": "Treatment.Time_elapsed in IFN", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "1450506_3_2535", "context": "Sixteen hours after the first administration of IFN, IFN was suspended by the symptoms of congestive heart failure (CHF).", "question": "Treatment.Duration in IFN", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "1450506_3_2536", "context": "Sixteen hours after the first administration of IFN, IFN was suspended by the symptoms of congestive heart failure (CHF).", "question": "Treatment.Disorder in IFN", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "1450506_3_2537", "context": "Sixteen hours after the first administration of IFN, IFN was suspended by the symptoms of congestive heart failure (CHF).", "question": "Combination.Drug in IFN", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "2924444_8_2538", "context": "We believe this is the first report of myocardial infarction due to coronary spasm, demonstrated by angiography associated with L-thyroxine therapy.", "question": "Treatment.Drug in L-thyroxine", "question_type": "Adverse_event.Treatment.Drug", "answers": "L-thyroxine"}, {"id": "2924444_8_2539", "context": "We believe this is the first report of myocardial infarction due to coronary spasm, demonstrated by angiography associated with L-thyroxine therapy.", "question": "Treatment.Dosage in L-thyroxine", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "2924444_8_2540", "context": "We believe this is the first report of myocardial infarction due to coronary spasm, demonstrated by angiography associated with L-thyroxine therapy.", "question": "Treatment.Freq in L-thyroxine", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2924444_8_2541", "context": "We believe this is the first report of myocardial infarction due to coronary spasm, demonstrated by angiography associated with L-thyroxine therapy.", "question": "Treatment.Route in L-thyroxine", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "2924444_8_2542", "context": "We believe this is the first report of myocardial infarction due to coronary spasm, demonstrated by angiography associated with L-thyroxine therapy.", "question": "Treatment.Time_elapsed in L-thyroxine", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2924444_8_2543", "context": "We believe this is the first report of myocardial infarction due to coronary spasm, demonstrated by angiography associated with L-thyroxine therapy.", "question": "Treatment.Duration in L-thyroxine", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2924444_8_2544", "context": "We believe this is the first report of myocardial infarction due to coronary spasm, demonstrated by angiography associated with L-thyroxine therapy.", "question": "Treatment.Disorder in L-thyroxine", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "2924444_8_2545", "context": "We believe this is the first report of myocardial infarction due to coronary spasm, demonstrated by angiography associated with L-thyroxine therapy.", "question": "Combination.Drug in L-thyroxine", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17952482_1_2546", "context": "A 58-year-old woman with rheumatoid arthritis (RA) developed fever, skin eruptions, leukocytopenia, and thrombocytopenia, 3 weeks after treatment with sulfasalazine.", "question": "Subject.Age in 58-year-old woman with rheumatoid arthritis (RA)", "question_type": "Adverse_event.Subject.Age", "answers": "58-year-old"}, {"id": "17952482_1_2547", "context": "A 58-year-old woman with rheumatoid arthritis (RA) developed fever, skin eruptions, leukocytopenia, and thrombocytopenia, 3 weeks after treatment with sulfasalazine.", "question": "Subject.Gender in 58-year-old woman with rheumatoid arthritis (RA)", "question_type": "Adverse_event.Subject.Gender", "answers": "woman"}, {"id": "17952482_1_2548", "context": "A 58-year-old woman with rheumatoid arthritis (RA) developed fever, skin eruptions, leukocytopenia, and thrombocytopenia, 3 weeks after treatment with sulfasalazine.", "question": "Subject.Population in 58-year-old woman with rheumatoid arthritis (RA)", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "17952482_1_2549", "context": "A 58-year-old woman with rheumatoid arthritis (RA) developed fever, skin eruptions, leukocytopenia, and thrombocytopenia, 3 weeks after treatment with sulfasalazine.", "question": "Subject.Race in 58-year-old woman with rheumatoid arthritis (RA)", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "17952482_1_2550", "context": "A 58-year-old woman with rheumatoid arthritis (RA) developed fever, skin eruptions, leukocytopenia, and thrombocytopenia, 3 weeks after treatment with sulfasalazine.", "question": "Subject.Disorder in 58-year-old woman with rheumatoid arthritis (RA)", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "17952482_1_2551", "context": "A 58-year-old woman with rheumatoid arthritis (RA) developed fever, skin eruptions, leukocytopenia, and thrombocytopenia, 3 weeks after treatment with sulfasalazine.", "question": "Treatment.Drug in 3 weeks after treatment with sulfasalazine", "question_type": "Adverse_event.Treatment.Drug", "answers": "sulfasalazine"}, {"id": "17952482_1_2552", "context": "A 58-year-old woman with rheumatoid arthritis (RA) developed fever, skin eruptions, leukocytopenia, and thrombocytopenia, 3 weeks after treatment with sulfasalazine.", "question": "Treatment.Dosage in 3 weeks after treatment with sulfasalazine", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17952482_1_2553", "context": "A 58-year-old woman with rheumatoid arthritis (RA) developed fever, skin eruptions, leukocytopenia, and thrombocytopenia, 3 weeks after treatment with sulfasalazine.", "question": "Treatment.Freq in 3 weeks after treatment with sulfasalazine", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17952482_1_2554", "context": "A 58-year-old woman with rheumatoid arthritis (RA) developed fever, skin eruptions, leukocytopenia, and thrombocytopenia, 3 weeks after treatment with sulfasalazine.", "question": "Treatment.Route in 3 weeks after treatment with sulfasalazine", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17952482_1_2555", "context": "A 58-year-old woman with rheumatoid arthritis (RA) developed fever, skin eruptions, leukocytopenia, and thrombocytopenia, 3 weeks after treatment with sulfasalazine.", "question": "Treatment.Time_elapsed in 3 weeks after treatment with sulfasalazine", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "3 weeks after"}, {"id": "17952482_1_2556", "context": "A 58-year-old woman with rheumatoid arthritis (RA) developed fever, skin eruptions, leukocytopenia, and thrombocytopenia, 3 weeks after treatment with sulfasalazine.", "question": "Treatment.Duration in 3 weeks after treatment with sulfasalazine", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17952482_1_2557", "context": "A 58-year-old woman with rheumatoid arthritis (RA) developed fever, skin eruptions, leukocytopenia, and thrombocytopenia, 3 weeks after treatment with sulfasalazine.", "question": "Treatment.Disorder in 3 weeks after treatment with sulfasalazine", "question_type": "Adverse_event.Treatment.Disorder", "answers": "rheumatoid arthritis (RA)"}, {"id": "17952482_1_2558", "context": "A 58-year-old woman with rheumatoid arthritis (RA) developed fever, skin eruptions, leukocytopenia, and thrombocytopenia, 3 weeks after treatment with sulfasalazine.", "question": "Combination.Drug in 3 weeks after treatment with sulfasalazine", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3449312_1_2559", "context": "Gold-induced aplastic anemia.", "question": "Treatment.Drug in Gold", "question_type": "Adverse_event.Treatment.Drug", "answers": "Gold"}, {"id": "3449312_1_2560", "context": "Gold-induced aplastic anemia.", "question": "Treatment.Dosage in Gold", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3449312_1_2561", "context": "Gold-induced aplastic anemia.", "question": "Treatment.Freq in Gold", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3449312_1_2562", "context": "Gold-induced aplastic anemia.", "question": "Treatment.Route in Gold", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3449312_1_2563", "context": "Gold-induced aplastic anemia.", "question": "Treatment.Time_elapsed in Gold", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3449312_1_2564", "context": "Gold-induced aplastic anemia.", "question": "Treatment.Duration in Gold", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3449312_1_2565", "context": "Gold-induced aplastic anemia.", "question": "Treatment.Disorder in Gold", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3449312_1_2566", "context": "Gold-induced aplastic anemia.", "question": "Combination.Drug in Gold", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15176542_1_2567", "context": "One patient developed large intramural esophageal hematoma as a complication of heparin therapy.", "question": "Subject.Age in One patient", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "15176542_1_2568", "context": "One patient developed large intramural esophageal hematoma as a complication of heparin therapy.", "question": "Subject.Gender in One patient", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15176542_1_2569", "context": "One patient developed large intramural esophageal hematoma as a complication of heparin therapy.", "question": "Subject.Population in One patient", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "15176542_1_2570", "context": "One patient developed large intramural esophageal hematoma as a complication of heparin therapy.", "question": "Subject.Race in One patient", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15176542_1_2571", "context": "One patient developed large intramural esophageal hematoma as a complication of heparin therapy.", "question": "Subject.Disorder in One patient", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15176542_1_2572", "context": "One patient developed large intramural esophageal hematoma as a complication of heparin therapy.", "question": "Treatment.Drug in a complication of heparin therapy", "question_type": "Adverse_event.Treatment.Drug", "answers": "heparin"}, {"id": "15176542_1_2573", "context": "One patient developed large intramural esophageal hematoma as a complication of heparin therapy.", "question": "Treatment.Dosage in a complication of heparin therapy", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15176542_1_2574", "context": "One patient developed large intramural esophageal hematoma as a complication of heparin therapy.", "question": "Treatment.Freq in a complication of heparin therapy", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15176542_1_2575", "context": "One patient developed large intramural esophageal hematoma as a complication of heparin therapy.", "question": "Treatment.Route in a complication of heparin therapy", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15176542_1_2576", "context": "One patient developed large intramural esophageal hematoma as a complication of heparin therapy.", "question": "Treatment.Time_elapsed in a complication of heparin therapy", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15176542_1_2577", "context": "One patient developed large intramural esophageal hematoma as a complication of heparin therapy.", "question": "Treatment.Duration in a complication of heparin therapy", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15176542_1_2578", "context": "One patient developed large intramural esophageal hematoma as a complication of heparin therapy.", "question": "Treatment.Disorder in a complication of heparin therapy", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15176542_1_2579", "context": "One patient developed large intramural esophageal hematoma as a complication of heparin therapy.", "question": "Combination.Drug in a complication of heparin therapy", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6478628_1_2580", "context": "Mammary gigantism is a rare complication of D-penicillamine treatment.", "question": "Treatment.Drug in D-penicillamine treatment", "question_type": "Adverse_event.Treatment.Drug", "answers": "D-penicillamine"}, {"id": "6478628_1_2581", "context": "Mammary gigantism is a rare complication of D-penicillamine treatment.", "question": "Treatment.Dosage in D-penicillamine treatment", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6478628_1_2582", "context": "Mammary gigantism is a rare complication of D-penicillamine treatment.", "question": "Treatment.Freq in D-penicillamine treatment", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6478628_1_2583", "context": "Mammary gigantism is a rare complication of D-penicillamine treatment.", "question": "Treatment.Route in D-penicillamine treatment", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6478628_1_2584", "context": "Mammary gigantism is a rare complication of D-penicillamine treatment.", "question": "Treatment.Time_elapsed in D-penicillamine treatment", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6478628_1_2585", "context": "Mammary gigantism is a rare complication of D-penicillamine treatment.", "question": "Treatment.Duration in D-penicillamine treatment", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6478628_1_2586", "context": "Mammary gigantism is a rare complication of D-penicillamine treatment.", "question": "Treatment.Disorder in D-penicillamine treatment", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6478628_1_2587", "context": "Mammary gigantism is a rare complication of D-penicillamine treatment.", "question": "Combination.Drug in D-penicillamine treatment", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9681092_8_2588", "context": "Cyclobenzaprine shares anticholinergic effects, tachycardia, and dysrhythmic potential with the tricyclic antidepressants (TCAs).", "question": "Treatment.Drug in Cyclobenzaprine; with the tricyclic antidepressants (TCAs)", "question_type": "Adverse_event.Treatment.Drug", "answers": "Cyclobenzaprine; tricyclic antidepressants"}, {"id": "9681092_8_2589", "context": "Cyclobenzaprine shares anticholinergic effects, tachycardia, and dysrhythmic potential with the tricyclic antidepressants (TCAs).", "question": "Treatment.Dosage in Cyclobenzaprine; with the tricyclic antidepressants (TCAs)", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9681092_8_2590", "context": "Cyclobenzaprine shares anticholinergic effects, tachycardia, and dysrhythmic potential with the tricyclic antidepressants (TCAs).", "question": "Treatment.Freq in Cyclobenzaprine; with the tricyclic antidepressants (TCAs)", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9681092_8_2591", "context": "Cyclobenzaprine shares anticholinergic effects, tachycardia, and dysrhythmic potential with the tricyclic antidepressants (TCAs).", "question": "Treatment.Route in Cyclobenzaprine; with the tricyclic antidepressants (TCAs)", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9681092_8_2592", "context": "Cyclobenzaprine shares anticholinergic effects, tachycardia, and dysrhythmic potential with the tricyclic antidepressants (TCAs).", "question": "Treatment.Time_elapsed in Cyclobenzaprine; with the tricyclic antidepressants (TCAs)", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9681092_8_2593", "context": "Cyclobenzaprine shares anticholinergic effects, tachycardia, and dysrhythmic potential with the tricyclic antidepressants (TCAs).", "question": "Treatment.Duration in Cyclobenzaprine; with the tricyclic antidepressants (TCAs)", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9681092_8_2594", "context": "Cyclobenzaprine shares anticholinergic effects, tachycardia, and dysrhythmic potential with the tricyclic antidepressants (TCAs).", "question": "Treatment.Disorder in Cyclobenzaprine; with the tricyclic antidepressants (TCAs)", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9681092_8_2595", "context": "Cyclobenzaprine shares anticholinergic effects, tachycardia, and dysrhythmic potential with the tricyclic antidepressants (TCAs).", "question": "Combination.Drug in Cyclobenzaprine; with the tricyclic antidepressants (TCAs)", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15235919_2_2596", "context": "The autopsy findings and a detailed medical history supported the conclusion that clozapine-induced hypersensitivity myocarditis was the most likely cause of death.", "question": "Treatment.Drug in clozapine", "question_type": "Adverse_event.Treatment.Drug", "answers": "clozapine"}, {"id": "15235919_2_2597", "context": "The autopsy findings and a detailed medical history supported the conclusion that clozapine-induced hypersensitivity myocarditis was the most likely cause of death.", "question": "Treatment.Dosage in clozapine", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15235919_2_2598", "context": "The autopsy findings and a detailed medical history supported the conclusion that clozapine-induced hypersensitivity myocarditis was the most likely cause of death.", "question": "Treatment.Freq in clozapine", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15235919_2_2599", "context": "The autopsy findings and a detailed medical history supported the conclusion that clozapine-induced hypersensitivity myocarditis was the most likely cause of death.", "question": "Treatment.Route in clozapine", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15235919_2_2600", "context": "The autopsy findings and a detailed medical history supported the conclusion that clozapine-induced hypersensitivity myocarditis was the most likely cause of death.", "question": "Treatment.Time_elapsed in clozapine", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15235919_2_2601", "context": "The autopsy findings and a detailed medical history supported the conclusion that clozapine-induced hypersensitivity myocarditis was the most likely cause of death.", "question": "Treatment.Duration in clozapine", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15235919_2_2602", "context": "The autopsy findings and a detailed medical history supported the conclusion that clozapine-induced hypersensitivity myocarditis was the most likely cause of death.", "question": "Treatment.Disorder in clozapine", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15235919_2_2603", "context": "The autopsy findings and a detailed medical history supported the conclusion that clozapine-induced hypersensitivity myocarditis was the most likely cause of death.", "question": "Combination.Drug in clozapine", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9466030_3_2604", "context": "PURPOSE: To present a case of respiratory depression following the administration of nebulised morphine.", "question": "Treatment.Drug in nebulised morphine", "question_type": "Adverse_event.Treatment.Drug", "answers": "morphine"}, {"id": "9466030_3_2605", "context": "PURPOSE: To present a case of respiratory depression following the administration of nebulised morphine.", "question": "Treatment.Dosage in nebulised morphine", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9466030_3_2606", "context": "PURPOSE: To present a case of respiratory depression following the administration of nebulised morphine.", "question": "Treatment.Freq in nebulised morphine", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9466030_3_2607", "context": "PURPOSE: To present a case of respiratory depression following the administration of nebulised morphine.", "question": "Treatment.Route in nebulised morphine", "question_type": "Adverse_event.Treatment.Route", "answers": "nebulised"}, {"id": "9466030_3_2608", "context": "PURPOSE: To present a case of respiratory depression following the administration of nebulised morphine.", "question": "Treatment.Time_elapsed in nebulised morphine", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9466030_3_2609", "context": "PURPOSE: To present a case of respiratory depression following the administration of nebulised morphine.", "question": "Treatment.Duration in nebulised morphine", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9466030_3_2610", "context": "PURPOSE: To present a case of respiratory depression following the administration of nebulised morphine.", "question": "Treatment.Disorder in nebulised morphine", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9466030_3_2611", "context": "PURPOSE: To present a case of respiratory depression following the administration of nebulised morphine.", "question": "Combination.Drug in nebulised morphine", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11554897_3_2612", "context": "METHODS: A 55-year-old woman became stuporous after overdose with lamotrigine (LTG) and valproic acid (VPA) tablets.", "question": "Subject.Age in A 55-year-old woman", "question_type": "Adverse_event.Subject.Age", "answers": "55-year-old"}, {"id": "11554897_3_2613", "context": "METHODS: A 55-year-old woman became stuporous after overdose with lamotrigine (LTG) and valproic acid (VPA) tablets.", "question": "Subject.Gender in A 55-year-old woman", "question_type": "Adverse_event.Subject.Gender", "answers": "woman"}, {"id": "11554897_3_2614", "context": "METHODS: A 55-year-old woman became stuporous after overdose with lamotrigine (LTG) and valproic acid (VPA) tablets.", "question": "Subject.Population in A 55-year-old woman", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "11554897_3_2615", "context": "METHODS: A 55-year-old woman became stuporous after overdose with lamotrigine (LTG) and valproic acid (VPA) tablets.", "question": "Subject.Race in A 55-year-old woman", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "11554897_3_2616", "context": "METHODS: A 55-year-old woman became stuporous after overdose with lamotrigine (LTG) and valproic acid (VPA) tablets.", "question": "Subject.Disorder in A 55-year-old woman", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "11554897_3_2617", "context": "METHODS: A 55-year-old woman became stuporous after overdose with lamotrigine (LTG) and valproic acid (VPA) tablets.", "question": "Treatment.Drug in overdose with lamotrigine (LTG) and valproic acid (VPA) tablets", "question_type": "Adverse_event.Treatment.Drug", "answers": "lamotrigine; valproic acid"}, {"id": "11554897_3_2618", "context": "METHODS: A 55-year-old woman became stuporous after overdose with lamotrigine (LTG) and valproic acid (VPA) tablets.", "question": "Treatment.Dosage in overdose with lamotrigine (LTG) and valproic acid (VPA) tablets", "question_type": "Adverse_event.Treatment.Dosage", "answers": "overdose"}, {"id": "11554897_3_2619", "context": "METHODS: A 55-year-old woman became stuporous after overdose with lamotrigine (LTG) and valproic acid (VPA) tablets.", "question": "Treatment.Freq in overdose with lamotrigine (LTG) and valproic acid (VPA) tablets", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11554897_3_2620", "context": "METHODS: A 55-year-old woman became stuporous after overdose with lamotrigine (LTG) and valproic acid (VPA) tablets.", "question": "Treatment.Route in overdose with lamotrigine (LTG) and valproic acid (VPA) tablets", "question_type": "Adverse_event.Treatment.Route", "answers": "tablets"}, {"id": "11554897_3_2621", "context": "METHODS: A 55-year-old woman became stuporous after overdose with lamotrigine (LTG) and valproic acid (VPA) tablets.", "question": "Treatment.Time_elapsed in overdose with lamotrigine (LTG) and valproic acid (VPA) tablets", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11554897_3_2622", "context": "METHODS: A 55-year-old woman became stuporous after overdose with lamotrigine (LTG) and valproic acid (VPA) tablets.", "question": "Treatment.Duration in overdose with lamotrigine (LTG) and valproic acid (VPA) tablets", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11554897_3_2623", "context": "METHODS: A 55-year-old woman became stuporous after overdose with lamotrigine (LTG) and valproic acid (VPA) tablets.", "question": "Treatment.Disorder in overdose with lamotrigine (LTG) and valproic acid (VPA) tablets", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11554897_3_2624", "context": "METHODS: A 55-year-old woman became stuporous after overdose with lamotrigine (LTG) and valproic acid (VPA) tablets.", "question": "Combination.Drug in overdose with lamotrigine (LTG) and valproic acid (VPA) tablets", "question_type": "Adverse_event.Combination.Drug", "answers": "lamotrigine; valproic acid"}, {"id": "16099004_1_2625", "context": "Recrudescence of imported falciparum malaria after quinine therapy: potential drug interaction with phenytoin.", "question": "Treatment.Drug in quinine; phenytoin", "question_type": "Adverse_event.Treatment.Drug", "answers": "quinine; phenytoin"}, {"id": "16099004_1_2626", "context": "Recrudescence of imported falciparum malaria after quinine therapy: potential drug interaction with phenytoin.", "question": "Treatment.Dosage in quinine; phenytoin", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16099004_1_2627", "context": "Recrudescence of imported falciparum malaria after quinine therapy: potential drug interaction with phenytoin.", "question": "Treatment.Freq in quinine; phenytoin", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16099004_1_2628", "context": "Recrudescence of imported falciparum malaria after quinine therapy: potential drug interaction with phenytoin.", "question": "Treatment.Route in quinine; phenytoin", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16099004_1_2629", "context": "Recrudescence of imported falciparum malaria after quinine therapy: potential drug interaction with phenytoin.", "question": "Treatment.Time_elapsed in quinine; phenytoin", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16099004_1_2630", "context": "Recrudescence of imported falciparum malaria after quinine therapy: potential drug interaction with phenytoin.", "question": "Treatment.Duration in quinine; phenytoin", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16099004_1_2631", "context": "Recrudescence of imported falciparum malaria after quinine therapy: potential drug interaction with phenytoin.", "question": "Treatment.Disorder in quinine; phenytoin", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16099004_1_2632", "context": "Recrudescence of imported falciparum malaria after quinine therapy: potential drug interaction with phenytoin.", "question": "Combination.Drug in quinine; phenytoin", "question_type": "Adverse_event.Combination.Drug", "answers": "phenytoin; quinine"}, {"id": "11978156_1_2633", "context": "CONCLUSIONS: Clinicians should be aware of the possible association of thrombocytopenia with lansoprazole and discontinue the drug if thrombocytopenia becomes apparent.", "question": "Treatment.Drug in lansoprazole", "question_type": "Adverse_event.Treatment.Drug", "answers": "lansoprazole"}, {"id": "11978156_1_2634", "context": "CONCLUSIONS: Clinicians should be aware of the possible association of thrombocytopenia with lansoprazole and discontinue the drug if thrombocytopenia becomes apparent.", "question": "Treatment.Dosage in lansoprazole", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11978156_1_2635", "context": "CONCLUSIONS: Clinicians should be aware of the possible association of thrombocytopenia with lansoprazole and discontinue the drug if thrombocytopenia becomes apparent.", "question": "Treatment.Freq in lansoprazole", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11978156_1_2636", "context": "CONCLUSIONS: Clinicians should be aware of the possible association of thrombocytopenia with lansoprazole and discontinue the drug if thrombocytopenia becomes apparent.", "question": "Treatment.Route in lansoprazole", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11978156_1_2637", "context": "CONCLUSIONS: Clinicians should be aware of the possible association of thrombocytopenia with lansoprazole and discontinue the drug if thrombocytopenia becomes apparent.", "question": "Treatment.Time_elapsed in lansoprazole", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11978156_1_2638", "context": "CONCLUSIONS: Clinicians should be aware of the possible association of thrombocytopenia with lansoprazole and discontinue the drug if thrombocytopenia becomes apparent.", "question": "Treatment.Duration in lansoprazole", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11978156_1_2639", "context": "CONCLUSIONS: Clinicians should be aware of the possible association of thrombocytopenia with lansoprazole and discontinue the drug if thrombocytopenia becomes apparent.", "question": "Treatment.Disorder in lansoprazole", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11978156_1_2640", "context": "CONCLUSIONS: Clinicians should be aware of the possible association of thrombocytopenia with lansoprazole and discontinue the drug if thrombocytopenia becomes apparent.", "question": "Combination.Drug in lansoprazole", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3549808_1_2641", "context": "One of the subjects who was using extemporaneous topical minoxidil had hypertension and arteriosclerotic disease and the other died of a myocardial infarction.", "question": "Subject.Age in One of the subjects", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "3549808_1_2642", "context": "One of the subjects who was using extemporaneous topical minoxidil had hypertension and arteriosclerotic disease and the other died of a myocardial infarction.", "question": "Subject.Gender in One of the subjects", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "3549808_1_2643", "context": "One of the subjects who was using extemporaneous topical minoxidil had hypertension and arteriosclerotic disease and the other died of a myocardial infarction.", "question": "Subject.Population in One of the subjects", "question_type": "Adverse_event.Subject.Population", "answers": "One"}, {"id": "3549808_1_2644", "context": "One of the subjects who was using extemporaneous topical minoxidil had hypertension and arteriosclerotic disease and the other died of a myocardial infarction.", "question": "Subject.Race in One of the subjects", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "3549808_1_2645", "context": "One of the subjects who was using extemporaneous topical minoxidil had hypertension and arteriosclerotic disease and the other died of a myocardial infarction.", "question": "Subject.Disorder in One of the subjects", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "3549808_1_2646", "context": "One of the subjects who was using extemporaneous topical minoxidil had hypertension and arteriosclerotic disease and the other died of a myocardial infarction.", "question": "Treatment.Drug in extemporaneous topical minoxidil", "question_type": "Adverse_event.Treatment.Drug", "answers": "minoxidil"}, {"id": "3549808_1_2647", "context": "One of the subjects who was using extemporaneous topical minoxidil had hypertension and arteriosclerotic disease and the other died of a myocardial infarction.", "question": "Treatment.Dosage in extemporaneous topical minoxidil", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3549808_1_2648", "context": "One of the subjects who was using extemporaneous topical minoxidil had hypertension and arteriosclerotic disease and the other died of a myocardial infarction.", "question": "Treatment.Freq in extemporaneous topical minoxidil", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3549808_1_2649", "context": "One of the subjects who was using extemporaneous topical minoxidil had hypertension and arteriosclerotic disease and the other died of a myocardial infarction.", "question": "Treatment.Route in extemporaneous topical minoxidil", "question_type": "Adverse_event.Treatment.Route", "answers": "topical"}, {"id": "3549808_1_2650", "context": "One of the subjects who was using extemporaneous topical minoxidil had hypertension and arteriosclerotic disease and the other died of a myocardial infarction.", "question": "Treatment.Time_elapsed in extemporaneous topical minoxidil", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3549808_1_2651", "context": "One of the subjects who was using extemporaneous topical minoxidil had hypertension and arteriosclerotic disease and the other died of a myocardial infarction.", "question": "Treatment.Duration in extemporaneous topical minoxidil", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3549808_1_2652", "context": "One of the subjects who was using extemporaneous topical minoxidil had hypertension and arteriosclerotic disease and the other died of a myocardial infarction.", "question": "Treatment.Disorder in extemporaneous topical minoxidil", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3549808_1_2653", "context": "One of the subjects who was using extemporaneous topical minoxidil had hypertension and arteriosclerotic disease and the other died of a myocardial infarction.", "question": "Combination.Drug in extemporaneous topical minoxidil", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3549808_1_2654", "context": "One of the subjects who was using extemporaneous topical minoxidil had hypertension and arteriosclerotic disease and the other died of a myocardial infarction.", "question": "Subject.Age in the other", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "3549808_1_2655", "context": "One of the subjects who was using extemporaneous topical minoxidil had hypertension and arteriosclerotic disease and the other died of a myocardial infarction.", "question": "Subject.Gender in the other", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "3549808_1_2656", "context": "One of the subjects who was using extemporaneous topical minoxidil had hypertension and arteriosclerotic disease and the other died of a myocardial infarction.", "question": "Subject.Population in the other", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "3549808_1_2657", "context": "One of the subjects who was using extemporaneous topical minoxidil had hypertension and arteriosclerotic disease and the other died of a myocardial infarction.", "question": "Subject.Race in the other", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "3549808_1_2658", "context": "One of the subjects who was using extemporaneous topical minoxidil had hypertension and arteriosclerotic disease and the other died of a myocardial infarction.", "question": "Subject.Disorder in the other", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "3549808_1_2659", "context": "One of the subjects who was using extemporaneous topical minoxidil had hypertension and arteriosclerotic disease and the other died of a myocardial infarction.", "question": "Treatment.Drug in extemporaneous topical minoxidil", "question_type": "Adverse_event.Treatment.Drug", "answers": "minoxidil"}, {"id": "3549808_1_2660", "context": "One of the subjects who was using extemporaneous topical minoxidil had hypertension and arteriosclerotic disease and the other died of a myocardial infarction.", "question": "Treatment.Dosage in extemporaneous topical minoxidil", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3549808_1_2661", "context": "One of the subjects who was using extemporaneous topical minoxidil had hypertension and arteriosclerotic disease and the other died of a myocardial infarction.", "question": "Treatment.Freq in extemporaneous topical minoxidil", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3549808_1_2662", "context": "One of the subjects who was using extemporaneous topical minoxidil had hypertension and arteriosclerotic disease and the other died of a myocardial infarction.", "question": "Treatment.Route in extemporaneous topical minoxidil", "question_type": "Adverse_event.Treatment.Route", "answers": "topical"}, {"id": "3549808_1_2663", "context": "One of the subjects who was using extemporaneous topical minoxidil had hypertension and arteriosclerotic disease and the other died of a myocardial infarction.", "question": "Treatment.Time_elapsed in extemporaneous topical minoxidil", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3549808_1_2664", "context": "One of the subjects who was using extemporaneous topical minoxidil had hypertension and arteriosclerotic disease and the other died of a myocardial infarction.", "question": "Treatment.Duration in extemporaneous topical minoxidil", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3549808_1_2665", "context": "One of the subjects who was using extemporaneous topical minoxidil had hypertension and arteriosclerotic disease and the other died of a myocardial infarction.", "question": "Treatment.Disorder in extemporaneous topical minoxidil", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3549808_1_2666", "context": "One of the subjects who was using extemporaneous topical minoxidil had hypertension and arteriosclerotic disease and the other died of a myocardial infarction.", "question": "Combination.Drug in extemporaneous topical minoxidil", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12390172_1_2667", "context": "CONCLUSION: Long-term treatment with rifabutin may have a reversible and previously undescribed side-effect on retinal function.", "question": "Treatment.Drug in rifabutin", "question_type": "Adverse_event.Treatment.Drug", "answers": "rifabutin"}, {"id": "12390172_1_2668", "context": "CONCLUSION: Long-term treatment with rifabutin may have a reversible and previously undescribed side-effect on retinal function.", "question": "Treatment.Dosage in rifabutin", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12390172_1_2669", "context": "CONCLUSION: Long-term treatment with rifabutin may have a reversible and previously undescribed side-effect on retinal function.", "question": "Treatment.Freq in rifabutin", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12390172_1_2670", "context": "CONCLUSION: Long-term treatment with rifabutin may have a reversible and previously undescribed side-effect on retinal function.", "question": "Treatment.Route in rifabutin", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12390172_1_2671", "context": "CONCLUSION: Long-term treatment with rifabutin may have a reversible and previously undescribed side-effect on retinal function.", "question": "Treatment.Time_elapsed in rifabutin", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12390172_1_2672", "context": "CONCLUSION: Long-term treatment with rifabutin may have a reversible and previously undescribed side-effect on retinal function.", "question": "Treatment.Duration in rifabutin", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12390172_1_2673", "context": "CONCLUSION: Long-term treatment with rifabutin may have a reversible and previously undescribed side-effect on retinal function.", "question": "Treatment.Disorder in rifabutin", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12390172_1_2674", "context": "CONCLUSION: Long-term treatment with rifabutin may have a reversible and previously undescribed side-effect on retinal function.", "question": "Combination.Drug in rifabutin", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6628806_2_2675", "context": "Toxic hepatitis due to combination therapy with methotrexate and etretinate in psoriasis.", "question": "Treatment.Drug in methotrexate and etretinate", "question_type": "Adverse_event.Treatment.Drug", "answers": "methotrexate; etretinate"}, {"id": "6628806_2_2676", "context": "Toxic hepatitis due to combination therapy with methotrexate and etretinate in psoriasis.", "question": "Treatment.Dosage in methotrexate and etretinate", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6628806_2_2677", "context": "Toxic hepatitis due to combination therapy with methotrexate and etretinate in psoriasis.", "question": "Treatment.Freq in methotrexate and etretinate", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6628806_2_2678", "context": "Toxic hepatitis due to combination therapy with methotrexate and etretinate in psoriasis.", "question": "Treatment.Route in methotrexate and etretinate", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6628806_2_2679", "context": "Toxic hepatitis due to combination therapy with methotrexate and etretinate in psoriasis.", "question": "Treatment.Time_elapsed in methotrexate and etretinate", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6628806_2_2680", "context": "Toxic hepatitis due to combination therapy with methotrexate and etretinate in psoriasis.", "question": "Treatment.Duration in methotrexate and etretinate", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6628806_2_2681", "context": "Toxic hepatitis due to combination therapy with methotrexate and etretinate in psoriasis.", "question": "Treatment.Disorder in methotrexate and etretinate", "question_type": "Adverse_event.Treatment.Disorder", "answers": "psoriasis"}, {"id": "6628806_2_2682", "context": "Toxic hepatitis due to combination therapy with methotrexate and etretinate in psoriasis.", "question": "Combination.Drug in methotrexate and etretinate", "question_type": "Adverse_event.Combination.Drug", "answers": "methotrexate; etretinate"}, {"id": "19934385_2_2683", "context": "To report the results of therapeutic drug monitoring of lopinavir/ritonavir and itraconazole concentrations in an HIV-infected male who was treated for histoplasmosis.", "question": "Subject.Age in an HIV-infected male", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "19934385_2_2684", "context": "To report the results of therapeutic drug monitoring of lopinavir/ritonavir and itraconazole concentrations in an HIV-infected male who was treated for histoplasmosis.", "question": "Subject.Gender in an HIV-infected male", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": "male"}, {"id": "19934385_2_2685", "context": "To report the results of therapeutic drug monitoring of lopinavir/ritonavir and itraconazole concentrations in an HIV-infected male who was treated for histoplasmosis.", "question": "Subject.Population in an HIV-infected male", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "19934385_2_2686", "context": "To report the results of therapeutic drug monitoring of lopinavir/ritonavir and itraconazole concentrations in an HIV-infected male who was treated for histoplasmosis.", "question": "Subject.Race in an HIV-infected male", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "19934385_2_2687", "context": "To report the results of therapeutic drug monitoring of lopinavir/ritonavir and itraconazole concentrations in an HIV-infected male who was treated for histoplasmosis.", "question": "Subject.Disorder in an HIV-infected male", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "19934385_2_2688", "context": "To report the results of therapeutic drug monitoring of lopinavir/ritonavir and itraconazole concentrations in an HIV-infected male who was treated for histoplasmosis.", "question": "Treatment.Drug in lopinavir/ritonavir and itraconazole concentrations", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "itraconazole; ritonavir; lopinavir"}, {"id": "19934385_2_2689", "context": "To report the results of therapeutic drug monitoring of lopinavir/ritonavir and itraconazole concentrations in an HIV-infected male who was treated for histoplasmosis.", "question": "Treatment.Dosage in lopinavir/ritonavir and itraconazole concentrations", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "19934385_2_2690", "context": "To report the results of therapeutic drug monitoring of lopinavir/ritonavir and itraconazole concentrations in an HIV-infected male who was treated for histoplasmosis.", "question": "Treatment.Freq in lopinavir/ritonavir and itraconazole concentrations", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "19934385_2_2691", "context": "To report the results of therapeutic drug monitoring of lopinavir/ritonavir and itraconazole concentrations in an HIV-infected male who was treated for histoplasmosis.", "question": "Treatment.Route in lopinavir/ritonavir and itraconazole concentrations", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "19934385_2_2692", "context": "To report the results of therapeutic drug monitoring of lopinavir/ritonavir and itraconazole concentrations in an HIV-infected male who was treated for histoplasmosis.", "question": "Treatment.Time_elapsed in lopinavir/ritonavir and itraconazole concentrations", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19934385_2_2693", "context": "To report the results of therapeutic drug monitoring of lopinavir/ritonavir and itraconazole concentrations in an HIV-infected male who was treated for histoplasmosis.", "question": "Treatment.Duration in lopinavir/ritonavir and itraconazole concentrations", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "19934385_2_2694", "context": "To report the results of therapeutic drug monitoring of lopinavir/ritonavir and itraconazole concentrations in an HIV-infected male who was treated for histoplasmosis.", "question": "Treatment.Disorder in lopinavir/ritonavir and itraconazole concentrations", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "histoplasmosis; HIV"}, {"id": "19934385_2_2695", "context": "To report the results of therapeutic drug monitoring of lopinavir/ritonavir and itraconazole concentrations in an HIV-infected male who was treated for histoplasmosis.", "question": "Combination.Drug in lopinavir/ritonavir and itraconazole concentrations", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": "lopinavir; ritonavir; itraconazole"}, {"id": "11476690_1_2696", "context": "Ulcer became worse after tobramycin and gentamycin treatment for 2 days.", "question": "Treatment.Drug in tobramycin and gentamycin", "question_type": "Adverse_event.Treatment.Drug", "answers": "tobramycin; gentamycin"}, {"id": "11476690_1_2697", "context": "Ulcer became worse after tobramycin and gentamycin treatment for 2 days.", "question": "Treatment.Dosage in tobramycin and gentamycin", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11476690_1_2698", "context": "Ulcer became worse after tobramycin and gentamycin treatment for 2 days.", "question": "Treatment.Freq in tobramycin and gentamycin", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11476690_1_2699", "context": "Ulcer became worse after tobramycin and gentamycin treatment for 2 days.", "question": "Treatment.Route in tobramycin and gentamycin", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11476690_1_2700", "context": "Ulcer became worse after tobramycin and gentamycin treatment for 2 days.", "question": "Treatment.Time_elapsed in tobramycin and gentamycin", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11476690_1_2701", "context": "Ulcer became worse after tobramycin and gentamycin treatment for 2 days.", "question": "Treatment.Duration in tobramycin and gentamycin", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11476690_1_2702", "context": "Ulcer became worse after tobramycin and gentamycin treatment for 2 days.", "question": "Treatment.Disorder in tobramycin and gentamycin", "question_type": "Adverse_event.Treatment.Disorder", "answers": "Ulcer"}, {"id": "11476690_1_2703", "context": "Ulcer became worse after tobramycin and gentamycin treatment for 2 days.", "question": "Combination.Drug in tobramycin and gentamycin", "question_type": "Adverse_event.Combination.Drug", "answers": "gentamycin; tobramycin"}, {"id": "12149193_3_2704", "context": "Thalidomide has proven activity in refractory multiple myeloma (MM), and although single-agent thalidomide has minimal prothrombogenic activity, its combination with cytotoxic chemotherapy is associated with a significantly increased risk of DVT.", "question": "Treatment.Drug in single-agent thalidomide; combination with cytotoxic chemotherapy", "question_type": "Adverse_event.Treatment.Drug", "answers": "thalidomide; cytotoxic"}, {"id": "12149193_3_2705", "context": "Thalidomide has proven activity in refractory multiple myeloma (MM), and although single-agent thalidomide has minimal prothrombogenic activity, its combination with cytotoxic chemotherapy is associated with a significantly increased risk of DVT.", "question": "Treatment.Dosage in single-agent thalidomide; combination with cytotoxic chemotherapy", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12149193_3_2706", "context": "Thalidomide has proven activity in refractory multiple myeloma (MM), and although single-agent thalidomide has minimal prothrombogenic activity, its combination with cytotoxic chemotherapy is associated with a significantly increased risk of DVT.", "question": "Treatment.Freq in single-agent thalidomide; combination with cytotoxic chemotherapy", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12149193_3_2707", "context": "Thalidomide has proven activity in refractory multiple myeloma (MM), and although single-agent thalidomide has minimal prothrombogenic activity, its combination with cytotoxic chemotherapy is associated with a significantly increased risk of DVT.", "question": "Treatment.Route in single-agent thalidomide; combination with cytotoxic chemotherapy", "question_type": "Adverse_event.Treatment.Route", "answers": "chemotherapy"}, {"id": "12149193_3_2708", "context": "Thalidomide has proven activity in refractory multiple myeloma (MM), and although single-agent thalidomide has minimal prothrombogenic activity, its combination with cytotoxic chemotherapy is associated with a significantly increased risk of DVT.", "question": "Treatment.Time_elapsed in single-agent thalidomide; combination with cytotoxic chemotherapy", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12149193_3_2709", "context": "Thalidomide has proven activity in refractory multiple myeloma (MM), and although single-agent thalidomide has minimal prothrombogenic activity, its combination with cytotoxic chemotherapy is associated with a significantly increased risk of DVT.", "question": "Treatment.Duration in single-agent thalidomide; combination with cytotoxic chemotherapy", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12149193_3_2710", "context": "Thalidomide has proven activity in refractory multiple myeloma (MM), and although single-agent thalidomide has minimal prothrombogenic activity, its combination with cytotoxic chemotherapy is associated with a significantly increased risk of DVT.", "question": "Treatment.Disorder in single-agent thalidomide; combination with cytotoxic chemotherapy", "question_type": "Adverse_event.Treatment.Disorder", "answers": "refractory multiple myeloma (MM)"}, {"id": "12149193_3_2711", "context": "Thalidomide has proven activity in refractory multiple myeloma (MM), and although single-agent thalidomide has minimal prothrombogenic activity, its combination with cytotoxic chemotherapy is associated with a significantly increased risk of DVT.", "question": "Combination.Drug in single-agent thalidomide; combination with cytotoxic chemotherapy", "question_type": "Adverse_event.Combination.Drug", "answers": "thalidomide; cytotoxic"}, {"id": "2357706_3_2712", "context": "These cases indicate that sulpiride can cause tardive dyskinesia and that this drug should be administered with caution.", "question": "Treatment.Drug in sulpiride", "question_type": "Adverse_event.Treatment.Drug", "answers": "sulpiride"}, {"id": "2357706_3_2713", "context": "These cases indicate that sulpiride can cause tardive dyskinesia and that this drug should be administered with caution.", "question": "Treatment.Dosage in sulpiride", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "2357706_3_2714", "context": "These cases indicate that sulpiride can cause tardive dyskinesia and that this drug should be administered with caution.", "question": "Treatment.Freq in sulpiride", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2357706_3_2715", "context": "These cases indicate that sulpiride can cause tardive dyskinesia and that this drug should be administered with caution.", "question": "Treatment.Route in sulpiride", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "2357706_3_2716", "context": "These cases indicate that sulpiride can cause tardive dyskinesia and that this drug should be administered with caution.", "question": "Treatment.Time_elapsed in sulpiride", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2357706_3_2717", "context": "These cases indicate that sulpiride can cause tardive dyskinesia and that this drug should be administered with caution.", "question": "Treatment.Duration in sulpiride", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2357706_3_2718", "context": "These cases indicate that sulpiride can cause tardive dyskinesia and that this drug should be administered with caution.", "question": "Treatment.Disorder in sulpiride", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "2357706_3_2719", "context": "These cases indicate that sulpiride can cause tardive dyskinesia and that this drug should be administered with caution.", "question": "Combination.Drug in sulpiride", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7789881_4_2720", "context": "Well-differentiated endometrial adenocarcinoma of the secretory type (FIGO Grade 1) with minimal myometrial invasion occurred in a postmenopausal patient on tamoxifen therapy 5 years after mastectomy for breast carcinoma.", "question": "Subject.Age in a postmenopausal patient", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "7789881_4_2721", "context": "Well-differentiated endometrial adenocarcinoma of the secretory type (FIGO Grade 1) with minimal myometrial invasion occurred in a postmenopausal patient on tamoxifen therapy 5 years after mastectomy for breast carcinoma.", "question": "Subject.Gender in a postmenopausal patient", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "7789881_4_2722", "context": "Well-differentiated endometrial adenocarcinoma of the secretory type (FIGO Grade 1) with minimal myometrial invasion occurred in a postmenopausal patient on tamoxifen therapy 5 years after mastectomy for breast carcinoma.", "question": "Subject.Population in a postmenopausal patient", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "7789881_4_2723", "context": "Well-differentiated endometrial adenocarcinoma of the secretory type (FIGO Grade 1) with minimal myometrial invasion occurred in a postmenopausal patient on tamoxifen therapy 5 years after mastectomy for breast carcinoma.", "question": "Subject.Race in a postmenopausal patient", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "7789881_4_2724", "context": "Well-differentiated endometrial adenocarcinoma of the secretory type (FIGO Grade 1) with minimal myometrial invasion occurred in a postmenopausal patient on tamoxifen therapy 5 years after mastectomy for breast carcinoma.", "question": "Subject.Disorder in a postmenopausal patient", "question_type": "Adverse_event.Subject.Disorder", "answers": "postmenopausal"}, {"id": "7789881_4_2725", "context": "Well-differentiated endometrial adenocarcinoma of the secretory type (FIGO Grade 1) with minimal myometrial invasion occurred in a postmenopausal patient on tamoxifen therapy 5 years after mastectomy for breast carcinoma.", "question": "Treatment.Drug in tamoxifen therapy 5 years after mastectomy for breast carcinoma.", "question_type": "Adverse_event.Treatment.Drug", "answers": "tamoxifen"}, {"id": "7789881_4_2726", "context": "Well-differentiated endometrial adenocarcinoma of the secretory type (FIGO Grade 1) with minimal myometrial invasion occurred in a postmenopausal patient on tamoxifen therapy 5 years after mastectomy for breast carcinoma.", "question": "Treatment.Dosage in tamoxifen therapy 5 years after mastectomy for breast carcinoma.", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7789881_4_2727", "context": "Well-differentiated endometrial adenocarcinoma of the secretory type (FIGO Grade 1) with minimal myometrial invasion occurred in a postmenopausal patient on tamoxifen therapy 5 years after mastectomy for breast carcinoma.", "question": "Treatment.Freq in tamoxifen therapy 5 years after mastectomy for breast carcinoma.", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7789881_4_2728", "context": "Well-differentiated endometrial adenocarcinoma of the secretory type (FIGO Grade 1) with minimal myometrial invasion occurred in a postmenopausal patient on tamoxifen therapy 5 years after mastectomy for breast carcinoma.", "question": "Treatment.Route in tamoxifen therapy 5 years after mastectomy for breast carcinoma.", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7789881_4_2729", "context": "Well-differentiated endometrial adenocarcinoma of the secretory type (FIGO Grade 1) with minimal myometrial invasion occurred in a postmenopausal patient on tamoxifen therapy 5 years after mastectomy for breast carcinoma.", "question": "Treatment.Time_elapsed in tamoxifen therapy 5 years after mastectomy for breast carcinoma.", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7789881_4_2730", "context": "Well-differentiated endometrial adenocarcinoma of the secretory type (FIGO Grade 1) with minimal myometrial invasion occurred in a postmenopausal patient on tamoxifen therapy 5 years after mastectomy for breast carcinoma.", "question": "Treatment.Duration in tamoxifen therapy 5 years after mastectomy for breast carcinoma.", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7789881_4_2731", "context": "Well-differentiated endometrial adenocarcinoma of the secretory type (FIGO Grade 1) with minimal myometrial invasion occurred in a postmenopausal patient on tamoxifen therapy 5 years after mastectomy for breast carcinoma.", "question": "Treatment.Disorder in tamoxifen therapy 5 years after mastectomy for breast carcinoma.", "question_type": "Adverse_event.Treatment.Disorder", "answers": "breast carcinoma"}, {"id": "7789881_4_2732", "context": "Well-differentiated endometrial adenocarcinoma of the secretory type (FIGO Grade 1) with minimal myometrial invasion occurred in a postmenopausal patient on tamoxifen therapy 5 years after mastectomy for breast carcinoma.", "question": "Combination.Drug in tamoxifen therapy 5 years after mastectomy for breast carcinoma.", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "2104570_1_2733", "context": "Secondary hematologic neoplasm after intravesical chemotherapy for superficial bladder carcinoma.", "question": "Treatment.Drug in intravesical chemotherapy", "question_type": "Adverse_event.Treatment.Drug", "answers": "intravesical"}, {"id": "2104570_1_2734", "context": "Secondary hematologic neoplasm after intravesical chemotherapy for superficial bladder carcinoma.", "question": "Treatment.Dosage in intravesical chemotherapy", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "2104570_1_2735", "context": "Secondary hematologic neoplasm after intravesical chemotherapy for superficial bladder carcinoma.", "question": "Treatment.Freq in intravesical chemotherapy", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2104570_1_2736", "context": "Secondary hematologic neoplasm after intravesical chemotherapy for superficial bladder carcinoma.", "question": "Treatment.Route in intravesical chemotherapy", "question_type": "Adverse_event.Treatment.Route", "answers": "chemotherapy"}, {"id": "2104570_1_2737", "context": "Secondary hematologic neoplasm after intravesical chemotherapy for superficial bladder carcinoma.", "question": "Treatment.Time_elapsed in intravesical chemotherapy", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2104570_1_2738", "context": "Secondary hematologic neoplasm after intravesical chemotherapy for superficial bladder carcinoma.", "question": "Treatment.Duration in intravesical chemotherapy", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2104570_1_2739", "context": "Secondary hematologic neoplasm after intravesical chemotherapy for superficial bladder carcinoma.", "question": "Treatment.Disorder in intravesical chemotherapy", "question_type": "Adverse_event.Treatment.Disorder", "answers": "bladder carcinoma"}, {"id": "2104570_1_2740", "context": "Secondary hematologic neoplasm after intravesical chemotherapy for superficial bladder carcinoma.", "question": "Combination.Drug in intravesical chemotherapy", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15463865_1_2741", "context": "Ciprofloxacin-induced renal insufficiency in cystic fibrosis.", "question": "Treatment.Drug in Ciprofloxacin", "question_type": "Adverse_event.Treatment.Drug", "answers": "Ciprofloxacin"}, {"id": "15463865_1_2742", "context": "Ciprofloxacin-induced renal insufficiency in cystic fibrosis.", "question": "Treatment.Dosage in Ciprofloxacin", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15463865_1_2743", "context": "Ciprofloxacin-induced renal insufficiency in cystic fibrosis.", "question": "Treatment.Freq in Ciprofloxacin", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15463865_1_2744", "context": "Ciprofloxacin-induced renal insufficiency in cystic fibrosis.", "question": "Treatment.Route in Ciprofloxacin", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15463865_1_2745", "context": "Ciprofloxacin-induced renal insufficiency in cystic fibrosis.", "question": "Treatment.Time_elapsed in Ciprofloxacin", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15463865_1_2746", "context": "Ciprofloxacin-induced renal insufficiency in cystic fibrosis.", "question": "Treatment.Duration in Ciprofloxacin", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15463865_1_2747", "context": "Ciprofloxacin-induced renal insufficiency in cystic fibrosis.", "question": "Treatment.Disorder in Ciprofloxacin", "question_type": "Adverse_event.Treatment.Disorder", "answers": "cystic fibrosis"}, {"id": "15463865_1_2748", "context": "Ciprofloxacin-induced renal insufficiency in cystic fibrosis.", "question": "Combination.Drug in Ciprofloxacin", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15701285_3_2749", "context": "While the introduction of carmustine wafers (Gliadel wafers) into the tumor resection cavity has been shown to be a beneficial therapy for malignant glioma, it is recognized that clinically significant cerebral edema is a potential adverse effect.", "question": "Treatment.Drug in the introduction of carmustine wafers (Gliadel wafers) into the tumor resection cavity", "question_type": "Adverse_event.Treatment.Drug", "answers": "carmustine wafers"}, {"id": "15701285_3_2750", "context": "While the introduction of carmustine wafers (Gliadel wafers) into the tumor resection cavity has been shown to be a beneficial therapy for malignant glioma, it is recognized that clinically significant cerebral edema is a potential adverse effect.", "question": "Treatment.Dosage in the introduction of carmustine wafers (Gliadel wafers) into the tumor resection cavity", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15701285_3_2751", "context": "While the introduction of carmustine wafers (Gliadel wafers) into the tumor resection cavity has been shown to be a beneficial therapy for malignant glioma, it is recognized that clinically significant cerebral edema is a potential adverse effect.", "question": "Treatment.Freq in the introduction of carmustine wafers (Gliadel wafers) into the tumor resection cavity", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15701285_3_2752", "context": "While the introduction of carmustine wafers (Gliadel wafers) into the tumor resection cavity has been shown to be a beneficial therapy for malignant glioma, it is recognized that clinically significant cerebral edema is a potential adverse effect.", "question": "Treatment.Route in the introduction of carmustine wafers (Gliadel wafers) into the tumor resection cavity", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15701285_3_2753", "context": "While the introduction of carmustine wafers (Gliadel wafers) into the tumor resection cavity has been shown to be a beneficial therapy for malignant glioma, it is recognized that clinically significant cerebral edema is a potential adverse effect.", "question": "Treatment.Time_elapsed in the introduction of carmustine wafers (Gliadel wafers) into the tumor resection cavity", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15701285_3_2754", "context": "While the introduction of carmustine wafers (Gliadel wafers) into the tumor resection cavity has been shown to be a beneficial therapy for malignant glioma, it is recognized that clinically significant cerebral edema is a potential adverse effect.", "question": "Treatment.Duration in the introduction of carmustine wafers (Gliadel wafers) into the tumor resection cavity", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15701285_3_2755", "context": "While the introduction of carmustine wafers (Gliadel wafers) into the tumor resection cavity has been shown to be a beneficial therapy for malignant glioma, it is recognized that clinically significant cerebral edema is a potential adverse effect.", "question": "Treatment.Disorder in the introduction of carmustine wafers (Gliadel wafers) into the tumor resection cavity", "question_type": "Adverse_event.Treatment.Disorder", "answers": "malignant glioma"}, {"id": "15701285_3_2756", "context": "While the introduction of carmustine wafers (Gliadel wafers) into the tumor resection cavity has been shown to be a beneficial therapy for malignant glioma, it is recognized that clinically significant cerebral edema is a potential adverse effect.", "question": "Combination.Drug in the introduction of carmustine wafers (Gliadel wafers) into the tumor resection cavity", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11573852_5_2757", "context": "Didanosine also has a potential for inducing seizures.", "question": "Treatment.Drug in Didanosine", "question_type": "Adverse_event.Treatment.Drug", "answers": "Didanosine"}, {"id": "11573852_5_2758", "context": "Didanosine also has a potential for inducing seizures.", "question": "Treatment.Dosage in Didanosine", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11573852_5_2759", "context": "Didanosine also has a potential for inducing seizures.", "question": "Treatment.Freq in Didanosine", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11573852_5_2760", "context": "Didanosine also has a potential for inducing seizures.", "question": "Treatment.Route in Didanosine", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11573852_5_2761", "context": "Didanosine also has a potential for inducing seizures.", "question": "Treatment.Time_elapsed in Didanosine", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11573852_5_2762", "context": "Didanosine also has a potential for inducing seizures.", "question": "Treatment.Duration in Didanosine", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11573852_5_2763", "context": "Didanosine also has a potential for inducing seizures.", "question": "Treatment.Disorder in Didanosine", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11573852_5_2764", "context": "Didanosine also has a potential for inducing seizures.", "question": "Combination.Drug in Didanosine", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12880504_2_2765", "context": "Obsessive-compulsive symptoms suddenly emerged 10 days after starting risperidone and resolved within 3 days of discontinuation.", "question": "Treatment.Drug in risperidone", "question_type": "Adverse_event.Treatment.Drug", "answers": "risperidone"}, {"id": "12880504_2_2766", "context": "Obsessive-compulsive symptoms suddenly emerged 10 days after starting risperidone and resolved within 3 days of discontinuation.", "question": "Treatment.Dosage in risperidone", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12880504_2_2767", "context": "Obsessive-compulsive symptoms suddenly emerged 10 days after starting risperidone and resolved within 3 days of discontinuation.", "question": "Treatment.Freq in risperidone", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12880504_2_2768", "context": "Obsessive-compulsive symptoms suddenly emerged 10 days after starting risperidone and resolved within 3 days of discontinuation.", "question": "Treatment.Route in risperidone", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12880504_2_2769", "context": "Obsessive-compulsive symptoms suddenly emerged 10 days after starting risperidone and resolved within 3 days of discontinuation.", "question": "Treatment.Time_elapsed in risperidone", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12880504_2_2770", "context": "Obsessive-compulsive symptoms suddenly emerged 10 days after starting risperidone and resolved within 3 days of discontinuation.", "question": "Treatment.Duration in risperidone", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12880504_2_2771", "context": "Obsessive-compulsive symptoms suddenly emerged 10 days after starting risperidone and resolved within 3 days of discontinuation.", "question": "Treatment.Disorder in risperidone", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12880504_2_2772", "context": "Obsessive-compulsive symptoms suddenly emerged 10 days after starting risperidone and resolved within 3 days of discontinuation.", "question": "Combination.Drug in risperidone", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15362597_1_2773", "context": "Refractory hypoglycemia from ciprofloxacin and glyburide interaction.", "question": "Treatment.Drug in ciprofloxacin and glyburide interaction", "question_type": "Adverse_event.Treatment.Drug", "answers": "ciprofloxacin; glyburide"}, {"id": "15362597_1_2774", "context": "Refractory hypoglycemia from ciprofloxacin and glyburide interaction.", "question": "Treatment.Dosage in ciprofloxacin and glyburide interaction", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15362597_1_2775", "context": "Refractory hypoglycemia from ciprofloxacin and glyburide interaction.", "question": "Treatment.Freq in ciprofloxacin and glyburide interaction", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15362597_1_2776", "context": "Refractory hypoglycemia from ciprofloxacin and glyburide interaction.", "question": "Treatment.Route in ciprofloxacin and glyburide interaction", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15362597_1_2777", "context": "Refractory hypoglycemia from ciprofloxacin and glyburide interaction.", "question": "Treatment.Time_elapsed in ciprofloxacin and glyburide interaction", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15362597_1_2778", "context": "Refractory hypoglycemia from ciprofloxacin and glyburide interaction.", "question": "Treatment.Duration in ciprofloxacin and glyburide interaction", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15362597_1_2779", "context": "Refractory hypoglycemia from ciprofloxacin and glyburide interaction.", "question": "Treatment.Disorder in ciprofloxacin and glyburide interaction", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15362597_1_2780", "context": "Refractory hypoglycemia from ciprofloxacin and glyburide interaction.", "question": "Combination.Drug in ciprofloxacin and glyburide interaction", "question_type": "Adverse_event.Combination.Drug", "answers": "glyburide; ciprofloxacin"}, {"id": "18556970_1_2781", "context": "Anaphylactic reaction to recombinant insulin-like growth factor-I.", "question": "Treatment.Drug in recombinant insulin-like growth factor-I", "question_type": "Adverse_event.Treatment.Drug", "answers": "recombinant insulin-like growth factor-I"}, {"id": "18556970_1_2782", "context": "Anaphylactic reaction to recombinant insulin-like growth factor-I.", "question": "Treatment.Dosage in recombinant insulin-like growth factor-I", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18556970_1_2783", "context": "Anaphylactic reaction to recombinant insulin-like growth factor-I.", "question": "Treatment.Freq in recombinant insulin-like growth factor-I", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18556970_1_2784", "context": "Anaphylactic reaction to recombinant insulin-like growth factor-I.", "question": "Treatment.Route in recombinant insulin-like growth factor-I", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18556970_1_2785", "context": "Anaphylactic reaction to recombinant insulin-like growth factor-I.", "question": "Treatment.Time_elapsed in recombinant insulin-like growth factor-I", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18556970_1_2786", "context": "Anaphylactic reaction to recombinant insulin-like growth factor-I.", "question": "Treatment.Duration in recombinant insulin-like growth factor-I", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18556970_1_2787", "context": "Anaphylactic reaction to recombinant insulin-like growth factor-I.", "question": "Treatment.Disorder in recombinant insulin-like growth factor-I", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18556970_1_2788", "context": "Anaphylactic reaction to recombinant insulin-like growth factor-I.", "question": "Combination.Drug in recombinant insulin-like growth factor-I", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "21350204_1_2789", "context": "Subtherapeutic warfarin is not associated with increased hemorrhage rates in ischemic strokes treated with tissue plasminogen activator.", "question": "Treatment.Drug in Subtherapeutic warfarin; treated with tissue plasminogen activator", "question_type": "Adverse_event.Treatment.Drug", "answers": "tissue plasminogen activator; warfarin"}, {"id": "21350204_1_2790", "context": "Subtherapeutic warfarin is not associated with increased hemorrhage rates in ischemic strokes treated with tissue plasminogen activator.", "question": "Treatment.Dosage in Subtherapeutic warfarin; treated with tissue plasminogen activator", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "21350204_1_2791", "context": "Subtherapeutic warfarin is not associated with increased hemorrhage rates in ischemic strokes treated with tissue plasminogen activator.", "question": "Treatment.Freq in Subtherapeutic warfarin; treated with tissue plasminogen activator", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "21350204_1_2792", "context": "Subtherapeutic warfarin is not associated with increased hemorrhage rates in ischemic strokes treated with tissue plasminogen activator.", "question": "Treatment.Route in Subtherapeutic warfarin; treated with tissue plasminogen activator", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "21350204_1_2793", "context": "Subtherapeutic warfarin is not associated with increased hemorrhage rates in ischemic strokes treated with tissue plasminogen activator.", "question": "Treatment.Time_elapsed in Subtherapeutic warfarin; treated with tissue plasminogen activator", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "21350204_1_2794", "context": "Subtherapeutic warfarin is not associated with increased hemorrhage rates in ischemic strokes treated with tissue plasminogen activator.", "question": "Treatment.Duration in Subtherapeutic warfarin; treated with tissue plasminogen activator", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "21350204_1_2795", "context": "Subtherapeutic warfarin is not associated with increased hemorrhage rates in ischemic strokes treated with tissue plasminogen activator.", "question": "Treatment.Disorder in Subtherapeutic warfarin; treated with tissue plasminogen activator", "question_type": "Adverse_event.Treatment.Disorder", "answers": "ischemic strokes"}, {"id": "21350204_1_2796", "context": "Subtherapeutic warfarin is not associated with increased hemorrhage rates in ischemic strokes treated with tissue plasminogen activator.", "question": "Combination.Drug in Subtherapeutic warfarin; treated with tissue plasminogen activator", "question_type": "Adverse_event.Combination.Drug", "answers": "warfarin; tissue plasminogen activator"}, {"id": "10510017_2_2797", "context": "Pediatric heparin-induced thrombocytopenia: management with Danaparoid (orgaran).", "question": "Subject.Age in Pediatric", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": "Pediatric"}, {"id": "10510017_2_2798", "context": "Pediatric heparin-induced thrombocytopenia: management with Danaparoid (orgaran).", "question": "Subject.Gender in Pediatric", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "10510017_2_2799", "context": "Pediatric heparin-induced thrombocytopenia: management with Danaparoid (orgaran).", "question": "Subject.Population in Pediatric", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "10510017_2_2800", "context": "Pediatric heparin-induced thrombocytopenia: management with Danaparoid (orgaran).", "question": "Subject.Race in Pediatric", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "10510017_2_2801", "context": "Pediatric heparin-induced thrombocytopenia: management with Danaparoid (orgaran).", "question": "Subject.Disorder in Pediatric", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "10510017_2_2802", "context": "Pediatric heparin-induced thrombocytopenia: management with Danaparoid (orgaran).", "question": "Treatment.Drug in Danaparoid (orgaran)", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "Danaparoid"}, {"id": "10510017_2_2803", "context": "Pediatric heparin-induced thrombocytopenia: management with Danaparoid (orgaran).", "question": "Treatment.Dosage in Danaparoid (orgaran)", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "10510017_2_2804", "context": "Pediatric heparin-induced thrombocytopenia: management with Danaparoid (orgaran).", "question": "Treatment.Freq in Danaparoid (orgaran)", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "10510017_2_2805", "context": "Pediatric heparin-induced thrombocytopenia: management with Danaparoid (orgaran).", "question": "Treatment.Route in Danaparoid (orgaran)", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "10510017_2_2806", "context": "Pediatric heparin-induced thrombocytopenia: management with Danaparoid (orgaran).", "question": "Treatment.Time_elapsed in Danaparoid (orgaran)", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10510017_2_2807", "context": "Pediatric heparin-induced thrombocytopenia: management with Danaparoid (orgaran).", "question": "Treatment.Duration in Danaparoid (orgaran)", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "10510017_2_2808", "context": "Pediatric heparin-induced thrombocytopenia: management with Danaparoid (orgaran).", "question": "Treatment.Disorder in Danaparoid (orgaran)", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "heparin-induced thrombocytopenia"}, {"id": "10510017_2_2809", "context": "Pediatric heparin-induced thrombocytopenia: management with Danaparoid (orgaran).", "question": "Combination.Drug in Danaparoid (orgaran)", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "10510017_2_2810", "context": "Pediatric heparin-induced thrombocytopenia: management with Danaparoid (orgaran).", "question": "Subject.Age in Pediatric", "question_type": "Adverse_event.Subject.Age", "answers": "Pediatric"}, {"id": "10510017_2_2811", "context": "Pediatric heparin-induced thrombocytopenia: management with Danaparoid (orgaran).", "question": "Subject.Gender in Pediatric", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "10510017_2_2812", "context": "Pediatric heparin-induced thrombocytopenia: management with Danaparoid (orgaran).", "question": "Subject.Population in Pediatric", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "10510017_2_2813", "context": "Pediatric heparin-induced thrombocytopenia: management with Danaparoid (orgaran).", "question": "Subject.Race in Pediatric", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "10510017_2_2814", "context": "Pediatric heparin-induced thrombocytopenia: management with Danaparoid (orgaran).", "question": "Subject.Disorder in Pediatric", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "10510017_2_2815", "context": "Pediatric heparin-induced thrombocytopenia: management with Danaparoid (orgaran).", "question": "Treatment.Drug in heparin", "question_type": "Adverse_event.Treatment.Drug", "answers": "heparin"}, {"id": "10510017_2_2816", "context": "Pediatric heparin-induced thrombocytopenia: management with Danaparoid (orgaran).", "question": "Treatment.Dosage in heparin", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10510017_2_2817", "context": "Pediatric heparin-induced thrombocytopenia: management with Danaparoid (orgaran).", "question": "Treatment.Freq in heparin", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10510017_2_2818", "context": "Pediatric heparin-induced thrombocytopenia: management with Danaparoid (orgaran).", "question": "Treatment.Route in heparin", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10510017_2_2819", "context": "Pediatric heparin-induced thrombocytopenia: management with Danaparoid (orgaran).", "question": "Treatment.Time_elapsed in heparin", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10510017_2_2820", "context": "Pediatric heparin-induced thrombocytopenia: management with Danaparoid (orgaran).", "question": "Treatment.Duration in heparin", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10510017_2_2821", "context": "Pediatric heparin-induced thrombocytopenia: management with Danaparoid (orgaran).", "question": "Treatment.Disorder in heparin", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10510017_2_2822", "context": "Pediatric heparin-induced thrombocytopenia: management with Danaparoid (orgaran).", "question": "Combination.Drug in heparin", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17426073_4_2823", "context": "Teicoplanin-induced agranulocytosis that followed vancomycin-induced agranulocytosis suggests a possible cross-reactivity between the 2 drugs.", "question": "Treatment.Drug in Teicoplanin; followed vancomycin", "question_type": "Adverse_event.Treatment.Drug", "answers": "Teicoplanin; vancomycin"}, {"id": "17426073_4_2824", "context": "Teicoplanin-induced agranulocytosis that followed vancomycin-induced agranulocytosis suggests a possible cross-reactivity between the 2 drugs.", "question": "Treatment.Dosage in Teicoplanin; followed vancomycin", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17426073_4_2825", "context": "Teicoplanin-induced agranulocytosis that followed vancomycin-induced agranulocytosis suggests a possible cross-reactivity between the 2 drugs.", "question": "Treatment.Freq in Teicoplanin; followed vancomycin", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17426073_4_2826", "context": "Teicoplanin-induced agranulocytosis that followed vancomycin-induced agranulocytosis suggests a possible cross-reactivity between the 2 drugs.", "question": "Treatment.Route in Teicoplanin; followed vancomycin", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17426073_4_2827", "context": "Teicoplanin-induced agranulocytosis that followed vancomycin-induced agranulocytosis suggests a possible cross-reactivity between the 2 drugs.", "question": "Treatment.Time_elapsed in Teicoplanin; followed vancomycin", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17426073_4_2828", "context": "Teicoplanin-induced agranulocytosis that followed vancomycin-induced agranulocytosis suggests a possible cross-reactivity between the 2 drugs.", "question": "Treatment.Duration in Teicoplanin; followed vancomycin", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17426073_4_2829", "context": "Teicoplanin-induced agranulocytosis that followed vancomycin-induced agranulocytosis suggests a possible cross-reactivity between the 2 drugs.", "question": "Treatment.Disorder in Teicoplanin; followed vancomycin", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17426073_4_2830", "context": "Teicoplanin-induced agranulocytosis that followed vancomycin-induced agranulocytosis suggests a possible cross-reactivity between the 2 drugs.", "question": "Combination.Drug in Teicoplanin; followed vancomycin", "question_type": "Adverse_event.Combination.Drug", "answers": "Teicoplanin; vancomycin"}, {"id": "946400_1_2831", "context": "A 55-year-old woman developed symptoms suggestive of hepatitis 12 weeks after first receiving methyldopa for hypertension.", "question": "Subject.Age in A 55-year-old woman", "question_type": "Adverse_event.Subject.Age", "answers": "55-year-old"}, {"id": "946400_1_2832", "context": "A 55-year-old woman developed symptoms suggestive of hepatitis 12 weeks after first receiving methyldopa for hypertension.", "question": "Subject.Gender in A 55-year-old woman", "question_type": "Adverse_event.Subject.Gender", "answers": "woman"}, {"id": "946400_1_2833", "context": "A 55-year-old woman developed symptoms suggestive of hepatitis 12 weeks after first receiving methyldopa for hypertension.", "question": "Subject.Population in A 55-year-old woman", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "946400_1_2834", "context": "A 55-year-old woman developed symptoms suggestive of hepatitis 12 weeks after first receiving methyldopa for hypertension.", "question": "Subject.Race in A 55-year-old woman", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "946400_1_2835", "context": "A 55-year-old woman developed symptoms suggestive of hepatitis 12 weeks after first receiving methyldopa for hypertension.", "question": "Subject.Disorder in A 55-year-old woman", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "946400_1_2836", "context": "A 55-year-old woman developed symptoms suggestive of hepatitis 12 weeks after first receiving methyldopa for hypertension.", "question": "Treatment.Drug in methyldopa", "question_type": "Adverse_event.Treatment.Drug", "answers": "methyldopa"}, {"id": "946400_1_2837", "context": "A 55-year-old woman developed symptoms suggestive of hepatitis 12 weeks after first receiving methyldopa for hypertension.", "question": "Treatment.Dosage in methyldopa", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "946400_1_2838", "context": "A 55-year-old woman developed symptoms suggestive of hepatitis 12 weeks after first receiving methyldopa for hypertension.", "question": "Treatment.Freq in methyldopa", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "946400_1_2839", "context": "A 55-year-old woman developed symptoms suggestive of hepatitis 12 weeks after first receiving methyldopa for hypertension.", "question": "Treatment.Route in methyldopa", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "946400_1_2840", "context": "A 55-year-old woman developed symptoms suggestive of hepatitis 12 weeks after first receiving methyldopa for hypertension.", "question": "Treatment.Time_elapsed in methyldopa", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "12 weeks"}, {"id": "946400_1_2841", "context": "A 55-year-old woman developed symptoms suggestive of hepatitis 12 weeks after first receiving methyldopa for hypertension.", "question": "Treatment.Duration in methyldopa", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "946400_1_2842", "context": "A 55-year-old woman developed symptoms suggestive of hepatitis 12 weeks after first receiving methyldopa for hypertension.", "question": "Treatment.Disorder in methyldopa", "question_type": "Adverse_event.Treatment.Disorder", "answers": "hypertension"}, {"id": "946400_1_2843", "context": "A 55-year-old woman developed symptoms suggestive of hepatitis 12 weeks after first receiving methyldopa for hypertension.", "question": "Combination.Drug in methyldopa", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "644545_1_2844", "context": "Cyclophosphamide can rarely cause interstitial pneumonitis and fibrosis.", "question": "Treatment.Drug in Cyclophosphamide", "question_type": "Adverse_event.Treatment.Drug", "answers": "Cyclophosphamide"}, {"id": "644545_1_2845", "context": "Cyclophosphamide can rarely cause interstitial pneumonitis and fibrosis.", "question": "Treatment.Dosage in Cyclophosphamide", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "644545_1_2846", "context": "Cyclophosphamide can rarely cause interstitial pneumonitis and fibrosis.", "question": "Treatment.Freq in Cyclophosphamide", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "644545_1_2847", "context": "Cyclophosphamide can rarely cause interstitial pneumonitis and fibrosis.", "question": "Treatment.Route in Cyclophosphamide", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "644545_1_2848", "context": "Cyclophosphamide can rarely cause interstitial pneumonitis and fibrosis.", "question": "Treatment.Time_elapsed in Cyclophosphamide", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "644545_1_2849", "context": "Cyclophosphamide can rarely cause interstitial pneumonitis and fibrosis.", "question": "Treatment.Duration in Cyclophosphamide", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "644545_1_2850", "context": "Cyclophosphamide can rarely cause interstitial pneumonitis and fibrosis.", "question": "Treatment.Disorder in Cyclophosphamide", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "644545_1_2851", "context": "Cyclophosphamide can rarely cause interstitial pneumonitis and fibrosis.", "question": "Combination.Drug in Cyclophosphamide", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7117795_1_2852", "context": "Flucytosine-associated diarrhea has been previously described in 6%-10% of patients receiving the drug.", "question": "Subject.Age in 6%-10% of patients", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "7117795_1_2853", "context": "Flucytosine-associated diarrhea has been previously described in 6%-10% of patients receiving the drug.", "question": "Subject.Gender in 6%-10% of patients", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "7117795_1_2854", "context": "Flucytosine-associated diarrhea has been previously described in 6%-10% of patients receiving the drug.", "question": "Subject.Population in 6%-10% of patients", "question_type": "Adverse_event.Subject.Population", "answers": "6%-10%"}, {"id": "7117795_1_2855", "context": "Flucytosine-associated diarrhea has been previously described in 6%-10% of patients receiving the drug.", "question": "Subject.Race in 6%-10% of patients", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "7117795_1_2856", "context": "Flucytosine-associated diarrhea has been previously described in 6%-10% of patients receiving the drug.", "question": "Subject.Disorder in 6%-10% of patients", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "7117795_1_2857", "context": "Flucytosine-associated diarrhea has been previously described in 6%-10% of patients receiving the drug.", "question": "Treatment.Drug in Flucytosine", "question_type": "Adverse_event.Treatment.Drug", "answers": "Flucytosine"}, {"id": "7117795_1_2858", "context": "Flucytosine-associated diarrhea has been previously described in 6%-10% of patients receiving the drug.", "question": "Treatment.Dosage in Flucytosine", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7117795_1_2859", "context": "Flucytosine-associated diarrhea has been previously described in 6%-10% of patients receiving the drug.", "question": "Treatment.Freq in Flucytosine", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7117795_1_2860", "context": "Flucytosine-associated diarrhea has been previously described in 6%-10% of patients receiving the drug.", "question": "Treatment.Route in Flucytosine", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7117795_1_2861", "context": "Flucytosine-associated diarrhea has been previously described in 6%-10% of patients receiving the drug.", "question": "Treatment.Time_elapsed in Flucytosine", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7117795_1_2862", "context": "Flucytosine-associated diarrhea has been previously described in 6%-10% of patients receiving the drug.", "question": "Treatment.Duration in Flucytosine", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7117795_1_2863", "context": "Flucytosine-associated diarrhea has been previously described in 6%-10% of patients receiving the drug.", "question": "Treatment.Disorder in Flucytosine", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7117795_1_2864", "context": "Flucytosine-associated diarrhea has been previously described in 6%-10% of patients receiving the drug.", "question": "Combination.Drug in Flucytosine", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "4051280_1_2865", "context": "IV propranolol was used as the initial treatment for his hyperadrenergic state, resulting in a decrease in heart rate but a paroxsymal increase in blood pressure.", "question": "Subject.Age in his hyperadrenergic state", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "4051280_1_2866", "context": "IV propranolol was used as the initial treatment for his hyperadrenergic state, resulting in a decrease in heart rate but a paroxsymal increase in blood pressure.", "question": "Subject.Gender in his hyperadrenergic state", "question_type": "Adverse_event.Subject.Gender", "answers": "his"}, {"id": "4051280_1_2867", "context": "IV propranolol was used as the initial treatment for his hyperadrenergic state, resulting in a decrease in heart rate but a paroxsymal increase in blood pressure.", "question": "Subject.Population in his hyperadrenergic state", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "4051280_1_2868", "context": "IV propranolol was used as the initial treatment for his hyperadrenergic state, resulting in a decrease in heart rate but a paroxsymal increase in blood pressure.", "question": "Subject.Race in his hyperadrenergic state", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "4051280_1_2869", "context": "IV propranolol was used as the initial treatment for his hyperadrenergic state, resulting in a decrease in heart rate but a paroxsymal increase in blood pressure.", "question": "Subject.Disorder in his hyperadrenergic state", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "4051280_1_2870", "context": "IV propranolol was used as the initial treatment for his hyperadrenergic state, resulting in a decrease in heart rate but a paroxsymal increase in blood pressure.", "question": "Treatment.Drug in IV propranolol", "question_type": "Adverse_event.Treatment.Drug", "answers": "propranolol"}, {"id": "4051280_1_2871", "context": "IV propranolol was used as the initial treatment for his hyperadrenergic state, resulting in a decrease in heart rate but a paroxsymal increase in blood pressure.", "question": "Treatment.Dosage in IV propranolol", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "4051280_1_2872", "context": "IV propranolol was used as the initial treatment for his hyperadrenergic state, resulting in a decrease in heart rate but a paroxsymal increase in blood pressure.", "question": "Treatment.Freq in IV propranolol", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "4051280_1_2873", "context": "IV propranolol was used as the initial treatment for his hyperadrenergic state, resulting in a decrease in heart rate but a paroxsymal increase in blood pressure.", "question": "Treatment.Route in IV propranolol", "question_type": "Adverse_event.Treatment.Route", "answers": "IV"}, {"id": "4051280_1_2874", "context": "IV propranolol was used as the initial treatment for his hyperadrenergic state, resulting in a decrease in heart rate but a paroxsymal increase in blood pressure.", "question": "Treatment.Time_elapsed in IV propranolol", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "4051280_1_2875", "context": "IV propranolol was used as the initial treatment for his hyperadrenergic state, resulting in a decrease in heart rate but a paroxsymal increase in blood pressure.", "question": "Treatment.Duration in IV propranolol", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "4051280_1_2876", "context": "IV propranolol was used as the initial treatment for his hyperadrenergic state, resulting in a decrease in heart rate but a paroxsymal increase in blood pressure.", "question": "Treatment.Disorder in IV propranolol", "question_type": "Adverse_event.Treatment.Disorder", "answers": "hyperadrenergic state"}, {"id": "4051280_1_2877", "context": "IV propranolol was used as the initial treatment for his hyperadrenergic state, resulting in a decrease in heart rate but a paroxsymal increase in blood pressure.", "question": "Combination.Drug in IV propranolol", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7789881_3_2878", "context": "We believe that this is the first report of secretory carcinoma of the endometrium associated with tamoxifen use.", "question": "Treatment.Drug in tamoxifen", "question_type": "Adverse_event.Treatment.Drug", "answers": "tamoxifen"}, {"id": "7789881_3_2879", "context": "We believe that this is the first report of secretory carcinoma of the endometrium associated with tamoxifen use.", "question": "Treatment.Dosage in tamoxifen", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7789881_3_2880", "context": "We believe that this is the first report of secretory carcinoma of the endometrium associated with tamoxifen use.", "question": "Treatment.Freq in tamoxifen", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7789881_3_2881", "context": "We believe that this is the first report of secretory carcinoma of the endometrium associated with tamoxifen use.", "question": "Treatment.Route in tamoxifen", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7789881_3_2882", "context": "We believe that this is the first report of secretory carcinoma of the endometrium associated with tamoxifen use.", "question": "Treatment.Time_elapsed in tamoxifen", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7789881_3_2883", "context": "We believe that this is the first report of secretory carcinoma of the endometrium associated with tamoxifen use.", "question": "Treatment.Duration in tamoxifen", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7789881_3_2884", "context": "We believe that this is the first report of secretory carcinoma of the endometrium associated with tamoxifen use.", "question": "Treatment.Disorder in tamoxifen", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7789881_3_2885", "context": "We believe that this is the first report of secretory carcinoma of the endometrium associated with tamoxifen use.", "question": "Combination.Drug in tamoxifen", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3513544_1_2886", "context": "Herpes simplex esophagitis in a renal transplant patient treated with cyclosporine A: a case report.", "question": "Subject.Age in renal transplant patient", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "3513544_1_2887", "context": "Herpes simplex esophagitis in a renal transplant patient treated with cyclosporine A: a case report.", "question": "Subject.Gender in renal transplant patient", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "3513544_1_2888", "context": "Herpes simplex esophagitis in a renal transplant patient treated with cyclosporine A: a case report.", "question": "Subject.Population in renal transplant patient", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "3513544_1_2889", "context": "Herpes simplex esophagitis in a renal transplant patient treated with cyclosporine A: a case report.", "question": "Subject.Race in renal transplant patient", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "3513544_1_2890", "context": "Herpes simplex esophagitis in a renal transplant patient treated with cyclosporine A: a case report.", "question": "Subject.Disorder in renal transplant patient", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "3513544_1_2891", "context": "Herpes simplex esophagitis in a renal transplant patient treated with cyclosporine A: a case report.", "question": "Treatment.Drug in cyclosporine", "question_type": "Adverse_event.Treatment.Drug", "answers": "cyclosporine"}, {"id": "3513544_1_2892", "context": "Herpes simplex esophagitis in a renal transplant patient treated with cyclosporine A: a case report.", "question": "Treatment.Dosage in cyclosporine", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3513544_1_2893", "context": "Herpes simplex esophagitis in a renal transplant patient treated with cyclosporine A: a case report.", "question": "Treatment.Freq in cyclosporine", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3513544_1_2894", "context": "Herpes simplex esophagitis in a renal transplant patient treated with cyclosporine A: a case report.", "question": "Treatment.Route in cyclosporine", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3513544_1_2895", "context": "Herpes simplex esophagitis in a renal transplant patient treated with cyclosporine A: a case report.", "question": "Treatment.Time_elapsed in cyclosporine", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3513544_1_2896", "context": "Herpes simplex esophagitis in a renal transplant patient treated with cyclosporine A: a case report.", "question": "Treatment.Duration in cyclosporine", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3513544_1_2897", "context": "Herpes simplex esophagitis in a renal transplant patient treated with cyclosporine A: a case report.", "question": "Treatment.Disorder in cyclosporine", "question_type": "Adverse_event.Treatment.Disorder", "answers": "renal transplant"}, {"id": "3513544_1_2898", "context": "Herpes simplex esophagitis in a renal transplant patient treated with cyclosporine A: a case report.", "question": "Combination.Drug in cyclosporine", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12763355_3_2899", "context": "This clinical course suggests that the sensorimotor polyneuropathy may have been caused by 5-ASA.", "question": "Treatment.Drug in 5-ASA", "question_type": "Adverse_event.Treatment.Drug", "answers": "5-ASA"}, {"id": "12763355_3_2900", "context": "This clinical course suggests that the sensorimotor polyneuropathy may have been caused by 5-ASA.", "question": "Treatment.Dosage in 5-ASA", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12763355_3_2901", "context": "This clinical course suggests that the sensorimotor polyneuropathy may have been caused by 5-ASA.", "question": "Treatment.Freq in 5-ASA", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12763355_3_2902", "context": "This clinical course suggests that the sensorimotor polyneuropathy may have been caused by 5-ASA.", "question": "Treatment.Route in 5-ASA", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12763355_3_2903", "context": "This clinical course suggests that the sensorimotor polyneuropathy may have been caused by 5-ASA.", "question": "Treatment.Time_elapsed in 5-ASA", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12763355_3_2904", "context": "This clinical course suggests that the sensorimotor polyneuropathy may have been caused by 5-ASA.", "question": "Treatment.Duration in 5-ASA", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12763355_3_2905", "context": "This clinical course suggests that the sensorimotor polyneuropathy may have been caused by 5-ASA.", "question": "Treatment.Disorder in 5-ASA", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12763355_3_2906", "context": "This clinical course suggests that the sensorimotor polyneuropathy may have been caused by 5-ASA.", "question": "Combination.Drug in 5-ASA", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18622319_1_2907", "context": "Spontaneous nasal septal perforation with antiangiogenic bevacizumab therapy.", "question": "Treatment.Drug in antiangiogenic bevacizumab therapy", "question_type": "Adverse_event.Treatment.Drug", "answers": "bevacizumab"}, {"id": "18622319_1_2908", "context": "Spontaneous nasal septal perforation with antiangiogenic bevacizumab therapy.", "question": "Treatment.Dosage in antiangiogenic bevacizumab therapy", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18622319_1_2909", "context": "Spontaneous nasal septal perforation with antiangiogenic bevacizumab therapy.", "question": "Treatment.Freq in antiangiogenic bevacizumab therapy", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18622319_1_2910", "context": "Spontaneous nasal septal perforation with antiangiogenic bevacizumab therapy.", "question": "Treatment.Route in antiangiogenic bevacizumab therapy", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18622319_1_2911", "context": "Spontaneous nasal septal perforation with antiangiogenic bevacizumab therapy.", "question": "Treatment.Time_elapsed in antiangiogenic bevacizumab therapy", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18622319_1_2912", "context": "Spontaneous nasal septal perforation with antiangiogenic bevacizumab therapy.", "question": "Treatment.Duration in antiangiogenic bevacizumab therapy", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18622319_1_2913", "context": "Spontaneous nasal septal perforation with antiangiogenic bevacizumab therapy.", "question": "Treatment.Disorder in antiangiogenic bevacizumab therapy", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18622319_1_2914", "context": "Spontaneous nasal septal perforation with antiangiogenic bevacizumab therapy.", "question": "Combination.Drug in antiangiogenic bevacizumab therapy", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10442258_3_2915", "context": "There are a few case reports on hair loss associated with tricyclic antidepressants and serotonin selective reuptake inhibitors (SSRIs), but none deal specifically with paroxetine.", "question": "Treatment.Drug in tricyclic antidepressants and serotonin selective reuptake inhibitors", "question_type": "Adverse_event.Treatment.Drug", "answers": "tricyclic antidepressants; serotonin selective reuptake inhibitors"}, {"id": "10442258_3_2916", "context": "There are a few case reports on hair loss associated with tricyclic antidepressants and serotonin selective reuptake inhibitors (SSRIs), but none deal specifically with paroxetine.", "question": "Treatment.Dosage in tricyclic antidepressants and serotonin selective reuptake inhibitors", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10442258_3_2917", "context": "There are a few case reports on hair loss associated with tricyclic antidepressants and serotonin selective reuptake inhibitors (SSRIs), but none deal specifically with paroxetine.", "question": "Treatment.Freq in tricyclic antidepressants and serotonin selective reuptake inhibitors", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10442258_3_2918", "context": "There are a few case reports on hair loss associated with tricyclic antidepressants and serotonin selective reuptake inhibitors (SSRIs), but none deal specifically with paroxetine.", "question": "Treatment.Route in tricyclic antidepressants and serotonin selective reuptake inhibitors", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10442258_3_2919", "context": "There are a few case reports on hair loss associated with tricyclic antidepressants and serotonin selective reuptake inhibitors (SSRIs), but none deal specifically with paroxetine.", "question": "Treatment.Time_elapsed in tricyclic antidepressants and serotonin selective reuptake inhibitors", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10442258_3_2920", "context": "There are a few case reports on hair loss associated with tricyclic antidepressants and serotonin selective reuptake inhibitors (SSRIs), but none deal specifically with paroxetine.", "question": "Treatment.Duration in tricyclic antidepressants and serotonin selective reuptake inhibitors", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10442258_3_2921", "context": "There are a few case reports on hair loss associated with tricyclic antidepressants and serotonin selective reuptake inhibitors (SSRIs), but none deal specifically with paroxetine.", "question": "Treatment.Disorder in tricyclic antidepressants and serotonin selective reuptake inhibitors", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10442258_3_2922", "context": "There are a few case reports on hair loss associated with tricyclic antidepressants and serotonin selective reuptake inhibitors (SSRIs), but none deal specifically with paroxetine.", "question": "Combination.Drug in tricyclic antidepressants and serotonin selective reuptake inhibitors", "question_type": "Adverse_event.Combination.Drug", "answers": "tricyclic antidepressants; serotonin selective reuptake inhibitors"}, {"id": "11903249_2_2923", "context": "There have been more than 20 observations of the appearance or aggravation of this granulomatosis with interferon alfa and more recently with the combination of interferon alfa plus ribavirin.", "question": "Treatment.Drug in interferon alfa and more recently with the combination of interferon alfa plus ribavirin", "question_type": "Adverse_event.Treatment.Drug", "answers": "interferon alfa; interferon alfa; ribavirin"}, {"id": "11903249_2_2924", "context": "There have been more than 20 observations of the appearance or aggravation of this granulomatosis with interferon alfa and more recently with the combination of interferon alfa plus ribavirin.", "question": "Treatment.Dosage in interferon alfa and more recently with the combination of interferon alfa plus ribavirin", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11903249_2_2925", "context": "There have been more than 20 observations of the appearance or aggravation of this granulomatosis with interferon alfa and more recently with the combination of interferon alfa plus ribavirin.", "question": "Treatment.Freq in interferon alfa and more recently with the combination of interferon alfa plus ribavirin", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11903249_2_2926", "context": "There have been more than 20 observations of the appearance or aggravation of this granulomatosis with interferon alfa and more recently with the combination of interferon alfa plus ribavirin.", "question": "Treatment.Route in interferon alfa and more recently with the combination of interferon alfa plus ribavirin", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11903249_2_2927", "context": "There have been more than 20 observations of the appearance or aggravation of this granulomatosis with interferon alfa and more recently with the combination of interferon alfa plus ribavirin.", "question": "Treatment.Time_elapsed in interferon alfa and more recently with the combination of interferon alfa plus ribavirin", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11903249_2_2928", "context": "There have been more than 20 observations of the appearance or aggravation of this granulomatosis with interferon alfa and more recently with the combination of interferon alfa plus ribavirin.", "question": "Treatment.Duration in interferon alfa and more recently with the combination of interferon alfa plus ribavirin", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11903249_2_2929", "context": "There have been more than 20 observations of the appearance or aggravation of this granulomatosis with interferon alfa and more recently with the combination of interferon alfa plus ribavirin.", "question": "Treatment.Disorder in interferon alfa and more recently with the combination of interferon alfa plus ribavirin", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11903249_2_2930", "context": "There have been more than 20 observations of the appearance or aggravation of this granulomatosis with interferon alfa and more recently with the combination of interferon alfa plus ribavirin.", "question": "Combination.Drug in interferon alfa and more recently with the combination of interferon alfa plus ribavirin", "question_type": "Adverse_event.Combination.Drug", "answers": "interferon alfa; ribavirin"}, {"id": "20065266_2_2931", "context": "CONCLUSION: A 37-year-old African- American man with G6PD deficiency developed hemolytic anemia, hepatitis, orthostatic hypotension, and aseptic meningitis simultaneously after using trimethoprim-sulfamethoxazole.", "question": "Subject.Age in A 37-year-old African- American man with G6PD deficiency", "question_type": "Adverse_event.Subject.Age", "answers": "37-year-old"}, {"id": "20065266_2_2932", "context": "CONCLUSION: A 37-year-old African- American man with G6PD deficiency developed hemolytic anemia, hepatitis, orthostatic hypotension, and aseptic meningitis simultaneously after using trimethoprim-sulfamethoxazole.", "question": "Subject.Gender in A 37-year-old African- American man with G6PD deficiency", "question_type": "Adverse_event.Subject.Gender", "answers": "man"}, {"id": "20065266_2_2933", "context": "CONCLUSION: A 37-year-old African- American man with G6PD deficiency developed hemolytic anemia, hepatitis, orthostatic hypotension, and aseptic meningitis simultaneously after using trimethoprim-sulfamethoxazole.", "question": "Subject.Population in A 37-year-old African- American man with G6PD deficiency", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "20065266_2_2934", "context": "CONCLUSION: A 37-year-old African- American man with G6PD deficiency developed hemolytic anemia, hepatitis, orthostatic hypotension, and aseptic meningitis simultaneously after using trimethoprim-sulfamethoxazole.", "question": "Subject.Race in A 37-year-old African- American man with G6PD deficiency", "question_type": "Adverse_event.Subject.Race", "answers": "African- American"}, {"id": "20065266_2_2935", "context": "CONCLUSION: A 37-year-old African- American man with G6PD deficiency developed hemolytic anemia, hepatitis, orthostatic hypotension, and aseptic meningitis simultaneously after using trimethoprim-sulfamethoxazole.", "question": "Subject.Disorder in A 37-year-old African- American man with G6PD deficiency", "question_type": "Adverse_event.Subject.Disorder", "answers": "G6PD deficiency"}, {"id": "20065266_2_2936", "context": "CONCLUSION: A 37-year-old African- American man with G6PD deficiency developed hemolytic anemia, hepatitis, orthostatic hypotension, and aseptic meningitis simultaneously after using trimethoprim-sulfamethoxazole.", "question": "Treatment.Drug in trimethoprim-sulfamethoxazole", "question_type": "Adverse_event.Treatment.Drug", "answers": "trimethoprim-sulfamethoxazole"}, {"id": "20065266_2_2937", "context": "CONCLUSION: A 37-year-old African- American man with G6PD deficiency developed hemolytic anemia, hepatitis, orthostatic hypotension, and aseptic meningitis simultaneously after using trimethoprim-sulfamethoxazole.", "question": "Treatment.Dosage in trimethoprim-sulfamethoxazole", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "20065266_2_2938", "context": "CONCLUSION: A 37-year-old African- American man with G6PD deficiency developed hemolytic anemia, hepatitis, orthostatic hypotension, and aseptic meningitis simultaneously after using trimethoprim-sulfamethoxazole.", "question": "Treatment.Freq in trimethoprim-sulfamethoxazole", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "20065266_2_2939", "context": "CONCLUSION: A 37-year-old African- American man with G6PD deficiency developed hemolytic anemia, hepatitis, orthostatic hypotension, and aseptic meningitis simultaneously after using trimethoprim-sulfamethoxazole.", "question": "Treatment.Route in trimethoprim-sulfamethoxazole", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "20065266_2_2940", "context": "CONCLUSION: A 37-year-old African- American man with G6PD deficiency developed hemolytic anemia, hepatitis, orthostatic hypotension, and aseptic meningitis simultaneously after using trimethoprim-sulfamethoxazole.", "question": "Treatment.Time_elapsed in trimethoprim-sulfamethoxazole", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "20065266_2_2941", "context": "CONCLUSION: A 37-year-old African- American man with G6PD deficiency developed hemolytic anemia, hepatitis, orthostatic hypotension, and aseptic meningitis simultaneously after using trimethoprim-sulfamethoxazole.", "question": "Treatment.Duration in trimethoprim-sulfamethoxazole", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "20065266_2_2942", "context": "CONCLUSION: A 37-year-old African- American man with G6PD deficiency developed hemolytic anemia, hepatitis, orthostatic hypotension, and aseptic meningitis simultaneously after using trimethoprim-sulfamethoxazole.", "question": "Treatment.Disorder in trimethoprim-sulfamethoxazole", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "20065266_2_2943", "context": "CONCLUSION: A 37-year-old African- American man with G6PD deficiency developed hemolytic anemia, hepatitis, orthostatic hypotension, and aseptic meningitis simultaneously after using trimethoprim-sulfamethoxazole.", "question": "Combination.Drug in trimethoprim-sulfamethoxazole", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "20009973_1_2944", "context": "All-trans retinoic acid-induced focal myositis, synovitis, and mononeuritis.", "question": "Treatment.Drug in All-trans retinoic acid", "question_type": "Adverse_event.Treatment.Drug", "answers": "All-trans retinoic acid"}, {"id": "20009973_1_2945", "context": "All-trans retinoic acid-induced focal myositis, synovitis, and mononeuritis.", "question": "Treatment.Dosage in All-trans retinoic acid", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "20009973_1_2946", "context": "All-trans retinoic acid-induced focal myositis, synovitis, and mononeuritis.", "question": "Treatment.Freq in All-trans retinoic acid", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "20009973_1_2947", "context": "All-trans retinoic acid-induced focal myositis, synovitis, and mononeuritis.", "question": "Treatment.Route in All-trans retinoic acid", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "20009973_1_2948", "context": "All-trans retinoic acid-induced focal myositis, synovitis, and mononeuritis.", "question": "Treatment.Time_elapsed in All-trans retinoic acid", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "20009973_1_2949", "context": "All-trans retinoic acid-induced focal myositis, synovitis, and mononeuritis.", "question": "Treatment.Duration in All-trans retinoic acid", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "20009973_1_2950", "context": "All-trans retinoic acid-induced focal myositis, synovitis, and mononeuritis.", "question": "Treatment.Disorder in All-trans retinoic acid", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "20009973_1_2951", "context": "All-trans retinoic acid-induced focal myositis, synovitis, and mononeuritis.", "question": "Combination.Drug in All-trans retinoic acid", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "2417800_4_2952", "context": "Oxygen potentiation of bleomycin-induced pulmonary toxicity is discussed.", "question": "Treatment.Drug in Oxygen potentiation of bleomycin", "question_type": "Adverse_event.Treatment.Drug", "answers": "Oxygen; bleomycin"}, {"id": "2417800_4_2953", "context": "Oxygen potentiation of bleomycin-induced pulmonary toxicity is discussed.", "question": "Treatment.Dosage in Oxygen potentiation of bleomycin", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "2417800_4_2954", "context": "Oxygen potentiation of bleomycin-induced pulmonary toxicity is discussed.", "question": "Treatment.Freq in Oxygen potentiation of bleomycin", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2417800_4_2955", "context": "Oxygen potentiation of bleomycin-induced pulmonary toxicity is discussed.", "question": "Treatment.Route in Oxygen potentiation of bleomycin", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "2417800_4_2956", "context": "Oxygen potentiation of bleomycin-induced pulmonary toxicity is discussed.", "question": "Treatment.Time_elapsed in Oxygen potentiation of bleomycin", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2417800_4_2957", "context": "Oxygen potentiation of bleomycin-induced pulmonary toxicity is discussed.", "question": "Treatment.Duration in Oxygen potentiation of bleomycin", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2417800_4_2958", "context": "Oxygen potentiation of bleomycin-induced pulmonary toxicity is discussed.", "question": "Treatment.Disorder in Oxygen potentiation of bleomycin", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "2417800_4_2959", "context": "Oxygen potentiation of bleomycin-induced pulmonary toxicity is discussed.", "question": "Combination.Drug in Oxygen potentiation of bleomycin", "question_type": "Adverse_event.Combination.Drug", "answers": "bleomycin; Oxygen"}, {"id": "11554897_1_2960", "context": "CONCLUSIONS: LTG overdose may result in a severe but reversible encephalopathy, a previously undescribed phenomenon.", "question": "Treatment.Drug in LTG overdose", "question_type": "Adverse_event.Treatment.Drug", "answers": "LTG"}, {"id": "11554897_1_2961", "context": "CONCLUSIONS: LTG overdose may result in a severe but reversible encephalopathy, a previously undescribed phenomenon.", "question": "Treatment.Dosage in LTG overdose", "question_type": "Adverse_event.Treatment.Dosage", "answers": "overdose"}, {"id": "11554897_1_2962", "context": "CONCLUSIONS: LTG overdose may result in a severe but reversible encephalopathy, a previously undescribed phenomenon.", "question": "Treatment.Freq in LTG overdose", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11554897_1_2963", "context": "CONCLUSIONS: LTG overdose may result in a severe but reversible encephalopathy, a previously undescribed phenomenon.", "question": "Treatment.Route in LTG overdose", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11554897_1_2964", "context": "CONCLUSIONS: LTG overdose may result in a severe but reversible encephalopathy, a previously undescribed phenomenon.", "question": "Treatment.Time_elapsed in LTG overdose", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11554897_1_2965", "context": "CONCLUSIONS: LTG overdose may result in a severe but reversible encephalopathy, a previously undescribed phenomenon.", "question": "Treatment.Duration in LTG overdose", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11554897_1_2966", "context": "CONCLUSIONS: LTG overdose may result in a severe but reversible encephalopathy, a previously undescribed phenomenon.", "question": "Treatment.Disorder in LTG overdose", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11554897_1_2967", "context": "CONCLUSIONS: LTG overdose may result in a severe but reversible encephalopathy, a previously undescribed phenomenon.", "question": "Combination.Drug in LTG overdose", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "14712320_7_2968", "context": "In this report, we describe a case of rhabdomyolysis and acute renal failure secondary to the interaction between danazol and simvastatin.", "question": "Treatment.Drug in interaction between danazol and simvastatin", "question_type": "Adverse_event.Treatment.Drug", "answers": "danazol; simvastatin"}, {"id": "14712320_7_2969", "context": "In this report, we describe a case of rhabdomyolysis and acute renal failure secondary to the interaction between danazol and simvastatin.", "question": "Treatment.Dosage in interaction between danazol and simvastatin", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "14712320_7_2970", "context": "In this report, we describe a case of rhabdomyolysis and acute renal failure secondary to the interaction between danazol and simvastatin.", "question": "Treatment.Freq in interaction between danazol and simvastatin", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "14712320_7_2971", "context": "In this report, we describe a case of rhabdomyolysis and acute renal failure secondary to the interaction between danazol and simvastatin.", "question": "Treatment.Route in interaction between danazol and simvastatin", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "14712320_7_2972", "context": "In this report, we describe a case of rhabdomyolysis and acute renal failure secondary to the interaction between danazol and simvastatin.", "question": "Treatment.Time_elapsed in interaction between danazol and simvastatin", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "14712320_7_2973", "context": "In this report, we describe a case of rhabdomyolysis and acute renal failure secondary to the interaction between danazol and simvastatin.", "question": "Treatment.Duration in interaction between danazol and simvastatin", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "14712320_7_2974", "context": "In this report, we describe a case of rhabdomyolysis and acute renal failure secondary to the interaction between danazol and simvastatin.", "question": "Treatment.Disorder in interaction between danazol and simvastatin", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "14712320_7_2975", "context": "In this report, we describe a case of rhabdomyolysis and acute renal failure secondary to the interaction between danazol and simvastatin.", "question": "Combination.Drug in interaction between danazol and simvastatin", "question_type": "Adverse_event.Combination.Drug", "answers": "danazol; simvastatin"}, {"id": "14660304_1_2976", "context": "Infectious toxicity of dexamethasone during all remission-induction chemotherapy: report of two cases and literature review.", "question": "Subject.Age in two cases", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "14660304_1_2977", "context": "Infectious toxicity of dexamethasone during all remission-induction chemotherapy: report of two cases and literature review.", "question": "Subject.Gender in two cases", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "14660304_1_2978", "context": "Infectious toxicity of dexamethasone during all remission-induction chemotherapy: report of two cases and literature review.", "question": "Subject.Population in two cases", "question_type": "Adverse_event.Subject.Population", "answers": "two"}, {"id": "14660304_1_2979", "context": "Infectious toxicity of dexamethasone during all remission-induction chemotherapy: report of two cases and literature review.", "question": "Subject.Race in two cases", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "14660304_1_2980", "context": "Infectious toxicity of dexamethasone during all remission-induction chemotherapy: report of two cases and literature review.", "question": "Subject.Disorder in two cases", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "14660304_1_2981", "context": "Infectious toxicity of dexamethasone during all remission-induction chemotherapy: report of two cases and literature review.", "question": "Treatment.Drug in dexamethasone; all remission-induction chemotherapy", "question_type": "Adverse_event.Treatment.Drug", "answers": "dexamethasone"}, {"id": "14660304_1_2982", "context": "Infectious toxicity of dexamethasone during all remission-induction chemotherapy: report of two cases and literature review.", "question": "Treatment.Dosage in dexamethasone; all remission-induction chemotherapy", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "14660304_1_2983", "context": "Infectious toxicity of dexamethasone during all remission-induction chemotherapy: report of two cases and literature review.", "question": "Treatment.Freq in dexamethasone; all remission-induction chemotherapy", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "14660304_1_2984", "context": "Infectious toxicity of dexamethasone during all remission-induction chemotherapy: report of two cases and literature review.", "question": "Treatment.Route in dexamethasone; all remission-induction chemotherapy", "question_type": "Adverse_event.Treatment.Route", "answers": "chemotherapy"}, {"id": "14660304_1_2985", "context": "Infectious toxicity of dexamethasone during all remission-induction chemotherapy: report of two cases and literature review.", "question": "Treatment.Time_elapsed in dexamethasone; all remission-induction chemotherapy", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "14660304_1_2986", "context": "Infectious toxicity of dexamethasone during all remission-induction chemotherapy: report of two cases and literature review.", "question": "Treatment.Duration in dexamethasone; all remission-induction chemotherapy", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "14660304_1_2987", "context": "Infectious toxicity of dexamethasone during all remission-induction chemotherapy: report of two cases and literature review.", "question": "Treatment.Disorder in dexamethasone; all remission-induction chemotherapy", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "14660304_1_2988", "context": "Infectious toxicity of dexamethasone during all remission-induction chemotherapy: report of two cases and literature review.", "question": "Combination.Drug in dexamethasone; all remission-induction chemotherapy", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "19531696_3_2989", "context": "A 56-year-old white male had been receiving chronic warfarin therapy for 11 years after mechanical heart valve replacement.", "question": "Subject.Age in A 56-year-old white male", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": "56-year-old"}, {"id": "19531696_3_2990", "context": "A 56-year-old white male had been receiving chronic warfarin therapy for 11 years after mechanical heart valve replacement.", "question": "Subject.Gender in A 56-year-old white male", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": "male"}, {"id": "19531696_3_2991", "context": "A 56-year-old white male had been receiving chronic warfarin therapy for 11 years after mechanical heart valve replacement.", "question": "Subject.Population in A 56-year-old white male", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "19531696_3_2992", "context": "A 56-year-old white male had been receiving chronic warfarin therapy for 11 years after mechanical heart valve replacement.", "question": "Subject.Race in A 56-year-old white male", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": "white"}, {"id": "19531696_3_2993", "context": "A 56-year-old white male had been receiving chronic warfarin therapy for 11 years after mechanical heart valve replacement.", "question": "Subject.Disorder in A 56-year-old white male", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "19531696_3_2994", "context": "A 56-year-old white male had been receiving chronic warfarin therapy for 11 years after mechanical heart valve replacement.", "question": "Treatment.Drug in chronic warfarin therapy for 11 years after mechanical heart valve replacement", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "warfarin"}, {"id": "19531696_3_2995", "context": "A 56-year-old white male had been receiving chronic warfarin therapy for 11 years after mechanical heart valve replacement.", "question": "Treatment.Dosage in chronic warfarin therapy for 11 years after mechanical heart valve replacement", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "19531696_3_2996", "context": "A 56-year-old white male had been receiving chronic warfarin therapy for 11 years after mechanical heart valve replacement.", "question": "Treatment.Freq in chronic warfarin therapy for 11 years after mechanical heart valve replacement", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "19531696_3_2997", "context": "A 56-year-old white male had been receiving chronic warfarin therapy for 11 years after mechanical heart valve replacement.", "question": "Treatment.Route in chronic warfarin therapy for 11 years after mechanical heart valve replacement", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "19531696_3_2998", "context": "A 56-year-old white male had been receiving chronic warfarin therapy for 11 years after mechanical heart valve replacement.", "question": "Treatment.Time_elapsed in chronic warfarin therapy for 11 years after mechanical heart valve replacement", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19531696_3_2999", "context": "A 56-year-old white male had been receiving chronic warfarin therapy for 11 years after mechanical heart valve replacement.", "question": "Treatment.Duration in chronic warfarin therapy for 11 years after mechanical heart valve replacement", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "19531696_3_3000", "context": "A 56-year-old white male had been receiving chronic warfarin therapy for 11 years after mechanical heart valve replacement.", "question": "Treatment.Disorder in chronic warfarin therapy for 11 years after mechanical heart valve replacement", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "19531696_3_3001", "context": "A 56-year-old white male had been receiving chronic warfarin therapy for 11 years after mechanical heart valve replacement.", "question": "Combination.Drug in chronic warfarin therapy for 11 years after mechanical heart valve replacement", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "12962465_3_3002", "context": "Isoniazid associated, painful, bilateral gynaecomastia.", "question": "Treatment.Drug in Isoniazid", "question_type": "Adverse_event.Treatment.Drug", "answers": "Isoniazid"}, {"id": "12962465_3_3003", "context": "Isoniazid associated, painful, bilateral gynaecomastia.", "question": "Treatment.Dosage in Isoniazid", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12962465_3_3004", "context": "Isoniazid associated, painful, bilateral gynaecomastia.", "question": "Treatment.Freq in Isoniazid", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12962465_3_3005", "context": "Isoniazid associated, painful, bilateral gynaecomastia.", "question": "Treatment.Route in Isoniazid", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12962465_3_3006", "context": "Isoniazid associated, painful, bilateral gynaecomastia.", "question": "Treatment.Time_elapsed in Isoniazid", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12962465_3_3007", "context": "Isoniazid associated, painful, bilateral gynaecomastia.", "question": "Treatment.Duration in Isoniazid", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12962465_3_3008", "context": "Isoniazid associated, painful, bilateral gynaecomastia.", "question": "Treatment.Disorder in Isoniazid", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12962465_3_3009", "context": "Isoniazid associated, painful, bilateral gynaecomastia.", "question": "Combination.Drug in Isoniazid", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "2924444_5_3010", "context": "Electrocardiographic findings and laboratory data indicated a diagnosis of acute myocardial infarction due to the L-thyroxine therapy.", "question": "Treatment.Drug in the L-thyroxine therapy.", "question_type": "Adverse_event.Treatment.Drug", "answers": "L-thyroxine"}, {"id": "2924444_5_3011", "context": "Electrocardiographic findings and laboratory data indicated a diagnosis of acute myocardial infarction due to the L-thyroxine therapy.", "question": "Treatment.Dosage in the L-thyroxine therapy.", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "2924444_5_3012", "context": "Electrocardiographic findings and laboratory data indicated a diagnosis of acute myocardial infarction due to the L-thyroxine therapy.", "question": "Treatment.Freq in the L-thyroxine therapy.", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2924444_5_3013", "context": "Electrocardiographic findings and laboratory data indicated a diagnosis of acute myocardial infarction due to the L-thyroxine therapy.", "question": "Treatment.Route in the L-thyroxine therapy.", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "2924444_5_3014", "context": "Electrocardiographic findings and laboratory data indicated a diagnosis of acute myocardial infarction due to the L-thyroxine therapy.", "question": "Treatment.Time_elapsed in the L-thyroxine therapy.", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2924444_5_3015", "context": "Electrocardiographic findings and laboratory data indicated a diagnosis of acute myocardial infarction due to the L-thyroxine therapy.", "question": "Treatment.Duration in the L-thyroxine therapy.", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2924444_5_3016", "context": "Electrocardiographic findings and laboratory data indicated a diagnosis of acute myocardial infarction due to the L-thyroxine therapy.", "question": "Treatment.Disorder in the L-thyroxine therapy.", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "2924444_5_3017", "context": "Electrocardiographic findings and laboratory data indicated a diagnosis of acute myocardial infarction due to the L-thyroxine therapy.", "question": "Combination.Drug in the L-thyroxine therapy.", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "20154441_1_3018", "context": "Combining methylephedrine and Chinese herbal drugs might carry a risk of stroke.", "question": "Treatment.Drug in Combining methylephedrine and Chinese herbal drugs", "question_type": "Adverse_event.Treatment.Drug", "answers": "methylephedrine; Chinese herbal drugs"}, {"id": "20154441_1_3019", "context": "Combining methylephedrine and Chinese herbal drugs might carry a risk of stroke.", "question": "Treatment.Dosage in Combining methylephedrine and Chinese herbal drugs", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "20154441_1_3020", "context": "Combining methylephedrine and Chinese herbal drugs might carry a risk of stroke.", "question": "Treatment.Freq in Combining methylephedrine and Chinese herbal drugs", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "20154441_1_3021", "context": "Combining methylephedrine and Chinese herbal drugs might carry a risk of stroke.", "question": "Treatment.Route in Combining methylephedrine and Chinese herbal drugs", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "20154441_1_3022", "context": "Combining methylephedrine and Chinese herbal drugs might carry a risk of stroke.", "question": "Treatment.Time_elapsed in Combining methylephedrine and Chinese herbal drugs", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "20154441_1_3023", "context": "Combining methylephedrine and Chinese herbal drugs might carry a risk of stroke.", "question": "Treatment.Duration in Combining methylephedrine and Chinese herbal drugs", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "20154441_1_3024", "context": "Combining methylephedrine and Chinese herbal drugs might carry a risk of stroke.", "question": "Treatment.Disorder in Combining methylephedrine and Chinese herbal drugs", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "20154441_1_3025", "context": "Combining methylephedrine and Chinese herbal drugs might carry a risk of stroke.", "question": "Combination.Drug in Combining methylephedrine and Chinese herbal drugs", "question_type": "Adverse_event.Combination.Drug", "answers": "methylephedrine; Chinese herbal drugs"}, {"id": "18025525_11_3026", "context": "Coadministration of 200 mg bid voriconazole with 400 mg (or higher) qd efavirenz is contraindicated due to the clinically significant effect of efavirenz on voriconazole pharmacokinetics.", "question": "Treatment.Drug in Coadministration of 200 mg bid voriconazole with 400 mg (or higher) qd efavirenz; efavirenz on voriconazole", "question_type": "Adverse_event.Treatment.Drug", "answers": "voriconazole; efavirenz; efavirenz; voriconazole"}, {"id": "18025525_11_3027", "context": "Coadministration of 200 mg bid voriconazole with 400 mg (or higher) qd efavirenz is contraindicated due to the clinically significant effect of efavirenz on voriconazole pharmacokinetics.", "question": "Treatment.Dosage in Coadministration of 200 mg bid voriconazole with 400 mg (or higher) qd efavirenz; efavirenz on voriconazole", "question_type": "Adverse_event.Treatment.Dosage", "answers": "200 mg; 400 mg"}, {"id": "18025525_11_3028", "context": "Coadministration of 200 mg bid voriconazole with 400 mg (or higher) qd efavirenz is contraindicated due to the clinically significant effect of efavirenz on voriconazole pharmacokinetics.", "question": "Treatment.Freq in Coadministration of 200 mg bid voriconazole with 400 mg (or higher) qd efavirenz; efavirenz on voriconazole", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18025525_11_3029", "context": "Coadministration of 200 mg bid voriconazole with 400 mg (or higher) qd efavirenz is contraindicated due to the clinically significant effect of efavirenz on voriconazole pharmacokinetics.", "question": "Treatment.Route in Coadministration of 200 mg bid voriconazole with 400 mg (or higher) qd efavirenz; efavirenz on voriconazole", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18025525_11_3030", "context": "Coadministration of 200 mg bid voriconazole with 400 mg (or higher) qd efavirenz is contraindicated due to the clinically significant effect of efavirenz on voriconazole pharmacokinetics.", "question": "Treatment.Time_elapsed in Coadministration of 200 mg bid voriconazole with 400 mg (or higher) qd efavirenz; efavirenz on voriconazole", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18025525_11_3031", "context": "Coadministration of 200 mg bid voriconazole with 400 mg (or higher) qd efavirenz is contraindicated due to the clinically significant effect of efavirenz on voriconazole pharmacokinetics.", "question": "Treatment.Duration in Coadministration of 200 mg bid voriconazole with 400 mg (or higher) qd efavirenz; efavirenz on voriconazole", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18025525_11_3032", "context": "Coadministration of 200 mg bid voriconazole with 400 mg (or higher) qd efavirenz is contraindicated due to the clinically significant effect of efavirenz on voriconazole pharmacokinetics.", "question": "Treatment.Disorder in Coadministration of 200 mg bid voriconazole with 400 mg (or higher) qd efavirenz; efavirenz on voriconazole", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18025525_11_3033", "context": "Coadministration of 200 mg bid voriconazole with 400 mg (or higher) qd efavirenz is contraindicated due to the clinically significant effect of efavirenz on voriconazole pharmacokinetics.", "question": "Combination.Drug in Coadministration of 200 mg bid voriconazole with 400 mg (or higher) qd efavirenz; efavirenz on voriconazole", "question_type": "Adverse_event.Combination.Drug", "answers": "voriconazole; efavirenz"}, {"id": "22010004_12_3034", "context": "An interaction between niacin and warfarin likely elevated the INR in this patient because of synergistic coagulopathy and pharmacokinetic effects of niacin.", "question": "Subject.Age in this patient", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "22010004_12_3035", "context": "An interaction between niacin and warfarin likely elevated the INR in this patient because of synergistic coagulopathy and pharmacokinetic effects of niacin.", "question": "Subject.Gender in this patient", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "22010004_12_3036", "context": "An interaction between niacin and warfarin likely elevated the INR in this patient because of synergistic coagulopathy and pharmacokinetic effects of niacin.", "question": "Subject.Population in this patient", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "22010004_12_3037", "context": "An interaction between niacin and warfarin likely elevated the INR in this patient because of synergistic coagulopathy and pharmacokinetic effects of niacin.", "question": "Subject.Race in this patient", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "22010004_12_3038", "context": "An interaction between niacin and warfarin likely elevated the INR in this patient because of synergistic coagulopathy and pharmacokinetic effects of niacin.", "question": "Subject.Disorder in this patient", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "22010004_12_3039", "context": "An interaction between niacin and warfarin likely elevated the INR in this patient because of synergistic coagulopathy and pharmacokinetic effects of niacin.", "question": "Treatment.Drug in interaction between niacin and warfarin", "question_type": "Adverse_event.Treatment.Drug", "answers": "niacin; warfarin"}, {"id": "22010004_12_3040", "context": "An interaction between niacin and warfarin likely elevated the INR in this patient because of synergistic coagulopathy and pharmacokinetic effects of niacin.", "question": "Treatment.Dosage in interaction between niacin and warfarin", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "22010004_12_3041", "context": "An interaction between niacin and warfarin likely elevated the INR in this patient because of synergistic coagulopathy and pharmacokinetic effects of niacin.", "question": "Treatment.Freq in interaction between niacin and warfarin", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "22010004_12_3042", "context": "An interaction between niacin and warfarin likely elevated the INR in this patient because of synergistic coagulopathy and pharmacokinetic effects of niacin.", "question": "Treatment.Route in interaction between niacin and warfarin", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "22010004_12_3043", "context": "An interaction between niacin and warfarin likely elevated the INR in this patient because of synergistic coagulopathy and pharmacokinetic effects of niacin.", "question": "Treatment.Time_elapsed in interaction between niacin and warfarin", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "22010004_12_3044", "context": "An interaction between niacin and warfarin likely elevated the INR in this patient because of synergistic coagulopathy and pharmacokinetic effects of niacin.", "question": "Treatment.Duration in interaction between niacin and warfarin", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "22010004_12_3045", "context": "An interaction between niacin and warfarin likely elevated the INR in this patient because of synergistic coagulopathy and pharmacokinetic effects of niacin.", "question": "Treatment.Disorder in interaction between niacin and warfarin", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "22010004_12_3046", "context": "An interaction between niacin and warfarin likely elevated the INR in this patient because of synergistic coagulopathy and pharmacokinetic effects of niacin.", "question": "Combination.Drug in interaction between niacin and warfarin", "question_type": "Adverse_event.Combination.Drug", "answers": "niacin; warfarin"}, {"id": "12692521_2_3047", "context": "We present two cases in which both patients suffered with CLS, which we believe was caused following administration of granulocyte colony-stimulating factor, to our knowledge not described in the intensive care patient previously.", "question": "Subject.Age in two cases in which both patients suffered with CLS", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "12692521_2_3048", "context": "We present two cases in which both patients suffered with CLS, which we believe was caused following administration of granulocyte colony-stimulating factor, to our knowledge not described in the intensive care patient previously.", "question": "Subject.Gender in two cases in which both patients suffered with CLS", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "12692521_2_3049", "context": "We present two cases in which both patients suffered with CLS, which we believe was caused following administration of granulocyte colony-stimulating factor, to our knowledge not described in the intensive care patient previously.", "question": "Subject.Population in two cases in which both patients suffered with CLS", "question_type": "Adverse_event.Subject.Population", "answers": "two"}, {"id": "12692521_2_3050", "context": "We present two cases in which both patients suffered with CLS, which we believe was caused following administration of granulocyte colony-stimulating factor, to our knowledge not described in the intensive care patient previously.", "question": "Subject.Race in two cases in which both patients suffered with CLS", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "12692521_2_3051", "context": "We present two cases in which both patients suffered with CLS, which we believe was caused following administration of granulocyte colony-stimulating factor, to our knowledge not described in the intensive care patient previously.", "question": "Subject.Disorder in two cases in which both patients suffered with CLS", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "12692521_2_3052", "context": "We present two cases in which both patients suffered with CLS, which we believe was caused following administration of granulocyte colony-stimulating factor, to our knowledge not described in the intensive care patient previously.", "question": "Treatment.Drug in granulocyte colony-stimulating factor", "question_type": "Adverse_event.Treatment.Drug", "answers": "granulocyte colony-stimulating facto"}, {"id": "12692521_2_3053", "context": "We present two cases in which both patients suffered with CLS, which we believe was caused following administration of granulocyte colony-stimulating factor, to our knowledge not described in the intensive care patient previously.", "question": "Treatment.Dosage in granulocyte colony-stimulating factor", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12692521_2_3054", "context": "We present two cases in which both patients suffered with CLS, which we believe was caused following administration of granulocyte colony-stimulating factor, to our knowledge not described in the intensive care patient previously.", "question": "Treatment.Freq in granulocyte colony-stimulating factor", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12692521_2_3055", "context": "We present two cases in which both patients suffered with CLS, which we believe was caused following administration of granulocyte colony-stimulating factor, to our knowledge not described in the intensive care patient previously.", "question": "Treatment.Route in granulocyte colony-stimulating factor", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12692521_2_3056", "context": "We present two cases in which both patients suffered with CLS, which we believe was caused following administration of granulocyte colony-stimulating factor, to our knowledge not described in the intensive care patient previously.", "question": "Treatment.Time_elapsed in granulocyte colony-stimulating factor", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12692521_2_3057", "context": "We present two cases in which both patients suffered with CLS, which we believe was caused following administration of granulocyte colony-stimulating factor, to our knowledge not described in the intensive care patient previously.", "question": "Treatment.Duration in granulocyte colony-stimulating factor", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12692521_2_3058", "context": "We present two cases in which both patients suffered with CLS, which we believe was caused following administration of granulocyte colony-stimulating factor, to our knowledge not described in the intensive care patient previously.", "question": "Treatment.Disorder in granulocyte colony-stimulating factor", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12692521_2_3059", "context": "We present two cases in which both patients suffered with CLS, which we believe was caused following administration of granulocyte colony-stimulating factor, to our knowledge not described in the intensive care patient previously.", "question": "Combination.Drug in granulocyte colony-stimulating factor", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12452753_1_3060", "context": "Capecitabine was discontinued and the allergic reactions resolved after the woman took diphenhydramine for 1 week.", "question": "Subject.Age in woman", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "12452753_1_3061", "context": "Capecitabine was discontinued and the allergic reactions resolved after the woman took diphenhydramine for 1 week.", "question": "Subject.Gender in woman", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": "woman"}, {"id": "12452753_1_3062", "context": "Capecitabine was discontinued and the allergic reactions resolved after the woman took diphenhydramine for 1 week.", "question": "Subject.Population in woman", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "12452753_1_3063", "context": "Capecitabine was discontinued and the allergic reactions resolved after the woman took diphenhydramine for 1 week.", "question": "Subject.Race in woman", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "12452753_1_3064", "context": "Capecitabine was discontinued and the allergic reactions resolved after the woman took diphenhydramine for 1 week.", "question": "Subject.Disorder in woman", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "12452753_1_3065", "context": "Capecitabine was discontinued and the allergic reactions resolved after the woman took diphenhydramine for 1 week.", "question": "Treatment.Drug in diphenhydramine for 1 week", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "diphenhydramine"}, {"id": "12452753_1_3066", "context": "Capecitabine was discontinued and the allergic reactions resolved after the woman took diphenhydramine for 1 week.", "question": "Treatment.Dosage in diphenhydramine for 1 week", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "12452753_1_3067", "context": "Capecitabine was discontinued and the allergic reactions resolved after the woman took diphenhydramine for 1 week.", "question": "Treatment.Freq in diphenhydramine for 1 week", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "12452753_1_3068", "context": "Capecitabine was discontinued and the allergic reactions resolved after the woman took diphenhydramine for 1 week.", "question": "Treatment.Route in diphenhydramine for 1 week", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "12452753_1_3069", "context": "Capecitabine was discontinued and the allergic reactions resolved after the woman took diphenhydramine for 1 week.", "question": "Treatment.Time_elapsed in diphenhydramine for 1 week", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": "1 week"}, {"id": "12452753_1_3070", "context": "Capecitabine was discontinued and the allergic reactions resolved after the woman took diphenhydramine for 1 week.", "question": "Treatment.Duration in diphenhydramine for 1 week", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "12452753_1_3071", "context": "Capecitabine was discontinued and the allergic reactions resolved after the woman took diphenhydramine for 1 week.", "question": "Treatment.Disorder in diphenhydramine for 1 week", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "12452753_1_3072", "context": "Capecitabine was discontinued and the allergic reactions resolved after the woman took diphenhydramine for 1 week.", "question": "Combination.Drug in diphenhydramine for 1 week", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "18812562_5_3073", "context": "Intravenous fluconazole 400 mg, followed by 100 mg every 24 hours according to impaired renal function, was immediately started; to avoid further nephrotoxicity, immunosuppressant therapy was switched from cyclosporine plus mycophenolate mofetil to oral everolimus 0.75 mg every 12 hours.", "question": "Treatment.Drug in Intravenous fluconazole 400 mg, followed by 100 mg every 24 hours; immunosuppressant therapy was switched from cyclosporine plus mycophenolate mofetil to oral everolimus 0.75 mg every 12 hours", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "everolimus; mycophenolate mofetil; cyclosporine; fluconazole"}, {"id": "18812562_5_3074", "context": "Intravenous fluconazole 400 mg, followed by 100 mg every 24 hours according to impaired renal function, was immediately started; to avoid further nephrotoxicity, immunosuppressant therapy was switched from cyclosporine plus mycophenolate mofetil to oral everolimus 0.75 mg every 12 hours.", "question": "Treatment.Dosage in Intravenous fluconazole 400 mg, followed by 100 mg every 24 hours; immunosuppressant therapy was switched from cyclosporine plus mycophenolate mofetil to oral everolimus 0.75 mg every 12 hours", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": "0.75 mg every 12 hours; 400 mg, followed by 100 mg every 24 hours"}, {"id": "18812562_5_3075", "context": "Intravenous fluconazole 400 mg, followed by 100 mg every 24 hours according to impaired renal function, was immediately started; to avoid further nephrotoxicity, immunosuppressant therapy was switched from cyclosporine plus mycophenolate mofetil to oral everolimus 0.75 mg every 12 hours.", "question": "Treatment.Freq in Intravenous fluconazole 400 mg, followed by 100 mg every 24 hours; immunosuppressant therapy was switched from cyclosporine plus mycophenolate mofetil to oral everolimus 0.75 mg every 12 hours", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "18812562_5_3076", "context": "Intravenous fluconazole 400 mg, followed by 100 mg every 24 hours according to impaired renal function, was immediately started; to avoid further nephrotoxicity, immunosuppressant therapy was switched from cyclosporine plus mycophenolate mofetil to oral everolimus 0.75 mg every 12 hours.", "question": "Treatment.Route in Intravenous fluconazole 400 mg, followed by 100 mg every 24 hours; immunosuppressant therapy was switched from cyclosporine plus mycophenolate mofetil to oral everolimus 0.75 mg every 12 hours", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": "oral; Intravenous"}, {"id": "18812562_5_3077", "context": "Intravenous fluconazole 400 mg, followed by 100 mg every 24 hours according to impaired renal function, was immediately started; to avoid further nephrotoxicity, immunosuppressant therapy was switched from cyclosporine plus mycophenolate mofetil to oral everolimus 0.75 mg every 12 hours.", "question": "Treatment.Time_elapsed in Intravenous fluconazole 400 mg, followed by 100 mg every 24 hours; immunosuppressant therapy was switched from cyclosporine plus mycophenolate mofetil to oral everolimus 0.75 mg every 12 hours", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18812562_5_3078", "context": "Intravenous fluconazole 400 mg, followed by 100 mg every 24 hours according to impaired renal function, was immediately started; to avoid further nephrotoxicity, immunosuppressant therapy was switched from cyclosporine plus mycophenolate mofetil to oral everolimus 0.75 mg every 12 hours.", "question": "Treatment.Duration in Intravenous fluconazole 400 mg, followed by 100 mg every 24 hours; immunosuppressant therapy was switched from cyclosporine plus mycophenolate mofetil to oral everolimus 0.75 mg every 12 hours", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "18812562_5_3079", "context": "Intravenous fluconazole 400 mg, followed by 100 mg every 24 hours according to impaired renal function, was immediately started; to avoid further nephrotoxicity, immunosuppressant therapy was switched from cyclosporine plus mycophenolate mofetil to oral everolimus 0.75 mg every 12 hours.", "question": "Treatment.Disorder in Intravenous fluconazole 400 mg, followed by 100 mg every 24 hours; immunosuppressant therapy was switched from cyclosporine plus mycophenolate mofetil to oral everolimus 0.75 mg every 12 hours", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "nephrotoxicity"}, {"id": "18812562_5_3080", "context": "Intravenous fluconazole 400 mg, followed by 100 mg every 24 hours according to impaired renal function, was immediately started; to avoid further nephrotoxicity, immunosuppressant therapy was switched from cyclosporine plus mycophenolate mofetil to oral everolimus 0.75 mg every 12 hours.", "question": "Combination.Drug in Intravenous fluconazole 400 mg, followed by 100 mg every 24 hours; immunosuppressant therapy was switched from cyclosporine plus mycophenolate mofetil to oral everolimus 0.75 mg every 12 hours", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": "cyclosporine; mycophenolate mofetil; fluconazole; everolimus"}, {"id": "1827039_2_3081", "context": "We report 3 patients with severe hepatocellular damage due to CPA therapy, 2 with fatal fulminant hepatitis.", "question": "Subject.Age in 3 patients", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "1827039_2_3082", "context": "We report 3 patients with severe hepatocellular damage due to CPA therapy, 2 with fatal fulminant hepatitis.", "question": "Subject.Gender in 3 patients", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "1827039_2_3083", "context": "We report 3 patients with severe hepatocellular damage due to CPA therapy, 2 with fatal fulminant hepatitis.", "question": "Subject.Population in 3 patients", "question_type": "Adverse_event.Subject.Population", "answers": "3"}, {"id": "1827039_2_3084", "context": "We report 3 patients with severe hepatocellular damage due to CPA therapy, 2 with fatal fulminant hepatitis.", "question": "Subject.Race in 3 patients", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "1827039_2_3085", "context": "We report 3 patients with severe hepatocellular damage due to CPA therapy, 2 with fatal fulminant hepatitis.", "question": "Subject.Disorder in 3 patients", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "1827039_2_3086", "context": "We report 3 patients with severe hepatocellular damage due to CPA therapy, 2 with fatal fulminant hepatitis.", "question": "Treatment.Drug in CPA", "question_type": "Adverse_event.Treatment.Drug", "answers": "CPA"}, {"id": "1827039_2_3087", "context": "We report 3 patients with severe hepatocellular damage due to CPA therapy, 2 with fatal fulminant hepatitis.", "question": "Treatment.Dosage in CPA", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "1827039_2_3088", "context": "We report 3 patients with severe hepatocellular damage due to CPA therapy, 2 with fatal fulminant hepatitis.", "question": "Treatment.Freq in CPA", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "1827039_2_3089", "context": "We report 3 patients with severe hepatocellular damage due to CPA therapy, 2 with fatal fulminant hepatitis.", "question": "Treatment.Route in CPA", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "1827039_2_3090", "context": "We report 3 patients with severe hepatocellular damage due to CPA therapy, 2 with fatal fulminant hepatitis.", "question": "Treatment.Time_elapsed in CPA", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "1827039_2_3091", "context": "We report 3 patients with severe hepatocellular damage due to CPA therapy, 2 with fatal fulminant hepatitis.", "question": "Treatment.Duration in CPA", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "1827039_2_3092", "context": "We report 3 patients with severe hepatocellular damage due to CPA therapy, 2 with fatal fulminant hepatitis.", "question": "Treatment.Disorder in CPA", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "1827039_2_3093", "context": "We report 3 patients with severe hepatocellular damage due to CPA therapy, 2 with fatal fulminant hepatitis.", "question": "Combination.Drug in CPA", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "1827039_2_3094", "context": "We report 3 patients with severe hepatocellular damage due to CPA therapy, 2 with fatal fulminant hepatitis.", "question": "Subject.Age in 2", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "1827039_2_3095", "context": "We report 3 patients with severe hepatocellular damage due to CPA therapy, 2 with fatal fulminant hepatitis.", "question": "Subject.Gender in 2", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "1827039_2_3096", "context": "We report 3 patients with severe hepatocellular damage due to CPA therapy, 2 with fatal fulminant hepatitis.", "question": "Subject.Population in 2", "question_type": "Adverse_event.Subject.Population", "answers": "2"}, {"id": "1827039_2_3097", "context": "We report 3 patients with severe hepatocellular damage due to CPA therapy, 2 with fatal fulminant hepatitis.", "question": "Subject.Race in 2", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "1827039_2_3098", "context": "We report 3 patients with severe hepatocellular damage due to CPA therapy, 2 with fatal fulminant hepatitis.", "question": "Subject.Disorder in 2", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "1827039_2_3099", "context": "We report 3 patients with severe hepatocellular damage due to CPA therapy, 2 with fatal fulminant hepatitis.", "question": "Treatment.Drug in CPA", "question_type": "Adverse_event.Treatment.Drug", "answers": "CPA"}, {"id": "1827039_2_3100", "context": "We report 3 patients with severe hepatocellular damage due to CPA therapy, 2 with fatal fulminant hepatitis.", "question": "Treatment.Dosage in CPA", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "1827039_2_3101", "context": "We report 3 patients with severe hepatocellular damage due to CPA therapy, 2 with fatal fulminant hepatitis.", "question": "Treatment.Freq in CPA", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "1827039_2_3102", "context": "We report 3 patients with severe hepatocellular damage due to CPA therapy, 2 with fatal fulminant hepatitis.", "question": "Treatment.Route in CPA", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "1827039_2_3103", "context": "We report 3 patients with severe hepatocellular damage due to CPA therapy, 2 with fatal fulminant hepatitis.", "question": "Treatment.Time_elapsed in CPA", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "1827039_2_3104", "context": "We report 3 patients with severe hepatocellular damage due to CPA therapy, 2 with fatal fulminant hepatitis.", "question": "Treatment.Duration in CPA", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "1827039_2_3105", "context": "We report 3 patients with severe hepatocellular damage due to CPA therapy, 2 with fatal fulminant hepatitis.", "question": "Treatment.Disorder in CPA", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "1827039_2_3106", "context": "We report 3 patients with severe hepatocellular damage due to CPA therapy, 2 with fatal fulminant hepatitis.", "question": "Combination.Drug in CPA", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12702914_2_3107", "context": "Soon after introduction of insulin therapy, she developed severe anasarca, including marked peripheral oedema, ascites and pleural effusion.", "question": "Subject.Age in she", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "12702914_2_3108", "context": "Soon after introduction of insulin therapy, she developed severe anasarca, including marked peripheral oedema, ascites and pleural effusion.", "question": "Subject.Gender in she", "question_type": "Adverse_event.Subject.Gender", "answers": "she"}, {"id": "12702914_2_3109", "context": "Soon after introduction of insulin therapy, she developed severe anasarca, including marked peripheral oedema, ascites and pleural effusion.", "question": "Subject.Population in she", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "12702914_2_3110", "context": "Soon after introduction of insulin therapy, she developed severe anasarca, including marked peripheral oedema, ascites and pleural effusion.", "question": "Subject.Race in she", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "12702914_2_3111", "context": "Soon after introduction of insulin therapy, she developed severe anasarca, including marked peripheral oedema, ascites and pleural effusion.", "question": "Subject.Disorder in she", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "12702914_2_3112", "context": "Soon after introduction of insulin therapy, she developed severe anasarca, including marked peripheral oedema, ascites and pleural effusion.", "question": "Treatment.Drug in insulin", "question_type": "Adverse_event.Treatment.Drug", "answers": "insulin"}, {"id": "12702914_2_3113", "context": "Soon after introduction of insulin therapy, she developed severe anasarca, including marked peripheral oedema, ascites and pleural effusion.", "question": "Treatment.Dosage in insulin", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12702914_2_3114", "context": "Soon after introduction of insulin therapy, she developed severe anasarca, including marked peripheral oedema, ascites and pleural effusion.", "question": "Treatment.Freq in insulin", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12702914_2_3115", "context": "Soon after introduction of insulin therapy, she developed severe anasarca, including marked peripheral oedema, ascites and pleural effusion.", "question": "Treatment.Route in insulin", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12702914_2_3116", "context": "Soon after introduction of insulin therapy, she developed severe anasarca, including marked peripheral oedema, ascites and pleural effusion.", "question": "Treatment.Time_elapsed in insulin", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12702914_2_3117", "context": "Soon after introduction of insulin therapy, she developed severe anasarca, including marked peripheral oedema, ascites and pleural effusion.", "question": "Treatment.Duration in insulin", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12702914_2_3118", "context": "Soon after introduction of insulin therapy, she developed severe anasarca, including marked peripheral oedema, ascites and pleural effusion.", "question": "Treatment.Disorder in insulin", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12702914_2_3119", "context": "Soon after introduction of insulin therapy, she developed severe anasarca, including marked peripheral oedema, ascites and pleural effusion.", "question": "Combination.Drug in insulin", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15053046_3_3120", "context": "We describe a continuous ambulatory peritoneal dialysis (CAPD) patient that developed vancomycin-induced agranulocytosis during treatment for methicillin-resistant Staphylococcus aureus (MRSA)-associated external cuff infection and pneumonia.", "question": "Subject.Age in a continuous ambulatory peritoneal dialysis (CAPD) patient", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "15053046_3_3121", "context": "We describe a continuous ambulatory peritoneal dialysis (CAPD) patient that developed vancomycin-induced agranulocytosis during treatment for methicillin-resistant Staphylococcus aureus (MRSA)-associated external cuff infection and pneumonia.", "question": "Subject.Gender in a continuous ambulatory peritoneal dialysis (CAPD) patient", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15053046_3_3122", "context": "We describe a continuous ambulatory peritoneal dialysis (CAPD) patient that developed vancomycin-induced agranulocytosis during treatment for methicillin-resistant Staphylococcus aureus (MRSA)-associated external cuff infection and pneumonia.", "question": "Subject.Population in a continuous ambulatory peritoneal dialysis (CAPD) patient", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "15053046_3_3123", "context": "We describe a continuous ambulatory peritoneal dialysis (CAPD) patient that developed vancomycin-induced agranulocytosis during treatment for methicillin-resistant Staphylococcus aureus (MRSA)-associated external cuff infection and pneumonia.", "question": "Subject.Race in a continuous ambulatory peritoneal dialysis (CAPD) patient", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15053046_3_3124", "context": "We describe a continuous ambulatory peritoneal dialysis (CAPD) patient that developed vancomycin-induced agranulocytosis during treatment for methicillin-resistant Staphylococcus aureus (MRSA)-associated external cuff infection and pneumonia.", "question": "Subject.Disorder in a continuous ambulatory peritoneal dialysis (CAPD) patient", "question_type": "Adverse_event.Subject.Disorder", "answers": "continuous ambulatory peritoneal dialysis (CAPD)"}, {"id": "15053046_3_3125", "context": "We describe a continuous ambulatory peritoneal dialysis (CAPD) patient that developed vancomycin-induced agranulocytosis during treatment for methicillin-resistant Staphylococcus aureus (MRSA)-associated external cuff infection and pneumonia.", "question": "Treatment.Drug in vancomycin", "question_type": "Adverse_event.Treatment.Drug", "answers": "vancomycin"}, {"id": "15053046_3_3126", "context": "We describe a continuous ambulatory peritoneal dialysis (CAPD) patient that developed vancomycin-induced agranulocytosis during treatment for methicillin-resistant Staphylococcus aureus (MRSA)-associated external cuff infection and pneumonia.", "question": "Treatment.Dosage in vancomycin", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15053046_3_3127", "context": "We describe a continuous ambulatory peritoneal dialysis (CAPD) patient that developed vancomycin-induced agranulocytosis during treatment for methicillin-resistant Staphylococcus aureus (MRSA)-associated external cuff infection and pneumonia.", "question": "Treatment.Freq in vancomycin", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15053046_3_3128", "context": "We describe a continuous ambulatory peritoneal dialysis (CAPD) patient that developed vancomycin-induced agranulocytosis during treatment for methicillin-resistant Staphylococcus aureus (MRSA)-associated external cuff infection and pneumonia.", "question": "Treatment.Route in vancomycin", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15053046_3_3129", "context": "We describe a continuous ambulatory peritoneal dialysis (CAPD) patient that developed vancomycin-induced agranulocytosis during treatment for methicillin-resistant Staphylococcus aureus (MRSA)-associated external cuff infection and pneumonia.", "question": "Treatment.Time_elapsed in vancomycin", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15053046_3_3130", "context": "We describe a continuous ambulatory peritoneal dialysis (CAPD) patient that developed vancomycin-induced agranulocytosis during treatment for methicillin-resistant Staphylococcus aureus (MRSA)-associated external cuff infection and pneumonia.", "question": "Treatment.Duration in vancomycin", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15053046_3_3131", "context": "We describe a continuous ambulatory peritoneal dialysis (CAPD) patient that developed vancomycin-induced agranulocytosis during treatment for methicillin-resistant Staphylococcus aureus (MRSA)-associated external cuff infection and pneumonia.", "question": "Treatment.Disorder in vancomycin", "question_type": "Adverse_event.Treatment.Disorder", "answers": "methicillin-resistant Staphylococcus aureus (MRSA)-associated external cuff infection and pneumonia"}, {"id": "15053046_3_3132", "context": "We describe a continuous ambulatory peritoneal dialysis (CAPD) patient that developed vancomycin-induced agranulocytosis during treatment for methicillin-resistant Staphylococcus aureus (MRSA)-associated external cuff infection and pneumonia.", "question": "Combination.Drug in vancomycin", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17667887_8_3133", "context": "In both cases, we believe that serotonin syndrome was produced by a combination of an antidepressant and an atypical antipsychotic.", "question": "Subject.Age in In both cases", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "17667887_8_3134", "context": "In both cases, we believe that serotonin syndrome was produced by a combination of an antidepressant and an atypical antipsychotic.", "question": "Subject.Gender in In both cases", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "17667887_8_3135", "context": "In both cases, we believe that serotonin syndrome was produced by a combination of an antidepressant and an atypical antipsychotic.", "question": "Subject.Population in In both cases", "question_type": "Adverse_event.Subject.Population", "answers": "both"}, {"id": "17667887_8_3136", "context": "In both cases, we believe that serotonin syndrome was produced by a combination of an antidepressant and an atypical antipsychotic.", "question": "Subject.Race in In both cases", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "17667887_8_3137", "context": "In both cases, we believe that serotonin syndrome was produced by a combination of an antidepressant and an atypical antipsychotic.", "question": "Subject.Disorder in In both cases", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "17667887_8_3138", "context": "In both cases, we believe that serotonin syndrome was produced by a combination of an antidepressant and an atypical antipsychotic.", "question": "Treatment.Drug in a combination of an antidepressant and an atypical antipsychotic", "question_type": "Adverse_event.Treatment.Drug", "answers": "antidepressant; atypical antipsychotic"}, {"id": "17667887_8_3139", "context": "In both cases, we believe that serotonin syndrome was produced by a combination of an antidepressant and an atypical antipsychotic.", "question": "Treatment.Dosage in a combination of an antidepressant and an atypical antipsychotic", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17667887_8_3140", "context": "In both cases, we believe that serotonin syndrome was produced by a combination of an antidepressant and an atypical antipsychotic.", "question": "Treatment.Freq in a combination of an antidepressant and an atypical antipsychotic", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17667887_8_3141", "context": "In both cases, we believe that serotonin syndrome was produced by a combination of an antidepressant and an atypical antipsychotic.", "question": "Treatment.Route in a combination of an antidepressant and an atypical antipsychotic", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17667887_8_3142", "context": "In both cases, we believe that serotonin syndrome was produced by a combination of an antidepressant and an atypical antipsychotic.", "question": "Treatment.Time_elapsed in a combination of an antidepressant and an atypical antipsychotic", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17667887_8_3143", "context": "In both cases, we believe that serotonin syndrome was produced by a combination of an antidepressant and an atypical antipsychotic.", "question": "Treatment.Duration in a combination of an antidepressant and an atypical antipsychotic", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17667887_8_3144", "context": "In both cases, we believe that serotonin syndrome was produced by a combination of an antidepressant and an atypical antipsychotic.", "question": "Treatment.Disorder in a combination of an antidepressant and an atypical antipsychotic", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17667887_8_3145", "context": "In both cases, we believe that serotonin syndrome was produced by a combination of an antidepressant and an atypical antipsychotic.", "question": "Combination.Drug in a combination of an antidepressant and an atypical antipsychotic", "question_type": "Adverse_event.Combination.Drug", "answers": "antidepressant; atypical antipsychotic"}, {"id": "3620420_6_3146", "context": "Cyclosporin side effects included hirsutism, hypertension, increased blood levels of urea and creatinine, and abnormalities in liver function tests.", "question": "Treatment.Drug in Cyclosporin", "question_type": "Adverse_event.Treatment.Drug", "answers": "Cyclosporin"}, {"id": "3620420_6_3147", "context": "Cyclosporin side effects included hirsutism, hypertension, increased blood levels of urea and creatinine, and abnormalities in liver function tests.", "question": "Treatment.Dosage in Cyclosporin", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3620420_6_3148", "context": "Cyclosporin side effects included hirsutism, hypertension, increased blood levels of urea and creatinine, and abnormalities in liver function tests.", "question": "Treatment.Freq in Cyclosporin", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3620420_6_3149", "context": "Cyclosporin side effects included hirsutism, hypertension, increased blood levels of urea and creatinine, and abnormalities in liver function tests.", "question": "Treatment.Route in Cyclosporin", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3620420_6_3150", "context": "Cyclosporin side effects included hirsutism, hypertension, increased blood levels of urea and creatinine, and abnormalities in liver function tests.", "question": "Treatment.Time_elapsed in Cyclosporin", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3620420_6_3151", "context": "Cyclosporin side effects included hirsutism, hypertension, increased blood levels of urea and creatinine, and abnormalities in liver function tests.", "question": "Treatment.Duration in Cyclosporin", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3620420_6_3152", "context": "Cyclosporin side effects included hirsutism, hypertension, increased blood levels of urea and creatinine, and abnormalities in liver function tests.", "question": "Treatment.Disorder in Cyclosporin", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3620420_6_3153", "context": "Cyclosporin side effects included hirsutism, hypertension, increased blood levels of urea and creatinine, and abnormalities in liver function tests.", "question": "Combination.Drug in Cyclosporin", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17329303_7_3154", "context": "She displayed severe hyperactivity, agitation and irritability upon switching to methylphenidate medication.", "question": "Treatment.Drug in switching to methylphenidate", "question_type": "Adverse_event.Treatment.Drug", "answers": "methylphenidate"}, {"id": "17329303_7_3155", "context": "She displayed severe hyperactivity, agitation and irritability upon switching to methylphenidate medication.", "question": "Treatment.Dosage in switching to methylphenidate", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17329303_7_3156", "context": "She displayed severe hyperactivity, agitation and irritability upon switching to methylphenidate medication.", "question": "Treatment.Freq in switching to methylphenidate", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17329303_7_3157", "context": "She displayed severe hyperactivity, agitation and irritability upon switching to methylphenidate medication.", "question": "Treatment.Route in switching to methylphenidate", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17329303_7_3158", "context": "She displayed severe hyperactivity, agitation and irritability upon switching to methylphenidate medication.", "question": "Treatment.Time_elapsed in switching to methylphenidate", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17329303_7_3159", "context": "She displayed severe hyperactivity, agitation and irritability upon switching to methylphenidate medication.", "question": "Treatment.Duration in switching to methylphenidate", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17329303_7_3160", "context": "She displayed severe hyperactivity, agitation and irritability upon switching to methylphenidate medication.", "question": "Treatment.Disorder in switching to methylphenidate", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17329303_7_3161", "context": "She displayed severe hyperactivity, agitation and irritability upon switching to methylphenidate medication.", "question": "Combination.Drug in switching to methylphenidate", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11573852_8_3162", "context": "To date, only three cases of seizures associated with amphotericin B have been reported in the literature, but healthcare providers should be aware of the potential for this rare adverse effect.", "question": "Subject.Age in three cases", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "11573852_8_3163", "context": "To date, only three cases of seizures associated with amphotericin B have been reported in the literature, but healthcare providers should be aware of the potential for this rare adverse effect.", "question": "Subject.Gender in three cases", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "11573852_8_3164", "context": "To date, only three cases of seizures associated with amphotericin B have been reported in the literature, but healthcare providers should be aware of the potential for this rare adverse effect.", "question": "Subject.Population in three cases", "question_type": "Adverse_event.Subject.Population", "answers": "three"}, {"id": "11573852_8_3165", "context": "To date, only three cases of seizures associated with amphotericin B have been reported in the literature, but healthcare providers should be aware of the potential for this rare adverse effect.", "question": "Subject.Race in three cases", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "11573852_8_3166", "context": "To date, only three cases of seizures associated with amphotericin B have been reported in the literature, but healthcare providers should be aware of the potential for this rare adverse effect.", "question": "Subject.Disorder in three cases", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "11573852_8_3167", "context": "To date, only three cases of seizures associated with amphotericin B have been reported in the literature, but healthcare providers should be aware of the potential for this rare adverse effect.", "question": "Treatment.Drug in amphotericin B", "question_type": "Adverse_event.Treatment.Drug", "answers": "amphotericin B"}, {"id": "11573852_8_3168", "context": "To date, only three cases of seizures associated with amphotericin B have been reported in the literature, but healthcare providers should be aware of the potential for this rare adverse effect.", "question": "Treatment.Dosage in amphotericin B", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11573852_8_3169", "context": "To date, only three cases of seizures associated with amphotericin B have been reported in the literature, but healthcare providers should be aware of the potential for this rare adverse effect.", "question": "Treatment.Freq in amphotericin B", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11573852_8_3170", "context": "To date, only three cases of seizures associated with amphotericin B have been reported in the literature, but healthcare providers should be aware of the potential for this rare adverse effect.", "question": "Treatment.Route in amphotericin B", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11573852_8_3171", "context": "To date, only three cases of seizures associated with amphotericin B have been reported in the literature, but healthcare providers should be aware of the potential for this rare adverse effect.", "question": "Treatment.Time_elapsed in amphotericin B", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11573852_8_3172", "context": "To date, only three cases of seizures associated with amphotericin B have been reported in the literature, but healthcare providers should be aware of the potential for this rare adverse effect.", "question": "Treatment.Duration in amphotericin B", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11573852_8_3173", "context": "To date, only three cases of seizures associated with amphotericin B have been reported in the literature, but healthcare providers should be aware of the potential for this rare adverse effect.", "question": "Treatment.Disorder in amphotericin B", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11573852_8_3174", "context": "To date, only three cases of seizures associated with amphotericin B have been reported in the literature, but healthcare providers should be aware of the potential for this rare adverse effect.", "question": "Combination.Drug in amphotericin B", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16355099_1_3175", "context": "Heparin-induced thrombocytopenia complicated with massive thrombosis of the inferior vena cava after filter placement.", "question": "Treatment.Drug in Heparin", "question_type": "Adverse_event.Treatment.Drug", "answers": "Heparin"}, {"id": "16355099_1_3176", "context": "Heparin-induced thrombocytopenia complicated with massive thrombosis of the inferior vena cava after filter placement.", "question": "Treatment.Dosage in Heparin", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16355099_1_3177", "context": "Heparin-induced thrombocytopenia complicated with massive thrombosis of the inferior vena cava after filter placement.", "question": "Treatment.Freq in Heparin", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16355099_1_3178", "context": "Heparin-induced thrombocytopenia complicated with massive thrombosis of the inferior vena cava after filter placement.", "question": "Treatment.Route in Heparin", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16355099_1_3179", "context": "Heparin-induced thrombocytopenia complicated with massive thrombosis of the inferior vena cava after filter placement.", "question": "Treatment.Time_elapsed in Heparin", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16355099_1_3180", "context": "Heparin-induced thrombocytopenia complicated with massive thrombosis of the inferior vena cava after filter placement.", "question": "Treatment.Duration in Heparin", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16355099_1_3181", "context": "Heparin-induced thrombocytopenia complicated with massive thrombosis of the inferior vena cava after filter placement.", "question": "Treatment.Disorder in Heparin", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16355099_1_3182", "context": "Heparin-induced thrombocytopenia complicated with massive thrombosis of the inferior vena cava after filter placement.", "question": "Combination.Drug in Heparin", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17473920_1_3183", "context": "Pharmacokinetics of methadone in human-immunodeficiency-virus-infected patients receiving nevirapine once daily.", "question": "Subject.Age in human-immunodeficiency-virus-infected patients", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "17473920_1_3184", "context": "Pharmacokinetics of methadone in human-immunodeficiency-virus-infected patients receiving nevirapine once daily.", "question": "Subject.Gender in human-immunodeficiency-virus-infected patients", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "17473920_1_3185", "context": "Pharmacokinetics of methadone in human-immunodeficiency-virus-infected patients receiving nevirapine once daily.", "question": "Subject.Population in human-immunodeficiency-virus-infected patients", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "17473920_1_3186", "context": "Pharmacokinetics of methadone in human-immunodeficiency-virus-infected patients receiving nevirapine once daily.", "question": "Subject.Race in human-immunodeficiency-virus-infected patients", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "17473920_1_3187", "context": "Pharmacokinetics of methadone in human-immunodeficiency-virus-infected patients receiving nevirapine once daily.", "question": "Subject.Disorder in human-immunodeficiency-virus-infected patients", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "17473920_1_3188", "context": "Pharmacokinetics of methadone in human-immunodeficiency-virus-infected patients receiving nevirapine once daily.", "question": "Treatment.Drug in methadone; nevirapine once daily", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "nevirapine; methadone"}, {"id": "17473920_1_3189", "context": "Pharmacokinetics of methadone in human-immunodeficiency-virus-infected patients receiving nevirapine once daily.", "question": "Treatment.Dosage in methadone; nevirapine once daily", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "17473920_1_3190", "context": "Pharmacokinetics of methadone in human-immunodeficiency-virus-infected patients receiving nevirapine once daily.", "question": "Treatment.Freq in methadone; nevirapine once daily", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": "once daily"}, {"id": "17473920_1_3191", "context": "Pharmacokinetics of methadone in human-immunodeficiency-virus-infected patients receiving nevirapine once daily.", "question": "Treatment.Route in methadone; nevirapine once daily", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "17473920_1_3192", "context": "Pharmacokinetics of methadone in human-immunodeficiency-virus-infected patients receiving nevirapine once daily.", "question": "Treatment.Time_elapsed in methadone; nevirapine once daily", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17473920_1_3193", "context": "Pharmacokinetics of methadone in human-immunodeficiency-virus-infected patients receiving nevirapine once daily.", "question": "Treatment.Duration in methadone; nevirapine once daily", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "17473920_1_3194", "context": "Pharmacokinetics of methadone in human-immunodeficiency-virus-infected patients receiving nevirapine once daily.", "question": "Treatment.Disorder in methadone; nevirapine once daily", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "human-immunodeficiency-virus"}, {"id": "17473920_1_3195", "context": "Pharmacokinetics of methadone in human-immunodeficiency-virus-infected patients receiving nevirapine once daily.", "question": "Combination.Drug in methadone; nevirapine once daily", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": "nevirapine; methadone"}, {"id": "3449312_2_3196", "context": "Three patients receiving gold salt treatment for rheumatoid arthritis developed severe aplastic anemia.", "question": "Subject.Age in Three patients", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "3449312_2_3197", "context": "Three patients receiving gold salt treatment for rheumatoid arthritis developed severe aplastic anemia.", "question": "Subject.Gender in Three patients", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "3449312_2_3198", "context": "Three patients receiving gold salt treatment for rheumatoid arthritis developed severe aplastic anemia.", "question": "Subject.Population in Three patients", "question_type": "Adverse_event.Subject.Population", "answers": "Three"}, {"id": "3449312_2_3199", "context": "Three patients receiving gold salt treatment for rheumatoid arthritis developed severe aplastic anemia.", "question": "Subject.Race in Three patients", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "3449312_2_3200", "context": "Three patients receiving gold salt treatment for rheumatoid arthritis developed severe aplastic anemia.", "question": "Subject.Disorder in Three patients", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "3449312_2_3201", "context": "Three patients receiving gold salt treatment for rheumatoid arthritis developed severe aplastic anemia.", "question": "Treatment.Drug in gold salt", "question_type": "Adverse_event.Treatment.Drug", "answers": "gold salt"}, {"id": "3449312_2_3202", "context": "Three patients receiving gold salt treatment for rheumatoid arthritis developed severe aplastic anemia.", "question": "Treatment.Dosage in gold salt", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3449312_2_3203", "context": "Three patients receiving gold salt treatment for rheumatoid arthritis developed severe aplastic anemia.", "question": "Treatment.Freq in gold salt", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3449312_2_3204", "context": "Three patients receiving gold salt treatment for rheumatoid arthritis developed severe aplastic anemia.", "question": "Treatment.Route in gold salt", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3449312_2_3205", "context": "Three patients receiving gold salt treatment for rheumatoid arthritis developed severe aplastic anemia.", "question": "Treatment.Time_elapsed in gold salt", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3449312_2_3206", "context": "Three patients receiving gold salt treatment for rheumatoid arthritis developed severe aplastic anemia.", "question": "Treatment.Duration in gold salt", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3449312_2_3207", "context": "Three patients receiving gold salt treatment for rheumatoid arthritis developed severe aplastic anemia.", "question": "Treatment.Disorder in gold salt", "question_type": "Adverse_event.Treatment.Disorder", "answers": "rheumatoid arthritis"}, {"id": "3449312_2_3208", "context": "Three patients receiving gold salt treatment for rheumatoid arthritis developed severe aplastic anemia.", "question": "Combination.Drug in gold salt", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12092878_2_3209", "context": "A case of anaphylactoid reaction due solely to the use of Gelofusine in a patient with non-haemorrhagic hypovolaemia is presented, with a discussion on the management and the use of allergy identification jewellery.", "question": "Subject.Age in patient with non-haemorrhagic hypovolaemia", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "12092878_2_3210", "context": "A case of anaphylactoid reaction due solely to the use of Gelofusine in a patient with non-haemorrhagic hypovolaemia is presented, with a discussion on the management and the use of allergy identification jewellery.", "question": "Subject.Gender in patient with non-haemorrhagic hypovolaemia", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "12092878_2_3211", "context": "A case of anaphylactoid reaction due solely to the use of Gelofusine in a patient with non-haemorrhagic hypovolaemia is presented, with a discussion on the management and the use of allergy identification jewellery.", "question": "Subject.Population in patient with non-haemorrhagic hypovolaemia", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "12092878_2_3212", "context": "A case of anaphylactoid reaction due solely to the use of Gelofusine in a patient with non-haemorrhagic hypovolaemia is presented, with a discussion on the management and the use of allergy identification jewellery.", "question": "Subject.Race in patient with non-haemorrhagic hypovolaemia", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "12092878_2_3213", "context": "A case of anaphylactoid reaction due solely to the use of Gelofusine in a patient with non-haemorrhagic hypovolaemia is presented, with a discussion on the management and the use of allergy identification jewellery.", "question": "Subject.Disorder in patient with non-haemorrhagic hypovolaemia", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "12092878_2_3214", "context": "A case of anaphylactoid reaction due solely to the use of Gelofusine in a patient with non-haemorrhagic hypovolaemia is presented, with a discussion on the management and the use of allergy identification jewellery.", "question": "Treatment.Drug in Gelofusine", "question_type": "Adverse_event.Treatment.Drug", "answers": "Gelofusine"}, {"id": "12092878_2_3215", "context": "A case of anaphylactoid reaction due solely to the use of Gelofusine in a patient with non-haemorrhagic hypovolaemia is presented, with a discussion on the management and the use of allergy identification jewellery.", "question": "Treatment.Dosage in Gelofusine", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12092878_2_3216", "context": "A case of anaphylactoid reaction due solely to the use of Gelofusine in a patient with non-haemorrhagic hypovolaemia is presented, with a discussion on the management and the use of allergy identification jewellery.", "question": "Treatment.Freq in Gelofusine", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12092878_2_3217", "context": "A case of anaphylactoid reaction due solely to the use of Gelofusine in a patient with non-haemorrhagic hypovolaemia is presented, with a discussion on the management and the use of allergy identification jewellery.", "question": "Treatment.Route in Gelofusine", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12092878_2_3218", "context": "A case of anaphylactoid reaction due solely to the use of Gelofusine in a patient with non-haemorrhagic hypovolaemia is presented, with a discussion on the management and the use of allergy identification jewellery.", "question": "Treatment.Time_elapsed in Gelofusine", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12092878_2_3219", "context": "A case of anaphylactoid reaction due solely to the use of Gelofusine in a patient with non-haemorrhagic hypovolaemia is presented, with a discussion on the management and the use of allergy identification jewellery.", "question": "Treatment.Duration in Gelofusine", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12092878_2_3220", "context": "A case of anaphylactoid reaction due solely to the use of Gelofusine in a patient with non-haemorrhagic hypovolaemia is presented, with a discussion on the management and the use of allergy identification jewellery.", "question": "Treatment.Disorder in Gelofusine", "question_type": "Adverse_event.Treatment.Disorder", "answers": "non-haemorrhagic hypovolaemia"}, {"id": "12092878_2_3221", "context": "A case of anaphylactoid reaction due solely to the use of Gelofusine in a patient with non-haemorrhagic hypovolaemia is presented, with a discussion on the management and the use of allergy identification jewellery.", "question": "Combination.Drug in Gelofusine", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6344831_3_3222", "context": "Nonoliguric acute renal failure after captopril therapy.", "question": "Treatment.Drug in captopril", "question_type": "Adverse_event.Treatment.Drug", "answers": "captopril"}, {"id": "6344831_3_3223", "context": "Nonoliguric acute renal failure after captopril therapy.", "question": "Treatment.Dosage in captopril", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6344831_3_3224", "context": "Nonoliguric acute renal failure after captopril therapy.", "question": "Treatment.Freq in captopril", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6344831_3_3225", "context": "Nonoliguric acute renal failure after captopril therapy.", "question": "Treatment.Route in captopril", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6344831_3_3226", "context": "Nonoliguric acute renal failure after captopril therapy.", "question": "Treatment.Time_elapsed in captopril", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6344831_3_3227", "context": "Nonoliguric acute renal failure after captopril therapy.", "question": "Treatment.Duration in captopril", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6344831_3_3228", "context": "Nonoliguric acute renal failure after captopril therapy.", "question": "Treatment.Disorder in captopril", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6344831_3_3229", "context": "Nonoliguric acute renal failure after captopril therapy.", "question": "Combination.Drug in captopril", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "19217693_3_3230", "context": "We report a patient with type 2 diabetes mellitus who, while treated with the antitumor necrosis factor-alpha blocking agent etanercept for severe plaque psoriasis, experienced persistent hypoglycemia requiring the lowering and eventual elimination of his previous insulin regimen.", "question": "Subject.Age in a patient with type 2 diabetes mellitus", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "19217693_3_3231", "context": "We report a patient with type 2 diabetes mellitus who, while treated with the antitumor necrosis factor-alpha blocking agent etanercept for severe plaque psoriasis, experienced persistent hypoglycemia requiring the lowering and eventual elimination of his previous insulin regimen.", "question": "Subject.Gender in a patient with type 2 diabetes mellitus", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "19217693_3_3232", "context": "We report a patient with type 2 diabetes mellitus who, while treated with the antitumor necrosis factor-alpha blocking agent etanercept for severe plaque psoriasis, experienced persistent hypoglycemia requiring the lowering and eventual elimination of his previous insulin regimen.", "question": "Subject.Population in a patient with type 2 diabetes mellitus", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "19217693_3_3233", "context": "We report a patient with type 2 diabetes mellitus who, while treated with the antitumor necrosis factor-alpha blocking agent etanercept for severe plaque psoriasis, experienced persistent hypoglycemia requiring the lowering and eventual elimination of his previous insulin regimen.", "question": "Subject.Race in a patient with type 2 diabetes mellitus", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "19217693_3_3234", "context": "We report a patient with type 2 diabetes mellitus who, while treated with the antitumor necrosis factor-alpha blocking agent etanercept for severe plaque psoriasis, experienced persistent hypoglycemia requiring the lowering and eventual elimination of his previous insulin regimen.", "question": "Subject.Disorder in a patient with type 2 diabetes mellitus", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "19217693_3_3235", "context": "We report a patient with type 2 diabetes mellitus who, while treated with the antitumor necrosis factor-alpha blocking agent etanercept for severe plaque psoriasis, experienced persistent hypoglycemia requiring the lowering and eventual elimination of his previous insulin regimen.", "question": "Treatment.Drug in the antitumor necrosis factor-alpha blocking agent etanercept; previous insulin regimen", "question_type": "Adverse_event.Treatment.Drug", "answers": "etanercept; insulin"}, {"id": "19217693_3_3236", "context": "We report a patient with type 2 diabetes mellitus who, while treated with the antitumor necrosis factor-alpha blocking agent etanercept for severe plaque psoriasis, experienced persistent hypoglycemia requiring the lowering and eventual elimination of his previous insulin regimen.", "question": "Treatment.Dosage in the antitumor necrosis factor-alpha blocking agent etanercept; previous insulin regimen", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "19217693_3_3237", "context": "We report a patient with type 2 diabetes mellitus who, while treated with the antitumor necrosis factor-alpha blocking agent etanercept for severe plaque psoriasis, experienced persistent hypoglycemia requiring the lowering and eventual elimination of his previous insulin regimen.", "question": "Treatment.Freq in the antitumor necrosis factor-alpha blocking agent etanercept; previous insulin regimen", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "19217693_3_3238", "context": "We report a patient with type 2 diabetes mellitus who, while treated with the antitumor necrosis factor-alpha blocking agent etanercept for severe plaque psoriasis, experienced persistent hypoglycemia requiring the lowering and eventual elimination of his previous insulin regimen.", "question": "Treatment.Route in the antitumor necrosis factor-alpha blocking agent etanercept; previous insulin regimen", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "19217693_3_3239", "context": "We report a patient with type 2 diabetes mellitus who, while treated with the antitumor necrosis factor-alpha blocking agent etanercept for severe plaque psoriasis, experienced persistent hypoglycemia requiring the lowering and eventual elimination of his previous insulin regimen.", "question": "Treatment.Time_elapsed in the antitumor necrosis factor-alpha blocking agent etanercept; previous insulin regimen", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19217693_3_3240", "context": "We report a patient with type 2 diabetes mellitus who, while treated with the antitumor necrosis factor-alpha blocking agent etanercept for severe plaque psoriasis, experienced persistent hypoglycemia requiring the lowering and eventual elimination of his previous insulin regimen.", "question": "Treatment.Duration in the antitumor necrosis factor-alpha blocking agent etanercept; previous insulin regimen", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "19217693_3_3241", "context": "We report a patient with type 2 diabetes mellitus who, while treated with the antitumor necrosis factor-alpha blocking agent etanercept for severe plaque psoriasis, experienced persistent hypoglycemia requiring the lowering and eventual elimination of his previous insulin regimen.", "question": "Treatment.Disorder in the antitumor necrosis factor-alpha blocking agent etanercept; previous insulin regimen", "question_type": "Adverse_event.Treatment.Disorder", "answers": "type 2 diabetes mellitus; severe plaque psoriasis"}, {"id": "19217693_3_3242", "context": "We report a patient with type 2 diabetes mellitus who, while treated with the antitumor necrosis factor-alpha blocking agent etanercept for severe plaque psoriasis, experienced persistent hypoglycemia requiring the lowering and eventual elimination of his previous insulin regimen.", "question": "Combination.Drug in the antitumor necrosis factor-alpha blocking agent etanercept; previous insulin regimen", "question_type": "Adverse_event.Combination.Drug", "answers": "insulin; etanercept"}, {"id": "12540009_4_3243", "context": "We report the first case of doxycycline-induced hypoglycemia in a young nondiabetic man.", "question": "Subject.Age in a young nondiabetic man", "question_type": "Adverse_event.Subject.Age", "answers": "young"}, {"id": "12540009_4_3244", "context": "We report the first case of doxycycline-induced hypoglycemia in a young nondiabetic man.", "question": "Subject.Gender in a young nondiabetic man", "question_type": "Adverse_event.Subject.Gender", "answers": "man"}, {"id": "12540009_4_3245", "context": "We report the first case of doxycycline-induced hypoglycemia in a young nondiabetic man.", "question": "Subject.Population in a young nondiabetic man", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "12540009_4_3246", "context": "We report the first case of doxycycline-induced hypoglycemia in a young nondiabetic man.", "question": "Subject.Race in a young nondiabetic man", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "12540009_4_3247", "context": "We report the first case of doxycycline-induced hypoglycemia in a young nondiabetic man.", "question": "Subject.Disorder in a young nondiabetic man", "question_type": "Adverse_event.Subject.Disorder", "answers": "nondiabetic"}, {"id": "12540009_4_3248", "context": "We report the first case of doxycycline-induced hypoglycemia in a young nondiabetic man.", "question": "Treatment.Drug in doxycycline", "question_type": "Adverse_event.Treatment.Drug", "answers": "doxycycline"}, {"id": "12540009_4_3249", "context": "We report the first case of doxycycline-induced hypoglycemia in a young nondiabetic man.", "question": "Treatment.Dosage in doxycycline", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12540009_4_3250", "context": "We report the first case of doxycycline-induced hypoglycemia in a young nondiabetic man.", "question": "Treatment.Freq in doxycycline", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12540009_4_3251", "context": "We report the first case of doxycycline-induced hypoglycemia in a young nondiabetic man.", "question": "Treatment.Route in doxycycline", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12540009_4_3252", "context": "We report the first case of doxycycline-induced hypoglycemia in a young nondiabetic man.", "question": "Treatment.Time_elapsed in doxycycline", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12540009_4_3253", "context": "We report the first case of doxycycline-induced hypoglycemia in a young nondiabetic man.", "question": "Treatment.Duration in doxycycline", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12540009_4_3254", "context": "We report the first case of doxycycline-induced hypoglycemia in a young nondiabetic man.", "question": "Treatment.Disorder in doxycycline", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12540009_4_3255", "context": "We report the first case of doxycycline-induced hypoglycemia in a young nondiabetic man.", "question": "Combination.Drug in doxycycline", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11573852_7_3256", "context": "The time course of events suggested that amphotericin B was the cause of the seizures in this AIDS patient.", "question": "Subject.Age in AIDS patient", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "11573852_7_3257", "context": "The time course of events suggested that amphotericin B was the cause of the seizures in this AIDS patient.", "question": "Subject.Gender in AIDS patient", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "11573852_7_3258", "context": "The time course of events suggested that amphotericin B was the cause of the seizures in this AIDS patient.", "question": "Subject.Population in AIDS patient", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "11573852_7_3259", "context": "The time course of events suggested that amphotericin B was the cause of the seizures in this AIDS patient.", "question": "Subject.Race in AIDS patient", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "11573852_7_3260", "context": "The time course of events suggested that amphotericin B was the cause of the seizures in this AIDS patient.", "question": "Subject.Disorder in AIDS patient", "question_type": "Adverse_event.Subject.Disorder", "answers": "AIDS"}, {"id": "11573852_7_3261", "context": "The time course of events suggested that amphotericin B was the cause of the seizures in this AIDS patient.", "question": "Treatment.Drug in amphotericin B", "question_type": "Adverse_event.Treatment.Drug", "answers": "amphotericin B"}, {"id": "11573852_7_3262", "context": "The time course of events suggested that amphotericin B was the cause of the seizures in this AIDS patient.", "question": "Treatment.Dosage in amphotericin B", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11573852_7_3263", "context": "The time course of events suggested that amphotericin B was the cause of the seizures in this AIDS patient.", "question": "Treatment.Freq in amphotericin B", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11573852_7_3264", "context": "The time course of events suggested that amphotericin B was the cause of the seizures in this AIDS patient.", "question": "Treatment.Route in amphotericin B", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11573852_7_3265", "context": "The time course of events suggested that amphotericin B was the cause of the seizures in this AIDS patient.", "question": "Treatment.Time_elapsed in amphotericin B", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11573852_7_3266", "context": "The time course of events suggested that amphotericin B was the cause of the seizures in this AIDS patient.", "question": "Treatment.Duration in amphotericin B", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11573852_7_3267", "context": "The time course of events suggested that amphotericin B was the cause of the seizures in this AIDS patient.", "question": "Treatment.Disorder in amphotericin B", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11573852_7_3268", "context": "The time course of events suggested that amphotericin B was the cause of the seizures in this AIDS patient.", "question": "Combination.Drug in amphotericin B", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "897744_1_3269", "context": "Focal glomerulonephritis and interstitial nephritis in methicillin-treated, heroin-related infective endocarditis.", "question": "Treatment.Drug in heroin", "question_type": "Adverse_event.Treatment.Drug", "answers": "heroin"}, {"id": "897744_1_3270", "context": "Focal glomerulonephritis and interstitial nephritis in methicillin-treated, heroin-related infective endocarditis.", "question": "Treatment.Dosage in heroin", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "897744_1_3271", "context": "Focal glomerulonephritis and interstitial nephritis in methicillin-treated, heroin-related infective endocarditis.", "question": "Treatment.Freq in heroin", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "897744_1_3272", "context": "Focal glomerulonephritis and interstitial nephritis in methicillin-treated, heroin-related infective endocarditis.", "question": "Treatment.Route in heroin", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "897744_1_3273", "context": "Focal glomerulonephritis and interstitial nephritis in methicillin-treated, heroin-related infective endocarditis.", "question": "Treatment.Time_elapsed in heroin", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "897744_1_3274", "context": "Focal glomerulonephritis and interstitial nephritis in methicillin-treated, heroin-related infective endocarditis.", "question": "Treatment.Duration in heroin", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "897744_1_3275", "context": "Focal glomerulonephritis and interstitial nephritis in methicillin-treated, heroin-related infective endocarditis.", "question": "Treatment.Disorder in heroin", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "897744_1_3276", "context": "Focal glomerulonephritis and interstitial nephritis in methicillin-treated, heroin-related infective endocarditis.", "question": "Combination.Drug in heroin", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "897744_1_3277", "context": "Focal glomerulonephritis and interstitial nephritis in methicillin-treated, heroin-related infective endocarditis.", "question": "Treatment.Drug in methicillin", "question_type": "Adverse_event.Treatment.Drug", "answers": "methicillin"}, {"id": "897744_1_3278", "context": "Focal glomerulonephritis and interstitial nephritis in methicillin-treated, heroin-related infective endocarditis.", "question": "Treatment.Dosage in methicillin", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "897744_1_3279", "context": "Focal glomerulonephritis and interstitial nephritis in methicillin-treated, heroin-related infective endocarditis.", "question": "Treatment.Freq in methicillin", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "897744_1_3280", "context": "Focal glomerulonephritis and interstitial nephritis in methicillin-treated, heroin-related infective endocarditis.", "question": "Treatment.Route in methicillin", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "897744_1_3281", "context": "Focal glomerulonephritis and interstitial nephritis in methicillin-treated, heroin-related infective endocarditis.", "question": "Treatment.Time_elapsed in methicillin", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "897744_1_3282", "context": "Focal glomerulonephritis and interstitial nephritis in methicillin-treated, heroin-related infective endocarditis.", "question": "Treatment.Duration in methicillin", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "897744_1_3283", "context": "Focal glomerulonephritis and interstitial nephritis in methicillin-treated, heroin-related infective endocarditis.", "question": "Treatment.Disorder in methicillin", "question_type": "Adverse_event.Treatment.Disorder", "answers": "heroin-related infective endocarditis"}, {"id": "897744_1_3284", "context": "Focal glomerulonephritis and interstitial nephritis in methicillin-treated, heroin-related infective endocarditis.", "question": "Combination.Drug in methicillin", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "1834424_2_3285", "context": "Allergic contact dermatitis from 4-chloro-7-nitrobenzofurazan.", "question": "Treatment.Drug in 4-chloro-7-nitrobenzofurazan", "question_type": "Adverse_event.Treatment.Drug", "answers": "4-chloro-7-nitrobenzofurazan"}, {"id": "1834424_2_3286", "context": "Allergic contact dermatitis from 4-chloro-7-nitrobenzofurazan.", "question": "Treatment.Dosage in 4-chloro-7-nitrobenzofurazan", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "1834424_2_3287", "context": "Allergic contact dermatitis from 4-chloro-7-nitrobenzofurazan.", "question": "Treatment.Freq in 4-chloro-7-nitrobenzofurazan", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "1834424_2_3288", "context": "Allergic contact dermatitis from 4-chloro-7-nitrobenzofurazan.", "question": "Treatment.Route in 4-chloro-7-nitrobenzofurazan", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "1834424_2_3289", "context": "Allergic contact dermatitis from 4-chloro-7-nitrobenzofurazan.", "question": "Treatment.Time_elapsed in 4-chloro-7-nitrobenzofurazan", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "1834424_2_3290", "context": "Allergic contact dermatitis from 4-chloro-7-nitrobenzofurazan.", "question": "Treatment.Duration in 4-chloro-7-nitrobenzofurazan", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "1834424_2_3291", "context": "Allergic contact dermatitis from 4-chloro-7-nitrobenzofurazan.", "question": "Treatment.Disorder in 4-chloro-7-nitrobenzofurazan", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "1834424_2_3292", "context": "Allergic contact dermatitis from 4-chloro-7-nitrobenzofurazan.", "question": "Combination.Drug in 4-chloro-7-nitrobenzofurazan", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16816519_2_3293", "context": "We describe a 5-year-old girl showed recovery of vincristine induced cranial polyneuropathy with pyridoxine and pyridostigmine treatment.", "question": "Subject.Age in a 5-year-old girl", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": "5-year-old"}, {"id": "16816519_2_3294", "context": "We describe a 5-year-old girl showed recovery of vincristine induced cranial polyneuropathy with pyridoxine and pyridostigmine treatment.", "question": "Subject.Gender in a 5-year-old girl", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": "girl"}, {"id": "16816519_2_3295", "context": "We describe a 5-year-old girl showed recovery of vincristine induced cranial polyneuropathy with pyridoxine and pyridostigmine treatment.", "question": "Subject.Population in a 5-year-old girl", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "16816519_2_3296", "context": "We describe a 5-year-old girl showed recovery of vincristine induced cranial polyneuropathy with pyridoxine and pyridostigmine treatment.", "question": "Subject.Race in a 5-year-old girl", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "16816519_2_3297", "context": "We describe a 5-year-old girl showed recovery of vincristine induced cranial polyneuropathy with pyridoxine and pyridostigmine treatment.", "question": "Subject.Disorder in a 5-year-old girl", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "16816519_2_3298", "context": "We describe a 5-year-old girl showed recovery of vincristine induced cranial polyneuropathy with pyridoxine and pyridostigmine treatment.", "question": "Treatment.Drug in pyridoxine and pyridostigmine treatment", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "pyridoxine; pyridostigmine"}, {"id": "16816519_2_3299", "context": "We describe a 5-year-old girl showed recovery of vincristine induced cranial polyneuropathy with pyridoxine and pyridostigmine treatment.", "question": "Treatment.Dosage in pyridoxine and pyridostigmine treatment", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "16816519_2_3300", "context": "We describe a 5-year-old girl showed recovery of vincristine induced cranial polyneuropathy with pyridoxine and pyridostigmine treatment.", "question": "Treatment.Freq in pyridoxine and pyridostigmine treatment", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "16816519_2_3301", "context": "We describe a 5-year-old girl showed recovery of vincristine induced cranial polyneuropathy with pyridoxine and pyridostigmine treatment.", "question": "Treatment.Route in pyridoxine and pyridostigmine treatment", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "16816519_2_3302", "context": "We describe a 5-year-old girl showed recovery of vincristine induced cranial polyneuropathy with pyridoxine and pyridostigmine treatment.", "question": "Treatment.Time_elapsed in pyridoxine and pyridostigmine treatment", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16816519_2_3303", "context": "We describe a 5-year-old girl showed recovery of vincristine induced cranial polyneuropathy with pyridoxine and pyridostigmine treatment.", "question": "Treatment.Duration in pyridoxine and pyridostigmine treatment", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "16816519_2_3304", "context": "We describe a 5-year-old girl showed recovery of vincristine induced cranial polyneuropathy with pyridoxine and pyridostigmine treatment.", "question": "Treatment.Disorder in pyridoxine and pyridostigmine treatment", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "16816519_2_3305", "context": "We describe a 5-year-old girl showed recovery of vincristine induced cranial polyneuropathy with pyridoxine and pyridostigmine treatment.", "question": "Combination.Drug in pyridoxine and pyridostigmine treatment", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": "pyridostigmine; pyridoxine"}, {"id": "9925865_3_3306", "context": "Lipoid pneumonia: a silent complication of mineral oil aspiration.", "question": "Treatment.Drug in mineral oil aspiration", "question_type": "Adverse_event.Treatment.Drug", "answers": "mineral oil"}, {"id": "9925865_3_3307", "context": "Lipoid pneumonia: a silent complication of mineral oil aspiration.", "question": "Treatment.Dosage in mineral oil aspiration", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9925865_3_3308", "context": "Lipoid pneumonia: a silent complication of mineral oil aspiration.", "question": "Treatment.Freq in mineral oil aspiration", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9925865_3_3309", "context": "Lipoid pneumonia: a silent complication of mineral oil aspiration.", "question": "Treatment.Route in mineral oil aspiration", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9925865_3_3310", "context": "Lipoid pneumonia: a silent complication of mineral oil aspiration.", "question": "Treatment.Time_elapsed in mineral oil aspiration", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9925865_3_3311", "context": "Lipoid pneumonia: a silent complication of mineral oil aspiration.", "question": "Treatment.Duration in mineral oil aspiration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9925865_3_3312", "context": "Lipoid pneumonia: a silent complication of mineral oil aspiration.", "question": "Treatment.Disorder in mineral oil aspiration", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9925865_3_3313", "context": "Lipoid pneumonia: a silent complication of mineral oil aspiration.", "question": "Combination.Drug in mineral oil aspiration", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10610018_1_3314", "context": "Elevated serum triglycerides with clozapine resolved with risperidone in four patients.", "question": "Subject.Age in four patients", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "10610018_1_3315", "context": "Elevated serum triglycerides with clozapine resolved with risperidone in four patients.", "question": "Subject.Gender in four patients", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "10610018_1_3316", "context": "Elevated serum triglycerides with clozapine resolved with risperidone in four patients.", "question": "Subject.Population in four patients", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": "four"}, {"id": "10610018_1_3317", "context": "Elevated serum triglycerides with clozapine resolved with risperidone in four patients.", "question": "Subject.Race in four patients", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "10610018_1_3318", "context": "Elevated serum triglycerides with clozapine resolved with risperidone in four patients.", "question": "Subject.Disorder in four patients", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "10610018_1_3319", "context": "Elevated serum triglycerides with clozapine resolved with risperidone in four patients.", "question": "Treatment.Drug in risperidone", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "risperidone"}, {"id": "10610018_1_3320", "context": "Elevated serum triglycerides with clozapine resolved with risperidone in four patients.", "question": "Treatment.Dosage in risperidone", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "10610018_1_3321", "context": "Elevated serum triglycerides with clozapine resolved with risperidone in four patients.", "question": "Treatment.Freq in risperidone", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "10610018_1_3322", "context": "Elevated serum triglycerides with clozapine resolved with risperidone in four patients.", "question": "Treatment.Route in risperidone", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "10610018_1_3323", "context": "Elevated serum triglycerides with clozapine resolved with risperidone in four patients.", "question": "Treatment.Time_elapsed in risperidone", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10610018_1_3324", "context": "Elevated serum triglycerides with clozapine resolved with risperidone in four patients.", "question": "Treatment.Duration in risperidone", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "10610018_1_3325", "context": "Elevated serum triglycerides with clozapine resolved with risperidone in four patients.", "question": "Treatment.Disorder in risperidone", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "Elevated serum triglycerides with clozapine"}, {"id": "10610018_1_3326", "context": "Elevated serum triglycerides with clozapine resolved with risperidone in four patients.", "question": "Combination.Drug in risperidone", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "10610018_1_3327", "context": "Elevated serum triglycerides with clozapine resolved with risperidone in four patients.", "question": "Treatment.Drug in clozapine", "question_type": "Adverse_event.Treatment.Drug", "answers": "clozapine"}, {"id": "10610018_1_3328", "context": "Elevated serum triglycerides with clozapine resolved with risperidone in four patients.", "question": "Treatment.Dosage in clozapine", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10610018_1_3329", "context": "Elevated serum triglycerides with clozapine resolved with risperidone in four patients.", "question": "Treatment.Freq in clozapine", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10610018_1_3330", "context": "Elevated serum triglycerides with clozapine resolved with risperidone in four patients.", "question": "Treatment.Route in clozapine", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10610018_1_3331", "context": "Elevated serum triglycerides with clozapine resolved with risperidone in four patients.", "question": "Treatment.Time_elapsed in clozapine", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10610018_1_3332", "context": "Elevated serum triglycerides with clozapine resolved with risperidone in four patients.", "question": "Treatment.Duration in clozapine", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10610018_1_3333", "context": "Elevated serum triglycerides with clozapine resolved with risperidone in four patients.", "question": "Treatment.Disorder in clozapine", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10610018_1_3334", "context": "Elevated serum triglycerides with clozapine resolved with risperidone in four patients.", "question": "Combination.Drug in clozapine", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8162401_3_3335", "context": "Seizures associated with fluoxetine therapy.", "question": "Treatment.Drug in fluoxetine therapy", "question_type": "Adverse_event.Treatment.Drug", "answers": "fluoxetine"}, {"id": "8162401_3_3336", "context": "Seizures associated with fluoxetine therapy.", "question": "Treatment.Dosage in fluoxetine therapy", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8162401_3_3337", "context": "Seizures associated with fluoxetine therapy.", "question": "Treatment.Freq in fluoxetine therapy", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8162401_3_3338", "context": "Seizures associated with fluoxetine therapy.", "question": "Treatment.Route in fluoxetine therapy", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8162401_3_3339", "context": "Seizures associated with fluoxetine therapy.", "question": "Treatment.Time_elapsed in fluoxetine therapy", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8162401_3_3340", "context": "Seizures associated with fluoxetine therapy.", "question": "Treatment.Duration in fluoxetine therapy", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8162401_3_3341", "context": "Seizures associated with fluoxetine therapy.", "question": "Treatment.Disorder in fluoxetine therapy", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8162401_3_3342", "context": "Seizures associated with fluoxetine therapy.", "question": "Combination.Drug in fluoxetine therapy", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18006091_1_3343", "context": "Sustained monomorphic ventricular tachycardia after adenosine infusion.", "question": "Treatment.Drug in adenosine infusion.", "question_type": "Adverse_event.Treatment.Drug", "answers": "adenosine"}, {"id": "18006091_1_3344", "context": "Sustained monomorphic ventricular tachycardia after adenosine infusion.", "question": "Treatment.Dosage in adenosine infusion.", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18006091_1_3345", "context": "Sustained monomorphic ventricular tachycardia after adenosine infusion.", "question": "Treatment.Freq in adenosine infusion.", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18006091_1_3346", "context": "Sustained monomorphic ventricular tachycardia after adenosine infusion.", "question": "Treatment.Route in adenosine infusion.", "question_type": "Adverse_event.Treatment.Route", "answers": "infusion"}, {"id": "18006091_1_3347", "context": "Sustained monomorphic ventricular tachycardia after adenosine infusion.", "question": "Treatment.Time_elapsed in adenosine infusion.", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18006091_1_3348", "context": "Sustained monomorphic ventricular tachycardia after adenosine infusion.", "question": "Treatment.Duration in adenosine infusion.", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18006091_1_3349", "context": "Sustained monomorphic ventricular tachycardia after adenosine infusion.", "question": "Treatment.Disorder in adenosine infusion.", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18006091_1_3350", "context": "Sustained monomorphic ventricular tachycardia after adenosine infusion.", "question": "Combination.Drug in adenosine infusion.", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7632529_1_3351", "context": "A 9-year-old boy developed acute renal failure following intravenous acyclovir (30 mg/kg per day) administered for 6 days to treat herpetic encephalitis.", "question": "Subject.Age in A 9-year-old boy", "question_type": "Adverse_event.Subject.Age", "answers": "9-year-old"}, {"id": "7632529_1_3352", "context": "A 9-year-old boy developed acute renal failure following intravenous acyclovir (30 mg/kg per day) administered for 6 days to treat herpetic encephalitis.", "question": "Subject.Gender in A 9-year-old boy", "question_type": "Adverse_event.Subject.Gender", "answers": "boy"}, {"id": "7632529_1_3353", "context": "A 9-year-old boy developed acute renal failure following intravenous acyclovir (30 mg/kg per day) administered for 6 days to treat herpetic encephalitis.", "question": "Subject.Population in A 9-year-old boy", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "7632529_1_3354", "context": "A 9-year-old boy developed acute renal failure following intravenous acyclovir (30 mg/kg per day) administered for 6 days to treat herpetic encephalitis.", "question": "Subject.Race in A 9-year-old boy", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "7632529_1_3355", "context": "A 9-year-old boy developed acute renal failure following intravenous acyclovir (30 mg/kg per day) administered for 6 days to treat herpetic encephalitis.", "question": "Subject.Disorder in A 9-year-old boy", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "7632529_1_3356", "context": "A 9-year-old boy developed acute renal failure following intravenous acyclovir (30 mg/kg per day) administered for 6 days to treat herpetic encephalitis.", "question": "Treatment.Drug in intravenous acyclovir", "question_type": "Adverse_event.Treatment.Drug", "answers": "intravenous acyclovir"}, {"id": "7632529_1_3357", "context": "A 9-year-old boy developed acute renal failure following intravenous acyclovir (30 mg/kg per day) administered for 6 days to treat herpetic encephalitis.", "question": "Treatment.Dosage in intravenous acyclovir", "question_type": "Adverse_event.Treatment.Dosage", "answers": "30 mg/kg"}, {"id": "7632529_1_3358", "context": "A 9-year-old boy developed acute renal failure following intravenous acyclovir (30 mg/kg per day) administered for 6 days to treat herpetic encephalitis.", "question": "Treatment.Freq in intravenous acyclovir", "question_type": "Adverse_event.Treatment.Freq", "answers": "per day"}, {"id": "7632529_1_3359", "context": "A 9-year-old boy developed acute renal failure following intravenous acyclovir (30 mg/kg per day) administered for 6 days to treat herpetic encephalitis.", "question": "Treatment.Route in intravenous acyclovir", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7632529_1_3360", "context": "A 9-year-old boy developed acute renal failure following intravenous acyclovir (30 mg/kg per day) administered for 6 days to treat herpetic encephalitis.", "question": "Treatment.Time_elapsed in intravenous acyclovir", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7632529_1_3361", "context": "A 9-year-old boy developed acute renal failure following intravenous acyclovir (30 mg/kg per day) administered for 6 days to treat herpetic encephalitis.", "question": "Treatment.Duration in intravenous acyclovir", "question_type": "Adverse_event.Treatment.Duration", "answers": "6 days"}, {"id": "7632529_1_3362", "context": "A 9-year-old boy developed acute renal failure following intravenous acyclovir (30 mg/kg per day) administered for 6 days to treat herpetic encephalitis.", "question": "Treatment.Disorder in intravenous acyclovir", "question_type": "Adverse_event.Treatment.Disorder", "answers": "herpetic encephalitis"}, {"id": "7632529_1_3363", "context": "A 9-year-old boy developed acute renal failure following intravenous acyclovir (30 mg/kg per day) administered for 6 days to treat herpetic encephalitis.", "question": "Combination.Drug in intravenous acyclovir", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18476934_3_3364", "context": "We report a 4-year-old girl who presented with acute bilateral blindness, a focal seizure and hypertension 10 days after commencing oxybutynin to treat enuresis.", "question": "Subject.Age in a 4-year-old girl", "question_type": "Adverse_event.Subject.Age", "answers": "4-year-old"}, {"id": "18476934_3_3365", "context": "We report a 4-year-old girl who presented with acute bilateral blindness, a focal seizure and hypertension 10 days after commencing oxybutynin to treat enuresis.", "question": "Subject.Gender in a 4-year-old girl", "question_type": "Adverse_event.Subject.Gender", "answers": "girl"}, {"id": "18476934_3_3366", "context": "We report a 4-year-old girl who presented with acute bilateral blindness, a focal seizure and hypertension 10 days after commencing oxybutynin to treat enuresis.", "question": "Subject.Population in a 4-year-old girl", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "18476934_3_3367", "context": "We report a 4-year-old girl who presented with acute bilateral blindness, a focal seizure and hypertension 10 days after commencing oxybutynin to treat enuresis.", "question": "Subject.Race in a 4-year-old girl", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "18476934_3_3368", "context": "We report a 4-year-old girl who presented with acute bilateral blindness, a focal seizure and hypertension 10 days after commencing oxybutynin to treat enuresis.", "question": "Subject.Disorder in a 4-year-old girl", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "18476934_3_3369", "context": "We report a 4-year-old girl who presented with acute bilateral blindness, a focal seizure and hypertension 10 days after commencing oxybutynin to treat enuresis.", "question": "Treatment.Drug in oxybutynin", "question_type": "Adverse_event.Treatment.Drug", "answers": "oxybutynin"}, {"id": "18476934_3_3370", "context": "We report a 4-year-old girl who presented with acute bilateral blindness, a focal seizure and hypertension 10 days after commencing oxybutynin to treat enuresis.", "question": "Treatment.Dosage in oxybutynin", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18476934_3_3371", "context": "We report a 4-year-old girl who presented with acute bilateral blindness, a focal seizure and hypertension 10 days after commencing oxybutynin to treat enuresis.", "question": "Treatment.Freq in oxybutynin", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18476934_3_3372", "context": "We report a 4-year-old girl who presented with acute bilateral blindness, a focal seizure and hypertension 10 days after commencing oxybutynin to treat enuresis.", "question": "Treatment.Route in oxybutynin", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18476934_3_3373", "context": "We report a 4-year-old girl who presented with acute bilateral blindness, a focal seizure and hypertension 10 days after commencing oxybutynin to treat enuresis.", "question": "Treatment.Time_elapsed in oxybutynin", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "10 days"}, {"id": "18476934_3_3374", "context": "We report a 4-year-old girl who presented with acute bilateral blindness, a focal seizure and hypertension 10 days after commencing oxybutynin to treat enuresis.", "question": "Treatment.Duration in oxybutynin", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18476934_3_3375", "context": "We report a 4-year-old girl who presented with acute bilateral blindness, a focal seizure and hypertension 10 days after commencing oxybutynin to treat enuresis.", "question": "Treatment.Disorder in oxybutynin", "question_type": "Adverse_event.Treatment.Disorder", "answers": "enuresis"}, {"id": "18476934_3_3376", "context": "We report a 4-year-old girl who presented with acute bilateral blindness, a focal seizure and hypertension 10 days after commencing oxybutynin to treat enuresis.", "question": "Combination.Drug in oxybutynin", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16580907_1_3377", "context": "Severe arrhythmia as a result of the interaction of cetirizine and pilsicainide in a patient with renal insufficiency: first case presentation showing competition for excretion via renal multidrug resistance protein 1 and organic cation transporter 2.", "question": "Subject.Age in a patient with renal insufficiency", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "16580907_1_3378", "context": "Severe arrhythmia as a result of the interaction of cetirizine and pilsicainide in a patient with renal insufficiency: first case presentation showing competition for excretion via renal multidrug resistance protein 1 and organic cation transporter 2.", "question": "Subject.Gender in a patient with renal insufficiency", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "16580907_1_3379", "context": "Severe arrhythmia as a result of the interaction of cetirizine and pilsicainide in a patient with renal insufficiency: first case presentation showing competition for excretion via renal multidrug resistance protein 1 and organic cation transporter 2.", "question": "Subject.Population in a patient with renal insufficiency", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "16580907_1_3380", "context": "Severe arrhythmia as a result of the interaction of cetirizine and pilsicainide in a patient with renal insufficiency: first case presentation showing competition for excretion via renal multidrug resistance protein 1 and organic cation transporter 2.", "question": "Subject.Race in a patient with renal insufficiency", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16580907_1_3381", "context": "Severe arrhythmia as a result of the interaction of cetirizine and pilsicainide in a patient with renal insufficiency: first case presentation showing competition for excretion via renal multidrug resistance protein 1 and organic cation transporter 2.", "question": "Subject.Disorder in a patient with renal insufficiency", "question_type": "Adverse_event.Subject.Disorder", "answers": "renal insufficiency"}, {"id": "16580907_1_3382", "context": "Severe arrhythmia as a result of the interaction of cetirizine and pilsicainide in a patient with renal insufficiency: first case presentation showing competition for excretion via renal multidrug resistance protein 1 and organic cation transporter 2.", "question": "Treatment.Drug in interaction of cetirizine and pilsicainide", "question_type": "Adverse_event.Treatment.Drug", "answers": "cetirizine; pilsicainide"}, {"id": "16580907_1_3383", "context": "Severe arrhythmia as a result of the interaction of cetirizine and pilsicainide in a patient with renal insufficiency: first case presentation showing competition for excretion via renal multidrug resistance protein 1 and organic cation transporter 2.", "question": "Treatment.Dosage in interaction of cetirizine and pilsicainide", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16580907_1_3384", "context": "Severe arrhythmia as a result of the interaction of cetirizine and pilsicainide in a patient with renal insufficiency: first case presentation showing competition for excretion via renal multidrug resistance protein 1 and organic cation transporter 2.", "question": "Treatment.Freq in interaction of cetirizine and pilsicainide", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16580907_1_3385", "context": "Severe arrhythmia as a result of the interaction of cetirizine and pilsicainide in a patient with renal insufficiency: first case presentation showing competition for excretion via renal multidrug resistance protein 1 and organic cation transporter 2.", "question": "Treatment.Route in interaction of cetirizine and pilsicainide", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16580907_1_3386", "context": "Severe arrhythmia as a result of the interaction of cetirizine and pilsicainide in a patient with renal insufficiency: first case presentation showing competition for excretion via renal multidrug resistance protein 1 and organic cation transporter 2.", "question": "Treatment.Time_elapsed in interaction of cetirizine and pilsicainide", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16580907_1_3387", "context": "Severe arrhythmia as a result of the interaction of cetirizine and pilsicainide in a patient with renal insufficiency: first case presentation showing competition for excretion via renal multidrug resistance protein 1 and organic cation transporter 2.", "question": "Treatment.Duration in interaction of cetirizine and pilsicainide", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16580907_1_3388", "context": "Severe arrhythmia as a result of the interaction of cetirizine and pilsicainide in a patient with renal insufficiency: first case presentation showing competition for excretion via renal multidrug resistance protein 1 and organic cation transporter 2.", "question": "Treatment.Disorder in interaction of cetirizine and pilsicainide", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16580907_1_3389", "context": "Severe arrhythmia as a result of the interaction of cetirizine and pilsicainide in a patient with renal insufficiency: first case presentation showing competition for excretion via renal multidrug resistance protein 1 and organic cation transporter 2.", "question": "Combination.Drug in interaction of cetirizine and pilsicainide", "question_type": "Adverse_event.Combination.Drug", "answers": "cetirizine; pilsicainide"}, {"id": "10465148_4_3390", "context": "Reported are three children who developed progressive paraparesis after intrathecal methotrexate administration followed by complete or partial recovery.", "question": "Subject.Age in three children", "question_type": "Adverse_event.Subject.Age", "answers": "children"}, {"id": "10465148_4_3391", "context": "Reported are three children who developed progressive paraparesis after intrathecal methotrexate administration followed by complete or partial recovery.", "question": "Subject.Gender in three children", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "10465148_4_3392", "context": "Reported are three children who developed progressive paraparesis after intrathecal methotrexate administration followed by complete or partial recovery.", "question": "Subject.Population in three children", "question_type": "Adverse_event.Subject.Population", "answers": "three"}, {"id": "10465148_4_3393", "context": "Reported are three children who developed progressive paraparesis after intrathecal methotrexate administration followed by complete or partial recovery.", "question": "Subject.Race in three children", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "10465148_4_3394", "context": "Reported are three children who developed progressive paraparesis after intrathecal methotrexate administration followed by complete or partial recovery.", "question": "Subject.Disorder in three children", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "10465148_4_3395", "context": "Reported are three children who developed progressive paraparesis after intrathecal methotrexate administration followed by complete or partial recovery.", "question": "Treatment.Drug in intrathecal methotrexate", "question_type": "Adverse_event.Treatment.Drug", "answers": "methotrexate"}, {"id": "10465148_4_3396", "context": "Reported are three children who developed progressive paraparesis after intrathecal methotrexate administration followed by complete or partial recovery.", "question": "Treatment.Dosage in intrathecal methotrexate", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10465148_4_3397", "context": "Reported are three children who developed progressive paraparesis after intrathecal methotrexate administration followed by complete or partial recovery.", "question": "Treatment.Freq in intrathecal methotrexate", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10465148_4_3398", "context": "Reported are three children who developed progressive paraparesis after intrathecal methotrexate administration followed by complete or partial recovery.", "question": "Treatment.Route in intrathecal methotrexate", "question_type": "Adverse_event.Treatment.Route", "answers": "intrathecal"}, {"id": "10465148_4_3399", "context": "Reported are three children who developed progressive paraparesis after intrathecal methotrexate administration followed by complete or partial recovery.", "question": "Treatment.Time_elapsed in intrathecal methotrexate", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10465148_4_3400", "context": "Reported are three children who developed progressive paraparesis after intrathecal methotrexate administration followed by complete or partial recovery.", "question": "Treatment.Duration in intrathecal methotrexate", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10465148_4_3401", "context": "Reported are three children who developed progressive paraparesis after intrathecal methotrexate administration followed by complete or partial recovery.", "question": "Treatment.Disorder in intrathecal methotrexate", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10465148_4_3402", "context": "Reported are three children who developed progressive paraparesis after intrathecal methotrexate administration followed by complete or partial recovery.", "question": "Combination.Drug in intrathecal methotrexate", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11428480_3_3403", "context": "We observed ventricular fibrillation in 2 patients who presented to the emergency department with pre-excited atrial fibrillation and were given 12 mg of adenosine.", "question": "Subject.Age in 2 patients who presented to the emergency department with pre-excited atrial fibrillation", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "11428480_3_3404", "context": "We observed ventricular fibrillation in 2 patients who presented to the emergency department with pre-excited atrial fibrillation and were given 12 mg of adenosine.", "question": "Subject.Gender in 2 patients who presented to the emergency department with pre-excited atrial fibrillation", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "11428480_3_3405", "context": "We observed ventricular fibrillation in 2 patients who presented to the emergency department with pre-excited atrial fibrillation and were given 12 mg of adenosine.", "question": "Subject.Population in 2 patients who presented to the emergency department with pre-excited atrial fibrillation", "question_type": "Adverse_event.Subject.Population", "answers": "2"}, {"id": "11428480_3_3406", "context": "We observed ventricular fibrillation in 2 patients who presented to the emergency department with pre-excited atrial fibrillation and were given 12 mg of adenosine.", "question": "Subject.Race in 2 patients who presented to the emergency department with pre-excited atrial fibrillation", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "11428480_3_3407", "context": "We observed ventricular fibrillation in 2 patients who presented to the emergency department with pre-excited atrial fibrillation and were given 12 mg of adenosine.", "question": "Subject.Disorder in 2 patients who presented to the emergency department with pre-excited atrial fibrillation", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "11428480_3_3408", "context": "We observed ventricular fibrillation in 2 patients who presented to the emergency department with pre-excited atrial fibrillation and were given 12 mg of adenosine.", "question": "Treatment.Drug in 12 mg of adenosine", "question_type": "Adverse_event.Treatment.Drug", "answers": "adenosine"}, {"id": "11428480_3_3409", "context": "We observed ventricular fibrillation in 2 patients who presented to the emergency department with pre-excited atrial fibrillation and were given 12 mg of adenosine.", "question": "Treatment.Dosage in 12 mg of adenosine", "question_type": "Adverse_event.Treatment.Dosage", "answers": "12 mg"}, {"id": "11428480_3_3410", "context": "We observed ventricular fibrillation in 2 patients who presented to the emergency department with pre-excited atrial fibrillation and were given 12 mg of adenosine.", "question": "Treatment.Freq in 12 mg of adenosine", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11428480_3_3411", "context": "We observed ventricular fibrillation in 2 patients who presented to the emergency department with pre-excited atrial fibrillation and were given 12 mg of adenosine.", "question": "Treatment.Route in 12 mg of adenosine", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11428480_3_3412", "context": "We observed ventricular fibrillation in 2 patients who presented to the emergency department with pre-excited atrial fibrillation and were given 12 mg of adenosine.", "question": "Treatment.Time_elapsed in 12 mg of adenosine", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11428480_3_3413", "context": "We observed ventricular fibrillation in 2 patients who presented to the emergency department with pre-excited atrial fibrillation and were given 12 mg of adenosine.", "question": "Treatment.Duration in 12 mg of adenosine", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11428480_3_3414", "context": "We observed ventricular fibrillation in 2 patients who presented to the emergency department with pre-excited atrial fibrillation and were given 12 mg of adenosine.", "question": "Treatment.Disorder in 12 mg of adenosine", "question_type": "Adverse_event.Treatment.Disorder", "answers": "pre-excited atrial fibrillation"}, {"id": "11428480_3_3415", "context": "We observed ventricular fibrillation in 2 patients who presented to the emergency department with pre-excited atrial fibrillation and were given 12 mg of adenosine.", "question": "Combination.Drug in 12 mg of adenosine", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17083890_5_3416", "context": "During administration of chemotherapy, the patient progressively developed a complex association of Beau's lines, transverse melanonychia, Muehrcke's lines, and diffuse hyperpigmentation of the skin.", "question": "Subject.Age in patient", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "17083890_5_3417", "context": "During administration of chemotherapy, the patient progressively developed a complex association of Beau's lines, transverse melanonychia, Muehrcke's lines, and diffuse hyperpigmentation of the skin.", "question": "Subject.Gender in patient", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "17083890_5_3418", "context": "During administration of chemotherapy, the patient progressively developed a complex association of Beau's lines, transverse melanonychia, Muehrcke's lines, and diffuse hyperpigmentation of the skin.", "question": "Subject.Population in patient", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "17083890_5_3419", "context": "During administration of chemotherapy, the patient progressively developed a complex association of Beau's lines, transverse melanonychia, Muehrcke's lines, and diffuse hyperpigmentation of the skin.", "question": "Subject.Race in patient", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "17083890_5_3420", "context": "During administration of chemotherapy, the patient progressively developed a complex association of Beau's lines, transverse melanonychia, Muehrcke's lines, and diffuse hyperpigmentation of the skin.", "question": "Subject.Disorder in patient", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "17083890_5_3421", "context": "During administration of chemotherapy, the patient progressively developed a complex association of Beau's lines, transverse melanonychia, Muehrcke's lines, and diffuse hyperpigmentation of the skin.", "question": "Treatment.Drug in chemotherapy", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "17083890_5_3422", "context": "During administration of chemotherapy, the patient progressively developed a complex association of Beau's lines, transverse melanonychia, Muehrcke's lines, and diffuse hyperpigmentation of the skin.", "question": "Treatment.Dosage in chemotherapy", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17083890_5_3423", "context": "During administration of chemotherapy, the patient progressively developed a complex association of Beau's lines, transverse melanonychia, Muehrcke's lines, and diffuse hyperpigmentation of the skin.", "question": "Treatment.Freq in chemotherapy", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17083890_5_3424", "context": "During administration of chemotherapy, the patient progressively developed a complex association of Beau's lines, transverse melanonychia, Muehrcke's lines, and diffuse hyperpigmentation of the skin.", "question": "Treatment.Route in chemotherapy", "question_type": "Adverse_event.Treatment.Route", "answers": "chemotherapy"}, {"id": "17083890_5_3425", "context": "During administration of chemotherapy, the patient progressively developed a complex association of Beau's lines, transverse melanonychia, Muehrcke's lines, and diffuse hyperpigmentation of the skin.", "question": "Treatment.Time_elapsed in chemotherapy", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17083890_5_3426", "context": "During administration of chemotherapy, the patient progressively developed a complex association of Beau's lines, transverse melanonychia, Muehrcke's lines, and diffuse hyperpigmentation of the skin.", "question": "Treatment.Duration in chemotherapy", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17083890_5_3427", "context": "During administration of chemotherapy, the patient progressively developed a complex association of Beau's lines, transverse melanonychia, Muehrcke's lines, and diffuse hyperpigmentation of the skin.", "question": "Treatment.Disorder in chemotherapy", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17083890_5_3428", "context": "During administration of chemotherapy, the patient progressively developed a complex association of Beau's lines, transverse melanonychia, Muehrcke's lines, and diffuse hyperpigmentation of the skin.", "question": "Combination.Drug in chemotherapy", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17083890_1_3429", "context": "Distinct patterns of chromonychia, Beau's lines, and melanoderma seen with vincristine, adriamycin, dexamethasone therapy for multiple myeloma.", "question": "Treatment.Drug in vincristine, adriamycin, dexamethasone", "question_type": "Adverse_event.Treatment.Drug", "answers": "vincristine; adriamycin; dexamethasone"}, {"id": "17083890_1_3430", "context": "Distinct patterns of chromonychia, Beau's lines, and melanoderma seen with vincristine, adriamycin, dexamethasone therapy for multiple myeloma.", "question": "Treatment.Dosage in vincristine, adriamycin, dexamethasone", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17083890_1_3431", "context": "Distinct patterns of chromonychia, Beau's lines, and melanoderma seen with vincristine, adriamycin, dexamethasone therapy for multiple myeloma.", "question": "Treatment.Freq in vincristine, adriamycin, dexamethasone", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17083890_1_3432", "context": "Distinct patterns of chromonychia, Beau's lines, and melanoderma seen with vincristine, adriamycin, dexamethasone therapy for multiple myeloma.", "question": "Treatment.Route in vincristine, adriamycin, dexamethasone", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17083890_1_3433", "context": "Distinct patterns of chromonychia, Beau's lines, and melanoderma seen with vincristine, adriamycin, dexamethasone therapy for multiple myeloma.", "question": "Treatment.Time_elapsed in vincristine, adriamycin, dexamethasone", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17083890_1_3434", "context": "Distinct patterns of chromonychia, Beau's lines, and melanoderma seen with vincristine, adriamycin, dexamethasone therapy for multiple myeloma.", "question": "Treatment.Duration in vincristine, adriamycin, dexamethasone", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17083890_1_3435", "context": "Distinct patterns of chromonychia, Beau's lines, and melanoderma seen with vincristine, adriamycin, dexamethasone therapy for multiple myeloma.", "question": "Treatment.Disorder in vincristine, adriamycin, dexamethasone", "question_type": "Adverse_event.Treatment.Disorder", "answers": "multiple myeloma"}, {"id": "17083890_1_3436", "context": "Distinct patterns of chromonychia, Beau's lines, and melanoderma seen with vincristine, adriamycin, dexamethasone therapy for multiple myeloma.", "question": "Combination.Drug in vincristine, adriamycin, dexamethasone", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10633877_3_3437", "context": "Theophylline intoxication mimicking diabetic ketoacidosis in a child.", "question": "Subject.Age in a child", "question_type": "Adverse_event.Subject.Age", "answers": "child"}, {"id": "10633877_3_3438", "context": "Theophylline intoxication mimicking diabetic ketoacidosis in a child.", "question": "Subject.Gender in a child", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "10633877_3_3439", "context": "Theophylline intoxication mimicking diabetic ketoacidosis in a child.", "question": "Subject.Population in a child", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "10633877_3_3440", "context": "Theophylline intoxication mimicking diabetic ketoacidosis in a child.", "question": "Subject.Race in a child", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "10633877_3_3441", "context": "Theophylline intoxication mimicking diabetic ketoacidosis in a child.", "question": "Subject.Disorder in a child", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "10633877_3_3442", "context": "Theophylline intoxication mimicking diabetic ketoacidosis in a child.", "question": "Treatment.Drug in Theophylline", "question_type": "Adverse_event.Treatment.Drug", "answers": "Theophylline"}, {"id": "10633877_3_3443", "context": "Theophylline intoxication mimicking diabetic ketoacidosis in a child.", "question": "Treatment.Dosage in Theophylline", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10633877_3_3444", "context": "Theophylline intoxication mimicking diabetic ketoacidosis in a child.", "question": "Treatment.Freq in Theophylline", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10633877_3_3445", "context": "Theophylline intoxication mimicking diabetic ketoacidosis in a child.", "question": "Treatment.Route in Theophylline", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10633877_3_3446", "context": "Theophylline intoxication mimicking diabetic ketoacidosis in a child.", "question": "Treatment.Time_elapsed in Theophylline", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10633877_3_3447", "context": "Theophylline intoxication mimicking diabetic ketoacidosis in a child.", "question": "Treatment.Duration in Theophylline", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10633877_3_3448", "context": "Theophylline intoxication mimicking diabetic ketoacidosis in a child.", "question": "Treatment.Disorder in Theophylline", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10633877_3_3449", "context": "Theophylline intoxication mimicking diabetic ketoacidosis in a child.", "question": "Combination.Drug in Theophylline", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18492617_3_3450", "context": "We describe a patient who, after receiving his first dose of pregabalin to relieve neuropathic pain, presented with a negative myoclonus.", "question": "Subject.Age in a patient", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "18492617_3_3451", "context": "We describe a patient who, after receiving his first dose of pregabalin to relieve neuropathic pain, presented with a negative myoclonus.", "question": "Subject.Gender in a patient", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "18492617_3_3452", "context": "We describe a patient who, after receiving his first dose of pregabalin to relieve neuropathic pain, presented with a negative myoclonus.", "question": "Subject.Population in a patient", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "18492617_3_3453", "context": "We describe a patient who, after receiving his first dose of pregabalin to relieve neuropathic pain, presented with a negative myoclonus.", "question": "Subject.Race in a patient", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "18492617_3_3454", "context": "We describe a patient who, after receiving his first dose of pregabalin to relieve neuropathic pain, presented with a negative myoclonus.", "question": "Subject.Disorder in a patient", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "18492617_3_3455", "context": "We describe a patient who, after receiving his first dose of pregabalin to relieve neuropathic pain, presented with a negative myoclonus.", "question": "Treatment.Drug in pregabalin", "question_type": "Adverse_event.Treatment.Drug", "answers": "pregabalin"}, {"id": "18492617_3_3456", "context": "We describe a patient who, after receiving his first dose of pregabalin to relieve neuropathic pain, presented with a negative myoclonus.", "question": "Treatment.Dosage in pregabalin", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18492617_3_3457", "context": "We describe a patient who, after receiving his first dose of pregabalin to relieve neuropathic pain, presented with a negative myoclonus.", "question": "Treatment.Freq in pregabalin", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18492617_3_3458", "context": "We describe a patient who, after receiving his first dose of pregabalin to relieve neuropathic pain, presented with a negative myoclonus.", "question": "Treatment.Route in pregabalin", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18492617_3_3459", "context": "We describe a patient who, after receiving his first dose of pregabalin to relieve neuropathic pain, presented with a negative myoclonus.", "question": "Treatment.Time_elapsed in pregabalin", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18492617_3_3460", "context": "We describe a patient who, after receiving his first dose of pregabalin to relieve neuropathic pain, presented with a negative myoclonus.", "question": "Treatment.Duration in pregabalin", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18492617_3_3461", "context": "We describe a patient who, after receiving his first dose of pregabalin to relieve neuropathic pain, presented with a negative myoclonus.", "question": "Treatment.Disorder in pregabalin", "question_type": "Adverse_event.Treatment.Disorder", "answers": "neuropathic pain"}, {"id": "18492617_3_3462", "context": "We describe a patient who, after receiving his first dose of pregabalin to relieve neuropathic pain, presented with a negative myoclonus.", "question": "Combination.Drug in pregabalin", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12452753_2_3463", "context": "CONCLUSIONS: The use of fluorouracil treatment with careful monitoring can be considered in a patient with mild allergic reactions to capecitabine.", "question": "Subject.Age in a patient with mild allergic reactions to capecitabine", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "12452753_2_3464", "context": "CONCLUSIONS: The use of fluorouracil treatment with careful monitoring can be considered in a patient with mild allergic reactions to capecitabine.", "question": "Subject.Gender in a patient with mild allergic reactions to capecitabine", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "12452753_2_3465", "context": "CONCLUSIONS: The use of fluorouracil treatment with careful monitoring can be considered in a patient with mild allergic reactions to capecitabine.", "question": "Subject.Population in a patient with mild allergic reactions to capecitabine", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "12452753_2_3466", "context": "CONCLUSIONS: The use of fluorouracil treatment with careful monitoring can be considered in a patient with mild allergic reactions to capecitabine.", "question": "Subject.Race in a patient with mild allergic reactions to capecitabine", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "12452753_2_3467", "context": "CONCLUSIONS: The use of fluorouracil treatment with careful monitoring can be considered in a patient with mild allergic reactions to capecitabine.", "question": "Subject.Disorder in a patient with mild allergic reactions to capecitabine", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": "allergic reactions to capecitabine"}, {"id": "12452753_2_3468", "context": "CONCLUSIONS: The use of fluorouracil treatment with careful monitoring can be considered in a patient with mild allergic reactions to capecitabine.", "question": "Treatment.Drug in fluorouracil treatment with careful monitoring", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "fluorouracil"}, {"id": "12452753_2_3469", "context": "CONCLUSIONS: The use of fluorouracil treatment with careful monitoring can be considered in a patient with mild allergic reactions to capecitabine.", "question": "Treatment.Dosage in fluorouracil treatment with careful monitoring", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "12452753_2_3470", "context": "CONCLUSIONS: The use of fluorouracil treatment with careful monitoring can be considered in a patient with mild allergic reactions to capecitabine.", "question": "Treatment.Freq in fluorouracil treatment with careful monitoring", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "12452753_2_3471", "context": "CONCLUSIONS: The use of fluorouracil treatment with careful monitoring can be considered in a patient with mild allergic reactions to capecitabine.", "question": "Treatment.Route in fluorouracil treatment with careful monitoring", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "12452753_2_3472", "context": "CONCLUSIONS: The use of fluorouracil treatment with careful monitoring can be considered in a patient with mild allergic reactions to capecitabine.", "question": "Treatment.Time_elapsed in fluorouracil treatment with careful monitoring", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12452753_2_3473", "context": "CONCLUSIONS: The use of fluorouracil treatment with careful monitoring can be considered in a patient with mild allergic reactions to capecitabine.", "question": "Treatment.Duration in fluorouracil treatment with careful monitoring", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "12452753_2_3474", "context": "CONCLUSIONS: The use of fluorouracil treatment with careful monitoring can be considered in a patient with mild allergic reactions to capecitabine.", "question": "Treatment.Disorder in fluorouracil treatment with careful monitoring", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "12452753_2_3475", "context": "CONCLUSIONS: The use of fluorouracil treatment with careful monitoring can be considered in a patient with mild allergic reactions to capecitabine.", "question": "Combination.Drug in fluorouracil treatment with careful monitoring", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "16313549_1_3476", "context": "Symptomatic hypocalcaemia and renal impairment associated with bisphosphonate treatment in patients with multiple myeloma.", "question": "Subject.Age in patients with multiple myeloma", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "16313549_1_3477", "context": "Symptomatic hypocalcaemia and renal impairment associated with bisphosphonate treatment in patients with multiple myeloma.", "question": "Subject.Gender in patients with multiple myeloma", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "16313549_1_3478", "context": "Symptomatic hypocalcaemia and renal impairment associated with bisphosphonate treatment in patients with multiple myeloma.", "question": "Subject.Population in patients with multiple myeloma", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "16313549_1_3479", "context": "Symptomatic hypocalcaemia and renal impairment associated with bisphosphonate treatment in patients with multiple myeloma.", "question": "Subject.Race in patients with multiple myeloma", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16313549_1_3480", "context": "Symptomatic hypocalcaemia and renal impairment associated with bisphosphonate treatment in patients with multiple myeloma.", "question": "Subject.Disorder in patients with multiple myeloma", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "16313549_1_3481", "context": "Symptomatic hypocalcaemia and renal impairment associated with bisphosphonate treatment in patients with multiple myeloma.", "question": "Treatment.Drug in bisphosphonate treatment", "question_type": "Adverse_event.Treatment.Drug", "answers": "bisphosphonate"}, {"id": "16313549_1_3482", "context": "Symptomatic hypocalcaemia and renal impairment associated with bisphosphonate treatment in patients with multiple myeloma.", "question": "Treatment.Dosage in bisphosphonate treatment", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16313549_1_3483", "context": "Symptomatic hypocalcaemia and renal impairment associated with bisphosphonate treatment in patients with multiple myeloma.", "question": "Treatment.Freq in bisphosphonate treatment", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16313549_1_3484", "context": "Symptomatic hypocalcaemia and renal impairment associated with bisphosphonate treatment in patients with multiple myeloma.", "question": "Treatment.Route in bisphosphonate treatment", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16313549_1_3485", "context": "Symptomatic hypocalcaemia and renal impairment associated with bisphosphonate treatment in patients with multiple myeloma.", "question": "Treatment.Time_elapsed in bisphosphonate treatment", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16313549_1_3486", "context": "Symptomatic hypocalcaemia and renal impairment associated with bisphosphonate treatment in patients with multiple myeloma.", "question": "Treatment.Duration in bisphosphonate treatment", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16313549_1_3487", "context": "Symptomatic hypocalcaemia and renal impairment associated with bisphosphonate treatment in patients with multiple myeloma.", "question": "Treatment.Disorder in bisphosphonate treatment", "question_type": "Adverse_event.Treatment.Disorder", "answers": "multiple myeloma"}, {"id": "16313549_1_3488", "context": "Symptomatic hypocalcaemia and renal impairment associated with bisphosphonate treatment in patients with multiple myeloma.", "question": "Combination.Drug in bisphosphonate treatment", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9681211_1_3489", "context": "Although this G-CSF-driven leucocytosis was alarming it did not appear to have adversely affected the patient's prognosis.", "question": "Treatment.Drug in G-CSF", "question_type": "Adverse_event.Treatment.Drug", "answers": "G-CSF"}, {"id": "9681211_1_3490", "context": "Although this G-CSF-driven leucocytosis was alarming it did not appear to have adversely affected the patient's prognosis.", "question": "Treatment.Dosage in G-CSF", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9681211_1_3491", "context": "Although this G-CSF-driven leucocytosis was alarming it did not appear to have adversely affected the patient's prognosis.", "question": "Treatment.Freq in G-CSF", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9681211_1_3492", "context": "Although this G-CSF-driven leucocytosis was alarming it did not appear to have adversely affected the patient's prognosis.", "question": "Treatment.Route in G-CSF", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9681211_1_3493", "context": "Although this G-CSF-driven leucocytosis was alarming it did not appear to have adversely affected the patient's prognosis.", "question": "Treatment.Time_elapsed in G-CSF", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9681211_1_3494", "context": "Although this G-CSF-driven leucocytosis was alarming it did not appear to have adversely affected the patient's prognosis.", "question": "Treatment.Duration in G-CSF", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9681211_1_3495", "context": "Although this G-CSF-driven leucocytosis was alarming it did not appear to have adversely affected the patient's prognosis.", "question": "Treatment.Disorder in G-CSF", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9681211_1_3496", "context": "Although this G-CSF-driven leucocytosis was alarming it did not appear to have adversely affected the patient's prognosis.", "question": "Combination.Drug in G-CSF", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "4018433_1_3497", "context": "A case of pyridoxine-dependent seizures is reported.", "question": "Subject.Age in A case", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "4018433_1_3498", "context": "A case of pyridoxine-dependent seizures is reported.", "question": "Subject.Gender in A case", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "4018433_1_3499", "context": "A case of pyridoxine-dependent seizures is reported.", "question": "Subject.Population in A case", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "4018433_1_3500", "context": "A case of pyridoxine-dependent seizures is reported.", "question": "Subject.Race in A case", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "4018433_1_3501", "context": "A case of pyridoxine-dependent seizures is reported.", "question": "Subject.Disorder in A case", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "4018433_1_3502", "context": "A case of pyridoxine-dependent seizures is reported.", "question": "Treatment.Drug in pyridoxine", "question_type": "Adverse_event.Treatment.Drug", "answers": "pyridoxine"}, {"id": "4018433_1_3503", "context": "A case of pyridoxine-dependent seizures is reported.", "question": "Treatment.Dosage in pyridoxine", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "4018433_1_3504", "context": "A case of pyridoxine-dependent seizures is reported.", "question": "Treatment.Freq in pyridoxine", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "4018433_1_3505", "context": "A case of pyridoxine-dependent seizures is reported.", "question": "Treatment.Route in pyridoxine", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "4018433_1_3506", "context": "A case of pyridoxine-dependent seizures is reported.", "question": "Treatment.Time_elapsed in pyridoxine", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "4018433_1_3507", "context": "A case of pyridoxine-dependent seizures is reported.", "question": "Treatment.Duration in pyridoxine", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "4018433_1_3508", "context": "A case of pyridoxine-dependent seizures is reported.", "question": "Treatment.Disorder in pyridoxine", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "4018433_1_3509", "context": "A case of pyridoxine-dependent seizures is reported.", "question": "Combination.Drug in pyridoxine", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "2417800_1_3510", "context": "A case of a 53-year-old man who developed acute pneumonitis after bleomycin and moderate oxygen administration is presented.", "question": "Subject.Age in A case of a 53-year-old man", "question_type": "Adverse_event.Subject.Age", "answers": "53-year-old"}, {"id": "2417800_1_3511", "context": "A case of a 53-year-old man who developed acute pneumonitis after bleomycin and moderate oxygen administration is presented.", "question": "Subject.Gender in A case of a 53-year-old man", "question_type": "Adverse_event.Subject.Gender", "answers": "man"}, {"id": "2417800_1_3512", "context": "A case of a 53-year-old man who developed acute pneumonitis after bleomycin and moderate oxygen administration is presented.", "question": "Subject.Population in A case of a 53-year-old man", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "2417800_1_3513", "context": "A case of a 53-year-old man who developed acute pneumonitis after bleomycin and moderate oxygen administration is presented.", "question": "Subject.Race in A case of a 53-year-old man", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "2417800_1_3514", "context": "A case of a 53-year-old man who developed acute pneumonitis after bleomycin and moderate oxygen administration is presented.", "question": "Subject.Disorder in A case of a 53-year-old man", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "2417800_1_3515", "context": "A case of a 53-year-old man who developed acute pneumonitis after bleomycin and moderate oxygen administration is presented.", "question": "Treatment.Drug in bleomycin and moderate oxygen", "question_type": "Adverse_event.Treatment.Drug", "answers": "bleomycin; oxygen"}, {"id": "2417800_1_3516", "context": "A case of a 53-year-old man who developed acute pneumonitis after bleomycin and moderate oxygen administration is presented.", "question": "Treatment.Dosage in bleomycin and moderate oxygen", "question_type": "Adverse_event.Treatment.Dosage", "answers": "moderate"}, {"id": "2417800_1_3517", "context": "A case of a 53-year-old man who developed acute pneumonitis after bleomycin and moderate oxygen administration is presented.", "question": "Treatment.Freq in bleomycin and moderate oxygen", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2417800_1_3518", "context": "A case of a 53-year-old man who developed acute pneumonitis after bleomycin and moderate oxygen administration is presented.", "question": "Treatment.Route in bleomycin and moderate oxygen", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "2417800_1_3519", "context": "A case of a 53-year-old man who developed acute pneumonitis after bleomycin and moderate oxygen administration is presented.", "question": "Treatment.Time_elapsed in bleomycin and moderate oxygen", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2417800_1_3520", "context": "A case of a 53-year-old man who developed acute pneumonitis after bleomycin and moderate oxygen administration is presented.", "question": "Treatment.Duration in bleomycin and moderate oxygen", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2417800_1_3521", "context": "A case of a 53-year-old man who developed acute pneumonitis after bleomycin and moderate oxygen administration is presented.", "question": "Treatment.Disorder in bleomycin and moderate oxygen", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "2417800_1_3522", "context": "A case of a 53-year-old man who developed acute pneumonitis after bleomycin and moderate oxygen administration is presented.", "question": "Combination.Drug in bleomycin and moderate oxygen", "question_type": "Adverse_event.Combination.Drug", "answers": "bleomycin; oxygen"}, {"id": "14530108_1_3523", "context": "Renal tubular acidosis secondary to FK506 in living donor liver transplantation: a case report.", "question": "Subject.Age in a case", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "14530108_1_3524", "context": "Renal tubular acidosis secondary to FK506 in living donor liver transplantation: a case report.", "question": "Subject.Gender in a case", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "14530108_1_3525", "context": "Renal tubular acidosis secondary to FK506 in living donor liver transplantation: a case report.", "question": "Subject.Population in a case", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "14530108_1_3526", "context": "Renal tubular acidosis secondary to FK506 in living donor liver transplantation: a case report.", "question": "Subject.Race in a case", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "14530108_1_3527", "context": "Renal tubular acidosis secondary to FK506 in living donor liver transplantation: a case report.", "question": "Subject.Disorder in a case", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "14530108_1_3528", "context": "Renal tubular acidosis secondary to FK506 in living donor liver transplantation: a case report.", "question": "Treatment.Drug in FK506", "question_type": "Adverse_event.Treatment.Drug", "answers": "FK506"}, {"id": "14530108_1_3529", "context": "Renal tubular acidosis secondary to FK506 in living donor liver transplantation: a case report.", "question": "Treatment.Dosage in FK506", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "14530108_1_3530", "context": "Renal tubular acidosis secondary to FK506 in living donor liver transplantation: a case report.", "question": "Treatment.Freq in FK506", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "14530108_1_3531", "context": "Renal tubular acidosis secondary to FK506 in living donor liver transplantation: a case report.", "question": "Treatment.Route in FK506", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "14530108_1_3532", "context": "Renal tubular acidosis secondary to FK506 in living donor liver transplantation: a case report.", "question": "Treatment.Time_elapsed in FK506", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "14530108_1_3533", "context": "Renal tubular acidosis secondary to FK506 in living donor liver transplantation: a case report.", "question": "Treatment.Duration in FK506", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "14530108_1_3534", "context": "Renal tubular acidosis secondary to FK506 in living donor liver transplantation: a case report.", "question": "Treatment.Disorder in FK506", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "14530108_1_3535", "context": "Renal tubular acidosis secondary to FK506 in living donor liver transplantation: a case report.", "question": "Combination.Drug in FK506", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "20020238_3_3536", "context": "Retinopathy in hepatitis C patients due to combination therapy with pegylated interferon and ribavirin.", "question": "Subject.Age in hepatitis C patients", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "20020238_3_3537", "context": "Retinopathy in hepatitis C patients due to combination therapy with pegylated interferon and ribavirin.", "question": "Subject.Gender in hepatitis C patients", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "20020238_3_3538", "context": "Retinopathy in hepatitis C patients due to combination therapy with pegylated interferon and ribavirin.", "question": "Subject.Population in hepatitis C patients", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "20020238_3_3539", "context": "Retinopathy in hepatitis C patients due to combination therapy with pegylated interferon and ribavirin.", "question": "Subject.Race in hepatitis C patients", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "20020238_3_3540", "context": "Retinopathy in hepatitis C patients due to combination therapy with pegylated interferon and ribavirin.", "question": "Subject.Disorder in hepatitis C patients", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "20020238_3_3541", "context": "Retinopathy in hepatitis C patients due to combination therapy with pegylated interferon and ribavirin.", "question": "Treatment.Drug in pegylated interferon and ribavirin", "question_type": "Adverse_event.Treatment.Drug", "answers": "pegylated interferon; ribavirin"}, {"id": "20020238_3_3542", "context": "Retinopathy in hepatitis C patients due to combination therapy with pegylated interferon and ribavirin.", "question": "Treatment.Dosage in pegylated interferon and ribavirin", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "20020238_3_3543", "context": "Retinopathy in hepatitis C patients due to combination therapy with pegylated interferon and ribavirin.", "question": "Treatment.Freq in pegylated interferon and ribavirin", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "20020238_3_3544", "context": "Retinopathy in hepatitis C patients due to combination therapy with pegylated interferon and ribavirin.", "question": "Treatment.Route in pegylated interferon and ribavirin", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "20020238_3_3545", "context": "Retinopathy in hepatitis C patients due to combination therapy with pegylated interferon and ribavirin.", "question": "Treatment.Time_elapsed in pegylated interferon and ribavirin", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "20020238_3_3546", "context": "Retinopathy in hepatitis C patients due to combination therapy with pegylated interferon and ribavirin.", "question": "Treatment.Duration in pegylated interferon and ribavirin", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "20020238_3_3547", "context": "Retinopathy in hepatitis C patients due to combination therapy with pegylated interferon and ribavirin.", "question": "Treatment.Disorder in pegylated interferon and ribavirin", "question_type": "Adverse_event.Treatment.Disorder", "answers": "hepatitis C"}, {"id": "20020238_3_3548", "context": "Retinopathy in hepatitis C patients due to combination therapy with pegylated interferon and ribavirin.", "question": "Combination.Drug in pegylated interferon and ribavirin", "question_type": "Adverse_event.Combination.Drug", "answers": "pegylated interferon; ribavirin"}, {"id": "16615675_1_3549", "context": "After excluding other causes of long QT syndrome, the HCQ was suspected as the cause of her ventricular tachycardia.", "question": "Subject.Age in her", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "16615675_1_3550", "context": "After excluding other causes of long QT syndrome, the HCQ was suspected as the cause of her ventricular tachycardia.", "question": "Subject.Gender in her", "question_type": "Adverse_event.Subject.Gender", "answers": "her"}, {"id": "16615675_1_3551", "context": "After excluding other causes of long QT syndrome, the HCQ was suspected as the cause of her ventricular tachycardia.", "question": "Subject.Population in her", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "16615675_1_3552", "context": "After excluding other causes of long QT syndrome, the HCQ was suspected as the cause of her ventricular tachycardia.", "question": "Subject.Race in her", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16615675_1_3553", "context": "After excluding other causes of long QT syndrome, the HCQ was suspected as the cause of her ventricular tachycardia.", "question": "Subject.Disorder in her", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "16615675_1_3554", "context": "After excluding other causes of long QT syndrome, the HCQ was suspected as the cause of her ventricular tachycardia.", "question": "Treatment.Drug in HCQ", "question_type": "Adverse_event.Treatment.Drug", "answers": "HCQ"}, {"id": "16615675_1_3555", "context": "After excluding other causes of long QT syndrome, the HCQ was suspected as the cause of her ventricular tachycardia.", "question": "Treatment.Dosage in HCQ", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16615675_1_3556", "context": "After excluding other causes of long QT syndrome, the HCQ was suspected as the cause of her ventricular tachycardia.", "question": "Treatment.Freq in HCQ", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16615675_1_3557", "context": "After excluding other causes of long QT syndrome, the HCQ was suspected as the cause of her ventricular tachycardia.", "question": "Treatment.Route in HCQ", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16615675_1_3558", "context": "After excluding other causes of long QT syndrome, the HCQ was suspected as the cause of her ventricular tachycardia.", "question": "Treatment.Time_elapsed in HCQ", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16615675_1_3559", "context": "After excluding other causes of long QT syndrome, the HCQ was suspected as the cause of her ventricular tachycardia.", "question": "Treatment.Duration in HCQ", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16615675_1_3560", "context": "After excluding other causes of long QT syndrome, the HCQ was suspected as the cause of her ventricular tachycardia.", "question": "Treatment.Disorder in HCQ", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16615675_1_3561", "context": "After excluding other causes of long QT syndrome, the HCQ was suspected as the cause of her ventricular tachycardia.", "question": "Combination.Drug in HCQ", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10907391_2_3562", "context": "Phantom limb pain as a manifestation of paclitaxel neurotoxicity.", "question": "Treatment.Drug in paclitaxel", "question_type": "Adverse_event.Treatment.Drug", "answers": "paclitaxel"}, {"id": "10907391_2_3563", "context": "Phantom limb pain as a manifestation of paclitaxel neurotoxicity.", "question": "Treatment.Dosage in paclitaxel", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10907391_2_3564", "context": "Phantom limb pain as a manifestation of paclitaxel neurotoxicity.", "question": "Treatment.Freq in paclitaxel", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10907391_2_3565", "context": "Phantom limb pain as a manifestation of paclitaxel neurotoxicity.", "question": "Treatment.Route in paclitaxel", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10907391_2_3566", "context": "Phantom limb pain as a manifestation of paclitaxel neurotoxicity.", "question": "Treatment.Time_elapsed in paclitaxel", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10907391_2_3567", "context": "Phantom limb pain as a manifestation of paclitaxel neurotoxicity.", "question": "Treatment.Duration in paclitaxel", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10907391_2_3568", "context": "Phantom limb pain as a manifestation of paclitaxel neurotoxicity.", "question": "Treatment.Disorder in paclitaxel", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10907391_2_3569", "context": "Phantom limb pain as a manifestation of paclitaxel neurotoxicity.", "question": "Combination.Drug in paclitaxel", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3159106_1_3570", "context": "A case of allopurinol hypersensitivity, possibly the first in a black African, is reported.", "question": "Subject.Age in a black African", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "3159106_1_3571", "context": "A case of allopurinol hypersensitivity, possibly the first in a black African, is reported.", "question": "Subject.Gender in a black African", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "3159106_1_3572", "context": "A case of allopurinol hypersensitivity, possibly the first in a black African, is reported.", "question": "Subject.Population in a black African", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "3159106_1_3573", "context": "A case of allopurinol hypersensitivity, possibly the first in a black African, is reported.", "question": "Subject.Race in a black African", "question_type": "Adverse_event.Subject.Race", "answers": "black African"}, {"id": "3159106_1_3574", "context": "A case of allopurinol hypersensitivity, possibly the first in a black African, is reported.", "question": "Subject.Disorder in a black African", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "3159106_1_3575", "context": "A case of allopurinol hypersensitivity, possibly the first in a black African, is reported.", "question": "Treatment.Drug in allopurinol", "question_type": "Adverse_event.Treatment.Drug", "answers": "allopurinol"}, {"id": "3159106_1_3576", "context": "A case of allopurinol hypersensitivity, possibly the first in a black African, is reported.", "question": "Treatment.Dosage in allopurinol", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3159106_1_3577", "context": "A case of allopurinol hypersensitivity, possibly the first in a black African, is reported.", "question": "Treatment.Freq in allopurinol", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3159106_1_3578", "context": "A case of allopurinol hypersensitivity, possibly the first in a black African, is reported.", "question": "Treatment.Route in allopurinol", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3159106_1_3579", "context": "A case of allopurinol hypersensitivity, possibly the first in a black African, is reported.", "question": "Treatment.Time_elapsed in allopurinol", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3159106_1_3580", "context": "A case of allopurinol hypersensitivity, possibly the first in a black African, is reported.", "question": "Treatment.Duration in allopurinol", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3159106_1_3581", "context": "A case of allopurinol hypersensitivity, possibly the first in a black African, is reported.", "question": "Treatment.Disorder in allopurinol", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3159106_1_3582", "context": "A case of allopurinol hypersensitivity, possibly the first in a black African, is reported.", "question": "Combination.Drug in allopurinol", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "14964753_5_3583", "context": "Ramipril was stopped and he required a course of steroids after which the rash improved slowly.", "question": "Subject.Age in he", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "14964753_5_3584", "context": "Ramipril was stopped and he required a course of steroids after which the rash improved slowly.", "question": "Subject.Gender in he", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": "he"}, {"id": "14964753_5_3585", "context": "Ramipril was stopped and he required a course of steroids after which the rash improved slowly.", "question": "Subject.Population in he", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "14964753_5_3586", "context": "Ramipril was stopped and he required a course of steroids after which the rash improved slowly.", "question": "Subject.Race in he", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "14964753_5_3587", "context": "Ramipril was stopped and he required a course of steroids after which the rash improved slowly.", "question": "Subject.Disorder in he", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "14964753_5_3588", "context": "Ramipril was stopped and he required a course of steroids after which the rash improved slowly.", "question": "Treatment.Drug in a course of steroids", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "steroids"}, {"id": "14964753_5_3589", "context": "Ramipril was stopped and he required a course of steroids after which the rash improved slowly.", "question": "Treatment.Dosage in a course of steroids", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": "a course"}, {"id": "14964753_5_3590", "context": "Ramipril was stopped and he required a course of steroids after which the rash improved slowly.", "question": "Treatment.Freq in a course of steroids", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "14964753_5_3591", "context": "Ramipril was stopped and he required a course of steroids after which the rash improved slowly.", "question": "Treatment.Route in a course of steroids", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "14964753_5_3592", "context": "Ramipril was stopped and he required a course of steroids after which the rash improved slowly.", "question": "Treatment.Time_elapsed in a course of steroids", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "14964753_5_3593", "context": "Ramipril was stopped and he required a course of steroids after which the rash improved slowly.", "question": "Treatment.Duration in a course of steroids", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "14964753_5_3594", "context": "Ramipril was stopped and he required a course of steroids after which the rash improved slowly.", "question": "Treatment.Disorder in a course of steroids", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "rash"}, {"id": "14964753_5_3595", "context": "Ramipril was stopped and he required a course of steroids after which the rash improved slowly.", "question": "Combination.Drug in a course of steroids", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "15961942_1_3596", "context": "Late development of diabetes mellitus after interferon-alfa and ribavirin therapy for chronic hepatitis C: a case report.", "question": "Treatment.Drug in interferon-alfa; ribavirin", "question_type": "Adverse_event.Treatment.Drug", "answers": "ribavirin; interferon-alfa"}, {"id": "15961942_1_3597", "context": "Late development of diabetes mellitus after interferon-alfa and ribavirin therapy for chronic hepatitis C: a case report.", "question": "Treatment.Dosage in interferon-alfa; ribavirin", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15961942_1_3598", "context": "Late development of diabetes mellitus after interferon-alfa and ribavirin therapy for chronic hepatitis C: a case report.", "question": "Treatment.Freq in interferon-alfa; ribavirin", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15961942_1_3599", "context": "Late development of diabetes mellitus after interferon-alfa and ribavirin therapy for chronic hepatitis C: a case report.", "question": "Treatment.Route in interferon-alfa; ribavirin", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15961942_1_3600", "context": "Late development of diabetes mellitus after interferon-alfa and ribavirin therapy for chronic hepatitis C: a case report.", "question": "Treatment.Time_elapsed in interferon-alfa; ribavirin", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15961942_1_3601", "context": "Late development of diabetes mellitus after interferon-alfa and ribavirin therapy for chronic hepatitis C: a case report.", "question": "Treatment.Duration in interferon-alfa; ribavirin", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15961942_1_3602", "context": "Late development of diabetes mellitus after interferon-alfa and ribavirin therapy for chronic hepatitis C: a case report.", "question": "Treatment.Disorder in interferon-alfa; ribavirin", "question_type": "Adverse_event.Treatment.Disorder", "answers": "chronic hepatitis C"}, {"id": "15961942_1_3603", "context": "Late development of diabetes mellitus after interferon-alfa and ribavirin therapy for chronic hepatitis C: a case report.", "question": "Combination.Drug in interferon-alfa; ribavirin", "question_type": "Adverse_event.Combination.Drug", "answers": "ribavirin; interferon-alfa"}, {"id": "9517515_2_3604", "context": "Second cancers including various types of hematological malignancy have been reported in patients with hairy cell leukemia treated with chemotherapy or interferon alfa.", "question": "Subject.Age in patients with hairy cell leukemia", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "9517515_2_3605", "context": "Second cancers including various types of hematological malignancy have been reported in patients with hairy cell leukemia treated with chemotherapy or interferon alfa.", "question": "Subject.Gender in patients with hairy cell leukemia", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "9517515_2_3606", "context": "Second cancers including various types of hematological malignancy have been reported in patients with hairy cell leukemia treated with chemotherapy or interferon alfa.", "question": "Subject.Population in patients with hairy cell leukemia", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "9517515_2_3607", "context": "Second cancers including various types of hematological malignancy have been reported in patients with hairy cell leukemia treated with chemotherapy or interferon alfa.", "question": "Subject.Race in patients with hairy cell leukemia", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "9517515_2_3608", "context": "Second cancers including various types of hematological malignancy have been reported in patients with hairy cell leukemia treated with chemotherapy or interferon alfa.", "question": "Subject.Disorder in patients with hairy cell leukemia", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "9517515_2_3609", "context": "Second cancers including various types of hematological malignancy have been reported in patients with hairy cell leukemia treated with chemotherapy or interferon alfa.", "question": "Treatment.Drug in chemotherapy or interferon alfa", "question_type": "Adverse_event.Treatment.Drug", "answers": "interferon alfa"}, {"id": "9517515_2_3610", "context": "Second cancers including various types of hematological malignancy have been reported in patients with hairy cell leukemia treated with chemotherapy or interferon alfa.", "question": "Treatment.Dosage in chemotherapy or interferon alfa", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9517515_2_3611", "context": "Second cancers including various types of hematological malignancy have been reported in patients with hairy cell leukemia treated with chemotherapy or interferon alfa.", "question": "Treatment.Freq in chemotherapy or interferon alfa", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9517515_2_3612", "context": "Second cancers including various types of hematological malignancy have been reported in patients with hairy cell leukemia treated with chemotherapy or interferon alfa.", "question": "Treatment.Route in chemotherapy or interferon alfa", "question_type": "Adverse_event.Treatment.Route", "answers": "chemotherapy"}, {"id": "9517515_2_3613", "context": "Second cancers including various types of hematological malignancy have been reported in patients with hairy cell leukemia treated with chemotherapy or interferon alfa.", "question": "Treatment.Time_elapsed in chemotherapy or interferon alfa", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9517515_2_3614", "context": "Second cancers including various types of hematological malignancy have been reported in patients with hairy cell leukemia treated with chemotherapy or interferon alfa.", "question": "Treatment.Duration in chemotherapy or interferon alfa", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9517515_2_3615", "context": "Second cancers including various types of hematological malignancy have been reported in patients with hairy cell leukemia treated with chemotherapy or interferon alfa.", "question": "Treatment.Disorder in chemotherapy or interferon alfa", "question_type": "Adverse_event.Treatment.Disorder", "answers": "hairy cell leukemia"}, {"id": "9517515_2_3616", "context": "Second cancers including various types of hematological malignancy have been reported in patients with hairy cell leukemia treated with chemotherapy or interferon alfa.", "question": "Combination.Drug in chemotherapy or interferon alfa", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8840640_1_3617", "context": "A patient with a large hydatid cyst of the left lobe of the liver developed metabolic acidosis following rather liberal use of cetrimide-chlorhexidine solution as a scolicidal agent.", "question": "Subject.Age in A patient with a large hydatid cyst of the left lobe of the liver", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "8840640_1_3618", "context": "A patient with a large hydatid cyst of the left lobe of the liver developed metabolic acidosis following rather liberal use of cetrimide-chlorhexidine solution as a scolicidal agent.", "question": "Subject.Gender in A patient with a large hydatid cyst of the left lobe of the liver", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "8840640_1_3619", "context": "A patient with a large hydatid cyst of the left lobe of the liver developed metabolic acidosis following rather liberal use of cetrimide-chlorhexidine solution as a scolicidal agent.", "question": "Subject.Population in A patient with a large hydatid cyst of the left lobe of the liver", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "8840640_1_3620", "context": "A patient with a large hydatid cyst of the left lobe of the liver developed metabolic acidosis following rather liberal use of cetrimide-chlorhexidine solution as a scolicidal agent.", "question": "Subject.Race in A patient with a large hydatid cyst of the left lobe of the liver", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "8840640_1_3621", "context": "A patient with a large hydatid cyst of the left lobe of the liver developed metabolic acidosis following rather liberal use of cetrimide-chlorhexidine solution as a scolicidal agent.", "question": "Subject.Disorder in A patient with a large hydatid cyst of the left lobe of the liver", "question_type": "Adverse_event.Subject.Disorder", "answers": "a large hydatid cyst of the left lobe of the liver"}, {"id": "8840640_1_3622", "context": "A patient with a large hydatid cyst of the left lobe of the liver developed metabolic acidosis following rather liberal use of cetrimide-chlorhexidine solution as a scolicidal agent.", "question": "Treatment.Drug in rather liberal use of cetrimide-chlorhexidine solution as a scolicidal agent", "question_type": "Adverse_event.Treatment.Drug", "answers": "cetrimide-chlorhexidine"}, {"id": "8840640_1_3623", "context": "A patient with a large hydatid cyst of the left lobe of the liver developed metabolic acidosis following rather liberal use of cetrimide-chlorhexidine solution as a scolicidal agent.", "question": "Treatment.Dosage in rather liberal use of cetrimide-chlorhexidine solution as a scolicidal agent", "question_type": "Adverse_event.Treatment.Dosage", "answers": "rather liberal use"}, {"id": "8840640_1_3624", "context": "A patient with a large hydatid cyst of the left lobe of the liver developed metabolic acidosis following rather liberal use of cetrimide-chlorhexidine solution as a scolicidal agent.", "question": "Treatment.Freq in rather liberal use of cetrimide-chlorhexidine solution as a scolicidal agent", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8840640_1_3625", "context": "A patient with a large hydatid cyst of the left lobe of the liver developed metabolic acidosis following rather liberal use of cetrimide-chlorhexidine solution as a scolicidal agent.", "question": "Treatment.Route in rather liberal use of cetrimide-chlorhexidine solution as a scolicidal agent", "question_type": "Adverse_event.Treatment.Route", "answers": "a scolicidal agent"}, {"id": "8840640_1_3626", "context": "A patient with a large hydatid cyst of the left lobe of the liver developed metabolic acidosis following rather liberal use of cetrimide-chlorhexidine solution as a scolicidal agent.", "question": "Treatment.Time_elapsed in rather liberal use of cetrimide-chlorhexidine solution as a scolicidal agent", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8840640_1_3627", "context": "A patient with a large hydatid cyst of the left lobe of the liver developed metabolic acidosis following rather liberal use of cetrimide-chlorhexidine solution as a scolicidal agent.", "question": "Treatment.Duration in rather liberal use of cetrimide-chlorhexidine solution as a scolicidal agent", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8840640_1_3628", "context": "A patient with a large hydatid cyst of the left lobe of the liver developed metabolic acidosis following rather liberal use of cetrimide-chlorhexidine solution as a scolicidal agent.", "question": "Treatment.Disorder in rather liberal use of cetrimide-chlorhexidine solution as a scolicidal agent", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8840640_1_3629", "context": "A patient with a large hydatid cyst of the left lobe of the liver developed metabolic acidosis following rather liberal use of cetrimide-chlorhexidine solution as a scolicidal agent.", "question": "Combination.Drug in rather liberal use of cetrimide-chlorhexidine solution as a scolicidal agent", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8329789_12_3630", "context": "INTERVENTIONS AND RESULTS: Cardiac complications were observed in five pediatric patients who received between 4.6 and 40.8 mg/kg/d of amphotericin B.", "question": "Subject.Age in five pediatric patients", "question_type": "Adverse_event.Subject.Age", "answers": "pediatric"}, {"id": "8329789_12_3631", "context": "INTERVENTIONS AND RESULTS: Cardiac complications were observed in five pediatric patients who received between 4.6 and 40.8 mg/kg/d of amphotericin B.", "question": "Subject.Gender in five pediatric patients", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "8329789_12_3632", "context": "INTERVENTIONS AND RESULTS: Cardiac complications were observed in five pediatric patients who received between 4.6 and 40.8 mg/kg/d of amphotericin B.", "question": "Subject.Population in five pediatric patients", "question_type": "Adverse_event.Subject.Population", "answers": "five"}, {"id": "8329789_12_3633", "context": "INTERVENTIONS AND RESULTS: Cardiac complications were observed in five pediatric patients who received between 4.6 and 40.8 mg/kg/d of amphotericin B.", "question": "Subject.Race in five pediatric patients", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "8329789_12_3634", "context": "INTERVENTIONS AND RESULTS: Cardiac complications were observed in five pediatric patients who received between 4.6 and 40.8 mg/kg/d of amphotericin B.", "question": "Subject.Disorder in five pediatric patients", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "8329789_12_3635", "context": "INTERVENTIONS AND RESULTS: Cardiac complications were observed in five pediatric patients who received between 4.6 and 40.8 mg/kg/d of amphotericin B.", "question": "Treatment.Drug in between 4.6 and 40.8 mg/kg/d of amphotericin B", "question_type": "Adverse_event.Treatment.Drug", "answers": "amphotericin B"}, {"id": "8329789_12_3636", "context": "INTERVENTIONS AND RESULTS: Cardiac complications were observed in five pediatric patients who received between 4.6 and 40.8 mg/kg/d of amphotericin B.", "question": "Treatment.Dosage in between 4.6 and 40.8 mg/kg/d of amphotericin B", "question_type": "Adverse_event.Treatment.Dosage", "answers": "4.6 and 40.8 mg/kg/d"}, {"id": "8329789_12_3637", "context": "INTERVENTIONS AND RESULTS: Cardiac complications were observed in five pediatric patients who received between 4.6 and 40.8 mg/kg/d of amphotericin B.", "question": "Treatment.Freq in between 4.6 and 40.8 mg/kg/d of amphotericin B", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8329789_12_3638", "context": "INTERVENTIONS AND RESULTS: Cardiac complications were observed in five pediatric patients who received between 4.6 and 40.8 mg/kg/d of amphotericin B.", "question": "Treatment.Route in between 4.6 and 40.8 mg/kg/d of amphotericin B", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8329789_12_3639", "context": "INTERVENTIONS AND RESULTS: Cardiac complications were observed in five pediatric patients who received between 4.6 and 40.8 mg/kg/d of amphotericin B.", "question": "Treatment.Time_elapsed in between 4.6 and 40.8 mg/kg/d of amphotericin B", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8329789_12_3640", "context": "INTERVENTIONS AND RESULTS: Cardiac complications were observed in five pediatric patients who received between 4.6 and 40.8 mg/kg/d of amphotericin B.", "question": "Treatment.Duration in between 4.6 and 40.8 mg/kg/d of amphotericin B", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8329789_12_3641", "context": "INTERVENTIONS AND RESULTS: Cardiac complications were observed in five pediatric patients who received between 4.6 and 40.8 mg/kg/d of amphotericin B.", "question": "Treatment.Disorder in between 4.6 and 40.8 mg/kg/d of amphotericin B", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8329789_12_3642", "context": "INTERVENTIONS AND RESULTS: Cardiac complications were observed in five pediatric patients who received between 4.6 and 40.8 mg/kg/d of amphotericin B.", "question": "Combination.Drug in between 4.6 and 40.8 mg/kg/d of amphotericin B", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16521231_2_3643", "context": "In this case report, we have described a patient with Crohn's disease who developed subfulminant hepatitis B after the fourth infusion of infliximab due to an unrecognized HBs-antigen carrier state.", "question": "Subject.Age in a patient with Crohn's disease", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "16521231_2_3644", "context": "In this case report, we have described a patient with Crohn's disease who developed subfulminant hepatitis B after the fourth infusion of infliximab due to an unrecognized HBs-antigen carrier state.", "question": "Subject.Gender in a patient with Crohn's disease", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "16521231_2_3645", "context": "In this case report, we have described a patient with Crohn's disease who developed subfulminant hepatitis B after the fourth infusion of infliximab due to an unrecognized HBs-antigen carrier state.", "question": "Subject.Population in a patient with Crohn's disease", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "16521231_2_3646", "context": "In this case report, we have described a patient with Crohn's disease who developed subfulminant hepatitis B after the fourth infusion of infliximab due to an unrecognized HBs-antigen carrier state.", "question": "Subject.Race in a patient with Crohn's disease", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16521231_2_3647", "context": "In this case report, we have described a patient with Crohn's disease who developed subfulminant hepatitis B after the fourth infusion of infliximab due to an unrecognized HBs-antigen carrier state.", "question": "Subject.Disorder in a patient with Crohn's disease", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "16521231_2_3648", "context": "In this case report, we have described a patient with Crohn's disease who developed subfulminant hepatitis B after the fourth infusion of infliximab due to an unrecognized HBs-antigen carrier state.", "question": "Treatment.Drug in fourth infusion of infliximab", "question_type": "Adverse_event.Treatment.Drug", "answers": "infliximab"}, {"id": "16521231_2_3649", "context": "In this case report, we have described a patient with Crohn's disease who developed subfulminant hepatitis B after the fourth infusion of infliximab due to an unrecognized HBs-antigen carrier state.", "question": "Treatment.Dosage in fourth infusion of infliximab", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16521231_2_3650", "context": "In this case report, we have described a patient with Crohn's disease who developed subfulminant hepatitis B after the fourth infusion of infliximab due to an unrecognized HBs-antigen carrier state.", "question": "Treatment.Freq in fourth infusion of infliximab", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16521231_2_3651", "context": "In this case report, we have described a patient with Crohn's disease who developed subfulminant hepatitis B after the fourth infusion of infliximab due to an unrecognized HBs-antigen carrier state.", "question": "Treatment.Route in fourth infusion of infliximab", "question_type": "Adverse_event.Treatment.Route", "answers": "infusion"}, {"id": "16521231_2_3652", "context": "In this case report, we have described a patient with Crohn's disease who developed subfulminant hepatitis B after the fourth infusion of infliximab due to an unrecognized HBs-antigen carrier state.", "question": "Treatment.Time_elapsed in fourth infusion of infliximab", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "fourth"}, {"id": "16521231_2_3653", "context": "In this case report, we have described a patient with Crohn's disease who developed subfulminant hepatitis B after the fourth infusion of infliximab due to an unrecognized HBs-antigen carrier state.", "question": "Treatment.Duration in fourth infusion of infliximab", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16521231_2_3654", "context": "In this case report, we have described a patient with Crohn's disease who developed subfulminant hepatitis B after the fourth infusion of infliximab due to an unrecognized HBs-antigen carrier state.", "question": "Treatment.Disorder in fourth infusion of infliximab", "question_type": "Adverse_event.Treatment.Disorder", "answers": "Crohn's disease"}, {"id": "16521231_2_3655", "context": "In this case report, we have described a patient with Crohn's disease who developed subfulminant hepatitis B after the fourth infusion of infliximab due to an unrecognized HBs-antigen carrier state.", "question": "Combination.Drug in fourth infusion of infliximab", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12149193_4_3656", "context": "We analyzed the incidence of DVT in 232 MM patients who received a combination of chemotherapy and thalidomide on 2 protocols that differed only by the inclusion of doxorubicin in one.", "question": "Subject.Age in 232 MM patients", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "12149193_4_3657", "context": "We analyzed the incidence of DVT in 232 MM patients who received a combination of chemotherapy and thalidomide on 2 protocols that differed only by the inclusion of doxorubicin in one.", "question": "Subject.Gender in 232 MM patients", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "12149193_4_3658", "context": "We analyzed the incidence of DVT in 232 MM patients who received a combination of chemotherapy and thalidomide on 2 protocols that differed only by the inclusion of doxorubicin in one.", "question": "Subject.Population in 232 MM patients", "question_type": "Adverse_event.Subject.Population", "answers": "232"}, {"id": "12149193_4_3659", "context": "We analyzed the incidence of DVT in 232 MM patients who received a combination of chemotherapy and thalidomide on 2 protocols that differed only by the inclusion of doxorubicin in one.", "question": "Subject.Race in 232 MM patients", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "12149193_4_3660", "context": "We analyzed the incidence of DVT in 232 MM patients who received a combination of chemotherapy and thalidomide on 2 protocols that differed only by the inclusion of doxorubicin in one.", "question": "Subject.Disorder in 232 MM patients", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "12149193_4_3661", "context": "We analyzed the incidence of DVT in 232 MM patients who received a combination of chemotherapy and thalidomide on 2 protocols that differed only by the inclusion of doxorubicin in one.", "question": "Treatment.Drug in chemotherapy; thalidomide", "question_type": "Adverse_event.Treatment.Drug", "answers": "chemotherapy; thalidomide"}, {"id": "12149193_4_3662", "context": "We analyzed the incidence of DVT in 232 MM patients who received a combination of chemotherapy and thalidomide on 2 protocols that differed only by the inclusion of doxorubicin in one.", "question": "Treatment.Dosage in chemotherapy; thalidomide", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12149193_4_3663", "context": "We analyzed the incidence of DVT in 232 MM patients who received a combination of chemotherapy and thalidomide on 2 protocols that differed only by the inclusion of doxorubicin in one.", "question": "Treatment.Freq in chemotherapy; thalidomide", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12149193_4_3664", "context": "We analyzed the incidence of DVT in 232 MM patients who received a combination of chemotherapy and thalidomide on 2 protocols that differed only by the inclusion of doxorubicin in one.", "question": "Treatment.Route in chemotherapy; thalidomide", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12149193_4_3665", "context": "We analyzed the incidence of DVT in 232 MM patients who received a combination of chemotherapy and thalidomide on 2 protocols that differed only by the inclusion of doxorubicin in one.", "question": "Treatment.Time_elapsed in chemotherapy; thalidomide", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12149193_4_3666", "context": "We analyzed the incidence of DVT in 232 MM patients who received a combination of chemotherapy and thalidomide on 2 protocols that differed only by the inclusion of doxorubicin in one.", "question": "Treatment.Duration in chemotherapy; thalidomide", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12149193_4_3667", "context": "We analyzed the incidence of DVT in 232 MM patients who received a combination of chemotherapy and thalidomide on 2 protocols that differed only by the inclusion of doxorubicin in one.", "question": "Treatment.Disorder in chemotherapy; thalidomide", "question_type": "Adverse_event.Treatment.Disorder", "answers": "MM"}, {"id": "12149193_4_3668", "context": "We analyzed the incidence of DVT in 232 MM patients who received a combination of chemotherapy and thalidomide on 2 protocols that differed only by the inclusion of doxorubicin in one.", "question": "Combination.Drug in chemotherapy; thalidomide", "question_type": "Adverse_event.Combination.Drug", "answers": "chemotherapy; thalidomide"}, {"id": "17109650_2_3669", "context": "Valvular heart disease in a patient taking benfluorex.", "question": "Subject.Age in a patient", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "17109650_2_3670", "context": "Valvular heart disease in a patient taking benfluorex.", "question": "Subject.Gender in a patient", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "17109650_2_3671", "context": "Valvular heart disease in a patient taking benfluorex.", "question": "Subject.Population in a patient", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "17109650_2_3672", "context": "Valvular heart disease in a patient taking benfluorex.", "question": "Subject.Race in a patient", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "17109650_2_3673", "context": "Valvular heart disease in a patient taking benfluorex.", "question": "Subject.Disorder in a patient", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "17109650_2_3674", "context": "Valvular heart disease in a patient taking benfluorex.", "question": "Treatment.Drug in benfluorex", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "17109650_2_3675", "context": "Valvular heart disease in a patient taking benfluorex.", "question": "Treatment.Dosage in benfluorex", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17109650_2_3676", "context": "Valvular heart disease in a patient taking benfluorex.", "question": "Treatment.Freq in benfluorex", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17109650_2_3677", "context": "Valvular heart disease in a patient taking benfluorex.", "question": "Treatment.Route in benfluorex", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17109650_2_3678", "context": "Valvular heart disease in a patient taking benfluorex.", "question": "Treatment.Time_elapsed in benfluorex", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17109650_2_3679", "context": "Valvular heart disease in a patient taking benfluorex.", "question": "Treatment.Duration in benfluorex", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17109650_2_3680", "context": "Valvular heart disease in a patient taking benfluorex.", "question": "Treatment.Disorder in benfluorex", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17109650_2_3681", "context": "Valvular heart disease in a patient taking benfluorex.", "question": "Combination.Drug in benfluorex", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18562412_3_3682", "context": "The fifth patient exhibited paraesthesia and agitation caused by olanzapine that was misdiagnosed as psychotic agitation.", "question": "Subject.Age in The fifth patient", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "18562412_3_3683", "context": "The fifth patient exhibited paraesthesia and agitation caused by olanzapine that was misdiagnosed as psychotic agitation.", "question": "Subject.Gender in The fifth patient", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "18562412_3_3684", "context": "The fifth patient exhibited paraesthesia and agitation caused by olanzapine that was misdiagnosed as psychotic agitation.", "question": "Subject.Population in The fifth patient", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "18562412_3_3685", "context": "The fifth patient exhibited paraesthesia and agitation caused by olanzapine that was misdiagnosed as psychotic agitation.", "question": "Subject.Race in The fifth patient", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "18562412_3_3686", "context": "The fifth patient exhibited paraesthesia and agitation caused by olanzapine that was misdiagnosed as psychotic agitation.", "question": "Subject.Disorder in The fifth patient", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "18562412_3_3687", "context": "The fifth patient exhibited paraesthesia and agitation caused by olanzapine that was misdiagnosed as psychotic agitation.", "question": "Treatment.Drug in olanzapine", "question_type": "Adverse_event.Treatment.Drug", "answers": "olanzapine"}, {"id": "18562412_3_3688", "context": "The fifth patient exhibited paraesthesia and agitation caused by olanzapine that was misdiagnosed as psychotic agitation.", "question": "Treatment.Dosage in olanzapine", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18562412_3_3689", "context": "The fifth patient exhibited paraesthesia and agitation caused by olanzapine that was misdiagnosed as psychotic agitation.", "question": "Treatment.Freq in olanzapine", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18562412_3_3690", "context": "The fifth patient exhibited paraesthesia and agitation caused by olanzapine that was misdiagnosed as psychotic agitation.", "question": "Treatment.Route in olanzapine", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18562412_3_3691", "context": "The fifth patient exhibited paraesthesia and agitation caused by olanzapine that was misdiagnosed as psychotic agitation.", "question": "Treatment.Time_elapsed in olanzapine", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18562412_3_3692", "context": "The fifth patient exhibited paraesthesia and agitation caused by olanzapine that was misdiagnosed as psychotic agitation.", "question": "Treatment.Duration in olanzapine", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18562412_3_3693", "context": "The fifth patient exhibited paraesthesia and agitation caused by olanzapine that was misdiagnosed as psychotic agitation.", "question": "Treatment.Disorder in olanzapine", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18562412_3_3694", "context": "The fifth patient exhibited paraesthesia and agitation caused by olanzapine that was misdiagnosed as psychotic agitation.", "question": "Combination.Drug in olanzapine", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8329789_11_3695", "context": "Hydrocortisone may decrease the incidence of mortality associated with cardiac arrhythmias in children receiving amphotericin B overdoses.", "question": "Subject.Age in cardiac arrhythmias in children", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": "children"}, {"id": "8329789_11_3696", "context": "Hydrocortisone may decrease the incidence of mortality associated with cardiac arrhythmias in children receiving amphotericin B overdoses.", "question": "Subject.Gender in cardiac arrhythmias in children", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "8329789_11_3697", "context": "Hydrocortisone may decrease the incidence of mortality associated with cardiac arrhythmias in children receiving amphotericin B overdoses.", "question": "Subject.Population in cardiac arrhythmias in children", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "8329789_11_3698", "context": "Hydrocortisone may decrease the incidence of mortality associated with cardiac arrhythmias in children receiving amphotericin B overdoses.", "question": "Subject.Race in cardiac arrhythmias in children", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "8329789_11_3699", "context": "Hydrocortisone may decrease the incidence of mortality associated with cardiac arrhythmias in children receiving amphotericin B overdoses.", "question": "Subject.Disorder in cardiac arrhythmias in children", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "8329789_11_3700", "context": "Hydrocortisone may decrease the incidence of mortality associated with cardiac arrhythmias in children receiving amphotericin B overdoses.", "question": "Treatment.Drug in Hydrocortisone", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "Hydrocortisone"}, {"id": "8329789_11_3701", "context": "Hydrocortisone may decrease the incidence of mortality associated with cardiac arrhythmias in children receiving amphotericin B overdoses.", "question": "Treatment.Dosage in Hydrocortisone", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "8329789_11_3702", "context": "Hydrocortisone may decrease the incidence of mortality associated with cardiac arrhythmias in children receiving amphotericin B overdoses.", "question": "Treatment.Freq in Hydrocortisone", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "8329789_11_3703", "context": "Hydrocortisone may decrease the incidence of mortality associated with cardiac arrhythmias in children receiving amphotericin B overdoses.", "question": "Treatment.Route in Hydrocortisone", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "8329789_11_3704", "context": "Hydrocortisone may decrease the incidence of mortality associated with cardiac arrhythmias in children receiving amphotericin B overdoses.", "question": "Treatment.Time_elapsed in Hydrocortisone", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8329789_11_3705", "context": "Hydrocortisone may decrease the incidence of mortality associated with cardiac arrhythmias in children receiving amphotericin B overdoses.", "question": "Treatment.Duration in Hydrocortisone", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "8329789_11_3706", "context": "Hydrocortisone may decrease the incidence of mortality associated with cardiac arrhythmias in children receiving amphotericin B overdoses.", "question": "Treatment.Disorder in Hydrocortisone", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "incidence of mortality"}, {"id": "8329789_11_3707", "context": "Hydrocortisone may decrease the incidence of mortality associated with cardiac arrhythmias in children receiving amphotericin B overdoses.", "question": "Combination.Drug in Hydrocortisone", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "8329789_11_3708", "context": "Hydrocortisone may decrease the incidence of mortality associated with cardiac arrhythmias in children receiving amphotericin B overdoses.", "question": "Subject.Age in cardiac arrhythmias in children", "question_type": "Adverse_event.Subject.Age", "answers": "children"}, {"id": "8329789_11_3709", "context": "Hydrocortisone may decrease the incidence of mortality associated with cardiac arrhythmias in children receiving amphotericin B overdoses.", "question": "Subject.Gender in cardiac arrhythmias in children", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "8329789_11_3710", "context": "Hydrocortisone may decrease the incidence of mortality associated with cardiac arrhythmias in children receiving amphotericin B overdoses.", "question": "Subject.Population in cardiac arrhythmias in children", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "8329789_11_3711", "context": "Hydrocortisone may decrease the incidence of mortality associated with cardiac arrhythmias in children receiving amphotericin B overdoses.", "question": "Subject.Race in cardiac arrhythmias in children", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "8329789_11_3712", "context": "Hydrocortisone may decrease the incidence of mortality associated with cardiac arrhythmias in children receiving amphotericin B overdoses.", "question": "Subject.Disorder in cardiac arrhythmias in children", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "8329789_11_3713", "context": "Hydrocortisone may decrease the incidence of mortality associated with cardiac arrhythmias in children receiving amphotericin B overdoses.", "question": "Treatment.Drug in amphotericin B overdoses", "question_type": "Adverse_event.Treatment.Drug", "answers": "amphotericin B"}, {"id": "8329789_11_3714", "context": "Hydrocortisone may decrease the incidence of mortality associated with cardiac arrhythmias in children receiving amphotericin B overdoses.", "question": "Treatment.Dosage in amphotericin B overdoses", "question_type": "Adverse_event.Treatment.Dosage", "answers": "overdoses"}, {"id": "8329789_11_3715", "context": "Hydrocortisone may decrease the incidence of mortality associated with cardiac arrhythmias in children receiving amphotericin B overdoses.", "question": "Treatment.Freq in amphotericin B overdoses", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8329789_11_3716", "context": "Hydrocortisone may decrease the incidence of mortality associated with cardiac arrhythmias in children receiving amphotericin B overdoses.", "question": "Treatment.Route in amphotericin B overdoses", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8329789_11_3717", "context": "Hydrocortisone may decrease the incidence of mortality associated with cardiac arrhythmias in children receiving amphotericin B overdoses.", "question": "Treatment.Time_elapsed in amphotericin B overdoses", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8329789_11_3718", "context": "Hydrocortisone may decrease the incidence of mortality associated with cardiac arrhythmias in children receiving amphotericin B overdoses.", "question": "Treatment.Duration in amphotericin B overdoses", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8329789_11_3719", "context": "Hydrocortisone may decrease the incidence of mortality associated with cardiac arrhythmias in children receiving amphotericin B overdoses.", "question": "Treatment.Disorder in amphotericin B overdoses", "question_type": "Adverse_event.Treatment.Disorder", "answers": "cardiac arrhythmias"}, {"id": "8329789_11_3720", "context": "Hydrocortisone may decrease the incidence of mortality associated with cardiac arrhythmias in children receiving amphotericin B overdoses.", "question": "Combination.Drug in amphotericin B overdoses", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8700794_1_3721", "context": "A review of the literature found 11 children and 2 adults in whom intranasal desmopressin was associated with hyponatremia, all of whom experienced seizures or altered mental status.", "question": "Subject.Age in 11 children and 2 adults", "question_type": "Adverse_event.Subject.Age", "answers": "children; adults"}, {"id": "8700794_1_3722", "context": "A review of the literature found 11 children and 2 adults in whom intranasal desmopressin was associated with hyponatremia, all of whom experienced seizures or altered mental status.", "question": "Subject.Gender in 11 children and 2 adults", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "8700794_1_3723", "context": "A review of the literature found 11 children and 2 adults in whom intranasal desmopressin was associated with hyponatremia, all of whom experienced seizures or altered mental status.", "question": "Subject.Population in 11 children and 2 adults", "question_type": "Adverse_event.Subject.Population", "answers": "11; 2"}, {"id": "8700794_1_3724", "context": "A review of the literature found 11 children and 2 adults in whom intranasal desmopressin was associated with hyponatremia, all of whom experienced seizures or altered mental status.", "question": "Subject.Race in 11 children and 2 adults", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "8700794_1_3725", "context": "A review of the literature found 11 children and 2 adults in whom intranasal desmopressin was associated with hyponatremia, all of whom experienced seizures or altered mental status.", "question": "Subject.Disorder in 11 children and 2 adults", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "8700794_1_3726", "context": "A review of the literature found 11 children and 2 adults in whom intranasal desmopressin was associated with hyponatremia, all of whom experienced seizures or altered mental status.", "question": "Treatment.Drug in intranasal desmopressin", "question_type": "Adverse_event.Treatment.Drug", "answers": "desmopressin"}, {"id": "8700794_1_3727", "context": "A review of the literature found 11 children and 2 adults in whom intranasal desmopressin was associated with hyponatremia, all of whom experienced seizures or altered mental status.", "question": "Treatment.Dosage in intranasal desmopressin", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8700794_1_3728", "context": "A review of the literature found 11 children and 2 adults in whom intranasal desmopressin was associated with hyponatremia, all of whom experienced seizures or altered mental status.", "question": "Treatment.Freq in intranasal desmopressin", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8700794_1_3729", "context": "A review of the literature found 11 children and 2 adults in whom intranasal desmopressin was associated with hyponatremia, all of whom experienced seizures or altered mental status.", "question": "Treatment.Route in intranasal desmopressin", "question_type": "Adverse_event.Treatment.Route", "answers": "intranasal"}, {"id": "8700794_1_3730", "context": "A review of the literature found 11 children and 2 adults in whom intranasal desmopressin was associated with hyponatremia, all of whom experienced seizures or altered mental status.", "question": "Treatment.Time_elapsed in intranasal desmopressin", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8700794_1_3731", "context": "A review of the literature found 11 children and 2 adults in whom intranasal desmopressin was associated with hyponatremia, all of whom experienced seizures or altered mental status.", "question": "Treatment.Duration in intranasal desmopressin", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8700794_1_3732", "context": "A review of the literature found 11 children and 2 adults in whom intranasal desmopressin was associated with hyponatremia, all of whom experienced seizures or altered mental status.", "question": "Treatment.Disorder in intranasal desmopressin", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8700794_1_3733", "context": "A review of the literature found 11 children and 2 adults in whom intranasal desmopressin was associated with hyponatremia, all of whom experienced seizures or altered mental status.", "question": "Combination.Drug in intranasal desmopressin", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7387219_1_3734", "context": "Hepatotoxicity associated with use of D-penicillamine in rheumatoid arthritis.", "question": "Treatment.Drug in D-penicillamine", "question_type": "Adverse_event.Treatment.Drug", "answers": "D-penicillamine"}, {"id": "7387219_1_3735", "context": "Hepatotoxicity associated with use of D-penicillamine in rheumatoid arthritis.", "question": "Treatment.Dosage in D-penicillamine", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7387219_1_3736", "context": "Hepatotoxicity associated with use of D-penicillamine in rheumatoid arthritis.", "question": "Treatment.Freq in D-penicillamine", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7387219_1_3737", "context": "Hepatotoxicity associated with use of D-penicillamine in rheumatoid arthritis.", "question": "Treatment.Route in D-penicillamine", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7387219_1_3738", "context": "Hepatotoxicity associated with use of D-penicillamine in rheumatoid arthritis.", "question": "Treatment.Time_elapsed in D-penicillamine", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7387219_1_3739", "context": "Hepatotoxicity associated with use of D-penicillamine in rheumatoid arthritis.", "question": "Treatment.Duration in D-penicillamine", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7387219_1_3740", "context": "Hepatotoxicity associated with use of D-penicillamine in rheumatoid arthritis.", "question": "Treatment.Disorder in D-penicillamine", "question_type": "Adverse_event.Treatment.Disorder", "answers": "rheumatoid arthritis"}, {"id": "7387219_1_3741", "context": "Hepatotoxicity associated with use of D-penicillamine in rheumatoid arthritis.", "question": "Combination.Drug in D-penicillamine", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8627446_1_3742", "context": "Accelerated nodulosis during methotrexate therapy for juvenile rheumatoid arthritis.", "question": "Treatment.Drug in methotrexate", "question_type": "Adverse_event.Treatment.Drug", "answers": "methotrexate"}, {"id": "8627446_1_3743", "context": "Accelerated nodulosis during methotrexate therapy for juvenile rheumatoid arthritis.", "question": "Treatment.Dosage in methotrexate", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8627446_1_3744", "context": "Accelerated nodulosis during methotrexate therapy for juvenile rheumatoid arthritis.", "question": "Treatment.Freq in methotrexate", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8627446_1_3745", "context": "Accelerated nodulosis during methotrexate therapy for juvenile rheumatoid arthritis.", "question": "Treatment.Route in methotrexate", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8627446_1_3746", "context": "Accelerated nodulosis during methotrexate therapy for juvenile rheumatoid arthritis.", "question": "Treatment.Time_elapsed in methotrexate", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8627446_1_3747", "context": "Accelerated nodulosis during methotrexate therapy for juvenile rheumatoid arthritis.", "question": "Treatment.Duration in methotrexate", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8627446_1_3748", "context": "Accelerated nodulosis during methotrexate therapy for juvenile rheumatoid arthritis.", "question": "Treatment.Disorder in methotrexate", "question_type": "Adverse_event.Treatment.Disorder", "answers": "juvenile rheumatoid arthritis"}, {"id": "8627446_1_3749", "context": "Accelerated nodulosis during methotrexate therapy for juvenile rheumatoid arthritis.", "question": "Combination.Drug in methotrexate", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8305778_6_3750", "context": "Amiodarone is a Class III antiarrhythmic with an adverse-effect profile involving many different organ systems.", "question": "Treatment.Drug in Amiodarone", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "8305778_6_3751", "context": "Amiodarone is a Class III antiarrhythmic with an adverse-effect profile involving many different organ systems.", "question": "Treatment.Dosage in Amiodarone", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8305778_6_3752", "context": "Amiodarone is a Class III antiarrhythmic with an adverse-effect profile involving many different organ systems.", "question": "Treatment.Freq in Amiodarone", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8305778_6_3753", "context": "Amiodarone is a Class III antiarrhythmic with an adverse-effect profile involving many different organ systems.", "question": "Treatment.Route in Amiodarone", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8305778_6_3754", "context": "Amiodarone is a Class III antiarrhythmic with an adverse-effect profile involving many different organ systems.", "question": "Treatment.Time_elapsed in Amiodarone", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8305778_6_3755", "context": "Amiodarone is a Class III antiarrhythmic with an adverse-effect profile involving many different organ systems.", "question": "Treatment.Duration in Amiodarone", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8305778_6_3756", "context": "Amiodarone is a Class III antiarrhythmic with an adverse-effect profile involving many different organ systems.", "question": "Treatment.Disorder in Amiodarone", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8305778_6_3757", "context": "Amiodarone is a Class III antiarrhythmic with an adverse-effect profile involving many different organ systems.", "question": "Combination.Drug in Amiodarone", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17083890_2_3758", "context": "Nail and skin alterations associated with the use of chemotherapy have been described in the last decade involving various combinations of two different types of nail changes.", "question": "Treatment.Drug in chemotherapy", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "17083890_2_3759", "context": "Nail and skin alterations associated with the use of chemotherapy have been described in the last decade involving various combinations of two different types of nail changes.", "question": "Treatment.Dosage in chemotherapy", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17083890_2_3760", "context": "Nail and skin alterations associated with the use of chemotherapy have been described in the last decade involving various combinations of two different types of nail changes.", "question": "Treatment.Freq in chemotherapy", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17083890_2_3761", "context": "Nail and skin alterations associated with the use of chemotherapy have been described in the last decade involving various combinations of two different types of nail changes.", "question": "Treatment.Route in chemotherapy", "question_type": "Adverse_event.Treatment.Route", "answers": "chemotherapy"}, {"id": "17083890_2_3762", "context": "Nail and skin alterations associated with the use of chemotherapy have been described in the last decade involving various combinations of two different types of nail changes.", "question": "Treatment.Time_elapsed in chemotherapy", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17083890_2_3763", "context": "Nail and skin alterations associated with the use of chemotherapy have been described in the last decade involving various combinations of two different types of nail changes.", "question": "Treatment.Duration in chemotherapy", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17083890_2_3764", "context": "Nail and skin alterations associated with the use of chemotherapy have been described in the last decade involving various combinations of two different types of nail changes.", "question": "Treatment.Disorder in chemotherapy", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17083890_2_3765", "context": "Nail and skin alterations associated with the use of chemotherapy have been described in the last decade involving various combinations of two different types of nail changes.", "question": "Combination.Drug in chemotherapy", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7117795_2_3766", "context": "This report describes a case of flucytosine-associated ulcerating enteritis in which the small bowel x-ray demonstrated severe luminal narrowing, ulceration, and marked separation of loops of bowel.", "question": "Treatment.Drug in flucytosine", "question_type": "Adverse_event.Treatment.Drug", "answers": "flucytosine"}, {"id": "7117795_2_3767", "context": "This report describes a case of flucytosine-associated ulcerating enteritis in which the small bowel x-ray demonstrated severe luminal narrowing, ulceration, and marked separation of loops of bowel.", "question": "Treatment.Dosage in flucytosine", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7117795_2_3768", "context": "This report describes a case of flucytosine-associated ulcerating enteritis in which the small bowel x-ray demonstrated severe luminal narrowing, ulceration, and marked separation of loops of bowel.", "question": "Treatment.Freq in flucytosine", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7117795_2_3769", "context": "This report describes a case of flucytosine-associated ulcerating enteritis in which the small bowel x-ray demonstrated severe luminal narrowing, ulceration, and marked separation of loops of bowel.", "question": "Treatment.Route in flucytosine", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7117795_2_3770", "context": "This report describes a case of flucytosine-associated ulcerating enteritis in which the small bowel x-ray demonstrated severe luminal narrowing, ulceration, and marked separation of loops of bowel.", "question": "Treatment.Time_elapsed in flucytosine", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7117795_2_3771", "context": "This report describes a case of flucytosine-associated ulcerating enteritis in which the small bowel x-ray demonstrated severe luminal narrowing, ulceration, and marked separation of loops of bowel.", "question": "Treatment.Duration in flucytosine", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7117795_2_3772", "context": "This report describes a case of flucytosine-associated ulcerating enteritis in which the small bowel x-ray demonstrated severe luminal narrowing, ulceration, and marked separation of loops of bowel.", "question": "Treatment.Disorder in flucytosine", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7117795_2_3773", "context": "This report describes a case of flucytosine-associated ulcerating enteritis in which the small bowel x-ray demonstrated severe luminal narrowing, ulceration, and marked separation of loops of bowel.", "question": "Combination.Drug in flucytosine", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "968449_1_3774", "context": "Chromosome abnormalities after chlorambucil therapy of polycythaemia vera.", "question": "Treatment.Drug in chlorambucil therapy", "question_type": "Adverse_event.Treatment.Drug", "answers": "chlorambucil"}, {"id": "968449_1_3775", "context": "Chromosome abnormalities after chlorambucil therapy of polycythaemia vera.", "question": "Treatment.Dosage in chlorambucil therapy", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "968449_1_3776", "context": "Chromosome abnormalities after chlorambucil therapy of polycythaemia vera.", "question": "Treatment.Freq in chlorambucil therapy", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "968449_1_3777", "context": "Chromosome abnormalities after chlorambucil therapy of polycythaemia vera.", "question": "Treatment.Route in chlorambucil therapy", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "968449_1_3778", "context": "Chromosome abnormalities after chlorambucil therapy of polycythaemia vera.", "question": "Treatment.Time_elapsed in chlorambucil therapy", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "968449_1_3779", "context": "Chromosome abnormalities after chlorambucil therapy of polycythaemia vera.", "question": "Treatment.Duration in chlorambucil therapy", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "968449_1_3780", "context": "Chromosome abnormalities after chlorambucil therapy of polycythaemia vera.", "question": "Treatment.Disorder in chlorambucil therapy", "question_type": "Adverse_event.Treatment.Disorder", "answers": "polycythaemia vera"}, {"id": "968449_1_3781", "context": "Chromosome abnormalities after chlorambucil therapy of polycythaemia vera.", "question": "Combination.Drug in chlorambucil therapy", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15944830_6_3782", "context": "With the use of optical coherence tomography (OCT), two patients with IFN-associated retinopathy who had developed macular edema and reduced visual acuity during the clinical course of IFN therapy were observed.", "question": "Treatment.Drug in IFN", "question_type": "Adverse_event.Treatment.Drug", "answers": "IFN"}, {"id": "15944830_6_3783", "context": "With the use of optical coherence tomography (OCT), two patients with IFN-associated retinopathy who had developed macular edema and reduced visual acuity during the clinical course of IFN therapy were observed.", "question": "Treatment.Dosage in IFN", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15944830_6_3784", "context": "With the use of optical coherence tomography (OCT), two patients with IFN-associated retinopathy who had developed macular edema and reduced visual acuity during the clinical course of IFN therapy were observed.", "question": "Treatment.Freq in IFN", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15944830_6_3785", "context": "With the use of optical coherence tomography (OCT), two patients with IFN-associated retinopathy who had developed macular edema and reduced visual acuity during the clinical course of IFN therapy were observed.", "question": "Treatment.Route in IFN", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15944830_6_3786", "context": "With the use of optical coherence tomography (OCT), two patients with IFN-associated retinopathy who had developed macular edema and reduced visual acuity during the clinical course of IFN therapy were observed.", "question": "Treatment.Time_elapsed in IFN", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15944830_6_3787", "context": "With the use of optical coherence tomography (OCT), two patients with IFN-associated retinopathy who had developed macular edema and reduced visual acuity during the clinical course of IFN therapy were observed.", "question": "Treatment.Duration in IFN", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15944830_6_3788", "context": "With the use of optical coherence tomography (OCT), two patients with IFN-associated retinopathy who had developed macular edema and reduced visual acuity during the clinical course of IFN therapy were observed.", "question": "Treatment.Disorder in IFN", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15944830_6_3789", "context": "With the use of optical coherence tomography (OCT), two patients with IFN-associated retinopathy who had developed macular edema and reduced visual acuity during the clinical course of IFN therapy were observed.", "question": "Combination.Drug in IFN", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16244351_1_3790", "context": "Atrial fibrillation after vardenafil therapy.", "question": "Treatment.Drug in vardenafil therapy", "question_type": "Adverse_event.Treatment.Drug", "answers": "vardenafil"}, {"id": "16244351_1_3791", "context": "Atrial fibrillation after vardenafil therapy.", "question": "Treatment.Dosage in vardenafil therapy", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16244351_1_3792", "context": "Atrial fibrillation after vardenafil therapy.", "question": "Treatment.Freq in vardenafil therapy", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16244351_1_3793", "context": "Atrial fibrillation after vardenafil therapy.", "question": "Treatment.Route in vardenafil therapy", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16244351_1_3794", "context": "Atrial fibrillation after vardenafil therapy.", "question": "Treatment.Time_elapsed in vardenafil therapy", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16244351_1_3795", "context": "Atrial fibrillation after vardenafil therapy.", "question": "Treatment.Duration in vardenafil therapy", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16244351_1_3796", "context": "Atrial fibrillation after vardenafil therapy.", "question": "Treatment.Disorder in vardenafil therapy", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16244351_1_3797", "context": "Atrial fibrillation after vardenafil therapy.", "question": "Combination.Drug in vardenafil therapy", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16122280_19_3798", "context": "In phase III clinical trials, the telithromycin 800 mg once-daily dose has been shown to provide close to the maximum antimicrobial activity against S. pneumoniae, Haemophilus influenzae and Staphylococcus aureus in patients with community-acquired pneumonia.", "question": "Subject.Age in patients with community-acquired pneumonia", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "16122280_19_3799", "context": "In phase III clinical trials, the telithromycin 800 mg once-daily dose has been shown to provide close to the maximum antimicrobial activity against S. pneumoniae, Haemophilus influenzae and Staphylococcus aureus in patients with community-acquired pneumonia.", "question": "Subject.Gender in patients with community-acquired pneumonia", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "16122280_19_3800", "context": "In phase III clinical trials, the telithromycin 800 mg once-daily dose has been shown to provide close to the maximum antimicrobial activity against S. pneumoniae, Haemophilus influenzae and Staphylococcus aureus in patients with community-acquired pneumonia.", "question": "Subject.Population in patients with community-acquired pneumonia", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "16122280_19_3801", "context": "In phase III clinical trials, the telithromycin 800 mg once-daily dose has been shown to provide close to the maximum antimicrobial activity against S. pneumoniae, Haemophilus influenzae and Staphylococcus aureus in patients with community-acquired pneumonia.", "question": "Subject.Race in patients with community-acquired pneumonia", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "16122280_19_3802", "context": "In phase III clinical trials, the telithromycin 800 mg once-daily dose has been shown to provide close to the maximum antimicrobial activity against S. pneumoniae, Haemophilus influenzae and Staphylococcus aureus in patients with community-acquired pneumonia.", "question": "Subject.Disorder in patients with community-acquired pneumonia", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "16122280_19_3803", "context": "In phase III clinical trials, the telithromycin 800 mg once-daily dose has been shown to provide close to the maximum antimicrobial activity against S. pneumoniae, Haemophilus influenzae and Staphylococcus aureus in patients with community-acquired pneumonia.", "question": "Treatment.Drug in telithromycin 800 mg once-daily dose", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "telithromycin"}, {"id": "16122280_19_3804", "context": "In phase III clinical trials, the telithromycin 800 mg once-daily dose has been shown to provide close to the maximum antimicrobial activity against S. pneumoniae, Haemophilus influenzae and Staphylococcus aureus in patients with community-acquired pneumonia.", "question": "Treatment.Dosage in telithromycin 800 mg once-daily dose", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": "800 mg"}, {"id": "16122280_19_3805", "context": "In phase III clinical trials, the telithromycin 800 mg once-daily dose has been shown to provide close to the maximum antimicrobial activity against S. pneumoniae, Haemophilus influenzae and Staphylococcus aureus in patients with community-acquired pneumonia.", "question": "Treatment.Freq in telithromycin 800 mg once-daily dose", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": "once-daily"}, {"id": "16122280_19_3806", "context": "In phase III clinical trials, the telithromycin 800 mg once-daily dose has been shown to provide close to the maximum antimicrobial activity against S. pneumoniae, Haemophilus influenzae and Staphylococcus aureus in patients with community-acquired pneumonia.", "question": "Treatment.Route in telithromycin 800 mg once-daily dose", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "16122280_19_3807", "context": "In phase III clinical trials, the telithromycin 800 mg once-daily dose has been shown to provide close to the maximum antimicrobial activity against S. pneumoniae, Haemophilus influenzae and Staphylococcus aureus in patients with community-acquired pneumonia.", "question": "Treatment.Time_elapsed in telithromycin 800 mg once-daily dose", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16122280_19_3808", "context": "In phase III clinical trials, the telithromycin 800 mg once-daily dose has been shown to provide close to the maximum antimicrobial activity against S. pneumoniae, Haemophilus influenzae and Staphylococcus aureus in patients with community-acquired pneumonia.", "question": "Treatment.Duration in telithromycin 800 mg once-daily dose", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "16122280_19_3809", "context": "In phase III clinical trials, the telithromycin 800 mg once-daily dose has been shown to provide close to the maximum antimicrobial activity against S. pneumoniae, Haemophilus influenzae and Staphylococcus aureus in patients with community-acquired pneumonia.", "question": "Treatment.Disorder in telithromycin 800 mg once-daily dose", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "S. pneumoniae; Haemophilus influenzae; Staphylococcus aureus; pneumonia"}, {"id": "16122280_19_3810", "context": "In phase III clinical trials, the telithromycin 800 mg once-daily dose has been shown to provide close to the maximum antimicrobial activity against S. pneumoniae, Haemophilus influenzae and Staphylococcus aureus in patients with community-acquired pneumonia.", "question": "Combination.Drug in telithromycin 800 mg once-daily dose", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "11247558_4_3811", "context": "We suggest that meloxicam might have intestinal toxic effects when taken in high doses, because of reduced COX-2 selectivity.", "question": "Treatment.Drug in meloxicam", "question_type": "Adverse_event.Treatment.Drug", "answers": "meloxicam"}, {"id": "11247558_4_3812", "context": "We suggest that meloxicam might have intestinal toxic effects when taken in high doses, because of reduced COX-2 selectivity.", "question": "Treatment.Dosage in meloxicam", "question_type": "Adverse_event.Treatment.Dosage", "answers": "high doses"}, {"id": "11247558_4_3813", "context": "We suggest that meloxicam might have intestinal toxic effects when taken in high doses, because of reduced COX-2 selectivity.", "question": "Treatment.Freq in meloxicam", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11247558_4_3814", "context": "We suggest that meloxicam might have intestinal toxic effects when taken in high doses, because of reduced COX-2 selectivity.", "question": "Treatment.Route in meloxicam", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11247558_4_3815", "context": "We suggest that meloxicam might have intestinal toxic effects when taken in high doses, because of reduced COX-2 selectivity.", "question": "Treatment.Time_elapsed in meloxicam", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11247558_4_3816", "context": "We suggest that meloxicam might have intestinal toxic effects when taken in high doses, because of reduced COX-2 selectivity.", "question": "Treatment.Duration in meloxicam", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11247558_4_3817", "context": "We suggest that meloxicam might have intestinal toxic effects when taken in high doses, because of reduced COX-2 selectivity.", "question": "Treatment.Disorder in meloxicam", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11247558_4_3818", "context": "We suggest that meloxicam might have intestinal toxic effects when taken in high doses, because of reduced COX-2 selectivity.", "question": "Combination.Drug in meloxicam", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3152997_1_3819", "context": "Atrial fibrillation following methylprednisolone pulse therapy.", "question": "Treatment.Drug in methylprednisolone pulse therapy", "question_type": "Adverse_event.Treatment.Drug", "answers": "methylprednisolone"}, {"id": "3152997_1_3820", "context": "Atrial fibrillation following methylprednisolone pulse therapy.", "question": "Treatment.Dosage in methylprednisolone pulse therapy", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3152997_1_3821", "context": "Atrial fibrillation following methylprednisolone pulse therapy.", "question": "Treatment.Freq in methylprednisolone pulse therapy", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3152997_1_3822", "context": "Atrial fibrillation following methylprednisolone pulse therapy.", "question": "Treatment.Route in methylprednisolone pulse therapy", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3152997_1_3823", "context": "Atrial fibrillation following methylprednisolone pulse therapy.", "question": "Treatment.Time_elapsed in methylprednisolone pulse therapy", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3152997_1_3824", "context": "Atrial fibrillation following methylprednisolone pulse therapy.", "question": "Treatment.Duration in methylprednisolone pulse therapy", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3152997_1_3825", "context": "Atrial fibrillation following methylprednisolone pulse therapy.", "question": "Treatment.Disorder in methylprednisolone pulse therapy", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3152997_1_3826", "context": "Atrial fibrillation following methylprednisolone pulse therapy.", "question": "Combination.Drug in methylprednisolone pulse therapy", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "2113320_2_3827", "context": "Subglottic stenosis in Wegener's granulomatosis: development during cyclophosphamide treatment with response to carbon dioxide laser therapy.", "question": "Treatment.Drug in cyclophosphamide treatment with response to carbon dioxide laser therapy", "question_type": "Adverse_event.Treatment.Drug", "answers": "cyclophosphamide"}, {"id": "2113320_2_3828", "context": "Subglottic stenosis in Wegener's granulomatosis: development during cyclophosphamide treatment with response to carbon dioxide laser therapy.", "question": "Treatment.Dosage in cyclophosphamide treatment with response to carbon dioxide laser therapy", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "2113320_2_3829", "context": "Subglottic stenosis in Wegener's granulomatosis: development during cyclophosphamide treatment with response to carbon dioxide laser therapy.", "question": "Treatment.Freq in cyclophosphamide treatment with response to carbon dioxide laser therapy", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2113320_2_3830", "context": "Subglottic stenosis in Wegener's granulomatosis: development during cyclophosphamide treatment with response to carbon dioxide laser therapy.", "question": "Treatment.Route in cyclophosphamide treatment with response to carbon dioxide laser therapy", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "2113320_2_3831", "context": "Subglottic stenosis in Wegener's granulomatosis: development during cyclophosphamide treatment with response to carbon dioxide laser therapy.", "question": "Treatment.Time_elapsed in cyclophosphamide treatment with response to carbon dioxide laser therapy", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2113320_2_3832", "context": "Subglottic stenosis in Wegener's granulomatosis: development during cyclophosphamide treatment with response to carbon dioxide laser therapy.", "question": "Treatment.Duration in cyclophosphamide treatment with response to carbon dioxide laser therapy", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2113320_2_3833", "context": "Subglottic stenosis in Wegener's granulomatosis: development during cyclophosphamide treatment with response to carbon dioxide laser therapy.", "question": "Treatment.Disorder in cyclophosphamide treatment with response to carbon dioxide laser therapy", "question_type": "Adverse_event.Treatment.Disorder", "answers": "Wegener's granulomatosis"}, {"id": "2113320_2_3834", "context": "Subglottic stenosis in Wegener's granulomatosis: development during cyclophosphamide treatment with response to carbon dioxide laser therapy.", "question": "Combination.Drug in cyclophosphamide treatment with response to carbon dioxide laser therapy", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18492617_2_3835", "context": "Pregabalin-induced cortical negative myoclonus in a patient with neuropathic pain.", "question": "Subject.Age in a patient with neuropathic pain", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "18492617_2_3836", "context": "Pregabalin-induced cortical negative myoclonus in a patient with neuropathic pain.", "question": "Subject.Gender in a patient with neuropathic pain", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "18492617_2_3837", "context": "Pregabalin-induced cortical negative myoclonus in a patient with neuropathic pain.", "question": "Subject.Population in a patient with neuropathic pain", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "18492617_2_3838", "context": "Pregabalin-induced cortical negative myoclonus in a patient with neuropathic pain.", "question": "Subject.Race in a patient with neuropathic pain", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "18492617_2_3839", "context": "Pregabalin-induced cortical negative myoclonus in a patient with neuropathic pain.", "question": "Subject.Disorder in a patient with neuropathic pain", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "18492617_2_3840", "context": "Pregabalin-induced cortical negative myoclonus in a patient with neuropathic pain.", "question": "Treatment.Drug in Pregabalin", "question_type": "Adverse_event.Treatment.Drug", "answers": "Pregabalin"}, {"id": "18492617_2_3841", "context": "Pregabalin-induced cortical negative myoclonus in a patient with neuropathic pain.", "question": "Treatment.Dosage in Pregabalin", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18492617_2_3842", "context": "Pregabalin-induced cortical negative myoclonus in a patient with neuropathic pain.", "question": "Treatment.Freq in Pregabalin", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18492617_2_3843", "context": "Pregabalin-induced cortical negative myoclonus in a patient with neuropathic pain.", "question": "Treatment.Route in Pregabalin", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18492617_2_3844", "context": "Pregabalin-induced cortical negative myoclonus in a patient with neuropathic pain.", "question": "Treatment.Time_elapsed in Pregabalin", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18492617_2_3845", "context": "Pregabalin-induced cortical negative myoclonus in a patient with neuropathic pain.", "question": "Treatment.Duration in Pregabalin", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18492617_2_3846", "context": "Pregabalin-induced cortical negative myoclonus in a patient with neuropathic pain.", "question": "Treatment.Disorder in Pregabalin", "question_type": "Adverse_event.Treatment.Disorder", "answers": "neuropathic pain"}, {"id": "18492617_2_3847", "context": "Pregabalin-induced cortical negative myoclonus in a patient with neuropathic pain.", "question": "Combination.Drug in Pregabalin", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12663440_12_3848", "context": "We conclude that quinine does not improve the survival of adult patients with de novo AML, even though it improves CR rate in a small subgroup of patients defined by rhodamine 123 efflux.", "question": "Subject.Age in a small subgroup of patients defined by rhodamine 123 efflux", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "12663440_12_3849", "context": "We conclude that quinine does not improve the survival of adult patients with de novo AML, even though it improves CR rate in a small subgroup of patients defined by rhodamine 123 efflux.", "question": "Subject.Gender in a small subgroup of patients defined by rhodamine 123 efflux", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "12663440_12_3850", "context": "We conclude that quinine does not improve the survival of adult patients with de novo AML, even though it improves CR rate in a small subgroup of patients defined by rhodamine 123 efflux.", "question": "Subject.Population in a small subgroup of patients defined by rhodamine 123 efflux", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": "a small subgroup"}, {"id": "12663440_12_3851", "context": "We conclude that quinine does not improve the survival of adult patients with de novo AML, even though it improves CR rate in a small subgroup of patients defined by rhodamine 123 efflux.", "question": "Subject.Race in a small subgroup of patients defined by rhodamine 123 efflux", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "12663440_12_3852", "context": "We conclude that quinine does not improve the survival of adult patients with de novo AML, even though it improves CR rate in a small subgroup of patients defined by rhodamine 123 efflux.", "question": "Subject.Disorder in a small subgroup of patients defined by rhodamine 123 efflux", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": "rhodamine 123 efflux"}, {"id": "12663440_12_3853", "context": "We conclude that quinine does not improve the survival of adult patients with de novo AML, even though it improves CR rate in a small subgroup of patients defined by rhodamine 123 efflux.", "question": "Treatment.Drug in quinine", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "quinine"}, {"id": "12663440_12_3854", "context": "We conclude that quinine does not improve the survival of adult patients with de novo AML, even though it improves CR rate in a small subgroup of patients defined by rhodamine 123 efflux.", "question": "Treatment.Dosage in quinine", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "12663440_12_3855", "context": "We conclude that quinine does not improve the survival of adult patients with de novo AML, even though it improves CR rate in a small subgroup of patients defined by rhodamine 123 efflux.", "question": "Treatment.Freq in quinine", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "12663440_12_3856", "context": "We conclude that quinine does not improve the survival of adult patients with de novo AML, even though it improves CR rate in a small subgroup of patients defined by rhodamine 123 efflux.", "question": "Treatment.Route in quinine", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "12663440_12_3857", "context": "We conclude that quinine does not improve the survival of adult patients with de novo AML, even though it improves CR rate in a small subgroup of patients defined by rhodamine 123 efflux.", "question": "Treatment.Time_elapsed in quinine", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12663440_12_3858", "context": "We conclude that quinine does not improve the survival of adult patients with de novo AML, even though it improves CR rate in a small subgroup of patients defined by rhodamine 123 efflux.", "question": "Treatment.Duration in quinine", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "12663440_12_3859", "context": "We conclude that quinine does not improve the survival of adult patients with de novo AML, even though it improves CR rate in a small subgroup of patients defined by rhodamine 123 efflux.", "question": "Treatment.Disorder in quinine", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "de novo AML"}, {"id": "12663440_12_3860", "context": "We conclude that quinine does not improve the survival of adult patients with de novo AML, even though it improves CR rate in a small subgroup of patients defined by rhodamine 123 efflux.", "question": "Combination.Drug in quinine", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "12663440_12_3861", "context": "We conclude that quinine does not improve the survival of adult patients with de novo AML, even though it improves CR rate in a small subgroup of patients defined by rhodamine 123 efflux.", "question": "Subject.Age in adult patients", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": "adult"}, {"id": "12663440_12_3862", "context": "We conclude that quinine does not improve the survival of adult patients with de novo AML, even though it improves CR rate in a small subgroup of patients defined by rhodamine 123 efflux.", "question": "Subject.Gender in adult patients", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "12663440_12_3863", "context": "We conclude that quinine does not improve the survival of adult patients with de novo AML, even though it improves CR rate in a small subgroup of patients defined by rhodamine 123 efflux.", "question": "Subject.Population in adult patients", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "12663440_12_3864", "context": "We conclude that quinine does not improve the survival of adult patients with de novo AML, even though it improves CR rate in a small subgroup of patients defined by rhodamine 123 efflux.", "question": "Subject.Race in adult patients", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "12663440_12_3865", "context": "We conclude that quinine does not improve the survival of adult patients with de novo AML, even though it improves CR rate in a small subgroup of patients defined by rhodamine 123 efflux.", "question": "Subject.Disorder in adult patients", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "12663440_12_3866", "context": "We conclude that quinine does not improve the survival of adult patients with de novo AML, even though it improves CR rate in a small subgroup of patients defined by rhodamine 123 efflux.", "question": "Treatment.Drug in quinine", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "quinine"}, {"id": "12663440_12_3867", "context": "We conclude that quinine does not improve the survival of adult patients with de novo AML, even though it improves CR rate in a small subgroup of patients defined by rhodamine 123 efflux.", "question": "Treatment.Dosage in quinine", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "12663440_12_3868", "context": "We conclude that quinine does not improve the survival of adult patients with de novo AML, even though it improves CR rate in a small subgroup of patients defined by rhodamine 123 efflux.", "question": "Treatment.Freq in quinine", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "12663440_12_3869", "context": "We conclude that quinine does not improve the survival of adult patients with de novo AML, even though it improves CR rate in a small subgroup of patients defined by rhodamine 123 efflux.", "question": "Treatment.Route in quinine", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "12663440_12_3870", "context": "We conclude that quinine does not improve the survival of adult patients with de novo AML, even though it improves CR rate in a small subgroup of patients defined by rhodamine 123 efflux.", "question": "Treatment.Time_elapsed in quinine", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12663440_12_3871", "context": "We conclude that quinine does not improve the survival of adult patients with de novo AML, even though it improves CR rate in a small subgroup of patients defined by rhodamine 123 efflux.", "question": "Treatment.Duration in quinine", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "12663440_12_3872", "context": "We conclude that quinine does not improve the survival of adult patients with de novo AML, even though it improves CR rate in a small subgroup of patients defined by rhodamine 123 efflux.", "question": "Treatment.Disorder in quinine", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "de novo AML"}, {"id": "12663440_12_3873", "context": "We conclude that quinine does not improve the survival of adult patients with de novo AML, even though it improves CR rate in a small subgroup of patients defined by rhodamine 123 efflux.", "question": "Combination.Drug in quinine", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "14530108_4_3874", "context": "The mechanism of RTA induced by FK506 has not yet been clearly elucidated.", "question": "Treatment.Drug in FK506", "question_type": "Adverse_event.Treatment.Drug", "answers": "FK506"}, {"id": "14530108_4_3875", "context": "The mechanism of RTA induced by FK506 has not yet been clearly elucidated.", "question": "Treatment.Dosage in FK506", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "14530108_4_3876", "context": "The mechanism of RTA induced by FK506 has not yet been clearly elucidated.", "question": "Treatment.Freq in FK506", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "14530108_4_3877", "context": "The mechanism of RTA induced by FK506 has not yet been clearly elucidated.", "question": "Treatment.Route in FK506", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "14530108_4_3878", "context": "The mechanism of RTA induced by FK506 has not yet been clearly elucidated.", "question": "Treatment.Time_elapsed in FK506", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "14530108_4_3879", "context": "The mechanism of RTA induced by FK506 has not yet been clearly elucidated.", "question": "Treatment.Duration in FK506", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "14530108_4_3880", "context": "The mechanism of RTA induced by FK506 has not yet been clearly elucidated.", "question": "Treatment.Disorder in FK506", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "14530108_4_3881", "context": "The mechanism of RTA induced by FK506 has not yet been clearly elucidated.", "question": "Combination.Drug in FK506", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17301517_2_3882", "context": "The risk of new-onset diabetic ketoacidosis in patients with diabetic risk factors who are taking perospirone hydrochloride or other atypical antipsychotics should be kept in mind.", "question": "Subject.Age in patients with diabetic risk factors", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "17301517_2_3883", "context": "The risk of new-onset diabetic ketoacidosis in patients with diabetic risk factors who are taking perospirone hydrochloride or other atypical antipsychotics should be kept in mind.", "question": "Subject.Gender in patients with diabetic risk factors", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "17301517_2_3884", "context": "The risk of new-onset diabetic ketoacidosis in patients with diabetic risk factors who are taking perospirone hydrochloride or other atypical antipsychotics should be kept in mind.", "question": "Subject.Population in patients with diabetic risk factors", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "17301517_2_3885", "context": "The risk of new-onset diabetic ketoacidosis in patients with diabetic risk factors who are taking perospirone hydrochloride or other atypical antipsychotics should be kept in mind.", "question": "Subject.Race in patients with diabetic risk factors", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "17301517_2_3886", "context": "The risk of new-onset diabetic ketoacidosis in patients with diabetic risk factors who are taking perospirone hydrochloride or other atypical antipsychotics should be kept in mind.", "question": "Subject.Disorder in patients with diabetic risk factors", "question_type": "Adverse_event.Subject.Disorder", "answers": "diabetic risk factors"}, {"id": "17301517_2_3887", "context": "The risk of new-onset diabetic ketoacidosis in patients with diabetic risk factors who are taking perospirone hydrochloride or other atypical antipsychotics should be kept in mind.", "question": "Treatment.Drug in perospirone hydrochloride or other atypical antipsychotics", "question_type": "Adverse_event.Treatment.Drug", "answers": "perospirone hydrochloride"}, {"id": "17301517_2_3888", "context": "The risk of new-onset diabetic ketoacidosis in patients with diabetic risk factors who are taking perospirone hydrochloride or other atypical antipsychotics should be kept in mind.", "question": "Treatment.Dosage in perospirone hydrochloride or other atypical antipsychotics", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17301517_2_3889", "context": "The risk of new-onset diabetic ketoacidosis in patients with diabetic risk factors who are taking perospirone hydrochloride or other atypical antipsychotics should be kept in mind.", "question": "Treatment.Freq in perospirone hydrochloride or other atypical antipsychotics", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17301517_2_3890", "context": "The risk of new-onset diabetic ketoacidosis in patients with diabetic risk factors who are taking perospirone hydrochloride or other atypical antipsychotics should be kept in mind.", "question": "Treatment.Route in perospirone hydrochloride or other atypical antipsychotics", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17301517_2_3891", "context": "The risk of new-onset diabetic ketoacidosis in patients with diabetic risk factors who are taking perospirone hydrochloride or other atypical antipsychotics should be kept in mind.", "question": "Treatment.Time_elapsed in perospirone hydrochloride or other atypical antipsychotics", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17301517_2_3892", "context": "The risk of new-onset diabetic ketoacidosis in patients with diabetic risk factors who are taking perospirone hydrochloride or other atypical antipsychotics should be kept in mind.", "question": "Treatment.Duration in perospirone hydrochloride or other atypical antipsychotics", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17301517_2_3893", "context": "The risk of new-onset diabetic ketoacidosis in patients with diabetic risk factors who are taking perospirone hydrochloride or other atypical antipsychotics should be kept in mind.", "question": "Treatment.Disorder in perospirone hydrochloride or other atypical antipsychotics", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17301517_2_3894", "context": "The risk of new-onset diabetic ketoacidosis in patients with diabetic risk factors who are taking perospirone hydrochloride or other atypical antipsychotics should be kept in mind.", "question": "Combination.Drug in perospirone hydrochloride or other atypical antipsychotics", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18487000_1_3895", "context": "Severe symptomatic hyponatremia during sibutramine therapy: a case report.", "question": "Treatment.Drug in sibutramine", "question_type": "Adverse_event.Treatment.Drug", "answers": "sibutramine"}, {"id": "18487000_1_3896", "context": "Severe symptomatic hyponatremia during sibutramine therapy: a case report.", "question": "Treatment.Dosage in sibutramine", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18487000_1_3897", "context": "Severe symptomatic hyponatremia during sibutramine therapy: a case report.", "question": "Treatment.Freq in sibutramine", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18487000_1_3898", "context": "Severe symptomatic hyponatremia during sibutramine therapy: a case report.", "question": "Treatment.Route in sibutramine", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18487000_1_3899", "context": "Severe symptomatic hyponatremia during sibutramine therapy: a case report.", "question": "Treatment.Time_elapsed in sibutramine", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18487000_1_3900", "context": "Severe symptomatic hyponatremia during sibutramine therapy: a case report.", "question": "Treatment.Duration in sibutramine", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18487000_1_3901", "context": "Severe symptomatic hyponatremia during sibutramine therapy: a case report.", "question": "Treatment.Disorder in sibutramine", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18487000_1_3902", "context": "Severe symptomatic hyponatremia during sibutramine therapy: a case report.", "question": "Combination.Drug in sibutramine", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15779196_2_3903", "context": "Zoledronic acid-induced severe hypocalcaemia in a prostate cancer patient with extensive osteoblastic bone metastases.", "question": "Subject.Age in prostate cancer patient with extensive osteoblastic bone metastases", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "15779196_2_3904", "context": "Zoledronic acid-induced severe hypocalcaemia in a prostate cancer patient with extensive osteoblastic bone metastases.", "question": "Subject.Gender in prostate cancer patient with extensive osteoblastic bone metastases", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15779196_2_3905", "context": "Zoledronic acid-induced severe hypocalcaemia in a prostate cancer patient with extensive osteoblastic bone metastases.", "question": "Subject.Population in prostate cancer patient with extensive osteoblastic bone metastases", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "15779196_2_3906", "context": "Zoledronic acid-induced severe hypocalcaemia in a prostate cancer patient with extensive osteoblastic bone metastases.", "question": "Subject.Race in prostate cancer patient with extensive osteoblastic bone metastases", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15779196_2_3907", "context": "Zoledronic acid-induced severe hypocalcaemia in a prostate cancer patient with extensive osteoblastic bone metastases.", "question": "Subject.Disorder in prostate cancer patient with extensive osteoblastic bone metastases", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15779196_2_3908", "context": "Zoledronic acid-induced severe hypocalcaemia in a prostate cancer patient with extensive osteoblastic bone metastases.", "question": "Treatment.Drug in Zoledronic acid", "question_type": "Adverse_event.Treatment.Drug", "answers": "Zoledronic acid"}, {"id": "15779196_2_3909", "context": "Zoledronic acid-induced severe hypocalcaemia in a prostate cancer patient with extensive osteoblastic bone metastases.", "question": "Treatment.Dosage in Zoledronic acid", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15779196_2_3910", "context": "Zoledronic acid-induced severe hypocalcaemia in a prostate cancer patient with extensive osteoblastic bone metastases.", "question": "Treatment.Freq in Zoledronic acid", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15779196_2_3911", "context": "Zoledronic acid-induced severe hypocalcaemia in a prostate cancer patient with extensive osteoblastic bone metastases.", "question": "Treatment.Route in Zoledronic acid", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15779196_2_3912", "context": "Zoledronic acid-induced severe hypocalcaemia in a prostate cancer patient with extensive osteoblastic bone metastases.", "question": "Treatment.Time_elapsed in Zoledronic acid", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15779196_2_3913", "context": "Zoledronic acid-induced severe hypocalcaemia in a prostate cancer patient with extensive osteoblastic bone metastases.", "question": "Treatment.Duration in Zoledronic acid", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15779196_2_3914", "context": "Zoledronic acid-induced severe hypocalcaemia in a prostate cancer patient with extensive osteoblastic bone metastases.", "question": "Treatment.Disorder in Zoledronic acid", "question_type": "Adverse_event.Treatment.Disorder", "answers": "prostate cancer; extensive osteoblastic bone metastases"}, {"id": "15779196_2_3915", "context": "Zoledronic acid-induced severe hypocalcaemia in a prostate cancer patient with extensive osteoblastic bone metastases.", "question": "Combination.Drug in Zoledronic acid", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12149193_9_3916", "context": "MM patients treated with thalidomide and doxorubicin have a high risk of developing DVT.", "question": "Subject.Age in MM patients", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "12149193_9_3917", "context": "MM patients treated with thalidomide and doxorubicin have a high risk of developing DVT.", "question": "Subject.Gender in MM patients", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "12149193_9_3918", "context": "MM patients treated with thalidomide and doxorubicin have a high risk of developing DVT.", "question": "Subject.Population in MM patients", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "12149193_9_3919", "context": "MM patients treated with thalidomide and doxorubicin have a high risk of developing DVT.", "question": "Subject.Race in MM patients", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "12149193_9_3920", "context": "MM patients treated with thalidomide and doxorubicin have a high risk of developing DVT.", "question": "Subject.Disorder in MM patients", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "12149193_9_3921", "context": "MM patients treated with thalidomide and doxorubicin have a high risk of developing DVT.", "question": "Treatment.Drug in thalidomide and doxorubicin", "question_type": "Adverse_event.Treatment.Drug", "answers": "thalidomide; doxorubicin"}, {"id": "12149193_9_3922", "context": "MM patients treated with thalidomide and doxorubicin have a high risk of developing DVT.", "question": "Treatment.Dosage in thalidomide and doxorubicin", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12149193_9_3923", "context": "MM patients treated with thalidomide and doxorubicin have a high risk of developing DVT.", "question": "Treatment.Freq in thalidomide and doxorubicin", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12149193_9_3924", "context": "MM patients treated with thalidomide and doxorubicin have a high risk of developing DVT.", "question": "Treatment.Route in thalidomide and doxorubicin", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12149193_9_3925", "context": "MM patients treated with thalidomide and doxorubicin have a high risk of developing DVT.", "question": "Treatment.Time_elapsed in thalidomide and doxorubicin", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12149193_9_3926", "context": "MM patients treated with thalidomide and doxorubicin have a high risk of developing DVT.", "question": "Treatment.Duration in thalidomide and doxorubicin", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12149193_9_3927", "context": "MM patients treated with thalidomide and doxorubicin have a high risk of developing DVT.", "question": "Treatment.Disorder in thalidomide and doxorubicin", "question_type": "Adverse_event.Treatment.Disorder", "answers": "MM"}, {"id": "12149193_9_3928", "context": "MM patients treated with thalidomide and doxorubicin have a high risk of developing DVT.", "question": "Combination.Drug in thalidomide and doxorubicin", "question_type": "Adverse_event.Combination.Drug", "answers": "thalidomide; doxorubicin"}, {"id": "19653965_1_3929", "context": "These two cases highlight the importance of considering lopinavir/ritonavir induced arrhythmias when dealing with HIV-positive individuals.", "question": "Subject.Age in HIV-positive individuals", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "19653965_1_3930", "context": "These two cases highlight the importance of considering lopinavir/ritonavir induced arrhythmias when dealing with HIV-positive individuals.", "question": "Subject.Gender in HIV-positive individuals", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "19653965_1_3931", "context": "These two cases highlight the importance of considering lopinavir/ritonavir induced arrhythmias when dealing with HIV-positive individuals.", "question": "Subject.Population in HIV-positive individuals", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "19653965_1_3932", "context": "These two cases highlight the importance of considering lopinavir/ritonavir induced arrhythmias when dealing with HIV-positive individuals.", "question": "Subject.Race in HIV-positive individuals", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "19653965_1_3933", "context": "These two cases highlight the importance of considering lopinavir/ritonavir induced arrhythmias when dealing with HIV-positive individuals.", "question": "Subject.Disorder in HIV-positive individuals", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "19653965_1_3934", "context": "These two cases highlight the importance of considering lopinavir/ritonavir induced arrhythmias when dealing with HIV-positive individuals.", "question": "Treatment.Drug in lopinavir/ritonavir", "question_type": "Adverse_event.Treatment.Drug", "answers": "lopinavir; ritonavir"}, {"id": "19653965_1_3935", "context": "These two cases highlight the importance of considering lopinavir/ritonavir induced arrhythmias when dealing with HIV-positive individuals.", "question": "Treatment.Dosage in lopinavir/ritonavir", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "19653965_1_3936", "context": "These two cases highlight the importance of considering lopinavir/ritonavir induced arrhythmias when dealing with HIV-positive individuals.", "question": "Treatment.Freq in lopinavir/ritonavir", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "19653965_1_3937", "context": "These two cases highlight the importance of considering lopinavir/ritonavir induced arrhythmias when dealing with HIV-positive individuals.", "question": "Treatment.Route in lopinavir/ritonavir", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "19653965_1_3938", "context": "These two cases highlight the importance of considering lopinavir/ritonavir induced arrhythmias when dealing with HIV-positive individuals.", "question": "Treatment.Time_elapsed in lopinavir/ritonavir", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19653965_1_3939", "context": "These two cases highlight the importance of considering lopinavir/ritonavir induced arrhythmias when dealing with HIV-positive individuals.", "question": "Treatment.Duration in lopinavir/ritonavir", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "19653965_1_3940", "context": "These two cases highlight the importance of considering lopinavir/ritonavir induced arrhythmias when dealing with HIV-positive individuals.", "question": "Treatment.Disorder in lopinavir/ritonavir", "question_type": "Adverse_event.Treatment.Disorder", "answers": "HIV"}, {"id": "19653965_1_3941", "context": "These two cases highlight the importance of considering lopinavir/ritonavir induced arrhythmias when dealing with HIV-positive individuals.", "question": "Combination.Drug in lopinavir/ritonavir", "question_type": "Adverse_event.Combination.Drug", "answers": "lopinavir; ritonavir"}, {"id": "11200291_1_3942", "context": "Atrial fibrillation occurring in a patient taking etanercept plus methotrexate for rheumatoid arthritis.", "question": "Subject.Age in a patient", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "11200291_1_3943", "context": "Atrial fibrillation occurring in a patient taking etanercept plus methotrexate for rheumatoid arthritis.", "question": "Subject.Gender in a patient", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "11200291_1_3944", "context": "Atrial fibrillation occurring in a patient taking etanercept plus methotrexate for rheumatoid arthritis.", "question": "Subject.Population in a patient", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "11200291_1_3945", "context": "Atrial fibrillation occurring in a patient taking etanercept plus methotrexate for rheumatoid arthritis.", "question": "Subject.Race in a patient", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "11200291_1_3946", "context": "Atrial fibrillation occurring in a patient taking etanercept plus methotrexate for rheumatoid arthritis.", "question": "Subject.Disorder in a patient", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "11200291_1_3947", "context": "Atrial fibrillation occurring in a patient taking etanercept plus methotrexate for rheumatoid arthritis.", "question": "Treatment.Drug in etanercept plus methotrexate for rheumatoid arthritis", "question_type": "Adverse_event.Treatment.Drug", "answers": "etanercept; methotrexate"}, {"id": "11200291_1_3948", "context": "Atrial fibrillation occurring in a patient taking etanercept plus methotrexate for rheumatoid arthritis.", "question": "Treatment.Dosage in etanercept plus methotrexate for rheumatoid arthritis", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11200291_1_3949", "context": "Atrial fibrillation occurring in a patient taking etanercept plus methotrexate for rheumatoid arthritis.", "question": "Treatment.Freq in etanercept plus methotrexate for rheumatoid arthritis", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11200291_1_3950", "context": "Atrial fibrillation occurring in a patient taking etanercept plus methotrexate for rheumatoid arthritis.", "question": "Treatment.Route in etanercept plus methotrexate for rheumatoid arthritis", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11200291_1_3951", "context": "Atrial fibrillation occurring in a patient taking etanercept plus methotrexate for rheumatoid arthritis.", "question": "Treatment.Time_elapsed in etanercept plus methotrexate for rheumatoid arthritis", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11200291_1_3952", "context": "Atrial fibrillation occurring in a patient taking etanercept plus methotrexate for rheumatoid arthritis.", "question": "Treatment.Duration in etanercept plus methotrexate for rheumatoid arthritis", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11200291_1_3953", "context": "Atrial fibrillation occurring in a patient taking etanercept plus methotrexate for rheumatoid arthritis.", "question": "Treatment.Disorder in etanercept plus methotrexate for rheumatoid arthritis", "question_type": "Adverse_event.Treatment.Disorder", "answers": "rheumatoid arthritis"}, {"id": "11200291_1_3954", "context": "Atrial fibrillation occurring in a patient taking etanercept plus methotrexate for rheumatoid arthritis.", "question": "Combination.Drug in etanercept plus methotrexate for rheumatoid arthritis", "question_type": "Adverse_event.Combination.Drug", "answers": "etanercept; methotrexate"}, {"id": "17083890_4_3955", "context": "We describe a 52-year-old male diagnosed with stage III multiple myeloma, who was treated with 5-monthly cycles of VAD (vincristine, adriamycin and dexamathasone).", "question": "Subject.Age in a 52-year-old male", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": "52-year-old"}, {"id": "17083890_4_3956", "context": "We describe a 52-year-old male diagnosed with stage III multiple myeloma, who was treated with 5-monthly cycles of VAD (vincristine, adriamycin and dexamathasone).", "question": "Subject.Gender in a 52-year-old male", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": "male"}, {"id": "17083890_4_3957", "context": "We describe a 52-year-old male diagnosed with stage III multiple myeloma, who was treated with 5-monthly cycles of VAD (vincristine, adriamycin and dexamathasone).", "question": "Subject.Population in a 52-year-old male", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "17083890_4_3958", "context": "We describe a 52-year-old male diagnosed with stage III multiple myeloma, who was treated with 5-monthly cycles of VAD (vincristine, adriamycin and dexamathasone).", "question": "Subject.Race in a 52-year-old male", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "17083890_4_3959", "context": "We describe a 52-year-old male diagnosed with stage III multiple myeloma, who was treated with 5-monthly cycles of VAD (vincristine, adriamycin and dexamathasone).", "question": "Subject.Disorder in a 52-year-old male", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "17083890_4_3960", "context": "We describe a 52-year-old male diagnosed with stage III multiple myeloma, who was treated with 5-monthly cycles of VAD (vincristine, adriamycin and dexamathasone).", "question": "Treatment.Drug in 5-monthly cycles of VAD (vincristine, adriamycin and dexamathasone)", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "vincristine; adriamycin; dexamathasone"}, {"id": "17083890_4_3961", "context": "We describe a 52-year-old male diagnosed with stage III multiple myeloma, who was treated with 5-monthly cycles of VAD (vincristine, adriamycin and dexamathasone).", "question": "Treatment.Dosage in 5-monthly cycles of VAD (vincristine, adriamycin and dexamathasone)", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "17083890_4_3962", "context": "We describe a 52-year-old male diagnosed with stage III multiple myeloma, who was treated with 5-monthly cycles of VAD (vincristine, adriamycin and dexamathasone).", "question": "Treatment.Freq in 5-monthly cycles of VAD (vincristine, adriamycin and dexamathasone)", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "17083890_4_3963", "context": "We describe a 52-year-old male diagnosed with stage III multiple myeloma, who was treated with 5-monthly cycles of VAD (vincristine, adriamycin and dexamathasone).", "question": "Treatment.Route in 5-monthly cycles of VAD (vincristine, adriamycin and dexamathasone)", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "17083890_4_3964", "context": "We describe a 52-year-old male diagnosed with stage III multiple myeloma, who was treated with 5-monthly cycles of VAD (vincristine, adriamycin and dexamathasone).", "question": "Treatment.Time_elapsed in 5-monthly cycles of VAD (vincristine, adriamycin and dexamathasone)", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17083890_4_3965", "context": "We describe a 52-year-old male diagnosed with stage III multiple myeloma, who was treated with 5-monthly cycles of VAD (vincristine, adriamycin and dexamathasone).", "question": "Treatment.Duration in 5-monthly cycles of VAD (vincristine, adriamycin and dexamathasone)", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": "5-monthly"}, {"id": "17083890_4_3966", "context": "We describe a 52-year-old male diagnosed with stage III multiple myeloma, who was treated with 5-monthly cycles of VAD (vincristine, adriamycin and dexamathasone).", "question": "Treatment.Disorder in 5-monthly cycles of VAD (vincristine, adriamycin and dexamathasone)", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "stage III multiple myeloma"}, {"id": "17083890_4_3967", "context": "We describe a 52-year-old male diagnosed with stage III multiple myeloma, who was treated with 5-monthly cycles of VAD (vincristine, adriamycin and dexamathasone).", "question": "Combination.Drug in 5-monthly cycles of VAD (vincristine, adriamycin and dexamathasone)", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": "vincristine; adriamycin; dexamathasone"}, {"id": "15965422_4_3968", "context": "We review the literature on previously reported cases of cutaneous necrosis after injection of standard interferon alfa or pegylated interferon alfa-2b and discuss the different pathophysiologic mechanisms that might be involved.", "question": "Treatment.Drug in standard interferon alfa; pegylated interferon alfa-2b", "question_type": "Adverse_event.Treatment.Drug", "answers": "standard interferon alfa; pegylated interferon alfa-2b"}, {"id": "15965422_4_3969", "context": "We review the literature on previously reported cases of cutaneous necrosis after injection of standard interferon alfa or pegylated interferon alfa-2b and discuss the different pathophysiologic mechanisms that might be involved.", "question": "Treatment.Dosage in standard interferon alfa; pegylated interferon alfa-2b", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15965422_4_3970", "context": "We review the literature on previously reported cases of cutaneous necrosis after injection of standard interferon alfa or pegylated interferon alfa-2b and discuss the different pathophysiologic mechanisms that might be involved.", "question": "Treatment.Freq in standard interferon alfa; pegylated interferon alfa-2b", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15965422_4_3971", "context": "We review the literature on previously reported cases of cutaneous necrosis after injection of standard interferon alfa or pegylated interferon alfa-2b and discuss the different pathophysiologic mechanisms that might be involved.", "question": "Treatment.Route in standard interferon alfa; pegylated interferon alfa-2b", "question_type": "Adverse_event.Treatment.Route", "answers": "injection"}, {"id": "15965422_4_3972", "context": "We review the literature on previously reported cases of cutaneous necrosis after injection of standard interferon alfa or pegylated interferon alfa-2b and discuss the different pathophysiologic mechanisms that might be involved.", "question": "Treatment.Time_elapsed in standard interferon alfa; pegylated interferon alfa-2b", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15965422_4_3973", "context": "We review the literature on previously reported cases of cutaneous necrosis after injection of standard interferon alfa or pegylated interferon alfa-2b and discuss the different pathophysiologic mechanisms that might be involved.", "question": "Treatment.Duration in standard interferon alfa; pegylated interferon alfa-2b", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15965422_4_3974", "context": "We review the literature on previously reported cases of cutaneous necrosis after injection of standard interferon alfa or pegylated interferon alfa-2b and discuss the different pathophysiologic mechanisms that might be involved.", "question": "Treatment.Disorder in standard interferon alfa; pegylated interferon alfa-2b", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15965422_4_3975", "context": "We review the literature on previously reported cases of cutaneous necrosis after injection of standard interferon alfa or pegylated interferon alfa-2b and discuss the different pathophysiologic mechanisms that might be involved.", "question": "Combination.Drug in standard interferon alfa; pegylated interferon alfa-2b", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "21350204_9_3976", "context": "Our cohort included 1739 patients with acute ischemic stroke treated with intravenous tissue plasminogen activator of whom 125 (7.2%) were receiving warfarin before admission and had an international normalized ratio <1.7.", "question": "Subject.Age in 1739 patients", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "21350204_9_3977", "context": "Our cohort included 1739 patients with acute ischemic stroke treated with intravenous tissue plasminogen activator of whom 125 (7.2%) were receiving warfarin before admission and had an international normalized ratio <1.7.", "question": "Subject.Gender in 1739 patients", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "21350204_9_3978", "context": "Our cohort included 1739 patients with acute ischemic stroke treated with intravenous tissue plasminogen activator of whom 125 (7.2%) were receiving warfarin before admission and had an international normalized ratio <1.7.", "question": "Subject.Population in 1739 patients", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": "1739"}, {"id": "21350204_9_3979", "context": "Our cohort included 1739 patients with acute ischemic stroke treated with intravenous tissue plasminogen activator of whom 125 (7.2%) were receiving warfarin before admission and had an international normalized ratio <1.7.", "question": "Subject.Race in 1739 patients", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "21350204_9_3980", "context": "Our cohort included 1739 patients with acute ischemic stroke treated with intravenous tissue plasminogen activator of whom 125 (7.2%) were receiving warfarin before admission and had an international normalized ratio <1.7.", "question": "Subject.Disorder in 1739 patients", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "21350204_9_3981", "context": "Our cohort included 1739 patients with acute ischemic stroke treated with intravenous tissue plasminogen activator of whom 125 (7.2%) were receiving warfarin before admission and had an international normalized ratio <1.7.", "question": "Treatment.Drug in intravenous tissue plasminogen activator", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "tissue plasminogen activator"}, {"id": "21350204_9_3982", "context": "Our cohort included 1739 patients with acute ischemic stroke treated with intravenous tissue plasminogen activator of whom 125 (7.2%) were receiving warfarin before admission and had an international normalized ratio <1.7.", "question": "Treatment.Dosage in intravenous tissue plasminogen activator", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "21350204_9_3983", "context": "Our cohort included 1739 patients with acute ischemic stroke treated with intravenous tissue plasminogen activator of whom 125 (7.2%) were receiving warfarin before admission and had an international normalized ratio <1.7.", "question": "Treatment.Freq in intravenous tissue plasminogen activator", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "21350204_9_3984", "context": "Our cohort included 1739 patients with acute ischemic stroke treated with intravenous tissue plasminogen activator of whom 125 (7.2%) were receiving warfarin before admission and had an international normalized ratio <1.7.", "question": "Treatment.Route in intravenous tissue plasminogen activator", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": "intravenous"}, {"id": "21350204_9_3985", "context": "Our cohort included 1739 patients with acute ischemic stroke treated with intravenous tissue plasminogen activator of whom 125 (7.2%) were receiving warfarin before admission and had an international normalized ratio <1.7.", "question": "Treatment.Time_elapsed in intravenous tissue plasminogen activator", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "21350204_9_3986", "context": "Our cohort included 1739 patients with acute ischemic stroke treated with intravenous tissue plasminogen activator of whom 125 (7.2%) were receiving warfarin before admission and had an international normalized ratio <1.7.", "question": "Treatment.Duration in intravenous tissue plasminogen activator", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "21350204_9_3987", "context": "Our cohort included 1739 patients with acute ischemic stroke treated with intravenous tissue plasminogen activator of whom 125 (7.2%) were receiving warfarin before admission and had an international normalized ratio <1.7.", "question": "Treatment.Disorder in intravenous tissue plasminogen activator", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "21350204_9_3988", "context": "Our cohort included 1739 patients with acute ischemic stroke treated with intravenous tissue plasminogen activator of whom 125 (7.2%) were receiving warfarin before admission and had an international normalized ratio <1.7.", "question": "Combination.Drug in intravenous tissue plasminogen activator", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "21350204_9_3989", "context": "Our cohort included 1739 patients with acute ischemic stroke treated with intravenous tissue plasminogen activator of whom 125 (7.2%) were receiving warfarin before admission and had an international normalized ratio <1.7.", "question": "Subject.Age in 125 (7.2%)", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "21350204_9_3990", "context": "Our cohort included 1739 patients with acute ischemic stroke treated with intravenous tissue plasminogen activator of whom 125 (7.2%) were receiving warfarin before admission and had an international normalized ratio <1.7.", "question": "Subject.Gender in 125 (7.2%)", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "21350204_9_3991", "context": "Our cohort included 1739 patients with acute ischemic stroke treated with intravenous tissue plasminogen activator of whom 125 (7.2%) were receiving warfarin before admission and had an international normalized ratio <1.7.", "question": "Subject.Population in 125 (7.2%)", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "21350204_9_3992", "context": "Our cohort included 1739 patients with acute ischemic stroke treated with intravenous tissue plasminogen activator of whom 125 (7.2%) were receiving warfarin before admission and had an international normalized ratio <1.7.", "question": "Subject.Race in 125 (7.2%)", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "21350204_9_3993", "context": "Our cohort included 1739 patients with acute ischemic stroke treated with intravenous tissue plasminogen activator of whom 125 (7.2%) were receiving warfarin before admission and had an international normalized ratio <1.7.", "question": "Subject.Disorder in 125 (7.2%)", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "21350204_9_3994", "context": "Our cohort included 1739 patients with acute ischemic stroke treated with intravenous tissue plasminogen activator of whom 125 (7.2%) were receiving warfarin before admission and had an international normalized ratio <1.7.", "question": "Treatment.Drug in warfarin before admission", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "warfarin"}, {"id": "21350204_9_3995", "context": "Our cohort included 1739 patients with acute ischemic stroke treated with intravenous tissue plasminogen activator of whom 125 (7.2%) were receiving warfarin before admission and had an international normalized ratio <1.7.", "question": "Treatment.Dosage in warfarin before admission", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "21350204_9_3996", "context": "Our cohort included 1739 patients with acute ischemic stroke treated with intravenous tissue plasminogen activator of whom 125 (7.2%) were receiving warfarin before admission and had an international normalized ratio <1.7.", "question": "Treatment.Freq in warfarin before admission", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "21350204_9_3997", "context": "Our cohort included 1739 patients with acute ischemic stroke treated with intravenous tissue plasminogen activator of whom 125 (7.2%) were receiving warfarin before admission and had an international normalized ratio <1.7.", "question": "Treatment.Route in warfarin before admission", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "21350204_9_3998", "context": "Our cohort included 1739 patients with acute ischemic stroke treated with intravenous tissue plasminogen activator of whom 125 (7.2%) were receiving warfarin before admission and had an international normalized ratio <1.7.", "question": "Treatment.Time_elapsed in warfarin before admission", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "21350204_9_3999", "context": "Our cohort included 1739 patients with acute ischemic stroke treated with intravenous tissue plasminogen activator of whom 125 (7.2%) were receiving warfarin before admission and had an international normalized ratio <1.7.", "question": "Treatment.Duration in warfarin before admission", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "21350204_9_4000", "context": "Our cohort included 1739 patients with acute ischemic stroke treated with intravenous tissue plasminogen activator of whom 125 (7.2%) were receiving warfarin before admission and had an international normalized ratio <1.7.", "question": "Treatment.Disorder in warfarin before admission", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "acute ischemic stroke"}, {"id": "21350204_9_4001", "context": "Our cohort included 1739 patients with acute ischemic stroke treated with intravenous tissue plasminogen activator of whom 125 (7.2%) were receiving warfarin before admission and had an international normalized ratio <1.7.", "question": "Combination.Drug in warfarin before admission", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "7495990_1_4002", "context": "Used injudiciously, naloxone can lead to withdrawal syndrome, return of severe pain, and other adverse effects.", "question": "Treatment.Drug in Used injudiciously, naloxone", "question_type": "Adverse_event.Treatment.Drug", "answers": "naloxone"}, {"id": "7495990_1_4003", "context": "Used injudiciously, naloxone can lead to withdrawal syndrome, return of severe pain, and other adverse effects.", "question": "Treatment.Dosage in Used injudiciously, naloxone", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7495990_1_4004", "context": "Used injudiciously, naloxone can lead to withdrawal syndrome, return of severe pain, and other adverse effects.", "question": "Treatment.Freq in Used injudiciously, naloxone", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7495990_1_4005", "context": "Used injudiciously, naloxone can lead to withdrawal syndrome, return of severe pain, and other adverse effects.", "question": "Treatment.Route in Used injudiciously, naloxone", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7495990_1_4006", "context": "Used injudiciously, naloxone can lead to withdrawal syndrome, return of severe pain, and other adverse effects.", "question": "Treatment.Time_elapsed in Used injudiciously, naloxone", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7495990_1_4007", "context": "Used injudiciously, naloxone can lead to withdrawal syndrome, return of severe pain, and other adverse effects.", "question": "Treatment.Duration in Used injudiciously, naloxone", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7495990_1_4008", "context": "Used injudiciously, naloxone can lead to withdrawal syndrome, return of severe pain, and other adverse effects.", "question": "Treatment.Disorder in Used injudiciously, naloxone", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7495990_1_4009", "context": "Used injudiciously, naloxone can lead to withdrawal syndrome, return of severe pain, and other adverse effects.", "question": "Combination.Drug in Used injudiciously, naloxone", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8700794_3_4010", "context": "When vague symptoms develop during desmopressin therapy, hyponatremia must be considered as part of the differential diagnosis.", "question": "Treatment.Drug in desmopressin", "question_type": "Adverse_event.Treatment.Drug", "answers": "desmopressin"}, {"id": "8700794_3_4011", "context": "When vague symptoms develop during desmopressin therapy, hyponatremia must be considered as part of the differential diagnosis.", "question": "Treatment.Dosage in desmopressin", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8700794_3_4012", "context": "When vague symptoms develop during desmopressin therapy, hyponatremia must be considered as part of the differential diagnosis.", "question": "Treatment.Freq in desmopressin", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8700794_3_4013", "context": "When vague symptoms develop during desmopressin therapy, hyponatremia must be considered as part of the differential diagnosis.", "question": "Treatment.Route in desmopressin", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8700794_3_4014", "context": "When vague symptoms develop during desmopressin therapy, hyponatremia must be considered as part of the differential diagnosis.", "question": "Treatment.Time_elapsed in desmopressin", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8700794_3_4015", "context": "When vague symptoms develop during desmopressin therapy, hyponatremia must be considered as part of the differential diagnosis.", "question": "Treatment.Duration in desmopressin", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8700794_3_4016", "context": "When vague symptoms develop during desmopressin therapy, hyponatremia must be considered as part of the differential diagnosis.", "question": "Treatment.Disorder in desmopressin", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8700794_3_4017", "context": "When vague symptoms develop during desmopressin therapy, hyponatremia must be considered as part of the differential diagnosis.", "question": "Combination.Drug in desmopressin", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "2104570_4_4018", "context": "Intravesical chemotherapy may be associated with a risk of secondary malignancy.", "question": "Treatment.Drug in Intravesical chemotherapy", "question_type": "Adverse_event.Treatment.Drug", "answers": "chemotherapy"}, {"id": "2104570_4_4019", "context": "Intravesical chemotherapy may be associated with a risk of secondary malignancy.", "question": "Treatment.Dosage in Intravesical chemotherapy", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "2104570_4_4020", "context": "Intravesical chemotherapy may be associated with a risk of secondary malignancy.", "question": "Treatment.Freq in Intravesical chemotherapy", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2104570_4_4021", "context": "Intravesical chemotherapy may be associated with a risk of secondary malignancy.", "question": "Treatment.Route in Intravesical chemotherapy", "question_type": "Adverse_event.Treatment.Route", "answers": "Intravesical"}, {"id": "2104570_4_4022", "context": "Intravesical chemotherapy may be associated with a risk of secondary malignancy.", "question": "Treatment.Time_elapsed in Intravesical chemotherapy", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2104570_4_4023", "context": "Intravesical chemotherapy may be associated with a risk of secondary malignancy.", "question": "Treatment.Duration in Intravesical chemotherapy", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2104570_4_4024", "context": "Intravesical chemotherapy may be associated with a risk of secondary malignancy.", "question": "Treatment.Disorder in Intravesical chemotherapy", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "2104570_4_4025", "context": "Intravesical chemotherapy may be associated with a risk of secondary malignancy.", "question": "Combination.Drug in Intravesical chemotherapy", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17329303_9_4026", "context": "In all the cases described here, it is only with the discontinuation of methylphenidate that the adverse reactions resolved and readministration of methylphenidate in two patients did not produce any adverse effect after a drug-free interval.", "question": "Treatment.Drug in discontinuation of methylphenidate", "question_type": "Adverse_event.Treatment.Drug", "answers": "methylphenidate"}, {"id": "17329303_9_4027", "context": "In all the cases described here, it is only with the discontinuation of methylphenidate that the adverse reactions resolved and readministration of methylphenidate in two patients did not produce any adverse effect after a drug-free interval.", "question": "Treatment.Dosage in discontinuation of methylphenidate", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17329303_9_4028", "context": "In all the cases described here, it is only with the discontinuation of methylphenidate that the adverse reactions resolved and readministration of methylphenidate in two patients did not produce any adverse effect after a drug-free interval.", "question": "Treatment.Freq in discontinuation of methylphenidate", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17329303_9_4029", "context": "In all the cases described here, it is only with the discontinuation of methylphenidate that the adverse reactions resolved and readministration of methylphenidate in two patients did not produce any adverse effect after a drug-free interval.", "question": "Treatment.Route in discontinuation of methylphenidate", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17329303_9_4030", "context": "In all the cases described here, it is only with the discontinuation of methylphenidate that the adverse reactions resolved and readministration of methylphenidate in two patients did not produce any adverse effect after a drug-free interval.", "question": "Treatment.Time_elapsed in discontinuation of methylphenidate", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17329303_9_4031", "context": "In all the cases described here, it is only with the discontinuation of methylphenidate that the adverse reactions resolved and readministration of methylphenidate in two patients did not produce any adverse effect after a drug-free interval.", "question": "Treatment.Duration in discontinuation of methylphenidate", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17329303_9_4032", "context": "In all the cases described here, it is only with the discontinuation of methylphenidate that the adverse reactions resolved and readministration of methylphenidate in two patients did not produce any adverse effect after a drug-free interval.", "question": "Treatment.Disorder in discontinuation of methylphenidate", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17329303_9_4033", "context": "In all the cases described here, it is only with the discontinuation of methylphenidate that the adverse reactions resolved and readministration of methylphenidate in two patients did not produce any adverse effect after a drug-free interval.", "question": "Combination.Drug in discontinuation of methylphenidate", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17329303_9_4034", "context": "In all the cases described here, it is only with the discontinuation of methylphenidate that the adverse reactions resolved and readministration of methylphenidate in two patients did not produce any adverse effect after a drug-free interval.", "question": "Subject.Age in two patients", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "17329303_9_4035", "context": "In all the cases described here, it is only with the discontinuation of methylphenidate that the adverse reactions resolved and readministration of methylphenidate in two patients did not produce any adverse effect after a drug-free interval.", "question": "Subject.Gender in two patients", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "17329303_9_4036", "context": "In all the cases described here, it is only with the discontinuation of methylphenidate that the adverse reactions resolved and readministration of methylphenidate in two patients did not produce any adverse effect after a drug-free interval.", "question": "Subject.Population in two patients", "question_type": "Adverse_event.Subject.Population", "answers": "two"}, {"id": "17329303_9_4037", "context": "In all the cases described here, it is only with the discontinuation of methylphenidate that the adverse reactions resolved and readministration of methylphenidate in two patients did not produce any adverse effect after a drug-free interval.", "question": "Subject.Race in two patients", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "17329303_9_4038", "context": "In all the cases described here, it is only with the discontinuation of methylphenidate that the adverse reactions resolved and readministration of methylphenidate in two patients did not produce any adverse effect after a drug-free interval.", "question": "Subject.Disorder in two patients", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "17329303_9_4039", "context": "In all the cases described here, it is only with the discontinuation of methylphenidate that the adverse reactions resolved and readministration of methylphenidate in two patients did not produce any adverse effect after a drug-free interval.", "question": "Treatment.Drug in methylphenidate", "question_type": "Adverse_event.Treatment.Drug", "answers": "methylphenidate"}, {"id": "17329303_9_4040", "context": "In all the cases described here, it is only with the discontinuation of methylphenidate that the adverse reactions resolved and readministration of methylphenidate in two patients did not produce any adverse effect after a drug-free interval.", "question": "Treatment.Dosage in methylphenidate", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17329303_9_4041", "context": "In all the cases described here, it is only with the discontinuation of methylphenidate that the adverse reactions resolved and readministration of methylphenidate in two patients did not produce any adverse effect after a drug-free interval.", "question": "Treatment.Freq in methylphenidate", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17329303_9_4042", "context": "In all the cases described here, it is only with the discontinuation of methylphenidate that the adverse reactions resolved and readministration of methylphenidate in two patients did not produce any adverse effect after a drug-free interval.", "question": "Treatment.Route in methylphenidate", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17329303_9_4043", "context": "In all the cases described here, it is only with the discontinuation of methylphenidate that the adverse reactions resolved and readministration of methylphenidate in two patients did not produce any adverse effect after a drug-free interval.", "question": "Treatment.Time_elapsed in methylphenidate", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17329303_9_4044", "context": "In all the cases described here, it is only with the discontinuation of methylphenidate that the adverse reactions resolved and readministration of methylphenidate in two patients did not produce any adverse effect after a drug-free interval.", "question": "Treatment.Duration in methylphenidate", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17329303_9_4045", "context": "In all the cases described here, it is only with the discontinuation of methylphenidate that the adverse reactions resolved and readministration of methylphenidate in two patients did not produce any adverse effect after a drug-free interval.", "question": "Treatment.Disorder in methylphenidate", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17329303_9_4046", "context": "In all the cases described here, it is only with the discontinuation of methylphenidate that the adverse reactions resolved and readministration of methylphenidate in two patients did not produce any adverse effect after a drug-free interval.", "question": "Combination.Drug in methylphenidate", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "897744_3_4047", "context": "Discontinuation of methicillin therapy and appropriate antibiotic treatment of endocarditis led to clinical improvement, emphasizing the need to promptly discontinue potential nephrotoxic agents when abnormalities in renal function appear.", "question": "Treatment.Drug in methicillin", "question_type": "Adverse_event.Treatment.Drug", "answers": "methicillin; antibiotic; nephrotoxic agents"}, {"id": "897744_3_4048", "context": "Discontinuation of methicillin therapy and appropriate antibiotic treatment of endocarditis led to clinical improvement, emphasizing the need to promptly discontinue potential nephrotoxic agents when abnormalities in renal function appear.", "question": "Treatment.Dosage in methicillin", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "897744_3_4049", "context": "Discontinuation of methicillin therapy and appropriate antibiotic treatment of endocarditis led to clinical improvement, emphasizing the need to promptly discontinue potential nephrotoxic agents when abnormalities in renal function appear.", "question": "Treatment.Freq in methicillin", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "897744_3_4050", "context": "Discontinuation of methicillin therapy and appropriate antibiotic treatment of endocarditis led to clinical improvement, emphasizing the need to promptly discontinue potential nephrotoxic agents when abnormalities in renal function appear.", "question": "Treatment.Route in methicillin", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "897744_3_4051", "context": "Discontinuation of methicillin therapy and appropriate antibiotic treatment of endocarditis led to clinical improvement, emphasizing the need to promptly discontinue potential nephrotoxic agents when abnormalities in renal function appear.", "question": "Treatment.Time_elapsed in methicillin", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "897744_3_4052", "context": "Discontinuation of methicillin therapy and appropriate antibiotic treatment of endocarditis led to clinical improvement, emphasizing the need to promptly discontinue potential nephrotoxic agents when abnormalities in renal function appear.", "question": "Treatment.Duration in methicillin", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "897744_3_4053", "context": "Discontinuation of methicillin therapy and appropriate antibiotic treatment of endocarditis led to clinical improvement, emphasizing the need to promptly discontinue potential nephrotoxic agents when abnormalities in renal function appear.", "question": "Treatment.Disorder in methicillin", "question_type": "Adverse_event.Treatment.Disorder", "answers": "endocarditis"}, {"id": "897744_3_4054", "context": "Discontinuation of methicillin therapy and appropriate antibiotic treatment of endocarditis led to clinical improvement, emphasizing the need to promptly discontinue potential nephrotoxic agents when abnormalities in renal function appear.", "question": "Combination.Drug in methicillin", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8864370_2_4055", "context": "CONCLUSIONS: This study confirmed that in most patients MTX-induced liver cirrhosis is not aggressive.", "question": "Subject.Age in most patients", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "8864370_2_4056", "context": "CONCLUSIONS: This study confirmed that in most patients MTX-induced liver cirrhosis is not aggressive.", "question": "Subject.Gender in most patients", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "8864370_2_4057", "context": "CONCLUSIONS: This study confirmed that in most patients MTX-induced liver cirrhosis is not aggressive.", "question": "Subject.Population in most patients", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "8864370_2_4058", "context": "CONCLUSIONS: This study confirmed that in most patients MTX-induced liver cirrhosis is not aggressive.", "question": "Subject.Race in most patients", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "8864370_2_4059", "context": "CONCLUSIONS: This study confirmed that in most patients MTX-induced liver cirrhosis is not aggressive.", "question": "Subject.Disorder in most patients", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "8864370_2_4060", "context": "CONCLUSIONS: This study confirmed that in most patients MTX-induced liver cirrhosis is not aggressive.", "question": "Treatment.Drug in MTX", "question_type": "Adverse_event.Treatment.Drug", "answers": "MTX"}, {"id": "8864370_2_4061", "context": "CONCLUSIONS: This study confirmed that in most patients MTX-induced liver cirrhosis is not aggressive.", "question": "Treatment.Dosage in MTX", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8864370_2_4062", "context": "CONCLUSIONS: This study confirmed that in most patients MTX-induced liver cirrhosis is not aggressive.", "question": "Treatment.Freq in MTX", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8864370_2_4063", "context": "CONCLUSIONS: This study confirmed that in most patients MTX-induced liver cirrhosis is not aggressive.", "question": "Treatment.Route in MTX", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8864370_2_4064", "context": "CONCLUSIONS: This study confirmed that in most patients MTX-induced liver cirrhosis is not aggressive.", "question": "Treatment.Time_elapsed in MTX", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8864370_2_4065", "context": "CONCLUSIONS: This study confirmed that in most patients MTX-induced liver cirrhosis is not aggressive.", "question": "Treatment.Duration in MTX", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8864370_2_4066", "context": "CONCLUSIONS: This study confirmed that in most patients MTX-induced liver cirrhosis is not aggressive.", "question": "Treatment.Disorder in MTX", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8864370_2_4067", "context": "CONCLUSIONS: This study confirmed that in most patients MTX-induced liver cirrhosis is not aggressive.", "question": "Combination.Drug in MTX", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "24679099_4_4068", "context": "We report the case of severe liver toxicity with jaundice during radiochemotherapy with temozolomide likely due to interaction with a popular Chinese herbal formula after surgery for glioblastoma.", "question": "Treatment.Drug in temozolomide; a popular Chinese herbal formula", "question_type": "Adverse_event.Treatment.Drug", "answers": "temozolomide; Chinese herbal formula"}, {"id": "24679099_4_4069", "context": "We report the case of severe liver toxicity with jaundice during radiochemotherapy with temozolomide likely due to interaction with a popular Chinese herbal formula after surgery for glioblastoma.", "question": "Treatment.Dosage in temozolomide; a popular Chinese herbal formula", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "24679099_4_4070", "context": "We report the case of severe liver toxicity with jaundice during radiochemotherapy with temozolomide likely due to interaction with a popular Chinese herbal formula after surgery for glioblastoma.", "question": "Treatment.Freq in temozolomide; a popular Chinese herbal formula", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "24679099_4_4071", "context": "We report the case of severe liver toxicity with jaundice during radiochemotherapy with temozolomide likely due to interaction with a popular Chinese herbal formula after surgery for glioblastoma.", "question": "Treatment.Route in temozolomide; a popular Chinese herbal formula", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "24679099_4_4072", "context": "We report the case of severe liver toxicity with jaundice during radiochemotherapy with temozolomide likely due to interaction with a popular Chinese herbal formula after surgery for glioblastoma.", "question": "Treatment.Time_elapsed in temozolomide; a popular Chinese herbal formula", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "24679099_4_4073", "context": "We report the case of severe liver toxicity with jaundice during radiochemotherapy with temozolomide likely due to interaction with a popular Chinese herbal formula after surgery for glioblastoma.", "question": "Treatment.Duration in temozolomide; a popular Chinese herbal formula", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "24679099_4_4074", "context": "We report the case of severe liver toxicity with jaundice during radiochemotherapy with temozolomide likely due to interaction with a popular Chinese herbal formula after surgery for glioblastoma.", "question": "Treatment.Disorder in temozolomide; a popular Chinese herbal formula", "question_type": "Adverse_event.Treatment.Disorder", "answers": "glioblastoma"}, {"id": "24679099_4_4075", "context": "We report the case of severe liver toxicity with jaundice during radiochemotherapy with temozolomide likely due to interaction with a popular Chinese herbal formula after surgery for glioblastoma.", "question": "Combination.Drug in temozolomide; a popular Chinese herbal formula", "question_type": "Adverse_event.Combination.Drug", "answers": "temozolomide; Chinese herbal formula"}, {"id": "11978156_3_4076", "context": "He was started on oral lansoprazole 60 mg twice daily and, on hospital day 2, his platelet count decreased to 102 x 10(3)/mm(3); on hospital day 3, the platelet count was 36 x 10(3)/mm(3).", "question": "Subject.Age in He", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "11978156_3_4077", "context": "He was started on oral lansoprazole 60 mg twice daily and, on hospital day 2, his platelet count decreased to 102 x 10(3)/mm(3); on hospital day 3, the platelet count was 36 x 10(3)/mm(3).", "question": "Subject.Gender in He", "question_type": "Adverse_event.Subject.Gender", "answers": "He"}, {"id": "11978156_3_4078", "context": "He was started on oral lansoprazole 60 mg twice daily and, on hospital day 2, his platelet count decreased to 102 x 10(3)/mm(3); on hospital day 3, the platelet count was 36 x 10(3)/mm(3).", "question": "Subject.Population in He", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "11978156_3_4079", "context": "He was started on oral lansoprazole 60 mg twice daily and, on hospital day 2, his platelet count decreased to 102 x 10(3)/mm(3); on hospital day 3, the platelet count was 36 x 10(3)/mm(3).", "question": "Subject.Race in He", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "11978156_3_4080", "context": "He was started on oral lansoprazole 60 mg twice daily and, on hospital day 2, his platelet count decreased to 102 x 10(3)/mm(3); on hospital day 3, the platelet count was 36 x 10(3)/mm(3).", "question": "Subject.Disorder in He", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "11978156_3_4081", "context": "He was started on oral lansoprazole 60 mg twice daily and, on hospital day 2, his platelet count decreased to 102 x 10(3)/mm(3); on hospital day 3, the platelet count was 36 x 10(3)/mm(3).", "question": "Treatment.Drug in oral lansoprazole 60 mg twice daily", "question_type": "Adverse_event.Treatment.Drug", "answers": "lansoprazole"}, {"id": "11978156_3_4082", "context": "He was started on oral lansoprazole 60 mg twice daily and, on hospital day 2, his platelet count decreased to 102 x 10(3)/mm(3); on hospital day 3, the platelet count was 36 x 10(3)/mm(3).", "question": "Treatment.Dosage in oral lansoprazole 60 mg twice daily", "question_type": "Adverse_event.Treatment.Dosage", "answers": "60 mg"}, {"id": "11978156_3_4083", "context": "He was started on oral lansoprazole 60 mg twice daily and, on hospital day 2, his platelet count decreased to 102 x 10(3)/mm(3); on hospital day 3, the platelet count was 36 x 10(3)/mm(3).", "question": "Treatment.Freq in oral lansoprazole 60 mg twice daily", "question_type": "Adverse_event.Treatment.Freq", "answers": "twice daily"}, {"id": "11978156_3_4084", "context": "He was started on oral lansoprazole 60 mg twice daily and, on hospital day 2, his platelet count decreased to 102 x 10(3)/mm(3); on hospital day 3, the platelet count was 36 x 10(3)/mm(3).", "question": "Treatment.Route in oral lansoprazole 60 mg twice daily", "question_type": "Adverse_event.Treatment.Route", "answers": "oral"}, {"id": "11978156_3_4085", "context": "He was started on oral lansoprazole 60 mg twice daily and, on hospital day 2, his platelet count decreased to 102 x 10(3)/mm(3); on hospital day 3, the platelet count was 36 x 10(3)/mm(3).", "question": "Treatment.Time_elapsed in oral lansoprazole 60 mg twice daily", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11978156_3_4086", "context": "He was started on oral lansoprazole 60 mg twice daily and, on hospital day 2, his platelet count decreased to 102 x 10(3)/mm(3); on hospital day 3, the platelet count was 36 x 10(3)/mm(3).", "question": "Treatment.Duration in oral lansoprazole 60 mg twice daily", "question_type": "Adverse_event.Treatment.Duration", "answers": "day 2"}, {"id": "11978156_3_4087", "context": "He was started on oral lansoprazole 60 mg twice daily and, on hospital day 2, his platelet count decreased to 102 x 10(3)/mm(3); on hospital day 3, the platelet count was 36 x 10(3)/mm(3).", "question": "Treatment.Disorder in oral lansoprazole 60 mg twice daily", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11978156_3_4088", "context": "He was started on oral lansoprazole 60 mg twice daily and, on hospital day 2, his platelet count decreased to 102 x 10(3)/mm(3); on hospital day 3, the platelet count was 36 x 10(3)/mm(3).", "question": "Combination.Drug in oral lansoprazole 60 mg twice daily", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8207519_1_4089", "context": "She received an accidental 450-mg bolus injection of morphine intrathecally and developed hypertension, status epilepticus, intracerebral hemorrhage, and respiratory failure.", "question": "Subject.Age in She", "question_type": "Adverse_event.Subject.Age", "answers": "She"}, {"id": "8207519_1_4090", "context": "She received an accidental 450-mg bolus injection of morphine intrathecally and developed hypertension, status epilepticus, intracerebral hemorrhage, and respiratory failure.", "question": "Subject.Gender in She", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "8207519_1_4091", "context": "She received an accidental 450-mg bolus injection of morphine intrathecally and developed hypertension, status epilepticus, intracerebral hemorrhage, and respiratory failure.", "question": "Subject.Population in She", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "8207519_1_4092", "context": "She received an accidental 450-mg bolus injection of morphine intrathecally and developed hypertension, status epilepticus, intracerebral hemorrhage, and respiratory failure.", "question": "Subject.Race in She", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "8207519_1_4093", "context": "She received an accidental 450-mg bolus injection of morphine intrathecally and developed hypertension, status epilepticus, intracerebral hemorrhage, and respiratory failure.", "question": "Subject.Disorder in She", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "8207519_1_4094", "context": "She received an accidental 450-mg bolus injection of morphine intrathecally and developed hypertension, status epilepticus, intracerebral hemorrhage, and respiratory failure.", "question": "Treatment.Drug in 450-mg bolus injection of morphine", "question_type": "Adverse_event.Treatment.Drug", "answers": "morphine"}, {"id": "8207519_1_4095", "context": "She received an accidental 450-mg bolus injection of morphine intrathecally and developed hypertension, status epilepticus, intracerebral hemorrhage, and respiratory failure.", "question": "Treatment.Dosage in 450-mg bolus injection of morphine", "question_type": "Adverse_event.Treatment.Dosage", "answers": "450-mg"}, {"id": "8207519_1_4096", "context": "She received an accidental 450-mg bolus injection of morphine intrathecally and developed hypertension, status epilepticus, intracerebral hemorrhage, and respiratory failure.", "question": "Treatment.Freq in 450-mg bolus injection of morphine", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8207519_1_4097", "context": "She received an accidental 450-mg bolus injection of morphine intrathecally and developed hypertension, status epilepticus, intracerebral hemorrhage, and respiratory failure.", "question": "Treatment.Route in 450-mg bolus injection of morphine", "question_type": "Adverse_event.Treatment.Route", "answers": "bolus injection"}, {"id": "8207519_1_4098", "context": "She received an accidental 450-mg bolus injection of morphine intrathecally and developed hypertension, status epilepticus, intracerebral hemorrhage, and respiratory failure.", "question": "Treatment.Time_elapsed in 450-mg bolus injection of morphine", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8207519_1_4099", "context": "She received an accidental 450-mg bolus injection of morphine intrathecally and developed hypertension, status epilepticus, intracerebral hemorrhage, and respiratory failure.", "question": "Treatment.Duration in 450-mg bolus injection of morphine", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8207519_1_4100", "context": "She received an accidental 450-mg bolus injection of morphine intrathecally and developed hypertension, status epilepticus, intracerebral hemorrhage, and respiratory failure.", "question": "Treatment.Disorder in 450-mg bolus injection of morphine", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8207519_1_4101", "context": "She received an accidental 450-mg bolus injection of morphine intrathecally and developed hypertension, status epilepticus, intracerebral hemorrhage, and respiratory failure.", "question": "Combination.Drug in 450-mg bolus injection of morphine", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "2357706_4_4102", "context": "We describe six patients who developed tardive dyskinesia after treatment with sulpiride for depression or gastrointestinal symptoms.", "question": "Subject.Age in six patients", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "2357706_4_4103", "context": "We describe six patients who developed tardive dyskinesia after treatment with sulpiride for depression or gastrointestinal symptoms.", "question": "Subject.Gender in six patients", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "2357706_4_4104", "context": "We describe six patients who developed tardive dyskinesia after treatment with sulpiride for depression or gastrointestinal symptoms.", "question": "Subject.Population in six patients", "question_type": "Adverse_event.Subject.Population", "answers": "six"}, {"id": "2357706_4_4105", "context": "We describe six patients who developed tardive dyskinesia after treatment with sulpiride for depression or gastrointestinal symptoms.", "question": "Subject.Race in six patients", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "2357706_4_4106", "context": "We describe six patients who developed tardive dyskinesia after treatment with sulpiride for depression or gastrointestinal symptoms.", "question": "Subject.Disorder in six patients", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "2357706_4_4107", "context": "We describe six patients who developed tardive dyskinesia after treatment with sulpiride for depression or gastrointestinal symptoms.", "question": "Treatment.Drug in sulpiride", "question_type": "Adverse_event.Treatment.Drug", "answers": "sulpiride"}, {"id": "2357706_4_4108", "context": "We describe six patients who developed tardive dyskinesia after treatment with sulpiride for depression or gastrointestinal symptoms.", "question": "Treatment.Dosage in sulpiride", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "2357706_4_4109", "context": "We describe six patients who developed tardive dyskinesia after treatment with sulpiride for depression or gastrointestinal symptoms.", "question": "Treatment.Freq in sulpiride", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2357706_4_4110", "context": "We describe six patients who developed tardive dyskinesia after treatment with sulpiride for depression or gastrointestinal symptoms.", "question": "Treatment.Route in sulpiride", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "2357706_4_4111", "context": "We describe six patients who developed tardive dyskinesia after treatment with sulpiride for depression or gastrointestinal symptoms.", "question": "Treatment.Time_elapsed in sulpiride", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2357706_4_4112", "context": "We describe six patients who developed tardive dyskinesia after treatment with sulpiride for depression or gastrointestinal symptoms.", "question": "Treatment.Duration in sulpiride", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2357706_4_4113", "context": "We describe six patients who developed tardive dyskinesia after treatment with sulpiride for depression or gastrointestinal symptoms.", "question": "Treatment.Disorder in sulpiride", "question_type": "Adverse_event.Treatment.Disorder", "answers": "depression; gastrointestinal symptoms"}, {"id": "2357706_4_4114", "context": "We describe six patients who developed tardive dyskinesia after treatment with sulpiride for depression or gastrointestinal symptoms.", "question": "Combination.Drug in sulpiride", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15827071_4_4115", "context": "A 38-year-old white female with cystic fibrosis treated with venlafaxine 300 mg/day for one year was prescribed linezolid 600 mg intravenously every 12 hours for treatment of methicillin-resistant Staphylococcus aureus (MRSA) pulmonary infection.", "question": "Subject.Age in A 38-year-old white female", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": "38-year-old"}, {"id": "15827071_4_4116", "context": "A 38-year-old white female with cystic fibrosis treated with venlafaxine 300 mg/day for one year was prescribed linezolid 600 mg intravenously every 12 hours for treatment of methicillin-resistant Staphylococcus aureus (MRSA) pulmonary infection.", "question": "Subject.Gender in A 38-year-old white female", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": "female"}, {"id": "15827071_4_4117", "context": "A 38-year-old white female with cystic fibrosis treated with venlafaxine 300 mg/day for one year was prescribed linezolid 600 mg intravenously every 12 hours for treatment of methicillin-resistant Staphylococcus aureus (MRSA) pulmonary infection.", "question": "Subject.Population in A 38-year-old white female", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "15827071_4_4118", "context": "A 38-year-old white female with cystic fibrosis treated with venlafaxine 300 mg/day for one year was prescribed linezolid 600 mg intravenously every 12 hours for treatment of methicillin-resistant Staphylococcus aureus (MRSA) pulmonary infection.", "question": "Subject.Race in A 38-year-old white female", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": "white"}, {"id": "15827071_4_4119", "context": "A 38-year-old white female with cystic fibrosis treated with venlafaxine 300 mg/day for one year was prescribed linezolid 600 mg intravenously every 12 hours for treatment of methicillin-resistant Staphylococcus aureus (MRSA) pulmonary infection.", "question": "Subject.Disorder in A 38-year-old white female", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "15827071_4_4120", "context": "A 38-year-old white female with cystic fibrosis treated with venlafaxine 300 mg/day for one year was prescribed linezolid 600 mg intravenously every 12 hours for treatment of methicillin-resistant Staphylococcus aureus (MRSA) pulmonary infection.", "question": "Treatment.Drug in venlafaxine 300 mg/day for one year", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "venlafaxine"}, {"id": "15827071_4_4121", "context": "A 38-year-old white female with cystic fibrosis treated with venlafaxine 300 mg/day for one year was prescribed linezolid 600 mg intravenously every 12 hours for treatment of methicillin-resistant Staphylococcus aureus (MRSA) pulmonary infection.", "question": "Treatment.Dosage in venlafaxine 300 mg/day for one year", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": "300 mg/day"}, {"id": "15827071_4_4122", "context": "A 38-year-old white female with cystic fibrosis treated with venlafaxine 300 mg/day for one year was prescribed linezolid 600 mg intravenously every 12 hours for treatment of methicillin-resistant Staphylococcus aureus (MRSA) pulmonary infection.", "question": "Treatment.Freq in venlafaxine 300 mg/day for one year", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "15827071_4_4123", "context": "A 38-year-old white female with cystic fibrosis treated with venlafaxine 300 mg/day for one year was prescribed linezolid 600 mg intravenously every 12 hours for treatment of methicillin-resistant Staphylococcus aureus (MRSA) pulmonary infection.", "question": "Treatment.Route in venlafaxine 300 mg/day for one year", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "15827071_4_4124", "context": "A 38-year-old white female with cystic fibrosis treated with venlafaxine 300 mg/day for one year was prescribed linezolid 600 mg intravenously every 12 hours for treatment of methicillin-resistant Staphylococcus aureus (MRSA) pulmonary infection.", "question": "Treatment.Time_elapsed in venlafaxine 300 mg/day for one year", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15827071_4_4125", "context": "A 38-year-old white female with cystic fibrosis treated with venlafaxine 300 mg/day for one year was prescribed linezolid 600 mg intravenously every 12 hours for treatment of methicillin-resistant Staphylococcus aureus (MRSA) pulmonary infection.", "question": "Treatment.Duration in venlafaxine 300 mg/day for one year", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": "one year"}, {"id": "15827071_4_4126", "context": "A 38-year-old white female with cystic fibrosis treated with venlafaxine 300 mg/day for one year was prescribed linezolid 600 mg intravenously every 12 hours for treatment of methicillin-resistant Staphylococcus aureus (MRSA) pulmonary infection.", "question": "Treatment.Disorder in venlafaxine 300 mg/day for one year", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "cystic fibrosis"}, {"id": "15827071_4_4127", "context": "A 38-year-old white female with cystic fibrosis treated with venlafaxine 300 mg/day for one year was prescribed linezolid 600 mg intravenously every 12 hours for treatment of methicillin-resistant Staphylococcus aureus (MRSA) pulmonary infection.", "question": "Combination.Drug in venlafaxine 300 mg/day for one year", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "15827071_4_4128", "context": "A 38-year-old white female with cystic fibrosis treated with venlafaxine 300 mg/day for one year was prescribed linezolid 600 mg intravenously every 12 hours for treatment of methicillin-resistant Staphylococcus aureus (MRSA) pulmonary infection.", "question": "Subject.Age in A 38-year-old white female", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": "38-year-old"}, {"id": "15827071_4_4129", "context": "A 38-year-old white female with cystic fibrosis treated with venlafaxine 300 mg/day for one year was prescribed linezolid 600 mg intravenously every 12 hours for treatment of methicillin-resistant Staphylococcus aureus (MRSA) pulmonary infection.", "question": "Subject.Gender in A 38-year-old white female", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": "female"}, {"id": "15827071_4_4130", "context": "A 38-year-old white female with cystic fibrosis treated with venlafaxine 300 mg/day for one year was prescribed linezolid 600 mg intravenously every 12 hours for treatment of methicillin-resistant Staphylococcus aureus (MRSA) pulmonary infection.", "question": "Subject.Population in A 38-year-old white female", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "15827071_4_4131", "context": "A 38-year-old white female with cystic fibrosis treated with venlafaxine 300 mg/day for one year was prescribed linezolid 600 mg intravenously every 12 hours for treatment of methicillin-resistant Staphylococcus aureus (MRSA) pulmonary infection.", "question": "Subject.Race in A 38-year-old white female", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": "white"}, {"id": "15827071_4_4132", "context": "A 38-year-old white female with cystic fibrosis treated with venlafaxine 300 mg/day for one year was prescribed linezolid 600 mg intravenously every 12 hours for treatment of methicillin-resistant Staphylococcus aureus (MRSA) pulmonary infection.", "question": "Subject.Disorder in A 38-year-old white female", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "15827071_4_4133", "context": "A 38-year-old white female with cystic fibrosis treated with venlafaxine 300 mg/day for one year was prescribed linezolid 600 mg intravenously every 12 hours for treatment of methicillin-resistant Staphylococcus aureus (MRSA) pulmonary infection.", "question": "Treatment.Drug in linezolid 600 mg intravenously every 12 hours", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "linezolid"}, {"id": "15827071_4_4134", "context": "A 38-year-old white female with cystic fibrosis treated with venlafaxine 300 mg/day for one year was prescribed linezolid 600 mg intravenously every 12 hours for treatment of methicillin-resistant Staphylococcus aureus (MRSA) pulmonary infection.", "question": "Treatment.Dosage in linezolid 600 mg intravenously every 12 hours", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": "600 mg"}, {"id": "15827071_4_4135", "context": "A 38-year-old white female with cystic fibrosis treated with venlafaxine 300 mg/day for one year was prescribed linezolid 600 mg intravenously every 12 hours for treatment of methicillin-resistant Staphylococcus aureus (MRSA) pulmonary infection.", "question": "Treatment.Freq in linezolid 600 mg intravenously every 12 hours", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": "every 12 hours"}, {"id": "15827071_4_4136", "context": "A 38-year-old white female with cystic fibrosis treated with venlafaxine 300 mg/day for one year was prescribed linezolid 600 mg intravenously every 12 hours for treatment of methicillin-resistant Staphylococcus aureus (MRSA) pulmonary infection.", "question": "Treatment.Route in linezolid 600 mg intravenously every 12 hours", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": "intravenously"}, {"id": "15827071_4_4137", "context": "A 38-year-old white female with cystic fibrosis treated with venlafaxine 300 mg/day for one year was prescribed linezolid 600 mg intravenously every 12 hours for treatment of methicillin-resistant Staphylococcus aureus (MRSA) pulmonary infection.", "question": "Treatment.Time_elapsed in linezolid 600 mg intravenously every 12 hours", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15827071_4_4138", "context": "A 38-year-old white female with cystic fibrosis treated with venlafaxine 300 mg/day for one year was prescribed linezolid 600 mg intravenously every 12 hours for treatment of methicillin-resistant Staphylococcus aureus (MRSA) pulmonary infection.", "question": "Treatment.Duration in linezolid 600 mg intravenously every 12 hours", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "15827071_4_4139", "context": "A 38-year-old white female with cystic fibrosis treated with venlafaxine 300 mg/day for one year was prescribed linezolid 600 mg intravenously every 12 hours for treatment of methicillin-resistant Staphylococcus aureus (MRSA) pulmonary infection.", "question": "Treatment.Disorder in linezolid 600 mg intravenously every 12 hours", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "methicillin-resistant Staphylococcus aureus (MRSA) pulmonary infection"}, {"id": "15827071_4_4140", "context": "A 38-year-old white female with cystic fibrosis treated with venlafaxine 300 mg/day for one year was prescribed linezolid 600 mg intravenously every 12 hours for treatment of methicillin-resistant Staphylococcus aureus (MRSA) pulmonary infection.", "question": "Combination.Drug in linezolid 600 mg intravenously every 12 hours", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "7448830_1_4141", "context": "Hepatotoxicity of hycanthone in patients with metastatic breast cancer.", "question": "Subject.Age in patients with metastatic breast cancer", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "7448830_1_4142", "context": "Hepatotoxicity of hycanthone in patients with metastatic breast cancer.", "question": "Subject.Gender in patients with metastatic breast cancer", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "7448830_1_4143", "context": "Hepatotoxicity of hycanthone in patients with metastatic breast cancer.", "question": "Subject.Population in patients with metastatic breast cancer", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "7448830_1_4144", "context": "Hepatotoxicity of hycanthone in patients with metastatic breast cancer.", "question": "Subject.Race in patients with metastatic breast cancer", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "7448830_1_4145", "context": "Hepatotoxicity of hycanthone in patients with metastatic breast cancer.", "question": "Subject.Disorder in patients with metastatic breast cancer", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "7448830_1_4146", "context": "Hepatotoxicity of hycanthone in patients with metastatic breast cancer.", "question": "Treatment.Drug in hycanthone", "question_type": "Adverse_event.Treatment.Drug", "answers": "hycanthone"}, {"id": "7448830_1_4147", "context": "Hepatotoxicity of hycanthone in patients with metastatic breast cancer.", "question": "Treatment.Dosage in hycanthone", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7448830_1_4148", "context": "Hepatotoxicity of hycanthone in patients with metastatic breast cancer.", "question": "Treatment.Freq in hycanthone", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7448830_1_4149", "context": "Hepatotoxicity of hycanthone in patients with metastatic breast cancer.", "question": "Treatment.Route in hycanthone", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7448830_1_4150", "context": "Hepatotoxicity of hycanthone in patients with metastatic breast cancer.", "question": "Treatment.Time_elapsed in hycanthone", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7448830_1_4151", "context": "Hepatotoxicity of hycanthone in patients with metastatic breast cancer.", "question": "Treatment.Duration in hycanthone", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7448830_1_4152", "context": "Hepatotoxicity of hycanthone in patients with metastatic breast cancer.", "question": "Treatment.Disorder in hycanthone", "question_type": "Adverse_event.Treatment.Disorder", "answers": "metastatic breast cancer"}, {"id": "7448830_1_4153", "context": "Hepatotoxicity of hycanthone in patients with metastatic breast cancer.", "question": "Combination.Drug in hycanthone", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16237130_2_4154", "context": "The authors report five additional cases of capecitabine-induced multifocal leukoencephalopathy.", "question": "Treatment.Drug in capecitabine", "question_type": "Adverse_event.Treatment.Drug", "answers": "capecitabine"}, {"id": "16237130_2_4155", "context": "The authors report five additional cases of capecitabine-induced multifocal leukoencephalopathy.", "question": "Treatment.Dosage in capecitabine", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16237130_2_4156", "context": "The authors report five additional cases of capecitabine-induced multifocal leukoencephalopathy.", "question": "Treatment.Freq in capecitabine", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16237130_2_4157", "context": "The authors report five additional cases of capecitabine-induced multifocal leukoencephalopathy.", "question": "Treatment.Route in capecitabine", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16237130_2_4158", "context": "The authors report five additional cases of capecitabine-induced multifocal leukoencephalopathy.", "question": "Treatment.Time_elapsed in capecitabine", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16237130_2_4159", "context": "The authors report five additional cases of capecitabine-induced multifocal leukoencephalopathy.", "question": "Treatment.Duration in capecitabine", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16237130_2_4160", "context": "The authors report five additional cases of capecitabine-induced multifocal leukoencephalopathy.", "question": "Treatment.Disorder in capecitabine", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16237130_2_4161", "context": "The authors report five additional cases of capecitabine-induced multifocal leukoencephalopathy.", "question": "Combination.Drug in capecitabine", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7545251_1_4162", "context": "Chlormadinone acetate withdrawal syndrome under combined androgen blockade for advanced prostate cancer.", "question": "Treatment.Drug in Chlormadinone acetate; androgen blockade", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "Chlormadinone acetate; androgen blockade"}, {"id": "7545251_1_4163", "context": "Chlormadinone acetate withdrawal syndrome under combined androgen blockade for advanced prostate cancer.", "question": "Treatment.Dosage in Chlormadinone acetate; androgen blockade", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "7545251_1_4164", "context": "Chlormadinone acetate withdrawal syndrome under combined androgen blockade for advanced prostate cancer.", "question": "Treatment.Freq in Chlormadinone acetate; androgen blockade", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "7545251_1_4165", "context": "Chlormadinone acetate withdrawal syndrome under combined androgen blockade for advanced prostate cancer.", "question": "Treatment.Route in Chlormadinone acetate; androgen blockade", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "7545251_1_4166", "context": "Chlormadinone acetate withdrawal syndrome under combined androgen blockade for advanced prostate cancer.", "question": "Treatment.Time_elapsed in Chlormadinone acetate; androgen blockade", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7545251_1_4167", "context": "Chlormadinone acetate withdrawal syndrome under combined androgen blockade for advanced prostate cancer.", "question": "Treatment.Duration in Chlormadinone acetate; androgen blockade", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "7545251_1_4168", "context": "Chlormadinone acetate withdrawal syndrome under combined androgen blockade for advanced prostate cancer.", "question": "Treatment.Disorder in Chlormadinone acetate; androgen blockade", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "advanced prostate cancer"}, {"id": "7545251_1_4169", "context": "Chlormadinone acetate withdrawal syndrome under combined androgen blockade for advanced prostate cancer.", "question": "Combination.Drug in Chlormadinone acetate; androgen blockade", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": "androgen blockade; Chlormadinone acetate"}, {"id": "18562412_2_4170", "context": "Restless legs syndrome and periodic limb movements during sleep probably associated with olanzapine.", "question": "Treatment.Drug in olanzapine", "question_type": "Adverse_event.Treatment.Drug", "answers": "olanzapine"}, {"id": "18562412_2_4171", "context": "Restless legs syndrome and periodic limb movements during sleep probably associated with olanzapine.", "question": "Treatment.Dosage in olanzapine", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18562412_2_4172", "context": "Restless legs syndrome and periodic limb movements during sleep probably associated with olanzapine.", "question": "Treatment.Freq in olanzapine", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18562412_2_4173", "context": "Restless legs syndrome and periodic limb movements during sleep probably associated with olanzapine.", "question": "Treatment.Route in olanzapine", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18562412_2_4174", "context": "Restless legs syndrome and periodic limb movements during sleep probably associated with olanzapine.", "question": "Treatment.Time_elapsed in olanzapine", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18562412_2_4175", "context": "Restless legs syndrome and periodic limb movements during sleep probably associated with olanzapine.", "question": "Treatment.Duration in olanzapine", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18562412_2_4176", "context": "Restless legs syndrome and periodic limb movements during sleep probably associated with olanzapine.", "question": "Treatment.Disorder in olanzapine", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18562412_2_4177", "context": "Restless legs syndrome and periodic limb movements during sleep probably associated with olanzapine.", "question": "Combination.Drug in olanzapine", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8329789_8_4178", "context": "Evaluation of the literature provides substantial evidence for the use of hydrocortisone in prevention of cardiac arrhythmias.", "question": "Treatment.Drug in hydrocortisone", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "hydrocortisone"}, {"id": "8329789_8_4179", "context": "Evaluation of the literature provides substantial evidence for the use of hydrocortisone in prevention of cardiac arrhythmias.", "question": "Treatment.Dosage in hydrocortisone", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "8329789_8_4180", "context": "Evaluation of the literature provides substantial evidence for the use of hydrocortisone in prevention of cardiac arrhythmias.", "question": "Treatment.Freq in hydrocortisone", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "8329789_8_4181", "context": "Evaluation of the literature provides substantial evidence for the use of hydrocortisone in prevention of cardiac arrhythmias.", "question": "Treatment.Route in hydrocortisone", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "8329789_8_4182", "context": "Evaluation of the literature provides substantial evidence for the use of hydrocortisone in prevention of cardiac arrhythmias.", "question": "Treatment.Time_elapsed in hydrocortisone", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8329789_8_4183", "context": "Evaluation of the literature provides substantial evidence for the use of hydrocortisone in prevention of cardiac arrhythmias.", "question": "Treatment.Duration in hydrocortisone", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "8329789_8_4184", "context": "Evaluation of the literature provides substantial evidence for the use of hydrocortisone in prevention of cardiac arrhythmias.", "question": "Treatment.Disorder in hydrocortisone", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "cardiac arrhythmias"}, {"id": "8329789_8_4185", "context": "Evaluation of the literature provides substantial evidence for the use of hydrocortisone in prevention of cardiac arrhythmias.", "question": "Combination.Drug in hydrocortisone", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "14530108_6_4186", "context": "We report a case of RTA secondary to FK506 administration in liver transplantation.", "question": "Subject.Age in a case of RTA", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "14530108_6_4187", "context": "We report a case of RTA secondary to FK506 administration in liver transplantation.", "question": "Subject.Gender in a case of RTA", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "14530108_6_4188", "context": "We report a case of RTA secondary to FK506 administration in liver transplantation.", "question": "Subject.Population in a case of RTA", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "14530108_6_4189", "context": "We report a case of RTA secondary to FK506 administration in liver transplantation.", "question": "Subject.Race in a case of RTA", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "14530108_6_4190", "context": "We report a case of RTA secondary to FK506 administration in liver transplantation.", "question": "Subject.Disorder in a case of RTA", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "14530108_6_4191", "context": "We report a case of RTA secondary to FK506 administration in liver transplantation.", "question": "Treatment.Drug in FK506 administration in liver transplantation", "question_type": "Adverse_event.Treatment.Drug", "answers": "FK506"}, {"id": "14530108_6_4192", "context": "We report a case of RTA secondary to FK506 administration in liver transplantation.", "question": "Treatment.Dosage in FK506 administration in liver transplantation", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "14530108_6_4193", "context": "We report a case of RTA secondary to FK506 administration in liver transplantation.", "question": "Treatment.Freq in FK506 administration in liver transplantation", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "14530108_6_4194", "context": "We report a case of RTA secondary to FK506 administration in liver transplantation.", "question": "Treatment.Route in FK506 administration in liver transplantation", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "14530108_6_4195", "context": "We report a case of RTA secondary to FK506 administration in liver transplantation.", "question": "Treatment.Time_elapsed in FK506 administration in liver transplantation", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "14530108_6_4196", "context": "We report a case of RTA secondary to FK506 administration in liver transplantation.", "question": "Treatment.Duration in FK506 administration in liver transplantation", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "14530108_6_4197", "context": "We report a case of RTA secondary to FK506 administration in liver transplantation.", "question": "Treatment.Disorder in FK506 administration in liver transplantation", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "14530108_6_4198", "context": "We report a case of RTA secondary to FK506 administration in liver transplantation.", "question": "Combination.Drug in FK506 administration in liver transplantation", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17959575_1_4199", "context": "Myoclonus associated with continuous dobutamine infusion in a patient with end-stage renal disease.", "question": "Subject.Age in a patient with end-stage renal disease", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "17959575_1_4200", "context": "Myoclonus associated with continuous dobutamine infusion in a patient with end-stage renal disease.", "question": "Subject.Gender in a patient with end-stage renal disease", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "17959575_1_4201", "context": "Myoclonus associated with continuous dobutamine infusion in a patient with end-stage renal disease.", "question": "Subject.Population in a patient with end-stage renal disease", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "17959575_1_4202", "context": "Myoclonus associated with continuous dobutamine infusion in a patient with end-stage renal disease.", "question": "Subject.Race in a patient with end-stage renal disease", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "17959575_1_4203", "context": "Myoclonus associated with continuous dobutamine infusion in a patient with end-stage renal disease.", "question": "Subject.Disorder in a patient with end-stage renal disease", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "17959575_1_4204", "context": "Myoclonus associated with continuous dobutamine infusion in a patient with end-stage renal disease.", "question": "Treatment.Drug in continuous dobutamine infusion", "question_type": "Adverse_event.Treatment.Drug", "answers": "dobutamine"}, {"id": "17959575_1_4205", "context": "Myoclonus associated with continuous dobutamine infusion in a patient with end-stage renal disease.", "question": "Treatment.Dosage in continuous dobutamine infusion", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17959575_1_4206", "context": "Myoclonus associated with continuous dobutamine infusion in a patient with end-stage renal disease.", "question": "Treatment.Freq in continuous dobutamine infusion", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17959575_1_4207", "context": "Myoclonus associated with continuous dobutamine infusion in a patient with end-stage renal disease.", "question": "Treatment.Route in continuous dobutamine infusion", "question_type": "Adverse_event.Treatment.Route", "answers": "infusion"}, {"id": "17959575_1_4208", "context": "Myoclonus associated with continuous dobutamine infusion in a patient with end-stage renal disease.", "question": "Treatment.Time_elapsed in continuous dobutamine infusion", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17959575_1_4209", "context": "Myoclonus associated with continuous dobutamine infusion in a patient with end-stage renal disease.", "question": "Treatment.Duration in continuous dobutamine infusion", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17959575_1_4210", "context": "Myoclonus associated with continuous dobutamine infusion in a patient with end-stage renal disease.", "question": "Treatment.Disorder in continuous dobutamine infusion", "question_type": "Adverse_event.Treatment.Disorder", "answers": "end-stage renal disease"}, {"id": "17959575_1_4211", "context": "Myoclonus associated with continuous dobutamine infusion in a patient with end-stage renal disease.", "question": "Combination.Drug in continuous dobutamine infusion", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6614033_2_4212", "context": "Amphotericin B nephrotoxicity in humans decreased by salt repletion.", "question": "Subject.Age in humans", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "6614033_2_4213", "context": "Amphotericin B nephrotoxicity in humans decreased by salt repletion.", "question": "Subject.Gender in humans", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "6614033_2_4214", "context": "Amphotericin B nephrotoxicity in humans decreased by salt repletion.", "question": "Subject.Population in humans", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "6614033_2_4215", "context": "Amphotericin B nephrotoxicity in humans decreased by salt repletion.", "question": "Subject.Race in humans", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "6614033_2_4216", "context": "Amphotericin B nephrotoxicity in humans decreased by salt repletion.", "question": "Subject.Disorder in humans", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "6614033_2_4217", "context": "Amphotericin B nephrotoxicity in humans decreased by salt repletion.", "question": "Treatment.Drug in salt repletion", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "salt"}, {"id": "6614033_2_4218", "context": "Amphotericin B nephrotoxicity in humans decreased by salt repletion.", "question": "Treatment.Dosage in salt repletion", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "6614033_2_4219", "context": "Amphotericin B nephrotoxicity in humans decreased by salt repletion.", "question": "Treatment.Freq in salt repletion", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "6614033_2_4220", "context": "Amphotericin B nephrotoxicity in humans decreased by salt repletion.", "question": "Treatment.Route in salt repletion", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "6614033_2_4221", "context": "Amphotericin B nephrotoxicity in humans decreased by salt repletion.", "question": "Treatment.Time_elapsed in salt repletion", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6614033_2_4222", "context": "Amphotericin B nephrotoxicity in humans decreased by salt repletion.", "question": "Treatment.Duration in salt repletion", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "6614033_2_4223", "context": "Amphotericin B nephrotoxicity in humans decreased by salt repletion.", "question": "Treatment.Disorder in salt repletion", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "6614033_2_4224", "context": "Amphotericin B nephrotoxicity in humans decreased by salt repletion.", "question": "Combination.Drug in salt repletion", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "8638872_2_4225", "context": "Only a few reports of overt jaundice are associated with streptokinase.", "question": "Treatment.Drug in streptokinase", "question_type": "Adverse_event.Treatment.Drug", "answers": "streptokinase"}, {"id": "8638872_2_4226", "context": "Only a few reports of overt jaundice are associated with streptokinase.", "question": "Treatment.Dosage in streptokinase", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8638872_2_4227", "context": "Only a few reports of overt jaundice are associated with streptokinase.", "question": "Treatment.Freq in streptokinase", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8638872_2_4228", "context": "Only a few reports of overt jaundice are associated with streptokinase.", "question": "Treatment.Route in streptokinase", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8638872_2_4229", "context": "Only a few reports of overt jaundice are associated with streptokinase.", "question": "Treatment.Time_elapsed in streptokinase", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8638872_2_4230", "context": "Only a few reports of overt jaundice are associated with streptokinase.", "question": "Treatment.Duration in streptokinase", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8638872_2_4231", "context": "Only a few reports of overt jaundice are associated with streptokinase.", "question": "Treatment.Disorder in streptokinase", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8638872_2_4232", "context": "Only a few reports of overt jaundice are associated with streptokinase.", "question": "Combination.Drug in streptokinase", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12885108_1_4233", "context": "Possible heart failure exacerbation associated with rosiglitazone: case report and literature review.", "question": "Treatment.Drug in rosiglitazone", "question_type": "Adverse_event.Treatment.Drug", "answers": "rosiglitazone"}, {"id": "12885108_1_4234", "context": "Possible heart failure exacerbation associated with rosiglitazone: case report and literature review.", "question": "Treatment.Dosage in rosiglitazone", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12885108_1_4235", "context": "Possible heart failure exacerbation associated with rosiglitazone: case report and literature review.", "question": "Treatment.Freq in rosiglitazone", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12885108_1_4236", "context": "Possible heart failure exacerbation associated with rosiglitazone: case report and literature review.", "question": "Treatment.Route in rosiglitazone", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12885108_1_4237", "context": "Possible heart failure exacerbation associated with rosiglitazone: case report and literature review.", "question": "Treatment.Time_elapsed in rosiglitazone", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12885108_1_4238", "context": "Possible heart failure exacerbation associated with rosiglitazone: case report and literature review.", "question": "Treatment.Duration in rosiglitazone", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12885108_1_4239", "context": "Possible heart failure exacerbation associated with rosiglitazone: case report and literature review.", "question": "Treatment.Disorder in rosiglitazone", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12885108_1_4240", "context": "Possible heart failure exacerbation associated with rosiglitazone: case report and literature review.", "question": "Combination.Drug in rosiglitazone", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11388112_2_4241", "context": "We report the first case of polymorphic ventricular tachycardia with normal QT interval associated with the oral use of levofloxacin in the absence of other etiologies known to cause these arrhythmias.", "question": "Subject.Age in the first case", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "11388112_2_4242", "context": "We report the first case of polymorphic ventricular tachycardia with normal QT interval associated with the oral use of levofloxacin in the absence of other etiologies known to cause these arrhythmias.", "question": "Subject.Gender in the first case", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "11388112_2_4243", "context": "We report the first case of polymorphic ventricular tachycardia with normal QT interval associated with the oral use of levofloxacin in the absence of other etiologies known to cause these arrhythmias.", "question": "Subject.Population in the first case", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "11388112_2_4244", "context": "We report the first case of polymorphic ventricular tachycardia with normal QT interval associated with the oral use of levofloxacin in the absence of other etiologies known to cause these arrhythmias.", "question": "Subject.Race in the first case", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "11388112_2_4245", "context": "We report the first case of polymorphic ventricular tachycardia with normal QT interval associated with the oral use of levofloxacin in the absence of other etiologies known to cause these arrhythmias.", "question": "Subject.Disorder in the first case", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "11388112_2_4246", "context": "We report the first case of polymorphic ventricular tachycardia with normal QT interval associated with the oral use of levofloxacin in the absence of other etiologies known to cause these arrhythmias.", "question": "Treatment.Drug in oral use of levofloxacin", "question_type": "Adverse_event.Treatment.Drug", "answers": "evofloxacin"}, {"id": "11388112_2_4247", "context": "We report the first case of polymorphic ventricular tachycardia with normal QT interval associated with the oral use of levofloxacin in the absence of other etiologies known to cause these arrhythmias.", "question": "Treatment.Dosage in oral use of levofloxacin", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11388112_2_4248", "context": "We report the first case of polymorphic ventricular tachycardia with normal QT interval associated with the oral use of levofloxacin in the absence of other etiologies known to cause these arrhythmias.", "question": "Treatment.Freq in oral use of levofloxacin", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11388112_2_4249", "context": "We report the first case of polymorphic ventricular tachycardia with normal QT interval associated with the oral use of levofloxacin in the absence of other etiologies known to cause these arrhythmias.", "question": "Treatment.Route in oral use of levofloxacin", "question_type": "Adverse_event.Treatment.Route", "answers": "oral"}, {"id": "11388112_2_4250", "context": "We report the first case of polymorphic ventricular tachycardia with normal QT interval associated with the oral use of levofloxacin in the absence of other etiologies known to cause these arrhythmias.", "question": "Treatment.Time_elapsed in oral use of levofloxacin", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11388112_2_4251", "context": "We report the first case of polymorphic ventricular tachycardia with normal QT interval associated with the oral use of levofloxacin in the absence of other etiologies known to cause these arrhythmias.", "question": "Treatment.Duration in oral use of levofloxacin", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11388112_2_4252", "context": "We report the first case of polymorphic ventricular tachycardia with normal QT interval associated with the oral use of levofloxacin in the absence of other etiologies known to cause these arrhythmias.", "question": "Treatment.Disorder in oral use of levofloxacin", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11388112_2_4253", "context": "We report the first case of polymorphic ventricular tachycardia with normal QT interval associated with the oral use of levofloxacin in the absence of other etiologies known to cause these arrhythmias.", "question": "Combination.Drug in oral use of levofloxacin", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8104147_2_4254", "context": "Reversible leukopenia was documented in an 81-year-old woman treated with adjunctive ibopamine 100 mg t.i.d. for chronic congestive heart failure.", "question": "Subject.Age in an 81-year-old woman", "question_type": "Adverse_event.Subject.Age", "answers": "81-year-old"}, {"id": "8104147_2_4255", "context": "Reversible leukopenia was documented in an 81-year-old woman treated with adjunctive ibopamine 100 mg t.i.d. for chronic congestive heart failure.", "question": "Subject.Gender in an 81-year-old woman", "question_type": "Adverse_event.Subject.Gender", "answers": "woman"}, {"id": "8104147_2_4256", "context": "Reversible leukopenia was documented in an 81-year-old woman treated with adjunctive ibopamine 100 mg t.i.d. for chronic congestive heart failure.", "question": "Subject.Population in an 81-year-old woman", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "8104147_2_4257", "context": "Reversible leukopenia was documented in an 81-year-old woman treated with adjunctive ibopamine 100 mg t.i.d. for chronic congestive heart failure.", "question": "Subject.Race in an 81-year-old woman", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "8104147_2_4258", "context": "Reversible leukopenia was documented in an 81-year-old woman treated with adjunctive ibopamine 100 mg t.i.d. for chronic congestive heart failure.", "question": "Subject.Disorder in an 81-year-old woman", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "8104147_2_4259", "context": "Reversible leukopenia was documented in an 81-year-old woman treated with adjunctive ibopamine 100 mg t.i.d. for chronic congestive heart failure.", "question": "Treatment.Drug in adjunctive ibopamine 100 mg t.i.d.", "question_type": "Adverse_event.Treatment.Drug", "answers": "ibopamine"}, {"id": "8104147_2_4260", "context": "Reversible leukopenia was documented in an 81-year-old woman treated with adjunctive ibopamine 100 mg t.i.d. for chronic congestive heart failure.", "question": "Treatment.Dosage in adjunctive ibopamine 100 mg t.i.d.", "question_type": "Adverse_event.Treatment.Dosage", "answers": "100 mg"}, {"id": "8104147_2_4261", "context": "Reversible leukopenia was documented in an 81-year-old woman treated with adjunctive ibopamine 100 mg t.i.d. for chronic congestive heart failure.", "question": "Treatment.Freq in adjunctive ibopamine 100 mg t.i.d.", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8104147_2_4262", "context": "Reversible leukopenia was documented in an 81-year-old woman treated with adjunctive ibopamine 100 mg t.i.d. for chronic congestive heart failure.", "question": "Treatment.Route in adjunctive ibopamine 100 mg t.i.d.", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8104147_2_4263", "context": "Reversible leukopenia was documented in an 81-year-old woman treated with adjunctive ibopamine 100 mg t.i.d. for chronic congestive heart failure.", "question": "Treatment.Time_elapsed in adjunctive ibopamine 100 mg t.i.d.", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8104147_2_4264", "context": "Reversible leukopenia was documented in an 81-year-old woman treated with adjunctive ibopamine 100 mg t.i.d. for chronic congestive heart failure.", "question": "Treatment.Duration in adjunctive ibopamine 100 mg t.i.d.", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8104147_2_4265", "context": "Reversible leukopenia was documented in an 81-year-old woman treated with adjunctive ibopamine 100 mg t.i.d. for chronic congestive heart failure.", "question": "Treatment.Disorder in adjunctive ibopamine 100 mg t.i.d.", "question_type": "Adverse_event.Treatment.Disorder", "answers": "chronic congestive heart failure"}, {"id": "8104147_2_4266", "context": "Reversible leukopenia was documented in an 81-year-old woman treated with adjunctive ibopamine 100 mg t.i.d. for chronic congestive heart failure.", "question": "Combination.Drug in adjunctive ibopamine 100 mg t.i.d.", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12702914_4_4267", "context": "We conjectured that the side effects of insulin, such as anti-natriuresis and increased vascular permeability, might be pronounced in the presence of the hepatic dysfunction that accompanies insulin insensitivity, hyperinsulinaemia and hypoalbuminaemia.", "question": "Treatment.Drug in insulin", "question_type": "Adverse_event.Treatment.Drug", "answers": "insulin"}, {"id": "12702914_4_4268", "context": "We conjectured that the side effects of insulin, such as anti-natriuresis and increased vascular permeability, might be pronounced in the presence of the hepatic dysfunction that accompanies insulin insensitivity, hyperinsulinaemia and hypoalbuminaemia.", "question": "Treatment.Dosage in insulin", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12702914_4_4269", "context": "We conjectured that the side effects of insulin, such as anti-natriuresis and increased vascular permeability, might be pronounced in the presence of the hepatic dysfunction that accompanies insulin insensitivity, hyperinsulinaemia and hypoalbuminaemia.", "question": "Treatment.Freq in insulin", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12702914_4_4270", "context": "We conjectured that the side effects of insulin, such as anti-natriuresis and increased vascular permeability, might be pronounced in the presence of the hepatic dysfunction that accompanies insulin insensitivity, hyperinsulinaemia and hypoalbuminaemia.", "question": "Treatment.Route in insulin", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12702914_4_4271", "context": "We conjectured that the side effects of insulin, such as anti-natriuresis and increased vascular permeability, might be pronounced in the presence of the hepatic dysfunction that accompanies insulin insensitivity, hyperinsulinaemia and hypoalbuminaemia.", "question": "Treatment.Time_elapsed in insulin", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12702914_4_4272", "context": "We conjectured that the side effects of insulin, such as anti-natriuresis and increased vascular permeability, might be pronounced in the presence of the hepatic dysfunction that accompanies insulin insensitivity, hyperinsulinaemia and hypoalbuminaemia.", "question": "Treatment.Duration in insulin", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12702914_4_4273", "context": "We conjectured that the side effects of insulin, such as anti-natriuresis and increased vascular permeability, might be pronounced in the presence of the hepatic dysfunction that accompanies insulin insensitivity, hyperinsulinaemia and hypoalbuminaemia.", "question": "Treatment.Disorder in insulin", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12702914_4_4274", "context": "We conjectured that the side effects of insulin, such as anti-natriuresis and increased vascular permeability, might be pronounced in the presence of the hepatic dysfunction that accompanies insulin insensitivity, hyperinsulinaemia and hypoalbuminaemia.", "question": "Combination.Drug in insulin", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "278642_1_4275", "context": "Acute myelogenous leukemia in patients receiving chlorambucil as long-term adjuvant chemotherapy for stage II breast cancer.", "question": "Subject.Age in patients", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "278642_1_4276", "context": "Acute myelogenous leukemia in patients receiving chlorambucil as long-term adjuvant chemotherapy for stage II breast cancer.", "question": "Subject.Gender in patients", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "278642_1_4277", "context": "Acute myelogenous leukemia in patients receiving chlorambucil as long-term adjuvant chemotherapy for stage II breast cancer.", "question": "Subject.Population in patients", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "278642_1_4278", "context": "Acute myelogenous leukemia in patients receiving chlorambucil as long-term adjuvant chemotherapy for stage II breast cancer.", "question": "Subject.Race in patients", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "278642_1_4279", "context": "Acute myelogenous leukemia in patients receiving chlorambucil as long-term adjuvant chemotherapy for stage II breast cancer.", "question": "Subject.Disorder in patients", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "278642_1_4280", "context": "Acute myelogenous leukemia in patients receiving chlorambucil as long-term adjuvant chemotherapy for stage II breast cancer.", "question": "Treatment.Drug in receiving chlorambucil as long-term adjuvant chemotherapy", "question_type": "Adverse_event.Treatment.Drug", "answers": "chlorambucil"}, {"id": "278642_1_4281", "context": "Acute myelogenous leukemia in patients receiving chlorambucil as long-term adjuvant chemotherapy for stage II breast cancer.", "question": "Treatment.Dosage in receiving chlorambucil as long-term adjuvant chemotherapy", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "278642_1_4282", "context": "Acute myelogenous leukemia in patients receiving chlorambucil as long-term adjuvant chemotherapy for stage II breast cancer.", "question": "Treatment.Freq in receiving chlorambucil as long-term adjuvant chemotherapy", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "278642_1_4283", "context": "Acute myelogenous leukemia in patients receiving chlorambucil as long-term adjuvant chemotherapy for stage II breast cancer.", "question": "Treatment.Route in receiving chlorambucil as long-term adjuvant chemotherapy", "question_type": "Adverse_event.Treatment.Route", "answers": "chemotherapy"}, {"id": "278642_1_4284", "context": "Acute myelogenous leukemia in patients receiving chlorambucil as long-term adjuvant chemotherapy for stage II breast cancer.", "question": "Treatment.Time_elapsed in receiving chlorambucil as long-term adjuvant chemotherapy", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "278642_1_4285", "context": "Acute myelogenous leukemia in patients receiving chlorambucil as long-term adjuvant chemotherapy for stage II breast cancer.", "question": "Treatment.Duration in receiving chlorambucil as long-term adjuvant chemotherapy", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "278642_1_4286", "context": "Acute myelogenous leukemia in patients receiving chlorambucil as long-term adjuvant chemotherapy for stage II breast cancer.", "question": "Treatment.Disorder in receiving chlorambucil as long-term adjuvant chemotherapy", "question_type": "Adverse_event.Treatment.Disorder", "answers": "stage II breast cancer."}, {"id": "278642_1_4287", "context": "Acute myelogenous leukemia in patients receiving chlorambucil as long-term adjuvant chemotherapy for stage II breast cancer.", "question": "Combination.Drug in receiving chlorambucil as long-term adjuvant chemotherapy", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7889679_1_4288", "context": "We report a case of generalized cutaneous sclerosis associated with muscle and oesophageal involvement in a patient exposed to herbicides containing bromocil, diuron and aminotriazole.", "question": "Treatment.Drug in herbicides containing bromocil, diuron and aminotriazole", "question_type": "Adverse_event.Treatment.Drug", "answers": "bromocil; diuron; aminotriazole"}, {"id": "7889679_1_4289", "context": "We report a case of generalized cutaneous sclerosis associated with muscle and oesophageal involvement in a patient exposed to herbicides containing bromocil, diuron and aminotriazole.", "question": "Treatment.Dosage in herbicides containing bromocil, diuron and aminotriazole", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7889679_1_4290", "context": "We report a case of generalized cutaneous sclerosis associated with muscle and oesophageal involvement in a patient exposed to herbicides containing bromocil, diuron and aminotriazole.", "question": "Treatment.Freq in herbicides containing bromocil, diuron and aminotriazole", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7889679_1_4291", "context": "We report a case of generalized cutaneous sclerosis associated with muscle and oesophageal involvement in a patient exposed to herbicides containing bromocil, diuron and aminotriazole.", "question": "Treatment.Route in herbicides containing bromocil, diuron and aminotriazole", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7889679_1_4292", "context": "We report a case of generalized cutaneous sclerosis associated with muscle and oesophageal involvement in a patient exposed to herbicides containing bromocil, diuron and aminotriazole.", "question": "Treatment.Time_elapsed in herbicides containing bromocil, diuron and aminotriazole", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7889679_1_4293", "context": "We report a case of generalized cutaneous sclerosis associated with muscle and oesophageal involvement in a patient exposed to herbicides containing bromocil, diuron and aminotriazole.", "question": "Treatment.Duration in herbicides containing bromocil, diuron and aminotriazole", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7889679_1_4294", "context": "We report a case of generalized cutaneous sclerosis associated with muscle and oesophageal involvement in a patient exposed to herbicides containing bromocil, diuron and aminotriazole.", "question": "Treatment.Disorder in herbicides containing bromocil, diuron and aminotriazole", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7889679_1_4295", "context": "We report a case of generalized cutaneous sclerosis associated with muscle and oesophageal involvement in a patient exposed to herbicides containing bromocil, diuron and aminotriazole.", "question": "Combination.Drug in herbicides containing bromocil, diuron and aminotriazole", "question_type": "Adverse_event.Combination.Drug", "answers": "diuron; bromocil; aminotriazole"}, {"id": "19097599_1_4296", "context": "Only 3 cases of imatinib-induced tumor lysis syndrome have been reported.", "question": "Treatment.Drug in imatinib", "question_type": "Adverse_event.Treatment.Drug", "answers": "imatinib"}, {"id": "19097599_1_4297", "context": "Only 3 cases of imatinib-induced tumor lysis syndrome have been reported.", "question": "Treatment.Dosage in imatinib", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "19097599_1_4298", "context": "Only 3 cases of imatinib-induced tumor lysis syndrome have been reported.", "question": "Treatment.Freq in imatinib", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "19097599_1_4299", "context": "Only 3 cases of imatinib-induced tumor lysis syndrome have been reported.", "question": "Treatment.Route in imatinib", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "19097599_1_4300", "context": "Only 3 cases of imatinib-induced tumor lysis syndrome have been reported.", "question": "Treatment.Time_elapsed in imatinib", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19097599_1_4301", "context": "Only 3 cases of imatinib-induced tumor lysis syndrome have been reported.", "question": "Treatment.Duration in imatinib", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "19097599_1_4302", "context": "Only 3 cases of imatinib-induced tumor lysis syndrome have been reported.", "question": "Treatment.Disorder in imatinib", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "19097599_1_4303", "context": "Only 3 cases of imatinib-induced tumor lysis syndrome have been reported.", "question": "Combination.Drug in imatinib", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "14964753_2_4304", "context": "A 61-year-old patient who had been treated with lisinopril in the past without any problems was commenced on ramipril for left ventricular dysfunction.", "question": "Subject.Age in A 61-year-old patient who had been treated with lisinopril in the past without any problems", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": "61-year-old"}, {"id": "14964753_2_4305", "context": "A 61-year-old patient who had been treated with lisinopril in the past without any problems was commenced on ramipril for left ventricular dysfunction.", "question": "Subject.Gender in A 61-year-old patient who had been treated with lisinopril in the past without any problems", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "14964753_2_4306", "context": "A 61-year-old patient who had been treated with lisinopril in the past without any problems was commenced on ramipril for left ventricular dysfunction.", "question": "Subject.Population in A 61-year-old patient who had been treated with lisinopril in the past without any problems", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "14964753_2_4307", "context": "A 61-year-old patient who had been treated with lisinopril in the past without any problems was commenced on ramipril for left ventricular dysfunction.", "question": "Subject.Race in A 61-year-old patient who had been treated with lisinopril in the past without any problems", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "14964753_2_4308", "context": "A 61-year-old patient who had been treated with lisinopril in the past without any problems was commenced on ramipril for left ventricular dysfunction.", "question": "Subject.Disorder in A 61-year-old patient who had been treated with lisinopril in the past without any problems", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "14964753_2_4309", "context": "A 61-year-old patient who had been treated with lisinopril in the past without any problems was commenced on ramipril for left ventricular dysfunction.", "question": "Treatment.Drug in ramipril", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "ramipril"}, {"id": "14964753_2_4310", "context": "A 61-year-old patient who had been treated with lisinopril in the past without any problems was commenced on ramipril for left ventricular dysfunction.", "question": "Treatment.Dosage in ramipril", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "14964753_2_4311", "context": "A 61-year-old patient who had been treated with lisinopril in the past without any problems was commenced on ramipril for left ventricular dysfunction.", "question": "Treatment.Freq in ramipril", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "14964753_2_4312", "context": "A 61-year-old patient who had been treated with lisinopril in the past without any problems was commenced on ramipril for left ventricular dysfunction.", "question": "Treatment.Route in ramipril", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "14964753_2_4313", "context": "A 61-year-old patient who had been treated with lisinopril in the past without any problems was commenced on ramipril for left ventricular dysfunction.", "question": "Treatment.Time_elapsed in ramipril", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "14964753_2_4314", "context": "A 61-year-old patient who had been treated with lisinopril in the past without any problems was commenced on ramipril for left ventricular dysfunction.", "question": "Treatment.Duration in ramipril", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "14964753_2_4315", "context": "A 61-year-old patient who had been treated with lisinopril in the past without any problems was commenced on ramipril for left ventricular dysfunction.", "question": "Treatment.Disorder in ramipril", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "left ventricular dysfunction"}, {"id": "14964753_2_4316", "context": "A 61-year-old patient who had been treated with lisinopril in the past without any problems was commenced on ramipril for left ventricular dysfunction.", "question": "Combination.Drug in ramipril", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "9760614_2_4317", "context": "However, repeated intracameral tPA injections may cause unwanted complications such as vitreous hemorrhage.", "question": "Treatment.Drug in repeated intracameral tPA injections", "question_type": "Adverse_event.Treatment.Drug", "answers": "tPA"}, {"id": "9760614_2_4318", "context": "However, repeated intracameral tPA injections may cause unwanted complications such as vitreous hemorrhage.", "question": "Treatment.Dosage in repeated intracameral tPA injections", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9760614_2_4319", "context": "However, repeated intracameral tPA injections may cause unwanted complications such as vitreous hemorrhage.", "question": "Treatment.Freq in repeated intracameral tPA injections", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9760614_2_4320", "context": "However, repeated intracameral tPA injections may cause unwanted complications such as vitreous hemorrhage.", "question": "Treatment.Route in repeated intracameral tPA injections", "question_type": "Adverse_event.Treatment.Route", "answers": "intracameral; injections"}, {"id": "9760614_2_4321", "context": "However, repeated intracameral tPA injections may cause unwanted complications such as vitreous hemorrhage.", "question": "Treatment.Time_elapsed in repeated intracameral tPA injections", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9760614_2_4322", "context": "However, repeated intracameral tPA injections may cause unwanted complications such as vitreous hemorrhage.", "question": "Treatment.Duration in repeated intracameral tPA injections", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9760614_2_4323", "context": "However, repeated intracameral tPA injections may cause unwanted complications such as vitreous hemorrhage.", "question": "Treatment.Disorder in repeated intracameral tPA injections", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9760614_2_4324", "context": "However, repeated intracameral tPA injections may cause unwanted complications such as vitreous hemorrhage.", "question": "Combination.Drug in repeated intracameral tPA injections", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9934637_3_4325", "context": "In this article, we present the case of a vitiligo patient who was admitted to our facility with an intense burn after the topical use of 8-methoxypsoralen solution as a suntanning agent.", "question": "Subject.Age in a vitiligo patient", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "9934637_3_4326", "context": "In this article, we present the case of a vitiligo patient who was admitted to our facility with an intense burn after the topical use of 8-methoxypsoralen solution as a suntanning agent.", "question": "Subject.Gender in a vitiligo patient", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "9934637_3_4327", "context": "In this article, we present the case of a vitiligo patient who was admitted to our facility with an intense burn after the topical use of 8-methoxypsoralen solution as a suntanning agent.", "question": "Subject.Population in a vitiligo patient", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "9934637_3_4328", "context": "In this article, we present the case of a vitiligo patient who was admitted to our facility with an intense burn after the topical use of 8-methoxypsoralen solution as a suntanning agent.", "question": "Subject.Race in a vitiligo patient", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "9934637_3_4329", "context": "In this article, we present the case of a vitiligo patient who was admitted to our facility with an intense burn after the topical use of 8-methoxypsoralen solution as a suntanning agent.", "question": "Subject.Disorder in a vitiligo patient", "question_type": "Adverse_event.Subject.Disorder", "answers": "vitiligo"}, {"id": "9934637_3_4330", "context": "In this article, we present the case of a vitiligo patient who was admitted to our facility with an intense burn after the topical use of 8-methoxypsoralen solution as a suntanning agent.", "question": "Treatment.Drug in topical use of 8-methoxypsoralen solution as a suntanning agent", "question_type": "Adverse_event.Treatment.Drug", "answers": "8-methoxypsoralen"}, {"id": "9934637_3_4331", "context": "In this article, we present the case of a vitiligo patient who was admitted to our facility with an intense burn after the topical use of 8-methoxypsoralen solution as a suntanning agent.", "question": "Treatment.Dosage in topical use of 8-methoxypsoralen solution as a suntanning agent", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9934637_3_4332", "context": "In this article, we present the case of a vitiligo patient who was admitted to our facility with an intense burn after the topical use of 8-methoxypsoralen solution as a suntanning agent.", "question": "Treatment.Freq in topical use of 8-methoxypsoralen solution as a suntanning agent", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9934637_3_4333", "context": "In this article, we present the case of a vitiligo patient who was admitted to our facility with an intense burn after the topical use of 8-methoxypsoralen solution as a suntanning agent.", "question": "Treatment.Route in topical use of 8-methoxypsoralen solution as a suntanning agent", "question_type": "Adverse_event.Treatment.Route", "answers": "topical"}, {"id": "9934637_3_4334", "context": "In this article, we present the case of a vitiligo patient who was admitted to our facility with an intense burn after the topical use of 8-methoxypsoralen solution as a suntanning agent.", "question": "Treatment.Time_elapsed in topical use of 8-methoxypsoralen solution as a suntanning agent", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9934637_3_4335", "context": "In this article, we present the case of a vitiligo patient who was admitted to our facility with an intense burn after the topical use of 8-methoxypsoralen solution as a suntanning agent.", "question": "Treatment.Duration in topical use of 8-methoxypsoralen solution as a suntanning agent", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9934637_3_4336", "context": "In this article, we present the case of a vitiligo patient who was admitted to our facility with an intense burn after the topical use of 8-methoxypsoralen solution as a suntanning agent.", "question": "Treatment.Disorder in topical use of 8-methoxypsoralen solution as a suntanning agent", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9934637_3_4337", "context": "In this article, we present the case of a vitiligo patient who was admitted to our facility with an intense burn after the topical use of 8-methoxypsoralen solution as a suntanning agent.", "question": "Combination.Drug in topical use of 8-methoxypsoralen solution as a suntanning agent", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7474364_3_4338", "context": "The frequency and relationship of granulocytopenia caused by sustained-release procainamide in patients with tachyarrhythmias are briefly discussed, and prior reported cases are reviewed.", "question": "Subject.Age in patients with tachyarrhythmias", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "7474364_3_4339", "context": "The frequency and relationship of granulocytopenia caused by sustained-release procainamide in patients with tachyarrhythmias are briefly discussed, and prior reported cases are reviewed.", "question": "Subject.Gender in patients with tachyarrhythmias", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "7474364_3_4340", "context": "The frequency and relationship of granulocytopenia caused by sustained-release procainamide in patients with tachyarrhythmias are briefly discussed, and prior reported cases are reviewed.", "question": "Subject.Population in patients with tachyarrhythmias", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "7474364_3_4341", "context": "The frequency and relationship of granulocytopenia caused by sustained-release procainamide in patients with tachyarrhythmias are briefly discussed, and prior reported cases are reviewed.", "question": "Subject.Race in patients with tachyarrhythmias", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "7474364_3_4342", "context": "The frequency and relationship of granulocytopenia caused by sustained-release procainamide in patients with tachyarrhythmias are briefly discussed, and prior reported cases are reviewed.", "question": "Subject.Disorder in patients with tachyarrhythmias", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "7474364_3_4343", "context": "The frequency and relationship of granulocytopenia caused by sustained-release procainamide in patients with tachyarrhythmias are briefly discussed, and prior reported cases are reviewed.", "question": "Treatment.Drug in procainamide", "question_type": "Adverse_event.Treatment.Drug", "answers": "procainamide"}, {"id": "7474364_3_4344", "context": "The frequency and relationship of granulocytopenia caused by sustained-release procainamide in patients with tachyarrhythmias are briefly discussed, and prior reported cases are reviewed.", "question": "Treatment.Dosage in procainamide", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7474364_3_4345", "context": "The frequency and relationship of granulocytopenia caused by sustained-release procainamide in patients with tachyarrhythmias are briefly discussed, and prior reported cases are reviewed.", "question": "Treatment.Freq in procainamide", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7474364_3_4346", "context": "The frequency and relationship of granulocytopenia caused by sustained-release procainamide in patients with tachyarrhythmias are briefly discussed, and prior reported cases are reviewed.", "question": "Treatment.Route in procainamide", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7474364_3_4347", "context": "The frequency and relationship of granulocytopenia caused by sustained-release procainamide in patients with tachyarrhythmias are briefly discussed, and prior reported cases are reviewed.", "question": "Treatment.Time_elapsed in procainamide", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7474364_3_4348", "context": "The frequency and relationship of granulocytopenia caused by sustained-release procainamide in patients with tachyarrhythmias are briefly discussed, and prior reported cases are reviewed.", "question": "Treatment.Duration in procainamide", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7474364_3_4349", "context": "The frequency and relationship of granulocytopenia caused by sustained-release procainamide in patients with tachyarrhythmias are briefly discussed, and prior reported cases are reviewed.", "question": "Treatment.Disorder in procainamide", "question_type": "Adverse_event.Treatment.Disorder", "answers": "tachyarrhythmias"}, {"id": "7474364_3_4350", "context": "The frequency and relationship of granulocytopenia caused by sustained-release procainamide in patients with tachyarrhythmias are briefly discussed, and prior reported cases are reviewed.", "question": "Combination.Drug in procainamide", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11642488_1_4351", "context": "Cicatricial entropion associated with chronic dipivefrin application.", "question": "Treatment.Drug in chronic dipivefrin application", "question_type": "Adverse_event.Treatment.Drug", "answers": "dipivefrin"}, {"id": "11642488_1_4352", "context": "Cicatricial entropion associated with chronic dipivefrin application.", "question": "Treatment.Dosage in chronic dipivefrin application", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11642488_1_4353", "context": "Cicatricial entropion associated with chronic dipivefrin application.", "question": "Treatment.Freq in chronic dipivefrin application", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11642488_1_4354", "context": "Cicatricial entropion associated with chronic dipivefrin application.", "question": "Treatment.Route in chronic dipivefrin application", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11642488_1_4355", "context": "Cicatricial entropion associated with chronic dipivefrin application.", "question": "Treatment.Time_elapsed in chronic dipivefrin application", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11642488_1_4356", "context": "Cicatricial entropion associated with chronic dipivefrin application.", "question": "Treatment.Duration in chronic dipivefrin application", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11642488_1_4357", "context": "Cicatricial entropion associated with chronic dipivefrin application.", "question": "Treatment.Disorder in chronic dipivefrin application", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11642488_1_4358", "context": "Cicatricial entropion associated with chronic dipivefrin application.", "question": "Combination.Drug in chronic dipivefrin application", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7174620_1_4359", "context": "Nine delirious patients suffering from lithium intoxication were examined with the Mini-Mental State Exam (MMS) to describe the clinical course of the disorder.", "question": "Subject.Age in Nine delirious patients", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "7174620_1_4360", "context": "Nine delirious patients suffering from lithium intoxication were examined with the Mini-Mental State Exam (MMS) to describe the clinical course of the disorder.", "question": "Subject.Gender in Nine delirious patients", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "7174620_1_4361", "context": "Nine delirious patients suffering from lithium intoxication were examined with the Mini-Mental State Exam (MMS) to describe the clinical course of the disorder.", "question": "Subject.Population in Nine delirious patients", "question_type": "Adverse_event.Subject.Population", "answers": "Nine"}, {"id": "7174620_1_4362", "context": "Nine delirious patients suffering from lithium intoxication were examined with the Mini-Mental State Exam (MMS) to describe the clinical course of the disorder.", "question": "Subject.Race in Nine delirious patients", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "7174620_1_4363", "context": "Nine delirious patients suffering from lithium intoxication were examined with the Mini-Mental State Exam (MMS) to describe the clinical course of the disorder.", "question": "Subject.Disorder in Nine delirious patients", "question_type": "Adverse_event.Subject.Disorder", "answers": "delirious"}, {"id": "7174620_1_4364", "context": "Nine delirious patients suffering from lithium intoxication were examined with the Mini-Mental State Exam (MMS) to describe the clinical course of the disorder.", "question": "Treatment.Drug in lithium", "question_type": "Adverse_event.Treatment.Drug", "answers": "lithium"}, {"id": "7174620_1_4365", "context": "Nine delirious patients suffering from lithium intoxication were examined with the Mini-Mental State Exam (MMS) to describe the clinical course of the disorder.", "question": "Treatment.Dosage in lithium", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7174620_1_4366", "context": "Nine delirious patients suffering from lithium intoxication were examined with the Mini-Mental State Exam (MMS) to describe the clinical course of the disorder.", "question": "Treatment.Freq in lithium", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7174620_1_4367", "context": "Nine delirious patients suffering from lithium intoxication were examined with the Mini-Mental State Exam (MMS) to describe the clinical course of the disorder.", "question": "Treatment.Route in lithium", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7174620_1_4368", "context": "Nine delirious patients suffering from lithium intoxication were examined with the Mini-Mental State Exam (MMS) to describe the clinical course of the disorder.", "question": "Treatment.Time_elapsed in lithium", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7174620_1_4369", "context": "Nine delirious patients suffering from lithium intoxication were examined with the Mini-Mental State Exam (MMS) to describe the clinical course of the disorder.", "question": "Treatment.Duration in lithium", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7174620_1_4370", "context": "Nine delirious patients suffering from lithium intoxication were examined with the Mini-Mental State Exam (MMS) to describe the clinical course of the disorder.", "question": "Treatment.Disorder in lithium", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7174620_1_4371", "context": "Nine delirious patients suffering from lithium intoxication were examined with the Mini-Mental State Exam (MMS) to describe the clinical course of the disorder.", "question": "Combination.Drug in lithium", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "19423476_1_4372", "context": "Cryptococcus neoformans fatal sepsis in a chronic lymphocytic leukemia patient treated with alemtuzumab: case report and review of the literature.", "question": "Subject.Age in a chronic lymphocytic leukemia patient", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "19423476_1_4373", "context": "Cryptococcus neoformans fatal sepsis in a chronic lymphocytic leukemia patient treated with alemtuzumab: case report and review of the literature.", "question": "Subject.Gender in a chronic lymphocytic leukemia patient", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "19423476_1_4374", "context": "Cryptococcus neoformans fatal sepsis in a chronic lymphocytic leukemia patient treated with alemtuzumab: case report and review of the literature.", "question": "Subject.Population in a chronic lymphocytic leukemia patient", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "19423476_1_4375", "context": "Cryptococcus neoformans fatal sepsis in a chronic lymphocytic leukemia patient treated with alemtuzumab: case report and review of the literature.", "question": "Subject.Race in a chronic lymphocytic leukemia patient", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "19423476_1_4376", "context": "Cryptococcus neoformans fatal sepsis in a chronic lymphocytic leukemia patient treated with alemtuzumab: case report and review of the literature.", "question": "Subject.Disorder in a chronic lymphocytic leukemia patient", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "19423476_1_4377", "context": "Cryptococcus neoformans fatal sepsis in a chronic lymphocytic leukemia patient treated with alemtuzumab: case report and review of the literature.", "question": "Treatment.Drug in alemtuzumab", "question_type": "Adverse_event.Treatment.Drug", "answers": "alemtuzumab"}, {"id": "19423476_1_4378", "context": "Cryptococcus neoformans fatal sepsis in a chronic lymphocytic leukemia patient treated with alemtuzumab: case report and review of the literature.", "question": "Treatment.Dosage in alemtuzumab", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "19423476_1_4379", "context": "Cryptococcus neoformans fatal sepsis in a chronic lymphocytic leukemia patient treated with alemtuzumab: case report and review of the literature.", "question": "Treatment.Freq in alemtuzumab", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "19423476_1_4380", "context": "Cryptococcus neoformans fatal sepsis in a chronic lymphocytic leukemia patient treated with alemtuzumab: case report and review of the literature.", "question": "Treatment.Route in alemtuzumab", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "19423476_1_4381", "context": "Cryptococcus neoformans fatal sepsis in a chronic lymphocytic leukemia patient treated with alemtuzumab: case report and review of the literature.", "question": "Treatment.Time_elapsed in alemtuzumab", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19423476_1_4382", "context": "Cryptococcus neoformans fatal sepsis in a chronic lymphocytic leukemia patient treated with alemtuzumab: case report and review of the literature.", "question": "Treatment.Duration in alemtuzumab", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "19423476_1_4383", "context": "Cryptococcus neoformans fatal sepsis in a chronic lymphocytic leukemia patient treated with alemtuzumab: case report and review of the literature.", "question": "Treatment.Disorder in alemtuzumab", "question_type": "Adverse_event.Treatment.Disorder", "answers": "chronic lymphocytic leukemia"}, {"id": "19423476_1_4384", "context": "Cryptococcus neoformans fatal sepsis in a chronic lymphocytic leukemia patient treated with alemtuzumab: case report and review of the literature.", "question": "Combination.Drug in alemtuzumab", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6597713_2_4385", "context": "Cholestyramine induced hyperchloremic metabolic acidosis.", "question": "Treatment.Drug in Cholestyramine", "question_type": "Adverse_event.Treatment.Drug", "answers": "Cholestyramine"}, {"id": "6597713_2_4386", "context": "Cholestyramine induced hyperchloremic metabolic acidosis.", "question": "Treatment.Dosage in Cholestyramine", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6597713_2_4387", "context": "Cholestyramine induced hyperchloremic metabolic acidosis.", "question": "Treatment.Freq in Cholestyramine", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6597713_2_4388", "context": "Cholestyramine induced hyperchloremic metabolic acidosis.", "question": "Treatment.Route in Cholestyramine", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6597713_2_4389", "context": "Cholestyramine induced hyperchloremic metabolic acidosis.", "question": "Treatment.Time_elapsed in Cholestyramine", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6597713_2_4390", "context": "Cholestyramine induced hyperchloremic metabolic acidosis.", "question": "Treatment.Duration in Cholestyramine", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6597713_2_4391", "context": "Cholestyramine induced hyperchloremic metabolic acidosis.", "question": "Treatment.Disorder in Cholestyramine", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6597713_2_4392", "context": "Cholestyramine induced hyperchloremic metabolic acidosis.", "question": "Combination.Drug in Cholestyramine", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11406880_2_4393", "context": "Methadone is recommended as being free of some of the neuropsychological side effects noticed with morphine, which are attributed to active metabolites.", "question": "Treatment.Drug in morphine", "question_type": "Adverse_event.Treatment.Drug", "answers": "morphine"}, {"id": "11406880_2_4394", "context": "Methadone is recommended as being free of some of the neuropsychological side effects noticed with morphine, which are attributed to active metabolites.", "question": "Treatment.Dosage in morphine", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11406880_2_4395", "context": "Methadone is recommended as being free of some of the neuropsychological side effects noticed with morphine, which are attributed to active metabolites.", "question": "Treatment.Freq in morphine", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11406880_2_4396", "context": "Methadone is recommended as being free of some of the neuropsychological side effects noticed with morphine, which are attributed to active metabolites.", "question": "Treatment.Route in morphine", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11406880_2_4397", "context": "Methadone is recommended as being free of some of the neuropsychological side effects noticed with morphine, which are attributed to active metabolites.", "question": "Treatment.Time_elapsed in morphine", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11406880_2_4398", "context": "Methadone is recommended as being free of some of the neuropsychological side effects noticed with morphine, which are attributed to active metabolites.", "question": "Treatment.Duration in morphine", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11406880_2_4399", "context": "Methadone is recommended as being free of some of the neuropsychological side effects noticed with morphine, which are attributed to active metabolites.", "question": "Treatment.Disorder in morphine", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11406880_2_4400", "context": "Methadone is recommended as being free of some of the neuropsychological side effects noticed with morphine, which are attributed to active metabolites.", "question": "Combination.Drug in morphine", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16948177_3_4401", "context": "This is the first reported case of BOOP associated with single-agent rituximab, and along with two other patients we describe, as well as two prior reports of BOOP in NHL patients receiving rituximab-based combinations, strengthens the possibility of a causal relationship.", "question": "Treatment.Drug in single-agent rituximab", "question_type": "Adverse_event.Treatment.Drug", "answers": "rituximab"}, {"id": "16948177_3_4402", "context": "This is the first reported case of BOOP associated with single-agent rituximab, and along with two other patients we describe, as well as two prior reports of BOOP in NHL patients receiving rituximab-based combinations, strengthens the possibility of a causal relationship.", "question": "Treatment.Dosage in single-agent rituximab", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16948177_3_4403", "context": "This is the first reported case of BOOP associated with single-agent rituximab, and along with two other patients we describe, as well as two prior reports of BOOP in NHL patients receiving rituximab-based combinations, strengthens the possibility of a causal relationship.", "question": "Treatment.Freq in single-agent rituximab", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16948177_3_4404", "context": "This is the first reported case of BOOP associated with single-agent rituximab, and along with two other patients we describe, as well as two prior reports of BOOP in NHL patients receiving rituximab-based combinations, strengthens the possibility of a causal relationship.", "question": "Treatment.Route in single-agent rituximab", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16948177_3_4405", "context": "This is the first reported case of BOOP associated with single-agent rituximab, and along with two other patients we describe, as well as two prior reports of BOOP in NHL patients receiving rituximab-based combinations, strengthens the possibility of a causal relationship.", "question": "Treatment.Time_elapsed in single-agent rituximab", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16948177_3_4406", "context": "This is the first reported case of BOOP associated with single-agent rituximab, and along with two other patients we describe, as well as two prior reports of BOOP in NHL patients receiving rituximab-based combinations, strengthens the possibility of a causal relationship.", "question": "Treatment.Duration in single-agent rituximab", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16948177_3_4407", "context": "This is the first reported case of BOOP associated with single-agent rituximab, and along with two other patients we describe, as well as two prior reports of BOOP in NHL patients receiving rituximab-based combinations, strengthens the possibility of a causal relationship.", "question": "Treatment.Disorder in single-agent rituximab", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16948177_3_4408", "context": "This is the first reported case of BOOP associated with single-agent rituximab, and along with two other patients we describe, as well as two prior reports of BOOP in NHL patients receiving rituximab-based combinations, strengthens the possibility of a causal relationship.", "question": "Combination.Drug in single-agent rituximab", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "14530108_5_4409", "context": "The treatment for acidosis and hyperkalaemia should be started as soon as RTA is diagnosed, and the dosage of FK506 should also be reduced if possible.", "question": "Treatment.Drug in FK506", "question_type": "Adverse_event.Treatment.Drug", "answers": "FK506"}, {"id": "14530108_5_4410", "context": "The treatment for acidosis and hyperkalaemia should be started as soon as RTA is diagnosed, and the dosage of FK506 should also be reduced if possible.", "question": "Treatment.Dosage in FK506", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "14530108_5_4411", "context": "The treatment for acidosis and hyperkalaemia should be started as soon as RTA is diagnosed, and the dosage of FK506 should also be reduced if possible.", "question": "Treatment.Freq in FK506", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "14530108_5_4412", "context": "The treatment for acidosis and hyperkalaemia should be started as soon as RTA is diagnosed, and the dosage of FK506 should also be reduced if possible.", "question": "Treatment.Route in FK506", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "14530108_5_4413", "context": "The treatment for acidosis and hyperkalaemia should be started as soon as RTA is diagnosed, and the dosage of FK506 should also be reduced if possible.", "question": "Treatment.Time_elapsed in FK506", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "14530108_5_4414", "context": "The treatment for acidosis and hyperkalaemia should be started as soon as RTA is diagnosed, and the dosage of FK506 should also be reduced if possible.", "question": "Treatment.Duration in FK506", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "14530108_5_4415", "context": "The treatment for acidosis and hyperkalaemia should be started as soon as RTA is diagnosed, and the dosage of FK506 should also be reduced if possible.", "question": "Treatment.Disorder in FK506", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "14530108_5_4416", "context": "The treatment for acidosis and hyperkalaemia should be started as soon as RTA is diagnosed, and the dosage of FK506 should also be reduced if possible.", "question": "Combination.Drug in FK506", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11518127_1_4417", "context": "A 62-year-old woman treated with pranlukast for 2 months developed interstitial pneumonitis with a high fever.", "question": "Subject.Age in A 62-year-old woman", "question_type": "Adverse_event.Subject.Age", "answers": "62-year-old"}, {"id": "11518127_1_4418", "context": "A 62-year-old woman treated with pranlukast for 2 months developed interstitial pneumonitis with a high fever.", "question": "Subject.Gender in A 62-year-old woman", "question_type": "Adverse_event.Subject.Gender", "answers": "woman"}, {"id": "11518127_1_4419", "context": "A 62-year-old woman treated with pranlukast for 2 months developed interstitial pneumonitis with a high fever.", "question": "Subject.Population in A 62-year-old woman", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "11518127_1_4420", "context": "A 62-year-old woman treated with pranlukast for 2 months developed interstitial pneumonitis with a high fever.", "question": "Subject.Race in A 62-year-old woman", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "11518127_1_4421", "context": "A 62-year-old woman treated with pranlukast for 2 months developed interstitial pneumonitis with a high fever.", "question": "Subject.Disorder in A 62-year-old woman", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "11518127_1_4422", "context": "A 62-year-old woman treated with pranlukast for 2 months developed interstitial pneumonitis with a high fever.", "question": "Treatment.Drug in treated with pranlukast for 2 months", "question_type": "Adverse_event.Treatment.Drug", "answers": "pranlukast"}, {"id": "11518127_1_4423", "context": "A 62-year-old woman treated with pranlukast for 2 months developed interstitial pneumonitis with a high fever.", "question": "Treatment.Dosage in treated with pranlukast for 2 months", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11518127_1_4424", "context": "A 62-year-old woman treated with pranlukast for 2 months developed interstitial pneumonitis with a high fever.", "question": "Treatment.Freq in treated with pranlukast for 2 months", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11518127_1_4425", "context": "A 62-year-old woman treated with pranlukast for 2 months developed interstitial pneumonitis with a high fever.", "question": "Treatment.Route in treated with pranlukast for 2 months", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11518127_1_4426", "context": "A 62-year-old woman treated with pranlukast for 2 months developed interstitial pneumonitis with a high fever.", "question": "Treatment.Time_elapsed in treated with pranlukast for 2 months", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11518127_1_4427", "context": "A 62-year-old woman treated with pranlukast for 2 months developed interstitial pneumonitis with a high fever.", "question": "Treatment.Duration in treated with pranlukast for 2 months", "question_type": "Adverse_event.Treatment.Duration", "answers": "2 months"}, {"id": "11518127_1_4428", "context": "A 62-year-old woman treated with pranlukast for 2 months developed interstitial pneumonitis with a high fever.", "question": "Treatment.Disorder in treated with pranlukast for 2 months", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11518127_1_4429", "context": "A 62-year-old woman treated with pranlukast for 2 months developed interstitial pneumonitis with a high fever.", "question": "Combination.Drug in treated with pranlukast for 2 months", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11359026_2_4430", "context": "Neurotoxicity of valacyclovir in peritoneal dialysis: a pharmacokinetic study.", "question": "Treatment.Drug in valacyclovir in peritoneal dialysis", "question_type": "Adverse_event.Treatment.Drug", "answers": "valacyclovir"}, {"id": "11359026_2_4431", "context": "Neurotoxicity of valacyclovir in peritoneal dialysis: a pharmacokinetic study.", "question": "Treatment.Dosage in valacyclovir in peritoneal dialysis", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11359026_2_4432", "context": "Neurotoxicity of valacyclovir in peritoneal dialysis: a pharmacokinetic study.", "question": "Treatment.Freq in valacyclovir in peritoneal dialysis", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11359026_2_4433", "context": "Neurotoxicity of valacyclovir in peritoneal dialysis: a pharmacokinetic study.", "question": "Treatment.Route in valacyclovir in peritoneal dialysis", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11359026_2_4434", "context": "Neurotoxicity of valacyclovir in peritoneal dialysis: a pharmacokinetic study.", "question": "Treatment.Time_elapsed in valacyclovir in peritoneal dialysis", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11359026_2_4435", "context": "Neurotoxicity of valacyclovir in peritoneal dialysis: a pharmacokinetic study.", "question": "Treatment.Duration in valacyclovir in peritoneal dialysis", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11359026_2_4436", "context": "Neurotoxicity of valacyclovir in peritoneal dialysis: a pharmacokinetic study.", "question": "Treatment.Disorder in valacyclovir in peritoneal dialysis", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11359026_2_4437", "context": "Neurotoxicity of valacyclovir in peritoneal dialysis: a pharmacokinetic study.", "question": "Combination.Drug in valacyclovir in peritoneal dialysis", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "20065266_3_4438", "context": "He had been taking trimethoprim-sulfamethoxazole for approximately eight days when he revisited his family physician, complaining of headaches, dizziness, difficulty with speech, weakness, and itching on the trunk of his body and legs, where a maculopapular rash was noted.", "question": "Subject.Age in He", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "20065266_3_4439", "context": "He had been taking trimethoprim-sulfamethoxazole for approximately eight days when he revisited his family physician, complaining of headaches, dizziness, difficulty with speech, weakness, and itching on the trunk of his body and legs, where a maculopapular rash was noted.", "question": "Subject.Gender in He", "question_type": "Adverse_event.Subject.Gender", "answers": "He"}, {"id": "20065266_3_4440", "context": "He had been taking trimethoprim-sulfamethoxazole for approximately eight days when he revisited his family physician, complaining of headaches, dizziness, difficulty with speech, weakness, and itching on the trunk of his body and legs, where a maculopapular rash was noted.", "question": "Subject.Population in He", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "20065266_3_4441", "context": "He had been taking trimethoprim-sulfamethoxazole for approximately eight days when he revisited his family physician, complaining of headaches, dizziness, difficulty with speech, weakness, and itching on the trunk of his body and legs, where a maculopapular rash was noted.", "question": "Subject.Race in He", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "20065266_3_4442", "context": "He had been taking trimethoprim-sulfamethoxazole for approximately eight days when he revisited his family physician, complaining of headaches, dizziness, difficulty with speech, weakness, and itching on the trunk of his body and legs, where a maculopapular rash was noted.", "question": "Subject.Disorder in He", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "20065266_3_4443", "context": "He had been taking trimethoprim-sulfamethoxazole for approximately eight days when he revisited his family physician, complaining of headaches, dizziness, difficulty with speech, weakness, and itching on the trunk of his body and legs, where a maculopapular rash was noted.", "question": "Treatment.Drug in trimethoprim-sulfamethoxazole for approximately eight days", "question_type": "Adverse_event.Treatment.Drug", "answers": "trimethoprim; sulfamethoxazole"}, {"id": "20065266_3_4444", "context": "He had been taking trimethoprim-sulfamethoxazole for approximately eight days when he revisited his family physician, complaining of headaches, dizziness, difficulty with speech, weakness, and itching on the trunk of his body and legs, where a maculopapular rash was noted.", "question": "Treatment.Dosage in trimethoprim-sulfamethoxazole for approximately eight days", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "20065266_3_4445", "context": "He had been taking trimethoprim-sulfamethoxazole for approximately eight days when he revisited his family physician, complaining of headaches, dizziness, difficulty with speech, weakness, and itching on the trunk of his body and legs, where a maculopapular rash was noted.", "question": "Treatment.Freq in trimethoprim-sulfamethoxazole for approximately eight days", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "20065266_3_4446", "context": "He had been taking trimethoprim-sulfamethoxazole for approximately eight days when he revisited his family physician, complaining of headaches, dizziness, difficulty with speech, weakness, and itching on the trunk of his body and legs, where a maculopapular rash was noted.", "question": "Treatment.Route in trimethoprim-sulfamethoxazole for approximately eight days", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "20065266_3_4447", "context": "He had been taking trimethoprim-sulfamethoxazole for approximately eight days when he revisited his family physician, complaining of headaches, dizziness, difficulty with speech, weakness, and itching on the trunk of his body and legs, where a maculopapular rash was noted.", "question": "Treatment.Time_elapsed in trimethoprim-sulfamethoxazole for approximately eight days", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "20065266_3_4448", "context": "He had been taking trimethoprim-sulfamethoxazole for approximately eight days when he revisited his family physician, complaining of headaches, dizziness, difficulty with speech, weakness, and itching on the trunk of his body and legs, where a maculopapular rash was noted.", "question": "Treatment.Duration in trimethoprim-sulfamethoxazole for approximately eight days", "question_type": "Adverse_event.Treatment.Duration", "answers": "eight days"}, {"id": "20065266_3_4449", "context": "He had been taking trimethoprim-sulfamethoxazole for approximately eight days when he revisited his family physician, complaining of headaches, dizziness, difficulty with speech, weakness, and itching on the trunk of his body and legs, where a maculopapular rash was noted.", "question": "Treatment.Disorder in trimethoprim-sulfamethoxazole for approximately eight days", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "20065266_3_4450", "context": "He had been taking trimethoprim-sulfamethoxazole for approximately eight days when he revisited his family physician, complaining of headaches, dizziness, difficulty with speech, weakness, and itching on the trunk of his body and legs, where a maculopapular rash was noted.", "question": "Combination.Drug in trimethoprim-sulfamethoxazole for approximately eight days", "question_type": "Adverse_event.Combination.Drug", "answers": "trimethoprim; sulfamethoxazole"}, {"id": "10970989_2_4451", "context": "We present an AIDS patient with severe and prolonged lactic acidosis on stavudine and lamivudine.", "question": "Subject.Age in an AIDS patient", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "10970989_2_4452", "context": "We present an AIDS patient with severe and prolonged lactic acidosis on stavudine and lamivudine.", "question": "Subject.Gender in an AIDS patient", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "10970989_2_4453", "context": "We present an AIDS patient with severe and prolonged lactic acidosis on stavudine and lamivudine.", "question": "Subject.Population in an AIDS patient", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "10970989_2_4454", "context": "We present an AIDS patient with severe and prolonged lactic acidosis on stavudine and lamivudine.", "question": "Subject.Race in an AIDS patient", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "10970989_2_4455", "context": "We present an AIDS patient with severe and prolonged lactic acidosis on stavudine and lamivudine.", "question": "Subject.Disorder in an AIDS patient", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "10970989_2_4456", "context": "We present an AIDS patient with severe and prolonged lactic acidosis on stavudine and lamivudine.", "question": "Treatment.Drug in stavudine and lamivudine", "question_type": "Adverse_event.Treatment.Drug", "answers": "stavudine; lamivudine"}, {"id": "10970989_2_4457", "context": "We present an AIDS patient with severe and prolonged lactic acidosis on stavudine and lamivudine.", "question": "Treatment.Dosage in stavudine and lamivudine", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10970989_2_4458", "context": "We present an AIDS patient with severe and prolonged lactic acidosis on stavudine and lamivudine.", "question": "Treatment.Freq in stavudine and lamivudine", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10970989_2_4459", "context": "We present an AIDS patient with severe and prolonged lactic acidosis on stavudine and lamivudine.", "question": "Treatment.Route in stavudine and lamivudine", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10970989_2_4460", "context": "We present an AIDS patient with severe and prolonged lactic acidosis on stavudine and lamivudine.", "question": "Treatment.Time_elapsed in stavudine and lamivudine", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10970989_2_4461", "context": "We present an AIDS patient with severe and prolonged lactic acidosis on stavudine and lamivudine.", "question": "Treatment.Duration in stavudine and lamivudine", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10970989_2_4462", "context": "We present an AIDS patient with severe and prolonged lactic acidosis on stavudine and lamivudine.", "question": "Treatment.Disorder in stavudine and lamivudine", "question_type": "Adverse_event.Treatment.Disorder", "answers": "AIDS"}, {"id": "10970989_2_4463", "context": "We present an AIDS patient with severe and prolonged lactic acidosis on stavudine and lamivudine.", "question": "Combination.Drug in stavudine and lamivudine", "question_type": "Adverse_event.Combination.Drug", "answers": "stavudine; lamivudine"}, {"id": "15235919_1_4464", "context": "Sudden cardiac death due to hypersensitivity myocarditis during clozapine treatment.", "question": "Treatment.Drug in clozapine", "question_type": "Adverse_event.Treatment.Drug", "answers": "clozapine"}, {"id": "15235919_1_4465", "context": "Sudden cardiac death due to hypersensitivity myocarditis during clozapine treatment.", "question": "Treatment.Dosage in clozapine", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15235919_1_4466", "context": "Sudden cardiac death due to hypersensitivity myocarditis during clozapine treatment.", "question": "Treatment.Freq in clozapine", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15235919_1_4467", "context": "Sudden cardiac death due to hypersensitivity myocarditis during clozapine treatment.", "question": "Treatment.Route in clozapine", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15235919_1_4468", "context": "Sudden cardiac death due to hypersensitivity myocarditis during clozapine treatment.", "question": "Treatment.Time_elapsed in clozapine", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15235919_1_4469", "context": "Sudden cardiac death due to hypersensitivity myocarditis during clozapine treatment.", "question": "Treatment.Duration in clozapine", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15235919_1_4470", "context": "Sudden cardiac death due to hypersensitivity myocarditis during clozapine treatment.", "question": "Treatment.Disorder in clozapine", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15235919_1_4471", "context": "Sudden cardiac death due to hypersensitivity myocarditis during clozapine treatment.", "question": "Combination.Drug in clozapine", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11171531_2_4472", "context": "It also highlights a current major etiologic question, that is, whether and to what degree lead exposure contributes to the development of hypertension, and raises the issue of whether lead-induced hypertension constitutes a subset of hypertension that is especially amenable to therapy with dietary calcium.", "question": "Treatment.Drug in lead exposure", "question_type": "Adverse_event.Treatment.Drug", "answers": "lead"}, {"id": "11171531_2_4473", "context": "It also highlights a current major etiologic question, that is, whether and to what degree lead exposure contributes to the development of hypertension, and raises the issue of whether lead-induced hypertension constitutes a subset of hypertension that is especially amenable to therapy with dietary calcium.", "question": "Treatment.Dosage in lead exposure", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11171531_2_4474", "context": "It also highlights a current major etiologic question, that is, whether and to what degree lead exposure contributes to the development of hypertension, and raises the issue of whether lead-induced hypertension constitutes a subset of hypertension that is especially amenable to therapy with dietary calcium.", "question": "Treatment.Freq in lead exposure", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11171531_2_4475", "context": "It also highlights a current major etiologic question, that is, whether and to what degree lead exposure contributes to the development of hypertension, and raises the issue of whether lead-induced hypertension constitutes a subset of hypertension that is especially amenable to therapy with dietary calcium.", "question": "Treatment.Route in lead exposure", "question_type": "Adverse_event.Treatment.Route", "answers": "exposure"}, {"id": "11171531_2_4476", "context": "It also highlights a current major etiologic question, that is, whether and to what degree lead exposure contributes to the development of hypertension, and raises the issue of whether lead-induced hypertension constitutes a subset of hypertension that is especially amenable to therapy with dietary calcium.", "question": "Treatment.Time_elapsed in lead exposure", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11171531_2_4477", "context": "It also highlights a current major etiologic question, that is, whether and to what degree lead exposure contributes to the development of hypertension, and raises the issue of whether lead-induced hypertension constitutes a subset of hypertension that is especially amenable to therapy with dietary calcium.", "question": "Treatment.Duration in lead exposure", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11171531_2_4478", "context": "It also highlights a current major etiologic question, that is, whether and to what degree lead exposure contributes to the development of hypertension, and raises the issue of whether lead-induced hypertension constitutes a subset of hypertension that is especially amenable to therapy with dietary calcium.", "question": "Treatment.Disorder in lead exposure", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11171531_2_4479", "context": "It also highlights a current major etiologic question, that is, whether and to what degree lead exposure contributes to the development of hypertension, and raises the issue of whether lead-induced hypertension constitutes a subset of hypertension that is especially amenable to therapy with dietary calcium.", "question": "Combination.Drug in lead exposure", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15489872_1_4480", "context": "We report an allogeneic bone marrow transplant recipient who developed CMV infection refractory to sequential therapy with ganciclovir, foscarnet, and cidofovir.", "question": "Subject.Age in allogeneic bone marrow transplant recipient", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "15489872_1_4481", "context": "We report an allogeneic bone marrow transplant recipient who developed CMV infection refractory to sequential therapy with ganciclovir, foscarnet, and cidofovir.", "question": "Subject.Gender in allogeneic bone marrow transplant recipient", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "15489872_1_4482", "context": "We report an allogeneic bone marrow transplant recipient who developed CMV infection refractory to sequential therapy with ganciclovir, foscarnet, and cidofovir.", "question": "Subject.Population in allogeneic bone marrow transplant recipient", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "15489872_1_4483", "context": "We report an allogeneic bone marrow transplant recipient who developed CMV infection refractory to sequential therapy with ganciclovir, foscarnet, and cidofovir.", "question": "Subject.Race in allogeneic bone marrow transplant recipient", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "15489872_1_4484", "context": "We report an allogeneic bone marrow transplant recipient who developed CMV infection refractory to sequential therapy with ganciclovir, foscarnet, and cidofovir.", "question": "Subject.Disorder in allogeneic bone marrow transplant recipient", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": "allogeneic bone marrow transplant"}, {"id": "15489872_1_4485", "context": "We report an allogeneic bone marrow transplant recipient who developed CMV infection refractory to sequential therapy with ganciclovir, foscarnet, and cidofovir.", "question": "Treatment.Drug in sequential therapy with ganciclovir, foscarnet, and cidofovir", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "ganciclovir; foscarnet; cidofovir"}, {"id": "15489872_1_4486", "context": "We report an allogeneic bone marrow transplant recipient who developed CMV infection refractory to sequential therapy with ganciclovir, foscarnet, and cidofovir.", "question": "Treatment.Dosage in sequential therapy with ganciclovir, foscarnet, and cidofovir", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "15489872_1_4487", "context": "We report an allogeneic bone marrow transplant recipient who developed CMV infection refractory to sequential therapy with ganciclovir, foscarnet, and cidofovir.", "question": "Treatment.Freq in sequential therapy with ganciclovir, foscarnet, and cidofovir", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "15489872_1_4488", "context": "We report an allogeneic bone marrow transplant recipient who developed CMV infection refractory to sequential therapy with ganciclovir, foscarnet, and cidofovir.", "question": "Treatment.Route in sequential therapy with ganciclovir, foscarnet, and cidofovir", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "15489872_1_4489", "context": "We report an allogeneic bone marrow transplant recipient who developed CMV infection refractory to sequential therapy with ganciclovir, foscarnet, and cidofovir.", "question": "Treatment.Time_elapsed in sequential therapy with ganciclovir, foscarnet, and cidofovir", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15489872_1_4490", "context": "We report an allogeneic bone marrow transplant recipient who developed CMV infection refractory to sequential therapy with ganciclovir, foscarnet, and cidofovir.", "question": "Treatment.Duration in sequential therapy with ganciclovir, foscarnet, and cidofovir", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "15489872_1_4491", "context": "We report an allogeneic bone marrow transplant recipient who developed CMV infection refractory to sequential therapy with ganciclovir, foscarnet, and cidofovir.", "question": "Treatment.Disorder in sequential therapy with ganciclovir, foscarnet, and cidofovir", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "CMV infection"}, {"id": "15489872_1_4492", "context": "We report an allogeneic bone marrow transplant recipient who developed CMV infection refractory to sequential therapy with ganciclovir, foscarnet, and cidofovir.", "question": "Combination.Drug in sequential therapy with ganciclovir, foscarnet, and cidofovir", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": "ganciclovir; foscarnet; cidofovir"}, {"id": "11518127_2_4493", "context": "Acute interstitial pneumonia induced by ONO-1078 (pranlukast), a leukotriene receptor antagonist.", "question": "Treatment.Drug in ONO-1078 (pranlukast)", "question_type": "Adverse_event.Treatment.Drug", "answers": "ONO-1078"}, {"id": "11518127_2_4494", "context": "Acute interstitial pneumonia induced by ONO-1078 (pranlukast), a leukotriene receptor antagonist.", "question": "Treatment.Dosage in ONO-1078 (pranlukast)", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11518127_2_4495", "context": "Acute interstitial pneumonia induced by ONO-1078 (pranlukast), a leukotriene receptor antagonist.", "question": "Treatment.Freq in ONO-1078 (pranlukast)", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11518127_2_4496", "context": "Acute interstitial pneumonia induced by ONO-1078 (pranlukast), a leukotriene receptor antagonist.", "question": "Treatment.Route in ONO-1078 (pranlukast)", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11518127_2_4497", "context": "Acute interstitial pneumonia induced by ONO-1078 (pranlukast), a leukotriene receptor antagonist.", "question": "Treatment.Time_elapsed in ONO-1078 (pranlukast)", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11518127_2_4498", "context": "Acute interstitial pneumonia induced by ONO-1078 (pranlukast), a leukotriene receptor antagonist.", "question": "Treatment.Duration in ONO-1078 (pranlukast)", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11518127_2_4499", "context": "Acute interstitial pneumonia induced by ONO-1078 (pranlukast), a leukotriene receptor antagonist.", "question": "Treatment.Disorder in ONO-1078 (pranlukast)", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11518127_2_4500", "context": "Acute interstitial pneumonia induced by ONO-1078 (pranlukast), a leukotriene receptor antagonist.", "question": "Combination.Drug in ONO-1078 (pranlukast)", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "20020238_2_4501", "context": "CONCLUSION: Significant ocular complications such as an irreversible decrease of visual acuity may develop in patients treated with pegylated interferon.", "question": "Subject.Age in patients", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "20020238_2_4502", "context": "CONCLUSION: Significant ocular complications such as an irreversible decrease of visual acuity may develop in patients treated with pegylated interferon.", "question": "Subject.Gender in patients", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "20020238_2_4503", "context": "CONCLUSION: Significant ocular complications such as an irreversible decrease of visual acuity may develop in patients treated with pegylated interferon.", "question": "Subject.Population in patients", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "20020238_2_4504", "context": "CONCLUSION: Significant ocular complications such as an irreversible decrease of visual acuity may develop in patients treated with pegylated interferon.", "question": "Subject.Race in patients", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "20020238_2_4505", "context": "CONCLUSION: Significant ocular complications such as an irreversible decrease of visual acuity may develop in patients treated with pegylated interferon.", "question": "Subject.Disorder in patients", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "20020238_2_4506", "context": "CONCLUSION: Significant ocular complications such as an irreversible decrease of visual acuity may develop in patients treated with pegylated interferon.", "question": "Treatment.Drug in pegylated interferon", "question_type": "Adverse_event.Treatment.Drug", "answers": "pegylated interferon"}, {"id": "20020238_2_4507", "context": "CONCLUSION: Significant ocular complications such as an irreversible decrease of visual acuity may develop in patients treated with pegylated interferon.", "question": "Treatment.Dosage in pegylated interferon", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "20020238_2_4508", "context": "CONCLUSION: Significant ocular complications such as an irreversible decrease of visual acuity may develop in patients treated with pegylated interferon.", "question": "Treatment.Freq in pegylated interferon", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "20020238_2_4509", "context": "CONCLUSION: Significant ocular complications such as an irreversible decrease of visual acuity may develop in patients treated with pegylated interferon.", "question": "Treatment.Route in pegylated interferon", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "20020238_2_4510", "context": "CONCLUSION: Significant ocular complications such as an irreversible decrease of visual acuity may develop in patients treated with pegylated interferon.", "question": "Treatment.Time_elapsed in pegylated interferon", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "20020238_2_4511", "context": "CONCLUSION: Significant ocular complications such as an irreversible decrease of visual acuity may develop in patients treated with pegylated interferon.", "question": "Treatment.Duration in pegylated interferon", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "20020238_2_4512", "context": "CONCLUSION: Significant ocular complications such as an irreversible decrease of visual acuity may develop in patients treated with pegylated interferon.", "question": "Treatment.Disorder in pegylated interferon", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "20020238_2_4513", "context": "CONCLUSION: Significant ocular complications such as an irreversible decrease of visual acuity may develop in patients treated with pegylated interferon.", "question": "Combination.Drug in pegylated interferon", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11335880_1_4514", "context": "CONCLUSIONS: This case report showed that the clinical appearance of Hashimoto's disease after IFN-alpha therapy for chronic C hepatitis in our patient was associated with a specific genetic predisposition (DR5) for this pathology.", "question": "Subject.Age in our patient", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "11335880_1_4515", "context": "CONCLUSIONS: This case report showed that the clinical appearance of Hashimoto's disease after IFN-alpha therapy for chronic C hepatitis in our patient was associated with a specific genetic predisposition (DR5) for this pathology.", "question": "Subject.Gender in our patient", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "11335880_1_4516", "context": "CONCLUSIONS: This case report showed that the clinical appearance of Hashimoto's disease after IFN-alpha therapy for chronic C hepatitis in our patient was associated with a specific genetic predisposition (DR5) for this pathology.", "question": "Subject.Population in our patient", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "11335880_1_4517", "context": "CONCLUSIONS: This case report showed that the clinical appearance of Hashimoto's disease after IFN-alpha therapy for chronic C hepatitis in our patient was associated with a specific genetic predisposition (DR5) for this pathology.", "question": "Subject.Race in our patient", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "11335880_1_4518", "context": "CONCLUSIONS: This case report showed that the clinical appearance of Hashimoto's disease after IFN-alpha therapy for chronic C hepatitis in our patient was associated with a specific genetic predisposition (DR5) for this pathology.", "question": "Subject.Disorder in our patient", "question_type": "Adverse_event.Subject.Disorder", "answers": "a specific genetic predisposition (DR5) for this pathology"}, {"id": "11335880_1_4519", "context": "CONCLUSIONS: This case report showed that the clinical appearance of Hashimoto's disease after IFN-alpha therapy for chronic C hepatitis in our patient was associated with a specific genetic predisposition (DR5) for this pathology.", "question": "Treatment.Drug in IFN-alpha", "question_type": "Adverse_event.Treatment.Drug", "answers": "IFN-alpha"}, {"id": "11335880_1_4520", "context": "CONCLUSIONS: This case report showed that the clinical appearance of Hashimoto's disease after IFN-alpha therapy for chronic C hepatitis in our patient was associated with a specific genetic predisposition (DR5) for this pathology.", "question": "Treatment.Dosage in IFN-alpha", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11335880_1_4521", "context": "CONCLUSIONS: This case report showed that the clinical appearance of Hashimoto's disease after IFN-alpha therapy for chronic C hepatitis in our patient was associated with a specific genetic predisposition (DR5) for this pathology.", "question": "Treatment.Freq in IFN-alpha", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11335880_1_4522", "context": "CONCLUSIONS: This case report showed that the clinical appearance of Hashimoto's disease after IFN-alpha therapy for chronic C hepatitis in our patient was associated with a specific genetic predisposition (DR5) for this pathology.", "question": "Treatment.Route in IFN-alpha", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11335880_1_4523", "context": "CONCLUSIONS: This case report showed that the clinical appearance of Hashimoto's disease after IFN-alpha therapy for chronic C hepatitis in our patient was associated with a specific genetic predisposition (DR5) for this pathology.", "question": "Treatment.Time_elapsed in IFN-alpha", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11335880_1_4524", "context": "CONCLUSIONS: This case report showed that the clinical appearance of Hashimoto's disease after IFN-alpha therapy for chronic C hepatitis in our patient was associated with a specific genetic predisposition (DR5) for this pathology.", "question": "Treatment.Duration in IFN-alpha", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11335880_1_4525", "context": "CONCLUSIONS: This case report showed that the clinical appearance of Hashimoto's disease after IFN-alpha therapy for chronic C hepatitis in our patient was associated with a specific genetic predisposition (DR5) for this pathology.", "question": "Treatment.Disorder in IFN-alpha", "question_type": "Adverse_event.Treatment.Disorder", "answers": "chronic C hepatitis"}, {"id": "11335880_1_4526", "context": "CONCLUSIONS: This case report showed that the clinical appearance of Hashimoto's disease after IFN-alpha therapy for chronic C hepatitis in our patient was associated with a specific genetic predisposition (DR5) for this pathology.", "question": "Combination.Drug in IFN-alpha", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18472517_2_4527", "context": "We present here a female patient who developed acute bilateral parotitis within minutes of i.v. enalaprilat injection and recovered within 24 hours of stopping the drug and with symptomatic treatment.", "question": "Subject.Age in a female patient", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "18472517_2_4528", "context": "We present here a female patient who developed acute bilateral parotitis within minutes of i.v. enalaprilat injection and recovered within 24 hours of stopping the drug and with symptomatic treatment.", "question": "Subject.Gender in a female patient", "question_type": "Adverse_event.Subject.Gender", "answers": "female"}, {"id": "18472517_2_4529", "context": "We present here a female patient who developed acute bilateral parotitis within minutes of i.v. enalaprilat injection and recovered within 24 hours of stopping the drug and with symptomatic treatment.", "question": "Subject.Population in a female patient", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "18472517_2_4530", "context": "We present here a female patient who developed acute bilateral parotitis within minutes of i.v. enalaprilat injection and recovered within 24 hours of stopping the drug and with symptomatic treatment.", "question": "Subject.Race in a female patient", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "18472517_2_4531", "context": "We present here a female patient who developed acute bilateral parotitis within minutes of i.v. enalaprilat injection and recovered within 24 hours of stopping the drug and with symptomatic treatment.", "question": "Subject.Disorder in a female patient", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "18472517_2_4532", "context": "We present here a female patient who developed acute bilateral parotitis within minutes of i.v. enalaprilat injection and recovered within 24 hours of stopping the drug and with symptomatic treatment.", "question": "Treatment.Drug in i.v. enalaprilat injection", "question_type": "Adverse_event.Treatment.Drug", "answers": "enalaprilat"}, {"id": "18472517_2_4533", "context": "We present here a female patient who developed acute bilateral parotitis within minutes of i.v. enalaprilat injection and recovered within 24 hours of stopping the drug and with symptomatic treatment.", "question": "Treatment.Dosage in i.v. enalaprilat injection", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18472517_2_4534", "context": "We present here a female patient who developed acute bilateral parotitis within minutes of i.v. enalaprilat injection and recovered within 24 hours of stopping the drug and with symptomatic treatment.", "question": "Treatment.Freq in i.v. enalaprilat injection", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18472517_2_4535", "context": "We present here a female patient who developed acute bilateral parotitis within minutes of i.v. enalaprilat injection and recovered within 24 hours of stopping the drug and with symptomatic treatment.", "question": "Treatment.Route in i.v. enalaprilat injection", "question_type": "Adverse_event.Treatment.Route", "answers": "injection"}, {"id": "18472517_2_4536", "context": "We present here a female patient who developed acute bilateral parotitis within minutes of i.v. enalaprilat injection and recovered within 24 hours of stopping the drug and with symptomatic treatment.", "question": "Treatment.Time_elapsed in i.v. enalaprilat injection", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "within minutes"}, {"id": "18472517_2_4537", "context": "We present here a female patient who developed acute bilateral parotitis within minutes of i.v. enalaprilat injection and recovered within 24 hours of stopping the drug and with symptomatic treatment.", "question": "Treatment.Duration in i.v. enalaprilat injection", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18472517_2_4538", "context": "We present here a female patient who developed acute bilateral parotitis within minutes of i.v. enalaprilat injection and recovered within 24 hours of stopping the drug and with symptomatic treatment.", "question": "Treatment.Disorder in i.v. enalaprilat injection", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18472517_2_4539", "context": "We present here a female patient who developed acute bilateral parotitis within minutes of i.v. enalaprilat injection and recovered within 24 hours of stopping the drug and with symptomatic treatment.", "question": "Combination.Drug in i.v. enalaprilat injection", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10907391_4_4540", "context": "We describe 2 patients with prior amputation who experienced phantom limb pain (PLP) after receiving paclitaxel therapy.", "question": "Subject.Age in 2 patients with prior amputation", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "10907391_4_4541", "context": "We describe 2 patients with prior amputation who experienced phantom limb pain (PLP) after receiving paclitaxel therapy.", "question": "Subject.Gender in 2 patients with prior amputation", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "10907391_4_4542", "context": "We describe 2 patients with prior amputation who experienced phantom limb pain (PLP) after receiving paclitaxel therapy.", "question": "Subject.Population in 2 patients with prior amputation", "question_type": "Adverse_event.Subject.Population", "answers": "2"}, {"id": "10907391_4_4543", "context": "We describe 2 patients with prior amputation who experienced phantom limb pain (PLP) after receiving paclitaxel therapy.", "question": "Subject.Race in 2 patients with prior amputation", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "10907391_4_4544", "context": "We describe 2 patients with prior amputation who experienced phantom limb pain (PLP) after receiving paclitaxel therapy.", "question": "Subject.Disorder in 2 patients with prior amputation", "question_type": "Adverse_event.Subject.Disorder", "answers": "prior amputation"}, {"id": "10907391_4_4545", "context": "We describe 2 patients with prior amputation who experienced phantom limb pain (PLP) after receiving paclitaxel therapy.", "question": "Treatment.Drug in paclitaxel therapy", "question_type": "Adverse_event.Treatment.Drug", "answers": "paclitaxel"}, {"id": "10907391_4_4546", "context": "We describe 2 patients with prior amputation who experienced phantom limb pain (PLP) after receiving paclitaxel therapy.", "question": "Treatment.Dosage in paclitaxel therapy", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10907391_4_4547", "context": "We describe 2 patients with prior amputation who experienced phantom limb pain (PLP) after receiving paclitaxel therapy.", "question": "Treatment.Freq in paclitaxel therapy", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10907391_4_4548", "context": "We describe 2 patients with prior amputation who experienced phantom limb pain (PLP) after receiving paclitaxel therapy.", "question": "Treatment.Route in paclitaxel therapy", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10907391_4_4549", "context": "We describe 2 patients with prior amputation who experienced phantom limb pain (PLP) after receiving paclitaxel therapy.", "question": "Treatment.Time_elapsed in paclitaxel therapy", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10907391_4_4550", "context": "We describe 2 patients with prior amputation who experienced phantom limb pain (PLP) after receiving paclitaxel therapy.", "question": "Treatment.Duration in paclitaxel therapy", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10907391_4_4551", "context": "We describe 2 patients with prior amputation who experienced phantom limb pain (PLP) after receiving paclitaxel therapy.", "question": "Treatment.Disorder in paclitaxel therapy", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10907391_4_4552", "context": "We describe 2 patients with prior amputation who experienced phantom limb pain (PLP) after receiving paclitaxel therapy.", "question": "Combination.Drug in paclitaxel therapy", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11191005_1_4553", "context": "There is evidence that the angiotensin II receptor antagonist, losartan, increases urate excretion by reducing reabsorption of urate in the renal proximal tubule.", "question": "Treatment.Drug in angiotensin II receptor antagonist, losartan", "question_type": "Adverse_event.Treatment.Drug", "answers": "losartan"}, {"id": "11191005_1_4554", "context": "There is evidence that the angiotensin II receptor antagonist, losartan, increases urate excretion by reducing reabsorption of urate in the renal proximal tubule.", "question": "Treatment.Dosage in angiotensin II receptor antagonist, losartan", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11191005_1_4555", "context": "There is evidence that the angiotensin II receptor antagonist, losartan, increases urate excretion by reducing reabsorption of urate in the renal proximal tubule.", "question": "Treatment.Freq in angiotensin II receptor antagonist, losartan", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11191005_1_4556", "context": "There is evidence that the angiotensin II receptor antagonist, losartan, increases urate excretion by reducing reabsorption of urate in the renal proximal tubule.", "question": "Treatment.Route in angiotensin II receptor antagonist, losartan", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11191005_1_4557", "context": "There is evidence that the angiotensin II receptor antagonist, losartan, increases urate excretion by reducing reabsorption of urate in the renal proximal tubule.", "question": "Treatment.Time_elapsed in angiotensin II receptor antagonist, losartan", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11191005_1_4558", "context": "There is evidence that the angiotensin II receptor antagonist, losartan, increases urate excretion by reducing reabsorption of urate in the renal proximal tubule.", "question": "Treatment.Duration in angiotensin II receptor antagonist, losartan", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11191005_1_4559", "context": "There is evidence that the angiotensin II receptor antagonist, losartan, increases urate excretion by reducing reabsorption of urate in the renal proximal tubule.", "question": "Treatment.Disorder in angiotensin II receptor antagonist, losartan", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11191005_1_4560", "context": "There is evidence that the angiotensin II receptor antagonist, losartan, increases urate excretion by reducing reabsorption of urate in the renal proximal tubule.", "question": "Combination.Drug in angiotensin II receptor antagonist, losartan", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11468878_1_4561", "context": "Although no coagulation study was done and the Meckel's diverticulum is normally associated with bleeding, the particular intensity of the following hemorrhage may have been favored by metformin.", "question": "Treatment.Drug in metformin", "question_type": "Adverse_event.Treatment.Drug", "answers": "metformin"}, {"id": "11468878_1_4562", "context": "Although no coagulation study was done and the Meckel's diverticulum is normally associated with bleeding, the particular intensity of the following hemorrhage may have been favored by metformin.", "question": "Treatment.Dosage in metformin", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11468878_1_4563", "context": "Although no coagulation study was done and the Meckel's diverticulum is normally associated with bleeding, the particular intensity of the following hemorrhage may have been favored by metformin.", "question": "Treatment.Freq in metformin", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11468878_1_4564", "context": "Although no coagulation study was done and the Meckel's diverticulum is normally associated with bleeding, the particular intensity of the following hemorrhage may have been favored by metformin.", "question": "Treatment.Route in metformin", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11468878_1_4565", "context": "Although no coagulation study was done and the Meckel's diverticulum is normally associated with bleeding, the particular intensity of the following hemorrhage may have been favored by metformin.", "question": "Treatment.Time_elapsed in metformin", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11468878_1_4566", "context": "Although no coagulation study was done and the Meckel's diverticulum is normally associated with bleeding, the particular intensity of the following hemorrhage may have been favored by metformin.", "question": "Treatment.Duration in metformin", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11468878_1_4567", "context": "Although no coagulation study was done and the Meckel's diverticulum is normally associated with bleeding, the particular intensity of the following hemorrhage may have been favored by metformin.", "question": "Treatment.Disorder in metformin", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11468878_1_4568", "context": "Although no coagulation study was done and the Meckel's diverticulum is normally associated with bleeding, the particular intensity of the following hemorrhage may have been favored by metformin.", "question": "Combination.Drug in metformin", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15468380_2_4569", "context": "We describe 2 patients with severe erosive rheumatoid arthritis and rheumatoid vasculitis, respectively, in whom infliximab therapy was associated with peripheral neuropathy due to necrotizing vasculitis in one patient and to progression of preexisting mononeuritis multiplex in the other.", "question": "Subject.Age in one patient", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "15468380_2_4570", "context": "We describe 2 patients with severe erosive rheumatoid arthritis and rheumatoid vasculitis, respectively, in whom infliximab therapy was associated with peripheral neuropathy due to necrotizing vasculitis in one patient and to progression of preexisting mononeuritis multiplex in the other.", "question": "Subject.Gender in one patient", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15468380_2_4571", "context": "We describe 2 patients with severe erosive rheumatoid arthritis and rheumatoid vasculitis, respectively, in whom infliximab therapy was associated with peripheral neuropathy due to necrotizing vasculitis in one patient and to progression of preexisting mononeuritis multiplex in the other.", "question": "Subject.Population in one patient", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "15468380_2_4572", "context": "We describe 2 patients with severe erosive rheumatoid arthritis and rheumatoid vasculitis, respectively, in whom infliximab therapy was associated with peripheral neuropathy due to necrotizing vasculitis in one patient and to progression of preexisting mononeuritis multiplex in the other.", "question": "Subject.Race in one patient", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15468380_2_4573", "context": "We describe 2 patients with severe erosive rheumatoid arthritis and rheumatoid vasculitis, respectively, in whom infliximab therapy was associated with peripheral neuropathy due to necrotizing vasculitis in one patient and to progression of preexisting mononeuritis multiplex in the other.", "question": "Subject.Disorder in one patient", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15468380_2_4574", "context": "We describe 2 patients with severe erosive rheumatoid arthritis and rheumatoid vasculitis, respectively, in whom infliximab therapy was associated with peripheral neuropathy due to necrotizing vasculitis in one patient and to progression of preexisting mononeuritis multiplex in the other.", "question": "Treatment.Drug in infliximab therapy", "question_type": "Adverse_event.Treatment.Drug", "answers": "infliximab"}, {"id": "15468380_2_4575", "context": "We describe 2 patients with severe erosive rheumatoid arthritis and rheumatoid vasculitis, respectively, in whom infliximab therapy was associated with peripheral neuropathy due to necrotizing vasculitis in one patient and to progression of preexisting mononeuritis multiplex in the other.", "question": "Treatment.Dosage in infliximab therapy", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15468380_2_4576", "context": "We describe 2 patients with severe erosive rheumatoid arthritis and rheumatoid vasculitis, respectively, in whom infliximab therapy was associated with peripheral neuropathy due to necrotizing vasculitis in one patient and to progression of preexisting mononeuritis multiplex in the other.", "question": "Treatment.Freq in infliximab therapy", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15468380_2_4577", "context": "We describe 2 patients with severe erosive rheumatoid arthritis and rheumatoid vasculitis, respectively, in whom infliximab therapy was associated with peripheral neuropathy due to necrotizing vasculitis in one patient and to progression of preexisting mononeuritis multiplex in the other.", "question": "Treatment.Route in infliximab therapy", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15468380_2_4578", "context": "We describe 2 patients with severe erosive rheumatoid arthritis and rheumatoid vasculitis, respectively, in whom infliximab therapy was associated with peripheral neuropathy due to necrotizing vasculitis in one patient and to progression of preexisting mononeuritis multiplex in the other.", "question": "Treatment.Time_elapsed in infliximab therapy", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15468380_2_4579", "context": "We describe 2 patients with severe erosive rheumatoid arthritis and rheumatoid vasculitis, respectively, in whom infliximab therapy was associated with peripheral neuropathy due to necrotizing vasculitis in one patient and to progression of preexisting mononeuritis multiplex in the other.", "question": "Treatment.Duration in infliximab therapy", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15468380_2_4580", "context": "We describe 2 patients with severe erosive rheumatoid arthritis and rheumatoid vasculitis, respectively, in whom infliximab therapy was associated with peripheral neuropathy due to necrotizing vasculitis in one patient and to progression of preexisting mononeuritis multiplex in the other.", "question": "Treatment.Disorder in infliximab therapy", "question_type": "Adverse_event.Treatment.Disorder", "answers": "necrotizing vasculitis"}, {"id": "15468380_2_4581", "context": "We describe 2 patients with severe erosive rheumatoid arthritis and rheumatoid vasculitis, respectively, in whom infliximab therapy was associated with peripheral neuropathy due to necrotizing vasculitis in one patient and to progression of preexisting mononeuritis multiplex in the other.", "question": "Combination.Drug in infliximab therapy", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15468380_2_4582", "context": "We describe 2 patients with severe erosive rheumatoid arthritis and rheumatoid vasculitis, respectively, in whom infliximab therapy was associated with peripheral neuropathy due to necrotizing vasculitis in one patient and to progression of preexisting mononeuritis multiplex in the other.", "question": "Subject.Age in preexisting mononeuritis multiplex in the other", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "15468380_2_4583", "context": "We describe 2 patients with severe erosive rheumatoid arthritis and rheumatoid vasculitis, respectively, in whom infliximab therapy was associated with peripheral neuropathy due to necrotizing vasculitis in one patient and to progression of preexisting mononeuritis multiplex in the other.", "question": "Subject.Gender in preexisting mononeuritis multiplex in the other", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15468380_2_4584", "context": "We describe 2 patients with severe erosive rheumatoid arthritis and rheumatoid vasculitis, respectively, in whom infliximab therapy was associated with peripheral neuropathy due to necrotizing vasculitis in one patient and to progression of preexisting mononeuritis multiplex in the other.", "question": "Subject.Population in preexisting mononeuritis multiplex in the other", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "15468380_2_4585", "context": "We describe 2 patients with severe erosive rheumatoid arthritis and rheumatoid vasculitis, respectively, in whom infliximab therapy was associated with peripheral neuropathy due to necrotizing vasculitis in one patient and to progression of preexisting mononeuritis multiplex in the other.", "question": "Subject.Race in preexisting mononeuritis multiplex in the other", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15468380_2_4586", "context": "We describe 2 patients with severe erosive rheumatoid arthritis and rheumatoid vasculitis, respectively, in whom infliximab therapy was associated with peripheral neuropathy due to necrotizing vasculitis in one patient and to progression of preexisting mononeuritis multiplex in the other.", "question": "Subject.Disorder in preexisting mononeuritis multiplex in the other", "question_type": "Adverse_event.Subject.Disorder", "answers": "preexisting mononeuritis multiplex"}, {"id": "15468380_2_4587", "context": "We describe 2 patients with severe erosive rheumatoid arthritis and rheumatoid vasculitis, respectively, in whom infliximab therapy was associated with peripheral neuropathy due to necrotizing vasculitis in one patient and to progression of preexisting mononeuritis multiplex in the other.", "question": "Treatment.Drug in infliximab therapy", "question_type": "Adverse_event.Treatment.Drug", "answers": "infliximab"}, {"id": "15468380_2_4588", "context": "We describe 2 patients with severe erosive rheumatoid arthritis and rheumatoid vasculitis, respectively, in whom infliximab therapy was associated with peripheral neuropathy due to necrotizing vasculitis in one patient and to progression of preexisting mononeuritis multiplex in the other.", "question": "Treatment.Dosage in infliximab therapy", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15468380_2_4589", "context": "We describe 2 patients with severe erosive rheumatoid arthritis and rheumatoid vasculitis, respectively, in whom infliximab therapy was associated with peripheral neuropathy due to necrotizing vasculitis in one patient and to progression of preexisting mononeuritis multiplex in the other.", "question": "Treatment.Freq in infliximab therapy", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15468380_2_4590", "context": "We describe 2 patients with severe erosive rheumatoid arthritis and rheumatoid vasculitis, respectively, in whom infliximab therapy was associated with peripheral neuropathy due to necrotizing vasculitis in one patient and to progression of preexisting mononeuritis multiplex in the other.", "question": "Treatment.Route in infliximab therapy", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15468380_2_4591", "context": "We describe 2 patients with severe erosive rheumatoid arthritis and rheumatoid vasculitis, respectively, in whom infliximab therapy was associated with peripheral neuropathy due to necrotizing vasculitis in one patient and to progression of preexisting mononeuritis multiplex in the other.", "question": "Treatment.Time_elapsed in infliximab therapy", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15468380_2_4592", "context": "We describe 2 patients with severe erosive rheumatoid arthritis and rheumatoid vasculitis, respectively, in whom infliximab therapy was associated with peripheral neuropathy due to necrotizing vasculitis in one patient and to progression of preexisting mononeuritis multiplex in the other.", "question": "Treatment.Duration in infliximab therapy", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15468380_2_4593", "context": "We describe 2 patients with severe erosive rheumatoid arthritis and rheumatoid vasculitis, respectively, in whom infliximab therapy was associated with peripheral neuropathy due to necrotizing vasculitis in one patient and to progression of preexisting mononeuritis multiplex in the other.", "question": "Treatment.Disorder in infliximab therapy", "question_type": "Adverse_event.Treatment.Disorder", "answers": "necrotizing vasculitis"}, {"id": "15468380_2_4594", "context": "We describe 2 patients with severe erosive rheumatoid arthritis and rheumatoid vasculitis, respectively, in whom infliximab therapy was associated with peripheral neuropathy due to necrotizing vasculitis in one patient and to progression of preexisting mononeuritis multiplex in the other.", "question": "Combination.Drug in infliximab therapy", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3586163_2_4595", "context": "Upper tract urothelial malignancy after cyclophosphamide therapy: a case report and literature review.", "question": "Treatment.Drug in cyclophosphamide therapy", "question_type": "Adverse_event.Treatment.Drug", "answers": "cyclophosphamide"}, {"id": "3586163_2_4596", "context": "Upper tract urothelial malignancy after cyclophosphamide therapy: a case report and literature review.", "question": "Treatment.Dosage in cyclophosphamide therapy", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3586163_2_4597", "context": "Upper tract urothelial malignancy after cyclophosphamide therapy: a case report and literature review.", "question": "Treatment.Freq in cyclophosphamide therapy", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3586163_2_4598", "context": "Upper tract urothelial malignancy after cyclophosphamide therapy: a case report and literature review.", "question": "Treatment.Route in cyclophosphamide therapy", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3586163_2_4599", "context": "Upper tract urothelial malignancy after cyclophosphamide therapy: a case report and literature review.", "question": "Treatment.Time_elapsed in cyclophosphamide therapy", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3586163_2_4600", "context": "Upper tract urothelial malignancy after cyclophosphamide therapy: a case report and literature review.", "question": "Treatment.Duration in cyclophosphamide therapy", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3586163_2_4601", "context": "Upper tract urothelial malignancy after cyclophosphamide therapy: a case report and literature review.", "question": "Treatment.Disorder in cyclophosphamide therapy", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3586163_2_4602", "context": "Upper tract urothelial malignancy after cyclophosphamide therapy: a case report and literature review.", "question": "Combination.Drug in cyclophosphamide therapy", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8864370_1_4603", "context": "BACKGROUND: Methotrexate (MTX) may induce liver damage, which in some psoriatics will lead to fibrosis or cirrhosis.", "question": "Treatment.Drug in Methotrexate (MTX)", "question_type": "Adverse_event.Treatment.Drug", "answers": "Methotrexate"}, {"id": "8864370_1_4604", "context": "BACKGROUND: Methotrexate (MTX) may induce liver damage, which in some psoriatics will lead to fibrosis or cirrhosis.", "question": "Treatment.Dosage in Methotrexate (MTX)", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8864370_1_4605", "context": "BACKGROUND: Methotrexate (MTX) may induce liver damage, which in some psoriatics will lead to fibrosis or cirrhosis.", "question": "Treatment.Freq in Methotrexate (MTX)", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8864370_1_4606", "context": "BACKGROUND: Methotrexate (MTX) may induce liver damage, which in some psoriatics will lead to fibrosis or cirrhosis.", "question": "Treatment.Route in Methotrexate (MTX)", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8864370_1_4607", "context": "BACKGROUND: Methotrexate (MTX) may induce liver damage, which in some psoriatics will lead to fibrosis or cirrhosis.", "question": "Treatment.Time_elapsed in Methotrexate (MTX)", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8864370_1_4608", "context": "BACKGROUND: Methotrexate (MTX) may induce liver damage, which in some psoriatics will lead to fibrosis or cirrhosis.", "question": "Treatment.Duration in Methotrexate (MTX)", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8864370_1_4609", "context": "BACKGROUND: Methotrexate (MTX) may induce liver damage, which in some psoriatics will lead to fibrosis or cirrhosis.", "question": "Treatment.Disorder in Methotrexate (MTX)", "question_type": "Adverse_event.Treatment.Disorder", "answers": "psoriatics"}, {"id": "8864370_1_4610", "context": "BACKGROUND: Methotrexate (MTX) may induce liver damage, which in some psoriatics will lead to fibrosis or cirrhosis.", "question": "Combination.Drug in Methotrexate (MTX)", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "19071894_5_4611", "context": "The infection proceeded even after treatment with fluconazole.", "question": "Treatment.Drug in fluconazole", "question_type": "Adverse_event.Treatment.Drug", "answers": "fluconazole"}, {"id": "19071894_5_4612", "context": "The infection proceeded even after treatment with fluconazole.", "question": "Treatment.Dosage in fluconazole", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "19071894_5_4613", "context": "The infection proceeded even after treatment with fluconazole.", "question": "Treatment.Freq in fluconazole", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "19071894_5_4614", "context": "The infection proceeded even after treatment with fluconazole.", "question": "Treatment.Route in fluconazole", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "19071894_5_4615", "context": "The infection proceeded even after treatment with fluconazole.", "question": "Treatment.Time_elapsed in fluconazole", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19071894_5_4616", "context": "The infection proceeded even after treatment with fluconazole.", "question": "Treatment.Duration in fluconazole", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "19071894_5_4617", "context": "The infection proceeded even after treatment with fluconazole.", "question": "Treatment.Disorder in fluconazole", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "19071894_5_4618", "context": "The infection proceeded even after treatment with fluconazole.", "question": "Combination.Drug in fluconazole", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9861579_1_4619", "context": "We report the case of intoxication of a 41-year-old female patient suffering from major depression with mirtazapine complicated by severe hypothermia.", "question": "Subject.Age in a 41-year-old female patient", "question_type": "Adverse_event.Subject.Age", "answers": "41-year-old"}, {"id": "9861579_1_4620", "context": "We report the case of intoxication of a 41-year-old female patient suffering from major depression with mirtazapine complicated by severe hypothermia.", "question": "Subject.Gender in a 41-year-old female patient", "question_type": "Adverse_event.Subject.Gender", "answers": "female"}, {"id": "9861579_1_4621", "context": "We report the case of intoxication of a 41-year-old female patient suffering from major depression with mirtazapine complicated by severe hypothermia.", "question": "Subject.Population in a 41-year-old female patient", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "9861579_1_4622", "context": "We report the case of intoxication of a 41-year-old female patient suffering from major depression with mirtazapine complicated by severe hypothermia.", "question": "Subject.Race in a 41-year-old female patient", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "9861579_1_4623", "context": "We report the case of intoxication of a 41-year-old female patient suffering from major depression with mirtazapine complicated by severe hypothermia.", "question": "Subject.Disorder in a 41-year-old female patient", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "9861579_1_4624", "context": "We report the case of intoxication of a 41-year-old female patient suffering from major depression with mirtazapine complicated by severe hypothermia.", "question": "Treatment.Drug in mirtazapine", "question_type": "Adverse_event.Treatment.Drug", "answers": "mirtazapine"}, {"id": "9861579_1_4625", "context": "We report the case of intoxication of a 41-year-old female patient suffering from major depression with mirtazapine complicated by severe hypothermia.", "question": "Treatment.Dosage in mirtazapine", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9861579_1_4626", "context": "We report the case of intoxication of a 41-year-old female patient suffering from major depression with mirtazapine complicated by severe hypothermia.", "question": "Treatment.Freq in mirtazapine", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9861579_1_4627", "context": "We report the case of intoxication of a 41-year-old female patient suffering from major depression with mirtazapine complicated by severe hypothermia.", "question": "Treatment.Route in mirtazapine", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9861579_1_4628", "context": "We report the case of intoxication of a 41-year-old female patient suffering from major depression with mirtazapine complicated by severe hypothermia.", "question": "Treatment.Time_elapsed in mirtazapine", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9861579_1_4629", "context": "We report the case of intoxication of a 41-year-old female patient suffering from major depression with mirtazapine complicated by severe hypothermia.", "question": "Treatment.Duration in mirtazapine", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9861579_1_4630", "context": "We report the case of intoxication of a 41-year-old female patient suffering from major depression with mirtazapine complicated by severe hypothermia.", "question": "Treatment.Disorder in mirtazapine", "question_type": "Adverse_event.Treatment.Disorder", "answers": "major depression"}, {"id": "9861579_1_4631", "context": "We report the case of intoxication of a 41-year-old female patient suffering from major depression with mirtazapine complicated by severe hypothermia.", "question": "Combination.Drug in mirtazapine", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16816519_9_4632", "context": "The bilateral ptosis markedly improved after 7 days of pyridoxine and pyridostigmine treatment and completely resolved after two weeks.", "question": "Treatment.Drug in pyridoxine and pyridostigmine treatment", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "pyridoxine; pyridostigmine"}, {"id": "16816519_9_4633", "context": "The bilateral ptosis markedly improved after 7 days of pyridoxine and pyridostigmine treatment and completely resolved after two weeks.", "question": "Treatment.Dosage in pyridoxine and pyridostigmine treatment", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "16816519_9_4634", "context": "The bilateral ptosis markedly improved after 7 days of pyridoxine and pyridostigmine treatment and completely resolved after two weeks.", "question": "Treatment.Freq in pyridoxine and pyridostigmine treatment", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "16816519_9_4635", "context": "The bilateral ptosis markedly improved after 7 days of pyridoxine and pyridostigmine treatment and completely resolved after two weeks.", "question": "Treatment.Route in pyridoxine and pyridostigmine treatment", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "16816519_9_4636", "context": "The bilateral ptosis markedly improved after 7 days of pyridoxine and pyridostigmine treatment and completely resolved after two weeks.", "question": "Treatment.Time_elapsed in pyridoxine and pyridostigmine treatment", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": "7 days"}, {"id": "16816519_9_4637", "context": "The bilateral ptosis markedly improved after 7 days of pyridoxine and pyridostigmine treatment and completely resolved after two weeks.", "question": "Treatment.Duration in pyridoxine and pyridostigmine treatment", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "16816519_9_4638", "context": "The bilateral ptosis markedly improved after 7 days of pyridoxine and pyridostigmine treatment and completely resolved after two weeks.", "question": "Treatment.Disorder in pyridoxine and pyridostigmine treatment", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "16816519_9_4639", "context": "The bilateral ptosis markedly improved after 7 days of pyridoxine and pyridostigmine treatment and completely resolved after two weeks.", "question": "Combination.Drug in pyridoxine and pyridostigmine treatment", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": "pyridoxine; pyridostigmine"}, {"id": "20065266_4_4640", "context": "PURPOSE: The case of a patient who developed aseptic meningitis, hemolytic anemia, hepatitis, and orthostatic hypotension simultaneously during treatment with trimethoprim-sulfamethoxazole is described.", "question": "Subject.Age in a patient", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "20065266_4_4641", "context": "PURPOSE: The case of a patient who developed aseptic meningitis, hemolytic anemia, hepatitis, and orthostatic hypotension simultaneously during treatment with trimethoprim-sulfamethoxazole is described.", "question": "Subject.Gender in a patient", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "20065266_4_4642", "context": "PURPOSE: The case of a patient who developed aseptic meningitis, hemolytic anemia, hepatitis, and orthostatic hypotension simultaneously during treatment with trimethoprim-sulfamethoxazole is described.", "question": "Subject.Population in a patient", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "20065266_4_4643", "context": "PURPOSE: The case of a patient who developed aseptic meningitis, hemolytic anemia, hepatitis, and orthostatic hypotension simultaneously during treatment with trimethoprim-sulfamethoxazole is described.", "question": "Subject.Race in a patient", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "20065266_4_4644", "context": "PURPOSE: The case of a patient who developed aseptic meningitis, hemolytic anemia, hepatitis, and orthostatic hypotension simultaneously during treatment with trimethoprim-sulfamethoxazole is described.", "question": "Subject.Disorder in a patient", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "20065266_4_4645", "context": "PURPOSE: The case of a patient who developed aseptic meningitis, hemolytic anemia, hepatitis, and orthostatic hypotension simultaneously during treatment with trimethoprim-sulfamethoxazole is described.", "question": "Treatment.Drug in trimethoprim-sulfamethoxazole", "question_type": "Adverse_event.Treatment.Drug", "answers": "trimethoprim-sulfamethoxazole"}, {"id": "20065266_4_4646", "context": "PURPOSE: The case of a patient who developed aseptic meningitis, hemolytic anemia, hepatitis, and orthostatic hypotension simultaneously during treatment with trimethoprim-sulfamethoxazole is described.", "question": "Treatment.Dosage in trimethoprim-sulfamethoxazole", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "20065266_4_4647", "context": "PURPOSE: The case of a patient who developed aseptic meningitis, hemolytic anemia, hepatitis, and orthostatic hypotension simultaneously during treatment with trimethoprim-sulfamethoxazole is described.", "question": "Treatment.Freq in trimethoprim-sulfamethoxazole", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "20065266_4_4648", "context": "PURPOSE: The case of a patient who developed aseptic meningitis, hemolytic anemia, hepatitis, and orthostatic hypotension simultaneously during treatment with trimethoprim-sulfamethoxazole is described.", "question": "Treatment.Route in trimethoprim-sulfamethoxazole", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "20065266_4_4649", "context": "PURPOSE: The case of a patient who developed aseptic meningitis, hemolytic anemia, hepatitis, and orthostatic hypotension simultaneously during treatment with trimethoprim-sulfamethoxazole is described.", "question": "Treatment.Time_elapsed in trimethoprim-sulfamethoxazole", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "20065266_4_4650", "context": "PURPOSE: The case of a patient who developed aseptic meningitis, hemolytic anemia, hepatitis, and orthostatic hypotension simultaneously during treatment with trimethoprim-sulfamethoxazole is described.", "question": "Treatment.Duration in trimethoprim-sulfamethoxazole", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "20065266_4_4651", "context": "PURPOSE: The case of a patient who developed aseptic meningitis, hemolytic anemia, hepatitis, and orthostatic hypotension simultaneously during treatment with trimethoprim-sulfamethoxazole is described.", "question": "Treatment.Disorder in trimethoprim-sulfamethoxazole", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "20065266_4_4652", "context": "PURPOSE: The case of a patient who developed aseptic meningitis, hemolytic anemia, hepatitis, and orthostatic hypotension simultaneously during treatment with trimethoprim-sulfamethoxazole is described.", "question": "Combination.Drug in trimethoprim-sulfamethoxazole", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12432978_2_4653", "context": "Seizures and extrapyramidal symptoms in a patient with Tourette's syndrome, Asperger's syndrome, and multiple sclerosis treated with interferon beta-1a and clomipramine.", "question": "Subject.Age in a patient with Tourette's syndrome, Asperger's syndrome, and multiple sclerosis", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "12432978_2_4654", "context": "Seizures and extrapyramidal symptoms in a patient with Tourette's syndrome, Asperger's syndrome, and multiple sclerosis treated with interferon beta-1a and clomipramine.", "question": "Subject.Gender in a patient with Tourette's syndrome, Asperger's syndrome, and multiple sclerosis", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "12432978_2_4655", "context": "Seizures and extrapyramidal symptoms in a patient with Tourette's syndrome, Asperger's syndrome, and multiple sclerosis treated with interferon beta-1a and clomipramine.", "question": "Subject.Population in a patient with Tourette's syndrome, Asperger's syndrome, and multiple sclerosis", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "12432978_2_4656", "context": "Seizures and extrapyramidal symptoms in a patient with Tourette's syndrome, Asperger's syndrome, and multiple sclerosis treated with interferon beta-1a and clomipramine.", "question": "Subject.Race in a patient with Tourette's syndrome, Asperger's syndrome, and multiple sclerosis", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "12432978_2_4657", "context": "Seizures and extrapyramidal symptoms in a patient with Tourette's syndrome, Asperger's syndrome, and multiple sclerosis treated with interferon beta-1a and clomipramine.", "question": "Subject.Disorder in a patient with Tourette's syndrome, Asperger's syndrome, and multiple sclerosis", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "12432978_2_4658", "context": "Seizures and extrapyramidal symptoms in a patient with Tourette's syndrome, Asperger's syndrome, and multiple sclerosis treated with interferon beta-1a and clomipramine.", "question": "Treatment.Drug in interferon beta-1a and clomipramine", "question_type": "Adverse_event.Treatment.Drug", "answers": "clomipramine; interferon beta-1a"}, {"id": "12432978_2_4659", "context": "Seizures and extrapyramidal symptoms in a patient with Tourette's syndrome, Asperger's syndrome, and multiple sclerosis treated with interferon beta-1a and clomipramine.", "question": "Treatment.Dosage in interferon beta-1a and clomipramine", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12432978_2_4660", "context": "Seizures and extrapyramidal symptoms in a patient with Tourette's syndrome, Asperger's syndrome, and multiple sclerosis treated with interferon beta-1a and clomipramine.", "question": "Treatment.Freq in interferon beta-1a and clomipramine", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12432978_2_4661", "context": "Seizures and extrapyramidal symptoms in a patient with Tourette's syndrome, Asperger's syndrome, and multiple sclerosis treated with interferon beta-1a and clomipramine.", "question": "Treatment.Route in interferon beta-1a and clomipramine", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12432978_2_4662", "context": "Seizures and extrapyramidal symptoms in a patient with Tourette's syndrome, Asperger's syndrome, and multiple sclerosis treated with interferon beta-1a and clomipramine.", "question": "Treatment.Time_elapsed in interferon beta-1a and clomipramine", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12432978_2_4663", "context": "Seizures and extrapyramidal symptoms in a patient with Tourette's syndrome, Asperger's syndrome, and multiple sclerosis treated with interferon beta-1a and clomipramine.", "question": "Treatment.Duration in interferon beta-1a and clomipramine", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12432978_2_4664", "context": "Seizures and extrapyramidal symptoms in a patient with Tourette's syndrome, Asperger's syndrome, and multiple sclerosis treated with interferon beta-1a and clomipramine.", "question": "Treatment.Disorder in interferon beta-1a and clomipramine", "question_type": "Adverse_event.Treatment.Disorder", "answers": "Tourette's syndrome; Asperger's syndrome; multiple sclerosis"}, {"id": "12432978_2_4665", "context": "Seizures and extrapyramidal symptoms in a patient with Tourette's syndrome, Asperger's syndrome, and multiple sclerosis treated with interferon beta-1a and clomipramine.", "question": "Combination.Drug in interferon beta-1a and clomipramine", "question_type": "Adverse_event.Combination.Drug", "answers": "interferon beta-1a; clomipramine"}, {"id": "8961730_1_4666", "context": "Psychotic disorder associated with isoniazid.", "question": "Treatment.Drug in isoniazid", "question_type": "Adverse_event.Treatment.Drug", "answers": "isoniazid"}, {"id": "8961730_1_4667", "context": "Psychotic disorder associated with isoniazid.", "question": "Treatment.Dosage in isoniazid", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8961730_1_4668", "context": "Psychotic disorder associated with isoniazid.", "question": "Treatment.Freq in isoniazid", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8961730_1_4669", "context": "Psychotic disorder associated with isoniazid.", "question": "Treatment.Route in isoniazid", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8961730_1_4670", "context": "Psychotic disorder associated with isoniazid.", "question": "Treatment.Time_elapsed in isoniazid", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8961730_1_4671", "context": "Psychotic disorder associated with isoniazid.", "question": "Treatment.Duration in isoniazid", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8961730_1_4672", "context": "Psychotic disorder associated with isoniazid.", "question": "Treatment.Disorder in isoniazid", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8961730_1_4673", "context": "Psychotic disorder associated with isoniazid.", "question": "Combination.Drug in isoniazid", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8551001_3_4674", "context": "The azathioprine dose was low (1 mg/kg) and pancytopenia occurred after 56 days therapy.", "question": "Treatment.Drug in 56 days therapy; The azathioprine dose was low (1 mg/kg)", "question_type": "Adverse_event.Treatment.Drug", "answers": "azathioprine"}, {"id": "8551001_3_4675", "context": "The azathioprine dose was low (1 mg/kg) and pancytopenia occurred after 56 days therapy.", "question": "Treatment.Dosage in 56 days therapy; The azathioprine dose was low (1 mg/kg)", "question_type": "Adverse_event.Treatment.Dosage", "answers": "1 mg/kg"}, {"id": "8551001_3_4676", "context": "The azathioprine dose was low (1 mg/kg) and pancytopenia occurred after 56 days therapy.", "question": "Treatment.Freq in 56 days therapy; The azathioprine dose was low (1 mg/kg)", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8551001_3_4677", "context": "The azathioprine dose was low (1 mg/kg) and pancytopenia occurred after 56 days therapy.", "question": "Treatment.Route in 56 days therapy; The azathioprine dose was low (1 mg/kg)", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8551001_3_4678", "context": "The azathioprine dose was low (1 mg/kg) and pancytopenia occurred after 56 days therapy.", "question": "Treatment.Time_elapsed in 56 days therapy; The azathioprine dose was low (1 mg/kg)", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "56 days"}, {"id": "8551001_3_4679", "context": "The azathioprine dose was low (1 mg/kg) and pancytopenia occurred after 56 days therapy.", "question": "Treatment.Duration in 56 days therapy; The azathioprine dose was low (1 mg/kg)", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8551001_3_4680", "context": "The azathioprine dose was low (1 mg/kg) and pancytopenia occurred after 56 days therapy.", "question": "Treatment.Disorder in 56 days therapy; The azathioprine dose was low (1 mg/kg)", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8551001_3_4681", "context": "The azathioprine dose was low (1 mg/kg) and pancytopenia occurred after 56 days therapy.", "question": "Combination.Drug in 56 days therapy; The azathioprine dose was low (1 mg/kg)", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10442258_5_4682", "context": "Findings on discontinuation and rechallenge supported the assumption that the hair loss was a side effect of the paroxetine.", "question": "Treatment.Drug in paroxetine.", "question_type": "Adverse_event.Treatment.Drug", "answers": "paroxetine"}, {"id": "10442258_5_4683", "context": "Findings on discontinuation and rechallenge supported the assumption that the hair loss was a side effect of the paroxetine.", "question": "Treatment.Dosage in paroxetine.", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10442258_5_4684", "context": "Findings on discontinuation and rechallenge supported the assumption that the hair loss was a side effect of the paroxetine.", "question": "Treatment.Freq in paroxetine.", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10442258_5_4685", "context": "Findings on discontinuation and rechallenge supported the assumption that the hair loss was a side effect of the paroxetine.", "question": "Treatment.Route in paroxetine.", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10442258_5_4686", "context": "Findings on discontinuation and rechallenge supported the assumption that the hair loss was a side effect of the paroxetine.", "question": "Treatment.Time_elapsed in paroxetine.", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10442258_5_4687", "context": "Findings on discontinuation and rechallenge supported the assumption that the hair loss was a side effect of the paroxetine.", "question": "Treatment.Duration in paroxetine.", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10442258_5_4688", "context": "Findings on discontinuation and rechallenge supported the assumption that the hair loss was a side effect of the paroxetine.", "question": "Treatment.Disorder in paroxetine.", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10442258_5_4689", "context": "Findings on discontinuation and rechallenge supported the assumption that the hair loss was a side effect of the paroxetine.", "question": "Combination.Drug in paroxetine.", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12546343_5_4690", "context": "The successful development and implementation of this protocol will have impact on patients who have anaphylactic reactions to MTX but require this medication for specific diseases.", "question": "Subject.Age in patients", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "12546343_5_4691", "context": "The successful development and implementation of this protocol will have impact on patients who have anaphylactic reactions to MTX but require this medication for specific diseases.", "question": "Subject.Gender in patients", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "12546343_5_4692", "context": "The successful development and implementation of this protocol will have impact on patients who have anaphylactic reactions to MTX but require this medication for specific diseases.", "question": "Subject.Population in patients", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "12546343_5_4693", "context": "The successful development and implementation of this protocol will have impact on patients who have anaphylactic reactions to MTX but require this medication for specific diseases.", "question": "Subject.Race in patients", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "12546343_5_4694", "context": "The successful development and implementation of this protocol will have impact on patients who have anaphylactic reactions to MTX but require this medication for specific diseases.", "question": "Subject.Disorder in patients", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "12546343_5_4695", "context": "The successful development and implementation of this protocol will have impact on patients who have anaphylactic reactions to MTX but require this medication for specific diseases.", "question": "Treatment.Drug in MTX", "question_type": "Adverse_event.Treatment.Drug", "answers": "MTX"}, {"id": "12546343_5_4696", "context": "The successful development and implementation of this protocol will have impact on patients who have anaphylactic reactions to MTX but require this medication for specific diseases.", "question": "Treatment.Dosage in MTX", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12546343_5_4697", "context": "The successful development and implementation of this protocol will have impact on patients who have anaphylactic reactions to MTX but require this medication for specific diseases.", "question": "Treatment.Freq in MTX", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12546343_5_4698", "context": "The successful development and implementation of this protocol will have impact on patients who have anaphylactic reactions to MTX but require this medication for specific diseases.", "question": "Treatment.Route in MTX", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12546343_5_4699", "context": "The successful development and implementation of this protocol will have impact on patients who have anaphylactic reactions to MTX but require this medication for specific diseases.", "question": "Treatment.Time_elapsed in MTX", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12546343_5_4700", "context": "The successful development and implementation of this protocol will have impact on patients who have anaphylactic reactions to MTX but require this medication for specific diseases.", "question": "Treatment.Duration in MTX", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12546343_5_4701", "context": "The successful development and implementation of this protocol will have impact on patients who have anaphylactic reactions to MTX but require this medication for specific diseases.", "question": "Treatment.Disorder in MTX", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12546343_5_4702", "context": "The successful development and implementation of this protocol will have impact on patients who have anaphylactic reactions to MTX but require this medication for specific diseases.", "question": "Combination.Drug in MTX", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18445989_2_4703", "context": "Clomiphene is a first line treatment for anovulation, a common cause of infertility.", "question": "Treatment.Drug in Clomiphene", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "Clomiphene"}, {"id": "18445989_2_4704", "context": "Clomiphene is a first line treatment for anovulation, a common cause of infertility.", "question": "Treatment.Dosage in Clomiphene", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "18445989_2_4705", "context": "Clomiphene is a first line treatment for anovulation, a common cause of infertility.", "question": "Treatment.Freq in Clomiphene", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "18445989_2_4706", "context": "Clomiphene is a first line treatment for anovulation, a common cause of infertility.", "question": "Treatment.Route in Clomiphene", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "18445989_2_4707", "context": "Clomiphene is a first line treatment for anovulation, a common cause of infertility.", "question": "Treatment.Time_elapsed in Clomiphene", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18445989_2_4708", "context": "Clomiphene is a first line treatment for anovulation, a common cause of infertility.", "question": "Treatment.Duration in Clomiphene", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "18445989_2_4709", "context": "Clomiphene is a first line treatment for anovulation, a common cause of infertility.", "question": "Treatment.Disorder in Clomiphene", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "anovulation"}, {"id": "18445989_2_4710", "context": "Clomiphene is a first line treatment for anovulation, a common cause of infertility.", "question": "Combination.Drug in Clomiphene", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "3290702_2_4711", "context": "A new case of Creutzfeldt-Jakob disease associated with human growth hormone therapy in New Zealand.", "question": "Subject.Age in A new case", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "3290702_2_4712", "context": "A new case of Creutzfeldt-Jakob disease associated with human growth hormone therapy in New Zealand.", "question": "Subject.Gender in A new case", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "3290702_2_4713", "context": "A new case of Creutzfeldt-Jakob disease associated with human growth hormone therapy in New Zealand.", "question": "Subject.Population in A new case", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "3290702_2_4714", "context": "A new case of Creutzfeldt-Jakob disease associated with human growth hormone therapy in New Zealand.", "question": "Subject.Race in A new case", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "3290702_2_4715", "context": "A new case of Creutzfeldt-Jakob disease associated with human growth hormone therapy in New Zealand.", "question": "Subject.Disorder in A new case", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "3290702_2_4716", "context": "A new case of Creutzfeldt-Jakob disease associated with human growth hormone therapy in New Zealand.", "question": "Treatment.Drug in human growth hormone", "question_type": "Adverse_event.Treatment.Drug", "answers": "human growth hormone"}, {"id": "3290702_2_4717", "context": "A new case of Creutzfeldt-Jakob disease associated with human growth hormone therapy in New Zealand.", "question": "Treatment.Dosage in human growth hormone", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3290702_2_4718", "context": "A new case of Creutzfeldt-Jakob disease associated with human growth hormone therapy in New Zealand.", "question": "Treatment.Freq in human growth hormone", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3290702_2_4719", "context": "A new case of Creutzfeldt-Jakob disease associated with human growth hormone therapy in New Zealand.", "question": "Treatment.Route in human growth hormone", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3290702_2_4720", "context": "A new case of Creutzfeldt-Jakob disease associated with human growth hormone therapy in New Zealand.", "question": "Treatment.Time_elapsed in human growth hormone", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3290702_2_4721", "context": "A new case of Creutzfeldt-Jakob disease associated with human growth hormone therapy in New Zealand.", "question": "Treatment.Duration in human growth hormone", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3290702_2_4722", "context": "A new case of Creutzfeldt-Jakob disease associated with human growth hormone therapy in New Zealand.", "question": "Treatment.Disorder in human growth hormone", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3290702_2_4723", "context": "A new case of Creutzfeldt-Jakob disease associated with human growth hormone therapy in New Zealand.", "question": "Combination.Drug in human growth hormone", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16939867_2_4724", "context": "This case study is the second report of localized purpura after prolonged lamotrigine treatment suggesting this may be an atypical lamotrigine-induced drug reaction.", "question": "Treatment.Drug in lamotrigine", "question_type": "Adverse_event.Treatment.Drug", "answers": "lamotrigine"}, {"id": "16939867_2_4725", "context": "This case study is the second report of localized purpura after prolonged lamotrigine treatment suggesting this may be an atypical lamotrigine-induced drug reaction.", "question": "Treatment.Dosage in lamotrigine", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16939867_2_4726", "context": "This case study is the second report of localized purpura after prolonged lamotrigine treatment suggesting this may be an atypical lamotrigine-induced drug reaction.", "question": "Treatment.Freq in lamotrigine", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16939867_2_4727", "context": "This case study is the second report of localized purpura after prolonged lamotrigine treatment suggesting this may be an atypical lamotrigine-induced drug reaction.", "question": "Treatment.Route in lamotrigine", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16939867_2_4728", "context": "This case study is the second report of localized purpura after prolonged lamotrigine treatment suggesting this may be an atypical lamotrigine-induced drug reaction.", "question": "Treatment.Time_elapsed in lamotrigine", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16939867_2_4729", "context": "This case study is the second report of localized purpura after prolonged lamotrigine treatment suggesting this may be an atypical lamotrigine-induced drug reaction.", "question": "Treatment.Duration in lamotrigine", "question_type": "Adverse_event.Treatment.Duration", "answers": "prolonged"}, {"id": "16939867_2_4730", "context": "This case study is the second report of localized purpura after prolonged lamotrigine treatment suggesting this may be an atypical lamotrigine-induced drug reaction.", "question": "Treatment.Disorder in lamotrigine", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16939867_2_4731", "context": "This case study is the second report of localized purpura after prolonged lamotrigine treatment suggesting this may be an atypical lamotrigine-induced drug reaction.", "question": "Combination.Drug in lamotrigine", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "19047493_1_4732", "context": "Extrapyramidal symptoms are well-documented complications of therapy with haloperidol, even when small doses are used.", "question": "Treatment.Drug in haloperidol; small doses", "question_type": "Adverse_event.Treatment.Drug", "answers": "haloperidol"}, {"id": "19047493_1_4733", "context": "Extrapyramidal symptoms are well-documented complications of therapy with haloperidol, even when small doses are used.", "question": "Treatment.Dosage in haloperidol; small doses", "question_type": "Adverse_event.Treatment.Dosage", "answers": "small doses"}, {"id": "19047493_1_4734", "context": "Extrapyramidal symptoms are well-documented complications of therapy with haloperidol, even when small doses are used.", "question": "Treatment.Freq in haloperidol; small doses", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "19047493_1_4735", "context": "Extrapyramidal symptoms are well-documented complications of therapy with haloperidol, even when small doses are used.", "question": "Treatment.Route in haloperidol; small doses", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "19047493_1_4736", "context": "Extrapyramidal symptoms are well-documented complications of therapy with haloperidol, even when small doses are used.", "question": "Treatment.Time_elapsed in haloperidol; small doses", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19047493_1_4737", "context": "Extrapyramidal symptoms are well-documented complications of therapy with haloperidol, even when small doses are used.", "question": "Treatment.Duration in haloperidol; small doses", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "19047493_1_4738", "context": "Extrapyramidal symptoms are well-documented complications of therapy with haloperidol, even when small doses are used.", "question": "Treatment.Disorder in haloperidol; small doses", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "19047493_1_4739", "context": "Extrapyramidal symptoms are well-documented complications of therapy with haloperidol, even when small doses are used.", "question": "Combination.Drug in haloperidol; small doses", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16580907_9_4740", "context": "Although cetirizine has less potential for causing arrhythmias than other histamine 1 blockers, such an interaction should be considered, especially in patients with renal insufficiency who are receiving pilsicainide.", "question": "Subject.Age in patients with renal insufficiency", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "16580907_9_4741", "context": "Although cetirizine has less potential for causing arrhythmias than other histamine 1 blockers, such an interaction should be considered, especially in patients with renal insufficiency who are receiving pilsicainide.", "question": "Subject.Gender in patients with renal insufficiency", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "16580907_9_4742", "context": "Although cetirizine has less potential for causing arrhythmias than other histamine 1 blockers, such an interaction should be considered, especially in patients with renal insufficiency who are receiving pilsicainide.", "question": "Subject.Population in patients with renal insufficiency", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "16580907_9_4743", "context": "Although cetirizine has less potential for causing arrhythmias than other histamine 1 blockers, such an interaction should be considered, especially in patients with renal insufficiency who are receiving pilsicainide.", "question": "Subject.Race in patients with renal insufficiency", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16580907_9_4744", "context": "Although cetirizine has less potential for causing arrhythmias than other histamine 1 blockers, such an interaction should be considered, especially in patients with renal insufficiency who are receiving pilsicainide.", "question": "Subject.Disorder in patients with renal insufficiency", "question_type": "Adverse_event.Subject.Disorder", "answers": "renal insufficiency"}, {"id": "16580907_9_4745", "context": "Although cetirizine has less potential for causing arrhythmias than other histamine 1 blockers, such an interaction should be considered, especially in patients with renal insufficiency who are receiving pilsicainide.", "question": "Treatment.Drug in cetirizine", "question_type": "Adverse_event.Treatment.Drug", "answers": "cetirizine"}, {"id": "16580907_9_4746", "context": "Although cetirizine has less potential for causing arrhythmias than other histamine 1 blockers, such an interaction should be considered, especially in patients with renal insufficiency who are receiving pilsicainide.", "question": "Treatment.Dosage in cetirizine", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16580907_9_4747", "context": "Although cetirizine has less potential for causing arrhythmias than other histamine 1 blockers, such an interaction should be considered, especially in patients with renal insufficiency who are receiving pilsicainide.", "question": "Treatment.Freq in cetirizine", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16580907_9_4748", "context": "Although cetirizine has less potential for causing arrhythmias than other histamine 1 blockers, such an interaction should be considered, especially in patients with renal insufficiency who are receiving pilsicainide.", "question": "Treatment.Route in cetirizine", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16580907_9_4749", "context": "Although cetirizine has less potential for causing arrhythmias than other histamine 1 blockers, such an interaction should be considered, especially in patients with renal insufficiency who are receiving pilsicainide.", "question": "Treatment.Time_elapsed in cetirizine", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16580907_9_4750", "context": "Although cetirizine has less potential for causing arrhythmias than other histamine 1 blockers, such an interaction should be considered, especially in patients with renal insufficiency who are receiving pilsicainide.", "question": "Treatment.Duration in cetirizine", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16580907_9_4751", "context": "Although cetirizine has less potential for causing arrhythmias than other histamine 1 blockers, such an interaction should be considered, especially in patients with renal insufficiency who are receiving pilsicainide.", "question": "Treatment.Disorder in cetirizine", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16580907_9_4752", "context": "Although cetirizine has less potential for causing arrhythmias than other histamine 1 blockers, such an interaction should be considered, especially in patients with renal insufficiency who are receiving pilsicainide.", "question": "Combination.Drug in cetirizine", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16948177_1_4753", "context": "Bronchiolitis obliterans with organizing pneumonia after rituximab therapy for non-Hodgkin's lymphoma.", "question": "Treatment.Drug in rituximab therapy", "question_type": "Adverse_event.Treatment.Drug", "answers": "rituximab"}, {"id": "16948177_1_4754", "context": "Bronchiolitis obliterans with organizing pneumonia after rituximab therapy for non-Hodgkin's lymphoma.", "question": "Treatment.Dosage in rituximab therapy", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16948177_1_4755", "context": "Bronchiolitis obliterans with organizing pneumonia after rituximab therapy for non-Hodgkin's lymphoma.", "question": "Treatment.Freq in rituximab therapy", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16948177_1_4756", "context": "Bronchiolitis obliterans with organizing pneumonia after rituximab therapy for non-Hodgkin's lymphoma.", "question": "Treatment.Route in rituximab therapy", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16948177_1_4757", "context": "Bronchiolitis obliterans with organizing pneumonia after rituximab therapy for non-Hodgkin's lymphoma.", "question": "Treatment.Time_elapsed in rituximab therapy", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16948177_1_4758", "context": "Bronchiolitis obliterans with organizing pneumonia after rituximab therapy for non-Hodgkin's lymphoma.", "question": "Treatment.Duration in rituximab therapy", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16948177_1_4759", "context": "Bronchiolitis obliterans with organizing pneumonia after rituximab therapy for non-Hodgkin's lymphoma.", "question": "Treatment.Disorder in rituximab therapy", "question_type": "Adverse_event.Treatment.Disorder", "answers": "non-Hodgkin's lymphoma"}, {"id": "16948177_1_4760", "context": "Bronchiolitis obliterans with organizing pneumonia after rituximab therapy for non-Hodgkin's lymphoma.", "question": "Combination.Drug in rituximab therapy", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9792602_1_4761", "context": "The case demonstrates that hypersensitivity reaction to pranlukast and resultant ATIN is possible, and that periodic urine testing in patients receiving pranlukast should be considered.", "question": "Treatment.Drug in pranlukast", "question_type": "Adverse_event.Treatment.Drug", "answers": "pranlukast; pranlukast"}, {"id": "9792602_1_4762", "context": "The case demonstrates that hypersensitivity reaction to pranlukast and resultant ATIN is possible, and that periodic urine testing in patients receiving pranlukast should be considered.", "question": "Treatment.Dosage in pranlukast", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9792602_1_4763", "context": "The case demonstrates that hypersensitivity reaction to pranlukast and resultant ATIN is possible, and that periodic urine testing in patients receiving pranlukast should be considered.", "question": "Treatment.Freq in pranlukast", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9792602_1_4764", "context": "The case demonstrates that hypersensitivity reaction to pranlukast and resultant ATIN is possible, and that periodic urine testing in patients receiving pranlukast should be considered.", "question": "Treatment.Route in pranlukast", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9792602_1_4765", "context": "The case demonstrates that hypersensitivity reaction to pranlukast and resultant ATIN is possible, and that periodic urine testing in patients receiving pranlukast should be considered.", "question": "Treatment.Time_elapsed in pranlukast", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9792602_1_4766", "context": "The case demonstrates that hypersensitivity reaction to pranlukast and resultant ATIN is possible, and that periodic urine testing in patients receiving pranlukast should be considered.", "question": "Treatment.Duration in pranlukast", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9792602_1_4767", "context": "The case demonstrates that hypersensitivity reaction to pranlukast and resultant ATIN is possible, and that periodic urine testing in patients receiving pranlukast should be considered.", "question": "Treatment.Disorder in pranlukast", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9792602_1_4768", "context": "The case demonstrates that hypersensitivity reaction to pranlukast and resultant ATIN is possible, and that periodic urine testing in patients receiving pranlukast should be considered.", "question": "Combination.Drug in pranlukast", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12546343_4_4769", "context": "Successful desensitization to high-dose methotrexate after systemic anaphylaxis.", "question": "Treatment.Drug in high-dose methotrexate", "question_type": "Adverse_event.Treatment.Drug", "answers": "methotrexate"}, {"id": "12546343_4_4770", "context": "Successful desensitization to high-dose methotrexate after systemic anaphylaxis.", "question": "Treatment.Dosage in high-dose methotrexate", "question_type": "Adverse_event.Treatment.Dosage", "answers": "high-dose"}, {"id": "12546343_4_4771", "context": "Successful desensitization to high-dose methotrexate after systemic anaphylaxis.", "question": "Treatment.Freq in high-dose methotrexate", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12546343_4_4772", "context": "Successful desensitization to high-dose methotrexate after systemic anaphylaxis.", "question": "Treatment.Route in high-dose methotrexate", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12546343_4_4773", "context": "Successful desensitization to high-dose methotrexate after systemic anaphylaxis.", "question": "Treatment.Time_elapsed in high-dose methotrexate", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12546343_4_4774", "context": "Successful desensitization to high-dose methotrexate after systemic anaphylaxis.", "question": "Treatment.Duration in high-dose methotrexate", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12546343_4_4775", "context": "Successful desensitization to high-dose methotrexate after systemic anaphylaxis.", "question": "Treatment.Disorder in high-dose methotrexate", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12546343_4_4776", "context": "Successful desensitization to high-dose methotrexate after systemic anaphylaxis.", "question": "Combination.Drug in high-dose methotrexate", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12546343_4_4777", "context": "Successful desensitization to high-dose methotrexate after systemic anaphylaxis.", "question": "Treatment.Drug in high-dose methotrexate", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "12546343_4_4778", "context": "Successful desensitization to high-dose methotrexate after systemic anaphylaxis.", "question": "Treatment.Dosage in high-dose methotrexate", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "12546343_4_4779", "context": "Successful desensitization to high-dose methotrexate after systemic anaphylaxis.", "question": "Treatment.Freq in high-dose methotrexate", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "12546343_4_4780", "context": "Successful desensitization to high-dose methotrexate after systemic anaphylaxis.", "question": "Treatment.Route in high-dose methotrexate", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "12546343_4_4781", "context": "Successful desensitization to high-dose methotrexate after systemic anaphylaxis.", "question": "Treatment.Time_elapsed in high-dose methotrexate", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12546343_4_4782", "context": "Successful desensitization to high-dose methotrexate after systemic anaphylaxis.", "question": "Treatment.Duration in high-dose methotrexate", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "12546343_4_4783", "context": "Successful desensitization to high-dose methotrexate after systemic anaphylaxis.", "question": "Treatment.Disorder in high-dose methotrexate", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "systemic anaphylaxis"}, {"id": "12546343_4_4784", "context": "Successful desensitization to high-dose methotrexate after systemic anaphylaxis.", "question": "Combination.Drug in high-dose methotrexate", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "7468565_4_4785", "context": "The patient's clinical presentation, histologic features on liver biopsy and favorable course after stopping the drug suggest that barbiturates can be added to the list of agents which can cause submassive hepatic necrosis.", "question": "Treatment.Drug in barbiturates", "question_type": "Adverse_event.Treatment.Drug", "answers": "barbiturates"}, {"id": "7468565_4_4786", "context": "The patient's clinical presentation, histologic features on liver biopsy and favorable course after stopping the drug suggest that barbiturates can be added to the list of agents which can cause submassive hepatic necrosis.", "question": "Treatment.Dosage in barbiturates", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7468565_4_4787", "context": "The patient's clinical presentation, histologic features on liver biopsy and favorable course after stopping the drug suggest that barbiturates can be added to the list of agents which can cause submassive hepatic necrosis.", "question": "Treatment.Freq in barbiturates", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7468565_4_4788", "context": "The patient's clinical presentation, histologic features on liver biopsy and favorable course after stopping the drug suggest that barbiturates can be added to the list of agents which can cause submassive hepatic necrosis.", "question": "Treatment.Route in barbiturates", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7468565_4_4789", "context": "The patient's clinical presentation, histologic features on liver biopsy and favorable course after stopping the drug suggest that barbiturates can be added to the list of agents which can cause submassive hepatic necrosis.", "question": "Treatment.Time_elapsed in barbiturates", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7468565_4_4790", "context": "The patient's clinical presentation, histologic features on liver biopsy and favorable course after stopping the drug suggest that barbiturates can be added to the list of agents which can cause submassive hepatic necrosis.", "question": "Treatment.Duration in barbiturates", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7468565_4_4791", "context": "The patient's clinical presentation, histologic features on liver biopsy and favorable course after stopping the drug suggest that barbiturates can be added to the list of agents which can cause submassive hepatic necrosis.", "question": "Treatment.Disorder in barbiturates", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7468565_4_4792", "context": "The patient's clinical presentation, histologic features on liver biopsy and favorable course after stopping the drug suggest that barbiturates can be added to the list of agents which can cause submassive hepatic necrosis.", "question": "Combination.Drug in barbiturates", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "19838099_1_4793", "context": "Although there have been numerous reports of effusions, none have provided complete pleural fluid analysis; therefore, we report 2 patients with dasatinib-induced pleural effusion with complete pleural fluid analysis.", "question": "Subject.Age in 2 patients", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "19838099_1_4794", "context": "Although there have been numerous reports of effusions, none have provided complete pleural fluid analysis; therefore, we report 2 patients with dasatinib-induced pleural effusion with complete pleural fluid analysis.", "question": "Subject.Gender in 2 patients", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "19838099_1_4795", "context": "Although there have been numerous reports of effusions, none have provided complete pleural fluid analysis; therefore, we report 2 patients with dasatinib-induced pleural effusion with complete pleural fluid analysis.", "question": "Subject.Population in 2 patients", "question_type": "Adverse_event.Subject.Population", "answers": "2"}, {"id": "19838099_1_4796", "context": "Although there have been numerous reports of effusions, none have provided complete pleural fluid analysis; therefore, we report 2 patients with dasatinib-induced pleural effusion with complete pleural fluid analysis.", "question": "Subject.Race in 2 patients", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "19838099_1_4797", "context": "Although there have been numerous reports of effusions, none have provided complete pleural fluid analysis; therefore, we report 2 patients with dasatinib-induced pleural effusion with complete pleural fluid analysis.", "question": "Subject.Disorder in 2 patients", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "19838099_1_4798", "context": "Although there have been numerous reports of effusions, none have provided complete pleural fluid analysis; therefore, we report 2 patients with dasatinib-induced pleural effusion with complete pleural fluid analysis.", "question": "Treatment.Drug in dasatinib", "question_type": "Adverse_event.Treatment.Drug", "answers": "dasatinib"}, {"id": "19838099_1_4799", "context": "Although there have been numerous reports of effusions, none have provided complete pleural fluid analysis; therefore, we report 2 patients with dasatinib-induced pleural effusion with complete pleural fluid analysis.", "question": "Treatment.Dosage in dasatinib", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "19838099_1_4800", "context": "Although there have been numerous reports of effusions, none have provided complete pleural fluid analysis; therefore, we report 2 patients with dasatinib-induced pleural effusion with complete pleural fluid analysis.", "question": "Treatment.Freq in dasatinib", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "19838099_1_4801", "context": "Although there have been numerous reports of effusions, none have provided complete pleural fluid analysis; therefore, we report 2 patients with dasatinib-induced pleural effusion with complete pleural fluid analysis.", "question": "Treatment.Route in dasatinib", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "19838099_1_4802", "context": "Although there have been numerous reports of effusions, none have provided complete pleural fluid analysis; therefore, we report 2 patients with dasatinib-induced pleural effusion with complete pleural fluid analysis.", "question": "Treatment.Time_elapsed in dasatinib", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19838099_1_4803", "context": "Although there have been numerous reports of effusions, none have provided complete pleural fluid analysis; therefore, we report 2 patients with dasatinib-induced pleural effusion with complete pleural fluid analysis.", "question": "Treatment.Duration in dasatinib", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "19838099_1_4804", "context": "Although there have been numerous reports of effusions, none have provided complete pleural fluid analysis; therefore, we report 2 patients with dasatinib-induced pleural effusion with complete pleural fluid analysis.", "question": "Treatment.Disorder in dasatinib", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "19838099_1_4805", "context": "Although there have been numerous reports of effusions, none have provided complete pleural fluid analysis; therefore, we report 2 patients with dasatinib-induced pleural effusion with complete pleural fluid analysis.", "question": "Combination.Drug in dasatinib", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "2523364_1_4806", "context": "Morphea after bromocriptine therapy.", "question": "Treatment.Drug in bromocriptine therapy", "question_type": "Adverse_event.Treatment.Drug", "answers": "bromocriptine"}, {"id": "2523364_1_4807", "context": "Morphea after bromocriptine therapy.", "question": "Treatment.Dosage in bromocriptine therapy", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "2523364_1_4808", "context": "Morphea after bromocriptine therapy.", "question": "Treatment.Freq in bromocriptine therapy", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2523364_1_4809", "context": "Morphea after bromocriptine therapy.", "question": "Treatment.Route in bromocriptine therapy", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "2523364_1_4810", "context": "Morphea after bromocriptine therapy.", "question": "Treatment.Time_elapsed in bromocriptine therapy", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2523364_1_4811", "context": "Morphea after bromocriptine therapy.", "question": "Treatment.Duration in bromocriptine therapy", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2523364_1_4812", "context": "Morphea after bromocriptine therapy.", "question": "Treatment.Disorder in bromocriptine therapy", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "2523364_1_4813", "context": "Morphea after bromocriptine therapy.", "question": "Combination.Drug in bromocriptine therapy", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12390172_2_4814", "context": "PURPOSE: To describe the clinical and electrophysiological findings in a young boy with decreased vision possibly due to retinal damage by rifabutin.", "question": "Subject.Age in a young boy", "question_type": "Adverse_event.Subject.Age", "answers": "young"}, {"id": "12390172_2_4815", "context": "PURPOSE: To describe the clinical and electrophysiological findings in a young boy with decreased vision possibly due to retinal damage by rifabutin.", "question": "Subject.Gender in a young boy", "question_type": "Adverse_event.Subject.Gender", "answers": "boy"}, {"id": "12390172_2_4816", "context": "PURPOSE: To describe the clinical and electrophysiological findings in a young boy with decreased vision possibly due to retinal damage by rifabutin.", "question": "Subject.Population in a young boy", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "12390172_2_4817", "context": "PURPOSE: To describe the clinical and electrophysiological findings in a young boy with decreased vision possibly due to retinal damage by rifabutin.", "question": "Subject.Race in a young boy", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "12390172_2_4818", "context": "PURPOSE: To describe the clinical and electrophysiological findings in a young boy with decreased vision possibly due to retinal damage by rifabutin.", "question": "Subject.Disorder in a young boy", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "12390172_2_4819", "context": "PURPOSE: To describe the clinical and electrophysiological findings in a young boy with decreased vision possibly due to retinal damage by rifabutin.", "question": "Treatment.Drug in rifabutin", "question_type": "Adverse_event.Treatment.Drug", "answers": "rifabutin"}, {"id": "12390172_2_4820", "context": "PURPOSE: To describe the clinical and electrophysiological findings in a young boy with decreased vision possibly due to retinal damage by rifabutin.", "question": "Treatment.Dosage in rifabutin", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12390172_2_4821", "context": "PURPOSE: To describe the clinical and electrophysiological findings in a young boy with decreased vision possibly due to retinal damage by rifabutin.", "question": "Treatment.Freq in rifabutin", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12390172_2_4822", "context": "PURPOSE: To describe the clinical and electrophysiological findings in a young boy with decreased vision possibly due to retinal damage by rifabutin.", "question": "Treatment.Route in rifabutin", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12390172_2_4823", "context": "PURPOSE: To describe the clinical and electrophysiological findings in a young boy with decreased vision possibly due to retinal damage by rifabutin.", "question": "Treatment.Time_elapsed in rifabutin", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12390172_2_4824", "context": "PURPOSE: To describe the clinical and electrophysiological findings in a young boy with decreased vision possibly due to retinal damage by rifabutin.", "question": "Treatment.Duration in rifabutin", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12390172_2_4825", "context": "PURPOSE: To describe the clinical and electrophysiological findings in a young boy with decreased vision possibly due to retinal damage by rifabutin.", "question": "Treatment.Disorder in rifabutin", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12390172_2_4826", "context": "PURPOSE: To describe the clinical and electrophysiological findings in a young boy with decreased vision possibly due to retinal damage by rifabutin.", "question": "Combination.Drug in rifabutin", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "2196696_3_4827", "context": "We reported a case of disulfiram-induced hepatitis with unique clinical features and compared our case with others in the literature.", "question": "Subject.Age in a case", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "2196696_3_4828", "context": "We reported a case of disulfiram-induced hepatitis with unique clinical features and compared our case with others in the literature.", "question": "Subject.Gender in a case", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "2196696_3_4829", "context": "We reported a case of disulfiram-induced hepatitis with unique clinical features and compared our case with others in the literature.", "question": "Subject.Population in a case", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "2196696_3_4830", "context": "We reported a case of disulfiram-induced hepatitis with unique clinical features and compared our case with others in the literature.", "question": "Subject.Race in a case", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "2196696_3_4831", "context": "We reported a case of disulfiram-induced hepatitis with unique clinical features and compared our case with others in the literature.", "question": "Subject.Disorder in a case", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "2196696_3_4832", "context": "We reported a case of disulfiram-induced hepatitis with unique clinical features and compared our case with others in the literature.", "question": "Treatment.Drug in disulfiram", "question_type": "Adverse_event.Treatment.Drug", "answers": "disulfiram"}, {"id": "2196696_3_4833", "context": "We reported a case of disulfiram-induced hepatitis with unique clinical features and compared our case with others in the literature.", "question": "Treatment.Dosage in disulfiram", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "2196696_3_4834", "context": "We reported a case of disulfiram-induced hepatitis with unique clinical features and compared our case with others in the literature.", "question": "Treatment.Freq in disulfiram", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2196696_3_4835", "context": "We reported a case of disulfiram-induced hepatitis with unique clinical features and compared our case with others in the literature.", "question": "Treatment.Route in disulfiram", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "2196696_3_4836", "context": "We reported a case of disulfiram-induced hepatitis with unique clinical features and compared our case with others in the literature.", "question": "Treatment.Time_elapsed in disulfiram", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2196696_3_4837", "context": "We reported a case of disulfiram-induced hepatitis with unique clinical features and compared our case with others in the literature.", "question": "Treatment.Duration in disulfiram", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2196696_3_4838", "context": "We reported a case of disulfiram-induced hepatitis with unique clinical features and compared our case with others in the literature.", "question": "Treatment.Disorder in disulfiram", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "2196696_3_4839", "context": "We reported a case of disulfiram-induced hepatitis with unique clinical features and compared our case with others in the literature.", "question": "Combination.Drug in disulfiram", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8739289_4_4840", "context": "We report a patient receiving chronic lithium therapy who presented with a transient CDI occurring in the setting of underlying chronic NDI.", "question": "Subject.Age in patient", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "8739289_4_4841", "context": "We report a patient receiving chronic lithium therapy who presented with a transient CDI occurring in the setting of underlying chronic NDI.", "question": "Subject.Gender in patient", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "8739289_4_4842", "context": "We report a patient receiving chronic lithium therapy who presented with a transient CDI occurring in the setting of underlying chronic NDI.", "question": "Subject.Population in patient", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "8739289_4_4843", "context": "We report a patient receiving chronic lithium therapy who presented with a transient CDI occurring in the setting of underlying chronic NDI.", "question": "Subject.Race in patient", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "8739289_4_4844", "context": "We report a patient receiving chronic lithium therapy who presented with a transient CDI occurring in the setting of underlying chronic NDI.", "question": "Subject.Disorder in patient", "question_type": "Adverse_event.Subject.Disorder", "answers": "underlying chronic NDI"}, {"id": "8739289_4_4845", "context": "We report a patient receiving chronic lithium therapy who presented with a transient CDI occurring in the setting of underlying chronic NDI.", "question": "Treatment.Drug in chronic lithium therapy", "question_type": "Adverse_event.Treatment.Drug", "answers": "lithium"}, {"id": "8739289_4_4846", "context": "We report a patient receiving chronic lithium therapy who presented with a transient CDI occurring in the setting of underlying chronic NDI.", "question": "Treatment.Dosage in chronic lithium therapy", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8739289_4_4847", "context": "We report a patient receiving chronic lithium therapy who presented with a transient CDI occurring in the setting of underlying chronic NDI.", "question": "Treatment.Freq in chronic lithium therapy", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8739289_4_4848", "context": "We report a patient receiving chronic lithium therapy who presented with a transient CDI occurring in the setting of underlying chronic NDI.", "question": "Treatment.Route in chronic lithium therapy", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8739289_4_4849", "context": "We report a patient receiving chronic lithium therapy who presented with a transient CDI occurring in the setting of underlying chronic NDI.", "question": "Treatment.Time_elapsed in chronic lithium therapy", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8739289_4_4850", "context": "We report a patient receiving chronic lithium therapy who presented with a transient CDI occurring in the setting of underlying chronic NDI.", "question": "Treatment.Duration in chronic lithium therapy", "question_type": "Adverse_event.Treatment.Duration", "answers": "chronic"}, {"id": "8739289_4_4851", "context": "We report a patient receiving chronic lithium therapy who presented with a transient CDI occurring in the setting of underlying chronic NDI.", "question": "Treatment.Disorder in chronic lithium therapy", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8739289_4_4852", "context": "We report a patient receiving chronic lithium therapy who presented with a transient CDI occurring in the setting of underlying chronic NDI.", "question": "Combination.Drug in chronic lithium therapy", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "20009973_2_4853", "context": "Here we report a patient with newly diagnosed acute promyelocytic leukemia who developed acute focal myositis, synovitis, and possible vasculitis, after receiving all-trans retinoic acid therapy.", "question": "Subject.Age in a patient with newly diagnosed acute promyelocytic leukemia", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "20009973_2_4854", "context": "Here we report a patient with newly diagnosed acute promyelocytic leukemia who developed acute focal myositis, synovitis, and possible vasculitis, after receiving all-trans retinoic acid therapy.", "question": "Subject.Gender in a patient with newly diagnosed acute promyelocytic leukemia", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "20009973_2_4855", "context": "Here we report a patient with newly diagnosed acute promyelocytic leukemia who developed acute focal myositis, synovitis, and possible vasculitis, after receiving all-trans retinoic acid therapy.", "question": "Subject.Population in a patient with newly diagnosed acute promyelocytic leukemia", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "20009973_2_4856", "context": "Here we report a patient with newly diagnosed acute promyelocytic leukemia who developed acute focal myositis, synovitis, and possible vasculitis, after receiving all-trans retinoic acid therapy.", "question": "Subject.Race in a patient with newly diagnosed acute promyelocytic leukemia", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "20009973_2_4857", "context": "Here we report a patient with newly diagnosed acute promyelocytic leukemia who developed acute focal myositis, synovitis, and possible vasculitis, after receiving all-trans retinoic acid therapy.", "question": "Subject.Disorder in a patient with newly diagnosed acute promyelocytic leukemia", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "20009973_2_4858", "context": "Here we report a patient with newly diagnosed acute promyelocytic leukemia who developed acute focal myositis, synovitis, and possible vasculitis, after receiving all-trans retinoic acid therapy.", "question": "Treatment.Drug in all-trans retinoic acid", "question_type": "Adverse_event.Treatment.Drug", "answers": "all-trans retinoic acid"}, {"id": "20009973_2_4859", "context": "Here we report a patient with newly diagnosed acute promyelocytic leukemia who developed acute focal myositis, synovitis, and possible vasculitis, after receiving all-trans retinoic acid therapy.", "question": "Treatment.Dosage in all-trans retinoic acid", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "20009973_2_4860", "context": "Here we report a patient with newly diagnosed acute promyelocytic leukemia who developed acute focal myositis, synovitis, and possible vasculitis, after receiving all-trans retinoic acid therapy.", "question": "Treatment.Freq in all-trans retinoic acid", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "20009973_2_4861", "context": "Here we report a patient with newly diagnosed acute promyelocytic leukemia who developed acute focal myositis, synovitis, and possible vasculitis, after receiving all-trans retinoic acid therapy.", "question": "Treatment.Route in all-trans retinoic acid", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "20009973_2_4862", "context": "Here we report a patient with newly diagnosed acute promyelocytic leukemia who developed acute focal myositis, synovitis, and possible vasculitis, after receiving all-trans retinoic acid therapy.", "question": "Treatment.Time_elapsed in all-trans retinoic acid", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "20009973_2_4863", "context": "Here we report a patient with newly diagnosed acute promyelocytic leukemia who developed acute focal myositis, synovitis, and possible vasculitis, after receiving all-trans retinoic acid therapy.", "question": "Treatment.Duration in all-trans retinoic acid", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "20009973_2_4864", "context": "Here we report a patient with newly diagnosed acute promyelocytic leukemia who developed acute focal myositis, synovitis, and possible vasculitis, after receiving all-trans retinoic acid therapy.", "question": "Treatment.Disorder in all-trans retinoic acid", "question_type": "Adverse_event.Treatment.Disorder", "answers": "acute promyelocytic leukemia"}, {"id": "20009973_2_4865", "context": "Here we report a patient with newly diagnosed acute promyelocytic leukemia who developed acute focal myositis, synovitis, and possible vasculitis, after receiving all-trans retinoic acid therapy.", "question": "Combination.Drug in all-trans retinoic acid", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "22550162_2_4866", "context": "We report a case of methotrexate toxicity potentially induced by a drug interaction between methotrexate and omeprazole in a 25-year-old man with osteosarcoma.", "question": "Subject.Age in a 25-year-old man with osteosarcoma", "question_type": "Adverse_event.Subject.Age", "answers": "25-year-old"}, {"id": "22550162_2_4867", "context": "We report a case of methotrexate toxicity potentially induced by a drug interaction between methotrexate and omeprazole in a 25-year-old man with osteosarcoma.", "question": "Subject.Gender in a 25-year-old man with osteosarcoma", "question_type": "Adverse_event.Subject.Gender", "answers": "man"}, {"id": "22550162_2_4868", "context": "We report a case of methotrexate toxicity potentially induced by a drug interaction between methotrexate and omeprazole in a 25-year-old man with osteosarcoma.", "question": "Subject.Population in a 25-year-old man with osteosarcoma", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "22550162_2_4869", "context": "We report a case of methotrexate toxicity potentially induced by a drug interaction between methotrexate and omeprazole in a 25-year-old man with osteosarcoma.", "question": "Subject.Race in a 25-year-old man with osteosarcoma", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "22550162_2_4870", "context": "We report a case of methotrexate toxicity potentially induced by a drug interaction between methotrexate and omeprazole in a 25-year-old man with osteosarcoma.", "question": "Subject.Disorder in a 25-year-old man with osteosarcoma", "question_type": "Adverse_event.Subject.Disorder", "answers": "osteosarcoma"}, {"id": "22550162_2_4871", "context": "We report a case of methotrexate toxicity potentially induced by a drug interaction between methotrexate and omeprazole in a 25-year-old man with osteosarcoma.", "question": "Treatment.Drug in methotrexate and omeprazole", "question_type": "Adverse_event.Treatment.Drug", "answers": "methotrexate; omeprazole"}, {"id": "22550162_2_4872", "context": "We report a case of methotrexate toxicity potentially induced by a drug interaction between methotrexate and omeprazole in a 25-year-old man with osteosarcoma.", "question": "Treatment.Dosage in methotrexate and omeprazole", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "22550162_2_4873", "context": "We report a case of methotrexate toxicity potentially induced by a drug interaction between methotrexate and omeprazole in a 25-year-old man with osteosarcoma.", "question": "Treatment.Freq in methotrexate and omeprazole", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "22550162_2_4874", "context": "We report a case of methotrexate toxicity potentially induced by a drug interaction between methotrexate and omeprazole in a 25-year-old man with osteosarcoma.", "question": "Treatment.Route in methotrexate and omeprazole", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "22550162_2_4875", "context": "We report a case of methotrexate toxicity potentially induced by a drug interaction between methotrexate and omeprazole in a 25-year-old man with osteosarcoma.", "question": "Treatment.Time_elapsed in methotrexate and omeprazole", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "22550162_2_4876", "context": "We report a case of methotrexate toxicity potentially induced by a drug interaction between methotrexate and omeprazole in a 25-year-old man with osteosarcoma.", "question": "Treatment.Duration in methotrexate and omeprazole", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "22550162_2_4877", "context": "We report a case of methotrexate toxicity potentially induced by a drug interaction between methotrexate and omeprazole in a 25-year-old man with osteosarcoma.", "question": "Treatment.Disorder in methotrexate and omeprazole", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "22550162_2_4878", "context": "We report a case of methotrexate toxicity potentially induced by a drug interaction between methotrexate and omeprazole in a 25-year-old man with osteosarcoma.", "question": "Combination.Drug in methotrexate and omeprazole", "question_type": "Adverse_event.Combination.Drug", "answers": "methotrexate; omeprazole"}, {"id": "18562412_1_4879", "context": "Increasing the olanzapine dosage severely aggravated the symptoms of RLS.", "question": "Treatment.Drug in Increasing the olanzapine dosage", "question_type": "Adverse_event.Treatment.Drug", "answers": "olanzapine"}, {"id": "18562412_1_4880", "context": "Increasing the olanzapine dosage severely aggravated the symptoms of RLS.", "question": "Treatment.Dosage in Increasing the olanzapine dosage", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18562412_1_4881", "context": "Increasing the olanzapine dosage severely aggravated the symptoms of RLS.", "question": "Treatment.Freq in Increasing the olanzapine dosage", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18562412_1_4882", "context": "Increasing the olanzapine dosage severely aggravated the symptoms of RLS.", "question": "Treatment.Route in Increasing the olanzapine dosage", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18562412_1_4883", "context": "Increasing the olanzapine dosage severely aggravated the symptoms of RLS.", "question": "Treatment.Time_elapsed in Increasing the olanzapine dosage", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18562412_1_4884", "context": "Increasing the olanzapine dosage severely aggravated the symptoms of RLS.", "question": "Treatment.Duration in Increasing the olanzapine dosage", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18562412_1_4885", "context": "Increasing the olanzapine dosage severely aggravated the symptoms of RLS.", "question": "Treatment.Disorder in Increasing the olanzapine dosage", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18562412_1_4886", "context": "Increasing the olanzapine dosage severely aggravated the symptoms of RLS.", "question": "Combination.Drug in Increasing the olanzapine dosage", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "19512997_2_4887", "context": "We report a case of 48-year-old woman with seizure disorder on divalproex sodium (Depakote) who presented with dyspnea.", "question": "Subject.Age in a case of 48-year-old woman with seizure disorder", "question_type": "Adverse_event.Subject.Age", "answers": "48-year-old"}, {"id": "19512997_2_4888", "context": "We report a case of 48-year-old woman with seizure disorder on divalproex sodium (Depakote) who presented with dyspnea.", "question": "Subject.Gender in a case of 48-year-old woman with seizure disorder", "question_type": "Adverse_event.Subject.Gender", "answers": "woman"}, {"id": "19512997_2_4889", "context": "We report a case of 48-year-old woman with seizure disorder on divalproex sodium (Depakote) who presented with dyspnea.", "question": "Subject.Population in a case of 48-year-old woman with seizure disorder", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "19512997_2_4890", "context": "We report a case of 48-year-old woman with seizure disorder on divalproex sodium (Depakote) who presented with dyspnea.", "question": "Subject.Race in a case of 48-year-old woman with seizure disorder", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "19512997_2_4891", "context": "We report a case of 48-year-old woman with seizure disorder on divalproex sodium (Depakote) who presented with dyspnea.", "question": "Subject.Disorder in a case of 48-year-old woman with seizure disorder", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "19512997_2_4892", "context": "We report a case of 48-year-old woman with seizure disorder on divalproex sodium (Depakote) who presented with dyspnea.", "question": "Treatment.Drug in divalproex sodium (Depakote)", "question_type": "Adverse_event.Treatment.Drug", "answers": "divalproex sodium"}, {"id": "19512997_2_4893", "context": "We report a case of 48-year-old woman with seizure disorder on divalproex sodium (Depakote) who presented with dyspnea.", "question": "Treatment.Dosage in divalproex sodium (Depakote)", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "19512997_2_4894", "context": "We report a case of 48-year-old woman with seizure disorder on divalproex sodium (Depakote) who presented with dyspnea.", "question": "Treatment.Freq in divalproex sodium (Depakote)", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "19512997_2_4895", "context": "We report a case of 48-year-old woman with seizure disorder on divalproex sodium (Depakote) who presented with dyspnea.", "question": "Treatment.Route in divalproex sodium (Depakote)", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "19512997_2_4896", "context": "We report a case of 48-year-old woman with seizure disorder on divalproex sodium (Depakote) who presented with dyspnea.", "question": "Treatment.Time_elapsed in divalproex sodium (Depakote)", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19512997_2_4897", "context": "We report a case of 48-year-old woman with seizure disorder on divalproex sodium (Depakote) who presented with dyspnea.", "question": "Treatment.Duration in divalproex sodium (Depakote)", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "19512997_2_4898", "context": "We report a case of 48-year-old woman with seizure disorder on divalproex sodium (Depakote) who presented with dyspnea.", "question": "Treatment.Disorder in divalproex sodium (Depakote)", "question_type": "Adverse_event.Treatment.Disorder", "answers": "seizure disorder"}, {"id": "19512997_2_4899", "context": "We report a case of 48-year-old woman with seizure disorder on divalproex sodium (Depakote) who presented with dyspnea.", "question": "Combination.Drug in divalproex sodium (Depakote)", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "19531696_2_4900", "context": "To report a probable interaction between warfarin and marijuana smoking, resulting in increased international normalized ratio (INR) values and bleeding complications.", "question": "Treatment.Drug in interaction between warfarin and marijuana smoking", "question_type": "Adverse_event.Treatment.Drug", "answers": "warfarin; marijuana"}, {"id": "19531696_2_4901", "context": "To report a probable interaction between warfarin and marijuana smoking, resulting in increased international normalized ratio (INR) values and bleeding complications.", "question": "Treatment.Dosage in interaction between warfarin and marijuana smoking", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "19531696_2_4902", "context": "To report a probable interaction between warfarin and marijuana smoking, resulting in increased international normalized ratio (INR) values and bleeding complications.", "question": "Treatment.Freq in interaction between warfarin and marijuana smoking", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "19531696_2_4903", "context": "To report a probable interaction between warfarin and marijuana smoking, resulting in increased international normalized ratio (INR) values and bleeding complications.", "question": "Treatment.Route in interaction between warfarin and marijuana smoking", "question_type": "Adverse_event.Treatment.Route", "answers": "smoking"}, {"id": "19531696_2_4904", "context": "To report a probable interaction between warfarin and marijuana smoking, resulting in increased international normalized ratio (INR) values and bleeding complications.", "question": "Treatment.Time_elapsed in interaction between warfarin and marijuana smoking", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19531696_2_4905", "context": "To report a probable interaction between warfarin and marijuana smoking, resulting in increased international normalized ratio (INR) values and bleeding complications.", "question": "Treatment.Duration in interaction between warfarin and marijuana smoking", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "19531696_2_4906", "context": "To report a probable interaction between warfarin and marijuana smoking, resulting in increased international normalized ratio (INR) values and bleeding complications.", "question": "Treatment.Disorder in interaction between warfarin and marijuana smoking", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "19531696_2_4907", "context": "To report a probable interaction between warfarin and marijuana smoking, resulting in increased international normalized ratio (INR) values and bleeding complications.", "question": "Combination.Drug in interaction between warfarin and marijuana smoking", "question_type": "Adverse_event.Combination.Drug", "answers": "warfarin; marijuana"}, {"id": "19653965_2_4908", "context": "Transient cardiac arrhythmias related to lopinavir/ritonavir in two patients with HIV infection.", "question": "Subject.Age in two patients with HIV infection", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "19653965_2_4909", "context": "Transient cardiac arrhythmias related to lopinavir/ritonavir in two patients with HIV infection.", "question": "Subject.Gender in two patients with HIV infection", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "19653965_2_4910", "context": "Transient cardiac arrhythmias related to lopinavir/ritonavir in two patients with HIV infection.", "question": "Subject.Population in two patients with HIV infection", "question_type": "Adverse_event.Subject.Population", "answers": "two"}, {"id": "19653965_2_4911", "context": "Transient cardiac arrhythmias related to lopinavir/ritonavir in two patients with HIV infection.", "question": "Subject.Race in two patients with HIV infection", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "19653965_2_4912", "context": "Transient cardiac arrhythmias related to lopinavir/ritonavir in two patients with HIV infection.", "question": "Subject.Disorder in two patients with HIV infection", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "19653965_2_4913", "context": "Transient cardiac arrhythmias related to lopinavir/ritonavir in two patients with HIV infection.", "question": "Treatment.Drug in lopinavir/ritonavir", "question_type": "Adverse_event.Treatment.Drug", "answers": "lopinavir; ritonavir"}, {"id": "19653965_2_4914", "context": "Transient cardiac arrhythmias related to lopinavir/ritonavir in two patients with HIV infection.", "question": "Treatment.Dosage in lopinavir/ritonavir", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "19653965_2_4915", "context": "Transient cardiac arrhythmias related to lopinavir/ritonavir in two patients with HIV infection.", "question": "Treatment.Freq in lopinavir/ritonavir", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "19653965_2_4916", "context": "Transient cardiac arrhythmias related to lopinavir/ritonavir in two patients with HIV infection.", "question": "Treatment.Route in lopinavir/ritonavir", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "19653965_2_4917", "context": "Transient cardiac arrhythmias related to lopinavir/ritonavir in two patients with HIV infection.", "question": "Treatment.Time_elapsed in lopinavir/ritonavir", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19653965_2_4918", "context": "Transient cardiac arrhythmias related to lopinavir/ritonavir in two patients with HIV infection.", "question": "Treatment.Duration in lopinavir/ritonavir", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "19653965_2_4919", "context": "Transient cardiac arrhythmias related to lopinavir/ritonavir in two patients with HIV infection.", "question": "Treatment.Disorder in lopinavir/ritonavir", "question_type": "Adverse_event.Treatment.Disorder", "answers": "HIV infection"}, {"id": "19653965_2_4920", "context": "Transient cardiac arrhythmias related to lopinavir/ritonavir in two patients with HIV infection.", "question": "Combination.Drug in lopinavir/ritonavir", "question_type": "Adverse_event.Combination.Drug", "answers": "lopinavir; ritonavir"}, {"id": "11688826_1_4921", "context": "Interestingly, the use of carboplatin (CBDCA) and VDS in the subsequent treatment course was well tolerated indicating that the SIADH was most likely to have been induced by administration of CDDP.", "question": "Treatment.Drug in CDDP", "question_type": "Adverse_event.Treatment.Drug", "answers": "CDDP"}, {"id": "11688826_1_4922", "context": "Interestingly, the use of carboplatin (CBDCA) and VDS in the subsequent treatment course was well tolerated indicating that the SIADH was most likely to have been induced by administration of CDDP.", "question": "Treatment.Dosage in CDDP", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11688826_1_4923", "context": "Interestingly, the use of carboplatin (CBDCA) and VDS in the subsequent treatment course was well tolerated indicating that the SIADH was most likely to have been induced by administration of CDDP.", "question": "Treatment.Freq in CDDP", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11688826_1_4924", "context": "Interestingly, the use of carboplatin (CBDCA) and VDS in the subsequent treatment course was well tolerated indicating that the SIADH was most likely to have been induced by administration of CDDP.", "question": "Treatment.Route in CDDP", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11688826_1_4925", "context": "Interestingly, the use of carboplatin (CBDCA) and VDS in the subsequent treatment course was well tolerated indicating that the SIADH was most likely to have been induced by administration of CDDP.", "question": "Treatment.Time_elapsed in CDDP", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11688826_1_4926", "context": "Interestingly, the use of carboplatin (CBDCA) and VDS in the subsequent treatment course was well tolerated indicating that the SIADH was most likely to have been induced by administration of CDDP.", "question": "Treatment.Duration in CDDP", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11688826_1_4927", "context": "Interestingly, the use of carboplatin (CBDCA) and VDS in the subsequent treatment course was well tolerated indicating that the SIADH was most likely to have been induced by administration of CDDP.", "question": "Treatment.Disorder in CDDP", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11688826_1_4928", "context": "Interestingly, the use of carboplatin (CBDCA) and VDS in the subsequent treatment course was well tolerated indicating that the SIADH was most likely to have been induced by administration of CDDP.", "question": "Combination.Drug in CDDP", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18957000_1_4929", "context": "Although heparin-dependent antibodies (HDAs) typically manifest with thrombocytopenia as in heparin-induced thrombocytopenia (HIT), they may also manifest with preserved platelet counts.", "question": "Treatment.Drug in heparin-dependent antibodies (HDAs)", "question_type": "Adverse_event.Treatment.Drug", "answers": "heparin"}, {"id": "18957000_1_4930", "context": "Although heparin-dependent antibodies (HDAs) typically manifest with thrombocytopenia as in heparin-induced thrombocytopenia (HIT), they may also manifest with preserved platelet counts.", "question": "Treatment.Dosage in heparin-dependent antibodies (HDAs)", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18957000_1_4931", "context": "Although heparin-dependent antibodies (HDAs) typically manifest with thrombocytopenia as in heparin-induced thrombocytopenia (HIT), they may also manifest with preserved platelet counts.", "question": "Treatment.Freq in heparin-dependent antibodies (HDAs)", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18957000_1_4932", "context": "Although heparin-dependent antibodies (HDAs) typically manifest with thrombocytopenia as in heparin-induced thrombocytopenia (HIT), they may also manifest with preserved platelet counts.", "question": "Treatment.Route in heparin-dependent antibodies (HDAs)", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18957000_1_4933", "context": "Although heparin-dependent antibodies (HDAs) typically manifest with thrombocytopenia as in heparin-induced thrombocytopenia (HIT), they may also manifest with preserved platelet counts.", "question": "Treatment.Time_elapsed in heparin-dependent antibodies (HDAs)", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18957000_1_4934", "context": "Although heparin-dependent antibodies (HDAs) typically manifest with thrombocytopenia as in heparin-induced thrombocytopenia (HIT), they may also manifest with preserved platelet counts.", "question": "Treatment.Duration in heparin-dependent antibodies (HDAs)", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18957000_1_4935", "context": "Although heparin-dependent antibodies (HDAs) typically manifest with thrombocytopenia as in heparin-induced thrombocytopenia (HIT), they may also manifest with preserved platelet counts.", "question": "Treatment.Disorder in heparin-dependent antibodies (HDAs)", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18957000_1_4936", "context": "Although heparin-dependent antibodies (HDAs) typically manifest with thrombocytopenia as in heparin-induced thrombocytopenia (HIT), they may also manifest with preserved platelet counts.", "question": "Combination.Drug in heparin-dependent antibodies (HDAs)", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "22010004_3_4937", "context": "A 69-year-old white female whose anticoagulation treatment had been stable for 18 months with warfarin 2.5 mg daily (17.5 mg/wk) presented to an anticoagulation clinic with a critically elevated INR of greater than 12.3 after a dose increase in extended-release niacin (Niaspan) from 500 mg to 1000 mg daily the previous week.", "question": "Subject.Age in 69-year-old white female", "question_type": "Adverse_event.Subject.Age", "answers": "69-year-old"}, {"id": "22010004_3_4938", "context": "A 69-year-old white female whose anticoagulation treatment had been stable for 18 months with warfarin 2.5 mg daily (17.5 mg/wk) presented to an anticoagulation clinic with a critically elevated INR of greater than 12.3 after a dose increase in extended-release niacin (Niaspan) from 500 mg to 1000 mg daily the previous week.", "question": "Subject.Gender in 69-year-old white female", "question_type": "Adverse_event.Subject.Gender", "answers": "female"}, {"id": "22010004_3_4939", "context": "A 69-year-old white female whose anticoagulation treatment had been stable for 18 months with warfarin 2.5 mg daily (17.5 mg/wk) presented to an anticoagulation clinic with a critically elevated INR of greater than 12.3 after a dose increase in extended-release niacin (Niaspan) from 500 mg to 1000 mg daily the previous week.", "question": "Subject.Population in 69-year-old white female", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "22010004_3_4940", "context": "A 69-year-old white female whose anticoagulation treatment had been stable for 18 months with warfarin 2.5 mg daily (17.5 mg/wk) presented to an anticoagulation clinic with a critically elevated INR of greater than 12.3 after a dose increase in extended-release niacin (Niaspan) from 500 mg to 1000 mg daily the previous week.", "question": "Subject.Race in 69-year-old white female", "question_type": "Adverse_event.Subject.Race", "answers": "white"}, {"id": "22010004_3_4941", "context": "A 69-year-old white female whose anticoagulation treatment had been stable for 18 months with warfarin 2.5 mg daily (17.5 mg/wk) presented to an anticoagulation clinic with a critically elevated INR of greater than 12.3 after a dose increase in extended-release niacin (Niaspan) from 500 mg to 1000 mg daily the previous week.", "question": "Subject.Disorder in 69-year-old white female", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "22010004_3_4942", "context": "A 69-year-old white female whose anticoagulation treatment had been stable for 18 months with warfarin 2.5 mg daily (17.5 mg/wk) presented to an anticoagulation clinic with a critically elevated INR of greater than 12.3 after a dose increase in extended-release niacin (Niaspan) from 500 mg to 1000 mg daily the previous week.", "question": "Treatment.Drug in anticoagulation treatment had been stable for 18 months with warfarin 2.5 mg daily (17.5 mg/wk); dose increase in extended-release niacin (Niaspan) from 500 mg to 1000 mg daily the previous week", "question_type": "Adverse_event.Treatment.Drug", "answers": "extended-release niacin; warfarin"}, {"id": "22010004_3_4943", "context": "A 69-year-old white female whose anticoagulation treatment had been stable for 18 months with warfarin 2.5 mg daily (17.5 mg/wk) presented to an anticoagulation clinic with a critically elevated INR of greater than 12.3 after a dose increase in extended-release niacin (Niaspan) from 500 mg to 1000 mg daily the previous week.", "question": "Treatment.Dosage in anticoagulation treatment had been stable for 18 months with warfarin 2.5 mg daily (17.5 mg/wk); dose increase in extended-release niacin (Niaspan) from 500 mg to 1000 mg daily the previous week", "question_type": "Adverse_event.Treatment.Dosage", "answers": "1000 mg; 2.5 mg"}, {"id": "22010004_3_4944", "context": "A 69-year-old white female whose anticoagulation treatment had been stable for 18 months with warfarin 2.5 mg daily (17.5 mg/wk) presented to an anticoagulation clinic with a critically elevated INR of greater than 12.3 after a dose increase in extended-release niacin (Niaspan) from 500 mg to 1000 mg daily the previous week.", "question": "Treatment.Freq in anticoagulation treatment had been stable for 18 months with warfarin 2.5 mg daily (17.5 mg/wk); dose increase in extended-release niacin (Niaspan) from 500 mg to 1000 mg daily the previous week", "question_type": "Adverse_event.Treatment.Freq", "answers": "daily; daily"}, {"id": "22010004_3_4945", "context": "A 69-year-old white female whose anticoagulation treatment had been stable for 18 months with warfarin 2.5 mg daily (17.5 mg/wk) presented to an anticoagulation clinic with a critically elevated INR of greater than 12.3 after a dose increase in extended-release niacin (Niaspan) from 500 mg to 1000 mg daily the previous week.", "question": "Treatment.Route in anticoagulation treatment had been stable for 18 months with warfarin 2.5 mg daily (17.5 mg/wk); dose increase in extended-release niacin (Niaspan) from 500 mg to 1000 mg daily the previous week", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "22010004_3_4946", "context": "A 69-year-old white female whose anticoagulation treatment had been stable for 18 months with warfarin 2.5 mg daily (17.5 mg/wk) presented to an anticoagulation clinic with a critically elevated INR of greater than 12.3 after a dose increase in extended-release niacin (Niaspan) from 500 mg to 1000 mg daily the previous week.", "question": "Treatment.Time_elapsed in anticoagulation treatment had been stable for 18 months with warfarin 2.5 mg daily (17.5 mg/wk); dose increase in extended-release niacin (Niaspan) from 500 mg to 1000 mg daily the previous week", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "22010004_3_4947", "context": "A 69-year-old white female whose anticoagulation treatment had been stable for 18 months with warfarin 2.5 mg daily (17.5 mg/wk) presented to an anticoagulation clinic with a critically elevated INR of greater than 12.3 after a dose increase in extended-release niacin (Niaspan) from 500 mg to 1000 mg daily the previous week.", "question": "Treatment.Duration in anticoagulation treatment had been stable for 18 months with warfarin 2.5 mg daily (17.5 mg/wk); dose increase in extended-release niacin (Niaspan) from 500 mg to 1000 mg daily the previous week", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "22010004_3_4948", "context": "A 69-year-old white female whose anticoagulation treatment had been stable for 18 months with warfarin 2.5 mg daily (17.5 mg/wk) presented to an anticoagulation clinic with a critically elevated INR of greater than 12.3 after a dose increase in extended-release niacin (Niaspan) from 500 mg to 1000 mg daily the previous week.", "question": "Treatment.Disorder in anticoagulation treatment had been stable for 18 months with warfarin 2.5 mg daily (17.5 mg/wk); dose increase in extended-release niacin (Niaspan) from 500 mg to 1000 mg daily the previous week", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "22010004_3_4949", "context": "A 69-year-old white female whose anticoagulation treatment had been stable for 18 months with warfarin 2.5 mg daily (17.5 mg/wk) presented to an anticoagulation clinic with a critically elevated INR of greater than 12.3 after a dose increase in extended-release niacin (Niaspan) from 500 mg to 1000 mg daily the previous week.", "question": "Combination.Drug in anticoagulation treatment had been stable for 18 months with warfarin 2.5 mg daily (17.5 mg/wk); dose increase in extended-release niacin (Niaspan) from 500 mg to 1000 mg daily the previous week", "question_type": "Adverse_event.Combination.Drug", "answers": "extended-release niacin; warfarin"}, {"id": "17346586_1_4950", "context": "The most serious dental side effect of bisphosphonate treatment (particularly when it is administered intravenously) is, paradoxically, osteonecrosis of the mandible or the maxilla represented by exposed nonhealing bone.", "question": "Treatment.Drug in bisphosphonate treatment (particularly when it is administered intravenously)", "question_type": "Adverse_event.Treatment.Drug", "answers": "bisphosphonate"}, {"id": "17346586_1_4951", "context": "The most serious dental side effect of bisphosphonate treatment (particularly when it is administered intravenously) is, paradoxically, osteonecrosis of the mandible or the maxilla represented by exposed nonhealing bone.", "question": "Treatment.Dosage in bisphosphonate treatment (particularly when it is administered intravenously)", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17346586_1_4952", "context": "The most serious dental side effect of bisphosphonate treatment (particularly when it is administered intravenously) is, paradoxically, osteonecrosis of the mandible or the maxilla represented by exposed nonhealing bone.", "question": "Treatment.Freq in bisphosphonate treatment (particularly when it is administered intravenously)", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17346586_1_4953", "context": "The most serious dental side effect of bisphosphonate treatment (particularly when it is administered intravenously) is, paradoxically, osteonecrosis of the mandible or the maxilla represented by exposed nonhealing bone.", "question": "Treatment.Route in bisphosphonate treatment (particularly when it is administered intravenously)", "question_type": "Adverse_event.Treatment.Route", "answers": "intravenously"}, {"id": "17346586_1_4954", "context": "The most serious dental side effect of bisphosphonate treatment (particularly when it is administered intravenously) is, paradoxically, osteonecrosis of the mandible or the maxilla represented by exposed nonhealing bone.", "question": "Treatment.Time_elapsed in bisphosphonate treatment (particularly when it is administered intravenously)", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17346586_1_4955", "context": "The most serious dental side effect of bisphosphonate treatment (particularly when it is administered intravenously) is, paradoxically, osteonecrosis of the mandible or the maxilla represented by exposed nonhealing bone.", "question": "Treatment.Duration in bisphosphonate treatment (particularly when it is administered intravenously)", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17346586_1_4956", "context": "The most serious dental side effect of bisphosphonate treatment (particularly when it is administered intravenously) is, paradoxically, osteonecrosis of the mandible or the maxilla represented by exposed nonhealing bone.", "question": "Treatment.Disorder in bisphosphonate treatment (particularly when it is administered intravenously)", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17346586_1_4957", "context": "The most serious dental side effect of bisphosphonate treatment (particularly when it is administered intravenously) is, paradoxically, osteonecrosis of the mandible or the maxilla represented by exposed nonhealing bone.", "question": "Combination.Drug in bisphosphonate treatment (particularly when it is administered intravenously)", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18160579_1_4958", "context": "Pericardial hemorrhage due to acetylsalicylic acid in a patient with essential thrombocythemia.", "question": "Treatment.Drug in acetylsalicylic acid", "question_type": "Adverse_event.Treatment.Drug", "answers": "acetylsalicylic acid"}, {"id": "18160579_1_4959", "context": "Pericardial hemorrhage due to acetylsalicylic acid in a patient with essential thrombocythemia.", "question": "Treatment.Dosage in acetylsalicylic acid", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18160579_1_4960", "context": "Pericardial hemorrhage due to acetylsalicylic acid in a patient with essential thrombocythemia.", "question": "Treatment.Freq in acetylsalicylic acid", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18160579_1_4961", "context": "Pericardial hemorrhage due to acetylsalicylic acid in a patient with essential thrombocythemia.", "question": "Treatment.Route in acetylsalicylic acid", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18160579_1_4962", "context": "Pericardial hemorrhage due to acetylsalicylic acid in a patient with essential thrombocythemia.", "question": "Treatment.Time_elapsed in acetylsalicylic acid", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18160579_1_4963", "context": "Pericardial hemorrhage due to acetylsalicylic acid in a patient with essential thrombocythemia.", "question": "Treatment.Duration in acetylsalicylic acid", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18160579_1_4964", "context": "Pericardial hemorrhage due to acetylsalicylic acid in a patient with essential thrombocythemia.", "question": "Treatment.Disorder in acetylsalicylic acid", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18160579_1_4965", "context": "Pericardial hemorrhage due to acetylsalicylic acid in a patient with essential thrombocythemia.", "question": "Combination.Drug in acetylsalicylic acid", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7387219_2_4966", "context": "These cases and a review of the literature suggested that hepatotoxicity, though rare, should be added to the list of adverse reactions to D-penicillamine.", "question": "Subject.Age in These cases", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "7387219_2_4967", "context": "These cases and a review of the literature suggested that hepatotoxicity, though rare, should be added to the list of adverse reactions to D-penicillamine.", "question": "Subject.Gender in These cases", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "7387219_2_4968", "context": "These cases and a review of the literature suggested that hepatotoxicity, though rare, should be added to the list of adverse reactions to D-penicillamine.", "question": "Subject.Population in These cases", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "7387219_2_4969", "context": "These cases and a review of the literature suggested that hepatotoxicity, though rare, should be added to the list of adverse reactions to D-penicillamine.", "question": "Subject.Race in These cases", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "7387219_2_4970", "context": "These cases and a review of the literature suggested that hepatotoxicity, though rare, should be added to the list of adverse reactions to D-penicillamine.", "question": "Subject.Disorder in These cases", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "7387219_2_4971", "context": "These cases and a review of the literature suggested that hepatotoxicity, though rare, should be added to the list of adverse reactions to D-penicillamine.", "question": "Treatment.Drug in D-penicillamine", "question_type": "Adverse_event.Treatment.Drug", "answers": "D-penicillamine"}, {"id": "7387219_2_4972", "context": "These cases and a review of the literature suggested that hepatotoxicity, though rare, should be added to the list of adverse reactions to D-penicillamine.", "question": "Treatment.Dosage in D-penicillamine", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7387219_2_4973", "context": "These cases and a review of the literature suggested that hepatotoxicity, though rare, should be added to the list of adverse reactions to D-penicillamine.", "question": "Treatment.Freq in D-penicillamine", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7387219_2_4974", "context": "These cases and a review of the literature suggested that hepatotoxicity, though rare, should be added to the list of adverse reactions to D-penicillamine.", "question": "Treatment.Route in D-penicillamine", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7387219_2_4975", "context": "These cases and a review of the literature suggested that hepatotoxicity, though rare, should be added to the list of adverse reactions to D-penicillamine.", "question": "Treatment.Time_elapsed in D-penicillamine", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7387219_2_4976", "context": "These cases and a review of the literature suggested that hepatotoxicity, though rare, should be added to the list of adverse reactions to D-penicillamine.", "question": "Treatment.Duration in D-penicillamine", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7387219_2_4977", "context": "These cases and a review of the literature suggested that hepatotoxicity, though rare, should be added to the list of adverse reactions to D-penicillamine.", "question": "Treatment.Disorder in D-penicillamine", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7387219_2_4978", "context": "These cases and a review of the literature suggested that hepatotoxicity, though rare, should be added to the list of adverse reactions to D-penicillamine.", "question": "Combination.Drug in D-penicillamine", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12962465_1_4979", "context": "After four months, while receiving RH, he developed painful bilateral gynaecomastia.", "question": "Treatment.Drug in receiving RH", "question_type": "Adverse_event.Treatment.Drug", "answers": "RH"}, {"id": "12962465_1_4980", "context": "After four months, while receiving RH, he developed painful bilateral gynaecomastia.", "question": "Treatment.Dosage in receiving RH", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12962465_1_4981", "context": "After four months, while receiving RH, he developed painful bilateral gynaecomastia.", "question": "Treatment.Freq in receiving RH", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12962465_1_4982", "context": "After four months, while receiving RH, he developed painful bilateral gynaecomastia.", "question": "Treatment.Route in receiving RH", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12962465_1_4983", "context": "After four months, while receiving RH, he developed painful bilateral gynaecomastia.", "question": "Treatment.Time_elapsed in receiving RH", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "After four months"}, {"id": "12962465_1_4984", "context": "After four months, while receiving RH, he developed painful bilateral gynaecomastia.", "question": "Treatment.Duration in receiving RH", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12962465_1_4985", "context": "After four months, while receiving RH, he developed painful bilateral gynaecomastia.", "question": "Treatment.Disorder in receiving RH", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12962465_1_4986", "context": "After four months, while receiving RH, he developed painful bilateral gynaecomastia.", "question": "Combination.Drug in receiving RH", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16580907_5_4987", "context": "The plasma concentrations of both drugs were significantly increased during the coadministration, and the cetirizine concentration decreased on cessation of pilsicainide despite the fact that treatment with cetirizine was continued, which suggested that the fainting was induced by the pharmacokinetic drug interaction.", "question": "Treatment.Drug in pilsicainide; cetirizine", "question_type": "Adverse_event.Treatment.Drug", "answers": "pilsicainide; cetirizine"}, {"id": "16580907_5_4988", "context": "The plasma concentrations of both drugs were significantly increased during the coadministration, and the cetirizine concentration decreased on cessation of pilsicainide despite the fact that treatment with cetirizine was continued, which suggested that the fainting was induced by the pharmacokinetic drug interaction.", "question": "Treatment.Dosage in pilsicainide; cetirizine", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16580907_5_4989", "context": "The plasma concentrations of both drugs were significantly increased during the coadministration, and the cetirizine concentration decreased on cessation of pilsicainide despite the fact that treatment with cetirizine was continued, which suggested that the fainting was induced by the pharmacokinetic drug interaction.", "question": "Treatment.Freq in pilsicainide; cetirizine", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16580907_5_4990", "context": "The plasma concentrations of both drugs were significantly increased during the coadministration, and the cetirizine concentration decreased on cessation of pilsicainide despite the fact that treatment with cetirizine was continued, which suggested that the fainting was induced by the pharmacokinetic drug interaction.", "question": "Treatment.Route in pilsicainide; cetirizine", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16580907_5_4991", "context": "The plasma concentrations of both drugs were significantly increased during the coadministration, and the cetirizine concentration decreased on cessation of pilsicainide despite the fact that treatment with cetirizine was continued, which suggested that the fainting was induced by the pharmacokinetic drug interaction.", "question": "Treatment.Time_elapsed in pilsicainide; cetirizine", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16580907_5_4992", "context": "The plasma concentrations of both drugs were significantly increased during the coadministration, and the cetirizine concentration decreased on cessation of pilsicainide despite the fact that treatment with cetirizine was continued, which suggested that the fainting was induced by the pharmacokinetic drug interaction.", "question": "Treatment.Duration in pilsicainide; cetirizine", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16580907_5_4993", "context": "The plasma concentrations of both drugs were significantly increased during the coadministration, and the cetirizine concentration decreased on cessation of pilsicainide despite the fact that treatment with cetirizine was continued, which suggested that the fainting was induced by the pharmacokinetic drug interaction.", "question": "Treatment.Disorder in pilsicainide; cetirizine", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16580907_5_4994", "context": "The plasma concentrations of both drugs were significantly increased during the coadministration, and the cetirizine concentration decreased on cessation of pilsicainide despite the fact that treatment with cetirizine was continued, which suggested that the fainting was induced by the pharmacokinetic drug interaction.", "question": "Combination.Drug in pilsicainide; cetirizine", "question_type": "Adverse_event.Combination.Drug", "answers": "pilsicainide; cetirizine"}, {"id": "11573852_6_4995", "context": "OBJECTIVE: To report a case of multiple episodes of seizure activity in an AIDS patent following amphotericin B infusion.", "question": "Subject.Age in an AIDS patent", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "11573852_6_4996", "context": "OBJECTIVE: To report a case of multiple episodes of seizure activity in an AIDS patent following amphotericin B infusion.", "question": "Subject.Gender in an AIDS patent", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "11573852_6_4997", "context": "OBJECTIVE: To report a case of multiple episodes of seizure activity in an AIDS patent following amphotericin B infusion.", "question": "Subject.Population in an AIDS patent", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "11573852_6_4998", "context": "OBJECTIVE: To report a case of multiple episodes of seizure activity in an AIDS patent following amphotericin B infusion.", "question": "Subject.Race in an AIDS patent", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "11573852_6_4999", "context": "OBJECTIVE: To report a case of multiple episodes of seizure activity in an AIDS patent following amphotericin B infusion.", "question": "Subject.Disorder in an AIDS patent", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "11573852_6_5000", "context": "OBJECTIVE: To report a case of multiple episodes of seizure activity in an AIDS patent following amphotericin B infusion.", "question": "Treatment.Drug in amphotericin B infusion", "question_type": "Adverse_event.Treatment.Drug", "answers": "amphotericin B"}, {"id": "11573852_6_5001", "context": "OBJECTIVE: To report a case of multiple episodes of seizure activity in an AIDS patent following amphotericin B infusion.", "question": "Treatment.Dosage in amphotericin B infusion", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11573852_6_5002", "context": "OBJECTIVE: To report a case of multiple episodes of seizure activity in an AIDS patent following amphotericin B infusion.", "question": "Treatment.Freq in amphotericin B infusion", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11573852_6_5003", "context": "OBJECTIVE: To report a case of multiple episodes of seizure activity in an AIDS patent following amphotericin B infusion.", "question": "Treatment.Route in amphotericin B infusion", "question_type": "Adverse_event.Treatment.Route", "answers": "infusion"}, {"id": "11573852_6_5004", "context": "OBJECTIVE: To report a case of multiple episodes of seizure activity in an AIDS patent following amphotericin B infusion.", "question": "Treatment.Time_elapsed in amphotericin B infusion", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11573852_6_5005", "context": "OBJECTIVE: To report a case of multiple episodes of seizure activity in an AIDS patent following amphotericin B infusion.", "question": "Treatment.Duration in amphotericin B infusion", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11573852_6_5006", "context": "OBJECTIVE: To report a case of multiple episodes of seizure activity in an AIDS patent following amphotericin B infusion.", "question": "Treatment.Disorder in amphotericin B infusion", "question_type": "Adverse_event.Treatment.Disorder", "answers": "AIDS"}, {"id": "11573852_6_5007", "context": "OBJECTIVE: To report a case of multiple episodes of seizure activity in an AIDS patent following amphotericin B infusion.", "question": "Combination.Drug in amphotericin B infusion", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9651465_3_5008", "context": "The vomiting occurred on switching to different pancreatic enzymes preparations, ie, Creon 10, Viokase, and Pancrease MT 16.", "question": "Treatment.Drug in different pancreatic enzymes preparations, ie, Creon 10, Viokase, and Pancrease MT 16", "question_type": "Adverse_event.Treatment.Drug", "answers": "Creon 10; Viokase; Pancrease MT 16"}, {"id": "9651465_3_5009", "context": "The vomiting occurred on switching to different pancreatic enzymes preparations, ie, Creon 10, Viokase, and Pancrease MT 16.", "question": "Treatment.Dosage in different pancreatic enzymes preparations, ie, Creon 10, Viokase, and Pancrease MT 16", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9651465_3_5010", "context": "The vomiting occurred on switching to different pancreatic enzymes preparations, ie, Creon 10, Viokase, and Pancrease MT 16.", "question": "Treatment.Freq in different pancreatic enzymes preparations, ie, Creon 10, Viokase, and Pancrease MT 16", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9651465_3_5011", "context": "The vomiting occurred on switching to different pancreatic enzymes preparations, ie, Creon 10, Viokase, and Pancrease MT 16.", "question": "Treatment.Route in different pancreatic enzymes preparations, ie, Creon 10, Viokase, and Pancrease MT 16", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9651465_3_5012", "context": "The vomiting occurred on switching to different pancreatic enzymes preparations, ie, Creon 10, Viokase, and Pancrease MT 16.", "question": "Treatment.Time_elapsed in different pancreatic enzymes preparations, ie, Creon 10, Viokase, and Pancrease MT 16", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9651465_3_5013", "context": "The vomiting occurred on switching to different pancreatic enzymes preparations, ie, Creon 10, Viokase, and Pancrease MT 16.", "question": "Treatment.Duration in different pancreatic enzymes preparations, ie, Creon 10, Viokase, and Pancrease MT 16", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9651465_3_5014", "context": "The vomiting occurred on switching to different pancreatic enzymes preparations, ie, Creon 10, Viokase, and Pancrease MT 16.", "question": "Treatment.Disorder in different pancreatic enzymes preparations, ie, Creon 10, Viokase, and Pancrease MT 16", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9651465_3_5015", "context": "The vomiting occurred on switching to different pancreatic enzymes preparations, ie, Creon 10, Viokase, and Pancrease MT 16.", "question": "Combination.Drug in different pancreatic enzymes preparations, ie, Creon 10, Viokase, and Pancrease MT 16", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "2357706_1_5016", "context": "Although tardive dyskinesia is a known adverse reaction of sustained treatment with traditional neuroleptic agents, it was only rarely reported in association with sulpiride, a selective D2-receptor antagonist.", "question": "Treatment.Drug in sulpiride", "question_type": "Adverse_event.Treatment.Drug", "answers": "sulpiride"}, {"id": "2357706_1_5017", "context": "Although tardive dyskinesia is a known adverse reaction of sustained treatment with traditional neuroleptic agents, it was only rarely reported in association with sulpiride, a selective D2-receptor antagonist.", "question": "Treatment.Dosage in sulpiride", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "2357706_1_5018", "context": "Although tardive dyskinesia is a known adverse reaction of sustained treatment with traditional neuroleptic agents, it was only rarely reported in association with sulpiride, a selective D2-receptor antagonist.", "question": "Treatment.Freq in sulpiride", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2357706_1_5019", "context": "Although tardive dyskinesia is a known adverse reaction of sustained treatment with traditional neuroleptic agents, it was only rarely reported in association with sulpiride, a selective D2-receptor antagonist.", "question": "Treatment.Route in sulpiride", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "2357706_1_5020", "context": "Although tardive dyskinesia is a known adverse reaction of sustained treatment with traditional neuroleptic agents, it was only rarely reported in association with sulpiride, a selective D2-receptor antagonist.", "question": "Treatment.Time_elapsed in sulpiride", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2357706_1_5021", "context": "Although tardive dyskinesia is a known adverse reaction of sustained treatment with traditional neuroleptic agents, it was only rarely reported in association with sulpiride, a selective D2-receptor antagonist.", "question": "Treatment.Duration in sulpiride", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2357706_1_5022", "context": "Although tardive dyskinesia is a known adverse reaction of sustained treatment with traditional neuroleptic agents, it was only rarely reported in association with sulpiride, a selective D2-receptor antagonist.", "question": "Treatment.Disorder in sulpiride", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "2357706_1_5023", "context": "Although tardive dyskinesia is a known adverse reaction of sustained treatment with traditional neuroleptic agents, it was only rarely reported in association with sulpiride, a selective D2-receptor antagonist.", "question": "Combination.Drug in sulpiride", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "19047493_2_5024", "context": "This report highlights a case of drug-induced dysphagia in a patient receiving haloperidol for obsessive nocturnal thoughts and auditory disturbances.", "question": "Subject.Age in a patient", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "19047493_2_5025", "context": "This report highlights a case of drug-induced dysphagia in a patient receiving haloperidol for obsessive nocturnal thoughts and auditory disturbances.", "question": "Subject.Gender in a patient", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "19047493_2_5026", "context": "This report highlights a case of drug-induced dysphagia in a patient receiving haloperidol for obsessive nocturnal thoughts and auditory disturbances.", "question": "Subject.Population in a patient", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "19047493_2_5027", "context": "This report highlights a case of drug-induced dysphagia in a patient receiving haloperidol for obsessive nocturnal thoughts and auditory disturbances.", "question": "Subject.Race in a patient", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "19047493_2_5028", "context": "This report highlights a case of drug-induced dysphagia in a patient receiving haloperidol for obsessive nocturnal thoughts and auditory disturbances.", "question": "Subject.Disorder in a patient", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "19047493_2_5029", "context": "This report highlights a case of drug-induced dysphagia in a patient receiving haloperidol for obsessive nocturnal thoughts and auditory disturbances.", "question": "Treatment.Drug in haloperido", "question_type": "Adverse_event.Treatment.Drug", "answers": "haloperidol"}, {"id": "19047493_2_5030", "context": "This report highlights a case of drug-induced dysphagia in a patient receiving haloperidol for obsessive nocturnal thoughts and auditory disturbances.", "question": "Treatment.Dosage in haloperido", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "19047493_2_5031", "context": "This report highlights a case of drug-induced dysphagia in a patient receiving haloperidol for obsessive nocturnal thoughts and auditory disturbances.", "question": "Treatment.Freq in haloperido", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "19047493_2_5032", "context": "This report highlights a case of drug-induced dysphagia in a patient receiving haloperidol for obsessive nocturnal thoughts and auditory disturbances.", "question": "Treatment.Route in haloperido", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "19047493_2_5033", "context": "This report highlights a case of drug-induced dysphagia in a patient receiving haloperidol for obsessive nocturnal thoughts and auditory disturbances.", "question": "Treatment.Time_elapsed in haloperido", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19047493_2_5034", "context": "This report highlights a case of drug-induced dysphagia in a patient receiving haloperidol for obsessive nocturnal thoughts and auditory disturbances.", "question": "Treatment.Duration in haloperido", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "19047493_2_5035", "context": "This report highlights a case of drug-induced dysphagia in a patient receiving haloperidol for obsessive nocturnal thoughts and auditory disturbances.", "question": "Treatment.Disorder in haloperido", "question_type": "Adverse_event.Treatment.Disorder", "answers": "obsessive nocturnal thoughts and auditory disturbances"}, {"id": "19047493_2_5036", "context": "This report highlights a case of drug-induced dysphagia in a patient receiving haloperidol for obsessive nocturnal thoughts and auditory disturbances.", "question": "Combination.Drug in haloperido", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15338554_3_5037", "context": "In addition to disease refractoriness, rare instances of disease progression from chronic phase to blast crisis during imatinib therapy have recently been anecdotally reported.", "question": "Treatment.Drug in imatinib therapy", "question_type": "Adverse_event.Treatment.Drug", "answers": "imatinib"}, {"id": "15338554_3_5038", "context": "In addition to disease refractoriness, rare instances of disease progression from chronic phase to blast crisis during imatinib therapy have recently been anecdotally reported.", "question": "Treatment.Dosage in imatinib therapy", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15338554_3_5039", "context": "In addition to disease refractoriness, rare instances of disease progression from chronic phase to blast crisis during imatinib therapy have recently been anecdotally reported.", "question": "Treatment.Freq in imatinib therapy", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15338554_3_5040", "context": "In addition to disease refractoriness, rare instances of disease progression from chronic phase to blast crisis during imatinib therapy have recently been anecdotally reported.", "question": "Treatment.Route in imatinib therapy", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15338554_3_5041", "context": "In addition to disease refractoriness, rare instances of disease progression from chronic phase to blast crisis during imatinib therapy have recently been anecdotally reported.", "question": "Treatment.Time_elapsed in imatinib therapy", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15338554_3_5042", "context": "In addition to disease refractoriness, rare instances of disease progression from chronic phase to blast crisis during imatinib therapy have recently been anecdotally reported.", "question": "Treatment.Duration in imatinib therapy", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15338554_3_5043", "context": "In addition to disease refractoriness, rare instances of disease progression from chronic phase to blast crisis during imatinib therapy have recently been anecdotally reported.", "question": "Treatment.Disorder in imatinib therapy", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15338554_3_5044", "context": "In addition to disease refractoriness, rare instances of disease progression from chronic phase to blast crisis during imatinib therapy have recently been anecdotally reported.", "question": "Combination.Drug in imatinib therapy", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "25540831_4_5045", "context": "We report a typical case of transient serotonin syndrome secondary to tramadol-Citalopram combination.", "question": "Subject.Age in a typical case", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "25540831_4_5046", "context": "We report a typical case of transient serotonin syndrome secondary to tramadol-Citalopram combination.", "question": "Subject.Gender in a typical case", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "25540831_4_5047", "context": "We report a typical case of transient serotonin syndrome secondary to tramadol-Citalopram combination.", "question": "Subject.Population in a typical case", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "25540831_4_5048", "context": "We report a typical case of transient serotonin syndrome secondary to tramadol-Citalopram combination.", "question": "Subject.Race in a typical case", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "25540831_4_5049", "context": "We report a typical case of transient serotonin syndrome secondary to tramadol-Citalopram combination.", "question": "Subject.Disorder in a typical case", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "25540831_4_5050", "context": "We report a typical case of transient serotonin syndrome secondary to tramadol-Citalopram combination.", "question": "Treatment.Drug in tramadol-Citalopram combination", "question_type": "Adverse_event.Treatment.Drug", "answers": "tramadol; Citalopram"}, {"id": "25540831_4_5051", "context": "We report a typical case of transient serotonin syndrome secondary to tramadol-Citalopram combination.", "question": "Treatment.Dosage in tramadol-Citalopram combination", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "25540831_4_5052", "context": "We report a typical case of transient serotonin syndrome secondary to tramadol-Citalopram combination.", "question": "Treatment.Freq in tramadol-Citalopram combination", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "25540831_4_5053", "context": "We report a typical case of transient serotonin syndrome secondary to tramadol-Citalopram combination.", "question": "Treatment.Route in tramadol-Citalopram combination", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "25540831_4_5054", "context": "We report a typical case of transient serotonin syndrome secondary to tramadol-Citalopram combination.", "question": "Treatment.Time_elapsed in tramadol-Citalopram combination", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "25540831_4_5055", "context": "We report a typical case of transient serotonin syndrome secondary to tramadol-Citalopram combination.", "question": "Treatment.Duration in tramadol-Citalopram combination", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "25540831_4_5056", "context": "We report a typical case of transient serotonin syndrome secondary to tramadol-Citalopram combination.", "question": "Treatment.Disorder in tramadol-Citalopram combination", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "25540831_4_5057", "context": "We report a typical case of transient serotonin syndrome secondary to tramadol-Citalopram combination.", "question": "Combination.Drug in tramadol-Citalopram combination", "question_type": "Adverse_event.Combination.Drug", "answers": "tramadol; Citalopram"}, {"id": "22550162_9_5058", "context": "Although use of the Naranjo adverse reaction probability scale indicated a probable relationship (score of 6) between the patient's development of methotrexate toxicity and omeprazole use, we believe this was a drug-drug interaction case consistent with previous reports in the literature.", "question": "Subject.Age in the patient", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "22550162_9_5059", "context": "Although use of the Naranjo adverse reaction probability scale indicated a probable relationship (score of 6) between the patient's development of methotrexate toxicity and omeprazole use, we believe this was a drug-drug interaction case consistent with previous reports in the literature.", "question": "Subject.Gender in the patient", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "22550162_9_5060", "context": "Although use of the Naranjo adverse reaction probability scale indicated a probable relationship (score of 6) between the patient's development of methotrexate toxicity and omeprazole use, we believe this was a drug-drug interaction case consistent with previous reports in the literature.", "question": "Subject.Population in the patient", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "22550162_9_5061", "context": "Although use of the Naranjo adverse reaction probability scale indicated a probable relationship (score of 6) between the patient's development of methotrexate toxicity and omeprazole use, we believe this was a drug-drug interaction case consistent with previous reports in the literature.", "question": "Subject.Race in the patient", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "22550162_9_5062", "context": "Although use of the Naranjo adverse reaction probability scale indicated a probable relationship (score of 6) between the patient's development of methotrexate toxicity and omeprazole use, we believe this was a drug-drug interaction case consistent with previous reports in the literature.", "question": "Subject.Disorder in the patient", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "22550162_9_5063", "context": "Although use of the Naranjo adverse reaction probability scale indicated a probable relationship (score of 6) between the patient's development of methotrexate toxicity and omeprazole use, we believe this was a drug-drug interaction case consistent with previous reports in the literature.", "question": "Treatment.Drug in methotrexate; and omeprazole use", "question_type": "Adverse_event.Treatment.Drug", "answers": "methotrexate; omeprazole"}, {"id": "22550162_9_5064", "context": "Although use of the Naranjo adverse reaction probability scale indicated a probable relationship (score of 6) between the patient's development of methotrexate toxicity and omeprazole use, we believe this was a drug-drug interaction case consistent with previous reports in the literature.", "question": "Treatment.Dosage in methotrexate; and omeprazole use", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "22550162_9_5065", "context": "Although use of the Naranjo adverse reaction probability scale indicated a probable relationship (score of 6) between the patient's development of methotrexate toxicity and omeprazole use, we believe this was a drug-drug interaction case consistent with previous reports in the literature.", "question": "Treatment.Freq in methotrexate; and omeprazole use", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "22550162_9_5066", "context": "Although use of the Naranjo adverse reaction probability scale indicated a probable relationship (score of 6) between the patient's development of methotrexate toxicity and omeprazole use, we believe this was a drug-drug interaction case consistent with previous reports in the literature.", "question": "Treatment.Route in methotrexate; and omeprazole use", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "22550162_9_5067", "context": "Although use of the Naranjo adverse reaction probability scale indicated a probable relationship (score of 6) between the patient's development of methotrexate toxicity and omeprazole use, we believe this was a drug-drug interaction case consistent with previous reports in the literature.", "question": "Treatment.Time_elapsed in methotrexate; and omeprazole use", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "22550162_9_5068", "context": "Although use of the Naranjo adverse reaction probability scale indicated a probable relationship (score of 6) between the patient's development of methotrexate toxicity and omeprazole use, we believe this was a drug-drug interaction case consistent with previous reports in the literature.", "question": "Treatment.Duration in methotrexate; and omeprazole use", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "22550162_9_5069", "context": "Although use of the Naranjo adverse reaction probability scale indicated a probable relationship (score of 6) between the patient's development of methotrexate toxicity and omeprazole use, we believe this was a drug-drug interaction case consistent with previous reports in the literature.", "question": "Treatment.Disorder in methotrexate; and omeprazole use", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "22550162_9_5070", "context": "Although use of the Naranjo adverse reaction probability scale indicated a probable relationship (score of 6) between the patient's development of methotrexate toxicity and omeprazole use, we believe this was a drug-drug interaction case consistent with previous reports in the literature.", "question": "Combination.Drug in methotrexate; and omeprazole use", "question_type": "Adverse_event.Combination.Drug", "answers": "methotrexate; omeprazole"}, {"id": "3620420_5_5071", "context": "Systemic cyclosporin (10 mg/kg/day) resulted in resolution of the corneal ulceration within two weeks of beginning treatment, and the patient has remained in remission after 15 months of therapy.", "question": "Subject.Age in patient", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "3620420_5_5072", "context": "Systemic cyclosporin (10 mg/kg/day) resulted in resolution of the corneal ulceration within two weeks of beginning treatment, and the patient has remained in remission after 15 months of therapy.", "question": "Subject.Gender in patient", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "3620420_5_5073", "context": "Systemic cyclosporin (10 mg/kg/day) resulted in resolution of the corneal ulceration within two weeks of beginning treatment, and the patient has remained in remission after 15 months of therapy.", "question": "Subject.Population in patient", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "3620420_5_5074", "context": "Systemic cyclosporin (10 mg/kg/day) resulted in resolution of the corneal ulceration within two weeks of beginning treatment, and the patient has remained in remission after 15 months of therapy.", "question": "Subject.Race in patient", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "3620420_5_5075", "context": "Systemic cyclosporin (10 mg/kg/day) resulted in resolution of the corneal ulceration within two weeks of beginning treatment, and the patient has remained in remission after 15 months of therapy.", "question": "Subject.Disorder in patient", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "3620420_5_5076", "context": "Systemic cyclosporin (10 mg/kg/day) resulted in resolution of the corneal ulceration within two weeks of beginning treatment, and the patient has remained in remission after 15 months of therapy.", "question": "Treatment.Drug in Systemic cyclosporin (10 mg/kg/day)", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "Systemic cyclosporin"}, {"id": "3620420_5_5077", "context": "Systemic cyclosporin (10 mg/kg/day) resulted in resolution of the corneal ulceration within two weeks of beginning treatment, and the patient has remained in remission after 15 months of therapy.", "question": "Treatment.Dosage in Systemic cyclosporin (10 mg/kg/day)", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": "10 mg/kg/day"}, {"id": "3620420_5_5078", "context": "Systemic cyclosporin (10 mg/kg/day) resulted in resolution of the corneal ulceration within two weeks of beginning treatment, and the patient has remained in remission after 15 months of therapy.", "question": "Treatment.Freq in Systemic cyclosporin (10 mg/kg/day)", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "3620420_5_5079", "context": "Systemic cyclosporin (10 mg/kg/day) resulted in resolution of the corneal ulceration within two weeks of beginning treatment, and the patient has remained in remission after 15 months of therapy.", "question": "Treatment.Route in Systemic cyclosporin (10 mg/kg/day)", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "3620420_5_5080", "context": "Systemic cyclosporin (10 mg/kg/day) resulted in resolution of the corneal ulceration within two weeks of beginning treatment, and the patient has remained in remission after 15 months of therapy.", "question": "Treatment.Time_elapsed in Systemic cyclosporin (10 mg/kg/day)", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3620420_5_5081", "context": "Systemic cyclosporin (10 mg/kg/day) resulted in resolution of the corneal ulceration within two weeks of beginning treatment, and the patient has remained in remission after 15 months of therapy.", "question": "Treatment.Duration in Systemic cyclosporin (10 mg/kg/day)", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "3620420_5_5082", "context": "Systemic cyclosporin (10 mg/kg/day) resulted in resolution of the corneal ulceration within two weeks of beginning treatment, and the patient has remained in remission after 15 months of therapy.", "question": "Treatment.Disorder in Systemic cyclosporin (10 mg/kg/day)", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "3620420_5_5083", "context": "Systemic cyclosporin (10 mg/kg/day) resulted in resolution of the corneal ulceration within two weeks of beginning treatment, and the patient has remained in remission after 15 months of therapy.", "question": "Combination.Drug in Systemic cyclosporin (10 mg/kg/day)", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "6578007_2_5084", "context": "We report a 59-year-old patient with chronic myeloid leukemia, who developed severe interstitial lung fibrosis after short term and sequential treatment with melphalan and busulfan.", "question": "Subject.Age in a 59-year-old patient with chronic myeloid leukemia", "question_type": "Adverse_event.Subject.Age", "answers": "59-year-old"}, {"id": "6578007_2_5085", "context": "We report a 59-year-old patient with chronic myeloid leukemia, who developed severe interstitial lung fibrosis after short term and sequential treatment with melphalan and busulfan.", "question": "Subject.Gender in a 59-year-old patient with chronic myeloid leukemia", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "6578007_2_5086", "context": "We report a 59-year-old patient with chronic myeloid leukemia, who developed severe interstitial lung fibrosis after short term and sequential treatment with melphalan and busulfan.", "question": "Subject.Population in a 59-year-old patient with chronic myeloid leukemia", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "6578007_2_5087", "context": "We report a 59-year-old patient with chronic myeloid leukemia, who developed severe interstitial lung fibrosis after short term and sequential treatment with melphalan and busulfan.", "question": "Subject.Race in a 59-year-old patient with chronic myeloid leukemia", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "6578007_2_5088", "context": "We report a 59-year-old patient with chronic myeloid leukemia, who developed severe interstitial lung fibrosis after short term and sequential treatment with melphalan and busulfan.", "question": "Subject.Disorder in a 59-year-old patient with chronic myeloid leukemia", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "6578007_2_5089", "context": "We report a 59-year-old patient with chronic myeloid leukemia, who developed severe interstitial lung fibrosis after short term and sequential treatment with melphalan and busulfan.", "question": "Treatment.Drug in short term and sequential treatment with melphalan and busulfan", "question_type": "Adverse_event.Treatment.Drug", "answers": "melphalan; busulfan"}, {"id": "6578007_2_5090", "context": "We report a 59-year-old patient with chronic myeloid leukemia, who developed severe interstitial lung fibrosis after short term and sequential treatment with melphalan and busulfan.", "question": "Treatment.Dosage in short term and sequential treatment with melphalan and busulfan", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6578007_2_5091", "context": "We report a 59-year-old patient with chronic myeloid leukemia, who developed severe interstitial lung fibrosis after short term and sequential treatment with melphalan and busulfan.", "question": "Treatment.Freq in short term and sequential treatment with melphalan and busulfan", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6578007_2_5092", "context": "We report a 59-year-old patient with chronic myeloid leukemia, who developed severe interstitial lung fibrosis after short term and sequential treatment with melphalan and busulfan.", "question": "Treatment.Route in short term and sequential treatment with melphalan and busulfan", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6578007_2_5093", "context": "We report a 59-year-old patient with chronic myeloid leukemia, who developed severe interstitial lung fibrosis after short term and sequential treatment with melphalan and busulfan.", "question": "Treatment.Time_elapsed in short term and sequential treatment with melphalan and busulfan", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "short term"}, {"id": "6578007_2_5094", "context": "We report a 59-year-old patient with chronic myeloid leukemia, who developed severe interstitial lung fibrosis after short term and sequential treatment with melphalan and busulfan.", "question": "Treatment.Duration in short term and sequential treatment with melphalan and busulfan", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6578007_2_5095", "context": "We report a 59-year-old patient with chronic myeloid leukemia, who developed severe interstitial lung fibrosis after short term and sequential treatment with melphalan and busulfan.", "question": "Treatment.Disorder in short term and sequential treatment with melphalan and busulfan", "question_type": "Adverse_event.Treatment.Disorder", "answers": "chronic myeloid leukemia"}, {"id": "6578007_2_5096", "context": "We report a 59-year-old patient with chronic myeloid leukemia, who developed severe interstitial lung fibrosis after short term and sequential treatment with melphalan and busulfan.", "question": "Combination.Drug in short term and sequential treatment with melphalan and busulfan", "question_type": "Adverse_event.Combination.Drug", "answers": "melphalan; busulfan"}, {"id": "12702914_1_5097", "context": "Does the use of insulin in a patient with liver dysfunction increase water retention in the body, i.e. cause insulin oedema?", "question": "Subject.Age in a patient with liver dysfunction", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "12702914_1_5098", "context": "Does the use of insulin in a patient with liver dysfunction increase water retention in the body, i.e. cause insulin oedema?", "question": "Subject.Gender in a patient with liver dysfunction", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "12702914_1_5099", "context": "Does the use of insulin in a patient with liver dysfunction increase water retention in the body, i.e. cause insulin oedema?", "question": "Subject.Population in a patient with liver dysfunction", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "12702914_1_5100", "context": "Does the use of insulin in a patient with liver dysfunction increase water retention in the body, i.e. cause insulin oedema?", "question": "Subject.Race in a patient with liver dysfunction", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "12702914_1_5101", "context": "Does the use of insulin in a patient with liver dysfunction increase water retention in the body, i.e. cause insulin oedema?", "question": "Subject.Disorder in a patient with liver dysfunction", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "12702914_1_5102", "context": "Does the use of insulin in a patient with liver dysfunction increase water retention in the body, i.e. cause insulin oedema?", "question": "Treatment.Drug in insulin", "question_type": "Adverse_event.Treatment.Drug", "answers": "insulin"}, {"id": "12702914_1_5103", "context": "Does the use of insulin in a patient with liver dysfunction increase water retention in the body, i.e. cause insulin oedema?", "question": "Treatment.Dosage in insulin", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12702914_1_5104", "context": "Does the use of insulin in a patient with liver dysfunction increase water retention in the body, i.e. cause insulin oedema?", "question": "Treatment.Freq in insulin", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12702914_1_5105", "context": "Does the use of insulin in a patient with liver dysfunction increase water retention in the body, i.e. cause insulin oedema?", "question": "Treatment.Route in insulin", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12702914_1_5106", "context": "Does the use of insulin in a patient with liver dysfunction increase water retention in the body, i.e. cause insulin oedema?", "question": "Treatment.Time_elapsed in insulin", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12702914_1_5107", "context": "Does the use of insulin in a patient with liver dysfunction increase water retention in the body, i.e. cause insulin oedema?", "question": "Treatment.Duration in insulin", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12702914_1_5108", "context": "Does the use of insulin in a patient with liver dysfunction increase water retention in the body, i.e. cause insulin oedema?", "question": "Treatment.Disorder in insulin", "question_type": "Adverse_event.Treatment.Disorder", "answers": "liver dysfunction"}, {"id": "12702914_1_5109", "context": "Does the use of insulin in a patient with liver dysfunction increase water retention in the body, i.e. cause insulin oedema?", "question": "Combination.Drug in insulin", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "1624172_2_5110", "context": "Sustained hypothyroidism induced by recombinant alpha interferon in patients with chronic hepatitis C.", "question": "Subject.Age in patients with chronic hepatitis C", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "1624172_2_5111", "context": "Sustained hypothyroidism induced by recombinant alpha interferon in patients with chronic hepatitis C.", "question": "Subject.Gender in patients with chronic hepatitis C", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "1624172_2_5112", "context": "Sustained hypothyroidism induced by recombinant alpha interferon in patients with chronic hepatitis C.", "question": "Subject.Population in patients with chronic hepatitis C", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "1624172_2_5113", "context": "Sustained hypothyroidism induced by recombinant alpha interferon in patients with chronic hepatitis C.", "question": "Subject.Race in patients with chronic hepatitis C", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "1624172_2_5114", "context": "Sustained hypothyroidism induced by recombinant alpha interferon in patients with chronic hepatitis C.", "question": "Subject.Disorder in patients with chronic hepatitis C", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "1624172_2_5115", "context": "Sustained hypothyroidism induced by recombinant alpha interferon in patients with chronic hepatitis C.", "question": "Treatment.Drug in recombinant alpha interferon", "question_type": "Adverse_event.Treatment.Drug", "answers": "recombinant alpha interferon"}, {"id": "1624172_2_5116", "context": "Sustained hypothyroidism induced by recombinant alpha interferon in patients with chronic hepatitis C.", "question": "Treatment.Dosage in recombinant alpha interferon", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "1624172_2_5117", "context": "Sustained hypothyroidism induced by recombinant alpha interferon in patients with chronic hepatitis C.", "question": "Treatment.Freq in recombinant alpha interferon", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "1624172_2_5118", "context": "Sustained hypothyroidism induced by recombinant alpha interferon in patients with chronic hepatitis C.", "question": "Treatment.Route in recombinant alpha interferon", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "1624172_2_5119", "context": "Sustained hypothyroidism induced by recombinant alpha interferon in patients with chronic hepatitis C.", "question": "Treatment.Time_elapsed in recombinant alpha interferon", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "1624172_2_5120", "context": "Sustained hypothyroidism induced by recombinant alpha interferon in patients with chronic hepatitis C.", "question": "Treatment.Duration in recombinant alpha interferon", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "1624172_2_5121", "context": "Sustained hypothyroidism induced by recombinant alpha interferon in patients with chronic hepatitis C.", "question": "Treatment.Disorder in recombinant alpha interferon", "question_type": "Adverse_event.Treatment.Disorder", "answers": "chronic hepatitis C"}, {"id": "1624172_2_5122", "context": "Sustained hypothyroidism induced by recombinant alpha interferon in patients with chronic hepatitis C.", "question": "Combination.Drug in recombinant alpha interferon", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "19512997_3_5123", "context": "Withdrawal of Depakote resulted in resolution of the effusion.", "question": "Treatment.Drug in Withdrawal of Depakote", "question_type": "Adverse_event.Treatment.Drug", "answers": "Depakote"}, {"id": "19512997_3_5124", "context": "Withdrawal of Depakote resulted in resolution of the effusion.", "question": "Treatment.Dosage in Withdrawal of Depakote", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "19512997_3_5125", "context": "Withdrawal of Depakote resulted in resolution of the effusion.", "question": "Treatment.Freq in Withdrawal of Depakote", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "19512997_3_5126", "context": "Withdrawal of Depakote resulted in resolution of the effusion.", "question": "Treatment.Route in Withdrawal of Depakote", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "19512997_3_5127", "context": "Withdrawal of Depakote resulted in resolution of the effusion.", "question": "Treatment.Time_elapsed in Withdrawal of Depakote", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19512997_3_5128", "context": "Withdrawal of Depakote resulted in resolution of the effusion.", "question": "Treatment.Duration in Withdrawal of Depakote", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "19512997_3_5129", "context": "Withdrawal of Depakote resulted in resolution of the effusion.", "question": "Treatment.Disorder in Withdrawal of Depakote", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "19512997_3_5130", "context": "Withdrawal of Depakote resulted in resolution of the effusion.", "question": "Combination.Drug in Withdrawal of Depakote", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11428480_1_5131", "context": "Adenosine-induced ventricular fibrillation.", "question": "Treatment.Drug in Adenosine", "question_type": "Adverse_event.Treatment.Drug", "answers": "Adenosine"}, {"id": "11428480_1_5132", "context": "Adenosine-induced ventricular fibrillation.", "question": "Treatment.Dosage in Adenosine", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11428480_1_5133", "context": "Adenosine-induced ventricular fibrillation.", "question": "Treatment.Freq in Adenosine", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11428480_1_5134", "context": "Adenosine-induced ventricular fibrillation.", "question": "Treatment.Route in Adenosine", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11428480_1_5135", "context": "Adenosine-induced ventricular fibrillation.", "question": "Treatment.Time_elapsed in Adenosine", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11428480_1_5136", "context": "Adenosine-induced ventricular fibrillation.", "question": "Treatment.Duration in Adenosine", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11428480_1_5137", "context": "Adenosine-induced ventricular fibrillation.", "question": "Treatment.Disorder in Adenosine", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11428480_1_5138", "context": "Adenosine-induced ventricular fibrillation.", "question": "Combination.Drug in Adenosine", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "23774436_1_5139", "context": "Evaluation of initial and steady-state gatifloxacin pharmacokinetics and dose in pulmonary tuberculosis patients by using monte carlo simulations.", "question": "Subject.Age in pulmonary tuberculosis patients", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "23774436_1_5140", "context": "Evaluation of initial and steady-state gatifloxacin pharmacokinetics and dose in pulmonary tuberculosis patients by using monte carlo simulations.", "question": "Subject.Gender in pulmonary tuberculosis patients", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "23774436_1_5141", "context": "Evaluation of initial and steady-state gatifloxacin pharmacokinetics and dose in pulmonary tuberculosis patients by using monte carlo simulations.", "question": "Subject.Population in pulmonary tuberculosis patients", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "23774436_1_5142", "context": "Evaluation of initial and steady-state gatifloxacin pharmacokinetics and dose in pulmonary tuberculosis patients by using monte carlo simulations.", "question": "Subject.Race in pulmonary tuberculosis patients", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "23774436_1_5143", "context": "Evaluation of initial and steady-state gatifloxacin pharmacokinetics and dose in pulmonary tuberculosis patients by using monte carlo simulations.", "question": "Subject.Disorder in pulmonary tuberculosis patients", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "23774436_1_5144", "context": "Evaluation of initial and steady-state gatifloxacin pharmacokinetics and dose in pulmonary tuberculosis patients by using monte carlo simulations.", "question": "Treatment.Drug in gatifloxacin", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "gatifloxacin"}, {"id": "23774436_1_5145", "context": "Evaluation of initial and steady-state gatifloxacin pharmacokinetics and dose in pulmonary tuberculosis patients by using monte carlo simulations.", "question": "Treatment.Dosage in gatifloxacin", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "23774436_1_5146", "context": "Evaluation of initial and steady-state gatifloxacin pharmacokinetics and dose in pulmonary tuberculosis patients by using monte carlo simulations.", "question": "Treatment.Freq in gatifloxacin", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "23774436_1_5147", "context": "Evaluation of initial and steady-state gatifloxacin pharmacokinetics and dose in pulmonary tuberculosis patients by using monte carlo simulations.", "question": "Treatment.Route in gatifloxacin", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "23774436_1_5148", "context": "Evaluation of initial and steady-state gatifloxacin pharmacokinetics and dose in pulmonary tuberculosis patients by using monte carlo simulations.", "question": "Treatment.Time_elapsed in gatifloxacin", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "23774436_1_5149", "context": "Evaluation of initial and steady-state gatifloxacin pharmacokinetics and dose in pulmonary tuberculosis patients by using monte carlo simulations.", "question": "Treatment.Duration in gatifloxacin", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "23774436_1_5150", "context": "Evaluation of initial and steady-state gatifloxacin pharmacokinetics and dose in pulmonary tuberculosis patients by using monte carlo simulations.", "question": "Treatment.Disorder in gatifloxacin", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "pulmonary tuberculosis"}, {"id": "23774436_1_5151", "context": "Evaluation of initial and steady-state gatifloxacin pharmacokinetics and dose in pulmonary tuberculosis patients by using monte carlo simulations.", "question": "Combination.Drug in gatifloxacin", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "14723711_5_5152", "context": "We report two patients with acne vulgaris with a fourth type of minocycline-induced cutaneous pigmentation.", "question": "Subject.Age in two patients with acne vulgaris", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "14723711_5_5153", "context": "We report two patients with acne vulgaris with a fourth type of minocycline-induced cutaneous pigmentation.", "question": "Subject.Gender in two patients with acne vulgaris", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "14723711_5_5154", "context": "We report two patients with acne vulgaris with a fourth type of minocycline-induced cutaneous pigmentation.", "question": "Subject.Population in two patients with acne vulgaris", "question_type": "Adverse_event.Subject.Population", "answers": "two"}, {"id": "14723711_5_5155", "context": "We report two patients with acne vulgaris with a fourth type of minocycline-induced cutaneous pigmentation.", "question": "Subject.Race in two patients with acne vulgaris", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "14723711_5_5156", "context": "We report two patients with acne vulgaris with a fourth type of minocycline-induced cutaneous pigmentation.", "question": "Subject.Disorder in two patients with acne vulgaris", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "14723711_5_5157", "context": "We report two patients with acne vulgaris with a fourth type of minocycline-induced cutaneous pigmentation.", "question": "Treatment.Drug in minocycline", "question_type": "Adverse_event.Treatment.Drug", "answers": "minocycline"}, {"id": "14723711_5_5158", "context": "We report two patients with acne vulgaris with a fourth type of minocycline-induced cutaneous pigmentation.", "question": "Treatment.Dosage in minocycline", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "14723711_5_5159", "context": "We report two patients with acne vulgaris with a fourth type of minocycline-induced cutaneous pigmentation.", "question": "Treatment.Freq in minocycline", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "14723711_5_5160", "context": "We report two patients with acne vulgaris with a fourth type of minocycline-induced cutaneous pigmentation.", "question": "Treatment.Route in minocycline", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "14723711_5_5161", "context": "We report two patients with acne vulgaris with a fourth type of minocycline-induced cutaneous pigmentation.", "question": "Treatment.Time_elapsed in minocycline", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "14723711_5_5162", "context": "We report two patients with acne vulgaris with a fourth type of minocycline-induced cutaneous pigmentation.", "question": "Treatment.Duration in minocycline", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "14723711_5_5163", "context": "We report two patients with acne vulgaris with a fourth type of minocycline-induced cutaneous pigmentation.", "question": "Treatment.Disorder in minocycline", "question_type": "Adverse_event.Treatment.Disorder", "answers": "acne vulgaris"}, {"id": "14723711_5_5164", "context": "We report two patients with acne vulgaris with a fourth type of minocycline-induced cutaneous pigmentation.", "question": "Combination.Drug in minocycline", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7720517_2_5165", "context": "Budesonide is a synthetic glucocorticosteroid that is commonly used in topical treatment of asthma and rhinitis.", "question": "Treatment.Drug in Budesonide", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "Budesonide"}, {"id": "7720517_2_5166", "context": "Budesonide is a synthetic glucocorticosteroid that is commonly used in topical treatment of asthma and rhinitis.", "question": "Treatment.Dosage in Budesonide", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "7720517_2_5167", "context": "Budesonide is a synthetic glucocorticosteroid that is commonly used in topical treatment of asthma and rhinitis.", "question": "Treatment.Freq in Budesonide", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "7720517_2_5168", "context": "Budesonide is a synthetic glucocorticosteroid that is commonly used in topical treatment of asthma and rhinitis.", "question": "Treatment.Route in Budesonide", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "7720517_2_5169", "context": "Budesonide is a synthetic glucocorticosteroid that is commonly used in topical treatment of asthma and rhinitis.", "question": "Treatment.Time_elapsed in Budesonide", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7720517_2_5170", "context": "Budesonide is a synthetic glucocorticosteroid that is commonly used in topical treatment of asthma and rhinitis.", "question": "Treatment.Duration in Budesonide", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "7720517_2_5171", "context": "Budesonide is a synthetic glucocorticosteroid that is commonly used in topical treatment of asthma and rhinitis.", "question": "Treatment.Disorder in Budesonide", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "asthma and rhinitis."}, {"id": "7720517_2_5172", "context": "Budesonide is a synthetic glucocorticosteroid that is commonly used in topical treatment of asthma and rhinitis.", "question": "Combination.Drug in Budesonide", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "3620420_1_5173", "context": "Cyclosporin therapy in Mooren's ulcer.", "question": "Treatment.Drug in Cyclosporin", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "Cyclosporin"}, {"id": "3620420_1_5174", "context": "Cyclosporin therapy in Mooren's ulcer.", "question": "Treatment.Dosage in Cyclosporin", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "3620420_1_5175", "context": "Cyclosporin therapy in Mooren's ulcer.", "question": "Treatment.Freq in Cyclosporin", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "3620420_1_5176", "context": "Cyclosporin therapy in Mooren's ulcer.", "question": "Treatment.Route in Cyclosporin", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "3620420_1_5177", "context": "Cyclosporin therapy in Mooren's ulcer.", "question": "Treatment.Time_elapsed in Cyclosporin", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3620420_1_5178", "context": "Cyclosporin therapy in Mooren's ulcer.", "question": "Treatment.Duration in Cyclosporin", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "3620420_1_5179", "context": "Cyclosporin therapy in Mooren's ulcer.", "question": "Treatment.Disorder in Cyclosporin", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "Mooren's ulcer"}, {"id": "3620420_1_5180", "context": "Cyclosporin therapy in Mooren's ulcer.", "question": "Combination.Drug in Cyclosporin", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "11359026_3_5181", "context": "She developed neurotoxicity with an adjustment dosage of valacyclovir for a cutaneous zoster infection.", "question": "Subject.Age in She", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "11359026_3_5182", "context": "She developed neurotoxicity with an adjustment dosage of valacyclovir for a cutaneous zoster infection.", "question": "Subject.Gender in She", "question_type": "Adverse_event.Subject.Gender", "answers": "She"}, {"id": "11359026_3_5183", "context": "She developed neurotoxicity with an adjustment dosage of valacyclovir for a cutaneous zoster infection.", "question": "Subject.Population in She", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "11359026_3_5184", "context": "She developed neurotoxicity with an adjustment dosage of valacyclovir for a cutaneous zoster infection.", "question": "Subject.Race in She", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "11359026_3_5185", "context": "She developed neurotoxicity with an adjustment dosage of valacyclovir for a cutaneous zoster infection.", "question": "Subject.Disorder in She", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "11359026_3_5186", "context": "She developed neurotoxicity with an adjustment dosage of valacyclovir for a cutaneous zoster infection.", "question": "Treatment.Drug in adjustment dosage of valacyclovir", "question_type": "Adverse_event.Treatment.Drug", "answers": "valacyclovir"}, {"id": "11359026_3_5187", "context": "She developed neurotoxicity with an adjustment dosage of valacyclovir for a cutaneous zoster infection.", "question": "Treatment.Dosage in adjustment dosage of valacyclovir", "question_type": "Adverse_event.Treatment.Dosage", "answers": "adjustment dosage"}, {"id": "11359026_3_5188", "context": "She developed neurotoxicity with an adjustment dosage of valacyclovir for a cutaneous zoster infection.", "question": "Treatment.Freq in adjustment dosage of valacyclovir", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11359026_3_5189", "context": "She developed neurotoxicity with an adjustment dosage of valacyclovir for a cutaneous zoster infection.", "question": "Treatment.Route in adjustment dosage of valacyclovir", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11359026_3_5190", "context": "She developed neurotoxicity with an adjustment dosage of valacyclovir for a cutaneous zoster infection.", "question": "Treatment.Time_elapsed in adjustment dosage of valacyclovir", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11359026_3_5191", "context": "She developed neurotoxicity with an adjustment dosage of valacyclovir for a cutaneous zoster infection.", "question": "Treatment.Duration in adjustment dosage of valacyclovir", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11359026_3_5192", "context": "She developed neurotoxicity with an adjustment dosage of valacyclovir for a cutaneous zoster infection.", "question": "Treatment.Disorder in adjustment dosage of valacyclovir", "question_type": "Adverse_event.Treatment.Disorder", "answers": "cutaneous zoster infection"}, {"id": "11359026_3_5193", "context": "She developed neurotoxicity with an adjustment dosage of valacyclovir for a cutaneous zoster infection.", "question": "Combination.Drug in adjustment dosage of valacyclovir", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11642488_3_5194", "context": "Nine eyes from 6 patients, 74 years to 90 years of age, referred by ophthalmologists for repair of cicatricial entropion after at least 2 years of twice-a-day application of dipivefrin.", "question": "Subject.Age in Nine eyes from 6 patients, 74 years to 90 years of age", "question_type": "Adverse_event.Subject.Age", "answers": "74 years to 90 years"}, {"id": "11642488_3_5195", "context": "Nine eyes from 6 patients, 74 years to 90 years of age, referred by ophthalmologists for repair of cicatricial entropion after at least 2 years of twice-a-day application of dipivefrin.", "question": "Subject.Gender in Nine eyes from 6 patients, 74 years to 90 years of age", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "11642488_3_5196", "context": "Nine eyes from 6 patients, 74 years to 90 years of age, referred by ophthalmologists for repair of cicatricial entropion after at least 2 years of twice-a-day application of dipivefrin.", "question": "Subject.Population in Nine eyes from 6 patients, 74 years to 90 years of age", "question_type": "Adverse_event.Subject.Population", "answers": "6"}, {"id": "11642488_3_5197", "context": "Nine eyes from 6 patients, 74 years to 90 years of age, referred by ophthalmologists for repair of cicatricial entropion after at least 2 years of twice-a-day application of dipivefrin.", "question": "Subject.Race in Nine eyes from 6 patients, 74 years to 90 years of age", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "11642488_3_5198", "context": "Nine eyes from 6 patients, 74 years to 90 years of age, referred by ophthalmologists for repair of cicatricial entropion after at least 2 years of twice-a-day application of dipivefrin.", "question": "Subject.Disorder in Nine eyes from 6 patients, 74 years to 90 years of age", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "11642488_3_5199", "context": "Nine eyes from 6 patients, 74 years to 90 years of age, referred by ophthalmologists for repair of cicatricial entropion after at least 2 years of twice-a-day application of dipivefrin.", "question": "Treatment.Drug in at least 2 years of twice-a-day application of dipivefrin", "question_type": "Adverse_event.Treatment.Drug", "answers": "dipivefrin"}, {"id": "11642488_3_5200", "context": "Nine eyes from 6 patients, 74 years to 90 years of age, referred by ophthalmologists for repair of cicatricial entropion after at least 2 years of twice-a-day application of dipivefrin.", "question": "Treatment.Dosage in at least 2 years of twice-a-day application of dipivefrin", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11642488_3_5201", "context": "Nine eyes from 6 patients, 74 years to 90 years of age, referred by ophthalmologists for repair of cicatricial entropion after at least 2 years of twice-a-day application of dipivefrin.", "question": "Treatment.Freq in at least 2 years of twice-a-day application of dipivefrin", "question_type": "Adverse_event.Treatment.Freq", "answers": "twice-a-day"}, {"id": "11642488_3_5202", "context": "Nine eyes from 6 patients, 74 years to 90 years of age, referred by ophthalmologists for repair of cicatricial entropion after at least 2 years of twice-a-day application of dipivefrin.", "question": "Treatment.Route in at least 2 years of twice-a-day application of dipivefrin", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11642488_3_5203", "context": "Nine eyes from 6 patients, 74 years to 90 years of age, referred by ophthalmologists for repair of cicatricial entropion after at least 2 years of twice-a-day application of dipivefrin.", "question": "Treatment.Time_elapsed in at least 2 years of twice-a-day application of dipivefrin", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11642488_3_5204", "context": "Nine eyes from 6 patients, 74 years to 90 years of age, referred by ophthalmologists for repair of cicatricial entropion after at least 2 years of twice-a-day application of dipivefrin.", "question": "Treatment.Duration in at least 2 years of twice-a-day application of dipivefrin", "question_type": "Adverse_event.Treatment.Duration", "answers": "2 years"}, {"id": "11642488_3_5205", "context": "Nine eyes from 6 patients, 74 years to 90 years of age, referred by ophthalmologists for repair of cicatricial entropion after at least 2 years of twice-a-day application of dipivefrin.", "question": "Treatment.Disorder in at least 2 years of twice-a-day application of dipivefrin", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11642488_3_5206", "context": "Nine eyes from 6 patients, 74 years to 90 years of age, referred by ophthalmologists for repair of cicatricial entropion after at least 2 years of twice-a-day application of dipivefrin.", "question": "Combination.Drug in at least 2 years of twice-a-day application of dipivefrin", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15965422_3_5207", "context": "We report 5 patients (3 patients with chronic hepatitis C treated with pegylated interferon alfa-2b in association with oral ribavirin and two patients with chronic myelocytic leukemia) who developed local cutaneous reactions at sites of injection after the administration of weekly subcutaneous injections of pegylated interferon alfa-2b at different doses.", "question": "Subject.Age in two patients with chronic myelocytic leukemia", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "15965422_3_5208", "context": "We report 5 patients (3 patients with chronic hepatitis C treated with pegylated interferon alfa-2b in association with oral ribavirin and two patients with chronic myelocytic leukemia) who developed local cutaneous reactions at sites of injection after the administration of weekly subcutaneous injections of pegylated interferon alfa-2b at different doses.", "question": "Subject.Gender in two patients with chronic myelocytic leukemia", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15965422_3_5209", "context": "We report 5 patients (3 patients with chronic hepatitis C treated with pegylated interferon alfa-2b in association with oral ribavirin and two patients with chronic myelocytic leukemia) who developed local cutaneous reactions at sites of injection after the administration of weekly subcutaneous injections of pegylated interferon alfa-2b at different doses.", "question": "Subject.Population in two patients with chronic myelocytic leukemia", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "15965422_3_5210", "context": "We report 5 patients (3 patients with chronic hepatitis C treated with pegylated interferon alfa-2b in association with oral ribavirin and two patients with chronic myelocytic leukemia) who developed local cutaneous reactions at sites of injection after the administration of weekly subcutaneous injections of pegylated interferon alfa-2b at different doses.", "question": "Subject.Race in two patients with chronic myelocytic leukemia", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15965422_3_5211", "context": "We report 5 patients (3 patients with chronic hepatitis C treated with pegylated interferon alfa-2b in association with oral ribavirin and two patients with chronic myelocytic leukemia) who developed local cutaneous reactions at sites of injection after the administration of weekly subcutaneous injections of pegylated interferon alfa-2b at different doses.", "question": "Subject.Disorder in two patients with chronic myelocytic leukemia", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15965422_3_5212", "context": "We report 5 patients (3 patients with chronic hepatitis C treated with pegylated interferon alfa-2b in association with oral ribavirin and two patients with chronic myelocytic leukemia) who developed local cutaneous reactions at sites of injection after the administration of weekly subcutaneous injections of pegylated interferon alfa-2b at different doses.", "question": "Treatment.Drug in administration of weekly subcutaneous injections of pegylated interferon alfa-2b at different doses", "question_type": "Adverse_event.Treatment.Drug", "answers": "pegylated interferon alfa-2b"}, {"id": "15965422_3_5213", "context": "We report 5 patients (3 patients with chronic hepatitis C treated with pegylated interferon alfa-2b in association with oral ribavirin and two patients with chronic myelocytic leukemia) who developed local cutaneous reactions at sites of injection after the administration of weekly subcutaneous injections of pegylated interferon alfa-2b at different doses.", "question": "Treatment.Dosage in administration of weekly subcutaneous injections of pegylated interferon alfa-2b at different doses", "question_type": "Adverse_event.Treatment.Dosage", "answers": "different doses"}, {"id": "15965422_3_5214", "context": "We report 5 patients (3 patients with chronic hepatitis C treated with pegylated interferon alfa-2b in association with oral ribavirin and two patients with chronic myelocytic leukemia) who developed local cutaneous reactions at sites of injection after the administration of weekly subcutaneous injections of pegylated interferon alfa-2b at different doses.", "question": "Treatment.Freq in administration of weekly subcutaneous injections of pegylated interferon alfa-2b at different doses", "question_type": "Adverse_event.Treatment.Freq", "answers": "weekly"}, {"id": "15965422_3_5215", "context": "We report 5 patients (3 patients with chronic hepatitis C treated with pegylated interferon alfa-2b in association with oral ribavirin and two patients with chronic myelocytic leukemia) who developed local cutaneous reactions at sites of injection after the administration of weekly subcutaneous injections of pegylated interferon alfa-2b at different doses.", "question": "Treatment.Route in administration of weekly subcutaneous injections of pegylated interferon alfa-2b at different doses", "question_type": "Adverse_event.Treatment.Route", "answers": "subcutaneous injections"}, {"id": "15965422_3_5216", "context": "We report 5 patients (3 patients with chronic hepatitis C treated with pegylated interferon alfa-2b in association with oral ribavirin and two patients with chronic myelocytic leukemia) who developed local cutaneous reactions at sites of injection after the administration of weekly subcutaneous injections of pegylated interferon alfa-2b at different doses.", "question": "Treatment.Time_elapsed in administration of weekly subcutaneous injections of pegylated interferon alfa-2b at different doses", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15965422_3_5217", "context": "We report 5 patients (3 patients with chronic hepatitis C treated with pegylated interferon alfa-2b in association with oral ribavirin and two patients with chronic myelocytic leukemia) who developed local cutaneous reactions at sites of injection after the administration of weekly subcutaneous injections of pegylated interferon alfa-2b at different doses.", "question": "Treatment.Duration in administration of weekly subcutaneous injections of pegylated interferon alfa-2b at different doses", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15965422_3_5218", "context": "We report 5 patients (3 patients with chronic hepatitis C treated with pegylated interferon alfa-2b in association with oral ribavirin and two patients with chronic myelocytic leukemia) who developed local cutaneous reactions at sites of injection after the administration of weekly subcutaneous injections of pegylated interferon alfa-2b at different doses.", "question": "Treatment.Disorder in administration of weekly subcutaneous injections of pegylated interferon alfa-2b at different doses", "question_type": "Adverse_event.Treatment.Disorder", "answers": "chronic myelocytic leukemia"}, {"id": "15965422_3_5219", "context": "We report 5 patients (3 patients with chronic hepatitis C treated with pegylated interferon alfa-2b in association with oral ribavirin and two patients with chronic myelocytic leukemia) who developed local cutaneous reactions at sites of injection after the administration of weekly subcutaneous injections of pegylated interferon alfa-2b at different doses.", "question": "Combination.Drug in administration of weekly subcutaneous injections of pegylated interferon alfa-2b at different doses", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15965422_3_5220", "context": "We report 5 patients (3 patients with chronic hepatitis C treated with pegylated interferon alfa-2b in association with oral ribavirin and two patients with chronic myelocytic leukemia) who developed local cutaneous reactions at sites of injection after the administration of weekly subcutaneous injections of pegylated interferon alfa-2b at different doses.", "question": "Subject.Age in 3 patients with chronic hepatitis C", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "15965422_3_5221", "context": "We report 5 patients (3 patients with chronic hepatitis C treated with pegylated interferon alfa-2b in association with oral ribavirin and two patients with chronic myelocytic leukemia) who developed local cutaneous reactions at sites of injection after the administration of weekly subcutaneous injections of pegylated interferon alfa-2b at different doses.", "question": "Subject.Gender in 3 patients with chronic hepatitis C", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15965422_3_5222", "context": "We report 5 patients (3 patients with chronic hepatitis C treated with pegylated interferon alfa-2b in association with oral ribavirin and two patients with chronic myelocytic leukemia) who developed local cutaneous reactions at sites of injection after the administration of weekly subcutaneous injections of pegylated interferon alfa-2b at different doses.", "question": "Subject.Population in 3 patients with chronic hepatitis C", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "15965422_3_5223", "context": "We report 5 patients (3 patients with chronic hepatitis C treated with pegylated interferon alfa-2b in association with oral ribavirin and two patients with chronic myelocytic leukemia) who developed local cutaneous reactions at sites of injection after the administration of weekly subcutaneous injections of pegylated interferon alfa-2b at different doses.", "question": "Subject.Race in 3 patients with chronic hepatitis C", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15965422_3_5224", "context": "We report 5 patients (3 patients with chronic hepatitis C treated with pegylated interferon alfa-2b in association with oral ribavirin and two patients with chronic myelocytic leukemia) who developed local cutaneous reactions at sites of injection after the administration of weekly subcutaneous injections of pegylated interferon alfa-2b at different doses.", "question": "Subject.Disorder in 3 patients with chronic hepatitis C", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15965422_3_5225", "context": "We report 5 patients (3 patients with chronic hepatitis C treated with pegylated interferon alfa-2b in association with oral ribavirin and two patients with chronic myelocytic leukemia) who developed local cutaneous reactions at sites of injection after the administration of weekly subcutaneous injections of pegylated interferon alfa-2b at different doses.", "question": "Treatment.Drug in pegylated interferon alfa-2b in association with oral ribavirin", "question_type": "Adverse_event.Treatment.Drug", "answers": "pegylated interferon alfa-2b; ribavirin"}, {"id": "15965422_3_5226", "context": "We report 5 patients (3 patients with chronic hepatitis C treated with pegylated interferon alfa-2b in association with oral ribavirin and two patients with chronic myelocytic leukemia) who developed local cutaneous reactions at sites of injection after the administration of weekly subcutaneous injections of pegylated interferon alfa-2b at different doses.", "question": "Treatment.Dosage in pegylated interferon alfa-2b in association with oral ribavirin", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15965422_3_5227", "context": "We report 5 patients (3 patients with chronic hepatitis C treated with pegylated interferon alfa-2b in association with oral ribavirin and two patients with chronic myelocytic leukemia) who developed local cutaneous reactions at sites of injection after the administration of weekly subcutaneous injections of pegylated interferon alfa-2b at different doses.", "question": "Treatment.Freq in pegylated interferon alfa-2b in association with oral ribavirin", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15965422_3_5228", "context": "We report 5 patients (3 patients with chronic hepatitis C treated with pegylated interferon alfa-2b in association with oral ribavirin and two patients with chronic myelocytic leukemia) who developed local cutaneous reactions at sites of injection after the administration of weekly subcutaneous injections of pegylated interferon alfa-2b at different doses.", "question": "Treatment.Route in pegylated interferon alfa-2b in association with oral ribavirin", "question_type": "Adverse_event.Treatment.Route", "answers": "oral"}, {"id": "15965422_3_5229", "context": "We report 5 patients (3 patients with chronic hepatitis C treated with pegylated interferon alfa-2b in association with oral ribavirin and two patients with chronic myelocytic leukemia) who developed local cutaneous reactions at sites of injection after the administration of weekly subcutaneous injections of pegylated interferon alfa-2b at different doses.", "question": "Treatment.Time_elapsed in pegylated interferon alfa-2b in association with oral ribavirin", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15965422_3_5230", "context": "We report 5 patients (3 patients with chronic hepatitis C treated with pegylated interferon alfa-2b in association with oral ribavirin and two patients with chronic myelocytic leukemia) who developed local cutaneous reactions at sites of injection after the administration of weekly subcutaneous injections of pegylated interferon alfa-2b at different doses.", "question": "Treatment.Duration in pegylated interferon alfa-2b in association with oral ribavirin", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15965422_3_5231", "context": "We report 5 patients (3 patients with chronic hepatitis C treated with pegylated interferon alfa-2b in association with oral ribavirin and two patients with chronic myelocytic leukemia) who developed local cutaneous reactions at sites of injection after the administration of weekly subcutaneous injections of pegylated interferon alfa-2b at different doses.", "question": "Treatment.Disorder in pegylated interferon alfa-2b in association with oral ribavirin", "question_type": "Adverse_event.Treatment.Disorder", "answers": "chronic hepatitis C"}, {"id": "15965422_3_5232", "context": "We report 5 patients (3 patients with chronic hepatitis C treated with pegylated interferon alfa-2b in association with oral ribavirin and two patients with chronic myelocytic leukemia) who developed local cutaneous reactions at sites of injection after the administration of weekly subcutaneous injections of pegylated interferon alfa-2b at different doses.", "question": "Combination.Drug in pegylated interferon alfa-2b in association with oral ribavirin", "question_type": "Adverse_event.Combination.Drug", "answers": "pegylated interferon alfa-2b; ribavirin"}, {"id": "20180933_2_5233", "context": "Artemether-lumefantrine (AL) is first-line treatment for uncomplicated malaria in many African countries.", "question": "Treatment.Drug in Artemether-lumefantrine (AL)", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "Artemether-lumefantrine"}, {"id": "20180933_2_5234", "context": "Artemether-lumefantrine (AL) is first-line treatment for uncomplicated malaria in many African countries.", "question": "Treatment.Dosage in Artemether-lumefantrine (AL)", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "20180933_2_5235", "context": "Artemether-lumefantrine (AL) is first-line treatment for uncomplicated malaria in many African countries.", "question": "Treatment.Freq in Artemether-lumefantrine (AL)", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "20180933_2_5236", "context": "Artemether-lumefantrine (AL) is first-line treatment for uncomplicated malaria in many African countries.", "question": "Treatment.Route in Artemether-lumefantrine (AL)", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "20180933_2_5237", "context": "Artemether-lumefantrine (AL) is first-line treatment for uncomplicated malaria in many African countries.", "question": "Treatment.Time_elapsed in Artemether-lumefantrine (AL)", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "20180933_2_5238", "context": "Artemether-lumefantrine (AL) is first-line treatment for uncomplicated malaria in many African countries.", "question": "Treatment.Duration in Artemether-lumefantrine (AL)", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "20180933_2_5239", "context": "Artemether-lumefantrine (AL) is first-line treatment for uncomplicated malaria in many African countries.", "question": "Treatment.Disorder in Artemether-lumefantrine (AL)", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "uncomplicated malaria"}, {"id": "20180933_2_5240", "context": "Artemether-lumefantrine (AL) is first-line treatment for uncomplicated malaria in many African countries.", "question": "Combination.Drug in Artemether-lumefantrine (AL)", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "17329303_10_5241", "context": "Functional regulation of certain neuroreceptors during risperidone treatment may lead to altered behavioural responses upon switching to methylphenidate.", "question": "Treatment.Drug in risperidone; switching to methylphenidate", "question_type": "Adverse_event.Treatment.Drug", "answers": "risperidone; methylphenidate"}, {"id": "17329303_10_5242", "context": "Functional regulation of certain neuroreceptors during risperidone treatment may lead to altered behavioural responses upon switching to methylphenidate.", "question": "Treatment.Dosage in risperidone; switching to methylphenidate", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17329303_10_5243", "context": "Functional regulation of certain neuroreceptors during risperidone treatment may lead to altered behavioural responses upon switching to methylphenidate.", "question": "Treatment.Freq in risperidone; switching to methylphenidate", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17329303_10_5244", "context": "Functional regulation of certain neuroreceptors during risperidone treatment may lead to altered behavioural responses upon switching to methylphenidate.", "question": "Treatment.Route in risperidone; switching to methylphenidate", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17329303_10_5245", "context": "Functional regulation of certain neuroreceptors during risperidone treatment may lead to altered behavioural responses upon switching to methylphenidate.", "question": "Treatment.Time_elapsed in risperidone; switching to methylphenidate", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17329303_10_5246", "context": "Functional regulation of certain neuroreceptors during risperidone treatment may lead to altered behavioural responses upon switching to methylphenidate.", "question": "Treatment.Duration in risperidone; switching to methylphenidate", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17329303_10_5247", "context": "Functional regulation of certain neuroreceptors during risperidone treatment may lead to altered behavioural responses upon switching to methylphenidate.", "question": "Treatment.Disorder in risperidone; switching to methylphenidate", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17329303_10_5248", "context": "Functional regulation of certain neuroreceptors during risperidone treatment may lead to altered behavioural responses upon switching to methylphenidate.", "question": "Combination.Drug in risperidone; switching to methylphenidate", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3508194_1_5249", "context": "Transient leucopenia and thrombocytopenia associated with sodium nitroprusside infusion.", "question": "Treatment.Drug in sodium nitroprusside infusion", "question_type": "Adverse_event.Treatment.Drug", "answers": "sodium nitroprusside"}, {"id": "3508194_1_5250", "context": "Transient leucopenia and thrombocytopenia associated with sodium nitroprusside infusion.", "question": "Treatment.Dosage in sodium nitroprusside infusion", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3508194_1_5251", "context": "Transient leucopenia and thrombocytopenia associated with sodium nitroprusside infusion.", "question": "Treatment.Freq in sodium nitroprusside infusion", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3508194_1_5252", "context": "Transient leucopenia and thrombocytopenia associated with sodium nitroprusside infusion.", "question": "Treatment.Route in sodium nitroprusside infusion", "question_type": "Adverse_event.Treatment.Route", "answers": "infusion"}, {"id": "3508194_1_5253", "context": "Transient leucopenia and thrombocytopenia associated with sodium nitroprusside infusion.", "question": "Treatment.Time_elapsed in sodium nitroprusside infusion", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3508194_1_5254", "context": "Transient leucopenia and thrombocytopenia associated with sodium nitroprusside infusion.", "question": "Treatment.Duration in sodium nitroprusside infusion", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3508194_1_5255", "context": "Transient leucopenia and thrombocytopenia associated with sodium nitroprusside infusion.", "question": "Treatment.Disorder in sodium nitroprusside infusion", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3508194_1_5256", "context": "Transient leucopenia and thrombocytopenia associated with sodium nitroprusside infusion.", "question": "Combination.Drug in sodium nitroprusside infusion", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7789881_2_5257", "context": "This unusual pattern of low-grade endometrial carcinoma adds to the spectrum of uterine neoplasia associated with tamoxifen therapy.", "question": "Treatment.Drug in tamoxifen", "question_type": "Adverse_event.Treatment.Drug", "answers": "tamoxifen"}, {"id": "7789881_2_5258", "context": "This unusual pattern of low-grade endometrial carcinoma adds to the spectrum of uterine neoplasia associated with tamoxifen therapy.", "question": "Treatment.Dosage in tamoxifen", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7789881_2_5259", "context": "This unusual pattern of low-grade endometrial carcinoma adds to the spectrum of uterine neoplasia associated with tamoxifen therapy.", "question": "Treatment.Freq in tamoxifen", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7789881_2_5260", "context": "This unusual pattern of low-grade endometrial carcinoma adds to the spectrum of uterine neoplasia associated with tamoxifen therapy.", "question": "Treatment.Route in tamoxifen", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7789881_2_5261", "context": "This unusual pattern of low-grade endometrial carcinoma adds to the spectrum of uterine neoplasia associated with tamoxifen therapy.", "question": "Treatment.Time_elapsed in tamoxifen", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7789881_2_5262", "context": "This unusual pattern of low-grade endometrial carcinoma adds to the spectrum of uterine neoplasia associated with tamoxifen therapy.", "question": "Treatment.Duration in tamoxifen", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7789881_2_5263", "context": "This unusual pattern of low-grade endometrial carcinoma adds to the spectrum of uterine neoplasia associated with tamoxifen therapy.", "question": "Treatment.Disorder in tamoxifen", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7789881_2_5264", "context": "This unusual pattern of low-grade endometrial carcinoma adds to the spectrum of uterine neoplasia associated with tamoxifen therapy.", "question": "Combination.Drug in tamoxifen", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7420580_1_5265", "context": "Inappropriate antidiuretic hormone secretion after high dose vinblastine.", "question": "Treatment.Drug in high dose vinblastine", "question_type": "Adverse_event.Treatment.Drug", "answers": "vinblastine"}, {"id": "7420580_1_5266", "context": "Inappropriate antidiuretic hormone secretion after high dose vinblastine.", "question": "Treatment.Dosage in high dose vinblastine", "question_type": "Adverse_event.Treatment.Dosage", "answers": "high dose"}, {"id": "7420580_1_5267", "context": "Inappropriate antidiuretic hormone secretion after high dose vinblastine.", "question": "Treatment.Freq in high dose vinblastine", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7420580_1_5268", "context": "Inappropriate antidiuretic hormone secretion after high dose vinblastine.", "question": "Treatment.Route in high dose vinblastine", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7420580_1_5269", "context": "Inappropriate antidiuretic hormone secretion after high dose vinblastine.", "question": "Treatment.Time_elapsed in high dose vinblastine", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7420580_1_5270", "context": "Inappropriate antidiuretic hormone secretion after high dose vinblastine.", "question": "Treatment.Duration in high dose vinblastine", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7420580_1_5271", "context": "Inappropriate antidiuretic hormone secretion after high dose vinblastine.", "question": "Treatment.Disorder in high dose vinblastine", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7420580_1_5272", "context": "Inappropriate antidiuretic hormone secretion after high dose vinblastine.", "question": "Combination.Drug in high dose vinblastine", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17373180_2_5273", "context": "Osteomyelitis occurring during infliximab treatment of severe psoriasis.", "question": "Treatment.Drug in infliximab", "question_type": "Adverse_event.Treatment.Drug", "answers": "infliximab"}, {"id": "17373180_2_5274", "context": "Osteomyelitis occurring during infliximab treatment of severe psoriasis.", "question": "Treatment.Dosage in infliximab", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17373180_2_5275", "context": "Osteomyelitis occurring during infliximab treatment of severe psoriasis.", "question": "Treatment.Freq in infliximab", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17373180_2_5276", "context": "Osteomyelitis occurring during infliximab treatment of severe psoriasis.", "question": "Treatment.Route in infliximab", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17373180_2_5277", "context": "Osteomyelitis occurring during infliximab treatment of severe psoriasis.", "question": "Treatment.Time_elapsed in infliximab", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17373180_2_5278", "context": "Osteomyelitis occurring during infliximab treatment of severe psoriasis.", "question": "Treatment.Duration in infliximab", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17373180_2_5279", "context": "Osteomyelitis occurring during infliximab treatment of severe psoriasis.", "question": "Treatment.Disorder in infliximab", "question_type": "Adverse_event.Treatment.Disorder", "answers": "severe psoriasis"}, {"id": "17373180_2_5280", "context": "Osteomyelitis occurring during infliximab treatment of severe psoriasis.", "question": "Combination.Drug in infliximab", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8452107_3_5281", "context": "We describe a patient with transitional cell carcinoma of the renal pelvis who developed respiratory dysfunction and an abnormal chest x-ray with diffuse interstitial opacities while on chemotherapy with piritrexim, a methotrexate analog.", "question": "Subject.Age in a patient with transitional cell carcinoma of the renal pelvis", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "8452107_3_5282", "context": "We describe a patient with transitional cell carcinoma of the renal pelvis who developed respiratory dysfunction and an abnormal chest x-ray with diffuse interstitial opacities while on chemotherapy with piritrexim, a methotrexate analog.", "question": "Subject.Gender in a patient with transitional cell carcinoma of the renal pelvis", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "8452107_3_5283", "context": "We describe a patient with transitional cell carcinoma of the renal pelvis who developed respiratory dysfunction and an abnormal chest x-ray with diffuse interstitial opacities while on chemotherapy with piritrexim, a methotrexate analog.", "question": "Subject.Population in a patient with transitional cell carcinoma of the renal pelvis", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "8452107_3_5284", "context": "We describe a patient with transitional cell carcinoma of the renal pelvis who developed respiratory dysfunction and an abnormal chest x-ray with diffuse interstitial opacities while on chemotherapy with piritrexim, a methotrexate analog.", "question": "Subject.Race in a patient with transitional cell carcinoma of the renal pelvis", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "8452107_3_5285", "context": "We describe a patient with transitional cell carcinoma of the renal pelvis who developed respiratory dysfunction and an abnormal chest x-ray with diffuse interstitial opacities while on chemotherapy with piritrexim, a methotrexate analog.", "question": "Subject.Disorder in a patient with transitional cell carcinoma of the renal pelvis", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "8452107_3_5286", "context": "We describe a patient with transitional cell carcinoma of the renal pelvis who developed respiratory dysfunction and an abnormal chest x-ray with diffuse interstitial opacities while on chemotherapy with piritrexim, a methotrexate analog.", "question": "Treatment.Drug in chemotherapy with piritrexim, a methotrexate analog", "question_type": "Adverse_event.Treatment.Drug", "answers": "piritrexim"}, {"id": "8452107_3_5287", "context": "We describe a patient with transitional cell carcinoma of the renal pelvis who developed respiratory dysfunction and an abnormal chest x-ray with diffuse interstitial opacities while on chemotherapy with piritrexim, a methotrexate analog.", "question": "Treatment.Dosage in chemotherapy with piritrexim, a methotrexate analog", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8452107_3_5288", "context": "We describe a patient with transitional cell carcinoma of the renal pelvis who developed respiratory dysfunction and an abnormal chest x-ray with diffuse interstitial opacities while on chemotherapy with piritrexim, a methotrexate analog.", "question": "Treatment.Freq in chemotherapy with piritrexim, a methotrexate analog", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8452107_3_5289", "context": "We describe a patient with transitional cell carcinoma of the renal pelvis who developed respiratory dysfunction and an abnormal chest x-ray with diffuse interstitial opacities while on chemotherapy with piritrexim, a methotrexate analog.", "question": "Treatment.Route in chemotherapy with piritrexim, a methotrexate analog", "question_type": "Adverse_event.Treatment.Route", "answers": "chemotherapy"}, {"id": "8452107_3_5290", "context": "We describe a patient with transitional cell carcinoma of the renal pelvis who developed respiratory dysfunction and an abnormal chest x-ray with diffuse interstitial opacities while on chemotherapy with piritrexim, a methotrexate analog.", "question": "Treatment.Time_elapsed in chemotherapy with piritrexim, a methotrexate analog", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8452107_3_5291", "context": "We describe a patient with transitional cell carcinoma of the renal pelvis who developed respiratory dysfunction and an abnormal chest x-ray with diffuse interstitial opacities while on chemotherapy with piritrexim, a methotrexate analog.", "question": "Treatment.Duration in chemotherapy with piritrexim, a methotrexate analog", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8452107_3_5292", "context": "We describe a patient with transitional cell carcinoma of the renal pelvis who developed respiratory dysfunction and an abnormal chest x-ray with diffuse interstitial opacities while on chemotherapy with piritrexim, a methotrexate analog.", "question": "Treatment.Disorder in chemotherapy with piritrexim, a methotrexate analog", "question_type": "Adverse_event.Treatment.Disorder", "answers": "transitional cell carcinoma of the renal pelvis"}, {"id": "8452107_3_5293", "context": "We describe a patient with transitional cell carcinoma of the renal pelvis who developed respiratory dysfunction and an abnormal chest x-ray with diffuse interstitial opacities while on chemotherapy with piritrexim, a methotrexate analog.", "question": "Combination.Drug in chemotherapy with piritrexim, a methotrexate analog", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "2690546_2_5294", "context": "Amiodarone induced torsades de pointe.", "question": "Treatment.Drug in Amiodarone", "question_type": "Adverse_event.Treatment.Drug", "answers": "Amiodarone"}, {"id": "2690546_2_5295", "context": "Amiodarone induced torsades de pointe.", "question": "Treatment.Dosage in Amiodarone", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "2690546_2_5296", "context": "Amiodarone induced torsades de pointe.", "question": "Treatment.Freq in Amiodarone", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2690546_2_5297", "context": "Amiodarone induced torsades de pointe.", "question": "Treatment.Route in Amiodarone", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "2690546_2_5298", "context": "Amiodarone induced torsades de pointe.", "question": "Treatment.Time_elapsed in Amiodarone", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2690546_2_5299", "context": "Amiodarone induced torsades de pointe.", "question": "Treatment.Duration in Amiodarone", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2690546_2_5300", "context": "Amiodarone induced torsades de pointe.", "question": "Treatment.Disorder in Amiodarone", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "2690546_2_5301", "context": "Amiodarone induced torsades de pointe.", "question": "Combination.Drug in Amiodarone", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "2113320_1_5302", "context": "A patient with Wegener's granulomatosis rapidly developed a circumferential subglottic stenosis while on a cyclophosphamide regimen that had caused resolution of systemic symptoms and pulmonary infiltrates.", "question": "Subject.Age in A patient with Wegener's granulomatosis", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "2113320_1_5303", "context": "A patient with Wegener's granulomatosis rapidly developed a circumferential subglottic stenosis while on a cyclophosphamide regimen that had caused resolution of systemic symptoms and pulmonary infiltrates.", "question": "Subject.Gender in A patient with Wegener's granulomatosis", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "2113320_1_5304", "context": "A patient with Wegener's granulomatosis rapidly developed a circumferential subglottic stenosis while on a cyclophosphamide regimen that had caused resolution of systemic symptoms and pulmonary infiltrates.", "question": "Subject.Population in A patient with Wegener's granulomatosis", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "2113320_1_5305", "context": "A patient with Wegener's granulomatosis rapidly developed a circumferential subglottic stenosis while on a cyclophosphamide regimen that had caused resolution of systemic symptoms and pulmonary infiltrates.", "question": "Subject.Race in A patient with Wegener's granulomatosis", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "2113320_1_5306", "context": "A patient with Wegener's granulomatosis rapidly developed a circumferential subglottic stenosis while on a cyclophosphamide regimen that had caused resolution of systemic symptoms and pulmonary infiltrates.", "question": "Subject.Disorder in A patient with Wegener's granulomatosis", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "2113320_1_5307", "context": "A patient with Wegener's granulomatosis rapidly developed a circumferential subglottic stenosis while on a cyclophosphamide regimen that had caused resolution of systemic symptoms and pulmonary infiltrates.", "question": "Treatment.Drug in cyclophosphamide regimen", "question_type": "Adverse_event.Treatment.Drug", "answers": "cyclophosphamide"}, {"id": "2113320_1_5308", "context": "A patient with Wegener's granulomatosis rapidly developed a circumferential subglottic stenosis while on a cyclophosphamide regimen that had caused resolution of systemic symptoms and pulmonary infiltrates.", "question": "Treatment.Dosage in cyclophosphamide regimen", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "2113320_1_5309", "context": "A patient with Wegener's granulomatosis rapidly developed a circumferential subglottic stenosis while on a cyclophosphamide regimen that had caused resolution of systemic symptoms and pulmonary infiltrates.", "question": "Treatment.Freq in cyclophosphamide regimen", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2113320_1_5310", "context": "A patient with Wegener's granulomatosis rapidly developed a circumferential subglottic stenosis while on a cyclophosphamide regimen that had caused resolution of systemic symptoms and pulmonary infiltrates.", "question": "Treatment.Route in cyclophosphamide regimen", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "2113320_1_5311", "context": "A patient with Wegener's granulomatosis rapidly developed a circumferential subglottic stenosis while on a cyclophosphamide regimen that had caused resolution of systemic symptoms and pulmonary infiltrates.", "question": "Treatment.Time_elapsed in cyclophosphamide regimen", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2113320_1_5312", "context": "A patient with Wegener's granulomatosis rapidly developed a circumferential subglottic stenosis while on a cyclophosphamide regimen that had caused resolution of systemic symptoms and pulmonary infiltrates.", "question": "Treatment.Duration in cyclophosphamide regimen", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2113320_1_5313", "context": "A patient with Wegener's granulomatosis rapidly developed a circumferential subglottic stenosis while on a cyclophosphamide regimen that had caused resolution of systemic symptoms and pulmonary infiltrates.", "question": "Treatment.Disorder in cyclophosphamide regimen", "question_type": "Adverse_event.Treatment.Disorder", "answers": "Wegener's granulomatosis"}, {"id": "2113320_1_5314", "context": "A patient with Wegener's granulomatosis rapidly developed a circumferential subglottic stenosis while on a cyclophosphamide regimen that had caused resolution of systemic symptoms and pulmonary infiltrates.", "question": "Combination.Drug in cyclophosphamide regimen", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8733532_1_5315", "context": "A case is presented which illustrates a probably fatal interaction between minoxidil and a coagulation disorder.", "question": "Subject.Age in A case", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "8733532_1_5316", "context": "A case is presented which illustrates a probably fatal interaction between minoxidil and a coagulation disorder.", "question": "Subject.Gender in A case", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "8733532_1_5317", "context": "A case is presented which illustrates a probably fatal interaction between minoxidil and a coagulation disorder.", "question": "Subject.Population in A case", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "8733532_1_5318", "context": "A case is presented which illustrates a probably fatal interaction between minoxidil and a coagulation disorder.", "question": "Subject.Race in A case", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "8733532_1_5319", "context": "A case is presented which illustrates a probably fatal interaction between minoxidil and a coagulation disorder.", "question": "Subject.Disorder in A case", "question_type": "Adverse_event.Subject.Disorder", "answers": "coagulation disorder"}, {"id": "8733532_1_5320", "context": "A case is presented which illustrates a probably fatal interaction between minoxidil and a coagulation disorder.", "question": "Treatment.Drug in minoxidil", "question_type": "Adverse_event.Treatment.Drug", "answers": "minoxidil"}, {"id": "8733532_1_5321", "context": "A case is presented which illustrates a probably fatal interaction between minoxidil and a coagulation disorder.", "question": "Treatment.Dosage in minoxidil", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8733532_1_5322", "context": "A case is presented which illustrates a probably fatal interaction between minoxidil and a coagulation disorder.", "question": "Treatment.Freq in minoxidil", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8733532_1_5323", "context": "A case is presented which illustrates a probably fatal interaction between minoxidil and a coagulation disorder.", "question": "Treatment.Route in minoxidil", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8733532_1_5324", "context": "A case is presented which illustrates a probably fatal interaction between minoxidil and a coagulation disorder.", "question": "Treatment.Time_elapsed in minoxidil", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8733532_1_5325", "context": "A case is presented which illustrates a probably fatal interaction between minoxidil and a coagulation disorder.", "question": "Treatment.Duration in minoxidil", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8733532_1_5326", "context": "A case is presented which illustrates a probably fatal interaction between minoxidil and a coagulation disorder.", "question": "Treatment.Disorder in minoxidil", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8733532_1_5327", "context": "A case is presented which illustrates a probably fatal interaction between minoxidil and a coagulation disorder.", "question": "Combination.Drug in minoxidil", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11406880_1_5328", "context": "Methadone-induced myoclonus in advanced cancer.", "question": "Treatment.Drug in Methadone", "question_type": "Adverse_event.Treatment.Drug", "answers": "Methadone"}, {"id": "11406880_1_5329", "context": "Methadone-induced myoclonus in advanced cancer.", "question": "Treatment.Dosage in Methadone", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11406880_1_5330", "context": "Methadone-induced myoclonus in advanced cancer.", "question": "Treatment.Freq in Methadone", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11406880_1_5331", "context": "Methadone-induced myoclonus in advanced cancer.", "question": "Treatment.Route in Methadone", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11406880_1_5332", "context": "Methadone-induced myoclonus in advanced cancer.", "question": "Treatment.Time_elapsed in Methadone", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11406880_1_5333", "context": "Methadone-induced myoclonus in advanced cancer.", "question": "Treatment.Duration in Methadone", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11406880_1_5334", "context": "Methadone-induced myoclonus in advanced cancer.", "question": "Treatment.Disorder in Methadone", "question_type": "Adverse_event.Treatment.Disorder", "answers": "advanced cancer"}, {"id": "11406880_1_5335", "context": "Methadone-induced myoclonus in advanced cancer.", "question": "Combination.Drug in Methadone", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11984077_1_5336", "context": "Life-threatening anaphylactoid reaction to amifostine used with concurrent chemoradiotherapy for nasopharyngeal cancer in a patient with dermatomyositis: a case report with literature review.", "question": "Subject.Age in a patient with dermatomyositis", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "11984077_1_5337", "context": "Life-threatening anaphylactoid reaction to amifostine used with concurrent chemoradiotherapy for nasopharyngeal cancer in a patient with dermatomyositis: a case report with literature review.", "question": "Subject.Gender in a patient with dermatomyositis", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "11984077_1_5338", "context": "Life-threatening anaphylactoid reaction to amifostine used with concurrent chemoradiotherapy for nasopharyngeal cancer in a patient with dermatomyositis: a case report with literature review.", "question": "Subject.Population in a patient with dermatomyositis", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "11984077_1_5339", "context": "Life-threatening anaphylactoid reaction to amifostine used with concurrent chemoradiotherapy for nasopharyngeal cancer in a patient with dermatomyositis: a case report with literature review.", "question": "Subject.Race in a patient with dermatomyositis", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "11984077_1_5340", "context": "Life-threatening anaphylactoid reaction to amifostine used with concurrent chemoradiotherapy for nasopharyngeal cancer in a patient with dermatomyositis: a case report with literature review.", "question": "Subject.Disorder in a patient with dermatomyositis", "question_type": "Adverse_event.Subject.Disorder", "answers": "dermatomyositis"}, {"id": "11984077_1_5341", "context": "Life-threatening anaphylactoid reaction to amifostine used with concurrent chemoradiotherapy for nasopharyngeal cancer in a patient with dermatomyositis: a case report with literature review.", "question": "Treatment.Drug in amifostine used with concurrent chemoradiotherapy", "question_type": "Adverse_event.Treatment.Drug", "answers": "amifostine; chemoradiotherapy"}, {"id": "11984077_1_5342", "context": "Life-threatening anaphylactoid reaction to amifostine used with concurrent chemoradiotherapy for nasopharyngeal cancer in a patient with dermatomyositis: a case report with literature review.", "question": "Treatment.Dosage in amifostine used with concurrent chemoradiotherapy", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11984077_1_5343", "context": "Life-threatening anaphylactoid reaction to amifostine used with concurrent chemoradiotherapy for nasopharyngeal cancer in a patient with dermatomyositis: a case report with literature review.", "question": "Treatment.Freq in amifostine used with concurrent chemoradiotherapy", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11984077_1_5344", "context": "Life-threatening anaphylactoid reaction to amifostine used with concurrent chemoradiotherapy for nasopharyngeal cancer in a patient with dermatomyositis: a case report with literature review.", "question": "Treatment.Route in amifostine used with concurrent chemoradiotherapy", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11984077_1_5345", "context": "Life-threatening anaphylactoid reaction to amifostine used with concurrent chemoradiotherapy for nasopharyngeal cancer in a patient with dermatomyositis: a case report with literature review.", "question": "Treatment.Time_elapsed in amifostine used with concurrent chemoradiotherapy", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11984077_1_5346", "context": "Life-threatening anaphylactoid reaction to amifostine used with concurrent chemoradiotherapy for nasopharyngeal cancer in a patient with dermatomyositis: a case report with literature review.", "question": "Treatment.Duration in amifostine used with concurrent chemoradiotherapy", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11984077_1_5347", "context": "Life-threatening anaphylactoid reaction to amifostine used with concurrent chemoradiotherapy for nasopharyngeal cancer in a patient with dermatomyositis: a case report with literature review.", "question": "Treatment.Disorder in amifostine used with concurrent chemoradiotherapy", "question_type": "Adverse_event.Treatment.Disorder", "answers": "nasopharyngeal cancer"}, {"id": "11984077_1_5348", "context": "Life-threatening anaphylactoid reaction to amifostine used with concurrent chemoradiotherapy for nasopharyngeal cancer in a patient with dermatomyositis: a case report with literature review.", "question": "Combination.Drug in amifostine used with concurrent chemoradiotherapy", "question_type": "Adverse_event.Combination.Drug", "answers": "amifostine; chemoradiotherapy"}, {"id": "19260037_4_5349", "context": "We conclude that while thrombocytopenia and schistocytosis can be seen in quinine-associated TTP/HUS, the pathophysiology seems to be distinct from that seen in most cases of idiopathic TTP (i.e., severely decreased ADAMTS13 with an inhibitor).", "question": "Treatment.Drug in quinine", "question_type": "Adverse_event.Treatment.Drug", "answers": "quinine"}, {"id": "19260037_4_5350", "context": "We conclude that while thrombocytopenia and schistocytosis can be seen in quinine-associated TTP/HUS, the pathophysiology seems to be distinct from that seen in most cases of idiopathic TTP (i.e., severely decreased ADAMTS13 with an inhibitor).", "question": "Treatment.Dosage in quinine", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "19260037_4_5351", "context": "We conclude that while thrombocytopenia and schistocytosis can be seen in quinine-associated TTP/HUS, the pathophysiology seems to be distinct from that seen in most cases of idiopathic TTP (i.e., severely decreased ADAMTS13 with an inhibitor).", "question": "Treatment.Freq in quinine", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "19260037_4_5352", "context": "We conclude that while thrombocytopenia and schistocytosis can be seen in quinine-associated TTP/HUS, the pathophysiology seems to be distinct from that seen in most cases of idiopathic TTP (i.e., severely decreased ADAMTS13 with an inhibitor).", "question": "Treatment.Route in quinine", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "19260037_4_5353", "context": "We conclude that while thrombocytopenia and schistocytosis can be seen in quinine-associated TTP/HUS, the pathophysiology seems to be distinct from that seen in most cases of idiopathic TTP (i.e., severely decreased ADAMTS13 with an inhibitor).", "question": "Treatment.Time_elapsed in quinine", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19260037_4_5354", "context": "We conclude that while thrombocytopenia and schistocytosis can be seen in quinine-associated TTP/HUS, the pathophysiology seems to be distinct from that seen in most cases of idiopathic TTP (i.e., severely decreased ADAMTS13 with an inhibitor).", "question": "Treatment.Duration in quinine", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "19260037_4_5355", "context": "We conclude that while thrombocytopenia and schistocytosis can be seen in quinine-associated TTP/HUS, the pathophysiology seems to be distinct from that seen in most cases of idiopathic TTP (i.e., severely decreased ADAMTS13 with an inhibitor).", "question": "Treatment.Disorder in quinine", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "19260037_4_5356", "context": "We conclude that while thrombocytopenia and schistocytosis can be seen in quinine-associated TTP/HUS, the pathophysiology seems to be distinct from that seen in most cases of idiopathic TTP (i.e., severely decreased ADAMTS13 with an inhibitor).", "question": "Combination.Drug in quinine", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "19690222_1_5357", "context": "CONCLUSIONS: Spontaneous hemothorax is a rare phenomenon in conjunction with LMWH but should be considered in cases of acute respiratory distress following commencement of LMWH.", "question": "Treatment.Drug in LMWH", "question_type": "Adverse_event.Treatment.Drug", "answers": "LMWH"}, {"id": "19690222_1_5358", "context": "CONCLUSIONS: Spontaneous hemothorax is a rare phenomenon in conjunction with LMWH but should be considered in cases of acute respiratory distress following commencement of LMWH.", "question": "Treatment.Dosage in LMWH", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "19690222_1_5359", "context": "CONCLUSIONS: Spontaneous hemothorax is a rare phenomenon in conjunction with LMWH but should be considered in cases of acute respiratory distress following commencement of LMWH.", "question": "Treatment.Freq in LMWH", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "19690222_1_5360", "context": "CONCLUSIONS: Spontaneous hemothorax is a rare phenomenon in conjunction with LMWH but should be considered in cases of acute respiratory distress following commencement of LMWH.", "question": "Treatment.Route in LMWH", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "19690222_1_5361", "context": "CONCLUSIONS: Spontaneous hemothorax is a rare phenomenon in conjunction with LMWH but should be considered in cases of acute respiratory distress following commencement of LMWH.", "question": "Treatment.Time_elapsed in LMWH", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19690222_1_5362", "context": "CONCLUSIONS: Spontaneous hemothorax is a rare phenomenon in conjunction with LMWH but should be considered in cases of acute respiratory distress following commencement of LMWH.", "question": "Treatment.Duration in LMWH", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "19690222_1_5363", "context": "CONCLUSIONS: Spontaneous hemothorax is a rare phenomenon in conjunction with LMWH but should be considered in cases of acute respiratory distress following commencement of LMWH.", "question": "Treatment.Disorder in LMWH", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "19690222_1_5364", "context": "CONCLUSIONS: Spontaneous hemothorax is a rare phenomenon in conjunction with LMWH but should be considered in cases of acute respiratory distress following commencement of LMWH.", "question": "Combination.Drug in LMWH", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17068466_1_5365", "context": "CONCLUSION: These cases suggest that moxifloxacin may interfere with the healing of corneal ulcers.", "question": "Subject.Age in These cases", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "17068466_1_5366", "context": "CONCLUSION: These cases suggest that moxifloxacin may interfere with the healing of corneal ulcers.", "question": "Subject.Gender in These cases", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "17068466_1_5367", "context": "CONCLUSION: These cases suggest that moxifloxacin may interfere with the healing of corneal ulcers.", "question": "Subject.Population in These cases", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "17068466_1_5368", "context": "CONCLUSION: These cases suggest that moxifloxacin may interfere with the healing of corneal ulcers.", "question": "Subject.Race in These cases", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "17068466_1_5369", "context": "CONCLUSION: These cases suggest that moxifloxacin may interfere with the healing of corneal ulcers.", "question": "Subject.Disorder in These cases", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "17068466_1_5370", "context": "CONCLUSION: These cases suggest that moxifloxacin may interfere with the healing of corneal ulcers.", "question": "Treatment.Drug in moxifloxacin", "question_type": "Adverse_event.Treatment.Drug", "answers": "moxifloxacin"}, {"id": "17068466_1_5371", "context": "CONCLUSION: These cases suggest that moxifloxacin may interfere with the healing of corneal ulcers.", "question": "Treatment.Dosage in moxifloxacin", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17068466_1_5372", "context": "CONCLUSION: These cases suggest that moxifloxacin may interfere with the healing of corneal ulcers.", "question": "Treatment.Freq in moxifloxacin", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17068466_1_5373", "context": "CONCLUSION: These cases suggest that moxifloxacin may interfere with the healing of corneal ulcers.", "question": "Treatment.Route in moxifloxacin", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17068466_1_5374", "context": "CONCLUSION: These cases suggest that moxifloxacin may interfere with the healing of corneal ulcers.", "question": "Treatment.Time_elapsed in moxifloxacin", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17068466_1_5375", "context": "CONCLUSION: These cases suggest that moxifloxacin may interfere with the healing of corneal ulcers.", "question": "Treatment.Duration in moxifloxacin", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17068466_1_5376", "context": "CONCLUSION: These cases suggest that moxifloxacin may interfere with the healing of corneal ulcers.", "question": "Treatment.Disorder in moxifloxacin", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17068466_1_5377", "context": "CONCLUSION: These cases suggest that moxifloxacin may interfere with the healing of corneal ulcers.", "question": "Combination.Drug in moxifloxacin", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "2568058_4_5378", "context": "Reinstitution of penicillamine treatment caused a recurrence thus proving a causal relationship between penicillamine and the described nail-changes.", "question": "Treatment.Drug in penicillamine", "question_type": "Adverse_event.Treatment.Drug", "answers": "penicillamine; penicillamine"}, {"id": "2568058_4_5379", "context": "Reinstitution of penicillamine treatment caused a recurrence thus proving a causal relationship between penicillamine and the described nail-changes.", "question": "Treatment.Dosage in penicillamine", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "2568058_4_5380", "context": "Reinstitution of penicillamine treatment caused a recurrence thus proving a causal relationship between penicillamine and the described nail-changes.", "question": "Treatment.Freq in penicillamine", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2568058_4_5381", "context": "Reinstitution of penicillamine treatment caused a recurrence thus proving a causal relationship between penicillamine and the described nail-changes.", "question": "Treatment.Route in penicillamine", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "2568058_4_5382", "context": "Reinstitution of penicillamine treatment caused a recurrence thus proving a causal relationship between penicillamine and the described nail-changes.", "question": "Treatment.Time_elapsed in penicillamine", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2568058_4_5383", "context": "Reinstitution of penicillamine treatment caused a recurrence thus proving a causal relationship between penicillamine and the described nail-changes.", "question": "Treatment.Duration in penicillamine", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2568058_4_5384", "context": "Reinstitution of penicillamine treatment caused a recurrence thus proving a causal relationship between penicillamine and the described nail-changes.", "question": "Treatment.Disorder in penicillamine", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "2568058_4_5385", "context": "Reinstitution of penicillamine treatment caused a recurrence thus proving a causal relationship between penicillamine and the described nail-changes.", "question": "Combination.Drug in penicillamine", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11672959_1_5386", "context": "A 34-year-old lady developed a constellation of dermatitis, fever, lymphadenopathy and hepatitis, beginning on the 17th day of a course of oral sulphasalazine for sero-negative rheumatoid arthritis.", "question": "Subject.Age in A 34-year-old lady", "question_type": "Adverse_event.Subject.Age", "answers": "34-year-old"}, {"id": "11672959_1_5387", "context": "A 34-year-old lady developed a constellation of dermatitis, fever, lymphadenopathy and hepatitis, beginning on the 17th day of a course of oral sulphasalazine for sero-negative rheumatoid arthritis.", "question": "Subject.Gender in A 34-year-old lady", "question_type": "Adverse_event.Subject.Gender", "answers": "lady"}, {"id": "11672959_1_5388", "context": "A 34-year-old lady developed a constellation of dermatitis, fever, lymphadenopathy and hepatitis, beginning on the 17th day of a course of oral sulphasalazine for sero-negative rheumatoid arthritis.", "question": "Subject.Population in A 34-year-old lady", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "11672959_1_5389", "context": "A 34-year-old lady developed a constellation of dermatitis, fever, lymphadenopathy and hepatitis, beginning on the 17th day of a course of oral sulphasalazine for sero-negative rheumatoid arthritis.", "question": "Subject.Race in A 34-year-old lady", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "11672959_1_5390", "context": "A 34-year-old lady developed a constellation of dermatitis, fever, lymphadenopathy and hepatitis, beginning on the 17th day of a course of oral sulphasalazine for sero-negative rheumatoid arthritis.", "question": "Subject.Disorder in A 34-year-old lady", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "11672959_1_5391", "context": "A 34-year-old lady developed a constellation of dermatitis, fever, lymphadenopathy and hepatitis, beginning on the 17th day of a course of oral sulphasalazine for sero-negative rheumatoid arthritis.", "question": "Treatment.Drug in a course of oral sulphasalazine", "question_type": "Adverse_event.Treatment.Drug", "answers": "sulphasalazine"}, {"id": "11672959_1_5392", "context": "A 34-year-old lady developed a constellation of dermatitis, fever, lymphadenopathy and hepatitis, beginning on the 17th day of a course of oral sulphasalazine for sero-negative rheumatoid arthritis.", "question": "Treatment.Dosage in a course of oral sulphasalazine", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11672959_1_5393", "context": "A 34-year-old lady developed a constellation of dermatitis, fever, lymphadenopathy and hepatitis, beginning on the 17th day of a course of oral sulphasalazine for sero-negative rheumatoid arthritis.", "question": "Treatment.Freq in a course of oral sulphasalazine", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11672959_1_5394", "context": "A 34-year-old lady developed a constellation of dermatitis, fever, lymphadenopathy and hepatitis, beginning on the 17th day of a course of oral sulphasalazine for sero-negative rheumatoid arthritis.", "question": "Treatment.Route in a course of oral sulphasalazine", "question_type": "Adverse_event.Treatment.Route", "answers": "oral"}, {"id": "11672959_1_5395", "context": "A 34-year-old lady developed a constellation of dermatitis, fever, lymphadenopathy and hepatitis, beginning on the 17th day of a course of oral sulphasalazine for sero-negative rheumatoid arthritis.", "question": "Treatment.Time_elapsed in a course of oral sulphasalazine", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11672959_1_5396", "context": "A 34-year-old lady developed a constellation of dermatitis, fever, lymphadenopathy and hepatitis, beginning on the 17th day of a course of oral sulphasalazine for sero-negative rheumatoid arthritis.", "question": "Treatment.Duration in a course of oral sulphasalazine", "question_type": "Adverse_event.Treatment.Duration", "answers": "17th day"}, {"id": "11672959_1_5397", "context": "A 34-year-old lady developed a constellation of dermatitis, fever, lymphadenopathy and hepatitis, beginning on the 17th day of a course of oral sulphasalazine for sero-negative rheumatoid arthritis.", "question": "Treatment.Disorder in a course of oral sulphasalazine", "question_type": "Adverse_event.Treatment.Disorder", "answers": "ero-negative rheumatoid arthritis"}, {"id": "11672959_1_5398", "context": "A 34-year-old lady developed a constellation of dermatitis, fever, lymphadenopathy and hepatitis, beginning on the 17th day of a course of oral sulphasalazine for sero-negative rheumatoid arthritis.", "question": "Combination.Drug in a course of oral sulphasalazine", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18477279_3_5399", "context": "He had been commenced on a course of fusidic acid at discharge in addition to his ongoing statin prescription and presented 4 weeks later with symptoms consistent with rhabdomyolysis.", "question": "Treatment.Drug in a course of fusidic acid at discharge in addition to his ongoing statin prescription", "question_type": "Adverse_event.Treatment.Drug", "answers": "statin; fusidic acid"}, {"id": "18477279_3_5400", "context": "He had been commenced on a course of fusidic acid at discharge in addition to his ongoing statin prescription and presented 4 weeks later with symptoms consistent with rhabdomyolysis.", "question": "Treatment.Dosage in a course of fusidic acid at discharge in addition to his ongoing statin prescription", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18477279_3_5401", "context": "He had been commenced on a course of fusidic acid at discharge in addition to his ongoing statin prescription and presented 4 weeks later with symptoms consistent with rhabdomyolysis.", "question": "Treatment.Freq in a course of fusidic acid at discharge in addition to his ongoing statin prescription", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18477279_3_5402", "context": "He had been commenced on a course of fusidic acid at discharge in addition to his ongoing statin prescription and presented 4 weeks later with symptoms consistent with rhabdomyolysis.", "question": "Treatment.Route in a course of fusidic acid at discharge in addition to his ongoing statin prescription", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18477279_3_5403", "context": "He had been commenced on a course of fusidic acid at discharge in addition to his ongoing statin prescription and presented 4 weeks later with symptoms consistent with rhabdomyolysis.", "question": "Treatment.Time_elapsed in a course of fusidic acid at discharge in addition to his ongoing statin prescription", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "4 weeks later"}, {"id": "18477279_3_5404", "context": "He had been commenced on a course of fusidic acid at discharge in addition to his ongoing statin prescription and presented 4 weeks later with symptoms consistent with rhabdomyolysis.", "question": "Treatment.Duration in a course of fusidic acid at discharge in addition to his ongoing statin prescription", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18477279_3_5405", "context": "He had been commenced on a course of fusidic acid at discharge in addition to his ongoing statin prescription and presented 4 weeks later with symptoms consistent with rhabdomyolysis.", "question": "Treatment.Disorder in a course of fusidic acid at discharge in addition to his ongoing statin prescription", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18477279_3_5406", "context": "He had been commenced on a course of fusidic acid at discharge in addition to his ongoing statin prescription and presented 4 weeks later with symptoms consistent with rhabdomyolysis.", "question": "Combination.Drug in a course of fusidic acid at discharge in addition to his ongoing statin prescription", "question_type": "Adverse_event.Combination.Drug", "answers": "fusidic acid; statin"}, {"id": "10456689_2_5407", "context": "1.\nArtelinic acid (AL), a water-soluble artemisinin analogue for treatment of multidrug resistant malaria, is metabolized to the active metabolite dihydroqinghaosu (DQHS) solely by  CYP3A4/5.", "question": "Treatment.Drug in Artelinic acid (AL), a water-soluble artemisinin analogue", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "Artelinic acid"}, {"id": "10456689_2_5408", "context": "1.\nArtelinic acid (AL), a water-soluble artemisinin analogue for treatment of multidrug resistant malaria, is metabolized to the active metabolite dihydroqinghaosu (DQHS) solely by  CYP3A4/5.", "question": "Treatment.Dosage in Artelinic acid (AL), a water-soluble artemisinin analogue", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "10456689_2_5409", "context": "1.\nArtelinic acid (AL), a water-soluble artemisinin analogue for treatment of multidrug resistant malaria, is metabolized to the active metabolite dihydroqinghaosu (DQHS) solely by  CYP3A4/5.", "question": "Treatment.Freq in Artelinic acid (AL), a water-soluble artemisinin analogue", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "10456689_2_5410", "context": "1.\nArtelinic acid (AL), a water-soluble artemisinin analogue for treatment of multidrug resistant malaria, is metabolized to the active metabolite dihydroqinghaosu (DQHS) solely by  CYP3A4/5.", "question": "Treatment.Route in Artelinic acid (AL), a water-soluble artemisinin analogue", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "10456689_2_5411", "context": "1.\nArtelinic acid (AL), a water-soluble artemisinin analogue for treatment of multidrug resistant malaria, is metabolized to the active metabolite dihydroqinghaosu (DQHS) solely by  CYP3A4/5.", "question": "Treatment.Time_elapsed in Artelinic acid (AL), a water-soluble artemisinin analogue", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10456689_2_5412", "context": "1.\nArtelinic acid (AL), a water-soluble artemisinin analogue for treatment of multidrug resistant malaria, is metabolized to the active metabolite dihydroqinghaosu (DQHS) solely by  CYP3A4/5.", "question": "Treatment.Duration in Artelinic acid (AL), a water-soluble artemisinin analogue", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "10456689_2_5413", "context": "1.\nArtelinic acid (AL), a water-soluble artemisinin analogue for treatment of multidrug resistant malaria, is metabolized to the active metabolite dihydroqinghaosu (DQHS) solely by  CYP3A4/5.", "question": "Treatment.Disorder in Artelinic acid (AL), a water-soluble artemisinin analogue", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "multidrug resistant malaria"}, {"id": "10456689_2_5414", "context": "1.\nArtelinic acid (AL), a water-soluble artemisinin analogue for treatment of multidrug resistant malaria, is metabolized to the active metabolite dihydroqinghaosu (DQHS) solely by  CYP3A4/5.", "question": "Combination.Drug in Artelinic acid (AL), a water-soluble artemisinin analogue", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "17331261_3_5415", "context": "Inhaled tobramycin solution-associated recurrent eosinophilia and severe persistent bronchospasm in a patient with cystic fibrosis: a case report.", "question": "Subject.Age in a patient with cystic fibrosis", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "17331261_3_5416", "context": "Inhaled tobramycin solution-associated recurrent eosinophilia and severe persistent bronchospasm in a patient with cystic fibrosis: a case report.", "question": "Subject.Gender in a patient with cystic fibrosis", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "17331261_3_5417", "context": "Inhaled tobramycin solution-associated recurrent eosinophilia and severe persistent bronchospasm in a patient with cystic fibrosis: a case report.", "question": "Subject.Population in a patient with cystic fibrosis", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "17331261_3_5418", "context": "Inhaled tobramycin solution-associated recurrent eosinophilia and severe persistent bronchospasm in a patient with cystic fibrosis: a case report.", "question": "Subject.Race in a patient with cystic fibrosis", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "17331261_3_5419", "context": "Inhaled tobramycin solution-associated recurrent eosinophilia and severe persistent bronchospasm in a patient with cystic fibrosis: a case report.", "question": "Subject.Disorder in a patient with cystic fibrosis", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "17331261_3_5420", "context": "Inhaled tobramycin solution-associated recurrent eosinophilia and severe persistent bronchospasm in a patient with cystic fibrosis: a case report.", "question": "Treatment.Drug in Inhaled tobramycin", "question_type": "Adverse_event.Treatment.Drug", "answers": "tobramycin"}, {"id": "17331261_3_5421", "context": "Inhaled tobramycin solution-associated recurrent eosinophilia and severe persistent bronchospasm in a patient with cystic fibrosis: a case report.", "question": "Treatment.Dosage in Inhaled tobramycin", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17331261_3_5422", "context": "Inhaled tobramycin solution-associated recurrent eosinophilia and severe persistent bronchospasm in a patient with cystic fibrosis: a case report.", "question": "Treatment.Freq in Inhaled tobramycin", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17331261_3_5423", "context": "Inhaled tobramycin solution-associated recurrent eosinophilia and severe persistent bronchospasm in a patient with cystic fibrosis: a case report.", "question": "Treatment.Route in Inhaled tobramycin", "question_type": "Adverse_event.Treatment.Route", "answers": "Inhaled"}, {"id": "17331261_3_5424", "context": "Inhaled tobramycin solution-associated recurrent eosinophilia and severe persistent bronchospasm in a patient with cystic fibrosis: a case report.", "question": "Treatment.Time_elapsed in Inhaled tobramycin", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17331261_3_5425", "context": "Inhaled tobramycin solution-associated recurrent eosinophilia and severe persistent bronchospasm in a patient with cystic fibrosis: a case report.", "question": "Treatment.Duration in Inhaled tobramycin", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17331261_3_5426", "context": "Inhaled tobramycin solution-associated recurrent eosinophilia and severe persistent bronchospasm in a patient with cystic fibrosis: a case report.", "question": "Treatment.Disorder in Inhaled tobramycin", "question_type": "Adverse_event.Treatment.Disorder", "answers": "cystic fibrosis"}, {"id": "17331261_3_5427", "context": "Inhaled tobramycin solution-associated recurrent eosinophilia and severe persistent bronchospasm in a patient with cystic fibrosis: a case report.", "question": "Combination.Drug in Inhaled tobramycin", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15719254_4_5428", "context": "The occurrence of BMTN in two children treated with RA in our unit is unlikely to be coincidental.", "question": "Subject.Age in two children", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": "children"}, {"id": "15719254_4_5429", "context": "The occurrence of BMTN in two children treated with RA in our unit is unlikely to be coincidental.", "question": "Subject.Gender in two children", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "15719254_4_5430", "context": "The occurrence of BMTN in two children treated with RA in our unit is unlikely to be coincidental.", "question": "Subject.Population in two children", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": "two"}, {"id": "15719254_4_5431", "context": "The occurrence of BMTN in two children treated with RA in our unit is unlikely to be coincidental.", "question": "Subject.Race in two children", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "15719254_4_5432", "context": "The occurrence of BMTN in two children treated with RA in our unit is unlikely to be coincidental.", "question": "Subject.Disorder in two children", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "15719254_4_5433", "context": "The occurrence of BMTN in two children treated with RA in our unit is unlikely to be coincidental.", "question": "Treatment.Drug in RA", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "RA"}, {"id": "15719254_4_5434", "context": "The occurrence of BMTN in two children treated with RA in our unit is unlikely to be coincidental.", "question": "Treatment.Dosage in RA", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "15719254_4_5435", "context": "The occurrence of BMTN in two children treated with RA in our unit is unlikely to be coincidental.", "question": "Treatment.Freq in RA", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "15719254_4_5436", "context": "The occurrence of BMTN in two children treated with RA in our unit is unlikely to be coincidental.", "question": "Treatment.Route in RA", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "15719254_4_5437", "context": "The occurrence of BMTN in two children treated with RA in our unit is unlikely to be coincidental.", "question": "Treatment.Time_elapsed in RA", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15719254_4_5438", "context": "The occurrence of BMTN in two children treated with RA in our unit is unlikely to be coincidental.", "question": "Treatment.Duration in RA", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "15719254_4_5439", "context": "The occurrence of BMTN in two children treated with RA in our unit is unlikely to be coincidental.", "question": "Treatment.Disorder in RA", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "15719254_4_5440", "context": "The occurrence of BMTN in two children treated with RA in our unit is unlikely to be coincidental.", "question": "Combination.Drug in RA", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "12665232_1_5441", "context": "Comeoscleral perforation after pterygium excision and intraoperative mitomycin C.", "question": "Treatment.Drug in pterygium excision and intraoperative mitomycin C", "question_type": "Adverse_event.Treatment.Drug", "answers": "mitomycin C"}, {"id": "12665232_1_5442", "context": "Comeoscleral perforation after pterygium excision and intraoperative mitomycin C.", "question": "Treatment.Dosage in pterygium excision and intraoperative mitomycin C", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12665232_1_5443", "context": "Comeoscleral perforation after pterygium excision and intraoperative mitomycin C.", "question": "Treatment.Freq in pterygium excision and intraoperative mitomycin C", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12665232_1_5444", "context": "Comeoscleral perforation after pterygium excision and intraoperative mitomycin C.", "question": "Treatment.Route in pterygium excision and intraoperative mitomycin C", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12665232_1_5445", "context": "Comeoscleral perforation after pterygium excision and intraoperative mitomycin C.", "question": "Treatment.Time_elapsed in pterygium excision and intraoperative mitomycin C", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12665232_1_5446", "context": "Comeoscleral perforation after pterygium excision and intraoperative mitomycin C.", "question": "Treatment.Duration in pterygium excision and intraoperative mitomycin C", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12665232_1_5447", "context": "Comeoscleral perforation after pterygium excision and intraoperative mitomycin C.", "question": "Treatment.Disorder in pterygium excision and intraoperative mitomycin C", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12665232_1_5448", "context": "Comeoscleral perforation after pterygium excision and intraoperative mitomycin C.", "question": "Combination.Drug in pterygium excision and intraoperative mitomycin C", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16237130_1_5449", "context": "Capecitabine-induced multifocal leukoencephalopathy: a report of five cases.", "question": "Subject.Age in five cases", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "16237130_1_5450", "context": "Capecitabine-induced multifocal leukoencephalopathy: a report of five cases.", "question": "Subject.Gender in five cases", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "16237130_1_5451", "context": "Capecitabine-induced multifocal leukoencephalopathy: a report of five cases.", "question": "Subject.Population in five cases", "question_type": "Adverse_event.Subject.Population", "answers": "five"}, {"id": "16237130_1_5452", "context": "Capecitabine-induced multifocal leukoencephalopathy: a report of five cases.", "question": "Subject.Race in five cases", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16237130_1_5453", "context": "Capecitabine-induced multifocal leukoencephalopathy: a report of five cases.", "question": "Subject.Disorder in five cases", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "16237130_1_5454", "context": "Capecitabine-induced multifocal leukoencephalopathy: a report of five cases.", "question": "Treatment.Drug in Capecitabine", "question_type": "Adverse_event.Treatment.Drug", "answers": "Capecitabine"}, {"id": "16237130_1_5455", "context": "Capecitabine-induced multifocal leukoencephalopathy: a report of five cases.", "question": "Treatment.Dosage in Capecitabine", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16237130_1_5456", "context": "Capecitabine-induced multifocal leukoencephalopathy: a report of five cases.", "question": "Treatment.Freq in Capecitabine", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16237130_1_5457", "context": "Capecitabine-induced multifocal leukoencephalopathy: a report of five cases.", "question": "Treatment.Route in Capecitabine", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16237130_1_5458", "context": "Capecitabine-induced multifocal leukoencephalopathy: a report of five cases.", "question": "Treatment.Time_elapsed in Capecitabine", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16237130_1_5459", "context": "Capecitabine-induced multifocal leukoencephalopathy: a report of five cases.", "question": "Treatment.Duration in Capecitabine", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16237130_1_5460", "context": "Capecitabine-induced multifocal leukoencephalopathy: a report of five cases.", "question": "Treatment.Disorder in Capecitabine", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16237130_1_5461", "context": "Capecitabine-induced multifocal leukoencephalopathy: a report of five cases.", "question": "Combination.Drug in Capecitabine", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15941649_3_5462", "context": "Vigabatrin-induced visual field defects are at present the most important safety issue in the use of the drug.", "question": "Treatment.Drug in Vigabatrin", "question_type": "Adverse_event.Treatment.Drug", "answers": "Vigabatrin"}, {"id": "15941649_3_5463", "context": "Vigabatrin-induced visual field defects are at present the most important safety issue in the use of the drug.", "question": "Treatment.Dosage in Vigabatrin", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15941649_3_5464", "context": "Vigabatrin-induced visual field defects are at present the most important safety issue in the use of the drug.", "question": "Treatment.Freq in Vigabatrin", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15941649_3_5465", "context": "Vigabatrin-induced visual field defects are at present the most important safety issue in the use of the drug.", "question": "Treatment.Route in Vigabatrin", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15941649_3_5466", "context": "Vigabatrin-induced visual field defects are at present the most important safety issue in the use of the drug.", "question": "Treatment.Time_elapsed in Vigabatrin", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15941649_3_5467", "context": "Vigabatrin-induced visual field defects are at present the most important safety issue in the use of the drug.", "question": "Treatment.Duration in Vigabatrin", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15941649_3_5468", "context": "Vigabatrin-induced visual field defects are at present the most important safety issue in the use of the drug.", "question": "Treatment.Disorder in Vigabatrin", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15941649_3_5469", "context": "Vigabatrin-induced visual field defects are at present the most important safety issue in the use of the drug.", "question": "Combination.Drug in Vigabatrin", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17667887_1_5470", "context": "Serotonin syndrome in elderly patients treated for psychotic depression with atypical antipsychotics and antidepressants: two case reports.", "question": "Subject.Age in elderly patients", "question_type": "Adverse_event.Subject.Age", "answers": "elderly"}, {"id": "17667887_1_5471", "context": "Serotonin syndrome in elderly patients treated for psychotic depression with atypical antipsychotics and antidepressants: two case reports.", "question": "Subject.Gender in elderly patients", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "17667887_1_5472", "context": "Serotonin syndrome in elderly patients treated for psychotic depression with atypical antipsychotics and antidepressants: two case reports.", "question": "Subject.Population in elderly patients", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "17667887_1_5473", "context": "Serotonin syndrome in elderly patients treated for psychotic depression with atypical antipsychotics and antidepressants: two case reports.", "question": "Subject.Race in elderly patients", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "17667887_1_5474", "context": "Serotonin syndrome in elderly patients treated for psychotic depression with atypical antipsychotics and antidepressants: two case reports.", "question": "Subject.Disorder in elderly patients", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "17667887_1_5475", "context": "Serotonin syndrome in elderly patients treated for psychotic depression with atypical antipsychotics and antidepressants: two case reports.", "question": "Treatment.Drug in atypical antipsychotics; antidepressants", "question_type": "Adverse_event.Treatment.Drug", "answers": "atypical antipsychotics; antidepressants"}, {"id": "17667887_1_5476", "context": "Serotonin syndrome in elderly patients treated for psychotic depression with atypical antipsychotics and antidepressants: two case reports.", "question": "Treatment.Dosage in atypical antipsychotics; antidepressants", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17667887_1_5477", "context": "Serotonin syndrome in elderly patients treated for psychotic depression with atypical antipsychotics and antidepressants: two case reports.", "question": "Treatment.Freq in atypical antipsychotics; antidepressants", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17667887_1_5478", "context": "Serotonin syndrome in elderly patients treated for psychotic depression with atypical antipsychotics and antidepressants: two case reports.", "question": "Treatment.Route in atypical antipsychotics; antidepressants", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17667887_1_5479", "context": "Serotonin syndrome in elderly patients treated for psychotic depression with atypical antipsychotics and antidepressants: two case reports.", "question": "Treatment.Time_elapsed in atypical antipsychotics; antidepressants", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17667887_1_5480", "context": "Serotonin syndrome in elderly patients treated for psychotic depression with atypical antipsychotics and antidepressants: two case reports.", "question": "Treatment.Duration in atypical antipsychotics; antidepressants", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17667887_1_5481", "context": "Serotonin syndrome in elderly patients treated for psychotic depression with atypical antipsychotics and antidepressants: two case reports.", "question": "Treatment.Disorder in atypical antipsychotics; antidepressants", "question_type": "Adverse_event.Treatment.Disorder", "answers": "psychotic depression"}, {"id": "17667887_1_5482", "context": "Serotonin syndrome in elderly patients treated for psychotic depression with atypical antipsychotics and antidepressants: two case reports.", "question": "Combination.Drug in atypical antipsychotics; antidepressants", "question_type": "Adverse_event.Combination.Drug", "answers": "atypical antipsychotics; antidepressants"}, {"id": "11903249_3_5483", "context": "We report two new cases of sarcoidosis in two patients with hepatitis C virus infection treated with interferon alfa and ribavirin.", "question": "Subject.Age in two patients with hepatitis C virus infection", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "11903249_3_5484", "context": "We report two new cases of sarcoidosis in two patients with hepatitis C virus infection treated with interferon alfa and ribavirin.", "question": "Subject.Gender in two patients with hepatitis C virus infection", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "11903249_3_5485", "context": "We report two new cases of sarcoidosis in two patients with hepatitis C virus infection treated with interferon alfa and ribavirin.", "question": "Subject.Population in two patients with hepatitis C virus infection", "question_type": "Adverse_event.Subject.Population", "answers": "two"}, {"id": "11903249_3_5486", "context": "We report two new cases of sarcoidosis in two patients with hepatitis C virus infection treated with interferon alfa and ribavirin.", "question": "Subject.Race in two patients with hepatitis C virus infection", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "11903249_3_5487", "context": "We report two new cases of sarcoidosis in two patients with hepatitis C virus infection treated with interferon alfa and ribavirin.", "question": "Subject.Disorder in two patients with hepatitis C virus infection", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "11903249_3_5488", "context": "We report two new cases of sarcoidosis in two patients with hepatitis C virus infection treated with interferon alfa and ribavirin.", "question": "Treatment.Drug in interferon alfa and ribavirin", "question_type": "Adverse_event.Treatment.Drug", "answers": "interferon alfa; ribavirin"}, {"id": "11903249_3_5489", "context": "We report two new cases of sarcoidosis in two patients with hepatitis C virus infection treated with interferon alfa and ribavirin.", "question": "Treatment.Dosage in interferon alfa and ribavirin", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11903249_3_5490", "context": "We report two new cases of sarcoidosis in two patients with hepatitis C virus infection treated with interferon alfa and ribavirin.", "question": "Treatment.Freq in interferon alfa and ribavirin", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11903249_3_5491", "context": "We report two new cases of sarcoidosis in two patients with hepatitis C virus infection treated with interferon alfa and ribavirin.", "question": "Treatment.Route in interferon alfa and ribavirin", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11903249_3_5492", "context": "We report two new cases of sarcoidosis in two patients with hepatitis C virus infection treated with interferon alfa and ribavirin.", "question": "Treatment.Time_elapsed in interferon alfa and ribavirin", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11903249_3_5493", "context": "We report two new cases of sarcoidosis in two patients with hepatitis C virus infection treated with interferon alfa and ribavirin.", "question": "Treatment.Duration in interferon alfa and ribavirin", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11903249_3_5494", "context": "We report two new cases of sarcoidosis in two patients with hepatitis C virus infection treated with interferon alfa and ribavirin.", "question": "Treatment.Disorder in interferon alfa and ribavirin", "question_type": "Adverse_event.Treatment.Disorder", "answers": "hepatitis C virus infection"}, {"id": "11903249_3_5495", "context": "We report two new cases of sarcoidosis in two patients with hepatitis C virus infection treated with interferon alfa and ribavirin.", "question": "Combination.Drug in interferon alfa and ribavirin", "question_type": "Adverse_event.Combination.Drug", "answers": "interferon alfa; ribavirin"}, {"id": "2523364_2_5496", "context": "A 57-year-old man developed morphea while taking bromocriptine.", "question": "Subject.Age in A 57-year-old man", "question_type": "Adverse_event.Subject.Age", "answers": "57-year-old"}, {"id": "2523364_2_5497", "context": "A 57-year-old man developed morphea while taking bromocriptine.", "question": "Subject.Gender in A 57-year-old man", "question_type": "Adverse_event.Subject.Gender", "answers": "man"}, {"id": "2523364_2_5498", "context": "A 57-year-old man developed morphea while taking bromocriptine.", "question": "Subject.Population in A 57-year-old man", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "2523364_2_5499", "context": "A 57-year-old man developed morphea while taking bromocriptine.", "question": "Subject.Race in A 57-year-old man", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "2523364_2_5500", "context": "A 57-year-old man developed morphea while taking bromocriptine.", "question": "Subject.Disorder in A 57-year-old man", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "2523364_2_5501", "context": "A 57-year-old man developed morphea while taking bromocriptine.", "question": "Treatment.Drug in bromocriptine", "question_type": "Adverse_event.Treatment.Drug", "answers": "bromocriptine"}, {"id": "2523364_2_5502", "context": "A 57-year-old man developed morphea while taking bromocriptine.", "question": "Treatment.Dosage in bromocriptine", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "2523364_2_5503", "context": "A 57-year-old man developed morphea while taking bromocriptine.", "question": "Treatment.Freq in bromocriptine", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2523364_2_5504", "context": "A 57-year-old man developed morphea while taking bromocriptine.", "question": "Treatment.Route in bromocriptine", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "2523364_2_5505", "context": "A 57-year-old man developed morphea while taking bromocriptine.", "question": "Treatment.Time_elapsed in bromocriptine", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2523364_2_5506", "context": "A 57-year-old man developed morphea while taking bromocriptine.", "question": "Treatment.Duration in bromocriptine", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2523364_2_5507", "context": "A 57-year-old man developed morphea while taking bromocriptine.", "question": "Treatment.Disorder in bromocriptine", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "2523364_2_5508", "context": "A 57-year-old man developed morphea while taking bromocriptine.", "question": "Combination.Drug in bromocriptine", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8739289_6_5509", "context": "Potential mechanisms regarding the pathophysiology of lithium-associated CDI are discussed.", "question": "Treatment.Drug in lithium", "question_type": "Adverse_event.Treatment.Drug", "answers": "lithium"}, {"id": "8739289_6_5510", "context": "Potential mechanisms regarding the pathophysiology of lithium-associated CDI are discussed.", "question": "Treatment.Dosage in lithium", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8739289_6_5511", "context": "Potential mechanisms regarding the pathophysiology of lithium-associated CDI are discussed.", "question": "Treatment.Freq in lithium", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8739289_6_5512", "context": "Potential mechanisms regarding the pathophysiology of lithium-associated CDI are discussed.", "question": "Treatment.Route in lithium", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8739289_6_5513", "context": "Potential mechanisms regarding the pathophysiology of lithium-associated CDI are discussed.", "question": "Treatment.Time_elapsed in lithium", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8739289_6_5514", "context": "Potential mechanisms regarding the pathophysiology of lithium-associated CDI are discussed.", "question": "Treatment.Duration in lithium", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8739289_6_5515", "context": "Potential mechanisms regarding the pathophysiology of lithium-associated CDI are discussed.", "question": "Treatment.Disorder in lithium", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8739289_6_5516", "context": "Potential mechanisms regarding the pathophysiology of lithium-associated CDI are discussed.", "question": "Combination.Drug in lithium", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18765315_2_5517", "context": "Acute coronary syndromes complicating the first infusion of rituximab.", "question": "Treatment.Drug in the first infusion of rituximab", "question_type": "Adverse_event.Treatment.Drug", "answers": "rituximab"}, {"id": "18765315_2_5518", "context": "Acute coronary syndromes complicating the first infusion of rituximab.", "question": "Treatment.Dosage in the first infusion of rituximab", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18765315_2_5519", "context": "Acute coronary syndromes complicating the first infusion of rituximab.", "question": "Treatment.Freq in the first infusion of rituximab", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18765315_2_5520", "context": "Acute coronary syndromes complicating the first infusion of rituximab.", "question": "Treatment.Route in the first infusion of rituximab", "question_type": "Adverse_event.Treatment.Route", "answers": "infusion"}, {"id": "18765315_2_5521", "context": "Acute coronary syndromes complicating the first infusion of rituximab.", "question": "Treatment.Time_elapsed in the first infusion of rituximab", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18765315_2_5522", "context": "Acute coronary syndromes complicating the first infusion of rituximab.", "question": "Treatment.Duration in the first infusion of rituximab", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18765315_2_5523", "context": "Acute coronary syndromes complicating the first infusion of rituximab.", "question": "Treatment.Disorder in the first infusion of rituximab", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18765315_2_5524", "context": "Acute coronary syndromes complicating the first infusion of rituximab.", "question": "Combination.Drug in the first infusion of rituximab", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "19690222_3_5525", "context": "Spontaneous hemothorax following anticoagulation with low-molecular-weight heparin.", "question": "Treatment.Drug in low-molecular-weight heparin", "question_type": "Adverse_event.Treatment.Drug", "answers": "low-molecular-weight heparin"}, {"id": "19690222_3_5526", "context": "Spontaneous hemothorax following anticoagulation with low-molecular-weight heparin.", "question": "Treatment.Dosage in low-molecular-weight heparin", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "19690222_3_5527", "context": "Spontaneous hemothorax following anticoagulation with low-molecular-weight heparin.", "question": "Treatment.Freq in low-molecular-weight heparin", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "19690222_3_5528", "context": "Spontaneous hemothorax following anticoagulation with low-molecular-weight heparin.", "question": "Treatment.Route in low-molecular-weight heparin", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "19690222_3_5529", "context": "Spontaneous hemothorax following anticoagulation with low-molecular-weight heparin.", "question": "Treatment.Time_elapsed in low-molecular-weight heparin", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19690222_3_5530", "context": "Spontaneous hemothorax following anticoagulation with low-molecular-weight heparin.", "question": "Treatment.Duration in low-molecular-weight heparin", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "19690222_3_5531", "context": "Spontaneous hemothorax following anticoagulation with low-molecular-weight heparin.", "question": "Treatment.Disorder in low-molecular-weight heparin", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "19690222_3_5532", "context": "Spontaneous hemothorax following anticoagulation with low-molecular-weight heparin.", "question": "Combination.Drug in low-molecular-weight heparin", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10715308_11_5533", "context": "There were no incremental increases in myelosuppression, peripheral neuropathy, or renal, hepatic, or cardiac toxicity and no deaths related to tirapazamine.", "question": "Treatment.Drug in tirapazamine", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "tirapazamine"}, {"id": "10715308_11_5534", "context": "There were no incremental increases in myelosuppression, peripheral neuropathy, or renal, hepatic, or cardiac toxicity and no deaths related to tirapazamine.", "question": "Treatment.Dosage in tirapazamine", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "10715308_11_5535", "context": "There were no incremental increases in myelosuppression, peripheral neuropathy, or renal, hepatic, or cardiac toxicity and no deaths related to tirapazamine.", "question": "Treatment.Freq in tirapazamine", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "10715308_11_5536", "context": "There were no incremental increases in myelosuppression, peripheral neuropathy, or renal, hepatic, or cardiac toxicity and no deaths related to tirapazamine.", "question": "Treatment.Route in tirapazamine", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "10715308_11_5537", "context": "There were no incremental increases in myelosuppression, peripheral neuropathy, or renal, hepatic, or cardiac toxicity and no deaths related to tirapazamine.", "question": "Treatment.Time_elapsed in tirapazamine", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10715308_11_5538", "context": "There were no incremental increases in myelosuppression, peripheral neuropathy, or renal, hepatic, or cardiac toxicity and no deaths related to tirapazamine.", "question": "Treatment.Duration in tirapazamine", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "10715308_11_5539", "context": "There were no incremental increases in myelosuppression, peripheral neuropathy, or renal, hepatic, or cardiac toxicity and no deaths related to tirapazamine.", "question": "Treatment.Disorder in tirapazamine", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "10715308_11_5540", "context": "There were no incremental increases in myelosuppression, peripheral neuropathy, or renal, hepatic, or cardiac toxicity and no deaths related to tirapazamine.", "question": "Combination.Drug in tirapazamine", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "10715308_3_5541", "context": "A phase III trial, Cisplatin and Tirapazamine in Subjects with Advanced Previously Untreated Non-Small-Cell Lung Tumors (CATAPULT I), was designed to determine the efficacy and safety of tirapazamine plus cisplatin for the treatment of non-small-cell lung cancer (NSCLC).", "question": "Treatment.Drug in tirapazamine plus cisplatin", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "tirapazamine; cisplatin"}, {"id": "10715308_3_5542", "context": "A phase III trial, Cisplatin and Tirapazamine in Subjects with Advanced Previously Untreated Non-Small-Cell Lung Tumors (CATAPULT I), was designed to determine the efficacy and safety of tirapazamine plus cisplatin for the treatment of non-small-cell lung cancer (NSCLC).", "question": "Treatment.Dosage in tirapazamine plus cisplatin", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "10715308_3_5543", "context": "A phase III trial, Cisplatin and Tirapazamine in Subjects with Advanced Previously Untreated Non-Small-Cell Lung Tumors (CATAPULT I), was designed to determine the efficacy and safety of tirapazamine plus cisplatin for the treatment of non-small-cell lung cancer (NSCLC).", "question": "Treatment.Freq in tirapazamine plus cisplatin", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "10715308_3_5544", "context": "A phase III trial, Cisplatin and Tirapazamine in Subjects with Advanced Previously Untreated Non-Small-Cell Lung Tumors (CATAPULT I), was designed to determine the efficacy and safety of tirapazamine plus cisplatin for the treatment of non-small-cell lung cancer (NSCLC).", "question": "Treatment.Route in tirapazamine plus cisplatin", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "10715308_3_5545", "context": "A phase III trial, Cisplatin and Tirapazamine in Subjects with Advanced Previously Untreated Non-Small-Cell Lung Tumors (CATAPULT I), was designed to determine the efficacy and safety of tirapazamine plus cisplatin for the treatment of non-small-cell lung cancer (NSCLC).", "question": "Treatment.Time_elapsed in tirapazamine plus cisplatin", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10715308_3_5546", "context": "A phase III trial, Cisplatin and Tirapazamine in Subjects with Advanced Previously Untreated Non-Small-Cell Lung Tumors (CATAPULT I), was designed to determine the efficacy and safety of tirapazamine plus cisplatin for the treatment of non-small-cell lung cancer (NSCLC).", "question": "Treatment.Duration in tirapazamine plus cisplatin", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "10715308_3_5547", "context": "A phase III trial, Cisplatin and Tirapazamine in Subjects with Advanced Previously Untreated Non-Small-Cell Lung Tumors (CATAPULT I), was designed to determine the efficacy and safety of tirapazamine plus cisplatin for the treatment of non-small-cell lung cancer (NSCLC).", "question": "Treatment.Disorder in tirapazamine plus cisplatin", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "non-small-cell lung cancer (NSCLC)"}, {"id": "10715308_3_5548", "context": "A phase III trial, Cisplatin and Tirapazamine in Subjects with Advanced Previously Untreated Non-Small-Cell Lung Tumors (CATAPULT I), was designed to determine the efficacy and safety of tirapazamine plus cisplatin for the treatment of non-small-cell lung cancer (NSCLC).", "question": "Combination.Drug in tirapazamine plus cisplatin", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": "tirapazamine; cisplatin"}, {"id": "17316160_3_5549", "context": "Combination antimicrobial regimens (e.g., linezolid with rifampin) aimed at improving bacterial eradication and preventing resistance are often used; however, most data supporting this treatment strategy are not from randomized controlled trials.", "question": "Treatment.Drug in Combination antimicrobial regimens (e.g., linezolid with rifampin)", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "linezolid; rifampin"}, {"id": "17316160_3_5550", "context": "Combination antimicrobial regimens (e.g., linezolid with rifampin) aimed at improving bacterial eradication and preventing resistance are often used; however, most data supporting this treatment strategy are not from randomized controlled trials.", "question": "Treatment.Dosage in Combination antimicrobial regimens (e.g., linezolid with rifampin)", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "17316160_3_5551", "context": "Combination antimicrobial regimens (e.g., linezolid with rifampin) aimed at improving bacterial eradication and preventing resistance are often used; however, most data supporting this treatment strategy are not from randomized controlled trials.", "question": "Treatment.Freq in Combination antimicrobial regimens (e.g., linezolid with rifampin)", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "17316160_3_5552", "context": "Combination antimicrobial regimens (e.g., linezolid with rifampin) aimed at improving bacterial eradication and preventing resistance are often used; however, most data supporting this treatment strategy are not from randomized controlled trials.", "question": "Treatment.Route in Combination antimicrobial regimens (e.g., linezolid with rifampin)", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "17316160_3_5553", "context": "Combination antimicrobial regimens (e.g., linezolid with rifampin) aimed at improving bacterial eradication and preventing resistance are often used; however, most data supporting this treatment strategy are not from randomized controlled trials.", "question": "Treatment.Time_elapsed in Combination antimicrobial regimens (e.g., linezolid with rifampin)", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17316160_3_5554", "context": "Combination antimicrobial regimens (e.g., linezolid with rifampin) aimed at improving bacterial eradication and preventing resistance are often used; however, most data supporting this treatment strategy are not from randomized controlled trials.", "question": "Treatment.Duration in Combination antimicrobial regimens (e.g., linezolid with rifampin)", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "17316160_3_5555", "context": "Combination antimicrobial regimens (e.g., linezolid with rifampin) aimed at improving bacterial eradication and preventing resistance are often used; however, most data supporting this treatment strategy are not from randomized controlled trials.", "question": "Treatment.Disorder in Combination antimicrobial regimens (e.g., linezolid with rifampin)", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "17316160_3_5556", "context": "Combination antimicrobial regimens (e.g., linezolid with rifampin) aimed at improving bacterial eradication and preventing resistance are often used; however, most data supporting this treatment strategy are not from randomized controlled trials.", "question": "Combination.Drug in Combination antimicrobial regimens (e.g., linezolid with rifampin)", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": "linezolid; rifampin"}, {"id": "17667887_10_5557", "context": "Clinicians treating elderly patients with a combination of serotonergic antidepressants and atypical antipsychotics for psychotic depression should be aware of the potential for serotonin syndrome.", "question": "Subject.Age in elderly patients", "question_type": "Adverse_event.Subject.Age", "answers": "elderly"}, {"id": "17667887_10_5558", "context": "Clinicians treating elderly patients with a combination of serotonergic antidepressants and atypical antipsychotics for psychotic depression should be aware of the potential for serotonin syndrome.", "question": "Subject.Gender in elderly patients", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "17667887_10_5559", "context": "Clinicians treating elderly patients with a combination of serotonergic antidepressants and atypical antipsychotics for psychotic depression should be aware of the potential for serotonin syndrome.", "question": "Subject.Population in elderly patients", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "17667887_10_5560", "context": "Clinicians treating elderly patients with a combination of serotonergic antidepressants and atypical antipsychotics for psychotic depression should be aware of the potential for serotonin syndrome.", "question": "Subject.Race in elderly patients", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "17667887_10_5561", "context": "Clinicians treating elderly patients with a combination of serotonergic antidepressants and atypical antipsychotics for psychotic depression should be aware of the potential for serotonin syndrome.", "question": "Subject.Disorder in elderly patients", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "17667887_10_5562", "context": "Clinicians treating elderly patients with a combination of serotonergic antidepressants and atypical antipsychotics for psychotic depression should be aware of the potential for serotonin syndrome.", "question": "Treatment.Drug in a combination of serotonergic antidepressants and atypical antipsychotics for psychotic depression", "question_type": "Adverse_event.Treatment.Drug", "answers": "serotonergic antidepressants; atypical antipsychotics"}, {"id": "17667887_10_5563", "context": "Clinicians treating elderly patients with a combination of serotonergic antidepressants and atypical antipsychotics for psychotic depression should be aware of the potential for serotonin syndrome.", "question": "Treatment.Dosage in a combination of serotonergic antidepressants and atypical antipsychotics for psychotic depression", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17667887_10_5564", "context": "Clinicians treating elderly patients with a combination of serotonergic antidepressants and atypical antipsychotics for psychotic depression should be aware of the potential for serotonin syndrome.", "question": "Treatment.Freq in a combination of serotonergic antidepressants and atypical antipsychotics for psychotic depression", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17667887_10_5565", "context": "Clinicians treating elderly patients with a combination of serotonergic antidepressants and atypical antipsychotics for psychotic depression should be aware of the potential for serotonin syndrome.", "question": "Treatment.Route in a combination of serotonergic antidepressants and atypical antipsychotics for psychotic depression", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17667887_10_5566", "context": "Clinicians treating elderly patients with a combination of serotonergic antidepressants and atypical antipsychotics for psychotic depression should be aware of the potential for serotonin syndrome.", "question": "Treatment.Time_elapsed in a combination of serotonergic antidepressants and atypical antipsychotics for psychotic depression", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17667887_10_5567", "context": "Clinicians treating elderly patients with a combination of serotonergic antidepressants and atypical antipsychotics for psychotic depression should be aware of the potential for serotonin syndrome.", "question": "Treatment.Duration in a combination of serotonergic antidepressants and atypical antipsychotics for psychotic depression", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17667887_10_5568", "context": "Clinicians treating elderly patients with a combination of serotonergic antidepressants and atypical antipsychotics for psychotic depression should be aware of the potential for serotonin syndrome.", "question": "Treatment.Disorder in a combination of serotonergic antidepressants and atypical antipsychotics for psychotic depression", "question_type": "Adverse_event.Treatment.Disorder", "answers": "psychotic depression"}, {"id": "17667887_10_5569", "context": "Clinicians treating elderly patients with a combination of serotonergic antidepressants and atypical antipsychotics for psychotic depression should be aware of the potential for serotonin syndrome.", "question": "Combination.Drug in a combination of serotonergic antidepressants and atypical antipsychotics for psychotic depression", "question_type": "Adverse_event.Combination.Drug", "answers": "serotonergic antidepressants; atypical antipsychotics"}, {"id": "18472517_1_5570", "context": "Enalaprilat induced acute parotitis.", "question": "Treatment.Drug in Enalaprilat", "question_type": "Adverse_event.Treatment.Drug", "answers": "Enalaprilat"}, {"id": "18472517_1_5571", "context": "Enalaprilat induced acute parotitis.", "question": "Treatment.Dosage in Enalaprilat", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18472517_1_5572", "context": "Enalaprilat induced acute parotitis.", "question": "Treatment.Freq in Enalaprilat", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18472517_1_5573", "context": "Enalaprilat induced acute parotitis.", "question": "Treatment.Route in Enalaprilat", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18472517_1_5574", "context": "Enalaprilat induced acute parotitis.", "question": "Treatment.Time_elapsed in Enalaprilat", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18472517_1_5575", "context": "Enalaprilat induced acute parotitis.", "question": "Treatment.Duration in Enalaprilat", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18472517_1_5576", "context": "Enalaprilat induced acute parotitis.", "question": "Treatment.Disorder in Enalaprilat", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18472517_1_5577", "context": "Enalaprilat induced acute parotitis.", "question": "Combination.Drug in Enalaprilat", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18477279_6_5578", "context": "We believe the most likely cause was hepatic inhibition of the CYP3A4 hepatic isoenzyme by fusidic acid resulting in an acute severe rise in plasma simvastatin level and extensive myocellular damage.", "question": "Treatment.Drug in fusidic acid", "question_type": "Adverse_event.Treatment.Drug", "answers": "fusidic acid"}, {"id": "18477279_6_5579", "context": "We believe the most likely cause was hepatic inhibition of the CYP3A4 hepatic isoenzyme by fusidic acid resulting in an acute severe rise in plasma simvastatin level and extensive myocellular damage.", "question": "Treatment.Dosage in fusidic acid", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18477279_6_5580", "context": "We believe the most likely cause was hepatic inhibition of the CYP3A4 hepatic isoenzyme by fusidic acid resulting in an acute severe rise in plasma simvastatin level and extensive myocellular damage.", "question": "Treatment.Freq in fusidic acid", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18477279_6_5581", "context": "We believe the most likely cause was hepatic inhibition of the CYP3A4 hepatic isoenzyme by fusidic acid resulting in an acute severe rise in plasma simvastatin level and extensive myocellular damage.", "question": "Treatment.Route in fusidic acid", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18477279_6_5582", "context": "We believe the most likely cause was hepatic inhibition of the CYP3A4 hepatic isoenzyme by fusidic acid resulting in an acute severe rise in plasma simvastatin level and extensive myocellular damage.", "question": "Treatment.Time_elapsed in fusidic acid", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18477279_6_5583", "context": "We believe the most likely cause was hepatic inhibition of the CYP3A4 hepatic isoenzyme by fusidic acid resulting in an acute severe rise in plasma simvastatin level and extensive myocellular damage.", "question": "Treatment.Duration in fusidic acid", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18477279_6_5584", "context": "We believe the most likely cause was hepatic inhibition of the CYP3A4 hepatic isoenzyme by fusidic acid resulting in an acute severe rise in plasma simvastatin level and extensive myocellular damage.", "question": "Treatment.Disorder in fusidic acid", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18477279_6_5585", "context": "We believe the most likely cause was hepatic inhibition of the CYP3A4 hepatic isoenzyme by fusidic acid resulting in an acute severe rise in plasma simvastatin level and extensive myocellular damage.", "question": "Combination.Drug in fusidic acid", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18160579_2_5586", "context": "The authors describe pericardial hemorrhage, which is related to the use of low-dose acetylsalicylic acid in a patient with essential thrombocythemia.", "question": "Subject.Age in a patient with essential thrombocythemia", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "18160579_2_5587", "context": "The authors describe pericardial hemorrhage, which is related to the use of low-dose acetylsalicylic acid in a patient with essential thrombocythemia.", "question": "Subject.Gender in a patient with essential thrombocythemia", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "18160579_2_5588", "context": "The authors describe pericardial hemorrhage, which is related to the use of low-dose acetylsalicylic acid in a patient with essential thrombocythemia.", "question": "Subject.Population in a patient with essential thrombocythemia", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "18160579_2_5589", "context": "The authors describe pericardial hemorrhage, which is related to the use of low-dose acetylsalicylic acid in a patient with essential thrombocythemia.", "question": "Subject.Race in a patient with essential thrombocythemia", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "18160579_2_5590", "context": "The authors describe pericardial hemorrhage, which is related to the use of low-dose acetylsalicylic acid in a patient with essential thrombocythemia.", "question": "Subject.Disorder in a patient with essential thrombocythemia", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "18160579_2_5591", "context": "The authors describe pericardial hemorrhage, which is related to the use of low-dose acetylsalicylic acid in a patient with essential thrombocythemia.", "question": "Treatment.Drug in low-dose acetylsalicylic acid", "question_type": "Adverse_event.Treatment.Drug", "answers": "acetylsalicylic acid"}, {"id": "18160579_2_5592", "context": "The authors describe pericardial hemorrhage, which is related to the use of low-dose acetylsalicylic acid in a patient with essential thrombocythemia.", "question": "Treatment.Dosage in low-dose acetylsalicylic acid", "question_type": "Adverse_event.Treatment.Dosage", "answers": "low-dose"}, {"id": "18160579_2_5593", "context": "The authors describe pericardial hemorrhage, which is related to the use of low-dose acetylsalicylic acid in a patient with essential thrombocythemia.", "question": "Treatment.Freq in low-dose acetylsalicylic acid", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18160579_2_5594", "context": "The authors describe pericardial hemorrhage, which is related to the use of low-dose acetylsalicylic acid in a patient with essential thrombocythemia.", "question": "Treatment.Route in low-dose acetylsalicylic acid", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18160579_2_5595", "context": "The authors describe pericardial hemorrhage, which is related to the use of low-dose acetylsalicylic acid in a patient with essential thrombocythemia.", "question": "Treatment.Time_elapsed in low-dose acetylsalicylic acid", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18160579_2_5596", "context": "The authors describe pericardial hemorrhage, which is related to the use of low-dose acetylsalicylic acid in a patient with essential thrombocythemia.", "question": "Treatment.Duration in low-dose acetylsalicylic acid", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18160579_2_5597", "context": "The authors describe pericardial hemorrhage, which is related to the use of low-dose acetylsalicylic acid in a patient with essential thrombocythemia.", "question": "Treatment.Disorder in low-dose acetylsalicylic acid", "question_type": "Adverse_event.Treatment.Disorder", "answers": "essential thrombocythemia"}, {"id": "18160579_2_5598", "context": "The authors describe pericardial hemorrhage, which is related to the use of low-dose acetylsalicylic acid in a patient with essential thrombocythemia.", "question": "Combination.Drug in low-dose acetylsalicylic acid", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17083890_7_5599", "context": "This complex pattern of nail and skin changes is accounted by synergy or an additive effect of chemotherapy agents on cellular proliferation of nail compartments.", "question": "Treatment.Drug in chemotherapy agents", "question_type": "Adverse_event.Treatment.Drug", "answers": "chemotherapy agents"}, {"id": "17083890_7_5600", "context": "This complex pattern of nail and skin changes is accounted by synergy or an additive effect of chemotherapy agents on cellular proliferation of nail compartments.", "question": "Treatment.Dosage in chemotherapy agents", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17083890_7_5601", "context": "This complex pattern of nail and skin changes is accounted by synergy or an additive effect of chemotherapy agents on cellular proliferation of nail compartments.", "question": "Treatment.Freq in chemotherapy agents", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17083890_7_5602", "context": "This complex pattern of nail and skin changes is accounted by synergy or an additive effect of chemotherapy agents on cellular proliferation of nail compartments.", "question": "Treatment.Route in chemotherapy agents", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17083890_7_5603", "context": "This complex pattern of nail and skin changes is accounted by synergy or an additive effect of chemotherapy agents on cellular proliferation of nail compartments.", "question": "Treatment.Time_elapsed in chemotherapy agents", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17083890_7_5604", "context": "This complex pattern of nail and skin changes is accounted by synergy or an additive effect of chemotherapy agents on cellular proliferation of nail compartments.", "question": "Treatment.Duration in chemotherapy agents", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17083890_7_5605", "context": "This complex pattern of nail and skin changes is accounted by synergy or an additive effect of chemotherapy agents on cellular proliferation of nail compartments.", "question": "Treatment.Disorder in chemotherapy agents", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17083890_7_5606", "context": "This complex pattern of nail and skin changes is accounted by synergy or an additive effect of chemotherapy agents on cellular proliferation of nail compartments.", "question": "Combination.Drug in chemotherapy agents", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12625995_1_5607", "context": "Akathisia is a relatively rare side effect with the newer atypical antipsychotic agents, particularly clozapine, and is easily misdiagnosed in children.", "question": "Subject.Age in i", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "12625995_1_5608", "context": "Akathisia is a relatively rare side effect with the newer atypical antipsychotic agents, particularly clozapine, and is easily misdiagnosed in children.", "question": "Subject.Gender in i", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "12625995_1_5609", "context": "Akathisia is a relatively rare side effect with the newer atypical antipsychotic agents, particularly clozapine, and is easily misdiagnosed in children.", "question": "Subject.Population in i", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "12625995_1_5610", "context": "Akathisia is a relatively rare side effect with the newer atypical antipsychotic agents, particularly clozapine, and is easily misdiagnosed in children.", "question": "Subject.Race in i", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "12625995_1_5611", "context": "Akathisia is a relatively rare side effect with the newer atypical antipsychotic agents, particularly clozapine, and is easily misdiagnosed in children.", "question": "Subject.Disorder in i", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "12625995_1_5612", "context": "Akathisia is a relatively rare side effect with the newer atypical antipsychotic agents, particularly clozapine, and is easily misdiagnosed in children.", "question": "Treatment.Drug in clozapine", "question_type": "Adverse_event.Treatment.Drug", "answers": "clozapine"}, {"id": "12625995_1_5613", "context": "Akathisia is a relatively rare side effect with the newer atypical antipsychotic agents, particularly clozapine, and is easily misdiagnosed in children.", "question": "Treatment.Dosage in clozapine", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12625995_1_5614", "context": "Akathisia is a relatively rare side effect with the newer atypical antipsychotic agents, particularly clozapine, and is easily misdiagnosed in children.", "question": "Treatment.Freq in clozapine", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12625995_1_5615", "context": "Akathisia is a relatively rare side effect with the newer atypical antipsychotic agents, particularly clozapine, and is easily misdiagnosed in children.", "question": "Treatment.Route in clozapine", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12625995_1_5616", "context": "Akathisia is a relatively rare side effect with the newer atypical antipsychotic agents, particularly clozapine, and is easily misdiagnosed in children.", "question": "Treatment.Time_elapsed in clozapine", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12625995_1_5617", "context": "Akathisia is a relatively rare side effect with the newer atypical antipsychotic agents, particularly clozapine, and is easily misdiagnosed in children.", "question": "Treatment.Duration in clozapine", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12625995_1_5618", "context": "Akathisia is a relatively rare side effect with the newer atypical antipsychotic agents, particularly clozapine, and is easily misdiagnosed in children.", "question": "Treatment.Disorder in clozapine", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12625995_1_5619", "context": "Akathisia is a relatively rare side effect with the newer atypical antipsychotic agents, particularly clozapine, and is easily misdiagnosed in children.", "question": "Combination.Drug in clozapine", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "1918672_1_5620", "context": "In this case, discontinuing piroxicam, a nonsteroidal anti-inflammatory drug, and starting a palliative treatment plan helped resolve a patient's ulcers.", "question": "Subject.Age in a patient's", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "1918672_1_5621", "context": "In this case, discontinuing piroxicam, a nonsteroidal anti-inflammatory drug, and starting a palliative treatment plan helped resolve a patient's ulcers.", "question": "Subject.Gender in a patient's", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "1918672_1_5622", "context": "In this case, discontinuing piroxicam, a nonsteroidal anti-inflammatory drug, and starting a palliative treatment plan helped resolve a patient's ulcers.", "question": "Subject.Population in a patient's", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "1918672_1_5623", "context": "In this case, discontinuing piroxicam, a nonsteroidal anti-inflammatory drug, and starting a palliative treatment plan helped resolve a patient's ulcers.", "question": "Subject.Race in a patient's", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "1918672_1_5624", "context": "In this case, discontinuing piroxicam, a nonsteroidal anti-inflammatory drug, and starting a palliative treatment plan helped resolve a patient's ulcers.", "question": "Subject.Disorder in a patient's", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "1918672_1_5625", "context": "In this case, discontinuing piroxicam, a nonsteroidal anti-inflammatory drug, and starting a palliative treatment plan helped resolve a patient's ulcers.", "question": "Treatment.Drug in discontinuing piroxicam, a nonsteroidal anti-inflammatory drug, and starting a palliative treatment", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "piroxicam"}, {"id": "1918672_1_5626", "context": "In this case, discontinuing piroxicam, a nonsteroidal anti-inflammatory drug, and starting a palliative treatment plan helped resolve a patient's ulcers.", "question": "Treatment.Dosage in discontinuing piroxicam, a nonsteroidal anti-inflammatory drug, and starting a palliative treatment", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "1918672_1_5627", "context": "In this case, discontinuing piroxicam, a nonsteroidal anti-inflammatory drug, and starting a palliative treatment plan helped resolve a patient's ulcers.", "question": "Treatment.Freq in discontinuing piroxicam, a nonsteroidal anti-inflammatory drug, and starting a palliative treatment", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "1918672_1_5628", "context": "In this case, discontinuing piroxicam, a nonsteroidal anti-inflammatory drug, and starting a palliative treatment plan helped resolve a patient's ulcers.", "question": "Treatment.Route in discontinuing piroxicam, a nonsteroidal anti-inflammatory drug, and starting a palliative treatment", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "1918672_1_5629", "context": "In this case, discontinuing piroxicam, a nonsteroidal anti-inflammatory drug, and starting a palliative treatment plan helped resolve a patient's ulcers.", "question": "Treatment.Time_elapsed in discontinuing piroxicam, a nonsteroidal anti-inflammatory drug, and starting a palliative treatment", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "1918672_1_5630", "context": "In this case, discontinuing piroxicam, a nonsteroidal anti-inflammatory drug, and starting a palliative treatment plan helped resolve a patient's ulcers.", "question": "Treatment.Duration in discontinuing piroxicam, a nonsteroidal anti-inflammatory drug, and starting a palliative treatment", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "1918672_1_5631", "context": "In this case, discontinuing piroxicam, a nonsteroidal anti-inflammatory drug, and starting a palliative treatment plan helped resolve a patient's ulcers.", "question": "Treatment.Disorder in discontinuing piroxicam, a nonsteroidal anti-inflammatory drug, and starting a palliative treatment", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "ulcers"}, {"id": "1918672_1_5632", "context": "In this case, discontinuing piroxicam, a nonsteroidal anti-inflammatory drug, and starting a palliative treatment plan helped resolve a patient's ulcers.", "question": "Combination.Drug in discontinuing piroxicam, a nonsteroidal anti-inflammatory drug, and starting a palliative treatment", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "9988365_2_5633", "context": "Eosinophilia has been encountered from 0.2 to 61.7% in clozapine-treated patients, mostly with a transient course and spontaneous remission.", "question": "Subject.Age in patients", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "9988365_2_5634", "context": "Eosinophilia has been encountered from 0.2 to 61.7% in clozapine-treated patients, mostly with a transient course and spontaneous remission.", "question": "Subject.Gender in patients", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "9988365_2_5635", "context": "Eosinophilia has been encountered from 0.2 to 61.7% in clozapine-treated patients, mostly with a transient course and spontaneous remission.", "question": "Subject.Population in patients", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "9988365_2_5636", "context": "Eosinophilia has been encountered from 0.2 to 61.7% in clozapine-treated patients, mostly with a transient course and spontaneous remission.", "question": "Subject.Race in patients", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "9988365_2_5637", "context": "Eosinophilia has been encountered from 0.2 to 61.7% in clozapine-treated patients, mostly with a transient course and spontaneous remission.", "question": "Subject.Disorder in patients", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "9988365_2_5638", "context": "Eosinophilia has been encountered from 0.2 to 61.7% in clozapine-treated patients, mostly with a transient course and spontaneous remission.", "question": "Treatment.Drug in clozapine", "question_type": "Adverse_event.Treatment.Drug", "answers": "clozapine"}, {"id": "9988365_2_5639", "context": "Eosinophilia has been encountered from 0.2 to 61.7% in clozapine-treated patients, mostly with a transient course and spontaneous remission.", "question": "Treatment.Dosage in clozapine", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9988365_2_5640", "context": "Eosinophilia has been encountered from 0.2 to 61.7% in clozapine-treated patients, mostly with a transient course and spontaneous remission.", "question": "Treatment.Freq in clozapine", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9988365_2_5641", "context": "Eosinophilia has been encountered from 0.2 to 61.7% in clozapine-treated patients, mostly with a transient course and spontaneous remission.", "question": "Treatment.Route in clozapine", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9988365_2_5642", "context": "Eosinophilia has been encountered from 0.2 to 61.7% in clozapine-treated patients, mostly with a transient course and spontaneous remission.", "question": "Treatment.Time_elapsed in clozapine", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9988365_2_5643", "context": "Eosinophilia has been encountered from 0.2 to 61.7% in clozapine-treated patients, mostly with a transient course and spontaneous remission.", "question": "Treatment.Duration in clozapine", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9988365_2_5644", "context": "Eosinophilia has been encountered from 0.2 to 61.7% in clozapine-treated patients, mostly with a transient course and spontaneous remission.", "question": "Treatment.Disorder in clozapine", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9988365_2_5645", "context": "Eosinophilia has been encountered from 0.2 to 61.7% in clozapine-treated patients, mostly with a transient course and spontaneous remission.", "question": "Combination.Drug in clozapine", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3954165_2_5646", "context": "We presented a patient with status asthmaticus treated with a combination of theophylline and prednisone who developed a perforated gastric ulcer.", "question": "Subject.Age in a patient with status asthmaticus", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "3954165_2_5647", "context": "We presented a patient with status asthmaticus treated with a combination of theophylline and prednisone who developed a perforated gastric ulcer.", "question": "Subject.Gender in a patient with status asthmaticus", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "3954165_2_5648", "context": "We presented a patient with status asthmaticus treated with a combination of theophylline and prednisone who developed a perforated gastric ulcer.", "question": "Subject.Population in a patient with status asthmaticus", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "3954165_2_5649", "context": "We presented a patient with status asthmaticus treated with a combination of theophylline and prednisone who developed a perforated gastric ulcer.", "question": "Subject.Race in a patient with status asthmaticus", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "3954165_2_5650", "context": "We presented a patient with status asthmaticus treated with a combination of theophylline and prednisone who developed a perforated gastric ulcer.", "question": "Subject.Disorder in a patient with status asthmaticus", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "3954165_2_5651", "context": "We presented a patient with status asthmaticus treated with a combination of theophylline and prednisone who developed a perforated gastric ulcer.", "question": "Treatment.Drug in theophylline and prednisone", "question_type": "Adverse_event.Treatment.Drug", "answers": "theophylline; prednisone"}, {"id": "3954165_2_5652", "context": "We presented a patient with status asthmaticus treated with a combination of theophylline and prednisone who developed a perforated gastric ulcer.", "question": "Treatment.Dosage in theophylline and prednisone", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3954165_2_5653", "context": "We presented a patient with status asthmaticus treated with a combination of theophylline and prednisone who developed a perforated gastric ulcer.", "question": "Treatment.Freq in theophylline and prednisone", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3954165_2_5654", "context": "We presented a patient with status asthmaticus treated with a combination of theophylline and prednisone who developed a perforated gastric ulcer.", "question": "Treatment.Route in theophylline and prednisone", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3954165_2_5655", "context": "We presented a patient with status asthmaticus treated with a combination of theophylline and prednisone who developed a perforated gastric ulcer.", "question": "Treatment.Time_elapsed in theophylline and prednisone", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3954165_2_5656", "context": "We presented a patient with status asthmaticus treated with a combination of theophylline and prednisone who developed a perforated gastric ulcer.", "question": "Treatment.Duration in theophylline and prednisone", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3954165_2_5657", "context": "We presented a patient with status asthmaticus treated with a combination of theophylline and prednisone who developed a perforated gastric ulcer.", "question": "Treatment.Disorder in theophylline and prednisone", "question_type": "Adverse_event.Treatment.Disorder", "answers": "status asthmaticus"}, {"id": "3954165_2_5658", "context": "We presented a patient with status asthmaticus treated with a combination of theophylline and prednisone who developed a perforated gastric ulcer.", "question": "Combination.Drug in theophylline and prednisone", "question_type": "Adverse_event.Combination.Drug", "answers": "theophylline; prednisone"}, {"id": "17157086_5_5659", "context": "We speculate on a causal relationship between the assumption of the additives and the fatal hepatitis and envisage a synergy between the additives and montelukast, which per se has well been studied as a hepatotoxic drug.", "question": "Treatment.Drug in montelukast", "question_type": "Adverse_event.Treatment.Drug", "answers": "montelukast"}, {"id": "17157086_5_5660", "context": "We speculate on a causal relationship between the assumption of the additives and the fatal hepatitis and envisage a synergy between the additives and montelukast, which per se has well been studied as a hepatotoxic drug.", "question": "Treatment.Dosage in montelukast", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17157086_5_5661", "context": "We speculate on a causal relationship between the assumption of the additives and the fatal hepatitis and envisage a synergy between the additives and montelukast, which per se has well been studied as a hepatotoxic drug.", "question": "Treatment.Freq in montelukast", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17157086_5_5662", "context": "We speculate on a causal relationship between the assumption of the additives and the fatal hepatitis and envisage a synergy between the additives and montelukast, which per se has well been studied as a hepatotoxic drug.", "question": "Treatment.Route in montelukast", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17157086_5_5663", "context": "We speculate on a causal relationship between the assumption of the additives and the fatal hepatitis and envisage a synergy between the additives and montelukast, which per se has well been studied as a hepatotoxic drug.", "question": "Treatment.Time_elapsed in montelukast", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17157086_5_5664", "context": "We speculate on a causal relationship between the assumption of the additives and the fatal hepatitis and envisage a synergy between the additives and montelukast, which per se has well been studied as a hepatotoxic drug.", "question": "Treatment.Duration in montelukast", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17157086_5_5665", "context": "We speculate on a causal relationship between the assumption of the additives and the fatal hepatitis and envisage a synergy between the additives and montelukast, which per se has well been studied as a hepatotoxic drug.", "question": "Treatment.Disorder in montelukast", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17157086_5_5666", "context": "We speculate on a causal relationship between the assumption of the additives and the fatal hepatitis and envisage a synergy between the additives and montelukast, which per se has well been studied as a hepatotoxic drug.", "question": "Combination.Drug in montelukast", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17157086_1_5667", "context": "Fatal liver failure following food supplements during chronic treatment with montelukast.", "question": "Treatment.Drug in food supplements during chronic treatment with montelukast", "question_type": "Adverse_event.Treatment.Drug", "answers": "food supplements; montelukast"}, {"id": "17157086_1_5668", "context": "Fatal liver failure following food supplements during chronic treatment with montelukast.", "question": "Treatment.Dosage in food supplements during chronic treatment with montelukast", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17157086_1_5669", "context": "Fatal liver failure following food supplements during chronic treatment with montelukast.", "question": "Treatment.Freq in food supplements during chronic treatment with montelukast", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17157086_1_5670", "context": "Fatal liver failure following food supplements during chronic treatment with montelukast.", "question": "Treatment.Route in food supplements during chronic treatment with montelukast", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17157086_1_5671", "context": "Fatal liver failure following food supplements during chronic treatment with montelukast.", "question": "Treatment.Time_elapsed in food supplements during chronic treatment with montelukast", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17157086_1_5672", "context": "Fatal liver failure following food supplements during chronic treatment with montelukast.", "question": "Treatment.Duration in food supplements during chronic treatment with montelukast", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17157086_1_5673", "context": "Fatal liver failure following food supplements during chronic treatment with montelukast.", "question": "Treatment.Disorder in food supplements during chronic treatment with montelukast", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17157086_1_5674", "context": "Fatal liver failure following food supplements during chronic treatment with montelukast.", "question": "Combination.Drug in food supplements during chronic treatment with montelukast", "question_type": "Adverse_event.Combination.Drug", "answers": "food supplements; montelukast"}, {"id": "8627446_4_5675", "context": "The nodules regressed after withdrawal of methotrexate therapy in one patient and were arrested with the addition of hydroxychloroquine in the other.", "question": "Subject.Age in one patient", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "8627446_4_5676", "context": "The nodules regressed after withdrawal of methotrexate therapy in one patient and were arrested with the addition of hydroxychloroquine in the other.", "question": "Subject.Gender in one patient", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "8627446_4_5677", "context": "The nodules regressed after withdrawal of methotrexate therapy in one patient and were arrested with the addition of hydroxychloroquine in the other.", "question": "Subject.Population in one patient", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": "one"}, {"id": "8627446_4_5678", "context": "The nodules regressed after withdrawal of methotrexate therapy in one patient and were arrested with the addition of hydroxychloroquine in the other.", "question": "Subject.Race in one patient", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "8627446_4_5679", "context": "The nodules regressed after withdrawal of methotrexate therapy in one patient and were arrested with the addition of hydroxychloroquine in the other.", "question": "Subject.Disorder in one patient", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "8627446_4_5680", "context": "The nodules regressed after withdrawal of methotrexate therapy in one patient and were arrested with the addition of hydroxychloroquine in the other.", "question": "Treatment.Drug in withdrawal of methotrexate therapy", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "methotrexate"}, {"id": "8627446_4_5681", "context": "The nodules regressed after withdrawal of methotrexate therapy in one patient and were arrested with the addition of hydroxychloroquine in the other.", "question": "Treatment.Dosage in withdrawal of methotrexate therapy", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "8627446_4_5682", "context": "The nodules regressed after withdrawal of methotrexate therapy in one patient and were arrested with the addition of hydroxychloroquine in the other.", "question": "Treatment.Freq in withdrawal of methotrexate therapy", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "8627446_4_5683", "context": "The nodules regressed after withdrawal of methotrexate therapy in one patient and were arrested with the addition of hydroxychloroquine in the other.", "question": "Treatment.Route in withdrawal of methotrexate therapy", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "8627446_4_5684", "context": "The nodules regressed after withdrawal of methotrexate therapy in one patient and were arrested with the addition of hydroxychloroquine in the other.", "question": "Treatment.Time_elapsed in withdrawal of methotrexate therapy", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8627446_4_5685", "context": "The nodules regressed after withdrawal of methotrexate therapy in one patient and were arrested with the addition of hydroxychloroquine in the other.", "question": "Treatment.Duration in withdrawal of methotrexate therapy", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "8627446_4_5686", "context": "The nodules regressed after withdrawal of methotrexate therapy in one patient and were arrested with the addition of hydroxychloroquine in the other.", "question": "Treatment.Disorder in withdrawal of methotrexate therapy", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "nodules"}, {"id": "8627446_4_5687", "context": "The nodules regressed after withdrawal of methotrexate therapy in one patient and were arrested with the addition of hydroxychloroquine in the other.", "question": "Combination.Drug in withdrawal of methotrexate therapy", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "8627446_4_5688", "context": "The nodules regressed after withdrawal of methotrexate therapy in one patient and were arrested with the addition of hydroxychloroquine in the other.", "question": "Subject.Age in one patient; the other", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "8627446_4_5689", "context": "The nodules regressed after withdrawal of methotrexate therapy in one patient and were arrested with the addition of hydroxychloroquine in the other.", "question": "Subject.Gender in one patient; the other", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "8627446_4_5690", "context": "The nodules regressed after withdrawal of methotrexate therapy in one patient and were arrested with the addition of hydroxychloroquine in the other.", "question": "Subject.Population in one patient; the other", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": "one"}, {"id": "8627446_4_5691", "context": "The nodules regressed after withdrawal of methotrexate therapy in one patient and were arrested with the addition of hydroxychloroquine in the other.", "question": "Subject.Race in one patient; the other", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "8627446_4_5692", "context": "The nodules regressed after withdrawal of methotrexate therapy in one patient and were arrested with the addition of hydroxychloroquine in the other.", "question": "Subject.Disorder in one patient; the other", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "8627446_4_5693", "context": "The nodules regressed after withdrawal of methotrexate therapy in one patient and were arrested with the addition of hydroxychloroquine in the other.", "question": "Treatment.Drug in the addition of hydroxychloroquine", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "hydroxychloroquine"}, {"id": "8627446_4_5694", "context": "The nodules regressed after withdrawal of methotrexate therapy in one patient and were arrested with the addition of hydroxychloroquine in the other.", "question": "Treatment.Dosage in the addition of hydroxychloroquine", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "8627446_4_5695", "context": "The nodules regressed after withdrawal of methotrexate therapy in one patient and were arrested with the addition of hydroxychloroquine in the other.", "question": "Treatment.Freq in the addition of hydroxychloroquine", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "8627446_4_5696", "context": "The nodules regressed after withdrawal of methotrexate therapy in one patient and were arrested with the addition of hydroxychloroquine in the other.", "question": "Treatment.Route in the addition of hydroxychloroquine", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "8627446_4_5697", "context": "The nodules regressed after withdrawal of methotrexate therapy in one patient and were arrested with the addition of hydroxychloroquine in the other.", "question": "Treatment.Time_elapsed in the addition of hydroxychloroquine", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8627446_4_5698", "context": "The nodules regressed after withdrawal of methotrexate therapy in one patient and were arrested with the addition of hydroxychloroquine in the other.", "question": "Treatment.Duration in the addition of hydroxychloroquine", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "8627446_4_5699", "context": "The nodules regressed after withdrawal of methotrexate therapy in one patient and were arrested with the addition of hydroxychloroquine in the other.", "question": "Treatment.Disorder in the addition of hydroxychloroquine", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "nodules"}, {"id": "8627446_4_5700", "context": "The nodules regressed after withdrawal of methotrexate therapy in one patient and were arrested with the addition of hydroxychloroquine in the other.", "question": "Combination.Drug in the addition of hydroxychloroquine", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "12661801_2_5701", "context": "Treatment of carbimazole-induced agranulocytosis and sepsis with granulocyte colony stimulating factor.", "question": "Treatment.Drug in granulocyte colony stimulating factor", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "granulocyte colony stimulating factor"}, {"id": "12661801_2_5702", "context": "Treatment of carbimazole-induced agranulocytosis and sepsis with granulocyte colony stimulating factor.", "question": "Treatment.Dosage in granulocyte colony stimulating factor", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "12661801_2_5703", "context": "Treatment of carbimazole-induced agranulocytosis and sepsis with granulocyte colony stimulating factor.", "question": "Treatment.Freq in granulocyte colony stimulating factor", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "12661801_2_5704", "context": "Treatment of carbimazole-induced agranulocytosis and sepsis with granulocyte colony stimulating factor.", "question": "Treatment.Route in granulocyte colony stimulating factor", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "12661801_2_5705", "context": "Treatment of carbimazole-induced agranulocytosis and sepsis with granulocyte colony stimulating factor.", "question": "Treatment.Time_elapsed in granulocyte colony stimulating factor", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12661801_2_5706", "context": "Treatment of carbimazole-induced agranulocytosis and sepsis with granulocyte colony stimulating factor.", "question": "Treatment.Duration in granulocyte colony stimulating factor", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "12661801_2_5707", "context": "Treatment of carbimazole-induced agranulocytosis and sepsis with granulocyte colony stimulating factor.", "question": "Treatment.Disorder in granulocyte colony stimulating factor", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "carbimazole-induced agranulocytosis and sepsis"}, {"id": "12661801_2_5708", "context": "Treatment of carbimazole-induced agranulocytosis and sepsis with granulocyte colony stimulating factor.", "question": "Combination.Drug in granulocyte colony stimulating factor", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "3954165_1_5709", "context": "A study following large patient groups on theophylline and a combination of theophylline and steroids might clarify the risk of ulcer formation in patients being treated with these medications for asthma.", "question": "Subject.Age in large patient groups", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "3954165_1_5710", "context": "A study following large patient groups on theophylline and a combination of theophylline and steroids might clarify the risk of ulcer formation in patients being treated with these medications for asthma.", "question": "Subject.Gender in large patient groups", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "3954165_1_5711", "context": "A study following large patient groups on theophylline and a combination of theophylline and steroids might clarify the risk of ulcer formation in patients being treated with these medications for asthma.", "question": "Subject.Population in large patient groups", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "3954165_1_5712", "context": "A study following large patient groups on theophylline and a combination of theophylline and steroids might clarify the risk of ulcer formation in patients being treated with these medications for asthma.", "question": "Subject.Race in large patient groups", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "3954165_1_5713", "context": "A study following large patient groups on theophylline and a combination of theophylline and steroids might clarify the risk of ulcer formation in patients being treated with these medications for asthma.", "question": "Subject.Disorder in large patient groups", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "3954165_1_5714", "context": "A study following large patient groups on theophylline and a combination of theophylline and steroids might clarify the risk of ulcer formation in patients being treated with these medications for asthma.", "question": "Treatment.Drug in theophylline and a combination of theophylline and steroids", "question_type": "Adverse_event.Treatment.Drug", "answers": "theophylline; theophylline; steroids"}, {"id": "3954165_1_5715", "context": "A study following large patient groups on theophylline and a combination of theophylline and steroids might clarify the risk of ulcer formation in patients being treated with these medications for asthma.", "question": "Treatment.Dosage in theophylline and a combination of theophylline and steroids", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3954165_1_5716", "context": "A study following large patient groups on theophylline and a combination of theophylline and steroids might clarify the risk of ulcer formation in patients being treated with these medications for asthma.", "question": "Treatment.Freq in theophylline and a combination of theophylline and steroids", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3954165_1_5717", "context": "A study following large patient groups on theophylline and a combination of theophylline and steroids might clarify the risk of ulcer formation in patients being treated with these medications for asthma.", "question": "Treatment.Route in theophylline and a combination of theophylline and steroids", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3954165_1_5718", "context": "A study following large patient groups on theophylline and a combination of theophylline and steroids might clarify the risk of ulcer formation in patients being treated with these medications for asthma.", "question": "Treatment.Time_elapsed in theophylline and a combination of theophylline and steroids", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3954165_1_5719", "context": "A study following large patient groups on theophylline and a combination of theophylline and steroids might clarify the risk of ulcer formation in patients being treated with these medications for asthma.", "question": "Treatment.Duration in theophylline and a combination of theophylline and steroids", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3954165_1_5720", "context": "A study following large patient groups on theophylline and a combination of theophylline and steroids might clarify the risk of ulcer formation in patients being treated with these medications for asthma.", "question": "Treatment.Disorder in theophylline and a combination of theophylline and steroids", "question_type": "Adverse_event.Treatment.Disorder", "answers": "asthma"}, {"id": "3954165_1_5721", "context": "A study following large patient groups on theophylline and a combination of theophylline and steroids might clarify the risk of ulcer formation in patients being treated with these medications for asthma.", "question": "Combination.Drug in theophylline and a combination of theophylline and steroids", "question_type": "Adverse_event.Combination.Drug", "answers": "theophylline; steroids"}, {"id": "9681092_10_5722", "context": "The combination of cyclobenzaprine and fluoxetine resulted in significant QT prolongation in our patient that progressed to torsade de pointes after preoperative droperidol administration.", "question": "Subject.Age in our patient", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "9681092_10_5723", "context": "The combination of cyclobenzaprine and fluoxetine resulted in significant QT prolongation in our patient that progressed to torsade de pointes after preoperative droperidol administration.", "question": "Subject.Gender in our patient", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "9681092_10_5724", "context": "The combination of cyclobenzaprine and fluoxetine resulted in significant QT prolongation in our patient that progressed to torsade de pointes after preoperative droperidol administration.", "question": "Subject.Population in our patient", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "9681092_10_5725", "context": "The combination of cyclobenzaprine and fluoxetine resulted in significant QT prolongation in our patient that progressed to torsade de pointes after preoperative droperidol administration.", "question": "Subject.Race in our patient", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "9681092_10_5726", "context": "The combination of cyclobenzaprine and fluoxetine resulted in significant QT prolongation in our patient that progressed to torsade de pointes after preoperative droperidol administration.", "question": "Subject.Disorder in our patient", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "9681092_10_5727", "context": "The combination of cyclobenzaprine and fluoxetine resulted in significant QT prolongation in our patient that progressed to torsade de pointes after preoperative droperidol administration.", "question": "Treatment.Drug in The combination of cyclobenzaprine and fluoxetine; preoperative droperidol administration", "question_type": "Adverse_event.Treatment.Drug", "answers": "cyclobenzaprine; fluoxetine; droperidol"}, {"id": "9681092_10_5728", "context": "The combination of cyclobenzaprine and fluoxetine resulted in significant QT prolongation in our patient that progressed to torsade de pointes after preoperative droperidol administration.", "question": "Treatment.Dosage in The combination of cyclobenzaprine and fluoxetine; preoperative droperidol administration", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9681092_10_5729", "context": "The combination of cyclobenzaprine and fluoxetine resulted in significant QT prolongation in our patient that progressed to torsade de pointes after preoperative droperidol administration.", "question": "Treatment.Freq in The combination of cyclobenzaprine and fluoxetine; preoperative droperidol administration", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9681092_10_5730", "context": "The combination of cyclobenzaprine and fluoxetine resulted in significant QT prolongation in our patient that progressed to torsade de pointes after preoperative droperidol administration.", "question": "Treatment.Route in The combination of cyclobenzaprine and fluoxetine; preoperative droperidol administration", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9681092_10_5731", "context": "The combination of cyclobenzaprine and fluoxetine resulted in significant QT prolongation in our patient that progressed to torsade de pointes after preoperative droperidol administration.", "question": "Treatment.Time_elapsed in The combination of cyclobenzaprine and fluoxetine; preoperative droperidol administration", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "preoperative"}, {"id": "9681092_10_5732", "context": "The combination of cyclobenzaprine and fluoxetine resulted in significant QT prolongation in our patient that progressed to torsade de pointes after preoperative droperidol administration.", "question": "Treatment.Duration in The combination of cyclobenzaprine and fluoxetine; preoperative droperidol administration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9681092_10_5733", "context": "The combination of cyclobenzaprine and fluoxetine resulted in significant QT prolongation in our patient that progressed to torsade de pointes after preoperative droperidol administration.", "question": "Treatment.Disorder in The combination of cyclobenzaprine and fluoxetine; preoperative droperidol administration", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9681092_10_5734", "context": "The combination of cyclobenzaprine and fluoxetine resulted in significant QT prolongation in our patient that progressed to torsade de pointes after preoperative droperidol administration.", "question": "Combination.Drug in The combination of cyclobenzaprine and fluoxetine; preoperative droperidol administration", "question_type": "Adverse_event.Combination.Drug", "answers": "cyclobenzaprine; fluoxetine; droperidol"}, {"id": "7887138_2_5735", "context": "INTRODUCTION-The aim of this case report is to present a 15-year follow-up of a patient with phenytoin (PHT) intoxication with unilateral gingival hyperplasia (GH).", "question": "Subject.Age in a patient", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "7887138_2_5736", "context": "INTRODUCTION-The aim of this case report is to present a 15-year follow-up of a patient with phenytoin (PHT) intoxication with unilateral gingival hyperplasia (GH).", "question": "Subject.Gender in a patient", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "7887138_2_5737", "context": "INTRODUCTION-The aim of this case report is to present a 15-year follow-up of a patient with phenytoin (PHT) intoxication with unilateral gingival hyperplasia (GH).", "question": "Subject.Population in a patient", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "7887138_2_5738", "context": "INTRODUCTION-The aim of this case report is to present a 15-year follow-up of a patient with phenytoin (PHT) intoxication with unilateral gingival hyperplasia (GH).", "question": "Subject.Race in a patient", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "7887138_2_5739", "context": "INTRODUCTION-The aim of this case report is to present a 15-year follow-up of a patient with phenytoin (PHT) intoxication with unilateral gingival hyperplasia (GH).", "question": "Subject.Disorder in a patient", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "7887138_2_5740", "context": "INTRODUCTION-The aim of this case report is to present a 15-year follow-up of a patient with phenytoin (PHT) intoxication with unilateral gingival hyperplasia (GH).", "question": "Treatment.Drug in phenytoin", "question_type": "Adverse_event.Treatment.Drug", "answers": "phenytoin"}, {"id": "7887138_2_5741", "context": "INTRODUCTION-The aim of this case report is to present a 15-year follow-up of a patient with phenytoin (PHT) intoxication with unilateral gingival hyperplasia (GH).", "question": "Treatment.Dosage in phenytoin", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7887138_2_5742", "context": "INTRODUCTION-The aim of this case report is to present a 15-year follow-up of a patient with phenytoin (PHT) intoxication with unilateral gingival hyperplasia (GH).", "question": "Treatment.Freq in phenytoin", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7887138_2_5743", "context": "INTRODUCTION-The aim of this case report is to present a 15-year follow-up of a patient with phenytoin (PHT) intoxication with unilateral gingival hyperplasia (GH).", "question": "Treatment.Route in phenytoin", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7887138_2_5744", "context": "INTRODUCTION-The aim of this case report is to present a 15-year follow-up of a patient with phenytoin (PHT) intoxication with unilateral gingival hyperplasia (GH).", "question": "Treatment.Time_elapsed in phenytoin", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7887138_2_5745", "context": "INTRODUCTION-The aim of this case report is to present a 15-year follow-up of a patient with phenytoin (PHT) intoxication with unilateral gingival hyperplasia (GH).", "question": "Treatment.Duration in phenytoin", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7887138_2_5746", "context": "INTRODUCTION-The aim of this case report is to present a 15-year follow-up of a patient with phenytoin (PHT) intoxication with unilateral gingival hyperplasia (GH).", "question": "Treatment.Disorder in phenytoin", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7887138_2_5747", "context": "INTRODUCTION-The aim of this case report is to present a 15-year follow-up of a patient with phenytoin (PHT) intoxication with unilateral gingival hyperplasia (GH).", "question": "Combination.Drug in phenytoin", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9039216_3_5748", "context": "This severe illness was likely caused by minocycline, and we speculate that minocycline may have acted as a superantigen, causing lymphocyte over-activation and massive cytokine release.", "question": "Treatment.Drug in minocycline", "question_type": "Adverse_event.Treatment.Drug", "answers": "minocycline"}, {"id": "9039216_3_5749", "context": "This severe illness was likely caused by minocycline, and we speculate that minocycline may have acted as a superantigen, causing lymphocyte over-activation and massive cytokine release.", "question": "Treatment.Dosage in minocycline", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9039216_3_5750", "context": "This severe illness was likely caused by minocycline, and we speculate that minocycline may have acted as a superantigen, causing lymphocyte over-activation and massive cytokine release.", "question": "Treatment.Freq in minocycline", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9039216_3_5751", "context": "This severe illness was likely caused by minocycline, and we speculate that minocycline may have acted as a superantigen, causing lymphocyte over-activation and massive cytokine release.", "question": "Treatment.Route in minocycline", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9039216_3_5752", "context": "This severe illness was likely caused by minocycline, and we speculate that minocycline may have acted as a superantigen, causing lymphocyte over-activation and massive cytokine release.", "question": "Treatment.Time_elapsed in minocycline", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9039216_3_5753", "context": "This severe illness was likely caused by minocycline, and we speculate that minocycline may have acted as a superantigen, causing lymphocyte over-activation and massive cytokine release.", "question": "Treatment.Duration in minocycline", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9039216_3_5754", "context": "This severe illness was likely caused by minocycline, and we speculate that minocycline may have acted as a superantigen, causing lymphocyte over-activation and massive cytokine release.", "question": "Treatment.Disorder in minocycline", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9039216_3_5755", "context": "This severe illness was likely caused by minocycline, and we speculate that minocycline may have acted as a superantigen, causing lymphocyte over-activation and massive cytokine release.", "question": "Combination.Drug in minocycline", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15681911_3_5756", "context": "RESULTS: Three patients who developed symptoms of inflammatory bowel disease (IBD) during rofecoxib exposure are described along with pathology findings.", "question": "Subject.Age in Three patients", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "15681911_3_5757", "context": "RESULTS: Three patients who developed symptoms of inflammatory bowel disease (IBD) during rofecoxib exposure are described along with pathology findings.", "question": "Subject.Gender in Three patients", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15681911_3_5758", "context": "RESULTS: Three patients who developed symptoms of inflammatory bowel disease (IBD) during rofecoxib exposure are described along with pathology findings.", "question": "Subject.Population in Three patients", "question_type": "Adverse_event.Subject.Population", "answers": "Three"}, {"id": "15681911_3_5759", "context": "RESULTS: Three patients who developed symptoms of inflammatory bowel disease (IBD) during rofecoxib exposure are described along with pathology findings.", "question": "Subject.Race in Three patients", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15681911_3_5760", "context": "RESULTS: Three patients who developed symptoms of inflammatory bowel disease (IBD) during rofecoxib exposure are described along with pathology findings.", "question": "Subject.Disorder in Three patients", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15681911_3_5761", "context": "RESULTS: Three patients who developed symptoms of inflammatory bowel disease (IBD) during rofecoxib exposure are described along with pathology findings.", "question": "Treatment.Drug in rofecoxib exposure", "question_type": "Adverse_event.Treatment.Drug", "answers": "rofecoxib"}, {"id": "15681911_3_5762", "context": "RESULTS: Three patients who developed symptoms of inflammatory bowel disease (IBD) during rofecoxib exposure are described along with pathology findings.", "question": "Treatment.Dosage in rofecoxib exposure", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15681911_3_5763", "context": "RESULTS: Three patients who developed symptoms of inflammatory bowel disease (IBD) during rofecoxib exposure are described along with pathology findings.", "question": "Treatment.Freq in rofecoxib exposure", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15681911_3_5764", "context": "RESULTS: Three patients who developed symptoms of inflammatory bowel disease (IBD) during rofecoxib exposure are described along with pathology findings.", "question": "Treatment.Route in rofecoxib exposure", "question_type": "Adverse_event.Treatment.Route", "answers": "exposure"}, {"id": "15681911_3_5765", "context": "RESULTS: Three patients who developed symptoms of inflammatory bowel disease (IBD) during rofecoxib exposure are described along with pathology findings.", "question": "Treatment.Time_elapsed in rofecoxib exposure", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15681911_3_5766", "context": "RESULTS: Three patients who developed symptoms of inflammatory bowel disease (IBD) during rofecoxib exposure are described along with pathology findings.", "question": "Treatment.Duration in rofecoxib exposure", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15681911_3_5767", "context": "RESULTS: Three patients who developed symptoms of inflammatory bowel disease (IBD) during rofecoxib exposure are described along with pathology findings.", "question": "Treatment.Disorder in rofecoxib exposure", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15681911_3_5768", "context": "RESULTS: Three patients who developed symptoms of inflammatory bowel disease (IBD) during rofecoxib exposure are described along with pathology findings.", "question": "Combination.Drug in rofecoxib exposure", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15112258_2_5769", "context": "Radiation recall refers to inflammatory reactions triggered by cytotoxic agents and develops in previously irradiated areas.", "question": "Treatment.Drug in cytotoxic agents", "question_type": "Adverse_event.Treatment.Drug", "answers": "cytotoxic"}, {"id": "15112258_2_5770", "context": "Radiation recall refers to inflammatory reactions triggered by cytotoxic agents and develops in previously irradiated areas.", "question": "Treatment.Dosage in cytotoxic agents", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15112258_2_5771", "context": "Radiation recall refers to inflammatory reactions triggered by cytotoxic agents and develops in previously irradiated areas.", "question": "Treatment.Freq in cytotoxic agents", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15112258_2_5772", "context": "Radiation recall refers to inflammatory reactions triggered by cytotoxic agents and develops in previously irradiated areas.", "question": "Treatment.Route in cytotoxic agents", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15112258_2_5773", "context": "Radiation recall refers to inflammatory reactions triggered by cytotoxic agents and develops in previously irradiated areas.", "question": "Treatment.Time_elapsed in cytotoxic agents", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15112258_2_5774", "context": "Radiation recall refers to inflammatory reactions triggered by cytotoxic agents and develops in previously irradiated areas.", "question": "Treatment.Duration in cytotoxic agents", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15112258_2_5775", "context": "Radiation recall refers to inflammatory reactions triggered by cytotoxic agents and develops in previously irradiated areas.", "question": "Treatment.Disorder in cytotoxic agents", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15112258_2_5776", "context": "Radiation recall refers to inflammatory reactions triggered by cytotoxic agents and develops in previously irradiated areas.", "question": "Combination.Drug in cytotoxic agents", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16507211_1_5777", "context": "Herein, we describe 2 patients who developed unusual CD8+ cutaneous lymphoproliferative disorders after treatment with efalizumab and infliximab.", "question": "Subject.Age in 2 patients", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "16507211_1_5778", "context": "Herein, we describe 2 patients who developed unusual CD8+ cutaneous lymphoproliferative disorders after treatment with efalizumab and infliximab.", "question": "Subject.Gender in 2 patients", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "16507211_1_5779", "context": "Herein, we describe 2 patients who developed unusual CD8+ cutaneous lymphoproliferative disorders after treatment with efalizumab and infliximab.", "question": "Subject.Population in 2 patients", "question_type": "Adverse_event.Subject.Population", "answers": "2"}, {"id": "16507211_1_5780", "context": "Herein, we describe 2 patients who developed unusual CD8+ cutaneous lymphoproliferative disorders after treatment with efalizumab and infliximab.", "question": "Subject.Race in 2 patients", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16507211_1_5781", "context": "Herein, we describe 2 patients who developed unusual CD8+ cutaneous lymphoproliferative disorders after treatment with efalizumab and infliximab.", "question": "Subject.Disorder in 2 patients", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "16507211_1_5782", "context": "Herein, we describe 2 patients who developed unusual CD8+ cutaneous lymphoproliferative disorders after treatment with efalizumab and infliximab.", "question": "Treatment.Drug in efalizumab and infliximab", "question_type": "Adverse_event.Treatment.Drug", "answers": "efalizumab; infliximab"}, {"id": "16507211_1_5783", "context": "Herein, we describe 2 patients who developed unusual CD8+ cutaneous lymphoproliferative disorders after treatment with efalizumab and infliximab.", "question": "Treatment.Dosage in efalizumab and infliximab", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16507211_1_5784", "context": "Herein, we describe 2 patients who developed unusual CD8+ cutaneous lymphoproliferative disorders after treatment with efalizumab and infliximab.", "question": "Treatment.Freq in efalizumab and infliximab", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16507211_1_5785", "context": "Herein, we describe 2 patients who developed unusual CD8+ cutaneous lymphoproliferative disorders after treatment with efalizumab and infliximab.", "question": "Treatment.Route in efalizumab and infliximab", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16507211_1_5786", "context": "Herein, we describe 2 patients who developed unusual CD8+ cutaneous lymphoproliferative disorders after treatment with efalizumab and infliximab.", "question": "Treatment.Time_elapsed in efalizumab and infliximab", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16507211_1_5787", "context": "Herein, we describe 2 patients who developed unusual CD8+ cutaneous lymphoproliferative disorders after treatment with efalizumab and infliximab.", "question": "Treatment.Duration in efalizumab and infliximab", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16507211_1_5788", "context": "Herein, we describe 2 patients who developed unusual CD8+ cutaneous lymphoproliferative disorders after treatment with efalizumab and infliximab.", "question": "Treatment.Disorder in efalizumab and infliximab", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16507211_1_5789", "context": "Herein, we describe 2 patients who developed unusual CD8+ cutaneous lymphoproliferative disorders after treatment with efalizumab and infliximab.", "question": "Combination.Drug in efalizumab and infliximab", "question_type": "Adverse_event.Combination.Drug", "answers": "efalizumab; infliximab"}, {"id": "12707728_1_5790", "context": "Intrathecal methotrexate-induced acute cerebellar syndrome.", "question": "Treatment.Drug in methotrexate", "question_type": "Adverse_event.Treatment.Drug", "answers": "methotrexate"}, {"id": "12707728_1_5791", "context": "Intrathecal methotrexate-induced acute cerebellar syndrome.", "question": "Treatment.Dosage in methotrexate", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12707728_1_5792", "context": "Intrathecal methotrexate-induced acute cerebellar syndrome.", "question": "Treatment.Freq in methotrexate", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12707728_1_5793", "context": "Intrathecal methotrexate-induced acute cerebellar syndrome.", "question": "Treatment.Route in methotrexate", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12707728_1_5794", "context": "Intrathecal methotrexate-induced acute cerebellar syndrome.", "question": "Treatment.Time_elapsed in methotrexate", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12707728_1_5795", "context": "Intrathecal methotrexate-induced acute cerebellar syndrome.", "question": "Treatment.Duration in methotrexate", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12707728_1_5796", "context": "Intrathecal methotrexate-induced acute cerebellar syndrome.", "question": "Treatment.Disorder in methotrexate", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12707728_1_5797", "context": "Intrathecal methotrexate-induced acute cerebellar syndrome.", "question": "Combination.Drug in methotrexate", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7468565_1_5798", "context": "Barbiturate-induced submassive hepatic necrosis.", "question": "Treatment.Drug in Barbiturate", "question_type": "Adverse_event.Treatment.Drug", "answers": "Barbiturate"}, {"id": "7468565_1_5799", "context": "Barbiturate-induced submassive hepatic necrosis.", "question": "Treatment.Dosage in Barbiturate", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7468565_1_5800", "context": "Barbiturate-induced submassive hepatic necrosis.", "question": "Treatment.Freq in Barbiturate", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7468565_1_5801", "context": "Barbiturate-induced submassive hepatic necrosis.", "question": "Treatment.Route in Barbiturate", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7468565_1_5802", "context": "Barbiturate-induced submassive hepatic necrosis.", "question": "Treatment.Time_elapsed in Barbiturate", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7468565_1_5803", "context": "Barbiturate-induced submassive hepatic necrosis.", "question": "Treatment.Duration in Barbiturate", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7468565_1_5804", "context": "Barbiturate-induced submassive hepatic necrosis.", "question": "Treatment.Disorder in Barbiturate", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7468565_1_5805", "context": "Barbiturate-induced submassive hepatic necrosis.", "question": "Combination.Drug in Barbiturate", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9094821_1_5806", "context": "The possible effects of tamoxifen upon the uterus are discussed in this article, in view of reports of tamoxifen associated with endometrial carcinoma and endometriosis.", "question": "Treatment.Drug in tamoxifen", "question_type": "Adverse_event.Treatment.Drug", "answers": "tamoxifen"}, {"id": "9094821_1_5807", "context": "The possible effects of tamoxifen upon the uterus are discussed in this article, in view of reports of tamoxifen associated with endometrial carcinoma and endometriosis.", "question": "Treatment.Dosage in tamoxifen", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9094821_1_5808", "context": "The possible effects of tamoxifen upon the uterus are discussed in this article, in view of reports of tamoxifen associated with endometrial carcinoma and endometriosis.", "question": "Treatment.Freq in tamoxifen", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9094821_1_5809", "context": "The possible effects of tamoxifen upon the uterus are discussed in this article, in view of reports of tamoxifen associated with endometrial carcinoma and endometriosis.", "question": "Treatment.Route in tamoxifen", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9094821_1_5810", "context": "The possible effects of tamoxifen upon the uterus are discussed in this article, in view of reports of tamoxifen associated with endometrial carcinoma and endometriosis.", "question": "Treatment.Time_elapsed in tamoxifen", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9094821_1_5811", "context": "The possible effects of tamoxifen upon the uterus are discussed in this article, in view of reports of tamoxifen associated with endometrial carcinoma and endometriosis.", "question": "Treatment.Duration in tamoxifen", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9094821_1_5812", "context": "The possible effects of tamoxifen upon the uterus are discussed in this article, in view of reports of tamoxifen associated with endometrial carcinoma and endometriosis.", "question": "Treatment.Disorder in tamoxifen", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9094821_1_5813", "context": "The possible effects of tamoxifen upon the uterus are discussed in this article, in view of reports of tamoxifen associated with endometrial carcinoma and endometriosis.", "question": "Combination.Drug in tamoxifen", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "2549018_6_5814", "context": "Three patients who had experienced neuroleptic-induced akathisia in the past reported that the symptoms of fluoxetine-induced akathisia were identical, although somewhat milder.", "question": "Subject.Age in Three patients", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "2549018_6_5815", "context": "Three patients who had experienced neuroleptic-induced akathisia in the past reported that the symptoms of fluoxetine-induced akathisia were identical, although somewhat milder.", "question": "Subject.Gender in Three patients", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "2549018_6_5816", "context": "Three patients who had experienced neuroleptic-induced akathisia in the past reported that the symptoms of fluoxetine-induced akathisia were identical, although somewhat milder.", "question": "Subject.Population in Three patients", "question_type": "Adverse_event.Subject.Population", "answers": "Three"}, {"id": "2549018_6_5817", "context": "Three patients who had experienced neuroleptic-induced akathisia in the past reported that the symptoms of fluoxetine-induced akathisia were identical, although somewhat milder.", "question": "Subject.Race in Three patients", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "2549018_6_5818", "context": "Three patients who had experienced neuroleptic-induced akathisia in the past reported that the symptoms of fluoxetine-induced akathisia were identical, although somewhat milder.", "question": "Subject.Disorder in Three patients", "question_type": "Adverse_event.Subject.Disorder", "answers": "neuroleptic-induced akathisia"}, {"id": "2549018_6_5819", "context": "Three patients who had experienced neuroleptic-induced akathisia in the past reported that the symptoms of fluoxetine-induced akathisia were identical, although somewhat milder.", "question": "Treatment.Drug in fluoxetine", "question_type": "Adverse_event.Treatment.Drug", "answers": "fluoxetine"}, {"id": "2549018_6_5820", "context": "Three patients who had experienced neuroleptic-induced akathisia in the past reported that the symptoms of fluoxetine-induced akathisia were identical, although somewhat milder.", "question": "Treatment.Dosage in fluoxetine", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "2549018_6_5821", "context": "Three patients who had experienced neuroleptic-induced akathisia in the past reported that the symptoms of fluoxetine-induced akathisia were identical, although somewhat milder.", "question": "Treatment.Freq in fluoxetine", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2549018_6_5822", "context": "Three patients who had experienced neuroleptic-induced akathisia in the past reported that the symptoms of fluoxetine-induced akathisia were identical, although somewhat milder.", "question": "Treatment.Route in fluoxetine", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "2549018_6_5823", "context": "Three patients who had experienced neuroleptic-induced akathisia in the past reported that the symptoms of fluoxetine-induced akathisia were identical, although somewhat milder.", "question": "Treatment.Time_elapsed in fluoxetine", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2549018_6_5824", "context": "Three patients who had experienced neuroleptic-induced akathisia in the past reported that the symptoms of fluoxetine-induced akathisia were identical, although somewhat milder.", "question": "Treatment.Duration in fluoxetine", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2549018_6_5825", "context": "Three patients who had experienced neuroleptic-induced akathisia in the past reported that the symptoms of fluoxetine-induced akathisia were identical, although somewhat milder.", "question": "Treatment.Disorder in fluoxetine", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "2549018_6_5826", "context": "Three patients who had experienced neuroleptic-induced akathisia in the past reported that the symptoms of fluoxetine-induced akathisia were identical, although somewhat milder.", "question": "Combination.Drug in fluoxetine", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "2549018_6_5827", "context": "Three patients who had experienced neuroleptic-induced akathisia in the past reported that the symptoms of fluoxetine-induced akathisia were identical, although somewhat milder.", "question": "Subject.Age in Three patients", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "2549018_6_5828", "context": "Three patients who had experienced neuroleptic-induced akathisia in the past reported that the symptoms of fluoxetine-induced akathisia were identical, although somewhat milder.", "question": "Subject.Gender in Three patients", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "2549018_6_5829", "context": "Three patients who had experienced neuroleptic-induced akathisia in the past reported that the symptoms of fluoxetine-induced akathisia were identical, although somewhat milder.", "question": "Subject.Population in Three patients", "question_type": "Adverse_event.Subject.Population", "answers": "Three"}, {"id": "2549018_6_5830", "context": "Three patients who had experienced neuroleptic-induced akathisia in the past reported that the symptoms of fluoxetine-induced akathisia were identical, although somewhat milder.", "question": "Subject.Race in Three patients", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "2549018_6_5831", "context": "Three patients who had experienced neuroleptic-induced akathisia in the past reported that the symptoms of fluoxetine-induced akathisia were identical, although somewhat milder.", "question": "Subject.Disorder in Three patients", "question_type": "Adverse_event.Subject.Disorder", "answers": "neuroleptic-induced akathisia"}, {"id": "2549018_6_5832", "context": "Three patients who had experienced neuroleptic-induced akathisia in the past reported that the symptoms of fluoxetine-induced akathisia were identical, although somewhat milder.", "question": "Treatment.Drug in neuroleptic", "question_type": "Adverse_event.Treatment.Drug", "answers": "neuroleptic"}, {"id": "2549018_6_5833", "context": "Three patients who had experienced neuroleptic-induced akathisia in the past reported that the symptoms of fluoxetine-induced akathisia were identical, although somewhat milder.", "question": "Treatment.Dosage in neuroleptic", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "2549018_6_5834", "context": "Three patients who had experienced neuroleptic-induced akathisia in the past reported that the symptoms of fluoxetine-induced akathisia were identical, although somewhat milder.", "question": "Treatment.Freq in neuroleptic", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2549018_6_5835", "context": "Three patients who had experienced neuroleptic-induced akathisia in the past reported that the symptoms of fluoxetine-induced akathisia were identical, although somewhat milder.", "question": "Treatment.Route in neuroleptic", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "2549018_6_5836", "context": "Three patients who had experienced neuroleptic-induced akathisia in the past reported that the symptoms of fluoxetine-induced akathisia were identical, although somewhat milder.", "question": "Treatment.Time_elapsed in neuroleptic", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2549018_6_5837", "context": "Three patients who had experienced neuroleptic-induced akathisia in the past reported that the symptoms of fluoxetine-induced akathisia were identical, although somewhat milder.", "question": "Treatment.Duration in neuroleptic", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2549018_6_5838", "context": "Three patients who had experienced neuroleptic-induced akathisia in the past reported that the symptoms of fluoxetine-induced akathisia were identical, although somewhat milder.", "question": "Treatment.Disorder in neuroleptic", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "2549018_6_5839", "context": "Three patients who had experienced neuroleptic-induced akathisia in the past reported that the symptoms of fluoxetine-induced akathisia were identical, although somewhat milder.", "question": "Combination.Drug in neuroleptic", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8700794_2_5840", "context": "Intranasal desmopressin-induced hyponatremia.", "question": "Treatment.Drug in Intranasal desmopressin", "question_type": "Adverse_event.Treatment.Drug", "answers": "desmopressin"}, {"id": "8700794_2_5841", "context": "Intranasal desmopressin-induced hyponatremia.", "question": "Treatment.Dosage in Intranasal desmopressin", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8700794_2_5842", "context": "Intranasal desmopressin-induced hyponatremia.", "question": "Treatment.Freq in Intranasal desmopressin", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8700794_2_5843", "context": "Intranasal desmopressin-induced hyponatremia.", "question": "Treatment.Route in Intranasal desmopressin", "question_type": "Adverse_event.Treatment.Route", "answers": "Intranasal"}, {"id": "8700794_2_5844", "context": "Intranasal desmopressin-induced hyponatremia.", "question": "Treatment.Time_elapsed in Intranasal desmopressin", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8700794_2_5845", "context": "Intranasal desmopressin-induced hyponatremia.", "question": "Treatment.Duration in Intranasal desmopressin", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8700794_2_5846", "context": "Intranasal desmopressin-induced hyponatremia.", "question": "Treatment.Disorder in Intranasal desmopressin", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8700794_2_5847", "context": "Intranasal desmopressin-induced hyponatremia.", "question": "Combination.Drug in Intranasal desmopressin", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9934637_4_5848", "context": "Sunburn may sometimes be a major injury in psoralen users because high doses or inappropriate use of the drug may render the skin extremely sensitive.", "question": "Subject.Age in users", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "9934637_4_5849", "context": "Sunburn may sometimes be a major injury in psoralen users because high doses or inappropriate use of the drug may render the skin extremely sensitive.", "question": "Subject.Gender in users", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "9934637_4_5850", "context": "Sunburn may sometimes be a major injury in psoralen users because high doses or inappropriate use of the drug may render the skin extremely sensitive.", "question": "Subject.Population in users", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "9934637_4_5851", "context": "Sunburn may sometimes be a major injury in psoralen users because high doses or inappropriate use of the drug may render the skin extremely sensitive.", "question": "Subject.Race in users", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "9934637_4_5852", "context": "Sunburn may sometimes be a major injury in psoralen users because high doses or inappropriate use of the drug may render the skin extremely sensitive.", "question": "Subject.Disorder in users", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "9934637_4_5853", "context": "Sunburn may sometimes be a major injury in psoralen users because high doses or inappropriate use of the drug may render the skin extremely sensitive.", "question": "Treatment.Drug in psoralen users because high doses or inappropriate use", "question_type": "Adverse_event.Treatment.Drug", "answers": "psoralen"}, {"id": "9934637_4_5854", "context": "Sunburn may sometimes be a major injury in psoralen users because high doses or inappropriate use of the drug may render the skin extremely sensitive.", "question": "Treatment.Dosage in psoralen users because high doses or inappropriate use", "question_type": "Adverse_event.Treatment.Dosage", "answers": "high doses"}, {"id": "9934637_4_5855", "context": "Sunburn may sometimes be a major injury in psoralen users because high doses or inappropriate use of the drug may render the skin extremely sensitive.", "question": "Treatment.Freq in psoralen users because high doses or inappropriate use", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9934637_4_5856", "context": "Sunburn may sometimes be a major injury in psoralen users because high doses or inappropriate use of the drug may render the skin extremely sensitive.", "question": "Treatment.Route in psoralen users because high doses or inappropriate use", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9934637_4_5857", "context": "Sunburn may sometimes be a major injury in psoralen users because high doses or inappropriate use of the drug may render the skin extremely sensitive.", "question": "Treatment.Time_elapsed in psoralen users because high doses or inappropriate use", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9934637_4_5858", "context": "Sunburn may sometimes be a major injury in psoralen users because high doses or inappropriate use of the drug may render the skin extremely sensitive.", "question": "Treatment.Duration in psoralen users because high doses or inappropriate use", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9934637_4_5859", "context": "Sunburn may sometimes be a major injury in psoralen users because high doses or inappropriate use of the drug may render the skin extremely sensitive.", "question": "Treatment.Disorder in psoralen users because high doses or inappropriate use", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9934637_4_5860", "context": "Sunburn may sometimes be a major injury in psoralen users because high doses or inappropriate use of the drug may render the skin extremely sensitive.", "question": "Combination.Drug in psoralen users because high doses or inappropriate use", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "2204409_2_5861", "context": "Methotrexate-induced leukoencephalopathy is treatable with high-dose folinic acid: a case report and analysis of the literature.", "question": "Treatment.Drug in high-dose folinic acid", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "folinic acid"}, {"id": "2204409_2_5862", "context": "Methotrexate-induced leukoencephalopathy is treatable with high-dose folinic acid: a case report and analysis of the literature.", "question": "Treatment.Dosage in high-dose folinic acid", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": "high-dose"}, {"id": "2204409_2_5863", "context": "Methotrexate-induced leukoencephalopathy is treatable with high-dose folinic acid: a case report and analysis of the literature.", "question": "Treatment.Freq in high-dose folinic acid", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "2204409_2_5864", "context": "Methotrexate-induced leukoencephalopathy is treatable with high-dose folinic acid: a case report and analysis of the literature.", "question": "Treatment.Route in high-dose folinic acid", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "2204409_2_5865", "context": "Methotrexate-induced leukoencephalopathy is treatable with high-dose folinic acid: a case report and analysis of the literature.", "question": "Treatment.Time_elapsed in high-dose folinic acid", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2204409_2_5866", "context": "Methotrexate-induced leukoencephalopathy is treatable with high-dose folinic acid: a case report and analysis of the literature.", "question": "Treatment.Duration in high-dose folinic acid", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "2204409_2_5867", "context": "Methotrexate-induced leukoencephalopathy is treatable with high-dose folinic acid: a case report and analysis of the literature.", "question": "Treatment.Disorder in high-dose folinic acid", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "Methotrexate-induced leukoencephalopathy"}, {"id": "2204409_2_5868", "context": "Methotrexate-induced leukoencephalopathy is treatable with high-dose folinic acid: a case report and analysis of the literature.", "question": "Combination.Drug in high-dose folinic acid", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "2204409_2_5869", "context": "Methotrexate-induced leukoencephalopathy is treatable with high-dose folinic acid: a case report and analysis of the literature.", "question": "Treatment.Drug in Methotrexate", "question_type": "Adverse_event.Treatment.Drug", "answers": "Methotrexate"}, {"id": "2204409_2_5870", "context": "Methotrexate-induced leukoencephalopathy is treatable with high-dose folinic acid: a case report and analysis of the literature.", "question": "Treatment.Dosage in Methotrexate", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "2204409_2_5871", "context": "Methotrexate-induced leukoencephalopathy is treatable with high-dose folinic acid: a case report and analysis of the literature.", "question": "Treatment.Freq in Methotrexate", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2204409_2_5872", "context": "Methotrexate-induced leukoencephalopathy is treatable with high-dose folinic acid: a case report and analysis of the literature.", "question": "Treatment.Route in Methotrexate", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "2204409_2_5873", "context": "Methotrexate-induced leukoencephalopathy is treatable with high-dose folinic acid: a case report and analysis of the literature.", "question": "Treatment.Time_elapsed in Methotrexate", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2204409_2_5874", "context": "Methotrexate-induced leukoencephalopathy is treatable with high-dose folinic acid: a case report and analysis of the literature.", "question": "Treatment.Duration in Methotrexate", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2204409_2_5875", "context": "Methotrexate-induced leukoencephalopathy is treatable with high-dose folinic acid: a case report and analysis of the literature.", "question": "Treatment.Disorder in Methotrexate", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "2204409_2_5876", "context": "Methotrexate-induced leukoencephalopathy is treatable with high-dose folinic acid: a case report and analysis of the literature.", "question": "Combination.Drug in Methotrexate", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18765315_5_5877", "context": "We reviewed the records of 3 patients with lymphoproliferative disorders who experienced acute coronary syndromes associated with their initial infusion of rituximab.", "question": "Subject.Age in 3 patients with lymphoproliferative disorders", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "18765315_5_5878", "context": "We reviewed the records of 3 patients with lymphoproliferative disorders who experienced acute coronary syndromes associated with their initial infusion of rituximab.", "question": "Subject.Gender in 3 patients with lymphoproliferative disorders", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "18765315_5_5879", "context": "We reviewed the records of 3 patients with lymphoproliferative disorders who experienced acute coronary syndromes associated with their initial infusion of rituximab.", "question": "Subject.Population in 3 patients with lymphoproliferative disorders", "question_type": "Adverse_event.Subject.Population", "answers": "3"}, {"id": "18765315_5_5880", "context": "We reviewed the records of 3 patients with lymphoproliferative disorders who experienced acute coronary syndromes associated with their initial infusion of rituximab.", "question": "Subject.Race in 3 patients with lymphoproliferative disorders", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "18765315_5_5881", "context": "We reviewed the records of 3 patients with lymphoproliferative disorders who experienced acute coronary syndromes associated with their initial infusion of rituximab.", "question": "Subject.Disorder in 3 patients with lymphoproliferative disorders", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "18765315_5_5882", "context": "We reviewed the records of 3 patients with lymphoproliferative disorders who experienced acute coronary syndromes associated with their initial infusion of rituximab.", "question": "Treatment.Drug in their initial infusion of rituximab", "question_type": "Adverse_event.Treatment.Drug", "answers": "rituximab"}, {"id": "18765315_5_5883", "context": "We reviewed the records of 3 patients with lymphoproliferative disorders who experienced acute coronary syndromes associated with their initial infusion of rituximab.", "question": "Treatment.Dosage in their initial infusion of rituximab", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18765315_5_5884", "context": "We reviewed the records of 3 patients with lymphoproliferative disorders who experienced acute coronary syndromes associated with their initial infusion of rituximab.", "question": "Treatment.Freq in their initial infusion of rituximab", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18765315_5_5885", "context": "We reviewed the records of 3 patients with lymphoproliferative disorders who experienced acute coronary syndromes associated with their initial infusion of rituximab.", "question": "Treatment.Route in their initial infusion of rituximab", "question_type": "Adverse_event.Treatment.Route", "answers": "infusion"}, {"id": "18765315_5_5886", "context": "We reviewed the records of 3 patients with lymphoproliferative disorders who experienced acute coronary syndromes associated with their initial infusion of rituximab.", "question": "Treatment.Time_elapsed in their initial infusion of rituximab", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18765315_5_5887", "context": "We reviewed the records of 3 patients with lymphoproliferative disorders who experienced acute coronary syndromes associated with their initial infusion of rituximab.", "question": "Treatment.Duration in their initial infusion of rituximab", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18765315_5_5888", "context": "We reviewed the records of 3 patients with lymphoproliferative disorders who experienced acute coronary syndromes associated with their initial infusion of rituximab.", "question": "Treatment.Disorder in their initial infusion of rituximab", "question_type": "Adverse_event.Treatment.Disorder", "answers": "lymphoproliferative disorders"}, {"id": "18765315_5_5889", "context": "We reviewed the records of 3 patients with lymphoproliferative disorders who experienced acute coronary syndromes associated with their initial infusion of rituximab.", "question": "Combination.Drug in their initial infusion of rituximab", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "14964753_8_5890", "context": "Previous successful treatment with one ACE inhibitor does not rule out the vasculitis caused by the drug from the same group.", "question": "Treatment.Drug in ACE inhibitor", "question_type": "Adverse_event.Treatment.Drug", "answers": "ACE inhibitor"}, {"id": "14964753_8_5891", "context": "Previous successful treatment with one ACE inhibitor does not rule out the vasculitis caused by the drug from the same group.", "question": "Treatment.Dosage in ACE inhibitor", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "14964753_8_5892", "context": "Previous successful treatment with one ACE inhibitor does not rule out the vasculitis caused by the drug from the same group.", "question": "Treatment.Freq in ACE inhibitor", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "14964753_8_5893", "context": "Previous successful treatment with one ACE inhibitor does not rule out the vasculitis caused by the drug from the same group.", "question": "Treatment.Route in ACE inhibitor", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "14964753_8_5894", "context": "Previous successful treatment with one ACE inhibitor does not rule out the vasculitis caused by the drug from the same group.", "question": "Treatment.Time_elapsed in ACE inhibitor", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "14964753_8_5895", "context": "Previous successful treatment with one ACE inhibitor does not rule out the vasculitis caused by the drug from the same group.", "question": "Treatment.Duration in ACE inhibitor", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "14964753_8_5896", "context": "Previous successful treatment with one ACE inhibitor does not rule out the vasculitis caused by the drug from the same group.", "question": "Treatment.Disorder in ACE inhibitor", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "14964753_8_5897", "context": "Previous successful treatment with one ACE inhibitor does not rule out the vasculitis caused by the drug from the same group.", "question": "Combination.Drug in ACE inhibitor", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11688826_3_5898", "context": "We report a patient with pulmonary adenocarcinoma complicated by the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) following systemic chemotherapy with cisplatin (CDDP) and vindesine (VDS).", "question": "Subject.Age in a patient with pulmonary adenocarcinoma", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "11688826_3_5899", "context": "We report a patient with pulmonary adenocarcinoma complicated by the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) following systemic chemotherapy with cisplatin (CDDP) and vindesine (VDS).", "question": "Subject.Gender in a patient with pulmonary adenocarcinoma", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "11688826_3_5900", "context": "We report a patient with pulmonary adenocarcinoma complicated by the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) following systemic chemotherapy with cisplatin (CDDP) and vindesine (VDS).", "question": "Subject.Population in a patient with pulmonary adenocarcinoma", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "11688826_3_5901", "context": "We report a patient with pulmonary adenocarcinoma complicated by the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) following systemic chemotherapy with cisplatin (CDDP) and vindesine (VDS).", "question": "Subject.Race in a patient with pulmonary adenocarcinoma", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "11688826_3_5902", "context": "We report a patient with pulmonary adenocarcinoma complicated by the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) following systemic chemotherapy with cisplatin (CDDP) and vindesine (VDS).", "question": "Subject.Disorder in a patient with pulmonary adenocarcinoma", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "11688826_3_5903", "context": "We report a patient with pulmonary adenocarcinoma complicated by the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) following systemic chemotherapy with cisplatin (CDDP) and vindesine (VDS).", "question": "Treatment.Drug in systemic chemotherapy with cisplatin (CDDP) and vindesine (VDS)", "question_type": "Adverse_event.Treatment.Drug", "answers": "cisplatin; vindesine"}, {"id": "11688826_3_5904", "context": "We report a patient with pulmonary adenocarcinoma complicated by the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) following systemic chemotherapy with cisplatin (CDDP) and vindesine (VDS).", "question": "Treatment.Dosage in systemic chemotherapy with cisplatin (CDDP) and vindesine (VDS)", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11688826_3_5905", "context": "We report a patient with pulmonary adenocarcinoma complicated by the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) following systemic chemotherapy with cisplatin (CDDP) and vindesine (VDS).", "question": "Treatment.Freq in systemic chemotherapy with cisplatin (CDDP) and vindesine (VDS)", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11688826_3_5906", "context": "We report a patient with pulmonary adenocarcinoma complicated by the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) following systemic chemotherapy with cisplatin (CDDP) and vindesine (VDS).", "question": "Treatment.Route in systemic chemotherapy with cisplatin (CDDP) and vindesine (VDS)", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11688826_3_5907", "context": "We report a patient with pulmonary adenocarcinoma complicated by the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) following systemic chemotherapy with cisplatin (CDDP) and vindesine (VDS).", "question": "Treatment.Time_elapsed in systemic chemotherapy with cisplatin (CDDP) and vindesine (VDS)", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11688826_3_5908", "context": "We report a patient with pulmonary adenocarcinoma complicated by the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) following systemic chemotherapy with cisplatin (CDDP) and vindesine (VDS).", "question": "Treatment.Duration in systemic chemotherapy with cisplatin (CDDP) and vindesine (VDS)", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11688826_3_5909", "context": "We report a patient with pulmonary adenocarcinoma complicated by the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) following systemic chemotherapy with cisplatin (CDDP) and vindesine (VDS).", "question": "Treatment.Disorder in systemic chemotherapy with cisplatin (CDDP) and vindesine (VDS)", "question_type": "Adverse_event.Treatment.Disorder", "answers": "pulmonary adenocarcinoma"}, {"id": "11688826_3_5910", "context": "We report a patient with pulmonary adenocarcinoma complicated by the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) following systemic chemotherapy with cisplatin (CDDP) and vindesine (VDS).", "question": "Combination.Drug in systemic chemotherapy with cisplatin (CDDP) and vindesine (VDS)", "question_type": "Adverse_event.Combination.Drug", "answers": "vindesine; cisplatin"}, {"id": "2196696_2_5911", "context": "Our patient had headache, mild fever, nausea, vomiting, rash, and eosinophilia after 3 weeks of disulfiram therapy.", "question": "Treatment.Drug in after 3 weeks of disulfiram", "question_type": "Adverse_event.Treatment.Drug", "answers": "disulfiram"}, {"id": "2196696_2_5912", "context": "Our patient had headache, mild fever, nausea, vomiting, rash, and eosinophilia after 3 weeks of disulfiram therapy.", "question": "Treatment.Dosage in after 3 weeks of disulfiram", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "2196696_2_5913", "context": "Our patient had headache, mild fever, nausea, vomiting, rash, and eosinophilia after 3 weeks of disulfiram therapy.", "question": "Treatment.Freq in after 3 weeks of disulfiram", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2196696_2_5914", "context": "Our patient had headache, mild fever, nausea, vomiting, rash, and eosinophilia after 3 weeks of disulfiram therapy.", "question": "Treatment.Route in after 3 weeks of disulfiram", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "2196696_2_5915", "context": "Our patient had headache, mild fever, nausea, vomiting, rash, and eosinophilia after 3 weeks of disulfiram therapy.", "question": "Treatment.Time_elapsed in after 3 weeks of disulfiram", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "after 3 weeks"}, {"id": "2196696_2_5916", "context": "Our patient had headache, mild fever, nausea, vomiting, rash, and eosinophilia after 3 weeks of disulfiram therapy.", "question": "Treatment.Duration in after 3 weeks of disulfiram", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2196696_2_5917", "context": "Our patient had headache, mild fever, nausea, vomiting, rash, and eosinophilia after 3 weeks of disulfiram therapy.", "question": "Treatment.Disorder in after 3 weeks of disulfiram", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "2196696_2_5918", "context": "Our patient had headache, mild fever, nausea, vomiting, rash, and eosinophilia after 3 weeks of disulfiram therapy.", "question": "Combination.Drug in after 3 weeks of disulfiram", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17316160_1_5919", "context": "Decreased serum linezolid levels in a critically ill patient receiving concomitant linezolid and rifampin.", "question": "Subject.Age in a critically ill patient", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "17316160_1_5920", "context": "Decreased serum linezolid levels in a critically ill patient receiving concomitant linezolid and rifampin.", "question": "Subject.Gender in a critically ill patient", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "17316160_1_5921", "context": "Decreased serum linezolid levels in a critically ill patient receiving concomitant linezolid and rifampin.", "question": "Subject.Population in a critically ill patient", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "17316160_1_5922", "context": "Decreased serum linezolid levels in a critically ill patient receiving concomitant linezolid and rifampin.", "question": "Subject.Race in a critically ill patient", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "17316160_1_5923", "context": "Decreased serum linezolid levels in a critically ill patient receiving concomitant linezolid and rifampin.", "question": "Subject.Disorder in a critically ill patient", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": "critically ill"}, {"id": "17316160_1_5924", "context": "Decreased serum linezolid levels in a critically ill patient receiving concomitant linezolid and rifampin.", "question": "Treatment.Drug in concomitant linezolid and rifampin", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "linezolid; rifampin"}, {"id": "17316160_1_5925", "context": "Decreased serum linezolid levels in a critically ill patient receiving concomitant linezolid and rifampin.", "question": "Treatment.Dosage in concomitant linezolid and rifampin", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "17316160_1_5926", "context": "Decreased serum linezolid levels in a critically ill patient receiving concomitant linezolid and rifampin.", "question": "Treatment.Freq in concomitant linezolid and rifampin", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "17316160_1_5927", "context": "Decreased serum linezolid levels in a critically ill patient receiving concomitant linezolid and rifampin.", "question": "Treatment.Route in concomitant linezolid and rifampin", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "17316160_1_5928", "context": "Decreased serum linezolid levels in a critically ill patient receiving concomitant linezolid and rifampin.", "question": "Treatment.Time_elapsed in concomitant linezolid and rifampin", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17316160_1_5929", "context": "Decreased serum linezolid levels in a critically ill patient receiving concomitant linezolid and rifampin.", "question": "Treatment.Duration in concomitant linezolid and rifampin", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "17316160_1_5930", "context": "Decreased serum linezolid levels in a critically ill patient receiving concomitant linezolid and rifampin.", "question": "Treatment.Disorder in concomitant linezolid and rifampin", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "17316160_1_5931", "context": "Decreased serum linezolid levels in a critically ill patient receiving concomitant linezolid and rifampin.", "question": "Combination.Drug in concomitant linezolid and rifampin", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": "linezolid; rifampin"}, {"id": "8329789_2_5932", "context": "OBJECTIVE: To report the first five cases of amphotericin B overdose with secondary cardiac complications in a pediatric population.", "question": "Subject.Age in first five cases of; a pediatric population", "question_type": "Adverse_event.Subject.Age", "answers": "pediatric"}, {"id": "8329789_2_5933", "context": "OBJECTIVE: To report the first five cases of amphotericin B overdose with secondary cardiac complications in a pediatric population.", "question": "Subject.Gender in first five cases of; a pediatric population", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "8329789_2_5934", "context": "OBJECTIVE: To report the first five cases of amphotericin B overdose with secondary cardiac complications in a pediatric population.", "question": "Subject.Population in first five cases of; a pediatric population", "question_type": "Adverse_event.Subject.Population", "answers": "five"}, {"id": "8329789_2_5935", "context": "OBJECTIVE: To report the first five cases of amphotericin B overdose with secondary cardiac complications in a pediatric population.", "question": "Subject.Race in first five cases of; a pediatric population", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "8329789_2_5936", "context": "OBJECTIVE: To report the first five cases of amphotericin B overdose with secondary cardiac complications in a pediatric population.", "question": "Subject.Disorder in first five cases of; a pediatric population", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "8329789_2_5937", "context": "OBJECTIVE: To report the first five cases of amphotericin B overdose with secondary cardiac complications in a pediatric population.", "question": "Treatment.Drug in amphotericin B overdose", "question_type": "Adverse_event.Treatment.Drug", "answers": "amphotericin B"}, {"id": "8329789_2_5938", "context": "OBJECTIVE: To report the first five cases of amphotericin B overdose with secondary cardiac complications in a pediatric population.", "question": "Treatment.Dosage in amphotericin B overdose", "question_type": "Adverse_event.Treatment.Dosage", "answers": "overdose"}, {"id": "8329789_2_5939", "context": "OBJECTIVE: To report the first five cases of amphotericin B overdose with secondary cardiac complications in a pediatric population.", "question": "Treatment.Freq in amphotericin B overdose", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8329789_2_5940", "context": "OBJECTIVE: To report the first five cases of amphotericin B overdose with secondary cardiac complications in a pediatric population.", "question": "Treatment.Route in amphotericin B overdose", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8329789_2_5941", "context": "OBJECTIVE: To report the first five cases of amphotericin B overdose with secondary cardiac complications in a pediatric population.", "question": "Treatment.Time_elapsed in amphotericin B overdose", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8329789_2_5942", "context": "OBJECTIVE: To report the first five cases of amphotericin B overdose with secondary cardiac complications in a pediatric population.", "question": "Treatment.Duration in amphotericin B overdose", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8329789_2_5943", "context": "OBJECTIVE: To report the first five cases of amphotericin B overdose with secondary cardiac complications in a pediatric population.", "question": "Treatment.Disorder in amphotericin B overdose", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8329789_2_5944", "context": "OBJECTIVE: To report the first five cases of amphotericin B overdose with secondary cardiac complications in a pediatric population.", "question": "Combination.Drug in amphotericin B overdose", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11573852_3_5945", "context": "CONCLUSIONS: Amphotericin B seems to be the probable cause of the seizures.", "question": "Treatment.Drug in Amphotericin B", "question_type": "Adverse_event.Treatment.Drug", "answers": "Amphotericin B"}, {"id": "11573852_3_5946", "context": "CONCLUSIONS: Amphotericin B seems to be the probable cause of the seizures.", "question": "Treatment.Dosage in Amphotericin B", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11573852_3_5947", "context": "CONCLUSIONS: Amphotericin B seems to be the probable cause of the seizures.", "question": "Treatment.Freq in Amphotericin B", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11573852_3_5948", "context": "CONCLUSIONS: Amphotericin B seems to be the probable cause of the seizures.", "question": "Treatment.Route in Amphotericin B", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11573852_3_5949", "context": "CONCLUSIONS: Amphotericin B seems to be the probable cause of the seizures.", "question": "Treatment.Time_elapsed in Amphotericin B", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11573852_3_5950", "context": "CONCLUSIONS: Amphotericin B seems to be the probable cause of the seizures.", "question": "Treatment.Duration in Amphotericin B", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11573852_3_5951", "context": "CONCLUSIONS: Amphotericin B seems to be the probable cause of the seizures.", "question": "Treatment.Disorder in Amphotericin B", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11573852_3_5952", "context": "CONCLUSIONS: Amphotericin B seems to be the probable cause of the seizures.", "question": "Combination.Drug in Amphotericin B", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12707728_2_5953", "context": "We describe a patient who developed acute cerebellar syndrome after prophylactic intrathecal methotrexate administration and recovered spontaneously.", "question": "Subject.Age in a patient", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "12707728_2_5954", "context": "We describe a patient who developed acute cerebellar syndrome after prophylactic intrathecal methotrexate administration and recovered spontaneously.", "question": "Subject.Gender in a patient", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "12707728_2_5955", "context": "We describe a patient who developed acute cerebellar syndrome after prophylactic intrathecal methotrexate administration and recovered spontaneously.", "question": "Subject.Population in a patient", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "12707728_2_5956", "context": "We describe a patient who developed acute cerebellar syndrome after prophylactic intrathecal methotrexate administration and recovered spontaneously.", "question": "Subject.Race in a patient", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "12707728_2_5957", "context": "We describe a patient who developed acute cerebellar syndrome after prophylactic intrathecal methotrexate administration and recovered spontaneously.", "question": "Subject.Disorder in a patient", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "12707728_2_5958", "context": "We describe a patient who developed acute cerebellar syndrome after prophylactic intrathecal methotrexate administration and recovered spontaneously.", "question": "Treatment.Drug in prophylactic intrathecal methotrexate administration", "question_type": "Adverse_event.Treatment.Drug", "answers": "methotrexate"}, {"id": "12707728_2_5959", "context": "We describe a patient who developed acute cerebellar syndrome after prophylactic intrathecal methotrexate administration and recovered spontaneously.", "question": "Treatment.Dosage in prophylactic intrathecal methotrexate administration", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12707728_2_5960", "context": "We describe a patient who developed acute cerebellar syndrome after prophylactic intrathecal methotrexate administration and recovered spontaneously.", "question": "Treatment.Freq in prophylactic intrathecal methotrexate administration", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12707728_2_5961", "context": "We describe a patient who developed acute cerebellar syndrome after prophylactic intrathecal methotrexate administration and recovered spontaneously.", "question": "Treatment.Route in prophylactic intrathecal methotrexate administration", "question_type": "Adverse_event.Treatment.Route", "answers": "intrathecal"}, {"id": "12707728_2_5962", "context": "We describe a patient who developed acute cerebellar syndrome after prophylactic intrathecal methotrexate administration and recovered spontaneously.", "question": "Treatment.Time_elapsed in prophylactic intrathecal methotrexate administration", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12707728_2_5963", "context": "We describe a patient who developed acute cerebellar syndrome after prophylactic intrathecal methotrexate administration and recovered spontaneously.", "question": "Treatment.Duration in prophylactic intrathecal methotrexate administration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12707728_2_5964", "context": "We describe a patient who developed acute cerebellar syndrome after prophylactic intrathecal methotrexate administration and recovered spontaneously.", "question": "Treatment.Disorder in prophylactic intrathecal methotrexate administration", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12707728_2_5965", "context": "We describe a patient who developed acute cerebellar syndrome after prophylactic intrathecal methotrexate administration and recovered spontaneously.", "question": "Combination.Drug in prophylactic intrathecal methotrexate administration", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11388112_1_5966", "context": "Levofloxacin induced polymorphic ventricular tachycardia with normal QT interval.", "question": "Treatment.Drug in Levofloxacin", "question_type": "Adverse_event.Treatment.Drug", "answers": "Levofloxacin"}, {"id": "11388112_1_5967", "context": "Levofloxacin induced polymorphic ventricular tachycardia with normal QT interval.", "question": "Treatment.Dosage in Levofloxacin", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11388112_1_5968", "context": "Levofloxacin induced polymorphic ventricular tachycardia with normal QT interval.", "question": "Treatment.Freq in Levofloxacin", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11388112_1_5969", "context": "Levofloxacin induced polymorphic ventricular tachycardia with normal QT interval.", "question": "Treatment.Route in Levofloxacin", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11388112_1_5970", "context": "Levofloxacin induced polymorphic ventricular tachycardia with normal QT interval.", "question": "Treatment.Time_elapsed in Levofloxacin", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11388112_1_5971", "context": "Levofloxacin induced polymorphic ventricular tachycardia with normal QT interval.", "question": "Treatment.Duration in Levofloxacin", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11388112_1_5972", "context": "Levofloxacin induced polymorphic ventricular tachycardia with normal QT interval.", "question": "Treatment.Disorder in Levofloxacin", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11388112_1_5973", "context": "Levofloxacin induced polymorphic ventricular tachycardia with normal QT interval.", "question": "Combination.Drug in Levofloxacin", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "25540831_7_5974", "context": "Most physicians are aware of serotonin syndrome secondary to antidepressants but do not think about other classes of medications such as analgesics.", "question": "Treatment.Drug in antidepressants", "question_type": "Adverse_event.Treatment.Drug", "answers": "antidepressants; analgesics"}, {"id": "25540831_7_5975", "context": "Most physicians are aware of serotonin syndrome secondary to antidepressants but do not think about other classes of medications such as analgesics.", "question": "Treatment.Dosage in antidepressants", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "25540831_7_5976", "context": "Most physicians are aware of serotonin syndrome secondary to antidepressants but do not think about other classes of medications such as analgesics.", "question": "Treatment.Freq in antidepressants", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "25540831_7_5977", "context": "Most physicians are aware of serotonin syndrome secondary to antidepressants but do not think about other classes of medications such as analgesics.", "question": "Treatment.Route in antidepressants", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "25540831_7_5978", "context": "Most physicians are aware of serotonin syndrome secondary to antidepressants but do not think about other classes of medications such as analgesics.", "question": "Treatment.Time_elapsed in antidepressants", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "25540831_7_5979", "context": "Most physicians are aware of serotonin syndrome secondary to antidepressants but do not think about other classes of medications such as analgesics.", "question": "Treatment.Duration in antidepressants", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "25540831_7_5980", "context": "Most physicians are aware of serotonin syndrome secondary to antidepressants but do not think about other classes of medications such as analgesics.", "question": "Treatment.Disorder in antidepressants", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "25540831_7_5981", "context": "Most physicians are aware of serotonin syndrome secondary to antidepressants but do not think about other classes of medications such as analgesics.", "question": "Combination.Drug in antidepressants", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "19071894_7_5982", "context": "Renal toxicity signs, induced by amphotericin B, progression of infection after fluconazole, and likely in vivo resistance to this triazole made this case difficult to treat.", "question": "Treatment.Drug in amphotericin B", "question_type": "Adverse_event.Treatment.Drug", "answers": "amphotericin B"}, {"id": "19071894_7_5983", "context": "Renal toxicity signs, induced by amphotericin B, progression of infection after fluconazole, and likely in vivo resistance to this triazole made this case difficult to treat.", "question": "Treatment.Dosage in amphotericin B", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "19071894_7_5984", "context": "Renal toxicity signs, induced by amphotericin B, progression of infection after fluconazole, and likely in vivo resistance to this triazole made this case difficult to treat.", "question": "Treatment.Freq in amphotericin B", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "19071894_7_5985", "context": "Renal toxicity signs, induced by amphotericin B, progression of infection after fluconazole, and likely in vivo resistance to this triazole made this case difficult to treat.", "question": "Treatment.Route in amphotericin B", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "19071894_7_5986", "context": "Renal toxicity signs, induced by amphotericin B, progression of infection after fluconazole, and likely in vivo resistance to this triazole made this case difficult to treat.", "question": "Treatment.Time_elapsed in amphotericin B", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19071894_7_5987", "context": "Renal toxicity signs, induced by amphotericin B, progression of infection after fluconazole, and likely in vivo resistance to this triazole made this case difficult to treat.", "question": "Treatment.Duration in amphotericin B", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "19071894_7_5988", "context": "Renal toxicity signs, induced by amphotericin B, progression of infection after fluconazole, and likely in vivo resistance to this triazole made this case difficult to treat.", "question": "Treatment.Disorder in amphotericin B", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "19071894_7_5989", "context": "Renal toxicity signs, induced by amphotericin B, progression of infection after fluconazole, and likely in vivo resistance to this triazole made this case difficult to treat.", "question": "Combination.Drug in amphotericin B", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "19071894_7_5990", "context": "Renal toxicity signs, induced by amphotericin B, progression of infection after fluconazole, and likely in vivo resistance to this triazole made this case difficult to treat.", "question": "Treatment.Drug in fluconazole", "question_type": "Adverse_event.Treatment.Drug", "answers": "fluconazole"}, {"id": "19071894_7_5991", "context": "Renal toxicity signs, induced by amphotericin B, progression of infection after fluconazole, and likely in vivo resistance to this triazole made this case difficult to treat.", "question": "Treatment.Dosage in fluconazole", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "19071894_7_5992", "context": "Renal toxicity signs, induced by amphotericin B, progression of infection after fluconazole, and likely in vivo resistance to this triazole made this case difficult to treat.", "question": "Treatment.Freq in fluconazole", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "19071894_7_5993", "context": "Renal toxicity signs, induced by amphotericin B, progression of infection after fluconazole, and likely in vivo resistance to this triazole made this case difficult to treat.", "question": "Treatment.Route in fluconazole", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "19071894_7_5994", "context": "Renal toxicity signs, induced by amphotericin B, progression of infection after fluconazole, and likely in vivo resistance to this triazole made this case difficult to treat.", "question": "Treatment.Time_elapsed in fluconazole", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19071894_7_5995", "context": "Renal toxicity signs, induced by amphotericin B, progression of infection after fluconazole, and likely in vivo resistance to this triazole made this case difficult to treat.", "question": "Treatment.Duration in fluconazole", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "19071894_7_5996", "context": "Renal toxicity signs, induced by amphotericin B, progression of infection after fluconazole, and likely in vivo resistance to this triazole made this case difficult to treat.", "question": "Treatment.Disorder in fluconazole", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "19071894_7_5997", "context": "Renal toxicity signs, induced by amphotericin B, progression of infection after fluconazole, and likely in vivo resistance to this triazole made this case difficult to treat.", "question": "Combination.Drug in fluconazole", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11319599_2_5998", "context": "We describe two patients with aspergillus arthritis of the knee joint following fludarabine-based non-myeloablative stem cell transplantation.", "question": "Subject.Age in two patients", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "11319599_2_5999", "context": "We describe two patients with aspergillus arthritis of the knee joint following fludarabine-based non-myeloablative stem cell transplantation.", "question": "Subject.Gender in two patients", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "11319599_2_6000", "context": "We describe two patients with aspergillus arthritis of the knee joint following fludarabine-based non-myeloablative stem cell transplantation.", "question": "Subject.Population in two patients", "question_type": "Adverse_event.Subject.Population", "answers": "two"}, {"id": "11319599_2_6001", "context": "We describe two patients with aspergillus arthritis of the knee joint following fludarabine-based non-myeloablative stem cell transplantation.", "question": "Subject.Race in two patients", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "11319599_2_6002", "context": "We describe two patients with aspergillus arthritis of the knee joint following fludarabine-based non-myeloablative stem cell transplantation.", "question": "Subject.Disorder in two patients", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "11319599_2_6003", "context": "We describe two patients with aspergillus arthritis of the knee joint following fludarabine-based non-myeloablative stem cell transplantation.", "question": "Treatment.Drug in fludarabine-based non-myeloablative stem cell transplantation", "question_type": "Adverse_event.Treatment.Drug", "answers": "fludarabine"}, {"id": "11319599_2_6004", "context": "We describe two patients with aspergillus arthritis of the knee joint following fludarabine-based non-myeloablative stem cell transplantation.", "question": "Treatment.Dosage in fludarabine-based non-myeloablative stem cell transplantation", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11319599_2_6005", "context": "We describe two patients with aspergillus arthritis of the knee joint following fludarabine-based non-myeloablative stem cell transplantation.", "question": "Treatment.Freq in fludarabine-based non-myeloablative stem cell transplantation", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11319599_2_6006", "context": "We describe two patients with aspergillus arthritis of the knee joint following fludarabine-based non-myeloablative stem cell transplantation.", "question": "Treatment.Route in fludarabine-based non-myeloablative stem cell transplantation", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11319599_2_6007", "context": "We describe two patients with aspergillus arthritis of the knee joint following fludarabine-based non-myeloablative stem cell transplantation.", "question": "Treatment.Time_elapsed in fludarabine-based non-myeloablative stem cell transplantation", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11319599_2_6008", "context": "We describe two patients with aspergillus arthritis of the knee joint following fludarabine-based non-myeloablative stem cell transplantation.", "question": "Treatment.Duration in fludarabine-based non-myeloablative stem cell transplantation", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11319599_2_6009", "context": "We describe two patients with aspergillus arthritis of the knee joint following fludarabine-based non-myeloablative stem cell transplantation.", "question": "Treatment.Disorder in fludarabine-based non-myeloablative stem cell transplantation", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11319599_2_6010", "context": "We describe two patients with aspergillus arthritis of the knee joint following fludarabine-based non-myeloablative stem cell transplantation.", "question": "Combination.Drug in fludarabine-based non-myeloablative stem cell transplantation", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8162401_1_6011", "context": "A case of fluoxetine induced seizures, in a person with Down syndrome, is described.", "question": "Subject.Age in a person with Down syndrome", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "8162401_1_6012", "context": "A case of fluoxetine induced seizures, in a person with Down syndrome, is described.", "question": "Subject.Gender in a person with Down syndrome", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "8162401_1_6013", "context": "A case of fluoxetine induced seizures, in a person with Down syndrome, is described.", "question": "Subject.Population in a person with Down syndrome", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "8162401_1_6014", "context": "A case of fluoxetine induced seizures, in a person with Down syndrome, is described.", "question": "Subject.Race in a person with Down syndrome", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "8162401_1_6015", "context": "A case of fluoxetine induced seizures, in a person with Down syndrome, is described.", "question": "Subject.Disorder in a person with Down syndrome", "question_type": "Adverse_event.Subject.Disorder", "answers": "Down syndrome"}, {"id": "8162401_1_6016", "context": "A case of fluoxetine induced seizures, in a person with Down syndrome, is described.", "question": "Treatment.Drug in fluoxetine", "question_type": "Adverse_event.Treatment.Drug", "answers": "fluoxetine"}, {"id": "8162401_1_6017", "context": "A case of fluoxetine induced seizures, in a person with Down syndrome, is described.", "question": "Treatment.Dosage in fluoxetine", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8162401_1_6018", "context": "A case of fluoxetine induced seizures, in a person with Down syndrome, is described.", "question": "Treatment.Freq in fluoxetine", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8162401_1_6019", "context": "A case of fluoxetine induced seizures, in a person with Down syndrome, is described.", "question": "Treatment.Route in fluoxetine", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8162401_1_6020", "context": "A case of fluoxetine induced seizures, in a person with Down syndrome, is described.", "question": "Treatment.Time_elapsed in fluoxetine", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8162401_1_6021", "context": "A case of fluoxetine induced seizures, in a person with Down syndrome, is described.", "question": "Treatment.Duration in fluoxetine", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8162401_1_6022", "context": "A case of fluoxetine induced seizures, in a person with Down syndrome, is described.", "question": "Treatment.Disorder in fluoxetine", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8162401_1_6023", "context": "A case of fluoxetine induced seizures, in a person with Down syndrome, is described.", "question": "Combination.Drug in fluoxetine", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10405480_3_6024", "context": "We report a case of acute generalized exanthematous pustulosis (AGEP) induced by salazosulfapyridine in a patient with ulcerative colitis.", "question": "Subject.Age in a patient with ulcerative colitis", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "10405480_3_6025", "context": "We report a case of acute generalized exanthematous pustulosis (AGEP) induced by salazosulfapyridine in a patient with ulcerative colitis.", "question": "Subject.Gender in a patient with ulcerative colitis", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "10405480_3_6026", "context": "We report a case of acute generalized exanthematous pustulosis (AGEP) induced by salazosulfapyridine in a patient with ulcerative colitis.", "question": "Subject.Population in a patient with ulcerative colitis", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "10405480_3_6027", "context": "We report a case of acute generalized exanthematous pustulosis (AGEP) induced by salazosulfapyridine in a patient with ulcerative colitis.", "question": "Subject.Race in a patient with ulcerative colitis", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "10405480_3_6028", "context": "We report a case of acute generalized exanthematous pustulosis (AGEP) induced by salazosulfapyridine in a patient with ulcerative colitis.", "question": "Subject.Disorder in a patient with ulcerative colitis", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "10405480_3_6029", "context": "We report a case of acute generalized exanthematous pustulosis (AGEP) induced by salazosulfapyridine in a patient with ulcerative colitis.", "question": "Treatment.Drug in salazosulfapyridine", "question_type": "Adverse_event.Treatment.Drug", "answers": "salazosulfapyridine"}, {"id": "10405480_3_6030", "context": "We report a case of acute generalized exanthematous pustulosis (AGEP) induced by salazosulfapyridine in a patient with ulcerative colitis.", "question": "Treatment.Dosage in salazosulfapyridine", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10405480_3_6031", "context": "We report a case of acute generalized exanthematous pustulosis (AGEP) induced by salazosulfapyridine in a patient with ulcerative colitis.", "question": "Treatment.Freq in salazosulfapyridine", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10405480_3_6032", "context": "We report a case of acute generalized exanthematous pustulosis (AGEP) induced by salazosulfapyridine in a patient with ulcerative colitis.", "question": "Treatment.Route in salazosulfapyridine", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10405480_3_6033", "context": "We report a case of acute generalized exanthematous pustulosis (AGEP) induced by salazosulfapyridine in a patient with ulcerative colitis.", "question": "Treatment.Time_elapsed in salazosulfapyridine", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10405480_3_6034", "context": "We report a case of acute generalized exanthematous pustulosis (AGEP) induced by salazosulfapyridine in a patient with ulcerative colitis.", "question": "Treatment.Duration in salazosulfapyridine", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10405480_3_6035", "context": "We report a case of acute generalized exanthematous pustulosis (AGEP) induced by salazosulfapyridine in a patient with ulcerative colitis.", "question": "Treatment.Disorder in salazosulfapyridine", "question_type": "Adverse_event.Treatment.Disorder", "answers": "ulcerative colitis"}, {"id": "10405480_3_6036", "context": "We report a case of acute generalized exanthematous pustulosis (AGEP) induced by salazosulfapyridine in a patient with ulcerative colitis.", "question": "Combination.Drug in salazosulfapyridine", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10414481_1_6037", "context": "Diclofenac-associated hepatitis.", "question": "Treatment.Drug in Diclofenac", "question_type": "Adverse_event.Treatment.Drug", "answers": "Diclofenac"}, {"id": "10414481_1_6038", "context": "Diclofenac-associated hepatitis.", "question": "Treatment.Dosage in Diclofenac", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10414481_1_6039", "context": "Diclofenac-associated hepatitis.", "question": "Treatment.Freq in Diclofenac", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10414481_1_6040", "context": "Diclofenac-associated hepatitis.", "question": "Treatment.Route in Diclofenac", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10414481_1_6041", "context": "Diclofenac-associated hepatitis.", "question": "Treatment.Time_elapsed in Diclofenac", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10414481_1_6042", "context": "Diclofenac-associated hepatitis.", "question": "Treatment.Duration in Diclofenac", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10414481_1_6043", "context": "Diclofenac-associated hepatitis.", "question": "Treatment.Disorder in Diclofenac", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10414481_1_6044", "context": "Diclofenac-associated hepatitis.", "question": "Combination.Drug in Diclofenac", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12729371_1_6045", "context": "Angioimmunoblastic lymphadenopathy with dysproteinemia following doxycycline administration.", "question": "Treatment.Drug in doxycycline administration", "question_type": "Adverse_event.Treatment.Drug", "answers": "doxycycline"}, {"id": "12729371_1_6046", "context": "Angioimmunoblastic lymphadenopathy with dysproteinemia following doxycycline administration.", "question": "Treatment.Dosage in doxycycline administration", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12729371_1_6047", "context": "Angioimmunoblastic lymphadenopathy with dysproteinemia following doxycycline administration.", "question": "Treatment.Freq in doxycycline administration", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12729371_1_6048", "context": "Angioimmunoblastic lymphadenopathy with dysproteinemia following doxycycline administration.", "question": "Treatment.Route in doxycycline administration", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12729371_1_6049", "context": "Angioimmunoblastic lymphadenopathy with dysproteinemia following doxycycline administration.", "question": "Treatment.Time_elapsed in doxycycline administration", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12729371_1_6050", "context": "Angioimmunoblastic lymphadenopathy with dysproteinemia following doxycycline administration.", "question": "Treatment.Duration in doxycycline administration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12729371_1_6051", "context": "Angioimmunoblastic lymphadenopathy with dysproteinemia following doxycycline administration.", "question": "Treatment.Disorder in doxycycline administration", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12729371_1_6052", "context": "Angioimmunoblastic lymphadenopathy with dysproteinemia following doxycycline administration.", "question": "Combination.Drug in doxycycline administration", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12540009_1_6053", "context": "Doxycycline-induced hypoglycemia in a nondiabetic young man.", "question": "Subject.Age in a nondiabetic young man", "question_type": "Adverse_event.Subject.Age", "answers": "young"}, {"id": "12540009_1_6054", "context": "Doxycycline-induced hypoglycemia in a nondiabetic young man.", "question": "Subject.Gender in a nondiabetic young man", "question_type": "Adverse_event.Subject.Gender", "answers": "man"}, {"id": "12540009_1_6055", "context": "Doxycycline-induced hypoglycemia in a nondiabetic young man.", "question": "Subject.Population in a nondiabetic young man", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "12540009_1_6056", "context": "Doxycycline-induced hypoglycemia in a nondiabetic young man.", "question": "Subject.Race in a nondiabetic young man", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "12540009_1_6057", "context": "Doxycycline-induced hypoglycemia in a nondiabetic young man.", "question": "Subject.Disorder in a nondiabetic young man", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "12540009_1_6058", "context": "Doxycycline-induced hypoglycemia in a nondiabetic young man.", "question": "Treatment.Drug in Doxycycline", "question_type": "Adverse_event.Treatment.Drug", "answers": "Doxycycline"}, {"id": "12540009_1_6059", "context": "Doxycycline-induced hypoglycemia in a nondiabetic young man.", "question": "Treatment.Dosage in Doxycycline", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12540009_1_6060", "context": "Doxycycline-induced hypoglycemia in a nondiabetic young man.", "question": "Treatment.Freq in Doxycycline", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12540009_1_6061", "context": "Doxycycline-induced hypoglycemia in a nondiabetic young man.", "question": "Treatment.Route in Doxycycline", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12540009_1_6062", "context": "Doxycycline-induced hypoglycemia in a nondiabetic young man.", "question": "Treatment.Time_elapsed in Doxycycline", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12540009_1_6063", "context": "Doxycycline-induced hypoglycemia in a nondiabetic young man.", "question": "Treatment.Duration in Doxycycline", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12540009_1_6064", "context": "Doxycycline-induced hypoglycemia in a nondiabetic young man.", "question": "Treatment.Disorder in Doxycycline", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12540009_1_6065", "context": "Doxycycline-induced hypoglycemia in a nondiabetic young man.", "question": "Combination.Drug in Doxycycline", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "968449_7_6066", "context": "Case 2 demonstrated after 40 months on chlorambucil the presence of a balanced translocation, t (1;5) (p36;q31) in 90% of the cells.", "question": "Subject.Age in Case 2", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "968449_7_6067", "context": "Case 2 demonstrated after 40 months on chlorambucil the presence of a balanced translocation, t (1;5) (p36;q31) in 90% of the cells.", "question": "Subject.Gender in Case 2", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "968449_7_6068", "context": "Case 2 demonstrated after 40 months on chlorambucil the presence of a balanced translocation, t (1;5) (p36;q31) in 90% of the cells.", "question": "Subject.Population in Case 2", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "968449_7_6069", "context": "Case 2 demonstrated after 40 months on chlorambucil the presence of a balanced translocation, t (1;5) (p36;q31) in 90% of the cells.", "question": "Subject.Race in Case 2", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "968449_7_6070", "context": "Case 2 demonstrated after 40 months on chlorambucil the presence of a balanced translocation, t (1;5) (p36;q31) in 90% of the cells.", "question": "Subject.Disorder in Case 2", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "968449_7_6071", "context": "Case 2 demonstrated after 40 months on chlorambucil the presence of a balanced translocation, t (1;5) (p36;q31) in 90% of the cells.", "question": "Treatment.Drug in 40 months on chlorambucil", "question_type": "Adverse_event.Treatment.Drug", "answers": "chlorambucil"}, {"id": "968449_7_6072", "context": "Case 2 demonstrated after 40 months on chlorambucil the presence of a balanced translocation, t (1;5) (p36;q31) in 90% of the cells.", "question": "Treatment.Dosage in 40 months on chlorambucil", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "968449_7_6073", "context": "Case 2 demonstrated after 40 months on chlorambucil the presence of a balanced translocation, t (1;5) (p36;q31) in 90% of the cells.", "question": "Treatment.Freq in 40 months on chlorambucil", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "968449_7_6074", "context": "Case 2 demonstrated after 40 months on chlorambucil the presence of a balanced translocation, t (1;5) (p36;q31) in 90% of the cells.", "question": "Treatment.Route in 40 months on chlorambucil", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "968449_7_6075", "context": "Case 2 demonstrated after 40 months on chlorambucil the presence of a balanced translocation, t (1;5) (p36;q31) in 90% of the cells.", "question": "Treatment.Time_elapsed in 40 months on chlorambucil", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "40 months"}, {"id": "968449_7_6076", "context": "Case 2 demonstrated after 40 months on chlorambucil the presence of a balanced translocation, t (1;5) (p36;q31) in 90% of the cells.", "question": "Treatment.Duration in 40 months on chlorambucil", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "968449_7_6077", "context": "Case 2 demonstrated after 40 months on chlorambucil the presence of a balanced translocation, t (1;5) (p36;q31) in 90% of the cells.", "question": "Treatment.Disorder in 40 months on chlorambucil", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "968449_7_6078", "context": "Case 2 demonstrated after 40 months on chlorambucil the presence of a balanced translocation, t (1;5) (p36;q31) in 90% of the cells.", "question": "Combination.Drug in 40 months on chlorambucil", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9792602_3_6079", "context": "Within 6 months of pranlukast withdrawal, anemia resolved and urinary sediment and renal function normalized.", "question": "Treatment.Drug in pranlukast", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "pranlukast"}, {"id": "9792602_3_6080", "context": "Within 6 months of pranlukast withdrawal, anemia resolved and urinary sediment and renal function normalized.", "question": "Treatment.Dosage in pranlukast", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "9792602_3_6081", "context": "Within 6 months of pranlukast withdrawal, anemia resolved and urinary sediment and renal function normalized.", "question": "Treatment.Freq in pranlukast", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "9792602_3_6082", "context": "Within 6 months of pranlukast withdrawal, anemia resolved and urinary sediment and renal function normalized.", "question": "Treatment.Route in pranlukast", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "9792602_3_6083", "context": "Within 6 months of pranlukast withdrawal, anemia resolved and urinary sediment and renal function normalized.", "question": "Treatment.Time_elapsed in pranlukast", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": "6 months"}, {"id": "9792602_3_6084", "context": "Within 6 months of pranlukast withdrawal, anemia resolved and urinary sediment and renal function normalized.", "question": "Treatment.Duration in pranlukast", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "9792602_3_6085", "context": "Within 6 months of pranlukast withdrawal, anemia resolved and urinary sediment and renal function normalized.", "question": "Treatment.Disorder in pranlukast", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "anemia; urinary sediment; renal function"}, {"id": "9792602_3_6086", "context": "Within 6 months of pranlukast withdrawal, anemia resolved and urinary sediment and renal function normalized.", "question": "Combination.Drug in pranlukast", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "16221163_1_6087", "context": "Sirolimus-associated hepatotoxicity in the kidney graft recipient.", "question": "Subject.Age in kidney graft recipient.", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "16221163_1_6088", "context": "Sirolimus-associated hepatotoxicity in the kidney graft recipient.", "question": "Subject.Gender in kidney graft recipient.", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "16221163_1_6089", "context": "Sirolimus-associated hepatotoxicity in the kidney graft recipient.", "question": "Subject.Population in kidney graft recipient.", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "16221163_1_6090", "context": "Sirolimus-associated hepatotoxicity in the kidney graft recipient.", "question": "Subject.Race in kidney graft recipient.", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16221163_1_6091", "context": "Sirolimus-associated hepatotoxicity in the kidney graft recipient.", "question": "Subject.Disorder in kidney graft recipient.", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "16221163_1_6092", "context": "Sirolimus-associated hepatotoxicity in the kidney graft recipient.", "question": "Treatment.Drug in Sirolimus", "question_type": "Adverse_event.Treatment.Drug", "answers": "Sirolimus"}, {"id": "16221163_1_6093", "context": "Sirolimus-associated hepatotoxicity in the kidney graft recipient.", "question": "Treatment.Dosage in Sirolimus", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16221163_1_6094", "context": "Sirolimus-associated hepatotoxicity in the kidney graft recipient.", "question": "Treatment.Freq in Sirolimus", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16221163_1_6095", "context": "Sirolimus-associated hepatotoxicity in the kidney graft recipient.", "question": "Treatment.Route in Sirolimus", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16221163_1_6096", "context": "Sirolimus-associated hepatotoxicity in the kidney graft recipient.", "question": "Treatment.Time_elapsed in Sirolimus", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16221163_1_6097", "context": "Sirolimus-associated hepatotoxicity in the kidney graft recipient.", "question": "Treatment.Duration in Sirolimus", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16221163_1_6098", "context": "Sirolimus-associated hepatotoxicity in the kidney graft recipient.", "question": "Treatment.Disorder in Sirolimus", "question_type": "Adverse_event.Treatment.Disorder", "answers": "kidney graft recipient"}, {"id": "16221163_1_6099", "context": "Sirolimus-associated hepatotoxicity in the kidney graft recipient.", "question": "Combination.Drug in Sirolimus", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12181031_1_6100", "context": "Although vasculitis has been reported in the course of hairy cell leukaemia, it has only rarely been reported as the consequence of cladribine treatment.", "question": "Treatment.Drug in cladribine", "question_type": "Adverse_event.Treatment.Drug", "answers": "cladribine"}, {"id": "12181031_1_6101", "context": "Although vasculitis has been reported in the course of hairy cell leukaemia, it has only rarely been reported as the consequence of cladribine treatment.", "question": "Treatment.Dosage in cladribine", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12181031_1_6102", "context": "Although vasculitis has been reported in the course of hairy cell leukaemia, it has only rarely been reported as the consequence of cladribine treatment.", "question": "Treatment.Freq in cladribine", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12181031_1_6103", "context": "Although vasculitis has been reported in the course of hairy cell leukaemia, it has only rarely been reported as the consequence of cladribine treatment.", "question": "Treatment.Route in cladribine", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12181031_1_6104", "context": "Although vasculitis has been reported in the course of hairy cell leukaemia, it has only rarely been reported as the consequence of cladribine treatment.", "question": "Treatment.Time_elapsed in cladribine", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12181031_1_6105", "context": "Although vasculitis has been reported in the course of hairy cell leukaemia, it has only rarely been reported as the consequence of cladribine treatment.", "question": "Treatment.Duration in cladribine", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12181031_1_6106", "context": "Although vasculitis has been reported in the course of hairy cell leukaemia, it has only rarely been reported as the consequence of cladribine treatment.", "question": "Treatment.Disorder in cladribine", "question_type": "Adverse_event.Treatment.Disorder", "answers": "hairy cell leukaemia"}, {"id": "12181031_1_6107", "context": "Although vasculitis has been reported in the course of hairy cell leukaemia, it has only rarely been reported as the consequence of cladribine treatment.", "question": "Combination.Drug in cladribine", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "19275460_6_6108", "context": "Despite aggressive medical management, including intravenous hydration and broad-spectrum antibiotics, the patient continued to become more confused, agitated, and despondent over the subsequent 24 hours.", "question": "Subject.Age in patient", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "19275460_6_6109", "context": "Despite aggressive medical management, including intravenous hydration and broad-spectrum antibiotics, the patient continued to become more confused, agitated, and despondent over the subsequent 24 hours.", "question": "Subject.Gender in patient", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "19275460_6_6110", "context": "Despite aggressive medical management, including intravenous hydration and broad-spectrum antibiotics, the patient continued to become more confused, agitated, and despondent over the subsequent 24 hours.", "question": "Subject.Population in patient", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "19275460_6_6111", "context": "Despite aggressive medical management, including intravenous hydration and broad-spectrum antibiotics, the patient continued to become more confused, agitated, and despondent over the subsequent 24 hours.", "question": "Subject.Race in patient", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "19275460_6_6112", "context": "Despite aggressive medical management, including intravenous hydration and broad-spectrum antibiotics, the patient continued to become more confused, agitated, and despondent over the subsequent 24 hours.", "question": "Subject.Disorder in patient", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "19275460_6_6113", "context": "Despite aggressive medical management, including intravenous hydration and broad-spectrum antibiotics, the patient continued to become more confused, agitated, and despondent over the subsequent 24 hours.", "question": "Treatment.Drug in intravenous hydration and broad-spectrum antibiotics", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "hydration; broad-spectrum antibiotics"}, {"id": "19275460_6_6114", "context": "Despite aggressive medical management, including intravenous hydration and broad-spectrum antibiotics, the patient continued to become more confused, agitated, and despondent over the subsequent 24 hours.", "question": "Treatment.Dosage in intravenous hydration and broad-spectrum antibiotics", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "19275460_6_6115", "context": "Despite aggressive medical management, including intravenous hydration and broad-spectrum antibiotics, the patient continued to become more confused, agitated, and despondent over the subsequent 24 hours.", "question": "Treatment.Freq in intravenous hydration and broad-spectrum antibiotics", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "19275460_6_6116", "context": "Despite aggressive medical management, including intravenous hydration and broad-spectrum antibiotics, the patient continued to become more confused, agitated, and despondent over the subsequent 24 hours.", "question": "Treatment.Route in intravenous hydration and broad-spectrum antibiotics", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": "intravenous"}, {"id": "19275460_6_6117", "context": "Despite aggressive medical management, including intravenous hydration and broad-spectrum antibiotics, the patient continued to become more confused, agitated, and despondent over the subsequent 24 hours.", "question": "Treatment.Time_elapsed in intravenous hydration and broad-spectrum antibiotics", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19275460_6_6118", "context": "Despite aggressive medical management, including intravenous hydration and broad-spectrum antibiotics, the patient continued to become more confused, agitated, and despondent over the subsequent 24 hours.", "question": "Treatment.Duration in intravenous hydration and broad-spectrum antibiotics", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "19275460_6_6119", "context": "Despite aggressive medical management, including intravenous hydration and broad-spectrum antibiotics, the patient continued to become more confused, agitated, and despondent over the subsequent 24 hours.", "question": "Treatment.Disorder in intravenous hydration and broad-spectrum antibiotics", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "19275460_6_6120", "context": "Despite aggressive medical management, including intravenous hydration and broad-spectrum antibiotics, the patient continued to become more confused, agitated, and despondent over the subsequent 24 hours.", "question": "Combination.Drug in intravenous hydration and broad-spectrum antibiotics", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": "hydration; broad-spectrum antibiotics"}, {"id": "17763133_1_6121", "context": "Cyclosporine is a potent inhibitor of simvastatin metabolism, and may therefore facilitate simvastatin-induced rhabdomyolysis.", "question": "Treatment.Drug in Cyclosporine is a potent inhibitor of simvastatin metabolism", "question_type": "Adverse_event.Treatment.Drug", "answers": "Cyclosporine"}, {"id": "17763133_1_6122", "context": "Cyclosporine is a potent inhibitor of simvastatin metabolism, and may therefore facilitate simvastatin-induced rhabdomyolysis.", "question": "Treatment.Dosage in Cyclosporine is a potent inhibitor of simvastatin metabolism", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17763133_1_6123", "context": "Cyclosporine is a potent inhibitor of simvastatin metabolism, and may therefore facilitate simvastatin-induced rhabdomyolysis.", "question": "Treatment.Freq in Cyclosporine is a potent inhibitor of simvastatin metabolism", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17763133_1_6124", "context": "Cyclosporine is a potent inhibitor of simvastatin metabolism, and may therefore facilitate simvastatin-induced rhabdomyolysis.", "question": "Treatment.Route in Cyclosporine is a potent inhibitor of simvastatin metabolism", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17763133_1_6125", "context": "Cyclosporine is a potent inhibitor of simvastatin metabolism, and may therefore facilitate simvastatin-induced rhabdomyolysis.", "question": "Treatment.Time_elapsed in Cyclosporine is a potent inhibitor of simvastatin metabolism", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17763133_1_6126", "context": "Cyclosporine is a potent inhibitor of simvastatin metabolism, and may therefore facilitate simvastatin-induced rhabdomyolysis.", "question": "Treatment.Duration in Cyclosporine is a potent inhibitor of simvastatin metabolism", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17763133_1_6127", "context": "Cyclosporine is a potent inhibitor of simvastatin metabolism, and may therefore facilitate simvastatin-induced rhabdomyolysis.", "question": "Treatment.Disorder in Cyclosporine is a potent inhibitor of simvastatin metabolism", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17763133_1_6128", "context": "Cyclosporine is a potent inhibitor of simvastatin metabolism, and may therefore facilitate simvastatin-induced rhabdomyolysis.", "question": "Combination.Drug in Cyclosporine is a potent inhibitor of simvastatin metabolism", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "20180933_1_6129", "context": "The effect of food consumption on lumefantrine bioavailability in African children receiving artemether-lumefantrine crushed or dispersible tablets (Coartem) for acute uncomplicated Plasmodium falciparum malaria.", "question": "Subject.Age in African children", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": "children"}, {"id": "20180933_1_6130", "context": "The effect of food consumption on lumefantrine bioavailability in African children receiving artemether-lumefantrine crushed or dispersible tablets (Coartem) for acute uncomplicated Plasmodium falciparum malaria.", "question": "Subject.Gender in African children", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "20180933_1_6131", "context": "The effect of food consumption on lumefantrine bioavailability in African children receiving artemether-lumefantrine crushed or dispersible tablets (Coartem) for acute uncomplicated Plasmodium falciparum malaria.", "question": "Subject.Population in African children", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "20180933_1_6132", "context": "The effect of food consumption on lumefantrine bioavailability in African children receiving artemether-lumefantrine crushed or dispersible tablets (Coartem) for acute uncomplicated Plasmodium falciparum malaria.", "question": "Subject.Race in African children", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": "African"}, {"id": "20180933_1_6133", "context": "The effect of food consumption on lumefantrine bioavailability in African children receiving artemether-lumefantrine crushed or dispersible tablets (Coartem) for acute uncomplicated Plasmodium falciparum malaria.", "question": "Subject.Disorder in African children", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "20180933_1_6134", "context": "The effect of food consumption on lumefantrine bioavailability in African children receiving artemether-lumefantrine crushed or dispersible tablets (Coartem) for acute uncomplicated Plasmodium falciparum malaria.", "question": "Treatment.Drug in artemether-lumefantrine crushed or dispersible tablets (Coartem)", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "artemether; lumefantrine"}, {"id": "20180933_1_6135", "context": "The effect of food consumption on lumefantrine bioavailability in African children receiving artemether-lumefantrine crushed or dispersible tablets (Coartem) for acute uncomplicated Plasmodium falciparum malaria.", "question": "Treatment.Dosage in artemether-lumefantrine crushed or dispersible tablets (Coartem)", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "20180933_1_6136", "context": "The effect of food consumption on lumefantrine bioavailability in African children receiving artemether-lumefantrine crushed or dispersible tablets (Coartem) for acute uncomplicated Plasmodium falciparum malaria.", "question": "Treatment.Freq in artemether-lumefantrine crushed or dispersible tablets (Coartem)", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "20180933_1_6137", "context": "The effect of food consumption on lumefantrine bioavailability in African children receiving artemether-lumefantrine crushed or dispersible tablets (Coartem) for acute uncomplicated Plasmodium falciparum malaria.", "question": "Treatment.Route in artemether-lumefantrine crushed or dispersible tablets (Coartem)", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": "dispersible tablets; crushed; tablets"}, {"id": "20180933_1_6138", "context": "The effect of food consumption on lumefantrine bioavailability in African children receiving artemether-lumefantrine crushed or dispersible tablets (Coartem) for acute uncomplicated Plasmodium falciparum malaria.", "question": "Treatment.Time_elapsed in artemether-lumefantrine crushed or dispersible tablets (Coartem)", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "20180933_1_6139", "context": "The effect of food consumption on lumefantrine bioavailability in African children receiving artemether-lumefantrine crushed or dispersible tablets (Coartem) for acute uncomplicated Plasmodium falciparum malaria.", "question": "Treatment.Duration in artemether-lumefantrine crushed or dispersible tablets (Coartem)", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "20180933_1_6140", "context": "The effect of food consumption on lumefantrine bioavailability in African children receiving artemether-lumefantrine crushed or dispersible tablets (Coartem) for acute uncomplicated Plasmodium falciparum malaria.", "question": "Treatment.Disorder in artemether-lumefantrine crushed or dispersible tablets (Coartem)", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "acute uncomplicated Plasmodium falciparum malaria"}, {"id": "20180933_1_6141", "context": "The effect of food consumption on lumefantrine bioavailability in African children receiving artemether-lumefantrine crushed or dispersible tablets (Coartem) for acute uncomplicated Plasmodium falciparum malaria.", "question": "Combination.Drug in artemether-lumefantrine crushed or dispersible tablets (Coartem)", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": "lumefantrine; artemether"}, {"id": "15827071_2_6142", "context": "To report 2 cases of serotonin toxicity (ST) associated with concomitant use of linezolid and serotonergic drugs and review previously published case reports.", "question": "Subject.Age in 2 cases", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "15827071_2_6143", "context": "To report 2 cases of serotonin toxicity (ST) associated with concomitant use of linezolid and serotonergic drugs and review previously published case reports.", "question": "Subject.Gender in 2 cases", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15827071_2_6144", "context": "To report 2 cases of serotonin toxicity (ST) associated with concomitant use of linezolid and serotonergic drugs and review previously published case reports.", "question": "Subject.Population in 2 cases", "question_type": "Adverse_event.Subject.Population", "answers": "2"}, {"id": "15827071_2_6145", "context": "To report 2 cases of serotonin toxicity (ST) associated with concomitant use of linezolid and serotonergic drugs and review previously published case reports.", "question": "Subject.Race in 2 cases", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15827071_2_6146", "context": "To report 2 cases of serotonin toxicity (ST) associated with concomitant use of linezolid and serotonergic drugs and review previously published case reports.", "question": "Subject.Disorder in 2 cases", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15827071_2_6147", "context": "To report 2 cases of serotonin toxicity (ST) associated with concomitant use of linezolid and serotonergic drugs and review previously published case reports.", "question": "Treatment.Drug in concomitant use of linezolid and serotonergic drugs", "question_type": "Adverse_event.Treatment.Drug", "answers": "linezolid; serotonergic"}, {"id": "15827071_2_6148", "context": "To report 2 cases of serotonin toxicity (ST) associated with concomitant use of linezolid and serotonergic drugs and review previously published case reports.", "question": "Treatment.Dosage in concomitant use of linezolid and serotonergic drugs", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15827071_2_6149", "context": "To report 2 cases of serotonin toxicity (ST) associated with concomitant use of linezolid and serotonergic drugs and review previously published case reports.", "question": "Treatment.Freq in concomitant use of linezolid and serotonergic drugs", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15827071_2_6150", "context": "To report 2 cases of serotonin toxicity (ST) associated with concomitant use of linezolid and serotonergic drugs and review previously published case reports.", "question": "Treatment.Route in concomitant use of linezolid and serotonergic drugs", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15827071_2_6151", "context": "To report 2 cases of serotonin toxicity (ST) associated with concomitant use of linezolid and serotonergic drugs and review previously published case reports.", "question": "Treatment.Time_elapsed in concomitant use of linezolid and serotonergic drugs", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15827071_2_6152", "context": "To report 2 cases of serotonin toxicity (ST) associated with concomitant use of linezolid and serotonergic drugs and review previously published case reports.", "question": "Treatment.Duration in concomitant use of linezolid and serotonergic drugs", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15827071_2_6153", "context": "To report 2 cases of serotonin toxicity (ST) associated with concomitant use of linezolid and serotonergic drugs and review previously published case reports.", "question": "Treatment.Disorder in concomitant use of linezolid and serotonergic drugs", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15827071_2_6154", "context": "To report 2 cases of serotonin toxicity (ST) associated with concomitant use of linezolid and serotonergic drugs and review previously published case reports.", "question": "Combination.Drug in concomitant use of linezolid and serotonergic drugs", "question_type": "Adverse_event.Combination.Drug", "answers": "linezolid; serotonergic"}, {"id": "17952482_3_6155", "context": "This case illustrates that the hemophagocytic syndrome associated with reactivation of EBV can occur as part of drug hypersensitivity reactions in RA patients taking sulfasalazine.", "question": "Treatment.Drug in sulfasalazine", "question_type": "Adverse_event.Treatment.Drug", "answers": "sulfasalazine"}, {"id": "17952482_3_6156", "context": "This case illustrates that the hemophagocytic syndrome associated with reactivation of EBV can occur as part of drug hypersensitivity reactions in RA patients taking sulfasalazine.", "question": "Treatment.Dosage in sulfasalazine", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17952482_3_6157", "context": "This case illustrates that the hemophagocytic syndrome associated with reactivation of EBV can occur as part of drug hypersensitivity reactions in RA patients taking sulfasalazine.", "question": "Treatment.Freq in sulfasalazine", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17952482_3_6158", "context": "This case illustrates that the hemophagocytic syndrome associated with reactivation of EBV can occur as part of drug hypersensitivity reactions in RA patients taking sulfasalazine.", "question": "Treatment.Route in sulfasalazine", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17952482_3_6159", "context": "This case illustrates that the hemophagocytic syndrome associated with reactivation of EBV can occur as part of drug hypersensitivity reactions in RA patients taking sulfasalazine.", "question": "Treatment.Time_elapsed in sulfasalazine", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17952482_3_6160", "context": "This case illustrates that the hemophagocytic syndrome associated with reactivation of EBV can occur as part of drug hypersensitivity reactions in RA patients taking sulfasalazine.", "question": "Treatment.Duration in sulfasalazine", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17952482_3_6161", "context": "This case illustrates that the hemophagocytic syndrome associated with reactivation of EBV can occur as part of drug hypersensitivity reactions in RA patients taking sulfasalazine.", "question": "Treatment.Disorder in sulfasalazine", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17952482_3_6162", "context": "This case illustrates that the hemophagocytic syndrome associated with reactivation of EBV can occur as part of drug hypersensitivity reactions in RA patients taking sulfasalazine.", "question": "Combination.Drug in sulfasalazine", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "2357706_2_6163", "context": "Tardive dyskinesia induced by sulpiride.", "question": "Treatment.Drug in sulpiride", "question_type": "Adverse_event.Treatment.Drug", "answers": "sulpiride"}, {"id": "2357706_2_6164", "context": "Tardive dyskinesia induced by sulpiride.", "question": "Treatment.Dosage in sulpiride", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "2357706_2_6165", "context": "Tardive dyskinesia induced by sulpiride.", "question": "Treatment.Freq in sulpiride", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2357706_2_6166", "context": "Tardive dyskinesia induced by sulpiride.", "question": "Treatment.Route in sulpiride", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "2357706_2_6167", "context": "Tardive dyskinesia induced by sulpiride.", "question": "Treatment.Time_elapsed in sulpiride", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2357706_2_6168", "context": "Tardive dyskinesia induced by sulpiride.", "question": "Treatment.Duration in sulpiride", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2357706_2_6169", "context": "Tardive dyskinesia induced by sulpiride.", "question": "Treatment.Disorder in sulpiride", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "2357706_2_6170", "context": "Tardive dyskinesia induced by sulpiride.", "question": "Combination.Drug in sulpiride", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9758325_1_6171", "context": "Seizures occurred in two patients with probable Alzheimer's disease who were receiving long-term treatment with metrifonate, an irreversible acetylcholinesterase inhibitor.", "question": "Subject.Age in two patients with probable Alzheimer's disease", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "9758325_1_6172", "context": "Seizures occurred in two patients with probable Alzheimer's disease who were receiving long-term treatment with metrifonate, an irreversible acetylcholinesterase inhibitor.", "question": "Subject.Gender in two patients with probable Alzheimer's disease", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "9758325_1_6173", "context": "Seizures occurred in two patients with probable Alzheimer's disease who were receiving long-term treatment with metrifonate, an irreversible acetylcholinesterase inhibitor.", "question": "Subject.Population in two patients with probable Alzheimer's disease", "question_type": "Adverse_event.Subject.Population", "answers": "two"}, {"id": "9758325_1_6174", "context": "Seizures occurred in two patients with probable Alzheimer's disease who were receiving long-term treatment with metrifonate, an irreversible acetylcholinesterase inhibitor.", "question": "Subject.Race in two patients with probable Alzheimer's disease", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "9758325_1_6175", "context": "Seizures occurred in two patients with probable Alzheimer's disease who were receiving long-term treatment with metrifonate, an irreversible acetylcholinesterase inhibitor.", "question": "Subject.Disorder in two patients with probable Alzheimer's disease", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "9758325_1_6176", "context": "Seizures occurred in two patients with probable Alzheimer's disease who were receiving long-term treatment with metrifonate, an irreversible acetylcholinesterase inhibitor.", "question": "Treatment.Drug in long-term treatment with metrifonate", "question_type": "Adverse_event.Treatment.Drug", "answers": "metrifonate"}, {"id": "9758325_1_6177", "context": "Seizures occurred in two patients with probable Alzheimer's disease who were receiving long-term treatment with metrifonate, an irreversible acetylcholinesterase inhibitor.", "question": "Treatment.Dosage in long-term treatment with metrifonate", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9758325_1_6178", "context": "Seizures occurred in two patients with probable Alzheimer's disease who were receiving long-term treatment with metrifonate, an irreversible acetylcholinesterase inhibitor.", "question": "Treatment.Freq in long-term treatment with metrifonate", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9758325_1_6179", "context": "Seizures occurred in two patients with probable Alzheimer's disease who were receiving long-term treatment with metrifonate, an irreversible acetylcholinesterase inhibitor.", "question": "Treatment.Route in long-term treatment with metrifonate", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9758325_1_6180", "context": "Seizures occurred in two patients with probable Alzheimer's disease who were receiving long-term treatment with metrifonate, an irreversible acetylcholinesterase inhibitor.", "question": "Treatment.Time_elapsed in long-term treatment with metrifonate", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9758325_1_6181", "context": "Seizures occurred in two patients with probable Alzheimer's disease who were receiving long-term treatment with metrifonate, an irreversible acetylcholinesterase inhibitor.", "question": "Treatment.Duration in long-term treatment with metrifonate", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9758325_1_6182", "context": "Seizures occurred in two patients with probable Alzheimer's disease who were receiving long-term treatment with metrifonate, an irreversible acetylcholinesterase inhibitor.", "question": "Treatment.Disorder in long-term treatment with metrifonate", "question_type": "Adverse_event.Treatment.Disorder", "answers": "Alzheimer's disease"}, {"id": "9758325_1_6183", "context": "Seizures occurred in two patients with probable Alzheimer's disease who were receiving long-term treatment with metrifonate, an irreversible acetylcholinesterase inhibitor.", "question": "Combination.Drug in long-term treatment with metrifonate", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11597289_16_6184", "context": "High-dose antithrombin III was associated with an increased risk of hemorrhage when administered with heparin.", "question": "Treatment.Drug in High-dose antithrombin III; heparin", "question_type": "Adverse_event.Treatment.Drug", "answers": "antithrombin III; heparin"}, {"id": "11597289_16_6185", "context": "High-dose antithrombin III was associated with an increased risk of hemorrhage when administered with heparin.", "question": "Treatment.Dosage in High-dose antithrombin III; heparin", "question_type": "Adverse_event.Treatment.Dosage", "answers": "High-dose"}, {"id": "11597289_16_6186", "context": "High-dose antithrombin III was associated with an increased risk of hemorrhage when administered with heparin.", "question": "Treatment.Freq in High-dose antithrombin III; heparin", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11597289_16_6187", "context": "High-dose antithrombin III was associated with an increased risk of hemorrhage when administered with heparin.", "question": "Treatment.Route in High-dose antithrombin III; heparin", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11597289_16_6188", "context": "High-dose antithrombin III was associated with an increased risk of hemorrhage when administered with heparin.", "question": "Treatment.Time_elapsed in High-dose antithrombin III; heparin", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11597289_16_6189", "context": "High-dose antithrombin III was associated with an increased risk of hemorrhage when administered with heparin.", "question": "Treatment.Duration in High-dose antithrombin III; heparin", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11597289_16_6190", "context": "High-dose antithrombin III was associated with an increased risk of hemorrhage when administered with heparin.", "question": "Treatment.Disorder in High-dose antithrombin III; heparin", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11597289_16_6191", "context": "High-dose antithrombin III was associated with an increased risk of hemorrhage when administered with heparin.", "question": "Combination.Drug in High-dose antithrombin III; heparin", "question_type": "Adverse_event.Combination.Drug", "answers": "antithrombin III; heparin"}, {"id": "3513544_3_6192", "context": "With the increasing use of Cyclosporine A in transplant patients, the incidence of herpes esophagitis may increase.", "question": "Subject.Age in transplant patients", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "3513544_3_6193", "context": "With the increasing use of Cyclosporine A in transplant patients, the incidence of herpes esophagitis may increase.", "question": "Subject.Gender in transplant patients", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "3513544_3_6194", "context": "With the increasing use of Cyclosporine A in transplant patients, the incidence of herpes esophagitis may increase.", "question": "Subject.Population in transplant patients", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "3513544_3_6195", "context": "With the increasing use of Cyclosporine A in transplant patients, the incidence of herpes esophagitis may increase.", "question": "Subject.Race in transplant patients", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "3513544_3_6196", "context": "With the increasing use of Cyclosporine A in transplant patients, the incidence of herpes esophagitis may increase.", "question": "Subject.Disorder in transplant patients", "question_type": "Adverse_event.Subject.Disorder", "answers": "transplant"}, {"id": "3513544_3_6197", "context": "With the increasing use of Cyclosporine A in transplant patients, the incidence of herpes esophagitis may increase.", "question": "Treatment.Drug in Cyclosporine A", "question_type": "Adverse_event.Treatment.Drug", "answers": "Cyclosporine A"}, {"id": "3513544_3_6198", "context": "With the increasing use of Cyclosporine A in transplant patients, the incidence of herpes esophagitis may increase.", "question": "Treatment.Dosage in Cyclosporine A", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3513544_3_6199", "context": "With the increasing use of Cyclosporine A in transplant patients, the incidence of herpes esophagitis may increase.", "question": "Treatment.Freq in Cyclosporine A", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3513544_3_6200", "context": "With the increasing use of Cyclosporine A in transplant patients, the incidence of herpes esophagitis may increase.", "question": "Treatment.Route in Cyclosporine A", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3513544_3_6201", "context": "With the increasing use of Cyclosporine A in transplant patients, the incidence of herpes esophagitis may increase.", "question": "Treatment.Time_elapsed in Cyclosporine A", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3513544_3_6202", "context": "With the increasing use of Cyclosporine A in transplant patients, the incidence of herpes esophagitis may increase.", "question": "Treatment.Duration in Cyclosporine A", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3513544_3_6203", "context": "With the increasing use of Cyclosporine A in transplant patients, the incidence of herpes esophagitis may increase.", "question": "Treatment.Disorder in Cyclosporine A", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3513544_3_6204", "context": "With the increasing use of Cyclosporine A in transplant patients, the incidence of herpes esophagitis may increase.", "question": "Combination.Drug in Cyclosporine A", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17473920_8_6205", "context": "After starting nevirapine treatment, nine out of ten patients experienced symptoms of abstinence syndrome, and methadone dose had to be increased by 20% on average during the course of the study.", "question": "Subject.Age in nine out of ten patients", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "17473920_8_6206", "context": "After starting nevirapine treatment, nine out of ten patients experienced symptoms of abstinence syndrome, and methadone dose had to be increased by 20% on average during the course of the study.", "question": "Subject.Gender in nine out of ten patients", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "17473920_8_6207", "context": "After starting nevirapine treatment, nine out of ten patients experienced symptoms of abstinence syndrome, and methadone dose had to be increased by 20% on average during the course of the study.", "question": "Subject.Population in nine out of ten patients", "question_type": "Adverse_event.Subject.Population", "answers": "nine out of ten"}, {"id": "17473920_8_6208", "context": "After starting nevirapine treatment, nine out of ten patients experienced symptoms of abstinence syndrome, and methadone dose had to be increased by 20% on average during the course of the study.", "question": "Subject.Race in nine out of ten patients", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "17473920_8_6209", "context": "After starting nevirapine treatment, nine out of ten patients experienced symptoms of abstinence syndrome, and methadone dose had to be increased by 20% on average during the course of the study.", "question": "Subject.Disorder in nine out of ten patients", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "17473920_8_6210", "context": "After starting nevirapine treatment, nine out of ten patients experienced symptoms of abstinence syndrome, and methadone dose had to be increased by 20% on average during the course of the study.", "question": "Treatment.Drug in nevirapine", "question_type": "Adverse_event.Treatment.Drug", "answers": "nevirapine"}, {"id": "17473920_8_6211", "context": "After starting nevirapine treatment, nine out of ten patients experienced symptoms of abstinence syndrome, and methadone dose had to be increased by 20% on average during the course of the study.", "question": "Treatment.Dosage in nevirapine", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17473920_8_6212", "context": "After starting nevirapine treatment, nine out of ten patients experienced symptoms of abstinence syndrome, and methadone dose had to be increased by 20% on average during the course of the study.", "question": "Treatment.Freq in nevirapine", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17473920_8_6213", "context": "After starting nevirapine treatment, nine out of ten patients experienced symptoms of abstinence syndrome, and methadone dose had to be increased by 20% on average during the course of the study.", "question": "Treatment.Route in nevirapine", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17473920_8_6214", "context": "After starting nevirapine treatment, nine out of ten patients experienced symptoms of abstinence syndrome, and methadone dose had to be increased by 20% on average during the course of the study.", "question": "Treatment.Time_elapsed in nevirapine", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17473920_8_6215", "context": "After starting nevirapine treatment, nine out of ten patients experienced symptoms of abstinence syndrome, and methadone dose had to be increased by 20% on average during the course of the study.", "question": "Treatment.Duration in nevirapine", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17473920_8_6216", "context": "After starting nevirapine treatment, nine out of ten patients experienced symptoms of abstinence syndrome, and methadone dose had to be increased by 20% on average during the course of the study.", "question": "Treatment.Disorder in nevirapine", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17473920_8_6217", "context": "After starting nevirapine treatment, nine out of ten patients experienced symptoms of abstinence syndrome, and methadone dose had to be increased by 20% on average during the course of the study.", "question": "Combination.Drug in nevirapine", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "19071894_4_6218", "context": "Treatment was begun with amphotericin B-deoxycholate but renal toxicity signs led to its substitution by fluconazole.", "question": "Treatment.Drug in amphotericin B-deoxycholate", "question_type": "Adverse_event.Treatment.Drug", "answers": "amphotericin B-deoxycholate; fluconazole"}, {"id": "19071894_4_6219", "context": "Treatment was begun with amphotericin B-deoxycholate but renal toxicity signs led to its substitution by fluconazole.", "question": "Treatment.Dosage in amphotericin B-deoxycholate", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "19071894_4_6220", "context": "Treatment was begun with amphotericin B-deoxycholate but renal toxicity signs led to its substitution by fluconazole.", "question": "Treatment.Freq in amphotericin B-deoxycholate", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "19071894_4_6221", "context": "Treatment was begun with amphotericin B-deoxycholate but renal toxicity signs led to its substitution by fluconazole.", "question": "Treatment.Route in amphotericin B-deoxycholate", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "19071894_4_6222", "context": "Treatment was begun with amphotericin B-deoxycholate but renal toxicity signs led to its substitution by fluconazole.", "question": "Treatment.Time_elapsed in amphotericin B-deoxycholate", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19071894_4_6223", "context": "Treatment was begun with amphotericin B-deoxycholate but renal toxicity signs led to its substitution by fluconazole.", "question": "Treatment.Duration in amphotericin B-deoxycholate", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "19071894_4_6224", "context": "Treatment was begun with amphotericin B-deoxycholate but renal toxicity signs led to its substitution by fluconazole.", "question": "Treatment.Disorder in amphotericin B-deoxycholate", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "19071894_4_6225", "context": "Treatment was begun with amphotericin B-deoxycholate but renal toxicity signs led to its substitution by fluconazole.", "question": "Combination.Drug in amphotericin B-deoxycholate", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16531969_3_6226", "context": "Post marketing studies of Interferon-beta (IFN beta) therapy in multiple sclerosis (MS) have demonstrated surprisingly high rates of hepatotoxicity.", "question": "Treatment.Drug in Interferon-beta", "question_type": "Adverse_event.Treatment.Drug", "answers": "Interferon-beta (IFN beta)"}, {"id": "16531969_3_6227", "context": "Post marketing studies of Interferon-beta (IFN beta) therapy in multiple sclerosis (MS) have demonstrated surprisingly high rates of hepatotoxicity.", "question": "Treatment.Dosage in Interferon-beta", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16531969_3_6228", "context": "Post marketing studies of Interferon-beta (IFN beta) therapy in multiple sclerosis (MS) have demonstrated surprisingly high rates of hepatotoxicity.", "question": "Treatment.Freq in Interferon-beta", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16531969_3_6229", "context": "Post marketing studies of Interferon-beta (IFN beta) therapy in multiple sclerosis (MS) have demonstrated surprisingly high rates of hepatotoxicity.", "question": "Treatment.Route in Interferon-beta", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16531969_3_6230", "context": "Post marketing studies of Interferon-beta (IFN beta) therapy in multiple sclerosis (MS) have demonstrated surprisingly high rates of hepatotoxicity.", "question": "Treatment.Time_elapsed in Interferon-beta", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16531969_3_6231", "context": "Post marketing studies of Interferon-beta (IFN beta) therapy in multiple sclerosis (MS) have demonstrated surprisingly high rates of hepatotoxicity.", "question": "Treatment.Duration in Interferon-beta", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16531969_3_6232", "context": "Post marketing studies of Interferon-beta (IFN beta) therapy in multiple sclerosis (MS) have demonstrated surprisingly high rates of hepatotoxicity.", "question": "Treatment.Disorder in Interferon-beta", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16531969_3_6233", "context": "Post marketing studies of Interferon-beta (IFN beta) therapy in multiple sclerosis (MS) have demonstrated surprisingly high rates of hepatotoxicity.", "question": "Combination.Drug in Interferon-beta", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18715650_2_6234", "context": "We describe the first case of disseminated salmonellosis in a patient treated with temozolomide.", "question": "Subject.Age in a patient", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "18715650_2_6235", "context": "We describe the first case of disseminated salmonellosis in a patient treated with temozolomide.", "question": "Subject.Gender in a patient", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "18715650_2_6236", "context": "We describe the first case of disseminated salmonellosis in a patient treated with temozolomide.", "question": "Subject.Population in a patient", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "18715650_2_6237", "context": "We describe the first case of disseminated salmonellosis in a patient treated with temozolomide.", "question": "Subject.Race in a patient", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "18715650_2_6238", "context": "We describe the first case of disseminated salmonellosis in a patient treated with temozolomide.", "question": "Subject.Disorder in a patient", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "18715650_2_6239", "context": "We describe the first case of disseminated salmonellosis in a patient treated with temozolomide.", "question": "Treatment.Drug in temozolomide", "question_type": "Adverse_event.Treatment.Drug", "answers": "temozolomide"}, {"id": "18715650_2_6240", "context": "We describe the first case of disseminated salmonellosis in a patient treated with temozolomide.", "question": "Treatment.Dosage in temozolomide", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18715650_2_6241", "context": "We describe the first case of disseminated salmonellosis in a patient treated with temozolomide.", "question": "Treatment.Freq in temozolomide", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18715650_2_6242", "context": "We describe the first case of disseminated salmonellosis in a patient treated with temozolomide.", "question": "Treatment.Route in temozolomide", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18715650_2_6243", "context": "We describe the first case of disseminated salmonellosis in a patient treated with temozolomide.", "question": "Treatment.Time_elapsed in temozolomide", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18715650_2_6244", "context": "We describe the first case of disseminated salmonellosis in a patient treated with temozolomide.", "question": "Treatment.Duration in temozolomide", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18715650_2_6245", "context": "We describe the first case of disseminated salmonellosis in a patient treated with temozolomide.", "question": "Treatment.Disorder in temozolomide", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18715650_2_6246", "context": "We describe the first case of disseminated salmonellosis in a patient treated with temozolomide.", "question": "Combination.Drug in temozolomide", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16368918_1_6247", "context": "OBJECTIVE: To describe a case of exacerbated mania potentially related to an interaction between lopinavir/ritonavir and valproic acid (VPA) and propose a mechanism of action for this interaction.", "question": "Treatment.Drug in interaction between lopinavir/ritonavir and valproic acid", "question_type": "Adverse_event.Treatment.Drug", "answers": "lopinavir; ritonavir; valproic acid"}, {"id": "16368918_1_6248", "context": "OBJECTIVE: To describe a case of exacerbated mania potentially related to an interaction between lopinavir/ritonavir and valproic acid (VPA) and propose a mechanism of action for this interaction.", "question": "Treatment.Dosage in interaction between lopinavir/ritonavir and valproic acid", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16368918_1_6249", "context": "OBJECTIVE: To describe a case of exacerbated mania potentially related to an interaction between lopinavir/ritonavir and valproic acid (VPA) and propose a mechanism of action for this interaction.", "question": "Treatment.Freq in interaction between lopinavir/ritonavir and valproic acid", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16368918_1_6250", "context": "OBJECTIVE: To describe a case of exacerbated mania potentially related to an interaction between lopinavir/ritonavir and valproic acid (VPA) and propose a mechanism of action for this interaction.", "question": "Treatment.Route in interaction between lopinavir/ritonavir and valproic acid", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16368918_1_6251", "context": "OBJECTIVE: To describe a case of exacerbated mania potentially related to an interaction between lopinavir/ritonavir and valproic acid (VPA) and propose a mechanism of action for this interaction.", "question": "Treatment.Time_elapsed in interaction between lopinavir/ritonavir and valproic acid", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16368918_1_6252", "context": "OBJECTIVE: To describe a case of exacerbated mania potentially related to an interaction between lopinavir/ritonavir and valproic acid (VPA) and propose a mechanism of action for this interaction.", "question": "Treatment.Duration in interaction between lopinavir/ritonavir and valproic acid", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16368918_1_6253", "context": "OBJECTIVE: To describe a case of exacerbated mania potentially related to an interaction between lopinavir/ritonavir and valproic acid (VPA) and propose a mechanism of action for this interaction.", "question": "Treatment.Disorder in interaction between lopinavir/ritonavir and valproic acid", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16368918_1_6254", "context": "OBJECTIVE: To describe a case of exacerbated mania potentially related to an interaction between lopinavir/ritonavir and valproic acid (VPA) and propose a mechanism of action for this interaction.", "question": "Combination.Drug in interaction between lopinavir/ritonavir and valproic acid", "question_type": "Adverse_event.Combination.Drug", "answers": "valproic acid; lopinavir; ritonavir"}, {"id": "6597713_4_6255", "context": "The first reported case, in an adult, of cholestyramine induced hyperchloremic metabolic acidosis is a 70 year old female with a two year history of primary biliary cirrhosis confirmed by histologic and immunologic criteria.", "question": "Subject.Age in a 70 year old female with a two year history of primary biliary cirrhosis", "question_type": "Adverse_event.Subject.Age", "answers": "70 year old"}, {"id": "6597713_4_6256", "context": "The first reported case, in an adult, of cholestyramine induced hyperchloremic metabolic acidosis is a 70 year old female with a two year history of primary biliary cirrhosis confirmed by histologic and immunologic criteria.", "question": "Subject.Gender in a 70 year old female with a two year history of primary biliary cirrhosis", "question_type": "Adverse_event.Subject.Gender", "answers": "female"}, {"id": "6597713_4_6257", "context": "The first reported case, in an adult, of cholestyramine induced hyperchloremic metabolic acidosis is a 70 year old female with a two year history of primary biliary cirrhosis confirmed by histologic and immunologic criteria.", "question": "Subject.Population in a 70 year old female with a two year history of primary biliary cirrhosis", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "6597713_4_6258", "context": "The first reported case, in an adult, of cholestyramine induced hyperchloremic metabolic acidosis is a 70 year old female with a two year history of primary biliary cirrhosis confirmed by histologic and immunologic criteria.", "question": "Subject.Race in a 70 year old female with a two year history of primary biliary cirrhosis", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "6597713_4_6259", "context": "The first reported case, in an adult, of cholestyramine induced hyperchloremic metabolic acidosis is a 70 year old female with a two year history of primary biliary cirrhosis confirmed by histologic and immunologic criteria.", "question": "Subject.Disorder in a 70 year old female with a two year history of primary biliary cirrhosis", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "6597713_4_6260", "context": "The first reported case, in an adult, of cholestyramine induced hyperchloremic metabolic acidosis is a 70 year old female with a two year history of primary biliary cirrhosis confirmed by histologic and immunologic criteria.", "question": "Treatment.Drug in cholestyramine", "question_type": "Adverse_event.Treatment.Drug", "answers": "cholestyramine"}, {"id": "6597713_4_6261", "context": "The first reported case, in an adult, of cholestyramine induced hyperchloremic metabolic acidosis is a 70 year old female with a two year history of primary biliary cirrhosis confirmed by histologic and immunologic criteria.", "question": "Treatment.Dosage in cholestyramine", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6597713_4_6262", "context": "The first reported case, in an adult, of cholestyramine induced hyperchloremic metabolic acidosis is a 70 year old female with a two year history of primary biliary cirrhosis confirmed by histologic and immunologic criteria.", "question": "Treatment.Freq in cholestyramine", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6597713_4_6263", "context": "The first reported case, in an adult, of cholestyramine induced hyperchloremic metabolic acidosis is a 70 year old female with a two year history of primary biliary cirrhosis confirmed by histologic and immunologic criteria.", "question": "Treatment.Route in cholestyramine", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6597713_4_6264", "context": "The first reported case, in an adult, of cholestyramine induced hyperchloremic metabolic acidosis is a 70 year old female with a two year history of primary biliary cirrhosis confirmed by histologic and immunologic criteria.", "question": "Treatment.Time_elapsed in cholestyramine", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6597713_4_6265", "context": "The first reported case, in an adult, of cholestyramine induced hyperchloremic metabolic acidosis is a 70 year old female with a two year history of primary biliary cirrhosis confirmed by histologic and immunologic criteria.", "question": "Treatment.Duration in cholestyramine", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6597713_4_6266", "context": "The first reported case, in an adult, of cholestyramine induced hyperchloremic metabolic acidosis is a 70 year old female with a two year history of primary biliary cirrhosis confirmed by histologic and immunologic criteria.", "question": "Treatment.Disorder in cholestyramine", "question_type": "Adverse_event.Treatment.Disorder", "answers": "primary biliary cirrhosis"}, {"id": "6597713_4_6267", "context": "The first reported case, in an adult, of cholestyramine induced hyperchloremic metabolic acidosis is a 70 year old female with a two year history of primary biliary cirrhosis confirmed by histologic and immunologic criteria.", "question": "Combination.Drug in cholestyramine", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "19423476_4_6268", "context": "We report a case of fatal C. neoformans fungemia in a neutropenic patient with a history of chronic lymphocytic leukemia treated with alemtuzumab.", "question": "Subject.Age in a neutropenic patient with a history of chronic lymphocytic leukemia", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "19423476_4_6269", "context": "We report a case of fatal C. neoformans fungemia in a neutropenic patient with a history of chronic lymphocytic leukemia treated with alemtuzumab.", "question": "Subject.Gender in a neutropenic patient with a history of chronic lymphocytic leukemia", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "19423476_4_6270", "context": "We report a case of fatal C. neoformans fungemia in a neutropenic patient with a history of chronic lymphocytic leukemia treated with alemtuzumab.", "question": "Subject.Population in a neutropenic patient with a history of chronic lymphocytic leukemia", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "19423476_4_6271", "context": "We report a case of fatal C. neoformans fungemia in a neutropenic patient with a history of chronic lymphocytic leukemia treated with alemtuzumab.", "question": "Subject.Race in a neutropenic patient with a history of chronic lymphocytic leukemia", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "19423476_4_6272", "context": "We report a case of fatal C. neoformans fungemia in a neutropenic patient with a history of chronic lymphocytic leukemia treated with alemtuzumab.", "question": "Subject.Disorder in a neutropenic patient with a history of chronic lymphocytic leukemia", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "19423476_4_6273", "context": "We report a case of fatal C. neoformans fungemia in a neutropenic patient with a history of chronic lymphocytic leukemia treated with alemtuzumab.", "question": "Treatment.Drug in alemtuzumab", "question_type": "Adverse_event.Treatment.Drug", "answers": "alemtuzumab"}, {"id": "19423476_4_6274", "context": "We report a case of fatal C. neoformans fungemia in a neutropenic patient with a history of chronic lymphocytic leukemia treated with alemtuzumab.", "question": "Treatment.Dosage in alemtuzumab", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "19423476_4_6275", "context": "We report a case of fatal C. neoformans fungemia in a neutropenic patient with a history of chronic lymphocytic leukemia treated with alemtuzumab.", "question": "Treatment.Freq in alemtuzumab", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "19423476_4_6276", "context": "We report a case of fatal C. neoformans fungemia in a neutropenic patient with a history of chronic lymphocytic leukemia treated with alemtuzumab.", "question": "Treatment.Route in alemtuzumab", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "19423476_4_6277", "context": "We report a case of fatal C. neoformans fungemia in a neutropenic patient with a history of chronic lymphocytic leukemia treated with alemtuzumab.", "question": "Treatment.Time_elapsed in alemtuzumab", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19423476_4_6278", "context": "We report a case of fatal C. neoformans fungemia in a neutropenic patient with a history of chronic lymphocytic leukemia treated with alemtuzumab.", "question": "Treatment.Duration in alemtuzumab", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "19423476_4_6279", "context": "We report a case of fatal C. neoformans fungemia in a neutropenic patient with a history of chronic lymphocytic leukemia treated with alemtuzumab.", "question": "Treatment.Disorder in alemtuzumab", "question_type": "Adverse_event.Treatment.Disorder", "answers": "chronic lymphocytic leukemia"}, {"id": "19423476_4_6280", "context": "We report a case of fatal C. neoformans fungemia in a neutropenic patient with a history of chronic lymphocytic leukemia treated with alemtuzumab.", "question": "Combination.Drug in alemtuzumab", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "22550162_6_6281", "context": "Aggressive hydration, urinary alkalinization, and leucovorin were continued during the period of elevated methotrexate levels, with the patient receiving a course of hemodialysis and a dose of carboxypeptidase G2.", "question": "Subject.Age in the patient", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "22550162_6_6282", "context": "Aggressive hydration, urinary alkalinization, and leucovorin were continued during the period of elevated methotrexate levels, with the patient receiving a course of hemodialysis and a dose of carboxypeptidase G2.", "question": "Subject.Gender in the patient", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "22550162_6_6283", "context": "Aggressive hydration, urinary alkalinization, and leucovorin were continued during the period of elevated methotrexate levels, with the patient receiving a course of hemodialysis and a dose of carboxypeptidase G2.", "question": "Subject.Population in the patient", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "22550162_6_6284", "context": "Aggressive hydration, urinary alkalinization, and leucovorin were continued during the period of elevated methotrexate levels, with the patient receiving a course of hemodialysis and a dose of carboxypeptidase G2.", "question": "Subject.Race in the patient", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "22550162_6_6285", "context": "Aggressive hydration, urinary alkalinization, and leucovorin were continued during the period of elevated methotrexate levels, with the patient receiving a course of hemodialysis and a dose of carboxypeptidase G2.", "question": "Subject.Disorder in the patient", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "22550162_6_6286", "context": "Aggressive hydration, urinary alkalinization, and leucovorin were continued during the period of elevated methotrexate levels, with the patient receiving a course of hemodialysis and a dose of carboxypeptidase G2.", "question": "Treatment.Drug in Aggressive hydration, urinary alkalinization, and leucovorin; elevated methotrexate; course of hemodialysis and a dose of carboxypeptidase G2", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "leucovorin; methotrexate; carboxypeptidase G2"}, {"id": "22550162_6_6287", "context": "Aggressive hydration, urinary alkalinization, and leucovorin were continued during the period of elevated methotrexate levels, with the patient receiving a course of hemodialysis and a dose of carboxypeptidase G2.", "question": "Treatment.Dosage in Aggressive hydration, urinary alkalinization, and leucovorin; elevated methotrexate; course of hemodialysis and a dose of carboxypeptidase G2", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": "a dose"}, {"id": "22550162_6_6288", "context": "Aggressive hydration, urinary alkalinization, and leucovorin were continued during the period of elevated methotrexate levels, with the patient receiving a course of hemodialysis and a dose of carboxypeptidase G2.", "question": "Treatment.Freq in Aggressive hydration, urinary alkalinization, and leucovorin; elevated methotrexate; course of hemodialysis and a dose of carboxypeptidase G2", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "22550162_6_6289", "context": "Aggressive hydration, urinary alkalinization, and leucovorin were continued during the period of elevated methotrexate levels, with the patient receiving a course of hemodialysis and a dose of carboxypeptidase G2.", "question": "Treatment.Route in Aggressive hydration, urinary alkalinization, and leucovorin; elevated methotrexate; course of hemodialysis and a dose of carboxypeptidase G2", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "22550162_6_6290", "context": "Aggressive hydration, urinary alkalinization, and leucovorin were continued during the period of elevated methotrexate levels, with the patient receiving a course of hemodialysis and a dose of carboxypeptidase G2.", "question": "Treatment.Time_elapsed in Aggressive hydration, urinary alkalinization, and leucovorin; elevated methotrexate; course of hemodialysis and a dose of carboxypeptidase G2", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "22550162_6_6291", "context": "Aggressive hydration, urinary alkalinization, and leucovorin were continued during the period of elevated methotrexate levels, with the patient receiving a course of hemodialysis and a dose of carboxypeptidase G2.", "question": "Treatment.Duration in Aggressive hydration, urinary alkalinization, and leucovorin; elevated methotrexate; course of hemodialysis and a dose of carboxypeptidase G2", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "22550162_6_6292", "context": "Aggressive hydration, urinary alkalinization, and leucovorin were continued during the period of elevated methotrexate levels, with the patient receiving a course of hemodialysis and a dose of carboxypeptidase G2.", "question": "Treatment.Disorder in Aggressive hydration, urinary alkalinization, and leucovorin; elevated methotrexate; course of hemodialysis and a dose of carboxypeptidase G2", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "22550162_6_6293", "context": "Aggressive hydration, urinary alkalinization, and leucovorin were continued during the period of elevated methotrexate levels, with the patient receiving a course of hemodialysis and a dose of carboxypeptidase G2.", "question": "Combination.Drug in Aggressive hydration, urinary alkalinization, and leucovorin; elevated methotrexate; course of hemodialysis and a dose of carboxypeptidase G2", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "2924444_1_6294", "context": "Acute myocardial infarction due to coronary spasm associated with L-thyroxine therapy.", "question": "Treatment.Drug in L-thyroxine", "question_type": "Adverse_event.Treatment.Drug", "answers": "L-thyroxine"}, {"id": "2924444_1_6295", "context": "Acute myocardial infarction due to coronary spasm associated with L-thyroxine therapy.", "question": "Treatment.Dosage in L-thyroxine", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "2924444_1_6296", "context": "Acute myocardial infarction due to coronary spasm associated with L-thyroxine therapy.", "question": "Treatment.Freq in L-thyroxine", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2924444_1_6297", "context": "Acute myocardial infarction due to coronary spasm associated with L-thyroxine therapy.", "question": "Treatment.Route in L-thyroxine", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "2924444_1_6298", "context": "Acute myocardial infarction due to coronary spasm associated with L-thyroxine therapy.", "question": "Treatment.Time_elapsed in L-thyroxine", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2924444_1_6299", "context": "Acute myocardial infarction due to coronary spasm associated with L-thyroxine therapy.", "question": "Treatment.Duration in L-thyroxine", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2924444_1_6300", "context": "Acute myocardial infarction due to coronary spasm associated with L-thyroxine therapy.", "question": "Treatment.Disorder in L-thyroxine", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "2924444_1_6301", "context": "Acute myocardial infarction due to coronary spasm associated with L-thyroxine therapy.", "question": "Combination.Drug in L-thyroxine", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12149193_7_6302", "context": "Only patients on DT-PACE but not DCEP-T experienced an increased incidence of DVT.", "question": "Subject.Age in patients", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "12149193_7_6303", "context": "Only patients on DT-PACE but not DCEP-T experienced an increased incidence of DVT.", "question": "Subject.Gender in patients", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "12149193_7_6304", "context": "Only patients on DT-PACE but not DCEP-T experienced an increased incidence of DVT.", "question": "Subject.Population in patients", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "12149193_7_6305", "context": "Only patients on DT-PACE but not DCEP-T experienced an increased incidence of DVT.", "question": "Subject.Race in patients", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "12149193_7_6306", "context": "Only patients on DT-PACE but not DCEP-T experienced an increased incidence of DVT.", "question": "Subject.Disorder in patients", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "12149193_7_6307", "context": "Only patients on DT-PACE but not DCEP-T experienced an increased incidence of DVT.", "question": "Treatment.Drug in DT-PACE but not DCEP-T", "question_type": "Adverse_event.Treatment.Drug", "answers": "DT-PACE; DCEP-T"}, {"id": "12149193_7_6308", "context": "Only patients on DT-PACE but not DCEP-T experienced an increased incidence of DVT.", "question": "Treatment.Dosage in DT-PACE but not DCEP-T", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12149193_7_6309", "context": "Only patients on DT-PACE but not DCEP-T experienced an increased incidence of DVT.", "question": "Treatment.Freq in DT-PACE but not DCEP-T", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12149193_7_6310", "context": "Only patients on DT-PACE but not DCEP-T experienced an increased incidence of DVT.", "question": "Treatment.Route in DT-PACE but not DCEP-T", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12149193_7_6311", "context": "Only patients on DT-PACE but not DCEP-T experienced an increased incidence of DVT.", "question": "Treatment.Time_elapsed in DT-PACE but not DCEP-T", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12149193_7_6312", "context": "Only patients on DT-PACE but not DCEP-T experienced an increased incidence of DVT.", "question": "Treatment.Duration in DT-PACE but not DCEP-T", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12149193_7_6313", "context": "Only patients on DT-PACE but not DCEP-T experienced an increased incidence of DVT.", "question": "Treatment.Disorder in DT-PACE but not DCEP-T", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12149193_7_6314", "context": "Only patients on DT-PACE but not DCEP-T experienced an increased incidence of DVT.", "question": "Combination.Drug in DT-PACE but not DCEP-T", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17316160_5_6315", "context": "To our knowledge, this is the first published report of a possible drug interaction in a critically ill patient receiving concomitant linezolid and rifampin.", "question": "Subject.Age in a critically ill patient", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "17316160_5_6316", "context": "To our knowledge, this is the first published report of a possible drug interaction in a critically ill patient receiving concomitant linezolid and rifampin.", "question": "Subject.Gender in a critically ill patient", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "17316160_5_6317", "context": "To our knowledge, this is the first published report of a possible drug interaction in a critically ill patient receiving concomitant linezolid and rifampin.", "question": "Subject.Population in a critically ill patient", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "17316160_5_6318", "context": "To our knowledge, this is the first published report of a possible drug interaction in a critically ill patient receiving concomitant linezolid and rifampin.", "question": "Subject.Race in a critically ill patient", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "17316160_5_6319", "context": "To our knowledge, this is the first published report of a possible drug interaction in a critically ill patient receiving concomitant linezolid and rifampin.", "question": "Subject.Disorder in a critically ill patient", "question_type": "Adverse_event.Subject.Disorder", "answers": "critically ill"}, {"id": "17316160_5_6320", "context": "To our knowledge, this is the first published report of a possible drug interaction in a critically ill patient receiving concomitant linezolid and rifampin.", "question": "Treatment.Drug in concomitant linezolid and rifampin", "question_type": "Adverse_event.Treatment.Drug", "answers": "linezolid; rifampin"}, {"id": "17316160_5_6321", "context": "To our knowledge, this is the first published report of a possible drug interaction in a critically ill patient receiving concomitant linezolid and rifampin.", "question": "Treatment.Dosage in concomitant linezolid and rifampin", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17316160_5_6322", "context": "To our knowledge, this is the first published report of a possible drug interaction in a critically ill patient receiving concomitant linezolid and rifampin.", "question": "Treatment.Freq in concomitant linezolid and rifampin", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17316160_5_6323", "context": "To our knowledge, this is the first published report of a possible drug interaction in a critically ill patient receiving concomitant linezolid and rifampin.", "question": "Treatment.Route in concomitant linezolid and rifampin", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17316160_5_6324", "context": "To our knowledge, this is the first published report of a possible drug interaction in a critically ill patient receiving concomitant linezolid and rifampin.", "question": "Treatment.Time_elapsed in concomitant linezolid and rifampin", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17316160_5_6325", "context": "To our knowledge, this is the first published report of a possible drug interaction in a critically ill patient receiving concomitant linezolid and rifampin.", "question": "Treatment.Duration in concomitant linezolid and rifampin", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17316160_5_6326", "context": "To our knowledge, this is the first published report of a possible drug interaction in a critically ill patient receiving concomitant linezolid and rifampin.", "question": "Treatment.Disorder in concomitant linezolid and rifampin", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17316160_5_6327", "context": "To our knowledge, this is the first published report of a possible drug interaction in a critically ill patient receiving concomitant linezolid and rifampin.", "question": "Combination.Drug in concomitant linezolid and rifampin", "question_type": "Adverse_event.Combination.Drug", "answers": "linezolid; rifampin"}, {"id": "8700794_4_6328", "context": "Within 24 hours of fluid restriction and cessation of desmopressin, her symptoms and hyponatremia resolved.", "question": "Subject.Age in her", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "8700794_4_6329", "context": "Within 24 hours of fluid restriction and cessation of desmopressin, her symptoms and hyponatremia resolved.", "question": "Subject.Gender in her", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": "her"}, {"id": "8700794_4_6330", "context": "Within 24 hours of fluid restriction and cessation of desmopressin, her symptoms and hyponatremia resolved.", "question": "Subject.Population in her", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "8700794_4_6331", "context": "Within 24 hours of fluid restriction and cessation of desmopressin, her symptoms and hyponatremia resolved.", "question": "Subject.Race in her", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "8700794_4_6332", "context": "Within 24 hours of fluid restriction and cessation of desmopressin, her symptoms and hyponatremia resolved.", "question": "Subject.Disorder in her", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "8700794_4_6333", "context": "Within 24 hours of fluid restriction and cessation of desmopressin, her symptoms and hyponatremia resolved.", "question": "Treatment.Drug in 24 hours of fluid restriction and cessation of desmopressin", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "desmopressin"}, {"id": "8700794_4_6334", "context": "Within 24 hours of fluid restriction and cessation of desmopressin, her symptoms and hyponatremia resolved.", "question": "Treatment.Dosage in 24 hours of fluid restriction and cessation of desmopressin", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "8700794_4_6335", "context": "Within 24 hours of fluid restriction and cessation of desmopressin, her symptoms and hyponatremia resolved.", "question": "Treatment.Freq in 24 hours of fluid restriction and cessation of desmopressin", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "8700794_4_6336", "context": "Within 24 hours of fluid restriction and cessation of desmopressin, her symptoms and hyponatremia resolved.", "question": "Treatment.Route in 24 hours of fluid restriction and cessation of desmopressin", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "8700794_4_6337", "context": "Within 24 hours of fluid restriction and cessation of desmopressin, her symptoms and hyponatremia resolved.", "question": "Treatment.Time_elapsed in 24 hours of fluid restriction and cessation of desmopressin", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8700794_4_6338", "context": "Within 24 hours of fluid restriction and cessation of desmopressin, her symptoms and hyponatremia resolved.", "question": "Treatment.Duration in 24 hours of fluid restriction and cessation of desmopressin", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": "24 hours"}, {"id": "8700794_4_6339", "context": "Within 24 hours of fluid restriction and cessation of desmopressin, her symptoms and hyponatremia resolved.", "question": "Treatment.Disorder in 24 hours of fluid restriction and cessation of desmopressin", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "8700794_4_6340", "context": "Within 24 hours of fluid restriction and cessation of desmopressin, her symptoms and hyponatremia resolved.", "question": "Combination.Drug in 24 hours of fluid restriction and cessation of desmopressin", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "1450506_1_6341", "context": "An adverse reaction to IFN was strongly suspected as the cause of CHF.", "question": "Treatment.Drug in IFN", "question_type": "Adverse_event.Treatment.Drug", "answers": "IFN"}, {"id": "1450506_1_6342", "context": "An adverse reaction to IFN was strongly suspected as the cause of CHF.", "question": "Treatment.Dosage in IFN", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "1450506_1_6343", "context": "An adverse reaction to IFN was strongly suspected as the cause of CHF.", "question": "Treatment.Freq in IFN", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "1450506_1_6344", "context": "An adverse reaction to IFN was strongly suspected as the cause of CHF.", "question": "Treatment.Route in IFN", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "1450506_1_6345", "context": "An adverse reaction to IFN was strongly suspected as the cause of CHF.", "question": "Treatment.Time_elapsed in IFN", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "1450506_1_6346", "context": "An adverse reaction to IFN was strongly suspected as the cause of CHF.", "question": "Treatment.Duration in IFN", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "1450506_1_6347", "context": "An adverse reaction to IFN was strongly suspected as the cause of CHF.", "question": "Treatment.Disorder in IFN", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "1450506_1_6348", "context": "An adverse reaction to IFN was strongly suspected as the cause of CHF.", "question": "Combination.Drug in IFN", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16164579_1_6349", "context": "A 51-year old physically fit woman experienced angio-oedema and hypotensive shock after irbesartan ingestion requiring noradrenaline infusion.", "question": "Subject.Age in A 51-year old physically fit woman", "question_type": "Adverse_event.Subject.Age", "answers": "51-year old"}, {"id": "16164579_1_6350", "context": "A 51-year old physically fit woman experienced angio-oedema and hypotensive shock after irbesartan ingestion requiring noradrenaline infusion.", "question": "Subject.Gender in A 51-year old physically fit woman", "question_type": "Adverse_event.Subject.Gender", "answers": "woman"}, {"id": "16164579_1_6351", "context": "A 51-year old physically fit woman experienced angio-oedema and hypotensive shock after irbesartan ingestion requiring noradrenaline infusion.", "question": "Subject.Population in A 51-year old physically fit woman", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "16164579_1_6352", "context": "A 51-year old physically fit woman experienced angio-oedema and hypotensive shock after irbesartan ingestion requiring noradrenaline infusion.", "question": "Subject.Race in A 51-year old physically fit woman", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16164579_1_6353", "context": "A 51-year old physically fit woman experienced angio-oedema and hypotensive shock after irbesartan ingestion requiring noradrenaline infusion.", "question": "Subject.Disorder in A 51-year old physically fit woman", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "16164579_1_6354", "context": "A 51-year old physically fit woman experienced angio-oedema and hypotensive shock after irbesartan ingestion requiring noradrenaline infusion.", "question": "Treatment.Drug in irbesartan ingestion", "question_type": "Adverse_event.Treatment.Drug", "answers": "irbesartan"}, {"id": "16164579_1_6355", "context": "A 51-year old physically fit woman experienced angio-oedema and hypotensive shock after irbesartan ingestion requiring noradrenaline infusion.", "question": "Treatment.Dosage in irbesartan ingestion", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16164579_1_6356", "context": "A 51-year old physically fit woman experienced angio-oedema and hypotensive shock after irbesartan ingestion requiring noradrenaline infusion.", "question": "Treatment.Freq in irbesartan ingestion", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16164579_1_6357", "context": "A 51-year old physically fit woman experienced angio-oedema and hypotensive shock after irbesartan ingestion requiring noradrenaline infusion.", "question": "Treatment.Route in irbesartan ingestion", "question_type": "Adverse_event.Treatment.Route", "answers": "ingestion"}, {"id": "16164579_1_6358", "context": "A 51-year old physically fit woman experienced angio-oedema and hypotensive shock after irbesartan ingestion requiring noradrenaline infusion.", "question": "Treatment.Time_elapsed in irbesartan ingestion", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16164579_1_6359", "context": "A 51-year old physically fit woman experienced angio-oedema and hypotensive shock after irbesartan ingestion requiring noradrenaline infusion.", "question": "Treatment.Duration in irbesartan ingestion", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16164579_1_6360", "context": "A 51-year old physically fit woman experienced angio-oedema and hypotensive shock after irbesartan ingestion requiring noradrenaline infusion.", "question": "Treatment.Disorder in irbesartan ingestion", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16164579_1_6361", "context": "A 51-year old physically fit woman experienced angio-oedema and hypotensive shock after irbesartan ingestion requiring noradrenaline infusion.", "question": "Combination.Drug in irbesartan ingestion", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15823103_3_6362", "context": "Our report suggested that CBDCA hypersensitivity was correlated with the total dose of previously administered platinum agents and that CBDCA should be excluded in patients who have received multiple platinum-based chemotherapy, even in platinum-sensitive cases, because CBDCA hypersensitivity can occur even with low-dose CBDCA administration.", "question": "Treatment.Drug in total dose of previously administered platinum agents", "question_type": "Adverse_event.Treatment.Drug", "answers": "platinum agents"}, {"id": "15823103_3_6363", "context": "Our report suggested that CBDCA hypersensitivity was correlated with the total dose of previously administered platinum agents and that CBDCA should be excluded in patients who have received multiple platinum-based chemotherapy, even in platinum-sensitive cases, because CBDCA hypersensitivity can occur even with low-dose CBDCA administration.", "question": "Treatment.Dosage in total dose of previously administered platinum agents", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15823103_3_6364", "context": "Our report suggested that CBDCA hypersensitivity was correlated with the total dose of previously administered platinum agents and that CBDCA should be excluded in patients who have received multiple platinum-based chemotherapy, even in platinum-sensitive cases, because CBDCA hypersensitivity can occur even with low-dose CBDCA administration.", "question": "Treatment.Freq in total dose of previously administered platinum agents", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15823103_3_6365", "context": "Our report suggested that CBDCA hypersensitivity was correlated with the total dose of previously administered platinum agents and that CBDCA should be excluded in patients who have received multiple platinum-based chemotherapy, even in platinum-sensitive cases, because CBDCA hypersensitivity can occur even with low-dose CBDCA administration.", "question": "Treatment.Route in total dose of previously administered platinum agents", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15823103_3_6366", "context": "Our report suggested that CBDCA hypersensitivity was correlated with the total dose of previously administered platinum agents and that CBDCA should be excluded in patients who have received multiple platinum-based chemotherapy, even in platinum-sensitive cases, because CBDCA hypersensitivity can occur even with low-dose CBDCA administration.", "question": "Treatment.Time_elapsed in total dose of previously administered platinum agents", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15823103_3_6367", "context": "Our report suggested that CBDCA hypersensitivity was correlated with the total dose of previously administered platinum agents and that CBDCA should be excluded in patients who have received multiple platinum-based chemotherapy, even in platinum-sensitive cases, because CBDCA hypersensitivity can occur even with low-dose CBDCA administration.", "question": "Treatment.Duration in total dose of previously administered platinum agents", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15823103_3_6368", "context": "Our report suggested that CBDCA hypersensitivity was correlated with the total dose of previously administered platinum agents and that CBDCA should be excluded in patients who have received multiple platinum-based chemotherapy, even in platinum-sensitive cases, because CBDCA hypersensitivity can occur even with low-dose CBDCA administration.", "question": "Treatment.Disorder in total dose of previously administered platinum agents", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15823103_3_6369", "context": "Our report suggested that CBDCA hypersensitivity was correlated with the total dose of previously administered platinum agents and that CBDCA should be excluded in patients who have received multiple platinum-based chemotherapy, even in platinum-sensitive cases, because CBDCA hypersensitivity can occur even with low-dose CBDCA administration.", "question": "Combination.Drug in total dose of previously administered platinum agents", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11978156_4_6370", "context": "Lansoprazole-induced thrombocytopenia.", "question": "Treatment.Drug in Lansoprazole", "question_type": "Adverse_event.Treatment.Drug", "answers": "Lansoprazole"}, {"id": "11978156_4_6371", "context": "Lansoprazole-induced thrombocytopenia.", "question": "Treatment.Dosage in Lansoprazole", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11978156_4_6372", "context": "Lansoprazole-induced thrombocytopenia.", "question": "Treatment.Freq in Lansoprazole", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11978156_4_6373", "context": "Lansoprazole-induced thrombocytopenia.", "question": "Treatment.Route in Lansoprazole", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11978156_4_6374", "context": "Lansoprazole-induced thrombocytopenia.", "question": "Treatment.Time_elapsed in Lansoprazole", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11978156_4_6375", "context": "Lansoprazole-induced thrombocytopenia.", "question": "Treatment.Duration in Lansoprazole", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11978156_4_6376", "context": "Lansoprazole-induced thrombocytopenia.", "question": "Treatment.Disorder in Lansoprazole", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11978156_4_6377", "context": "Lansoprazole-induced thrombocytopenia.", "question": "Combination.Drug in Lansoprazole", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15965422_2_6378", "context": "Cutaneous necrosis as a result of interferon alfa is an infrequent complication with unknown pathogenesis, in which a cutaneous local immune-mediated inflammatory process might be involved.", "question": "Treatment.Drug in interferon alfa", "question_type": "Adverse_event.Treatment.Drug", "answers": "interferon alfa"}, {"id": "15965422_2_6379", "context": "Cutaneous necrosis as a result of interferon alfa is an infrequent complication with unknown pathogenesis, in which a cutaneous local immune-mediated inflammatory process might be involved.", "question": "Treatment.Dosage in interferon alfa", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15965422_2_6380", "context": "Cutaneous necrosis as a result of interferon alfa is an infrequent complication with unknown pathogenesis, in which a cutaneous local immune-mediated inflammatory process might be involved.", "question": "Treatment.Freq in interferon alfa", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15965422_2_6381", "context": "Cutaneous necrosis as a result of interferon alfa is an infrequent complication with unknown pathogenesis, in which a cutaneous local immune-mediated inflammatory process might be involved.", "question": "Treatment.Route in interferon alfa", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15965422_2_6382", "context": "Cutaneous necrosis as a result of interferon alfa is an infrequent complication with unknown pathogenesis, in which a cutaneous local immune-mediated inflammatory process might be involved.", "question": "Treatment.Time_elapsed in interferon alfa", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15965422_2_6383", "context": "Cutaneous necrosis as a result of interferon alfa is an infrequent complication with unknown pathogenesis, in which a cutaneous local immune-mediated inflammatory process might be involved.", "question": "Treatment.Duration in interferon alfa", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15965422_2_6384", "context": "Cutaneous necrosis as a result of interferon alfa is an infrequent complication with unknown pathogenesis, in which a cutaneous local immune-mediated inflammatory process might be involved.", "question": "Treatment.Disorder in interferon alfa", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15965422_2_6385", "context": "Cutaneous necrosis as a result of interferon alfa is an infrequent complication with unknown pathogenesis, in which a cutaneous local immune-mediated inflammatory process might be involved.", "question": "Combination.Drug in interferon alfa", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9681092_1_6386", "context": "Torsade de pointes resulting from the addition of droperidol to an existing cytochrome P450 drug interaction.", "question": "Treatment.Drug in droperidol; cytochrome P450", "question_type": "Adverse_event.Treatment.Drug", "answers": "droperidol; cytochrome P450"}, {"id": "9681092_1_6387", "context": "Torsade de pointes resulting from the addition of droperidol to an existing cytochrome P450 drug interaction.", "question": "Treatment.Dosage in droperidol; cytochrome P450", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9681092_1_6388", "context": "Torsade de pointes resulting from the addition of droperidol to an existing cytochrome P450 drug interaction.", "question": "Treatment.Freq in droperidol; cytochrome P450", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9681092_1_6389", "context": "Torsade de pointes resulting from the addition of droperidol to an existing cytochrome P450 drug interaction.", "question": "Treatment.Route in droperidol; cytochrome P450", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9681092_1_6390", "context": "Torsade de pointes resulting from the addition of droperidol to an existing cytochrome P450 drug interaction.", "question": "Treatment.Time_elapsed in droperidol; cytochrome P450", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9681092_1_6391", "context": "Torsade de pointes resulting from the addition of droperidol to an existing cytochrome P450 drug interaction.", "question": "Treatment.Duration in droperidol; cytochrome P450", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9681092_1_6392", "context": "Torsade de pointes resulting from the addition of droperidol to an existing cytochrome P450 drug interaction.", "question": "Treatment.Disorder in droperidol; cytochrome P450", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9681092_1_6393", "context": "Torsade de pointes resulting from the addition of droperidol to an existing cytochrome P450 drug interaction.", "question": "Combination.Drug in droperidol; cytochrome P450", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17952482_2_6394", "context": "Sulfasalazine-induced hypersensitivity syndrome and hemophagocytic syndrome associated with reactivation of Epstein-Barr virus.", "question": "Treatment.Drug in Sulfasalazine", "question_type": "Adverse_event.Treatment.Drug", "answers": "Sulfasalazine"}, {"id": "17952482_2_6395", "context": "Sulfasalazine-induced hypersensitivity syndrome and hemophagocytic syndrome associated with reactivation of Epstein-Barr virus.", "question": "Treatment.Dosage in Sulfasalazine", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17952482_2_6396", "context": "Sulfasalazine-induced hypersensitivity syndrome and hemophagocytic syndrome associated with reactivation of Epstein-Barr virus.", "question": "Treatment.Freq in Sulfasalazine", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17952482_2_6397", "context": "Sulfasalazine-induced hypersensitivity syndrome and hemophagocytic syndrome associated with reactivation of Epstein-Barr virus.", "question": "Treatment.Route in Sulfasalazine", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17952482_2_6398", "context": "Sulfasalazine-induced hypersensitivity syndrome and hemophagocytic syndrome associated with reactivation of Epstein-Barr virus.", "question": "Treatment.Time_elapsed in Sulfasalazine", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17952482_2_6399", "context": "Sulfasalazine-induced hypersensitivity syndrome and hemophagocytic syndrome associated with reactivation of Epstein-Barr virus.", "question": "Treatment.Duration in Sulfasalazine", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17952482_2_6400", "context": "Sulfasalazine-induced hypersensitivity syndrome and hemophagocytic syndrome associated with reactivation of Epstein-Barr virus.", "question": "Treatment.Disorder in Sulfasalazine", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17952482_2_6401", "context": "Sulfasalazine-induced hypersensitivity syndrome and hemophagocytic syndrome associated with reactivation of Epstein-Barr virus.", "question": "Combination.Drug in Sulfasalazine", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11335880_4_6402", "context": "OBJECTIVES: The authors described a case of Hashimoto's disease during interferon-alpha (IFN-alpha) treatment for chronic viral C hepatitis in a patient with the specific genetic susceptibility associated with the thyroid disease.", "question": "Subject.Age in a patient with the specific genetic susceptibility associated with the thyroid disease", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "11335880_4_6403", "context": "OBJECTIVES: The authors described a case of Hashimoto's disease during interferon-alpha (IFN-alpha) treatment for chronic viral C hepatitis in a patient with the specific genetic susceptibility associated with the thyroid disease.", "question": "Subject.Gender in a patient with the specific genetic susceptibility associated with the thyroid disease", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "11335880_4_6404", "context": "OBJECTIVES: The authors described a case of Hashimoto's disease during interferon-alpha (IFN-alpha) treatment for chronic viral C hepatitis in a patient with the specific genetic susceptibility associated with the thyroid disease.", "question": "Subject.Population in a patient with the specific genetic susceptibility associated with the thyroid disease", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "11335880_4_6405", "context": "OBJECTIVES: The authors described a case of Hashimoto's disease during interferon-alpha (IFN-alpha) treatment for chronic viral C hepatitis in a patient with the specific genetic susceptibility associated with the thyroid disease.", "question": "Subject.Race in a patient with the specific genetic susceptibility associated with the thyroid disease", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "11335880_4_6406", "context": "OBJECTIVES: The authors described a case of Hashimoto's disease during interferon-alpha (IFN-alpha) treatment for chronic viral C hepatitis in a patient with the specific genetic susceptibility associated with the thyroid disease.", "question": "Subject.Disorder in a patient with the specific genetic susceptibility associated with the thyroid disease", "question_type": "Adverse_event.Subject.Disorder", "answers": "specific genetic susceptibility"}, {"id": "11335880_4_6407", "context": "OBJECTIVES: The authors described a case of Hashimoto's disease during interferon-alpha (IFN-alpha) treatment for chronic viral C hepatitis in a patient with the specific genetic susceptibility associated with the thyroid disease.", "question": "Treatment.Drug in interferon-alpha (IFN-alpha) treatment", "question_type": "Adverse_event.Treatment.Drug", "answers": "interferon-alpha"}, {"id": "11335880_4_6408", "context": "OBJECTIVES: The authors described a case of Hashimoto's disease during interferon-alpha (IFN-alpha) treatment for chronic viral C hepatitis in a patient with the specific genetic susceptibility associated with the thyroid disease.", "question": "Treatment.Dosage in interferon-alpha (IFN-alpha) treatment", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11335880_4_6409", "context": "OBJECTIVES: The authors described a case of Hashimoto's disease during interferon-alpha (IFN-alpha) treatment for chronic viral C hepatitis in a patient with the specific genetic susceptibility associated with the thyroid disease.", "question": "Treatment.Freq in interferon-alpha (IFN-alpha) treatment", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11335880_4_6410", "context": "OBJECTIVES: The authors described a case of Hashimoto's disease during interferon-alpha (IFN-alpha) treatment for chronic viral C hepatitis in a patient with the specific genetic susceptibility associated with the thyroid disease.", "question": "Treatment.Route in interferon-alpha (IFN-alpha) treatment", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11335880_4_6411", "context": "OBJECTIVES: The authors described a case of Hashimoto's disease during interferon-alpha (IFN-alpha) treatment for chronic viral C hepatitis in a patient with the specific genetic susceptibility associated with the thyroid disease.", "question": "Treatment.Time_elapsed in interferon-alpha (IFN-alpha) treatment", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11335880_4_6412", "context": "OBJECTIVES: The authors described a case of Hashimoto's disease during interferon-alpha (IFN-alpha) treatment for chronic viral C hepatitis in a patient with the specific genetic susceptibility associated with the thyroid disease.", "question": "Treatment.Duration in interferon-alpha (IFN-alpha) treatment", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11335880_4_6413", "context": "OBJECTIVES: The authors described a case of Hashimoto's disease during interferon-alpha (IFN-alpha) treatment for chronic viral C hepatitis in a patient with the specific genetic susceptibility associated with the thyroid disease.", "question": "Treatment.Disorder in interferon-alpha (IFN-alpha) treatment", "question_type": "Adverse_event.Treatment.Disorder", "answers": "chronic viral C hepatitis"}, {"id": "11335880_4_6414", "context": "OBJECTIVES: The authors described a case of Hashimoto's disease during interferon-alpha (IFN-alpha) treatment for chronic viral C hepatitis in a patient with the specific genetic susceptibility associated with the thyroid disease.", "question": "Combination.Drug in interferon-alpha (IFN-alpha) treatment", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8739289_2_6415", "context": "Nephrogenic diabetes insipidus (NDI) is a well-documented complication of lithium use.", "question": "Treatment.Drug in lithium", "question_type": "Adverse_event.Treatment.Drug", "answers": "lithium"}, {"id": "8739289_2_6416", "context": "Nephrogenic diabetes insipidus (NDI) is a well-documented complication of lithium use.", "question": "Treatment.Dosage in lithium", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8739289_2_6417", "context": "Nephrogenic diabetes insipidus (NDI) is a well-documented complication of lithium use.", "question": "Treatment.Freq in lithium", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8739289_2_6418", "context": "Nephrogenic diabetes insipidus (NDI) is a well-documented complication of lithium use.", "question": "Treatment.Route in lithium", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8739289_2_6419", "context": "Nephrogenic diabetes insipidus (NDI) is a well-documented complication of lithium use.", "question": "Treatment.Time_elapsed in lithium", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8739289_2_6420", "context": "Nephrogenic diabetes insipidus (NDI) is a well-documented complication of lithium use.", "question": "Treatment.Duration in lithium", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8739289_2_6421", "context": "Nephrogenic diabetes insipidus (NDI) is a well-documented complication of lithium use.", "question": "Treatment.Disorder in lithium", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8739289_2_6422", "context": "Nephrogenic diabetes insipidus (NDI) is a well-documented complication of lithium use.", "question": "Combination.Drug in lithium", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15827071_1_6423", "context": "Serotonin toxicity associated with concomitant use of linezolid.", "question": "Treatment.Drug in concomitant use of linezolid; Serotonin", "question_type": "Adverse_event.Treatment.Drug", "answers": "linezolid; Serotonin"}, {"id": "15827071_1_6424", "context": "Serotonin toxicity associated with concomitant use of linezolid.", "question": "Treatment.Dosage in concomitant use of linezolid; Serotonin", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15827071_1_6425", "context": "Serotonin toxicity associated with concomitant use of linezolid.", "question": "Treatment.Freq in concomitant use of linezolid; Serotonin", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15827071_1_6426", "context": "Serotonin toxicity associated with concomitant use of linezolid.", "question": "Treatment.Route in concomitant use of linezolid; Serotonin", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15827071_1_6427", "context": "Serotonin toxicity associated with concomitant use of linezolid.", "question": "Treatment.Time_elapsed in concomitant use of linezolid; Serotonin", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15827071_1_6428", "context": "Serotonin toxicity associated with concomitant use of linezolid.", "question": "Treatment.Duration in concomitant use of linezolid; Serotonin", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15827071_1_6429", "context": "Serotonin toxicity associated with concomitant use of linezolid.", "question": "Treatment.Disorder in concomitant use of linezolid; Serotonin", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15827071_1_6430", "context": "Serotonin toxicity associated with concomitant use of linezolid.", "question": "Combination.Drug in concomitant use of linezolid; Serotonin", "question_type": "Adverse_event.Combination.Drug", "answers": "Serotonin; linezolid"}, {"id": "16221163_3_6431", "context": "We report the case of a 30-year-old male after kidney transplantation, treated with steroids, cyclosporin A and SRL, with steroid-resistant acute rejection in anamnesis.", "question": "Subject.Age in the case of a 30-year-old male", "question_type": "Adverse_event.Subject.Age", "answers": "30-year-old"}, {"id": "16221163_3_6432", "context": "We report the case of a 30-year-old male after kidney transplantation, treated with steroids, cyclosporin A and SRL, with steroid-resistant acute rejection in anamnesis.", "question": "Subject.Gender in the case of a 30-year-old male", "question_type": "Adverse_event.Subject.Gender", "answers": "male"}, {"id": "16221163_3_6433", "context": "We report the case of a 30-year-old male after kidney transplantation, treated with steroids, cyclosporin A and SRL, with steroid-resistant acute rejection in anamnesis.", "question": "Subject.Population in the case of a 30-year-old male", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "16221163_3_6434", "context": "We report the case of a 30-year-old male after kidney transplantation, treated with steroids, cyclosporin A and SRL, with steroid-resistant acute rejection in anamnesis.", "question": "Subject.Race in the case of a 30-year-old male", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16221163_3_6435", "context": "We report the case of a 30-year-old male after kidney transplantation, treated with steroids, cyclosporin A and SRL, with steroid-resistant acute rejection in anamnesis.", "question": "Subject.Disorder in the case of a 30-year-old male", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "16221163_3_6436", "context": "We report the case of a 30-year-old male after kidney transplantation, treated with steroids, cyclosporin A and SRL, with steroid-resistant acute rejection in anamnesis.", "question": "Treatment.Drug in kidney transplantation, treated with steroids, cyclosporin A and SRL", "question_type": "Adverse_event.Treatment.Drug", "answers": "steroids; cyclosporin A; SRL"}, {"id": "16221163_3_6437", "context": "We report the case of a 30-year-old male after kidney transplantation, treated with steroids, cyclosporin A and SRL, with steroid-resistant acute rejection in anamnesis.", "question": "Treatment.Dosage in kidney transplantation, treated with steroids, cyclosporin A and SRL", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16221163_3_6438", "context": "We report the case of a 30-year-old male after kidney transplantation, treated with steroids, cyclosporin A and SRL, with steroid-resistant acute rejection in anamnesis.", "question": "Treatment.Freq in kidney transplantation, treated with steroids, cyclosporin A and SRL", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16221163_3_6439", "context": "We report the case of a 30-year-old male after kidney transplantation, treated with steroids, cyclosporin A and SRL, with steroid-resistant acute rejection in anamnesis.", "question": "Treatment.Route in kidney transplantation, treated with steroids, cyclosporin A and SRL", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16221163_3_6440", "context": "We report the case of a 30-year-old male after kidney transplantation, treated with steroids, cyclosporin A and SRL, with steroid-resistant acute rejection in anamnesis.", "question": "Treatment.Time_elapsed in kidney transplantation, treated with steroids, cyclosporin A and SRL", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16221163_3_6441", "context": "We report the case of a 30-year-old male after kidney transplantation, treated with steroids, cyclosporin A and SRL, with steroid-resistant acute rejection in anamnesis.", "question": "Treatment.Duration in kidney transplantation, treated with steroids, cyclosporin A and SRL", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16221163_3_6442", "context": "We report the case of a 30-year-old male after kidney transplantation, treated with steroids, cyclosporin A and SRL, with steroid-resistant acute rejection in anamnesis.", "question": "Treatment.Disorder in kidney transplantation, treated with steroids, cyclosporin A and SRL", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16221163_3_6443", "context": "We report the case of a 30-year-old male after kidney transplantation, treated with steroids, cyclosporin A and SRL, with steroid-resistant acute rejection in anamnesis.", "question": "Combination.Drug in kidney transplantation, treated with steroids, cyclosporin A and SRL", "question_type": "Adverse_event.Combination.Drug", "answers": "steroids; cyclosporin A; SRL"}, {"id": "8933322_2_6444", "context": "Infants are particularly susceptible to chronic nitrate-induced methemoglobinemia because of their low stomach acid production, large numbers of nitrite-reducing bacteria, and the relatively easy oxidation of fetal hemoglobin.", "question": "Subject.Age in Infants", "question_type": "Adverse_event.Subject.Age", "answers": "Infants"}, {"id": "8933322_2_6445", "context": "Infants are particularly susceptible to chronic nitrate-induced methemoglobinemia because of their low stomach acid production, large numbers of nitrite-reducing bacteria, and the relatively easy oxidation of fetal hemoglobin.", "question": "Subject.Gender in Infants", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "8933322_2_6446", "context": "Infants are particularly susceptible to chronic nitrate-induced methemoglobinemia because of their low stomach acid production, large numbers of nitrite-reducing bacteria, and the relatively easy oxidation of fetal hemoglobin.", "question": "Subject.Population in Infants", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "8933322_2_6447", "context": "Infants are particularly susceptible to chronic nitrate-induced methemoglobinemia because of their low stomach acid production, large numbers of nitrite-reducing bacteria, and the relatively easy oxidation of fetal hemoglobin.", "question": "Subject.Race in Infants", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "8933322_2_6448", "context": "Infants are particularly susceptible to chronic nitrate-induced methemoglobinemia because of their low stomach acid production, large numbers of nitrite-reducing bacteria, and the relatively easy oxidation of fetal hemoglobin.", "question": "Subject.Disorder in Infants", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "8933322_2_6449", "context": "Infants are particularly susceptible to chronic nitrate-induced methemoglobinemia because of their low stomach acid production, large numbers of nitrite-reducing bacteria, and the relatively easy oxidation of fetal hemoglobin.", "question": "Treatment.Drug in nitrate", "question_type": "Adverse_event.Treatment.Drug", "answers": "nitrate"}, {"id": "8933322_2_6450", "context": "Infants are particularly susceptible to chronic nitrate-induced methemoglobinemia because of their low stomach acid production, large numbers of nitrite-reducing bacteria, and the relatively easy oxidation of fetal hemoglobin.", "question": "Treatment.Dosage in nitrate", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8933322_2_6451", "context": "Infants are particularly susceptible to chronic nitrate-induced methemoglobinemia because of their low stomach acid production, large numbers of nitrite-reducing bacteria, and the relatively easy oxidation of fetal hemoglobin.", "question": "Treatment.Freq in nitrate", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8933322_2_6452", "context": "Infants are particularly susceptible to chronic nitrate-induced methemoglobinemia because of their low stomach acid production, large numbers of nitrite-reducing bacteria, and the relatively easy oxidation of fetal hemoglobin.", "question": "Treatment.Route in nitrate", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8933322_2_6453", "context": "Infants are particularly susceptible to chronic nitrate-induced methemoglobinemia because of their low stomach acid production, large numbers of nitrite-reducing bacteria, and the relatively easy oxidation of fetal hemoglobin.", "question": "Treatment.Time_elapsed in nitrate", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8933322_2_6454", "context": "Infants are particularly susceptible to chronic nitrate-induced methemoglobinemia because of their low stomach acid production, large numbers of nitrite-reducing bacteria, and the relatively easy oxidation of fetal hemoglobin.", "question": "Treatment.Duration in nitrate", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8933322_2_6455", "context": "Infants are particularly susceptible to chronic nitrate-induced methemoglobinemia because of their low stomach acid production, large numbers of nitrite-reducing bacteria, and the relatively easy oxidation of fetal hemoglobin.", "question": "Treatment.Disorder in nitrate", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8933322_2_6456", "context": "Infants are particularly susceptible to chronic nitrate-induced methemoglobinemia because of their low stomach acid production, large numbers of nitrite-reducing bacteria, and the relatively easy oxidation of fetal hemoglobin.", "question": "Combination.Drug in nitrate", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16580907_2_6457", "context": "A 72-year-old woman with renal insufficiency who was taking oral pilsicainide (150 mg/d) complained of feeling faint 3 days after she was prescribed oral cetirizine (20 mg/d).", "question": "Subject.Age in A 72-year-old woman with renal insufficiency", "question_type": "Adverse_event.Subject.Age", "answers": "72-year-old"}, {"id": "16580907_2_6458", "context": "A 72-year-old woman with renal insufficiency who was taking oral pilsicainide (150 mg/d) complained of feeling faint 3 days after she was prescribed oral cetirizine (20 mg/d).", "question": "Subject.Gender in A 72-year-old woman with renal insufficiency", "question_type": "Adverse_event.Subject.Gender", "answers": "woman"}, {"id": "16580907_2_6459", "context": "A 72-year-old woman with renal insufficiency who was taking oral pilsicainide (150 mg/d) complained of feeling faint 3 days after she was prescribed oral cetirizine (20 mg/d).", "question": "Subject.Population in A 72-year-old woman with renal insufficiency", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "16580907_2_6460", "context": "A 72-year-old woman with renal insufficiency who was taking oral pilsicainide (150 mg/d) complained of feeling faint 3 days after she was prescribed oral cetirizine (20 mg/d).", "question": "Subject.Race in A 72-year-old woman with renal insufficiency", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16580907_2_6461", "context": "A 72-year-old woman with renal insufficiency who was taking oral pilsicainide (150 mg/d) complained of feeling faint 3 days after she was prescribed oral cetirizine (20 mg/d).", "question": "Subject.Disorder in A 72-year-old woman with renal insufficiency", "question_type": "Adverse_event.Subject.Disorder", "answers": "renal insufficiency"}, {"id": "16580907_2_6462", "context": "A 72-year-old woman with renal insufficiency who was taking oral pilsicainide (150 mg/d) complained of feeling faint 3 days after she was prescribed oral cetirizine (20 mg/d).", "question": "Treatment.Drug in taking oral pilsicainide (150 mg/d); 3 days after she was prescribed oral cetirizine (20 mg/d)", "question_type": "Adverse_event.Treatment.Drug", "answers": "pilsicainide; cetirizine"}, {"id": "16580907_2_6463", "context": "A 72-year-old woman with renal insufficiency who was taking oral pilsicainide (150 mg/d) complained of feeling faint 3 days after she was prescribed oral cetirizine (20 mg/d).", "question": "Treatment.Dosage in taking oral pilsicainide (150 mg/d); 3 days after she was prescribed oral cetirizine (20 mg/d)", "question_type": "Adverse_event.Treatment.Dosage", "answers": "150 mg/d; 20 mg/d"}, {"id": "16580907_2_6464", "context": "A 72-year-old woman with renal insufficiency who was taking oral pilsicainide (150 mg/d) complained of feeling faint 3 days after she was prescribed oral cetirizine (20 mg/d).", "question": "Treatment.Freq in taking oral pilsicainide (150 mg/d); 3 days after she was prescribed oral cetirizine (20 mg/d)", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16580907_2_6465", "context": "A 72-year-old woman with renal insufficiency who was taking oral pilsicainide (150 mg/d) complained of feeling faint 3 days after she was prescribed oral cetirizine (20 mg/d).", "question": "Treatment.Route in taking oral pilsicainide (150 mg/d); 3 days after she was prescribed oral cetirizine (20 mg/d)", "question_type": "Adverse_event.Treatment.Route", "answers": "oral; oral"}, {"id": "16580907_2_6466", "context": "A 72-year-old woman with renal insufficiency who was taking oral pilsicainide (150 mg/d) complained of feeling faint 3 days after she was prescribed oral cetirizine (20 mg/d).", "question": "Treatment.Time_elapsed in taking oral pilsicainide (150 mg/d); 3 days after she was prescribed oral cetirizine (20 mg/d)", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "3 days"}, {"id": "16580907_2_6467", "context": "A 72-year-old woman with renal insufficiency who was taking oral pilsicainide (150 mg/d) complained of feeling faint 3 days after she was prescribed oral cetirizine (20 mg/d).", "question": "Treatment.Duration in taking oral pilsicainide (150 mg/d); 3 days after she was prescribed oral cetirizine (20 mg/d)", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16580907_2_6468", "context": "A 72-year-old woman with renal insufficiency who was taking oral pilsicainide (150 mg/d) complained of feeling faint 3 days after she was prescribed oral cetirizine (20 mg/d).", "question": "Treatment.Disorder in taking oral pilsicainide (150 mg/d); 3 days after she was prescribed oral cetirizine (20 mg/d)", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16580907_2_6469", "context": "A 72-year-old woman with renal insufficiency who was taking oral pilsicainide (150 mg/d) complained of feeling faint 3 days after she was prescribed oral cetirizine (20 mg/d).", "question": "Combination.Drug in taking oral pilsicainide (150 mg/d); 3 days after she was prescribed oral cetirizine (20 mg/d)", "question_type": "Adverse_event.Combination.Drug", "answers": "cetirizine; pilsicainide"}, {"id": "16615675_2_6470", "context": "Chronic hydroxychloroquine use associated with QT prolongation and refractory ventricular arrhythmia.", "question": "Treatment.Drug in Chronic hydroxychloroquine", "question_type": "Adverse_event.Treatment.Drug", "answers": "hydroxychloroquine"}, {"id": "16615675_2_6471", "context": "Chronic hydroxychloroquine use associated with QT prolongation and refractory ventricular arrhythmia.", "question": "Treatment.Dosage in Chronic hydroxychloroquine", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16615675_2_6472", "context": "Chronic hydroxychloroquine use associated with QT prolongation and refractory ventricular arrhythmia.", "question": "Treatment.Freq in Chronic hydroxychloroquine", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16615675_2_6473", "context": "Chronic hydroxychloroquine use associated with QT prolongation and refractory ventricular arrhythmia.", "question": "Treatment.Route in Chronic hydroxychloroquine", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16615675_2_6474", "context": "Chronic hydroxychloroquine use associated with QT prolongation and refractory ventricular arrhythmia.", "question": "Treatment.Time_elapsed in Chronic hydroxychloroquine", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16615675_2_6475", "context": "Chronic hydroxychloroquine use associated with QT prolongation and refractory ventricular arrhythmia.", "question": "Treatment.Duration in Chronic hydroxychloroquine", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16615675_2_6476", "context": "Chronic hydroxychloroquine use associated with QT prolongation and refractory ventricular arrhythmia.", "question": "Treatment.Disorder in Chronic hydroxychloroquine", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16615675_2_6477", "context": "Chronic hydroxychloroquine use associated with QT prolongation and refractory ventricular arrhythmia.", "question": "Combination.Drug in Chronic hydroxychloroquine", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10610018_3_6478", "context": "This increase when clozapine was switched to risperidone and vice versa is consistent with our previous report of elevated serum triglyceride levels in clozapine-treated patients.", "question": "Subject.Age in patients", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "10610018_3_6479", "context": "This increase when clozapine was switched to risperidone and vice versa is consistent with our previous report of elevated serum triglyceride levels in clozapine-treated patients.", "question": "Subject.Gender in patients", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "10610018_3_6480", "context": "This increase when clozapine was switched to risperidone and vice versa is consistent with our previous report of elevated serum triglyceride levels in clozapine-treated patients.", "question": "Subject.Population in patients", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "10610018_3_6481", "context": "This increase when clozapine was switched to risperidone and vice versa is consistent with our previous report of elevated serum triglyceride levels in clozapine-treated patients.", "question": "Subject.Race in patients", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "10610018_3_6482", "context": "This increase when clozapine was switched to risperidone and vice versa is consistent with our previous report of elevated serum triglyceride levels in clozapine-treated patients.", "question": "Subject.Disorder in patients", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "10610018_3_6483", "context": "This increase when clozapine was switched to risperidone and vice versa is consistent with our previous report of elevated serum triglyceride levels in clozapine-treated patients.", "question": "Treatment.Drug in clozapine was switched to risperidone and vice versa", "question_type": "Adverse_event.Treatment.Drug", "answers": "clozapine; risperidone"}, {"id": "10610018_3_6484", "context": "This increase when clozapine was switched to risperidone and vice versa is consistent with our previous report of elevated serum triglyceride levels in clozapine-treated patients.", "question": "Treatment.Dosage in clozapine was switched to risperidone and vice versa", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10610018_3_6485", "context": "This increase when clozapine was switched to risperidone and vice versa is consistent with our previous report of elevated serum triglyceride levels in clozapine-treated patients.", "question": "Treatment.Freq in clozapine was switched to risperidone and vice versa", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10610018_3_6486", "context": "This increase when clozapine was switched to risperidone and vice versa is consistent with our previous report of elevated serum triglyceride levels in clozapine-treated patients.", "question": "Treatment.Route in clozapine was switched to risperidone and vice versa", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10610018_3_6487", "context": "This increase when clozapine was switched to risperidone and vice versa is consistent with our previous report of elevated serum triglyceride levels in clozapine-treated patients.", "question": "Treatment.Time_elapsed in clozapine was switched to risperidone and vice versa", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10610018_3_6488", "context": "This increase when clozapine was switched to risperidone and vice versa is consistent with our previous report of elevated serum triglyceride levels in clozapine-treated patients.", "question": "Treatment.Duration in clozapine was switched to risperidone and vice versa", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10610018_3_6489", "context": "This increase when clozapine was switched to risperidone and vice versa is consistent with our previous report of elevated serum triglyceride levels in clozapine-treated patients.", "question": "Treatment.Disorder in clozapine was switched to risperidone and vice versa", "question_type": "Adverse_event.Treatment.Disorder", "answers": "elevated serum triglyceride levels"}, {"id": "10610018_3_6490", "context": "This increase when clozapine was switched to risperidone and vice versa is consistent with our previous report of elevated serum triglyceride levels in clozapine-treated patients.", "question": "Combination.Drug in clozapine was switched to risperidone and vice versa", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12763355_2_6491", "context": "Sensorimotor polyneuropathy with 5-aminosalicylic acid: a case report.", "question": "Subject.Age in a case", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "12763355_2_6492", "context": "Sensorimotor polyneuropathy with 5-aminosalicylic acid: a case report.", "question": "Subject.Gender in a case", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "12763355_2_6493", "context": "Sensorimotor polyneuropathy with 5-aminosalicylic acid: a case report.", "question": "Subject.Population in a case", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "12763355_2_6494", "context": "Sensorimotor polyneuropathy with 5-aminosalicylic acid: a case report.", "question": "Subject.Race in a case", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "12763355_2_6495", "context": "Sensorimotor polyneuropathy with 5-aminosalicylic acid: a case report.", "question": "Subject.Disorder in a case", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "12763355_2_6496", "context": "Sensorimotor polyneuropathy with 5-aminosalicylic acid: a case report.", "question": "Treatment.Drug in 5-aminosalicylic acid", "question_type": "Adverse_event.Treatment.Drug", "answers": "5-aminosalicylic acid"}, {"id": "12763355_2_6497", "context": "Sensorimotor polyneuropathy with 5-aminosalicylic acid: a case report.", "question": "Treatment.Dosage in 5-aminosalicylic acid", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12763355_2_6498", "context": "Sensorimotor polyneuropathy with 5-aminosalicylic acid: a case report.", "question": "Treatment.Freq in 5-aminosalicylic acid", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12763355_2_6499", "context": "Sensorimotor polyneuropathy with 5-aminosalicylic acid: a case report.", "question": "Treatment.Route in 5-aminosalicylic acid", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12763355_2_6500", "context": "Sensorimotor polyneuropathy with 5-aminosalicylic acid: a case report.", "question": "Treatment.Time_elapsed in 5-aminosalicylic acid", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12763355_2_6501", "context": "Sensorimotor polyneuropathy with 5-aminosalicylic acid: a case report.", "question": "Treatment.Duration in 5-aminosalicylic acid", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12763355_2_6502", "context": "Sensorimotor polyneuropathy with 5-aminosalicylic acid: a case report.", "question": "Treatment.Disorder in 5-aminosalicylic acid", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12763355_2_6503", "context": "Sensorimotor polyneuropathy with 5-aminosalicylic acid: a case report.", "question": "Combination.Drug in 5-aminosalicylic acid", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8329789_7_6504", "context": "Hydrocortisone prophylaxis and verapamil therapy were the primary therapies used in patient 1 (the only survivor).", "question": "Subject.Age in patient 1 (the only survivor)", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "8329789_7_6505", "context": "Hydrocortisone prophylaxis and verapamil therapy were the primary therapies used in patient 1 (the only survivor).", "question": "Subject.Gender in patient 1 (the only survivor)", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "8329789_7_6506", "context": "Hydrocortisone prophylaxis and verapamil therapy were the primary therapies used in patient 1 (the only survivor).", "question": "Subject.Population in patient 1 (the only survivor)", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "8329789_7_6507", "context": "Hydrocortisone prophylaxis and verapamil therapy were the primary therapies used in patient 1 (the only survivor).", "question": "Subject.Race in patient 1 (the only survivor)", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "8329789_7_6508", "context": "Hydrocortisone prophylaxis and verapamil therapy were the primary therapies used in patient 1 (the only survivor).", "question": "Subject.Disorder in patient 1 (the only survivor)", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "8329789_7_6509", "context": "Hydrocortisone prophylaxis and verapamil therapy were the primary therapies used in patient 1 (the only survivor).", "question": "Treatment.Drug in Hydrocortisone prophylaxis and verapamil therapy", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "Hydrocortisone; verapamil"}, {"id": "8329789_7_6510", "context": "Hydrocortisone prophylaxis and verapamil therapy were the primary therapies used in patient 1 (the only survivor).", "question": "Treatment.Dosage in Hydrocortisone prophylaxis and verapamil therapy", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "8329789_7_6511", "context": "Hydrocortisone prophylaxis and verapamil therapy were the primary therapies used in patient 1 (the only survivor).", "question": "Treatment.Freq in Hydrocortisone prophylaxis and verapamil therapy", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "8329789_7_6512", "context": "Hydrocortisone prophylaxis and verapamil therapy were the primary therapies used in patient 1 (the only survivor).", "question": "Treatment.Route in Hydrocortisone prophylaxis and verapamil therapy", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "8329789_7_6513", "context": "Hydrocortisone prophylaxis and verapamil therapy were the primary therapies used in patient 1 (the only survivor).", "question": "Treatment.Time_elapsed in Hydrocortisone prophylaxis and verapamil therapy", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8329789_7_6514", "context": "Hydrocortisone prophylaxis and verapamil therapy were the primary therapies used in patient 1 (the only survivor).", "question": "Treatment.Duration in Hydrocortisone prophylaxis and verapamil therapy", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "8329789_7_6515", "context": "Hydrocortisone prophylaxis and verapamil therapy were the primary therapies used in patient 1 (the only survivor).", "question": "Treatment.Disorder in Hydrocortisone prophylaxis and verapamil therapy", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "8329789_7_6516", "context": "Hydrocortisone prophylaxis and verapamil therapy were the primary therapies used in patient 1 (the only survivor).", "question": "Combination.Drug in Hydrocortisone prophylaxis and verapamil therapy", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "160443_2_6517", "context": "The clinical aspect closely resembled classical transient global amnesia but the episode after clioquinol lasted longer (24 hours to three days) and a more or less extensive retrograde amnesia persisted permanently.", "question": "Treatment.Drug in clioquinol", "question_type": "Adverse_event.Treatment.Drug", "answers": "clioquinol"}, {"id": "160443_2_6518", "context": "The clinical aspect closely resembled classical transient global amnesia but the episode after clioquinol lasted longer (24 hours to three days) and a more or less extensive retrograde amnesia persisted permanently.", "question": "Treatment.Dosage in clioquinol", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "160443_2_6519", "context": "The clinical aspect closely resembled classical transient global amnesia but the episode after clioquinol lasted longer (24 hours to three days) and a more or less extensive retrograde amnesia persisted permanently.", "question": "Treatment.Freq in clioquinol", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "160443_2_6520", "context": "The clinical aspect closely resembled classical transient global amnesia but the episode after clioquinol lasted longer (24 hours to three days) and a more or less extensive retrograde amnesia persisted permanently.", "question": "Treatment.Route in clioquinol", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "160443_2_6521", "context": "The clinical aspect closely resembled classical transient global amnesia but the episode after clioquinol lasted longer (24 hours to three days) and a more or less extensive retrograde amnesia persisted permanently.", "question": "Treatment.Time_elapsed in clioquinol", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "160443_2_6522", "context": "The clinical aspect closely resembled classical transient global amnesia but the episode after clioquinol lasted longer (24 hours to three days) and a more or less extensive retrograde amnesia persisted permanently.", "question": "Treatment.Duration in clioquinol", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "160443_2_6523", "context": "The clinical aspect closely resembled classical transient global amnesia but the episode after clioquinol lasted longer (24 hours to three days) and a more or less extensive retrograde amnesia persisted permanently.", "question": "Treatment.Disorder in clioquinol", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "160443_2_6524", "context": "The clinical aspect closely resembled classical transient global amnesia but the episode after clioquinol lasted longer (24 hours to three days) and a more or less extensive retrograde amnesia persisted permanently.", "question": "Combination.Drug in clioquinol", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12729371_2_6525", "context": "We report a case of AILD in an 80-year-old male who presented with a generalized pruritic maculopapular eruption and fever following doxycycline administration.", "question": "Subject.Age in a case of AILD in an 80-year-old male", "question_type": "Adverse_event.Subject.Age", "answers": "80-year-old"}, {"id": "12729371_2_6526", "context": "We report a case of AILD in an 80-year-old male who presented with a generalized pruritic maculopapular eruption and fever following doxycycline administration.", "question": "Subject.Gender in a case of AILD in an 80-year-old male", "question_type": "Adverse_event.Subject.Gender", "answers": "male"}, {"id": "12729371_2_6527", "context": "We report a case of AILD in an 80-year-old male who presented with a generalized pruritic maculopapular eruption and fever following doxycycline administration.", "question": "Subject.Population in a case of AILD in an 80-year-old male", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "12729371_2_6528", "context": "We report a case of AILD in an 80-year-old male who presented with a generalized pruritic maculopapular eruption and fever following doxycycline administration.", "question": "Subject.Race in a case of AILD in an 80-year-old male", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "12729371_2_6529", "context": "We report a case of AILD in an 80-year-old male who presented with a generalized pruritic maculopapular eruption and fever following doxycycline administration.", "question": "Subject.Disorder in a case of AILD in an 80-year-old male", "question_type": "Adverse_event.Subject.Disorder", "answers": "AILD"}, {"id": "12729371_2_6530", "context": "We report a case of AILD in an 80-year-old male who presented with a generalized pruritic maculopapular eruption and fever following doxycycline administration.", "question": "Treatment.Drug in doxycycline administration", "question_type": "Adverse_event.Treatment.Drug", "answers": "doxycycline"}, {"id": "12729371_2_6531", "context": "We report a case of AILD in an 80-year-old male who presented with a generalized pruritic maculopapular eruption and fever following doxycycline administration.", "question": "Treatment.Dosage in doxycycline administration", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12729371_2_6532", "context": "We report a case of AILD in an 80-year-old male who presented with a generalized pruritic maculopapular eruption and fever following doxycycline administration.", "question": "Treatment.Freq in doxycycline administration", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12729371_2_6533", "context": "We report a case of AILD in an 80-year-old male who presented with a generalized pruritic maculopapular eruption and fever following doxycycline administration.", "question": "Treatment.Route in doxycycline administration", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12729371_2_6534", "context": "We report a case of AILD in an 80-year-old male who presented with a generalized pruritic maculopapular eruption and fever following doxycycline administration.", "question": "Treatment.Time_elapsed in doxycycline administration", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12729371_2_6535", "context": "We report a case of AILD in an 80-year-old male who presented with a generalized pruritic maculopapular eruption and fever following doxycycline administration.", "question": "Treatment.Duration in doxycycline administration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12729371_2_6536", "context": "We report a case of AILD in an 80-year-old male who presented with a generalized pruritic maculopapular eruption and fever following doxycycline administration.", "question": "Treatment.Disorder in doxycycline administration", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12729371_2_6537", "context": "We report a case of AILD in an 80-year-old male who presented with a generalized pruritic maculopapular eruption and fever following doxycycline administration.", "question": "Combination.Drug in doxycycline administration", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16092915_2_6538", "context": "OBJECTIVE: To our knowledge, this is the first published case report of an adolescent girl with a mitochondrial disorder and depression who displayed both new-onset psychotic and increased mood symptoms during treatment with risperidone.", "question": "Subject.Age in an adolescent girl with a mitochondrial disorder and depression", "question_type": "Adverse_event.Subject.Age", "answers": "adolescent"}, {"id": "16092915_2_6539", "context": "OBJECTIVE: To our knowledge, this is the first published case report of an adolescent girl with a mitochondrial disorder and depression who displayed both new-onset psychotic and increased mood symptoms during treatment with risperidone.", "question": "Subject.Gender in an adolescent girl with a mitochondrial disorder and depression", "question_type": "Adverse_event.Subject.Gender", "answers": "girl"}, {"id": "16092915_2_6540", "context": "OBJECTIVE: To our knowledge, this is the first published case report of an adolescent girl with a mitochondrial disorder and depression who displayed both new-onset psychotic and increased mood symptoms during treatment with risperidone.", "question": "Subject.Population in an adolescent girl with a mitochondrial disorder and depression", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "16092915_2_6541", "context": "OBJECTIVE: To our knowledge, this is the first published case report of an adolescent girl with a mitochondrial disorder and depression who displayed both new-onset psychotic and increased mood symptoms during treatment with risperidone.", "question": "Subject.Race in an adolescent girl with a mitochondrial disorder and depression", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16092915_2_6542", "context": "OBJECTIVE: To our knowledge, this is the first published case report of an adolescent girl with a mitochondrial disorder and depression who displayed both new-onset psychotic and increased mood symptoms during treatment with risperidone.", "question": "Subject.Disorder in an adolescent girl with a mitochondrial disorder and depression", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "16092915_2_6543", "context": "OBJECTIVE: To our knowledge, this is the first published case report of an adolescent girl with a mitochondrial disorder and depression who displayed both new-onset psychotic and increased mood symptoms during treatment with risperidone.", "question": "Treatment.Drug in risperidone", "question_type": "Adverse_event.Treatment.Drug", "answers": "risperidone"}, {"id": "16092915_2_6544", "context": "OBJECTIVE: To our knowledge, this is the first published case report of an adolescent girl with a mitochondrial disorder and depression who displayed both new-onset psychotic and increased mood symptoms during treatment with risperidone.", "question": "Treatment.Dosage in risperidone", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16092915_2_6545", "context": "OBJECTIVE: To our knowledge, this is the first published case report of an adolescent girl with a mitochondrial disorder and depression who displayed both new-onset psychotic and increased mood symptoms during treatment with risperidone.", "question": "Treatment.Freq in risperidone", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16092915_2_6546", "context": "OBJECTIVE: To our knowledge, this is the first published case report of an adolescent girl with a mitochondrial disorder and depression who displayed both new-onset psychotic and increased mood symptoms during treatment with risperidone.", "question": "Treatment.Route in risperidone", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16092915_2_6547", "context": "OBJECTIVE: To our knowledge, this is the first published case report of an adolescent girl with a mitochondrial disorder and depression who displayed both new-onset psychotic and increased mood symptoms during treatment with risperidone.", "question": "Treatment.Time_elapsed in risperidone", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16092915_2_6548", "context": "OBJECTIVE: To our knowledge, this is the first published case report of an adolescent girl with a mitochondrial disorder and depression who displayed both new-onset psychotic and increased mood symptoms during treatment with risperidone.", "question": "Treatment.Duration in risperidone", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16092915_2_6549", "context": "OBJECTIVE: To our knowledge, this is the first published case report of an adolescent girl with a mitochondrial disorder and depression who displayed both new-onset psychotic and increased mood symptoms during treatment with risperidone.", "question": "Treatment.Disorder in risperidone", "question_type": "Adverse_event.Treatment.Disorder", "answers": "mitochondrial disorder; depression"}, {"id": "16092915_2_6550", "context": "OBJECTIVE: To our knowledge, this is the first published case report of an adolescent girl with a mitochondrial disorder and depression who displayed both new-onset psychotic and increased mood symptoms during treatment with risperidone.", "question": "Combination.Drug in risperidone", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9733234_1_6551", "context": "Young children undergoing cisplatin chemotherapy are known to be at risk for progressive sensorineural hearing loss.", "question": "Subject.Age in Young children", "question_type": "Adverse_event.Subject.Age", "answers": "Young; children"}, {"id": "9733234_1_6552", "context": "Young children undergoing cisplatin chemotherapy are known to be at risk for progressive sensorineural hearing loss.", "question": "Subject.Gender in Young children", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "9733234_1_6553", "context": "Young children undergoing cisplatin chemotherapy are known to be at risk for progressive sensorineural hearing loss.", "question": "Subject.Population in Young children", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "9733234_1_6554", "context": "Young children undergoing cisplatin chemotherapy are known to be at risk for progressive sensorineural hearing loss.", "question": "Subject.Race in Young children", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "9733234_1_6555", "context": "Young children undergoing cisplatin chemotherapy are known to be at risk for progressive sensorineural hearing loss.", "question": "Subject.Disorder in Young children", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "9733234_1_6556", "context": "Young children undergoing cisplatin chemotherapy are known to be at risk for progressive sensorineural hearing loss.", "question": "Treatment.Drug in undergoing cisplatin chemotherapy", "question_type": "Adverse_event.Treatment.Drug", "answers": "cisplatin"}, {"id": "9733234_1_6557", "context": "Young children undergoing cisplatin chemotherapy are known to be at risk for progressive sensorineural hearing loss.", "question": "Treatment.Dosage in undergoing cisplatin chemotherapy", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9733234_1_6558", "context": "Young children undergoing cisplatin chemotherapy are known to be at risk for progressive sensorineural hearing loss.", "question": "Treatment.Freq in undergoing cisplatin chemotherapy", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9733234_1_6559", "context": "Young children undergoing cisplatin chemotherapy are known to be at risk for progressive sensorineural hearing loss.", "question": "Treatment.Route in undergoing cisplatin chemotherapy", "question_type": "Adverse_event.Treatment.Route", "answers": "chemotherapy"}, {"id": "9733234_1_6560", "context": "Young children undergoing cisplatin chemotherapy are known to be at risk for progressive sensorineural hearing loss.", "question": "Treatment.Time_elapsed in undergoing cisplatin chemotherapy", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9733234_1_6561", "context": "Young children undergoing cisplatin chemotherapy are known to be at risk for progressive sensorineural hearing loss.", "question": "Treatment.Duration in undergoing cisplatin chemotherapy", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9733234_1_6562", "context": "Young children undergoing cisplatin chemotherapy are known to be at risk for progressive sensorineural hearing loss.", "question": "Treatment.Disorder in undergoing cisplatin chemotherapy", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9733234_1_6563", "context": "Young children undergoing cisplatin chemotherapy are known to be at risk for progressive sensorineural hearing loss.", "question": "Combination.Drug in undergoing cisplatin chemotherapy", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12692521_1_6564", "context": "Systemic capillary leak syndrome after granulocyte colony-stimulating factor (G-CSF).", "question": "Treatment.Drug in granulocyte colony-stimulating factor (G-CSF)", "question_type": "Adverse_event.Treatment.Drug", "answers": "granulocyte colony-stimulating factor"}, {"id": "12692521_1_6565", "context": "Systemic capillary leak syndrome after granulocyte colony-stimulating factor (G-CSF).", "question": "Treatment.Dosage in granulocyte colony-stimulating factor (G-CSF)", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12692521_1_6566", "context": "Systemic capillary leak syndrome after granulocyte colony-stimulating factor (G-CSF).", "question": "Treatment.Freq in granulocyte colony-stimulating factor (G-CSF)", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12692521_1_6567", "context": "Systemic capillary leak syndrome after granulocyte colony-stimulating factor (G-CSF).", "question": "Treatment.Route in granulocyte colony-stimulating factor (G-CSF)", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12692521_1_6568", "context": "Systemic capillary leak syndrome after granulocyte colony-stimulating factor (G-CSF).", "question": "Treatment.Time_elapsed in granulocyte colony-stimulating factor (G-CSF)", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12692521_1_6569", "context": "Systemic capillary leak syndrome after granulocyte colony-stimulating factor (G-CSF).", "question": "Treatment.Duration in granulocyte colony-stimulating factor (G-CSF)", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12692521_1_6570", "context": "Systemic capillary leak syndrome after granulocyte colony-stimulating factor (G-CSF).", "question": "Treatment.Disorder in granulocyte colony-stimulating factor (G-CSF)", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12692521_1_6571", "context": "Systemic capillary leak syndrome after granulocyte colony-stimulating factor (G-CSF).", "question": "Combination.Drug in granulocyte colony-stimulating factor (G-CSF)", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16449538_2_6572", "context": "CASE SUMMARIES: Two patients who received ifosfamide-containing chemotherapy developed NCSE.", "question": "Subject.Age in Two patients", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "16449538_2_6573", "context": "CASE SUMMARIES: Two patients who received ifosfamide-containing chemotherapy developed NCSE.", "question": "Subject.Gender in Two patients", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "16449538_2_6574", "context": "CASE SUMMARIES: Two patients who received ifosfamide-containing chemotherapy developed NCSE.", "question": "Subject.Population in Two patients", "question_type": "Adverse_event.Subject.Population", "answers": "Two"}, {"id": "16449538_2_6575", "context": "CASE SUMMARIES: Two patients who received ifosfamide-containing chemotherapy developed NCSE.", "question": "Subject.Race in Two patients", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16449538_2_6576", "context": "CASE SUMMARIES: Two patients who received ifosfamide-containing chemotherapy developed NCSE.", "question": "Subject.Disorder in Two patients", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "16449538_2_6577", "context": "CASE SUMMARIES: Two patients who received ifosfamide-containing chemotherapy developed NCSE.", "question": "Treatment.Drug in ifosfamide-containing chemotherapy", "question_type": "Adverse_event.Treatment.Drug", "answers": "ifosfamide"}, {"id": "16449538_2_6578", "context": "CASE SUMMARIES: Two patients who received ifosfamide-containing chemotherapy developed NCSE.", "question": "Treatment.Dosage in ifosfamide-containing chemotherapy", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16449538_2_6579", "context": "CASE SUMMARIES: Two patients who received ifosfamide-containing chemotherapy developed NCSE.", "question": "Treatment.Freq in ifosfamide-containing chemotherapy", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16449538_2_6580", "context": "CASE SUMMARIES: Two patients who received ifosfamide-containing chemotherapy developed NCSE.", "question": "Treatment.Route in ifosfamide-containing chemotherapy", "question_type": "Adverse_event.Treatment.Route", "answers": "chemotherapy"}, {"id": "16449538_2_6581", "context": "CASE SUMMARIES: Two patients who received ifosfamide-containing chemotherapy developed NCSE.", "question": "Treatment.Time_elapsed in ifosfamide-containing chemotherapy", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16449538_2_6582", "context": "CASE SUMMARIES: Two patients who received ifosfamide-containing chemotherapy developed NCSE.", "question": "Treatment.Duration in ifosfamide-containing chemotherapy", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16449538_2_6583", "context": "CASE SUMMARIES: Two patients who received ifosfamide-containing chemotherapy developed NCSE.", "question": "Treatment.Disorder in ifosfamide-containing chemotherapy", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16449538_2_6584", "context": "CASE SUMMARIES: Two patients who received ifosfamide-containing chemotherapy developed NCSE.", "question": "Combination.Drug in ifosfamide-containing chemotherapy", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10456487_3_6585", "context": "One of the monohydroxy-metabolites has been incriminated with tacrine-induced hepatotoxicity.", "question": "Treatment.Drug in tacrine", "question_type": "Adverse_event.Treatment.Drug", "answers": "tacrine"}, {"id": "10456487_3_6586", "context": "One of the monohydroxy-metabolites has been incriminated with tacrine-induced hepatotoxicity.", "question": "Treatment.Dosage in tacrine", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10456487_3_6587", "context": "One of the monohydroxy-metabolites has been incriminated with tacrine-induced hepatotoxicity.", "question": "Treatment.Freq in tacrine", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10456487_3_6588", "context": "One of the monohydroxy-metabolites has been incriminated with tacrine-induced hepatotoxicity.", "question": "Treatment.Route in tacrine", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10456487_3_6589", "context": "One of the monohydroxy-metabolites has been incriminated with tacrine-induced hepatotoxicity.", "question": "Treatment.Time_elapsed in tacrine", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10456487_3_6590", "context": "One of the monohydroxy-metabolites has been incriminated with tacrine-induced hepatotoxicity.", "question": "Treatment.Duration in tacrine", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10456487_3_6591", "context": "One of the monohydroxy-metabolites has been incriminated with tacrine-induced hepatotoxicity.", "question": "Treatment.Disorder in tacrine", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10456487_3_6592", "context": "One of the monohydroxy-metabolites has been incriminated with tacrine-induced hepatotoxicity.", "question": "Combination.Drug in tacrine", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "20020238_1_6593", "context": "BACKGROUND: To assess the nature, incidence, and risk factors of retinopathy associated with pegylated interferon and ribavirin combination therapy in chronic hepatitis C patients.", "question": "Subject.Age in chronic hepatitis C patients", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "20020238_1_6594", "context": "BACKGROUND: To assess the nature, incidence, and risk factors of retinopathy associated with pegylated interferon and ribavirin combination therapy in chronic hepatitis C patients.", "question": "Subject.Gender in chronic hepatitis C patients", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "20020238_1_6595", "context": "BACKGROUND: To assess the nature, incidence, and risk factors of retinopathy associated with pegylated interferon and ribavirin combination therapy in chronic hepatitis C patients.", "question": "Subject.Population in chronic hepatitis C patients", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "20020238_1_6596", "context": "BACKGROUND: To assess the nature, incidence, and risk factors of retinopathy associated with pegylated interferon and ribavirin combination therapy in chronic hepatitis C patients.", "question": "Subject.Race in chronic hepatitis C patients", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "20020238_1_6597", "context": "BACKGROUND: To assess the nature, incidence, and risk factors of retinopathy associated with pegylated interferon and ribavirin combination therapy in chronic hepatitis C patients.", "question": "Subject.Disorder in chronic hepatitis C patients", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "20020238_1_6598", "context": "BACKGROUND: To assess the nature, incidence, and risk factors of retinopathy associated with pegylated interferon and ribavirin combination therapy in chronic hepatitis C patients.", "question": "Treatment.Drug in pegylated interferon and ribavirin combination therapy", "question_type": "Adverse_event.Treatment.Drug", "answers": "ribavirin; pegylated interferon"}, {"id": "20020238_1_6599", "context": "BACKGROUND: To assess the nature, incidence, and risk factors of retinopathy associated with pegylated interferon and ribavirin combination therapy in chronic hepatitis C patients.", "question": "Treatment.Dosage in pegylated interferon and ribavirin combination therapy", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "20020238_1_6600", "context": "BACKGROUND: To assess the nature, incidence, and risk factors of retinopathy associated with pegylated interferon and ribavirin combination therapy in chronic hepatitis C patients.", "question": "Treatment.Freq in pegylated interferon and ribavirin combination therapy", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "20020238_1_6601", "context": "BACKGROUND: To assess the nature, incidence, and risk factors of retinopathy associated with pegylated interferon and ribavirin combination therapy in chronic hepatitis C patients.", "question": "Treatment.Route in pegylated interferon and ribavirin combination therapy", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "20020238_1_6602", "context": "BACKGROUND: To assess the nature, incidence, and risk factors of retinopathy associated with pegylated interferon and ribavirin combination therapy in chronic hepatitis C patients.", "question": "Treatment.Time_elapsed in pegylated interferon and ribavirin combination therapy", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "20020238_1_6603", "context": "BACKGROUND: To assess the nature, incidence, and risk factors of retinopathy associated with pegylated interferon and ribavirin combination therapy in chronic hepatitis C patients.", "question": "Treatment.Duration in pegylated interferon and ribavirin combination therapy", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "20020238_1_6604", "context": "BACKGROUND: To assess the nature, incidence, and risk factors of retinopathy associated with pegylated interferon and ribavirin combination therapy in chronic hepatitis C patients.", "question": "Treatment.Disorder in pegylated interferon and ribavirin combination therapy", "question_type": "Adverse_event.Treatment.Disorder", "answers": "chronic hepatitis C"}, {"id": "20020238_1_6605", "context": "BACKGROUND: To assess the nature, incidence, and risk factors of retinopathy associated with pegylated interferon and ribavirin combination therapy in chronic hepatitis C patients.", "question": "Combination.Drug in pegylated interferon and ribavirin combination therapy", "question_type": "Adverse_event.Combination.Drug", "answers": "ribavirin; pegylated interferon"}, {"id": "12149193_1_6606", "context": "Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy.", "question": "Subject.Age in myeloma patients", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "12149193_1_6607", "context": "Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy.", "question": "Subject.Gender in myeloma patients", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "12149193_1_6608", "context": "Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy.", "question": "Subject.Population in myeloma patients", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "12149193_1_6609", "context": "Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy.", "question": "Subject.Race in myeloma patients", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "12149193_1_6610", "context": "Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy.", "question": "Subject.Disorder in myeloma patients", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "12149193_1_6611", "context": "Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy.", "question": "Treatment.Drug in doxorubicin; thalidomide", "question_type": "Adverse_event.Treatment.Drug", "answers": "doxorubicin; thalidomide"}, {"id": "12149193_1_6612", "context": "Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy.", "question": "Treatment.Dosage in doxorubicin; thalidomide", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12149193_1_6613", "context": "Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy.", "question": "Treatment.Freq in doxorubicin; thalidomide", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12149193_1_6614", "context": "Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy.", "question": "Treatment.Route in doxorubicin; thalidomide", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12149193_1_6615", "context": "Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy.", "question": "Treatment.Time_elapsed in doxorubicin; thalidomide", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12149193_1_6616", "context": "Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy.", "question": "Treatment.Duration in doxorubicin; thalidomide", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12149193_1_6617", "context": "Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy.", "question": "Treatment.Disorder in doxorubicin; thalidomide", "question_type": "Adverse_event.Treatment.Disorder", "answers": "myeloma"}, {"id": "12149193_1_6618", "context": "Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy.", "question": "Combination.Drug in doxorubicin; thalidomide", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15053046_2_6619", "context": "Agranulocytosis is a rare adverse effect associated with prolonged vancomycin therapy, and is potentially serious, especially in end stage renal disease (ESRD) patients.", "question": "Subject.Age in end stage renal disease (ESRD) patients", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "15053046_2_6620", "context": "Agranulocytosis is a rare adverse effect associated with prolonged vancomycin therapy, and is potentially serious, especially in end stage renal disease (ESRD) patients.", "question": "Subject.Gender in end stage renal disease (ESRD) patients", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15053046_2_6621", "context": "Agranulocytosis is a rare adverse effect associated with prolonged vancomycin therapy, and is potentially serious, especially in end stage renal disease (ESRD) patients.", "question": "Subject.Population in end stage renal disease (ESRD) patients", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "15053046_2_6622", "context": "Agranulocytosis is a rare adverse effect associated with prolonged vancomycin therapy, and is potentially serious, especially in end stage renal disease (ESRD) patients.", "question": "Subject.Race in end stage renal disease (ESRD) patients", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15053046_2_6623", "context": "Agranulocytosis is a rare adverse effect associated with prolonged vancomycin therapy, and is potentially serious, especially in end stage renal disease (ESRD) patients.", "question": "Subject.Disorder in end stage renal disease (ESRD) patients", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15053046_2_6624", "context": "Agranulocytosis is a rare adverse effect associated with prolonged vancomycin therapy, and is potentially serious, especially in end stage renal disease (ESRD) patients.", "question": "Treatment.Drug in prolonged vancomycin therapy", "question_type": "Adverse_event.Treatment.Drug", "answers": "vancomycin"}, {"id": "15053046_2_6625", "context": "Agranulocytosis is a rare adverse effect associated with prolonged vancomycin therapy, and is potentially serious, especially in end stage renal disease (ESRD) patients.", "question": "Treatment.Dosage in prolonged vancomycin therapy", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15053046_2_6626", "context": "Agranulocytosis is a rare adverse effect associated with prolonged vancomycin therapy, and is potentially serious, especially in end stage renal disease (ESRD) patients.", "question": "Treatment.Freq in prolonged vancomycin therapy", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15053046_2_6627", "context": "Agranulocytosis is a rare adverse effect associated with prolonged vancomycin therapy, and is potentially serious, especially in end stage renal disease (ESRD) patients.", "question": "Treatment.Route in prolonged vancomycin therapy", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15053046_2_6628", "context": "Agranulocytosis is a rare adverse effect associated with prolonged vancomycin therapy, and is potentially serious, especially in end stage renal disease (ESRD) patients.", "question": "Treatment.Time_elapsed in prolonged vancomycin therapy", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15053046_2_6629", "context": "Agranulocytosis is a rare adverse effect associated with prolonged vancomycin therapy, and is potentially serious, especially in end stage renal disease (ESRD) patients.", "question": "Treatment.Duration in prolonged vancomycin therapy", "question_type": "Adverse_event.Treatment.Duration", "answers": "prolonged"}, {"id": "15053046_2_6630", "context": "Agranulocytosis is a rare adverse effect associated with prolonged vancomycin therapy, and is potentially serious, especially in end stage renal disease (ESRD) patients.", "question": "Treatment.Disorder in prolonged vancomycin therapy", "question_type": "Adverse_event.Treatment.Disorder", "answers": "end stage renal disease (ESRD)"}, {"id": "15053046_2_6631", "context": "Agranulocytosis is a rare adverse effect associated with prolonged vancomycin therapy, and is potentially serious, especially in end stage renal disease (ESRD) patients.", "question": "Combination.Drug in prolonged vancomycin therapy", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8551001_4_6632", "context": "Thiopurine methyltransferase deficiency occurs at a frequency of one in 300 and is associated with profound myelosuppression after a short course of azathioprine.", "question": "Treatment.Drug in a short course of azathioprine", "question_type": "Adverse_event.Treatment.Drug", "answers": "azathioprine"}, {"id": "8551001_4_6633", "context": "Thiopurine methyltransferase deficiency occurs at a frequency of one in 300 and is associated with profound myelosuppression after a short course of azathioprine.", "question": "Treatment.Dosage in a short course of azathioprine", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8551001_4_6634", "context": "Thiopurine methyltransferase deficiency occurs at a frequency of one in 300 and is associated with profound myelosuppression after a short course of azathioprine.", "question": "Treatment.Freq in a short course of azathioprine", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8551001_4_6635", "context": "Thiopurine methyltransferase deficiency occurs at a frequency of one in 300 and is associated with profound myelosuppression after a short course of azathioprine.", "question": "Treatment.Route in a short course of azathioprine", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8551001_4_6636", "context": "Thiopurine methyltransferase deficiency occurs at a frequency of one in 300 and is associated with profound myelosuppression after a short course of azathioprine.", "question": "Treatment.Time_elapsed in a short course of azathioprine", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "a short course"}, {"id": "8551001_4_6637", "context": "Thiopurine methyltransferase deficiency occurs at a frequency of one in 300 and is associated with profound myelosuppression after a short course of azathioprine.", "question": "Treatment.Duration in a short course of azathioprine", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8551001_4_6638", "context": "Thiopurine methyltransferase deficiency occurs at a frequency of one in 300 and is associated with profound myelosuppression after a short course of azathioprine.", "question": "Treatment.Disorder in a short course of azathioprine", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8551001_4_6639", "context": "Thiopurine methyltransferase deficiency occurs at a frequency of one in 300 and is associated with profound myelosuppression after a short course of azathioprine.", "question": "Combination.Drug in a short course of azathioprine", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3967536_1_6640", "context": "Hypotension and sinus arrest with nifedipine in pulmonary hypertension.", "question": "Treatment.Drug in nifedipine", "question_type": "Adverse_event.Treatment.Drug", "answers": "nifedipine"}, {"id": "3967536_1_6641", "context": "Hypotension and sinus arrest with nifedipine in pulmonary hypertension.", "question": "Treatment.Dosage in nifedipine", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3967536_1_6642", "context": "Hypotension and sinus arrest with nifedipine in pulmonary hypertension.", "question": "Treatment.Freq in nifedipine", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3967536_1_6643", "context": "Hypotension and sinus arrest with nifedipine in pulmonary hypertension.", "question": "Treatment.Route in nifedipine", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3967536_1_6644", "context": "Hypotension and sinus arrest with nifedipine in pulmonary hypertension.", "question": "Treatment.Time_elapsed in nifedipine", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3967536_1_6645", "context": "Hypotension and sinus arrest with nifedipine in pulmonary hypertension.", "question": "Treatment.Duration in nifedipine", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3967536_1_6646", "context": "Hypotension and sinus arrest with nifedipine in pulmonary hypertension.", "question": "Treatment.Disorder in nifedipine", "question_type": "Adverse_event.Treatment.Disorder", "answers": "pulmonary hypertension"}, {"id": "3967536_1_6647", "context": "Hypotension and sinus arrest with nifedipine in pulmonary hypertension.", "question": "Combination.Drug in nifedipine", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9709726_1_6648", "context": "We describe children and adolescents with chronic hematologic and oncologic diseases who exhibited drug-seeking behavior or anticholinergic symptoms with the use of diphenhydramine.", "question": "Subject.Age in children and adolescents with chronic hematologic and oncologic diseases", "question_type": "Adverse_event.Subject.Age", "answers": "children; adolescents"}, {"id": "9709726_1_6649", "context": "We describe children and adolescents with chronic hematologic and oncologic diseases who exhibited drug-seeking behavior or anticholinergic symptoms with the use of diphenhydramine.", "question": "Subject.Gender in children and adolescents with chronic hematologic and oncologic diseases", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "9709726_1_6650", "context": "We describe children and adolescents with chronic hematologic and oncologic diseases who exhibited drug-seeking behavior or anticholinergic symptoms with the use of diphenhydramine.", "question": "Subject.Population in children and adolescents with chronic hematologic and oncologic diseases", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "9709726_1_6651", "context": "We describe children and adolescents with chronic hematologic and oncologic diseases who exhibited drug-seeking behavior or anticholinergic symptoms with the use of diphenhydramine.", "question": "Subject.Race in children and adolescents with chronic hematologic and oncologic diseases", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "9709726_1_6652", "context": "We describe children and adolescents with chronic hematologic and oncologic diseases who exhibited drug-seeking behavior or anticholinergic symptoms with the use of diphenhydramine.", "question": "Subject.Disorder in children and adolescents with chronic hematologic and oncologic diseases", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "9709726_1_6653", "context": "We describe children and adolescents with chronic hematologic and oncologic diseases who exhibited drug-seeking behavior or anticholinergic symptoms with the use of diphenhydramine.", "question": "Treatment.Drug in diphenhydramine", "question_type": "Adverse_event.Treatment.Drug", "answers": "diphenhydramine"}, {"id": "9709726_1_6654", "context": "We describe children and adolescents with chronic hematologic and oncologic diseases who exhibited drug-seeking behavior or anticholinergic symptoms with the use of diphenhydramine.", "question": "Treatment.Dosage in diphenhydramine", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9709726_1_6655", "context": "We describe children and adolescents with chronic hematologic and oncologic diseases who exhibited drug-seeking behavior or anticholinergic symptoms with the use of diphenhydramine.", "question": "Treatment.Freq in diphenhydramine", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9709726_1_6656", "context": "We describe children and adolescents with chronic hematologic and oncologic diseases who exhibited drug-seeking behavior or anticholinergic symptoms with the use of diphenhydramine.", "question": "Treatment.Route in diphenhydramine", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9709726_1_6657", "context": "We describe children and adolescents with chronic hematologic and oncologic diseases who exhibited drug-seeking behavior or anticholinergic symptoms with the use of diphenhydramine.", "question": "Treatment.Time_elapsed in diphenhydramine", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9709726_1_6658", "context": "We describe children and adolescents with chronic hematologic and oncologic diseases who exhibited drug-seeking behavior or anticholinergic symptoms with the use of diphenhydramine.", "question": "Treatment.Duration in diphenhydramine", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9709726_1_6659", "context": "We describe children and adolescents with chronic hematologic and oncologic diseases who exhibited drug-seeking behavior or anticholinergic symptoms with the use of diphenhydramine.", "question": "Treatment.Disorder in diphenhydramine", "question_type": "Adverse_event.Treatment.Disorder", "answers": "chronic hematologic and oncologic diseases"}, {"id": "9709726_1_6660", "context": "We describe children and adolescents with chronic hematologic and oncologic diseases who exhibited drug-seeking behavior or anticholinergic symptoms with the use of diphenhydramine.", "question": "Combination.Drug in diphenhydramine", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8739289_1_6661", "context": "Transient central diabetes insipidus in the setting of underlying chronic nephrogenic diabetes insipidus associated with lithium use.", "question": "Treatment.Drug in lithium", "question_type": "Adverse_event.Treatment.Drug", "answers": "lithium"}, {"id": "8739289_1_6662", "context": "Transient central diabetes insipidus in the setting of underlying chronic nephrogenic diabetes insipidus associated with lithium use.", "question": "Treatment.Dosage in lithium", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8739289_1_6663", "context": "Transient central diabetes insipidus in the setting of underlying chronic nephrogenic diabetes insipidus associated with lithium use.", "question": "Treatment.Freq in lithium", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8739289_1_6664", "context": "Transient central diabetes insipidus in the setting of underlying chronic nephrogenic diabetes insipidus associated with lithium use.", "question": "Treatment.Route in lithium", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8739289_1_6665", "context": "Transient central diabetes insipidus in the setting of underlying chronic nephrogenic diabetes insipidus associated with lithium use.", "question": "Treatment.Time_elapsed in lithium", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8739289_1_6666", "context": "Transient central diabetes insipidus in the setting of underlying chronic nephrogenic diabetes insipidus associated with lithium use.", "question": "Treatment.Duration in lithium", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8739289_1_6667", "context": "Transient central diabetes insipidus in the setting of underlying chronic nephrogenic diabetes insipidus associated with lithium use.", "question": "Treatment.Disorder in lithium", "question_type": "Adverse_event.Treatment.Disorder", "answers": "chronic nephrogenic diabetes insipidus"}, {"id": "8739289_1_6668", "context": "Transient central diabetes insipidus in the setting of underlying chronic nephrogenic diabetes insipidus associated with lithium use.", "question": "Combination.Drug in lithium", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8636829_1_6669", "context": "A macrophage activation syndrome, possibly related to methotrexate toxicity, developed in a boy with systemic juvenile rheumatoid arthritis.", "question": "Subject.Age in a boy with systemic juvenile rheumatoid arthritis", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "8636829_1_6670", "context": "A macrophage activation syndrome, possibly related to methotrexate toxicity, developed in a boy with systemic juvenile rheumatoid arthritis.", "question": "Subject.Gender in a boy with systemic juvenile rheumatoid arthritis", "question_type": "Adverse_event.Subject.Gender", "answers": "boy"}, {"id": "8636829_1_6671", "context": "A macrophage activation syndrome, possibly related to methotrexate toxicity, developed in a boy with systemic juvenile rheumatoid arthritis.", "question": "Subject.Population in a boy with systemic juvenile rheumatoid arthritis", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "8636829_1_6672", "context": "A macrophage activation syndrome, possibly related to methotrexate toxicity, developed in a boy with systemic juvenile rheumatoid arthritis.", "question": "Subject.Race in a boy with systemic juvenile rheumatoid arthritis", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "8636829_1_6673", "context": "A macrophage activation syndrome, possibly related to methotrexate toxicity, developed in a boy with systemic juvenile rheumatoid arthritis.", "question": "Subject.Disorder in a boy with systemic juvenile rheumatoid arthritis", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "8636829_1_6674", "context": "A macrophage activation syndrome, possibly related to methotrexate toxicity, developed in a boy with systemic juvenile rheumatoid arthritis.", "question": "Treatment.Drug in methotrexate toxicity", "question_type": "Adverse_event.Treatment.Drug", "answers": "methotrexate"}, {"id": "8636829_1_6675", "context": "A macrophage activation syndrome, possibly related to methotrexate toxicity, developed in a boy with systemic juvenile rheumatoid arthritis.", "question": "Treatment.Dosage in methotrexate toxicity", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8636829_1_6676", "context": "A macrophage activation syndrome, possibly related to methotrexate toxicity, developed in a boy with systemic juvenile rheumatoid arthritis.", "question": "Treatment.Freq in methotrexate toxicity", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8636829_1_6677", "context": "A macrophage activation syndrome, possibly related to methotrexate toxicity, developed in a boy with systemic juvenile rheumatoid arthritis.", "question": "Treatment.Route in methotrexate toxicity", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8636829_1_6678", "context": "A macrophage activation syndrome, possibly related to methotrexate toxicity, developed in a boy with systemic juvenile rheumatoid arthritis.", "question": "Treatment.Time_elapsed in methotrexate toxicity", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8636829_1_6679", "context": "A macrophage activation syndrome, possibly related to methotrexate toxicity, developed in a boy with systemic juvenile rheumatoid arthritis.", "question": "Treatment.Duration in methotrexate toxicity", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8636829_1_6680", "context": "A macrophage activation syndrome, possibly related to methotrexate toxicity, developed in a boy with systemic juvenile rheumatoid arthritis.", "question": "Treatment.Disorder in methotrexate toxicity", "question_type": "Adverse_event.Treatment.Disorder", "answers": "systemic juvenile rheumatoid arthritis"}, {"id": "8636829_1_6681", "context": "A macrophage activation syndrome, possibly related to methotrexate toxicity, developed in a boy with systemic juvenile rheumatoid arthritis.", "question": "Combination.Drug in methotrexate toxicity", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6507240_1_6682", "context": "Hyponatremia in patients treated with lorcainide, a new antiarrhythmic drug.", "question": "Subject.Age in patients", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "6507240_1_6683", "context": "Hyponatremia in patients treated with lorcainide, a new antiarrhythmic drug.", "question": "Subject.Gender in patients", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "6507240_1_6684", "context": "Hyponatremia in patients treated with lorcainide, a new antiarrhythmic drug.", "question": "Subject.Population in patients", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "6507240_1_6685", "context": "Hyponatremia in patients treated with lorcainide, a new antiarrhythmic drug.", "question": "Subject.Race in patients", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "6507240_1_6686", "context": "Hyponatremia in patients treated with lorcainide, a new antiarrhythmic drug.", "question": "Subject.Disorder in patients", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "6507240_1_6687", "context": "Hyponatremia in patients treated with lorcainide, a new antiarrhythmic drug.", "question": "Treatment.Drug in lorcainide", "question_type": "Adverse_event.Treatment.Drug", "answers": "lorcainide"}, {"id": "6507240_1_6688", "context": "Hyponatremia in patients treated with lorcainide, a new antiarrhythmic drug.", "question": "Treatment.Dosage in lorcainide", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6507240_1_6689", "context": "Hyponatremia in patients treated with lorcainide, a new antiarrhythmic drug.", "question": "Treatment.Freq in lorcainide", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6507240_1_6690", "context": "Hyponatremia in patients treated with lorcainide, a new antiarrhythmic drug.", "question": "Treatment.Route in lorcainide", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6507240_1_6691", "context": "Hyponatremia in patients treated with lorcainide, a new antiarrhythmic drug.", "question": "Treatment.Time_elapsed in lorcainide", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6507240_1_6692", "context": "Hyponatremia in patients treated with lorcainide, a new antiarrhythmic drug.", "question": "Treatment.Duration in lorcainide", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6507240_1_6693", "context": "Hyponatremia in patients treated with lorcainide, a new antiarrhythmic drug.", "question": "Treatment.Disorder in lorcainide", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6507240_1_6694", "context": "Hyponatremia in patients treated with lorcainide, a new antiarrhythmic drug.", "question": "Combination.Drug in lorcainide", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8186884_2_6695", "context": "Electrical proarrhythmia with procainamide: a new ICD-drug interaction.", "question": "Treatment.Drug in procainamide", "question_type": "Adverse_event.Treatment.Drug", "answers": "procainamide"}, {"id": "8186884_2_6696", "context": "Electrical proarrhythmia with procainamide: a new ICD-drug interaction.", "question": "Treatment.Dosage in procainamide", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8186884_2_6697", "context": "Electrical proarrhythmia with procainamide: a new ICD-drug interaction.", "question": "Treatment.Freq in procainamide", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8186884_2_6698", "context": "Electrical proarrhythmia with procainamide: a new ICD-drug interaction.", "question": "Treatment.Route in procainamide", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8186884_2_6699", "context": "Electrical proarrhythmia with procainamide: a new ICD-drug interaction.", "question": "Treatment.Time_elapsed in procainamide", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8186884_2_6700", "context": "Electrical proarrhythmia with procainamide: a new ICD-drug interaction.", "question": "Treatment.Duration in procainamide", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8186884_2_6701", "context": "Electrical proarrhythmia with procainamide: a new ICD-drug interaction.", "question": "Treatment.Disorder in procainamide", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8186884_2_6702", "context": "Electrical proarrhythmia with procainamide: a new ICD-drug interaction.", "question": "Combination.Drug in procainamide", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9681092_2_6703", "context": "To report a case of QT prolongation associated with concomitant cyclobenzaprine and fluoxetine administration followed by torsade de pointes potentiated by droperidol.", "question": "Treatment.Drug in concomitant cyclobenzaprine and fluoxetine administration", "question_type": "Adverse_event.Treatment.Drug", "answers": "cyclobenzaprine; fluoxetine"}, {"id": "9681092_2_6704", "context": "To report a case of QT prolongation associated with concomitant cyclobenzaprine and fluoxetine administration followed by torsade de pointes potentiated by droperidol.", "question": "Treatment.Dosage in concomitant cyclobenzaprine and fluoxetine administration", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9681092_2_6705", "context": "To report a case of QT prolongation associated with concomitant cyclobenzaprine and fluoxetine administration followed by torsade de pointes potentiated by droperidol.", "question": "Treatment.Freq in concomitant cyclobenzaprine and fluoxetine administration", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9681092_2_6706", "context": "To report a case of QT prolongation associated with concomitant cyclobenzaprine and fluoxetine administration followed by torsade de pointes potentiated by droperidol.", "question": "Treatment.Route in concomitant cyclobenzaprine and fluoxetine administration", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9681092_2_6707", "context": "To report a case of QT prolongation associated with concomitant cyclobenzaprine and fluoxetine administration followed by torsade de pointes potentiated by droperidol.", "question": "Treatment.Time_elapsed in concomitant cyclobenzaprine and fluoxetine administration", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9681092_2_6708", "context": "To report a case of QT prolongation associated with concomitant cyclobenzaprine and fluoxetine administration followed by torsade de pointes potentiated by droperidol.", "question": "Treatment.Duration in concomitant cyclobenzaprine and fluoxetine administration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9681092_2_6709", "context": "To report a case of QT prolongation associated with concomitant cyclobenzaprine and fluoxetine administration followed by torsade de pointes potentiated by droperidol.", "question": "Treatment.Disorder in concomitant cyclobenzaprine and fluoxetine administration", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9681092_2_6710", "context": "To report a case of QT prolongation associated with concomitant cyclobenzaprine and fluoxetine administration followed by torsade de pointes potentiated by droperidol.", "question": "Combination.Drug in concomitant cyclobenzaprine and fluoxetine administration", "question_type": "Adverse_event.Combination.Drug", "answers": "cyclobenzaprine; fluoxetine"}, {"id": "9681092_2_6711", "context": "To report a case of QT prolongation associated with concomitant cyclobenzaprine and fluoxetine administration followed by torsade de pointes potentiated by droperidol.", "question": "Treatment.Drug in droperidol", "question_type": "Adverse_event.Treatment.Drug", "answers": "droperidol"}, {"id": "9681092_2_6712", "context": "To report a case of QT prolongation associated with concomitant cyclobenzaprine and fluoxetine administration followed by torsade de pointes potentiated by droperidol.", "question": "Treatment.Dosage in droperidol", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9681092_2_6713", "context": "To report a case of QT prolongation associated with concomitant cyclobenzaprine and fluoxetine administration followed by torsade de pointes potentiated by droperidol.", "question": "Treatment.Freq in droperidol", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9681092_2_6714", "context": "To report a case of QT prolongation associated with concomitant cyclobenzaprine and fluoxetine administration followed by torsade de pointes potentiated by droperidol.", "question": "Treatment.Route in droperidol", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9681092_2_6715", "context": "To report a case of QT prolongation associated with concomitant cyclobenzaprine and fluoxetine administration followed by torsade de pointes potentiated by droperidol.", "question": "Treatment.Time_elapsed in droperidol", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9681092_2_6716", "context": "To report a case of QT prolongation associated with concomitant cyclobenzaprine and fluoxetine administration followed by torsade de pointes potentiated by droperidol.", "question": "Treatment.Duration in droperidol", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9681092_2_6717", "context": "To report a case of QT prolongation associated with concomitant cyclobenzaprine and fluoxetine administration followed by torsade de pointes potentiated by droperidol.", "question": "Treatment.Disorder in droperidol", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9681092_2_6718", "context": "To report a case of QT prolongation associated with concomitant cyclobenzaprine and fluoxetine administration followed by torsade de pointes potentiated by droperidol.", "question": "Combination.Drug in droperidol", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6597713_3_6719", "context": "It is presumed that her hyperchloremic metabolic acidosis was secondary to cholestyramine because of the similarity to pediatric reports; the rapid and lasting response to intravenous sodium bicarbonate; the absence of another etiology; normal serum potassium, chloride and bicarbonate despite continued spironolactone therapy after recovery.", "question": "Treatment.Drug in cholestyramine", "question_type": "Adverse_event.Treatment.Drug", "answers": "cholestyramine"}, {"id": "6597713_3_6720", "context": "It is presumed that her hyperchloremic metabolic acidosis was secondary to cholestyramine because of the similarity to pediatric reports; the rapid and lasting response to intravenous sodium bicarbonate; the absence of another etiology; normal serum potassium, chloride and bicarbonate despite continued spironolactone therapy after recovery.", "question": "Treatment.Dosage in cholestyramine", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6597713_3_6721", "context": "It is presumed that her hyperchloremic metabolic acidosis was secondary to cholestyramine because of the similarity to pediatric reports; the rapid and lasting response to intravenous sodium bicarbonate; the absence of another etiology; normal serum potassium, chloride and bicarbonate despite continued spironolactone therapy after recovery.", "question": "Treatment.Freq in cholestyramine", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6597713_3_6722", "context": "It is presumed that her hyperchloremic metabolic acidosis was secondary to cholestyramine because of the similarity to pediatric reports; the rapid and lasting response to intravenous sodium bicarbonate; the absence of another etiology; normal serum potassium, chloride and bicarbonate despite continued spironolactone therapy after recovery.", "question": "Treatment.Route in cholestyramine", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6597713_3_6723", "context": "It is presumed that her hyperchloremic metabolic acidosis was secondary to cholestyramine because of the similarity to pediatric reports; the rapid and lasting response to intravenous sodium bicarbonate; the absence of another etiology; normal serum potassium, chloride and bicarbonate despite continued spironolactone therapy after recovery.", "question": "Treatment.Time_elapsed in cholestyramine", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6597713_3_6724", "context": "It is presumed that her hyperchloremic metabolic acidosis was secondary to cholestyramine because of the similarity to pediatric reports; the rapid and lasting response to intravenous sodium bicarbonate; the absence of another etiology; normal serum potassium, chloride and bicarbonate despite continued spironolactone therapy after recovery.", "question": "Treatment.Duration in cholestyramine", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6597713_3_6725", "context": "It is presumed that her hyperchloremic metabolic acidosis was secondary to cholestyramine because of the similarity to pediatric reports; the rapid and lasting response to intravenous sodium bicarbonate; the absence of another etiology; normal serum potassium, chloride and bicarbonate despite continued spironolactone therapy after recovery.", "question": "Treatment.Disorder in cholestyramine", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6597713_3_6726", "context": "It is presumed that her hyperchloremic metabolic acidosis was secondary to cholestyramine because of the similarity to pediatric reports; the rapid and lasting response to intravenous sodium bicarbonate; the absence of another etiology; normal serum potassium, chloride and bicarbonate despite continued spironolactone therapy after recovery.", "question": "Combination.Drug in cholestyramine", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8551001_1_6727", "context": "Azathioprine can cause severe myelosuppression.", "question": "Treatment.Drug in Azathioprine", "question_type": "Adverse_event.Treatment.Drug", "answers": "Azathioprine"}, {"id": "8551001_1_6728", "context": "Azathioprine can cause severe myelosuppression.", "question": "Treatment.Dosage in Azathioprine", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8551001_1_6729", "context": "Azathioprine can cause severe myelosuppression.", "question": "Treatment.Freq in Azathioprine", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8551001_1_6730", "context": "Azathioprine can cause severe myelosuppression.", "question": "Treatment.Route in Azathioprine", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8551001_1_6731", "context": "Azathioprine can cause severe myelosuppression.", "question": "Treatment.Time_elapsed in Azathioprine", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8551001_1_6732", "context": "Azathioprine can cause severe myelosuppression.", "question": "Treatment.Duration in Azathioprine", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8551001_1_6733", "context": "Azathioprine can cause severe myelosuppression.", "question": "Treatment.Disorder in Azathioprine", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8551001_1_6734", "context": "Azathioprine can cause severe myelosuppression.", "question": "Combination.Drug in Azathioprine", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7789881_1_6735", "context": "Secretory endometrial adenocarcinoma in a patient on tamoxifen for breast cancer: a report of a case.", "question": "Subject.Age in a patient", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "7789881_1_6736", "context": "Secretory endometrial adenocarcinoma in a patient on tamoxifen for breast cancer: a report of a case.", "question": "Subject.Gender in a patient", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "7789881_1_6737", "context": "Secretory endometrial adenocarcinoma in a patient on tamoxifen for breast cancer: a report of a case.", "question": "Subject.Population in a patient", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "7789881_1_6738", "context": "Secretory endometrial adenocarcinoma in a patient on tamoxifen for breast cancer: a report of a case.", "question": "Subject.Race in a patient", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "7789881_1_6739", "context": "Secretory endometrial adenocarcinoma in a patient on tamoxifen for breast cancer: a report of a case.", "question": "Subject.Disorder in a patient", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "7789881_1_6740", "context": "Secretory endometrial adenocarcinoma in a patient on tamoxifen for breast cancer: a report of a case.", "question": "Treatment.Drug in tamoxifen for breast cancer", "question_type": "Adverse_event.Treatment.Drug", "answers": "tamoxifen"}, {"id": "7789881_1_6741", "context": "Secretory endometrial adenocarcinoma in a patient on tamoxifen for breast cancer: a report of a case.", "question": "Treatment.Dosage in tamoxifen for breast cancer", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7789881_1_6742", "context": "Secretory endometrial adenocarcinoma in a patient on tamoxifen for breast cancer: a report of a case.", "question": "Treatment.Freq in tamoxifen for breast cancer", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7789881_1_6743", "context": "Secretory endometrial adenocarcinoma in a patient on tamoxifen for breast cancer: a report of a case.", "question": "Treatment.Route in tamoxifen for breast cancer", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7789881_1_6744", "context": "Secretory endometrial adenocarcinoma in a patient on tamoxifen for breast cancer: a report of a case.", "question": "Treatment.Time_elapsed in tamoxifen for breast cancer", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7789881_1_6745", "context": "Secretory endometrial adenocarcinoma in a patient on tamoxifen for breast cancer: a report of a case.", "question": "Treatment.Duration in tamoxifen for breast cancer", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7789881_1_6746", "context": "Secretory endometrial adenocarcinoma in a patient on tamoxifen for breast cancer: a report of a case.", "question": "Treatment.Disorder in tamoxifen for breast cancer", "question_type": "Adverse_event.Treatment.Disorder", "answers": "breast cancer"}, {"id": "7789881_1_6747", "context": "Secretory endometrial adenocarcinoma in a patient on tamoxifen for breast cancer: a report of a case.", "question": "Combination.Drug in tamoxifen for breast cancer", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12452753_4_6748", "context": "It was postulated that the allergic reaction was most likely caused by capecitabine or the intermediate metabolites based on the immediate reappearance of symptoms from the rechallenge, pharmacokinetic data, and well-tolerance of fluorouracil.", "question": "Treatment.Drug in capecitabine or the intermediate metabolite", "question_type": "Adverse_event.Treatment.Drug", "answers": "capecitabine"}, {"id": "12452753_4_6749", "context": "It was postulated that the allergic reaction was most likely caused by capecitabine or the intermediate metabolites based on the immediate reappearance of symptoms from the rechallenge, pharmacokinetic data, and well-tolerance of fluorouracil.", "question": "Treatment.Dosage in capecitabine or the intermediate metabolite", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12452753_4_6750", "context": "It was postulated that the allergic reaction was most likely caused by capecitabine or the intermediate metabolites based on the immediate reappearance of symptoms from the rechallenge, pharmacokinetic data, and well-tolerance of fluorouracil.", "question": "Treatment.Freq in capecitabine or the intermediate metabolite", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12452753_4_6751", "context": "It was postulated that the allergic reaction was most likely caused by capecitabine or the intermediate metabolites based on the immediate reappearance of symptoms from the rechallenge, pharmacokinetic data, and well-tolerance of fluorouracil.", "question": "Treatment.Route in capecitabine or the intermediate metabolite", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12452753_4_6752", "context": "It was postulated that the allergic reaction was most likely caused by capecitabine or the intermediate metabolites based on the immediate reappearance of symptoms from the rechallenge, pharmacokinetic data, and well-tolerance of fluorouracil.", "question": "Treatment.Time_elapsed in capecitabine or the intermediate metabolite", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12452753_4_6753", "context": "It was postulated that the allergic reaction was most likely caused by capecitabine or the intermediate metabolites based on the immediate reappearance of symptoms from the rechallenge, pharmacokinetic data, and well-tolerance of fluorouracil.", "question": "Treatment.Duration in capecitabine or the intermediate metabolite", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12452753_4_6754", "context": "It was postulated that the allergic reaction was most likely caused by capecitabine or the intermediate metabolites based on the immediate reappearance of symptoms from the rechallenge, pharmacokinetic data, and well-tolerance of fluorouracil.", "question": "Treatment.Disorder in capecitabine or the intermediate metabolite", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12452753_4_6755", "context": "It was postulated that the allergic reaction was most likely caused by capecitabine or the intermediate metabolites based on the immediate reappearance of symptoms from the rechallenge, pharmacokinetic data, and well-tolerance of fluorouracil.", "question": "Combination.Drug in capecitabine or the intermediate metabolite", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10465148_1_6756", "context": "Anterior lumbosacral radiculopathy after intrathecal methotrexate treatment.", "question": "Treatment.Drug in intrathecal methotrexate", "question_type": "Adverse_event.Treatment.Drug", "answers": "methotrexate"}, {"id": "10465148_1_6757", "context": "Anterior lumbosacral radiculopathy after intrathecal methotrexate treatment.", "question": "Treatment.Dosage in intrathecal methotrexate", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10465148_1_6758", "context": "Anterior lumbosacral radiculopathy after intrathecal methotrexate treatment.", "question": "Treatment.Freq in intrathecal methotrexate", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10465148_1_6759", "context": "Anterior lumbosacral radiculopathy after intrathecal methotrexate treatment.", "question": "Treatment.Route in intrathecal methotrexate", "question_type": "Adverse_event.Treatment.Route", "answers": "intrathecal"}, {"id": "10465148_1_6760", "context": "Anterior lumbosacral radiculopathy after intrathecal methotrexate treatment.", "question": "Treatment.Time_elapsed in intrathecal methotrexate", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10465148_1_6761", "context": "Anterior lumbosacral radiculopathy after intrathecal methotrexate treatment.", "question": "Treatment.Duration in intrathecal methotrexate", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10465148_1_6762", "context": "Anterior lumbosacral radiculopathy after intrathecal methotrexate treatment.", "question": "Treatment.Disorder in intrathecal methotrexate", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10465148_1_6763", "context": "Anterior lumbosacral radiculopathy after intrathecal methotrexate treatment.", "question": "Combination.Drug in intrathecal methotrexate", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "19512997_1_6764", "context": "Divalproex sodium-induced eosinophilic pleural effusion.", "question": "Treatment.Drug in Divalproex sodium", "question_type": "Adverse_event.Treatment.Drug", "answers": "Divalproex sodium"}, {"id": "19512997_1_6765", "context": "Divalproex sodium-induced eosinophilic pleural effusion.", "question": "Treatment.Dosage in Divalproex sodium", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "19512997_1_6766", "context": "Divalproex sodium-induced eosinophilic pleural effusion.", "question": "Treatment.Freq in Divalproex sodium", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "19512997_1_6767", "context": "Divalproex sodium-induced eosinophilic pleural effusion.", "question": "Treatment.Route in Divalproex sodium", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "19512997_1_6768", "context": "Divalproex sodium-induced eosinophilic pleural effusion.", "question": "Treatment.Time_elapsed in Divalproex sodium", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19512997_1_6769", "context": "Divalproex sodium-induced eosinophilic pleural effusion.", "question": "Treatment.Duration in Divalproex sodium", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "19512997_1_6770", "context": "Divalproex sodium-induced eosinophilic pleural effusion.", "question": "Treatment.Disorder in Divalproex sodium", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "19512997_1_6771", "context": "Divalproex sodium-induced eosinophilic pleural effusion.", "question": "Combination.Drug in Divalproex sodium", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10405480_1_6772", "context": "A 26-year-old Japanese man, who had been receiving medical attention for ulcerative colitis for one year, presented with diffuse erythema and pustules on his face and trunk, malaise, and fever up to 39 degrees C one day after the administration of salazosulfapyridine.", "question": "Subject.Age in A 26-year-old Japanese man, who had been receiving medical attention for ulcerative colitis for one year", "question_type": "Adverse_event.Subject.Age", "answers": "26-year-old"}, {"id": "10405480_1_6773", "context": "A 26-year-old Japanese man, who had been receiving medical attention for ulcerative colitis for one year, presented with diffuse erythema and pustules on his face and trunk, malaise, and fever up to 39 degrees C one day after the administration of salazosulfapyridine.", "question": "Subject.Gender in A 26-year-old Japanese man, who had been receiving medical attention for ulcerative colitis for one year", "question_type": "Adverse_event.Subject.Gender", "answers": "man"}, {"id": "10405480_1_6774", "context": "A 26-year-old Japanese man, who had been receiving medical attention for ulcerative colitis for one year, presented with diffuse erythema and pustules on his face and trunk, malaise, and fever up to 39 degrees C one day after the administration of salazosulfapyridine.", "question": "Subject.Population in A 26-year-old Japanese man, who had been receiving medical attention for ulcerative colitis for one year", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "10405480_1_6775", "context": "A 26-year-old Japanese man, who had been receiving medical attention for ulcerative colitis for one year, presented with diffuse erythema and pustules on his face and trunk, malaise, and fever up to 39 degrees C one day after the administration of salazosulfapyridine.", "question": "Subject.Race in A 26-year-old Japanese man, who had been receiving medical attention for ulcerative colitis for one year", "question_type": "Adverse_event.Subject.Race", "answers": "Japanese"}, {"id": "10405480_1_6776", "context": "A 26-year-old Japanese man, who had been receiving medical attention for ulcerative colitis for one year, presented with diffuse erythema and pustules on his face and trunk, malaise, and fever up to 39 degrees C one day after the administration of salazosulfapyridine.", "question": "Subject.Disorder in A 26-year-old Japanese man, who had been receiving medical attention for ulcerative colitis for one year", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "10405480_1_6777", "context": "A 26-year-old Japanese man, who had been receiving medical attention for ulcerative colitis for one year, presented with diffuse erythema and pustules on his face and trunk, malaise, and fever up to 39 degrees C one day after the administration of salazosulfapyridine.", "question": "Treatment.Drug in salazosulfapyridine", "question_type": "Adverse_event.Treatment.Drug", "answers": "salazosulfapyridine"}, {"id": "10405480_1_6778", "context": "A 26-year-old Japanese man, who had been receiving medical attention for ulcerative colitis for one year, presented with diffuse erythema and pustules on his face and trunk, malaise, and fever up to 39 degrees C one day after the administration of salazosulfapyridine.", "question": "Treatment.Dosage in salazosulfapyridine", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10405480_1_6779", "context": "A 26-year-old Japanese man, who had been receiving medical attention for ulcerative colitis for one year, presented with diffuse erythema and pustules on his face and trunk, malaise, and fever up to 39 degrees C one day after the administration of salazosulfapyridine.", "question": "Treatment.Freq in salazosulfapyridine", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10405480_1_6780", "context": "A 26-year-old Japanese man, who had been receiving medical attention for ulcerative colitis for one year, presented with diffuse erythema and pustules on his face and trunk, malaise, and fever up to 39 degrees C one day after the administration of salazosulfapyridine.", "question": "Treatment.Route in salazosulfapyridine", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10405480_1_6781", "context": "A 26-year-old Japanese man, who had been receiving medical attention for ulcerative colitis for one year, presented with diffuse erythema and pustules on his face and trunk, malaise, and fever up to 39 degrees C one day after the administration of salazosulfapyridine.", "question": "Treatment.Time_elapsed in salazosulfapyridine", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "one day"}, {"id": "10405480_1_6782", "context": "A 26-year-old Japanese man, who had been receiving medical attention for ulcerative colitis for one year, presented with diffuse erythema and pustules on his face and trunk, malaise, and fever up to 39 degrees C one day after the administration of salazosulfapyridine.", "question": "Treatment.Duration in salazosulfapyridine", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10405480_1_6783", "context": "A 26-year-old Japanese man, who had been receiving medical attention for ulcerative colitis for one year, presented with diffuse erythema and pustules on his face and trunk, malaise, and fever up to 39 degrees C one day after the administration of salazosulfapyridine.", "question": "Treatment.Disorder in salazosulfapyridine", "question_type": "Adverse_event.Treatment.Disorder", "answers": "ulcerative colitis"}, {"id": "10405480_1_6784", "context": "A 26-year-old Japanese man, who had been receiving medical attention for ulcerative colitis for one year, presented with diffuse erythema and pustules on his face and trunk, malaise, and fever up to 39 degrees C one day after the administration of salazosulfapyridine.", "question": "Combination.Drug in salazosulfapyridine", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11573852_1_6785", "context": "Amphotericin B-induced seizures in a patient with AIDS.", "question": "Subject.Age in a patient with AIDS", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "11573852_1_6786", "context": "Amphotericin B-induced seizures in a patient with AIDS.", "question": "Subject.Gender in a patient with AIDS", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "11573852_1_6787", "context": "Amphotericin B-induced seizures in a patient with AIDS.", "question": "Subject.Population in a patient with AIDS", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "11573852_1_6788", "context": "Amphotericin B-induced seizures in a patient with AIDS.", "question": "Subject.Race in a patient with AIDS", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "11573852_1_6789", "context": "Amphotericin B-induced seizures in a patient with AIDS.", "question": "Subject.Disorder in a patient with AIDS", "question_type": "Adverse_event.Subject.Disorder", "answers": "AIDS"}, {"id": "11573852_1_6790", "context": "Amphotericin B-induced seizures in a patient with AIDS.", "question": "Treatment.Drug in Amphotericin B", "question_type": "Adverse_event.Treatment.Drug", "answers": "Amphotericin B"}, {"id": "11573852_1_6791", "context": "Amphotericin B-induced seizures in a patient with AIDS.", "question": "Treatment.Dosage in Amphotericin B", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11573852_1_6792", "context": "Amphotericin B-induced seizures in a patient with AIDS.", "question": "Treatment.Freq in Amphotericin B", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11573852_1_6793", "context": "Amphotericin B-induced seizures in a patient with AIDS.", "question": "Treatment.Route in Amphotericin B", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11573852_1_6794", "context": "Amphotericin B-induced seizures in a patient with AIDS.", "question": "Treatment.Time_elapsed in Amphotericin B", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11573852_1_6795", "context": "Amphotericin B-induced seizures in a patient with AIDS.", "question": "Treatment.Duration in Amphotericin B", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11573852_1_6796", "context": "Amphotericin B-induced seizures in a patient with AIDS.", "question": "Treatment.Disorder in Amphotericin B", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11573852_1_6797", "context": "Amphotericin B-induced seizures in a patient with AIDS.", "question": "Combination.Drug in Amphotericin B", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "2154663_2_6798", "context": "Concomitant irradiation apparently enhanced the skin toxicity of aminoglutethimide or possibly aminoglutethimide had a radiosensitizing role in this patient.", "question": "Subject.Age in this patient", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "2154663_2_6799", "context": "Concomitant irradiation apparently enhanced the skin toxicity of aminoglutethimide or possibly aminoglutethimide had a radiosensitizing role in this patient.", "question": "Subject.Gender in this patient", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "2154663_2_6800", "context": "Concomitant irradiation apparently enhanced the skin toxicity of aminoglutethimide or possibly aminoglutethimide had a radiosensitizing role in this patient.", "question": "Subject.Population in this patient", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "2154663_2_6801", "context": "Concomitant irradiation apparently enhanced the skin toxicity of aminoglutethimide or possibly aminoglutethimide had a radiosensitizing role in this patient.", "question": "Subject.Race in this patient", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "2154663_2_6802", "context": "Concomitant irradiation apparently enhanced the skin toxicity of aminoglutethimide or possibly aminoglutethimide had a radiosensitizing role in this patient.", "question": "Subject.Disorder in this patient", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "2154663_2_6803", "context": "Concomitant irradiation apparently enhanced the skin toxicity of aminoglutethimide or possibly aminoglutethimide had a radiosensitizing role in this patient.", "question": "Treatment.Drug in Concomitant irradiation; aminoglutethimide", "question_type": "Adverse_event.Treatment.Drug", "answers": "aminoglutethimide; irradiation"}, {"id": "2154663_2_6804", "context": "Concomitant irradiation apparently enhanced the skin toxicity of aminoglutethimide or possibly aminoglutethimide had a radiosensitizing role in this patient.", "question": "Treatment.Dosage in Concomitant irradiation; aminoglutethimide", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "2154663_2_6805", "context": "Concomitant irradiation apparently enhanced the skin toxicity of aminoglutethimide or possibly aminoglutethimide had a radiosensitizing role in this patient.", "question": "Treatment.Freq in Concomitant irradiation; aminoglutethimide", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2154663_2_6806", "context": "Concomitant irradiation apparently enhanced the skin toxicity of aminoglutethimide or possibly aminoglutethimide had a radiosensitizing role in this patient.", "question": "Treatment.Route in Concomitant irradiation; aminoglutethimide", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "2154663_2_6807", "context": "Concomitant irradiation apparently enhanced the skin toxicity of aminoglutethimide or possibly aminoglutethimide had a radiosensitizing role in this patient.", "question": "Treatment.Time_elapsed in Concomitant irradiation; aminoglutethimide", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2154663_2_6808", "context": "Concomitant irradiation apparently enhanced the skin toxicity of aminoglutethimide or possibly aminoglutethimide had a radiosensitizing role in this patient.", "question": "Treatment.Duration in Concomitant irradiation; aminoglutethimide", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2154663_2_6809", "context": "Concomitant irradiation apparently enhanced the skin toxicity of aminoglutethimide or possibly aminoglutethimide had a radiosensitizing role in this patient.", "question": "Treatment.Disorder in Concomitant irradiation; aminoglutethimide", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "2154663_2_6810", "context": "Concomitant irradiation apparently enhanced the skin toxicity of aminoglutethimide or possibly aminoglutethimide had a radiosensitizing role in this patient.", "question": "Combination.Drug in Concomitant irradiation; aminoglutethimide", "question_type": "Adverse_event.Combination.Drug", "answers": "irradiation; aminoglutethimide"}, {"id": "8996514_1_6811", "context": "CASE DESCRIPTION: A 59-year-old man with known neurocysticercosis developed a large cerebral infarction during praziquantel therapy.", "question": "Subject.Age in A 59-year-old man with known neurocysticercosis", "question_type": "Adverse_event.Subject.Age", "answers": "59-year-old"}, {"id": "8996514_1_6812", "context": "CASE DESCRIPTION: A 59-year-old man with known neurocysticercosis developed a large cerebral infarction during praziquantel therapy.", "question": "Subject.Gender in A 59-year-old man with known neurocysticercosis", "question_type": "Adverse_event.Subject.Gender", "answers": "man"}, {"id": "8996514_1_6813", "context": "CASE DESCRIPTION: A 59-year-old man with known neurocysticercosis developed a large cerebral infarction during praziquantel therapy.", "question": "Subject.Population in A 59-year-old man with known neurocysticercosis", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "8996514_1_6814", "context": "CASE DESCRIPTION: A 59-year-old man with known neurocysticercosis developed a large cerebral infarction during praziquantel therapy.", "question": "Subject.Race in A 59-year-old man with known neurocysticercosis", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "8996514_1_6815", "context": "CASE DESCRIPTION: A 59-year-old man with known neurocysticercosis developed a large cerebral infarction during praziquantel therapy.", "question": "Subject.Disorder in A 59-year-old man with known neurocysticercosis", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "8996514_1_6816", "context": "CASE DESCRIPTION: A 59-year-old man with known neurocysticercosis developed a large cerebral infarction during praziquantel therapy.", "question": "Treatment.Drug in during praziquantel therapy", "question_type": "Adverse_event.Treatment.Drug", "answers": "praziquantel"}, {"id": "8996514_1_6817", "context": "CASE DESCRIPTION: A 59-year-old man with known neurocysticercosis developed a large cerebral infarction during praziquantel therapy.", "question": "Treatment.Dosage in during praziquantel therapy", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8996514_1_6818", "context": "CASE DESCRIPTION: A 59-year-old man with known neurocysticercosis developed a large cerebral infarction during praziquantel therapy.", "question": "Treatment.Freq in during praziquantel therapy", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8996514_1_6819", "context": "CASE DESCRIPTION: A 59-year-old man with known neurocysticercosis developed a large cerebral infarction during praziquantel therapy.", "question": "Treatment.Route in during praziquantel therapy", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8996514_1_6820", "context": "CASE DESCRIPTION: A 59-year-old man with known neurocysticercosis developed a large cerebral infarction during praziquantel therapy.", "question": "Treatment.Time_elapsed in during praziquantel therapy", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8996514_1_6821", "context": "CASE DESCRIPTION: A 59-year-old man with known neurocysticercosis developed a large cerebral infarction during praziquantel therapy.", "question": "Treatment.Duration in during praziquantel therapy", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8996514_1_6822", "context": "CASE DESCRIPTION: A 59-year-old man with known neurocysticercosis developed a large cerebral infarction during praziquantel therapy.", "question": "Treatment.Disorder in during praziquantel therapy", "question_type": "Adverse_event.Treatment.Disorder", "answers": "neurocysticercosis"}, {"id": "8996514_1_6823", "context": "CASE DESCRIPTION: A 59-year-old man with known neurocysticercosis developed a large cerebral infarction during praziquantel therapy.", "question": "Combination.Drug in during praziquantel therapy", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12181031_3_6824", "context": "We describe a 73-year-old woman who developed serious systemic vasculitis with associated thrombocytopenia in the course of treatment with cladribine.", "question": "Subject.Age in a 73-year-old woman", "question_type": "Adverse_event.Subject.Age", "answers": "73-year-old"}, {"id": "12181031_3_6825", "context": "We describe a 73-year-old woman who developed serious systemic vasculitis with associated thrombocytopenia in the course of treatment with cladribine.", "question": "Subject.Gender in a 73-year-old woman", "question_type": "Adverse_event.Subject.Gender", "answers": "woman"}, {"id": "12181031_3_6826", "context": "We describe a 73-year-old woman who developed serious systemic vasculitis with associated thrombocytopenia in the course of treatment with cladribine.", "question": "Subject.Population in a 73-year-old woman", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "12181031_3_6827", "context": "We describe a 73-year-old woman who developed serious systemic vasculitis with associated thrombocytopenia in the course of treatment with cladribine.", "question": "Subject.Race in a 73-year-old woman", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "12181031_3_6828", "context": "We describe a 73-year-old woman who developed serious systemic vasculitis with associated thrombocytopenia in the course of treatment with cladribine.", "question": "Subject.Disorder in a 73-year-old woman", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "12181031_3_6829", "context": "We describe a 73-year-old woman who developed serious systemic vasculitis with associated thrombocytopenia in the course of treatment with cladribine.", "question": "Treatment.Drug in cladribine", "question_type": "Adverse_event.Treatment.Drug", "answers": "cladribine"}, {"id": "12181031_3_6830", "context": "We describe a 73-year-old woman who developed serious systemic vasculitis with associated thrombocytopenia in the course of treatment with cladribine.", "question": "Treatment.Dosage in cladribine", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12181031_3_6831", "context": "We describe a 73-year-old woman who developed serious systemic vasculitis with associated thrombocytopenia in the course of treatment with cladribine.", "question": "Treatment.Freq in cladribine", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12181031_3_6832", "context": "We describe a 73-year-old woman who developed serious systemic vasculitis with associated thrombocytopenia in the course of treatment with cladribine.", "question": "Treatment.Route in cladribine", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12181031_3_6833", "context": "We describe a 73-year-old woman who developed serious systemic vasculitis with associated thrombocytopenia in the course of treatment with cladribine.", "question": "Treatment.Time_elapsed in cladribine", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12181031_3_6834", "context": "We describe a 73-year-old woman who developed serious systemic vasculitis with associated thrombocytopenia in the course of treatment with cladribine.", "question": "Treatment.Duration in cladribine", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12181031_3_6835", "context": "We describe a 73-year-old woman who developed serious systemic vasculitis with associated thrombocytopenia in the course of treatment with cladribine.", "question": "Treatment.Disorder in cladribine", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12181031_3_6836", "context": "We describe a 73-year-old woman who developed serious systemic vasculitis with associated thrombocytopenia in the course of treatment with cladribine.", "question": "Combination.Drug in cladribine", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17083890_8_6837", "context": "All changes disappeared 4 months after the discontinuation of VAD chemotherapy, which further pointed out towards adriamycin and vincristine as possible etiologic agents.", "question": "Treatment.Drug in adriamycin and vincristine", "question_type": "Adverse_event.Treatment.Drug", "answers": "adriamycin; vincristine"}, {"id": "17083890_8_6838", "context": "All changes disappeared 4 months after the discontinuation of VAD chemotherapy, which further pointed out towards adriamycin and vincristine as possible etiologic agents.", "question": "Treatment.Dosage in adriamycin and vincristine", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17083890_8_6839", "context": "All changes disappeared 4 months after the discontinuation of VAD chemotherapy, which further pointed out towards adriamycin and vincristine as possible etiologic agents.", "question": "Treatment.Freq in adriamycin and vincristine", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17083890_8_6840", "context": "All changes disappeared 4 months after the discontinuation of VAD chemotherapy, which further pointed out towards adriamycin and vincristine as possible etiologic agents.", "question": "Treatment.Route in adriamycin and vincristine", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17083890_8_6841", "context": "All changes disappeared 4 months after the discontinuation of VAD chemotherapy, which further pointed out towards adriamycin and vincristine as possible etiologic agents.", "question": "Treatment.Time_elapsed in adriamycin and vincristine", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17083890_8_6842", "context": "All changes disappeared 4 months after the discontinuation of VAD chemotherapy, which further pointed out towards adriamycin and vincristine as possible etiologic agents.", "question": "Treatment.Duration in adriamycin and vincristine", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17083890_8_6843", "context": "All changes disappeared 4 months after the discontinuation of VAD chemotherapy, which further pointed out towards adriamycin and vincristine as possible etiologic agents.", "question": "Treatment.Disorder in adriamycin and vincristine", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17083890_8_6844", "context": "All changes disappeared 4 months after the discontinuation of VAD chemotherapy, which further pointed out towards adriamycin and vincristine as possible etiologic agents.", "question": "Combination.Drug in adriamycin and vincristine", "question_type": "Adverse_event.Combination.Drug", "answers": "adriamycin; vincristine"}, {"id": "24679099_7_6845", "context": "Because of further progression combination treatment of bevacizumab and irinotecan was started and again no liver toxicity was observed.", "question": "Treatment.Drug in bevacizumab and irinotecan", "question_type": "Adverse_event.Treatment.Drug", "answers": "bevacizumab; irinotecan"}, {"id": "24679099_7_6846", "context": "Because of further progression combination treatment of bevacizumab and irinotecan was started and again no liver toxicity was observed.", "question": "Treatment.Dosage in bevacizumab and irinotecan", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "24679099_7_6847", "context": "Because of further progression combination treatment of bevacizumab and irinotecan was started and again no liver toxicity was observed.", "question": "Treatment.Freq in bevacizumab and irinotecan", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "24679099_7_6848", "context": "Because of further progression combination treatment of bevacizumab and irinotecan was started and again no liver toxicity was observed.", "question": "Treatment.Route in bevacizumab and irinotecan", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "24679099_7_6849", "context": "Because of further progression combination treatment of bevacizumab and irinotecan was started and again no liver toxicity was observed.", "question": "Treatment.Time_elapsed in bevacizumab and irinotecan", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "24679099_7_6850", "context": "Because of further progression combination treatment of bevacizumab and irinotecan was started and again no liver toxicity was observed.", "question": "Treatment.Duration in bevacizumab and irinotecan", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "24679099_7_6851", "context": "Because of further progression combination treatment of bevacizumab and irinotecan was started and again no liver toxicity was observed.", "question": "Treatment.Disorder in bevacizumab and irinotecan", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "24679099_7_6852", "context": "Because of further progression combination treatment of bevacizumab and irinotecan was started and again no liver toxicity was observed.", "question": "Combination.Drug in bevacizumab and irinotecan", "question_type": "Adverse_event.Combination.Drug", "answers": "bevacizumab; irinotecan"}, {"id": "3609047_2_6853", "context": "Torsade de pointes represents a potential complication of chronic amiodarone therapy.", "question": "Treatment.Drug in chronic amiodarone therapy", "question_type": "Adverse_event.Treatment.Drug", "answers": "amiodarone"}, {"id": "3609047_2_6854", "context": "Torsade de pointes represents a potential complication of chronic amiodarone therapy.", "question": "Treatment.Dosage in chronic amiodarone therapy", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3609047_2_6855", "context": "Torsade de pointes represents a potential complication of chronic amiodarone therapy.", "question": "Treatment.Freq in chronic amiodarone therapy", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3609047_2_6856", "context": "Torsade de pointes represents a potential complication of chronic amiodarone therapy.", "question": "Treatment.Route in chronic amiodarone therapy", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3609047_2_6857", "context": "Torsade de pointes represents a potential complication of chronic amiodarone therapy.", "question": "Treatment.Time_elapsed in chronic amiodarone therapy", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3609047_2_6858", "context": "Torsade de pointes represents a potential complication of chronic amiodarone therapy.", "question": "Treatment.Duration in chronic amiodarone therapy", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3609047_2_6859", "context": "Torsade de pointes represents a potential complication of chronic amiodarone therapy.", "question": "Treatment.Disorder in chronic amiodarone therapy", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3609047_2_6860", "context": "Torsade de pointes represents a potential complication of chronic amiodarone therapy.", "question": "Combination.Drug in chronic amiodarone therapy", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9988365_1_6861", "context": "Eosinophilia caused by clozapine was observed in challenge, preceded by a faster neutrophil production and consecutive decrease (z = 2.27, p = 0.01).", "question": "Treatment.Drug in clozapine", "question_type": "Adverse_event.Treatment.Drug", "answers": "clozapine"}, {"id": "9988365_1_6862", "context": "Eosinophilia caused by clozapine was observed in challenge, preceded by a faster neutrophil production and consecutive decrease (z = 2.27, p = 0.01).", "question": "Treatment.Dosage in clozapine", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9988365_1_6863", "context": "Eosinophilia caused by clozapine was observed in challenge, preceded by a faster neutrophil production and consecutive decrease (z = 2.27, p = 0.01).", "question": "Treatment.Freq in clozapine", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9988365_1_6864", "context": "Eosinophilia caused by clozapine was observed in challenge, preceded by a faster neutrophil production and consecutive decrease (z = 2.27, p = 0.01).", "question": "Treatment.Route in clozapine", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9988365_1_6865", "context": "Eosinophilia caused by clozapine was observed in challenge, preceded by a faster neutrophil production and consecutive decrease (z = 2.27, p = 0.01).", "question": "Treatment.Time_elapsed in clozapine", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9988365_1_6866", "context": "Eosinophilia caused by clozapine was observed in challenge, preceded by a faster neutrophil production and consecutive decrease (z = 2.27, p = 0.01).", "question": "Treatment.Duration in clozapine", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9988365_1_6867", "context": "Eosinophilia caused by clozapine was observed in challenge, preceded by a faster neutrophil production and consecutive decrease (z = 2.27, p = 0.01).", "question": "Treatment.Disorder in clozapine", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9988365_1_6868", "context": "Eosinophilia caused by clozapine was observed in challenge, preceded by a faster neutrophil production and consecutive decrease (z = 2.27, p = 0.01).", "question": "Combination.Drug in clozapine", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17667887_3_6869", "context": "The first case is a 69-year-old man who was admitted for depression with psychosis and treated with trazodone, risperidone, and sertraline.", "question": "Subject.Age in a 69-year-old man who was admitted for depression with psychosis", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": "69-year-old"}, {"id": "17667887_3_6870", "context": "The first case is a 69-year-old man who was admitted for depression with psychosis and treated with trazodone, risperidone, and sertraline.", "question": "Subject.Gender in a 69-year-old man who was admitted for depression with psychosis", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": "man"}, {"id": "17667887_3_6871", "context": "The first case is a 69-year-old man who was admitted for depression with psychosis and treated with trazodone, risperidone, and sertraline.", "question": "Subject.Population in a 69-year-old man who was admitted for depression with psychosis", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "17667887_3_6872", "context": "The first case is a 69-year-old man who was admitted for depression with psychosis and treated with trazodone, risperidone, and sertraline.", "question": "Subject.Race in a 69-year-old man who was admitted for depression with psychosis", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "17667887_3_6873", "context": "The first case is a 69-year-old man who was admitted for depression with psychosis and treated with trazodone, risperidone, and sertraline.", "question": "Subject.Disorder in a 69-year-old man who was admitted for depression with psychosis", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "17667887_3_6874", "context": "The first case is a 69-year-old man who was admitted for depression with psychosis and treated with trazodone, risperidone, and sertraline.", "question": "Treatment.Drug in trazodone, risperidone, and sertraline", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "trazodone; risperidone; sertraline"}, {"id": "17667887_3_6875", "context": "The first case is a 69-year-old man who was admitted for depression with psychosis and treated with trazodone, risperidone, and sertraline.", "question": "Treatment.Dosage in trazodone, risperidone, and sertraline", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "17667887_3_6876", "context": "The first case is a 69-year-old man who was admitted for depression with psychosis and treated with trazodone, risperidone, and sertraline.", "question": "Treatment.Freq in trazodone, risperidone, and sertraline", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "17667887_3_6877", "context": "The first case is a 69-year-old man who was admitted for depression with psychosis and treated with trazodone, risperidone, and sertraline.", "question": "Treatment.Route in trazodone, risperidone, and sertraline", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "17667887_3_6878", "context": "The first case is a 69-year-old man who was admitted for depression with psychosis and treated with trazodone, risperidone, and sertraline.", "question": "Treatment.Time_elapsed in trazodone, risperidone, and sertraline", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17667887_3_6879", "context": "The first case is a 69-year-old man who was admitted for depression with psychosis and treated with trazodone, risperidone, and sertraline.", "question": "Treatment.Duration in trazodone, risperidone, and sertraline", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "17667887_3_6880", "context": "The first case is a 69-year-old man who was admitted for depression with psychosis and treated with trazodone, risperidone, and sertraline.", "question": "Treatment.Disorder in trazodone, risperidone, and sertraline", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "depression with psychosis"}, {"id": "17667887_3_6881", "context": "The first case is a 69-year-old man who was admitted for depression with psychosis and treated with trazodone, risperidone, and sertraline.", "question": "Combination.Drug in trazodone, risperidone, and sertraline", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": "risperidone; sertraline; trazodone"}, {"id": "6221046_2_6882", "context": "Multiple complications of propylthiouracil treatment: granulocytopenia, eosinophilia, skin reaction and hepatitis with lymphocyte sensitization.", "question": "Treatment.Drug in propylthiouracil", "question_type": "Adverse_event.Treatment.Drug", "answers": "propylthiouracil"}, {"id": "6221046_2_6883", "context": "Multiple complications of propylthiouracil treatment: granulocytopenia, eosinophilia, skin reaction and hepatitis with lymphocyte sensitization.", "question": "Treatment.Dosage in propylthiouracil", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6221046_2_6884", "context": "Multiple complications of propylthiouracil treatment: granulocytopenia, eosinophilia, skin reaction and hepatitis with lymphocyte sensitization.", "question": "Treatment.Freq in propylthiouracil", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6221046_2_6885", "context": "Multiple complications of propylthiouracil treatment: granulocytopenia, eosinophilia, skin reaction and hepatitis with lymphocyte sensitization.", "question": "Treatment.Route in propylthiouracil", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6221046_2_6886", "context": "Multiple complications of propylthiouracil treatment: granulocytopenia, eosinophilia, skin reaction and hepatitis with lymphocyte sensitization.", "question": "Treatment.Time_elapsed in propylthiouracil", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6221046_2_6887", "context": "Multiple complications of propylthiouracil treatment: granulocytopenia, eosinophilia, skin reaction and hepatitis with lymphocyte sensitization.", "question": "Treatment.Duration in propylthiouracil", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6221046_2_6888", "context": "Multiple complications of propylthiouracil treatment: granulocytopenia, eosinophilia, skin reaction and hepatitis with lymphocyte sensitization.", "question": "Treatment.Disorder in propylthiouracil", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6221046_2_6889", "context": "Multiple complications of propylthiouracil treatment: granulocytopenia, eosinophilia, skin reaction and hepatitis with lymphocyte sensitization.", "question": "Combination.Drug in propylthiouracil", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10456487_15_6890", "context": "Whether concomitant fluvoxamine treatment reduces tacrine-induced hepatotoxicity needs further study.", "question": "Treatment.Drug in tacrine", "question_type": "Adverse_event.Treatment.Drug", "answers": "tacrine"}, {"id": "10456487_15_6891", "context": "Whether concomitant fluvoxamine treatment reduces tacrine-induced hepatotoxicity needs further study.", "question": "Treatment.Dosage in tacrine", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10456487_15_6892", "context": "Whether concomitant fluvoxamine treatment reduces tacrine-induced hepatotoxicity needs further study.", "question": "Treatment.Freq in tacrine", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10456487_15_6893", "context": "Whether concomitant fluvoxamine treatment reduces tacrine-induced hepatotoxicity needs further study.", "question": "Treatment.Route in tacrine", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10456487_15_6894", "context": "Whether concomitant fluvoxamine treatment reduces tacrine-induced hepatotoxicity needs further study.", "question": "Treatment.Time_elapsed in tacrine", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10456487_15_6895", "context": "Whether concomitant fluvoxamine treatment reduces tacrine-induced hepatotoxicity needs further study.", "question": "Treatment.Duration in tacrine", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10456487_15_6896", "context": "Whether concomitant fluvoxamine treatment reduces tacrine-induced hepatotoxicity needs further study.", "question": "Treatment.Disorder in tacrine", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10456487_15_6897", "context": "Whether concomitant fluvoxamine treatment reduces tacrine-induced hepatotoxicity needs further study.", "question": "Combination.Drug in tacrine", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10456487_15_6898", "context": "Whether concomitant fluvoxamine treatment reduces tacrine-induced hepatotoxicity needs further study.", "question": "Treatment.Drug in concomitant fluvoxamine", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "fluvoxamine"}, {"id": "10456487_15_6899", "context": "Whether concomitant fluvoxamine treatment reduces tacrine-induced hepatotoxicity needs further study.", "question": "Treatment.Dosage in concomitant fluvoxamine", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "10456487_15_6900", "context": "Whether concomitant fluvoxamine treatment reduces tacrine-induced hepatotoxicity needs further study.", "question": "Treatment.Freq in concomitant fluvoxamine", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "10456487_15_6901", "context": "Whether concomitant fluvoxamine treatment reduces tacrine-induced hepatotoxicity needs further study.", "question": "Treatment.Route in concomitant fluvoxamine", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "10456487_15_6902", "context": "Whether concomitant fluvoxamine treatment reduces tacrine-induced hepatotoxicity needs further study.", "question": "Treatment.Time_elapsed in concomitant fluvoxamine", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10456487_15_6903", "context": "Whether concomitant fluvoxamine treatment reduces tacrine-induced hepatotoxicity needs further study.", "question": "Treatment.Duration in concomitant fluvoxamine", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "10456487_15_6904", "context": "Whether concomitant fluvoxamine treatment reduces tacrine-induced hepatotoxicity needs further study.", "question": "Treatment.Disorder in concomitant fluvoxamine", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "tacrine-induced hepatotoxicity"}, {"id": "10456487_15_6905", "context": "Whether concomitant fluvoxamine treatment reduces tacrine-induced hepatotoxicity needs further study.", "question": "Combination.Drug in concomitant fluvoxamine", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "3718111_3_6906", "context": "Severe hyperkalemia occurred in a patient with radiation pneumonitis and glaucoma shortly after beginning prednisone therapy.", "question": "Subject.Age in a patient with radiation pneumonitis and glaucoma", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "3718111_3_6907", "context": "Severe hyperkalemia occurred in a patient with radiation pneumonitis and glaucoma shortly after beginning prednisone therapy.", "question": "Subject.Gender in a patient with radiation pneumonitis and glaucoma", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "3718111_3_6908", "context": "Severe hyperkalemia occurred in a patient with radiation pneumonitis and glaucoma shortly after beginning prednisone therapy.", "question": "Subject.Population in a patient with radiation pneumonitis and glaucoma", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "3718111_3_6909", "context": "Severe hyperkalemia occurred in a patient with radiation pneumonitis and glaucoma shortly after beginning prednisone therapy.", "question": "Subject.Race in a patient with radiation pneumonitis and glaucoma", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "3718111_3_6910", "context": "Severe hyperkalemia occurred in a patient with radiation pneumonitis and glaucoma shortly after beginning prednisone therapy.", "question": "Subject.Disorder in a patient with radiation pneumonitis and glaucoma", "question_type": "Adverse_event.Subject.Disorder", "answers": "glaucoma"}, {"id": "3718111_3_6911", "context": "Severe hyperkalemia occurred in a patient with radiation pneumonitis and glaucoma shortly after beginning prednisone therapy.", "question": "Treatment.Drug in prednisone", "question_type": "Adverse_event.Treatment.Drug", "answers": "prednisone"}, {"id": "3718111_3_6912", "context": "Severe hyperkalemia occurred in a patient with radiation pneumonitis and glaucoma shortly after beginning prednisone therapy.", "question": "Treatment.Dosage in prednisone", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3718111_3_6913", "context": "Severe hyperkalemia occurred in a patient with radiation pneumonitis and glaucoma shortly after beginning prednisone therapy.", "question": "Treatment.Freq in prednisone", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3718111_3_6914", "context": "Severe hyperkalemia occurred in a patient with radiation pneumonitis and glaucoma shortly after beginning prednisone therapy.", "question": "Treatment.Route in prednisone", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3718111_3_6915", "context": "Severe hyperkalemia occurred in a patient with radiation pneumonitis and glaucoma shortly after beginning prednisone therapy.", "question": "Treatment.Time_elapsed in prednisone", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3718111_3_6916", "context": "Severe hyperkalemia occurred in a patient with radiation pneumonitis and glaucoma shortly after beginning prednisone therapy.", "question": "Treatment.Duration in prednisone", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3718111_3_6917", "context": "Severe hyperkalemia occurred in a patient with radiation pneumonitis and glaucoma shortly after beginning prednisone therapy.", "question": "Treatment.Disorder in prednisone", "question_type": "Adverse_event.Treatment.Disorder", "answers": "radiation pneumonitis"}, {"id": "3718111_3_6918", "context": "Severe hyperkalemia occurred in a patient with radiation pneumonitis and glaucoma shortly after beginning prednisone therapy.", "question": "Combination.Drug in prednisone", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9651465_2_6919", "context": "She was treated with Pancrease MT 16, but had consistent vomiting 1 to 2 hours after administration of enzymes.", "question": "Treatment.Drug in enzymes", "question_type": "Adverse_event.Treatment.Drug", "answers": "Pancrease MT 16; enzymes"}, {"id": "9651465_2_6920", "context": "She was treated with Pancrease MT 16, but had consistent vomiting 1 to 2 hours after administration of enzymes.", "question": "Treatment.Dosage in enzymes", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9651465_2_6921", "context": "She was treated with Pancrease MT 16, but had consistent vomiting 1 to 2 hours after administration of enzymes.", "question": "Treatment.Freq in enzymes", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9651465_2_6922", "context": "She was treated with Pancrease MT 16, but had consistent vomiting 1 to 2 hours after administration of enzymes.", "question": "Treatment.Route in enzymes", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9651465_2_6923", "context": "She was treated with Pancrease MT 16, but had consistent vomiting 1 to 2 hours after administration of enzymes.", "question": "Treatment.Time_elapsed in enzymes", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "1 to 2 hours"}, {"id": "9651465_2_6924", "context": "She was treated with Pancrease MT 16, but had consistent vomiting 1 to 2 hours after administration of enzymes.", "question": "Treatment.Duration in enzymes", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9651465_2_6925", "context": "She was treated with Pancrease MT 16, but had consistent vomiting 1 to 2 hours after administration of enzymes.", "question": "Treatment.Disorder in enzymes", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9651465_2_6926", "context": "She was treated with Pancrease MT 16, but had consistent vomiting 1 to 2 hours after administration of enzymes.", "question": "Combination.Drug in enzymes", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15701285_2_6927", "context": "Following are two clinical case reports demonstrating profound cerebral edema associated with implantation of Gliadel wafers.", "question": "Subject.Age in two clinical case", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "15701285_2_6928", "context": "Following are two clinical case reports demonstrating profound cerebral edema associated with implantation of Gliadel wafers.", "question": "Subject.Gender in two clinical case", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15701285_2_6929", "context": "Following are two clinical case reports demonstrating profound cerebral edema associated with implantation of Gliadel wafers.", "question": "Subject.Population in two clinical case", "question_type": "Adverse_event.Subject.Population", "answers": "two"}, {"id": "15701285_2_6930", "context": "Following are two clinical case reports demonstrating profound cerebral edema associated with implantation of Gliadel wafers.", "question": "Subject.Race in two clinical case", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15701285_2_6931", "context": "Following are two clinical case reports demonstrating profound cerebral edema associated with implantation of Gliadel wafers.", "question": "Subject.Disorder in two clinical case", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15701285_2_6932", "context": "Following are two clinical case reports demonstrating profound cerebral edema associated with implantation of Gliadel wafers.", "question": "Treatment.Drug in implantation of Gliadel wafers", "question_type": "Adverse_event.Treatment.Drug", "answers": "Gliadel wafers"}, {"id": "15701285_2_6933", "context": "Following are two clinical case reports demonstrating profound cerebral edema associated with implantation of Gliadel wafers.", "question": "Treatment.Dosage in implantation of Gliadel wafers", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15701285_2_6934", "context": "Following are two clinical case reports demonstrating profound cerebral edema associated with implantation of Gliadel wafers.", "question": "Treatment.Freq in implantation of Gliadel wafers", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15701285_2_6935", "context": "Following are two clinical case reports demonstrating profound cerebral edema associated with implantation of Gliadel wafers.", "question": "Treatment.Route in implantation of Gliadel wafers", "question_type": "Adverse_event.Treatment.Route", "answers": "implantation"}, {"id": "15701285_2_6936", "context": "Following are two clinical case reports demonstrating profound cerebral edema associated with implantation of Gliadel wafers.", "question": "Treatment.Time_elapsed in implantation of Gliadel wafers", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15701285_2_6937", "context": "Following are two clinical case reports demonstrating profound cerebral edema associated with implantation of Gliadel wafers.", "question": "Treatment.Duration in implantation of Gliadel wafers", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15701285_2_6938", "context": "Following are two clinical case reports demonstrating profound cerebral edema associated with implantation of Gliadel wafers.", "question": "Treatment.Disorder in implantation of Gliadel wafers", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15701285_2_6939", "context": "Following are two clinical case reports demonstrating profound cerebral edema associated with implantation of Gliadel wafers.", "question": "Combination.Drug in implantation of Gliadel wafers", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15279668_4_6940", "context": "At this point, a new antifungal agent had been commenced, suggesting a possible drug interaction enhancing the risk of known neurological toxicity with this regime.", "question": "Treatment.Drug in a new antifungal agent", "question_type": "Adverse_event.Treatment.Drug", "answers": "antifungal agent"}, {"id": "15279668_4_6941", "context": "At this point, a new antifungal agent had been commenced, suggesting a possible drug interaction enhancing the risk of known neurological toxicity with this regime.", "question": "Treatment.Dosage in a new antifungal agent", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15279668_4_6942", "context": "At this point, a new antifungal agent had been commenced, suggesting a possible drug interaction enhancing the risk of known neurological toxicity with this regime.", "question": "Treatment.Freq in a new antifungal agent", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15279668_4_6943", "context": "At this point, a new antifungal agent had been commenced, suggesting a possible drug interaction enhancing the risk of known neurological toxicity with this regime.", "question": "Treatment.Route in a new antifungal agent", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15279668_4_6944", "context": "At this point, a new antifungal agent had been commenced, suggesting a possible drug interaction enhancing the risk of known neurological toxicity with this regime.", "question": "Treatment.Time_elapsed in a new antifungal agent", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15279668_4_6945", "context": "At this point, a new antifungal agent had been commenced, suggesting a possible drug interaction enhancing the risk of known neurological toxicity with this regime.", "question": "Treatment.Duration in a new antifungal agent", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15279668_4_6946", "context": "At this point, a new antifungal agent had been commenced, suggesting a possible drug interaction enhancing the risk of known neurological toxicity with this regime.", "question": "Treatment.Disorder in a new antifungal agent", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15279668_4_6947", "context": "At this point, a new antifungal agent had been commenced, suggesting a possible drug interaction enhancing the risk of known neurological toxicity with this regime.", "question": "Combination.Drug in a new antifungal agent", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15941649_2_6948", "context": "The knowledge concerning VGB-associated visual dysfunction in pediatric patients, particularly in those who have been exposed to VGB in utero is limited.", "question": "Subject.Age in pediatric patients", "question_type": "Adverse_event.Subject.Age", "answers": "pediatric"}, {"id": "15941649_2_6949", "context": "The knowledge concerning VGB-associated visual dysfunction in pediatric patients, particularly in those who have been exposed to VGB in utero is limited.", "question": "Subject.Gender in pediatric patients", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15941649_2_6950", "context": "The knowledge concerning VGB-associated visual dysfunction in pediatric patients, particularly in those who have been exposed to VGB in utero is limited.", "question": "Subject.Population in pediatric patients", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "15941649_2_6951", "context": "The knowledge concerning VGB-associated visual dysfunction in pediatric patients, particularly in those who have been exposed to VGB in utero is limited.", "question": "Subject.Race in pediatric patients", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15941649_2_6952", "context": "The knowledge concerning VGB-associated visual dysfunction in pediatric patients, particularly in those who have been exposed to VGB in utero is limited.", "question": "Subject.Disorder in pediatric patients", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15941649_2_6953", "context": "The knowledge concerning VGB-associated visual dysfunction in pediatric patients, particularly in those who have been exposed to VGB in utero is limited.", "question": "Treatment.Drug in VGB", "question_type": "Adverse_event.Treatment.Drug", "answers": "VGB"}, {"id": "15941649_2_6954", "context": "The knowledge concerning VGB-associated visual dysfunction in pediatric patients, particularly in those who have been exposed to VGB in utero is limited.", "question": "Treatment.Dosage in VGB", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15941649_2_6955", "context": "The knowledge concerning VGB-associated visual dysfunction in pediatric patients, particularly in those who have been exposed to VGB in utero is limited.", "question": "Treatment.Freq in VGB", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15941649_2_6956", "context": "The knowledge concerning VGB-associated visual dysfunction in pediatric patients, particularly in those who have been exposed to VGB in utero is limited.", "question": "Treatment.Route in VGB", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15941649_2_6957", "context": "The knowledge concerning VGB-associated visual dysfunction in pediatric patients, particularly in those who have been exposed to VGB in utero is limited.", "question": "Treatment.Time_elapsed in VGB", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15941649_2_6958", "context": "The knowledge concerning VGB-associated visual dysfunction in pediatric patients, particularly in those who have been exposed to VGB in utero is limited.", "question": "Treatment.Duration in VGB", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15941649_2_6959", "context": "The knowledge concerning VGB-associated visual dysfunction in pediatric patients, particularly in those who have been exposed to VGB in utero is limited.", "question": "Treatment.Disorder in VGB", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15941649_2_6960", "context": "The knowledge concerning VGB-associated visual dysfunction in pediatric patients, particularly in those who have been exposed to VGB in utero is limited.", "question": "Combination.Drug in VGB", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "19097599_2_6961", "context": "We herein described an additional patient with BCR-ABL (ela2) positive acute lymphoblastic leukemia who developed tumor lysis syndrome after 10-day treatment with imatinib.", "question": "Subject.Age in patient with BCR-ABL (ela2) positive acute lymphoblastic leukemia", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "19097599_2_6962", "context": "We herein described an additional patient with BCR-ABL (ela2) positive acute lymphoblastic leukemia who developed tumor lysis syndrome after 10-day treatment with imatinib.", "question": "Subject.Gender in patient with BCR-ABL (ela2) positive acute lymphoblastic leukemia", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "19097599_2_6963", "context": "We herein described an additional patient with BCR-ABL (ela2) positive acute lymphoblastic leukemia who developed tumor lysis syndrome after 10-day treatment with imatinib.", "question": "Subject.Population in patient with BCR-ABL (ela2) positive acute lymphoblastic leukemia", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "19097599_2_6964", "context": "We herein described an additional patient with BCR-ABL (ela2) positive acute lymphoblastic leukemia who developed tumor lysis syndrome after 10-day treatment with imatinib.", "question": "Subject.Race in patient with BCR-ABL (ela2) positive acute lymphoblastic leukemia", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "19097599_2_6965", "context": "We herein described an additional patient with BCR-ABL (ela2) positive acute lymphoblastic leukemia who developed tumor lysis syndrome after 10-day treatment with imatinib.", "question": "Subject.Disorder in patient with BCR-ABL (ela2) positive acute lymphoblastic leukemia", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "19097599_2_6966", "context": "We herein described an additional patient with BCR-ABL (ela2) positive acute lymphoblastic leukemia who developed tumor lysis syndrome after 10-day treatment with imatinib.", "question": "Treatment.Drug in 10-day treatment with imatinib", "question_type": "Adverse_event.Treatment.Drug", "answers": "imatinib"}, {"id": "19097599_2_6967", "context": "We herein described an additional patient with BCR-ABL (ela2) positive acute lymphoblastic leukemia who developed tumor lysis syndrome after 10-day treatment with imatinib.", "question": "Treatment.Dosage in 10-day treatment with imatinib", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "19097599_2_6968", "context": "We herein described an additional patient with BCR-ABL (ela2) positive acute lymphoblastic leukemia who developed tumor lysis syndrome after 10-day treatment with imatinib.", "question": "Treatment.Freq in 10-day treatment with imatinib", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "19097599_2_6969", "context": "We herein described an additional patient with BCR-ABL (ela2) positive acute lymphoblastic leukemia who developed tumor lysis syndrome after 10-day treatment with imatinib.", "question": "Treatment.Route in 10-day treatment with imatinib", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "19097599_2_6970", "context": "We herein described an additional patient with BCR-ABL (ela2) positive acute lymphoblastic leukemia who developed tumor lysis syndrome after 10-day treatment with imatinib.", "question": "Treatment.Time_elapsed in 10-day treatment with imatinib", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "10-day"}, {"id": "19097599_2_6971", "context": "We herein described an additional patient with BCR-ABL (ela2) positive acute lymphoblastic leukemia who developed tumor lysis syndrome after 10-day treatment with imatinib.", "question": "Treatment.Duration in 10-day treatment with imatinib", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "19097599_2_6972", "context": "We herein described an additional patient with BCR-ABL (ela2) positive acute lymphoblastic leukemia who developed tumor lysis syndrome after 10-day treatment with imatinib.", "question": "Treatment.Disorder in 10-day treatment with imatinib", "question_type": "Adverse_event.Treatment.Disorder", "answers": "BCR-ABL (ela2) positive acute lymphoblastic leukemia"}, {"id": "19097599_2_6973", "context": "We herein described an additional patient with BCR-ABL (ela2) positive acute lymphoblastic leukemia who developed tumor lysis syndrome after 10-day treatment with imatinib.", "question": "Combination.Drug in 10-day treatment with imatinib", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9792602_2_6974", "context": "Tubulointerstitial nephritis induced by the leukotriene receptor antagonist pranlukast.", "question": "Treatment.Drug in pranlukast", "question_type": "Adverse_event.Treatment.Drug", "answers": "pranlukast"}, {"id": "9792602_2_6975", "context": "Tubulointerstitial nephritis induced by the leukotriene receptor antagonist pranlukast.", "question": "Treatment.Dosage in pranlukast", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9792602_2_6976", "context": "Tubulointerstitial nephritis induced by the leukotriene receptor antagonist pranlukast.", "question": "Treatment.Freq in pranlukast", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9792602_2_6977", "context": "Tubulointerstitial nephritis induced by the leukotriene receptor antagonist pranlukast.", "question": "Treatment.Route in pranlukast", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9792602_2_6978", "context": "Tubulointerstitial nephritis induced by the leukotriene receptor antagonist pranlukast.", "question": "Treatment.Time_elapsed in pranlukast", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9792602_2_6979", "context": "Tubulointerstitial nephritis induced by the leukotriene receptor antagonist pranlukast.", "question": "Treatment.Duration in pranlukast", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9792602_2_6980", "context": "Tubulointerstitial nephritis induced by the leukotriene receptor antagonist pranlukast.", "question": "Treatment.Disorder in pranlukast", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9792602_2_6981", "context": "Tubulointerstitial nephritis induced by the leukotriene receptor antagonist pranlukast.", "question": "Combination.Drug in pranlukast", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "23471710_2_6982", "context": "Two drugs commonly used in triple-drug therapy for treatment of a Helicobacter pylori infection, clarithromycin and omeprazole, have rarely been associated with hypoglycemia when given alone.", "question": "Treatment.Drug in clarithromycin and omeprazole", "question_type": "Adverse_event.Treatment.Drug", "answers": "clarithromycin; omeprazole"}, {"id": "23471710_2_6983", "context": "Two drugs commonly used in triple-drug therapy for treatment of a Helicobacter pylori infection, clarithromycin and omeprazole, have rarely been associated with hypoglycemia when given alone.", "question": "Treatment.Dosage in clarithromycin and omeprazole", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "23471710_2_6984", "context": "Two drugs commonly used in triple-drug therapy for treatment of a Helicobacter pylori infection, clarithromycin and omeprazole, have rarely been associated with hypoglycemia when given alone.", "question": "Treatment.Freq in clarithromycin and omeprazole", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "23471710_2_6985", "context": "Two drugs commonly used in triple-drug therapy for treatment of a Helicobacter pylori infection, clarithromycin and omeprazole, have rarely been associated with hypoglycemia when given alone.", "question": "Treatment.Route in clarithromycin and omeprazole", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "23471710_2_6986", "context": "Two drugs commonly used in triple-drug therapy for treatment of a Helicobacter pylori infection, clarithromycin and omeprazole, have rarely been associated with hypoglycemia when given alone.", "question": "Treatment.Time_elapsed in clarithromycin and omeprazole", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "23471710_2_6987", "context": "Two drugs commonly used in triple-drug therapy for treatment of a Helicobacter pylori infection, clarithromycin and omeprazole, have rarely been associated with hypoglycemia when given alone.", "question": "Treatment.Duration in clarithromycin and omeprazole", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "23471710_2_6988", "context": "Two drugs commonly used in triple-drug therapy for treatment of a Helicobacter pylori infection, clarithromycin and omeprazole, have rarely been associated with hypoglycemia when given alone.", "question": "Treatment.Disorder in clarithromycin and omeprazole", "question_type": "Adverse_event.Treatment.Disorder", "answers": "a Helicobacter pylori infection"}, {"id": "23471710_2_6989", "context": "Two drugs commonly used in triple-drug therapy for treatment of a Helicobacter pylori infection, clarithromycin and omeprazole, have rarely been associated with hypoglycemia when given alone.", "question": "Combination.Drug in clarithromycin and omeprazole", "question_type": "Adverse_event.Combination.Drug", "answers": "clarithromycin; omeprazole"}, {"id": "14660304_4_6990", "context": "We describe the infectious toxicities experienced by the first two patients in our institution treated with dexamethasone (10 mg/m(2)/day for 4 weeks with gradual tapering) during induction according to the dexamethasone arm of BFM 2000 and review the relevant literature that suggests an increased risk of infectious complications with dexamethasone.", "question": "Subject.Age in first two patients in our institution", "question_type": "Adverse_event.Subject.Age", "answers": "two"}, {"id": "14660304_4_6991", "context": "We describe the infectious toxicities experienced by the first two patients in our institution treated with dexamethasone (10 mg/m(2)/day for 4 weeks with gradual tapering) during induction according to the dexamethasone arm of BFM 2000 and review the relevant literature that suggests an increased risk of infectious complications with dexamethasone.", "question": "Subject.Gender in first two patients in our institution", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "14660304_4_6992", "context": "We describe the infectious toxicities experienced by the first two patients in our institution treated with dexamethasone (10 mg/m(2)/day for 4 weeks with gradual tapering) during induction according to the dexamethasone arm of BFM 2000 and review the relevant literature that suggests an increased risk of infectious complications with dexamethasone.", "question": "Subject.Population in first two patients in our institution", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "14660304_4_6993", "context": "We describe the infectious toxicities experienced by the first two patients in our institution treated with dexamethasone (10 mg/m(2)/day for 4 weeks with gradual tapering) during induction according to the dexamethasone arm of BFM 2000 and review the relevant literature that suggests an increased risk of infectious complications with dexamethasone.", "question": "Subject.Race in first two patients in our institution", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "14660304_4_6994", "context": "We describe the infectious toxicities experienced by the first two patients in our institution treated with dexamethasone (10 mg/m(2)/day for 4 weeks with gradual tapering) during induction according to the dexamethasone arm of BFM 2000 and review the relevant literature that suggests an increased risk of infectious complications with dexamethasone.", "question": "Subject.Disorder in first two patients in our institution", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "14660304_4_6995", "context": "We describe the infectious toxicities experienced by the first two patients in our institution treated with dexamethasone (10 mg/m(2)/day for 4 weeks with gradual tapering) during induction according to the dexamethasone arm of BFM 2000 and review the relevant literature that suggests an increased risk of infectious complications with dexamethasone.", "question": "Treatment.Drug in treated with dexamethasone (10 mg/m(2)/day for 4 weeks with gradual tapering) during induction according to the dexamethasone arm of BFM 2000", "question_type": "Adverse_event.Treatment.Drug", "answers": "dexamethasone; dexamethasone"}, {"id": "14660304_4_6996", "context": "We describe the infectious toxicities experienced by the first two patients in our institution treated with dexamethasone (10 mg/m(2)/day for 4 weeks with gradual tapering) during induction according to the dexamethasone arm of BFM 2000 and review the relevant literature that suggests an increased risk of infectious complications with dexamethasone.", "question": "Treatment.Dosage in treated with dexamethasone (10 mg/m(2)/day for 4 weeks with gradual tapering) during induction according to the dexamethasone arm of BFM 2000", "question_type": "Adverse_event.Treatment.Dosage", "answers": "10 mg/m"}, {"id": "14660304_4_6997", "context": "We describe the infectious toxicities experienced by the first two patients in our institution treated with dexamethasone (10 mg/m(2)/day for 4 weeks with gradual tapering) during induction according to the dexamethasone arm of BFM 2000 and review the relevant literature that suggests an increased risk of infectious complications with dexamethasone.", "question": "Treatment.Freq in treated with dexamethasone (10 mg/m(2)/day for 4 weeks with gradual tapering) during induction according to the dexamethasone arm of BFM 2000", "question_type": "Adverse_event.Treatment.Freq", "answers": "day"}, {"id": "14660304_4_6998", "context": "We describe the infectious toxicities experienced by the first two patients in our institution treated with dexamethasone (10 mg/m(2)/day for 4 weeks with gradual tapering) during induction according to the dexamethasone arm of BFM 2000 and review the relevant literature that suggests an increased risk of infectious complications with dexamethasone.", "question": "Treatment.Route in treated with dexamethasone (10 mg/m(2)/day for 4 weeks with gradual tapering) during induction according to the dexamethasone arm of BFM 2000", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "14660304_4_6999", "context": "We describe the infectious toxicities experienced by the first two patients in our institution treated with dexamethasone (10 mg/m(2)/day for 4 weeks with gradual tapering) during induction according to the dexamethasone arm of BFM 2000 and review the relevant literature that suggests an increased risk of infectious complications with dexamethasone.", "question": "Treatment.Time_elapsed in treated with dexamethasone (10 mg/m(2)/day for 4 weeks with gradual tapering) during induction according to the dexamethasone arm of BFM 2000", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "4 weeks"}, {"id": "14660304_4_7000", "context": "We describe the infectious toxicities experienced by the first two patients in our institution treated with dexamethasone (10 mg/m(2)/day for 4 weeks with gradual tapering) during induction according to the dexamethasone arm of BFM 2000 and review the relevant literature that suggests an increased risk of infectious complications with dexamethasone.", "question": "Treatment.Duration in treated with dexamethasone (10 mg/m(2)/day for 4 weeks with gradual tapering) during induction according to the dexamethasone arm of BFM 2000", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "14660304_4_7001", "context": "We describe the infectious toxicities experienced by the first two patients in our institution treated with dexamethasone (10 mg/m(2)/day for 4 weeks with gradual tapering) during induction according to the dexamethasone arm of BFM 2000 and review the relevant literature that suggests an increased risk of infectious complications with dexamethasone.", "question": "Treatment.Disorder in treated with dexamethasone (10 mg/m(2)/day for 4 weeks with gradual tapering) during induction according to the dexamethasone arm of BFM 2000", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "14660304_4_7002", "context": "We describe the infectious toxicities experienced by the first two patients in our institution treated with dexamethasone (10 mg/m(2)/day for 4 weeks with gradual tapering) during induction according to the dexamethasone arm of BFM 2000 and review the relevant literature that suggests an increased risk of infectious complications with dexamethasone.", "question": "Combination.Drug in treated with dexamethasone (10 mg/m(2)/day for 4 weeks with gradual tapering) during induction according to the dexamethasone arm of BFM 2000", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6510223_4_7003", "context": "This case demonstrates that there is no cross reactivity between glyburide and chlorpropamide in producing hemolytic anemia.", "question": "Treatment.Drug in glyburide and chlorpropamide", "question_type": "Adverse_event.Treatment.Drug", "answers": "glyburide; chlorpropamide"}, {"id": "6510223_4_7004", "context": "This case demonstrates that there is no cross reactivity between glyburide and chlorpropamide in producing hemolytic anemia.", "question": "Treatment.Dosage in glyburide and chlorpropamide", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6510223_4_7005", "context": "This case demonstrates that there is no cross reactivity between glyburide and chlorpropamide in producing hemolytic anemia.", "question": "Treatment.Freq in glyburide and chlorpropamide", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6510223_4_7006", "context": "This case demonstrates that there is no cross reactivity between glyburide and chlorpropamide in producing hemolytic anemia.", "question": "Treatment.Route in glyburide and chlorpropamide", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6510223_4_7007", "context": "This case demonstrates that there is no cross reactivity between glyburide and chlorpropamide in producing hemolytic anemia.", "question": "Treatment.Time_elapsed in glyburide and chlorpropamide", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6510223_4_7008", "context": "This case demonstrates that there is no cross reactivity between glyburide and chlorpropamide in producing hemolytic anemia.", "question": "Treatment.Duration in glyburide and chlorpropamide", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6510223_4_7009", "context": "This case demonstrates that there is no cross reactivity between glyburide and chlorpropamide in producing hemolytic anemia.", "question": "Treatment.Disorder in glyburide and chlorpropamide", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6510223_4_7010", "context": "This case demonstrates that there is no cross reactivity between glyburide and chlorpropamide in producing hemolytic anemia.", "question": "Combination.Drug in glyburide and chlorpropamide", "question_type": "Adverse_event.Combination.Drug", "answers": "glyburide; chlorpropamide"}, {"id": "10586009_1_7011", "context": "Codeine intoxication in the neonate.", "question": "Subject.Age in neonate", "question_type": "Adverse_event.Subject.Age", "answers": "neonate"}, {"id": "10586009_1_7012", "context": "Codeine intoxication in the neonate.", "question": "Subject.Gender in neonate", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "10586009_1_7013", "context": "Codeine intoxication in the neonate.", "question": "Subject.Population in neonate", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "10586009_1_7014", "context": "Codeine intoxication in the neonate.", "question": "Subject.Race in neonate", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "10586009_1_7015", "context": "Codeine intoxication in the neonate.", "question": "Subject.Disorder in neonate", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "10586009_1_7016", "context": "Codeine intoxication in the neonate.", "question": "Treatment.Drug in Codeine", "question_type": "Adverse_event.Treatment.Drug", "answers": "Codeine"}, {"id": "10586009_1_7017", "context": "Codeine intoxication in the neonate.", "question": "Treatment.Dosage in Codeine", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10586009_1_7018", "context": "Codeine intoxication in the neonate.", "question": "Treatment.Freq in Codeine", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10586009_1_7019", "context": "Codeine intoxication in the neonate.", "question": "Treatment.Route in Codeine", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10586009_1_7020", "context": "Codeine intoxication in the neonate.", "question": "Treatment.Time_elapsed in Codeine", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10586009_1_7021", "context": "Codeine intoxication in the neonate.", "question": "Treatment.Duration in Codeine", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10586009_1_7022", "context": "Codeine intoxication in the neonate.", "question": "Treatment.Disorder in Codeine", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10586009_1_7023", "context": "Codeine intoxication in the neonate.", "question": "Combination.Drug in Codeine", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9760614_1_7024", "context": "However, 1 eye had vitreous hemorrhage after repeated injections of tPA.", "question": "Treatment.Drug in repeated injections of tPA", "question_type": "Adverse_event.Treatment.Drug", "answers": "tPA"}, {"id": "9760614_1_7025", "context": "However, 1 eye had vitreous hemorrhage after repeated injections of tPA.", "question": "Treatment.Dosage in repeated injections of tPA", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9760614_1_7026", "context": "However, 1 eye had vitreous hemorrhage after repeated injections of tPA.", "question": "Treatment.Freq in repeated injections of tPA", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9760614_1_7027", "context": "However, 1 eye had vitreous hemorrhage after repeated injections of tPA.", "question": "Treatment.Route in repeated injections of tPA", "question_type": "Adverse_event.Treatment.Route", "answers": "injections"}, {"id": "9760614_1_7028", "context": "However, 1 eye had vitreous hemorrhage after repeated injections of tPA.", "question": "Treatment.Time_elapsed in repeated injections of tPA", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9760614_1_7029", "context": "However, 1 eye had vitreous hemorrhage after repeated injections of tPA.", "question": "Treatment.Duration in repeated injections of tPA", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9760614_1_7030", "context": "However, 1 eye had vitreous hemorrhage after repeated injections of tPA.", "question": "Treatment.Disorder in repeated injections of tPA", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9760614_1_7031", "context": "However, 1 eye had vitreous hemorrhage after repeated injections of tPA.", "question": "Combination.Drug in repeated injections of tPA", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "1389744_2_7032", "context": "Dilated cardiomyopathy associated with chronic overuse of an adrenaline inhaler.", "question": "Treatment.Drug in chronic overuse of an adrenaline inhaler", "question_type": "Adverse_event.Treatment.Drug", "answers": "adrenaline"}, {"id": "1389744_2_7033", "context": "Dilated cardiomyopathy associated with chronic overuse of an adrenaline inhaler.", "question": "Treatment.Dosage in chronic overuse of an adrenaline inhaler", "question_type": "Adverse_event.Treatment.Dosage", "answers": "chronic overuse"}, {"id": "1389744_2_7034", "context": "Dilated cardiomyopathy associated with chronic overuse of an adrenaline inhaler.", "question": "Treatment.Freq in chronic overuse of an adrenaline inhaler", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "1389744_2_7035", "context": "Dilated cardiomyopathy associated with chronic overuse of an adrenaline inhaler.", "question": "Treatment.Route in chronic overuse of an adrenaline inhaler", "question_type": "Adverse_event.Treatment.Route", "answers": "inhaler"}, {"id": "1389744_2_7036", "context": "Dilated cardiomyopathy associated with chronic overuse of an adrenaline inhaler.", "question": "Treatment.Time_elapsed in chronic overuse of an adrenaline inhaler", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "1389744_2_7037", "context": "Dilated cardiomyopathy associated with chronic overuse of an adrenaline inhaler.", "question": "Treatment.Duration in chronic overuse of an adrenaline inhaler", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "1389744_2_7038", "context": "Dilated cardiomyopathy associated with chronic overuse of an adrenaline inhaler.", "question": "Treatment.Disorder in chronic overuse of an adrenaline inhaler", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "1389744_2_7039", "context": "Dilated cardiomyopathy associated with chronic overuse of an adrenaline inhaler.", "question": "Combination.Drug in chronic overuse of an adrenaline inhaler", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "14530108_3_7040", "context": "Surgeons and physicians should therefore be aware of the potential for RTA to occur with FK506 after any organ transplantation.", "question": "Treatment.Drug in FK506 after any organ transplantation", "question_type": "Adverse_event.Treatment.Drug", "answers": "FK506"}, {"id": "14530108_3_7041", "context": "Surgeons and physicians should therefore be aware of the potential for RTA to occur with FK506 after any organ transplantation.", "question": "Treatment.Dosage in FK506 after any organ transplantation", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "14530108_3_7042", "context": "Surgeons and physicians should therefore be aware of the potential for RTA to occur with FK506 after any organ transplantation.", "question": "Treatment.Freq in FK506 after any organ transplantation", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "14530108_3_7043", "context": "Surgeons and physicians should therefore be aware of the potential for RTA to occur with FK506 after any organ transplantation.", "question": "Treatment.Route in FK506 after any organ transplantation", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "14530108_3_7044", "context": "Surgeons and physicians should therefore be aware of the potential for RTA to occur with FK506 after any organ transplantation.", "question": "Treatment.Time_elapsed in FK506 after any organ transplantation", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "14530108_3_7045", "context": "Surgeons and physicians should therefore be aware of the potential for RTA to occur with FK506 after any organ transplantation.", "question": "Treatment.Duration in FK506 after any organ transplantation", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "14530108_3_7046", "context": "Surgeons and physicians should therefore be aware of the potential for RTA to occur with FK506 after any organ transplantation.", "question": "Treatment.Disorder in FK506 after any organ transplantation", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "14530108_3_7047", "context": "Surgeons and physicians should therefore be aware of the potential for RTA to occur with FK506 after any organ transplantation.", "question": "Combination.Drug in FK506 after any organ transplantation", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6826112_2_7048", "context": "Thirty patients with hepatic reactions to cyclofenil, a non-steroidal drug with a stimulating effect on ovulation, are reviewed.", "question": "Subject.Age in Thirty patients", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "6826112_2_7049", "context": "Thirty patients with hepatic reactions to cyclofenil, a non-steroidal drug with a stimulating effect on ovulation, are reviewed.", "question": "Subject.Gender in Thirty patients", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "6826112_2_7050", "context": "Thirty patients with hepatic reactions to cyclofenil, a non-steroidal drug with a stimulating effect on ovulation, are reviewed.", "question": "Subject.Population in Thirty patients", "question_type": "Adverse_event.Subject.Population", "answers": "Thirty"}, {"id": "6826112_2_7051", "context": "Thirty patients with hepatic reactions to cyclofenil, a non-steroidal drug with a stimulating effect on ovulation, are reviewed.", "question": "Subject.Race in Thirty patients", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "6826112_2_7052", "context": "Thirty patients with hepatic reactions to cyclofenil, a non-steroidal drug with a stimulating effect on ovulation, are reviewed.", "question": "Subject.Disorder in Thirty patients", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "6826112_2_7053", "context": "Thirty patients with hepatic reactions to cyclofenil, a non-steroidal drug with a stimulating effect on ovulation, are reviewed.", "question": "Treatment.Drug in cyclofenil", "question_type": "Adverse_event.Treatment.Drug", "answers": "cyclofenil"}, {"id": "6826112_2_7054", "context": "Thirty patients with hepatic reactions to cyclofenil, a non-steroidal drug with a stimulating effect on ovulation, are reviewed.", "question": "Treatment.Dosage in cyclofenil", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6826112_2_7055", "context": "Thirty patients with hepatic reactions to cyclofenil, a non-steroidal drug with a stimulating effect on ovulation, are reviewed.", "question": "Treatment.Freq in cyclofenil", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6826112_2_7056", "context": "Thirty patients with hepatic reactions to cyclofenil, a non-steroidal drug with a stimulating effect on ovulation, are reviewed.", "question": "Treatment.Route in cyclofenil", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6826112_2_7057", "context": "Thirty patients with hepatic reactions to cyclofenil, a non-steroidal drug with a stimulating effect on ovulation, are reviewed.", "question": "Treatment.Time_elapsed in cyclofenil", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6826112_2_7058", "context": "Thirty patients with hepatic reactions to cyclofenil, a non-steroidal drug with a stimulating effect on ovulation, are reviewed.", "question": "Treatment.Duration in cyclofenil", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6826112_2_7059", "context": "Thirty patients with hepatic reactions to cyclofenil, a non-steroidal drug with a stimulating effect on ovulation, are reviewed.", "question": "Treatment.Disorder in cyclofenil", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6826112_2_7060", "context": "Thirty patients with hepatic reactions to cyclofenil, a non-steroidal drug with a stimulating effect on ovulation, are reviewed.", "question": "Combination.Drug in cyclofenil", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "19275460_3_7061", "context": "Though serotonin syndrome is most often associated with ingestion of more than one serotonergic drug, many other mechanisms have been associated with serotonergic excess.", "question": "Treatment.Drug in ingestion of more than one serotonergic drug", "question_type": "Adverse_event.Treatment.Drug", "answers": "serotonergic drug"}, {"id": "19275460_3_7062", "context": "Though serotonin syndrome is most often associated with ingestion of more than one serotonergic drug, many other mechanisms have been associated with serotonergic excess.", "question": "Treatment.Dosage in ingestion of more than one serotonergic drug", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "19275460_3_7063", "context": "Though serotonin syndrome is most often associated with ingestion of more than one serotonergic drug, many other mechanisms have been associated with serotonergic excess.", "question": "Treatment.Freq in ingestion of more than one serotonergic drug", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "19275460_3_7064", "context": "Though serotonin syndrome is most often associated with ingestion of more than one serotonergic drug, many other mechanisms have been associated with serotonergic excess.", "question": "Treatment.Route in ingestion of more than one serotonergic drug", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "19275460_3_7065", "context": "Though serotonin syndrome is most often associated with ingestion of more than one serotonergic drug, many other mechanisms have been associated with serotonergic excess.", "question": "Treatment.Time_elapsed in ingestion of more than one serotonergic drug", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19275460_3_7066", "context": "Though serotonin syndrome is most often associated with ingestion of more than one serotonergic drug, many other mechanisms have been associated with serotonergic excess.", "question": "Treatment.Duration in ingestion of more than one serotonergic drug", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "19275460_3_7067", "context": "Though serotonin syndrome is most often associated with ingestion of more than one serotonergic drug, many other mechanisms have been associated with serotonergic excess.", "question": "Treatment.Disorder in ingestion of more than one serotonergic drug", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "19275460_3_7068", "context": "Though serotonin syndrome is most often associated with ingestion of more than one serotonergic drug, many other mechanisms have been associated with serotonergic excess.", "question": "Combination.Drug in ingestion of more than one serotonergic drug", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "2276822_1_7069", "context": "Because of a hypersensitivity reaction, initial therapy with penicillin G and gentamicin was stopped and substituted with cefazolin.", "question": "Treatment.Drug in penicillin G; gentamicin", "question_type": "Adverse_event.Treatment.Drug", "answers": "penicillin G; gentamicin; cefazolin"}, {"id": "2276822_1_7070", "context": "Because of a hypersensitivity reaction, initial therapy with penicillin G and gentamicin was stopped and substituted with cefazolin.", "question": "Treatment.Dosage in penicillin G; gentamicin", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "2276822_1_7071", "context": "Because of a hypersensitivity reaction, initial therapy with penicillin G and gentamicin was stopped and substituted with cefazolin.", "question": "Treatment.Freq in penicillin G; gentamicin", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2276822_1_7072", "context": "Because of a hypersensitivity reaction, initial therapy with penicillin G and gentamicin was stopped and substituted with cefazolin.", "question": "Treatment.Route in penicillin G; gentamicin", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "2276822_1_7073", "context": "Because of a hypersensitivity reaction, initial therapy with penicillin G and gentamicin was stopped and substituted with cefazolin.", "question": "Treatment.Time_elapsed in penicillin G; gentamicin", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2276822_1_7074", "context": "Because of a hypersensitivity reaction, initial therapy with penicillin G and gentamicin was stopped and substituted with cefazolin.", "question": "Treatment.Duration in penicillin G; gentamicin", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2276822_1_7075", "context": "Because of a hypersensitivity reaction, initial therapy with penicillin G and gentamicin was stopped and substituted with cefazolin.", "question": "Treatment.Disorder in penicillin G; gentamicin", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "2276822_1_7076", "context": "Because of a hypersensitivity reaction, initial therapy with penicillin G and gentamicin was stopped and substituted with cefazolin.", "question": "Combination.Drug in penicillin G; gentamicin", "question_type": "Adverse_event.Combination.Drug", "answers": "penicillin G; gentamicin"}, {"id": "15944830_4_7077", "context": "Ophthalmologists should be aware of the ocular side effects of IFN therapy and carefully monitor patients for the possible occurrence of hypoalbuminemia and thrombocytopenia.", "question": "Subject.Age in patients", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "15944830_4_7078", "context": "Ophthalmologists should be aware of the ocular side effects of IFN therapy and carefully monitor patients for the possible occurrence of hypoalbuminemia and thrombocytopenia.", "question": "Subject.Gender in patients", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15944830_4_7079", "context": "Ophthalmologists should be aware of the ocular side effects of IFN therapy and carefully monitor patients for the possible occurrence of hypoalbuminemia and thrombocytopenia.", "question": "Subject.Population in patients", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "15944830_4_7080", "context": "Ophthalmologists should be aware of the ocular side effects of IFN therapy and carefully monitor patients for the possible occurrence of hypoalbuminemia and thrombocytopenia.", "question": "Subject.Race in patients", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15944830_4_7081", "context": "Ophthalmologists should be aware of the ocular side effects of IFN therapy and carefully monitor patients for the possible occurrence of hypoalbuminemia and thrombocytopenia.", "question": "Subject.Disorder in patients", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15944830_4_7082", "context": "Ophthalmologists should be aware of the ocular side effects of IFN therapy and carefully monitor patients for the possible occurrence of hypoalbuminemia and thrombocytopenia.", "question": "Treatment.Drug in IFN", "question_type": "Adverse_event.Treatment.Drug", "answers": "IFN"}, {"id": "15944830_4_7083", "context": "Ophthalmologists should be aware of the ocular side effects of IFN therapy and carefully monitor patients for the possible occurrence of hypoalbuminemia and thrombocytopenia.", "question": "Treatment.Dosage in IFN", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15944830_4_7084", "context": "Ophthalmologists should be aware of the ocular side effects of IFN therapy and carefully monitor patients for the possible occurrence of hypoalbuminemia and thrombocytopenia.", "question": "Treatment.Freq in IFN", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15944830_4_7085", "context": "Ophthalmologists should be aware of the ocular side effects of IFN therapy and carefully monitor patients for the possible occurrence of hypoalbuminemia and thrombocytopenia.", "question": "Treatment.Route in IFN", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15944830_4_7086", "context": "Ophthalmologists should be aware of the ocular side effects of IFN therapy and carefully monitor patients for the possible occurrence of hypoalbuminemia and thrombocytopenia.", "question": "Treatment.Time_elapsed in IFN", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15944830_4_7087", "context": "Ophthalmologists should be aware of the ocular side effects of IFN therapy and carefully monitor patients for the possible occurrence of hypoalbuminemia and thrombocytopenia.", "question": "Treatment.Duration in IFN", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15944830_4_7088", "context": "Ophthalmologists should be aware of the ocular side effects of IFN therapy and carefully monitor patients for the possible occurrence of hypoalbuminemia and thrombocytopenia.", "question": "Treatment.Disorder in IFN", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15944830_4_7089", "context": "Ophthalmologists should be aware of the ocular side effects of IFN therapy and carefully monitor patients for the possible occurrence of hypoalbuminemia and thrombocytopenia.", "question": "Combination.Drug in IFN", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18562412_6_7090", "context": "The third patient had been suffering from serious akathisia while on risperidone, and was cured after switching to olanzapine, but thereafter the patient suffered from RLS at nighttime.", "question": "Subject.Age in The third patient", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "18562412_6_7091", "context": "The third patient had been suffering from serious akathisia while on risperidone, and was cured after switching to olanzapine, but thereafter the patient suffered from RLS at nighttime.", "question": "Subject.Gender in The third patient", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "18562412_6_7092", "context": "The third patient had been suffering from serious akathisia while on risperidone, and was cured after switching to olanzapine, but thereafter the patient suffered from RLS at nighttime.", "question": "Subject.Population in The third patient", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "18562412_6_7093", "context": "The third patient had been suffering from serious akathisia while on risperidone, and was cured after switching to olanzapine, but thereafter the patient suffered from RLS at nighttime.", "question": "Subject.Race in The third patient", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "18562412_6_7094", "context": "The third patient had been suffering from serious akathisia while on risperidone, and was cured after switching to olanzapine, but thereafter the patient suffered from RLS at nighttime.", "question": "Subject.Disorder in The third patient", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "18562412_6_7095", "context": "The third patient had been suffering from serious akathisia while on risperidone, and was cured after switching to olanzapine, but thereafter the patient suffered from RLS at nighttime.", "question": "Treatment.Drug in risperidone", "question_type": "Adverse_event.Treatment.Drug", "answers": "risperidone"}, {"id": "18562412_6_7096", "context": "The third patient had been suffering from serious akathisia while on risperidone, and was cured after switching to olanzapine, but thereafter the patient suffered from RLS at nighttime.", "question": "Treatment.Dosage in risperidone", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18562412_6_7097", "context": "The third patient had been suffering from serious akathisia while on risperidone, and was cured after switching to olanzapine, but thereafter the patient suffered from RLS at nighttime.", "question": "Treatment.Freq in risperidone", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18562412_6_7098", "context": "The third patient had been suffering from serious akathisia while on risperidone, and was cured after switching to olanzapine, but thereafter the patient suffered from RLS at nighttime.", "question": "Treatment.Route in risperidone", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18562412_6_7099", "context": "The third patient had been suffering from serious akathisia while on risperidone, and was cured after switching to olanzapine, but thereafter the patient suffered from RLS at nighttime.", "question": "Treatment.Time_elapsed in risperidone", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18562412_6_7100", "context": "The third patient had been suffering from serious akathisia while on risperidone, and was cured after switching to olanzapine, but thereafter the patient suffered from RLS at nighttime.", "question": "Treatment.Duration in risperidone", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18562412_6_7101", "context": "The third patient had been suffering from serious akathisia while on risperidone, and was cured after switching to olanzapine, but thereafter the patient suffered from RLS at nighttime.", "question": "Treatment.Disorder in risperidone", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18562412_6_7102", "context": "The third patient had been suffering from serious akathisia while on risperidone, and was cured after switching to olanzapine, but thereafter the patient suffered from RLS at nighttime.", "question": "Combination.Drug in risperidone", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18562412_6_7103", "context": "The third patient had been suffering from serious akathisia while on risperidone, and was cured after switching to olanzapine, but thereafter the patient suffered from RLS at nighttime.", "question": "Subject.Age in The third patient", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "18562412_6_7104", "context": "The third patient had been suffering from serious akathisia while on risperidone, and was cured after switching to olanzapine, but thereafter the patient suffered from RLS at nighttime.", "question": "Subject.Gender in The third patient", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "18562412_6_7105", "context": "The third patient had been suffering from serious akathisia while on risperidone, and was cured after switching to olanzapine, but thereafter the patient suffered from RLS at nighttime.", "question": "Subject.Population in The third patient", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "18562412_6_7106", "context": "The third patient had been suffering from serious akathisia while on risperidone, and was cured after switching to olanzapine, but thereafter the patient suffered from RLS at nighttime.", "question": "Subject.Race in The third patient", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "18562412_6_7107", "context": "The third patient had been suffering from serious akathisia while on risperidone, and was cured after switching to olanzapine, but thereafter the patient suffered from RLS at nighttime.", "question": "Subject.Disorder in The third patient", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "18562412_6_7108", "context": "The third patient had been suffering from serious akathisia while on risperidone, and was cured after switching to olanzapine, but thereafter the patient suffered from RLS at nighttime.", "question": "Treatment.Drug in switching to olanzapine", "question_type": "Adverse_event.Treatment.Drug", "answers": "olanzapine"}, {"id": "18562412_6_7109", "context": "The third patient had been suffering from serious akathisia while on risperidone, and was cured after switching to olanzapine, but thereafter the patient suffered from RLS at nighttime.", "question": "Treatment.Dosage in switching to olanzapine", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18562412_6_7110", "context": "The third patient had been suffering from serious akathisia while on risperidone, and was cured after switching to olanzapine, but thereafter the patient suffered from RLS at nighttime.", "question": "Treatment.Freq in switching to olanzapine", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18562412_6_7111", "context": "The third patient had been suffering from serious akathisia while on risperidone, and was cured after switching to olanzapine, but thereafter the patient suffered from RLS at nighttime.", "question": "Treatment.Route in switching to olanzapine", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18562412_6_7112", "context": "The third patient had been suffering from serious akathisia while on risperidone, and was cured after switching to olanzapine, but thereafter the patient suffered from RLS at nighttime.", "question": "Treatment.Time_elapsed in switching to olanzapine", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18562412_6_7113", "context": "The third patient had been suffering from serious akathisia while on risperidone, and was cured after switching to olanzapine, but thereafter the patient suffered from RLS at nighttime.", "question": "Treatment.Duration in switching to olanzapine", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18562412_6_7114", "context": "The third patient had been suffering from serious akathisia while on risperidone, and was cured after switching to olanzapine, but thereafter the patient suffered from RLS at nighttime.", "question": "Treatment.Disorder in switching to olanzapine", "question_type": "Adverse_event.Treatment.Disorder", "answers": "akathisia"}, {"id": "18562412_6_7115", "context": "The third patient had been suffering from serious akathisia while on risperidone, and was cured after switching to olanzapine, but thereafter the patient suffered from RLS at nighttime.", "question": "Combination.Drug in switching to olanzapine", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6510223_1_7116", "context": "Chlorpropamide-induced hemolytic anemia.", "question": "Treatment.Drug in Chlorpropamide", "question_type": "Adverse_event.Treatment.Drug", "answers": "Chlorpropamide"}, {"id": "6510223_1_7117", "context": "Chlorpropamide-induced hemolytic anemia.", "question": "Treatment.Dosage in Chlorpropamide", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6510223_1_7118", "context": "Chlorpropamide-induced hemolytic anemia.", "question": "Treatment.Freq in Chlorpropamide", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6510223_1_7119", "context": "Chlorpropamide-induced hemolytic anemia.", "question": "Treatment.Route in Chlorpropamide", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6510223_1_7120", "context": "Chlorpropamide-induced hemolytic anemia.", "question": "Treatment.Time_elapsed in Chlorpropamide", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6510223_1_7121", "context": "Chlorpropamide-induced hemolytic anemia.", "question": "Treatment.Duration in Chlorpropamide", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6510223_1_7122", "context": "Chlorpropamide-induced hemolytic anemia.", "question": "Treatment.Disorder in Chlorpropamide", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6510223_1_7123", "context": "Chlorpropamide-induced hemolytic anemia.", "question": "Combination.Drug in Chlorpropamide", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16099004_3_7124", "context": "We report recrudescence of imported Plasmodium falciparum malaria following quinine treatment in the context of concurrent phenytoin use.", "question": "Treatment.Drug in quinine treatment in the context of concurrent phenytoin use", "question_type": "Adverse_event.Treatment.Drug", "answers": "quinine; phenytoin"}, {"id": "16099004_3_7125", "context": "We report recrudescence of imported Plasmodium falciparum malaria following quinine treatment in the context of concurrent phenytoin use.", "question": "Treatment.Dosage in quinine treatment in the context of concurrent phenytoin use", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16099004_3_7126", "context": "We report recrudescence of imported Plasmodium falciparum malaria following quinine treatment in the context of concurrent phenytoin use.", "question": "Treatment.Freq in quinine treatment in the context of concurrent phenytoin use", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16099004_3_7127", "context": "We report recrudescence of imported Plasmodium falciparum malaria following quinine treatment in the context of concurrent phenytoin use.", "question": "Treatment.Route in quinine treatment in the context of concurrent phenytoin use", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16099004_3_7128", "context": "We report recrudescence of imported Plasmodium falciparum malaria following quinine treatment in the context of concurrent phenytoin use.", "question": "Treatment.Time_elapsed in quinine treatment in the context of concurrent phenytoin use", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16099004_3_7129", "context": "We report recrudescence of imported Plasmodium falciparum malaria following quinine treatment in the context of concurrent phenytoin use.", "question": "Treatment.Duration in quinine treatment in the context of concurrent phenytoin use", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16099004_3_7130", "context": "We report recrudescence of imported Plasmodium falciparum malaria following quinine treatment in the context of concurrent phenytoin use.", "question": "Treatment.Disorder in quinine treatment in the context of concurrent phenytoin use", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16099004_3_7131", "context": "We report recrudescence of imported Plasmodium falciparum malaria following quinine treatment in the context of concurrent phenytoin use.", "question": "Combination.Drug in quinine treatment in the context of concurrent phenytoin use", "question_type": "Adverse_event.Combination.Drug", "answers": "phenytoin; quinine"}, {"id": "15719254_2_7132", "context": "It is likely that RA contributed to the deterioration in renal function in these patients.", "question": "Treatment.Drug in RA", "question_type": "Adverse_event.Treatment.Drug", "answers": "RA"}, {"id": "15719254_2_7133", "context": "It is likely that RA contributed to the deterioration in renal function in these patients.", "question": "Treatment.Dosage in RA", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15719254_2_7134", "context": "It is likely that RA contributed to the deterioration in renal function in these patients.", "question": "Treatment.Freq in RA", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15719254_2_7135", "context": "It is likely that RA contributed to the deterioration in renal function in these patients.", "question": "Treatment.Route in RA", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15719254_2_7136", "context": "It is likely that RA contributed to the deterioration in renal function in these patients.", "question": "Treatment.Time_elapsed in RA", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15719254_2_7137", "context": "It is likely that RA contributed to the deterioration in renal function in these patients.", "question": "Treatment.Duration in RA", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15719254_2_7138", "context": "It is likely that RA contributed to the deterioration in renal function in these patients.", "question": "Treatment.Disorder in RA", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15719254_2_7139", "context": "It is likely that RA contributed to the deterioration in renal function in these patients.", "question": "Combination.Drug in RA", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6303138_1_7140", "context": "Marked sinus tachycardia resulting from the synergistic effects of marijuana and nortriptyline.", "question": "Treatment.Drug in marijuana and nortriptyline", "question_type": "Adverse_event.Treatment.Drug", "answers": "marijuana; nortriptyline"}, {"id": "6303138_1_7141", "context": "Marked sinus tachycardia resulting from the synergistic effects of marijuana and nortriptyline.", "question": "Treatment.Dosage in marijuana and nortriptyline", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6303138_1_7142", "context": "Marked sinus tachycardia resulting from the synergistic effects of marijuana and nortriptyline.", "question": "Treatment.Freq in marijuana and nortriptyline", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6303138_1_7143", "context": "Marked sinus tachycardia resulting from the synergistic effects of marijuana and nortriptyline.", "question": "Treatment.Route in marijuana and nortriptyline", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6303138_1_7144", "context": "Marked sinus tachycardia resulting from the synergistic effects of marijuana and nortriptyline.", "question": "Treatment.Time_elapsed in marijuana and nortriptyline", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6303138_1_7145", "context": "Marked sinus tachycardia resulting from the synergistic effects of marijuana and nortriptyline.", "question": "Treatment.Duration in marijuana and nortriptyline", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6303138_1_7146", "context": "Marked sinus tachycardia resulting from the synergistic effects of marijuana and nortriptyline.", "question": "Treatment.Disorder in marijuana and nortriptyline", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6303138_1_7147", "context": "Marked sinus tachycardia resulting from the synergistic effects of marijuana and nortriptyline.", "question": "Combination.Drug in marijuana and nortriptyline", "question_type": "Adverse_event.Combination.Drug", "answers": "marijuana; nortriptyline"}, {"id": "17373180_1_7148", "context": "Infliximab and its serious adverse effects are discussed, and other cases of osteomyelitis with infliximab use are also reviewed.", "question": "Treatment.Drug in infliximab", "question_type": "Adverse_event.Treatment.Drug", "answers": "infliximab; Infliximab"}, {"id": "17373180_1_7149", "context": "Infliximab and its serious adverse effects are discussed, and other cases of osteomyelitis with infliximab use are also reviewed.", "question": "Treatment.Dosage in infliximab", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17373180_1_7150", "context": "Infliximab and its serious adverse effects are discussed, and other cases of osteomyelitis with infliximab use are also reviewed.", "question": "Treatment.Freq in infliximab", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17373180_1_7151", "context": "Infliximab and its serious adverse effects are discussed, and other cases of osteomyelitis with infliximab use are also reviewed.", "question": "Treatment.Route in infliximab", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17373180_1_7152", "context": "Infliximab and its serious adverse effects are discussed, and other cases of osteomyelitis with infliximab use are also reviewed.", "question": "Treatment.Time_elapsed in infliximab", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17373180_1_7153", "context": "Infliximab and its serious adverse effects are discussed, and other cases of osteomyelitis with infliximab use are also reviewed.", "question": "Treatment.Duration in infliximab", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17373180_1_7154", "context": "Infliximab and its serious adverse effects are discussed, and other cases of osteomyelitis with infliximab use are also reviewed.", "question": "Treatment.Disorder in infliximab", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17373180_1_7155", "context": "Infliximab and its serious adverse effects are discussed, and other cases of osteomyelitis with infliximab use are also reviewed.", "question": "Combination.Drug in infliximab", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "14723711_1_7156", "context": "A new type of minocycline-induced cutaneous hyperpigmentation.", "question": "Treatment.Drug in minocycline", "question_type": "Adverse_event.Treatment.Drug", "answers": "minocycline"}, {"id": "14723711_1_7157", "context": "A new type of minocycline-induced cutaneous hyperpigmentation.", "question": "Treatment.Dosage in minocycline", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "14723711_1_7158", "context": "A new type of minocycline-induced cutaneous hyperpigmentation.", "question": "Treatment.Freq in minocycline", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "14723711_1_7159", "context": "A new type of minocycline-induced cutaneous hyperpigmentation.", "question": "Treatment.Route in minocycline", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "14723711_1_7160", "context": "A new type of minocycline-induced cutaneous hyperpigmentation.", "question": "Treatment.Time_elapsed in minocycline", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "14723711_1_7161", "context": "A new type of minocycline-induced cutaneous hyperpigmentation.", "question": "Treatment.Duration in minocycline", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "14723711_1_7162", "context": "A new type of minocycline-induced cutaneous hyperpigmentation.", "question": "Treatment.Disorder in minocycline", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "14723711_1_7163", "context": "A new type of minocycline-induced cutaneous hyperpigmentation.", "question": "Combination.Drug in minocycline", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9491301_3_7164", "context": "Stroke is an infrequent but recognized complication of heroin addiction.", "question": "Treatment.Drug in heroin addiction", "question_type": "Adverse_event.Treatment.Drug", "answers": "heroin"}, {"id": "9491301_3_7165", "context": "Stroke is an infrequent but recognized complication of heroin addiction.", "question": "Treatment.Dosage in heroin addiction", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9491301_3_7166", "context": "Stroke is an infrequent but recognized complication of heroin addiction.", "question": "Treatment.Freq in heroin addiction", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9491301_3_7167", "context": "Stroke is an infrequent but recognized complication of heroin addiction.", "question": "Treatment.Route in heroin addiction", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9491301_3_7168", "context": "Stroke is an infrequent but recognized complication of heroin addiction.", "question": "Treatment.Time_elapsed in heroin addiction", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9491301_3_7169", "context": "Stroke is an infrequent but recognized complication of heroin addiction.", "question": "Treatment.Duration in heroin addiction", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9491301_3_7170", "context": "Stroke is an infrequent but recognized complication of heroin addiction.", "question": "Treatment.Disorder in heroin addiction", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9491301_3_7171", "context": "Stroke is an infrequent but recognized complication of heroin addiction.", "question": "Combination.Drug in heroin addiction", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "2461837_1_7172", "context": "Although this type of hyperpigmentation has been previously seen in patients with cancer who are receiving bleomycin, this is, to our knowledge, the first reported case of bleomycin-induced hyperpigmentation in an AIDS patient and should be added to the growing list of cutaneous eruptions seen in these patients.", "question": "Subject.Age in an AIDS patient", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "2461837_1_7173", "context": "Although this type of hyperpigmentation has been previously seen in patients with cancer who are receiving bleomycin, this is, to our knowledge, the first reported case of bleomycin-induced hyperpigmentation in an AIDS patient and should be added to the growing list of cutaneous eruptions seen in these patients.", "question": "Subject.Gender in an AIDS patient", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "2461837_1_7174", "context": "Although this type of hyperpigmentation has been previously seen in patients with cancer who are receiving bleomycin, this is, to our knowledge, the first reported case of bleomycin-induced hyperpigmentation in an AIDS patient and should be added to the growing list of cutaneous eruptions seen in these patients.", "question": "Subject.Population in an AIDS patient", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "2461837_1_7175", "context": "Although this type of hyperpigmentation has been previously seen in patients with cancer who are receiving bleomycin, this is, to our knowledge, the first reported case of bleomycin-induced hyperpigmentation in an AIDS patient and should be added to the growing list of cutaneous eruptions seen in these patients.", "question": "Subject.Race in an AIDS patient", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "2461837_1_7176", "context": "Although this type of hyperpigmentation has been previously seen in patients with cancer who are receiving bleomycin, this is, to our knowledge, the first reported case of bleomycin-induced hyperpigmentation in an AIDS patient and should be added to the growing list of cutaneous eruptions seen in these patients.", "question": "Subject.Disorder in an AIDS patient", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "2461837_1_7177", "context": "Although this type of hyperpigmentation has been previously seen in patients with cancer who are receiving bleomycin, this is, to our knowledge, the first reported case of bleomycin-induced hyperpigmentation in an AIDS patient and should be added to the growing list of cutaneous eruptions seen in these patients.", "question": "Treatment.Drug in bleomycin", "question_type": "Adverse_event.Treatment.Drug", "answers": "bleomycin"}, {"id": "2461837_1_7178", "context": "Although this type of hyperpigmentation has been previously seen in patients with cancer who are receiving bleomycin, this is, to our knowledge, the first reported case of bleomycin-induced hyperpigmentation in an AIDS patient and should be added to the growing list of cutaneous eruptions seen in these patients.", "question": "Treatment.Dosage in bleomycin", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "2461837_1_7179", "context": "Although this type of hyperpigmentation has been previously seen in patients with cancer who are receiving bleomycin, this is, to our knowledge, the first reported case of bleomycin-induced hyperpigmentation in an AIDS patient and should be added to the growing list of cutaneous eruptions seen in these patients.", "question": "Treatment.Freq in bleomycin", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2461837_1_7180", "context": "Although this type of hyperpigmentation has been previously seen in patients with cancer who are receiving bleomycin, this is, to our knowledge, the first reported case of bleomycin-induced hyperpigmentation in an AIDS patient and should be added to the growing list of cutaneous eruptions seen in these patients.", "question": "Treatment.Route in bleomycin", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "2461837_1_7181", "context": "Although this type of hyperpigmentation has been previously seen in patients with cancer who are receiving bleomycin, this is, to our knowledge, the first reported case of bleomycin-induced hyperpigmentation in an AIDS patient and should be added to the growing list of cutaneous eruptions seen in these patients.", "question": "Treatment.Time_elapsed in bleomycin", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2461837_1_7182", "context": "Although this type of hyperpigmentation has been previously seen in patients with cancer who are receiving bleomycin, this is, to our knowledge, the first reported case of bleomycin-induced hyperpigmentation in an AIDS patient and should be added to the growing list of cutaneous eruptions seen in these patients.", "question": "Treatment.Duration in bleomycin", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2461837_1_7183", "context": "Although this type of hyperpigmentation has been previously seen in patients with cancer who are receiving bleomycin, this is, to our knowledge, the first reported case of bleomycin-induced hyperpigmentation in an AIDS patient and should be added to the growing list of cutaneous eruptions seen in these patients.", "question": "Treatment.Disorder in bleomycin", "question_type": "Adverse_event.Treatment.Disorder", "answers": "AIDS"}, {"id": "2461837_1_7184", "context": "Although this type of hyperpigmentation has been previously seen in patients with cancer who are receiving bleomycin, this is, to our knowledge, the first reported case of bleomycin-induced hyperpigmentation in an AIDS patient and should be added to the growing list of cutaneous eruptions seen in these patients.", "question": "Combination.Drug in bleomycin", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6625005_1_7185", "context": "Case report of withdrawal dyskinesia associated with amoxapine.", "question": "Subject.Age in Case", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "6625005_1_7186", "context": "Case report of withdrawal dyskinesia associated with amoxapine.", "question": "Subject.Gender in Case", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "6625005_1_7187", "context": "Case report of withdrawal dyskinesia associated with amoxapine.", "question": "Subject.Population in Case", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "6625005_1_7188", "context": "Case report of withdrawal dyskinesia associated with amoxapine.", "question": "Subject.Race in Case", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "6625005_1_7189", "context": "Case report of withdrawal dyskinesia associated with amoxapine.", "question": "Subject.Disorder in Case", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "6625005_1_7190", "context": "Case report of withdrawal dyskinesia associated with amoxapine.", "question": "Treatment.Drug in amoxapine", "question_type": "Adverse_event.Treatment.Drug", "answers": "amoxapine"}, {"id": "6625005_1_7191", "context": "Case report of withdrawal dyskinesia associated with amoxapine.", "question": "Treatment.Dosage in amoxapine", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6625005_1_7192", "context": "Case report of withdrawal dyskinesia associated with amoxapine.", "question": "Treatment.Freq in amoxapine", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6625005_1_7193", "context": "Case report of withdrawal dyskinesia associated with amoxapine.", "question": "Treatment.Route in amoxapine", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6625005_1_7194", "context": "Case report of withdrawal dyskinesia associated with amoxapine.", "question": "Treatment.Time_elapsed in amoxapine", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6625005_1_7195", "context": "Case report of withdrawal dyskinesia associated with amoxapine.", "question": "Treatment.Duration in amoxapine", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6625005_1_7196", "context": "Case report of withdrawal dyskinesia associated with amoxapine.", "question": "Treatment.Disorder in amoxapine", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6625005_1_7197", "context": "Case report of withdrawal dyskinesia associated with amoxapine.", "question": "Combination.Drug in amoxapine", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "21350204_2_7198", "context": "Concern exists that preadmission warfarin use may be associated with an increased risk of intracerebral hemorrhage in patients with ischemic stroke receiving intravenous tissue plasminogen activator, even in those with an international normalized ratio <1.7.", "question": "Subject.Age in patients with ischemic stroke", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "21350204_2_7199", "context": "Concern exists that preadmission warfarin use may be associated with an increased risk of intracerebral hemorrhage in patients with ischemic stroke receiving intravenous tissue plasminogen activator, even in those with an international normalized ratio <1.7.", "question": "Subject.Gender in patients with ischemic stroke", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "21350204_2_7200", "context": "Concern exists that preadmission warfarin use may be associated with an increased risk of intracerebral hemorrhage in patients with ischemic stroke receiving intravenous tissue plasminogen activator, even in those with an international normalized ratio <1.7.", "question": "Subject.Population in patients with ischemic stroke", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "21350204_2_7201", "context": "Concern exists that preadmission warfarin use may be associated with an increased risk of intracerebral hemorrhage in patients with ischemic stroke receiving intravenous tissue plasminogen activator, even in those with an international normalized ratio <1.7.", "question": "Subject.Race in patients with ischemic stroke", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "21350204_2_7202", "context": "Concern exists that preadmission warfarin use may be associated with an increased risk of intracerebral hemorrhage in patients with ischemic stroke receiving intravenous tissue plasminogen activator, even in those with an international normalized ratio <1.7.", "question": "Subject.Disorder in patients with ischemic stroke", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "21350204_2_7203", "context": "Concern exists that preadmission warfarin use may be associated with an increased risk of intracerebral hemorrhage in patients with ischemic stroke receiving intravenous tissue plasminogen activator, even in those with an international normalized ratio <1.7.", "question": "Treatment.Drug in receiving intravenous tissue plasminogen activator; preadmission warfarin", "question_type": "Adverse_event.Treatment.Drug", "answers": "warfarin; ntravenous tissue plasminogen activator"}, {"id": "21350204_2_7204", "context": "Concern exists that preadmission warfarin use may be associated with an increased risk of intracerebral hemorrhage in patients with ischemic stroke receiving intravenous tissue plasminogen activator, even in those with an international normalized ratio <1.7.", "question": "Treatment.Dosage in receiving intravenous tissue plasminogen activator; preadmission warfarin", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "21350204_2_7205", "context": "Concern exists that preadmission warfarin use may be associated with an increased risk of intracerebral hemorrhage in patients with ischemic stroke receiving intravenous tissue plasminogen activator, even in those with an international normalized ratio <1.7.", "question": "Treatment.Freq in receiving intravenous tissue plasminogen activator; preadmission warfarin", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "21350204_2_7206", "context": "Concern exists that preadmission warfarin use may be associated with an increased risk of intracerebral hemorrhage in patients with ischemic stroke receiving intravenous tissue plasminogen activator, even in those with an international normalized ratio <1.7.", "question": "Treatment.Route in receiving intravenous tissue plasminogen activator; preadmission warfarin", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "21350204_2_7207", "context": "Concern exists that preadmission warfarin use may be associated with an increased risk of intracerebral hemorrhage in patients with ischemic stroke receiving intravenous tissue plasminogen activator, even in those with an international normalized ratio <1.7.", "question": "Treatment.Time_elapsed in receiving intravenous tissue plasminogen activator; preadmission warfarin", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "21350204_2_7208", "context": "Concern exists that preadmission warfarin use may be associated with an increased risk of intracerebral hemorrhage in patients with ischemic stroke receiving intravenous tissue plasminogen activator, even in those with an international normalized ratio <1.7.", "question": "Treatment.Duration in receiving intravenous tissue plasminogen activator; preadmission warfarin", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "21350204_2_7209", "context": "Concern exists that preadmission warfarin use may be associated with an increased risk of intracerebral hemorrhage in patients with ischemic stroke receiving intravenous tissue plasminogen activator, even in those with an international normalized ratio <1.7.", "question": "Treatment.Disorder in receiving intravenous tissue plasminogen activator; preadmission warfarin", "question_type": "Adverse_event.Treatment.Disorder", "answers": "ischemic stroke"}, {"id": "21350204_2_7210", "context": "Concern exists that preadmission warfarin use may be associated with an increased risk of intracerebral hemorrhage in patients with ischemic stroke receiving intravenous tissue plasminogen activator, even in those with an international normalized ratio <1.7.", "question": "Combination.Drug in receiving intravenous tissue plasminogen activator; preadmission warfarin", "question_type": "Adverse_event.Combination.Drug", "answers": "warfarin; ntravenous tissue plasminogen activator"}, {"id": "7035691_1_7211", "context": "Transient anuria following administration of angiotensin I-converting enzyme inhibitor (SQ 14225) in a patient with renal artery stenosis of the solitary kidney successfully treated with renal autotransplantation.", "question": "Subject.Age in a patient with renal artery stenosis of the solitary kidney", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "7035691_1_7212", "context": "Transient anuria following administration of angiotensin I-converting enzyme inhibitor (SQ 14225) in a patient with renal artery stenosis of the solitary kidney successfully treated with renal autotransplantation.", "question": "Subject.Gender in a patient with renal artery stenosis of the solitary kidney", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "7035691_1_7213", "context": "Transient anuria following administration of angiotensin I-converting enzyme inhibitor (SQ 14225) in a patient with renal artery stenosis of the solitary kidney successfully treated with renal autotransplantation.", "question": "Subject.Population in a patient with renal artery stenosis of the solitary kidney", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "7035691_1_7214", "context": "Transient anuria following administration of angiotensin I-converting enzyme inhibitor (SQ 14225) in a patient with renal artery stenosis of the solitary kidney successfully treated with renal autotransplantation.", "question": "Subject.Race in a patient with renal artery stenosis of the solitary kidney", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "7035691_1_7215", "context": "Transient anuria following administration of angiotensin I-converting enzyme inhibitor (SQ 14225) in a patient with renal artery stenosis of the solitary kidney successfully treated with renal autotransplantation.", "question": "Subject.Disorder in a patient with renal artery stenosis of the solitary kidney", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "7035691_1_7216", "context": "Transient anuria following administration of angiotensin I-converting enzyme inhibitor (SQ 14225) in a patient with renal artery stenosis of the solitary kidney successfully treated with renal autotransplantation.", "question": "Treatment.Drug in angiotensin I-converting enzyme inhibitor (SQ 14225)", "question_type": "Adverse_event.Treatment.Drug", "answers": "angiotensin I-converting enzyme inhibitor"}, {"id": "7035691_1_7217", "context": "Transient anuria following administration of angiotensin I-converting enzyme inhibitor (SQ 14225) in a patient with renal artery stenosis of the solitary kidney successfully treated with renal autotransplantation.", "question": "Treatment.Dosage in angiotensin I-converting enzyme inhibitor (SQ 14225)", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7035691_1_7218", "context": "Transient anuria following administration of angiotensin I-converting enzyme inhibitor (SQ 14225) in a patient with renal artery stenosis of the solitary kidney successfully treated with renal autotransplantation.", "question": "Treatment.Freq in angiotensin I-converting enzyme inhibitor (SQ 14225)", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7035691_1_7219", "context": "Transient anuria following administration of angiotensin I-converting enzyme inhibitor (SQ 14225) in a patient with renal artery stenosis of the solitary kidney successfully treated with renal autotransplantation.", "question": "Treatment.Route in angiotensin I-converting enzyme inhibitor (SQ 14225)", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7035691_1_7220", "context": "Transient anuria following administration of angiotensin I-converting enzyme inhibitor (SQ 14225) in a patient with renal artery stenosis of the solitary kidney successfully treated with renal autotransplantation.", "question": "Treatment.Time_elapsed in angiotensin I-converting enzyme inhibitor (SQ 14225)", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7035691_1_7221", "context": "Transient anuria following administration of angiotensin I-converting enzyme inhibitor (SQ 14225) in a patient with renal artery stenosis of the solitary kidney successfully treated with renal autotransplantation.", "question": "Treatment.Duration in angiotensin I-converting enzyme inhibitor (SQ 14225)", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7035691_1_7222", "context": "Transient anuria following administration of angiotensin I-converting enzyme inhibitor (SQ 14225) in a patient with renal artery stenosis of the solitary kidney successfully treated with renal autotransplantation.", "question": "Treatment.Disorder in angiotensin I-converting enzyme inhibitor (SQ 14225)", "question_type": "Adverse_event.Treatment.Disorder", "answers": "renal artery stenosis of the solitary kidney"}, {"id": "7035691_1_7223", "context": "Transient anuria following administration of angiotensin I-converting enzyme inhibitor (SQ 14225) in a patient with renal artery stenosis of the solitary kidney successfully treated with renal autotransplantation.", "question": "Combination.Drug in angiotensin I-converting enzyme inhibitor (SQ 14225)", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7035691_1_7224", "context": "Transient anuria following administration of angiotensin I-converting enzyme inhibitor (SQ 14225) in a patient with renal artery stenosis of the solitary kidney successfully treated with renal autotransplantation.", "question": "Subject.Age in a patient with renal artery stenosis of the solitary kidney", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "7035691_1_7225", "context": "Transient anuria following administration of angiotensin I-converting enzyme inhibitor (SQ 14225) in a patient with renal artery stenosis of the solitary kidney successfully treated with renal autotransplantation.", "question": "Subject.Gender in a patient with renal artery stenosis of the solitary kidney", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "7035691_1_7226", "context": "Transient anuria following administration of angiotensin I-converting enzyme inhibitor (SQ 14225) in a patient with renal artery stenosis of the solitary kidney successfully treated with renal autotransplantation.", "question": "Subject.Population in a patient with renal artery stenosis of the solitary kidney", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "7035691_1_7227", "context": "Transient anuria following administration of angiotensin I-converting enzyme inhibitor (SQ 14225) in a patient with renal artery stenosis of the solitary kidney successfully treated with renal autotransplantation.", "question": "Subject.Race in a patient with renal artery stenosis of the solitary kidney", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "7035691_1_7228", "context": "Transient anuria following administration of angiotensin I-converting enzyme inhibitor (SQ 14225) in a patient with renal artery stenosis of the solitary kidney successfully treated with renal autotransplantation.", "question": "Subject.Disorder in a patient with renal artery stenosis of the solitary kidney", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "7035691_1_7229", "context": "Transient anuria following administration of angiotensin I-converting enzyme inhibitor (SQ 14225) in a patient with renal artery stenosis of the solitary kidney successfully treated with renal autotransplantation.", "question": "Treatment.Drug in renal autotransplantation", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "7035691_1_7230", "context": "Transient anuria following administration of angiotensin I-converting enzyme inhibitor (SQ 14225) in a patient with renal artery stenosis of the solitary kidney successfully treated with renal autotransplantation.", "question": "Treatment.Dosage in renal autotransplantation", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "7035691_1_7231", "context": "Transient anuria following administration of angiotensin I-converting enzyme inhibitor (SQ 14225) in a patient with renal artery stenosis of the solitary kidney successfully treated with renal autotransplantation.", "question": "Treatment.Freq in renal autotransplantation", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "7035691_1_7232", "context": "Transient anuria following administration of angiotensin I-converting enzyme inhibitor (SQ 14225) in a patient with renal artery stenosis of the solitary kidney successfully treated with renal autotransplantation.", "question": "Treatment.Route in renal autotransplantation", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "7035691_1_7233", "context": "Transient anuria following administration of angiotensin I-converting enzyme inhibitor (SQ 14225) in a patient with renal artery stenosis of the solitary kidney successfully treated with renal autotransplantation.", "question": "Treatment.Time_elapsed in renal autotransplantation", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7035691_1_7234", "context": "Transient anuria following administration of angiotensin I-converting enzyme inhibitor (SQ 14225) in a patient with renal artery stenosis of the solitary kidney successfully treated with renal autotransplantation.", "question": "Treatment.Duration in renal autotransplantation", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "7035691_1_7235", "context": "Transient anuria following administration of angiotensin I-converting enzyme inhibitor (SQ 14225) in a patient with renal artery stenosis of the solitary kidney successfully treated with renal autotransplantation.", "question": "Treatment.Disorder in renal autotransplantation", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "Transient anuria"}, {"id": "7035691_1_7236", "context": "Transient anuria following administration of angiotensin I-converting enzyme inhibitor (SQ 14225) in a patient with renal artery stenosis of the solitary kidney successfully treated with renal autotransplantation.", "question": "Combination.Drug in renal autotransplantation", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "9517515_1_7237", "context": "Development of essential thrombocythemia in a patient treated with interferon alfa and pentostatin for hairy cell leukemia.", "question": "Subject.Age in a patient", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "9517515_1_7238", "context": "Development of essential thrombocythemia in a patient treated with interferon alfa and pentostatin for hairy cell leukemia.", "question": "Subject.Gender in a patient", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "9517515_1_7239", "context": "Development of essential thrombocythemia in a patient treated with interferon alfa and pentostatin for hairy cell leukemia.", "question": "Subject.Population in a patient", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "9517515_1_7240", "context": "Development of essential thrombocythemia in a patient treated with interferon alfa and pentostatin for hairy cell leukemia.", "question": "Subject.Race in a patient", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "9517515_1_7241", "context": "Development of essential thrombocythemia in a patient treated with interferon alfa and pentostatin for hairy cell leukemia.", "question": "Subject.Disorder in a patient", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "9517515_1_7242", "context": "Development of essential thrombocythemia in a patient treated with interferon alfa and pentostatin for hairy cell leukemia.", "question": "Treatment.Drug in interferon alfa and pentostatin", "question_type": "Adverse_event.Treatment.Drug", "answers": "interferon alfa; pentostatin"}, {"id": "9517515_1_7243", "context": "Development of essential thrombocythemia in a patient treated with interferon alfa and pentostatin for hairy cell leukemia.", "question": "Treatment.Dosage in interferon alfa and pentostatin", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9517515_1_7244", "context": "Development of essential thrombocythemia in a patient treated with interferon alfa and pentostatin for hairy cell leukemia.", "question": "Treatment.Freq in interferon alfa and pentostatin", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9517515_1_7245", "context": "Development of essential thrombocythemia in a patient treated with interferon alfa and pentostatin for hairy cell leukemia.", "question": "Treatment.Route in interferon alfa and pentostatin", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9517515_1_7246", "context": "Development of essential thrombocythemia in a patient treated with interferon alfa and pentostatin for hairy cell leukemia.", "question": "Treatment.Time_elapsed in interferon alfa and pentostatin", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9517515_1_7247", "context": "Development of essential thrombocythemia in a patient treated with interferon alfa and pentostatin for hairy cell leukemia.", "question": "Treatment.Duration in interferon alfa and pentostatin", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9517515_1_7248", "context": "Development of essential thrombocythemia in a patient treated with interferon alfa and pentostatin for hairy cell leukemia.", "question": "Treatment.Disorder in interferon alfa and pentostatin", "question_type": "Adverse_event.Treatment.Disorder", "answers": "hairy cell leukemia"}, {"id": "9517515_1_7249", "context": "Development of essential thrombocythemia in a patient treated with interferon alfa and pentostatin for hairy cell leukemia.", "question": "Combination.Drug in interferon alfa and pentostatin", "question_type": "Adverse_event.Combination.Drug", "answers": "interferon alfa; pentostatin"}, {"id": "12399645_1_7250", "context": "A case of SIADH induced by mizoribin administration.", "question": "Subject.Age in A case", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "12399645_1_7251", "context": "A case of SIADH induced by mizoribin administration.", "question": "Subject.Gender in A case", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "12399645_1_7252", "context": "A case of SIADH induced by mizoribin administration.", "question": "Subject.Population in A case", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "12399645_1_7253", "context": "A case of SIADH induced by mizoribin administration.", "question": "Subject.Race in A case", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "12399645_1_7254", "context": "A case of SIADH induced by mizoribin administration.", "question": "Subject.Disorder in A case", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "12399645_1_7255", "context": "A case of SIADH induced by mizoribin administration.", "question": "Treatment.Drug in mizoribin administration", "question_type": "Adverse_event.Treatment.Drug", "answers": "mizoribin"}, {"id": "12399645_1_7256", "context": "A case of SIADH induced by mizoribin administration.", "question": "Treatment.Dosage in mizoribin administration", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12399645_1_7257", "context": "A case of SIADH induced by mizoribin administration.", "question": "Treatment.Freq in mizoribin administration", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12399645_1_7258", "context": "A case of SIADH induced by mizoribin administration.", "question": "Treatment.Route in mizoribin administration", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12399645_1_7259", "context": "A case of SIADH induced by mizoribin administration.", "question": "Treatment.Time_elapsed in mizoribin administration", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12399645_1_7260", "context": "A case of SIADH induced by mizoribin administration.", "question": "Treatment.Duration in mizoribin administration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12399645_1_7261", "context": "A case of SIADH induced by mizoribin administration.", "question": "Treatment.Disorder in mizoribin administration", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12399645_1_7262", "context": "A case of SIADH induced by mizoribin administration.", "question": "Combination.Drug in mizoribin administration", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15053046_4_7263", "context": "The agranulocytosis was rapidly resolved by granulocyte colony-stimulating factor (G-CSF) therapy and by the discontinuation of vancomycin.", "question": "Treatment.Drug in granulocyte colony-stimulating factor (G-CSF) therapy and by the discontinuation of vancomycin", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "granulocyte colony-stimulating factor; vancomycin"}, {"id": "15053046_4_7264", "context": "The agranulocytosis was rapidly resolved by granulocyte colony-stimulating factor (G-CSF) therapy and by the discontinuation of vancomycin.", "question": "Treatment.Dosage in granulocyte colony-stimulating factor (G-CSF) therapy and by the discontinuation of vancomycin", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "15053046_4_7265", "context": "The agranulocytosis was rapidly resolved by granulocyte colony-stimulating factor (G-CSF) therapy and by the discontinuation of vancomycin.", "question": "Treatment.Freq in granulocyte colony-stimulating factor (G-CSF) therapy and by the discontinuation of vancomycin", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "15053046_4_7266", "context": "The agranulocytosis was rapidly resolved by granulocyte colony-stimulating factor (G-CSF) therapy and by the discontinuation of vancomycin.", "question": "Treatment.Route in granulocyte colony-stimulating factor (G-CSF) therapy and by the discontinuation of vancomycin", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "15053046_4_7267", "context": "The agranulocytosis was rapidly resolved by granulocyte colony-stimulating factor (G-CSF) therapy and by the discontinuation of vancomycin.", "question": "Treatment.Time_elapsed in granulocyte colony-stimulating factor (G-CSF) therapy and by the discontinuation of vancomycin", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15053046_4_7268", "context": "The agranulocytosis was rapidly resolved by granulocyte colony-stimulating factor (G-CSF) therapy and by the discontinuation of vancomycin.", "question": "Treatment.Duration in granulocyte colony-stimulating factor (G-CSF) therapy and by the discontinuation of vancomycin", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "15053046_4_7269", "context": "The agranulocytosis was rapidly resolved by granulocyte colony-stimulating factor (G-CSF) therapy and by the discontinuation of vancomycin.", "question": "Treatment.Disorder in granulocyte colony-stimulating factor (G-CSF) therapy and by the discontinuation of vancomycin", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "15053046_4_7270", "context": "The agranulocytosis was rapidly resolved by granulocyte colony-stimulating factor (G-CSF) therapy and by the discontinuation of vancomycin.", "question": "Combination.Drug in granulocyte colony-stimulating factor (G-CSF) therapy and by the discontinuation of vancomycin", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "11406880_3_7271", "context": "A patient that received methadone for cancer-associated pain developed myoclonus as a side effect.", "question": "Subject.Age in A patient", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "11406880_3_7272", "context": "A patient that received methadone for cancer-associated pain developed myoclonus as a side effect.", "question": "Subject.Gender in A patient", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "11406880_3_7273", "context": "A patient that received methadone for cancer-associated pain developed myoclonus as a side effect.", "question": "Subject.Population in A patient", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "11406880_3_7274", "context": "A patient that received methadone for cancer-associated pain developed myoclonus as a side effect.", "question": "Subject.Race in A patient", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "11406880_3_7275", "context": "A patient that received methadone for cancer-associated pain developed myoclonus as a side effect.", "question": "Subject.Disorder in A patient", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "11406880_3_7276", "context": "A patient that received methadone for cancer-associated pain developed myoclonus as a side effect.", "question": "Treatment.Drug in methadone", "question_type": "Adverse_event.Treatment.Drug", "answers": "methadone"}, {"id": "11406880_3_7277", "context": "A patient that received methadone for cancer-associated pain developed myoclonus as a side effect.", "question": "Treatment.Dosage in methadone", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11406880_3_7278", "context": "A patient that received methadone for cancer-associated pain developed myoclonus as a side effect.", "question": "Treatment.Freq in methadone", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11406880_3_7279", "context": "A patient that received methadone for cancer-associated pain developed myoclonus as a side effect.", "question": "Treatment.Route in methadone", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11406880_3_7280", "context": "A patient that received methadone for cancer-associated pain developed myoclonus as a side effect.", "question": "Treatment.Time_elapsed in methadone", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11406880_3_7281", "context": "A patient that received methadone for cancer-associated pain developed myoclonus as a side effect.", "question": "Treatment.Duration in methadone", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11406880_3_7282", "context": "A patient that received methadone for cancer-associated pain developed myoclonus as a side effect.", "question": "Treatment.Disorder in methadone", "question_type": "Adverse_event.Treatment.Disorder", "answers": "cancer-associated pain"}, {"id": "11406880_3_7283", "context": "A patient that received methadone for cancer-associated pain developed myoclonus as a side effect.", "question": "Combination.Drug in methadone", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9224230_1_7284", "context": "These cases were considered unusual in light of the short delay of their onset after initiation of immunosuppressive therapy and their fulminant course: 3 of these patients died of PCP occurring during the first month of treatment with prednisone.", "question": "Subject.Age in 3 of these patients", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "9224230_1_7285", "context": "These cases were considered unusual in light of the short delay of their onset after initiation of immunosuppressive therapy and their fulminant course: 3 of these patients died of PCP occurring during the first month of treatment with prednisone.", "question": "Subject.Gender in 3 of these patients", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "9224230_1_7286", "context": "These cases were considered unusual in light of the short delay of their onset after initiation of immunosuppressive therapy and their fulminant course: 3 of these patients died of PCP occurring during the first month of treatment with prednisone.", "question": "Subject.Population in 3 of these patients", "question_type": "Adverse_event.Subject.Population", "answers": "3"}, {"id": "9224230_1_7287", "context": "These cases were considered unusual in light of the short delay of their onset after initiation of immunosuppressive therapy and their fulminant course: 3 of these patients died of PCP occurring during the first month of treatment with prednisone.", "question": "Subject.Race in 3 of these patients", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "9224230_1_7288", "context": "These cases were considered unusual in light of the short delay of their onset after initiation of immunosuppressive therapy and their fulminant course: 3 of these patients died of PCP occurring during the first month of treatment with prednisone.", "question": "Subject.Disorder in 3 of these patients", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "9224230_1_7289", "context": "These cases were considered unusual in light of the short delay of their onset after initiation of immunosuppressive therapy and their fulminant course: 3 of these patients died of PCP occurring during the first month of treatment with prednisone.", "question": "Treatment.Drug in first month of treatment with prednisone", "question_type": "Adverse_event.Treatment.Drug", "answers": "prednisone"}, {"id": "9224230_1_7290", "context": "These cases were considered unusual in light of the short delay of their onset after initiation of immunosuppressive therapy and their fulminant course: 3 of these patients died of PCP occurring during the first month of treatment with prednisone.", "question": "Treatment.Dosage in first month of treatment with prednisone", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9224230_1_7291", "context": "These cases were considered unusual in light of the short delay of their onset after initiation of immunosuppressive therapy and their fulminant course: 3 of these patients died of PCP occurring during the first month of treatment with prednisone.", "question": "Treatment.Freq in first month of treatment with prednisone", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9224230_1_7292", "context": "These cases were considered unusual in light of the short delay of their onset after initiation of immunosuppressive therapy and their fulminant course: 3 of these patients died of PCP occurring during the first month of treatment with prednisone.", "question": "Treatment.Route in first month of treatment with prednisone", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9224230_1_7293", "context": "These cases were considered unusual in light of the short delay of their onset after initiation of immunosuppressive therapy and their fulminant course: 3 of these patients died of PCP occurring during the first month of treatment with prednisone.", "question": "Treatment.Time_elapsed in first month of treatment with prednisone", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9224230_1_7294", "context": "These cases were considered unusual in light of the short delay of their onset after initiation of immunosuppressive therapy and their fulminant course: 3 of these patients died of PCP occurring during the first month of treatment with prednisone.", "question": "Treatment.Duration in first month of treatment with prednisone", "question_type": "Adverse_event.Treatment.Duration", "answers": "first month"}, {"id": "9224230_1_7295", "context": "These cases were considered unusual in light of the short delay of their onset after initiation of immunosuppressive therapy and their fulminant course: 3 of these patients died of PCP occurring during the first month of treatment with prednisone.", "question": "Treatment.Disorder in first month of treatment with prednisone", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9224230_1_7296", "context": "These cases were considered unusual in light of the short delay of their onset after initiation of immunosuppressive therapy and their fulminant course: 3 of these patients died of PCP occurring during the first month of treatment with prednisone.", "question": "Combination.Drug in first month of treatment with prednisone", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16816519_5_7297", "context": "Five days after the fourth dose of vincristine, she presented with bilateral ptosis.", "question": "Subject.Age in she", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "16816519_5_7298", "context": "Five days after the fourth dose of vincristine, she presented with bilateral ptosis.", "question": "Subject.Gender in she", "question_type": "Adverse_event.Subject.Gender", "answers": "she"}, {"id": "16816519_5_7299", "context": "Five days after the fourth dose of vincristine, she presented with bilateral ptosis.", "question": "Subject.Population in she", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "16816519_5_7300", "context": "Five days after the fourth dose of vincristine, she presented with bilateral ptosis.", "question": "Subject.Race in she", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16816519_5_7301", "context": "Five days after the fourth dose of vincristine, she presented with bilateral ptosis.", "question": "Subject.Disorder in she", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "16816519_5_7302", "context": "Five days after the fourth dose of vincristine, she presented with bilateral ptosis.", "question": "Treatment.Drug in Five days after the fourth dose of vincristine", "question_type": "Adverse_event.Treatment.Drug", "answers": "vincristine"}, {"id": "16816519_5_7303", "context": "Five days after the fourth dose of vincristine, she presented with bilateral ptosis.", "question": "Treatment.Dosage in Five days after the fourth dose of vincristine", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16816519_5_7304", "context": "Five days after the fourth dose of vincristine, she presented with bilateral ptosis.", "question": "Treatment.Freq in Five days after the fourth dose of vincristine", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16816519_5_7305", "context": "Five days after the fourth dose of vincristine, she presented with bilateral ptosis.", "question": "Treatment.Route in Five days after the fourth dose of vincristine", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16816519_5_7306", "context": "Five days after the fourth dose of vincristine, she presented with bilateral ptosis.", "question": "Treatment.Time_elapsed in Five days after the fourth dose of vincristine", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "Five days"}, {"id": "16816519_5_7307", "context": "Five days after the fourth dose of vincristine, she presented with bilateral ptosis.", "question": "Treatment.Duration in Five days after the fourth dose of vincristine", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16816519_5_7308", "context": "Five days after the fourth dose of vincristine, she presented with bilateral ptosis.", "question": "Treatment.Disorder in Five days after the fourth dose of vincristine", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16816519_5_7309", "context": "Five days after the fourth dose of vincristine, she presented with bilateral ptosis.", "question": "Combination.Drug in Five days after the fourth dose of vincristine", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "19249953_7_7310", "context": "As it had been 10 months since her last dosage adjustment of diltiazem, it was unlikely that the statin-induced rhabdomyolysis was precipitated by diltiazem.", "question": "Treatment.Drug in diltiazem", "question_type": "Adverse_event.Treatment.Drug", "answers": "diltiazem"}, {"id": "19249953_7_7311", "context": "As it had been 10 months since her last dosage adjustment of diltiazem, it was unlikely that the statin-induced rhabdomyolysis was precipitated by diltiazem.", "question": "Treatment.Dosage in diltiazem", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "19249953_7_7312", "context": "As it had been 10 months since her last dosage adjustment of diltiazem, it was unlikely that the statin-induced rhabdomyolysis was precipitated by diltiazem.", "question": "Treatment.Freq in diltiazem", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "19249953_7_7313", "context": "As it had been 10 months since her last dosage adjustment of diltiazem, it was unlikely that the statin-induced rhabdomyolysis was precipitated by diltiazem.", "question": "Treatment.Route in diltiazem", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "19249953_7_7314", "context": "As it had been 10 months since her last dosage adjustment of diltiazem, it was unlikely that the statin-induced rhabdomyolysis was precipitated by diltiazem.", "question": "Treatment.Time_elapsed in diltiazem", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19249953_7_7315", "context": "As it had been 10 months since her last dosage adjustment of diltiazem, it was unlikely that the statin-induced rhabdomyolysis was precipitated by diltiazem.", "question": "Treatment.Duration in diltiazem", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "19249953_7_7316", "context": "As it had been 10 months since her last dosage adjustment of diltiazem, it was unlikely that the statin-induced rhabdomyolysis was precipitated by diltiazem.", "question": "Treatment.Disorder in diltiazem", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "19249953_7_7317", "context": "As it had been 10 months since her last dosage adjustment of diltiazem, it was unlikely that the statin-induced rhabdomyolysis was precipitated by diltiazem.", "question": "Combination.Drug in diltiazem", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "278642_2_7318", "context": "After the chlorambucil was discontinued, the wbc count began to slowly rise and the patient developed clinical AML.", "question": "Subject.Age in the patient", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "278642_2_7319", "context": "After the chlorambucil was discontinued, the wbc count began to slowly rise and the patient developed clinical AML.", "question": "Subject.Gender in the patient", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "278642_2_7320", "context": "After the chlorambucil was discontinued, the wbc count began to slowly rise and the patient developed clinical AML.", "question": "Subject.Population in the patient", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "278642_2_7321", "context": "After the chlorambucil was discontinued, the wbc count began to slowly rise and the patient developed clinical AML.", "question": "Subject.Race in the patient", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "278642_2_7322", "context": "After the chlorambucil was discontinued, the wbc count began to slowly rise and the patient developed clinical AML.", "question": "Subject.Disorder in the patient", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "278642_2_7323", "context": "After the chlorambucil was discontinued, the wbc count began to slowly rise and the patient developed clinical AML.", "question": "Treatment.Drug in chlorambucil", "question_type": "Adverse_event.Treatment.Drug", "answers": "chlorambucil"}, {"id": "278642_2_7324", "context": "After the chlorambucil was discontinued, the wbc count began to slowly rise and the patient developed clinical AML.", "question": "Treatment.Dosage in chlorambucil", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "278642_2_7325", "context": "After the chlorambucil was discontinued, the wbc count began to slowly rise and the patient developed clinical AML.", "question": "Treatment.Freq in chlorambucil", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "278642_2_7326", "context": "After the chlorambucil was discontinued, the wbc count began to slowly rise and the patient developed clinical AML.", "question": "Treatment.Route in chlorambucil", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "278642_2_7327", "context": "After the chlorambucil was discontinued, the wbc count began to slowly rise and the patient developed clinical AML.", "question": "Treatment.Time_elapsed in chlorambucil", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "278642_2_7328", "context": "After the chlorambucil was discontinued, the wbc count began to slowly rise and the patient developed clinical AML.", "question": "Treatment.Duration in chlorambucil", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "278642_2_7329", "context": "After the chlorambucil was discontinued, the wbc count began to slowly rise and the patient developed clinical AML.", "question": "Treatment.Disorder in chlorambucil", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "278642_2_7330", "context": "After the chlorambucil was discontinued, the wbc count began to slowly rise and the patient developed clinical AML.", "question": "Combination.Drug in chlorambucil", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16816519_7_7331", "context": "She received 3.8 mg cumulative dose of vincristin before development of ptosis.", "question": "Subject.Age in She", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "16816519_7_7332", "context": "She received 3.8 mg cumulative dose of vincristin before development of ptosis.", "question": "Subject.Gender in She", "question_type": "Adverse_event.Subject.Gender", "answers": "She"}, {"id": "16816519_7_7333", "context": "She received 3.8 mg cumulative dose of vincristin before development of ptosis.", "question": "Subject.Population in She", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "16816519_7_7334", "context": "She received 3.8 mg cumulative dose of vincristin before development of ptosis.", "question": "Subject.Race in She", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16816519_7_7335", "context": "She received 3.8 mg cumulative dose of vincristin before development of ptosis.", "question": "Subject.Disorder in She", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "16816519_7_7336", "context": "She received 3.8 mg cumulative dose of vincristin before development of ptosis.", "question": "Treatment.Drug in 3.8 mg cumulative dose of vincristin", "question_type": "Adverse_event.Treatment.Drug", "answers": "vincristin"}, {"id": "16816519_7_7337", "context": "She received 3.8 mg cumulative dose of vincristin before development of ptosis.", "question": "Treatment.Dosage in 3.8 mg cumulative dose of vincristin", "question_type": "Adverse_event.Treatment.Dosage", "answers": "3.8 mg"}, {"id": "16816519_7_7338", "context": "She received 3.8 mg cumulative dose of vincristin before development of ptosis.", "question": "Treatment.Freq in 3.8 mg cumulative dose of vincristin", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16816519_7_7339", "context": "She received 3.8 mg cumulative dose of vincristin before development of ptosis.", "question": "Treatment.Route in 3.8 mg cumulative dose of vincristin", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16816519_7_7340", "context": "She received 3.8 mg cumulative dose of vincristin before development of ptosis.", "question": "Treatment.Time_elapsed in 3.8 mg cumulative dose of vincristin", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16816519_7_7341", "context": "She received 3.8 mg cumulative dose of vincristin before development of ptosis.", "question": "Treatment.Duration in 3.8 mg cumulative dose of vincristin", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16816519_7_7342", "context": "She received 3.8 mg cumulative dose of vincristin before development of ptosis.", "question": "Treatment.Disorder in 3.8 mg cumulative dose of vincristin", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16816519_7_7343", "context": "She received 3.8 mg cumulative dose of vincristin before development of ptosis.", "question": "Combination.Drug in 3.8 mg cumulative dose of vincristin", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "2429270_3_7344", "context": "In addition, the tachycardia persisted and was repeatedly spontaneously reinitiated for prolonged periods after procainamide.", "question": "Treatment.Drug in procainamide", "question_type": "Adverse_event.Treatment.Drug", "answers": "procainamide"}, {"id": "2429270_3_7345", "context": "In addition, the tachycardia persisted and was repeatedly spontaneously reinitiated for prolonged periods after procainamide.", "question": "Treatment.Dosage in procainamide", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "2429270_3_7346", "context": "In addition, the tachycardia persisted and was repeatedly spontaneously reinitiated for prolonged periods after procainamide.", "question": "Treatment.Freq in procainamide", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2429270_3_7347", "context": "In addition, the tachycardia persisted and was repeatedly spontaneously reinitiated for prolonged periods after procainamide.", "question": "Treatment.Route in procainamide", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "2429270_3_7348", "context": "In addition, the tachycardia persisted and was repeatedly spontaneously reinitiated for prolonged periods after procainamide.", "question": "Treatment.Time_elapsed in procainamide", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2429270_3_7349", "context": "In addition, the tachycardia persisted and was repeatedly spontaneously reinitiated for prolonged periods after procainamide.", "question": "Treatment.Duration in procainamide", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2429270_3_7350", "context": "In addition, the tachycardia persisted and was repeatedly spontaneously reinitiated for prolonged periods after procainamide.", "question": "Treatment.Disorder in procainamide", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "2429270_3_7351", "context": "In addition, the tachycardia persisted and was repeatedly spontaneously reinitiated for prolonged periods after procainamide.", "question": "Combination.Drug in procainamide", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9527943_2_7352", "context": "One patient had a lower average heart rate and two patients had lower average mean blood pressure values during propranolol treatment, none of which was clinically significant.", "question": "Subject.Age in two patients", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "9527943_2_7353", "context": "One patient had a lower average heart rate and two patients had lower average mean blood pressure values during propranolol treatment, none of which was clinically significant.", "question": "Subject.Gender in two patients", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "9527943_2_7354", "context": "One patient had a lower average heart rate and two patients had lower average mean blood pressure values during propranolol treatment, none of which was clinically significant.", "question": "Subject.Population in two patients", "question_type": "Adverse_event.Subject.Population", "answers": "two"}, {"id": "9527943_2_7355", "context": "One patient had a lower average heart rate and two patients had lower average mean blood pressure values during propranolol treatment, none of which was clinically significant.", "question": "Subject.Race in two patients", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "9527943_2_7356", "context": "One patient had a lower average heart rate and two patients had lower average mean blood pressure values during propranolol treatment, none of which was clinically significant.", "question": "Subject.Disorder in two patients", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "9527943_2_7357", "context": "One patient had a lower average heart rate and two patients had lower average mean blood pressure values during propranolol treatment, none of which was clinically significant.", "question": "Treatment.Drug in propranolol", "question_type": "Adverse_event.Treatment.Drug", "answers": "propranolol"}, {"id": "9527943_2_7358", "context": "One patient had a lower average heart rate and two patients had lower average mean blood pressure values during propranolol treatment, none of which was clinically significant.", "question": "Treatment.Dosage in propranolol", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9527943_2_7359", "context": "One patient had a lower average heart rate and two patients had lower average mean blood pressure values during propranolol treatment, none of which was clinically significant.", "question": "Treatment.Freq in propranolol", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9527943_2_7360", "context": "One patient had a lower average heart rate and two patients had lower average mean blood pressure values during propranolol treatment, none of which was clinically significant.", "question": "Treatment.Route in propranolol", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9527943_2_7361", "context": "One patient had a lower average heart rate and two patients had lower average mean blood pressure values during propranolol treatment, none of which was clinically significant.", "question": "Treatment.Time_elapsed in propranolol", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9527943_2_7362", "context": "One patient had a lower average heart rate and two patients had lower average mean blood pressure values during propranolol treatment, none of which was clinically significant.", "question": "Treatment.Duration in propranolol", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9527943_2_7363", "context": "One patient had a lower average heart rate and two patients had lower average mean blood pressure values during propranolol treatment, none of which was clinically significant.", "question": "Treatment.Disorder in propranolol", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9527943_2_7364", "context": "One patient had a lower average heart rate and two patients had lower average mean blood pressure values during propranolol treatment, none of which was clinically significant.", "question": "Combination.Drug in propranolol", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9527943_2_7365", "context": "One patient had a lower average heart rate and two patients had lower average mean blood pressure values during propranolol treatment, none of which was clinically significant.", "question": "Subject.Age in One patient", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "9527943_2_7366", "context": "One patient had a lower average heart rate and two patients had lower average mean blood pressure values during propranolol treatment, none of which was clinically significant.", "question": "Subject.Gender in One patient", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "9527943_2_7367", "context": "One patient had a lower average heart rate and two patients had lower average mean blood pressure values during propranolol treatment, none of which was clinically significant.", "question": "Subject.Population in One patient", "question_type": "Adverse_event.Subject.Population", "answers": "One"}, {"id": "9527943_2_7368", "context": "One patient had a lower average heart rate and two patients had lower average mean blood pressure values during propranolol treatment, none of which was clinically significant.", "question": "Subject.Race in One patient", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "9527943_2_7369", "context": "One patient had a lower average heart rate and two patients had lower average mean blood pressure values during propranolol treatment, none of which was clinically significant.", "question": "Subject.Disorder in One patient", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "9527943_2_7370", "context": "One patient had a lower average heart rate and two patients had lower average mean blood pressure values during propranolol treatment, none of which was clinically significant.", "question": "Treatment.Drug in propranolol", "question_type": "Adverse_event.Treatment.Drug", "answers": "propranolol"}, {"id": "9527943_2_7371", "context": "One patient had a lower average heart rate and two patients had lower average mean blood pressure values during propranolol treatment, none of which was clinically significant.", "question": "Treatment.Dosage in propranolol", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9527943_2_7372", "context": "One patient had a lower average heart rate and two patients had lower average mean blood pressure values during propranolol treatment, none of which was clinically significant.", "question": "Treatment.Freq in propranolol", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9527943_2_7373", "context": "One patient had a lower average heart rate and two patients had lower average mean blood pressure values during propranolol treatment, none of which was clinically significant.", "question": "Treatment.Route in propranolol", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9527943_2_7374", "context": "One patient had a lower average heart rate and two patients had lower average mean blood pressure values during propranolol treatment, none of which was clinically significant.", "question": "Treatment.Time_elapsed in propranolol", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9527943_2_7375", "context": "One patient had a lower average heart rate and two patients had lower average mean blood pressure values during propranolol treatment, none of which was clinically significant.", "question": "Treatment.Duration in propranolol", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9527943_2_7376", "context": "One patient had a lower average heart rate and two patients had lower average mean blood pressure values during propranolol treatment, none of which was clinically significant.", "question": "Treatment.Disorder in propranolol", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9527943_2_7377", "context": "One patient had a lower average heart rate and two patients had lower average mean blood pressure values during propranolol treatment, none of which was clinically significant.", "question": "Combination.Drug in propranolol", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7685228_2_7378", "context": "We have successfully overcome severe neutropenia in an RA patient treated with gold salts, using granulocyte colony-stimulating factor (G-CSF), reducing the duration of neutropenia and risk of infection.", "question": "Subject.Age in an RA patient treated with gold salts", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "7685228_2_7379", "context": "We have successfully overcome severe neutropenia in an RA patient treated with gold salts, using granulocyte colony-stimulating factor (G-CSF), reducing the duration of neutropenia and risk of infection.", "question": "Subject.Gender in an RA patient treated with gold salts", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "7685228_2_7380", "context": "We have successfully overcome severe neutropenia in an RA patient treated with gold salts, using granulocyte colony-stimulating factor (G-CSF), reducing the duration of neutropenia and risk of infection.", "question": "Subject.Population in an RA patient treated with gold salts", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "7685228_2_7381", "context": "We have successfully overcome severe neutropenia in an RA patient treated with gold salts, using granulocyte colony-stimulating factor (G-CSF), reducing the duration of neutropenia and risk of infection.", "question": "Subject.Race in an RA patient treated with gold salts", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "7685228_2_7382", "context": "We have successfully overcome severe neutropenia in an RA patient treated with gold salts, using granulocyte colony-stimulating factor (G-CSF), reducing the duration of neutropenia and risk of infection.", "question": "Subject.Disorder in an RA patient treated with gold salts", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": "RA"}, {"id": "7685228_2_7383", "context": "We have successfully overcome severe neutropenia in an RA patient treated with gold salts, using granulocyte colony-stimulating factor (G-CSF), reducing the duration of neutropenia and risk of infection.", "question": "Treatment.Drug in granulocyte colony-stimulating factor (G-CSF)", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "granulocyte colony-stimulating factor"}, {"id": "7685228_2_7384", "context": "We have successfully overcome severe neutropenia in an RA patient treated with gold salts, using granulocyte colony-stimulating factor (G-CSF), reducing the duration of neutropenia and risk of infection.", "question": "Treatment.Dosage in granulocyte colony-stimulating factor (G-CSF)", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "7685228_2_7385", "context": "We have successfully overcome severe neutropenia in an RA patient treated with gold salts, using granulocyte colony-stimulating factor (G-CSF), reducing the duration of neutropenia and risk of infection.", "question": "Treatment.Freq in granulocyte colony-stimulating factor (G-CSF)", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "7685228_2_7386", "context": "We have successfully overcome severe neutropenia in an RA patient treated with gold salts, using granulocyte colony-stimulating factor (G-CSF), reducing the duration of neutropenia and risk of infection.", "question": "Treatment.Route in granulocyte colony-stimulating factor (G-CSF)", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "7685228_2_7387", "context": "We have successfully overcome severe neutropenia in an RA patient treated with gold salts, using granulocyte colony-stimulating factor (G-CSF), reducing the duration of neutropenia and risk of infection.", "question": "Treatment.Time_elapsed in granulocyte colony-stimulating factor (G-CSF)", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7685228_2_7388", "context": "We have successfully overcome severe neutropenia in an RA patient treated with gold salts, using granulocyte colony-stimulating factor (G-CSF), reducing the duration of neutropenia and risk of infection.", "question": "Treatment.Duration in granulocyte colony-stimulating factor (G-CSF)", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "7685228_2_7389", "context": "We have successfully overcome severe neutropenia in an RA patient treated with gold salts, using granulocyte colony-stimulating factor (G-CSF), reducing the duration of neutropenia and risk of infection.", "question": "Treatment.Disorder in granulocyte colony-stimulating factor (G-CSF)", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "severe neutropenia"}, {"id": "7685228_2_7390", "context": "We have successfully overcome severe neutropenia in an RA patient treated with gold salts, using granulocyte colony-stimulating factor (G-CSF), reducing the duration of neutropenia and risk of infection.", "question": "Combination.Drug in granulocyte colony-stimulating factor (G-CSF)", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "7685228_2_7391", "context": "We have successfully overcome severe neutropenia in an RA patient treated with gold salts, using granulocyte colony-stimulating factor (G-CSF), reducing the duration of neutropenia and risk of infection.", "question": "Treatment.Drug in gold salts", "question_type": "Adverse_event.Treatment.Drug", "answers": "gold salts"}, {"id": "7685228_2_7392", "context": "We have successfully overcome severe neutropenia in an RA patient treated with gold salts, using granulocyte colony-stimulating factor (G-CSF), reducing the duration of neutropenia and risk of infection.", "question": "Treatment.Dosage in gold salts", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7685228_2_7393", "context": "We have successfully overcome severe neutropenia in an RA patient treated with gold salts, using granulocyte colony-stimulating factor (G-CSF), reducing the duration of neutropenia and risk of infection.", "question": "Treatment.Freq in gold salts", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7685228_2_7394", "context": "We have successfully overcome severe neutropenia in an RA patient treated with gold salts, using granulocyte colony-stimulating factor (G-CSF), reducing the duration of neutropenia and risk of infection.", "question": "Treatment.Route in gold salts", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7685228_2_7395", "context": "We have successfully overcome severe neutropenia in an RA patient treated with gold salts, using granulocyte colony-stimulating factor (G-CSF), reducing the duration of neutropenia and risk of infection.", "question": "Treatment.Time_elapsed in gold salts", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7685228_2_7396", "context": "We have successfully overcome severe neutropenia in an RA patient treated with gold salts, using granulocyte colony-stimulating factor (G-CSF), reducing the duration of neutropenia and risk of infection.", "question": "Treatment.Duration in gold salts", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7685228_2_7397", "context": "We have successfully overcome severe neutropenia in an RA patient treated with gold salts, using granulocyte colony-stimulating factor (G-CSF), reducing the duration of neutropenia and risk of infection.", "question": "Treatment.Disorder in gold salts", "question_type": "Adverse_event.Treatment.Disorder", "answers": "RA"}, {"id": "7685228_2_7398", "context": "We have successfully overcome severe neutropenia in an RA patient treated with gold salts, using granulocyte colony-stimulating factor (G-CSF), reducing the duration of neutropenia and risk of infection.", "question": "Combination.Drug in gold salts", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10907391_1_7399", "context": "A third patient experienced disabling neurotoxicity in the extremity of a prior ulnar nerve and tendon transposition after receiving paclitaxel.", "question": "Subject.Age in A third patient", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "10907391_1_7400", "context": "A third patient experienced disabling neurotoxicity in the extremity of a prior ulnar nerve and tendon transposition after receiving paclitaxel.", "question": "Subject.Gender in A third patient", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "10907391_1_7401", "context": "A third patient experienced disabling neurotoxicity in the extremity of a prior ulnar nerve and tendon transposition after receiving paclitaxel.", "question": "Subject.Population in A third patient", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "10907391_1_7402", "context": "A third patient experienced disabling neurotoxicity in the extremity of a prior ulnar nerve and tendon transposition after receiving paclitaxel.", "question": "Subject.Race in A third patient", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "10907391_1_7403", "context": "A third patient experienced disabling neurotoxicity in the extremity of a prior ulnar nerve and tendon transposition after receiving paclitaxel.", "question": "Subject.Disorder in A third patient", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "10907391_1_7404", "context": "A third patient experienced disabling neurotoxicity in the extremity of a prior ulnar nerve and tendon transposition after receiving paclitaxel.", "question": "Treatment.Drug in paclitaxel", "question_type": "Adverse_event.Treatment.Drug", "answers": "paclitaxel"}, {"id": "10907391_1_7405", "context": "A third patient experienced disabling neurotoxicity in the extremity of a prior ulnar nerve and tendon transposition after receiving paclitaxel.", "question": "Treatment.Dosage in paclitaxel", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10907391_1_7406", "context": "A third patient experienced disabling neurotoxicity in the extremity of a prior ulnar nerve and tendon transposition after receiving paclitaxel.", "question": "Treatment.Freq in paclitaxel", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10907391_1_7407", "context": "A third patient experienced disabling neurotoxicity in the extremity of a prior ulnar nerve and tendon transposition after receiving paclitaxel.", "question": "Treatment.Route in paclitaxel", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10907391_1_7408", "context": "A third patient experienced disabling neurotoxicity in the extremity of a prior ulnar nerve and tendon transposition after receiving paclitaxel.", "question": "Treatment.Time_elapsed in paclitaxel", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10907391_1_7409", "context": "A third patient experienced disabling neurotoxicity in the extremity of a prior ulnar nerve and tendon transposition after receiving paclitaxel.", "question": "Treatment.Duration in paclitaxel", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10907391_1_7410", "context": "A third patient experienced disabling neurotoxicity in the extremity of a prior ulnar nerve and tendon transposition after receiving paclitaxel.", "question": "Treatment.Disorder in paclitaxel", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10907391_1_7411", "context": "A third patient experienced disabling neurotoxicity in the extremity of a prior ulnar nerve and tendon transposition after receiving paclitaxel.", "question": "Combination.Drug in paclitaxel", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12702914_5_7412", "context": "While 40 mg/day of prednisolone improved hepatic dysfunction dramatically, her diabetic milieu deteriorated seriously.", "question": "Treatment.Drug in 40 mg/day of prednisolone", "question_type": "Adverse_event.Treatment.Drug", "answers": "prednisolone"}, {"id": "12702914_5_7413", "context": "While 40 mg/day of prednisolone improved hepatic dysfunction dramatically, her diabetic milieu deteriorated seriously.", "question": "Treatment.Dosage in 40 mg/day of prednisolone", "question_type": "Adverse_event.Treatment.Dosage", "answers": "40 mg/day"}, {"id": "12702914_5_7414", "context": "While 40 mg/day of prednisolone improved hepatic dysfunction dramatically, her diabetic milieu deteriorated seriously.", "question": "Treatment.Freq in 40 mg/day of prednisolone", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12702914_5_7415", "context": "While 40 mg/day of prednisolone improved hepatic dysfunction dramatically, her diabetic milieu deteriorated seriously.", "question": "Treatment.Route in 40 mg/day of prednisolone", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12702914_5_7416", "context": "While 40 mg/day of prednisolone improved hepatic dysfunction dramatically, her diabetic milieu deteriorated seriously.", "question": "Treatment.Time_elapsed in 40 mg/day of prednisolone", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12702914_5_7417", "context": "While 40 mg/day of prednisolone improved hepatic dysfunction dramatically, her diabetic milieu deteriorated seriously.", "question": "Treatment.Duration in 40 mg/day of prednisolone", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12702914_5_7418", "context": "While 40 mg/day of prednisolone improved hepatic dysfunction dramatically, her diabetic milieu deteriorated seriously.", "question": "Treatment.Disorder in 40 mg/day of prednisolone", "question_type": "Adverse_event.Treatment.Disorder", "answers": "hepatic dysfunction"}, {"id": "12702914_5_7419", "context": "While 40 mg/day of prednisolone improved hepatic dysfunction dramatically, her diabetic milieu deteriorated seriously.", "question": "Combination.Drug in 40 mg/day of prednisolone", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12702914_5_7420", "context": "While 40 mg/day of prednisolone improved hepatic dysfunction dramatically, her diabetic milieu deteriorated seriously.", "question": "Treatment.Drug in 40 mg/day of prednisolone", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "prednisolone"}, {"id": "12702914_5_7421", "context": "While 40 mg/day of prednisolone improved hepatic dysfunction dramatically, her diabetic milieu deteriorated seriously.", "question": "Treatment.Dosage in 40 mg/day of prednisolone", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": "40 mg/day"}, {"id": "12702914_5_7422", "context": "While 40 mg/day of prednisolone improved hepatic dysfunction dramatically, her diabetic milieu deteriorated seriously.", "question": "Treatment.Freq in 40 mg/day of prednisolone", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "12702914_5_7423", "context": "While 40 mg/day of prednisolone improved hepatic dysfunction dramatically, her diabetic milieu deteriorated seriously.", "question": "Treatment.Route in 40 mg/day of prednisolone", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "12702914_5_7424", "context": "While 40 mg/day of prednisolone improved hepatic dysfunction dramatically, her diabetic milieu deteriorated seriously.", "question": "Treatment.Time_elapsed in 40 mg/day of prednisolone", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12702914_5_7425", "context": "While 40 mg/day of prednisolone improved hepatic dysfunction dramatically, her diabetic milieu deteriorated seriously.", "question": "Treatment.Duration in 40 mg/day of prednisolone", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "12702914_5_7426", "context": "While 40 mg/day of prednisolone improved hepatic dysfunction dramatically, her diabetic milieu deteriorated seriously.", "question": "Treatment.Disorder in 40 mg/day of prednisolone", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "hepatic dysfunction"}, {"id": "12702914_5_7427", "context": "While 40 mg/day of prednisolone improved hepatic dysfunction dramatically, her diabetic milieu deteriorated seriously.", "question": "Combination.Drug in 40 mg/day of prednisolone", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "15463865_2_7428", "context": "Acute renal insufficiency is known to occur in patients who are taking ciprofloxacin, particularly the elderly.", "question": "Subject.Age in patients; elderly", "question_type": "Adverse_event.Subject.Age", "answers": "elderly"}, {"id": "15463865_2_7429", "context": "Acute renal insufficiency is known to occur in patients who are taking ciprofloxacin, particularly the elderly.", "question": "Subject.Gender in patients; elderly", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15463865_2_7430", "context": "Acute renal insufficiency is known to occur in patients who are taking ciprofloxacin, particularly the elderly.", "question": "Subject.Population in patients; elderly", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "15463865_2_7431", "context": "Acute renal insufficiency is known to occur in patients who are taking ciprofloxacin, particularly the elderly.", "question": "Subject.Race in patients; elderly", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15463865_2_7432", "context": "Acute renal insufficiency is known to occur in patients who are taking ciprofloxacin, particularly the elderly.", "question": "Subject.Disorder in patients; elderly", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15463865_2_7433", "context": "Acute renal insufficiency is known to occur in patients who are taking ciprofloxacin, particularly the elderly.", "question": "Treatment.Drug in ciprofloxacin", "question_type": "Adverse_event.Treatment.Drug", "answers": "ciprofloxacin"}, {"id": "15463865_2_7434", "context": "Acute renal insufficiency is known to occur in patients who are taking ciprofloxacin, particularly the elderly.", "question": "Treatment.Dosage in ciprofloxacin", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15463865_2_7435", "context": "Acute renal insufficiency is known to occur in patients who are taking ciprofloxacin, particularly the elderly.", "question": "Treatment.Freq in ciprofloxacin", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15463865_2_7436", "context": "Acute renal insufficiency is known to occur in patients who are taking ciprofloxacin, particularly the elderly.", "question": "Treatment.Route in ciprofloxacin", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15463865_2_7437", "context": "Acute renal insufficiency is known to occur in patients who are taking ciprofloxacin, particularly the elderly.", "question": "Treatment.Time_elapsed in ciprofloxacin", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15463865_2_7438", "context": "Acute renal insufficiency is known to occur in patients who are taking ciprofloxacin, particularly the elderly.", "question": "Treatment.Duration in ciprofloxacin", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15463865_2_7439", "context": "Acute renal insufficiency is known to occur in patients who are taking ciprofloxacin, particularly the elderly.", "question": "Treatment.Disorder in ciprofloxacin", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15463865_2_7440", "context": "Acute renal insufficiency is known to occur in patients who are taking ciprofloxacin, particularly the elderly.", "question": "Combination.Drug in ciprofloxacin", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "95811_1_7441", "context": "A 61-year-old man developed clinical lupus syndrome with positive antinuclear antibody, positive lupus erythematosus (LE) cell preparation, and diffuse proliferative glomerulonephritis following 26 months of procainamide therapy.", "question": "Subject.Age in 61-year-old man", "question_type": "Adverse_event.Subject.Age", "answers": "61-year-old"}, {"id": "95811_1_7442", "context": "A 61-year-old man developed clinical lupus syndrome with positive antinuclear antibody, positive lupus erythematosus (LE) cell preparation, and diffuse proliferative glomerulonephritis following 26 months of procainamide therapy.", "question": "Subject.Gender in 61-year-old man", "question_type": "Adverse_event.Subject.Gender", "answers": "man"}, {"id": "95811_1_7443", "context": "A 61-year-old man developed clinical lupus syndrome with positive antinuclear antibody, positive lupus erythematosus (LE) cell preparation, and diffuse proliferative glomerulonephritis following 26 months of procainamide therapy.", "question": "Subject.Population in 61-year-old man", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "95811_1_7444", "context": "A 61-year-old man developed clinical lupus syndrome with positive antinuclear antibody, positive lupus erythematosus (LE) cell preparation, and diffuse proliferative glomerulonephritis following 26 months of procainamide therapy.", "question": "Subject.Race in 61-year-old man", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "95811_1_7445", "context": "A 61-year-old man developed clinical lupus syndrome with positive antinuclear antibody, positive lupus erythematosus (LE) cell preparation, and diffuse proliferative glomerulonephritis following 26 months of procainamide therapy.", "question": "Subject.Disorder in 61-year-old man", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "95811_1_7446", "context": "A 61-year-old man developed clinical lupus syndrome with positive antinuclear antibody, positive lupus erythematosus (LE) cell preparation, and diffuse proliferative glomerulonephritis following 26 months of procainamide therapy.", "question": "Treatment.Drug in 26 months of procainamide therapy", "question_type": "Adverse_event.Treatment.Drug", "answers": "procainamide"}, {"id": "95811_1_7447", "context": "A 61-year-old man developed clinical lupus syndrome with positive antinuclear antibody, positive lupus erythematosus (LE) cell preparation, and diffuse proliferative glomerulonephritis following 26 months of procainamide therapy.", "question": "Treatment.Dosage in 26 months of procainamide therapy", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "95811_1_7448", "context": "A 61-year-old man developed clinical lupus syndrome with positive antinuclear antibody, positive lupus erythematosus (LE) cell preparation, and diffuse proliferative glomerulonephritis following 26 months of procainamide therapy.", "question": "Treatment.Freq in 26 months of procainamide therapy", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "95811_1_7449", "context": "A 61-year-old man developed clinical lupus syndrome with positive antinuclear antibody, positive lupus erythematosus (LE) cell preparation, and diffuse proliferative glomerulonephritis following 26 months of procainamide therapy.", "question": "Treatment.Route in 26 months of procainamide therapy", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "95811_1_7450", "context": "A 61-year-old man developed clinical lupus syndrome with positive antinuclear antibody, positive lupus erythematosus (LE) cell preparation, and diffuse proliferative glomerulonephritis following 26 months of procainamide therapy.", "question": "Treatment.Time_elapsed in 26 months of procainamide therapy", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "95811_1_7451", "context": "A 61-year-old man developed clinical lupus syndrome with positive antinuclear antibody, positive lupus erythematosus (LE) cell preparation, and diffuse proliferative glomerulonephritis following 26 months of procainamide therapy.", "question": "Treatment.Duration in 26 months of procainamide therapy", "question_type": "Adverse_event.Treatment.Duration", "answers": "26 months"}, {"id": "95811_1_7452", "context": "A 61-year-old man developed clinical lupus syndrome with positive antinuclear antibody, positive lupus erythematosus (LE) cell preparation, and diffuse proliferative glomerulonephritis following 26 months of procainamide therapy.", "question": "Treatment.Disorder in 26 months of procainamide therapy", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "95811_1_7453", "context": "A 61-year-old man developed clinical lupus syndrome with positive antinuclear antibody, positive lupus erythematosus (LE) cell preparation, and diffuse proliferative glomerulonephritis following 26 months of procainamide therapy.", "question": "Combination.Drug in 26 months of procainamide therapy", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10510017_4_7454", "context": "We report the successful treatment of heparin-induced thrombocytopenia and subsequent hemorrhagic complications postoperatively in a 2-year-old child with Danaparoid (orgaran).", "question": "Subject.Age in a 2-year-old child", "question_type": "Adverse_event.Subject.Age", "answers": "2-year-old child"}, {"id": "10510017_4_7455", "context": "We report the successful treatment of heparin-induced thrombocytopenia and subsequent hemorrhagic complications postoperatively in a 2-year-old child with Danaparoid (orgaran).", "question": "Subject.Gender in a 2-year-old child", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "10510017_4_7456", "context": "We report the successful treatment of heparin-induced thrombocytopenia and subsequent hemorrhagic complications postoperatively in a 2-year-old child with Danaparoid (orgaran).", "question": "Subject.Population in a 2-year-old child", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "10510017_4_7457", "context": "We report the successful treatment of heparin-induced thrombocytopenia and subsequent hemorrhagic complications postoperatively in a 2-year-old child with Danaparoid (orgaran).", "question": "Subject.Race in a 2-year-old child", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "10510017_4_7458", "context": "We report the successful treatment of heparin-induced thrombocytopenia and subsequent hemorrhagic complications postoperatively in a 2-year-old child with Danaparoid (orgaran).", "question": "Subject.Disorder in a 2-year-old child", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "10510017_4_7459", "context": "We report the successful treatment of heparin-induced thrombocytopenia and subsequent hemorrhagic complications postoperatively in a 2-year-old child with Danaparoid (orgaran).", "question": "Treatment.Drug in heparin", "question_type": "Adverse_event.Treatment.Drug", "answers": "heparin"}, {"id": "10510017_4_7460", "context": "We report the successful treatment of heparin-induced thrombocytopenia and subsequent hemorrhagic complications postoperatively in a 2-year-old child with Danaparoid (orgaran).", "question": "Treatment.Dosage in heparin", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10510017_4_7461", "context": "We report the successful treatment of heparin-induced thrombocytopenia and subsequent hemorrhagic complications postoperatively in a 2-year-old child with Danaparoid (orgaran).", "question": "Treatment.Freq in heparin", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10510017_4_7462", "context": "We report the successful treatment of heparin-induced thrombocytopenia and subsequent hemorrhagic complications postoperatively in a 2-year-old child with Danaparoid (orgaran).", "question": "Treatment.Route in heparin", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10510017_4_7463", "context": "We report the successful treatment of heparin-induced thrombocytopenia and subsequent hemorrhagic complications postoperatively in a 2-year-old child with Danaparoid (orgaran).", "question": "Treatment.Time_elapsed in heparin", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10510017_4_7464", "context": "We report the successful treatment of heparin-induced thrombocytopenia and subsequent hemorrhagic complications postoperatively in a 2-year-old child with Danaparoid (orgaran).", "question": "Treatment.Duration in heparin", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10510017_4_7465", "context": "We report the successful treatment of heparin-induced thrombocytopenia and subsequent hemorrhagic complications postoperatively in a 2-year-old child with Danaparoid (orgaran).", "question": "Treatment.Disorder in heparin", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10510017_4_7466", "context": "We report the successful treatment of heparin-induced thrombocytopenia and subsequent hemorrhagic complications postoperatively in a 2-year-old child with Danaparoid (orgaran).", "question": "Combination.Drug in heparin", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10510017_4_7467", "context": "We report the successful treatment of heparin-induced thrombocytopenia and subsequent hemorrhagic complications postoperatively in a 2-year-old child with Danaparoid (orgaran).", "question": "Subject.Age in a 2-year-old child", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": "2-year-old child"}, {"id": "10510017_4_7468", "context": "We report the successful treatment of heparin-induced thrombocytopenia and subsequent hemorrhagic complications postoperatively in a 2-year-old child with Danaparoid (orgaran).", "question": "Subject.Gender in a 2-year-old child", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "10510017_4_7469", "context": "We report the successful treatment of heparin-induced thrombocytopenia and subsequent hemorrhagic complications postoperatively in a 2-year-old child with Danaparoid (orgaran).", "question": "Subject.Population in a 2-year-old child", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "10510017_4_7470", "context": "We report the successful treatment of heparin-induced thrombocytopenia and subsequent hemorrhagic complications postoperatively in a 2-year-old child with Danaparoid (orgaran).", "question": "Subject.Race in a 2-year-old child", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "10510017_4_7471", "context": "We report the successful treatment of heparin-induced thrombocytopenia and subsequent hemorrhagic complications postoperatively in a 2-year-old child with Danaparoid (orgaran).", "question": "Subject.Disorder in a 2-year-old child", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "10510017_4_7472", "context": "We report the successful treatment of heparin-induced thrombocytopenia and subsequent hemorrhagic complications postoperatively in a 2-year-old child with Danaparoid (orgaran).", "question": "Treatment.Drug in Danaparoid (orgaran)", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "Danaparoid"}, {"id": "10510017_4_7473", "context": "We report the successful treatment of heparin-induced thrombocytopenia and subsequent hemorrhagic complications postoperatively in a 2-year-old child with Danaparoid (orgaran).", "question": "Treatment.Dosage in Danaparoid (orgaran)", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "10510017_4_7474", "context": "We report the successful treatment of heparin-induced thrombocytopenia and subsequent hemorrhagic complications postoperatively in a 2-year-old child with Danaparoid (orgaran).", "question": "Treatment.Freq in Danaparoid (orgaran)", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "10510017_4_7475", "context": "We report the successful treatment of heparin-induced thrombocytopenia and subsequent hemorrhagic complications postoperatively in a 2-year-old child with Danaparoid (orgaran).", "question": "Treatment.Route in Danaparoid (orgaran)", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "10510017_4_7476", "context": "We report the successful treatment of heparin-induced thrombocytopenia and subsequent hemorrhagic complications postoperatively in a 2-year-old child with Danaparoid (orgaran).", "question": "Treatment.Time_elapsed in Danaparoid (orgaran)", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10510017_4_7477", "context": "We report the successful treatment of heparin-induced thrombocytopenia and subsequent hemorrhagic complications postoperatively in a 2-year-old child with Danaparoid (orgaran).", "question": "Treatment.Duration in Danaparoid (orgaran)", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "10510017_4_7478", "context": "We report the successful treatment of heparin-induced thrombocytopenia and subsequent hemorrhagic complications postoperatively in a 2-year-old child with Danaparoid (orgaran).", "question": "Treatment.Disorder in Danaparoid (orgaran)", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "heparin-induced thrombocytopenia and subsequent hemorrhagic complications"}, {"id": "10510017_4_7479", "context": "We report the successful treatment of heparin-induced thrombocytopenia and subsequent hemorrhagic complications postoperatively in a 2-year-old child with Danaparoid (orgaran).", "question": "Combination.Drug in Danaparoid (orgaran)", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "18775393_2_7480", "context": "Laryngeal dyspnea in relation to an interaction between acenocoumarol and topical econazole lotion.", "question": "Treatment.Drug in acenocoumarol; topical econazole lotion", "question_type": "Adverse_event.Treatment.Drug", "answers": "acenocoumarol; topical econazole"}, {"id": "18775393_2_7481", "context": "Laryngeal dyspnea in relation to an interaction between acenocoumarol and topical econazole lotion.", "question": "Treatment.Dosage in acenocoumarol; topical econazole lotion", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18775393_2_7482", "context": "Laryngeal dyspnea in relation to an interaction between acenocoumarol and topical econazole lotion.", "question": "Treatment.Freq in acenocoumarol; topical econazole lotion", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18775393_2_7483", "context": "Laryngeal dyspnea in relation to an interaction between acenocoumarol and topical econazole lotion.", "question": "Treatment.Route in acenocoumarol; topical econazole lotion", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18775393_2_7484", "context": "Laryngeal dyspnea in relation to an interaction between acenocoumarol and topical econazole lotion.", "question": "Treatment.Time_elapsed in acenocoumarol; topical econazole lotion", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18775393_2_7485", "context": "Laryngeal dyspnea in relation to an interaction between acenocoumarol and topical econazole lotion.", "question": "Treatment.Duration in acenocoumarol; topical econazole lotion", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18775393_2_7486", "context": "Laryngeal dyspnea in relation to an interaction between acenocoumarol and topical econazole lotion.", "question": "Treatment.Disorder in acenocoumarol; topical econazole lotion", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18775393_2_7487", "context": "Laryngeal dyspnea in relation to an interaction between acenocoumarol and topical econazole lotion.", "question": "Combination.Drug in acenocoumarol; topical econazole lotion", "question_type": "Adverse_event.Combination.Drug", "answers": "acenocoumarol; topical econazole"}, {"id": "24927617_2_7488", "context": "A 46-year old man with a chronic hepatitis C virus infection received triple therapy with ribavirin, pegylated interferon and telaprevir.", "question": "Subject.Age in A 46-year old man with a chronic hepatitis C virus infection", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": "46-year old"}, {"id": "24927617_2_7489", "context": "A 46-year old man with a chronic hepatitis C virus infection received triple therapy with ribavirin, pegylated interferon and telaprevir.", "question": "Subject.Gender in A 46-year old man with a chronic hepatitis C virus infection", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": "man"}, {"id": "24927617_2_7490", "context": "A 46-year old man with a chronic hepatitis C virus infection received triple therapy with ribavirin, pegylated interferon and telaprevir.", "question": "Subject.Population in A 46-year old man with a chronic hepatitis C virus infection", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "24927617_2_7491", "context": "A 46-year old man with a chronic hepatitis C virus infection received triple therapy with ribavirin, pegylated interferon and telaprevir.", "question": "Subject.Race in A 46-year old man with a chronic hepatitis C virus infection", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "24927617_2_7492", "context": "A 46-year old man with a chronic hepatitis C virus infection received triple therapy with ribavirin, pegylated interferon and telaprevir.", "question": "Subject.Disorder in A 46-year old man with a chronic hepatitis C virus infection", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "24927617_2_7493", "context": "A 46-year old man with a chronic hepatitis C virus infection received triple therapy with ribavirin, pegylated interferon and telaprevir.", "question": "Treatment.Drug in triple therapy with ribavirin, pegylated interferon and telaprevir", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "ribavirin; pegylated interferon; telaprevir"}, {"id": "24927617_2_7494", "context": "A 46-year old man with a chronic hepatitis C virus infection received triple therapy with ribavirin, pegylated interferon and telaprevir.", "question": "Treatment.Dosage in triple therapy with ribavirin, pegylated interferon and telaprevir", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "24927617_2_7495", "context": "A 46-year old man with a chronic hepatitis C virus infection received triple therapy with ribavirin, pegylated interferon and telaprevir.", "question": "Treatment.Freq in triple therapy with ribavirin, pegylated interferon and telaprevir", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "24927617_2_7496", "context": "A 46-year old man with a chronic hepatitis C virus infection received triple therapy with ribavirin, pegylated interferon and telaprevir.", "question": "Treatment.Route in triple therapy with ribavirin, pegylated interferon and telaprevir", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "24927617_2_7497", "context": "A 46-year old man with a chronic hepatitis C virus infection received triple therapy with ribavirin, pegylated interferon and telaprevir.", "question": "Treatment.Time_elapsed in triple therapy with ribavirin, pegylated interferon and telaprevir", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "24927617_2_7498", "context": "A 46-year old man with a chronic hepatitis C virus infection received triple therapy with ribavirin, pegylated interferon and telaprevir.", "question": "Treatment.Duration in triple therapy with ribavirin, pegylated interferon and telaprevir", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "24927617_2_7499", "context": "A 46-year old man with a chronic hepatitis C virus infection received triple therapy with ribavirin, pegylated interferon and telaprevir.", "question": "Treatment.Disorder in triple therapy with ribavirin, pegylated interferon and telaprevir", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "a chronic hepatitis C virus infection"}, {"id": "24927617_2_7500", "context": "A 46-year old man with a chronic hepatitis C virus infection received triple therapy with ribavirin, pegylated interferon and telaprevir.", "question": "Combination.Drug in triple therapy with ribavirin, pegylated interferon and telaprevir", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": "ribavirin; pegylated interferon; telaprevir"}, {"id": "17176478_2_7501", "context": "Leishmania infantum leishmaniasis in corticosteroid--treated patients.", "question": "Treatment.Drug in corticosteroid", "question_type": "Adverse_event.Treatment.Drug", "answers": "corticosteroid"}, {"id": "17176478_2_7502", "context": "Leishmania infantum leishmaniasis in corticosteroid--treated patients.", "question": "Treatment.Dosage in corticosteroid", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17176478_2_7503", "context": "Leishmania infantum leishmaniasis in corticosteroid--treated patients.", "question": "Treatment.Freq in corticosteroid", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17176478_2_7504", "context": "Leishmania infantum leishmaniasis in corticosteroid--treated patients.", "question": "Treatment.Route in corticosteroid", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17176478_2_7505", "context": "Leishmania infantum leishmaniasis in corticosteroid--treated patients.", "question": "Treatment.Time_elapsed in corticosteroid", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17176478_2_7506", "context": "Leishmania infantum leishmaniasis in corticosteroid--treated patients.", "question": "Treatment.Duration in corticosteroid", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17176478_2_7507", "context": "Leishmania infantum leishmaniasis in corticosteroid--treated patients.", "question": "Treatment.Disorder in corticosteroid", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17176478_2_7508", "context": "Leishmania infantum leishmaniasis in corticosteroid--treated patients.", "question": "Combination.Drug in corticosteroid", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15028328_3_7509", "context": "The patient developed occipital infarcts and was found to have extremely elevated levels of PPA in his blood and dialysis fluid.", "question": "Subject.Age in The patient", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "15028328_3_7510", "context": "The patient developed occipital infarcts and was found to have extremely elevated levels of PPA in his blood and dialysis fluid.", "question": "Subject.Gender in The patient", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15028328_3_7511", "context": "The patient developed occipital infarcts and was found to have extremely elevated levels of PPA in his blood and dialysis fluid.", "question": "Subject.Population in The patient", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "15028328_3_7512", "context": "The patient developed occipital infarcts and was found to have extremely elevated levels of PPA in his blood and dialysis fluid.", "question": "Subject.Race in The patient", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15028328_3_7513", "context": "The patient developed occipital infarcts and was found to have extremely elevated levels of PPA in his blood and dialysis fluid.", "question": "Subject.Disorder in The patient", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15028328_3_7514", "context": "The patient developed occipital infarcts and was found to have extremely elevated levels of PPA in his blood and dialysis fluid.", "question": "Treatment.Drug in extremely elevated levels of PPA", "question_type": "Adverse_event.Treatment.Drug", "answers": "PPA"}, {"id": "15028328_3_7515", "context": "The patient developed occipital infarcts and was found to have extremely elevated levels of PPA in his blood and dialysis fluid.", "question": "Treatment.Dosage in extremely elevated levels of PPA", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15028328_3_7516", "context": "The patient developed occipital infarcts and was found to have extremely elevated levels of PPA in his blood and dialysis fluid.", "question": "Treatment.Freq in extremely elevated levels of PPA", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15028328_3_7517", "context": "The patient developed occipital infarcts and was found to have extremely elevated levels of PPA in his blood and dialysis fluid.", "question": "Treatment.Route in extremely elevated levels of PPA", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15028328_3_7518", "context": "The patient developed occipital infarcts and was found to have extremely elevated levels of PPA in his blood and dialysis fluid.", "question": "Treatment.Time_elapsed in extremely elevated levels of PPA", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15028328_3_7519", "context": "The patient developed occipital infarcts and was found to have extremely elevated levels of PPA in his blood and dialysis fluid.", "question": "Treatment.Duration in extremely elevated levels of PPA", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15028328_3_7520", "context": "The patient developed occipital infarcts and was found to have extremely elevated levels of PPA in his blood and dialysis fluid.", "question": "Treatment.Disorder in extremely elevated levels of PPA", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15028328_3_7521", "context": "The patient developed occipital infarcts and was found to have extremely elevated levels of PPA in his blood and dialysis fluid.", "question": "Combination.Drug in extremely elevated levels of PPA", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17329303_2_7522", "context": "As atypical antipsychotics are increasingly used in the treatment of childhood behavioural disorders either as monotherapy or in combination with other medications, there is a need to know more about their safety, in particular during switching to and from methylphenidate treatment, as antipsychotics and methylphenidate have opposing effects on dopaminergic neurotransmission.", "question": "Treatment.Drug in atypical antipsychotics; as monotherapy or in combination with other medications", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "atypical antipsychotics"}, {"id": "17329303_2_7523", "context": "As atypical antipsychotics are increasingly used in the treatment of childhood behavioural disorders either as monotherapy or in combination with other medications, there is a need to know more about their safety, in particular during switching to and from methylphenidate treatment, as antipsychotics and methylphenidate have opposing effects on dopaminergic neurotransmission.", "question": "Treatment.Dosage in atypical antipsychotics; as monotherapy or in combination with other medications", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "17329303_2_7524", "context": "As atypical antipsychotics are increasingly used in the treatment of childhood behavioural disorders either as monotherapy or in combination with other medications, there is a need to know more about their safety, in particular during switching to and from methylphenidate treatment, as antipsychotics and methylphenidate have opposing effects on dopaminergic neurotransmission.", "question": "Treatment.Freq in atypical antipsychotics; as monotherapy or in combination with other medications", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "17329303_2_7525", "context": "As atypical antipsychotics are increasingly used in the treatment of childhood behavioural disorders either as monotherapy or in combination with other medications, there is a need to know more about their safety, in particular during switching to and from methylphenidate treatment, as antipsychotics and methylphenidate have opposing effects on dopaminergic neurotransmission.", "question": "Treatment.Route in atypical antipsychotics; as monotherapy or in combination with other medications", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "17329303_2_7526", "context": "As atypical antipsychotics are increasingly used in the treatment of childhood behavioural disorders either as monotherapy or in combination with other medications, there is a need to know more about their safety, in particular during switching to and from methylphenidate treatment, as antipsychotics and methylphenidate have opposing effects on dopaminergic neurotransmission.", "question": "Treatment.Time_elapsed in atypical antipsychotics; as monotherapy or in combination with other medications", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17329303_2_7527", "context": "As atypical antipsychotics are increasingly used in the treatment of childhood behavioural disorders either as monotherapy or in combination with other medications, there is a need to know more about their safety, in particular during switching to and from methylphenidate treatment, as antipsychotics and methylphenidate have opposing effects on dopaminergic neurotransmission.", "question": "Treatment.Duration in atypical antipsychotics; as monotherapy or in combination with other medications", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "17329303_2_7528", "context": "As atypical antipsychotics are increasingly used in the treatment of childhood behavioural disorders either as monotherapy or in combination with other medications, there is a need to know more about their safety, in particular during switching to and from methylphenidate treatment, as antipsychotics and methylphenidate have opposing effects on dopaminergic neurotransmission.", "question": "Treatment.Disorder in atypical antipsychotics; as monotherapy or in combination with other medications", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "childhood behavioural disorders"}, {"id": "17329303_2_7529", "context": "As atypical antipsychotics are increasingly used in the treatment of childhood behavioural disorders either as monotherapy or in combination with other medications, there is a need to know more about their safety, in particular during switching to and from methylphenidate treatment, as antipsychotics and methylphenidate have opposing effects on dopaminergic neurotransmission.", "question": "Combination.Drug in atypical antipsychotics; as monotherapy or in combination with other medications", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "15468380_1_7530", "context": "Sensory neuropathy revealing necrotizing vasculitis during infliximab therapy for rheumatoid arthritis.", "question": "Treatment.Drug in infliximab therapy", "question_type": "Adverse_event.Treatment.Drug", "answers": "infliximab"}, {"id": "15468380_1_7531", "context": "Sensory neuropathy revealing necrotizing vasculitis during infliximab therapy for rheumatoid arthritis.", "question": "Treatment.Dosage in infliximab therapy", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15468380_1_7532", "context": "Sensory neuropathy revealing necrotizing vasculitis during infliximab therapy for rheumatoid arthritis.", "question": "Treatment.Freq in infliximab therapy", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15468380_1_7533", "context": "Sensory neuropathy revealing necrotizing vasculitis during infliximab therapy for rheumatoid arthritis.", "question": "Treatment.Route in infliximab therapy", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15468380_1_7534", "context": "Sensory neuropathy revealing necrotizing vasculitis during infliximab therapy for rheumatoid arthritis.", "question": "Treatment.Time_elapsed in infliximab therapy", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15468380_1_7535", "context": "Sensory neuropathy revealing necrotizing vasculitis during infliximab therapy for rheumatoid arthritis.", "question": "Treatment.Duration in infliximab therapy", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15468380_1_7536", "context": "Sensory neuropathy revealing necrotizing vasculitis during infliximab therapy for rheumatoid arthritis.", "question": "Treatment.Disorder in infliximab therapy", "question_type": "Adverse_event.Treatment.Disorder", "answers": "rheumatoid arthritis"}, {"id": "15468380_1_7537", "context": "Sensory neuropathy revealing necrotizing vasculitis during infliximab therapy for rheumatoid arthritis.", "question": "Combination.Drug in infliximab therapy", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17710018_2_7538", "context": "Because etoposide-induced pulmonary toxicity is an uncommon but serious adverse event, clinicians must be vigilant about the possibility of it, so that the optimal treatment can start as soon as possible.", "question": "Treatment.Drug in etoposide", "question_type": "Adverse_event.Treatment.Drug", "answers": "etoposide"}, {"id": "17710018_2_7539", "context": "Because etoposide-induced pulmonary toxicity is an uncommon but serious adverse event, clinicians must be vigilant about the possibility of it, so that the optimal treatment can start as soon as possible.", "question": "Treatment.Dosage in etoposide", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17710018_2_7540", "context": "Because etoposide-induced pulmonary toxicity is an uncommon but serious adverse event, clinicians must be vigilant about the possibility of it, so that the optimal treatment can start as soon as possible.", "question": "Treatment.Freq in etoposide", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17710018_2_7541", "context": "Because etoposide-induced pulmonary toxicity is an uncommon but serious adverse event, clinicians must be vigilant about the possibility of it, so that the optimal treatment can start as soon as possible.", "question": "Treatment.Route in etoposide", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17710018_2_7542", "context": "Because etoposide-induced pulmonary toxicity is an uncommon but serious adverse event, clinicians must be vigilant about the possibility of it, so that the optimal treatment can start as soon as possible.", "question": "Treatment.Time_elapsed in etoposide", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17710018_2_7543", "context": "Because etoposide-induced pulmonary toxicity is an uncommon but serious adverse event, clinicians must be vigilant about the possibility of it, so that the optimal treatment can start as soon as possible.", "question": "Treatment.Duration in etoposide", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17710018_2_7544", "context": "Because etoposide-induced pulmonary toxicity is an uncommon but serious adverse event, clinicians must be vigilant about the possibility of it, so that the optimal treatment can start as soon as possible.", "question": "Treatment.Disorder in etoposide", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17710018_2_7545", "context": "Because etoposide-induced pulmonary toxicity is an uncommon but serious adverse event, clinicians must be vigilant about the possibility of it, so that the optimal treatment can start as soon as possible.", "question": "Combination.Drug in etoposide", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17959575_12_7546", "context": "On March 13 the patient was again admitted for worsening CHF and was started on continuous dobutamine infusion.", "question": "Subject.Age in the patient was again admitted for worsening CHF", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "17959575_12_7547", "context": "On March 13 the patient was again admitted for worsening CHF and was started on continuous dobutamine infusion.", "question": "Subject.Gender in the patient was again admitted for worsening CHF", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "17959575_12_7548", "context": "On March 13 the patient was again admitted for worsening CHF and was started on continuous dobutamine infusion.", "question": "Subject.Population in the patient was again admitted for worsening CHF", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "17959575_12_7549", "context": "On March 13 the patient was again admitted for worsening CHF and was started on continuous dobutamine infusion.", "question": "Subject.Race in the patient was again admitted for worsening CHF", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "17959575_12_7550", "context": "On March 13 the patient was again admitted for worsening CHF and was started on continuous dobutamine infusion.", "question": "Subject.Disorder in the patient was again admitted for worsening CHF", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "17959575_12_7551", "context": "On March 13 the patient was again admitted for worsening CHF and was started on continuous dobutamine infusion.", "question": "Treatment.Drug in continuous dobutamine infusion", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "dobutamine"}, {"id": "17959575_12_7552", "context": "On March 13 the patient was again admitted for worsening CHF and was started on continuous dobutamine infusion.", "question": "Treatment.Dosage in continuous dobutamine infusion", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "17959575_12_7553", "context": "On March 13 the patient was again admitted for worsening CHF and was started on continuous dobutamine infusion.", "question": "Treatment.Freq in continuous dobutamine infusion", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": "continuous"}, {"id": "17959575_12_7554", "context": "On March 13 the patient was again admitted for worsening CHF and was started on continuous dobutamine infusion.", "question": "Treatment.Route in continuous dobutamine infusion", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": "infusion"}, {"id": "17959575_12_7555", "context": "On March 13 the patient was again admitted for worsening CHF and was started on continuous dobutamine infusion.", "question": "Treatment.Time_elapsed in continuous dobutamine infusion", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17959575_12_7556", "context": "On March 13 the patient was again admitted for worsening CHF and was started on continuous dobutamine infusion.", "question": "Treatment.Duration in continuous dobutamine infusion", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "17959575_12_7557", "context": "On March 13 the patient was again admitted for worsening CHF and was started on continuous dobutamine infusion.", "question": "Treatment.Disorder in continuous dobutamine infusion", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "17959575_12_7558", "context": "On March 13 the patient was again admitted for worsening CHF and was started on continuous dobutamine infusion.", "question": "Combination.Drug in continuous dobutamine infusion", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "22550162_1_7559", "context": "Suspected methotrexate toxicity from omeprazole: a case review of carboxypeptidase G2 use in a methotrexate-experienced patient with methotrexate toxicity and a review of the literature.", "question": "Treatment.Drug in omeprazole", "question_type": "Adverse_event.Treatment.Drug", "answers": "omeprazole"}, {"id": "22550162_1_7560", "context": "Suspected methotrexate toxicity from omeprazole: a case review of carboxypeptidase G2 use in a methotrexate-experienced patient with methotrexate toxicity and a review of the literature.", "question": "Treatment.Dosage in omeprazole", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "22550162_1_7561", "context": "Suspected methotrexate toxicity from omeprazole: a case review of carboxypeptidase G2 use in a methotrexate-experienced patient with methotrexate toxicity and a review of the literature.", "question": "Treatment.Freq in omeprazole", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "22550162_1_7562", "context": "Suspected methotrexate toxicity from omeprazole: a case review of carboxypeptidase G2 use in a methotrexate-experienced patient with methotrexate toxicity and a review of the literature.", "question": "Treatment.Route in omeprazole", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "22550162_1_7563", "context": "Suspected methotrexate toxicity from omeprazole: a case review of carboxypeptidase G2 use in a methotrexate-experienced patient with methotrexate toxicity and a review of the literature.", "question": "Treatment.Time_elapsed in omeprazole", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "22550162_1_7564", "context": "Suspected methotrexate toxicity from omeprazole: a case review of carboxypeptidase G2 use in a methotrexate-experienced patient with methotrexate toxicity and a review of the literature.", "question": "Treatment.Duration in omeprazole", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "22550162_1_7565", "context": "Suspected methotrexate toxicity from omeprazole: a case review of carboxypeptidase G2 use in a methotrexate-experienced patient with methotrexate toxicity and a review of the literature.", "question": "Treatment.Disorder in omeprazole", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "22550162_1_7566", "context": "Suspected methotrexate toxicity from omeprazole: a case review of carboxypeptidase G2 use in a methotrexate-experienced patient with methotrexate toxicity and a review of the literature.", "question": "Combination.Drug in omeprazole", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "22550162_1_7567", "context": "Suspected methotrexate toxicity from omeprazole: a case review of carboxypeptidase G2 use in a methotrexate-experienced patient with methotrexate toxicity and a review of the literature.", "question": "Subject.Age in methotrexate-experienced patient", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "22550162_1_7568", "context": "Suspected methotrexate toxicity from omeprazole: a case review of carboxypeptidase G2 use in a methotrexate-experienced patient with methotrexate toxicity and a review of the literature.", "question": "Subject.Gender in methotrexate-experienced patient", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "22550162_1_7569", "context": "Suspected methotrexate toxicity from omeprazole: a case review of carboxypeptidase G2 use in a methotrexate-experienced patient with methotrexate toxicity and a review of the literature.", "question": "Subject.Population in methotrexate-experienced patient", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "22550162_1_7570", "context": "Suspected methotrexate toxicity from omeprazole: a case review of carboxypeptidase G2 use in a methotrexate-experienced patient with methotrexate toxicity and a review of the literature.", "question": "Subject.Race in methotrexate-experienced patient", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "22550162_1_7571", "context": "Suspected methotrexate toxicity from omeprazole: a case review of carboxypeptidase G2 use in a methotrexate-experienced patient with methotrexate toxicity and a review of the literature.", "question": "Subject.Disorder in methotrexate-experienced patient", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "22550162_1_7572", "context": "Suspected methotrexate toxicity from omeprazole: a case review of carboxypeptidase G2 use in a methotrexate-experienced patient with methotrexate toxicity and a review of the literature.", "question": "Treatment.Drug in carboxypeptidase G2", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "carboxypeptidase G2"}, {"id": "22550162_1_7573", "context": "Suspected methotrexate toxicity from omeprazole: a case review of carboxypeptidase G2 use in a methotrexate-experienced patient with methotrexate toxicity and a review of the literature.", "question": "Treatment.Dosage in carboxypeptidase G2", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "22550162_1_7574", "context": "Suspected methotrexate toxicity from omeprazole: a case review of carboxypeptidase G2 use in a methotrexate-experienced patient with methotrexate toxicity and a review of the literature.", "question": "Treatment.Freq in carboxypeptidase G2", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "22550162_1_7575", "context": "Suspected methotrexate toxicity from omeprazole: a case review of carboxypeptidase G2 use in a methotrexate-experienced patient with methotrexate toxicity and a review of the literature.", "question": "Treatment.Route in carboxypeptidase G2", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "22550162_1_7576", "context": "Suspected methotrexate toxicity from omeprazole: a case review of carboxypeptidase G2 use in a methotrexate-experienced patient with methotrexate toxicity and a review of the literature.", "question": "Treatment.Time_elapsed in carboxypeptidase G2", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "22550162_1_7577", "context": "Suspected methotrexate toxicity from omeprazole: a case review of carboxypeptidase G2 use in a methotrexate-experienced patient with methotrexate toxicity and a review of the literature.", "question": "Treatment.Duration in carboxypeptidase G2", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "22550162_1_7578", "context": "Suspected methotrexate toxicity from omeprazole: a case review of carboxypeptidase G2 use in a methotrexate-experienced patient with methotrexate toxicity and a review of the literature.", "question": "Treatment.Disorder in carboxypeptidase G2", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "methotrexate toxicity"}, {"id": "22550162_1_7579", "context": "Suspected methotrexate toxicity from omeprazole: a case review of carboxypeptidase G2 use in a methotrexate-experienced patient with methotrexate toxicity and a review of the literature.", "question": "Combination.Drug in carboxypeptidase G2", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "22550162_1_7580", "context": "Suspected methotrexate toxicity from omeprazole: a case review of carboxypeptidase G2 use in a methotrexate-experienced patient with methotrexate toxicity and a review of the literature.", "question": "Treatment.Drug in methotrexate", "question_type": "Adverse_event.Treatment.Drug", "answers": "methotrexate"}, {"id": "22550162_1_7581", "context": "Suspected methotrexate toxicity from omeprazole: a case review of carboxypeptidase G2 use in a methotrexate-experienced patient with methotrexate toxicity and a review of the literature.", "question": "Treatment.Dosage in methotrexate", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "22550162_1_7582", "context": "Suspected methotrexate toxicity from omeprazole: a case review of carboxypeptidase G2 use in a methotrexate-experienced patient with methotrexate toxicity and a review of the literature.", "question": "Treatment.Freq in methotrexate", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "22550162_1_7583", "context": "Suspected methotrexate toxicity from omeprazole: a case review of carboxypeptidase G2 use in a methotrexate-experienced patient with methotrexate toxicity and a review of the literature.", "question": "Treatment.Route in methotrexate", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "22550162_1_7584", "context": "Suspected methotrexate toxicity from omeprazole: a case review of carboxypeptidase G2 use in a methotrexate-experienced patient with methotrexate toxicity and a review of the literature.", "question": "Treatment.Time_elapsed in methotrexate", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "22550162_1_7585", "context": "Suspected methotrexate toxicity from omeprazole: a case review of carboxypeptidase G2 use in a methotrexate-experienced patient with methotrexate toxicity and a review of the literature.", "question": "Treatment.Duration in methotrexate", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "22550162_1_7586", "context": "Suspected methotrexate toxicity from omeprazole: a case review of carboxypeptidase G2 use in a methotrexate-experienced patient with methotrexate toxicity and a review of the literature.", "question": "Treatment.Disorder in methotrexate", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "22550162_1_7587", "context": "Suspected methotrexate toxicity from omeprazole: a case review of carboxypeptidase G2 use in a methotrexate-experienced patient with methotrexate toxicity and a review of the literature.", "question": "Combination.Drug in methotrexate", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16688722_2_7588", "context": "We report a 53-year-old-man who developed rippling muscle disease (RMD) 2 months after starting simvastatin therapy for hypercholesterolemia.", "question": "Subject.Age in a 53-year-old-man", "question_type": "Adverse_event.Subject.Age", "answers": "53-year-old"}, {"id": "16688722_2_7589", "context": "We report a 53-year-old-man who developed rippling muscle disease (RMD) 2 months after starting simvastatin therapy for hypercholesterolemia.", "question": "Subject.Gender in a 53-year-old-man", "question_type": "Adverse_event.Subject.Gender", "answers": "man"}, {"id": "16688722_2_7590", "context": "We report a 53-year-old-man who developed rippling muscle disease (RMD) 2 months after starting simvastatin therapy for hypercholesterolemia.", "question": "Subject.Population in a 53-year-old-man", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "16688722_2_7591", "context": "We report a 53-year-old-man who developed rippling muscle disease (RMD) 2 months after starting simvastatin therapy for hypercholesterolemia.", "question": "Subject.Race in a 53-year-old-man", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16688722_2_7592", "context": "We report a 53-year-old-man who developed rippling muscle disease (RMD) 2 months after starting simvastatin therapy for hypercholesterolemia.", "question": "Subject.Disorder in a 53-year-old-man", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "16688722_2_7593", "context": "We report a 53-year-old-man who developed rippling muscle disease (RMD) 2 months after starting simvastatin therapy for hypercholesterolemia.", "question": "Treatment.Drug in 2 months after starting simvastatin therapy", "question_type": "Adverse_event.Treatment.Drug", "answers": "simvastatin"}, {"id": "16688722_2_7594", "context": "We report a 53-year-old-man who developed rippling muscle disease (RMD) 2 months after starting simvastatin therapy for hypercholesterolemia.", "question": "Treatment.Dosage in 2 months after starting simvastatin therapy", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16688722_2_7595", "context": "We report a 53-year-old-man who developed rippling muscle disease (RMD) 2 months after starting simvastatin therapy for hypercholesterolemia.", "question": "Treatment.Freq in 2 months after starting simvastatin therapy", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16688722_2_7596", "context": "We report a 53-year-old-man who developed rippling muscle disease (RMD) 2 months after starting simvastatin therapy for hypercholesterolemia.", "question": "Treatment.Route in 2 months after starting simvastatin therapy", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16688722_2_7597", "context": "We report a 53-year-old-man who developed rippling muscle disease (RMD) 2 months after starting simvastatin therapy for hypercholesterolemia.", "question": "Treatment.Time_elapsed in 2 months after starting simvastatin therapy", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "2 months"}, {"id": "16688722_2_7598", "context": "We report a 53-year-old-man who developed rippling muscle disease (RMD) 2 months after starting simvastatin therapy for hypercholesterolemia.", "question": "Treatment.Duration in 2 months after starting simvastatin therapy", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16688722_2_7599", "context": "We report a 53-year-old-man who developed rippling muscle disease (RMD) 2 months after starting simvastatin therapy for hypercholesterolemia.", "question": "Treatment.Disorder in 2 months after starting simvastatin therapy", "question_type": "Adverse_event.Treatment.Disorder", "answers": "hypercholesterolemia"}, {"id": "16688722_2_7600", "context": "We report a 53-year-old-man who developed rippling muscle disease (RMD) 2 months after starting simvastatin therapy for hypercholesterolemia.", "question": "Combination.Drug in 2 months after starting simvastatin therapy", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6597713_1_7601", "context": "After taking cholestyramine II sachets twice daily for two months she presented with lethargy, confusion and drowsiness.", "question": "Subject.Age in she", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "6597713_1_7602", "context": "After taking cholestyramine II sachets twice daily for two months she presented with lethargy, confusion and drowsiness.", "question": "Subject.Gender in she", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "6597713_1_7603", "context": "After taking cholestyramine II sachets twice daily for two months she presented with lethargy, confusion and drowsiness.", "question": "Subject.Population in she", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "6597713_1_7604", "context": "After taking cholestyramine II sachets twice daily for two months she presented with lethargy, confusion and drowsiness.", "question": "Subject.Race in she", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "6597713_1_7605", "context": "After taking cholestyramine II sachets twice daily for two months she presented with lethargy, confusion and drowsiness.", "question": "Subject.Disorder in she", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "6597713_1_7606", "context": "After taking cholestyramine II sachets twice daily for two months she presented with lethargy, confusion and drowsiness.", "question": "Treatment.Drug in cholestyramine II sachets twice daily for two months", "question_type": "Adverse_event.Treatment.Drug", "answers": "cholestyramine II"}, {"id": "6597713_1_7607", "context": "After taking cholestyramine II sachets twice daily for two months she presented with lethargy, confusion and drowsiness.", "question": "Treatment.Dosage in cholestyramine II sachets twice daily for two months", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6597713_1_7608", "context": "After taking cholestyramine II sachets twice daily for two months she presented with lethargy, confusion and drowsiness.", "question": "Treatment.Freq in cholestyramine II sachets twice daily for two months", "question_type": "Adverse_event.Treatment.Freq", "answers": "twice daily"}, {"id": "6597713_1_7609", "context": "After taking cholestyramine II sachets twice daily for two months she presented with lethargy, confusion and drowsiness.", "question": "Treatment.Route in cholestyramine II sachets twice daily for two months", "question_type": "Adverse_event.Treatment.Route", "answers": "sachets"}, {"id": "6597713_1_7610", "context": "After taking cholestyramine II sachets twice daily for two months she presented with lethargy, confusion and drowsiness.", "question": "Treatment.Time_elapsed in cholestyramine II sachets twice daily for two months", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6597713_1_7611", "context": "After taking cholestyramine II sachets twice daily for two months she presented with lethargy, confusion and drowsiness.", "question": "Treatment.Duration in cholestyramine II sachets twice daily for two months", "question_type": "Adverse_event.Treatment.Duration", "answers": "two months"}, {"id": "6597713_1_7612", "context": "After taking cholestyramine II sachets twice daily for two months she presented with lethargy, confusion and drowsiness.", "question": "Treatment.Disorder in cholestyramine II sachets twice daily for two months", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6597713_1_7613", "context": "After taking cholestyramine II sachets twice daily for two months she presented with lethargy, confusion and drowsiness.", "question": "Combination.Drug in cholestyramine II sachets twice daily for two months", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "2429270_2_7614", "context": "Escape atrial complexes, which occurred following junctional premature complexes, failed to initiate tachycardia in the control state but tachycardia was always reinitiated by an identical escape sequence after procainamide.", "question": "Treatment.Drug in procainamide", "question_type": "Adverse_event.Treatment.Drug", "answers": "procainamide"}, {"id": "2429270_2_7615", "context": "Escape atrial complexes, which occurred following junctional premature complexes, failed to initiate tachycardia in the control state but tachycardia was always reinitiated by an identical escape sequence after procainamide.", "question": "Treatment.Dosage in procainamide", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "2429270_2_7616", "context": "Escape atrial complexes, which occurred following junctional premature complexes, failed to initiate tachycardia in the control state but tachycardia was always reinitiated by an identical escape sequence after procainamide.", "question": "Treatment.Freq in procainamide", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2429270_2_7617", "context": "Escape atrial complexes, which occurred following junctional premature complexes, failed to initiate tachycardia in the control state but tachycardia was always reinitiated by an identical escape sequence after procainamide.", "question": "Treatment.Route in procainamide", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "2429270_2_7618", "context": "Escape atrial complexes, which occurred following junctional premature complexes, failed to initiate tachycardia in the control state but tachycardia was always reinitiated by an identical escape sequence after procainamide.", "question": "Treatment.Time_elapsed in procainamide", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2429270_2_7619", "context": "Escape atrial complexes, which occurred following junctional premature complexes, failed to initiate tachycardia in the control state but tachycardia was always reinitiated by an identical escape sequence after procainamide.", "question": "Treatment.Duration in procainamide", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2429270_2_7620", "context": "Escape atrial complexes, which occurred following junctional premature complexes, failed to initiate tachycardia in the control state but tachycardia was always reinitiated by an identical escape sequence after procainamide.", "question": "Treatment.Disorder in procainamide", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "2429270_2_7621", "context": "Escape atrial complexes, which occurred following junctional premature complexes, failed to initiate tachycardia in the control state but tachycardia was always reinitiated by an identical escape sequence after procainamide.", "question": "Combination.Drug in procainamide", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12149193_2_7622", "context": "Ten percent of newly diagnosed myeloma patients treated with any type of chemotherapy develop deep venous thrombosis (DVT).", "question": "Subject.Age in myeloma patients", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "12149193_2_7623", "context": "Ten percent of newly diagnosed myeloma patients treated with any type of chemotherapy develop deep venous thrombosis (DVT).", "question": "Subject.Gender in myeloma patients", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "12149193_2_7624", "context": "Ten percent of newly diagnosed myeloma patients treated with any type of chemotherapy develop deep venous thrombosis (DVT).", "question": "Subject.Population in myeloma patients", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "12149193_2_7625", "context": "Ten percent of newly diagnosed myeloma patients treated with any type of chemotherapy develop deep venous thrombosis (DVT).", "question": "Subject.Race in myeloma patients", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "12149193_2_7626", "context": "Ten percent of newly diagnosed myeloma patients treated with any type of chemotherapy develop deep venous thrombosis (DVT).", "question": "Subject.Disorder in myeloma patients", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "12149193_2_7627", "context": "Ten percent of newly diagnosed myeloma patients treated with any type of chemotherapy develop deep venous thrombosis (DVT).", "question": "Treatment.Drug in any type of chemotherapy", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "12149193_2_7628", "context": "Ten percent of newly diagnosed myeloma patients treated with any type of chemotherapy develop deep venous thrombosis (DVT).", "question": "Treatment.Dosage in any type of chemotherapy", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12149193_2_7629", "context": "Ten percent of newly diagnosed myeloma patients treated with any type of chemotherapy develop deep venous thrombosis (DVT).", "question": "Treatment.Freq in any type of chemotherapy", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12149193_2_7630", "context": "Ten percent of newly diagnosed myeloma patients treated with any type of chemotherapy develop deep venous thrombosis (DVT).", "question": "Treatment.Route in any type of chemotherapy", "question_type": "Adverse_event.Treatment.Route", "answers": "chemotherapy"}, {"id": "12149193_2_7631", "context": "Ten percent of newly diagnosed myeloma patients treated with any type of chemotherapy develop deep venous thrombosis (DVT).", "question": "Treatment.Time_elapsed in any type of chemotherapy", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12149193_2_7632", "context": "Ten percent of newly diagnosed myeloma patients treated with any type of chemotherapy develop deep venous thrombosis (DVT).", "question": "Treatment.Duration in any type of chemotherapy", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12149193_2_7633", "context": "Ten percent of newly diagnosed myeloma patients treated with any type of chemotherapy develop deep venous thrombosis (DVT).", "question": "Treatment.Disorder in any type of chemotherapy", "question_type": "Adverse_event.Treatment.Disorder", "answers": "myeloma"}, {"id": "12149193_2_7634", "context": "Ten percent of newly diagnosed myeloma patients treated with any type of chemotherapy develop deep venous thrombosis (DVT).", "question": "Combination.Drug in any type of chemotherapy", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12399645_3_7635", "context": "In summary, we report herein the first case of SIADH believed to be an adverse effect of mizoribin, which may therefore needed to be added to the list of drugs which can induce SIADH.", "question": "Subject.Age in the first case", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "12399645_3_7636", "context": "In summary, we report herein the first case of SIADH believed to be an adverse effect of mizoribin, which may therefore needed to be added to the list of drugs which can induce SIADH.", "question": "Subject.Gender in the first case", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "12399645_3_7637", "context": "In summary, we report herein the first case of SIADH believed to be an adverse effect of mizoribin, which may therefore needed to be added to the list of drugs which can induce SIADH.", "question": "Subject.Population in the first case", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "12399645_3_7638", "context": "In summary, we report herein the first case of SIADH believed to be an adverse effect of mizoribin, which may therefore needed to be added to the list of drugs which can induce SIADH.", "question": "Subject.Race in the first case", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "12399645_3_7639", "context": "In summary, we report herein the first case of SIADH believed to be an adverse effect of mizoribin, which may therefore needed to be added to the list of drugs which can induce SIADH.", "question": "Subject.Disorder in the first case", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "12399645_3_7640", "context": "In summary, we report herein the first case of SIADH believed to be an adverse effect of mizoribin, which may therefore needed to be added to the list of drugs which can induce SIADH.", "question": "Treatment.Drug in mizoribin", "question_type": "Adverse_event.Treatment.Drug", "answers": "mizoribin"}, {"id": "12399645_3_7641", "context": "In summary, we report herein the first case of SIADH believed to be an adverse effect of mizoribin, which may therefore needed to be added to the list of drugs which can induce SIADH.", "question": "Treatment.Dosage in mizoribin", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12399645_3_7642", "context": "In summary, we report herein the first case of SIADH believed to be an adverse effect of mizoribin, which may therefore needed to be added to the list of drugs which can induce SIADH.", "question": "Treatment.Freq in mizoribin", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12399645_3_7643", "context": "In summary, we report herein the first case of SIADH believed to be an adverse effect of mizoribin, which may therefore needed to be added to the list of drugs which can induce SIADH.", "question": "Treatment.Route in mizoribin", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12399645_3_7644", "context": "In summary, we report herein the first case of SIADH believed to be an adverse effect of mizoribin, which may therefore needed to be added to the list of drugs which can induce SIADH.", "question": "Treatment.Time_elapsed in mizoribin", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12399645_3_7645", "context": "In summary, we report herein the first case of SIADH believed to be an adverse effect of mizoribin, which may therefore needed to be added to the list of drugs which can induce SIADH.", "question": "Treatment.Duration in mizoribin", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12399645_3_7646", "context": "In summary, we report herein the first case of SIADH believed to be an adverse effect of mizoribin, which may therefore needed to be added to the list of drugs which can induce SIADH.", "question": "Treatment.Disorder in mizoribin", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12399645_3_7647", "context": "In summary, we report herein the first case of SIADH believed to be an adverse effect of mizoribin, which may therefore needed to be added to the list of drugs which can induce SIADH.", "question": "Combination.Drug in mizoribin", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3115809_3_7648", "context": "Isoniazid and ethambutol as a cause of optic neuropathy.", "question": "Treatment.Drug in Isoniazid and ethambutol", "question_type": "Adverse_event.Treatment.Drug", "answers": "Isoniazid; ethambutol"}, {"id": "3115809_3_7649", "context": "Isoniazid and ethambutol as a cause of optic neuropathy.", "question": "Treatment.Dosage in Isoniazid and ethambutol", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3115809_3_7650", "context": "Isoniazid and ethambutol as a cause of optic neuropathy.", "question": "Treatment.Freq in Isoniazid and ethambutol", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3115809_3_7651", "context": "Isoniazid and ethambutol as a cause of optic neuropathy.", "question": "Treatment.Route in Isoniazid and ethambutol", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3115809_3_7652", "context": "Isoniazid and ethambutol as a cause of optic neuropathy.", "question": "Treatment.Time_elapsed in Isoniazid and ethambutol", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3115809_3_7653", "context": "Isoniazid and ethambutol as a cause of optic neuropathy.", "question": "Treatment.Duration in Isoniazid and ethambutol", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3115809_3_7654", "context": "Isoniazid and ethambutol as a cause of optic neuropathy.", "question": "Treatment.Disorder in Isoniazid and ethambutol", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3115809_3_7655", "context": "Isoniazid and ethambutol as a cause of optic neuropathy.", "question": "Combination.Drug in Isoniazid and ethambutol", "question_type": "Adverse_event.Combination.Drug", "answers": "Isoniazid; ethambutol"}, {"id": "12452753_3_7656", "context": "Fluorouracil for allergic reactions to capecitabine.", "question": "Treatment.Drug in capecitabine", "question_type": "Adverse_event.Treatment.Drug", "answers": "capecitabine"}, {"id": "12452753_3_7657", "context": "Fluorouracil for allergic reactions to capecitabine.", "question": "Treatment.Dosage in capecitabine", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12452753_3_7658", "context": "Fluorouracil for allergic reactions to capecitabine.", "question": "Treatment.Freq in capecitabine", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12452753_3_7659", "context": "Fluorouracil for allergic reactions to capecitabine.", "question": "Treatment.Route in capecitabine", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12452753_3_7660", "context": "Fluorouracil for allergic reactions to capecitabine.", "question": "Treatment.Time_elapsed in capecitabine", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12452753_3_7661", "context": "Fluorouracil for allergic reactions to capecitabine.", "question": "Treatment.Duration in capecitabine", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12452753_3_7662", "context": "Fluorouracil for allergic reactions to capecitabine.", "question": "Treatment.Disorder in capecitabine", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12452753_3_7663", "context": "Fluorouracil for allergic reactions to capecitabine.", "question": "Combination.Drug in capecitabine", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12452753_3_7664", "context": "Fluorouracil for allergic reactions to capecitabine.", "question": "Treatment.Drug in Fluorouracil", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "Fluorouracil"}, {"id": "12452753_3_7665", "context": "Fluorouracil for allergic reactions to capecitabine.", "question": "Treatment.Dosage in Fluorouracil", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "12452753_3_7666", "context": "Fluorouracil for allergic reactions to capecitabine.", "question": "Treatment.Freq in Fluorouracil", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "12452753_3_7667", "context": "Fluorouracil for allergic reactions to capecitabine.", "question": "Treatment.Route in Fluorouracil", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "12452753_3_7668", "context": "Fluorouracil for allergic reactions to capecitabine.", "question": "Treatment.Time_elapsed in Fluorouracil", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12452753_3_7669", "context": "Fluorouracil for allergic reactions to capecitabine.", "question": "Treatment.Duration in Fluorouracil", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "12452753_3_7670", "context": "Fluorouracil for allergic reactions to capecitabine.", "question": "Treatment.Disorder in Fluorouracil", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "allergic reactions to capecitabine"}, {"id": "12452753_3_7671", "context": "Fluorouracil for allergic reactions to capecitabine.", "question": "Combination.Drug in Fluorouracil", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "4018433_2_7672", "context": "Administration of pyridoxine to an infant after a long period of convulsions was followed by acute hypotonia.", "question": "Subject.Age in an infant", "question_type": "Adverse_event.Subject.Age", "answers": "infant"}, {"id": "4018433_2_7673", "context": "Administration of pyridoxine to an infant after a long period of convulsions was followed by acute hypotonia.", "question": "Subject.Gender in an infant", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "4018433_2_7674", "context": "Administration of pyridoxine to an infant after a long period of convulsions was followed by acute hypotonia.", "question": "Subject.Population in an infant", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "4018433_2_7675", "context": "Administration of pyridoxine to an infant after a long period of convulsions was followed by acute hypotonia.", "question": "Subject.Race in an infant", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "4018433_2_7676", "context": "Administration of pyridoxine to an infant after a long period of convulsions was followed by acute hypotonia.", "question": "Subject.Disorder in an infant", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "4018433_2_7677", "context": "Administration of pyridoxine to an infant after a long period of convulsions was followed by acute hypotonia.", "question": "Treatment.Drug in pyridoxine", "question_type": "Adverse_event.Treatment.Drug", "answers": "pyridoxine"}, {"id": "4018433_2_7678", "context": "Administration of pyridoxine to an infant after a long period of convulsions was followed by acute hypotonia.", "question": "Treatment.Dosage in pyridoxine", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "4018433_2_7679", "context": "Administration of pyridoxine to an infant after a long period of convulsions was followed by acute hypotonia.", "question": "Treatment.Freq in pyridoxine", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "4018433_2_7680", "context": "Administration of pyridoxine to an infant after a long period of convulsions was followed by acute hypotonia.", "question": "Treatment.Route in pyridoxine", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "4018433_2_7681", "context": "Administration of pyridoxine to an infant after a long period of convulsions was followed by acute hypotonia.", "question": "Treatment.Time_elapsed in pyridoxine", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "4018433_2_7682", "context": "Administration of pyridoxine to an infant after a long period of convulsions was followed by acute hypotonia.", "question": "Treatment.Duration in pyridoxine", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "4018433_2_7683", "context": "Administration of pyridoxine to an infant after a long period of convulsions was followed by acute hypotonia.", "question": "Treatment.Disorder in pyridoxine", "question_type": "Adverse_event.Treatment.Disorder", "answers": "convulsions"}, {"id": "4018433_2_7684", "context": "Administration of pyridoxine to an infant after a long period of convulsions was followed by acute hypotonia.", "question": "Combination.Drug in pyridoxine", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11059196_1_7685", "context": "Acute pancreatitis in a child with idiopathic ulcerative colitis on long-term 5-aminosalicylic acid therapy.", "question": "Subject.Age in a child with idiopathic ulcerative colitis", "question_type": "Adverse_event.Subject.Age", "answers": "child"}, {"id": "11059196_1_7686", "context": "Acute pancreatitis in a child with idiopathic ulcerative colitis on long-term 5-aminosalicylic acid therapy.", "question": "Subject.Gender in a child with idiopathic ulcerative colitis", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "11059196_1_7687", "context": "Acute pancreatitis in a child with idiopathic ulcerative colitis on long-term 5-aminosalicylic acid therapy.", "question": "Subject.Population in a child with idiopathic ulcerative colitis", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "11059196_1_7688", "context": "Acute pancreatitis in a child with idiopathic ulcerative colitis on long-term 5-aminosalicylic acid therapy.", "question": "Subject.Race in a child with idiopathic ulcerative colitis", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "11059196_1_7689", "context": "Acute pancreatitis in a child with idiopathic ulcerative colitis on long-term 5-aminosalicylic acid therapy.", "question": "Subject.Disorder in a child with idiopathic ulcerative colitis", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "11059196_1_7690", "context": "Acute pancreatitis in a child with idiopathic ulcerative colitis on long-term 5-aminosalicylic acid therapy.", "question": "Treatment.Drug in long-term 5-aminosalicylic acid therapy", "question_type": "Adverse_event.Treatment.Drug", "answers": "5-aminosalicylic acid"}, {"id": "11059196_1_7691", "context": "Acute pancreatitis in a child with idiopathic ulcerative colitis on long-term 5-aminosalicylic acid therapy.", "question": "Treatment.Dosage in long-term 5-aminosalicylic acid therapy", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11059196_1_7692", "context": "Acute pancreatitis in a child with idiopathic ulcerative colitis on long-term 5-aminosalicylic acid therapy.", "question": "Treatment.Freq in long-term 5-aminosalicylic acid therapy", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11059196_1_7693", "context": "Acute pancreatitis in a child with idiopathic ulcerative colitis on long-term 5-aminosalicylic acid therapy.", "question": "Treatment.Route in long-term 5-aminosalicylic acid therapy", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11059196_1_7694", "context": "Acute pancreatitis in a child with idiopathic ulcerative colitis on long-term 5-aminosalicylic acid therapy.", "question": "Treatment.Time_elapsed in long-term 5-aminosalicylic acid therapy", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11059196_1_7695", "context": "Acute pancreatitis in a child with idiopathic ulcerative colitis on long-term 5-aminosalicylic acid therapy.", "question": "Treatment.Duration in long-term 5-aminosalicylic acid therapy", "question_type": "Adverse_event.Treatment.Duration", "answers": "long-term"}, {"id": "11059196_1_7696", "context": "Acute pancreatitis in a child with idiopathic ulcerative colitis on long-term 5-aminosalicylic acid therapy.", "question": "Treatment.Disorder in long-term 5-aminosalicylic acid therapy", "question_type": "Adverse_event.Treatment.Disorder", "answers": "idiopathic ulcerative colitis"}, {"id": "11059196_1_7697", "context": "Acute pancreatitis in a child with idiopathic ulcerative colitis on long-term 5-aminosalicylic acid therapy.", "question": "Combination.Drug in long-term 5-aminosalicylic acid therapy", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11597289_2_7698", "context": "High-dose antithrombin III in severe sepsis: a randomized controlled trial.", "question": "Treatment.Drug in High-dose antithrombin III", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "antithrombin III"}, {"id": "11597289_2_7699", "context": "High-dose antithrombin III in severe sepsis: a randomized controlled trial.", "question": "Treatment.Dosage in High-dose antithrombin III", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": "High-dose"}, {"id": "11597289_2_7700", "context": "High-dose antithrombin III in severe sepsis: a randomized controlled trial.", "question": "Treatment.Freq in High-dose antithrombin III", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "11597289_2_7701", "context": "High-dose antithrombin III in severe sepsis: a randomized controlled trial.", "question": "Treatment.Route in High-dose antithrombin III", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "11597289_2_7702", "context": "High-dose antithrombin III in severe sepsis: a randomized controlled trial.", "question": "Treatment.Time_elapsed in High-dose antithrombin III", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11597289_2_7703", "context": "High-dose antithrombin III in severe sepsis: a randomized controlled trial.", "question": "Treatment.Duration in High-dose antithrombin III", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "11597289_2_7704", "context": "High-dose antithrombin III in severe sepsis: a randomized controlled trial.", "question": "Treatment.Disorder in High-dose antithrombin III", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "severe sepsis"}, {"id": "11597289_2_7705", "context": "High-dose antithrombin III in severe sepsis: a randomized controlled trial.", "question": "Combination.Drug in High-dose antithrombin III", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "7459812_1_7706", "context": "Fatal interstitial pneumonitis following high-dose intermittent chlorambucil therapy for chronic lymphocyte leukemia.", "question": "Treatment.Drug in high-dose intermittent chlorambucil therapy", "question_type": "Adverse_event.Treatment.Drug", "answers": "chlorambucil"}, {"id": "7459812_1_7707", "context": "Fatal interstitial pneumonitis following high-dose intermittent chlorambucil therapy for chronic lymphocyte leukemia.", "question": "Treatment.Dosage in high-dose intermittent chlorambucil therapy", "question_type": "Adverse_event.Treatment.Dosage", "answers": "high-dose"}, {"id": "7459812_1_7708", "context": "Fatal interstitial pneumonitis following high-dose intermittent chlorambucil therapy for chronic lymphocyte leukemia.", "question": "Treatment.Freq in high-dose intermittent chlorambucil therapy", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7459812_1_7709", "context": "Fatal interstitial pneumonitis following high-dose intermittent chlorambucil therapy for chronic lymphocyte leukemia.", "question": "Treatment.Route in high-dose intermittent chlorambucil therapy", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7459812_1_7710", "context": "Fatal interstitial pneumonitis following high-dose intermittent chlorambucil therapy for chronic lymphocyte leukemia.", "question": "Treatment.Time_elapsed in high-dose intermittent chlorambucil therapy", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7459812_1_7711", "context": "Fatal interstitial pneumonitis following high-dose intermittent chlorambucil therapy for chronic lymphocyte leukemia.", "question": "Treatment.Duration in high-dose intermittent chlorambucil therapy", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7459812_1_7712", "context": "Fatal interstitial pneumonitis following high-dose intermittent chlorambucil therapy for chronic lymphocyte leukemia.", "question": "Treatment.Disorder in high-dose intermittent chlorambucil therapy", "question_type": "Adverse_event.Treatment.Disorder", "answers": "chronic lymphocyte leukemia"}, {"id": "7459812_1_7713", "context": "Fatal interstitial pneumonitis following high-dose intermittent chlorambucil therapy for chronic lymphocyte leukemia.", "question": "Combination.Drug in high-dose intermittent chlorambucil therapy", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "647693_3_7714", "context": "These findings suggest that the corneal and retinal changes are the result of a toxic effect of tamoxifen when used in the doses and duration described.", "question": "Treatment.Drug in tamoxifen", "question_type": "Adverse_event.Treatment.Drug", "answers": "tamoxifen"}, {"id": "647693_3_7715", "context": "These findings suggest that the corneal and retinal changes are the result of a toxic effect of tamoxifen when used in the doses and duration described.", "question": "Treatment.Dosage in tamoxifen", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "647693_3_7716", "context": "These findings suggest that the corneal and retinal changes are the result of a toxic effect of tamoxifen when used in the doses and duration described.", "question": "Treatment.Freq in tamoxifen", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "647693_3_7717", "context": "These findings suggest that the corneal and retinal changes are the result of a toxic effect of tamoxifen when used in the doses and duration described.", "question": "Treatment.Route in tamoxifen", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "647693_3_7718", "context": "These findings suggest that the corneal and retinal changes are the result of a toxic effect of tamoxifen when used in the doses and duration described.", "question": "Treatment.Time_elapsed in tamoxifen", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "647693_3_7719", "context": "These findings suggest that the corneal and retinal changes are the result of a toxic effect of tamoxifen when used in the doses and duration described.", "question": "Treatment.Duration in tamoxifen", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "647693_3_7720", "context": "These findings suggest that the corneal and retinal changes are the result of a toxic effect of tamoxifen when used in the doses and duration described.", "question": "Treatment.Disorder in tamoxifen", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "647693_3_7721", "context": "These findings suggest that the corneal and retinal changes are the result of a toxic effect of tamoxifen when used in the doses and duration described.", "question": "Combination.Drug in tamoxifen", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "20171144_1_7722", "context": "Common adverse events (frequency 10%) of lacosamide doses up to 600 mg/day include nonspecific central nervous system effects (e.g., dizziness, ataxia, diplopia, and somnolence).", "question": "Treatment.Drug in lacosamide doses up to 600 mg/day", "question_type": "Adverse_event.Treatment.Drug", "answers": "lacosamide"}, {"id": "20171144_1_7723", "context": "Common adverse events (frequency 10%) of lacosamide doses up to 600 mg/day include nonspecific central nervous system effects (e.g., dizziness, ataxia, diplopia, and somnolence).", "question": "Treatment.Dosage in lacosamide doses up to 600 mg/day", "question_type": "Adverse_event.Treatment.Dosage", "answers": "600 mg/day"}, {"id": "20171144_1_7724", "context": "Common adverse events (frequency 10%) of lacosamide doses up to 600 mg/day include nonspecific central nervous system effects (e.g., dizziness, ataxia, diplopia, and somnolence).", "question": "Treatment.Freq in lacosamide doses up to 600 mg/day", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "20171144_1_7725", "context": "Common adverse events (frequency 10%) of lacosamide doses up to 600 mg/day include nonspecific central nervous system effects (e.g., dizziness, ataxia, diplopia, and somnolence).", "question": "Treatment.Route in lacosamide doses up to 600 mg/day", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "20171144_1_7726", "context": "Common adverse events (frequency 10%) of lacosamide doses up to 600 mg/day include nonspecific central nervous system effects (e.g., dizziness, ataxia, diplopia, and somnolence).", "question": "Treatment.Time_elapsed in lacosamide doses up to 600 mg/day", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "20171144_1_7727", "context": "Common adverse events (frequency 10%) of lacosamide doses up to 600 mg/day include nonspecific central nervous system effects (e.g., dizziness, ataxia, diplopia, and somnolence).", "question": "Treatment.Duration in lacosamide doses up to 600 mg/day", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "20171144_1_7728", "context": "Common adverse events (frequency 10%) of lacosamide doses up to 600 mg/day include nonspecific central nervous system effects (e.g., dizziness, ataxia, diplopia, and somnolence).", "question": "Treatment.Disorder in lacosamide doses up to 600 mg/day", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "20171144_1_7729", "context": "Common adverse events (frequency 10%) of lacosamide doses up to 600 mg/day include nonspecific central nervous system effects (e.g., dizziness, ataxia, diplopia, and somnolence).", "question": "Combination.Drug in lacosamide doses up to 600 mg/day", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17667887_2_7730", "context": "We report two cases of serotonin syndrome in elderly patients during treatment of psychotic depression with atypical antipsychotics and antidepressants.", "question": "Subject.Age in elderly patients", "question_type": "Adverse_event.Subject.Age", "answers": "elderly"}, {"id": "17667887_2_7731", "context": "We report two cases of serotonin syndrome in elderly patients during treatment of psychotic depression with atypical antipsychotics and antidepressants.", "question": "Subject.Gender in elderly patients", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "17667887_2_7732", "context": "We report two cases of serotonin syndrome in elderly patients during treatment of psychotic depression with atypical antipsychotics and antidepressants.", "question": "Subject.Population in elderly patients", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "17667887_2_7733", "context": "We report two cases of serotonin syndrome in elderly patients during treatment of psychotic depression with atypical antipsychotics and antidepressants.", "question": "Subject.Race in elderly patients", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "17667887_2_7734", "context": "We report two cases of serotonin syndrome in elderly patients during treatment of psychotic depression with atypical antipsychotics and antidepressants.", "question": "Subject.Disorder in elderly patients", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "17667887_2_7735", "context": "We report two cases of serotonin syndrome in elderly patients during treatment of psychotic depression with atypical antipsychotics and antidepressants.", "question": "Treatment.Drug in atypical antipsychotics and antidepressants", "question_type": "Adverse_event.Treatment.Drug", "answers": "atypical antipsychotics; antidepressants"}, {"id": "17667887_2_7736", "context": "We report two cases of serotonin syndrome in elderly patients during treatment of psychotic depression with atypical antipsychotics and antidepressants.", "question": "Treatment.Dosage in atypical antipsychotics and antidepressants", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17667887_2_7737", "context": "We report two cases of serotonin syndrome in elderly patients during treatment of psychotic depression with atypical antipsychotics and antidepressants.", "question": "Treatment.Freq in atypical antipsychotics and antidepressants", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17667887_2_7738", "context": "We report two cases of serotonin syndrome in elderly patients during treatment of psychotic depression with atypical antipsychotics and antidepressants.", "question": "Treatment.Route in atypical antipsychotics and antidepressants", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17667887_2_7739", "context": "We report two cases of serotonin syndrome in elderly patients during treatment of psychotic depression with atypical antipsychotics and antidepressants.", "question": "Treatment.Time_elapsed in atypical antipsychotics and antidepressants", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17667887_2_7740", "context": "We report two cases of serotonin syndrome in elderly patients during treatment of psychotic depression with atypical antipsychotics and antidepressants.", "question": "Treatment.Duration in atypical antipsychotics and antidepressants", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17667887_2_7741", "context": "We report two cases of serotonin syndrome in elderly patients during treatment of psychotic depression with atypical antipsychotics and antidepressants.", "question": "Treatment.Disorder in atypical antipsychotics and antidepressants", "question_type": "Adverse_event.Treatment.Disorder", "answers": "psychotic depression"}, {"id": "17667887_2_7742", "context": "We report two cases of serotonin syndrome in elderly patients during treatment of psychotic depression with atypical antipsychotics and antidepressants.", "question": "Combination.Drug in atypical antipsychotics and antidepressants", "question_type": "Adverse_event.Combination.Drug", "answers": "atypical antipsychotics; antidepressants"}, {"id": "8452107_1_7743", "context": "Piritrexim-induced pulmonary toxicity.", "question": "Treatment.Drug in Piritrexim", "question_type": "Adverse_event.Treatment.Drug", "answers": "Piritrexim"}, {"id": "8452107_1_7744", "context": "Piritrexim-induced pulmonary toxicity.", "question": "Treatment.Dosage in Piritrexim", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8452107_1_7745", "context": "Piritrexim-induced pulmonary toxicity.", "question": "Treatment.Freq in Piritrexim", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8452107_1_7746", "context": "Piritrexim-induced pulmonary toxicity.", "question": "Treatment.Route in Piritrexim", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8452107_1_7747", "context": "Piritrexim-induced pulmonary toxicity.", "question": "Treatment.Time_elapsed in Piritrexim", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8452107_1_7748", "context": "Piritrexim-induced pulmonary toxicity.", "question": "Treatment.Duration in Piritrexim", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8452107_1_7749", "context": "Piritrexim-induced pulmonary toxicity.", "question": "Treatment.Disorder in Piritrexim", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8452107_1_7750", "context": "Piritrexim-induced pulmonary toxicity.", "question": "Combination.Drug in Piritrexim", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15338554_6_7751", "context": "Progression of chronic myeloid leukemia to blast crisis during treatment with imatinib mesylate.", "question": "Treatment.Drug in imatinib mesylate", "question_type": "Adverse_event.Treatment.Drug", "answers": "imatinib mesylate"}, {"id": "15338554_6_7752", "context": "Progression of chronic myeloid leukemia to blast crisis during treatment with imatinib mesylate.", "question": "Treatment.Dosage in imatinib mesylate", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15338554_6_7753", "context": "Progression of chronic myeloid leukemia to blast crisis during treatment with imatinib mesylate.", "question": "Treatment.Freq in imatinib mesylate", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15338554_6_7754", "context": "Progression of chronic myeloid leukemia to blast crisis during treatment with imatinib mesylate.", "question": "Treatment.Route in imatinib mesylate", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15338554_6_7755", "context": "Progression of chronic myeloid leukemia to blast crisis during treatment with imatinib mesylate.", "question": "Treatment.Time_elapsed in imatinib mesylate", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15338554_6_7756", "context": "Progression of chronic myeloid leukemia to blast crisis during treatment with imatinib mesylate.", "question": "Treatment.Duration in imatinib mesylate", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15338554_6_7757", "context": "Progression of chronic myeloid leukemia to blast crisis during treatment with imatinib mesylate.", "question": "Treatment.Disorder in imatinib mesylate", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15338554_6_7758", "context": "Progression of chronic myeloid leukemia to blast crisis during treatment with imatinib mesylate.", "question": "Combination.Drug in imatinib mesylate", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "19648225_3_7759", "context": "Presentation of three palliative care patients who were given ketamine as an analgesic and subsequently developed significant and debilitating urological symptoms.", "question": "Subject.Age in three palliative care patients", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "19648225_3_7760", "context": "Presentation of three palliative care patients who were given ketamine as an analgesic and subsequently developed significant and debilitating urological symptoms.", "question": "Subject.Gender in three palliative care patients", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "19648225_3_7761", "context": "Presentation of three palliative care patients who were given ketamine as an analgesic and subsequently developed significant and debilitating urological symptoms.", "question": "Subject.Population in three palliative care patients", "question_type": "Adverse_event.Subject.Population", "answers": "three"}, {"id": "19648225_3_7762", "context": "Presentation of three palliative care patients who were given ketamine as an analgesic and subsequently developed significant and debilitating urological symptoms.", "question": "Subject.Race in three palliative care patients", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "19648225_3_7763", "context": "Presentation of three palliative care patients who were given ketamine as an analgesic and subsequently developed significant and debilitating urological symptoms.", "question": "Subject.Disorder in three palliative care patients", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "19648225_3_7764", "context": "Presentation of three palliative care patients who were given ketamine as an analgesic and subsequently developed significant and debilitating urological symptoms.", "question": "Treatment.Drug in ketamine", "question_type": "Adverse_event.Treatment.Drug", "answers": "ketamine"}, {"id": "19648225_3_7765", "context": "Presentation of three palliative care patients who were given ketamine as an analgesic and subsequently developed significant and debilitating urological symptoms.", "question": "Treatment.Dosage in ketamine", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "19648225_3_7766", "context": "Presentation of three palliative care patients who were given ketamine as an analgesic and subsequently developed significant and debilitating urological symptoms.", "question": "Treatment.Freq in ketamine", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "19648225_3_7767", "context": "Presentation of three palliative care patients who were given ketamine as an analgesic and subsequently developed significant and debilitating urological symptoms.", "question": "Treatment.Route in ketamine", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "19648225_3_7768", "context": "Presentation of three palliative care patients who were given ketamine as an analgesic and subsequently developed significant and debilitating urological symptoms.", "question": "Treatment.Time_elapsed in ketamine", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19648225_3_7769", "context": "Presentation of three palliative care patients who were given ketamine as an analgesic and subsequently developed significant and debilitating urological symptoms.", "question": "Treatment.Duration in ketamine", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "19648225_3_7770", "context": "Presentation of three palliative care patients who were given ketamine as an analgesic and subsequently developed significant and debilitating urological symptoms.", "question": "Treatment.Disorder in ketamine", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "19648225_3_7771", "context": "Presentation of three palliative care patients who were given ketamine as an analgesic and subsequently developed significant and debilitating urological symptoms.", "question": "Combination.Drug in ketamine", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "19058340_1_7772", "context": "A 52 year-old male patient diagnosed of ankylosing spondylitis presented with an iron deficiency anemia after a ten-month treatment of methotrexate.", "question": "Subject.Age in A 52 year-old male patient diagnosed of ankylosing spondylitis", "question_type": "Adverse_event.Subject.Age", "answers": "52 year-old"}, {"id": "19058340_1_7773", "context": "A 52 year-old male patient diagnosed of ankylosing spondylitis presented with an iron deficiency anemia after a ten-month treatment of methotrexate.", "question": "Subject.Gender in A 52 year-old male patient diagnosed of ankylosing spondylitis", "question_type": "Adverse_event.Subject.Gender", "answers": "male"}, {"id": "19058340_1_7774", "context": "A 52 year-old male patient diagnosed of ankylosing spondylitis presented with an iron deficiency anemia after a ten-month treatment of methotrexate.", "question": "Subject.Population in A 52 year-old male patient diagnosed of ankylosing spondylitis", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "19058340_1_7775", "context": "A 52 year-old male patient diagnosed of ankylosing spondylitis presented with an iron deficiency anemia after a ten-month treatment of methotrexate.", "question": "Subject.Race in A 52 year-old male patient diagnosed of ankylosing spondylitis", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "19058340_1_7776", "context": "A 52 year-old male patient diagnosed of ankylosing spondylitis presented with an iron deficiency anemia after a ten-month treatment of methotrexate.", "question": "Subject.Disorder in A 52 year-old male patient diagnosed of ankylosing spondylitis", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "19058340_1_7777", "context": "A 52 year-old male patient diagnosed of ankylosing spondylitis presented with an iron deficiency anemia after a ten-month treatment of methotrexate.", "question": "Treatment.Drug in a ten-month treatment of methotrexate", "question_type": "Adverse_event.Treatment.Drug", "answers": "methotrexate"}, {"id": "19058340_1_7778", "context": "A 52 year-old male patient diagnosed of ankylosing spondylitis presented with an iron deficiency anemia after a ten-month treatment of methotrexate.", "question": "Treatment.Dosage in a ten-month treatment of methotrexate", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "19058340_1_7779", "context": "A 52 year-old male patient diagnosed of ankylosing spondylitis presented with an iron deficiency anemia after a ten-month treatment of methotrexate.", "question": "Treatment.Freq in a ten-month treatment of methotrexate", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "19058340_1_7780", "context": "A 52 year-old male patient diagnosed of ankylosing spondylitis presented with an iron deficiency anemia after a ten-month treatment of methotrexate.", "question": "Treatment.Route in a ten-month treatment of methotrexate", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "19058340_1_7781", "context": "A 52 year-old male patient diagnosed of ankylosing spondylitis presented with an iron deficiency anemia after a ten-month treatment of methotrexate.", "question": "Treatment.Time_elapsed in a ten-month treatment of methotrexate", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "ten-month"}, {"id": "19058340_1_7782", "context": "A 52 year-old male patient diagnosed of ankylosing spondylitis presented with an iron deficiency anemia after a ten-month treatment of methotrexate.", "question": "Treatment.Duration in a ten-month treatment of methotrexate", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "19058340_1_7783", "context": "A 52 year-old male patient diagnosed of ankylosing spondylitis presented with an iron deficiency anemia after a ten-month treatment of methotrexate.", "question": "Treatment.Disorder in a ten-month treatment of methotrexate", "question_type": "Adverse_event.Treatment.Disorder", "answers": "ankylosing spondylitis"}, {"id": "19058340_1_7784", "context": "A 52 year-old male patient diagnosed of ankylosing spondylitis presented with an iron deficiency anemia after a ten-month treatment of methotrexate.", "question": "Combination.Drug in a ten-month treatment of methotrexate", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "19423476_6_7785", "context": "The international literature regarding opportunistic infections after immunosuppressive therapy with alemtuzumab with particular attention on fungal infections has also been reviewed.", "question": "Treatment.Drug in immunosuppressive therapy with alemtuzumab", "question_type": "Adverse_event.Treatment.Drug", "answers": "alemtuzumab"}, {"id": "19423476_6_7786", "context": "The international literature regarding opportunistic infections after immunosuppressive therapy with alemtuzumab with particular attention on fungal infections has also been reviewed.", "question": "Treatment.Dosage in immunosuppressive therapy with alemtuzumab", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "19423476_6_7787", "context": "The international literature regarding opportunistic infections after immunosuppressive therapy with alemtuzumab with particular attention on fungal infections has also been reviewed.", "question": "Treatment.Freq in immunosuppressive therapy with alemtuzumab", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "19423476_6_7788", "context": "The international literature regarding opportunistic infections after immunosuppressive therapy with alemtuzumab with particular attention on fungal infections has also been reviewed.", "question": "Treatment.Route in immunosuppressive therapy with alemtuzumab", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "19423476_6_7789", "context": "The international literature regarding opportunistic infections after immunosuppressive therapy with alemtuzumab with particular attention on fungal infections has also been reviewed.", "question": "Treatment.Time_elapsed in immunosuppressive therapy with alemtuzumab", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19423476_6_7790", "context": "The international literature regarding opportunistic infections after immunosuppressive therapy with alemtuzumab with particular attention on fungal infections has also been reviewed.", "question": "Treatment.Duration in immunosuppressive therapy with alemtuzumab", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "19423476_6_7791", "context": "The international literature regarding opportunistic infections after immunosuppressive therapy with alemtuzumab with particular attention on fungal infections has also been reviewed.", "question": "Treatment.Disorder in immunosuppressive therapy with alemtuzumab", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "19423476_6_7792", "context": "The international literature regarding opportunistic infections after immunosuppressive therapy with alemtuzumab with particular attention on fungal infections has also been reviewed.", "question": "Combination.Drug in immunosuppressive therapy with alemtuzumab", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9681092_13_7793", "context": "Clinicians should be aware of the dysrhythmic potential of cyclobenzaprine and fluoxetine, monitor for other cytochrome P450 inhibitors, and avoid concomitant drugs known to prolong the QT interval.", "question": "Treatment.Drug in cyclobenzaprine and fluoxetin", "question_type": "Adverse_event.Treatment.Drug", "answers": "cyclobenzaprine; fluoxetine"}, {"id": "9681092_13_7794", "context": "Clinicians should be aware of the dysrhythmic potential of cyclobenzaprine and fluoxetine, monitor for other cytochrome P450 inhibitors, and avoid concomitant drugs known to prolong the QT interval.", "question": "Treatment.Dosage in cyclobenzaprine and fluoxetin", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9681092_13_7795", "context": "Clinicians should be aware of the dysrhythmic potential of cyclobenzaprine and fluoxetine, monitor for other cytochrome P450 inhibitors, and avoid concomitant drugs known to prolong the QT interval.", "question": "Treatment.Freq in cyclobenzaprine and fluoxetin", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9681092_13_7796", "context": "Clinicians should be aware of the dysrhythmic potential of cyclobenzaprine and fluoxetine, monitor for other cytochrome P450 inhibitors, and avoid concomitant drugs known to prolong the QT interval.", "question": "Treatment.Route in cyclobenzaprine and fluoxetin", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9681092_13_7797", "context": "Clinicians should be aware of the dysrhythmic potential of cyclobenzaprine and fluoxetine, monitor for other cytochrome P450 inhibitors, and avoid concomitant drugs known to prolong the QT interval.", "question": "Treatment.Time_elapsed in cyclobenzaprine and fluoxetin", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9681092_13_7798", "context": "Clinicians should be aware of the dysrhythmic potential of cyclobenzaprine and fluoxetine, monitor for other cytochrome P450 inhibitors, and avoid concomitant drugs known to prolong the QT interval.", "question": "Treatment.Duration in cyclobenzaprine and fluoxetin", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9681092_13_7799", "context": "Clinicians should be aware of the dysrhythmic potential of cyclobenzaprine and fluoxetine, monitor for other cytochrome P450 inhibitors, and avoid concomitant drugs known to prolong the QT interval.", "question": "Treatment.Disorder in cyclobenzaprine and fluoxetin", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9681092_13_7800", "context": "Clinicians should be aware of the dysrhythmic potential of cyclobenzaprine and fluoxetine, monitor for other cytochrome P450 inhibitors, and avoid concomitant drugs known to prolong the QT interval.", "question": "Combination.Drug in cyclobenzaprine and fluoxetin", "question_type": "Adverse_event.Combination.Drug", "answers": "cyclobenzaprine; fluoxetine"}, {"id": "10405480_2_7801", "context": "Acute generalized exanthematous pustulosis induced by salazosulfapyridine in a patient with ulcerative colitis.", "question": "Subject.Age in a patient with ulcerative colitis", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "10405480_2_7802", "context": "Acute generalized exanthematous pustulosis induced by salazosulfapyridine in a patient with ulcerative colitis.", "question": "Subject.Gender in a patient with ulcerative colitis", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "10405480_2_7803", "context": "Acute generalized exanthematous pustulosis induced by salazosulfapyridine in a patient with ulcerative colitis.", "question": "Subject.Population in a patient with ulcerative colitis", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "10405480_2_7804", "context": "Acute generalized exanthematous pustulosis induced by salazosulfapyridine in a patient with ulcerative colitis.", "question": "Subject.Race in a patient with ulcerative colitis", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "10405480_2_7805", "context": "Acute generalized exanthematous pustulosis induced by salazosulfapyridine in a patient with ulcerative colitis.", "question": "Subject.Disorder in a patient with ulcerative colitis", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "10405480_2_7806", "context": "Acute generalized exanthematous pustulosis induced by salazosulfapyridine in a patient with ulcerative colitis.", "question": "Treatment.Drug in salazosulfapyridine", "question_type": "Adverse_event.Treatment.Drug", "answers": "salazosulfapyridine"}, {"id": "10405480_2_7807", "context": "Acute generalized exanthematous pustulosis induced by salazosulfapyridine in a patient with ulcerative colitis.", "question": "Treatment.Dosage in salazosulfapyridine", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10405480_2_7808", "context": "Acute generalized exanthematous pustulosis induced by salazosulfapyridine in a patient with ulcerative colitis.", "question": "Treatment.Freq in salazosulfapyridine", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10405480_2_7809", "context": "Acute generalized exanthematous pustulosis induced by salazosulfapyridine in a patient with ulcerative colitis.", "question": "Treatment.Route in salazosulfapyridine", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10405480_2_7810", "context": "Acute generalized exanthematous pustulosis induced by salazosulfapyridine in a patient with ulcerative colitis.", "question": "Treatment.Time_elapsed in salazosulfapyridine", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10405480_2_7811", "context": "Acute generalized exanthematous pustulosis induced by salazosulfapyridine in a patient with ulcerative colitis.", "question": "Treatment.Duration in salazosulfapyridine", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10405480_2_7812", "context": "Acute generalized exanthematous pustulosis induced by salazosulfapyridine in a patient with ulcerative colitis.", "question": "Treatment.Disorder in salazosulfapyridine", "question_type": "Adverse_event.Treatment.Disorder", "answers": "ulcerative colitis"}, {"id": "10405480_2_7813", "context": "Acute generalized exanthematous pustulosis induced by salazosulfapyridine in a patient with ulcerative colitis.", "question": "Combination.Drug in salazosulfapyridine", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17627694_1_7814", "context": "CONCLUSION: Acetic acid is corrosive and may cause vagina bleeding.", "question": "Treatment.Drug in Acetic acid", "question_type": "Adverse_event.Treatment.Drug", "answers": "Acetic acid"}, {"id": "17627694_1_7815", "context": "CONCLUSION: Acetic acid is corrosive and may cause vagina bleeding.", "question": "Treatment.Dosage in Acetic acid", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17627694_1_7816", "context": "CONCLUSION: Acetic acid is corrosive and may cause vagina bleeding.", "question": "Treatment.Freq in Acetic acid", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17627694_1_7817", "context": "CONCLUSION: Acetic acid is corrosive and may cause vagina bleeding.", "question": "Treatment.Route in Acetic acid", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17627694_1_7818", "context": "CONCLUSION: Acetic acid is corrosive and may cause vagina bleeding.", "question": "Treatment.Time_elapsed in Acetic acid", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17627694_1_7819", "context": "CONCLUSION: Acetic acid is corrosive and may cause vagina bleeding.", "question": "Treatment.Duration in Acetic acid", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17627694_1_7820", "context": "CONCLUSION: Acetic acid is corrosive and may cause vagina bleeding.", "question": "Treatment.Disorder in Acetic acid", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17627694_1_7821", "context": "CONCLUSION: Acetic acid is corrosive and may cause vagina bleeding.", "question": "Combination.Drug in Acetic acid", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16244351_3_7822", "context": "We report a case admitted with a first-detected, symptomatic paroxysmal atrial fibrillation in a healthy patient after self-medication with vardenafil.", "question": "Subject.Age in a healthy patient", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "16244351_3_7823", "context": "We report a case admitted with a first-detected, symptomatic paroxysmal atrial fibrillation in a healthy patient after self-medication with vardenafil.", "question": "Subject.Gender in a healthy patient", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "16244351_3_7824", "context": "We report a case admitted with a first-detected, symptomatic paroxysmal atrial fibrillation in a healthy patient after self-medication with vardenafil.", "question": "Subject.Population in a healthy patient", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "16244351_3_7825", "context": "We report a case admitted with a first-detected, symptomatic paroxysmal atrial fibrillation in a healthy patient after self-medication with vardenafil.", "question": "Subject.Race in a healthy patient", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16244351_3_7826", "context": "We report a case admitted with a first-detected, symptomatic paroxysmal atrial fibrillation in a healthy patient after self-medication with vardenafil.", "question": "Subject.Disorder in a healthy patient", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "16244351_3_7827", "context": "We report a case admitted with a first-detected, symptomatic paroxysmal atrial fibrillation in a healthy patient after self-medication with vardenafil.", "question": "Treatment.Drug in vardenafil", "question_type": "Adverse_event.Treatment.Drug", "answers": "vardenafil"}, {"id": "16244351_3_7828", "context": "We report a case admitted with a first-detected, symptomatic paroxysmal atrial fibrillation in a healthy patient after self-medication with vardenafil.", "question": "Treatment.Dosage in vardenafil", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16244351_3_7829", "context": "We report a case admitted with a first-detected, symptomatic paroxysmal atrial fibrillation in a healthy patient after self-medication with vardenafil.", "question": "Treatment.Freq in vardenafil", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16244351_3_7830", "context": "We report a case admitted with a first-detected, symptomatic paroxysmal atrial fibrillation in a healthy patient after self-medication with vardenafil.", "question": "Treatment.Route in vardenafil", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16244351_3_7831", "context": "We report a case admitted with a first-detected, symptomatic paroxysmal atrial fibrillation in a healthy patient after self-medication with vardenafil.", "question": "Treatment.Time_elapsed in vardenafil", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16244351_3_7832", "context": "We report a case admitted with a first-detected, symptomatic paroxysmal atrial fibrillation in a healthy patient after self-medication with vardenafil.", "question": "Treatment.Duration in vardenafil", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16244351_3_7833", "context": "We report a case admitted with a first-detected, symptomatic paroxysmal atrial fibrillation in a healthy patient after self-medication with vardenafil.", "question": "Treatment.Disorder in vardenafil", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16244351_3_7834", "context": "We report a case admitted with a first-detected, symptomatic paroxysmal atrial fibrillation in a healthy patient after self-medication with vardenafil.", "question": "Combination.Drug in vardenafil", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7362333_1_7835", "context": "Propranolol: an unrecognized cause of central nervous system dysfunction in patients undergoing cardiopulmonary bypass.", "question": "Subject.Age in patients undergoing cardiopulmonary bypass", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "7362333_1_7836", "context": "Propranolol: an unrecognized cause of central nervous system dysfunction in patients undergoing cardiopulmonary bypass.", "question": "Subject.Gender in patients undergoing cardiopulmonary bypass", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "7362333_1_7837", "context": "Propranolol: an unrecognized cause of central nervous system dysfunction in patients undergoing cardiopulmonary bypass.", "question": "Subject.Population in patients undergoing cardiopulmonary bypass", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "7362333_1_7838", "context": "Propranolol: an unrecognized cause of central nervous system dysfunction in patients undergoing cardiopulmonary bypass.", "question": "Subject.Race in patients undergoing cardiopulmonary bypass", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "7362333_1_7839", "context": "Propranolol: an unrecognized cause of central nervous system dysfunction in patients undergoing cardiopulmonary bypass.", "question": "Subject.Disorder in patients undergoing cardiopulmonary bypass", "question_type": "Adverse_event.Subject.Disorder", "answers": "cardiopulmonary bypass"}, {"id": "7362333_1_7840", "context": "Propranolol: an unrecognized cause of central nervous system dysfunction in patients undergoing cardiopulmonary bypass.", "question": "Treatment.Drug in Propranolol", "question_type": "Adverse_event.Treatment.Drug", "answers": "Propranolol"}, {"id": "7362333_1_7841", "context": "Propranolol: an unrecognized cause of central nervous system dysfunction in patients undergoing cardiopulmonary bypass.", "question": "Treatment.Dosage in Propranolol", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7362333_1_7842", "context": "Propranolol: an unrecognized cause of central nervous system dysfunction in patients undergoing cardiopulmonary bypass.", "question": "Treatment.Freq in Propranolol", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7362333_1_7843", "context": "Propranolol: an unrecognized cause of central nervous system dysfunction in patients undergoing cardiopulmonary bypass.", "question": "Treatment.Route in Propranolol", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7362333_1_7844", "context": "Propranolol: an unrecognized cause of central nervous system dysfunction in patients undergoing cardiopulmonary bypass.", "question": "Treatment.Time_elapsed in Propranolol", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7362333_1_7845", "context": "Propranolol: an unrecognized cause of central nervous system dysfunction in patients undergoing cardiopulmonary bypass.", "question": "Treatment.Duration in Propranolol", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7362333_1_7846", "context": "Propranolol: an unrecognized cause of central nervous system dysfunction in patients undergoing cardiopulmonary bypass.", "question": "Treatment.Disorder in Propranolol", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7362333_1_7847", "context": "Propranolol: an unrecognized cause of central nervous system dysfunction in patients undergoing cardiopulmonary bypass.", "question": "Combination.Drug in Propranolol", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15681911_1_7848", "context": "CONCLUSIONS: Symptoms and pathologic changes of colitis are associated with exposure to rofecoxib.", "question": "Treatment.Drug in rofecoxib", "question_type": "Adverse_event.Treatment.Drug", "answers": "rofecoxib"}, {"id": "15681911_1_7849", "context": "CONCLUSIONS: Symptoms and pathologic changes of colitis are associated with exposure to rofecoxib.", "question": "Treatment.Dosage in rofecoxib", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15681911_1_7850", "context": "CONCLUSIONS: Symptoms and pathologic changes of colitis are associated with exposure to rofecoxib.", "question": "Treatment.Freq in rofecoxib", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15681911_1_7851", "context": "CONCLUSIONS: Symptoms and pathologic changes of colitis are associated with exposure to rofecoxib.", "question": "Treatment.Route in rofecoxib", "question_type": "Adverse_event.Treatment.Route", "answers": "exposure"}, {"id": "15681911_1_7852", "context": "CONCLUSIONS: Symptoms and pathologic changes of colitis are associated with exposure to rofecoxib.", "question": "Treatment.Time_elapsed in rofecoxib", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15681911_1_7853", "context": "CONCLUSIONS: Symptoms and pathologic changes of colitis are associated with exposure to rofecoxib.", "question": "Treatment.Duration in rofecoxib", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15681911_1_7854", "context": "CONCLUSIONS: Symptoms and pathologic changes of colitis are associated with exposure to rofecoxib.", "question": "Treatment.Disorder in rofecoxib", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15681911_1_7855", "context": "CONCLUSIONS: Symptoms and pathologic changes of colitis are associated with exposure to rofecoxib.", "question": "Combination.Drug in rofecoxib", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16507380_13_7856", "context": "A possible drug-drug interaction between IFN alfa 11 MU TIW and gemfibrozil 600 mg BID was reported in a patient undergoing treatment for IFN-induced hypertriglyceridemia.", "question": "Subject.Age in a patient", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "16507380_13_7857", "context": "A possible drug-drug interaction between IFN alfa 11 MU TIW and gemfibrozil 600 mg BID was reported in a patient undergoing treatment for IFN-induced hypertriglyceridemia.", "question": "Subject.Gender in a patient", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "16507380_13_7858", "context": "A possible drug-drug interaction between IFN alfa 11 MU TIW and gemfibrozil 600 mg BID was reported in a patient undergoing treatment for IFN-induced hypertriglyceridemia.", "question": "Subject.Population in a patient", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "16507380_13_7859", "context": "A possible drug-drug interaction between IFN alfa 11 MU TIW and gemfibrozil 600 mg BID was reported in a patient undergoing treatment for IFN-induced hypertriglyceridemia.", "question": "Subject.Race in a patient", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16507380_13_7860", "context": "A possible drug-drug interaction between IFN alfa 11 MU TIW and gemfibrozil 600 mg BID was reported in a patient undergoing treatment for IFN-induced hypertriglyceridemia.", "question": "Subject.Disorder in a patient", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "16507380_13_7861", "context": "A possible drug-drug interaction between IFN alfa 11 MU TIW and gemfibrozil 600 mg BID was reported in a patient undergoing treatment for IFN-induced hypertriglyceridemia.", "question": "Treatment.Drug in drug-drug interaction between IFN alfa 11 MU TIW and gemfibrozil 600 mg BID", "question_type": "Adverse_event.Treatment.Drug", "answers": "IFN alfa; gemfibrozil"}, {"id": "16507380_13_7862", "context": "A possible drug-drug interaction between IFN alfa 11 MU TIW and gemfibrozil 600 mg BID was reported in a patient undergoing treatment for IFN-induced hypertriglyceridemia.", "question": "Treatment.Dosage in drug-drug interaction between IFN alfa 11 MU TIW and gemfibrozil 600 mg BID", "question_type": "Adverse_event.Treatment.Dosage", "answers": "600 mg; 11 MU"}, {"id": "16507380_13_7863", "context": "A possible drug-drug interaction between IFN alfa 11 MU TIW and gemfibrozil 600 mg BID was reported in a patient undergoing treatment for IFN-induced hypertriglyceridemia.", "question": "Treatment.Freq in drug-drug interaction between IFN alfa 11 MU TIW and gemfibrozil 600 mg BID", "question_type": "Adverse_event.Treatment.Freq", "answers": "BID; TIW"}, {"id": "16507380_13_7864", "context": "A possible drug-drug interaction between IFN alfa 11 MU TIW and gemfibrozil 600 mg BID was reported in a patient undergoing treatment for IFN-induced hypertriglyceridemia.", "question": "Treatment.Route in drug-drug interaction between IFN alfa 11 MU TIW and gemfibrozil 600 mg BID", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16507380_13_7865", "context": "A possible drug-drug interaction between IFN alfa 11 MU TIW and gemfibrozil 600 mg BID was reported in a patient undergoing treatment for IFN-induced hypertriglyceridemia.", "question": "Treatment.Time_elapsed in drug-drug interaction between IFN alfa 11 MU TIW and gemfibrozil 600 mg BID", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16507380_13_7866", "context": "A possible drug-drug interaction between IFN alfa 11 MU TIW and gemfibrozil 600 mg BID was reported in a patient undergoing treatment for IFN-induced hypertriglyceridemia.", "question": "Treatment.Duration in drug-drug interaction between IFN alfa 11 MU TIW and gemfibrozil 600 mg BID", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16507380_13_7867", "context": "A possible drug-drug interaction between IFN alfa 11 MU TIW and gemfibrozil 600 mg BID was reported in a patient undergoing treatment for IFN-induced hypertriglyceridemia.", "question": "Treatment.Disorder in drug-drug interaction between IFN alfa 11 MU TIW and gemfibrozil 600 mg BID", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16507380_13_7868", "context": "A possible drug-drug interaction between IFN alfa 11 MU TIW and gemfibrozil 600 mg BID was reported in a patient undergoing treatment for IFN-induced hypertriglyceridemia.", "question": "Combination.Drug in drug-drug interaction between IFN alfa 11 MU TIW and gemfibrozil 600 mg BID", "question_type": "Adverse_event.Combination.Drug", "answers": "IFN alfa; gemfibrozil"}, {"id": "12181031_2_7869", "context": "Systemic vasculitis complicating hairy cell leukaemia treatment with cladribine.", "question": "Treatment.Drug in cladribine", "question_type": "Adverse_event.Treatment.Drug", "answers": "cladribine"}, {"id": "12181031_2_7870", "context": "Systemic vasculitis complicating hairy cell leukaemia treatment with cladribine.", "question": "Treatment.Dosage in cladribine", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12181031_2_7871", "context": "Systemic vasculitis complicating hairy cell leukaemia treatment with cladribine.", "question": "Treatment.Freq in cladribine", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12181031_2_7872", "context": "Systemic vasculitis complicating hairy cell leukaemia treatment with cladribine.", "question": "Treatment.Route in cladribine", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12181031_2_7873", "context": "Systemic vasculitis complicating hairy cell leukaemia treatment with cladribine.", "question": "Treatment.Time_elapsed in cladribine", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12181031_2_7874", "context": "Systemic vasculitis complicating hairy cell leukaemia treatment with cladribine.", "question": "Treatment.Duration in cladribine", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12181031_2_7875", "context": "Systemic vasculitis complicating hairy cell leukaemia treatment with cladribine.", "question": "Treatment.Disorder in cladribine", "question_type": "Adverse_event.Treatment.Disorder", "answers": "hairy cell leukaemia"}, {"id": "12181031_2_7876", "context": "Systemic vasculitis complicating hairy cell leukaemia treatment with cladribine.", "question": "Combination.Drug in cladribine", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11126885_2_7877", "context": "Quinine is universally used for the very common symptom of night leg cramps.", "question": "Treatment.Drug in Quinine", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "Quinine"}, {"id": "11126885_2_7878", "context": "Quinine is universally used for the very common symptom of night leg cramps.", "question": "Treatment.Dosage in Quinine", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "11126885_2_7879", "context": "Quinine is universally used for the very common symptom of night leg cramps.", "question": "Treatment.Freq in Quinine", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "11126885_2_7880", "context": "Quinine is universally used for the very common symptom of night leg cramps.", "question": "Treatment.Route in Quinine", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "11126885_2_7881", "context": "Quinine is universally used for the very common symptom of night leg cramps.", "question": "Treatment.Time_elapsed in Quinine", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11126885_2_7882", "context": "Quinine is universally used for the very common symptom of night leg cramps.", "question": "Treatment.Duration in Quinine", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "11126885_2_7883", "context": "Quinine is universally used for the very common symptom of night leg cramps.", "question": "Treatment.Disorder in Quinine", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "night leg cramps"}, {"id": "11126885_2_7884", "context": "Quinine is universally used for the very common symptom of night leg cramps.", "question": "Combination.Drug in Quinine", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "8864370_3_7885", "context": "However, continued low-dose MTX led, in spite of normal liver tests, 8 years after the last biopsy to liver failure and death in 1 of our patients.", "question": "Treatment.Drug in low-dose MTX", "question_type": "Adverse_event.Treatment.Drug", "answers": "MTX"}, {"id": "8864370_3_7886", "context": "However, continued low-dose MTX led, in spite of normal liver tests, 8 years after the last biopsy to liver failure and death in 1 of our patients.", "question": "Treatment.Dosage in low-dose MTX", "question_type": "Adverse_event.Treatment.Dosage", "answers": "low-dose"}, {"id": "8864370_3_7887", "context": "However, continued low-dose MTX led, in spite of normal liver tests, 8 years after the last biopsy to liver failure and death in 1 of our patients.", "question": "Treatment.Freq in low-dose MTX", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8864370_3_7888", "context": "However, continued low-dose MTX led, in spite of normal liver tests, 8 years after the last biopsy to liver failure and death in 1 of our patients.", "question": "Treatment.Route in low-dose MTX", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8864370_3_7889", "context": "However, continued low-dose MTX led, in spite of normal liver tests, 8 years after the last biopsy to liver failure and death in 1 of our patients.", "question": "Treatment.Time_elapsed in low-dose MTX", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8864370_3_7890", "context": "However, continued low-dose MTX led, in spite of normal liver tests, 8 years after the last biopsy to liver failure and death in 1 of our patients.", "question": "Treatment.Duration in low-dose MTX", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8864370_3_7891", "context": "However, continued low-dose MTX led, in spite of normal liver tests, 8 years after the last biopsy to liver failure and death in 1 of our patients.", "question": "Treatment.Disorder in low-dose MTX", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8864370_3_7892", "context": "However, continued low-dose MTX led, in spite of normal liver tests, 8 years after the last biopsy to liver failure and death in 1 of our patients.", "question": "Combination.Drug in low-dose MTX", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11597289_5_7893", "context": "Antithrombin III may provide protection from multiorgan failure and improve survival in severely ill patients.", "question": "Subject.Age in severely ill patients", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "11597289_5_7894", "context": "Antithrombin III may provide protection from multiorgan failure and improve survival in severely ill patients.", "question": "Subject.Gender in severely ill patients", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "11597289_5_7895", "context": "Antithrombin III may provide protection from multiorgan failure and improve survival in severely ill patients.", "question": "Subject.Population in severely ill patients", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "11597289_5_7896", "context": "Antithrombin III may provide protection from multiorgan failure and improve survival in severely ill patients.", "question": "Subject.Race in severely ill patients", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "11597289_5_7897", "context": "Antithrombin III may provide protection from multiorgan failure and improve survival in severely ill patients.", "question": "Subject.Disorder in severely ill patients", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "11597289_5_7898", "context": "Antithrombin III may provide protection from multiorgan failure and improve survival in severely ill patients.", "question": "Treatment.Drug in Antithrombin III; multiorgan failure", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "Antithrombin III"}, {"id": "11597289_5_7899", "context": "Antithrombin III may provide protection from multiorgan failure and improve survival in severely ill patients.", "question": "Treatment.Dosage in Antithrombin III; multiorgan failure", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "11597289_5_7900", "context": "Antithrombin III may provide protection from multiorgan failure and improve survival in severely ill patients.", "question": "Treatment.Freq in Antithrombin III; multiorgan failure", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "11597289_5_7901", "context": "Antithrombin III may provide protection from multiorgan failure and improve survival in severely ill patients.", "question": "Treatment.Route in Antithrombin III; multiorgan failure", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "11597289_5_7902", "context": "Antithrombin III may provide protection from multiorgan failure and improve survival in severely ill patients.", "question": "Treatment.Time_elapsed in Antithrombin III; multiorgan failure", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11597289_5_7903", "context": "Antithrombin III may provide protection from multiorgan failure and improve survival in severely ill patients.", "question": "Treatment.Duration in Antithrombin III; multiorgan failure", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "11597289_5_7904", "context": "Antithrombin III may provide protection from multiorgan failure and improve survival in severely ill patients.", "question": "Treatment.Disorder in Antithrombin III; multiorgan failure", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "multiorgan failure; severely ill"}, {"id": "11597289_5_7905", "context": "Antithrombin III may provide protection from multiorgan failure and improve survival in severely ill patients.", "question": "Combination.Drug in Antithrombin III; multiorgan failure", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "7235792_3_7906", "context": "In the second case, five cardiac arrests due to ventricular tachycardia and fibrillation occurred during several hours after beginning a trial of bretylium maintenance therapy for complex ventricular ectopy.", "question": "Subject.Age in In the second case", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "7235792_3_7907", "context": "In the second case, five cardiac arrests due to ventricular tachycardia and fibrillation occurred during several hours after beginning a trial of bretylium maintenance therapy for complex ventricular ectopy.", "question": "Subject.Gender in In the second case", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "7235792_3_7908", "context": "In the second case, five cardiac arrests due to ventricular tachycardia and fibrillation occurred during several hours after beginning a trial of bretylium maintenance therapy for complex ventricular ectopy.", "question": "Subject.Population in In the second case", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "7235792_3_7909", "context": "In the second case, five cardiac arrests due to ventricular tachycardia and fibrillation occurred during several hours after beginning a trial of bretylium maintenance therapy for complex ventricular ectopy.", "question": "Subject.Race in In the second case", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "7235792_3_7910", "context": "In the second case, five cardiac arrests due to ventricular tachycardia and fibrillation occurred during several hours after beginning a trial of bretylium maintenance therapy for complex ventricular ectopy.", "question": "Subject.Disorder in In the second case", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "7235792_3_7911", "context": "In the second case, five cardiac arrests due to ventricular tachycardia and fibrillation occurred during several hours after beginning a trial of bretylium maintenance therapy for complex ventricular ectopy.", "question": "Treatment.Drug in several hours after beginning a trial of bretylium maintenance therapy", "question_type": "Adverse_event.Treatment.Drug", "answers": "bretylium"}, {"id": "7235792_3_7912", "context": "In the second case, five cardiac arrests due to ventricular tachycardia and fibrillation occurred during several hours after beginning a trial of bretylium maintenance therapy for complex ventricular ectopy.", "question": "Treatment.Dosage in several hours after beginning a trial of bretylium maintenance therapy", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7235792_3_7913", "context": "In the second case, five cardiac arrests due to ventricular tachycardia and fibrillation occurred during several hours after beginning a trial of bretylium maintenance therapy for complex ventricular ectopy.", "question": "Treatment.Freq in several hours after beginning a trial of bretylium maintenance therapy", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7235792_3_7914", "context": "In the second case, five cardiac arrests due to ventricular tachycardia and fibrillation occurred during several hours after beginning a trial of bretylium maintenance therapy for complex ventricular ectopy.", "question": "Treatment.Route in several hours after beginning a trial of bretylium maintenance therapy", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7235792_3_7915", "context": "In the second case, five cardiac arrests due to ventricular tachycardia and fibrillation occurred during several hours after beginning a trial of bretylium maintenance therapy for complex ventricular ectopy.", "question": "Treatment.Time_elapsed in several hours after beginning a trial of bretylium maintenance therapy", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "several hours after"}, {"id": "7235792_3_7916", "context": "In the second case, five cardiac arrests due to ventricular tachycardia and fibrillation occurred during several hours after beginning a trial of bretylium maintenance therapy for complex ventricular ectopy.", "question": "Treatment.Duration in several hours after beginning a trial of bretylium maintenance therapy", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7235792_3_7917", "context": "In the second case, five cardiac arrests due to ventricular tachycardia and fibrillation occurred during several hours after beginning a trial of bretylium maintenance therapy for complex ventricular ectopy.", "question": "Treatment.Disorder in several hours after beginning a trial of bretylium maintenance therapy", "question_type": "Adverse_event.Treatment.Disorder", "answers": "complex ventricular ectopy"}, {"id": "7235792_3_7918", "context": "In the second case, five cardiac arrests due to ventricular tachycardia and fibrillation occurred during several hours after beginning a trial of bretylium maintenance therapy for complex ventricular ectopy.", "question": "Combination.Drug in several hours after beginning a trial of bretylium maintenance therapy", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8739289_3_7919", "context": "The association of central diabetes insipidus (CDI) with lithium use is rare.", "question": "Treatment.Drug in lithium", "question_type": "Adverse_event.Treatment.Drug", "answers": "lithium"}, {"id": "8739289_3_7920", "context": "The association of central diabetes insipidus (CDI) with lithium use is rare.", "question": "Treatment.Dosage in lithium", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8739289_3_7921", "context": "The association of central diabetes insipidus (CDI) with lithium use is rare.", "question": "Treatment.Freq in lithium", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8739289_3_7922", "context": "The association of central diabetes insipidus (CDI) with lithium use is rare.", "question": "Treatment.Route in lithium", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8739289_3_7923", "context": "The association of central diabetes insipidus (CDI) with lithium use is rare.", "question": "Treatment.Time_elapsed in lithium", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8739289_3_7924", "context": "The association of central diabetes insipidus (CDI) with lithium use is rare.", "question": "Treatment.Duration in lithium", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8739289_3_7925", "context": "The association of central diabetes insipidus (CDI) with lithium use is rare.", "question": "Treatment.Disorder in lithium", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8739289_3_7926", "context": "The association of central diabetes insipidus (CDI) with lithium use is rare.", "question": "Combination.Drug in lithium", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17426073_2_7927", "context": "However, a new episode of neutropenia, with a WBC count of 2.8 x 10(3)/mm3 and ANC of 0.448 x 10(3)/mm3, occurred 11 days after teicoplanin initiation.", "question": "Treatment.Drug in 11 days after teicoplanin initiation", "question_type": "Adverse_event.Treatment.Drug", "answers": "teicoplanin"}, {"id": "17426073_2_7928", "context": "However, a new episode of neutropenia, with a WBC count of 2.8 x 10(3)/mm3 and ANC of 0.448 x 10(3)/mm3, occurred 11 days after teicoplanin initiation.", "question": "Treatment.Dosage in 11 days after teicoplanin initiation", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17426073_2_7929", "context": "However, a new episode of neutropenia, with a WBC count of 2.8 x 10(3)/mm3 and ANC of 0.448 x 10(3)/mm3, occurred 11 days after teicoplanin initiation.", "question": "Treatment.Freq in 11 days after teicoplanin initiation", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17426073_2_7930", "context": "However, a new episode of neutropenia, with a WBC count of 2.8 x 10(3)/mm3 and ANC of 0.448 x 10(3)/mm3, occurred 11 days after teicoplanin initiation.", "question": "Treatment.Route in 11 days after teicoplanin initiation", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17426073_2_7931", "context": "However, a new episode of neutropenia, with a WBC count of 2.8 x 10(3)/mm3 and ANC of 0.448 x 10(3)/mm3, occurred 11 days after teicoplanin initiation.", "question": "Treatment.Time_elapsed in 11 days after teicoplanin initiation", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "11 days"}, {"id": "17426073_2_7932", "context": "However, a new episode of neutropenia, with a WBC count of 2.8 x 10(3)/mm3 and ANC of 0.448 x 10(3)/mm3, occurred 11 days after teicoplanin initiation.", "question": "Treatment.Duration in 11 days after teicoplanin initiation", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17426073_2_7933", "context": "However, a new episode of neutropenia, with a WBC count of 2.8 x 10(3)/mm3 and ANC of 0.448 x 10(3)/mm3, occurred 11 days after teicoplanin initiation.", "question": "Treatment.Disorder in 11 days after teicoplanin initiation", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17426073_2_7934", "context": "However, a new episode of neutropenia, with a WBC count of 2.8 x 10(3)/mm3 and ANC of 0.448 x 10(3)/mm3, occurred 11 days after teicoplanin initiation.", "question": "Combination.Drug in 11 days after teicoplanin initiation", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7448830_4_7935", "context": "In a phase II study of hycanthone in patients with breast cancer we have recently observed severe hepatotoxicity, even at lower doses, which resulted in two drug-related deaths.", "question": "Subject.Age in patients with breast cancer", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "7448830_4_7936", "context": "In a phase II study of hycanthone in patients with breast cancer we have recently observed severe hepatotoxicity, even at lower doses, which resulted in two drug-related deaths.", "question": "Subject.Gender in patients with breast cancer", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "7448830_4_7937", "context": "In a phase II study of hycanthone in patients with breast cancer we have recently observed severe hepatotoxicity, even at lower doses, which resulted in two drug-related deaths.", "question": "Subject.Population in patients with breast cancer", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "7448830_4_7938", "context": "In a phase II study of hycanthone in patients with breast cancer we have recently observed severe hepatotoxicity, even at lower doses, which resulted in two drug-related deaths.", "question": "Subject.Race in patients with breast cancer", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "7448830_4_7939", "context": "In a phase II study of hycanthone in patients with breast cancer we have recently observed severe hepatotoxicity, even at lower doses, which resulted in two drug-related deaths.", "question": "Subject.Disorder in patients with breast cancer", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "7448830_4_7940", "context": "In a phase II study of hycanthone in patients with breast cancer we have recently observed severe hepatotoxicity, even at lower doses, which resulted in two drug-related deaths.", "question": "Treatment.Drug in hycanthone", "question_type": "Adverse_event.Treatment.Drug", "answers": "hycanthone"}, {"id": "7448830_4_7941", "context": "In a phase II study of hycanthone in patients with breast cancer we have recently observed severe hepatotoxicity, even at lower doses, which resulted in two drug-related deaths.", "question": "Treatment.Dosage in hycanthone", "question_type": "Adverse_event.Treatment.Dosage", "answers": "lower doses"}, {"id": "7448830_4_7942", "context": "In a phase II study of hycanthone in patients with breast cancer we have recently observed severe hepatotoxicity, even at lower doses, which resulted in two drug-related deaths.", "question": "Treatment.Freq in hycanthone", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7448830_4_7943", "context": "In a phase II study of hycanthone in patients with breast cancer we have recently observed severe hepatotoxicity, even at lower doses, which resulted in two drug-related deaths.", "question": "Treatment.Route in hycanthone", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7448830_4_7944", "context": "In a phase II study of hycanthone in patients with breast cancer we have recently observed severe hepatotoxicity, even at lower doses, which resulted in two drug-related deaths.", "question": "Treatment.Time_elapsed in hycanthone", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7448830_4_7945", "context": "In a phase II study of hycanthone in patients with breast cancer we have recently observed severe hepatotoxicity, even at lower doses, which resulted in two drug-related deaths.", "question": "Treatment.Duration in hycanthone", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7448830_4_7946", "context": "In a phase II study of hycanthone in patients with breast cancer we have recently observed severe hepatotoxicity, even at lower doses, which resulted in two drug-related deaths.", "question": "Treatment.Disorder in hycanthone", "question_type": "Adverse_event.Treatment.Disorder", "answers": "breast cancer"}, {"id": "7448830_4_7947", "context": "In a phase II study of hycanthone in patients with breast cancer we have recently observed severe hepatotoxicity, even at lower doses, which resulted in two drug-related deaths.", "question": "Combination.Drug in hycanthone", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11008259_3_7948", "context": "This is the first report of non-convulsive status epilepticus provoked by tiagabine in adolescent patients.", "question": "Subject.Age in adolescent patients", "question_type": "Adverse_event.Subject.Age", "answers": "adolescent"}, {"id": "11008259_3_7949", "context": "This is the first report of non-convulsive status epilepticus provoked by tiagabine in adolescent patients.", "question": "Subject.Gender in adolescent patients", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "11008259_3_7950", "context": "This is the first report of non-convulsive status epilepticus provoked by tiagabine in adolescent patients.", "question": "Subject.Population in adolescent patients", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "11008259_3_7951", "context": "This is the first report of non-convulsive status epilepticus provoked by tiagabine in adolescent patients.", "question": "Subject.Race in adolescent patients", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "11008259_3_7952", "context": "This is the first report of non-convulsive status epilepticus provoked by tiagabine in adolescent patients.", "question": "Subject.Disorder in adolescent patients", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "11008259_3_7953", "context": "This is the first report of non-convulsive status epilepticus provoked by tiagabine in adolescent patients.", "question": "Treatment.Drug in tiagabine", "question_type": "Adverse_event.Treatment.Drug", "answers": "tiagabine"}, {"id": "11008259_3_7954", "context": "This is the first report of non-convulsive status epilepticus provoked by tiagabine in adolescent patients.", "question": "Treatment.Dosage in tiagabine", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11008259_3_7955", "context": "This is the first report of non-convulsive status epilepticus provoked by tiagabine in adolescent patients.", "question": "Treatment.Freq in tiagabine", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11008259_3_7956", "context": "This is the first report of non-convulsive status epilepticus provoked by tiagabine in adolescent patients.", "question": "Treatment.Route in tiagabine", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11008259_3_7957", "context": "This is the first report of non-convulsive status epilepticus provoked by tiagabine in adolescent patients.", "question": "Treatment.Time_elapsed in tiagabine", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11008259_3_7958", "context": "This is the first report of non-convulsive status epilepticus provoked by tiagabine in adolescent patients.", "question": "Treatment.Duration in tiagabine", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11008259_3_7959", "context": "This is the first report of non-convulsive status epilepticus provoked by tiagabine in adolescent patients.", "question": "Treatment.Disorder in tiagabine", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11008259_3_7960", "context": "This is the first report of non-convulsive status epilepticus provoked by tiagabine in adolescent patients.", "question": "Combination.Drug in tiagabine", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "180258_2_7961", "context": "Two patients are described who developed sensory neuropathy after the ingestion of 30.6 and 114 g metronidazole respectively.", "question": "Subject.Age in Two patients", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "180258_2_7962", "context": "Two patients are described who developed sensory neuropathy after the ingestion of 30.6 and 114 g metronidazole respectively.", "question": "Subject.Gender in Two patients", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "180258_2_7963", "context": "Two patients are described who developed sensory neuropathy after the ingestion of 30.6 and 114 g metronidazole respectively.", "question": "Subject.Population in Two patients", "question_type": "Adverse_event.Subject.Population", "answers": "Two"}, {"id": "180258_2_7964", "context": "Two patients are described who developed sensory neuropathy after the ingestion of 30.6 and 114 g metronidazole respectively.", "question": "Subject.Race in Two patients", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "180258_2_7965", "context": "Two patients are described who developed sensory neuropathy after the ingestion of 30.6 and 114 g metronidazole respectively.", "question": "Subject.Disorder in Two patients", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "180258_2_7966", "context": "Two patients are described who developed sensory neuropathy after the ingestion of 30.6 and 114 g metronidazole respectively.", "question": "Treatment.Drug in the ingestion of 30.6 and 114 g metronidazole", "question_type": "Adverse_event.Treatment.Drug", "answers": "metronidazole"}, {"id": "180258_2_7967", "context": "Two patients are described who developed sensory neuropathy after the ingestion of 30.6 and 114 g metronidazole respectively.", "question": "Treatment.Dosage in the ingestion of 30.6 and 114 g metronidazole", "question_type": "Adverse_event.Treatment.Dosage", "answers": "114 g; 30.6; g"}, {"id": "180258_2_7968", "context": "Two patients are described who developed sensory neuropathy after the ingestion of 30.6 and 114 g metronidazole respectively.", "question": "Treatment.Freq in the ingestion of 30.6 and 114 g metronidazole", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "180258_2_7969", "context": "Two patients are described who developed sensory neuropathy after the ingestion of 30.6 and 114 g metronidazole respectively.", "question": "Treatment.Route in the ingestion of 30.6 and 114 g metronidazole", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "180258_2_7970", "context": "Two patients are described who developed sensory neuropathy after the ingestion of 30.6 and 114 g metronidazole respectively.", "question": "Treatment.Time_elapsed in the ingestion of 30.6 and 114 g metronidazole", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "180258_2_7971", "context": "Two patients are described who developed sensory neuropathy after the ingestion of 30.6 and 114 g metronidazole respectively.", "question": "Treatment.Duration in the ingestion of 30.6 and 114 g metronidazole", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "180258_2_7972", "context": "Two patients are described who developed sensory neuropathy after the ingestion of 30.6 and 114 g metronidazole respectively.", "question": "Treatment.Disorder in the ingestion of 30.6 and 114 g metronidazole", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "180258_2_7973", "context": "Two patients are described who developed sensory neuropathy after the ingestion of 30.6 and 114 g metronidazole respectively.", "question": "Combination.Drug in the ingestion of 30.6 and 114 g metronidazole", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15463865_3_7974", "context": "We report two young patients with cystic fibrosis who presented with acute renal insufficiency after 2-3 weeks of oral ciprofloxacin therapy.", "question": "Subject.Age in two young patients with cystic fibrosis", "question_type": "Adverse_event.Subject.Age", "answers": "young"}, {"id": "15463865_3_7975", "context": "We report two young patients with cystic fibrosis who presented with acute renal insufficiency after 2-3 weeks of oral ciprofloxacin therapy.", "question": "Subject.Gender in two young patients with cystic fibrosis", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15463865_3_7976", "context": "We report two young patients with cystic fibrosis who presented with acute renal insufficiency after 2-3 weeks of oral ciprofloxacin therapy.", "question": "Subject.Population in two young patients with cystic fibrosis", "question_type": "Adverse_event.Subject.Population", "answers": "two"}, {"id": "15463865_3_7977", "context": "We report two young patients with cystic fibrosis who presented with acute renal insufficiency after 2-3 weeks of oral ciprofloxacin therapy.", "question": "Subject.Race in two young patients with cystic fibrosis", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15463865_3_7978", "context": "We report two young patients with cystic fibrosis who presented with acute renal insufficiency after 2-3 weeks of oral ciprofloxacin therapy.", "question": "Subject.Disorder in two young patients with cystic fibrosis", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15463865_3_7979", "context": "We report two young patients with cystic fibrosis who presented with acute renal insufficiency after 2-3 weeks of oral ciprofloxacin therapy.", "question": "Treatment.Drug in 2-3 weeks of oral ciprofloxacin therapy", "question_type": "Adverse_event.Treatment.Drug", "answers": "ciprofloxacin"}, {"id": "15463865_3_7980", "context": "We report two young patients with cystic fibrosis who presented with acute renal insufficiency after 2-3 weeks of oral ciprofloxacin therapy.", "question": "Treatment.Dosage in 2-3 weeks of oral ciprofloxacin therapy", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15463865_3_7981", "context": "We report two young patients with cystic fibrosis who presented with acute renal insufficiency after 2-3 weeks of oral ciprofloxacin therapy.", "question": "Treatment.Freq in 2-3 weeks of oral ciprofloxacin therapy", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15463865_3_7982", "context": "We report two young patients with cystic fibrosis who presented with acute renal insufficiency after 2-3 weeks of oral ciprofloxacin therapy.", "question": "Treatment.Route in 2-3 weeks of oral ciprofloxacin therapy", "question_type": "Adverse_event.Treatment.Route", "answers": "oral"}, {"id": "15463865_3_7983", "context": "We report two young patients with cystic fibrosis who presented with acute renal insufficiency after 2-3 weeks of oral ciprofloxacin therapy.", "question": "Treatment.Time_elapsed in 2-3 weeks of oral ciprofloxacin therapy", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "2-3 weeks"}, {"id": "15463865_3_7984", "context": "We report two young patients with cystic fibrosis who presented with acute renal insufficiency after 2-3 weeks of oral ciprofloxacin therapy.", "question": "Treatment.Duration in 2-3 weeks of oral ciprofloxacin therapy", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15463865_3_7985", "context": "We report two young patients with cystic fibrosis who presented with acute renal insufficiency after 2-3 weeks of oral ciprofloxacin therapy.", "question": "Treatment.Disorder in 2-3 weeks of oral ciprofloxacin therapy", "question_type": "Adverse_event.Treatment.Disorder", "answers": "cystic fibrosis"}, {"id": "15463865_3_7986", "context": "We report two young patients with cystic fibrosis who presented with acute renal insufficiency after 2-3 weeks of oral ciprofloxacin therapy.", "question": "Combination.Drug in 2-3 weeks of oral ciprofloxacin therapy", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15827071_8_7987", "context": "A 37-year-old male with multiple myeloma received citalopram 40 mg/day and trazodone 150 mg/day for anxiety-related disorders.", "question": "Subject.Age in A 37-year-old male with multiple myeloma", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": "37-year-old"}, {"id": "15827071_8_7988", "context": "A 37-year-old male with multiple myeloma received citalopram 40 mg/day and trazodone 150 mg/day for anxiety-related disorders.", "question": "Subject.Gender in A 37-year-old male with multiple myeloma", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": "male"}, {"id": "15827071_8_7989", "context": "A 37-year-old male with multiple myeloma received citalopram 40 mg/day and trazodone 150 mg/day for anxiety-related disorders.", "question": "Subject.Population in A 37-year-old male with multiple myeloma", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "15827071_8_7990", "context": "A 37-year-old male with multiple myeloma received citalopram 40 mg/day and trazodone 150 mg/day for anxiety-related disorders.", "question": "Subject.Race in A 37-year-old male with multiple myeloma", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "15827071_8_7991", "context": "A 37-year-old male with multiple myeloma received citalopram 40 mg/day and trazodone 150 mg/day for anxiety-related disorders.", "question": "Subject.Disorder in A 37-year-old male with multiple myeloma", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": "multiple myeloma"}, {"id": "15827071_8_7992", "context": "A 37-year-old male with multiple myeloma received citalopram 40 mg/day and trazodone 150 mg/day for anxiety-related disorders.", "question": "Treatment.Drug in citalopram 40 mg/day and trazodone 150 mg/day", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "citalopram; trazodone"}, {"id": "15827071_8_7993", "context": "A 37-year-old male with multiple myeloma received citalopram 40 mg/day and trazodone 150 mg/day for anxiety-related disorders.", "question": "Treatment.Dosage in citalopram 40 mg/day and trazodone 150 mg/day", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": "40 mg/day; 150 mg/day"}, {"id": "15827071_8_7994", "context": "A 37-year-old male with multiple myeloma received citalopram 40 mg/day and trazodone 150 mg/day for anxiety-related disorders.", "question": "Treatment.Freq in citalopram 40 mg/day and trazodone 150 mg/day", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "15827071_8_7995", "context": "A 37-year-old male with multiple myeloma received citalopram 40 mg/day and trazodone 150 mg/day for anxiety-related disorders.", "question": "Treatment.Route in citalopram 40 mg/day and trazodone 150 mg/day", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "15827071_8_7996", "context": "A 37-year-old male with multiple myeloma received citalopram 40 mg/day and trazodone 150 mg/day for anxiety-related disorders.", "question": "Treatment.Time_elapsed in citalopram 40 mg/day and trazodone 150 mg/day", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15827071_8_7997", "context": "A 37-year-old male with multiple myeloma received citalopram 40 mg/day and trazodone 150 mg/day for anxiety-related disorders.", "question": "Treatment.Duration in citalopram 40 mg/day and trazodone 150 mg/day", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "15827071_8_7998", "context": "A 37-year-old male with multiple myeloma received citalopram 40 mg/day and trazodone 150 mg/day for anxiety-related disorders.", "question": "Treatment.Disorder in citalopram 40 mg/day and trazodone 150 mg/day", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "anxiety-related disorders"}, {"id": "15827071_8_7999", "context": "A 37-year-old male with multiple myeloma received citalopram 40 mg/day and trazodone 150 mg/day for anxiety-related disorders.", "question": "Combination.Drug in citalopram 40 mg/day and trazodone 150 mg/day", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": "citalopram; trazodone"}, {"id": "11335880_3_8000", "context": "Hashimoto's disease during interferon-alpha therapy in a patient with pre-treatment negative anti-thyroid autoantibodies and with the specific genetic susceptibility to the thyroid disease.", "question": "Subject.Age in a patient with pre-treatment negative anti-thyroid autoantibodies and with the specific genetic susceptibility to the thyroid disease", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "11335880_3_8001", "context": "Hashimoto's disease during interferon-alpha therapy in a patient with pre-treatment negative anti-thyroid autoantibodies and with the specific genetic susceptibility to the thyroid disease.", "question": "Subject.Gender in a patient with pre-treatment negative anti-thyroid autoantibodies and with the specific genetic susceptibility to the thyroid disease", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "11335880_3_8002", "context": "Hashimoto's disease during interferon-alpha therapy in a patient with pre-treatment negative anti-thyroid autoantibodies and with the specific genetic susceptibility to the thyroid disease.", "question": "Subject.Population in a patient with pre-treatment negative anti-thyroid autoantibodies and with the specific genetic susceptibility to the thyroid disease", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "11335880_3_8003", "context": "Hashimoto's disease during interferon-alpha therapy in a patient with pre-treatment negative anti-thyroid autoantibodies and with the specific genetic susceptibility to the thyroid disease.", "question": "Subject.Race in a patient with pre-treatment negative anti-thyroid autoantibodies and with the specific genetic susceptibility to the thyroid disease", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "11335880_3_8004", "context": "Hashimoto's disease during interferon-alpha therapy in a patient with pre-treatment negative anti-thyroid autoantibodies and with the specific genetic susceptibility to the thyroid disease.", "question": "Subject.Disorder in a patient with pre-treatment negative anti-thyroid autoantibodies and with the specific genetic susceptibility to the thyroid disease", "question_type": "Adverse_event.Subject.Disorder", "answers": "specific genetic susceptibility to the thyroid disease"}, {"id": "11335880_3_8005", "context": "Hashimoto's disease during interferon-alpha therapy in a patient with pre-treatment negative anti-thyroid autoantibodies and with the specific genetic susceptibility to the thyroid disease.", "question": "Treatment.Drug in interferon-alpha", "question_type": "Adverse_event.Treatment.Drug", "answers": "interferon-alpha"}, {"id": "11335880_3_8006", "context": "Hashimoto's disease during interferon-alpha therapy in a patient with pre-treatment negative anti-thyroid autoantibodies and with the specific genetic susceptibility to the thyroid disease.", "question": "Treatment.Dosage in interferon-alpha", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11335880_3_8007", "context": "Hashimoto's disease during interferon-alpha therapy in a patient with pre-treatment negative anti-thyroid autoantibodies and with the specific genetic susceptibility to the thyroid disease.", "question": "Treatment.Freq in interferon-alpha", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11335880_3_8008", "context": "Hashimoto's disease during interferon-alpha therapy in a patient with pre-treatment negative anti-thyroid autoantibodies and with the specific genetic susceptibility to the thyroid disease.", "question": "Treatment.Route in interferon-alpha", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11335880_3_8009", "context": "Hashimoto's disease during interferon-alpha therapy in a patient with pre-treatment negative anti-thyroid autoantibodies and with the specific genetic susceptibility to the thyroid disease.", "question": "Treatment.Time_elapsed in interferon-alpha", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11335880_3_8010", "context": "Hashimoto's disease during interferon-alpha therapy in a patient with pre-treatment negative anti-thyroid autoantibodies and with the specific genetic susceptibility to the thyroid disease.", "question": "Treatment.Duration in interferon-alpha", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11335880_3_8011", "context": "Hashimoto's disease during interferon-alpha therapy in a patient with pre-treatment negative anti-thyroid autoantibodies and with the specific genetic susceptibility to the thyroid disease.", "question": "Treatment.Disorder in interferon-alpha", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11335880_3_8012", "context": "Hashimoto's disease during interferon-alpha therapy in a patient with pre-treatment negative anti-thyroid autoantibodies and with the specific genetic susceptibility to the thyroid disease.", "question": "Combination.Drug in interferon-alpha", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9039216_2_8013", "context": "Fever, lymphadenopathy, eosinophilia, lymphocytosis, hepatitis, and dermatitis: a severe adverse reaction to minocycline.", "question": "Treatment.Drug in minocycline", "question_type": "Adverse_event.Treatment.Drug", "answers": "minocycline"}, {"id": "9039216_2_8014", "context": "Fever, lymphadenopathy, eosinophilia, lymphocytosis, hepatitis, and dermatitis: a severe adverse reaction to minocycline.", "question": "Treatment.Dosage in minocycline", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9039216_2_8015", "context": "Fever, lymphadenopathy, eosinophilia, lymphocytosis, hepatitis, and dermatitis: a severe adverse reaction to minocycline.", "question": "Treatment.Freq in minocycline", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9039216_2_8016", "context": "Fever, lymphadenopathy, eosinophilia, lymphocytosis, hepatitis, and dermatitis: a severe adverse reaction to minocycline.", "question": "Treatment.Route in minocycline", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9039216_2_8017", "context": "Fever, lymphadenopathy, eosinophilia, lymphocytosis, hepatitis, and dermatitis: a severe adverse reaction to minocycline.", "question": "Treatment.Time_elapsed in minocycline", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9039216_2_8018", "context": "Fever, lymphadenopathy, eosinophilia, lymphocytosis, hepatitis, and dermatitis: a severe adverse reaction to minocycline.", "question": "Treatment.Duration in minocycline", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9039216_2_8019", "context": "Fever, lymphadenopathy, eosinophilia, lymphocytosis, hepatitis, and dermatitis: a severe adverse reaction to minocycline.", "question": "Treatment.Disorder in minocycline", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9039216_2_8020", "context": "Fever, lymphadenopathy, eosinophilia, lymphocytosis, hepatitis, and dermatitis: a severe adverse reaction to minocycline.", "question": "Combination.Drug in minocycline", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16092915_1_8021", "context": "CONCLUSIONS: This observation of \"on-off\" risperidone treatment suggests that risperidone may have worsened both psychiatric and physical manifestations of the mitochondrial disorder in this adolescent.", "question": "Subject.Age in mitochondrial disorder in this adolescent", "question_type": "Adverse_event.Subject.Age", "answers": "adolescent"}, {"id": "16092915_1_8022", "context": "CONCLUSIONS: This observation of \"on-off\" risperidone treatment suggests that risperidone may have worsened both psychiatric and physical manifestations of the mitochondrial disorder in this adolescent.", "question": "Subject.Gender in mitochondrial disorder in this adolescent", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "16092915_1_8023", "context": "CONCLUSIONS: This observation of \"on-off\" risperidone treatment suggests that risperidone may have worsened both psychiatric and physical manifestations of the mitochondrial disorder in this adolescent.", "question": "Subject.Population in mitochondrial disorder in this adolescent", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "16092915_1_8024", "context": "CONCLUSIONS: This observation of \"on-off\" risperidone treatment suggests that risperidone may have worsened both psychiatric and physical manifestations of the mitochondrial disorder in this adolescent.", "question": "Subject.Race in mitochondrial disorder in this adolescent", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16092915_1_8025", "context": "CONCLUSIONS: This observation of \"on-off\" risperidone treatment suggests that risperidone may have worsened both psychiatric and physical manifestations of the mitochondrial disorder in this adolescent.", "question": "Subject.Disorder in mitochondrial disorder in this adolescent", "question_type": "Adverse_event.Subject.Disorder", "answers": "mitochondrial disorder"}, {"id": "16092915_1_8026", "context": "CONCLUSIONS: This observation of \"on-off\" risperidone treatment suggests that risperidone may have worsened both psychiatric and physical manifestations of the mitochondrial disorder in this adolescent.", "question": "Treatment.Drug in risperidone", "question_type": "Adverse_event.Treatment.Drug", "answers": "risperidone"}, {"id": "16092915_1_8027", "context": "CONCLUSIONS: This observation of \"on-off\" risperidone treatment suggests that risperidone may have worsened both psychiatric and physical manifestations of the mitochondrial disorder in this adolescent.", "question": "Treatment.Dosage in risperidone", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16092915_1_8028", "context": "CONCLUSIONS: This observation of \"on-off\" risperidone treatment suggests that risperidone may have worsened both psychiatric and physical manifestations of the mitochondrial disorder in this adolescent.", "question": "Treatment.Freq in risperidone", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16092915_1_8029", "context": "CONCLUSIONS: This observation of \"on-off\" risperidone treatment suggests that risperidone may have worsened both psychiatric and physical manifestations of the mitochondrial disorder in this adolescent.", "question": "Treatment.Route in risperidone", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16092915_1_8030", "context": "CONCLUSIONS: This observation of \"on-off\" risperidone treatment suggests that risperidone may have worsened both psychiatric and physical manifestations of the mitochondrial disorder in this adolescent.", "question": "Treatment.Time_elapsed in risperidone", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16092915_1_8031", "context": "CONCLUSIONS: This observation of \"on-off\" risperidone treatment suggests that risperidone may have worsened both psychiatric and physical manifestations of the mitochondrial disorder in this adolescent.", "question": "Treatment.Duration in risperidone", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16092915_1_8032", "context": "CONCLUSIONS: This observation of \"on-off\" risperidone treatment suggests that risperidone may have worsened both psychiatric and physical manifestations of the mitochondrial disorder in this adolescent.", "question": "Treatment.Disorder in risperidone", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16092915_1_8033", "context": "CONCLUSIONS: This observation of \"on-off\" risperidone treatment suggests that risperidone may have worsened both psychiatric and physical manifestations of the mitochondrial disorder in this adolescent.", "question": "Combination.Drug in risperidone", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11008259_2_8034", "context": "The events of non-convulsive status epilepticus subsided following reduction in tiagabine dosages.", "question": "Treatment.Drug in reduction in tiagabine dosages", "question_type": "Adverse_event.Treatment.Drug", "answers": "tiagabine"}, {"id": "11008259_2_8035", "context": "The events of non-convulsive status epilepticus subsided following reduction in tiagabine dosages.", "question": "Treatment.Dosage in reduction in tiagabine dosages", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11008259_2_8036", "context": "The events of non-convulsive status epilepticus subsided following reduction in tiagabine dosages.", "question": "Treatment.Freq in reduction in tiagabine dosages", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11008259_2_8037", "context": "The events of non-convulsive status epilepticus subsided following reduction in tiagabine dosages.", "question": "Treatment.Route in reduction in tiagabine dosages", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11008259_2_8038", "context": "The events of non-convulsive status epilepticus subsided following reduction in tiagabine dosages.", "question": "Treatment.Time_elapsed in reduction in tiagabine dosages", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11008259_2_8039", "context": "The events of non-convulsive status epilepticus subsided following reduction in tiagabine dosages.", "question": "Treatment.Duration in reduction in tiagabine dosages", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11008259_2_8040", "context": "The events of non-convulsive status epilepticus subsided following reduction in tiagabine dosages.", "question": "Treatment.Disorder in reduction in tiagabine dosages", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11008259_2_8041", "context": "The events of non-convulsive status epilepticus subsided following reduction in tiagabine dosages.", "question": "Combination.Drug in reduction in tiagabine dosages", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17426073_1_8042", "context": "CONCLUSIONS: For all patients with vancomycin-induced neutropenia, possible cross-reactivity of teicoplanin should be monitored.", "question": "Subject.Age in patients", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "17426073_1_8043", "context": "CONCLUSIONS: For all patients with vancomycin-induced neutropenia, possible cross-reactivity of teicoplanin should be monitored.", "question": "Subject.Gender in patients", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "17426073_1_8044", "context": "CONCLUSIONS: For all patients with vancomycin-induced neutropenia, possible cross-reactivity of teicoplanin should be monitored.", "question": "Subject.Population in patients", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "17426073_1_8045", "context": "CONCLUSIONS: For all patients with vancomycin-induced neutropenia, possible cross-reactivity of teicoplanin should be monitored.", "question": "Subject.Race in patients", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "17426073_1_8046", "context": "CONCLUSIONS: For all patients with vancomycin-induced neutropenia, possible cross-reactivity of teicoplanin should be monitored.", "question": "Subject.Disorder in patients", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "17426073_1_8047", "context": "CONCLUSIONS: For all patients with vancomycin-induced neutropenia, possible cross-reactivity of teicoplanin should be monitored.", "question": "Treatment.Drug in vancomycin", "question_type": "Adverse_event.Treatment.Drug", "answers": "vancomycin; teicoplanin"}, {"id": "17426073_1_8048", "context": "CONCLUSIONS: For all patients with vancomycin-induced neutropenia, possible cross-reactivity of teicoplanin should be monitored.", "question": "Treatment.Dosage in vancomycin", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17426073_1_8049", "context": "CONCLUSIONS: For all patients with vancomycin-induced neutropenia, possible cross-reactivity of teicoplanin should be monitored.", "question": "Treatment.Freq in vancomycin", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17426073_1_8050", "context": "CONCLUSIONS: For all patients with vancomycin-induced neutropenia, possible cross-reactivity of teicoplanin should be monitored.", "question": "Treatment.Route in vancomycin", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17426073_1_8051", "context": "CONCLUSIONS: For all patients with vancomycin-induced neutropenia, possible cross-reactivity of teicoplanin should be monitored.", "question": "Treatment.Time_elapsed in vancomycin", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17426073_1_8052", "context": "CONCLUSIONS: For all patients with vancomycin-induced neutropenia, possible cross-reactivity of teicoplanin should be monitored.", "question": "Treatment.Duration in vancomycin", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17426073_1_8053", "context": "CONCLUSIONS: For all patients with vancomycin-induced neutropenia, possible cross-reactivity of teicoplanin should be monitored.", "question": "Treatment.Disorder in vancomycin", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17426073_1_8054", "context": "CONCLUSIONS: For all patients with vancomycin-induced neutropenia, possible cross-reactivity of teicoplanin should be monitored.", "question": "Combination.Drug in vancomycin", "question_type": "Adverse_event.Combination.Drug", "answers": "teicoplanin; vancomycin"}, {"id": "19058340_2_8055", "context": "Methotrexate induced sprue-like syndrome.", "question": "Treatment.Drug in Methotrexate", "question_type": "Adverse_event.Treatment.Drug", "answers": "Methotrexate"}, {"id": "19058340_2_8056", "context": "Methotrexate induced sprue-like syndrome.", "question": "Treatment.Dosage in Methotrexate", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "19058340_2_8057", "context": "Methotrexate induced sprue-like syndrome.", "question": "Treatment.Freq in Methotrexate", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "19058340_2_8058", "context": "Methotrexate induced sprue-like syndrome.", "question": "Treatment.Route in Methotrexate", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "19058340_2_8059", "context": "Methotrexate induced sprue-like syndrome.", "question": "Treatment.Time_elapsed in Methotrexate", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19058340_2_8060", "context": "Methotrexate induced sprue-like syndrome.", "question": "Treatment.Duration in Methotrexate", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "19058340_2_8061", "context": "Methotrexate induced sprue-like syndrome.", "question": "Treatment.Disorder in Methotrexate", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "19058340_2_8062", "context": "Methotrexate induced sprue-like syndrome.", "question": "Combination.Drug in Methotrexate", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "22010004_9_8063", "context": "Because of the described effects of niacin on the coagulation cascade and the possibility for pharmacokinetic interactions, there is a potential for synergistic coagulopathy when combined with warfarin therapy.", "question": "Treatment.Drug in niacin; combined with warfarin therapy", "question_type": "Adverse_event.Treatment.Drug", "answers": "niacin; warfarin"}, {"id": "22010004_9_8064", "context": "Because of the described effects of niacin on the coagulation cascade and the possibility for pharmacokinetic interactions, there is a potential for synergistic coagulopathy when combined with warfarin therapy.", "question": "Treatment.Dosage in niacin; combined with warfarin therapy", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "22010004_9_8065", "context": "Because of the described effects of niacin on the coagulation cascade and the possibility for pharmacokinetic interactions, there is a potential for synergistic coagulopathy when combined with warfarin therapy.", "question": "Treatment.Freq in niacin; combined with warfarin therapy", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "22010004_9_8066", "context": "Because of the described effects of niacin on the coagulation cascade and the possibility for pharmacokinetic interactions, there is a potential for synergistic coagulopathy when combined with warfarin therapy.", "question": "Treatment.Route in niacin; combined with warfarin therapy", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "22010004_9_8067", "context": "Because of the described effects of niacin on the coagulation cascade and the possibility for pharmacokinetic interactions, there is a potential for synergistic coagulopathy when combined with warfarin therapy.", "question": "Treatment.Time_elapsed in niacin; combined with warfarin therapy", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "22010004_9_8068", "context": "Because of the described effects of niacin on the coagulation cascade and the possibility for pharmacokinetic interactions, there is a potential for synergistic coagulopathy when combined with warfarin therapy.", "question": "Treatment.Duration in niacin; combined with warfarin therapy", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "22010004_9_8069", "context": "Because of the described effects of niacin on the coagulation cascade and the possibility for pharmacokinetic interactions, there is a potential for synergistic coagulopathy when combined with warfarin therapy.", "question": "Treatment.Disorder in niacin; combined with warfarin therapy", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "22010004_9_8070", "context": "Because of the described effects of niacin on the coagulation cascade and the possibility for pharmacokinetic interactions, there is a potential for synergistic coagulopathy when combined with warfarin therapy.", "question": "Combination.Drug in niacin; combined with warfarin therapy", "question_type": "Adverse_event.Combination.Drug", "answers": "warfarin; niacin"}, {"id": "8186884_3_8071", "context": "The failure of therapy with disopyramide and mexiletine to reproduce this observation suggests either a previously unreported electrophysiologic effect of, or idiosyncratic response to, procainamide.", "question": "Treatment.Drug in procainamide", "question_type": "Adverse_event.Treatment.Drug", "answers": "procainamide"}, {"id": "8186884_3_8072", "context": "The failure of therapy with disopyramide and mexiletine to reproduce this observation suggests either a previously unreported electrophysiologic effect of, or idiosyncratic response to, procainamide.", "question": "Treatment.Dosage in procainamide", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8186884_3_8073", "context": "The failure of therapy with disopyramide and mexiletine to reproduce this observation suggests either a previously unreported electrophysiologic effect of, or idiosyncratic response to, procainamide.", "question": "Treatment.Freq in procainamide", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8186884_3_8074", "context": "The failure of therapy with disopyramide and mexiletine to reproduce this observation suggests either a previously unreported electrophysiologic effect of, or idiosyncratic response to, procainamide.", "question": "Treatment.Route in procainamide", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8186884_3_8075", "context": "The failure of therapy with disopyramide and mexiletine to reproduce this observation suggests either a previously unreported electrophysiologic effect of, or idiosyncratic response to, procainamide.", "question": "Treatment.Time_elapsed in procainamide", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8186884_3_8076", "context": "The failure of therapy with disopyramide and mexiletine to reproduce this observation suggests either a previously unreported electrophysiologic effect of, or idiosyncratic response to, procainamide.", "question": "Treatment.Duration in procainamide", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8186884_3_8077", "context": "The failure of therapy with disopyramide and mexiletine to reproduce this observation suggests either a previously unreported electrophysiologic effect of, or idiosyncratic response to, procainamide.", "question": "Treatment.Disorder in procainamide", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8186884_3_8078", "context": "The failure of therapy with disopyramide and mexiletine to reproduce this observation suggests either a previously unreported electrophysiologic effect of, or idiosyncratic response to, procainamide.", "question": "Combination.Drug in procainamide", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15944830_5_8079", "context": "The former patient had complained once that his visual acuity had decreased after the termination of IFN therapy, and the latter patient complained twice during IFN therapy that his visual acuity had decreased.", "question": "Subject.Age in The former patient", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "15944830_5_8080", "context": "The former patient had complained once that his visual acuity had decreased after the termination of IFN therapy, and the latter patient complained twice during IFN therapy that his visual acuity had decreased.", "question": "Subject.Gender in The former patient", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15944830_5_8081", "context": "The former patient had complained once that his visual acuity had decreased after the termination of IFN therapy, and the latter patient complained twice during IFN therapy that his visual acuity had decreased.", "question": "Subject.Population in The former patient", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "15944830_5_8082", "context": "The former patient had complained once that his visual acuity had decreased after the termination of IFN therapy, and the latter patient complained twice during IFN therapy that his visual acuity had decreased.", "question": "Subject.Race in The former patient", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15944830_5_8083", "context": "The former patient had complained once that his visual acuity had decreased after the termination of IFN therapy, and the latter patient complained twice during IFN therapy that his visual acuity had decreased.", "question": "Subject.Disorder in The former patient", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15944830_5_8084", "context": "The former patient had complained once that his visual acuity had decreased after the termination of IFN therapy, and the latter patient complained twice during IFN therapy that his visual acuity had decreased.", "question": "Treatment.Drug in IFN", "question_type": "Adverse_event.Treatment.Drug", "answers": "IFN"}, {"id": "15944830_5_8085", "context": "The former patient had complained once that his visual acuity had decreased after the termination of IFN therapy, and the latter patient complained twice during IFN therapy that his visual acuity had decreased.", "question": "Treatment.Dosage in IFN", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15944830_5_8086", "context": "The former patient had complained once that his visual acuity had decreased after the termination of IFN therapy, and the latter patient complained twice during IFN therapy that his visual acuity had decreased.", "question": "Treatment.Freq in IFN", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15944830_5_8087", "context": "The former patient had complained once that his visual acuity had decreased after the termination of IFN therapy, and the latter patient complained twice during IFN therapy that his visual acuity had decreased.", "question": "Treatment.Route in IFN", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15944830_5_8088", "context": "The former patient had complained once that his visual acuity had decreased after the termination of IFN therapy, and the latter patient complained twice during IFN therapy that his visual acuity had decreased.", "question": "Treatment.Time_elapsed in IFN", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15944830_5_8089", "context": "The former patient had complained once that his visual acuity had decreased after the termination of IFN therapy, and the latter patient complained twice during IFN therapy that his visual acuity had decreased.", "question": "Treatment.Duration in IFN", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15944830_5_8090", "context": "The former patient had complained once that his visual acuity had decreased after the termination of IFN therapy, and the latter patient complained twice during IFN therapy that his visual acuity had decreased.", "question": "Treatment.Disorder in IFN", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15944830_5_8091", "context": "The former patient had complained once that his visual acuity had decreased after the termination of IFN therapy, and the latter patient complained twice during IFN therapy that his visual acuity had decreased.", "question": "Combination.Drug in IFN", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15944830_5_8092", "context": "The former patient had complained once that his visual acuity had decreased after the termination of IFN therapy, and the latter patient complained twice during IFN therapy that his visual acuity had decreased.", "question": "Subject.Age in patient", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "15944830_5_8093", "context": "The former patient had complained once that his visual acuity had decreased after the termination of IFN therapy, and the latter patient complained twice during IFN therapy that his visual acuity had decreased.", "question": "Subject.Gender in patient", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15944830_5_8094", "context": "The former patient had complained once that his visual acuity had decreased after the termination of IFN therapy, and the latter patient complained twice during IFN therapy that his visual acuity had decreased.", "question": "Subject.Population in patient", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "15944830_5_8095", "context": "The former patient had complained once that his visual acuity had decreased after the termination of IFN therapy, and the latter patient complained twice during IFN therapy that his visual acuity had decreased.", "question": "Subject.Race in patient", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15944830_5_8096", "context": "The former patient had complained once that his visual acuity had decreased after the termination of IFN therapy, and the latter patient complained twice during IFN therapy that his visual acuity had decreased.", "question": "Subject.Disorder in patient", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15944830_5_8097", "context": "The former patient had complained once that his visual acuity had decreased after the termination of IFN therapy, and the latter patient complained twice during IFN therapy that his visual acuity had decreased.", "question": "Treatment.Drug in IFN therapy", "question_type": "Adverse_event.Treatment.Drug", "answers": "IFN"}, {"id": "15944830_5_8098", "context": "The former patient had complained once that his visual acuity had decreased after the termination of IFN therapy, and the latter patient complained twice during IFN therapy that his visual acuity had decreased.", "question": "Treatment.Dosage in IFN therapy", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15944830_5_8099", "context": "The former patient had complained once that his visual acuity had decreased after the termination of IFN therapy, and the latter patient complained twice during IFN therapy that his visual acuity had decreased.", "question": "Treatment.Freq in IFN therapy", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15944830_5_8100", "context": "The former patient had complained once that his visual acuity had decreased after the termination of IFN therapy, and the latter patient complained twice during IFN therapy that his visual acuity had decreased.", "question": "Treatment.Route in IFN therapy", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15944830_5_8101", "context": "The former patient had complained once that his visual acuity had decreased after the termination of IFN therapy, and the latter patient complained twice during IFN therapy that his visual acuity had decreased.", "question": "Treatment.Time_elapsed in IFN therapy", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15944830_5_8102", "context": "The former patient had complained once that his visual acuity had decreased after the termination of IFN therapy, and the latter patient complained twice during IFN therapy that his visual acuity had decreased.", "question": "Treatment.Duration in IFN therapy", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15944830_5_8103", "context": "The former patient had complained once that his visual acuity had decreased after the termination of IFN therapy, and the latter patient complained twice during IFN therapy that his visual acuity had decreased.", "question": "Treatment.Disorder in IFN therapy", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15944830_5_8104", "context": "The former patient had complained once that his visual acuity had decreased after the termination of IFN therapy, and the latter patient complained twice during IFN therapy that his visual acuity had decreased.", "question": "Combination.Drug in IFN therapy", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11573852_4_8105", "context": "Despite administration of phenytoin and lorazepam, the seizures persisted and occurred only during amphotercin B administration.", "question": "Treatment.Drug in amphotercin B", "question_type": "Adverse_event.Treatment.Drug", "answers": "amphotercin B"}, {"id": "11573852_4_8106", "context": "Despite administration of phenytoin and lorazepam, the seizures persisted and occurred only during amphotercin B administration.", "question": "Treatment.Dosage in amphotercin B", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11573852_4_8107", "context": "Despite administration of phenytoin and lorazepam, the seizures persisted and occurred only during amphotercin B administration.", "question": "Treatment.Freq in amphotercin B", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11573852_4_8108", "context": "Despite administration of phenytoin and lorazepam, the seizures persisted and occurred only during amphotercin B administration.", "question": "Treatment.Route in amphotercin B", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11573852_4_8109", "context": "Despite administration of phenytoin and lorazepam, the seizures persisted and occurred only during amphotercin B administration.", "question": "Treatment.Time_elapsed in amphotercin B", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11573852_4_8110", "context": "Despite administration of phenytoin and lorazepam, the seizures persisted and occurred only during amphotercin B administration.", "question": "Treatment.Duration in amphotercin B", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11573852_4_8111", "context": "Despite administration of phenytoin and lorazepam, the seizures persisted and occurred only during amphotercin B administration.", "question": "Treatment.Disorder in amphotercin B", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11573852_4_8112", "context": "Despite administration of phenytoin and lorazepam, the seizures persisted and occurred only during amphotercin B administration.", "question": "Combination.Drug in amphotercin B", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11247558_3_8113", "context": "We describe a patient who presented with bloody diarrhoea after 15 mg meloxicam daily for 10 days for osteoarthritis.", "question": "Subject.Age in a patient who presented with bloody diarrhoea; osteoarthritis", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "11247558_3_8114", "context": "We describe a patient who presented with bloody diarrhoea after 15 mg meloxicam daily for 10 days for osteoarthritis.", "question": "Subject.Gender in a patient who presented with bloody diarrhoea; osteoarthritis", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "11247558_3_8115", "context": "We describe a patient who presented with bloody diarrhoea after 15 mg meloxicam daily for 10 days for osteoarthritis.", "question": "Subject.Population in a patient who presented with bloody diarrhoea; osteoarthritis", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "11247558_3_8116", "context": "We describe a patient who presented with bloody diarrhoea after 15 mg meloxicam daily for 10 days for osteoarthritis.", "question": "Subject.Race in a patient who presented with bloody diarrhoea; osteoarthritis", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "11247558_3_8117", "context": "We describe a patient who presented with bloody diarrhoea after 15 mg meloxicam daily for 10 days for osteoarthritis.", "question": "Subject.Disorder in a patient who presented with bloody diarrhoea; osteoarthritis", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "11247558_3_8118", "context": "We describe a patient who presented with bloody diarrhoea after 15 mg meloxicam daily for 10 days for osteoarthritis.", "question": "Treatment.Drug in 15 mg meloxicam daily for 10 days", "question_type": "Adverse_event.Treatment.Drug", "answers": "meloxicam"}, {"id": "11247558_3_8119", "context": "We describe a patient who presented with bloody diarrhoea after 15 mg meloxicam daily for 10 days for osteoarthritis.", "question": "Treatment.Dosage in 15 mg meloxicam daily for 10 days", "question_type": "Adverse_event.Treatment.Dosage", "answers": "15 mg"}, {"id": "11247558_3_8120", "context": "We describe a patient who presented with bloody diarrhoea after 15 mg meloxicam daily for 10 days for osteoarthritis.", "question": "Treatment.Freq in 15 mg meloxicam daily for 10 days", "question_type": "Adverse_event.Treatment.Freq", "answers": "daily"}, {"id": "11247558_3_8121", "context": "We describe a patient who presented with bloody diarrhoea after 15 mg meloxicam daily for 10 days for osteoarthritis.", "question": "Treatment.Route in 15 mg meloxicam daily for 10 days", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11247558_3_8122", "context": "We describe a patient who presented with bloody diarrhoea after 15 mg meloxicam daily for 10 days for osteoarthritis.", "question": "Treatment.Time_elapsed in 15 mg meloxicam daily for 10 days", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11247558_3_8123", "context": "We describe a patient who presented with bloody diarrhoea after 15 mg meloxicam daily for 10 days for osteoarthritis.", "question": "Treatment.Duration in 15 mg meloxicam daily for 10 days", "question_type": "Adverse_event.Treatment.Duration", "answers": "10 days"}, {"id": "11247558_3_8124", "context": "We describe a patient who presented with bloody diarrhoea after 15 mg meloxicam daily for 10 days for osteoarthritis.", "question": "Treatment.Disorder in 15 mg meloxicam daily for 10 days", "question_type": "Adverse_event.Treatment.Disorder", "answers": "osteoarthritis"}, {"id": "11247558_3_8125", "context": "We describe a patient who presented with bloody diarrhoea after 15 mg meloxicam daily for 10 days for osteoarthritis.", "question": "Combination.Drug in 15 mg meloxicam daily for 10 days", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7235792_2_8126", "context": "In the first patient, two episodes of ventricular tachycardia requiring cardioversion occurred in close temporal sequence with administering bretylium.", "question": "Subject.Age in first patient", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "7235792_2_8127", "context": "In the first patient, two episodes of ventricular tachycardia requiring cardioversion occurred in close temporal sequence with administering bretylium.", "question": "Subject.Gender in first patient", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "7235792_2_8128", "context": "In the first patient, two episodes of ventricular tachycardia requiring cardioversion occurred in close temporal sequence with administering bretylium.", "question": "Subject.Population in first patient", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "7235792_2_8129", "context": "In the first patient, two episodes of ventricular tachycardia requiring cardioversion occurred in close temporal sequence with administering bretylium.", "question": "Subject.Race in first patient", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "7235792_2_8130", "context": "In the first patient, two episodes of ventricular tachycardia requiring cardioversion occurred in close temporal sequence with administering bretylium.", "question": "Subject.Disorder in first patient", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "7235792_2_8131", "context": "In the first patient, two episodes of ventricular tachycardia requiring cardioversion occurred in close temporal sequence with administering bretylium.", "question": "Treatment.Drug in close temporal sequence with administering bretylium", "question_type": "Adverse_event.Treatment.Drug", "answers": "bretylium"}, {"id": "7235792_2_8132", "context": "In the first patient, two episodes of ventricular tachycardia requiring cardioversion occurred in close temporal sequence with administering bretylium.", "question": "Treatment.Dosage in close temporal sequence with administering bretylium", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7235792_2_8133", "context": "In the first patient, two episodes of ventricular tachycardia requiring cardioversion occurred in close temporal sequence with administering bretylium.", "question": "Treatment.Freq in close temporal sequence with administering bretylium", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7235792_2_8134", "context": "In the first patient, two episodes of ventricular tachycardia requiring cardioversion occurred in close temporal sequence with administering bretylium.", "question": "Treatment.Route in close temporal sequence with administering bretylium", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7235792_2_8135", "context": "In the first patient, two episodes of ventricular tachycardia requiring cardioversion occurred in close temporal sequence with administering bretylium.", "question": "Treatment.Time_elapsed in close temporal sequence with administering bretylium", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "close temporal sequence"}, {"id": "7235792_2_8136", "context": "In the first patient, two episodes of ventricular tachycardia requiring cardioversion occurred in close temporal sequence with administering bretylium.", "question": "Treatment.Duration in close temporal sequence with administering bretylium", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7235792_2_8137", "context": "In the first patient, two episodes of ventricular tachycardia requiring cardioversion occurred in close temporal sequence with administering bretylium.", "question": "Treatment.Disorder in close temporal sequence with administering bretylium", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7235792_2_8138", "context": "In the first patient, two episodes of ventricular tachycardia requiring cardioversion occurred in close temporal sequence with administering bretylium.", "question": "Combination.Drug in close temporal sequence with administering bretylium", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3030084_1_8139", "context": "Transient phenytoin induced IgA deficiency and permanent IgE increase.", "question": "Treatment.Drug in phenytoin", "question_type": "Adverse_event.Treatment.Drug", "answers": "phenytoin"}, {"id": "3030084_1_8140", "context": "Transient phenytoin induced IgA deficiency and permanent IgE increase.", "question": "Treatment.Dosage in phenytoin", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3030084_1_8141", "context": "Transient phenytoin induced IgA deficiency and permanent IgE increase.", "question": "Treatment.Freq in phenytoin", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3030084_1_8142", "context": "Transient phenytoin induced IgA deficiency and permanent IgE increase.", "question": "Treatment.Route in phenytoin", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3030084_1_8143", "context": "Transient phenytoin induced IgA deficiency and permanent IgE increase.", "question": "Treatment.Time_elapsed in phenytoin", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3030084_1_8144", "context": "Transient phenytoin induced IgA deficiency and permanent IgE increase.", "question": "Treatment.Duration in phenytoin", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3030084_1_8145", "context": "Transient phenytoin induced IgA deficiency and permanent IgE increase.", "question": "Treatment.Disorder in phenytoin", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3030084_1_8146", "context": "Transient phenytoin induced IgA deficiency and permanent IgE increase.", "question": "Combination.Drug in phenytoin", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15701285_1_8147", "context": "Cerebral edema associated with Gliadel wafers: two case studies.", "question": "Treatment.Drug in Gliadel wafers", "question_type": "Adverse_event.Treatment.Drug", "answers": "Gliadel"}, {"id": "15701285_1_8148", "context": "Cerebral edema associated with Gliadel wafers: two case studies.", "question": "Treatment.Dosage in Gliadel wafers", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15701285_1_8149", "context": "Cerebral edema associated with Gliadel wafers: two case studies.", "question": "Treatment.Freq in Gliadel wafers", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15701285_1_8150", "context": "Cerebral edema associated with Gliadel wafers: two case studies.", "question": "Treatment.Route in Gliadel wafers", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15701285_1_8151", "context": "Cerebral edema associated with Gliadel wafers: two case studies.", "question": "Treatment.Time_elapsed in Gliadel wafers", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15701285_1_8152", "context": "Cerebral edema associated with Gliadel wafers: two case studies.", "question": "Treatment.Duration in Gliadel wafers", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15701285_1_8153", "context": "Cerebral edema associated with Gliadel wafers: two case studies.", "question": "Treatment.Disorder in Gliadel wafers", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15701285_1_8154", "context": "Cerebral edema associated with Gliadel wafers: two case studies.", "question": "Combination.Drug in Gliadel wafers", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8305778_4_8155", "context": "Following the development of restless leg syndrome, therapy with clonazepam 0.5 mg qhs was initiated.", "question": "Treatment.Drug in clonazepam 0.5 mg qhs", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "clonazepam"}, {"id": "8305778_4_8156", "context": "Following the development of restless leg syndrome, therapy with clonazepam 0.5 mg qhs was initiated.", "question": "Treatment.Dosage in clonazepam 0.5 mg qhs", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": "0.5 mg qhs"}, {"id": "8305778_4_8157", "context": "Following the development of restless leg syndrome, therapy with clonazepam 0.5 mg qhs was initiated.", "question": "Treatment.Freq in clonazepam 0.5 mg qhs", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "8305778_4_8158", "context": "Following the development of restless leg syndrome, therapy with clonazepam 0.5 mg qhs was initiated.", "question": "Treatment.Route in clonazepam 0.5 mg qhs", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "8305778_4_8159", "context": "Following the development of restless leg syndrome, therapy with clonazepam 0.5 mg qhs was initiated.", "question": "Treatment.Time_elapsed in clonazepam 0.5 mg qhs", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8305778_4_8160", "context": "Following the development of restless leg syndrome, therapy with clonazepam 0.5 mg qhs was initiated.", "question": "Treatment.Duration in clonazepam 0.5 mg qhs", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "8305778_4_8161", "context": "Following the development of restless leg syndrome, therapy with clonazepam 0.5 mg qhs was initiated.", "question": "Treatment.Disorder in clonazepam 0.5 mg qhs", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "restless leg syndrome"}, {"id": "8305778_4_8162", "context": "Following the development of restless leg syndrome, therapy with clonazepam 0.5 mg qhs was initiated.", "question": "Combination.Drug in clonazepam 0.5 mg qhs", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "15362597_2_8163", "context": "We present a case of a diabetic patient taking glyburide who was prescribed ciprofloxacin and developed prolonged hypoglycemia, which persisted for over 24 hours.", "question": "Subject.Age in a case of a diabetic patient taking glyburide", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "15362597_2_8164", "context": "We present a case of a diabetic patient taking glyburide who was prescribed ciprofloxacin and developed prolonged hypoglycemia, which persisted for over 24 hours.", "question": "Subject.Gender in a case of a diabetic patient taking glyburide", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15362597_2_8165", "context": "We present a case of a diabetic patient taking glyburide who was prescribed ciprofloxacin and developed prolonged hypoglycemia, which persisted for over 24 hours.", "question": "Subject.Population in a case of a diabetic patient taking glyburide", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "15362597_2_8166", "context": "We present a case of a diabetic patient taking glyburide who was prescribed ciprofloxacin and developed prolonged hypoglycemia, which persisted for over 24 hours.", "question": "Subject.Race in a case of a diabetic patient taking glyburide", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15362597_2_8167", "context": "We present a case of a diabetic patient taking glyburide who was prescribed ciprofloxacin and developed prolonged hypoglycemia, which persisted for over 24 hours.", "question": "Subject.Disorder in a case of a diabetic patient taking glyburide", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15362597_2_8168", "context": "We present a case of a diabetic patient taking glyburide who was prescribed ciprofloxacin and developed prolonged hypoglycemia, which persisted for over 24 hours.", "question": "Treatment.Drug in ciprofloxacin", "question_type": "Adverse_event.Treatment.Drug", "answers": "glyburide; ciprofloxacin"}, {"id": "15362597_2_8169", "context": "We present a case of a diabetic patient taking glyburide who was prescribed ciprofloxacin and developed prolonged hypoglycemia, which persisted for over 24 hours.", "question": "Treatment.Dosage in ciprofloxacin", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15362597_2_8170", "context": "We present a case of a diabetic patient taking glyburide who was prescribed ciprofloxacin and developed prolonged hypoglycemia, which persisted for over 24 hours.", "question": "Treatment.Freq in ciprofloxacin", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15362597_2_8171", "context": "We present a case of a diabetic patient taking glyburide who was prescribed ciprofloxacin and developed prolonged hypoglycemia, which persisted for over 24 hours.", "question": "Treatment.Route in ciprofloxacin", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15362597_2_8172", "context": "We present a case of a diabetic patient taking glyburide who was prescribed ciprofloxacin and developed prolonged hypoglycemia, which persisted for over 24 hours.", "question": "Treatment.Time_elapsed in ciprofloxacin", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15362597_2_8173", "context": "We present a case of a diabetic patient taking glyburide who was prescribed ciprofloxacin and developed prolonged hypoglycemia, which persisted for over 24 hours.", "question": "Treatment.Duration in ciprofloxacin", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15362597_2_8174", "context": "We present a case of a diabetic patient taking glyburide who was prescribed ciprofloxacin and developed prolonged hypoglycemia, which persisted for over 24 hours.", "question": "Treatment.Disorder in ciprofloxacin", "question_type": "Adverse_event.Treatment.Disorder", "answers": "diabetic"}, {"id": "15362597_2_8175", "context": "We present a case of a diabetic patient taking glyburide who was prescribed ciprofloxacin and developed prolonged hypoglycemia, which persisted for over 24 hours.", "question": "Combination.Drug in ciprofloxacin", "question_type": "Adverse_event.Combination.Drug", "answers": "glyburide; ciprofloxacin"}, {"id": "12399645_4_8176", "context": "We describe a 74-year-old man with rheumatoid arthritis (RA) who developed syndrome of inappropriate secretion of antidiuretic hormone (SIADH) 1.5 months after commencement of mizoribin prescription when his arthritis was improved.", "question": "Subject.Age in a 74-year-old man with rheumatoid arthritis (RA)", "question_type": "Adverse_event.Subject.Age", "answers": "74-year-old"}, {"id": "12399645_4_8177", "context": "We describe a 74-year-old man with rheumatoid arthritis (RA) who developed syndrome of inappropriate secretion of antidiuretic hormone (SIADH) 1.5 months after commencement of mizoribin prescription when his arthritis was improved.", "question": "Subject.Gender in a 74-year-old man with rheumatoid arthritis (RA)", "question_type": "Adverse_event.Subject.Gender", "answers": "man"}, {"id": "12399645_4_8178", "context": "We describe a 74-year-old man with rheumatoid arthritis (RA) who developed syndrome of inappropriate secretion of antidiuretic hormone (SIADH) 1.5 months after commencement of mizoribin prescription when his arthritis was improved.", "question": "Subject.Population in a 74-year-old man with rheumatoid arthritis (RA)", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "12399645_4_8179", "context": "We describe a 74-year-old man with rheumatoid arthritis (RA) who developed syndrome of inappropriate secretion of antidiuretic hormone (SIADH) 1.5 months after commencement of mizoribin prescription when his arthritis was improved.", "question": "Subject.Race in a 74-year-old man with rheumatoid arthritis (RA)", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "12399645_4_8180", "context": "We describe a 74-year-old man with rheumatoid arthritis (RA) who developed syndrome of inappropriate secretion of antidiuretic hormone (SIADH) 1.5 months after commencement of mizoribin prescription when his arthritis was improved.", "question": "Subject.Disorder in a 74-year-old man with rheumatoid arthritis (RA)", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "12399645_4_8181", "context": "We describe a 74-year-old man with rheumatoid arthritis (RA) who developed syndrome of inappropriate secretion of antidiuretic hormone (SIADH) 1.5 months after commencement of mizoribin prescription when his arthritis was improved.", "question": "Treatment.Drug in 1.5 months after commencement of mizoribin prescription", "question_type": "Adverse_event.Treatment.Drug", "answers": "mizoribin"}, {"id": "12399645_4_8182", "context": "We describe a 74-year-old man with rheumatoid arthritis (RA) who developed syndrome of inappropriate secretion of antidiuretic hormone (SIADH) 1.5 months after commencement of mizoribin prescription when his arthritis was improved.", "question": "Treatment.Dosage in 1.5 months after commencement of mizoribin prescription", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12399645_4_8183", "context": "We describe a 74-year-old man with rheumatoid arthritis (RA) who developed syndrome of inappropriate secretion of antidiuretic hormone (SIADH) 1.5 months after commencement of mizoribin prescription when his arthritis was improved.", "question": "Treatment.Freq in 1.5 months after commencement of mizoribin prescription", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12399645_4_8184", "context": "We describe a 74-year-old man with rheumatoid arthritis (RA) who developed syndrome of inappropriate secretion of antidiuretic hormone (SIADH) 1.5 months after commencement of mizoribin prescription when his arthritis was improved.", "question": "Treatment.Route in 1.5 months after commencement of mizoribin prescription", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12399645_4_8185", "context": "We describe a 74-year-old man with rheumatoid arthritis (RA) who developed syndrome of inappropriate secretion of antidiuretic hormone (SIADH) 1.5 months after commencement of mizoribin prescription when his arthritis was improved.", "question": "Treatment.Time_elapsed in 1.5 months after commencement of mizoribin prescription", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "1.5 months after"}, {"id": "12399645_4_8186", "context": "We describe a 74-year-old man with rheumatoid arthritis (RA) who developed syndrome of inappropriate secretion of antidiuretic hormone (SIADH) 1.5 months after commencement of mizoribin prescription when his arthritis was improved.", "question": "Treatment.Duration in 1.5 months after commencement of mizoribin prescription", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12399645_4_8187", "context": "We describe a 74-year-old man with rheumatoid arthritis (RA) who developed syndrome of inappropriate secretion of antidiuretic hormone (SIADH) 1.5 months after commencement of mizoribin prescription when his arthritis was improved.", "question": "Treatment.Disorder in 1.5 months after commencement of mizoribin prescription", "question_type": "Adverse_event.Treatment.Disorder", "answers": "rheumatoid arthritis"}, {"id": "12399645_4_8188", "context": "We describe a 74-year-old man with rheumatoid arthritis (RA) who developed syndrome of inappropriate secretion of antidiuretic hormone (SIADH) 1.5 months after commencement of mizoribin prescription when his arthritis was improved.", "question": "Combination.Drug in 1.5 months after commencement of mizoribin prescription", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16682062_2_8189", "context": "To our knowledge, this is the first case of ivermectin-induced severe liver disease published in the literature.", "question": "Treatment.Drug in ivermectin", "question_type": "Adverse_event.Treatment.Drug", "answers": "ivermectin"}, {"id": "16682062_2_8190", "context": "To our knowledge, this is the first case of ivermectin-induced severe liver disease published in the literature.", "question": "Treatment.Dosage in ivermectin", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16682062_2_8191", "context": "To our knowledge, this is the first case of ivermectin-induced severe liver disease published in the literature.", "question": "Treatment.Freq in ivermectin", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16682062_2_8192", "context": "To our knowledge, this is the first case of ivermectin-induced severe liver disease published in the literature.", "question": "Treatment.Route in ivermectin", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16682062_2_8193", "context": "To our knowledge, this is the first case of ivermectin-induced severe liver disease published in the literature.", "question": "Treatment.Time_elapsed in ivermectin", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16682062_2_8194", "context": "To our knowledge, this is the first case of ivermectin-induced severe liver disease published in the literature.", "question": "Treatment.Duration in ivermectin", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16682062_2_8195", "context": "To our knowledge, this is the first case of ivermectin-induced severe liver disease published in the literature.", "question": "Treatment.Disorder in ivermectin", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16682062_2_8196", "context": "To our knowledge, this is the first case of ivermectin-induced severe liver disease published in the literature.", "question": "Combination.Drug in ivermectin", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10348150_3_8197", "context": "This is the first case of hydroxyurea-induced acute interstitial pneumonitis reported in the literature.", "question": "Treatment.Drug in hydroxyurea", "question_type": "Adverse_event.Treatment.Drug", "answers": "hydroxyurea"}, {"id": "10348150_3_8198", "context": "This is the first case of hydroxyurea-induced acute interstitial pneumonitis reported in the literature.", "question": "Treatment.Dosage in hydroxyurea", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10348150_3_8199", "context": "This is the first case of hydroxyurea-induced acute interstitial pneumonitis reported in the literature.", "question": "Treatment.Freq in hydroxyurea", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10348150_3_8200", "context": "This is the first case of hydroxyurea-induced acute interstitial pneumonitis reported in the literature.", "question": "Treatment.Route in hydroxyurea", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10348150_3_8201", "context": "This is the first case of hydroxyurea-induced acute interstitial pneumonitis reported in the literature.", "question": "Treatment.Time_elapsed in hydroxyurea", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10348150_3_8202", "context": "This is the first case of hydroxyurea-induced acute interstitial pneumonitis reported in the literature.", "question": "Treatment.Duration in hydroxyurea", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10348150_3_8203", "context": "This is the first case of hydroxyurea-induced acute interstitial pneumonitis reported in the literature.", "question": "Treatment.Disorder in hydroxyurea", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10348150_3_8204", "context": "This is the first case of hydroxyurea-induced acute interstitial pneumonitis reported in the literature.", "question": "Combination.Drug in hydroxyurea", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17301517_1_8205", "context": "A 32-year-old man with a family history of type 2 diabetes mellitus presented with circulatory collapse and deep coma after 9 days of treatment with perospirone hydrochloride, a recently developed atypical antipsychotic agent available only in Japan.", "question": "Subject.Age in A 32-year-old man with a family history of type 2 diabetes mellitus", "question_type": "Adverse_event.Subject.Age", "answers": "32-year-old"}, {"id": "17301517_1_8206", "context": "A 32-year-old man with a family history of type 2 diabetes mellitus presented with circulatory collapse and deep coma after 9 days of treatment with perospirone hydrochloride, a recently developed atypical antipsychotic agent available only in Japan.", "question": "Subject.Gender in A 32-year-old man with a family history of type 2 diabetes mellitus", "question_type": "Adverse_event.Subject.Gender", "answers": "man"}, {"id": "17301517_1_8207", "context": "A 32-year-old man with a family history of type 2 diabetes mellitus presented with circulatory collapse and deep coma after 9 days of treatment with perospirone hydrochloride, a recently developed atypical antipsychotic agent available only in Japan.", "question": "Subject.Population in A 32-year-old man with a family history of type 2 diabetes mellitus", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "17301517_1_8208", "context": "A 32-year-old man with a family history of type 2 diabetes mellitus presented with circulatory collapse and deep coma after 9 days of treatment with perospirone hydrochloride, a recently developed atypical antipsychotic agent available only in Japan.", "question": "Subject.Race in A 32-year-old man with a family history of type 2 diabetes mellitus", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "17301517_1_8209", "context": "A 32-year-old man with a family history of type 2 diabetes mellitus presented with circulatory collapse and deep coma after 9 days of treatment with perospirone hydrochloride, a recently developed atypical antipsychotic agent available only in Japan.", "question": "Subject.Disorder in A 32-year-old man with a family history of type 2 diabetes mellitus", "question_type": "Adverse_event.Subject.Disorder", "answers": "type 2 diabetes mellitus"}, {"id": "17301517_1_8210", "context": "A 32-year-old man with a family history of type 2 diabetes mellitus presented with circulatory collapse and deep coma after 9 days of treatment with perospirone hydrochloride, a recently developed atypical antipsychotic agent available only in Japan.", "question": "Treatment.Drug in 9 days of treatment with perospirone hydrochloride", "question_type": "Adverse_event.Treatment.Drug", "answers": "perospirone hydrochloride"}, {"id": "17301517_1_8211", "context": "A 32-year-old man with a family history of type 2 diabetes mellitus presented with circulatory collapse and deep coma after 9 days of treatment with perospirone hydrochloride, a recently developed atypical antipsychotic agent available only in Japan.", "question": "Treatment.Dosage in 9 days of treatment with perospirone hydrochloride", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17301517_1_8212", "context": "A 32-year-old man with a family history of type 2 diabetes mellitus presented with circulatory collapse and deep coma after 9 days of treatment with perospirone hydrochloride, a recently developed atypical antipsychotic agent available only in Japan.", "question": "Treatment.Freq in 9 days of treatment with perospirone hydrochloride", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17301517_1_8213", "context": "A 32-year-old man with a family history of type 2 diabetes mellitus presented with circulatory collapse and deep coma after 9 days of treatment with perospirone hydrochloride, a recently developed atypical antipsychotic agent available only in Japan.", "question": "Treatment.Route in 9 days of treatment with perospirone hydrochloride", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17301517_1_8214", "context": "A 32-year-old man with a family history of type 2 diabetes mellitus presented with circulatory collapse and deep coma after 9 days of treatment with perospirone hydrochloride, a recently developed atypical antipsychotic agent available only in Japan.", "question": "Treatment.Time_elapsed in 9 days of treatment with perospirone hydrochloride", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "after 9 days"}, {"id": "17301517_1_8215", "context": "A 32-year-old man with a family history of type 2 diabetes mellitus presented with circulatory collapse and deep coma after 9 days of treatment with perospirone hydrochloride, a recently developed atypical antipsychotic agent available only in Japan.", "question": "Treatment.Duration in 9 days of treatment with perospirone hydrochloride", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17301517_1_8216", "context": "A 32-year-old man with a family history of type 2 diabetes mellitus presented with circulatory collapse and deep coma after 9 days of treatment with perospirone hydrochloride, a recently developed atypical antipsychotic agent available only in Japan.", "question": "Treatment.Disorder in 9 days of treatment with perospirone hydrochloride", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17301517_1_8217", "context": "A 32-year-old man with a family history of type 2 diabetes mellitus presented with circulatory collapse and deep coma after 9 days of treatment with perospirone hydrochloride, a recently developed atypical antipsychotic agent available only in Japan.", "question": "Combination.Drug in 9 days of treatment with perospirone hydrochloride", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16615675_3_8218", "context": "CONCLUSION: The chronic use of HCQ for rheumatic diseases, or as an anti-malarial drug, should be balanced against the risk of developing potentially lethal cardiac arrhythmias.", "question": "Treatment.Drug in chronic use of HCQ", "question_type": "Adverse_event.Treatment.Drug", "answers": "HCQ"}, {"id": "16615675_3_8219", "context": "CONCLUSION: The chronic use of HCQ for rheumatic diseases, or as an anti-malarial drug, should be balanced against the risk of developing potentially lethal cardiac arrhythmias.", "question": "Treatment.Dosage in chronic use of HCQ", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16615675_3_8220", "context": "CONCLUSION: The chronic use of HCQ for rheumatic diseases, or as an anti-malarial drug, should be balanced against the risk of developing potentially lethal cardiac arrhythmias.", "question": "Treatment.Freq in chronic use of HCQ", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16615675_3_8221", "context": "CONCLUSION: The chronic use of HCQ for rheumatic diseases, or as an anti-malarial drug, should be balanced against the risk of developing potentially lethal cardiac arrhythmias.", "question": "Treatment.Route in chronic use of HCQ", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16615675_3_8222", "context": "CONCLUSION: The chronic use of HCQ for rheumatic diseases, or as an anti-malarial drug, should be balanced against the risk of developing potentially lethal cardiac arrhythmias.", "question": "Treatment.Time_elapsed in chronic use of HCQ", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16615675_3_8223", "context": "CONCLUSION: The chronic use of HCQ for rheumatic diseases, or as an anti-malarial drug, should be balanced against the risk of developing potentially lethal cardiac arrhythmias.", "question": "Treatment.Duration in chronic use of HCQ", "question_type": "Adverse_event.Treatment.Duration", "answers": "chronic"}, {"id": "16615675_3_8224", "context": "CONCLUSION: The chronic use of HCQ for rheumatic diseases, or as an anti-malarial drug, should be balanced against the risk of developing potentially lethal cardiac arrhythmias.", "question": "Treatment.Disorder in chronic use of HCQ", "question_type": "Adverse_event.Treatment.Disorder", "answers": "rheumatic diseases"}, {"id": "16615675_3_8225", "context": "CONCLUSION: The chronic use of HCQ for rheumatic diseases, or as an anti-malarial drug, should be balanced against the risk of developing potentially lethal cardiac arrhythmias.", "question": "Combination.Drug in chronic use of HCQ", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3400849_1_8226", "context": "Myoclonic spasms following intrathecal morphine.", "question": "Treatment.Drug in intrathecal morphine", "question_type": "Adverse_event.Treatment.Drug", "answers": "morphine."}, {"id": "3400849_1_8227", "context": "Myoclonic spasms following intrathecal morphine.", "question": "Treatment.Dosage in intrathecal morphine", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3400849_1_8228", "context": "Myoclonic spasms following intrathecal morphine.", "question": "Treatment.Freq in intrathecal morphine", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3400849_1_8229", "context": "Myoclonic spasms following intrathecal morphine.", "question": "Treatment.Route in intrathecal morphine", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3400849_1_8230", "context": "Myoclonic spasms following intrathecal morphine.", "question": "Treatment.Time_elapsed in intrathecal morphine", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3400849_1_8231", "context": "Myoclonic spasms following intrathecal morphine.", "question": "Treatment.Duration in intrathecal morphine", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3400849_1_8232", "context": "Myoclonic spasms following intrathecal morphine.", "question": "Treatment.Disorder in intrathecal morphine", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3400849_1_8233", "context": "Myoclonic spasms following intrathecal morphine.", "question": "Combination.Drug in intrathecal morphine", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6324592_2_8234", "context": "This is the first report of a disulfiram-like reaction with cefmenoxime.", "question": "Treatment.Drug in cefmenoxime", "question_type": "Adverse_event.Treatment.Drug", "answers": "cefmenoxime"}, {"id": "6324592_2_8235", "context": "This is the first report of a disulfiram-like reaction with cefmenoxime.", "question": "Treatment.Dosage in cefmenoxime", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6324592_2_8236", "context": "This is the first report of a disulfiram-like reaction with cefmenoxime.", "question": "Treatment.Freq in cefmenoxime", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6324592_2_8237", "context": "This is the first report of a disulfiram-like reaction with cefmenoxime.", "question": "Treatment.Route in cefmenoxime", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6324592_2_8238", "context": "This is the first report of a disulfiram-like reaction with cefmenoxime.", "question": "Treatment.Time_elapsed in cefmenoxime", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6324592_2_8239", "context": "This is the first report of a disulfiram-like reaction with cefmenoxime.", "question": "Treatment.Duration in cefmenoxime", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6324592_2_8240", "context": "This is the first report of a disulfiram-like reaction with cefmenoxime.", "question": "Treatment.Disorder in cefmenoxime", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6324592_2_8241", "context": "This is the first report of a disulfiram-like reaction with cefmenoxime.", "question": "Combination.Drug in cefmenoxime", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "22010004_2_8242", "context": "To report a case of a probable interaction between warfarin and extended-release niacin that may have led to synergistic coagulopathy and to inform health care providers of a need for more frequent monitoring of international normalized ratio (INR) in patients taking these drugs concomitantly.", "question": "Treatment.Drug in warfarin and extended-release niacin", "question_type": "Adverse_event.Treatment.Drug", "answers": "warfarin; niacin"}, {"id": "22010004_2_8243", "context": "To report a case of a probable interaction between warfarin and extended-release niacin that may have led to synergistic coagulopathy and to inform health care providers of a need for more frequent monitoring of international normalized ratio (INR) in patients taking these drugs concomitantly.", "question": "Treatment.Dosage in warfarin and extended-release niacin", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "22010004_2_8244", "context": "To report a case of a probable interaction between warfarin and extended-release niacin that may have led to synergistic coagulopathy and to inform health care providers of a need for more frequent monitoring of international normalized ratio (INR) in patients taking these drugs concomitantly.", "question": "Treatment.Freq in warfarin and extended-release niacin", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "22010004_2_8245", "context": "To report a case of a probable interaction between warfarin and extended-release niacin that may have led to synergistic coagulopathy and to inform health care providers of a need for more frequent monitoring of international normalized ratio (INR) in patients taking these drugs concomitantly.", "question": "Treatment.Route in warfarin and extended-release niacin", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "22010004_2_8246", "context": "To report a case of a probable interaction between warfarin and extended-release niacin that may have led to synergistic coagulopathy and to inform health care providers of a need for more frequent monitoring of international normalized ratio (INR) in patients taking these drugs concomitantly.", "question": "Treatment.Time_elapsed in warfarin and extended-release niacin", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "22010004_2_8247", "context": "To report a case of a probable interaction between warfarin and extended-release niacin that may have led to synergistic coagulopathy and to inform health care providers of a need for more frequent monitoring of international normalized ratio (INR) in patients taking these drugs concomitantly.", "question": "Treatment.Duration in warfarin and extended-release niacin", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "22010004_2_8248", "context": "To report a case of a probable interaction between warfarin and extended-release niacin that may have led to synergistic coagulopathy and to inform health care providers of a need for more frequent monitoring of international normalized ratio (INR) in patients taking these drugs concomitantly.", "question": "Treatment.Disorder in warfarin and extended-release niacin", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "22010004_2_8249", "context": "To report a case of a probable interaction between warfarin and extended-release niacin that may have led to synergistic coagulopathy and to inform health care providers of a need for more frequent monitoring of international normalized ratio (INR) in patients taking these drugs concomitantly.", "question": "Combination.Drug in warfarin and extended-release niacin", "question_type": "Adverse_event.Combination.Drug", "answers": "niacin; warfarin"}, {"id": "19838099_2_8250", "context": "Dasatinib-induced pleural effusions: a lymphatic network disorder?", "question": "Treatment.Drug in Dasatinib", "question_type": "Adverse_event.Treatment.Drug", "answers": "Dasatinib"}, {"id": "19838099_2_8251", "context": "Dasatinib-induced pleural effusions: a lymphatic network disorder?", "question": "Treatment.Dosage in Dasatinib", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "19838099_2_8252", "context": "Dasatinib-induced pleural effusions: a lymphatic network disorder?", "question": "Treatment.Freq in Dasatinib", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "19838099_2_8253", "context": "Dasatinib-induced pleural effusions: a lymphatic network disorder?", "question": "Treatment.Route in Dasatinib", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "19838099_2_8254", "context": "Dasatinib-induced pleural effusions: a lymphatic network disorder?", "question": "Treatment.Time_elapsed in Dasatinib", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19838099_2_8255", "context": "Dasatinib-induced pleural effusions: a lymphatic network disorder?", "question": "Treatment.Duration in Dasatinib", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "19838099_2_8256", "context": "Dasatinib-induced pleural effusions: a lymphatic network disorder?", "question": "Treatment.Disorder in Dasatinib", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "19838099_2_8257", "context": "Dasatinib-induced pleural effusions: a lymphatic network disorder?", "question": "Combination.Drug in Dasatinib", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9819544_3_8258", "context": "This article reports the case of an otherwise healthy patient who experienced permanent sensorineural hearing loss after a brief course of naproxen and reviews the literature on NSAID-related permanent sensorineural hearing loss.", "question": "Subject.Age in an otherwise healthy patient", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "9819544_3_8259", "context": "This article reports the case of an otherwise healthy patient who experienced permanent sensorineural hearing loss after a brief course of naproxen and reviews the literature on NSAID-related permanent sensorineural hearing loss.", "question": "Subject.Gender in an otherwise healthy patient", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "9819544_3_8260", "context": "This article reports the case of an otherwise healthy patient who experienced permanent sensorineural hearing loss after a brief course of naproxen and reviews the literature on NSAID-related permanent sensorineural hearing loss.", "question": "Subject.Population in an otherwise healthy patient", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "9819544_3_8261", "context": "This article reports the case of an otherwise healthy patient who experienced permanent sensorineural hearing loss after a brief course of naproxen and reviews the literature on NSAID-related permanent sensorineural hearing loss.", "question": "Subject.Race in an otherwise healthy patient", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "9819544_3_8262", "context": "This article reports the case of an otherwise healthy patient who experienced permanent sensorineural hearing loss after a brief course of naproxen and reviews the literature on NSAID-related permanent sensorineural hearing loss.", "question": "Subject.Disorder in an otherwise healthy patient", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "9819544_3_8263", "context": "This article reports the case of an otherwise healthy patient who experienced permanent sensorineural hearing loss after a brief course of naproxen and reviews the literature on NSAID-related permanent sensorineural hearing loss.", "question": "Treatment.Drug in a brief course of naproxen", "question_type": "Adverse_event.Treatment.Drug", "answers": "naproxen"}, {"id": "9819544_3_8264", "context": "This article reports the case of an otherwise healthy patient who experienced permanent sensorineural hearing loss after a brief course of naproxen and reviews the literature on NSAID-related permanent sensorineural hearing loss.", "question": "Treatment.Dosage in a brief course of naproxen", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9819544_3_8265", "context": "This article reports the case of an otherwise healthy patient who experienced permanent sensorineural hearing loss after a brief course of naproxen and reviews the literature on NSAID-related permanent sensorineural hearing loss.", "question": "Treatment.Freq in a brief course of naproxen", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9819544_3_8266", "context": "This article reports the case of an otherwise healthy patient who experienced permanent sensorineural hearing loss after a brief course of naproxen and reviews the literature on NSAID-related permanent sensorineural hearing loss.", "question": "Treatment.Route in a brief course of naproxen", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9819544_3_8267", "context": "This article reports the case of an otherwise healthy patient who experienced permanent sensorineural hearing loss after a brief course of naproxen and reviews the literature on NSAID-related permanent sensorineural hearing loss.", "question": "Treatment.Time_elapsed in a brief course of naproxen", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9819544_3_8268", "context": "This article reports the case of an otherwise healthy patient who experienced permanent sensorineural hearing loss after a brief course of naproxen and reviews the literature on NSAID-related permanent sensorineural hearing loss.", "question": "Treatment.Duration in a brief course of naproxen", "question_type": "Adverse_event.Treatment.Duration", "answers": "brief course"}, {"id": "9819544_3_8269", "context": "This article reports the case of an otherwise healthy patient who experienced permanent sensorineural hearing loss after a brief course of naproxen and reviews the literature on NSAID-related permanent sensorineural hearing loss.", "question": "Treatment.Disorder in a brief course of naproxen", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9819544_3_8270", "context": "This article reports the case of an otherwise healthy patient who experienced permanent sensorineural hearing loss after a brief course of naproxen and reviews the literature on NSAID-related permanent sensorineural hearing loss.", "question": "Combination.Drug in a brief course of naproxen", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9695308_1_8271", "context": "Administration of steroid and decreasing the dose of PTU produced a good clinical response and the ANCA disappeared.", "question": "Treatment.Drug in steroid; PTU", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "steroid; PTU"}, {"id": "9695308_1_8272", "context": "Administration of steroid and decreasing the dose of PTU produced a good clinical response and the ANCA disappeared.", "question": "Treatment.Dosage in steroid; PTU", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "9695308_1_8273", "context": "Administration of steroid and decreasing the dose of PTU produced a good clinical response and the ANCA disappeared.", "question": "Treatment.Freq in steroid; PTU", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "9695308_1_8274", "context": "Administration of steroid and decreasing the dose of PTU produced a good clinical response and the ANCA disappeared.", "question": "Treatment.Route in steroid; PTU", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "9695308_1_8275", "context": "Administration of steroid and decreasing the dose of PTU produced a good clinical response and the ANCA disappeared.", "question": "Treatment.Time_elapsed in steroid; PTU", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9695308_1_8276", "context": "Administration of steroid and decreasing the dose of PTU produced a good clinical response and the ANCA disappeared.", "question": "Treatment.Duration in steroid; PTU", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "9695308_1_8277", "context": "Administration of steroid and decreasing the dose of PTU produced a good clinical response and the ANCA disappeared.", "question": "Treatment.Disorder in steroid; PTU", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "9695308_1_8278", "context": "Administration of steroid and decreasing the dose of PTU produced a good clinical response and the ANCA disappeared.", "question": "Combination.Drug in steroid; PTU", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "18562412_5_8279", "context": "The second patient exhibited sudden PLMS following olanzapine injection.", "question": "Subject.Age in The second patient", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "18562412_5_8280", "context": "The second patient exhibited sudden PLMS following olanzapine injection.", "question": "Subject.Gender in The second patient", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "18562412_5_8281", "context": "The second patient exhibited sudden PLMS following olanzapine injection.", "question": "Subject.Population in The second patient", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "18562412_5_8282", "context": "The second patient exhibited sudden PLMS following olanzapine injection.", "question": "Subject.Race in The second patient", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "18562412_5_8283", "context": "The second patient exhibited sudden PLMS following olanzapine injection.", "question": "Subject.Disorder in The second patient", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "18562412_5_8284", "context": "The second patient exhibited sudden PLMS following olanzapine injection.", "question": "Treatment.Drug in olanzapine injection", "question_type": "Adverse_event.Treatment.Drug", "answers": "olanzapine"}, {"id": "18562412_5_8285", "context": "The second patient exhibited sudden PLMS following olanzapine injection.", "question": "Treatment.Dosage in olanzapine injection", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18562412_5_8286", "context": "The second patient exhibited sudden PLMS following olanzapine injection.", "question": "Treatment.Freq in olanzapine injection", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18562412_5_8287", "context": "The second patient exhibited sudden PLMS following olanzapine injection.", "question": "Treatment.Route in olanzapine injection", "question_type": "Adverse_event.Treatment.Route", "answers": "injection"}, {"id": "18562412_5_8288", "context": "The second patient exhibited sudden PLMS following olanzapine injection.", "question": "Treatment.Time_elapsed in olanzapine injection", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18562412_5_8289", "context": "The second patient exhibited sudden PLMS following olanzapine injection.", "question": "Treatment.Duration in olanzapine injection", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18562412_5_8290", "context": "The second patient exhibited sudden PLMS following olanzapine injection.", "question": "Treatment.Disorder in olanzapine injection", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18562412_5_8291", "context": "The second patient exhibited sudden PLMS following olanzapine injection.", "question": "Combination.Drug in olanzapine injection", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11428480_2_8292", "context": "However, adenosine shortens the antegrade refractoriness of accessory atrioventricular connections and may cause acceleration of the ventricular rate during atrial fibrillation.", "question": "Treatment.Drug in adenosine", "question_type": "Adverse_event.Treatment.Drug", "answers": "adenosine"}, {"id": "11428480_2_8293", "context": "However, adenosine shortens the antegrade refractoriness of accessory atrioventricular connections and may cause acceleration of the ventricular rate during atrial fibrillation.", "question": "Treatment.Dosage in adenosine", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11428480_2_8294", "context": "However, adenosine shortens the antegrade refractoriness of accessory atrioventricular connections and may cause acceleration of the ventricular rate during atrial fibrillation.", "question": "Treatment.Freq in adenosine", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11428480_2_8295", "context": "However, adenosine shortens the antegrade refractoriness of accessory atrioventricular connections and may cause acceleration of the ventricular rate during atrial fibrillation.", "question": "Treatment.Route in adenosine", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11428480_2_8296", "context": "However, adenosine shortens the antegrade refractoriness of accessory atrioventricular connections and may cause acceleration of the ventricular rate during atrial fibrillation.", "question": "Treatment.Time_elapsed in adenosine", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11428480_2_8297", "context": "However, adenosine shortens the antegrade refractoriness of accessory atrioventricular connections and may cause acceleration of the ventricular rate during atrial fibrillation.", "question": "Treatment.Duration in adenosine", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11428480_2_8298", "context": "However, adenosine shortens the antegrade refractoriness of accessory atrioventricular connections and may cause acceleration of the ventricular rate during atrial fibrillation.", "question": "Treatment.Disorder in adenosine", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11428480_2_8299", "context": "However, adenosine shortens the antegrade refractoriness of accessory atrioventricular connections and may cause acceleration of the ventricular rate during atrial fibrillation.", "question": "Combination.Drug in adenosine", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "19249953_5_8300", "context": "A cardiology consultation performed on the day of admission determined that a markedly elevated creatine kinase-myocardial band isoenzyme level and borderline-high troponin I level were diagnostic of rhabdomyolysis secondary to statin use.", "question": "Treatment.Drug in statin", "question_type": "Adverse_event.Treatment.Drug", "answers": "statin"}, {"id": "19249953_5_8301", "context": "A cardiology consultation performed on the day of admission determined that a markedly elevated creatine kinase-myocardial band isoenzyme level and borderline-high troponin I level were diagnostic of rhabdomyolysis secondary to statin use.", "question": "Treatment.Dosage in statin", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "19249953_5_8302", "context": "A cardiology consultation performed on the day of admission determined that a markedly elevated creatine kinase-myocardial band isoenzyme level and borderline-high troponin I level were diagnostic of rhabdomyolysis secondary to statin use.", "question": "Treatment.Freq in statin", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "19249953_5_8303", "context": "A cardiology consultation performed on the day of admission determined that a markedly elevated creatine kinase-myocardial band isoenzyme level and borderline-high troponin I level were diagnostic of rhabdomyolysis secondary to statin use.", "question": "Treatment.Route in statin", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "19249953_5_8304", "context": "A cardiology consultation performed on the day of admission determined that a markedly elevated creatine kinase-myocardial band isoenzyme level and borderline-high troponin I level were diagnostic of rhabdomyolysis secondary to statin use.", "question": "Treatment.Time_elapsed in statin", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19249953_5_8305", "context": "A cardiology consultation performed on the day of admission determined that a markedly elevated creatine kinase-myocardial band isoenzyme level and borderline-high troponin I level were diagnostic of rhabdomyolysis secondary to statin use.", "question": "Treatment.Duration in statin", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "19249953_5_8306", "context": "A cardiology consultation performed on the day of admission determined that a markedly elevated creatine kinase-myocardial band isoenzyme level and borderline-high troponin I level were diagnostic of rhabdomyolysis secondary to statin use.", "question": "Treatment.Disorder in statin", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "19249953_5_8307", "context": "A cardiology consultation performed on the day of admission determined that a markedly elevated creatine kinase-myocardial band isoenzyme level and borderline-high troponin I level were diagnostic of rhabdomyolysis secondary to statin use.", "question": "Combination.Drug in statin", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9651465_1_8308", "context": "METHODS: Double-blind, placebo-controlled titrated oral challenges with pancreatic enzymes resulted in definite vomiting within 1 to 1.5 hours after challenges with Viokase and Pancrease MT 16, but not with placebo.", "question": "Treatment.Drug in Viokase and Pancrease MT 16", "question_type": "Adverse_event.Treatment.Drug", "answers": "Viokase; Pancrease MT 16"}, {"id": "9651465_1_8309", "context": "METHODS: Double-blind, placebo-controlled titrated oral challenges with pancreatic enzymes resulted in definite vomiting within 1 to 1.5 hours after challenges with Viokase and Pancrease MT 16, but not with placebo.", "question": "Treatment.Dosage in Viokase and Pancrease MT 16", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9651465_1_8310", "context": "METHODS: Double-blind, placebo-controlled titrated oral challenges with pancreatic enzymes resulted in definite vomiting within 1 to 1.5 hours after challenges with Viokase and Pancrease MT 16, but not with placebo.", "question": "Treatment.Freq in Viokase and Pancrease MT 16", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9651465_1_8311", "context": "METHODS: Double-blind, placebo-controlled titrated oral challenges with pancreatic enzymes resulted in definite vomiting within 1 to 1.5 hours after challenges with Viokase and Pancrease MT 16, but not with placebo.", "question": "Treatment.Route in Viokase and Pancrease MT 16", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9651465_1_8312", "context": "METHODS: Double-blind, placebo-controlled titrated oral challenges with pancreatic enzymes resulted in definite vomiting within 1 to 1.5 hours after challenges with Viokase and Pancrease MT 16, but not with placebo.", "question": "Treatment.Time_elapsed in Viokase and Pancrease MT 16", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9651465_1_8313", "context": "METHODS: Double-blind, placebo-controlled titrated oral challenges with pancreatic enzymes resulted in definite vomiting within 1 to 1.5 hours after challenges with Viokase and Pancrease MT 16, but not with placebo.", "question": "Treatment.Duration in Viokase and Pancrease MT 16", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9651465_1_8314", "context": "METHODS: Double-blind, placebo-controlled titrated oral challenges with pancreatic enzymes resulted in definite vomiting within 1 to 1.5 hours after challenges with Viokase and Pancrease MT 16, but not with placebo.", "question": "Treatment.Disorder in Viokase and Pancrease MT 16", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9651465_1_8315", "context": "METHODS: Double-blind, placebo-controlled titrated oral challenges with pancreatic enzymes resulted in definite vomiting within 1 to 1.5 hours after challenges with Viokase and Pancrease MT 16, but not with placebo.", "question": "Combination.Drug in Viokase and Pancrease MT 16", "question_type": "Adverse_event.Combination.Drug", "answers": "Viokase; Pancrease MT 16"}, {"id": "25204404_2_8316", "context": "Abiraterone acetate, an androgen biosynthesis inhibitor, prolongs survival in men with metastatic castration-resistant prostate cancer (mCRPC) in the pre- and post-chemotherapy setting as demonstrated by the pivotal phase III studies COU-AA-301 and COU-AA-302.", "question": "Subject.Age in men with metastatic castration-resistant prostate cancer (mCRPC)", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "25204404_2_8317", "context": "Abiraterone acetate, an androgen biosynthesis inhibitor, prolongs survival in men with metastatic castration-resistant prostate cancer (mCRPC) in the pre- and post-chemotherapy setting as demonstrated by the pivotal phase III studies COU-AA-301 and COU-AA-302.", "question": "Subject.Gender in men with metastatic castration-resistant prostate cancer (mCRPC)", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": "men"}, {"id": "25204404_2_8318", "context": "Abiraterone acetate, an androgen biosynthesis inhibitor, prolongs survival in men with metastatic castration-resistant prostate cancer (mCRPC) in the pre- and post-chemotherapy setting as demonstrated by the pivotal phase III studies COU-AA-301 and COU-AA-302.", "question": "Subject.Population in men with metastatic castration-resistant prostate cancer (mCRPC)", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "25204404_2_8319", "context": "Abiraterone acetate, an androgen biosynthesis inhibitor, prolongs survival in men with metastatic castration-resistant prostate cancer (mCRPC) in the pre- and post-chemotherapy setting as demonstrated by the pivotal phase III studies COU-AA-301 and COU-AA-302.", "question": "Subject.Race in men with metastatic castration-resistant prostate cancer (mCRPC)", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "25204404_2_8320", "context": "Abiraterone acetate, an androgen biosynthesis inhibitor, prolongs survival in men with metastatic castration-resistant prostate cancer (mCRPC) in the pre- and post-chemotherapy setting as demonstrated by the pivotal phase III studies COU-AA-301 and COU-AA-302.", "question": "Subject.Disorder in men with metastatic castration-resistant prostate cancer (mCRPC)", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "25204404_2_8321", "context": "Abiraterone acetate, an androgen biosynthesis inhibitor, prolongs survival in men with metastatic castration-resistant prostate cancer (mCRPC) in the pre- and post-chemotherapy setting as demonstrated by the pivotal phase III studies COU-AA-301 and COU-AA-302.", "question": "Treatment.Drug in Abiraterone acetate, an androgen biosynthesis inhibitor", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "Abiraterone acetate"}, {"id": "25204404_2_8322", "context": "Abiraterone acetate, an androgen biosynthesis inhibitor, prolongs survival in men with metastatic castration-resistant prostate cancer (mCRPC) in the pre- and post-chemotherapy setting as demonstrated by the pivotal phase III studies COU-AA-301 and COU-AA-302.", "question": "Treatment.Dosage in Abiraterone acetate, an androgen biosynthesis inhibitor", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "25204404_2_8323", "context": "Abiraterone acetate, an androgen biosynthesis inhibitor, prolongs survival in men with metastatic castration-resistant prostate cancer (mCRPC) in the pre- and post-chemotherapy setting as demonstrated by the pivotal phase III studies COU-AA-301 and COU-AA-302.", "question": "Treatment.Freq in Abiraterone acetate, an androgen biosynthesis inhibitor", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "25204404_2_8324", "context": "Abiraterone acetate, an androgen biosynthesis inhibitor, prolongs survival in men with metastatic castration-resistant prostate cancer (mCRPC) in the pre- and post-chemotherapy setting as demonstrated by the pivotal phase III studies COU-AA-301 and COU-AA-302.", "question": "Treatment.Route in Abiraterone acetate, an androgen biosynthesis inhibitor", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "25204404_2_8325", "context": "Abiraterone acetate, an androgen biosynthesis inhibitor, prolongs survival in men with metastatic castration-resistant prostate cancer (mCRPC) in the pre- and post-chemotherapy setting as demonstrated by the pivotal phase III studies COU-AA-301 and COU-AA-302.", "question": "Treatment.Time_elapsed in Abiraterone acetate, an androgen biosynthesis inhibitor", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "25204404_2_8326", "context": "Abiraterone acetate, an androgen biosynthesis inhibitor, prolongs survival in men with metastatic castration-resistant prostate cancer (mCRPC) in the pre- and post-chemotherapy setting as demonstrated by the pivotal phase III studies COU-AA-301 and COU-AA-302.", "question": "Treatment.Duration in Abiraterone acetate, an androgen biosynthesis inhibitor", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "25204404_2_8327", "context": "Abiraterone acetate, an androgen biosynthesis inhibitor, prolongs survival in men with metastatic castration-resistant prostate cancer (mCRPC) in the pre- and post-chemotherapy setting as demonstrated by the pivotal phase III studies COU-AA-301 and COU-AA-302.", "question": "Treatment.Disorder in Abiraterone acetate, an androgen biosynthesis inhibitor", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "metastatic castration-resistant prostate cancer"}, {"id": "25204404_2_8328", "context": "Abiraterone acetate, an androgen biosynthesis inhibitor, prolongs survival in men with metastatic castration-resistant prostate cancer (mCRPC) in the pre- and post-chemotherapy setting as demonstrated by the pivotal phase III studies COU-AA-301 and COU-AA-302.", "question": "Combination.Drug in Abiraterone acetate, an androgen biosynthesis inhibitor", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "12455453_2_8329", "context": "Reduction of methylprednisolone dosage rather than insulin therapy resulted in better control of glycemia.", "question": "Treatment.Drug in Reduction of methylprednisolone dosage rather than insulin therapy", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "methylprednisolone"}, {"id": "12455453_2_8330", "context": "Reduction of methylprednisolone dosage rather than insulin therapy resulted in better control of glycemia.", "question": "Treatment.Dosage in Reduction of methylprednisolone dosage rather than insulin therapy", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": "Reduction"}, {"id": "12455453_2_8331", "context": "Reduction of methylprednisolone dosage rather than insulin therapy resulted in better control of glycemia.", "question": "Treatment.Freq in Reduction of methylprednisolone dosage rather than insulin therapy", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "12455453_2_8332", "context": "Reduction of methylprednisolone dosage rather than insulin therapy resulted in better control of glycemia.", "question": "Treatment.Route in Reduction of methylprednisolone dosage rather than insulin therapy", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "12455453_2_8333", "context": "Reduction of methylprednisolone dosage rather than insulin therapy resulted in better control of glycemia.", "question": "Treatment.Time_elapsed in Reduction of methylprednisolone dosage rather than insulin therapy", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12455453_2_8334", "context": "Reduction of methylprednisolone dosage rather than insulin therapy resulted in better control of glycemia.", "question": "Treatment.Duration in Reduction of methylprednisolone dosage rather than insulin therapy", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "12455453_2_8335", "context": "Reduction of methylprednisolone dosage rather than insulin therapy resulted in better control of glycemia.", "question": "Treatment.Disorder in Reduction of methylprednisolone dosage rather than insulin therapy", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "glycemia"}, {"id": "12455453_2_8336", "context": "Reduction of methylprednisolone dosage rather than insulin therapy resulted in better control of glycemia.", "question": "Combination.Drug in Reduction of methylprednisolone dosage rather than insulin therapy", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "17725438_1_8337", "context": "Here, we report a case of RFP-induced hypothyroidism without underlying thyroid disease.", "question": "Treatment.Drug in RFP", "question_type": "Adverse_event.Treatment.Drug", "answers": "RFP"}, {"id": "17725438_1_8338", "context": "Here, we report a case of RFP-induced hypothyroidism without underlying thyroid disease.", "question": "Treatment.Dosage in RFP", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17725438_1_8339", "context": "Here, we report a case of RFP-induced hypothyroidism without underlying thyroid disease.", "question": "Treatment.Freq in RFP", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17725438_1_8340", "context": "Here, we report a case of RFP-induced hypothyroidism without underlying thyroid disease.", "question": "Treatment.Route in RFP", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17725438_1_8341", "context": "Here, we report a case of RFP-induced hypothyroidism without underlying thyroid disease.", "question": "Treatment.Time_elapsed in RFP", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17725438_1_8342", "context": "Here, we report a case of RFP-induced hypothyroidism without underlying thyroid disease.", "question": "Treatment.Duration in RFP", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17725438_1_8343", "context": "Here, we report a case of RFP-induced hypothyroidism without underlying thyroid disease.", "question": "Treatment.Disorder in RFP", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17725438_1_8344", "context": "Here, we report a case of RFP-induced hypothyroidism without underlying thyroid disease.", "question": "Combination.Drug in RFP", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "14964753_9_8345", "context": "Here we report ramipril-induced cutaneous vasculitis in a patient who required steroid therapy to control it.", "question": "Subject.Age in a patient", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "14964753_9_8346", "context": "Here we report ramipril-induced cutaneous vasculitis in a patient who required steroid therapy to control it.", "question": "Subject.Gender in a patient", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "14964753_9_8347", "context": "Here we report ramipril-induced cutaneous vasculitis in a patient who required steroid therapy to control it.", "question": "Subject.Population in a patient", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "14964753_9_8348", "context": "Here we report ramipril-induced cutaneous vasculitis in a patient who required steroid therapy to control it.", "question": "Subject.Race in a patient", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "14964753_9_8349", "context": "Here we report ramipril-induced cutaneous vasculitis in a patient who required steroid therapy to control it.", "question": "Subject.Disorder in a patient", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "14964753_9_8350", "context": "Here we report ramipril-induced cutaneous vasculitis in a patient who required steroid therapy to control it.", "question": "Treatment.Drug in ramipril", "question_type": "Adverse_event.Treatment.Drug", "answers": "ramipril"}, {"id": "14964753_9_8351", "context": "Here we report ramipril-induced cutaneous vasculitis in a patient who required steroid therapy to control it.", "question": "Treatment.Dosage in ramipril", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "14964753_9_8352", "context": "Here we report ramipril-induced cutaneous vasculitis in a patient who required steroid therapy to control it.", "question": "Treatment.Freq in ramipril", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "14964753_9_8353", "context": "Here we report ramipril-induced cutaneous vasculitis in a patient who required steroid therapy to control it.", "question": "Treatment.Route in ramipril", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "14964753_9_8354", "context": "Here we report ramipril-induced cutaneous vasculitis in a patient who required steroid therapy to control it.", "question": "Treatment.Time_elapsed in ramipril", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "14964753_9_8355", "context": "Here we report ramipril-induced cutaneous vasculitis in a patient who required steroid therapy to control it.", "question": "Treatment.Duration in ramipril", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "14964753_9_8356", "context": "Here we report ramipril-induced cutaneous vasculitis in a patient who required steroid therapy to control it.", "question": "Treatment.Disorder in ramipril", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "14964753_9_8357", "context": "Here we report ramipril-induced cutaneous vasculitis in a patient who required steroid therapy to control it.", "question": "Combination.Drug in ramipril", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8186884_1_8358", "context": "A 78-year-old man with a transvenous cardioverter defibrillator system developed frequent shocks during oral procainamide therapy.", "question": "Subject.Age in A 78-year-old man with a transvenous cardioverter defibrillator system", "question_type": "Adverse_event.Subject.Age", "answers": "78-year-old"}, {"id": "8186884_1_8359", "context": "A 78-year-old man with a transvenous cardioverter defibrillator system developed frequent shocks during oral procainamide therapy.", "question": "Subject.Gender in A 78-year-old man with a transvenous cardioverter defibrillator system", "question_type": "Adverse_event.Subject.Gender", "answers": "man"}, {"id": "8186884_1_8360", "context": "A 78-year-old man with a transvenous cardioverter defibrillator system developed frequent shocks during oral procainamide therapy.", "question": "Subject.Population in A 78-year-old man with a transvenous cardioverter defibrillator system", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "8186884_1_8361", "context": "A 78-year-old man with a transvenous cardioverter defibrillator system developed frequent shocks during oral procainamide therapy.", "question": "Subject.Race in A 78-year-old man with a transvenous cardioverter defibrillator system", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "8186884_1_8362", "context": "A 78-year-old man with a transvenous cardioverter defibrillator system developed frequent shocks during oral procainamide therapy.", "question": "Subject.Disorder in A 78-year-old man with a transvenous cardioverter defibrillator system", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "8186884_1_8363", "context": "A 78-year-old man with a transvenous cardioverter defibrillator system developed frequent shocks during oral procainamide therapy.", "question": "Treatment.Drug in during oral procainamide therapy", "question_type": "Adverse_event.Treatment.Drug", "answers": "procainamide"}, {"id": "8186884_1_8364", "context": "A 78-year-old man with a transvenous cardioverter defibrillator system developed frequent shocks during oral procainamide therapy.", "question": "Treatment.Dosage in during oral procainamide therapy", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8186884_1_8365", "context": "A 78-year-old man with a transvenous cardioverter defibrillator system developed frequent shocks during oral procainamide therapy.", "question": "Treatment.Freq in during oral procainamide therapy", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8186884_1_8366", "context": "A 78-year-old man with a transvenous cardioverter defibrillator system developed frequent shocks during oral procainamide therapy.", "question": "Treatment.Route in during oral procainamide therapy", "question_type": "Adverse_event.Treatment.Route", "answers": "oral"}, {"id": "8186884_1_8367", "context": "A 78-year-old man with a transvenous cardioverter defibrillator system developed frequent shocks during oral procainamide therapy.", "question": "Treatment.Time_elapsed in during oral procainamide therapy", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8186884_1_8368", "context": "A 78-year-old man with a transvenous cardioverter defibrillator system developed frequent shocks during oral procainamide therapy.", "question": "Treatment.Duration in during oral procainamide therapy", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8186884_1_8369", "context": "A 78-year-old man with a transvenous cardioverter defibrillator system developed frequent shocks during oral procainamide therapy.", "question": "Treatment.Disorder in during oral procainamide therapy", "question_type": "Adverse_event.Treatment.Disorder", "answers": "a transvenous cardioverter defibrillator system"}, {"id": "8186884_1_8370", "context": "A 78-year-old man with a transvenous cardioverter defibrillator system developed frequent shocks during oral procainamide therapy.", "question": "Combination.Drug in during oral procainamide therapy", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11590881_2_8371", "context": "A 53 year old Greenlandic male was admitted twice over a period of 4 years with a new complete right bundle branch block after ingestion of 10 g and 4 g of carbamazepine respectively.", "question": "Subject.Age in A 53 year old Greenlandic male", "question_type": "Adverse_event.Subject.Age", "answers": "53 year old"}, {"id": "11590881_2_8372", "context": "A 53 year old Greenlandic male was admitted twice over a period of 4 years with a new complete right bundle branch block after ingestion of 10 g and 4 g of carbamazepine respectively.", "question": "Subject.Gender in A 53 year old Greenlandic male", "question_type": "Adverse_event.Subject.Gender", "answers": "male"}, {"id": "11590881_2_8373", "context": "A 53 year old Greenlandic male was admitted twice over a period of 4 years with a new complete right bundle branch block after ingestion of 10 g and 4 g of carbamazepine respectively.", "question": "Subject.Population in A 53 year old Greenlandic male", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "11590881_2_8374", "context": "A 53 year old Greenlandic male was admitted twice over a period of 4 years with a new complete right bundle branch block after ingestion of 10 g and 4 g of carbamazepine respectively.", "question": "Subject.Race in A 53 year old Greenlandic male", "question_type": "Adverse_event.Subject.Race", "answers": "Greenlandic"}, {"id": "11590881_2_8375", "context": "A 53 year old Greenlandic male was admitted twice over a period of 4 years with a new complete right bundle branch block after ingestion of 10 g and 4 g of carbamazepine respectively.", "question": "Subject.Disorder in A 53 year old Greenlandic male", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "11590881_2_8376", "context": "A 53 year old Greenlandic male was admitted twice over a period of 4 years with a new complete right bundle branch block after ingestion of 10 g and 4 g of carbamazepine respectively.", "question": "Treatment.Drug in ingestion of 10 g and 4 g of carbamazepine", "question_type": "Adverse_event.Treatment.Drug", "answers": "carbamazepine"}, {"id": "11590881_2_8377", "context": "A 53 year old Greenlandic male was admitted twice over a period of 4 years with a new complete right bundle branch block after ingestion of 10 g and 4 g of carbamazepine respectively.", "question": "Treatment.Dosage in ingestion of 10 g and 4 g of carbamazepine", "question_type": "Adverse_event.Treatment.Dosage", "answers": "10 g and 4 g"}, {"id": "11590881_2_8378", "context": "A 53 year old Greenlandic male was admitted twice over a period of 4 years with a new complete right bundle branch block after ingestion of 10 g and 4 g of carbamazepine respectively.", "question": "Treatment.Freq in ingestion of 10 g and 4 g of carbamazepine", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11590881_2_8379", "context": "A 53 year old Greenlandic male was admitted twice over a period of 4 years with a new complete right bundle branch block after ingestion of 10 g and 4 g of carbamazepine respectively.", "question": "Treatment.Route in ingestion of 10 g and 4 g of carbamazepine", "question_type": "Adverse_event.Treatment.Route", "answers": "ingestion"}, {"id": "11590881_2_8380", "context": "A 53 year old Greenlandic male was admitted twice over a period of 4 years with a new complete right bundle branch block after ingestion of 10 g and 4 g of carbamazepine respectively.", "question": "Treatment.Time_elapsed in ingestion of 10 g and 4 g of carbamazepine", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11590881_2_8381", "context": "A 53 year old Greenlandic male was admitted twice over a period of 4 years with a new complete right bundle branch block after ingestion of 10 g and 4 g of carbamazepine respectively.", "question": "Treatment.Duration in ingestion of 10 g and 4 g of carbamazepine", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11590881_2_8382", "context": "A 53 year old Greenlandic male was admitted twice over a period of 4 years with a new complete right bundle branch block after ingestion of 10 g and 4 g of carbamazepine respectively.", "question": "Treatment.Disorder in ingestion of 10 g and 4 g of carbamazepine", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11590881_2_8383", "context": "A 53 year old Greenlandic male was admitted twice over a period of 4 years with a new complete right bundle branch block after ingestion of 10 g and 4 g of carbamazepine respectively.", "question": "Combination.Drug in ingestion of 10 g and 4 g of carbamazepine", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15112258_14_8384", "context": "In contrast, other common agents for the most part trigger cutaneous inflammation.", "question": "Treatment.Drug in other common agents for the most part", "question_type": "Adverse_event.Treatment.Drug", "answers": "other common agents"}, {"id": "15112258_14_8385", "context": "In contrast, other common agents for the most part trigger cutaneous inflammation.", "question": "Treatment.Dosage in other common agents for the most part", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15112258_14_8386", "context": "In contrast, other common agents for the most part trigger cutaneous inflammation.", "question": "Treatment.Freq in other common agents for the most part", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15112258_14_8387", "context": "In contrast, other common agents for the most part trigger cutaneous inflammation.", "question": "Treatment.Route in other common agents for the most part", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15112258_14_8388", "context": "In contrast, other common agents for the most part trigger cutaneous inflammation.", "question": "Treatment.Time_elapsed in other common agents for the most part", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15112258_14_8389", "context": "In contrast, other common agents for the most part trigger cutaneous inflammation.", "question": "Treatment.Duration in other common agents for the most part", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15112258_14_8390", "context": "In contrast, other common agents for the most part trigger cutaneous inflammation.", "question": "Treatment.Disorder in other common agents for the most part", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15112258_14_8391", "context": "In contrast, other common agents for the most part trigger cutaneous inflammation.", "question": "Combination.Drug in other common agents for the most part", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10619721_1_8392", "context": "In both patients the rippling phenomena worsened with pyridostigmine treatment but markedly improved after immunosuppression with azathioprine.", "question": "Subject.Age in both patients", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "10619721_1_8393", "context": "In both patients the rippling phenomena worsened with pyridostigmine treatment but markedly improved after immunosuppression with azathioprine.", "question": "Subject.Gender in both patients", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "10619721_1_8394", "context": "In both patients the rippling phenomena worsened with pyridostigmine treatment but markedly improved after immunosuppression with azathioprine.", "question": "Subject.Population in both patients", "question_type": "Adverse_event.Subject.Population", "answers": "both"}, {"id": "10619721_1_8395", "context": "In both patients the rippling phenomena worsened with pyridostigmine treatment but markedly improved after immunosuppression with azathioprine.", "question": "Subject.Race in both patients", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "10619721_1_8396", "context": "In both patients the rippling phenomena worsened with pyridostigmine treatment but markedly improved after immunosuppression with azathioprine.", "question": "Subject.Disorder in both patients", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "10619721_1_8397", "context": "In both patients the rippling phenomena worsened with pyridostigmine treatment but markedly improved after immunosuppression with azathioprine.", "question": "Treatment.Drug in pyridostigmine", "question_type": "Adverse_event.Treatment.Drug", "answers": "pyridostigmine"}, {"id": "10619721_1_8398", "context": "In both patients the rippling phenomena worsened with pyridostigmine treatment but markedly improved after immunosuppression with azathioprine.", "question": "Treatment.Dosage in pyridostigmine", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10619721_1_8399", "context": "In both patients the rippling phenomena worsened with pyridostigmine treatment but markedly improved after immunosuppression with azathioprine.", "question": "Treatment.Freq in pyridostigmine", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10619721_1_8400", "context": "In both patients the rippling phenomena worsened with pyridostigmine treatment but markedly improved after immunosuppression with azathioprine.", "question": "Treatment.Route in pyridostigmine", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10619721_1_8401", "context": "In both patients the rippling phenomena worsened with pyridostigmine treatment but markedly improved after immunosuppression with azathioprine.", "question": "Treatment.Time_elapsed in pyridostigmine", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10619721_1_8402", "context": "In both patients the rippling phenomena worsened with pyridostigmine treatment but markedly improved after immunosuppression with azathioprine.", "question": "Treatment.Duration in pyridostigmine", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10619721_1_8403", "context": "In both patients the rippling phenomena worsened with pyridostigmine treatment but markedly improved after immunosuppression with azathioprine.", "question": "Treatment.Disorder in pyridostigmine", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10619721_1_8404", "context": "In both patients the rippling phenomena worsened with pyridostigmine treatment but markedly improved after immunosuppression with azathioprine.", "question": "Combination.Drug in pyridostigmine", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8175330_2_8405", "context": "We present findings from three patients who experienced a psoriasiform eruption apparently due to the antiepileptic agents sodium valproate and carbamazepine.", "question": "Subject.Age in three patients", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "8175330_2_8406", "context": "We present findings from three patients who experienced a psoriasiform eruption apparently due to the antiepileptic agents sodium valproate and carbamazepine.", "question": "Subject.Gender in three patients", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "8175330_2_8407", "context": "We present findings from three patients who experienced a psoriasiform eruption apparently due to the antiepileptic agents sodium valproate and carbamazepine.", "question": "Subject.Population in three patients", "question_type": "Adverse_event.Subject.Population", "answers": "three"}, {"id": "8175330_2_8408", "context": "We present findings from three patients who experienced a psoriasiform eruption apparently due to the antiepileptic agents sodium valproate and carbamazepine.", "question": "Subject.Race in three patients", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "8175330_2_8409", "context": "We present findings from three patients who experienced a psoriasiform eruption apparently due to the antiepileptic agents sodium valproate and carbamazepine.", "question": "Subject.Disorder in three patients", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "8175330_2_8410", "context": "We present findings from three patients who experienced a psoriasiform eruption apparently due to the antiepileptic agents sodium valproate and carbamazepine.", "question": "Treatment.Drug in antiepileptic agents sodium valproate and carbamazepine", "question_type": "Adverse_event.Treatment.Drug", "answers": "sodium valproate; carbamazepine"}, {"id": "8175330_2_8411", "context": "We present findings from three patients who experienced a psoriasiform eruption apparently due to the antiepileptic agents sodium valproate and carbamazepine.", "question": "Treatment.Dosage in antiepileptic agents sodium valproate and carbamazepine", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8175330_2_8412", "context": "We present findings from three patients who experienced a psoriasiform eruption apparently due to the antiepileptic agents sodium valproate and carbamazepine.", "question": "Treatment.Freq in antiepileptic agents sodium valproate and carbamazepine", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8175330_2_8413", "context": "We present findings from three patients who experienced a psoriasiform eruption apparently due to the antiepileptic agents sodium valproate and carbamazepine.", "question": "Treatment.Route in antiepileptic agents sodium valproate and carbamazepine", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8175330_2_8414", "context": "We present findings from three patients who experienced a psoriasiform eruption apparently due to the antiepileptic agents sodium valproate and carbamazepine.", "question": "Treatment.Time_elapsed in antiepileptic agents sodium valproate and carbamazepine", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8175330_2_8415", "context": "We present findings from three patients who experienced a psoriasiform eruption apparently due to the antiepileptic agents sodium valproate and carbamazepine.", "question": "Treatment.Duration in antiepileptic agents sodium valproate and carbamazepine", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8175330_2_8416", "context": "We present findings from three patients who experienced a psoriasiform eruption apparently due to the antiepileptic agents sodium valproate and carbamazepine.", "question": "Treatment.Disorder in antiepileptic agents sodium valproate and carbamazepine", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8175330_2_8417", "context": "We present findings from three patients who experienced a psoriasiform eruption apparently due to the antiepileptic agents sodium valproate and carbamazepine.", "question": "Combination.Drug in antiepileptic agents sodium valproate and carbamazepine", "question_type": "Adverse_event.Combination.Drug", "answers": "sodium valproate; carbamazepine"}, {"id": "3620420_4_8418", "context": "We report here such a case with bilateral Mooren's ulcer that failed to respond to local therapy with topical corticosteroids, silver nitrate, and conjunctival resection, as well as systemic immunosuppression with corticosteroids, cyclophosphamide, and azathioprine.", "question": "Subject.Age in a case with bilateral Mooren's ulcer", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "3620420_4_8419", "context": "We report here such a case with bilateral Mooren's ulcer that failed to respond to local therapy with topical corticosteroids, silver nitrate, and conjunctival resection, as well as systemic immunosuppression with corticosteroids, cyclophosphamide, and azathioprine.", "question": "Subject.Gender in a case with bilateral Mooren's ulcer", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "3620420_4_8420", "context": "We report here such a case with bilateral Mooren's ulcer that failed to respond to local therapy with topical corticosteroids, silver nitrate, and conjunctival resection, as well as systemic immunosuppression with corticosteroids, cyclophosphamide, and azathioprine.", "question": "Subject.Population in a case with bilateral Mooren's ulcer", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "3620420_4_8421", "context": "We report here such a case with bilateral Mooren's ulcer that failed to respond to local therapy with topical corticosteroids, silver nitrate, and conjunctival resection, as well as systemic immunosuppression with corticosteroids, cyclophosphamide, and azathioprine.", "question": "Subject.Race in a case with bilateral Mooren's ulcer", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "3620420_4_8422", "context": "We report here such a case with bilateral Mooren's ulcer that failed to respond to local therapy with topical corticosteroids, silver nitrate, and conjunctival resection, as well as systemic immunosuppression with corticosteroids, cyclophosphamide, and azathioprine.", "question": "Subject.Disorder in a case with bilateral Mooren's ulcer", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "3620420_4_8423", "context": "We report here such a case with bilateral Mooren's ulcer that failed to respond to local therapy with topical corticosteroids, silver nitrate, and conjunctival resection, as well as systemic immunosuppression with corticosteroids, cyclophosphamide, and azathioprine.", "question": "Treatment.Drug in local therapy with topical corticosteroids, silver nitrate, and conjunctival resection, as well as systemic immunosuppression with corticosteroids, cyclophosphamide, and azathioprine", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "corticosteroids; silver nitrate; corticosteroids; cyclophosphamide; azathioprine"}, {"id": "3620420_4_8424", "context": "We report here such a case with bilateral Mooren's ulcer that failed to respond to local therapy with topical corticosteroids, silver nitrate, and conjunctival resection, as well as systemic immunosuppression with corticosteroids, cyclophosphamide, and azathioprine.", "question": "Treatment.Dosage in local therapy with topical corticosteroids, silver nitrate, and conjunctival resection, as well as systemic immunosuppression with corticosteroids, cyclophosphamide, and azathioprine", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "3620420_4_8425", "context": "We report here such a case with bilateral Mooren's ulcer that failed to respond to local therapy with topical corticosteroids, silver nitrate, and conjunctival resection, as well as systemic immunosuppression with corticosteroids, cyclophosphamide, and azathioprine.", "question": "Treatment.Freq in local therapy with topical corticosteroids, silver nitrate, and conjunctival resection, as well as systemic immunosuppression with corticosteroids, cyclophosphamide, and azathioprine", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "3620420_4_8426", "context": "We report here such a case with bilateral Mooren's ulcer that failed to respond to local therapy with topical corticosteroids, silver nitrate, and conjunctival resection, as well as systemic immunosuppression with corticosteroids, cyclophosphamide, and azathioprine.", "question": "Treatment.Route in local therapy with topical corticosteroids, silver nitrate, and conjunctival resection, as well as systemic immunosuppression with corticosteroids, cyclophosphamide, and azathioprine", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": "topical"}, {"id": "3620420_4_8427", "context": "We report here such a case with bilateral Mooren's ulcer that failed to respond to local therapy with topical corticosteroids, silver nitrate, and conjunctival resection, as well as systemic immunosuppression with corticosteroids, cyclophosphamide, and azathioprine.", "question": "Treatment.Time_elapsed in local therapy with topical corticosteroids, silver nitrate, and conjunctival resection, as well as systemic immunosuppression with corticosteroids, cyclophosphamide, and azathioprine", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3620420_4_8428", "context": "We report here such a case with bilateral Mooren's ulcer that failed to respond to local therapy with topical corticosteroids, silver nitrate, and conjunctival resection, as well as systemic immunosuppression with corticosteroids, cyclophosphamide, and azathioprine.", "question": "Treatment.Duration in local therapy with topical corticosteroids, silver nitrate, and conjunctival resection, as well as systemic immunosuppression with corticosteroids, cyclophosphamide, and azathioprine", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "3620420_4_8429", "context": "We report here such a case with bilateral Mooren's ulcer that failed to respond to local therapy with topical corticosteroids, silver nitrate, and conjunctival resection, as well as systemic immunosuppression with corticosteroids, cyclophosphamide, and azathioprine.", "question": "Treatment.Disorder in local therapy with topical corticosteroids, silver nitrate, and conjunctival resection, as well as systemic immunosuppression with corticosteroids, cyclophosphamide, and azathioprine", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "bilateral Mooren's ulcer"}, {"id": "3620420_4_8430", "context": "We report here such a case with bilateral Mooren's ulcer that failed to respond to local therapy with topical corticosteroids, silver nitrate, and conjunctival resection, as well as systemic immunosuppression with corticosteroids, cyclophosphamide, and azathioprine.", "question": "Combination.Drug in local therapy with topical corticosteroids, silver nitrate, and conjunctival resection, as well as systemic immunosuppression with corticosteroids, cyclophosphamide, and azathioprine", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": "corticosteroids; silver nitrate; corticosteroids; cyclophosphamide; azathioprine"}, {"id": "12635752_2_8431", "context": "Successful treatment with carbimazole of a hyperthyroid pregnancy with hepatic impairment after propylthiouracil administration: a case report.", "question": "Treatment.Drug in carbimazole", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "carbimazole"}, {"id": "12635752_2_8432", "context": "Successful treatment with carbimazole of a hyperthyroid pregnancy with hepatic impairment after propylthiouracil administration: a case report.", "question": "Treatment.Dosage in carbimazole", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "12635752_2_8433", "context": "Successful treatment with carbimazole of a hyperthyroid pregnancy with hepatic impairment after propylthiouracil administration: a case report.", "question": "Treatment.Freq in carbimazole", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "12635752_2_8434", "context": "Successful treatment with carbimazole of a hyperthyroid pregnancy with hepatic impairment after propylthiouracil administration: a case report.", "question": "Treatment.Route in carbimazole", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "12635752_2_8435", "context": "Successful treatment with carbimazole of a hyperthyroid pregnancy with hepatic impairment after propylthiouracil administration: a case report.", "question": "Treatment.Time_elapsed in carbimazole", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12635752_2_8436", "context": "Successful treatment with carbimazole of a hyperthyroid pregnancy with hepatic impairment after propylthiouracil administration: a case report.", "question": "Treatment.Duration in carbimazole", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "12635752_2_8437", "context": "Successful treatment with carbimazole of a hyperthyroid pregnancy with hepatic impairment after propylthiouracil administration: a case report.", "question": "Treatment.Disorder in carbimazole", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "a hyperthyroid pregnancy with hepatic impairment after propylthiouracil administration"}, {"id": "12635752_2_8438", "context": "Successful treatment with carbimazole of a hyperthyroid pregnancy with hepatic impairment after propylthiouracil administration: a case report.", "question": "Combination.Drug in carbimazole", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "12635752_2_8439", "context": "Successful treatment with carbimazole of a hyperthyroid pregnancy with hepatic impairment after propylthiouracil administration: a case report.", "question": "Treatment.Drug in propylthiouracil", "question_type": "Adverse_event.Treatment.Drug", "answers": "propylthiouracil"}, {"id": "12635752_2_8440", "context": "Successful treatment with carbimazole of a hyperthyroid pregnancy with hepatic impairment after propylthiouracil administration: a case report.", "question": "Treatment.Dosage in propylthiouracil", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12635752_2_8441", "context": "Successful treatment with carbimazole of a hyperthyroid pregnancy with hepatic impairment after propylthiouracil administration: a case report.", "question": "Treatment.Freq in propylthiouracil", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12635752_2_8442", "context": "Successful treatment with carbimazole of a hyperthyroid pregnancy with hepatic impairment after propylthiouracil administration: a case report.", "question": "Treatment.Route in propylthiouracil", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12635752_2_8443", "context": "Successful treatment with carbimazole of a hyperthyroid pregnancy with hepatic impairment after propylthiouracil administration: a case report.", "question": "Treatment.Time_elapsed in propylthiouracil", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12635752_2_8444", "context": "Successful treatment with carbimazole of a hyperthyroid pregnancy with hepatic impairment after propylthiouracil administration: a case report.", "question": "Treatment.Duration in propylthiouracil", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12635752_2_8445", "context": "Successful treatment with carbimazole of a hyperthyroid pregnancy with hepatic impairment after propylthiouracil administration: a case report.", "question": "Treatment.Disorder in propylthiouracil", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12635752_2_8446", "context": "Successful treatment with carbimazole of a hyperthyroid pregnancy with hepatic impairment after propylthiouracil administration: a case report.", "question": "Combination.Drug in propylthiouracil", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8638872_1_8447", "context": "Jaundice induced by streptokinase.", "question": "Treatment.Drug in streptokinase", "question_type": "Adverse_event.Treatment.Drug", "answers": "streptokinase"}, {"id": "8638872_1_8448", "context": "Jaundice induced by streptokinase.", "question": "Treatment.Dosage in streptokinase", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8638872_1_8449", "context": "Jaundice induced by streptokinase.", "question": "Treatment.Freq in streptokinase", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8638872_1_8450", "context": "Jaundice induced by streptokinase.", "question": "Treatment.Route in streptokinase", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8638872_1_8451", "context": "Jaundice induced by streptokinase.", "question": "Treatment.Time_elapsed in streptokinase", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8638872_1_8452", "context": "Jaundice induced by streptokinase.", "question": "Treatment.Duration in streptokinase", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8638872_1_8453", "context": "Jaundice induced by streptokinase.", "question": "Treatment.Disorder in streptokinase", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8638872_1_8454", "context": "Jaundice induced by streptokinase.", "question": "Combination.Drug in streptokinase", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16355099_4_8455", "context": "When thrombosis develops during heparin treatment, it is important to suspect HITTs and to assay for the associated antibodies, regardless of the actual platelet count.", "question": "Treatment.Drug in heparin", "question_type": "Adverse_event.Treatment.Drug", "answers": "heparin"}, {"id": "16355099_4_8456", "context": "When thrombosis develops during heparin treatment, it is important to suspect HITTs and to assay for the associated antibodies, regardless of the actual platelet count.", "question": "Treatment.Dosage in heparin", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16355099_4_8457", "context": "When thrombosis develops during heparin treatment, it is important to suspect HITTs and to assay for the associated antibodies, regardless of the actual platelet count.", "question": "Treatment.Freq in heparin", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16355099_4_8458", "context": "When thrombosis develops during heparin treatment, it is important to suspect HITTs and to assay for the associated antibodies, regardless of the actual platelet count.", "question": "Treatment.Route in heparin", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16355099_4_8459", "context": "When thrombosis develops during heparin treatment, it is important to suspect HITTs and to assay for the associated antibodies, regardless of the actual platelet count.", "question": "Treatment.Time_elapsed in heparin", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16355099_4_8460", "context": "When thrombosis develops during heparin treatment, it is important to suspect HITTs and to assay for the associated antibodies, regardless of the actual platelet count.", "question": "Treatment.Duration in heparin", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16355099_4_8461", "context": "When thrombosis develops during heparin treatment, it is important to suspect HITTs and to assay for the associated antibodies, regardless of the actual platelet count.", "question": "Treatment.Disorder in heparin", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16355099_4_8462", "context": "When thrombosis develops during heparin treatment, it is important to suspect HITTs and to assay for the associated antibodies, regardless of the actual platelet count.", "question": "Combination.Drug in heparin", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3620420_8_8463", "context": "The results in this case suggest that cyclosporin is an effective agent in patients with severe sight threatening Mooren's ulcer.", "question": "Subject.Age in patients with severe sight threatening Mooren's ulcer", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "3620420_8_8464", "context": "The results in this case suggest that cyclosporin is an effective agent in patients with severe sight threatening Mooren's ulcer.", "question": "Subject.Gender in patients with severe sight threatening Mooren's ulcer", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "3620420_8_8465", "context": "The results in this case suggest that cyclosporin is an effective agent in patients with severe sight threatening Mooren's ulcer.", "question": "Subject.Population in patients with severe sight threatening Mooren's ulcer", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "3620420_8_8466", "context": "The results in this case suggest that cyclosporin is an effective agent in patients with severe sight threatening Mooren's ulcer.", "question": "Subject.Race in patients with severe sight threatening Mooren's ulcer", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "3620420_8_8467", "context": "The results in this case suggest that cyclosporin is an effective agent in patients with severe sight threatening Mooren's ulcer.", "question": "Subject.Disorder in patients with severe sight threatening Mooren's ulcer", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "3620420_8_8468", "context": "The results in this case suggest that cyclosporin is an effective agent in patients with severe sight threatening Mooren's ulcer.", "question": "Treatment.Drug in cyclosporin", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "cyclosporin"}, {"id": "3620420_8_8469", "context": "The results in this case suggest that cyclosporin is an effective agent in patients with severe sight threatening Mooren's ulcer.", "question": "Treatment.Dosage in cyclosporin", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "3620420_8_8470", "context": "The results in this case suggest that cyclosporin is an effective agent in patients with severe sight threatening Mooren's ulcer.", "question": "Treatment.Freq in cyclosporin", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "3620420_8_8471", "context": "The results in this case suggest that cyclosporin is an effective agent in patients with severe sight threatening Mooren's ulcer.", "question": "Treatment.Route in cyclosporin", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "3620420_8_8472", "context": "The results in this case suggest that cyclosporin is an effective agent in patients with severe sight threatening Mooren's ulcer.", "question": "Treatment.Time_elapsed in cyclosporin", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3620420_8_8473", "context": "The results in this case suggest that cyclosporin is an effective agent in patients with severe sight threatening Mooren's ulcer.", "question": "Treatment.Duration in cyclosporin", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "3620420_8_8474", "context": "The results in this case suggest that cyclosporin is an effective agent in patients with severe sight threatening Mooren's ulcer.", "question": "Treatment.Disorder in cyclosporin", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "Mooren's ulcer"}, {"id": "3620420_8_8475", "context": "The results in this case suggest that cyclosporin is an effective agent in patients with severe sight threatening Mooren's ulcer.", "question": "Combination.Drug in cyclosporin", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "8329789_9_8476", "context": "CONCLUSIONS: Amphotericin B overdose can be fatal in children and infants.", "question": "Subject.Age in children and infants", "question_type": "Adverse_event.Subject.Age", "answers": "children; infants"}, {"id": "8329789_9_8477", "context": "CONCLUSIONS: Amphotericin B overdose can be fatal in children and infants.", "question": "Subject.Gender in children and infants", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "8329789_9_8478", "context": "CONCLUSIONS: Amphotericin B overdose can be fatal in children and infants.", "question": "Subject.Population in children and infants", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "8329789_9_8479", "context": "CONCLUSIONS: Amphotericin B overdose can be fatal in children and infants.", "question": "Subject.Race in children and infants", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "8329789_9_8480", "context": "CONCLUSIONS: Amphotericin B overdose can be fatal in children and infants.", "question": "Subject.Disorder in children and infants", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "8329789_9_8481", "context": "CONCLUSIONS: Amphotericin B overdose can be fatal in children and infants.", "question": "Treatment.Drug in Amphotericin B overdose", "question_type": "Adverse_event.Treatment.Drug", "answers": "Amphotericin B"}, {"id": "8329789_9_8482", "context": "CONCLUSIONS: Amphotericin B overdose can be fatal in children and infants.", "question": "Treatment.Dosage in Amphotericin B overdose", "question_type": "Adverse_event.Treatment.Dosage", "answers": "overdose"}, {"id": "8329789_9_8483", "context": "CONCLUSIONS: Amphotericin B overdose can be fatal in children and infants.", "question": "Treatment.Freq in Amphotericin B overdose", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8329789_9_8484", "context": "CONCLUSIONS: Amphotericin B overdose can be fatal in children and infants.", "question": "Treatment.Route in Amphotericin B overdose", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8329789_9_8485", "context": "CONCLUSIONS: Amphotericin B overdose can be fatal in children and infants.", "question": "Treatment.Time_elapsed in Amphotericin B overdose", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8329789_9_8486", "context": "CONCLUSIONS: Amphotericin B overdose can be fatal in children and infants.", "question": "Treatment.Duration in Amphotericin B overdose", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8329789_9_8487", "context": "CONCLUSIONS: Amphotericin B overdose can be fatal in children and infants.", "question": "Treatment.Disorder in Amphotericin B overdose", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8329789_9_8488", "context": "CONCLUSIONS: Amphotericin B overdose can be fatal in children and infants.", "question": "Combination.Drug in Amphotericin B overdose", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "369675_1_8489", "context": "Five and one-half years after the diagnosis of myeloma, while in remission on cyclophosphamide therapy, the patient experienced severe abdominal right lower quadrant pain due to a large cecal lymphoma.", "question": "Subject.Age in diagnosis of myeloma; patient", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "369675_1_8490", "context": "Five and one-half years after the diagnosis of myeloma, while in remission on cyclophosphamide therapy, the patient experienced severe abdominal right lower quadrant pain due to a large cecal lymphoma.", "question": "Subject.Gender in diagnosis of myeloma; patient", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "369675_1_8491", "context": "Five and one-half years after the diagnosis of myeloma, while in remission on cyclophosphamide therapy, the patient experienced severe abdominal right lower quadrant pain due to a large cecal lymphoma.", "question": "Subject.Population in diagnosis of myeloma; patient", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "369675_1_8492", "context": "Five and one-half years after the diagnosis of myeloma, while in remission on cyclophosphamide therapy, the patient experienced severe abdominal right lower quadrant pain due to a large cecal lymphoma.", "question": "Subject.Race in diagnosis of myeloma; patient", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "369675_1_8493", "context": "Five and one-half years after the diagnosis of myeloma, while in remission on cyclophosphamide therapy, the patient experienced severe abdominal right lower quadrant pain due to a large cecal lymphoma.", "question": "Subject.Disorder in diagnosis of myeloma; patient", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "369675_1_8494", "context": "Five and one-half years after the diagnosis of myeloma, while in remission on cyclophosphamide therapy, the patient experienced severe abdominal right lower quadrant pain due to a large cecal lymphoma.", "question": "Treatment.Drug in cyclophosphamide therapy", "question_type": "Adverse_event.Treatment.Drug", "answers": "cyclophosphamide"}, {"id": "369675_1_8495", "context": "Five and one-half years after the diagnosis of myeloma, while in remission on cyclophosphamide therapy, the patient experienced severe abdominal right lower quadrant pain due to a large cecal lymphoma.", "question": "Treatment.Dosage in cyclophosphamide therapy", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "369675_1_8496", "context": "Five and one-half years after the diagnosis of myeloma, while in remission on cyclophosphamide therapy, the patient experienced severe abdominal right lower quadrant pain due to a large cecal lymphoma.", "question": "Treatment.Freq in cyclophosphamide therapy", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "369675_1_8497", "context": "Five and one-half years after the diagnosis of myeloma, while in remission on cyclophosphamide therapy, the patient experienced severe abdominal right lower quadrant pain due to a large cecal lymphoma.", "question": "Treatment.Route in cyclophosphamide therapy", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "369675_1_8498", "context": "Five and one-half years after the diagnosis of myeloma, while in remission on cyclophosphamide therapy, the patient experienced severe abdominal right lower quadrant pain due to a large cecal lymphoma.", "question": "Treatment.Time_elapsed in cyclophosphamide therapy", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "369675_1_8499", "context": "Five and one-half years after the diagnosis of myeloma, while in remission on cyclophosphamide therapy, the patient experienced severe abdominal right lower quadrant pain due to a large cecal lymphoma.", "question": "Treatment.Duration in cyclophosphamide therapy", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "369675_1_8500", "context": "Five and one-half years after the diagnosis of myeloma, while in remission on cyclophosphamide therapy, the patient experienced severe abdominal right lower quadrant pain due to a large cecal lymphoma.", "question": "Treatment.Disorder in cyclophosphamide therapy", "question_type": "Adverse_event.Treatment.Disorder", "answers": "myeloma"}, {"id": "369675_1_8501", "context": "Five and one-half years after the diagnosis of myeloma, while in remission on cyclophosphamide therapy, the patient experienced severe abdominal right lower quadrant pain due to a large cecal lymphoma.", "question": "Combination.Drug in cyclophosphamide therapy", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9681211_2_8502", "context": "Leukaemoid monocytosis in M4 AML following chemotherapy and G-CSF.", "question": "Treatment.Drug in chemotherapy and G-CSF", "question_type": "Adverse_event.Treatment.Drug", "answers": "G-CSF"}, {"id": "9681211_2_8503", "context": "Leukaemoid monocytosis in M4 AML following chemotherapy and G-CSF.", "question": "Treatment.Dosage in chemotherapy and G-CSF", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9681211_2_8504", "context": "Leukaemoid monocytosis in M4 AML following chemotherapy and G-CSF.", "question": "Treatment.Freq in chemotherapy and G-CSF", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9681211_2_8505", "context": "Leukaemoid monocytosis in M4 AML following chemotherapy and G-CSF.", "question": "Treatment.Route in chemotherapy and G-CSF", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9681211_2_8506", "context": "Leukaemoid monocytosis in M4 AML following chemotherapy and G-CSF.", "question": "Treatment.Time_elapsed in chemotherapy and G-CSF", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9681211_2_8507", "context": "Leukaemoid monocytosis in M4 AML following chemotherapy and G-CSF.", "question": "Treatment.Duration in chemotherapy and G-CSF", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9681211_2_8508", "context": "Leukaemoid monocytosis in M4 AML following chemotherapy and G-CSF.", "question": "Treatment.Disorder in chemotherapy and G-CSF", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9681211_2_8509", "context": "Leukaemoid monocytosis in M4 AML following chemotherapy and G-CSF.", "question": "Combination.Drug in chemotherapy and G-CSF", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9426968_1_8510", "context": "Vitiligo associated with alpha-interferon in a patient with chronic active hepatitis C.", "question": "Subject.Age in a patient with chronic active hepatitis C", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "9426968_1_8511", "context": "Vitiligo associated with alpha-interferon in a patient with chronic active hepatitis C.", "question": "Subject.Gender in a patient with chronic active hepatitis C", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "9426968_1_8512", "context": "Vitiligo associated with alpha-interferon in a patient with chronic active hepatitis C.", "question": "Subject.Population in a patient with chronic active hepatitis C", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "9426968_1_8513", "context": "Vitiligo associated with alpha-interferon in a patient with chronic active hepatitis C.", "question": "Subject.Race in a patient with chronic active hepatitis C", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "9426968_1_8514", "context": "Vitiligo associated with alpha-interferon in a patient with chronic active hepatitis C.", "question": "Subject.Disorder in a patient with chronic active hepatitis C", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "9426968_1_8515", "context": "Vitiligo associated with alpha-interferon in a patient with chronic active hepatitis C.", "question": "Treatment.Drug in alpha-interferon", "question_type": "Adverse_event.Treatment.Drug", "answers": "alpha-interferon"}, {"id": "9426968_1_8516", "context": "Vitiligo associated with alpha-interferon in a patient with chronic active hepatitis C.", "question": "Treatment.Dosage in alpha-interferon", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9426968_1_8517", "context": "Vitiligo associated with alpha-interferon in a patient with chronic active hepatitis C.", "question": "Treatment.Freq in alpha-interferon", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9426968_1_8518", "context": "Vitiligo associated with alpha-interferon in a patient with chronic active hepatitis C.", "question": "Treatment.Route in alpha-interferon", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9426968_1_8519", "context": "Vitiligo associated with alpha-interferon in a patient with chronic active hepatitis C.", "question": "Treatment.Time_elapsed in alpha-interferon", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9426968_1_8520", "context": "Vitiligo associated with alpha-interferon in a patient with chronic active hepatitis C.", "question": "Treatment.Duration in alpha-interferon", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9426968_1_8521", "context": "Vitiligo associated with alpha-interferon in a patient with chronic active hepatitis C.", "question": "Treatment.Disorder in alpha-interferon", "question_type": "Adverse_event.Treatment.Disorder", "answers": "chronic active hepatitis C"}, {"id": "9426968_1_8522", "context": "Vitiligo associated with alpha-interferon in a patient with chronic active hepatitis C.", "question": "Combination.Drug in alpha-interferon", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "1759924_2_8523", "context": "We report a case of fulminant neuroleptic malignant syndrome in a man aged 70 developing within 12 hours of starting six-hourly intravenous metoclopramide.", "question": "Subject.Age in a man aged 70", "question_type": "Adverse_event.Subject.Age", "answers": "aged 70"}, {"id": "1759924_2_8524", "context": "We report a case of fulminant neuroleptic malignant syndrome in a man aged 70 developing within 12 hours of starting six-hourly intravenous metoclopramide.", "question": "Subject.Gender in a man aged 70", "question_type": "Adverse_event.Subject.Gender", "answers": "man"}, {"id": "1759924_2_8525", "context": "We report a case of fulminant neuroleptic malignant syndrome in a man aged 70 developing within 12 hours of starting six-hourly intravenous metoclopramide.", "question": "Subject.Population in a man aged 70", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "1759924_2_8526", "context": "We report a case of fulminant neuroleptic malignant syndrome in a man aged 70 developing within 12 hours of starting six-hourly intravenous metoclopramide.", "question": "Subject.Race in a man aged 70", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "1759924_2_8527", "context": "We report a case of fulminant neuroleptic malignant syndrome in a man aged 70 developing within 12 hours of starting six-hourly intravenous metoclopramide.", "question": "Subject.Disorder in a man aged 70", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "1759924_2_8528", "context": "We report a case of fulminant neuroleptic malignant syndrome in a man aged 70 developing within 12 hours of starting six-hourly intravenous metoclopramide.", "question": "Treatment.Drug in six-hourly intravenous metoclopramide", "question_type": "Adverse_event.Treatment.Drug", "answers": "metoclopramide"}, {"id": "1759924_2_8529", "context": "We report a case of fulminant neuroleptic malignant syndrome in a man aged 70 developing within 12 hours of starting six-hourly intravenous metoclopramide.", "question": "Treatment.Dosage in six-hourly intravenous metoclopramide", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "1759924_2_8530", "context": "We report a case of fulminant neuroleptic malignant syndrome in a man aged 70 developing within 12 hours of starting six-hourly intravenous metoclopramide.", "question": "Treatment.Freq in six-hourly intravenous metoclopramide", "question_type": "Adverse_event.Treatment.Freq", "answers": "six-hourly"}, {"id": "1759924_2_8531", "context": "We report a case of fulminant neuroleptic malignant syndrome in a man aged 70 developing within 12 hours of starting six-hourly intravenous metoclopramide.", "question": "Treatment.Route in six-hourly intravenous metoclopramide", "question_type": "Adverse_event.Treatment.Route", "answers": "intravenous"}, {"id": "1759924_2_8532", "context": "We report a case of fulminant neuroleptic malignant syndrome in a man aged 70 developing within 12 hours of starting six-hourly intravenous metoclopramide.", "question": "Treatment.Time_elapsed in six-hourly intravenous metoclopramide", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "within 12 hours"}, {"id": "1759924_2_8533", "context": "We report a case of fulminant neuroleptic malignant syndrome in a man aged 70 developing within 12 hours of starting six-hourly intravenous metoclopramide.", "question": "Treatment.Duration in six-hourly intravenous metoclopramide", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "1759924_2_8534", "context": "We report a case of fulminant neuroleptic malignant syndrome in a man aged 70 developing within 12 hours of starting six-hourly intravenous metoclopramide.", "question": "Treatment.Disorder in six-hourly intravenous metoclopramide", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "1759924_2_8535", "context": "We report a case of fulminant neuroleptic malignant syndrome in a man aged 70 developing within 12 hours of starting six-hourly intravenous metoclopramide.", "question": "Combination.Drug in six-hourly intravenous metoclopramide", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17331261_1_8536", "context": "CASE PRESENTATION: We report a patient with CF who developed recurrent eosinophilia and severe persistent bronchospasm following repeated administration of preservative-free tobramycin by inhalation, beginning at 16 months of age.", "question": "Subject.Age in a patient with CF; beginning at 16 months of age", "question_type": "Adverse_event.Subject.Age", "answers": "16 months"}, {"id": "17331261_1_8537", "context": "CASE PRESENTATION: We report a patient with CF who developed recurrent eosinophilia and severe persistent bronchospasm following repeated administration of preservative-free tobramycin by inhalation, beginning at 16 months of age.", "question": "Subject.Gender in a patient with CF; beginning at 16 months of age", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "17331261_1_8538", "context": "CASE PRESENTATION: We report a patient with CF who developed recurrent eosinophilia and severe persistent bronchospasm following repeated administration of preservative-free tobramycin by inhalation, beginning at 16 months of age.", "question": "Subject.Population in a patient with CF; beginning at 16 months of age", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "17331261_1_8539", "context": "CASE PRESENTATION: We report a patient with CF who developed recurrent eosinophilia and severe persistent bronchospasm following repeated administration of preservative-free tobramycin by inhalation, beginning at 16 months of age.", "question": "Subject.Race in a patient with CF; beginning at 16 months of age", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "17331261_1_8540", "context": "CASE PRESENTATION: We report a patient with CF who developed recurrent eosinophilia and severe persistent bronchospasm following repeated administration of preservative-free tobramycin by inhalation, beginning at 16 months of age.", "question": "Subject.Disorder in a patient with CF; beginning at 16 months of age", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "17331261_1_8541", "context": "CASE PRESENTATION: We report a patient with CF who developed recurrent eosinophilia and severe persistent bronchospasm following repeated administration of preservative-free tobramycin by inhalation, beginning at 16 months of age.", "question": "Treatment.Drug in repeated administration of preservative-free tobramycin by inhalation", "question_type": "Adverse_event.Treatment.Drug", "answers": "tobramycin"}, {"id": "17331261_1_8542", "context": "CASE PRESENTATION: We report a patient with CF who developed recurrent eosinophilia and severe persistent bronchospasm following repeated administration of preservative-free tobramycin by inhalation, beginning at 16 months of age.", "question": "Treatment.Dosage in repeated administration of preservative-free tobramycin by inhalation", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17331261_1_8543", "context": "CASE PRESENTATION: We report a patient with CF who developed recurrent eosinophilia and severe persistent bronchospasm following repeated administration of preservative-free tobramycin by inhalation, beginning at 16 months of age.", "question": "Treatment.Freq in repeated administration of preservative-free tobramycin by inhalation", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17331261_1_8544", "context": "CASE PRESENTATION: We report a patient with CF who developed recurrent eosinophilia and severe persistent bronchospasm following repeated administration of preservative-free tobramycin by inhalation, beginning at 16 months of age.", "question": "Treatment.Route in repeated administration of preservative-free tobramycin by inhalation", "question_type": "Adverse_event.Treatment.Route", "answers": "inhalation"}, {"id": "17331261_1_8545", "context": "CASE PRESENTATION: We report a patient with CF who developed recurrent eosinophilia and severe persistent bronchospasm following repeated administration of preservative-free tobramycin by inhalation, beginning at 16 months of age.", "question": "Treatment.Time_elapsed in repeated administration of preservative-free tobramycin by inhalation", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17331261_1_8546", "context": "CASE PRESENTATION: We report a patient with CF who developed recurrent eosinophilia and severe persistent bronchospasm following repeated administration of preservative-free tobramycin by inhalation, beginning at 16 months of age.", "question": "Treatment.Duration in repeated administration of preservative-free tobramycin by inhalation", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17331261_1_8547", "context": "CASE PRESENTATION: We report a patient with CF who developed recurrent eosinophilia and severe persistent bronchospasm following repeated administration of preservative-free tobramycin by inhalation, beginning at 16 months of age.", "question": "Treatment.Disorder in repeated administration of preservative-free tobramycin by inhalation", "question_type": "Adverse_event.Treatment.Disorder", "answers": "CF"}, {"id": "17331261_1_8548", "context": "CASE PRESENTATION: We report a patient with CF who developed recurrent eosinophilia and severe persistent bronchospasm following repeated administration of preservative-free tobramycin by inhalation, beginning at 16 months of age.", "question": "Combination.Drug in repeated administration of preservative-free tobramycin by inhalation", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9491301_1_8549", "context": "Ballistic movements due to ischemic infarcts after intravenous heroin overdose: report of two cases.", "question": "Subject.Age in two cases", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "9491301_1_8550", "context": "Ballistic movements due to ischemic infarcts after intravenous heroin overdose: report of two cases.", "question": "Subject.Gender in two cases", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "9491301_1_8551", "context": "Ballistic movements due to ischemic infarcts after intravenous heroin overdose: report of two cases.", "question": "Subject.Population in two cases", "question_type": "Adverse_event.Subject.Population", "answers": "two"}, {"id": "9491301_1_8552", "context": "Ballistic movements due to ischemic infarcts after intravenous heroin overdose: report of two cases.", "question": "Subject.Race in two cases", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "9491301_1_8553", "context": "Ballistic movements due to ischemic infarcts after intravenous heroin overdose: report of two cases.", "question": "Subject.Disorder in two cases", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "9491301_1_8554", "context": "Ballistic movements due to ischemic infarcts after intravenous heroin overdose: report of two cases.", "question": "Treatment.Drug in intravenous heroin overdose", "question_type": "Adverse_event.Treatment.Drug", "answers": "heroin"}, {"id": "9491301_1_8555", "context": "Ballistic movements due to ischemic infarcts after intravenous heroin overdose: report of two cases.", "question": "Treatment.Dosage in intravenous heroin overdose", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9491301_1_8556", "context": "Ballistic movements due to ischemic infarcts after intravenous heroin overdose: report of two cases.", "question": "Treatment.Freq in intravenous heroin overdose", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9491301_1_8557", "context": "Ballistic movements due to ischemic infarcts after intravenous heroin overdose: report of two cases.", "question": "Treatment.Route in intravenous heroin overdose", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9491301_1_8558", "context": "Ballistic movements due to ischemic infarcts after intravenous heroin overdose: report of two cases.", "question": "Treatment.Time_elapsed in intravenous heroin overdose", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9491301_1_8559", "context": "Ballistic movements due to ischemic infarcts after intravenous heroin overdose: report of two cases.", "question": "Treatment.Duration in intravenous heroin overdose", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9491301_1_8560", "context": "Ballistic movements due to ischemic infarcts after intravenous heroin overdose: report of two cases.", "question": "Treatment.Disorder in intravenous heroin overdose", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9491301_1_8561", "context": "Ballistic movements due to ischemic infarcts after intravenous heroin overdose: report of two cases.", "question": "Combination.Drug in intravenous heroin overdose", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7468565_3_8562", "context": "A case of barbiturate-induced submassive hepatic necrosis is presented and the literature is reviewed.", "question": "Subject.Age in A case", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "7468565_3_8563", "context": "A case of barbiturate-induced submassive hepatic necrosis is presented and the literature is reviewed.", "question": "Subject.Gender in A case", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "7468565_3_8564", "context": "A case of barbiturate-induced submassive hepatic necrosis is presented and the literature is reviewed.", "question": "Subject.Population in A case", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "7468565_3_8565", "context": "A case of barbiturate-induced submassive hepatic necrosis is presented and the literature is reviewed.", "question": "Subject.Race in A case", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "7468565_3_8566", "context": "A case of barbiturate-induced submassive hepatic necrosis is presented and the literature is reviewed.", "question": "Subject.Disorder in A case", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "7468565_3_8567", "context": "A case of barbiturate-induced submassive hepatic necrosis is presented and the literature is reviewed.", "question": "Treatment.Drug in barbiturate", "question_type": "Adverse_event.Treatment.Drug", "answers": "barbiturate"}, {"id": "7468565_3_8568", "context": "A case of barbiturate-induced submassive hepatic necrosis is presented and the literature is reviewed.", "question": "Treatment.Dosage in barbiturate", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7468565_3_8569", "context": "A case of barbiturate-induced submassive hepatic necrosis is presented and the literature is reviewed.", "question": "Treatment.Freq in barbiturate", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7468565_3_8570", "context": "A case of barbiturate-induced submassive hepatic necrosis is presented and the literature is reviewed.", "question": "Treatment.Route in barbiturate", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7468565_3_8571", "context": "A case of barbiturate-induced submassive hepatic necrosis is presented and the literature is reviewed.", "question": "Treatment.Time_elapsed in barbiturate", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7468565_3_8572", "context": "A case of barbiturate-induced submassive hepatic necrosis is presented and the literature is reviewed.", "question": "Treatment.Duration in barbiturate", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7468565_3_8573", "context": "A case of barbiturate-induced submassive hepatic necrosis is presented and the literature is reviewed.", "question": "Treatment.Disorder in barbiturate", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7468565_3_8574", "context": "A case of barbiturate-induced submassive hepatic necrosis is presented and the literature is reviewed.", "question": "Combination.Drug in barbiturate", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3967572_5_8575", "context": "With combined use, clinicians should be aware, when phenytoin is added, of the potential for reexacerbation of pulmonary symptomatology due to lowered serum theophylline concentrations.", "question": "Treatment.Drug in phenytoin is added; theophylline", "question_type": "Adverse_event.Treatment.Drug", "answers": "phenytoin; theophylline"}, {"id": "3967572_5_8576", "context": "With combined use, clinicians should be aware, when phenytoin is added, of the potential for reexacerbation of pulmonary symptomatology due to lowered serum theophylline concentrations.", "question": "Treatment.Dosage in phenytoin is added; theophylline", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3967572_5_8577", "context": "With combined use, clinicians should be aware, when phenytoin is added, of the potential for reexacerbation of pulmonary symptomatology due to lowered serum theophylline concentrations.", "question": "Treatment.Freq in phenytoin is added; theophylline", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3967572_5_8578", "context": "With combined use, clinicians should be aware, when phenytoin is added, of the potential for reexacerbation of pulmonary symptomatology due to lowered serum theophylline concentrations.", "question": "Treatment.Route in phenytoin is added; theophylline", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3967572_5_8579", "context": "With combined use, clinicians should be aware, when phenytoin is added, of the potential for reexacerbation of pulmonary symptomatology due to lowered serum theophylline concentrations.", "question": "Treatment.Time_elapsed in phenytoin is added; theophylline", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3967572_5_8580", "context": "With combined use, clinicians should be aware, when phenytoin is added, of the potential for reexacerbation of pulmonary symptomatology due to lowered serum theophylline concentrations.", "question": "Treatment.Duration in phenytoin is added; theophylline", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3967572_5_8581", "context": "With combined use, clinicians should be aware, when phenytoin is added, of the potential for reexacerbation of pulmonary symptomatology due to lowered serum theophylline concentrations.", "question": "Treatment.Disorder in phenytoin is added; theophylline", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3967572_5_8582", "context": "With combined use, clinicians should be aware, when phenytoin is added, of the potential for reexacerbation of pulmonary symptomatology due to lowered serum theophylline concentrations.", "question": "Combination.Drug in phenytoin is added; theophylline", "question_type": "Adverse_event.Combination.Drug", "answers": "phenytoin; theophylline"}, {"id": "2549018_3_8583", "context": "Fluoxetine-induced akathisia: clinical and theoretical implications.", "question": "Treatment.Drug in Fluoxetine", "question_type": "Adverse_event.Treatment.Drug", "answers": "Fluoxetine"}, {"id": "2549018_3_8584", "context": "Fluoxetine-induced akathisia: clinical and theoretical implications.", "question": "Treatment.Dosage in Fluoxetine", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "2549018_3_8585", "context": "Fluoxetine-induced akathisia: clinical and theoretical implications.", "question": "Treatment.Freq in Fluoxetine", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2549018_3_8586", "context": "Fluoxetine-induced akathisia: clinical and theoretical implications.", "question": "Treatment.Route in Fluoxetine", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "2549018_3_8587", "context": "Fluoxetine-induced akathisia: clinical and theoretical implications.", "question": "Treatment.Time_elapsed in Fluoxetine", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2549018_3_8588", "context": "Fluoxetine-induced akathisia: clinical and theoretical implications.", "question": "Treatment.Duration in Fluoxetine", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2549018_3_8589", "context": "Fluoxetine-induced akathisia: clinical and theoretical implications.", "question": "Treatment.Disorder in Fluoxetine", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "2549018_3_8590", "context": "Fluoxetine-induced akathisia: clinical and theoretical implications.", "question": "Combination.Drug in Fluoxetine", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16001348_1_8591", "context": "Lansoprazole-associated collagenous colitis: a case report.", "question": "Treatment.Drug in Lansoprazole", "question_type": "Adverse_event.Treatment.Drug", "answers": "Lansoprazole"}, {"id": "16001348_1_8592", "context": "Lansoprazole-associated collagenous colitis: a case report.", "question": "Treatment.Dosage in Lansoprazole", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16001348_1_8593", "context": "Lansoprazole-associated collagenous colitis: a case report.", "question": "Treatment.Freq in Lansoprazole", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16001348_1_8594", "context": "Lansoprazole-associated collagenous colitis: a case report.", "question": "Treatment.Route in Lansoprazole", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16001348_1_8595", "context": "Lansoprazole-associated collagenous colitis: a case report.", "question": "Treatment.Time_elapsed in Lansoprazole", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16001348_1_8596", "context": "Lansoprazole-associated collagenous colitis: a case report.", "question": "Treatment.Duration in Lansoprazole", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16001348_1_8597", "context": "Lansoprazole-associated collagenous colitis: a case report.", "question": "Treatment.Disorder in Lansoprazole", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16001348_1_8598", "context": "Lansoprazole-associated collagenous colitis: a case report.", "question": "Combination.Drug in Lansoprazole", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "2863342_2_8599", "context": "We discuss a variety of bronchopulmonary complications of IBD and their association with sulfasalazine.", "question": "Treatment.Drug in sulfasalazine", "question_type": "Adverse_event.Treatment.Drug", "answers": "sulfasalazine"}, {"id": "2863342_2_8600", "context": "We discuss a variety of bronchopulmonary complications of IBD and their association with sulfasalazine.", "question": "Treatment.Dosage in sulfasalazine", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "2863342_2_8601", "context": "We discuss a variety of bronchopulmonary complications of IBD and their association with sulfasalazine.", "question": "Treatment.Freq in sulfasalazine", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2863342_2_8602", "context": "We discuss a variety of bronchopulmonary complications of IBD and their association with sulfasalazine.", "question": "Treatment.Route in sulfasalazine", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "2863342_2_8603", "context": "We discuss a variety of bronchopulmonary complications of IBD and their association with sulfasalazine.", "question": "Treatment.Time_elapsed in sulfasalazine", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2863342_2_8604", "context": "We discuss a variety of bronchopulmonary complications of IBD and their association with sulfasalazine.", "question": "Treatment.Duration in sulfasalazine", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2863342_2_8605", "context": "We discuss a variety of bronchopulmonary complications of IBD and their association with sulfasalazine.", "question": "Treatment.Disorder in sulfasalazine", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "2863342_2_8606", "context": "We discuss a variety of bronchopulmonary complications of IBD and their association with sulfasalazine.", "question": "Combination.Drug in sulfasalazine", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15961942_2_8607", "context": "OBJECTIVE: To report the late development of immune-mediated diabetes mellitus after completion of alfa-interferon therapy for hepatitis C in an Asian patient.", "question": "Subject.Age in an Asian patient", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "15961942_2_8608", "context": "OBJECTIVE: To report the late development of immune-mediated diabetes mellitus after completion of alfa-interferon therapy for hepatitis C in an Asian patient.", "question": "Subject.Gender in an Asian patient", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15961942_2_8609", "context": "OBJECTIVE: To report the late development of immune-mediated diabetes mellitus after completion of alfa-interferon therapy for hepatitis C in an Asian patient.", "question": "Subject.Population in an Asian patient", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "15961942_2_8610", "context": "OBJECTIVE: To report the late development of immune-mediated diabetes mellitus after completion of alfa-interferon therapy for hepatitis C in an Asian patient.", "question": "Subject.Race in an Asian patient", "question_type": "Adverse_event.Subject.Race", "answers": "Asian"}, {"id": "15961942_2_8611", "context": "OBJECTIVE: To report the late development of immune-mediated diabetes mellitus after completion of alfa-interferon therapy for hepatitis C in an Asian patient.", "question": "Subject.Disorder in an Asian patient", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15961942_2_8612", "context": "OBJECTIVE: To report the late development of immune-mediated diabetes mellitus after completion of alfa-interferon therapy for hepatitis C in an Asian patient.", "question": "Treatment.Drug in alfa-interferon", "question_type": "Adverse_event.Treatment.Drug", "answers": "alfa-interferon"}, {"id": "15961942_2_8613", "context": "OBJECTIVE: To report the late development of immune-mediated diabetes mellitus after completion of alfa-interferon therapy for hepatitis C in an Asian patient.", "question": "Treatment.Dosage in alfa-interferon", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15961942_2_8614", "context": "OBJECTIVE: To report the late development of immune-mediated diabetes mellitus after completion of alfa-interferon therapy for hepatitis C in an Asian patient.", "question": "Treatment.Freq in alfa-interferon", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15961942_2_8615", "context": "OBJECTIVE: To report the late development of immune-mediated diabetes mellitus after completion of alfa-interferon therapy for hepatitis C in an Asian patient.", "question": "Treatment.Route in alfa-interferon", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15961942_2_8616", "context": "OBJECTIVE: To report the late development of immune-mediated diabetes mellitus after completion of alfa-interferon therapy for hepatitis C in an Asian patient.", "question": "Treatment.Time_elapsed in alfa-interferon", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15961942_2_8617", "context": "OBJECTIVE: To report the late development of immune-mediated diabetes mellitus after completion of alfa-interferon therapy for hepatitis C in an Asian patient.", "question": "Treatment.Duration in alfa-interferon", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15961942_2_8618", "context": "OBJECTIVE: To report the late development of immune-mediated diabetes mellitus after completion of alfa-interferon therapy for hepatitis C in an Asian patient.", "question": "Treatment.Disorder in alfa-interferon", "question_type": "Adverse_event.Treatment.Disorder", "answers": "hepatitis C"}, {"id": "15961942_2_8619", "context": "OBJECTIVE: To report the late development of immune-mediated diabetes mellitus after completion of alfa-interferon therapy for hepatitis C in an Asian patient.", "question": "Combination.Drug in alfa-interferon", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10715308_10_8620", "context": "The tirapazamine-plus-cisplatin regimen was associated with mild to moderate adverse events, including acute, reversible hearing loss, reversible, intermittent muscle cramping, diarrhea, skin rash, nausea, and vomiting.", "question": "Treatment.Drug in tirapazamine-plus-cisplatin regimen", "question_type": "Adverse_event.Treatment.Drug", "answers": "tirapazamine; cisplatin"}, {"id": "10715308_10_8621", "context": "The tirapazamine-plus-cisplatin regimen was associated with mild to moderate adverse events, including acute, reversible hearing loss, reversible, intermittent muscle cramping, diarrhea, skin rash, nausea, and vomiting.", "question": "Treatment.Dosage in tirapazamine-plus-cisplatin regimen", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10715308_10_8622", "context": "The tirapazamine-plus-cisplatin regimen was associated with mild to moderate adverse events, including acute, reversible hearing loss, reversible, intermittent muscle cramping, diarrhea, skin rash, nausea, and vomiting.", "question": "Treatment.Freq in tirapazamine-plus-cisplatin regimen", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10715308_10_8623", "context": "The tirapazamine-plus-cisplatin regimen was associated with mild to moderate adverse events, including acute, reversible hearing loss, reversible, intermittent muscle cramping, diarrhea, skin rash, nausea, and vomiting.", "question": "Treatment.Route in tirapazamine-plus-cisplatin regimen", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10715308_10_8624", "context": "The tirapazamine-plus-cisplatin regimen was associated with mild to moderate adverse events, including acute, reversible hearing loss, reversible, intermittent muscle cramping, diarrhea, skin rash, nausea, and vomiting.", "question": "Treatment.Time_elapsed in tirapazamine-plus-cisplatin regimen", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10715308_10_8625", "context": "The tirapazamine-plus-cisplatin regimen was associated with mild to moderate adverse events, including acute, reversible hearing loss, reversible, intermittent muscle cramping, diarrhea, skin rash, nausea, and vomiting.", "question": "Treatment.Duration in tirapazamine-plus-cisplatin regimen", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10715308_10_8626", "context": "The tirapazamine-plus-cisplatin regimen was associated with mild to moderate adverse events, including acute, reversible hearing loss, reversible, intermittent muscle cramping, diarrhea, skin rash, nausea, and vomiting.", "question": "Treatment.Disorder in tirapazamine-plus-cisplatin regimen", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10715308_10_8627", "context": "The tirapazamine-plus-cisplatin regimen was associated with mild to moderate adverse events, including acute, reversible hearing loss, reversible, intermittent muscle cramping, diarrhea, skin rash, nausea, and vomiting.", "question": "Combination.Drug in tirapazamine-plus-cisplatin regimen", "question_type": "Adverse_event.Combination.Drug", "answers": "tirapazamine; cisplatin"}, {"id": "12665232_2_8628", "context": "To the best of our knowledge, corneoscleral melting in the first postoperative week after a single intraoperative application of mitomycin C has not been reported.", "question": "Treatment.Drug in a single intraoperative application of mitomycin C", "question_type": "Adverse_event.Treatment.Drug", "answers": "mitomycin C"}, {"id": "12665232_2_8629", "context": "To the best of our knowledge, corneoscleral melting in the first postoperative week after a single intraoperative application of mitomycin C has not been reported.", "question": "Treatment.Dosage in a single intraoperative application of mitomycin C", "question_type": "Adverse_event.Treatment.Dosage", "answers": "a single intraoperative application"}, {"id": "12665232_2_8630", "context": "To the best of our knowledge, corneoscleral melting in the first postoperative week after a single intraoperative application of mitomycin C has not been reported.", "question": "Treatment.Freq in a single intraoperative application of mitomycin C", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12665232_2_8631", "context": "To the best of our knowledge, corneoscleral melting in the first postoperative week after a single intraoperative application of mitomycin C has not been reported.", "question": "Treatment.Route in a single intraoperative application of mitomycin C", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12665232_2_8632", "context": "To the best of our knowledge, corneoscleral melting in the first postoperative week after a single intraoperative application of mitomycin C has not been reported.", "question": "Treatment.Time_elapsed in a single intraoperative application of mitomycin C", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12665232_2_8633", "context": "To the best of our knowledge, corneoscleral melting in the first postoperative week after a single intraoperative application of mitomycin C has not been reported.", "question": "Treatment.Duration in a single intraoperative application of mitomycin C", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12665232_2_8634", "context": "To the best of our knowledge, corneoscleral melting in the first postoperative week after a single intraoperative application of mitomycin C has not been reported.", "question": "Treatment.Disorder in a single intraoperative application of mitomycin C", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12665232_2_8635", "context": "To the best of our knowledge, corneoscleral melting in the first postoperative week after a single intraoperative application of mitomycin C has not been reported.", "question": "Combination.Drug in a single intraoperative application of mitomycin C", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3259776_2_8636", "context": "Thrombo-embolic complication after streptokinase therapy of pulmonary emboli.", "question": "Treatment.Drug in streptokinase", "question_type": "Adverse_event.Treatment.Drug", "answers": "streptokinase"}, {"id": "3259776_2_8637", "context": "Thrombo-embolic complication after streptokinase therapy of pulmonary emboli.", "question": "Treatment.Dosage in streptokinase", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3259776_2_8638", "context": "Thrombo-embolic complication after streptokinase therapy of pulmonary emboli.", "question": "Treatment.Freq in streptokinase", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3259776_2_8639", "context": "Thrombo-embolic complication after streptokinase therapy of pulmonary emboli.", "question": "Treatment.Route in streptokinase", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3259776_2_8640", "context": "Thrombo-embolic complication after streptokinase therapy of pulmonary emboli.", "question": "Treatment.Time_elapsed in streptokinase", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3259776_2_8641", "context": "Thrombo-embolic complication after streptokinase therapy of pulmonary emboli.", "question": "Treatment.Duration in streptokinase", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3259776_2_8642", "context": "Thrombo-embolic complication after streptokinase therapy of pulmonary emboli.", "question": "Treatment.Disorder in streptokinase", "question_type": "Adverse_event.Treatment.Disorder", "answers": "pulmonary emboli."}, {"id": "3259776_2_8643", "context": "Thrombo-embolic complication after streptokinase therapy of pulmonary emboli.", "question": "Combination.Drug in streptokinase", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7986915_1_8644", "context": "Amebic abscess of the spleen complicated by metronidazole-induced neurotoxicity: case report.", "question": "Subject.Age in case", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "7986915_1_8645", "context": "Amebic abscess of the spleen complicated by metronidazole-induced neurotoxicity: case report.", "question": "Subject.Gender in case", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "7986915_1_8646", "context": "Amebic abscess of the spleen complicated by metronidazole-induced neurotoxicity: case report.", "question": "Subject.Population in case", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "7986915_1_8647", "context": "Amebic abscess of the spleen complicated by metronidazole-induced neurotoxicity: case report.", "question": "Subject.Race in case", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "7986915_1_8648", "context": "Amebic abscess of the spleen complicated by metronidazole-induced neurotoxicity: case report.", "question": "Subject.Disorder in case", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "7986915_1_8649", "context": "Amebic abscess of the spleen complicated by metronidazole-induced neurotoxicity: case report.", "question": "Treatment.Drug in metronidazole", "question_type": "Adverse_event.Treatment.Drug", "answers": "metronidazole"}, {"id": "7986915_1_8650", "context": "Amebic abscess of the spleen complicated by metronidazole-induced neurotoxicity: case report.", "question": "Treatment.Dosage in metronidazole", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7986915_1_8651", "context": "Amebic abscess of the spleen complicated by metronidazole-induced neurotoxicity: case report.", "question": "Treatment.Freq in metronidazole", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7986915_1_8652", "context": "Amebic abscess of the spleen complicated by metronidazole-induced neurotoxicity: case report.", "question": "Treatment.Route in metronidazole", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7986915_1_8653", "context": "Amebic abscess of the spleen complicated by metronidazole-induced neurotoxicity: case report.", "question": "Treatment.Time_elapsed in metronidazole", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7986915_1_8654", "context": "Amebic abscess of the spleen complicated by metronidazole-induced neurotoxicity: case report.", "question": "Treatment.Duration in metronidazole", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7986915_1_8655", "context": "Amebic abscess of the spleen complicated by metronidazole-induced neurotoxicity: case report.", "question": "Treatment.Disorder in metronidazole", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7986915_1_8656", "context": "Amebic abscess of the spleen complicated by metronidazole-induced neurotoxicity: case report.", "question": "Combination.Drug in metronidazole", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16521231_3_8657", "context": "Subfulminant hepatitis B after infliximab in Crohn's disease: need for HBV-screening?", "question": "Treatment.Drug in infliximab", "question_type": "Adverse_event.Treatment.Drug", "answers": "infliximab"}, {"id": "16521231_3_8658", "context": "Subfulminant hepatitis B after infliximab in Crohn's disease: need for HBV-screening?", "question": "Treatment.Dosage in infliximab", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16521231_3_8659", "context": "Subfulminant hepatitis B after infliximab in Crohn's disease: need for HBV-screening?", "question": "Treatment.Freq in infliximab", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16521231_3_8660", "context": "Subfulminant hepatitis B after infliximab in Crohn's disease: need for HBV-screening?", "question": "Treatment.Route in infliximab", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16521231_3_8661", "context": "Subfulminant hepatitis B after infliximab in Crohn's disease: need for HBV-screening?", "question": "Treatment.Time_elapsed in infliximab", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16521231_3_8662", "context": "Subfulminant hepatitis B after infliximab in Crohn's disease: need for HBV-screening?", "question": "Treatment.Duration in infliximab", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16521231_3_8663", "context": "Subfulminant hepatitis B after infliximab in Crohn's disease: need for HBV-screening?", "question": "Treatment.Disorder in infliximab", "question_type": "Adverse_event.Treatment.Disorder", "answers": "Crohn's disease"}, {"id": "16521231_3_8664", "context": "Subfulminant hepatitis B after infliximab in Crohn's disease: need for HBV-screening?", "question": "Combination.Drug in infliximab", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18715650_1_8665", "context": "Disseminated salmonellosis in a patient treated with temozolomide.", "question": "Subject.Age in a patient", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "18715650_1_8666", "context": "Disseminated salmonellosis in a patient treated with temozolomide.", "question": "Subject.Gender in a patient", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "18715650_1_8667", "context": "Disseminated salmonellosis in a patient treated with temozolomide.", "question": "Subject.Population in a patient", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "18715650_1_8668", "context": "Disseminated salmonellosis in a patient treated with temozolomide.", "question": "Subject.Race in a patient", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "18715650_1_8669", "context": "Disseminated salmonellosis in a patient treated with temozolomide.", "question": "Subject.Disorder in a patient", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "18715650_1_8670", "context": "Disseminated salmonellosis in a patient treated with temozolomide.", "question": "Treatment.Drug in temozolomide", "question_type": "Adverse_event.Treatment.Drug", "answers": "temozolomide"}, {"id": "18715650_1_8671", "context": "Disseminated salmonellosis in a patient treated with temozolomide.", "question": "Treatment.Dosage in temozolomide", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18715650_1_8672", "context": "Disseminated salmonellosis in a patient treated with temozolomide.", "question": "Treatment.Freq in temozolomide", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18715650_1_8673", "context": "Disseminated salmonellosis in a patient treated with temozolomide.", "question": "Treatment.Route in temozolomide", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18715650_1_8674", "context": "Disseminated salmonellosis in a patient treated with temozolomide.", "question": "Treatment.Time_elapsed in temozolomide", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18715650_1_8675", "context": "Disseminated salmonellosis in a patient treated with temozolomide.", "question": "Treatment.Duration in temozolomide", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18715650_1_8676", "context": "Disseminated salmonellosis in a patient treated with temozolomide.", "question": "Treatment.Disorder in temozolomide", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18715650_1_8677", "context": "Disseminated salmonellosis in a patient treated with temozolomide.", "question": "Combination.Drug in temozolomide", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16221163_2_8678", "context": "The aim of our paper was to describe hepatotoxicity of sirolimus (SRL) in a kidney graft recipient.", "question": "Subject.Age in a kidney graft recipient", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "16221163_2_8679", "context": "The aim of our paper was to describe hepatotoxicity of sirolimus (SRL) in a kidney graft recipient.", "question": "Subject.Gender in a kidney graft recipient", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "16221163_2_8680", "context": "The aim of our paper was to describe hepatotoxicity of sirolimus (SRL) in a kidney graft recipient.", "question": "Subject.Population in a kidney graft recipient", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "16221163_2_8681", "context": "The aim of our paper was to describe hepatotoxicity of sirolimus (SRL) in a kidney graft recipient.", "question": "Subject.Race in a kidney graft recipient", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16221163_2_8682", "context": "The aim of our paper was to describe hepatotoxicity of sirolimus (SRL) in a kidney graft recipient.", "question": "Subject.Disorder in a kidney graft recipient", "question_type": "Adverse_event.Subject.Disorder", "answers": "kidney graft"}, {"id": "16221163_2_8683", "context": "The aim of our paper was to describe hepatotoxicity of sirolimus (SRL) in a kidney graft recipient.", "question": "Treatment.Drug in sirolimus (SRL)", "question_type": "Adverse_event.Treatment.Drug", "answers": "sirolimus"}, {"id": "16221163_2_8684", "context": "The aim of our paper was to describe hepatotoxicity of sirolimus (SRL) in a kidney graft recipient.", "question": "Treatment.Dosage in sirolimus (SRL)", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16221163_2_8685", "context": "The aim of our paper was to describe hepatotoxicity of sirolimus (SRL) in a kidney graft recipient.", "question": "Treatment.Freq in sirolimus (SRL)", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16221163_2_8686", "context": "The aim of our paper was to describe hepatotoxicity of sirolimus (SRL) in a kidney graft recipient.", "question": "Treatment.Route in sirolimus (SRL)", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16221163_2_8687", "context": "The aim of our paper was to describe hepatotoxicity of sirolimus (SRL) in a kidney graft recipient.", "question": "Treatment.Time_elapsed in sirolimus (SRL)", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16221163_2_8688", "context": "The aim of our paper was to describe hepatotoxicity of sirolimus (SRL) in a kidney graft recipient.", "question": "Treatment.Duration in sirolimus (SRL)", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16221163_2_8689", "context": "The aim of our paper was to describe hepatotoxicity of sirolimus (SRL) in a kidney graft recipient.", "question": "Treatment.Disorder in sirolimus (SRL)", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16221163_2_8690", "context": "The aim of our paper was to describe hepatotoxicity of sirolimus (SRL) in a kidney graft recipient.", "question": "Combination.Drug in sirolimus (SRL)", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3744305_1_8691", "context": "Idiosyncratic pulmonary reactions to nitrofurantoin are not unusual, often presenting as eosinophilic pneumonia.", "question": "Treatment.Drug in nitrofurantoin", "question_type": "Adverse_event.Treatment.Drug", "answers": "nitrofurantoin"}, {"id": "3744305_1_8692", "context": "Idiosyncratic pulmonary reactions to nitrofurantoin are not unusual, often presenting as eosinophilic pneumonia.", "question": "Treatment.Dosage in nitrofurantoin", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3744305_1_8693", "context": "Idiosyncratic pulmonary reactions to nitrofurantoin are not unusual, often presenting as eosinophilic pneumonia.", "question": "Treatment.Freq in nitrofurantoin", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3744305_1_8694", "context": "Idiosyncratic pulmonary reactions to nitrofurantoin are not unusual, often presenting as eosinophilic pneumonia.", "question": "Treatment.Route in nitrofurantoin", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3744305_1_8695", "context": "Idiosyncratic pulmonary reactions to nitrofurantoin are not unusual, often presenting as eosinophilic pneumonia.", "question": "Treatment.Time_elapsed in nitrofurantoin", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3744305_1_8696", "context": "Idiosyncratic pulmonary reactions to nitrofurantoin are not unusual, often presenting as eosinophilic pneumonia.", "question": "Treatment.Duration in nitrofurantoin", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3744305_1_8697", "context": "Idiosyncratic pulmonary reactions to nitrofurantoin are not unusual, often presenting as eosinophilic pneumonia.", "question": "Treatment.Disorder in nitrofurantoin", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3744305_1_8698", "context": "Idiosyncratic pulmonary reactions to nitrofurantoin are not unusual, often presenting as eosinophilic pneumonia.", "question": "Combination.Drug in nitrofurantoin", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17937473_3_8699", "context": "The NZ Pharmacovigilance Centre has received 7 additional reports of severe infections in patients with RA taking leflunomide.", "question": "Subject.Age in patients with RA", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "17937473_3_8700", "context": "The NZ Pharmacovigilance Centre has received 7 additional reports of severe infections in patients with RA taking leflunomide.", "question": "Subject.Gender in patients with RA", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "17937473_3_8701", "context": "The NZ Pharmacovigilance Centre has received 7 additional reports of severe infections in patients with RA taking leflunomide.", "question": "Subject.Population in patients with RA", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "17937473_3_8702", "context": "The NZ Pharmacovigilance Centre has received 7 additional reports of severe infections in patients with RA taking leflunomide.", "question": "Subject.Race in patients with RA", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "17937473_3_8703", "context": "The NZ Pharmacovigilance Centre has received 7 additional reports of severe infections in patients with RA taking leflunomide.", "question": "Subject.Disorder in patients with RA", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "17937473_3_8704", "context": "The NZ Pharmacovigilance Centre has received 7 additional reports of severe infections in patients with RA taking leflunomide.", "question": "Treatment.Drug in leflunomide", "question_type": "Adverse_event.Treatment.Drug", "answers": "leflunomide"}, {"id": "17937473_3_8705", "context": "The NZ Pharmacovigilance Centre has received 7 additional reports of severe infections in patients with RA taking leflunomide.", "question": "Treatment.Dosage in leflunomide", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17937473_3_8706", "context": "The NZ Pharmacovigilance Centre has received 7 additional reports of severe infections in patients with RA taking leflunomide.", "question": "Treatment.Freq in leflunomide", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17937473_3_8707", "context": "The NZ Pharmacovigilance Centre has received 7 additional reports of severe infections in patients with RA taking leflunomide.", "question": "Treatment.Route in leflunomide", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17937473_3_8708", "context": "The NZ Pharmacovigilance Centre has received 7 additional reports of severe infections in patients with RA taking leflunomide.", "question": "Treatment.Time_elapsed in leflunomide", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17937473_3_8709", "context": "The NZ Pharmacovigilance Centre has received 7 additional reports of severe infections in patients with RA taking leflunomide.", "question": "Treatment.Duration in leflunomide", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17937473_3_8710", "context": "The NZ Pharmacovigilance Centre has received 7 additional reports of severe infections in patients with RA taking leflunomide.", "question": "Treatment.Disorder in leflunomide", "question_type": "Adverse_event.Treatment.Disorder", "answers": "RA"}, {"id": "17937473_3_8711", "context": "The NZ Pharmacovigilance Centre has received 7 additional reports of severe infections in patients with RA taking leflunomide.", "question": "Combination.Drug in leflunomide", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6102186_5_8712", "context": "In addition, loading with one low oral dose of serine produced psychotic symptoms 5 h later which lasted 3-6 h.", "question": "Treatment.Drug in one low oral dose of serine; 5 h later", "question_type": "Adverse_event.Treatment.Drug", "answers": "serine"}, {"id": "6102186_5_8713", "context": "In addition, loading with one low oral dose of serine produced psychotic symptoms 5 h later which lasted 3-6 h.", "question": "Treatment.Dosage in one low oral dose of serine; 5 h later", "question_type": "Adverse_event.Treatment.Dosage", "answers": "low; dose"}, {"id": "6102186_5_8714", "context": "In addition, loading with one low oral dose of serine produced psychotic symptoms 5 h later which lasted 3-6 h.", "question": "Treatment.Freq in one low oral dose of serine; 5 h later", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6102186_5_8715", "context": "In addition, loading with one low oral dose of serine produced psychotic symptoms 5 h later which lasted 3-6 h.", "question": "Treatment.Route in one low oral dose of serine; 5 h later", "question_type": "Adverse_event.Treatment.Route", "answers": "oral"}, {"id": "6102186_5_8716", "context": "In addition, loading with one low oral dose of serine produced psychotic symptoms 5 h later which lasted 3-6 h.", "question": "Treatment.Time_elapsed in one low oral dose of serine; 5 h later", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "5 h"}, {"id": "6102186_5_8717", "context": "In addition, loading with one low oral dose of serine produced psychotic symptoms 5 h later which lasted 3-6 h.", "question": "Treatment.Duration in one low oral dose of serine; 5 h later", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6102186_5_8718", "context": "In addition, loading with one low oral dose of serine produced psychotic symptoms 5 h later which lasted 3-6 h.", "question": "Treatment.Disorder in one low oral dose of serine; 5 h later", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6102186_5_8719", "context": "In addition, loading with one low oral dose of serine produced psychotic symptoms 5 h later which lasted 3-6 h.", "question": "Combination.Drug in one low oral dose of serine; 5 h later", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16939867_1_8720", "context": "Localized purpura associated with lamotrigine.", "question": "Treatment.Drug in lamotrigine", "question_type": "Adverse_event.Treatment.Drug", "answers": "lamotrigine"}, {"id": "16939867_1_8721", "context": "Localized purpura associated with lamotrigine.", "question": "Treatment.Dosage in lamotrigine", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16939867_1_8722", "context": "Localized purpura associated with lamotrigine.", "question": "Treatment.Freq in lamotrigine", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16939867_1_8723", "context": "Localized purpura associated with lamotrigine.", "question": "Treatment.Route in lamotrigine", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16939867_1_8724", "context": "Localized purpura associated with lamotrigine.", "question": "Treatment.Time_elapsed in lamotrigine", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16939867_1_8725", "context": "Localized purpura associated with lamotrigine.", "question": "Treatment.Duration in lamotrigine", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16939867_1_8726", "context": "Localized purpura associated with lamotrigine.", "question": "Treatment.Disorder in lamotrigine", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16939867_1_8727", "context": "Localized purpura associated with lamotrigine.", "question": "Combination.Drug in lamotrigine", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "20065266_1_8728", "context": "Aseptic meningitis, hemolytic anemia, hepatitis, and orthostatic hypotension in a patient treated with trimethoprim-sulfamethoxazole.", "question": "Subject.Age in a patient", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "20065266_1_8729", "context": "Aseptic meningitis, hemolytic anemia, hepatitis, and orthostatic hypotension in a patient treated with trimethoprim-sulfamethoxazole.", "question": "Subject.Gender in a patient", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "20065266_1_8730", "context": "Aseptic meningitis, hemolytic anemia, hepatitis, and orthostatic hypotension in a patient treated with trimethoprim-sulfamethoxazole.", "question": "Subject.Population in a patient", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "20065266_1_8731", "context": "Aseptic meningitis, hemolytic anemia, hepatitis, and orthostatic hypotension in a patient treated with trimethoprim-sulfamethoxazole.", "question": "Subject.Race in a patient", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "20065266_1_8732", "context": "Aseptic meningitis, hemolytic anemia, hepatitis, and orthostatic hypotension in a patient treated with trimethoprim-sulfamethoxazole.", "question": "Subject.Disorder in a patient", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "20065266_1_8733", "context": "Aseptic meningitis, hemolytic anemia, hepatitis, and orthostatic hypotension in a patient treated with trimethoprim-sulfamethoxazole.", "question": "Treatment.Drug in trimethoprim-sulfamethoxazole", "question_type": "Adverse_event.Treatment.Drug", "answers": "trimethoprim; sulfamethoxazole"}, {"id": "20065266_1_8734", "context": "Aseptic meningitis, hemolytic anemia, hepatitis, and orthostatic hypotension in a patient treated with trimethoprim-sulfamethoxazole.", "question": "Treatment.Dosage in trimethoprim-sulfamethoxazole", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "20065266_1_8735", "context": "Aseptic meningitis, hemolytic anemia, hepatitis, and orthostatic hypotension in a patient treated with trimethoprim-sulfamethoxazole.", "question": "Treatment.Freq in trimethoprim-sulfamethoxazole", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "20065266_1_8736", "context": "Aseptic meningitis, hemolytic anemia, hepatitis, and orthostatic hypotension in a patient treated with trimethoprim-sulfamethoxazole.", "question": "Treatment.Route in trimethoprim-sulfamethoxazole", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "20065266_1_8737", "context": "Aseptic meningitis, hemolytic anemia, hepatitis, and orthostatic hypotension in a patient treated with trimethoprim-sulfamethoxazole.", "question": "Treatment.Time_elapsed in trimethoprim-sulfamethoxazole", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "20065266_1_8738", "context": "Aseptic meningitis, hemolytic anemia, hepatitis, and orthostatic hypotension in a patient treated with trimethoprim-sulfamethoxazole.", "question": "Treatment.Duration in trimethoprim-sulfamethoxazole", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "20065266_1_8739", "context": "Aseptic meningitis, hemolytic anemia, hepatitis, and orthostatic hypotension in a patient treated with trimethoprim-sulfamethoxazole.", "question": "Treatment.Disorder in trimethoprim-sulfamethoxazole", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "20065266_1_8740", "context": "Aseptic meningitis, hemolytic anemia, hepatitis, and orthostatic hypotension in a patient treated with trimethoprim-sulfamethoxazole.", "question": "Combination.Drug in trimethoprim-sulfamethoxazole", "question_type": "Adverse_event.Combination.Drug", "answers": "trimethoprim; sulfamethoxazole"}, {"id": "16352777_3_8741", "context": "Torsemide appears to also be a part of a long list of agents that can cause pancreatitis.", "question": "Treatment.Drug in Torsemide", "question_type": "Adverse_event.Treatment.Drug", "answers": "Torsemide"}, {"id": "16352777_3_8742", "context": "Torsemide appears to also be a part of a long list of agents that can cause pancreatitis.", "question": "Treatment.Dosage in Torsemide", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16352777_3_8743", "context": "Torsemide appears to also be a part of a long list of agents that can cause pancreatitis.", "question": "Treatment.Freq in Torsemide", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16352777_3_8744", "context": "Torsemide appears to also be a part of a long list of agents that can cause pancreatitis.", "question": "Treatment.Route in Torsemide", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16352777_3_8745", "context": "Torsemide appears to also be a part of a long list of agents that can cause pancreatitis.", "question": "Treatment.Time_elapsed in Torsemide", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16352777_3_8746", "context": "Torsemide appears to also be a part of a long list of agents that can cause pancreatitis.", "question": "Treatment.Duration in Torsemide", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16352777_3_8747", "context": "Torsemide appears to also be a part of a long list of agents that can cause pancreatitis.", "question": "Treatment.Disorder in Torsemide", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16352777_3_8748", "context": "Torsemide appears to also be a part of a long list of agents that can cause pancreatitis.", "question": "Combination.Drug in Torsemide", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "2863342_1_8749", "context": "Sulfasalazine has been associated with bronchopulmonary complications of inflammatory bowel disease (IBD) in adults.", "question": "Subject.Age in adults", "question_type": "Adverse_event.Subject.Age", "answers": "adults"}, {"id": "2863342_1_8750", "context": "Sulfasalazine has been associated with bronchopulmonary complications of inflammatory bowel disease (IBD) in adults.", "question": "Subject.Gender in adults", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "2863342_1_8751", "context": "Sulfasalazine has been associated with bronchopulmonary complications of inflammatory bowel disease (IBD) in adults.", "question": "Subject.Population in adults", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "2863342_1_8752", "context": "Sulfasalazine has been associated with bronchopulmonary complications of inflammatory bowel disease (IBD) in adults.", "question": "Subject.Race in adults", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "2863342_1_8753", "context": "Sulfasalazine has been associated with bronchopulmonary complications of inflammatory bowel disease (IBD) in adults.", "question": "Subject.Disorder in adults", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "2863342_1_8754", "context": "Sulfasalazine has been associated with bronchopulmonary complications of inflammatory bowel disease (IBD) in adults.", "question": "Treatment.Drug in Sulfasalazine", "question_type": "Adverse_event.Treatment.Drug", "answers": "Sulfasalazine"}, {"id": "2863342_1_8755", "context": "Sulfasalazine has been associated with bronchopulmonary complications of inflammatory bowel disease (IBD) in adults.", "question": "Treatment.Dosage in Sulfasalazine", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "2863342_1_8756", "context": "Sulfasalazine has been associated with bronchopulmonary complications of inflammatory bowel disease (IBD) in adults.", "question": "Treatment.Freq in Sulfasalazine", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2863342_1_8757", "context": "Sulfasalazine has been associated with bronchopulmonary complications of inflammatory bowel disease (IBD) in adults.", "question": "Treatment.Route in Sulfasalazine", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "2863342_1_8758", "context": "Sulfasalazine has been associated with bronchopulmonary complications of inflammatory bowel disease (IBD) in adults.", "question": "Treatment.Time_elapsed in Sulfasalazine", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2863342_1_8759", "context": "Sulfasalazine has been associated with bronchopulmonary complications of inflammatory bowel disease (IBD) in adults.", "question": "Treatment.Duration in Sulfasalazine", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2863342_1_8760", "context": "Sulfasalazine has been associated with bronchopulmonary complications of inflammatory bowel disease (IBD) in adults.", "question": "Treatment.Disorder in Sulfasalazine", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "2863342_1_8761", "context": "Sulfasalazine has been associated with bronchopulmonary complications of inflammatory bowel disease (IBD) in adults.", "question": "Combination.Drug in Sulfasalazine", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10348150_1_8762", "context": "Hydroxyurea-induced acute interstitial pneumonitis in a patient with essential thrombocythemia.", "question": "Subject.Age in a patient with essential thrombocythemia", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "10348150_1_8763", "context": "Hydroxyurea-induced acute interstitial pneumonitis in a patient with essential thrombocythemia.", "question": "Subject.Gender in a patient with essential thrombocythemia", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "10348150_1_8764", "context": "Hydroxyurea-induced acute interstitial pneumonitis in a patient with essential thrombocythemia.", "question": "Subject.Population in a patient with essential thrombocythemia", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "10348150_1_8765", "context": "Hydroxyurea-induced acute interstitial pneumonitis in a patient with essential thrombocythemia.", "question": "Subject.Race in a patient with essential thrombocythemia", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "10348150_1_8766", "context": "Hydroxyurea-induced acute interstitial pneumonitis in a patient with essential thrombocythemia.", "question": "Subject.Disorder in a patient with essential thrombocythemia", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "10348150_1_8767", "context": "Hydroxyurea-induced acute interstitial pneumonitis in a patient with essential thrombocythemia.", "question": "Treatment.Drug in Hydroxyurea", "question_type": "Adverse_event.Treatment.Drug", "answers": "Hydroxyurea"}, {"id": "10348150_1_8768", "context": "Hydroxyurea-induced acute interstitial pneumonitis in a patient with essential thrombocythemia.", "question": "Treatment.Dosage in Hydroxyurea", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10348150_1_8769", "context": "Hydroxyurea-induced acute interstitial pneumonitis in a patient with essential thrombocythemia.", "question": "Treatment.Freq in Hydroxyurea", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10348150_1_8770", "context": "Hydroxyurea-induced acute interstitial pneumonitis in a patient with essential thrombocythemia.", "question": "Treatment.Route in Hydroxyurea", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10348150_1_8771", "context": "Hydroxyurea-induced acute interstitial pneumonitis in a patient with essential thrombocythemia.", "question": "Treatment.Time_elapsed in Hydroxyurea", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10348150_1_8772", "context": "Hydroxyurea-induced acute interstitial pneumonitis in a patient with essential thrombocythemia.", "question": "Treatment.Duration in Hydroxyurea", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10348150_1_8773", "context": "Hydroxyurea-induced acute interstitial pneumonitis in a patient with essential thrombocythemia.", "question": "Treatment.Disorder in Hydroxyurea", "question_type": "Adverse_event.Treatment.Disorder", "answers": "essential thrombocythemia"}, {"id": "10348150_1_8774", "context": "Hydroxyurea-induced acute interstitial pneumonitis in a patient with essential thrombocythemia.", "question": "Combination.Drug in Hydroxyurea", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16001348_9_8775", "context": "The reported case represents an unusual association between medication with the proton pump inhibitor lansoprazole and the development of collagenous colitis suggesting the importance of evaluation of drug use in patients with microscopic colitis.", "question": "Subject.Age in patients with microscopic colitis", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "16001348_9_8776", "context": "The reported case represents an unusual association between medication with the proton pump inhibitor lansoprazole and the development of collagenous colitis suggesting the importance of evaluation of drug use in patients with microscopic colitis.", "question": "Subject.Gender in patients with microscopic colitis", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "16001348_9_8777", "context": "The reported case represents an unusual association between medication with the proton pump inhibitor lansoprazole and the development of collagenous colitis suggesting the importance of evaluation of drug use in patients with microscopic colitis.", "question": "Subject.Population in patients with microscopic colitis", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "16001348_9_8778", "context": "The reported case represents an unusual association between medication with the proton pump inhibitor lansoprazole and the development of collagenous colitis suggesting the importance of evaluation of drug use in patients with microscopic colitis.", "question": "Subject.Race in patients with microscopic colitis", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16001348_9_8779", "context": "The reported case represents an unusual association between medication with the proton pump inhibitor lansoprazole and the development of collagenous colitis suggesting the importance of evaluation of drug use in patients with microscopic colitis.", "question": "Subject.Disorder in patients with microscopic colitis", "question_type": "Adverse_event.Subject.Disorder", "answers": "microscopic colitis"}, {"id": "16001348_9_8780", "context": "The reported case represents an unusual association between medication with the proton pump inhibitor lansoprazole and the development of collagenous colitis suggesting the importance of evaluation of drug use in patients with microscopic colitis.", "question": "Treatment.Drug in proton pump inhibitor lansoprazole", "question_type": "Adverse_event.Treatment.Drug", "answers": "lansoprazole"}, {"id": "16001348_9_8781", "context": "The reported case represents an unusual association between medication with the proton pump inhibitor lansoprazole and the development of collagenous colitis suggesting the importance of evaluation of drug use in patients with microscopic colitis.", "question": "Treatment.Dosage in proton pump inhibitor lansoprazole", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16001348_9_8782", "context": "The reported case represents an unusual association between medication with the proton pump inhibitor lansoprazole and the development of collagenous colitis suggesting the importance of evaluation of drug use in patients with microscopic colitis.", "question": "Treatment.Freq in proton pump inhibitor lansoprazole", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16001348_9_8783", "context": "The reported case represents an unusual association between medication with the proton pump inhibitor lansoprazole and the development of collagenous colitis suggesting the importance of evaluation of drug use in patients with microscopic colitis.", "question": "Treatment.Route in proton pump inhibitor lansoprazole", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16001348_9_8784", "context": "The reported case represents an unusual association between medication with the proton pump inhibitor lansoprazole and the development of collagenous colitis suggesting the importance of evaluation of drug use in patients with microscopic colitis.", "question": "Treatment.Time_elapsed in proton pump inhibitor lansoprazole", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16001348_9_8785", "context": "The reported case represents an unusual association between medication with the proton pump inhibitor lansoprazole and the development of collagenous colitis suggesting the importance of evaluation of drug use in patients with microscopic colitis.", "question": "Treatment.Duration in proton pump inhibitor lansoprazole", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16001348_9_8786", "context": "The reported case represents an unusual association between medication with the proton pump inhibitor lansoprazole and the development of collagenous colitis suggesting the importance of evaluation of drug use in patients with microscopic colitis.", "question": "Treatment.Disorder in proton pump inhibitor lansoprazole", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16001348_9_8787", "context": "The reported case represents an unusual association between medication with the proton pump inhibitor lansoprazole and the development of collagenous colitis suggesting the importance of evaluation of drug use in patients with microscopic colitis.", "question": "Combination.Drug in proton pump inhibitor lansoprazole", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "644545_3_8788", "context": "The temporal sequence of the respiratory insufficiency and the histopathology, when compared to the previous examples in the literature, suggest that cyclophosphamide was aetiologically responsible for the lung disease.", "question": "Treatment.Drug in cyclophosphamide", "question_type": "Adverse_event.Treatment.Drug", "answers": "cyclophosphamide"}, {"id": "644545_3_8789", "context": "The temporal sequence of the respiratory insufficiency and the histopathology, when compared to the previous examples in the literature, suggest that cyclophosphamide was aetiologically responsible for the lung disease.", "question": "Treatment.Dosage in cyclophosphamide", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "644545_3_8790", "context": "The temporal sequence of the respiratory insufficiency and the histopathology, when compared to the previous examples in the literature, suggest that cyclophosphamide was aetiologically responsible for the lung disease.", "question": "Treatment.Freq in cyclophosphamide", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "644545_3_8791", "context": "The temporal sequence of the respiratory insufficiency and the histopathology, when compared to the previous examples in the literature, suggest that cyclophosphamide was aetiologically responsible for the lung disease.", "question": "Treatment.Route in cyclophosphamide", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "644545_3_8792", "context": "The temporal sequence of the respiratory insufficiency and the histopathology, when compared to the previous examples in the literature, suggest that cyclophosphamide was aetiologically responsible for the lung disease.", "question": "Treatment.Time_elapsed in cyclophosphamide", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "644545_3_8793", "context": "The temporal sequence of the respiratory insufficiency and the histopathology, when compared to the previous examples in the literature, suggest that cyclophosphamide was aetiologically responsible for the lung disease.", "question": "Treatment.Duration in cyclophosphamide", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "644545_3_8794", "context": "The temporal sequence of the respiratory insufficiency and the histopathology, when compared to the previous examples in the literature, suggest that cyclophosphamide was aetiologically responsible for the lung disease.", "question": "Treatment.Disorder in cyclophosphamide", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "644545_3_8795", "context": "The temporal sequence of the respiratory insufficiency and the histopathology, when compared to the previous examples in the literature, suggest that cyclophosphamide was aetiologically responsible for the lung disease.", "question": "Combination.Drug in cyclophosphamide", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16001348_2_8796", "context": "A 57-year-old man developed chronic, watery diarrhea four weeks after Helicobacter pylori eradication therapy including lansoprazole followed by lansoprazole monotherapy for gastroesophageal reflux disease.", "question": "Subject.Age in 57-year-old man", "question_type": "Adverse_event.Subject.Age", "answers": "57-year-old"}, {"id": "16001348_2_8797", "context": "A 57-year-old man developed chronic, watery diarrhea four weeks after Helicobacter pylori eradication therapy including lansoprazole followed by lansoprazole monotherapy for gastroesophageal reflux disease.", "question": "Subject.Gender in 57-year-old man", "question_type": "Adverse_event.Subject.Gender", "answers": "man"}, {"id": "16001348_2_8798", "context": "A 57-year-old man developed chronic, watery diarrhea four weeks after Helicobacter pylori eradication therapy including lansoprazole followed by lansoprazole monotherapy for gastroesophageal reflux disease.", "question": "Subject.Population in 57-year-old man", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "16001348_2_8799", "context": "A 57-year-old man developed chronic, watery diarrhea four weeks after Helicobacter pylori eradication therapy including lansoprazole followed by lansoprazole monotherapy for gastroesophageal reflux disease.", "question": "Subject.Race in 57-year-old man", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16001348_2_8800", "context": "A 57-year-old man developed chronic, watery diarrhea four weeks after Helicobacter pylori eradication therapy including lansoprazole followed by lansoprazole monotherapy for gastroesophageal reflux disease.", "question": "Subject.Disorder in 57-year-old man", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "16001348_2_8801", "context": "A 57-year-old man developed chronic, watery diarrhea four weeks after Helicobacter pylori eradication therapy including lansoprazole followed by lansoprazole monotherapy for gastroesophageal reflux disease.", "question": "Treatment.Drug in four weeks after Helicobacter pylori eradication therapy including lansoprazole followed by lansoprazole monotherapy for gastroesophageal reflux disease", "question_type": "Adverse_event.Treatment.Drug", "answers": "lansoprazole; lansoprazole"}, {"id": "16001348_2_8802", "context": "A 57-year-old man developed chronic, watery diarrhea four weeks after Helicobacter pylori eradication therapy including lansoprazole followed by lansoprazole monotherapy for gastroesophageal reflux disease.", "question": "Treatment.Dosage in four weeks after Helicobacter pylori eradication therapy including lansoprazole followed by lansoprazole monotherapy for gastroesophageal reflux disease", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16001348_2_8803", "context": "A 57-year-old man developed chronic, watery diarrhea four weeks after Helicobacter pylori eradication therapy including lansoprazole followed by lansoprazole monotherapy for gastroesophageal reflux disease.", "question": "Treatment.Freq in four weeks after Helicobacter pylori eradication therapy including lansoprazole followed by lansoprazole monotherapy for gastroesophageal reflux disease", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16001348_2_8804", "context": "A 57-year-old man developed chronic, watery diarrhea four weeks after Helicobacter pylori eradication therapy including lansoprazole followed by lansoprazole monotherapy for gastroesophageal reflux disease.", "question": "Treatment.Route in four weeks after Helicobacter pylori eradication therapy including lansoprazole followed by lansoprazole monotherapy for gastroesophageal reflux disease", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16001348_2_8805", "context": "A 57-year-old man developed chronic, watery diarrhea four weeks after Helicobacter pylori eradication therapy including lansoprazole followed by lansoprazole monotherapy for gastroesophageal reflux disease.", "question": "Treatment.Time_elapsed in four weeks after Helicobacter pylori eradication therapy including lansoprazole followed by lansoprazole monotherapy for gastroesophageal reflux disease", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "four weeks"}, {"id": "16001348_2_8806", "context": "A 57-year-old man developed chronic, watery diarrhea four weeks after Helicobacter pylori eradication therapy including lansoprazole followed by lansoprazole monotherapy for gastroesophageal reflux disease.", "question": "Treatment.Duration in four weeks after Helicobacter pylori eradication therapy including lansoprazole followed by lansoprazole monotherapy for gastroesophageal reflux disease", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16001348_2_8807", "context": "A 57-year-old man developed chronic, watery diarrhea four weeks after Helicobacter pylori eradication therapy including lansoprazole followed by lansoprazole monotherapy for gastroesophageal reflux disease.", "question": "Treatment.Disorder in four weeks after Helicobacter pylori eradication therapy including lansoprazole followed by lansoprazole monotherapy for gastroesophageal reflux disease", "question_type": "Adverse_event.Treatment.Disorder", "answers": "gastroesophageal reflux disease"}, {"id": "16001348_2_8808", "context": "A 57-year-old man developed chronic, watery diarrhea four weeks after Helicobacter pylori eradication therapy including lansoprazole followed by lansoprazole monotherapy for gastroesophageal reflux disease.", "question": "Combination.Drug in four weeks after Helicobacter pylori eradication therapy including lansoprazole followed by lansoprazole monotherapy for gastroesophageal reflux disease", "question_type": "Adverse_event.Combination.Drug", "answers": "lansoprazole; lansoprazole"}, {"id": "10327035_2_8809", "context": "We believe that this represents an unusual case of moderate-dose MTX-induced neurotoxicity in a patient with gastric cancer, which has not previously been reported.", "question": "Subject.Age in patient with gastric cancer", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "10327035_2_8810", "context": "We believe that this represents an unusual case of moderate-dose MTX-induced neurotoxicity in a patient with gastric cancer, which has not previously been reported.", "question": "Subject.Gender in patient with gastric cancer", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "10327035_2_8811", "context": "We believe that this represents an unusual case of moderate-dose MTX-induced neurotoxicity in a patient with gastric cancer, which has not previously been reported.", "question": "Subject.Population in patient with gastric cancer", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "10327035_2_8812", "context": "We believe that this represents an unusual case of moderate-dose MTX-induced neurotoxicity in a patient with gastric cancer, which has not previously been reported.", "question": "Subject.Race in patient with gastric cancer", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "10327035_2_8813", "context": "We believe that this represents an unusual case of moderate-dose MTX-induced neurotoxicity in a patient with gastric cancer, which has not previously been reported.", "question": "Subject.Disorder in patient with gastric cancer", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "10327035_2_8814", "context": "We believe that this represents an unusual case of moderate-dose MTX-induced neurotoxicity in a patient with gastric cancer, which has not previously been reported.", "question": "Treatment.Drug in moderate-dose MTX", "question_type": "Adverse_event.Treatment.Drug", "answers": "MTX"}, {"id": "10327035_2_8815", "context": "We believe that this represents an unusual case of moderate-dose MTX-induced neurotoxicity in a patient with gastric cancer, which has not previously been reported.", "question": "Treatment.Dosage in moderate-dose MTX", "question_type": "Adverse_event.Treatment.Dosage", "answers": "moderate-dose"}, {"id": "10327035_2_8816", "context": "We believe that this represents an unusual case of moderate-dose MTX-induced neurotoxicity in a patient with gastric cancer, which has not previously been reported.", "question": "Treatment.Freq in moderate-dose MTX", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10327035_2_8817", "context": "We believe that this represents an unusual case of moderate-dose MTX-induced neurotoxicity in a patient with gastric cancer, which has not previously been reported.", "question": "Treatment.Route in moderate-dose MTX", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10327035_2_8818", "context": "We believe that this represents an unusual case of moderate-dose MTX-induced neurotoxicity in a patient with gastric cancer, which has not previously been reported.", "question": "Treatment.Time_elapsed in moderate-dose MTX", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10327035_2_8819", "context": "We believe that this represents an unusual case of moderate-dose MTX-induced neurotoxicity in a patient with gastric cancer, which has not previously been reported.", "question": "Treatment.Duration in moderate-dose MTX", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10327035_2_8820", "context": "We believe that this represents an unusual case of moderate-dose MTX-induced neurotoxicity in a patient with gastric cancer, which has not previously been reported.", "question": "Treatment.Disorder in moderate-dose MTX", "question_type": "Adverse_event.Treatment.Disorder", "answers": "gastric cancer"}, {"id": "10327035_2_8821", "context": "We believe that this represents an unusual case of moderate-dose MTX-induced neurotoxicity in a patient with gastric cancer, which has not previously been reported.", "question": "Combination.Drug in moderate-dose MTX", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18672645_1_8822", "context": "The patient expired after seven cycles of treatment had been completed because of pulmonary fibrosis and the drug toxicity of bleomycin.", "question": "Subject.Age in The patient", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "18672645_1_8823", "context": "The patient expired after seven cycles of treatment had been completed because of pulmonary fibrosis and the drug toxicity of bleomycin.", "question": "Subject.Gender in The patient", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "18672645_1_8824", "context": "The patient expired after seven cycles of treatment had been completed because of pulmonary fibrosis and the drug toxicity of bleomycin.", "question": "Subject.Population in The patient", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "18672645_1_8825", "context": "The patient expired after seven cycles of treatment had been completed because of pulmonary fibrosis and the drug toxicity of bleomycin.", "question": "Subject.Race in The patient", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "18672645_1_8826", "context": "The patient expired after seven cycles of treatment had been completed because of pulmonary fibrosis and the drug toxicity of bleomycin.", "question": "Subject.Disorder in The patient", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "18672645_1_8827", "context": "The patient expired after seven cycles of treatment had been completed because of pulmonary fibrosis and the drug toxicity of bleomycin.", "question": "Treatment.Drug in seven cycles of treatment; drug toxicity of bleomycin", "question_type": "Adverse_event.Treatment.Drug", "answers": "bleomycin"}, {"id": "18672645_1_8828", "context": "The patient expired after seven cycles of treatment had been completed because of pulmonary fibrosis and the drug toxicity of bleomycin.", "question": "Treatment.Dosage in seven cycles of treatment; drug toxicity of bleomycin", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18672645_1_8829", "context": "The patient expired after seven cycles of treatment had been completed because of pulmonary fibrosis and the drug toxicity of bleomycin.", "question": "Treatment.Freq in seven cycles of treatment; drug toxicity of bleomycin", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18672645_1_8830", "context": "The patient expired after seven cycles of treatment had been completed because of pulmonary fibrosis and the drug toxicity of bleomycin.", "question": "Treatment.Route in seven cycles of treatment; drug toxicity of bleomycin", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18672645_1_8831", "context": "The patient expired after seven cycles of treatment had been completed because of pulmonary fibrosis and the drug toxicity of bleomycin.", "question": "Treatment.Time_elapsed in seven cycles of treatment; drug toxicity of bleomycin", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18672645_1_8832", "context": "The patient expired after seven cycles of treatment had been completed because of pulmonary fibrosis and the drug toxicity of bleomycin.", "question": "Treatment.Duration in seven cycles of treatment; drug toxicity of bleomycin", "question_type": "Adverse_event.Treatment.Duration", "answers": "seven cycles"}, {"id": "18672645_1_8833", "context": "The patient expired after seven cycles of treatment had been completed because of pulmonary fibrosis and the drug toxicity of bleomycin.", "question": "Treatment.Disorder in seven cycles of treatment; drug toxicity of bleomycin", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18672645_1_8834", "context": "The patient expired after seven cycles of treatment had been completed because of pulmonary fibrosis and the drug toxicity of bleomycin.", "question": "Combination.Drug in seven cycles of treatment; drug toxicity of bleomycin", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12149193_8_8835", "context": "A statistical association between the incidence of DVT and combination chemotherapy including doxorubicin (P =.02) was observed; this association was confirmed on multivariate analysis.", "question": "Treatment.Drug in combination chemotherapy including doxorubicin (P =.02)", "question_type": "Adverse_event.Treatment.Drug", "answers": "chemotherapy; doxorubicin"}, {"id": "12149193_8_8836", "context": "A statistical association between the incidence of DVT and combination chemotherapy including doxorubicin (P =.02) was observed; this association was confirmed on multivariate analysis.", "question": "Treatment.Dosage in combination chemotherapy including doxorubicin (P =.02)", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12149193_8_8837", "context": "A statistical association between the incidence of DVT and combination chemotherapy including doxorubicin (P =.02) was observed; this association was confirmed on multivariate analysis.", "question": "Treatment.Freq in combination chemotherapy including doxorubicin (P =.02)", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12149193_8_8838", "context": "A statistical association between the incidence of DVT and combination chemotherapy including doxorubicin (P =.02) was observed; this association was confirmed on multivariate analysis.", "question": "Treatment.Route in combination chemotherapy including doxorubicin (P =.02)", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12149193_8_8839", "context": "A statistical association between the incidence of DVT and combination chemotherapy including doxorubicin (P =.02) was observed; this association was confirmed on multivariate analysis.", "question": "Treatment.Time_elapsed in combination chemotherapy including doxorubicin (P =.02)", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12149193_8_8840", "context": "A statistical association between the incidence of DVT and combination chemotherapy including doxorubicin (P =.02) was observed; this association was confirmed on multivariate analysis.", "question": "Treatment.Duration in combination chemotherapy including doxorubicin (P =.02)", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12149193_8_8841", "context": "A statistical association between the incidence of DVT and combination chemotherapy including doxorubicin (P =.02) was observed; this association was confirmed on multivariate analysis.", "question": "Treatment.Disorder in combination chemotherapy including doxorubicin (P =.02)", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12149193_8_8842", "context": "A statistical association between the incidence of DVT and combination chemotherapy including doxorubicin (P =.02) was observed; this association was confirmed on multivariate analysis.", "question": "Combination.Drug in combination chemotherapy including doxorubicin (P =.02)", "question_type": "Adverse_event.Combination.Drug", "answers": "chemotherapy; doxorubicin"}, {"id": "2417800_3_8843", "context": "Bleomycin pneumonitis potentiated by oxygen administration.", "question": "Treatment.Drug in oxygen administration", "question_type": "Adverse_event.Treatment.Drug", "answers": "oxygen"}, {"id": "2417800_3_8844", "context": "Bleomycin pneumonitis potentiated by oxygen administration.", "question": "Treatment.Dosage in oxygen administration", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "2417800_3_8845", "context": "Bleomycin pneumonitis potentiated by oxygen administration.", "question": "Treatment.Freq in oxygen administration", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2417800_3_8846", "context": "Bleomycin pneumonitis potentiated by oxygen administration.", "question": "Treatment.Route in oxygen administration", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "2417800_3_8847", "context": "Bleomycin pneumonitis potentiated by oxygen administration.", "question": "Treatment.Time_elapsed in oxygen administration", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2417800_3_8848", "context": "Bleomycin pneumonitis potentiated by oxygen administration.", "question": "Treatment.Duration in oxygen administration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2417800_3_8849", "context": "Bleomycin pneumonitis potentiated by oxygen administration.", "question": "Treatment.Disorder in oxygen administration", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "2417800_3_8850", "context": "Bleomycin pneumonitis potentiated by oxygen administration.", "question": "Combination.Drug in oxygen administration", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12455453_1_8851", "context": "After five and six weeks of continuous oral administration of methylprednisolone, the boys developed steroid diabetes.", "question": "Subject.Age in boys", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "12455453_1_8852", "context": "After five and six weeks of continuous oral administration of methylprednisolone, the boys developed steroid diabetes.", "question": "Subject.Gender in boys", "question_type": "Adverse_event.Subject.Gender", "answers": "boys"}, {"id": "12455453_1_8853", "context": "After five and six weeks of continuous oral administration of methylprednisolone, the boys developed steroid diabetes.", "question": "Subject.Population in boys", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "12455453_1_8854", "context": "After five and six weeks of continuous oral administration of methylprednisolone, the boys developed steroid diabetes.", "question": "Subject.Race in boys", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "12455453_1_8855", "context": "After five and six weeks of continuous oral administration of methylprednisolone, the boys developed steroid diabetes.", "question": "Subject.Disorder in boys", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "12455453_1_8856", "context": "After five and six weeks of continuous oral administration of methylprednisolone, the boys developed steroid diabetes.", "question": "Treatment.Drug in After five and six weeks of continuous oral administration of methylprednisolone", "question_type": "Adverse_event.Treatment.Drug", "answers": "methylprednisolone"}, {"id": "12455453_1_8857", "context": "After five and six weeks of continuous oral administration of methylprednisolone, the boys developed steroid diabetes.", "question": "Treatment.Dosage in After five and six weeks of continuous oral administration of methylprednisolone", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12455453_1_8858", "context": "After five and six weeks of continuous oral administration of methylprednisolone, the boys developed steroid diabetes.", "question": "Treatment.Freq in After five and six weeks of continuous oral administration of methylprednisolone", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12455453_1_8859", "context": "After five and six weeks of continuous oral administration of methylprednisolone, the boys developed steroid diabetes.", "question": "Treatment.Route in After five and six weeks of continuous oral administration of methylprednisolone", "question_type": "Adverse_event.Treatment.Route", "answers": "oral"}, {"id": "12455453_1_8860", "context": "After five and six weeks of continuous oral administration of methylprednisolone, the boys developed steroid diabetes.", "question": "Treatment.Time_elapsed in After five and six weeks of continuous oral administration of methylprednisolone", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12455453_1_8861", "context": "After five and six weeks of continuous oral administration of methylprednisolone, the boys developed steroid diabetes.", "question": "Treatment.Duration in After five and six weeks of continuous oral administration of methylprednisolone", "question_type": "Adverse_event.Treatment.Duration", "answers": "After five and six weeks"}, {"id": "12455453_1_8862", "context": "After five and six weeks of continuous oral administration of methylprednisolone, the boys developed steroid diabetes.", "question": "Treatment.Disorder in After five and six weeks of continuous oral administration of methylprednisolone", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12455453_1_8863", "context": "After five and six weeks of continuous oral administration of methylprednisolone, the boys developed steroid diabetes.", "question": "Combination.Drug in After five and six weeks of continuous oral administration of methylprednisolone", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18775393_1_8864", "context": "CONCLUSION: This report describes a case of a probable interaction between topical econazole lotion 1% and acenocoumarol that resulted in overanticoagulation and a life-threatening laryngeal hematoma in this elderly patient.", "question": "Subject.Age in elderly patient", "question_type": "Adverse_event.Subject.Age", "answers": "elderly"}, {"id": "18775393_1_8865", "context": "CONCLUSION: This report describes a case of a probable interaction between topical econazole lotion 1% and acenocoumarol that resulted in overanticoagulation and a life-threatening laryngeal hematoma in this elderly patient.", "question": "Subject.Gender in elderly patient", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "18775393_1_8866", "context": "CONCLUSION: This report describes a case of a probable interaction between topical econazole lotion 1% and acenocoumarol that resulted in overanticoagulation and a life-threatening laryngeal hematoma in this elderly patient.", "question": "Subject.Population in elderly patient", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "18775393_1_8867", "context": "CONCLUSION: This report describes a case of a probable interaction between topical econazole lotion 1% and acenocoumarol that resulted in overanticoagulation and a life-threatening laryngeal hematoma in this elderly patient.", "question": "Subject.Race in elderly patient", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "18775393_1_8868", "context": "CONCLUSION: This report describes a case of a probable interaction between topical econazole lotion 1% and acenocoumarol that resulted in overanticoagulation and a life-threatening laryngeal hematoma in this elderly patient.", "question": "Subject.Disorder in elderly patient", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "18775393_1_8869", "context": "CONCLUSION: This report describes a case of a probable interaction between topical econazole lotion 1% and acenocoumarol that resulted in overanticoagulation and a life-threatening laryngeal hematoma in this elderly patient.", "question": "Treatment.Drug in a probable interaction between topical econazole lotion 1% and acenocoumarol", "question_type": "Adverse_event.Treatment.Drug", "answers": "econazole; acenocoumarol"}, {"id": "18775393_1_8870", "context": "CONCLUSION: This report describes a case of a probable interaction between topical econazole lotion 1% and acenocoumarol that resulted in overanticoagulation and a life-threatening laryngeal hematoma in this elderly patient.", "question": "Treatment.Dosage in a probable interaction between topical econazole lotion 1% and acenocoumarol", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18775393_1_8871", "context": "CONCLUSION: This report describes a case of a probable interaction between topical econazole lotion 1% and acenocoumarol that resulted in overanticoagulation and a life-threatening laryngeal hematoma in this elderly patient.", "question": "Treatment.Freq in a probable interaction between topical econazole lotion 1% and acenocoumarol", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18775393_1_8872", "context": "CONCLUSION: This report describes a case of a probable interaction between topical econazole lotion 1% and acenocoumarol that resulted in overanticoagulation and a life-threatening laryngeal hematoma in this elderly patient.", "question": "Treatment.Route in a probable interaction between topical econazole lotion 1% and acenocoumarol", "question_type": "Adverse_event.Treatment.Route", "answers": "topical; lotion"}, {"id": "18775393_1_8873", "context": "CONCLUSION: This report describes a case of a probable interaction between topical econazole lotion 1% and acenocoumarol that resulted in overanticoagulation and a life-threatening laryngeal hematoma in this elderly patient.", "question": "Treatment.Time_elapsed in a probable interaction between topical econazole lotion 1% and acenocoumarol", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18775393_1_8874", "context": "CONCLUSION: This report describes a case of a probable interaction between topical econazole lotion 1% and acenocoumarol that resulted in overanticoagulation and a life-threatening laryngeal hematoma in this elderly patient.", "question": "Treatment.Duration in a probable interaction between topical econazole lotion 1% and acenocoumarol", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18775393_1_8875", "context": "CONCLUSION: This report describes a case of a probable interaction between topical econazole lotion 1% and acenocoumarol that resulted in overanticoagulation and a life-threatening laryngeal hematoma in this elderly patient.", "question": "Treatment.Disorder in a probable interaction between topical econazole lotion 1% and acenocoumarol", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18775393_1_8876", "context": "CONCLUSION: This report describes a case of a probable interaction between topical econazole lotion 1% and acenocoumarol that resulted in overanticoagulation and a life-threatening laryngeal hematoma in this elderly patient.", "question": "Combination.Drug in a probable interaction between topical econazole lotion 1% and acenocoumarol", "question_type": "Adverse_event.Combination.Drug", "answers": "econazole; acenocoumarol"}, {"id": "15529178_1_8877", "context": "Pulmonary lymphohistiocytic reactions temporally related to etanercept therapy.", "question": "Treatment.Drug in etanercept", "question_type": "Adverse_event.Treatment.Drug", "answers": "etanercept"}, {"id": "15529178_1_8878", "context": "Pulmonary lymphohistiocytic reactions temporally related to etanercept therapy.", "question": "Treatment.Dosage in etanercept", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15529178_1_8879", "context": "Pulmonary lymphohistiocytic reactions temporally related to etanercept therapy.", "question": "Treatment.Freq in etanercept", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15529178_1_8880", "context": "Pulmonary lymphohistiocytic reactions temporally related to etanercept therapy.", "question": "Treatment.Route in etanercept", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15529178_1_8881", "context": "Pulmonary lymphohistiocytic reactions temporally related to etanercept therapy.", "question": "Treatment.Time_elapsed in etanercept", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15529178_1_8882", "context": "Pulmonary lymphohistiocytic reactions temporally related to etanercept therapy.", "question": "Treatment.Duration in etanercept", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15529178_1_8883", "context": "Pulmonary lymphohistiocytic reactions temporally related to etanercept therapy.", "question": "Treatment.Disorder in etanercept", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15529178_1_8884", "context": "Pulmonary lymphohistiocytic reactions temporally related to etanercept therapy.", "question": "Combination.Drug in etanercept", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16459502_2_8885", "context": "Disseminated tuberculous lesions post intravesical BCG therapy are rare but need to be identified and treated quickly.", "question": "Treatment.Drug in BCG", "question_type": "Adverse_event.Treatment.Drug", "answers": "BCG"}, {"id": "16459502_2_8886", "context": "Disseminated tuberculous lesions post intravesical BCG therapy are rare but need to be identified and treated quickly.", "question": "Treatment.Dosage in BCG", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16459502_2_8887", "context": "Disseminated tuberculous lesions post intravesical BCG therapy are rare but need to be identified and treated quickly.", "question": "Treatment.Freq in BCG", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16459502_2_8888", "context": "Disseminated tuberculous lesions post intravesical BCG therapy are rare but need to be identified and treated quickly.", "question": "Treatment.Route in BCG", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16459502_2_8889", "context": "Disseminated tuberculous lesions post intravesical BCG therapy are rare but need to be identified and treated quickly.", "question": "Treatment.Time_elapsed in BCG", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16459502_2_8890", "context": "Disseminated tuberculous lesions post intravesical BCG therapy are rare but need to be identified and treated quickly.", "question": "Treatment.Duration in BCG", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16459502_2_8891", "context": "Disseminated tuberculous lesions post intravesical BCG therapy are rare but need to be identified and treated quickly.", "question": "Treatment.Disorder in BCG", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16459502_2_8892", "context": "Disseminated tuberculous lesions post intravesical BCG therapy are rare but need to be identified and treated quickly.", "question": "Combination.Drug in BCG", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "14712320_5_8893", "context": "Rhabdomyolysis can occur with all statins when used alone and particularly when combined with other drugs that are themselves myotoxic or that elevate the concentration of the statin.", "question": "Treatment.Drug in statins; other drugs that are themselves myotoxic or that elevate the concentration of the statin", "question_type": "Adverse_event.Treatment.Drug", "answers": "statins"}, {"id": "14712320_5_8894", "context": "Rhabdomyolysis can occur with all statins when used alone and particularly when combined with other drugs that are themselves myotoxic or that elevate the concentration of the statin.", "question": "Treatment.Dosage in statins; other drugs that are themselves myotoxic or that elevate the concentration of the statin", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "14712320_5_8895", "context": "Rhabdomyolysis can occur with all statins when used alone and particularly when combined with other drugs that are themselves myotoxic or that elevate the concentration of the statin.", "question": "Treatment.Freq in statins; other drugs that are themselves myotoxic or that elevate the concentration of the statin", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "14712320_5_8896", "context": "Rhabdomyolysis can occur with all statins when used alone and particularly when combined with other drugs that are themselves myotoxic or that elevate the concentration of the statin.", "question": "Treatment.Route in statins; other drugs that are themselves myotoxic or that elevate the concentration of the statin", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "14712320_5_8897", "context": "Rhabdomyolysis can occur with all statins when used alone and particularly when combined with other drugs that are themselves myotoxic or that elevate the concentration of the statin.", "question": "Treatment.Time_elapsed in statins; other drugs that are themselves myotoxic or that elevate the concentration of the statin", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "14712320_5_8898", "context": "Rhabdomyolysis can occur with all statins when used alone and particularly when combined with other drugs that are themselves myotoxic or that elevate the concentration of the statin.", "question": "Treatment.Duration in statins; other drugs that are themselves myotoxic or that elevate the concentration of the statin", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "14712320_5_8899", "context": "Rhabdomyolysis can occur with all statins when used alone and particularly when combined with other drugs that are themselves myotoxic or that elevate the concentration of the statin.", "question": "Treatment.Disorder in statins; other drugs that are themselves myotoxic or that elevate the concentration of the statin", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "14712320_5_8900", "context": "Rhabdomyolysis can occur with all statins when used alone and particularly when combined with other drugs that are themselves myotoxic or that elevate the concentration of the statin.", "question": "Combination.Drug in statins; other drugs that are themselves myotoxic or that elevate the concentration of the statin", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "4044222_2_8901", "context": "Amiodarone-induced dysthyroidism.", "question": "Treatment.Drug in Amiodarone", "question_type": "Adverse_event.Treatment.Drug", "answers": "Amiodarone"}, {"id": "4044222_2_8902", "context": "Amiodarone-induced dysthyroidism.", "question": "Treatment.Dosage in Amiodarone", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "4044222_2_8903", "context": "Amiodarone-induced dysthyroidism.", "question": "Treatment.Freq in Amiodarone", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "4044222_2_8904", "context": "Amiodarone-induced dysthyroidism.", "question": "Treatment.Route in Amiodarone", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "4044222_2_8905", "context": "Amiodarone-induced dysthyroidism.", "question": "Treatment.Time_elapsed in Amiodarone", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "4044222_2_8906", "context": "Amiodarone-induced dysthyroidism.", "question": "Treatment.Duration in Amiodarone", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "4044222_2_8907", "context": "Amiodarone-induced dysthyroidism.", "question": "Treatment.Disorder in Amiodarone", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "4044222_2_8908", "context": "Amiodarone-induced dysthyroidism.", "question": "Combination.Drug in Amiodarone", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6108450_2_8909", "context": "Two patients with imminent gangrene of the extremities caused by ergot-induced arteriospasm underwent mechanical dilatation of the arteries when conventional measures such as anticoagulation, vasodilation, and sympathetic blockade produced no improvement.", "question": "Treatment.Drug in ergot", "question_type": "Adverse_event.Treatment.Drug", "answers": "ergot"}, {"id": "6108450_2_8910", "context": "Two patients with imminent gangrene of the extremities caused by ergot-induced arteriospasm underwent mechanical dilatation of the arteries when conventional measures such as anticoagulation, vasodilation, and sympathetic blockade produced no improvement.", "question": "Treatment.Dosage in ergot", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6108450_2_8911", "context": "Two patients with imminent gangrene of the extremities caused by ergot-induced arteriospasm underwent mechanical dilatation of the arteries when conventional measures such as anticoagulation, vasodilation, and sympathetic blockade produced no improvement.", "question": "Treatment.Freq in ergot", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6108450_2_8912", "context": "Two patients with imminent gangrene of the extremities caused by ergot-induced arteriospasm underwent mechanical dilatation of the arteries when conventional measures such as anticoagulation, vasodilation, and sympathetic blockade produced no improvement.", "question": "Treatment.Route in ergot", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6108450_2_8913", "context": "Two patients with imminent gangrene of the extremities caused by ergot-induced arteriospasm underwent mechanical dilatation of the arteries when conventional measures such as anticoagulation, vasodilation, and sympathetic blockade produced no improvement.", "question": "Treatment.Time_elapsed in ergot", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6108450_2_8914", "context": "Two patients with imminent gangrene of the extremities caused by ergot-induced arteriospasm underwent mechanical dilatation of the arteries when conventional measures such as anticoagulation, vasodilation, and sympathetic blockade produced no improvement.", "question": "Treatment.Duration in ergot", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6108450_2_8915", "context": "Two patients with imminent gangrene of the extremities caused by ergot-induced arteriospasm underwent mechanical dilatation of the arteries when conventional measures such as anticoagulation, vasodilation, and sympathetic blockade produced no improvement.", "question": "Treatment.Disorder in ergot", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6108450_2_8916", "context": "Two patients with imminent gangrene of the extremities caused by ergot-induced arteriospasm underwent mechanical dilatation of the arteries when conventional measures such as anticoagulation, vasodilation, and sympathetic blockade produced no improvement.", "question": "Combination.Drug in ergot", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6108450_2_8917", "context": "Two patients with imminent gangrene of the extremities caused by ergot-induced arteriospasm underwent mechanical dilatation of the arteries when conventional measures such as anticoagulation, vasodilation, and sympathetic blockade produced no improvement.", "question": "Subject.Age in Two patients", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "6108450_2_8918", "context": "Two patients with imminent gangrene of the extremities caused by ergot-induced arteriospasm underwent mechanical dilatation of the arteries when conventional measures such as anticoagulation, vasodilation, and sympathetic blockade produced no improvement.", "question": "Subject.Gender in Two patients", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "6108450_2_8919", "context": "Two patients with imminent gangrene of the extremities caused by ergot-induced arteriospasm underwent mechanical dilatation of the arteries when conventional measures such as anticoagulation, vasodilation, and sympathetic blockade produced no improvement.", "question": "Subject.Population in Two patients", "question_type": "Adverse_event.Subject.Population", "answers": "Two"}, {"id": "6108450_2_8920", "context": "Two patients with imminent gangrene of the extremities caused by ergot-induced arteriospasm underwent mechanical dilatation of the arteries when conventional measures such as anticoagulation, vasodilation, and sympathetic blockade produced no improvement.", "question": "Subject.Race in Two patients", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "6108450_2_8921", "context": "Two patients with imminent gangrene of the extremities caused by ergot-induced arteriospasm underwent mechanical dilatation of the arteries when conventional measures such as anticoagulation, vasodilation, and sympathetic blockade produced no improvement.", "question": "Subject.Disorder in Two patients", "question_type": "Adverse_event.Subject.Disorder", "answers": "ergot-induced arteriospasm"}, {"id": "6108450_2_8922", "context": "Two patients with imminent gangrene of the extremities caused by ergot-induced arteriospasm underwent mechanical dilatation of the arteries when conventional measures such as anticoagulation, vasodilation, and sympathetic blockade produced no improvement.", "question": "Treatment.Drug in ergot", "question_type": "Adverse_event.Treatment.Drug", "answers": "ergot"}, {"id": "6108450_2_8923", "context": "Two patients with imminent gangrene of the extremities caused by ergot-induced arteriospasm underwent mechanical dilatation of the arteries when conventional measures such as anticoagulation, vasodilation, and sympathetic blockade produced no improvement.", "question": "Treatment.Dosage in ergot", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6108450_2_8924", "context": "Two patients with imminent gangrene of the extremities caused by ergot-induced arteriospasm underwent mechanical dilatation of the arteries when conventional measures such as anticoagulation, vasodilation, and sympathetic blockade produced no improvement.", "question": "Treatment.Freq in ergot", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6108450_2_8925", "context": "Two patients with imminent gangrene of the extremities caused by ergot-induced arteriospasm underwent mechanical dilatation of the arteries when conventional measures such as anticoagulation, vasodilation, and sympathetic blockade produced no improvement.", "question": "Treatment.Route in ergot", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6108450_2_8926", "context": "Two patients with imminent gangrene of the extremities caused by ergot-induced arteriospasm underwent mechanical dilatation of the arteries when conventional measures such as anticoagulation, vasodilation, and sympathetic blockade produced no improvement.", "question": "Treatment.Time_elapsed in ergot", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6108450_2_8927", "context": "Two patients with imminent gangrene of the extremities caused by ergot-induced arteriospasm underwent mechanical dilatation of the arteries when conventional measures such as anticoagulation, vasodilation, and sympathetic blockade produced no improvement.", "question": "Treatment.Duration in ergot", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6108450_2_8928", "context": "Two patients with imminent gangrene of the extremities caused by ergot-induced arteriospasm underwent mechanical dilatation of the arteries when conventional measures such as anticoagulation, vasodilation, and sympathetic blockade produced no improvement.", "question": "Treatment.Disorder in ergot", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6108450_2_8929", "context": "Two patients with imminent gangrene of the extremities caused by ergot-induced arteriospasm underwent mechanical dilatation of the arteries when conventional measures such as anticoagulation, vasodilation, and sympathetic blockade produced no improvement.", "question": "Combination.Drug in ergot", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18765315_1_8930", "context": "Acute coronary syndromes can be associated with the infusion of rituximab.", "question": "Treatment.Drug in infusion of rituximab", "question_type": "Adverse_event.Treatment.Drug", "answers": "rituximab"}, {"id": "18765315_1_8931", "context": "Acute coronary syndromes can be associated with the infusion of rituximab.", "question": "Treatment.Dosage in infusion of rituximab", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18765315_1_8932", "context": "Acute coronary syndromes can be associated with the infusion of rituximab.", "question": "Treatment.Freq in infusion of rituximab", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18765315_1_8933", "context": "Acute coronary syndromes can be associated with the infusion of rituximab.", "question": "Treatment.Route in infusion of rituximab", "question_type": "Adverse_event.Treatment.Route", "answers": "infusion"}, {"id": "18765315_1_8934", "context": "Acute coronary syndromes can be associated with the infusion of rituximab.", "question": "Treatment.Time_elapsed in infusion of rituximab", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18765315_1_8935", "context": "Acute coronary syndromes can be associated with the infusion of rituximab.", "question": "Treatment.Duration in infusion of rituximab", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18765315_1_8936", "context": "Acute coronary syndromes can be associated with the infusion of rituximab.", "question": "Treatment.Disorder in infusion of rituximab", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18765315_1_8937", "context": "Acute coronary syndromes can be associated with the infusion of rituximab.", "question": "Combination.Drug in infusion of rituximab", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9466030_2_8938", "context": "Approximately 15 min after the first administration of nebulised morphine the patient became markedly bradypneic (respiratory rate: 4-5 bpm), hypotensive (BP 70/40 mmHg), and responded only partially to command.", "question": "Subject.Age in patient", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "9466030_2_8939", "context": "Approximately 15 min after the first administration of nebulised morphine the patient became markedly bradypneic (respiratory rate: 4-5 bpm), hypotensive (BP 70/40 mmHg), and responded only partially to command.", "question": "Subject.Gender in patient", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "9466030_2_8940", "context": "Approximately 15 min after the first administration of nebulised morphine the patient became markedly bradypneic (respiratory rate: 4-5 bpm), hypotensive (BP 70/40 mmHg), and responded only partially to command.", "question": "Subject.Population in patient", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "9466030_2_8941", "context": "Approximately 15 min after the first administration of nebulised morphine the patient became markedly bradypneic (respiratory rate: 4-5 bpm), hypotensive (BP 70/40 mmHg), and responded only partially to command.", "question": "Subject.Race in patient", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "9466030_2_8942", "context": "Approximately 15 min after the first administration of nebulised morphine the patient became markedly bradypneic (respiratory rate: 4-5 bpm), hypotensive (BP 70/40 mmHg), and responded only partially to command.", "question": "Subject.Disorder in patient", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "9466030_2_8943", "context": "Approximately 15 min after the first administration of nebulised morphine the patient became markedly bradypneic (respiratory rate: 4-5 bpm), hypotensive (BP 70/40 mmHg), and responded only partially to command.", "question": "Treatment.Drug in nebulised morphine", "question_type": "Adverse_event.Treatment.Drug", "answers": "morphine"}, {"id": "9466030_2_8944", "context": "Approximately 15 min after the first administration of nebulised morphine the patient became markedly bradypneic (respiratory rate: 4-5 bpm), hypotensive (BP 70/40 mmHg), and responded only partially to command.", "question": "Treatment.Dosage in nebulised morphine", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9466030_2_8945", "context": "Approximately 15 min after the first administration of nebulised morphine the patient became markedly bradypneic (respiratory rate: 4-5 bpm), hypotensive (BP 70/40 mmHg), and responded only partially to command.", "question": "Treatment.Freq in nebulised morphine", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9466030_2_8946", "context": "Approximately 15 min after the first administration of nebulised morphine the patient became markedly bradypneic (respiratory rate: 4-5 bpm), hypotensive (BP 70/40 mmHg), and responded only partially to command.", "question": "Treatment.Route in nebulised morphine", "question_type": "Adverse_event.Treatment.Route", "answers": "nebulised"}, {"id": "9466030_2_8947", "context": "Approximately 15 min after the first administration of nebulised morphine the patient became markedly bradypneic (respiratory rate: 4-5 bpm), hypotensive (BP 70/40 mmHg), and responded only partially to command.", "question": "Treatment.Time_elapsed in nebulised morphine", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "15 min"}, {"id": "9466030_2_8948", "context": "Approximately 15 min after the first administration of nebulised morphine the patient became markedly bradypneic (respiratory rate: 4-5 bpm), hypotensive (BP 70/40 mmHg), and responded only partially to command.", "question": "Treatment.Duration in nebulised morphine", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9466030_2_8949", "context": "Approximately 15 min after the first administration of nebulised morphine the patient became markedly bradypneic (respiratory rate: 4-5 bpm), hypotensive (BP 70/40 mmHg), and responded only partially to command.", "question": "Treatment.Disorder in nebulised morphine", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9466030_2_8950", "context": "Approximately 15 min after the first administration of nebulised morphine the patient became markedly bradypneic (respiratory rate: 4-5 bpm), hypotensive (BP 70/40 mmHg), and responded only partially to command.", "question": "Combination.Drug in nebulised morphine", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "2549018_1_8951", "context": "Akathisia appeared to be a common side effect of fluoxetine and generally responded well to treatment with the beta-adrenergic antagonist propranolol, dose reduction, or both.", "question": "Treatment.Drug in beta-adrenergic antagonist propranolol", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "fluoxetine"}, {"id": "2549018_1_8952", "context": "Akathisia appeared to be a common side effect of fluoxetine and generally responded well to treatment with the beta-adrenergic antagonist propranolol, dose reduction, or both.", "question": "Treatment.Dosage in beta-adrenergic antagonist propranolol", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "2549018_1_8953", "context": "Akathisia appeared to be a common side effect of fluoxetine and generally responded well to treatment with the beta-adrenergic antagonist propranolol, dose reduction, or both.", "question": "Treatment.Freq in beta-adrenergic antagonist propranolol", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "2549018_1_8954", "context": "Akathisia appeared to be a common side effect of fluoxetine and generally responded well to treatment with the beta-adrenergic antagonist propranolol, dose reduction, or both.", "question": "Treatment.Route in beta-adrenergic antagonist propranolol", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "2549018_1_8955", "context": "Akathisia appeared to be a common side effect of fluoxetine and generally responded well to treatment with the beta-adrenergic antagonist propranolol, dose reduction, or both.", "question": "Treatment.Time_elapsed in beta-adrenergic antagonist propranolol", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2549018_1_8956", "context": "Akathisia appeared to be a common side effect of fluoxetine and generally responded well to treatment with the beta-adrenergic antagonist propranolol, dose reduction, or both.", "question": "Treatment.Duration in beta-adrenergic antagonist propranolol", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "2549018_1_8957", "context": "Akathisia appeared to be a common side effect of fluoxetine and generally responded well to treatment with the beta-adrenergic antagonist propranolol, dose reduction, or both.", "question": "Treatment.Disorder in beta-adrenergic antagonist propranolol", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "Akathisia"}, {"id": "2549018_1_8958", "context": "Akathisia appeared to be a common side effect of fluoxetine and generally responded well to treatment with the beta-adrenergic antagonist propranolol, dose reduction, or both.", "question": "Combination.Drug in beta-adrenergic antagonist propranolol", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "9934637_1_8959", "context": "An unusual cause of burn injury: unsupervised use of drugs that contain psoralens.", "question": "Treatment.Drug in use of drugs that contain psoralens.", "question_type": "Adverse_event.Treatment.Drug", "answers": "psoralens"}, {"id": "9934637_1_8960", "context": "An unusual cause of burn injury: unsupervised use of drugs that contain psoralens.", "question": "Treatment.Dosage in use of drugs that contain psoralens.", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9934637_1_8961", "context": "An unusual cause of burn injury: unsupervised use of drugs that contain psoralens.", "question": "Treatment.Freq in use of drugs that contain psoralens.", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9934637_1_8962", "context": "An unusual cause of burn injury: unsupervised use of drugs that contain psoralens.", "question": "Treatment.Route in use of drugs that contain psoralens.", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9934637_1_8963", "context": "An unusual cause of burn injury: unsupervised use of drugs that contain psoralens.", "question": "Treatment.Time_elapsed in use of drugs that contain psoralens.", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9934637_1_8964", "context": "An unusual cause of burn injury: unsupervised use of drugs that contain psoralens.", "question": "Treatment.Duration in use of drugs that contain psoralens.", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9934637_1_8965", "context": "An unusual cause of burn injury: unsupervised use of drugs that contain psoralens.", "question": "Treatment.Disorder in use of drugs that contain psoralens.", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9934637_1_8966", "context": "An unusual cause of burn injury: unsupervised use of drugs that contain psoralens.", "question": "Combination.Drug in use of drugs that contain psoralens.", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11984077_3_8967", "context": "The patient suffered a life-threatening anaphylactoid reaction to amifostine.", "question": "Subject.Age in patient", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "11984077_3_8968", "context": "The patient suffered a life-threatening anaphylactoid reaction to amifostine.", "question": "Subject.Gender in patient", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "11984077_3_8969", "context": "The patient suffered a life-threatening anaphylactoid reaction to amifostine.", "question": "Subject.Population in patient", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "11984077_3_8970", "context": "The patient suffered a life-threatening anaphylactoid reaction to amifostine.", "question": "Subject.Race in patient", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "11984077_3_8971", "context": "The patient suffered a life-threatening anaphylactoid reaction to amifostine.", "question": "Subject.Disorder in patient", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "11984077_3_8972", "context": "The patient suffered a life-threatening anaphylactoid reaction to amifostine.", "question": "Treatment.Drug in amifostine", "question_type": "Adverse_event.Treatment.Drug", "answers": "amifostine"}, {"id": "11984077_3_8973", "context": "The patient suffered a life-threatening anaphylactoid reaction to amifostine.", "question": "Treatment.Dosage in amifostine", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11984077_3_8974", "context": "The patient suffered a life-threatening anaphylactoid reaction to amifostine.", "question": "Treatment.Freq in amifostine", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11984077_3_8975", "context": "The patient suffered a life-threatening anaphylactoid reaction to amifostine.", "question": "Treatment.Route in amifostine", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11984077_3_8976", "context": "The patient suffered a life-threatening anaphylactoid reaction to amifostine.", "question": "Treatment.Time_elapsed in amifostine", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11984077_3_8977", "context": "The patient suffered a life-threatening anaphylactoid reaction to amifostine.", "question": "Treatment.Duration in amifostine", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11984077_3_8978", "context": "The patient suffered a life-threatening anaphylactoid reaction to amifostine.", "question": "Treatment.Disorder in amifostine", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11984077_3_8979", "context": "The patient suffered a life-threatening anaphylactoid reaction to amifostine.", "question": "Combination.Drug in amifostine", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16313549_2_8980", "context": "We report three cases of severe hypocalcaemia associated with i.v. bisphosphonate treatment in patients with multiple myeloma.", "question": "Subject.Age in patients with multiple myeloma", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "16313549_2_8981", "context": "We report three cases of severe hypocalcaemia associated with i.v. bisphosphonate treatment in patients with multiple myeloma.", "question": "Subject.Gender in patients with multiple myeloma", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "16313549_2_8982", "context": "We report three cases of severe hypocalcaemia associated with i.v. bisphosphonate treatment in patients with multiple myeloma.", "question": "Subject.Population in patients with multiple myeloma", "question_type": "Adverse_event.Subject.Population", "answers": "three"}, {"id": "16313549_2_8983", "context": "We report three cases of severe hypocalcaemia associated with i.v. bisphosphonate treatment in patients with multiple myeloma.", "question": "Subject.Race in patients with multiple myeloma", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16313549_2_8984", "context": "We report three cases of severe hypocalcaemia associated with i.v. bisphosphonate treatment in patients with multiple myeloma.", "question": "Subject.Disorder in patients with multiple myeloma", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "16313549_2_8985", "context": "We report three cases of severe hypocalcaemia associated with i.v. bisphosphonate treatment in patients with multiple myeloma.", "question": "Treatment.Drug in i.v. bisphosphonate treatment", "question_type": "Adverse_event.Treatment.Drug", "answers": "bisphosphonate"}, {"id": "16313549_2_8986", "context": "We report three cases of severe hypocalcaemia associated with i.v. bisphosphonate treatment in patients with multiple myeloma.", "question": "Treatment.Dosage in i.v. bisphosphonate treatment", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16313549_2_8987", "context": "We report three cases of severe hypocalcaemia associated with i.v. bisphosphonate treatment in patients with multiple myeloma.", "question": "Treatment.Freq in i.v. bisphosphonate treatment", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16313549_2_8988", "context": "We report three cases of severe hypocalcaemia associated with i.v. bisphosphonate treatment in patients with multiple myeloma.", "question": "Treatment.Route in i.v. bisphosphonate treatment", "question_type": "Adverse_event.Treatment.Route", "answers": "i.v."}, {"id": "16313549_2_8989", "context": "We report three cases of severe hypocalcaemia associated with i.v. bisphosphonate treatment in patients with multiple myeloma.", "question": "Treatment.Time_elapsed in i.v. bisphosphonate treatment", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16313549_2_8990", "context": "We report three cases of severe hypocalcaemia associated with i.v. bisphosphonate treatment in patients with multiple myeloma.", "question": "Treatment.Duration in i.v. bisphosphonate treatment", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16313549_2_8991", "context": "We report three cases of severe hypocalcaemia associated with i.v. bisphosphonate treatment in patients with multiple myeloma.", "question": "Treatment.Disorder in i.v. bisphosphonate treatment", "question_type": "Adverse_event.Treatment.Disorder", "answers": "multiple myeloma"}, {"id": "16313549_2_8992", "context": "We report three cases of severe hypocalcaemia associated with i.v. bisphosphonate treatment in patients with multiple myeloma.", "question": "Combination.Drug in i.v. bisphosphonate treatment", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "1829999_2_8993", "context": "We report a case of exfoliative dermatitis clearly linked to intravenous and intraperitoneal administration of tobramycin.", "question": "Subject.Age in a case", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "1829999_2_8994", "context": "We report a case of exfoliative dermatitis clearly linked to intravenous and intraperitoneal administration of tobramycin.", "question": "Subject.Gender in a case", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "1829999_2_8995", "context": "We report a case of exfoliative dermatitis clearly linked to intravenous and intraperitoneal administration of tobramycin.", "question": "Subject.Population in a case", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "1829999_2_8996", "context": "We report a case of exfoliative dermatitis clearly linked to intravenous and intraperitoneal administration of tobramycin.", "question": "Subject.Race in a case", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "1829999_2_8997", "context": "We report a case of exfoliative dermatitis clearly linked to intravenous and intraperitoneal administration of tobramycin.", "question": "Subject.Disorder in a case", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "1829999_2_8998", "context": "We report a case of exfoliative dermatitis clearly linked to intravenous and intraperitoneal administration of tobramycin.", "question": "Treatment.Drug in intravenous and intraperitoneal administration of tobramycin", "question_type": "Adverse_event.Treatment.Drug", "answers": "tobramycin"}, {"id": "1829999_2_8999", "context": "We report a case of exfoliative dermatitis clearly linked to intravenous and intraperitoneal administration of tobramycin.", "question": "Treatment.Dosage in intravenous and intraperitoneal administration of tobramycin", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "1829999_2_9000", "context": "We report a case of exfoliative dermatitis clearly linked to intravenous and intraperitoneal administration of tobramycin.", "question": "Treatment.Freq in intravenous and intraperitoneal administration of tobramycin", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "1829999_2_9001", "context": "We report a case of exfoliative dermatitis clearly linked to intravenous and intraperitoneal administration of tobramycin.", "question": "Treatment.Route in intravenous and intraperitoneal administration of tobramycin", "question_type": "Adverse_event.Treatment.Route", "answers": "intravenous; intraperitoneal"}, {"id": "1829999_2_9002", "context": "We report a case of exfoliative dermatitis clearly linked to intravenous and intraperitoneal administration of tobramycin.", "question": "Treatment.Time_elapsed in intravenous and intraperitoneal administration of tobramycin", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "1829999_2_9003", "context": "We report a case of exfoliative dermatitis clearly linked to intravenous and intraperitoneal administration of tobramycin.", "question": "Treatment.Duration in intravenous and intraperitoneal administration of tobramycin", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "1829999_2_9004", "context": "We report a case of exfoliative dermatitis clearly linked to intravenous and intraperitoneal administration of tobramycin.", "question": "Treatment.Disorder in intravenous and intraperitoneal administration of tobramycin", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "1829999_2_9005", "context": "We report a case of exfoliative dermatitis clearly linked to intravenous and intraperitoneal administration of tobramycin.", "question": "Combination.Drug in intravenous and intraperitoneal administration of tobramycin", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "95811_2_9006", "context": "Glomerulonephritis in procainamide induced lupus erythematosus: report of a case and review of the literature.", "question": "Treatment.Drug in procainamide", "question_type": "Adverse_event.Treatment.Drug", "answers": "procainamide"}, {"id": "95811_2_9007", "context": "Glomerulonephritis in procainamide induced lupus erythematosus: report of a case and review of the literature.", "question": "Treatment.Dosage in procainamide", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "95811_2_9008", "context": "Glomerulonephritis in procainamide induced lupus erythematosus: report of a case and review of the literature.", "question": "Treatment.Freq in procainamide", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "95811_2_9009", "context": "Glomerulonephritis in procainamide induced lupus erythematosus: report of a case and review of the literature.", "question": "Treatment.Route in procainamide", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "95811_2_9010", "context": "Glomerulonephritis in procainamide induced lupus erythematosus: report of a case and review of the literature.", "question": "Treatment.Time_elapsed in procainamide", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "95811_2_9011", "context": "Glomerulonephritis in procainamide induced lupus erythematosus: report of a case and review of the literature.", "question": "Treatment.Duration in procainamide", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "95811_2_9012", "context": "Glomerulonephritis in procainamide induced lupus erythematosus: report of a case and review of the literature.", "question": "Treatment.Disorder in procainamide", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "95811_2_9013", "context": "Glomerulonephritis in procainamide induced lupus erythematosus: report of a case and review of the literature.", "question": "Combination.Drug in procainamide", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8645078_4_9014", "context": "Patients treated with captopril who develop \"atypical cholangitis\" should be suspected of having captopril-associated liver damage.", "question": "Subject.Age in Patients", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "8645078_4_9015", "context": "Patients treated with captopril who develop \"atypical cholangitis\" should be suspected of having captopril-associated liver damage.", "question": "Subject.Gender in Patients", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "8645078_4_9016", "context": "Patients treated with captopril who develop \"atypical cholangitis\" should be suspected of having captopril-associated liver damage.", "question": "Subject.Population in Patients", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "8645078_4_9017", "context": "Patients treated with captopril who develop \"atypical cholangitis\" should be suspected of having captopril-associated liver damage.", "question": "Subject.Race in Patients", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "8645078_4_9018", "context": "Patients treated with captopril who develop \"atypical cholangitis\" should be suspected of having captopril-associated liver damage.", "question": "Subject.Disorder in Patients", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "8645078_4_9019", "context": "Patients treated with captopril who develop \"atypical cholangitis\" should be suspected of having captopril-associated liver damage.", "question": "Treatment.Drug in captopril", "question_type": "Adverse_event.Treatment.Drug", "answers": "captopril; captopril"}, {"id": "8645078_4_9020", "context": "Patients treated with captopril who develop \"atypical cholangitis\" should be suspected of having captopril-associated liver damage.", "question": "Treatment.Dosage in captopril", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8645078_4_9021", "context": "Patients treated with captopril who develop \"atypical cholangitis\" should be suspected of having captopril-associated liver damage.", "question": "Treatment.Freq in captopril", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8645078_4_9022", "context": "Patients treated with captopril who develop \"atypical cholangitis\" should be suspected of having captopril-associated liver damage.", "question": "Treatment.Route in captopril", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8645078_4_9023", "context": "Patients treated with captopril who develop \"atypical cholangitis\" should be suspected of having captopril-associated liver damage.", "question": "Treatment.Time_elapsed in captopril", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8645078_4_9024", "context": "Patients treated with captopril who develop \"atypical cholangitis\" should be suspected of having captopril-associated liver damage.", "question": "Treatment.Duration in captopril", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8645078_4_9025", "context": "Patients treated with captopril who develop \"atypical cholangitis\" should be suspected of having captopril-associated liver damage.", "question": "Treatment.Disorder in captopril", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8645078_4_9026", "context": "Patients treated with captopril who develop \"atypical cholangitis\" should be suspected of having captopril-associated liver damage.", "question": "Combination.Drug in captopril", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10586009_2_9027", "context": "We report a case of codeine intoxication in the neonate, in which the drug was prescribed for cough control during an emergency department visit.", "question": "Subject.Age in in the neonate; for cough control during an emergency department visit", "question_type": "Adverse_event.Subject.Age", "answers": "neonate"}, {"id": "10586009_2_9028", "context": "We report a case of codeine intoxication in the neonate, in which the drug was prescribed for cough control during an emergency department visit.", "question": "Subject.Gender in in the neonate; for cough control during an emergency department visit", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "10586009_2_9029", "context": "We report a case of codeine intoxication in the neonate, in which the drug was prescribed for cough control during an emergency department visit.", "question": "Subject.Population in in the neonate; for cough control during an emergency department visit", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "10586009_2_9030", "context": "We report a case of codeine intoxication in the neonate, in which the drug was prescribed for cough control during an emergency department visit.", "question": "Subject.Race in in the neonate; for cough control during an emergency department visit", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "10586009_2_9031", "context": "We report a case of codeine intoxication in the neonate, in which the drug was prescribed for cough control during an emergency department visit.", "question": "Subject.Disorder in in the neonate; for cough control during an emergency department visit", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "10586009_2_9032", "context": "We report a case of codeine intoxication in the neonate, in which the drug was prescribed for cough control during an emergency department visit.", "question": "Treatment.Drug in codeine", "question_type": "Adverse_event.Treatment.Drug", "answers": "codeine"}, {"id": "10586009_2_9033", "context": "We report a case of codeine intoxication in the neonate, in which the drug was prescribed for cough control during an emergency department visit.", "question": "Treatment.Dosage in codeine", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10586009_2_9034", "context": "We report a case of codeine intoxication in the neonate, in which the drug was prescribed for cough control during an emergency department visit.", "question": "Treatment.Freq in codeine", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10586009_2_9035", "context": "We report a case of codeine intoxication in the neonate, in which the drug was prescribed for cough control during an emergency department visit.", "question": "Treatment.Route in codeine", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10586009_2_9036", "context": "We report a case of codeine intoxication in the neonate, in which the drug was prescribed for cough control during an emergency department visit.", "question": "Treatment.Time_elapsed in codeine", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10586009_2_9037", "context": "We report a case of codeine intoxication in the neonate, in which the drug was prescribed for cough control during an emergency department visit.", "question": "Treatment.Duration in codeine", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10586009_2_9038", "context": "We report a case of codeine intoxication in the neonate, in which the drug was prescribed for cough control during an emergency department visit.", "question": "Treatment.Disorder in codeine", "question_type": "Adverse_event.Treatment.Disorder", "answers": "cough"}, {"id": "10586009_2_9039", "context": "We report a case of codeine intoxication in the neonate, in which the drug was prescribed for cough control during an emergency department visit.", "question": "Combination.Drug in codeine", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17763133_2_9040", "context": "Discontinuation of simvastatin and cyclosporine resulted in resolution of rhabdomyolysis and normalization of renal function.", "question": "Treatment.Drug in Discontinuation of simvastatin and cyclosporine", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "simvastatin; cyclosporine"}, {"id": "17763133_2_9041", "context": "Discontinuation of simvastatin and cyclosporine resulted in resolution of rhabdomyolysis and normalization of renal function.", "question": "Treatment.Dosage in Discontinuation of simvastatin and cyclosporine", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "17763133_2_9042", "context": "Discontinuation of simvastatin and cyclosporine resulted in resolution of rhabdomyolysis and normalization of renal function.", "question": "Treatment.Freq in Discontinuation of simvastatin and cyclosporine", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "17763133_2_9043", "context": "Discontinuation of simvastatin and cyclosporine resulted in resolution of rhabdomyolysis and normalization of renal function.", "question": "Treatment.Route in Discontinuation of simvastatin and cyclosporine", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "17763133_2_9044", "context": "Discontinuation of simvastatin and cyclosporine resulted in resolution of rhabdomyolysis and normalization of renal function.", "question": "Treatment.Time_elapsed in Discontinuation of simvastatin and cyclosporine", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17763133_2_9045", "context": "Discontinuation of simvastatin and cyclosporine resulted in resolution of rhabdomyolysis and normalization of renal function.", "question": "Treatment.Duration in Discontinuation of simvastatin and cyclosporine", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "17763133_2_9046", "context": "Discontinuation of simvastatin and cyclosporine resulted in resolution of rhabdomyolysis and normalization of renal function.", "question": "Treatment.Disorder in Discontinuation of simvastatin and cyclosporine", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "rhabdomyolysis"}, {"id": "17763133_2_9047", "context": "Discontinuation of simvastatin and cyclosporine resulted in resolution of rhabdomyolysis and normalization of renal function.", "question": "Combination.Drug in Discontinuation of simvastatin and cyclosporine", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "15028328_2_9048", "context": "Phenylpropanolamine (PPA) recently has been publicly implicated as a cause of stroke and other neurologic events.", "question": "Treatment.Drug in Phenylpropanolamine (PPA)", "question_type": "Adverse_event.Treatment.Drug", "answers": "Phenylpropanolamine"}, {"id": "15028328_2_9049", "context": "Phenylpropanolamine (PPA) recently has been publicly implicated as a cause of stroke and other neurologic events.", "question": "Treatment.Dosage in Phenylpropanolamine (PPA)", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15028328_2_9050", "context": "Phenylpropanolamine (PPA) recently has been publicly implicated as a cause of stroke and other neurologic events.", "question": "Treatment.Freq in Phenylpropanolamine (PPA)", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15028328_2_9051", "context": "Phenylpropanolamine (PPA) recently has been publicly implicated as a cause of stroke and other neurologic events.", "question": "Treatment.Route in Phenylpropanolamine (PPA)", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15028328_2_9052", "context": "Phenylpropanolamine (PPA) recently has been publicly implicated as a cause of stroke and other neurologic events.", "question": "Treatment.Time_elapsed in Phenylpropanolamine (PPA)", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15028328_2_9053", "context": "Phenylpropanolamine (PPA) recently has been publicly implicated as a cause of stroke and other neurologic events.", "question": "Treatment.Duration in Phenylpropanolamine (PPA)", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15028328_2_9054", "context": "Phenylpropanolamine (PPA) recently has been publicly implicated as a cause of stroke and other neurologic events.", "question": "Treatment.Disorder in Phenylpropanolamine (PPA)", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15028328_2_9055", "context": "Phenylpropanolamine (PPA) recently has been publicly implicated as a cause of stroke and other neurologic events.", "question": "Combination.Drug in Phenylpropanolamine (PPA)", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "22010004_1_9056", "context": "Critically elevated INR in a patient on warfarin after increase in extended-release niacin dose.", "question": "Subject.Age in a patient", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "22010004_1_9057", "context": "Critically elevated INR in a patient on warfarin after increase in extended-release niacin dose.", "question": "Subject.Gender in a patient", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "22010004_1_9058", "context": "Critically elevated INR in a patient on warfarin after increase in extended-release niacin dose.", "question": "Subject.Population in a patient", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "22010004_1_9059", "context": "Critically elevated INR in a patient on warfarin after increase in extended-release niacin dose.", "question": "Subject.Race in a patient", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "22010004_1_9060", "context": "Critically elevated INR in a patient on warfarin after increase in extended-release niacin dose.", "question": "Subject.Disorder in a patient", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "22010004_1_9061", "context": "Critically elevated INR in a patient on warfarin after increase in extended-release niacin dose.", "question": "Treatment.Drug in warfarin; increase in extended-release niacin dose", "question_type": "Adverse_event.Treatment.Drug", "answers": "warfarin; niacin"}, {"id": "22010004_1_9062", "context": "Critically elevated INR in a patient on warfarin after increase in extended-release niacin dose.", "question": "Treatment.Dosage in warfarin; increase in extended-release niacin dose", "question_type": "Adverse_event.Treatment.Dosage", "answers": "increase in; dose"}, {"id": "22010004_1_9063", "context": "Critically elevated INR in a patient on warfarin after increase in extended-release niacin dose.", "question": "Treatment.Freq in warfarin; increase in extended-release niacin dose", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "22010004_1_9064", "context": "Critically elevated INR in a patient on warfarin after increase in extended-release niacin dose.", "question": "Treatment.Route in warfarin; increase in extended-release niacin dose", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "22010004_1_9065", "context": "Critically elevated INR in a patient on warfarin after increase in extended-release niacin dose.", "question": "Treatment.Time_elapsed in warfarin; increase in extended-release niacin dose", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "22010004_1_9066", "context": "Critically elevated INR in a patient on warfarin after increase in extended-release niacin dose.", "question": "Treatment.Duration in warfarin; increase in extended-release niacin dose", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "22010004_1_9067", "context": "Critically elevated INR in a patient on warfarin after increase in extended-release niacin dose.", "question": "Treatment.Disorder in warfarin; increase in extended-release niacin dose", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "22010004_1_9068", "context": "Critically elevated INR in a patient on warfarin after increase in extended-release niacin dose.", "question": "Combination.Drug in warfarin; increase in extended-release niacin dose", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17329303_5_9069", "context": "He developed severe hyperactivity and agitation on taking methylphenidate after the discontinuation of risperidone treatment.", "question": "Subject.Age in He", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "17329303_5_9070", "context": "He developed severe hyperactivity and agitation on taking methylphenidate after the discontinuation of risperidone treatment.", "question": "Subject.Gender in He", "question_type": "Adverse_event.Subject.Gender", "answers": "He"}, {"id": "17329303_5_9071", "context": "He developed severe hyperactivity and agitation on taking methylphenidate after the discontinuation of risperidone treatment.", "question": "Subject.Population in He", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "17329303_5_9072", "context": "He developed severe hyperactivity and agitation on taking methylphenidate after the discontinuation of risperidone treatment.", "question": "Subject.Race in He", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "17329303_5_9073", "context": "He developed severe hyperactivity and agitation on taking methylphenidate after the discontinuation of risperidone treatment.", "question": "Subject.Disorder in He", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "17329303_5_9074", "context": "He developed severe hyperactivity and agitation on taking methylphenidate after the discontinuation of risperidone treatment.", "question": "Treatment.Drug in methylphenidate after the discontinuation of risperidone", "question_type": "Adverse_event.Treatment.Drug", "answers": "methylphenidate; risperidone"}, {"id": "17329303_5_9075", "context": "He developed severe hyperactivity and agitation on taking methylphenidate after the discontinuation of risperidone treatment.", "question": "Treatment.Dosage in methylphenidate after the discontinuation of risperidone", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17329303_5_9076", "context": "He developed severe hyperactivity and agitation on taking methylphenidate after the discontinuation of risperidone treatment.", "question": "Treatment.Freq in methylphenidate after the discontinuation of risperidone", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17329303_5_9077", "context": "He developed severe hyperactivity and agitation on taking methylphenidate after the discontinuation of risperidone treatment.", "question": "Treatment.Route in methylphenidate after the discontinuation of risperidone", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17329303_5_9078", "context": "He developed severe hyperactivity and agitation on taking methylphenidate after the discontinuation of risperidone treatment.", "question": "Treatment.Time_elapsed in methylphenidate after the discontinuation of risperidone", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17329303_5_9079", "context": "He developed severe hyperactivity and agitation on taking methylphenidate after the discontinuation of risperidone treatment.", "question": "Treatment.Duration in methylphenidate after the discontinuation of risperidone", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17329303_5_9080", "context": "He developed severe hyperactivity and agitation on taking methylphenidate after the discontinuation of risperidone treatment.", "question": "Treatment.Disorder in methylphenidate after the discontinuation of risperidone", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17329303_5_9081", "context": "He developed severe hyperactivity and agitation on taking methylphenidate after the discontinuation of risperidone treatment.", "question": "Combination.Drug in methylphenidate after the discontinuation of risperidone", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12390172_4_9082", "context": "We suggest that objective evaluation of retinal function with electrophysiological methods should be performed in patients with visual disturbance during treatment with rifabutin.", "question": "Treatment.Drug in rifabutin", "question_type": "Adverse_event.Treatment.Drug", "answers": "rifabutin"}, {"id": "12390172_4_9083", "context": "We suggest that objective evaluation of retinal function with electrophysiological methods should be performed in patients with visual disturbance during treatment with rifabutin.", "question": "Treatment.Dosage in rifabutin", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12390172_4_9084", "context": "We suggest that objective evaluation of retinal function with electrophysiological methods should be performed in patients with visual disturbance during treatment with rifabutin.", "question": "Treatment.Freq in rifabutin", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12390172_4_9085", "context": "We suggest that objective evaluation of retinal function with electrophysiological methods should be performed in patients with visual disturbance during treatment with rifabutin.", "question": "Treatment.Route in rifabutin", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12390172_4_9086", "context": "We suggest that objective evaluation of retinal function with electrophysiological methods should be performed in patients with visual disturbance during treatment with rifabutin.", "question": "Treatment.Time_elapsed in rifabutin", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12390172_4_9087", "context": "We suggest that objective evaluation of retinal function with electrophysiological methods should be performed in patients with visual disturbance during treatment with rifabutin.", "question": "Treatment.Duration in rifabutin", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12390172_4_9088", "context": "We suggest that objective evaluation of retinal function with electrophysiological methods should be performed in patients with visual disturbance during treatment with rifabutin.", "question": "Treatment.Disorder in rifabutin", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12390172_4_9089", "context": "We suggest that objective evaluation of retinal function with electrophysiological methods should be performed in patients with visual disturbance during treatment with rifabutin.", "question": "Combination.Drug in rifabutin", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3290702_1_9090", "context": "A clinically atypical, neuropathologically verified case of Creutzfeldt-Jakob disease is described in a 32-year-old New Zealand woman with idiopathic hypopituitarism who had been treated in late adolescence (1970 to 1973) with human growth hormone processed from pooled cadaveric pituitary glands.", "question": "Subject.Age in a 32-year-old New Zealand woman with idiopathic hypopituitarism", "question_type": "Adverse_event.Subject.Age", "answers": "32-year-old"}, {"id": "3290702_1_9091", "context": "A clinically atypical, neuropathologically verified case of Creutzfeldt-Jakob disease is described in a 32-year-old New Zealand woman with idiopathic hypopituitarism who had been treated in late adolescence (1970 to 1973) with human growth hormone processed from pooled cadaveric pituitary glands.", "question": "Subject.Gender in a 32-year-old New Zealand woman with idiopathic hypopituitarism", "question_type": "Adverse_event.Subject.Gender", "answers": "woman"}, {"id": "3290702_1_9092", "context": "A clinically atypical, neuropathologically verified case of Creutzfeldt-Jakob disease is described in a 32-year-old New Zealand woman with idiopathic hypopituitarism who had been treated in late adolescence (1970 to 1973) with human growth hormone processed from pooled cadaveric pituitary glands.", "question": "Subject.Population in a 32-year-old New Zealand woman with idiopathic hypopituitarism", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "3290702_1_9093", "context": "A clinically atypical, neuropathologically verified case of Creutzfeldt-Jakob disease is described in a 32-year-old New Zealand woman with idiopathic hypopituitarism who had been treated in late adolescence (1970 to 1973) with human growth hormone processed from pooled cadaveric pituitary glands.", "question": "Subject.Race in a 32-year-old New Zealand woman with idiopathic hypopituitarism", "question_type": "Adverse_event.Subject.Race", "answers": "New Zealand"}, {"id": "3290702_1_9094", "context": "A clinically atypical, neuropathologically verified case of Creutzfeldt-Jakob disease is described in a 32-year-old New Zealand woman with idiopathic hypopituitarism who had been treated in late adolescence (1970 to 1973) with human growth hormone processed from pooled cadaveric pituitary glands.", "question": "Subject.Disorder in a 32-year-old New Zealand woman with idiopathic hypopituitarism", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "3290702_1_9095", "context": "A clinically atypical, neuropathologically verified case of Creutzfeldt-Jakob disease is described in a 32-year-old New Zealand woman with idiopathic hypopituitarism who had been treated in late adolescence (1970 to 1973) with human growth hormone processed from pooled cadaveric pituitary glands.", "question": "Treatment.Drug in human growth hormone", "question_type": "Adverse_event.Treatment.Drug", "answers": "human growth hormone"}, {"id": "3290702_1_9096", "context": "A clinically atypical, neuropathologically verified case of Creutzfeldt-Jakob disease is described in a 32-year-old New Zealand woman with idiopathic hypopituitarism who had been treated in late adolescence (1970 to 1973) with human growth hormone processed from pooled cadaveric pituitary glands.", "question": "Treatment.Dosage in human growth hormone", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3290702_1_9097", "context": "A clinically atypical, neuropathologically verified case of Creutzfeldt-Jakob disease is described in a 32-year-old New Zealand woman with idiopathic hypopituitarism who had been treated in late adolescence (1970 to 1973) with human growth hormone processed from pooled cadaveric pituitary glands.", "question": "Treatment.Freq in human growth hormone", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3290702_1_9098", "context": "A clinically atypical, neuropathologically verified case of Creutzfeldt-Jakob disease is described in a 32-year-old New Zealand woman with idiopathic hypopituitarism who had been treated in late adolescence (1970 to 1973) with human growth hormone processed from pooled cadaveric pituitary glands.", "question": "Treatment.Route in human growth hormone", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3290702_1_9099", "context": "A clinically atypical, neuropathologically verified case of Creutzfeldt-Jakob disease is described in a 32-year-old New Zealand woman with idiopathic hypopituitarism who had been treated in late adolescence (1970 to 1973) with human growth hormone processed from pooled cadaveric pituitary glands.", "question": "Treatment.Time_elapsed in human growth hormone", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3290702_1_9100", "context": "A clinically atypical, neuropathologically verified case of Creutzfeldt-Jakob disease is described in a 32-year-old New Zealand woman with idiopathic hypopituitarism who had been treated in late adolescence (1970 to 1973) with human growth hormone processed from pooled cadaveric pituitary glands.", "question": "Treatment.Duration in human growth hormone", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3290702_1_9101", "context": "A clinically atypical, neuropathologically verified case of Creutzfeldt-Jakob disease is described in a 32-year-old New Zealand woman with idiopathic hypopituitarism who had been treated in late adolescence (1970 to 1973) with human growth hormone processed from pooled cadaveric pituitary glands.", "question": "Treatment.Disorder in human growth hormone", "question_type": "Adverse_event.Treatment.Disorder", "answers": "idiopathic hypopituitarism"}, {"id": "3290702_1_9102", "context": "A clinically atypical, neuropathologically verified case of Creutzfeldt-Jakob disease is described in a 32-year-old New Zealand woman with idiopathic hypopituitarism who had been treated in late adolescence (1970 to 1973) with human growth hormone processed from pooled cadaveric pituitary glands.", "question": "Combination.Drug in human growth hormone", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16099004_2_9103", "context": "Quinine remains a reliable treatment for falciparum malaria in most parts of the world.", "question": "Treatment.Drug in Quinine", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "Quinine"}, {"id": "16099004_2_9104", "context": "Quinine remains a reliable treatment for falciparum malaria in most parts of the world.", "question": "Treatment.Dosage in Quinine", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "16099004_2_9105", "context": "Quinine remains a reliable treatment for falciparum malaria in most parts of the world.", "question": "Treatment.Freq in Quinine", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "16099004_2_9106", "context": "Quinine remains a reliable treatment for falciparum malaria in most parts of the world.", "question": "Treatment.Route in Quinine", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "16099004_2_9107", "context": "Quinine remains a reliable treatment for falciparum malaria in most parts of the world.", "question": "Treatment.Time_elapsed in Quinine", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16099004_2_9108", "context": "Quinine remains a reliable treatment for falciparum malaria in most parts of the world.", "question": "Treatment.Duration in Quinine", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "16099004_2_9109", "context": "Quinine remains a reliable treatment for falciparum malaria in most parts of the world.", "question": "Treatment.Disorder in Quinine", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "falciparum malaria"}, {"id": "16099004_2_9110", "context": "Quinine remains a reliable treatment for falciparum malaria in most parts of the world.", "question": "Combination.Drug in Quinine", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "17068466_3_9111", "context": "Severe corneal toxicity after topical fluoroquinolone therapy: report of two cases.", "question": "Treatment.Drug in topical fluoroquinolone therapy", "question_type": "Adverse_event.Treatment.Drug", "answers": "fluoroquinolone"}, {"id": "17068466_3_9112", "context": "Severe corneal toxicity after topical fluoroquinolone therapy: report of two cases.", "question": "Treatment.Dosage in topical fluoroquinolone therapy", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17068466_3_9113", "context": "Severe corneal toxicity after topical fluoroquinolone therapy: report of two cases.", "question": "Treatment.Freq in topical fluoroquinolone therapy", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17068466_3_9114", "context": "Severe corneal toxicity after topical fluoroquinolone therapy: report of two cases.", "question": "Treatment.Route in topical fluoroquinolone therapy", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17068466_3_9115", "context": "Severe corneal toxicity after topical fluoroquinolone therapy: report of two cases.", "question": "Treatment.Time_elapsed in topical fluoroquinolone therapy", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17068466_3_9116", "context": "Severe corneal toxicity after topical fluoroquinolone therapy: report of two cases.", "question": "Treatment.Duration in topical fluoroquinolone therapy", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17068466_3_9117", "context": "Severe corneal toxicity after topical fluoroquinolone therapy: report of two cases.", "question": "Treatment.Disorder in topical fluoroquinolone therapy", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17068466_3_9118", "context": "Severe corneal toxicity after topical fluoroquinolone therapy: report of two cases.", "question": "Combination.Drug in topical fluoroquinolone therapy", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12452753_6_9119", "context": "She developed a generalized rash and itching, sore throat, and dizziness approximately 4 hours after the first dose of capecitabine.", "question": "Treatment.Drug in approximately 4 hours after the first dose of capecitabine", "question_type": "Adverse_event.Treatment.Drug", "answers": "capecitabine"}, {"id": "12452753_6_9120", "context": "She developed a generalized rash and itching, sore throat, and dizziness approximately 4 hours after the first dose of capecitabine.", "question": "Treatment.Dosage in approximately 4 hours after the first dose of capecitabine", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12452753_6_9121", "context": "She developed a generalized rash and itching, sore throat, and dizziness approximately 4 hours after the first dose of capecitabine.", "question": "Treatment.Freq in approximately 4 hours after the first dose of capecitabine", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12452753_6_9122", "context": "She developed a generalized rash and itching, sore throat, and dizziness approximately 4 hours after the first dose of capecitabine.", "question": "Treatment.Route in approximately 4 hours after the first dose of capecitabine", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12452753_6_9123", "context": "She developed a generalized rash and itching, sore throat, and dizziness approximately 4 hours after the first dose of capecitabine.", "question": "Treatment.Time_elapsed in approximately 4 hours after the first dose of capecitabine", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "4 hours"}, {"id": "12452753_6_9124", "context": "She developed a generalized rash and itching, sore throat, and dizziness approximately 4 hours after the first dose of capecitabine.", "question": "Treatment.Duration in approximately 4 hours after the first dose of capecitabine", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12452753_6_9125", "context": "She developed a generalized rash and itching, sore throat, and dizziness approximately 4 hours after the first dose of capecitabine.", "question": "Treatment.Disorder in approximately 4 hours after the first dose of capecitabine", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12452753_6_9126", "context": "She developed a generalized rash and itching, sore throat, and dizziness approximately 4 hours after the first dose of capecitabine.", "question": "Combination.Drug in approximately 4 hours after the first dose of capecitabine", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8162401_2_9127", "context": "Seizures associated with fluoxetine therapy are uncommon.", "question": "Treatment.Drug in fluoxetine therapy", "question_type": "Adverse_event.Treatment.Drug", "answers": "fluoxetine"}, {"id": "8162401_2_9128", "context": "Seizures associated with fluoxetine therapy are uncommon.", "question": "Treatment.Dosage in fluoxetine therapy", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8162401_2_9129", "context": "Seizures associated with fluoxetine therapy are uncommon.", "question": "Treatment.Freq in fluoxetine therapy", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8162401_2_9130", "context": "Seizures associated with fluoxetine therapy are uncommon.", "question": "Treatment.Route in fluoxetine therapy", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8162401_2_9131", "context": "Seizures associated with fluoxetine therapy are uncommon.", "question": "Treatment.Time_elapsed in fluoxetine therapy", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8162401_2_9132", "context": "Seizures associated with fluoxetine therapy are uncommon.", "question": "Treatment.Duration in fluoxetine therapy", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8162401_2_9133", "context": "Seizures associated with fluoxetine therapy are uncommon.", "question": "Treatment.Disorder in fluoxetine therapy", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8162401_2_9134", "context": "Seizures associated with fluoxetine therapy are uncommon.", "question": "Combination.Drug in fluoxetine therapy", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10337682_1_9135", "context": "A 14-year-old girl with newly diagnosed SLE developed a pruritic bullous eruption while on prednisone.", "question": "Subject.Age in A 14-year-old girl with newly diagnosed SLE", "question_type": "Adverse_event.Subject.Age", "answers": "14-year-old"}, {"id": "10337682_1_9136", "context": "A 14-year-old girl with newly diagnosed SLE developed a pruritic bullous eruption while on prednisone.", "question": "Subject.Gender in A 14-year-old girl with newly diagnosed SLE", "question_type": "Adverse_event.Subject.Gender", "answers": "girl"}, {"id": "10337682_1_9137", "context": "A 14-year-old girl with newly diagnosed SLE developed a pruritic bullous eruption while on prednisone.", "question": "Subject.Population in A 14-year-old girl with newly diagnosed SLE", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "10337682_1_9138", "context": "A 14-year-old girl with newly diagnosed SLE developed a pruritic bullous eruption while on prednisone.", "question": "Subject.Race in A 14-year-old girl with newly diagnosed SLE", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "10337682_1_9139", "context": "A 14-year-old girl with newly diagnosed SLE developed a pruritic bullous eruption while on prednisone.", "question": "Subject.Disorder in A 14-year-old girl with newly diagnosed SLE", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "10337682_1_9140", "context": "A 14-year-old girl with newly diagnosed SLE developed a pruritic bullous eruption while on prednisone.", "question": "Treatment.Drug in prednisone", "question_type": "Adverse_event.Treatment.Drug", "answers": "prednisone"}, {"id": "10337682_1_9141", "context": "A 14-year-old girl with newly diagnosed SLE developed a pruritic bullous eruption while on prednisone.", "question": "Treatment.Dosage in prednisone", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10337682_1_9142", "context": "A 14-year-old girl with newly diagnosed SLE developed a pruritic bullous eruption while on prednisone.", "question": "Treatment.Freq in prednisone", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10337682_1_9143", "context": "A 14-year-old girl with newly diagnosed SLE developed a pruritic bullous eruption while on prednisone.", "question": "Treatment.Route in prednisone", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10337682_1_9144", "context": "A 14-year-old girl with newly diagnosed SLE developed a pruritic bullous eruption while on prednisone.", "question": "Treatment.Time_elapsed in prednisone", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10337682_1_9145", "context": "A 14-year-old girl with newly diagnosed SLE developed a pruritic bullous eruption while on prednisone.", "question": "Treatment.Duration in prednisone", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10337682_1_9146", "context": "A 14-year-old girl with newly diagnosed SLE developed a pruritic bullous eruption while on prednisone.", "question": "Treatment.Disorder in prednisone", "question_type": "Adverse_event.Treatment.Disorder", "answers": "SLE"}, {"id": "10337682_1_9147", "context": "A 14-year-old girl with newly diagnosed SLE developed a pruritic bullous eruption while on prednisone.", "question": "Combination.Drug in prednisone", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8175330_1_9148", "context": "Sodium valproate and carbamazepine, antiepileptic drugs that are associated with a relatively low rate of adverse cutaneous reactions, should be added to the growing list of drugs that produce psoriasiform eruptions.", "question": "Treatment.Drug in Sodium valproate and carbamazepine", "question_type": "Adverse_event.Treatment.Drug", "answers": "carbamazepine; Sodium valproate"}, {"id": "8175330_1_9149", "context": "Sodium valproate and carbamazepine, antiepileptic drugs that are associated with a relatively low rate of adverse cutaneous reactions, should be added to the growing list of drugs that produce psoriasiform eruptions.", "question": "Treatment.Dosage in Sodium valproate and carbamazepine", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8175330_1_9150", "context": "Sodium valproate and carbamazepine, antiepileptic drugs that are associated with a relatively low rate of adverse cutaneous reactions, should be added to the growing list of drugs that produce psoriasiform eruptions.", "question": "Treatment.Freq in Sodium valproate and carbamazepine", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8175330_1_9151", "context": "Sodium valproate and carbamazepine, antiepileptic drugs that are associated with a relatively low rate of adverse cutaneous reactions, should be added to the growing list of drugs that produce psoriasiform eruptions.", "question": "Treatment.Route in Sodium valproate and carbamazepine", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8175330_1_9152", "context": "Sodium valproate and carbamazepine, antiepileptic drugs that are associated with a relatively low rate of adverse cutaneous reactions, should be added to the growing list of drugs that produce psoriasiform eruptions.", "question": "Treatment.Time_elapsed in Sodium valproate and carbamazepine", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8175330_1_9153", "context": "Sodium valproate and carbamazepine, antiepileptic drugs that are associated with a relatively low rate of adverse cutaneous reactions, should be added to the growing list of drugs that produce psoriasiform eruptions.", "question": "Treatment.Duration in Sodium valproate and carbamazepine", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8175330_1_9154", "context": "Sodium valproate and carbamazepine, antiepileptic drugs that are associated with a relatively low rate of adverse cutaneous reactions, should be added to the growing list of drugs that produce psoriasiform eruptions.", "question": "Treatment.Disorder in Sodium valproate and carbamazepine", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8175330_1_9155", "context": "Sodium valproate and carbamazepine, antiepileptic drugs that are associated with a relatively low rate of adverse cutaneous reactions, should be added to the growing list of drugs that produce psoriasiform eruptions.", "question": "Combination.Drug in Sodium valproate and carbamazepine", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10715308_1_9156", "context": "Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: A report of the international CATAPULT I study group.", "question": "Treatment.Drug in Tirapazamine plus cisplatin", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "cisplatin; Tirapazamine"}, {"id": "10715308_1_9157", "context": "Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: A report of the international CATAPULT I study group.", "question": "Treatment.Dosage in Tirapazamine plus cisplatin", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "10715308_1_9158", "context": "Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: A report of the international CATAPULT I study group.", "question": "Treatment.Freq in Tirapazamine plus cisplatin", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "10715308_1_9159", "context": "Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: A report of the international CATAPULT I study group.", "question": "Treatment.Route in Tirapazamine plus cisplatin", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "10715308_1_9160", "context": "Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: A report of the international CATAPULT I study group.", "question": "Treatment.Time_elapsed in Tirapazamine plus cisplatin", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10715308_1_9161", "context": "Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: A report of the international CATAPULT I study group.", "question": "Treatment.Duration in Tirapazamine plus cisplatin", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "10715308_1_9162", "context": "Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: A report of the international CATAPULT I study group.", "question": "Treatment.Disorder in Tirapazamine plus cisplatin", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "advanced non-small-cell lung cancer"}, {"id": "10715308_1_9163", "context": "Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: A report of the international CATAPULT I study group.", "question": "Combination.Drug in Tirapazamine plus cisplatin", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": "cisplatin; Tirapazamine"}, {"id": "1829999_1_9164", "context": "Exfoliative dermatitis secondary to tobramycin sulfate.", "question": "Treatment.Drug in tobramycin sulfate.", "question_type": "Adverse_event.Treatment.Drug", "answers": "tobramycin sulfate"}, {"id": "1829999_1_9165", "context": "Exfoliative dermatitis secondary to tobramycin sulfate.", "question": "Treatment.Dosage in tobramycin sulfate.", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "1829999_1_9166", "context": "Exfoliative dermatitis secondary to tobramycin sulfate.", "question": "Treatment.Freq in tobramycin sulfate.", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "1829999_1_9167", "context": "Exfoliative dermatitis secondary to tobramycin sulfate.", "question": "Treatment.Route in tobramycin sulfate.", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "1829999_1_9168", "context": "Exfoliative dermatitis secondary to tobramycin sulfate.", "question": "Treatment.Time_elapsed in tobramycin sulfate.", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "1829999_1_9169", "context": "Exfoliative dermatitis secondary to tobramycin sulfate.", "question": "Treatment.Duration in tobramycin sulfate.", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "1829999_1_9170", "context": "Exfoliative dermatitis secondary to tobramycin sulfate.", "question": "Treatment.Disorder in tobramycin sulfate.", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "1829999_1_9171", "context": "Exfoliative dermatitis secondary to tobramycin sulfate.", "question": "Combination.Drug in tobramycin sulfate.", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "20110001_3_9172", "context": "Kaposi's sarcoma in a patient treated with imatinib mesylate for chronic myeloid leukemia.", "question": "Subject.Age in a patient", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "20110001_3_9173", "context": "Kaposi's sarcoma in a patient treated with imatinib mesylate for chronic myeloid leukemia.", "question": "Subject.Gender in a patient", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "20110001_3_9174", "context": "Kaposi's sarcoma in a patient treated with imatinib mesylate for chronic myeloid leukemia.", "question": "Subject.Population in a patient", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "20110001_3_9175", "context": "Kaposi's sarcoma in a patient treated with imatinib mesylate for chronic myeloid leukemia.", "question": "Subject.Race in a patient", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "20110001_3_9176", "context": "Kaposi's sarcoma in a patient treated with imatinib mesylate for chronic myeloid leukemia.", "question": "Subject.Disorder in a patient", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "20110001_3_9177", "context": "Kaposi's sarcoma in a patient treated with imatinib mesylate for chronic myeloid leukemia.", "question": "Treatment.Drug in imatinib mesylate", "question_type": "Adverse_event.Treatment.Drug", "answers": "imatinib mesylate"}, {"id": "20110001_3_9178", "context": "Kaposi's sarcoma in a patient treated with imatinib mesylate for chronic myeloid leukemia.", "question": "Treatment.Dosage in imatinib mesylate", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "20110001_3_9179", "context": "Kaposi's sarcoma in a patient treated with imatinib mesylate for chronic myeloid leukemia.", "question": "Treatment.Freq in imatinib mesylate", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "20110001_3_9180", "context": "Kaposi's sarcoma in a patient treated with imatinib mesylate for chronic myeloid leukemia.", "question": "Treatment.Route in imatinib mesylate", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "20110001_3_9181", "context": "Kaposi's sarcoma in a patient treated with imatinib mesylate for chronic myeloid leukemia.", "question": "Treatment.Time_elapsed in imatinib mesylate", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "20110001_3_9182", "context": "Kaposi's sarcoma in a patient treated with imatinib mesylate for chronic myeloid leukemia.", "question": "Treatment.Duration in imatinib mesylate", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "20110001_3_9183", "context": "Kaposi's sarcoma in a patient treated with imatinib mesylate for chronic myeloid leukemia.", "question": "Treatment.Disorder in imatinib mesylate", "question_type": "Adverse_event.Treatment.Disorder", "answers": "chronic myeloid leukemia"}, {"id": "20110001_3_9184", "context": "Kaposi's sarcoma in a patient treated with imatinib mesylate for chronic myeloid leukemia.", "question": "Combination.Drug in imatinib mesylate", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6303138_2_9185", "context": "A young patient experienced marked sinus tachycardia while smoking marijuana and receiving therapeutic doses of nortriptyline.", "question": "Subject.Age in young patient", "question_type": "Adverse_event.Subject.Age", "answers": "young"}, {"id": "6303138_2_9186", "context": "A young patient experienced marked sinus tachycardia while smoking marijuana and receiving therapeutic doses of nortriptyline.", "question": "Subject.Gender in young patient", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "6303138_2_9187", "context": "A young patient experienced marked sinus tachycardia while smoking marijuana and receiving therapeutic doses of nortriptyline.", "question": "Subject.Population in young patient", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "6303138_2_9188", "context": "A young patient experienced marked sinus tachycardia while smoking marijuana and receiving therapeutic doses of nortriptyline.", "question": "Subject.Race in young patient", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "6303138_2_9189", "context": "A young patient experienced marked sinus tachycardia while smoking marijuana and receiving therapeutic doses of nortriptyline.", "question": "Subject.Disorder in young patient", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "6303138_2_9190", "context": "A young patient experienced marked sinus tachycardia while smoking marijuana and receiving therapeutic doses of nortriptyline.", "question": "Treatment.Drug in nortriptyline", "question_type": "Adverse_event.Treatment.Drug", "answers": "nortriptyline"}, {"id": "6303138_2_9191", "context": "A young patient experienced marked sinus tachycardia while smoking marijuana and receiving therapeutic doses of nortriptyline.", "question": "Treatment.Dosage in nortriptyline", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6303138_2_9192", "context": "A young patient experienced marked sinus tachycardia while smoking marijuana and receiving therapeutic doses of nortriptyline.", "question": "Treatment.Freq in nortriptyline", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6303138_2_9193", "context": "A young patient experienced marked sinus tachycardia while smoking marijuana and receiving therapeutic doses of nortriptyline.", "question": "Treatment.Route in nortriptyline", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6303138_2_9194", "context": "A young patient experienced marked sinus tachycardia while smoking marijuana and receiving therapeutic doses of nortriptyline.", "question": "Treatment.Time_elapsed in nortriptyline", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6303138_2_9195", "context": "A young patient experienced marked sinus tachycardia while smoking marijuana and receiving therapeutic doses of nortriptyline.", "question": "Treatment.Duration in nortriptyline", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6303138_2_9196", "context": "A young patient experienced marked sinus tachycardia while smoking marijuana and receiving therapeutic doses of nortriptyline.", "question": "Treatment.Disorder in nortriptyline", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6303138_2_9197", "context": "A young patient experienced marked sinus tachycardia while smoking marijuana and receiving therapeutic doses of nortriptyline.", "question": "Combination.Drug in nortriptyline", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3501467_2_9198", "context": "Hypogammaglobulinemia associated with gold therapy: evidence for a partial maturation blockade of B cells.", "question": "Treatment.Drug in gold therapy", "question_type": "Adverse_event.Treatment.Drug", "answers": "gold"}, {"id": "3501467_2_9199", "context": "Hypogammaglobulinemia associated with gold therapy: evidence for a partial maturation blockade of B cells.", "question": "Treatment.Dosage in gold therapy", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3501467_2_9200", "context": "Hypogammaglobulinemia associated with gold therapy: evidence for a partial maturation blockade of B cells.", "question": "Treatment.Freq in gold therapy", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3501467_2_9201", "context": "Hypogammaglobulinemia associated with gold therapy: evidence for a partial maturation blockade of B cells.", "question": "Treatment.Route in gold therapy", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3501467_2_9202", "context": "Hypogammaglobulinemia associated with gold therapy: evidence for a partial maturation blockade of B cells.", "question": "Treatment.Time_elapsed in gold therapy", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3501467_2_9203", "context": "Hypogammaglobulinemia associated with gold therapy: evidence for a partial maturation blockade of B cells.", "question": "Treatment.Duration in gold therapy", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3501467_2_9204", "context": "Hypogammaglobulinemia associated with gold therapy: evidence for a partial maturation blockade of B cells.", "question": "Treatment.Disorder in gold therapy", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3501467_2_9205", "context": "Hypogammaglobulinemia associated with gold therapy: evidence for a partial maturation blockade of B cells.", "question": "Combination.Drug in gold therapy", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6614033_3_9206", "context": "Experience with five patients in whom impaired renal function developed early during amphotericin B therapy is reported.", "question": "Subject.Age in five patients", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "6614033_3_9207", "context": "Experience with five patients in whom impaired renal function developed early during amphotericin B therapy is reported.", "question": "Subject.Gender in five patients", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "6614033_3_9208", "context": "Experience with five patients in whom impaired renal function developed early during amphotericin B therapy is reported.", "question": "Subject.Population in five patients", "question_type": "Adverse_event.Subject.Population", "answers": "five"}, {"id": "6614033_3_9209", "context": "Experience with five patients in whom impaired renal function developed early during amphotericin B therapy is reported.", "question": "Subject.Race in five patients", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "6614033_3_9210", "context": "Experience with five patients in whom impaired renal function developed early during amphotericin B therapy is reported.", "question": "Subject.Disorder in five patients", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "6614033_3_9211", "context": "Experience with five patients in whom impaired renal function developed early during amphotericin B therapy is reported.", "question": "Treatment.Drug in amphotericin B therapy", "question_type": "Adverse_event.Treatment.Drug", "answers": "amphotericin B"}, {"id": "6614033_3_9212", "context": "Experience with five patients in whom impaired renal function developed early during amphotericin B therapy is reported.", "question": "Treatment.Dosage in amphotericin B therapy", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6614033_3_9213", "context": "Experience with five patients in whom impaired renal function developed early during amphotericin B therapy is reported.", "question": "Treatment.Freq in amphotericin B therapy", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6614033_3_9214", "context": "Experience with five patients in whom impaired renal function developed early during amphotericin B therapy is reported.", "question": "Treatment.Route in amphotericin B therapy", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6614033_3_9215", "context": "Experience with five patients in whom impaired renal function developed early during amphotericin B therapy is reported.", "question": "Treatment.Time_elapsed in amphotericin B therapy", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6614033_3_9216", "context": "Experience with five patients in whom impaired renal function developed early during amphotericin B therapy is reported.", "question": "Treatment.Duration in amphotericin B therapy", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6614033_3_9217", "context": "Experience with five patients in whom impaired renal function developed early during amphotericin B therapy is reported.", "question": "Treatment.Disorder in amphotericin B therapy", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6614033_3_9218", "context": "Experience with five patients in whom impaired renal function developed early during amphotericin B therapy is reported.", "question": "Combination.Drug in amphotericin B therapy", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15529178_2_9219", "context": "This report details the pulmonary pathologic findings in four patients with rheumatoid arthritis, who developed new onset of pulmonary signs and symptoms with alveolar infiltrates temporally related to the institution of etanercept therapy.", "question": "Subject.Age in four patients with rheumatoid arthritis", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "15529178_2_9220", "context": "This report details the pulmonary pathologic findings in four patients with rheumatoid arthritis, who developed new onset of pulmonary signs and symptoms with alveolar infiltrates temporally related to the institution of etanercept therapy.", "question": "Subject.Gender in four patients with rheumatoid arthritis", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15529178_2_9221", "context": "This report details the pulmonary pathologic findings in four patients with rheumatoid arthritis, who developed new onset of pulmonary signs and symptoms with alveolar infiltrates temporally related to the institution of etanercept therapy.", "question": "Subject.Population in four patients with rheumatoid arthritis", "question_type": "Adverse_event.Subject.Population", "answers": "four"}, {"id": "15529178_2_9222", "context": "This report details the pulmonary pathologic findings in four patients with rheumatoid arthritis, who developed new onset of pulmonary signs and symptoms with alveolar infiltrates temporally related to the institution of etanercept therapy.", "question": "Subject.Race in four patients with rheumatoid arthritis", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15529178_2_9223", "context": "This report details the pulmonary pathologic findings in four patients with rheumatoid arthritis, who developed new onset of pulmonary signs and symptoms with alveolar infiltrates temporally related to the institution of etanercept therapy.", "question": "Subject.Disorder in four patients with rheumatoid arthritis", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15529178_2_9224", "context": "This report details the pulmonary pathologic findings in four patients with rheumatoid arthritis, who developed new onset of pulmonary signs and symptoms with alveolar infiltrates temporally related to the institution of etanercept therapy.", "question": "Treatment.Drug in institution of etanercept therapy", "question_type": "Adverse_event.Treatment.Drug", "answers": "etanercept"}, {"id": "15529178_2_9225", "context": "This report details the pulmonary pathologic findings in four patients with rheumatoid arthritis, who developed new onset of pulmonary signs and symptoms with alveolar infiltrates temporally related to the institution of etanercept therapy.", "question": "Treatment.Dosage in institution of etanercept therapy", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15529178_2_9226", "context": "This report details the pulmonary pathologic findings in four patients with rheumatoid arthritis, who developed new onset of pulmonary signs and symptoms with alveolar infiltrates temporally related to the institution of etanercept therapy.", "question": "Treatment.Freq in institution of etanercept therapy", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15529178_2_9227", "context": "This report details the pulmonary pathologic findings in four patients with rheumatoid arthritis, who developed new onset of pulmonary signs and symptoms with alveolar infiltrates temporally related to the institution of etanercept therapy.", "question": "Treatment.Route in institution of etanercept therapy", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15529178_2_9228", "context": "This report details the pulmonary pathologic findings in four patients with rheumatoid arthritis, who developed new onset of pulmonary signs and symptoms with alveolar infiltrates temporally related to the institution of etanercept therapy.", "question": "Treatment.Time_elapsed in institution of etanercept therapy", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15529178_2_9229", "context": "This report details the pulmonary pathologic findings in four patients with rheumatoid arthritis, who developed new onset of pulmonary signs and symptoms with alveolar infiltrates temporally related to the institution of etanercept therapy.", "question": "Treatment.Duration in institution of etanercept therapy", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15529178_2_9230", "context": "This report details the pulmonary pathologic findings in four patients with rheumatoid arthritis, who developed new onset of pulmonary signs and symptoms with alveolar infiltrates temporally related to the institution of etanercept therapy.", "question": "Treatment.Disorder in institution of etanercept therapy", "question_type": "Adverse_event.Treatment.Disorder", "answers": "rheumatoid arthritis"}, {"id": "15529178_2_9231", "context": "This report details the pulmonary pathologic findings in four patients with rheumatoid arthritis, who developed new onset of pulmonary signs and symptoms with alveolar infiltrates temporally related to the institution of etanercept therapy.", "question": "Combination.Drug in institution of etanercept therapy", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17331261_2_9232", "context": "CONCLUSION: Hypersensitivity reaction should be considered in patients who develop recurrent eosinophilia and deterioration of pulmonary function following the use of tobramycin by inhalation or by intravenous administration.", "question": "Subject.Age in patients", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "17331261_2_9233", "context": "CONCLUSION: Hypersensitivity reaction should be considered in patients who develop recurrent eosinophilia and deterioration of pulmonary function following the use of tobramycin by inhalation or by intravenous administration.", "question": "Subject.Gender in patients", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "17331261_2_9234", "context": "CONCLUSION: Hypersensitivity reaction should be considered in patients who develop recurrent eosinophilia and deterioration of pulmonary function following the use of tobramycin by inhalation or by intravenous administration.", "question": "Subject.Population in patients", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "17331261_2_9235", "context": "CONCLUSION: Hypersensitivity reaction should be considered in patients who develop recurrent eosinophilia and deterioration of pulmonary function following the use of tobramycin by inhalation or by intravenous administration.", "question": "Subject.Race in patients", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "17331261_2_9236", "context": "CONCLUSION: Hypersensitivity reaction should be considered in patients who develop recurrent eosinophilia and deterioration of pulmonary function following the use of tobramycin by inhalation or by intravenous administration.", "question": "Subject.Disorder in patients", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "17331261_2_9237", "context": "CONCLUSION: Hypersensitivity reaction should be considered in patients who develop recurrent eosinophilia and deterioration of pulmonary function following the use of tobramycin by inhalation or by intravenous administration.", "question": "Treatment.Drug in use of tobramycin by inhalation or by intravenous administration", "question_type": "Adverse_event.Treatment.Drug", "answers": "tobramycin"}, {"id": "17331261_2_9238", "context": "CONCLUSION: Hypersensitivity reaction should be considered in patients who develop recurrent eosinophilia and deterioration of pulmonary function following the use of tobramycin by inhalation or by intravenous administration.", "question": "Treatment.Dosage in use of tobramycin by inhalation or by intravenous administration", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17331261_2_9239", "context": "CONCLUSION: Hypersensitivity reaction should be considered in patients who develop recurrent eosinophilia and deterioration of pulmonary function following the use of tobramycin by inhalation or by intravenous administration.", "question": "Treatment.Freq in use of tobramycin by inhalation or by intravenous administration", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17331261_2_9240", "context": "CONCLUSION: Hypersensitivity reaction should be considered in patients who develop recurrent eosinophilia and deterioration of pulmonary function following the use of tobramycin by inhalation or by intravenous administration.", "question": "Treatment.Route in use of tobramycin by inhalation or by intravenous administration", "question_type": "Adverse_event.Treatment.Route", "answers": "inhalation; ntravenous administration."}, {"id": "17331261_2_9241", "context": "CONCLUSION: Hypersensitivity reaction should be considered in patients who develop recurrent eosinophilia and deterioration of pulmonary function following the use of tobramycin by inhalation or by intravenous administration.", "question": "Treatment.Time_elapsed in use of tobramycin by inhalation or by intravenous administration", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17331261_2_9242", "context": "CONCLUSION: Hypersensitivity reaction should be considered in patients who develop recurrent eosinophilia and deterioration of pulmonary function following the use of tobramycin by inhalation or by intravenous administration.", "question": "Treatment.Duration in use of tobramycin by inhalation or by intravenous administration", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17331261_2_9243", "context": "CONCLUSION: Hypersensitivity reaction should be considered in patients who develop recurrent eosinophilia and deterioration of pulmonary function following the use of tobramycin by inhalation or by intravenous administration.", "question": "Treatment.Disorder in use of tobramycin by inhalation or by intravenous administration", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17331261_2_9244", "context": "CONCLUSION: Hypersensitivity reaction should be considered in patients who develop recurrent eosinophilia and deterioration of pulmonary function following the use of tobramycin by inhalation or by intravenous administration.", "question": "Combination.Drug in use of tobramycin by inhalation or by intravenous administration", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16449538_4_9245", "context": "NCSE, an epileptic disorder in which typical convulsive activity is absent, has previously been reported in only 4 patients receiving ifosfamide.", "question": "Subject.Age in 4 patients", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "16449538_4_9246", "context": "NCSE, an epileptic disorder in which typical convulsive activity is absent, has previously been reported in only 4 patients receiving ifosfamide.", "question": "Subject.Gender in 4 patients", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "16449538_4_9247", "context": "NCSE, an epileptic disorder in which typical convulsive activity is absent, has previously been reported in only 4 patients receiving ifosfamide.", "question": "Subject.Population in 4 patients", "question_type": "Adverse_event.Subject.Population", "answers": "4"}, {"id": "16449538_4_9248", "context": "NCSE, an epileptic disorder in which typical convulsive activity is absent, has previously been reported in only 4 patients receiving ifosfamide.", "question": "Subject.Race in 4 patients", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16449538_4_9249", "context": "NCSE, an epileptic disorder in which typical convulsive activity is absent, has previously been reported in only 4 patients receiving ifosfamide.", "question": "Subject.Disorder in 4 patients", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "16449538_4_9250", "context": "NCSE, an epileptic disorder in which typical convulsive activity is absent, has previously been reported in only 4 patients receiving ifosfamide.", "question": "Treatment.Drug in ifosfamide", "question_type": "Adverse_event.Treatment.Drug", "answers": "ifosfamide"}, {"id": "16449538_4_9251", "context": "NCSE, an epileptic disorder in which typical convulsive activity is absent, has previously been reported in only 4 patients receiving ifosfamide.", "question": "Treatment.Dosage in ifosfamide", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16449538_4_9252", "context": "NCSE, an epileptic disorder in which typical convulsive activity is absent, has previously been reported in only 4 patients receiving ifosfamide.", "question": "Treatment.Freq in ifosfamide", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16449538_4_9253", "context": "NCSE, an epileptic disorder in which typical convulsive activity is absent, has previously been reported in only 4 patients receiving ifosfamide.", "question": "Treatment.Route in ifosfamide", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16449538_4_9254", "context": "NCSE, an epileptic disorder in which typical convulsive activity is absent, has previously been reported in only 4 patients receiving ifosfamide.", "question": "Treatment.Time_elapsed in ifosfamide", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16449538_4_9255", "context": "NCSE, an epileptic disorder in which typical convulsive activity is absent, has previously been reported in only 4 patients receiving ifosfamide.", "question": "Treatment.Duration in ifosfamide", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16449538_4_9256", "context": "NCSE, an epileptic disorder in which typical convulsive activity is absent, has previously been reported in only 4 patients receiving ifosfamide.", "question": "Treatment.Disorder in ifosfamide", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16449538_4_9257", "context": "NCSE, an epileptic disorder in which typical convulsive activity is absent, has previously been reported in only 4 patients receiving ifosfamide.", "question": "Combination.Drug in ifosfamide", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18487000_3_9258", "context": "We describe a case of life-threatening hyponatremia associated with sibutramine use in an obese woman.", "question": "Subject.Age in obese woman", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "18487000_3_9259", "context": "We describe a case of life-threatening hyponatremia associated with sibutramine use in an obese woman.", "question": "Subject.Gender in obese woman", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "18487000_3_9260", "context": "We describe a case of life-threatening hyponatremia associated with sibutramine use in an obese woman.", "question": "Subject.Population in obese woman", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "18487000_3_9261", "context": "We describe a case of life-threatening hyponatremia associated with sibutramine use in an obese woman.", "question": "Subject.Race in obese woman", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "18487000_3_9262", "context": "We describe a case of life-threatening hyponatremia associated with sibutramine use in an obese woman.", "question": "Subject.Disorder in obese woman", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "18487000_3_9263", "context": "We describe a case of life-threatening hyponatremia associated with sibutramine use in an obese woman.", "question": "Treatment.Drug in sibutramine", "question_type": "Adverse_event.Treatment.Drug", "answers": "sibutramine"}, {"id": "18487000_3_9264", "context": "We describe a case of life-threatening hyponatremia associated with sibutramine use in an obese woman.", "question": "Treatment.Dosage in sibutramine", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18487000_3_9265", "context": "We describe a case of life-threatening hyponatremia associated with sibutramine use in an obese woman.", "question": "Treatment.Freq in sibutramine", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18487000_3_9266", "context": "We describe a case of life-threatening hyponatremia associated with sibutramine use in an obese woman.", "question": "Treatment.Route in sibutramine", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18487000_3_9267", "context": "We describe a case of life-threatening hyponatremia associated with sibutramine use in an obese woman.", "question": "Treatment.Time_elapsed in sibutramine", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18487000_3_9268", "context": "We describe a case of life-threatening hyponatremia associated with sibutramine use in an obese woman.", "question": "Treatment.Duration in sibutramine", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18487000_3_9269", "context": "We describe a case of life-threatening hyponatremia associated with sibutramine use in an obese woman.", "question": "Treatment.Disorder in sibutramine", "question_type": "Adverse_event.Treatment.Disorder", "answers": "obese"}, {"id": "18487000_3_9270", "context": "We describe a case of life-threatening hyponatremia associated with sibutramine use in an obese woman.", "question": "Combination.Drug in sibutramine", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "19448237_1_9271", "context": "Polymyoclonus seizure resulting from accidental injection of tranexamic acid in spinal anesthesia.", "question": "Treatment.Drug in accidental injection of tranexamic acid in spinal anesthesia", "question_type": "Adverse_event.Treatment.Drug", "answers": "tranexamic acid"}, {"id": "19448237_1_9272", "context": "Polymyoclonus seizure resulting from accidental injection of tranexamic acid in spinal anesthesia.", "question": "Treatment.Dosage in accidental injection of tranexamic acid in spinal anesthesia", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "19448237_1_9273", "context": "Polymyoclonus seizure resulting from accidental injection of tranexamic acid in spinal anesthesia.", "question": "Treatment.Freq in accidental injection of tranexamic acid in spinal anesthesia", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "19448237_1_9274", "context": "Polymyoclonus seizure resulting from accidental injection of tranexamic acid in spinal anesthesia.", "question": "Treatment.Route in accidental injection of tranexamic acid in spinal anesthesia", "question_type": "Adverse_event.Treatment.Route", "answers": "injection"}, {"id": "19448237_1_9275", "context": "Polymyoclonus seizure resulting from accidental injection of tranexamic acid in spinal anesthesia.", "question": "Treatment.Time_elapsed in accidental injection of tranexamic acid in spinal anesthesia", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19448237_1_9276", "context": "Polymyoclonus seizure resulting from accidental injection of tranexamic acid in spinal anesthesia.", "question": "Treatment.Duration in accidental injection of tranexamic acid in spinal anesthesia", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "19448237_1_9277", "context": "Polymyoclonus seizure resulting from accidental injection of tranexamic acid in spinal anesthesia.", "question": "Treatment.Disorder in accidental injection of tranexamic acid in spinal anesthesia", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "19448237_1_9278", "context": "Polymyoclonus seizure resulting from accidental injection of tranexamic acid in spinal anesthesia.", "question": "Combination.Drug in accidental injection of tranexamic acid in spinal anesthesia", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "14712320_3_9279", "context": "Hydroxymethylglutaryl coenzyme A reductase inhibitors (statins) have been associated with myopathy and rhabdomyolysis.", "question": "Treatment.Drug in Hydroxymethylglutaryl coenzyme A reductase inhibitors (statins)", "question_type": "Adverse_event.Treatment.Drug", "answers": "Hydroxymethylglutaryl coenzyme A reductase inhibitors"}, {"id": "14712320_3_9280", "context": "Hydroxymethylglutaryl coenzyme A reductase inhibitors (statins) have been associated with myopathy and rhabdomyolysis.", "question": "Treatment.Dosage in Hydroxymethylglutaryl coenzyme A reductase inhibitors (statins)", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "14712320_3_9281", "context": "Hydroxymethylglutaryl coenzyme A reductase inhibitors (statins) have been associated with myopathy and rhabdomyolysis.", "question": "Treatment.Freq in Hydroxymethylglutaryl coenzyme A reductase inhibitors (statins)", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "14712320_3_9282", "context": "Hydroxymethylglutaryl coenzyme A reductase inhibitors (statins) have been associated with myopathy and rhabdomyolysis.", "question": "Treatment.Route in Hydroxymethylglutaryl coenzyme A reductase inhibitors (statins)", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "14712320_3_9283", "context": "Hydroxymethylglutaryl coenzyme A reductase inhibitors (statins) have been associated with myopathy and rhabdomyolysis.", "question": "Treatment.Time_elapsed in Hydroxymethylglutaryl coenzyme A reductase inhibitors (statins)", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "14712320_3_9284", "context": "Hydroxymethylglutaryl coenzyme A reductase inhibitors (statins) have been associated with myopathy and rhabdomyolysis.", "question": "Treatment.Duration in Hydroxymethylglutaryl coenzyme A reductase inhibitors (statins)", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "14712320_3_9285", "context": "Hydroxymethylglutaryl coenzyme A reductase inhibitors (statins) have been associated with myopathy and rhabdomyolysis.", "question": "Treatment.Disorder in Hydroxymethylglutaryl coenzyme A reductase inhibitors (statins)", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "14712320_3_9286", "context": "Hydroxymethylglutaryl coenzyme A reductase inhibitors (statins) have been associated with myopathy and rhabdomyolysis.", "question": "Combination.Drug in Hydroxymethylglutaryl coenzyme A reductase inhibitors (statins)", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "4051280_2_9287", "context": "Propranolol-induced hypertension in treatment of cocaine intoxication.", "question": "Treatment.Drug in Propranolol", "question_type": "Adverse_event.Treatment.Drug", "answers": "Propranolol"}, {"id": "4051280_2_9288", "context": "Propranolol-induced hypertension in treatment of cocaine intoxication.", "question": "Treatment.Dosage in Propranolol", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "4051280_2_9289", "context": "Propranolol-induced hypertension in treatment of cocaine intoxication.", "question": "Treatment.Freq in Propranolol", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "4051280_2_9290", "context": "Propranolol-induced hypertension in treatment of cocaine intoxication.", "question": "Treatment.Route in Propranolol", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "4051280_2_9291", "context": "Propranolol-induced hypertension in treatment of cocaine intoxication.", "question": "Treatment.Time_elapsed in Propranolol", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "4051280_2_9292", "context": "Propranolol-induced hypertension in treatment of cocaine intoxication.", "question": "Treatment.Duration in Propranolol", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "4051280_2_9293", "context": "Propranolol-induced hypertension in treatment of cocaine intoxication.", "question": "Treatment.Disorder in Propranolol", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "4051280_2_9294", "context": "Propranolol-induced hypertension in treatment of cocaine intoxication.", "question": "Combination.Drug in Propranolol", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10970989_1_9295", "context": "This is the second report of lactic acidosis in a patient on stavudine and lamivudine.", "question": "Subject.Age in a patient", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "10970989_1_9296", "context": "This is the second report of lactic acidosis in a patient on stavudine and lamivudine.", "question": "Subject.Gender in a patient", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "10970989_1_9297", "context": "This is the second report of lactic acidosis in a patient on stavudine and lamivudine.", "question": "Subject.Population in a patient", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "10970989_1_9298", "context": "This is the second report of lactic acidosis in a patient on stavudine and lamivudine.", "question": "Subject.Race in a patient", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "10970989_1_9299", "context": "This is the second report of lactic acidosis in a patient on stavudine and lamivudine.", "question": "Subject.Disorder in a patient", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "10970989_1_9300", "context": "This is the second report of lactic acidosis in a patient on stavudine and lamivudine.", "question": "Treatment.Drug in stavudine and lamivudine", "question_type": "Adverse_event.Treatment.Drug", "answers": "stavudine; lamivudine"}, {"id": "10970989_1_9301", "context": "This is the second report of lactic acidosis in a patient on stavudine and lamivudine.", "question": "Treatment.Dosage in stavudine and lamivudine", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10970989_1_9302", "context": "This is the second report of lactic acidosis in a patient on stavudine and lamivudine.", "question": "Treatment.Freq in stavudine and lamivudine", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10970989_1_9303", "context": "This is the second report of lactic acidosis in a patient on stavudine and lamivudine.", "question": "Treatment.Route in stavudine and lamivudine", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10970989_1_9304", "context": "This is the second report of lactic acidosis in a patient on stavudine and lamivudine.", "question": "Treatment.Time_elapsed in stavudine and lamivudine", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10970989_1_9305", "context": "This is the second report of lactic acidosis in a patient on stavudine and lamivudine.", "question": "Treatment.Duration in stavudine and lamivudine", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10970989_1_9306", "context": "This is the second report of lactic acidosis in a patient on stavudine and lamivudine.", "question": "Treatment.Disorder in stavudine and lamivudine", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10970989_1_9307", "context": "This is the second report of lactic acidosis in a patient on stavudine and lamivudine.", "question": "Combination.Drug in stavudine and lamivudine", "question_type": "Adverse_event.Combination.Drug", "answers": "lamivudine; stavudine"}, {"id": "7035691_2_9308", "context": "We report on a patient with renal artery stenosis who had only 1 kidney and in whom acute renal impairment developed with transient anuria after the administration of captopril.", "question": "Subject.Age in a patient with renal artery stenosis who had only 1 kidney", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "7035691_2_9309", "context": "We report on a patient with renal artery stenosis who had only 1 kidney and in whom acute renal impairment developed with transient anuria after the administration of captopril.", "question": "Subject.Gender in a patient with renal artery stenosis who had only 1 kidney", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "7035691_2_9310", "context": "We report on a patient with renal artery stenosis who had only 1 kidney and in whom acute renal impairment developed with transient anuria after the administration of captopril.", "question": "Subject.Population in a patient with renal artery stenosis who had only 1 kidney", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "7035691_2_9311", "context": "We report on a patient with renal artery stenosis who had only 1 kidney and in whom acute renal impairment developed with transient anuria after the administration of captopril.", "question": "Subject.Race in a patient with renal artery stenosis who had only 1 kidney", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "7035691_2_9312", "context": "We report on a patient with renal artery stenosis who had only 1 kidney and in whom acute renal impairment developed with transient anuria after the administration of captopril.", "question": "Subject.Disorder in a patient with renal artery stenosis who had only 1 kidney", "question_type": "Adverse_event.Subject.Disorder", "answers": "renal artery stenosis who had only 1 kidney"}, {"id": "7035691_2_9313", "context": "We report on a patient with renal artery stenosis who had only 1 kidney and in whom acute renal impairment developed with transient anuria after the administration of captopril.", "question": "Treatment.Drug in the administration of captopril", "question_type": "Adverse_event.Treatment.Drug", "answers": "captopril"}, {"id": "7035691_2_9314", "context": "We report on a patient with renal artery stenosis who had only 1 kidney and in whom acute renal impairment developed with transient anuria after the administration of captopril.", "question": "Treatment.Dosage in the administration of captopril", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7035691_2_9315", "context": "We report on a patient with renal artery stenosis who had only 1 kidney and in whom acute renal impairment developed with transient anuria after the administration of captopril.", "question": "Treatment.Freq in the administration of captopril", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7035691_2_9316", "context": "We report on a patient with renal artery stenosis who had only 1 kidney and in whom acute renal impairment developed with transient anuria after the administration of captopril.", "question": "Treatment.Route in the administration of captopril", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7035691_2_9317", "context": "We report on a patient with renal artery stenosis who had only 1 kidney and in whom acute renal impairment developed with transient anuria after the administration of captopril.", "question": "Treatment.Time_elapsed in the administration of captopril", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7035691_2_9318", "context": "We report on a patient with renal artery stenosis who had only 1 kidney and in whom acute renal impairment developed with transient anuria after the administration of captopril.", "question": "Treatment.Duration in the administration of captopril", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7035691_2_9319", "context": "We report on a patient with renal artery stenosis who had only 1 kidney and in whom acute renal impairment developed with transient anuria after the administration of captopril.", "question": "Treatment.Disorder in the administration of captopril", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7035691_2_9320", "context": "We report on a patient with renal artery stenosis who had only 1 kidney and in whom acute renal impairment developed with transient anuria after the administration of captopril.", "question": "Combination.Drug in the administration of captopril", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11795358_1_9321", "context": "However, in the mid-to-late 1980s, a series of letters to the editor and case reports announced an association between tamoxifen therapy in women with breast cancer and the development of endometrial carcinoma.", "question": "Subject.Age in women with breast cancer", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "11795358_1_9322", "context": "However, in the mid-to-late 1980s, a series of letters to the editor and case reports announced an association between tamoxifen therapy in women with breast cancer and the development of endometrial carcinoma.", "question": "Subject.Gender in women with breast cancer", "question_type": "Adverse_event.Subject.Gender", "answers": "women"}, {"id": "11795358_1_9323", "context": "However, in the mid-to-late 1980s, a series of letters to the editor and case reports announced an association between tamoxifen therapy in women with breast cancer and the development of endometrial carcinoma.", "question": "Subject.Population in women with breast cancer", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "11795358_1_9324", "context": "However, in the mid-to-late 1980s, a series of letters to the editor and case reports announced an association between tamoxifen therapy in women with breast cancer and the development of endometrial carcinoma.", "question": "Subject.Race in women with breast cancer", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "11795358_1_9325", "context": "However, in the mid-to-late 1980s, a series of letters to the editor and case reports announced an association between tamoxifen therapy in women with breast cancer and the development of endometrial carcinoma.", "question": "Subject.Disorder in women with breast cancer", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "11795358_1_9326", "context": "However, in the mid-to-late 1980s, a series of letters to the editor and case reports announced an association between tamoxifen therapy in women with breast cancer and the development of endometrial carcinoma.", "question": "Treatment.Drug in tamoxifen", "question_type": "Adverse_event.Treatment.Drug", "answers": "tamoxifen"}, {"id": "11795358_1_9327", "context": "However, in the mid-to-late 1980s, a series of letters to the editor and case reports announced an association between tamoxifen therapy in women with breast cancer and the development of endometrial carcinoma.", "question": "Treatment.Dosage in tamoxifen", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11795358_1_9328", "context": "However, in the mid-to-late 1980s, a series of letters to the editor and case reports announced an association between tamoxifen therapy in women with breast cancer and the development of endometrial carcinoma.", "question": "Treatment.Freq in tamoxifen", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11795358_1_9329", "context": "However, in the mid-to-late 1980s, a series of letters to the editor and case reports announced an association between tamoxifen therapy in women with breast cancer and the development of endometrial carcinoma.", "question": "Treatment.Route in tamoxifen", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11795358_1_9330", "context": "However, in the mid-to-late 1980s, a series of letters to the editor and case reports announced an association between tamoxifen therapy in women with breast cancer and the development of endometrial carcinoma.", "question": "Treatment.Time_elapsed in tamoxifen", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11795358_1_9331", "context": "However, in the mid-to-late 1980s, a series of letters to the editor and case reports announced an association between tamoxifen therapy in women with breast cancer and the development of endometrial carcinoma.", "question": "Treatment.Duration in tamoxifen", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11795358_1_9332", "context": "However, in the mid-to-late 1980s, a series of letters to the editor and case reports announced an association between tamoxifen therapy in women with breast cancer and the development of endometrial carcinoma.", "question": "Treatment.Disorder in tamoxifen", "question_type": "Adverse_event.Treatment.Disorder", "answers": "breast cancer"}, {"id": "11795358_1_9333", "context": "However, in the mid-to-late 1980s, a series of letters to the editor and case reports announced an association between tamoxifen therapy in women with breast cancer and the development of endometrial carcinoma.", "question": "Combination.Drug in tamoxifen", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17763133_3_9334", "context": "Simvastatin-induced rhabdomyolysis following cyclosporine treatment for uveitis.", "question": "Treatment.Drug in cyclosporine treatment; Simvastatin", "question_type": "Adverse_event.Treatment.Drug", "answers": "Simvastatin; cyclosporine"}, {"id": "17763133_3_9335", "context": "Simvastatin-induced rhabdomyolysis following cyclosporine treatment for uveitis.", "question": "Treatment.Dosage in cyclosporine treatment; Simvastatin", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17763133_3_9336", "context": "Simvastatin-induced rhabdomyolysis following cyclosporine treatment for uveitis.", "question": "Treatment.Freq in cyclosporine treatment; Simvastatin", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17763133_3_9337", "context": "Simvastatin-induced rhabdomyolysis following cyclosporine treatment for uveitis.", "question": "Treatment.Route in cyclosporine treatment; Simvastatin", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17763133_3_9338", "context": "Simvastatin-induced rhabdomyolysis following cyclosporine treatment for uveitis.", "question": "Treatment.Time_elapsed in cyclosporine treatment; Simvastatin", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17763133_3_9339", "context": "Simvastatin-induced rhabdomyolysis following cyclosporine treatment for uveitis.", "question": "Treatment.Duration in cyclosporine treatment; Simvastatin", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17763133_3_9340", "context": "Simvastatin-induced rhabdomyolysis following cyclosporine treatment for uveitis.", "question": "Treatment.Disorder in cyclosporine treatment; Simvastatin", "question_type": "Adverse_event.Treatment.Disorder", "answers": "uveitis"}, {"id": "17763133_3_9341", "context": "Simvastatin-induced rhabdomyolysis following cyclosporine treatment for uveitis.", "question": "Combination.Drug in cyclosporine treatment; Simvastatin", "question_type": "Adverse_event.Combination.Drug", "answers": "cyclosporine; Simvastatin"}, {"id": "12663440_2_9342", "context": "Based on our previous demonstration that quinine could be used clinically to reverse P-glycoprotein-mediated resistance, we designed a multicenter, randomized trial aiming to determine whether quinine would improve the survival of adult patients (15-60 years old) with de novo acute myelogenous leukemia (AML).", "question": "Subject.Age in adult patients (15-60 years old)", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": "adult; 15-60 years old"}, {"id": "12663440_2_9343", "context": "Based on our previous demonstration that quinine could be used clinically to reverse P-glycoprotein-mediated resistance, we designed a multicenter, randomized trial aiming to determine whether quinine would improve the survival of adult patients (15-60 years old) with de novo acute myelogenous leukemia (AML).", "question": "Subject.Gender in adult patients (15-60 years old)", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "12663440_2_9344", "context": "Based on our previous demonstration that quinine could be used clinically to reverse P-glycoprotein-mediated resistance, we designed a multicenter, randomized trial aiming to determine whether quinine would improve the survival of adult patients (15-60 years old) with de novo acute myelogenous leukemia (AML).", "question": "Subject.Population in adult patients (15-60 years old)", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "12663440_2_9345", "context": "Based on our previous demonstration that quinine could be used clinically to reverse P-glycoprotein-mediated resistance, we designed a multicenter, randomized trial aiming to determine whether quinine would improve the survival of adult patients (15-60 years old) with de novo acute myelogenous leukemia (AML).", "question": "Subject.Race in adult patients (15-60 years old)", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "12663440_2_9346", "context": "Based on our previous demonstration that quinine could be used clinically to reverse P-glycoprotein-mediated resistance, we designed a multicenter, randomized trial aiming to determine whether quinine would improve the survival of adult patients (15-60 years old) with de novo acute myelogenous leukemia (AML).", "question": "Subject.Disorder in adult patients (15-60 years old)", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "12663440_2_9347", "context": "Based on our previous demonstration that quinine could be used clinically to reverse P-glycoprotein-mediated resistance, we designed a multicenter, randomized trial aiming to determine whether quinine would improve the survival of adult patients (15-60 years old) with de novo acute myelogenous leukemia (AML).", "question": "Treatment.Drug in quinine", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "quinine"}, {"id": "12663440_2_9348", "context": "Based on our previous demonstration that quinine could be used clinically to reverse P-glycoprotein-mediated resistance, we designed a multicenter, randomized trial aiming to determine whether quinine would improve the survival of adult patients (15-60 years old) with de novo acute myelogenous leukemia (AML).", "question": "Treatment.Dosage in quinine", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "12663440_2_9349", "context": "Based on our previous demonstration that quinine could be used clinically to reverse P-glycoprotein-mediated resistance, we designed a multicenter, randomized trial aiming to determine whether quinine would improve the survival of adult patients (15-60 years old) with de novo acute myelogenous leukemia (AML).", "question": "Treatment.Freq in quinine", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "12663440_2_9350", "context": "Based on our previous demonstration that quinine could be used clinically to reverse P-glycoprotein-mediated resistance, we designed a multicenter, randomized trial aiming to determine whether quinine would improve the survival of adult patients (15-60 years old) with de novo acute myelogenous leukemia (AML).", "question": "Treatment.Route in quinine", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "12663440_2_9351", "context": "Based on our previous demonstration that quinine could be used clinically to reverse P-glycoprotein-mediated resistance, we designed a multicenter, randomized trial aiming to determine whether quinine would improve the survival of adult patients (15-60 years old) with de novo acute myelogenous leukemia (AML).", "question": "Treatment.Time_elapsed in quinine", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12663440_2_9352", "context": "Based on our previous demonstration that quinine could be used clinically to reverse P-glycoprotein-mediated resistance, we designed a multicenter, randomized trial aiming to determine whether quinine would improve the survival of adult patients (15-60 years old) with de novo acute myelogenous leukemia (AML).", "question": "Treatment.Duration in quinine", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "12663440_2_9353", "context": "Based on our previous demonstration that quinine could be used clinically to reverse P-glycoprotein-mediated resistance, we designed a multicenter, randomized trial aiming to determine whether quinine would improve the survival of adult patients (15-60 years old) with de novo acute myelogenous leukemia (AML).", "question": "Treatment.Disorder in quinine", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "de novo acute myelogenous leukemia (AML)"}, {"id": "12663440_2_9354", "context": "Based on our previous demonstration that quinine could be used clinically to reverse P-glycoprotein-mediated resistance, we designed a multicenter, randomized trial aiming to determine whether quinine would improve the survival of adult patients (15-60 years old) with de novo acute myelogenous leukemia (AML).", "question": "Combination.Drug in quinine", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "16816519_1_9355", "context": "Vincristine induced cranial polyneuropathy.", "question": "Treatment.Drug in Vincristine", "question_type": "Adverse_event.Treatment.Drug", "answers": "Vincristine"}, {"id": "16816519_1_9356", "context": "Vincristine induced cranial polyneuropathy.", "question": "Treatment.Dosage in Vincristine", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16816519_1_9357", "context": "Vincristine induced cranial polyneuropathy.", "question": "Treatment.Freq in Vincristine", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16816519_1_9358", "context": "Vincristine induced cranial polyneuropathy.", "question": "Treatment.Route in Vincristine", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16816519_1_9359", "context": "Vincristine induced cranial polyneuropathy.", "question": "Treatment.Time_elapsed in Vincristine", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16816519_1_9360", "context": "Vincristine induced cranial polyneuropathy.", "question": "Treatment.Duration in Vincristine", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16816519_1_9361", "context": "Vincristine induced cranial polyneuropathy.", "question": "Treatment.Disorder in Vincristine", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16816519_1_9362", "context": "Vincristine induced cranial polyneuropathy.", "question": "Combination.Drug in Vincristine", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17697264_1_9363", "context": "Here we describe another case of VOD occurring after LT, but in which the causative role was played by azathioprine.", "question": "Treatment.Drug in azathioprine", "question_type": "Adverse_event.Treatment.Drug", "answers": "azathioprine"}, {"id": "17697264_1_9364", "context": "Here we describe another case of VOD occurring after LT, but in which the causative role was played by azathioprine.", "question": "Treatment.Dosage in azathioprine", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17697264_1_9365", "context": "Here we describe another case of VOD occurring after LT, but in which the causative role was played by azathioprine.", "question": "Treatment.Freq in azathioprine", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17697264_1_9366", "context": "Here we describe another case of VOD occurring after LT, but in which the causative role was played by azathioprine.", "question": "Treatment.Route in azathioprine", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17697264_1_9367", "context": "Here we describe another case of VOD occurring after LT, but in which the causative role was played by azathioprine.", "question": "Treatment.Time_elapsed in azathioprine", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17697264_1_9368", "context": "Here we describe another case of VOD occurring after LT, but in which the causative role was played by azathioprine.", "question": "Treatment.Duration in azathioprine", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17697264_1_9369", "context": "Here we describe another case of VOD occurring after LT, but in which the causative role was played by azathioprine.", "question": "Treatment.Disorder in azathioprine", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17697264_1_9370", "context": "Here we describe another case of VOD occurring after LT, but in which the causative role was played by azathioprine.", "question": "Combination.Drug in azathioprine", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "19260037_2_9371", "context": "A retrospective review of TTP patients with quinine-associated thrombotic microangiopathy (TMA) for whom ADAMTS13 was measured before plasma exchange was performed.", "question": "Subject.Age in TTP patients", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "19260037_2_9372", "context": "A retrospective review of TTP patients with quinine-associated thrombotic microangiopathy (TMA) for whom ADAMTS13 was measured before plasma exchange was performed.", "question": "Subject.Gender in TTP patients", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "19260037_2_9373", "context": "A retrospective review of TTP patients with quinine-associated thrombotic microangiopathy (TMA) for whom ADAMTS13 was measured before plasma exchange was performed.", "question": "Subject.Population in TTP patients", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "19260037_2_9374", "context": "A retrospective review of TTP patients with quinine-associated thrombotic microangiopathy (TMA) for whom ADAMTS13 was measured before plasma exchange was performed.", "question": "Subject.Race in TTP patients", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "19260037_2_9375", "context": "A retrospective review of TTP patients with quinine-associated thrombotic microangiopathy (TMA) for whom ADAMTS13 was measured before plasma exchange was performed.", "question": "Subject.Disorder in TTP patients", "question_type": "Adverse_event.Subject.Disorder", "answers": "TTP"}, {"id": "19260037_2_9376", "context": "A retrospective review of TTP patients with quinine-associated thrombotic microangiopathy (TMA) for whom ADAMTS13 was measured before plasma exchange was performed.", "question": "Treatment.Drug in quinine", "question_type": "Adverse_event.Treatment.Drug", "answers": "quinine"}, {"id": "19260037_2_9377", "context": "A retrospective review of TTP patients with quinine-associated thrombotic microangiopathy (TMA) for whom ADAMTS13 was measured before plasma exchange was performed.", "question": "Treatment.Dosage in quinine", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "19260037_2_9378", "context": "A retrospective review of TTP patients with quinine-associated thrombotic microangiopathy (TMA) for whom ADAMTS13 was measured before plasma exchange was performed.", "question": "Treatment.Freq in quinine", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "19260037_2_9379", "context": "A retrospective review of TTP patients with quinine-associated thrombotic microangiopathy (TMA) for whom ADAMTS13 was measured before plasma exchange was performed.", "question": "Treatment.Route in quinine", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "19260037_2_9380", "context": "A retrospective review of TTP patients with quinine-associated thrombotic microangiopathy (TMA) for whom ADAMTS13 was measured before plasma exchange was performed.", "question": "Treatment.Time_elapsed in quinine", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19260037_2_9381", "context": "A retrospective review of TTP patients with quinine-associated thrombotic microangiopathy (TMA) for whom ADAMTS13 was measured before plasma exchange was performed.", "question": "Treatment.Duration in quinine", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "19260037_2_9382", "context": "A retrospective review of TTP patients with quinine-associated thrombotic microangiopathy (TMA) for whom ADAMTS13 was measured before plasma exchange was performed.", "question": "Treatment.Disorder in quinine", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "19260037_2_9383", "context": "A retrospective review of TTP patients with quinine-associated thrombotic microangiopathy (TMA) for whom ADAMTS13 was measured before plasma exchange was performed.", "question": "Combination.Drug in quinine", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18306483_1_9384", "context": "Rituximab-CHOP induced interstitial pneumonitis in patients with disseminated extranodal marginal zone B cell lymphoma.", "question": "Subject.Age in patients with disseminated extranodal marginal zone B cell lymphoma", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "18306483_1_9385", "context": "Rituximab-CHOP induced interstitial pneumonitis in patients with disseminated extranodal marginal zone B cell lymphoma.", "question": "Subject.Gender in patients with disseminated extranodal marginal zone B cell lymphoma", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "18306483_1_9386", "context": "Rituximab-CHOP induced interstitial pneumonitis in patients with disseminated extranodal marginal zone B cell lymphoma.", "question": "Subject.Population in patients with disseminated extranodal marginal zone B cell lymphoma", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "18306483_1_9387", "context": "Rituximab-CHOP induced interstitial pneumonitis in patients with disseminated extranodal marginal zone B cell lymphoma.", "question": "Subject.Race in patients with disseminated extranodal marginal zone B cell lymphoma", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "18306483_1_9388", "context": "Rituximab-CHOP induced interstitial pneumonitis in patients with disseminated extranodal marginal zone B cell lymphoma.", "question": "Subject.Disorder in patients with disseminated extranodal marginal zone B cell lymphoma", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "18306483_1_9389", "context": "Rituximab-CHOP induced interstitial pneumonitis in patients with disseminated extranodal marginal zone B cell lymphoma.", "question": "Treatment.Drug in Rituximab-CHOP", "question_type": "Adverse_event.Treatment.Drug", "answers": "Rituximab-CHOP"}, {"id": "18306483_1_9390", "context": "Rituximab-CHOP induced interstitial pneumonitis in patients with disseminated extranodal marginal zone B cell lymphoma.", "question": "Treatment.Dosage in Rituximab-CHOP", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18306483_1_9391", "context": "Rituximab-CHOP induced interstitial pneumonitis in patients with disseminated extranodal marginal zone B cell lymphoma.", "question": "Treatment.Freq in Rituximab-CHOP", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18306483_1_9392", "context": "Rituximab-CHOP induced interstitial pneumonitis in patients with disseminated extranodal marginal zone B cell lymphoma.", "question": "Treatment.Route in Rituximab-CHOP", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18306483_1_9393", "context": "Rituximab-CHOP induced interstitial pneumonitis in patients with disseminated extranodal marginal zone B cell lymphoma.", "question": "Treatment.Time_elapsed in Rituximab-CHOP", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18306483_1_9394", "context": "Rituximab-CHOP induced interstitial pneumonitis in patients with disseminated extranodal marginal zone B cell lymphoma.", "question": "Treatment.Duration in Rituximab-CHOP", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18306483_1_9395", "context": "Rituximab-CHOP induced interstitial pneumonitis in patients with disseminated extranodal marginal zone B cell lymphoma.", "question": "Treatment.Disorder in Rituximab-CHOP", "question_type": "Adverse_event.Treatment.Disorder", "answers": "disseminated extranodal marginal zone B cell lymphoma"}, {"id": "18306483_1_9396", "context": "Rituximab-CHOP induced interstitial pneumonitis in patients with disseminated extranodal marginal zone B cell lymphoma.", "question": "Combination.Drug in Rituximab-CHOP", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "2234880_2_9397", "context": "Nitrendipine is an experimental calcium channel blocking agent that also appears to cause the side effect of drug-induced gingival hyperplasia.", "question": "Treatment.Drug in Nitrendipine is an experimental calcium channel blocking agent", "question_type": "Adverse_event.Treatment.Drug", "answers": "Nitrendipine"}, {"id": "2234880_2_9398", "context": "Nitrendipine is an experimental calcium channel blocking agent that also appears to cause the side effect of drug-induced gingival hyperplasia.", "question": "Treatment.Dosage in Nitrendipine is an experimental calcium channel blocking agent", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "2234880_2_9399", "context": "Nitrendipine is an experimental calcium channel blocking agent that also appears to cause the side effect of drug-induced gingival hyperplasia.", "question": "Treatment.Freq in Nitrendipine is an experimental calcium channel blocking agent", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2234880_2_9400", "context": "Nitrendipine is an experimental calcium channel blocking agent that also appears to cause the side effect of drug-induced gingival hyperplasia.", "question": "Treatment.Route in Nitrendipine is an experimental calcium channel blocking agent", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "2234880_2_9401", "context": "Nitrendipine is an experimental calcium channel blocking agent that also appears to cause the side effect of drug-induced gingival hyperplasia.", "question": "Treatment.Time_elapsed in Nitrendipine is an experimental calcium channel blocking agent", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2234880_2_9402", "context": "Nitrendipine is an experimental calcium channel blocking agent that also appears to cause the side effect of drug-induced gingival hyperplasia.", "question": "Treatment.Duration in Nitrendipine is an experimental calcium channel blocking agent", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2234880_2_9403", "context": "Nitrendipine is an experimental calcium channel blocking agent that also appears to cause the side effect of drug-induced gingival hyperplasia.", "question": "Treatment.Disorder in Nitrendipine is an experimental calcium channel blocking agent", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "2234880_2_9404", "context": "Nitrendipine is an experimental calcium channel blocking agent that also appears to cause the side effect of drug-induced gingival hyperplasia.", "question": "Combination.Drug in Nitrendipine is an experimental calcium channel blocking agent", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18950384_1_9405", "context": "The present study describes a patient who had unusual weight fluctuation under corticosteroid and psychotropic treatment such as mianserin and aripiprazole.", "question": "Subject.Age in patient", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "18950384_1_9406", "context": "The present study describes a patient who had unusual weight fluctuation under corticosteroid and psychotropic treatment such as mianserin and aripiprazole.", "question": "Subject.Gender in patient", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "18950384_1_9407", "context": "The present study describes a patient who had unusual weight fluctuation under corticosteroid and psychotropic treatment such as mianserin and aripiprazole.", "question": "Subject.Population in patient", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "18950384_1_9408", "context": "The present study describes a patient who had unusual weight fluctuation under corticosteroid and psychotropic treatment such as mianserin and aripiprazole.", "question": "Subject.Race in patient", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "18950384_1_9409", "context": "The present study describes a patient who had unusual weight fluctuation under corticosteroid and psychotropic treatment such as mianserin and aripiprazole.", "question": "Subject.Disorder in patient", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "18950384_1_9410", "context": "The present study describes a patient who had unusual weight fluctuation under corticosteroid and psychotropic treatment such as mianserin and aripiprazole.", "question": "Treatment.Drug in corticosteroid and psychotropic treatment such as mianserin and aripiprazole", "question_type": "Adverse_event.Treatment.Drug", "answers": "mianserin; aripiprazole"}, {"id": "18950384_1_9411", "context": "The present study describes a patient who had unusual weight fluctuation under corticosteroid and psychotropic treatment such as mianserin and aripiprazole.", "question": "Treatment.Dosage in corticosteroid and psychotropic treatment such as mianserin and aripiprazole", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18950384_1_9412", "context": "The present study describes a patient who had unusual weight fluctuation under corticosteroid and psychotropic treatment such as mianserin and aripiprazole.", "question": "Treatment.Freq in corticosteroid and psychotropic treatment such as mianserin and aripiprazole", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18950384_1_9413", "context": "The present study describes a patient who had unusual weight fluctuation under corticosteroid and psychotropic treatment such as mianserin and aripiprazole.", "question": "Treatment.Route in corticosteroid and psychotropic treatment such as mianserin and aripiprazole", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18950384_1_9414", "context": "The present study describes a patient who had unusual weight fluctuation under corticosteroid and psychotropic treatment such as mianserin and aripiprazole.", "question": "Treatment.Time_elapsed in corticosteroid and psychotropic treatment such as mianserin and aripiprazole", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18950384_1_9415", "context": "The present study describes a patient who had unusual weight fluctuation under corticosteroid and psychotropic treatment such as mianserin and aripiprazole.", "question": "Treatment.Duration in corticosteroid and psychotropic treatment such as mianserin and aripiprazole", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18950384_1_9416", "context": "The present study describes a patient who had unusual weight fluctuation under corticosteroid and psychotropic treatment such as mianserin and aripiprazole.", "question": "Treatment.Disorder in corticosteroid and psychotropic treatment such as mianserin and aripiprazole", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18950384_1_9417", "context": "The present study describes a patient who had unusual weight fluctuation under corticosteroid and psychotropic treatment such as mianserin and aripiprazole.", "question": "Combination.Drug in corticosteroid and psychotropic treatment such as mianserin and aripiprazole", "question_type": "Adverse_event.Combination.Drug", "answers": "mianserin; aripiprazole"}, {"id": "12625995_2_9418", "context": "Clozapine-induced akathisia in children with schizophrenia.", "question": "Subject.Age in children with schizophrenia", "question_type": "Adverse_event.Subject.Age", "answers": "children"}, {"id": "12625995_2_9419", "context": "Clozapine-induced akathisia in children with schizophrenia.", "question": "Subject.Gender in children with schizophrenia", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "12625995_2_9420", "context": "Clozapine-induced akathisia in children with schizophrenia.", "question": "Subject.Population in children with schizophrenia", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "12625995_2_9421", "context": "Clozapine-induced akathisia in children with schizophrenia.", "question": "Subject.Race in children with schizophrenia", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "12625995_2_9422", "context": "Clozapine-induced akathisia in children with schizophrenia.", "question": "Subject.Disorder in children with schizophrenia", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "12625995_2_9423", "context": "Clozapine-induced akathisia in children with schizophrenia.", "question": "Treatment.Drug in Clozapine", "question_type": "Adverse_event.Treatment.Drug", "answers": "Clozapine"}, {"id": "12625995_2_9424", "context": "Clozapine-induced akathisia in children with schizophrenia.", "question": "Treatment.Dosage in Clozapine", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12625995_2_9425", "context": "Clozapine-induced akathisia in children with schizophrenia.", "question": "Treatment.Freq in Clozapine", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12625995_2_9426", "context": "Clozapine-induced akathisia in children with schizophrenia.", "question": "Treatment.Route in Clozapine", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12625995_2_9427", "context": "Clozapine-induced akathisia in children with schizophrenia.", "question": "Treatment.Time_elapsed in Clozapine", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12625995_2_9428", "context": "Clozapine-induced akathisia in children with schizophrenia.", "question": "Treatment.Duration in Clozapine", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12625995_2_9429", "context": "Clozapine-induced akathisia in children with schizophrenia.", "question": "Treatment.Disorder in Clozapine", "question_type": "Adverse_event.Treatment.Disorder", "answers": "schizophrenia"}, {"id": "12625995_2_9430", "context": "Clozapine-induced akathisia in children with schizophrenia.", "question": "Combination.Drug in Clozapine", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10715308_4_9431", "context": "Patients with previously untreated NSCLC were randomized to receive either tirapazamine (390 mg/m(2) infused over 2 hours) followed 1 hour later by cisplatin (75 mg/m(2) over 1 hour) or 75 mg/m(2) of cisplatin alone, every 3 weeks for a maximum of eight cycles.", "question": "Subject.Age in Patients with previously untreated NSCLC", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "10715308_4_9432", "context": "Patients with previously untreated NSCLC were randomized to receive either tirapazamine (390 mg/m(2) infused over 2 hours) followed 1 hour later by cisplatin (75 mg/m(2) over 1 hour) or 75 mg/m(2) of cisplatin alone, every 3 weeks for a maximum of eight cycles.", "question": "Subject.Gender in Patients with previously untreated NSCLC", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "10715308_4_9433", "context": "Patients with previously untreated NSCLC were randomized to receive either tirapazamine (390 mg/m(2) infused over 2 hours) followed 1 hour later by cisplatin (75 mg/m(2) over 1 hour) or 75 mg/m(2) of cisplatin alone, every 3 weeks for a maximum of eight cycles.", "question": "Subject.Population in Patients with previously untreated NSCLC", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "10715308_4_9434", "context": "Patients with previously untreated NSCLC were randomized to receive either tirapazamine (390 mg/m(2) infused over 2 hours) followed 1 hour later by cisplatin (75 mg/m(2) over 1 hour) or 75 mg/m(2) of cisplatin alone, every 3 weeks for a maximum of eight cycles.", "question": "Subject.Race in Patients with previously untreated NSCLC", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "10715308_4_9435", "context": "Patients with previously untreated NSCLC were randomized to receive either tirapazamine (390 mg/m(2) infused over 2 hours) followed 1 hour later by cisplatin (75 mg/m(2) over 1 hour) or 75 mg/m(2) of cisplatin alone, every 3 weeks for a maximum of eight cycles.", "question": "Subject.Disorder in Patients with previously untreated NSCLC", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "10715308_4_9436", "context": "Patients with previously untreated NSCLC were randomized to receive either tirapazamine (390 mg/m(2) infused over 2 hours) followed 1 hour later by cisplatin (75 mg/m(2) over 1 hour) or 75 mg/m(2) of cisplatin alone, every 3 weeks for a maximum of eight cycles.", "question": "Treatment.Drug in either tirapazamine (390 mg/m(2) infused over 2 hours) followed 1 hour later by cisplatin (75 mg/m(2) over 1 hour) or 75 mg/m(2) of cisplatin alone, every 3 weeks for a maximum of eight cycles", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "tirapazamine; cisplatin; cisplatin"}, {"id": "10715308_4_9437", "context": "Patients with previously untreated NSCLC were randomized to receive either tirapazamine (390 mg/m(2) infused over 2 hours) followed 1 hour later by cisplatin (75 mg/m(2) over 1 hour) or 75 mg/m(2) of cisplatin alone, every 3 weeks for a maximum of eight cycles.", "question": "Treatment.Dosage in either tirapazamine (390 mg/m(2) infused over 2 hours) followed 1 hour later by cisplatin (75 mg/m(2) over 1 hour) or 75 mg/m(2) of cisplatin alone, every 3 weeks for a maximum of eight cycles", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": "390 mg/m(2); 75 mg/m(2); 75 mg/m(2)"}, {"id": "10715308_4_9438", "context": "Patients with previously untreated NSCLC were randomized to receive either tirapazamine (390 mg/m(2) infused over 2 hours) followed 1 hour later by cisplatin (75 mg/m(2) over 1 hour) or 75 mg/m(2) of cisplatin alone, every 3 weeks for a maximum of eight cycles.", "question": "Treatment.Freq in either tirapazamine (390 mg/m(2) infused over 2 hours) followed 1 hour later by cisplatin (75 mg/m(2) over 1 hour) or 75 mg/m(2) of cisplatin alone, every 3 weeks for a maximum of eight cycles", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": "every 3 weeks for a maximum of eight cycles"}, {"id": "10715308_4_9439", "context": "Patients with previously untreated NSCLC were randomized to receive either tirapazamine (390 mg/m(2) infused over 2 hours) followed 1 hour later by cisplatin (75 mg/m(2) over 1 hour) or 75 mg/m(2) of cisplatin alone, every 3 weeks for a maximum of eight cycles.", "question": "Treatment.Route in either tirapazamine (390 mg/m(2) infused over 2 hours) followed 1 hour later by cisplatin (75 mg/m(2) over 1 hour) or 75 mg/m(2) of cisplatin alone, every 3 weeks for a maximum of eight cycles", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": "infused"}, {"id": "10715308_4_9440", "context": "Patients with previously untreated NSCLC were randomized to receive either tirapazamine (390 mg/m(2) infused over 2 hours) followed 1 hour later by cisplatin (75 mg/m(2) over 1 hour) or 75 mg/m(2) of cisplatin alone, every 3 weeks for a maximum of eight cycles.", "question": "Treatment.Time_elapsed in either tirapazamine (390 mg/m(2) infused over 2 hours) followed 1 hour later by cisplatin (75 mg/m(2) over 1 hour) or 75 mg/m(2) of cisplatin alone, every 3 weeks for a maximum of eight cycles", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": "over 2 hours; over 1 hour"}, {"id": "10715308_4_9441", "context": "Patients with previously untreated NSCLC were randomized to receive either tirapazamine (390 mg/m(2) infused over 2 hours) followed 1 hour later by cisplatin (75 mg/m(2) over 1 hour) or 75 mg/m(2) of cisplatin alone, every 3 weeks for a maximum of eight cycles.", "question": "Treatment.Duration in either tirapazamine (390 mg/m(2) infused over 2 hours) followed 1 hour later by cisplatin (75 mg/m(2) over 1 hour) or 75 mg/m(2) of cisplatin alone, every 3 weeks for a maximum of eight cycles", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "10715308_4_9442", "context": "Patients with previously untreated NSCLC were randomized to receive either tirapazamine (390 mg/m(2) infused over 2 hours) followed 1 hour later by cisplatin (75 mg/m(2) over 1 hour) or 75 mg/m(2) of cisplatin alone, every 3 weeks for a maximum of eight cycles.", "question": "Treatment.Disorder in either tirapazamine (390 mg/m(2) infused over 2 hours) followed 1 hour later by cisplatin (75 mg/m(2) over 1 hour) or 75 mg/m(2) of cisplatin alone, every 3 weeks for a maximum of eight cycles", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "NSCLC"}, {"id": "10715308_4_9443", "context": "Patients with previously untreated NSCLC were randomized to receive either tirapazamine (390 mg/m(2) infused over 2 hours) followed 1 hour later by cisplatin (75 mg/m(2) over 1 hour) or 75 mg/m(2) of cisplatin alone, every 3 weeks for a maximum of eight cycles.", "question": "Combination.Drug in either tirapazamine (390 mg/m(2) infused over 2 hours) followed 1 hour later by cisplatin (75 mg/m(2) over 1 hour) or 75 mg/m(2) of cisplatin alone, every 3 weeks for a maximum of eight cycles", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": "tirapazamine; cisplatin"}, {"id": "11720625_3_9444", "context": "Drug interactions between macrolide antibiotics such as erythomycin and pharmacologic agents that prolong the QT interval have been known to cause TdP. However, clarithromycin is thought to be less frequently associated with drug induced TdP, because it inactivates hepatic cytochrome P-450 to a lesser extent than erythromycin.", "question": "Treatment.Drug in Drug interactions between macrolide antibiotics such as erythomycin and pharmacologic agents that prolong the QT interval", "question_type": "Adverse_event.Treatment.Drug", "answers": "erythomycin; pharmacologic agents; macrolide antibiotics"}, {"id": "11720625_3_9445", "context": "Drug interactions between macrolide antibiotics such as erythomycin and pharmacologic agents that prolong the QT interval have been known to cause TdP. However, clarithromycin is thought to be less frequently associated with drug induced TdP, because it inactivates hepatic cytochrome P-450 to a lesser extent than erythromycin.", "question": "Treatment.Dosage in Drug interactions between macrolide antibiotics such as erythomycin and pharmacologic agents that prolong the QT interval", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11720625_3_9446", "context": "Drug interactions between macrolide antibiotics such as erythomycin and pharmacologic agents that prolong the QT interval have been known to cause TdP. However, clarithromycin is thought to be less frequently associated with drug induced TdP, because it inactivates hepatic cytochrome P-450 to a lesser extent than erythromycin.", "question": "Treatment.Freq in Drug interactions between macrolide antibiotics such as erythomycin and pharmacologic agents that prolong the QT interval", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11720625_3_9447", "context": "Drug interactions between macrolide antibiotics such as erythomycin and pharmacologic agents that prolong the QT interval have been known to cause TdP. However, clarithromycin is thought to be less frequently associated with drug induced TdP, because it inactivates hepatic cytochrome P-450 to a lesser extent than erythromycin.", "question": "Treatment.Route in Drug interactions between macrolide antibiotics such as erythomycin and pharmacologic agents that prolong the QT interval", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11720625_3_9448", "context": "Drug interactions between macrolide antibiotics such as erythomycin and pharmacologic agents that prolong the QT interval have been known to cause TdP. However, clarithromycin is thought to be less frequently associated with drug induced TdP, because it inactivates hepatic cytochrome P-450 to a lesser extent than erythromycin.", "question": "Treatment.Time_elapsed in Drug interactions between macrolide antibiotics such as erythomycin and pharmacologic agents that prolong the QT interval", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11720625_3_9449", "context": "Drug interactions between macrolide antibiotics such as erythomycin and pharmacologic agents that prolong the QT interval have been known to cause TdP. However, clarithromycin is thought to be less frequently associated with drug induced TdP, because it inactivates hepatic cytochrome P-450 to a lesser extent than erythromycin.", "question": "Treatment.Duration in Drug interactions between macrolide antibiotics such as erythomycin and pharmacologic agents that prolong the QT interval", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11720625_3_9450", "context": "Drug interactions between macrolide antibiotics such as erythomycin and pharmacologic agents that prolong the QT interval have been known to cause TdP. However, clarithromycin is thought to be less frequently associated with drug induced TdP, because it inactivates hepatic cytochrome P-450 to a lesser extent than erythromycin.", "question": "Treatment.Disorder in Drug interactions between macrolide antibiotics such as erythomycin and pharmacologic agents that prolong the QT interval", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11720625_3_9451", "context": "Drug interactions between macrolide antibiotics such as erythomycin and pharmacologic agents that prolong the QT interval have been known to cause TdP. However, clarithromycin is thought to be less frequently associated with drug induced TdP, because it inactivates hepatic cytochrome P-450 to a lesser extent than erythromycin.", "question": "Combination.Drug in Drug interactions between macrolide antibiotics such as erythomycin and pharmacologic agents that prolong the QT interval", "question_type": "Adverse_event.Combination.Drug", "answers": "erythomycin; pharmacologic agents"}, {"id": "20180933_5_9452", "context": "In a randomised, investigator-blinded, multicentre phase III efficacy trial, 899 infants and children with acute uncomplicated Plasmodium falciparum malaria received six doses of AL according to body weight over 3 days either as crushed tablets (Coartem) or as dispersible tablets.", "question": "Subject.Age in 899 infants and children with acute uncomplicated Plasmodium falciparum malaria", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": "infants and children"}, {"id": "20180933_5_9453", "context": "In a randomised, investigator-blinded, multicentre phase III efficacy trial, 899 infants and children with acute uncomplicated Plasmodium falciparum malaria received six doses of AL according to body weight over 3 days either as crushed tablets (Coartem) or as dispersible tablets.", "question": "Subject.Gender in 899 infants and children with acute uncomplicated Plasmodium falciparum malaria", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "20180933_5_9454", "context": "In a randomised, investigator-blinded, multicentre phase III efficacy trial, 899 infants and children with acute uncomplicated Plasmodium falciparum malaria received six doses of AL according to body weight over 3 days either as crushed tablets (Coartem) or as dispersible tablets.", "question": "Subject.Population in 899 infants and children with acute uncomplicated Plasmodium falciparum malaria", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": "899"}, {"id": "20180933_5_9455", "context": "In a randomised, investigator-blinded, multicentre phase III efficacy trial, 899 infants and children with acute uncomplicated Plasmodium falciparum malaria received six doses of AL according to body weight over 3 days either as crushed tablets (Coartem) or as dispersible tablets.", "question": "Subject.Race in 899 infants and children with acute uncomplicated Plasmodium falciparum malaria", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "20180933_5_9456", "context": "In a randomised, investigator-blinded, multicentre phase III efficacy trial, 899 infants and children with acute uncomplicated Plasmodium falciparum malaria received six doses of AL according to body weight over 3 days either as crushed tablets (Coartem) or as dispersible tablets.", "question": "Subject.Disorder in 899 infants and children with acute uncomplicated Plasmodium falciparum malaria", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "20180933_5_9457", "context": "In a randomised, investigator-blinded, multicentre phase III efficacy trial, 899 infants and children with acute uncomplicated Plasmodium falciparum malaria received six doses of AL according to body weight over 3 days either as crushed tablets (Coartem) or as dispersible tablets.", "question": "Treatment.Drug in six doses of AL according to body weight over 3 days either as crushed tablets (Coartem) or as dispersible tablets", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "AL"}, {"id": "20180933_5_9458", "context": "In a randomised, investigator-blinded, multicentre phase III efficacy trial, 899 infants and children with acute uncomplicated Plasmodium falciparum malaria received six doses of AL according to body weight over 3 days either as crushed tablets (Coartem) or as dispersible tablets.", "question": "Treatment.Dosage in six doses of AL according to body weight over 3 days either as crushed tablets (Coartem) or as dispersible tablets", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": "six doses"}, {"id": "20180933_5_9459", "context": "In a randomised, investigator-blinded, multicentre phase III efficacy trial, 899 infants and children with acute uncomplicated Plasmodium falciparum malaria received six doses of AL according to body weight over 3 days either as crushed tablets (Coartem) or as dispersible tablets.", "question": "Treatment.Freq in six doses of AL according to body weight over 3 days either as crushed tablets (Coartem) or as dispersible tablets", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "20180933_5_9460", "context": "In a randomised, investigator-blinded, multicentre phase III efficacy trial, 899 infants and children with acute uncomplicated Plasmodium falciparum malaria received six doses of AL according to body weight over 3 days either as crushed tablets (Coartem) or as dispersible tablets.", "question": "Treatment.Route in six doses of AL according to body weight over 3 days either as crushed tablets (Coartem) or as dispersible tablets", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": "crushed tablets; dispersible tablets"}, {"id": "20180933_5_9461", "context": "In a randomised, investigator-blinded, multicentre phase III efficacy trial, 899 infants and children with acute uncomplicated Plasmodium falciparum malaria received six doses of AL according to body weight over 3 days either as crushed tablets (Coartem) or as dispersible tablets.", "question": "Treatment.Time_elapsed in six doses of AL according to body weight over 3 days either as crushed tablets (Coartem) or as dispersible tablets", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "20180933_5_9462", "context": "In a randomised, investigator-blinded, multicentre phase III efficacy trial, 899 infants and children with acute uncomplicated Plasmodium falciparum malaria received six doses of AL according to body weight over 3 days either as crushed tablets (Coartem) or as dispersible tablets.", "question": "Treatment.Duration in six doses of AL according to body weight over 3 days either as crushed tablets (Coartem) or as dispersible tablets", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": "3 days"}, {"id": "20180933_5_9463", "context": "In a randomised, investigator-blinded, multicentre phase III efficacy trial, 899 infants and children with acute uncomplicated Plasmodium falciparum malaria received six doses of AL according to body weight over 3 days either as crushed tablets (Coartem) or as dispersible tablets.", "question": "Treatment.Disorder in six doses of AL according to body weight over 3 days either as crushed tablets (Coartem) or as dispersible tablets", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "Plasmodium falciparum malaria"}, {"id": "20180933_5_9464", "context": "In a randomised, investigator-blinded, multicentre phase III efficacy trial, 899 infants and children with acute uncomplicated Plasmodium falciparum malaria received six doses of AL according to body weight over 3 days either as crushed tablets (Coartem) or as dispersible tablets.", "question": "Combination.Drug in six doses of AL according to body weight over 3 days either as crushed tablets (Coartem) or as dispersible tablets", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "1389744_1_9465", "context": "A patient presented with dilated cardiomyopathy after many years of overusing an adrenaline inhaler.", "question": "Subject.Age in A patient", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "1389744_1_9466", "context": "A patient presented with dilated cardiomyopathy after many years of overusing an adrenaline inhaler.", "question": "Subject.Gender in A patient", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "1389744_1_9467", "context": "A patient presented with dilated cardiomyopathy after many years of overusing an adrenaline inhaler.", "question": "Subject.Population in A patient", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "1389744_1_9468", "context": "A patient presented with dilated cardiomyopathy after many years of overusing an adrenaline inhaler.", "question": "Subject.Race in A patient", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "1389744_1_9469", "context": "A patient presented with dilated cardiomyopathy after many years of overusing an adrenaline inhaler.", "question": "Subject.Disorder in A patient", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "1389744_1_9470", "context": "A patient presented with dilated cardiomyopathy after many years of overusing an adrenaline inhaler.", "question": "Treatment.Drug in many years of overusing an adrenaline inhaler", "question_type": "Adverse_event.Treatment.Drug", "answers": "adrenaline"}, {"id": "1389744_1_9471", "context": "A patient presented with dilated cardiomyopathy after many years of overusing an adrenaline inhaler.", "question": "Treatment.Dosage in many years of overusing an adrenaline inhaler", "question_type": "Adverse_event.Treatment.Dosage", "answers": "overusing"}, {"id": "1389744_1_9472", "context": "A patient presented with dilated cardiomyopathy after many years of overusing an adrenaline inhaler.", "question": "Treatment.Freq in many years of overusing an adrenaline inhaler", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "1389744_1_9473", "context": "A patient presented with dilated cardiomyopathy after many years of overusing an adrenaline inhaler.", "question": "Treatment.Route in many years of overusing an adrenaline inhaler", "question_type": "Adverse_event.Treatment.Route", "answers": "inhaler"}, {"id": "1389744_1_9474", "context": "A patient presented with dilated cardiomyopathy after many years of overusing an adrenaline inhaler.", "question": "Treatment.Time_elapsed in many years of overusing an adrenaline inhaler", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "1389744_1_9475", "context": "A patient presented with dilated cardiomyopathy after many years of overusing an adrenaline inhaler.", "question": "Treatment.Duration in many years of overusing an adrenaline inhaler", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "1389744_1_9476", "context": "A patient presented with dilated cardiomyopathy after many years of overusing an adrenaline inhaler.", "question": "Treatment.Disorder in many years of overusing an adrenaline inhaler", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "1389744_1_9477", "context": "A patient presented with dilated cardiomyopathy after many years of overusing an adrenaline inhaler.", "question": "Combination.Drug in many years of overusing an adrenaline inhaler", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6625005_2_9478", "context": "Occurrence of withdrawal dyskinesia indicates that the neuroleptic effects of amoxapine may be clinically significant.", "question": "Treatment.Drug in amoxapine", "question_type": "Adverse_event.Treatment.Drug", "answers": "amoxapine"}, {"id": "6625005_2_9479", "context": "Occurrence of withdrawal dyskinesia indicates that the neuroleptic effects of amoxapine may be clinically significant.", "question": "Treatment.Dosage in amoxapine", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6625005_2_9480", "context": "Occurrence of withdrawal dyskinesia indicates that the neuroleptic effects of amoxapine may be clinically significant.", "question": "Treatment.Freq in amoxapine", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6625005_2_9481", "context": "Occurrence of withdrawal dyskinesia indicates that the neuroleptic effects of amoxapine may be clinically significant.", "question": "Treatment.Route in amoxapine", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6625005_2_9482", "context": "Occurrence of withdrawal dyskinesia indicates that the neuroleptic effects of amoxapine may be clinically significant.", "question": "Treatment.Time_elapsed in amoxapine", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6625005_2_9483", "context": "Occurrence of withdrawal dyskinesia indicates that the neuroleptic effects of amoxapine may be clinically significant.", "question": "Treatment.Duration in amoxapine", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6625005_2_9484", "context": "Occurrence of withdrawal dyskinesia indicates that the neuroleptic effects of amoxapine may be clinically significant.", "question": "Treatment.Disorder in amoxapine", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6625005_2_9485", "context": "Occurrence of withdrawal dyskinesia indicates that the neuroleptic effects of amoxapine may be clinically significant.", "question": "Combination.Drug in amoxapine", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10442258_1_9486", "context": "Hair loss associated with paroxetine treatment: a case report.", "question": "Subject.Age in a case", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "10442258_1_9487", "context": "Hair loss associated with paroxetine treatment: a case report.", "question": "Subject.Gender in a case", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "10442258_1_9488", "context": "Hair loss associated with paroxetine treatment: a case report.", "question": "Subject.Population in a case", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "10442258_1_9489", "context": "Hair loss associated with paroxetine treatment: a case report.", "question": "Subject.Race in a case", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "10442258_1_9490", "context": "Hair loss associated with paroxetine treatment: a case report.", "question": "Subject.Disorder in a case", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "10442258_1_9491", "context": "Hair loss associated with paroxetine treatment: a case report.", "question": "Treatment.Drug in paroxetine", "question_type": "Adverse_event.Treatment.Drug", "answers": "paroxetine"}, {"id": "10442258_1_9492", "context": "Hair loss associated with paroxetine treatment: a case report.", "question": "Treatment.Dosage in paroxetine", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10442258_1_9493", "context": "Hair loss associated with paroxetine treatment: a case report.", "question": "Treatment.Freq in paroxetine", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10442258_1_9494", "context": "Hair loss associated with paroxetine treatment: a case report.", "question": "Treatment.Route in paroxetine", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10442258_1_9495", "context": "Hair loss associated with paroxetine treatment: a case report.", "question": "Treatment.Time_elapsed in paroxetine", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10442258_1_9496", "context": "Hair loss associated with paroxetine treatment: a case report.", "question": "Treatment.Duration in paroxetine", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10442258_1_9497", "context": "Hair loss associated with paroxetine treatment: a case report.", "question": "Treatment.Disorder in paroxetine", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10442258_1_9498", "context": "Hair loss associated with paroxetine treatment: a case report.", "question": "Combination.Drug in paroxetine", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15760792_4_9499", "context": "RESULTS: In a 22-year-old Thai woman with Graves' disease, tinnitus, hearing impairment in the left ear (with progression to the right ear), and vertigo developed after 3 years of therapy with PTU.", "question": "Subject.Age in a 22-year-old Thai woman with Graves' disease", "question_type": "Adverse_event.Subject.Age", "answers": "22-year-old"}, {"id": "15760792_4_9500", "context": "RESULTS: In a 22-year-old Thai woman with Graves' disease, tinnitus, hearing impairment in the left ear (with progression to the right ear), and vertigo developed after 3 years of therapy with PTU.", "question": "Subject.Gender in a 22-year-old Thai woman with Graves' disease", "question_type": "Adverse_event.Subject.Gender", "answers": "woman"}, {"id": "15760792_4_9501", "context": "RESULTS: In a 22-year-old Thai woman with Graves' disease, tinnitus, hearing impairment in the left ear (with progression to the right ear), and vertigo developed after 3 years of therapy with PTU.", "question": "Subject.Population in a 22-year-old Thai woman with Graves' disease", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "15760792_4_9502", "context": "RESULTS: In a 22-year-old Thai woman with Graves' disease, tinnitus, hearing impairment in the left ear (with progression to the right ear), and vertigo developed after 3 years of therapy with PTU.", "question": "Subject.Race in a 22-year-old Thai woman with Graves' disease", "question_type": "Adverse_event.Subject.Race", "answers": "Thai"}, {"id": "15760792_4_9503", "context": "RESULTS: In a 22-year-old Thai woman with Graves' disease, tinnitus, hearing impairment in the left ear (with progression to the right ear), and vertigo developed after 3 years of therapy with PTU.", "question": "Subject.Disorder in a 22-year-old Thai woman with Graves' disease", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15760792_4_9504", "context": "RESULTS: In a 22-year-old Thai woman with Graves' disease, tinnitus, hearing impairment in the left ear (with progression to the right ear), and vertigo developed after 3 years of therapy with PTU.", "question": "Treatment.Drug in after 3 years of therapy with PTU", "question_type": "Adverse_event.Treatment.Drug", "answers": "PTU"}, {"id": "15760792_4_9505", "context": "RESULTS: In a 22-year-old Thai woman with Graves' disease, tinnitus, hearing impairment in the left ear (with progression to the right ear), and vertigo developed after 3 years of therapy with PTU.", "question": "Treatment.Dosage in after 3 years of therapy with PTU", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15760792_4_9506", "context": "RESULTS: In a 22-year-old Thai woman with Graves' disease, tinnitus, hearing impairment in the left ear (with progression to the right ear), and vertigo developed after 3 years of therapy with PTU.", "question": "Treatment.Freq in after 3 years of therapy with PTU", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15760792_4_9507", "context": "RESULTS: In a 22-year-old Thai woman with Graves' disease, tinnitus, hearing impairment in the left ear (with progression to the right ear), and vertigo developed after 3 years of therapy with PTU.", "question": "Treatment.Route in after 3 years of therapy with PTU", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15760792_4_9508", "context": "RESULTS: In a 22-year-old Thai woman with Graves' disease, tinnitus, hearing impairment in the left ear (with progression to the right ear), and vertigo developed after 3 years of therapy with PTU.", "question": "Treatment.Time_elapsed in after 3 years of therapy with PTU", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "after 3 years"}, {"id": "15760792_4_9509", "context": "RESULTS: In a 22-year-old Thai woman with Graves' disease, tinnitus, hearing impairment in the left ear (with progression to the right ear), and vertigo developed after 3 years of therapy with PTU.", "question": "Treatment.Duration in after 3 years of therapy with PTU", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15760792_4_9510", "context": "RESULTS: In a 22-year-old Thai woman with Graves' disease, tinnitus, hearing impairment in the left ear (with progression to the right ear), and vertigo developed after 3 years of therapy with PTU.", "question": "Treatment.Disorder in after 3 years of therapy with PTU", "question_type": "Adverse_event.Treatment.Disorder", "answers": "Graves' disease"}, {"id": "15760792_4_9511", "context": "RESULTS: In a 22-year-old Thai woman with Graves' disease, tinnitus, hearing impairment in the left ear (with progression to the right ear), and vertigo developed after 3 years of therapy with PTU.", "question": "Combination.Drug in after 3 years of therapy with PTU", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6578007_1_9512", "context": "Additive pulmonary toxicity with melphalan and busulfan therapy.", "question": "Treatment.Drug in melphalan and busulfan therapy", "question_type": "Adverse_event.Treatment.Drug", "answers": "melphalan; busulfan"}, {"id": "6578007_1_9513", "context": "Additive pulmonary toxicity with melphalan and busulfan therapy.", "question": "Treatment.Dosage in melphalan and busulfan therapy", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6578007_1_9514", "context": "Additive pulmonary toxicity with melphalan and busulfan therapy.", "question": "Treatment.Freq in melphalan and busulfan therapy", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6578007_1_9515", "context": "Additive pulmonary toxicity with melphalan and busulfan therapy.", "question": "Treatment.Route in melphalan and busulfan therapy", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6578007_1_9516", "context": "Additive pulmonary toxicity with melphalan and busulfan therapy.", "question": "Treatment.Time_elapsed in melphalan and busulfan therapy", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6578007_1_9517", "context": "Additive pulmonary toxicity with melphalan and busulfan therapy.", "question": "Treatment.Duration in melphalan and busulfan therapy", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6578007_1_9518", "context": "Additive pulmonary toxicity with melphalan and busulfan therapy.", "question": "Treatment.Disorder in melphalan and busulfan therapy", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6578007_1_9519", "context": "Additive pulmonary toxicity with melphalan and busulfan therapy.", "question": "Combination.Drug in melphalan and busulfan therapy", "question_type": "Adverse_event.Combination.Drug", "answers": "melphalan; busulfan"}, {"id": "16682062_3_9520", "context": "We report the case of a 20-year-old woman originally from Cameroon who was infected by the L. loa parasite and developed severe hepatitis, identified 1 month after a single dose of ivermectin.", "question": "Subject.Age in 20-year-old woman originally from Cameroon who was infected by the L. loa parasite", "question_type": "Adverse_event.Subject.Age", "answers": "20-year-old"}, {"id": "16682062_3_9521", "context": "We report the case of a 20-year-old woman originally from Cameroon who was infected by the L. loa parasite and developed severe hepatitis, identified 1 month after a single dose of ivermectin.", "question": "Subject.Gender in 20-year-old woman originally from Cameroon who was infected by the L. loa parasite", "question_type": "Adverse_event.Subject.Gender", "answers": "woman"}, {"id": "16682062_3_9522", "context": "We report the case of a 20-year-old woman originally from Cameroon who was infected by the L. loa parasite and developed severe hepatitis, identified 1 month after a single dose of ivermectin.", "question": "Subject.Population in 20-year-old woman originally from Cameroon who was infected by the L. loa parasite", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "16682062_3_9523", "context": "We report the case of a 20-year-old woman originally from Cameroon who was infected by the L. loa parasite and developed severe hepatitis, identified 1 month after a single dose of ivermectin.", "question": "Subject.Race in 20-year-old woman originally from Cameroon who was infected by the L. loa parasite", "question_type": "Adverse_event.Subject.Race", "answers": "Cameroon"}, {"id": "16682062_3_9524", "context": "We report the case of a 20-year-old woman originally from Cameroon who was infected by the L. loa parasite and developed severe hepatitis, identified 1 month after a single dose of ivermectin.", "question": "Subject.Disorder in 20-year-old woman originally from Cameroon who was infected by the L. loa parasite", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "16682062_3_9525", "context": "We report the case of a 20-year-old woman originally from Cameroon who was infected by the L. loa parasite and developed severe hepatitis, identified 1 month after a single dose of ivermectin.", "question": "Treatment.Drug in 1 month after a single dose of ivermectin", "question_type": "Adverse_event.Treatment.Drug", "answers": "ivermectin"}, {"id": "16682062_3_9526", "context": "We report the case of a 20-year-old woman originally from Cameroon who was infected by the L. loa parasite and developed severe hepatitis, identified 1 month after a single dose of ivermectin.", "question": "Treatment.Dosage in 1 month after a single dose of ivermectin", "question_type": "Adverse_event.Treatment.Dosage", "answers": "single dose"}, {"id": "16682062_3_9527", "context": "We report the case of a 20-year-old woman originally from Cameroon who was infected by the L. loa parasite and developed severe hepatitis, identified 1 month after a single dose of ivermectin.", "question": "Treatment.Freq in 1 month after a single dose of ivermectin", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16682062_3_9528", "context": "We report the case of a 20-year-old woman originally from Cameroon who was infected by the L. loa parasite and developed severe hepatitis, identified 1 month after a single dose of ivermectin.", "question": "Treatment.Route in 1 month after a single dose of ivermectin", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16682062_3_9529", "context": "We report the case of a 20-year-old woman originally from Cameroon who was infected by the L. loa parasite and developed severe hepatitis, identified 1 month after a single dose of ivermectin.", "question": "Treatment.Time_elapsed in 1 month after a single dose of ivermectin", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "1 month"}, {"id": "16682062_3_9530", "context": "We report the case of a 20-year-old woman originally from Cameroon who was infected by the L. loa parasite and developed severe hepatitis, identified 1 month after a single dose of ivermectin.", "question": "Treatment.Duration in 1 month after a single dose of ivermectin", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16682062_3_9531", "context": "We report the case of a 20-year-old woman originally from Cameroon who was infected by the L. loa parasite and developed severe hepatitis, identified 1 month after a single dose of ivermectin.", "question": "Treatment.Disorder in 1 month after a single dose of ivermectin", "question_type": "Adverse_event.Treatment.Disorder", "answers": "infected by the L. loa parasite"}, {"id": "16682062_3_9532", "context": "We report the case of a 20-year-old woman originally from Cameroon who was infected by the L. loa parasite and developed severe hepatitis, identified 1 month after a single dose of ivermectin.", "question": "Combination.Drug in 1 month after a single dose of ivermectin", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8739289_5_9533", "context": "To the best of our knowledge, this is the first case of lithium-associated CDI and NDI presenting concurrently.", "question": "Treatment.Drug in lithium", "question_type": "Adverse_event.Treatment.Drug", "answers": "lithium"}, {"id": "8739289_5_9534", "context": "To the best of our knowledge, this is the first case of lithium-associated CDI and NDI presenting concurrently.", "question": "Treatment.Dosage in lithium", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8739289_5_9535", "context": "To the best of our knowledge, this is the first case of lithium-associated CDI and NDI presenting concurrently.", "question": "Treatment.Freq in lithium", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8739289_5_9536", "context": "To the best of our knowledge, this is the first case of lithium-associated CDI and NDI presenting concurrently.", "question": "Treatment.Route in lithium", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8739289_5_9537", "context": "To the best of our knowledge, this is the first case of lithium-associated CDI and NDI presenting concurrently.", "question": "Treatment.Time_elapsed in lithium", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8739289_5_9538", "context": "To the best of our knowledge, this is the first case of lithium-associated CDI and NDI presenting concurrently.", "question": "Treatment.Duration in lithium", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8739289_5_9539", "context": "To the best of our knowledge, this is the first case of lithium-associated CDI and NDI presenting concurrently.", "question": "Treatment.Disorder in lithium", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8739289_5_9540", "context": "To the best of our knowledge, this is the first case of lithium-associated CDI and NDI presenting concurrently.", "question": "Combination.Drug in lithium", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11795358_2_9541", "context": "In this healthy population, the relative risk of developing endometrial carcinoma in the tamoxifen arm was 2.54, although when stratified by age, in women over 50, the risk grew to 4.01.", "question": "Subject.Age in healthy population", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "11795358_2_9542", "context": "In this healthy population, the relative risk of developing endometrial carcinoma in the tamoxifen arm was 2.54, although when stratified by age, in women over 50, the risk grew to 4.01.", "question": "Subject.Gender in healthy population", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "11795358_2_9543", "context": "In this healthy population, the relative risk of developing endometrial carcinoma in the tamoxifen arm was 2.54, although when stratified by age, in women over 50, the risk grew to 4.01.", "question": "Subject.Population in healthy population", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "11795358_2_9544", "context": "In this healthy population, the relative risk of developing endometrial carcinoma in the tamoxifen arm was 2.54, although when stratified by age, in women over 50, the risk grew to 4.01.", "question": "Subject.Race in healthy population", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "11795358_2_9545", "context": "In this healthy population, the relative risk of developing endometrial carcinoma in the tamoxifen arm was 2.54, although when stratified by age, in women over 50, the risk grew to 4.01.", "question": "Subject.Disorder in healthy population", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "11795358_2_9546", "context": "In this healthy population, the relative risk of developing endometrial carcinoma in the tamoxifen arm was 2.54, although when stratified by age, in women over 50, the risk grew to 4.01.", "question": "Treatment.Drug in tamoxifen", "question_type": "Adverse_event.Treatment.Drug", "answers": "tamoxifen"}, {"id": "11795358_2_9547", "context": "In this healthy population, the relative risk of developing endometrial carcinoma in the tamoxifen arm was 2.54, although when stratified by age, in women over 50, the risk grew to 4.01.", "question": "Treatment.Dosage in tamoxifen", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11795358_2_9548", "context": "In this healthy population, the relative risk of developing endometrial carcinoma in the tamoxifen arm was 2.54, although when stratified by age, in women over 50, the risk grew to 4.01.", "question": "Treatment.Freq in tamoxifen", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11795358_2_9549", "context": "In this healthy population, the relative risk of developing endometrial carcinoma in the tamoxifen arm was 2.54, although when stratified by age, in women over 50, the risk grew to 4.01.", "question": "Treatment.Route in tamoxifen", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11795358_2_9550", "context": "In this healthy population, the relative risk of developing endometrial carcinoma in the tamoxifen arm was 2.54, although when stratified by age, in women over 50, the risk grew to 4.01.", "question": "Treatment.Time_elapsed in tamoxifen", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11795358_2_9551", "context": "In this healthy population, the relative risk of developing endometrial carcinoma in the tamoxifen arm was 2.54, although when stratified by age, in women over 50, the risk grew to 4.01.", "question": "Treatment.Duration in tamoxifen", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11795358_2_9552", "context": "In this healthy population, the relative risk of developing endometrial carcinoma in the tamoxifen arm was 2.54, although when stratified by age, in women over 50, the risk grew to 4.01.", "question": "Treatment.Disorder in tamoxifen", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11795358_2_9553", "context": "In this healthy population, the relative risk of developing endometrial carcinoma in the tamoxifen arm was 2.54, although when stratified by age, in women over 50, the risk grew to 4.01.", "question": "Combination.Drug in tamoxifen", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7235792_4_9554", "context": "Paradoxical ventricular tachycardia and fibrillation after intravenous bretylium therapy.", "question": "Treatment.Drug in intravenous bretylium", "question_type": "Adverse_event.Treatment.Drug", "answers": "bretylium"}, {"id": "7235792_4_9555", "context": "Paradoxical ventricular tachycardia and fibrillation after intravenous bretylium therapy.", "question": "Treatment.Dosage in intravenous bretylium", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7235792_4_9556", "context": "Paradoxical ventricular tachycardia and fibrillation after intravenous bretylium therapy.", "question": "Treatment.Freq in intravenous bretylium", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7235792_4_9557", "context": "Paradoxical ventricular tachycardia and fibrillation after intravenous bretylium therapy.", "question": "Treatment.Route in intravenous bretylium", "question_type": "Adverse_event.Treatment.Route", "answers": "intravenous"}, {"id": "7235792_4_9558", "context": "Paradoxical ventricular tachycardia and fibrillation after intravenous bretylium therapy.", "question": "Treatment.Time_elapsed in intravenous bretylium", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7235792_4_9559", "context": "Paradoxical ventricular tachycardia and fibrillation after intravenous bretylium therapy.", "question": "Treatment.Duration in intravenous bretylium", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7235792_4_9560", "context": "Paradoxical ventricular tachycardia and fibrillation after intravenous bretylium therapy.", "question": "Treatment.Disorder in intravenous bretylium", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7235792_4_9561", "context": "Paradoxical ventricular tachycardia and fibrillation after intravenous bretylium therapy.", "question": "Combination.Drug in intravenous bretylium", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11978156_5_9562", "context": "OBJECTIVE: To describe a case of thrombocytopenia associated with the administration of lansoprazole.", "question": "Subject.Age in a case", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "11978156_5_9563", "context": "OBJECTIVE: To describe a case of thrombocytopenia associated with the administration of lansoprazole.", "question": "Subject.Gender in a case", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "11978156_5_9564", "context": "OBJECTIVE: To describe a case of thrombocytopenia associated with the administration of lansoprazole.", "question": "Subject.Population in a case", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "11978156_5_9565", "context": "OBJECTIVE: To describe a case of thrombocytopenia associated with the administration of lansoprazole.", "question": "Subject.Race in a case", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "11978156_5_9566", "context": "OBJECTIVE: To describe a case of thrombocytopenia associated with the administration of lansoprazole.", "question": "Subject.Disorder in a case", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "11978156_5_9567", "context": "OBJECTIVE: To describe a case of thrombocytopenia associated with the administration of lansoprazole.", "question": "Treatment.Drug in lansoprazole", "question_type": "Adverse_event.Treatment.Drug", "answers": "lansoprazole"}, {"id": "11978156_5_9568", "context": "OBJECTIVE: To describe a case of thrombocytopenia associated with the administration of lansoprazole.", "question": "Treatment.Dosage in lansoprazole", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11978156_5_9569", "context": "OBJECTIVE: To describe a case of thrombocytopenia associated with the administration of lansoprazole.", "question": "Treatment.Freq in lansoprazole", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11978156_5_9570", "context": "OBJECTIVE: To describe a case of thrombocytopenia associated with the administration of lansoprazole.", "question": "Treatment.Route in lansoprazole", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11978156_5_9571", "context": "OBJECTIVE: To describe a case of thrombocytopenia associated with the administration of lansoprazole.", "question": "Treatment.Time_elapsed in lansoprazole", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11978156_5_9572", "context": "OBJECTIVE: To describe a case of thrombocytopenia associated with the administration of lansoprazole.", "question": "Treatment.Duration in lansoprazole", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11978156_5_9573", "context": "OBJECTIVE: To describe a case of thrombocytopenia associated with the administration of lansoprazole.", "question": "Treatment.Disorder in lansoprazole", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11978156_5_9574", "context": "OBJECTIVE: To describe a case of thrombocytopenia associated with the administration of lansoprazole.", "question": "Combination.Drug in lansoprazole", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3115809_1_9575", "context": "A patient developed optic neuropathy while being treated with isoniazid and ethambutol.", "question": "Subject.Age in A patient", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "3115809_1_9576", "context": "A patient developed optic neuropathy while being treated with isoniazid and ethambutol.", "question": "Subject.Gender in A patient", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "3115809_1_9577", "context": "A patient developed optic neuropathy while being treated with isoniazid and ethambutol.", "question": "Subject.Population in A patient", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "3115809_1_9578", "context": "A patient developed optic neuropathy while being treated with isoniazid and ethambutol.", "question": "Subject.Race in A patient", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "3115809_1_9579", "context": "A patient developed optic neuropathy while being treated with isoniazid and ethambutol.", "question": "Subject.Disorder in A patient", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "3115809_1_9580", "context": "A patient developed optic neuropathy while being treated with isoniazid and ethambutol.", "question": "Treatment.Drug in isoniazid and ethambutol", "question_type": "Adverse_event.Treatment.Drug", "answers": "isoniazid; ethambutol"}, {"id": "3115809_1_9581", "context": "A patient developed optic neuropathy while being treated with isoniazid and ethambutol.", "question": "Treatment.Dosage in isoniazid and ethambutol", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3115809_1_9582", "context": "A patient developed optic neuropathy while being treated with isoniazid and ethambutol.", "question": "Treatment.Freq in isoniazid and ethambutol", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3115809_1_9583", "context": "A patient developed optic neuropathy while being treated with isoniazid and ethambutol.", "question": "Treatment.Route in isoniazid and ethambutol", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3115809_1_9584", "context": "A patient developed optic neuropathy while being treated with isoniazid and ethambutol.", "question": "Treatment.Time_elapsed in isoniazid and ethambutol", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3115809_1_9585", "context": "A patient developed optic neuropathy while being treated with isoniazid and ethambutol.", "question": "Treatment.Duration in isoniazid and ethambutol", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3115809_1_9586", "context": "A patient developed optic neuropathy while being treated with isoniazid and ethambutol.", "question": "Treatment.Disorder in isoniazid and ethambutol", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3115809_1_9587", "context": "A patient developed optic neuropathy while being treated with isoniazid and ethambutol.", "question": "Combination.Drug in isoniazid and ethambutol", "question_type": "Adverse_event.Combination.Drug", "answers": "isoniazid; ethambutol"}, {"id": "18622319_3_9588", "context": "This case describes a 52-year-old white woman who developed a spontaneous nasal septal perforation after given the antiangiogenic drug, bevacizumab, for metastatic ovarian cancer treatment.", "question": "Subject.Age in a 52-year-old white woman", "question_type": "Adverse_event.Subject.Age", "answers": "52-year-old"}, {"id": "18622319_3_9589", "context": "This case describes a 52-year-old white woman who developed a spontaneous nasal septal perforation after given the antiangiogenic drug, bevacizumab, for metastatic ovarian cancer treatment.", "question": "Subject.Gender in a 52-year-old white woman", "question_type": "Adverse_event.Subject.Gender", "answers": "woman"}, {"id": "18622319_3_9590", "context": "This case describes a 52-year-old white woman who developed a spontaneous nasal septal perforation after given the antiangiogenic drug, bevacizumab, for metastatic ovarian cancer treatment.", "question": "Subject.Population in a 52-year-old white woman", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "18622319_3_9591", "context": "This case describes a 52-year-old white woman who developed a spontaneous nasal septal perforation after given the antiangiogenic drug, bevacizumab, for metastatic ovarian cancer treatment.", "question": "Subject.Race in a 52-year-old white woman", "question_type": "Adverse_event.Subject.Race", "answers": "white"}, {"id": "18622319_3_9592", "context": "This case describes a 52-year-old white woman who developed a spontaneous nasal septal perforation after given the antiangiogenic drug, bevacizumab, for metastatic ovarian cancer treatment.", "question": "Subject.Disorder in a 52-year-old white woman", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "18622319_3_9593", "context": "This case describes a 52-year-old white woman who developed a spontaneous nasal septal perforation after given the antiangiogenic drug, bevacizumab, for metastatic ovarian cancer treatment.", "question": "Treatment.Drug in antiangiogenic drug, bevacizumab", "question_type": "Adverse_event.Treatment.Drug", "answers": "bevacizumab"}, {"id": "18622319_3_9594", "context": "This case describes a 52-year-old white woman who developed a spontaneous nasal septal perforation after given the antiangiogenic drug, bevacizumab, for metastatic ovarian cancer treatment.", "question": "Treatment.Dosage in antiangiogenic drug, bevacizumab", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18622319_3_9595", "context": "This case describes a 52-year-old white woman who developed a spontaneous nasal septal perforation after given the antiangiogenic drug, bevacizumab, for metastatic ovarian cancer treatment.", "question": "Treatment.Freq in antiangiogenic drug, bevacizumab", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18622319_3_9596", "context": "This case describes a 52-year-old white woman who developed a spontaneous nasal septal perforation after given the antiangiogenic drug, bevacizumab, for metastatic ovarian cancer treatment.", "question": "Treatment.Route in antiangiogenic drug, bevacizumab", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18622319_3_9597", "context": "This case describes a 52-year-old white woman who developed a spontaneous nasal septal perforation after given the antiangiogenic drug, bevacizumab, for metastatic ovarian cancer treatment.", "question": "Treatment.Time_elapsed in antiangiogenic drug, bevacizumab", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18622319_3_9598", "context": "This case describes a 52-year-old white woman who developed a spontaneous nasal septal perforation after given the antiangiogenic drug, bevacizumab, for metastatic ovarian cancer treatment.", "question": "Treatment.Duration in antiangiogenic drug, bevacizumab", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18622319_3_9599", "context": "This case describes a 52-year-old white woman who developed a spontaneous nasal septal perforation after given the antiangiogenic drug, bevacizumab, for metastatic ovarian cancer treatment.", "question": "Treatment.Disorder in antiangiogenic drug, bevacizumab", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18622319_3_9600", "context": "This case describes a 52-year-old white woman who developed a spontaneous nasal septal perforation after given the antiangiogenic drug, bevacizumab, for metastatic ovarian cancer treatment.", "question": "Combination.Drug in antiangiogenic drug, bevacizumab", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "2104570_5_9601", "context": "Two cases are reported of patients who developed a hematologic malignancy several years after intravesical chemotherapy of superficial bladder cancer with etoglucid, doxorubicin, and mitomycin C.", "question": "Subject.Age in Two cases are reported of patients", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "2104570_5_9602", "context": "Two cases are reported of patients who developed a hematologic malignancy several years after intravesical chemotherapy of superficial bladder cancer with etoglucid, doxorubicin, and mitomycin C.", "question": "Subject.Gender in Two cases are reported of patients", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "2104570_5_9603", "context": "Two cases are reported of patients who developed a hematologic malignancy several years after intravesical chemotherapy of superficial bladder cancer with etoglucid, doxorubicin, and mitomycin C.", "question": "Subject.Population in Two cases are reported of patients", "question_type": "Adverse_event.Subject.Population", "answers": "Two"}, {"id": "2104570_5_9604", "context": "Two cases are reported of patients who developed a hematologic malignancy several years after intravesical chemotherapy of superficial bladder cancer with etoglucid, doxorubicin, and mitomycin C.", "question": "Subject.Race in Two cases are reported of patients", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "2104570_5_9605", "context": "Two cases are reported of patients who developed a hematologic malignancy several years after intravesical chemotherapy of superficial bladder cancer with etoglucid, doxorubicin, and mitomycin C.", "question": "Subject.Disorder in Two cases are reported of patients", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "2104570_5_9606", "context": "Two cases are reported of patients who developed a hematologic malignancy several years after intravesical chemotherapy of superficial bladder cancer with etoglucid, doxorubicin, and mitomycin C.", "question": "Treatment.Drug in etoglucid, doxorubicin, and mitomycin C; several years after intravesical chemotherapy of superficial bladder cancer with etoglucid, doxorubicin, and mitomycin C", "question_type": "Adverse_event.Treatment.Drug", "answers": "etoglucid; doxorubicin; mitomycin C"}, {"id": "2104570_5_9607", "context": "Two cases are reported of patients who developed a hematologic malignancy several years after intravesical chemotherapy of superficial bladder cancer with etoglucid, doxorubicin, and mitomycin C.", "question": "Treatment.Dosage in etoglucid, doxorubicin, and mitomycin C; several years after intravesical chemotherapy of superficial bladder cancer with etoglucid, doxorubicin, and mitomycin C", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "2104570_5_9608", "context": "Two cases are reported of patients who developed a hematologic malignancy several years after intravesical chemotherapy of superficial bladder cancer with etoglucid, doxorubicin, and mitomycin C.", "question": "Treatment.Freq in etoglucid, doxorubicin, and mitomycin C; several years after intravesical chemotherapy of superficial bladder cancer with etoglucid, doxorubicin, and mitomycin C", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2104570_5_9609", "context": "Two cases are reported of patients who developed a hematologic malignancy several years after intravesical chemotherapy of superficial bladder cancer with etoglucid, doxorubicin, and mitomycin C.", "question": "Treatment.Route in etoglucid, doxorubicin, and mitomycin C; several years after intravesical chemotherapy of superficial bladder cancer with etoglucid, doxorubicin, and mitomycin C", "question_type": "Adverse_event.Treatment.Route", "answers": "intravesical chemotherapy"}, {"id": "2104570_5_9610", "context": "Two cases are reported of patients who developed a hematologic malignancy several years after intravesical chemotherapy of superficial bladder cancer with etoglucid, doxorubicin, and mitomycin C.", "question": "Treatment.Time_elapsed in etoglucid, doxorubicin, and mitomycin C; several years after intravesical chemotherapy of superficial bladder cancer with etoglucid, doxorubicin, and mitomycin C", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2104570_5_9611", "context": "Two cases are reported of patients who developed a hematologic malignancy several years after intravesical chemotherapy of superficial bladder cancer with etoglucid, doxorubicin, and mitomycin C.", "question": "Treatment.Duration in etoglucid, doxorubicin, and mitomycin C; several years after intravesical chemotherapy of superficial bladder cancer with etoglucid, doxorubicin, and mitomycin C", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2104570_5_9612", "context": "Two cases are reported of patients who developed a hematologic malignancy several years after intravesical chemotherapy of superficial bladder cancer with etoglucid, doxorubicin, and mitomycin C.", "question": "Treatment.Disorder in etoglucid, doxorubicin, and mitomycin C; several years after intravesical chemotherapy of superficial bladder cancer with etoglucid, doxorubicin, and mitomycin C", "question_type": "Adverse_event.Treatment.Disorder", "answers": "superficial bladder cancer"}, {"id": "2104570_5_9613", "context": "Two cases are reported of patients who developed a hematologic malignancy several years after intravesical chemotherapy of superficial bladder cancer with etoglucid, doxorubicin, and mitomycin C.", "question": "Combination.Drug in etoglucid, doxorubicin, and mitomycin C; several years after intravesical chemotherapy of superficial bladder cancer with etoglucid, doxorubicin, and mitomycin C", "question_type": "Adverse_event.Combination.Drug", "answers": "mitomycin C; doxorubicin; etoglucid"}, {"id": "17937473_1_9614", "context": "Eleven patients developed infection requiring hospitalization while taking leflunomide including: lower respiratory tract infections (3), cellulitis (2), disseminated herpes zoster (2), probable TB liver (1), abdominal sepsis (1), mycotic aneurysm (1) and gastroenteritis (1).", "question": "Subject.Age in Eleven patients", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "17937473_1_9615", "context": "Eleven patients developed infection requiring hospitalization while taking leflunomide including: lower respiratory tract infections (3), cellulitis (2), disseminated herpes zoster (2), probable TB liver (1), abdominal sepsis (1), mycotic aneurysm (1) and gastroenteritis (1).", "question": "Subject.Gender in Eleven patients", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "17937473_1_9616", "context": "Eleven patients developed infection requiring hospitalization while taking leflunomide including: lower respiratory tract infections (3), cellulitis (2), disseminated herpes zoster (2), probable TB liver (1), abdominal sepsis (1), mycotic aneurysm (1) and gastroenteritis (1).", "question": "Subject.Population in Eleven patients", "question_type": "Adverse_event.Subject.Population", "answers": "Eleven"}, {"id": "17937473_1_9617", "context": "Eleven patients developed infection requiring hospitalization while taking leflunomide including: lower respiratory tract infections (3), cellulitis (2), disseminated herpes zoster (2), probable TB liver (1), abdominal sepsis (1), mycotic aneurysm (1) and gastroenteritis (1).", "question": "Subject.Race in Eleven patients", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "17937473_1_9618", "context": "Eleven patients developed infection requiring hospitalization while taking leflunomide including: lower respiratory tract infections (3), cellulitis (2), disseminated herpes zoster (2), probable TB liver (1), abdominal sepsis (1), mycotic aneurysm (1) and gastroenteritis (1).", "question": "Subject.Disorder in Eleven patients", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "17937473_1_9619", "context": "Eleven patients developed infection requiring hospitalization while taking leflunomide including: lower respiratory tract infections (3), cellulitis (2), disseminated herpes zoster (2), probable TB liver (1), abdominal sepsis (1), mycotic aneurysm (1) and gastroenteritis (1).", "question": "Treatment.Drug in leflunomide", "question_type": "Adverse_event.Treatment.Drug", "answers": "leflunomide"}, {"id": "17937473_1_9620", "context": "Eleven patients developed infection requiring hospitalization while taking leflunomide including: lower respiratory tract infections (3), cellulitis (2), disseminated herpes zoster (2), probable TB liver (1), abdominal sepsis (1), mycotic aneurysm (1) and gastroenteritis (1).", "question": "Treatment.Dosage in leflunomide", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17937473_1_9621", "context": "Eleven patients developed infection requiring hospitalization while taking leflunomide including: lower respiratory tract infections (3), cellulitis (2), disseminated herpes zoster (2), probable TB liver (1), abdominal sepsis (1), mycotic aneurysm (1) and gastroenteritis (1).", "question": "Treatment.Freq in leflunomide", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17937473_1_9622", "context": "Eleven patients developed infection requiring hospitalization while taking leflunomide including: lower respiratory tract infections (3), cellulitis (2), disseminated herpes zoster (2), probable TB liver (1), abdominal sepsis (1), mycotic aneurysm (1) and gastroenteritis (1).", "question": "Treatment.Route in leflunomide", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17937473_1_9623", "context": "Eleven patients developed infection requiring hospitalization while taking leflunomide including: lower respiratory tract infections (3), cellulitis (2), disseminated herpes zoster (2), probable TB liver (1), abdominal sepsis (1), mycotic aneurysm (1) and gastroenteritis (1).", "question": "Treatment.Time_elapsed in leflunomide", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17937473_1_9624", "context": "Eleven patients developed infection requiring hospitalization while taking leflunomide including: lower respiratory tract infections (3), cellulitis (2), disseminated herpes zoster (2), probable TB liver (1), abdominal sepsis (1), mycotic aneurysm (1) and gastroenteritis (1).", "question": "Treatment.Duration in leflunomide", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17937473_1_9625", "context": "Eleven patients developed infection requiring hospitalization while taking leflunomide including: lower respiratory tract infections (3), cellulitis (2), disseminated herpes zoster (2), probable TB liver (1), abdominal sepsis (1), mycotic aneurysm (1) and gastroenteritis (1).", "question": "Treatment.Disorder in leflunomide", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17937473_1_9626", "context": "Eleven patients developed infection requiring hospitalization while taking leflunomide including: lower respiratory tract infections (3), cellulitis (2), disseminated herpes zoster (2), probable TB liver (1), abdominal sepsis (1), mycotic aneurysm (1) and gastroenteritis (1).", "question": "Combination.Drug in leflunomide", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11247558_2_9627", "context": "Symptoms and endoscopic lesions quickly regressed within 1 week of meloxicam withdrawal.", "question": "Treatment.Drug in within 1 week of meloxicam withdrawal", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "meloxicam"}, {"id": "11247558_2_9628", "context": "Symptoms and endoscopic lesions quickly regressed within 1 week of meloxicam withdrawal.", "question": "Treatment.Dosage in within 1 week of meloxicam withdrawal", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "11247558_2_9629", "context": "Symptoms and endoscopic lesions quickly regressed within 1 week of meloxicam withdrawal.", "question": "Treatment.Freq in within 1 week of meloxicam withdrawal", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "11247558_2_9630", "context": "Symptoms and endoscopic lesions quickly regressed within 1 week of meloxicam withdrawal.", "question": "Treatment.Route in within 1 week of meloxicam withdrawal", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "11247558_2_9631", "context": "Symptoms and endoscopic lesions quickly regressed within 1 week of meloxicam withdrawal.", "question": "Treatment.Time_elapsed in within 1 week of meloxicam withdrawal", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": "1 week"}, {"id": "11247558_2_9632", "context": "Symptoms and endoscopic lesions quickly regressed within 1 week of meloxicam withdrawal.", "question": "Treatment.Duration in within 1 week of meloxicam withdrawal", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "11247558_2_9633", "context": "Symptoms and endoscopic lesions quickly regressed within 1 week of meloxicam withdrawal.", "question": "Treatment.Disorder in within 1 week of meloxicam withdrawal", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "Symptoms and endoscopic lesions"}, {"id": "11247558_2_9634", "context": "Symptoms and endoscopic lesions quickly regressed within 1 week of meloxicam withdrawal.", "question": "Combination.Drug in within 1 week of meloxicam withdrawal", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "14712320_1_9635", "context": "Potential drug interaction between simvastatin and danazol causing rhabdomyolysis.", "question": "Treatment.Drug in drug interaction between simvastatin and danazol", "question_type": "Adverse_event.Treatment.Drug", "answers": "simvastatin; danazol"}, {"id": "14712320_1_9636", "context": "Potential drug interaction between simvastatin and danazol causing rhabdomyolysis.", "question": "Treatment.Dosage in drug interaction between simvastatin and danazol", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "14712320_1_9637", "context": "Potential drug interaction between simvastatin and danazol causing rhabdomyolysis.", "question": "Treatment.Freq in drug interaction between simvastatin and danazol", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "14712320_1_9638", "context": "Potential drug interaction between simvastatin and danazol causing rhabdomyolysis.", "question": "Treatment.Route in drug interaction between simvastatin and danazol", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "14712320_1_9639", "context": "Potential drug interaction between simvastatin and danazol causing rhabdomyolysis.", "question": "Treatment.Time_elapsed in drug interaction between simvastatin and danazol", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "14712320_1_9640", "context": "Potential drug interaction between simvastatin and danazol causing rhabdomyolysis.", "question": "Treatment.Duration in drug interaction between simvastatin and danazol", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "14712320_1_9641", "context": "Potential drug interaction between simvastatin and danazol causing rhabdomyolysis.", "question": "Treatment.Disorder in drug interaction between simvastatin and danazol", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "14712320_1_9642", "context": "Potential drug interaction between simvastatin and danazol causing rhabdomyolysis.", "question": "Combination.Drug in drug interaction between simvastatin and danazol", "question_type": "Adverse_event.Combination.Drug", "answers": "simvastatin; danazol"}, {"id": "1450506_2_9643", "context": "Multiple myeloma complicated by congestive heart failure following first administration of recombinant alpha-interferon.", "question": "Treatment.Drug in first administration of recombinant alpha-interferon", "question_type": "Adverse_event.Treatment.Drug", "answers": "recombinant alpha-interferon"}, {"id": "1450506_2_9644", "context": "Multiple myeloma complicated by congestive heart failure following first administration of recombinant alpha-interferon.", "question": "Treatment.Dosage in first administration of recombinant alpha-interferon", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "1450506_2_9645", "context": "Multiple myeloma complicated by congestive heart failure following first administration of recombinant alpha-interferon.", "question": "Treatment.Freq in first administration of recombinant alpha-interferon", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "1450506_2_9646", "context": "Multiple myeloma complicated by congestive heart failure following first administration of recombinant alpha-interferon.", "question": "Treatment.Route in first administration of recombinant alpha-interferon", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "1450506_2_9647", "context": "Multiple myeloma complicated by congestive heart failure following first administration of recombinant alpha-interferon.", "question": "Treatment.Time_elapsed in first administration of recombinant alpha-interferon", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "1450506_2_9648", "context": "Multiple myeloma complicated by congestive heart failure following first administration of recombinant alpha-interferon.", "question": "Treatment.Duration in first administration of recombinant alpha-interferon", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "1450506_2_9649", "context": "Multiple myeloma complicated by congestive heart failure following first administration of recombinant alpha-interferon.", "question": "Treatment.Disorder in first administration of recombinant alpha-interferon", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "1450506_2_9650", "context": "Multiple myeloma complicated by congestive heart failure following first administration of recombinant alpha-interferon.", "question": "Combination.Drug in first administration of recombinant alpha-interferon", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15823103_1_9651", "context": "Carboplatin hypersensitivity induced by low-dose paclitaxel/carboplatin in multiple platinum-treated patients with recurrent ovarian cancer.", "question": "Subject.Age in multiple platinum-treated patients with recurrent ovarian cancer", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "15823103_1_9652", "context": "Carboplatin hypersensitivity induced by low-dose paclitaxel/carboplatin in multiple platinum-treated patients with recurrent ovarian cancer.", "question": "Subject.Gender in multiple platinum-treated patients with recurrent ovarian cancer", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15823103_1_9653", "context": "Carboplatin hypersensitivity induced by low-dose paclitaxel/carboplatin in multiple platinum-treated patients with recurrent ovarian cancer.", "question": "Subject.Population in multiple platinum-treated patients with recurrent ovarian cancer", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "15823103_1_9654", "context": "Carboplatin hypersensitivity induced by low-dose paclitaxel/carboplatin in multiple platinum-treated patients with recurrent ovarian cancer.", "question": "Subject.Race in multiple platinum-treated patients with recurrent ovarian cancer", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15823103_1_9655", "context": "Carboplatin hypersensitivity induced by low-dose paclitaxel/carboplatin in multiple platinum-treated patients with recurrent ovarian cancer.", "question": "Subject.Disorder in multiple platinum-treated patients with recurrent ovarian cancer", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15823103_1_9656", "context": "Carboplatin hypersensitivity induced by low-dose paclitaxel/carboplatin in multiple platinum-treated patients with recurrent ovarian cancer.", "question": "Treatment.Drug in low-dose paclitaxel/carboplatin", "question_type": "Adverse_event.Treatment.Drug", "answers": "paclitaxel; carboplatin; platinum"}, {"id": "15823103_1_9657", "context": "Carboplatin hypersensitivity induced by low-dose paclitaxel/carboplatin in multiple platinum-treated patients with recurrent ovarian cancer.", "question": "Treatment.Dosage in low-dose paclitaxel/carboplatin", "question_type": "Adverse_event.Treatment.Dosage", "answers": "low-dose"}, {"id": "15823103_1_9658", "context": "Carboplatin hypersensitivity induced by low-dose paclitaxel/carboplatin in multiple platinum-treated patients with recurrent ovarian cancer.", "question": "Treatment.Freq in low-dose paclitaxel/carboplatin", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15823103_1_9659", "context": "Carboplatin hypersensitivity induced by low-dose paclitaxel/carboplatin in multiple platinum-treated patients with recurrent ovarian cancer.", "question": "Treatment.Route in low-dose paclitaxel/carboplatin", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15823103_1_9660", "context": "Carboplatin hypersensitivity induced by low-dose paclitaxel/carboplatin in multiple platinum-treated patients with recurrent ovarian cancer.", "question": "Treatment.Time_elapsed in low-dose paclitaxel/carboplatin", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15823103_1_9661", "context": "Carboplatin hypersensitivity induced by low-dose paclitaxel/carboplatin in multiple platinum-treated patients with recurrent ovarian cancer.", "question": "Treatment.Duration in low-dose paclitaxel/carboplatin", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15823103_1_9662", "context": "Carboplatin hypersensitivity induced by low-dose paclitaxel/carboplatin in multiple platinum-treated patients with recurrent ovarian cancer.", "question": "Treatment.Disorder in low-dose paclitaxel/carboplatin", "question_type": "Adverse_event.Treatment.Disorder", "answers": "recurrent ovarian cancer"}, {"id": "15823103_1_9663", "context": "Carboplatin hypersensitivity induced by low-dose paclitaxel/carboplatin in multiple platinum-treated patients with recurrent ovarian cancer.", "question": "Combination.Drug in low-dose paclitaxel/carboplatin", "question_type": "Adverse_event.Combination.Drug", "answers": "paclitaxel; carboplatin"}, {"id": "2104570_2_9664", "context": "Two cases are reported of patients who developed a hematologic malignancy several years after intravesical chemotherapy of superficial bladder cancer with etoglucid, doxorubicin, and mitomycin C.", "question": "Subject.Age in patients", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "2104570_2_9665", "context": "Two cases are reported of patients who developed a hematologic malignancy several years after intravesical chemotherapy of superficial bladder cancer with etoglucid, doxorubicin, and mitomycin C.", "question": "Subject.Gender in patients", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "2104570_2_9666", "context": "Two cases are reported of patients who developed a hematologic malignancy several years after intravesical chemotherapy of superficial bladder cancer with etoglucid, doxorubicin, and mitomycin C.", "question": "Subject.Population in patients", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "2104570_2_9667", "context": "Two cases are reported of patients who developed a hematologic malignancy several years after intravesical chemotherapy of superficial bladder cancer with etoglucid, doxorubicin, and mitomycin C.", "question": "Subject.Race in patients", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "2104570_2_9668", "context": "Two cases are reported of patients who developed a hematologic malignancy several years after intravesical chemotherapy of superficial bladder cancer with etoglucid, doxorubicin, and mitomycin C.", "question": "Subject.Disorder in patients", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "2104570_2_9669", "context": "Two cases are reported of patients who developed a hematologic malignancy several years after intravesical chemotherapy of superficial bladder cancer with etoglucid, doxorubicin, and mitomycin C.", "question": "Treatment.Drug in several years after intravesical chemotherapy; with etoglucid, doxorubicin, and mitomycin C", "question_type": "Adverse_event.Treatment.Drug", "answers": "etoglucid; doxorubicin; mitomycin C"}, {"id": "2104570_2_9670", "context": "Two cases are reported of patients who developed a hematologic malignancy several years after intravesical chemotherapy of superficial bladder cancer with etoglucid, doxorubicin, and mitomycin C.", "question": "Treatment.Dosage in several years after intravesical chemotherapy; with etoglucid, doxorubicin, and mitomycin C", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "2104570_2_9671", "context": "Two cases are reported of patients who developed a hematologic malignancy several years after intravesical chemotherapy of superficial bladder cancer with etoglucid, doxorubicin, and mitomycin C.", "question": "Treatment.Freq in several years after intravesical chemotherapy; with etoglucid, doxorubicin, and mitomycin C", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2104570_2_9672", "context": "Two cases are reported of patients who developed a hematologic malignancy several years after intravesical chemotherapy of superficial bladder cancer with etoglucid, doxorubicin, and mitomycin C.", "question": "Treatment.Route in several years after intravesical chemotherapy; with etoglucid, doxorubicin, and mitomycin C", "question_type": "Adverse_event.Treatment.Route", "answers": "intravesical"}, {"id": "2104570_2_9673", "context": "Two cases are reported of patients who developed a hematologic malignancy several years after intravesical chemotherapy of superficial bladder cancer with etoglucid, doxorubicin, and mitomycin C.", "question": "Treatment.Time_elapsed in several years after intravesical chemotherapy; with etoglucid, doxorubicin, and mitomycin C", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "several years after"}, {"id": "2104570_2_9674", "context": "Two cases are reported of patients who developed a hematologic malignancy several years after intravesical chemotherapy of superficial bladder cancer with etoglucid, doxorubicin, and mitomycin C.", "question": "Treatment.Duration in several years after intravesical chemotherapy; with etoglucid, doxorubicin, and mitomycin C", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2104570_2_9675", "context": "Two cases are reported of patients who developed a hematologic malignancy several years after intravesical chemotherapy of superficial bladder cancer with etoglucid, doxorubicin, and mitomycin C.", "question": "Treatment.Disorder in several years after intravesical chemotherapy; with etoglucid, doxorubicin, and mitomycin C", "question_type": "Adverse_event.Treatment.Disorder", "answers": "superficial bladder cancer"}, {"id": "2104570_2_9676", "context": "Two cases are reported of patients who developed a hematologic malignancy several years after intravesical chemotherapy of superficial bladder cancer with etoglucid, doxorubicin, and mitomycin C.", "question": "Combination.Drug in several years after intravesical chemotherapy; with etoglucid, doxorubicin, and mitomycin C", "question_type": "Adverse_event.Combination.Drug", "answers": "mitomycin C; doxorubicin; etoglucid"}, {"id": "11573852_2_9677", "context": "CASE SUMMARY: A 46-year-old African-American man experienced recurrent grand mal seizures during intravenous infusion of amphotericin B, then petit mal seizures as the infusion was stopped and the drug concentrations decreased with time.", "question": "Subject.Age in A 46-year-old African-American man", "question_type": "Adverse_event.Subject.Age", "answers": "46-year-old"}, {"id": "11573852_2_9678", "context": "CASE SUMMARY: A 46-year-old African-American man experienced recurrent grand mal seizures during intravenous infusion of amphotericin B, then petit mal seizures as the infusion was stopped and the drug concentrations decreased with time.", "question": "Subject.Gender in A 46-year-old African-American man", "question_type": "Adverse_event.Subject.Gender", "answers": "man"}, {"id": "11573852_2_9679", "context": "CASE SUMMARY: A 46-year-old African-American man experienced recurrent grand mal seizures during intravenous infusion of amphotericin B, then petit mal seizures as the infusion was stopped and the drug concentrations decreased with time.", "question": "Subject.Population in A 46-year-old African-American man", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "11573852_2_9680", "context": "CASE SUMMARY: A 46-year-old African-American man experienced recurrent grand mal seizures during intravenous infusion of amphotericin B, then petit mal seizures as the infusion was stopped and the drug concentrations decreased with time.", "question": "Subject.Race in A 46-year-old African-American man", "question_type": "Adverse_event.Subject.Race", "answers": "African-American"}, {"id": "11573852_2_9681", "context": "CASE SUMMARY: A 46-year-old African-American man experienced recurrent grand mal seizures during intravenous infusion of amphotericin B, then petit mal seizures as the infusion was stopped and the drug concentrations decreased with time.", "question": "Subject.Disorder in A 46-year-old African-American man", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "11573852_2_9682", "context": "CASE SUMMARY: A 46-year-old African-American man experienced recurrent grand mal seizures during intravenous infusion of amphotericin B, then petit mal seizures as the infusion was stopped and the drug concentrations decreased with time.", "question": "Treatment.Drug in intravenous infusion of amphotericin B", "question_type": "Adverse_event.Treatment.Drug", "answers": "amphotericin B"}, {"id": "11573852_2_9683", "context": "CASE SUMMARY: A 46-year-old African-American man experienced recurrent grand mal seizures during intravenous infusion of amphotericin B, then petit mal seizures as the infusion was stopped and the drug concentrations decreased with time.", "question": "Treatment.Dosage in intravenous infusion of amphotericin B", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11573852_2_9684", "context": "CASE SUMMARY: A 46-year-old African-American man experienced recurrent grand mal seizures during intravenous infusion of amphotericin B, then petit mal seizures as the infusion was stopped and the drug concentrations decreased with time.", "question": "Treatment.Freq in intravenous infusion of amphotericin B", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11573852_2_9685", "context": "CASE SUMMARY: A 46-year-old African-American man experienced recurrent grand mal seizures during intravenous infusion of amphotericin B, then petit mal seizures as the infusion was stopped and the drug concentrations decreased with time.", "question": "Treatment.Route in intravenous infusion of amphotericin B", "question_type": "Adverse_event.Treatment.Route", "answers": "intravenous infusion"}, {"id": "11573852_2_9686", "context": "CASE SUMMARY: A 46-year-old African-American man experienced recurrent grand mal seizures during intravenous infusion of amphotericin B, then petit mal seizures as the infusion was stopped and the drug concentrations decreased with time.", "question": "Treatment.Time_elapsed in intravenous infusion of amphotericin B", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11573852_2_9687", "context": "CASE SUMMARY: A 46-year-old African-American man experienced recurrent grand mal seizures during intravenous infusion of amphotericin B, then petit mal seizures as the infusion was stopped and the drug concentrations decreased with time.", "question": "Treatment.Duration in intravenous infusion of amphotericin B", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11573852_2_9688", "context": "CASE SUMMARY: A 46-year-old African-American man experienced recurrent grand mal seizures during intravenous infusion of amphotericin B, then petit mal seizures as the infusion was stopped and the drug concentrations decreased with time.", "question": "Treatment.Disorder in intravenous infusion of amphotericin B", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11573852_2_9689", "context": "CASE SUMMARY: A 46-year-old African-American man experienced recurrent grand mal seizures during intravenous infusion of amphotericin B, then petit mal seizures as the infusion was stopped and the drug concentrations decreased with time.", "question": "Combination.Drug in intravenous infusion of amphotericin B", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16948177_2_9690", "context": "Moreover, these findings suggest that the incidence of BOOP following rituximab therapy may be higher than has been previously appreciated.", "question": "Treatment.Drug in rituximab therapy", "question_type": "Adverse_event.Treatment.Drug", "answers": "rituximab"}, {"id": "16948177_2_9691", "context": "Moreover, these findings suggest that the incidence of BOOP following rituximab therapy may be higher than has been previously appreciated.", "question": "Treatment.Dosage in rituximab therapy", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16948177_2_9692", "context": "Moreover, these findings suggest that the incidence of BOOP following rituximab therapy may be higher than has been previously appreciated.", "question": "Treatment.Freq in rituximab therapy", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16948177_2_9693", "context": "Moreover, these findings suggest that the incidence of BOOP following rituximab therapy may be higher than has been previously appreciated.", "question": "Treatment.Route in rituximab therapy", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16948177_2_9694", "context": "Moreover, these findings suggest that the incidence of BOOP following rituximab therapy may be higher than has been previously appreciated.", "question": "Treatment.Time_elapsed in rituximab therapy", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16948177_2_9695", "context": "Moreover, these findings suggest that the incidence of BOOP following rituximab therapy may be higher than has been previously appreciated.", "question": "Treatment.Duration in rituximab therapy", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16948177_2_9696", "context": "Moreover, these findings suggest that the incidence of BOOP following rituximab therapy may be higher than has been previously appreciated.", "question": "Treatment.Disorder in rituximab therapy", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16948177_2_9697", "context": "Moreover, these findings suggest that the incidence of BOOP following rituximab therapy may be higher than has been previously appreciated.", "question": "Combination.Drug in rituximab therapy", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "1624172_4_9698", "context": "Two cases of hypothyroidism in patients with chronic hepatitis C treated with recombinant alpha interferon are reported.", "question": "Subject.Age in Two cases", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "1624172_4_9699", "context": "Two cases of hypothyroidism in patients with chronic hepatitis C treated with recombinant alpha interferon are reported.", "question": "Subject.Gender in Two cases", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "1624172_4_9700", "context": "Two cases of hypothyroidism in patients with chronic hepatitis C treated with recombinant alpha interferon are reported.", "question": "Subject.Population in Two cases", "question_type": "Adverse_event.Subject.Population", "answers": "Two"}, {"id": "1624172_4_9701", "context": "Two cases of hypothyroidism in patients with chronic hepatitis C treated with recombinant alpha interferon are reported.", "question": "Subject.Race in Two cases", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "1624172_4_9702", "context": "Two cases of hypothyroidism in patients with chronic hepatitis C treated with recombinant alpha interferon are reported.", "question": "Subject.Disorder in Two cases", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "1624172_4_9703", "context": "Two cases of hypothyroidism in patients with chronic hepatitis C treated with recombinant alpha interferon are reported.", "question": "Treatment.Drug in recombinant alpha interferon", "question_type": "Adverse_event.Treatment.Drug", "answers": "recombinant alpha interferon"}, {"id": "1624172_4_9704", "context": "Two cases of hypothyroidism in patients with chronic hepatitis C treated with recombinant alpha interferon are reported.", "question": "Treatment.Dosage in recombinant alpha interferon", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "1624172_4_9705", "context": "Two cases of hypothyroidism in patients with chronic hepatitis C treated with recombinant alpha interferon are reported.", "question": "Treatment.Freq in recombinant alpha interferon", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "1624172_4_9706", "context": "Two cases of hypothyroidism in patients with chronic hepatitis C treated with recombinant alpha interferon are reported.", "question": "Treatment.Route in recombinant alpha interferon", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "1624172_4_9707", "context": "Two cases of hypothyroidism in patients with chronic hepatitis C treated with recombinant alpha interferon are reported.", "question": "Treatment.Time_elapsed in recombinant alpha interferon", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "1624172_4_9708", "context": "Two cases of hypothyroidism in patients with chronic hepatitis C treated with recombinant alpha interferon are reported.", "question": "Treatment.Duration in recombinant alpha interferon", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "1624172_4_9709", "context": "Two cases of hypothyroidism in patients with chronic hepatitis C treated with recombinant alpha interferon are reported.", "question": "Treatment.Disorder in recombinant alpha interferon", "question_type": "Adverse_event.Treatment.Disorder", "answers": "chronic hepatitis C"}, {"id": "1624172_4_9710", "context": "Two cases of hypothyroidism in patients with chronic hepatitis C treated with recombinant alpha interferon are reported.", "question": "Combination.Drug in recombinant alpha interferon", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15760792_2_9711", "context": "OBJECTIVE: To report the case of a young woman with Graves' disease in whom ototoxicity developed because of propylthiouracil (PTU)-induced antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis.", "question": "Subject.Age in young woman with Graves' disease", "question_type": "Adverse_event.Subject.Age", "answers": "young"}, {"id": "15760792_2_9712", "context": "OBJECTIVE: To report the case of a young woman with Graves' disease in whom ototoxicity developed because of propylthiouracil (PTU)-induced antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis.", "question": "Subject.Gender in young woman with Graves' disease", "question_type": "Adverse_event.Subject.Gender", "answers": "woman"}, {"id": "15760792_2_9713", "context": "OBJECTIVE: To report the case of a young woman with Graves' disease in whom ototoxicity developed because of propylthiouracil (PTU)-induced antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis.", "question": "Subject.Population in young woman with Graves' disease", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "15760792_2_9714", "context": "OBJECTIVE: To report the case of a young woman with Graves' disease in whom ototoxicity developed because of propylthiouracil (PTU)-induced antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis.", "question": "Subject.Race in young woman with Graves' disease", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15760792_2_9715", "context": "OBJECTIVE: To report the case of a young woman with Graves' disease in whom ototoxicity developed because of propylthiouracil (PTU)-induced antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis.", "question": "Subject.Disorder in young woman with Graves' disease", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15760792_2_9716", "context": "OBJECTIVE: To report the case of a young woman with Graves' disease in whom ototoxicity developed because of propylthiouracil (PTU)-induced antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis.", "question": "Treatment.Drug in propylthiouracil (PTU)", "question_type": "Adverse_event.Treatment.Drug", "answers": "propylthiouracil"}, {"id": "15760792_2_9717", "context": "OBJECTIVE: To report the case of a young woman with Graves' disease in whom ototoxicity developed because of propylthiouracil (PTU)-induced antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis.", "question": "Treatment.Dosage in propylthiouracil (PTU)", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15760792_2_9718", "context": "OBJECTIVE: To report the case of a young woman with Graves' disease in whom ototoxicity developed because of propylthiouracil (PTU)-induced antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis.", "question": "Treatment.Freq in propylthiouracil (PTU)", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15760792_2_9719", "context": "OBJECTIVE: To report the case of a young woman with Graves' disease in whom ototoxicity developed because of propylthiouracil (PTU)-induced antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis.", "question": "Treatment.Route in propylthiouracil (PTU)", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15760792_2_9720", "context": "OBJECTIVE: To report the case of a young woman with Graves' disease in whom ototoxicity developed because of propylthiouracil (PTU)-induced antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis.", "question": "Treatment.Time_elapsed in propylthiouracil (PTU)", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15760792_2_9721", "context": "OBJECTIVE: To report the case of a young woman with Graves' disease in whom ototoxicity developed because of propylthiouracil (PTU)-induced antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis.", "question": "Treatment.Duration in propylthiouracil (PTU)", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15760792_2_9722", "context": "OBJECTIVE: To report the case of a young woman with Graves' disease in whom ototoxicity developed because of propylthiouracil (PTU)-induced antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis.", "question": "Treatment.Disorder in propylthiouracil (PTU)", "question_type": "Adverse_event.Treatment.Disorder", "answers": "Graves' disease"}, {"id": "15760792_2_9723", "context": "OBJECTIVE: To report the case of a young woman with Graves' disease in whom ototoxicity developed because of propylthiouracil (PTU)-induced antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis.", "question": "Combination.Drug in propylthiouracil (PTU)", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11468878_2_9724", "context": "An obese patient, not diabetic, treated with metformin for some weeks, was referred to us with severe inferior digestive hemorrhage, diagnosed with Meckel's diverticulum.", "question": "Subject.Age in An obese patient, not diabetic", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "11468878_2_9725", "context": "An obese patient, not diabetic, treated with metformin for some weeks, was referred to us with severe inferior digestive hemorrhage, diagnosed with Meckel's diverticulum.", "question": "Subject.Gender in An obese patient, not diabetic", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "11468878_2_9726", "context": "An obese patient, not diabetic, treated with metformin for some weeks, was referred to us with severe inferior digestive hemorrhage, diagnosed with Meckel's diverticulum.", "question": "Subject.Population in An obese patient, not diabetic", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "11468878_2_9727", "context": "An obese patient, not diabetic, treated with metformin for some weeks, was referred to us with severe inferior digestive hemorrhage, diagnosed with Meckel's diverticulum.", "question": "Subject.Race in An obese patient, not diabetic", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "11468878_2_9728", "context": "An obese patient, not diabetic, treated with metformin for some weeks, was referred to us with severe inferior digestive hemorrhage, diagnosed with Meckel's diverticulum.", "question": "Subject.Disorder in An obese patient, not diabetic", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "11468878_2_9729", "context": "An obese patient, not diabetic, treated with metformin for some weeks, was referred to us with severe inferior digestive hemorrhage, diagnosed with Meckel's diverticulum.", "question": "Treatment.Drug in metformin for some weeks", "question_type": "Adverse_event.Treatment.Drug", "answers": "metformin"}, {"id": "11468878_2_9730", "context": "An obese patient, not diabetic, treated with metformin for some weeks, was referred to us with severe inferior digestive hemorrhage, diagnosed with Meckel's diverticulum.", "question": "Treatment.Dosage in metformin for some weeks", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11468878_2_9731", "context": "An obese patient, not diabetic, treated with metformin for some weeks, was referred to us with severe inferior digestive hemorrhage, diagnosed with Meckel's diverticulum.", "question": "Treatment.Freq in metformin for some weeks", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11468878_2_9732", "context": "An obese patient, not diabetic, treated with metformin for some weeks, was referred to us with severe inferior digestive hemorrhage, diagnosed with Meckel's diverticulum.", "question": "Treatment.Route in metformin for some weeks", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11468878_2_9733", "context": "An obese patient, not diabetic, treated with metformin for some weeks, was referred to us with severe inferior digestive hemorrhage, diagnosed with Meckel's diverticulum.", "question": "Treatment.Time_elapsed in metformin for some weeks", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11468878_2_9734", "context": "An obese patient, not diabetic, treated with metformin for some weeks, was referred to us with severe inferior digestive hemorrhage, diagnosed with Meckel's diverticulum.", "question": "Treatment.Duration in metformin for some weeks", "question_type": "Adverse_event.Treatment.Duration", "answers": "some weeks"}, {"id": "11468878_2_9735", "context": "An obese patient, not diabetic, treated with metformin for some weeks, was referred to us with severe inferior digestive hemorrhage, diagnosed with Meckel's diverticulum.", "question": "Treatment.Disorder in metformin for some weeks", "question_type": "Adverse_event.Treatment.Disorder", "answers": "obese"}, {"id": "11468878_2_9736", "context": "An obese patient, not diabetic, treated with metformin for some weeks, was referred to us with severe inferior digestive hemorrhage, diagnosed with Meckel's diverticulum.", "question": "Combination.Drug in metformin for some weeks", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "2690546_1_9737", "context": "Although a lot of amiodarone-induced torsades de pointe have been published, a review of all these cases and the underlying risk-factors has never been made.", "question": "Treatment.Drug in amiodarone", "question_type": "Adverse_event.Treatment.Drug", "answers": "amiodarone"}, {"id": "2690546_1_9738", "context": "Although a lot of amiodarone-induced torsades de pointe have been published, a review of all these cases and the underlying risk-factors has never been made.", "question": "Treatment.Dosage in amiodarone", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "2690546_1_9739", "context": "Although a lot of amiodarone-induced torsades de pointe have been published, a review of all these cases and the underlying risk-factors has never been made.", "question": "Treatment.Freq in amiodarone", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2690546_1_9740", "context": "Although a lot of amiodarone-induced torsades de pointe have been published, a review of all these cases and the underlying risk-factors has never been made.", "question": "Treatment.Route in amiodarone", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "2690546_1_9741", "context": "Although a lot of amiodarone-induced torsades de pointe have been published, a review of all these cases and the underlying risk-factors has never been made.", "question": "Treatment.Time_elapsed in amiodarone", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2690546_1_9742", "context": "Although a lot of amiodarone-induced torsades de pointe have been published, a review of all these cases and the underlying risk-factors has never been made.", "question": "Treatment.Duration in amiodarone", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2690546_1_9743", "context": "Although a lot of amiodarone-induced torsades de pointe have been published, a review of all these cases and the underlying risk-factors has never been made.", "question": "Treatment.Disorder in amiodarone", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "2690546_1_9744", "context": "Although a lot of amiodarone-induced torsades de pointe have been published, a review of all these cases and the underlying risk-factors has never been made.", "question": "Combination.Drug in amiodarone", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15823103_2_9745", "context": "However, one patient exhibited severe hypersensitivity reactions including cardiac arrest and apnea, and another four patients developed eruptions, hypotension, and tachycardia soon after administration of CBDCA.", "question": "Subject.Age in one patient", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "15823103_2_9746", "context": "However, one patient exhibited severe hypersensitivity reactions including cardiac arrest and apnea, and another four patients developed eruptions, hypotension, and tachycardia soon after administration of CBDCA.", "question": "Subject.Gender in one patient", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15823103_2_9747", "context": "However, one patient exhibited severe hypersensitivity reactions including cardiac arrest and apnea, and another four patients developed eruptions, hypotension, and tachycardia soon after administration of CBDCA.", "question": "Subject.Population in one patient", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "15823103_2_9748", "context": "However, one patient exhibited severe hypersensitivity reactions including cardiac arrest and apnea, and another four patients developed eruptions, hypotension, and tachycardia soon after administration of CBDCA.", "question": "Subject.Race in one patient", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15823103_2_9749", "context": "However, one patient exhibited severe hypersensitivity reactions including cardiac arrest and apnea, and another four patients developed eruptions, hypotension, and tachycardia soon after administration of CBDCA.", "question": "Subject.Disorder in one patient", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15823103_2_9750", "context": "However, one patient exhibited severe hypersensitivity reactions including cardiac arrest and apnea, and another four patients developed eruptions, hypotension, and tachycardia soon after administration of CBDCA.", "question": "Treatment.Drug in CBDCA", "question_type": "Adverse_event.Treatment.Drug", "answers": "CBDCA"}, {"id": "15823103_2_9751", "context": "However, one patient exhibited severe hypersensitivity reactions including cardiac arrest and apnea, and another four patients developed eruptions, hypotension, and tachycardia soon after administration of CBDCA.", "question": "Treatment.Dosage in CBDCA", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15823103_2_9752", "context": "However, one patient exhibited severe hypersensitivity reactions including cardiac arrest and apnea, and another four patients developed eruptions, hypotension, and tachycardia soon after administration of CBDCA.", "question": "Treatment.Freq in CBDCA", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15823103_2_9753", "context": "However, one patient exhibited severe hypersensitivity reactions including cardiac arrest and apnea, and another four patients developed eruptions, hypotension, and tachycardia soon after administration of CBDCA.", "question": "Treatment.Route in CBDCA", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15823103_2_9754", "context": "However, one patient exhibited severe hypersensitivity reactions including cardiac arrest and apnea, and another four patients developed eruptions, hypotension, and tachycardia soon after administration of CBDCA.", "question": "Treatment.Time_elapsed in CBDCA", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15823103_2_9755", "context": "However, one patient exhibited severe hypersensitivity reactions including cardiac arrest and apnea, and another four patients developed eruptions, hypotension, and tachycardia soon after administration of CBDCA.", "question": "Treatment.Duration in CBDCA", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15823103_2_9756", "context": "However, one patient exhibited severe hypersensitivity reactions including cardiac arrest and apnea, and another four patients developed eruptions, hypotension, and tachycardia soon after administration of CBDCA.", "question": "Treatment.Disorder in CBDCA", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15823103_2_9757", "context": "However, one patient exhibited severe hypersensitivity reactions including cardiac arrest and apnea, and another four patients developed eruptions, hypotension, and tachycardia soon after administration of CBDCA.", "question": "Combination.Drug in CBDCA", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15823103_2_9758", "context": "However, one patient exhibited severe hypersensitivity reactions including cardiac arrest and apnea, and another four patients developed eruptions, hypotension, and tachycardia soon after administration of CBDCA.", "question": "Subject.Age in four patients", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "15823103_2_9759", "context": "However, one patient exhibited severe hypersensitivity reactions including cardiac arrest and apnea, and another four patients developed eruptions, hypotension, and tachycardia soon after administration of CBDCA.", "question": "Subject.Gender in four patients", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15823103_2_9760", "context": "However, one patient exhibited severe hypersensitivity reactions including cardiac arrest and apnea, and another four patients developed eruptions, hypotension, and tachycardia soon after administration of CBDCA.", "question": "Subject.Population in four patients", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "15823103_2_9761", "context": "However, one patient exhibited severe hypersensitivity reactions including cardiac arrest and apnea, and another four patients developed eruptions, hypotension, and tachycardia soon after administration of CBDCA.", "question": "Subject.Race in four patients", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15823103_2_9762", "context": "However, one patient exhibited severe hypersensitivity reactions including cardiac arrest and apnea, and another four patients developed eruptions, hypotension, and tachycardia soon after administration of CBDCA.", "question": "Subject.Disorder in four patients", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15823103_2_9763", "context": "However, one patient exhibited severe hypersensitivity reactions including cardiac arrest and apnea, and another four patients developed eruptions, hypotension, and tachycardia soon after administration of CBDCA.", "question": "Treatment.Drug in CBDCA", "question_type": "Adverse_event.Treatment.Drug", "answers": "CBDCA"}, {"id": "15823103_2_9764", "context": "However, one patient exhibited severe hypersensitivity reactions including cardiac arrest and apnea, and another four patients developed eruptions, hypotension, and tachycardia soon after administration of CBDCA.", "question": "Treatment.Dosage in CBDCA", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15823103_2_9765", "context": "However, one patient exhibited severe hypersensitivity reactions including cardiac arrest and apnea, and another four patients developed eruptions, hypotension, and tachycardia soon after administration of CBDCA.", "question": "Treatment.Freq in CBDCA", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15823103_2_9766", "context": "However, one patient exhibited severe hypersensitivity reactions including cardiac arrest and apnea, and another four patients developed eruptions, hypotension, and tachycardia soon after administration of CBDCA.", "question": "Treatment.Route in CBDCA", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15823103_2_9767", "context": "However, one patient exhibited severe hypersensitivity reactions including cardiac arrest and apnea, and another four patients developed eruptions, hypotension, and tachycardia soon after administration of CBDCA.", "question": "Treatment.Time_elapsed in CBDCA", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15823103_2_9768", "context": "However, one patient exhibited severe hypersensitivity reactions including cardiac arrest and apnea, and another four patients developed eruptions, hypotension, and tachycardia soon after administration of CBDCA.", "question": "Treatment.Duration in CBDCA", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15823103_2_9769", "context": "However, one patient exhibited severe hypersensitivity reactions including cardiac arrest and apnea, and another four patients developed eruptions, hypotension, and tachycardia soon after administration of CBDCA.", "question": "Treatment.Disorder in CBDCA", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15823103_2_9770", "context": "However, one patient exhibited severe hypersensitivity reactions including cardiac arrest and apnea, and another four patients developed eruptions, hypotension, and tachycardia soon after administration of CBDCA.", "question": "Combination.Drug in CBDCA", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17329303_3_9771", "context": "This report is about three cases of children who developed severe adverse reactions during switching from risperidone to methylphenidate.", "question": "Subject.Age in three cases of children", "question_type": "Adverse_event.Subject.Age", "answers": "children"}, {"id": "17329303_3_9772", "context": "This report is about three cases of children who developed severe adverse reactions during switching from risperidone to methylphenidate.", "question": "Subject.Gender in three cases of children", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "17329303_3_9773", "context": "This report is about three cases of children who developed severe adverse reactions during switching from risperidone to methylphenidate.", "question": "Subject.Population in three cases of children", "question_type": "Adverse_event.Subject.Population", "answers": "three"}, {"id": "17329303_3_9774", "context": "This report is about three cases of children who developed severe adverse reactions during switching from risperidone to methylphenidate.", "question": "Subject.Race in three cases of children", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "17329303_3_9775", "context": "This report is about three cases of children who developed severe adverse reactions during switching from risperidone to methylphenidate.", "question": "Subject.Disorder in three cases of children", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "17329303_3_9776", "context": "This report is about three cases of children who developed severe adverse reactions during switching from risperidone to methylphenidate.", "question": "Treatment.Drug in during switching from risperidone to methylphenidate", "question_type": "Adverse_event.Treatment.Drug", "answers": "risperidone; methylphenidate"}, {"id": "17329303_3_9777", "context": "This report is about three cases of children who developed severe adverse reactions during switching from risperidone to methylphenidate.", "question": "Treatment.Dosage in during switching from risperidone to methylphenidate", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17329303_3_9778", "context": "This report is about three cases of children who developed severe adverse reactions during switching from risperidone to methylphenidate.", "question": "Treatment.Freq in during switching from risperidone to methylphenidate", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17329303_3_9779", "context": "This report is about three cases of children who developed severe adverse reactions during switching from risperidone to methylphenidate.", "question": "Treatment.Route in during switching from risperidone to methylphenidate", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17329303_3_9780", "context": "This report is about three cases of children who developed severe adverse reactions during switching from risperidone to methylphenidate.", "question": "Treatment.Time_elapsed in during switching from risperidone to methylphenidate", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17329303_3_9781", "context": "This report is about three cases of children who developed severe adverse reactions during switching from risperidone to methylphenidate.", "question": "Treatment.Duration in during switching from risperidone to methylphenidate", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17329303_3_9782", "context": "This report is about three cases of children who developed severe adverse reactions during switching from risperidone to methylphenidate.", "question": "Treatment.Disorder in during switching from risperidone to methylphenidate", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17329303_3_9783", "context": "This report is about three cases of children who developed severe adverse reactions during switching from risperidone to methylphenidate.", "question": "Combination.Drug in during switching from risperidone to methylphenidate", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10414481_2_9784", "context": "This patient, who had a history of osteoarthritis, had severe hepatitis 5 weeks after being started on diclofenac for increasing pain in the joints.", "question": "Subject.Age in This patient, who had a history of osteoarthritis", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "10414481_2_9785", "context": "This patient, who had a history of osteoarthritis, had severe hepatitis 5 weeks after being started on diclofenac for increasing pain in the joints.", "question": "Subject.Gender in This patient, who had a history of osteoarthritis", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "10414481_2_9786", "context": "This patient, who had a history of osteoarthritis, had severe hepatitis 5 weeks after being started on diclofenac for increasing pain in the joints.", "question": "Subject.Population in This patient, who had a history of osteoarthritis", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "10414481_2_9787", "context": "This patient, who had a history of osteoarthritis, had severe hepatitis 5 weeks after being started on diclofenac for increasing pain in the joints.", "question": "Subject.Race in This patient, who had a history of osteoarthritis", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "10414481_2_9788", "context": "This patient, who had a history of osteoarthritis, had severe hepatitis 5 weeks after being started on diclofenac for increasing pain in the joints.", "question": "Subject.Disorder in This patient, who had a history of osteoarthritis", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "10414481_2_9789", "context": "This patient, who had a history of osteoarthritis, had severe hepatitis 5 weeks after being started on diclofenac for increasing pain in the joints.", "question": "Treatment.Drug in 5 weeks after being started on diclofenac", "question_type": "Adverse_event.Treatment.Drug", "answers": "diclofenac"}, {"id": "10414481_2_9790", "context": "This patient, who had a history of osteoarthritis, had severe hepatitis 5 weeks after being started on diclofenac for increasing pain in the joints.", "question": "Treatment.Dosage in 5 weeks after being started on diclofenac", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10414481_2_9791", "context": "This patient, who had a history of osteoarthritis, had severe hepatitis 5 weeks after being started on diclofenac for increasing pain in the joints.", "question": "Treatment.Freq in 5 weeks after being started on diclofenac", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10414481_2_9792", "context": "This patient, who had a history of osteoarthritis, had severe hepatitis 5 weeks after being started on diclofenac for increasing pain in the joints.", "question": "Treatment.Route in 5 weeks after being started on diclofenac", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10414481_2_9793", "context": "This patient, who had a history of osteoarthritis, had severe hepatitis 5 weeks after being started on diclofenac for increasing pain in the joints.", "question": "Treatment.Time_elapsed in 5 weeks after being started on diclofenac", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "5 weeks"}, {"id": "10414481_2_9794", "context": "This patient, who had a history of osteoarthritis, had severe hepatitis 5 weeks after being started on diclofenac for increasing pain in the joints.", "question": "Treatment.Duration in 5 weeks after being started on diclofenac", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10414481_2_9795", "context": "This patient, who had a history of osteoarthritis, had severe hepatitis 5 weeks after being started on diclofenac for increasing pain in the joints.", "question": "Treatment.Disorder in 5 weeks after being started on diclofenac", "question_type": "Adverse_event.Treatment.Disorder", "answers": "increasing pain in the joints"}, {"id": "10414481_2_9796", "context": "This patient, who had a history of osteoarthritis, had severe hepatitis 5 weeks after being started on diclofenac for increasing pain in the joints.", "question": "Combination.Drug in 5 weeks after being started on diclofenac", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16816519_4_9797", "context": "She received chemotherapy according to the previously described modified St. Jude total therapy studies XIII.", "question": "Subject.Age in She", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "16816519_4_9798", "context": "She received chemotherapy according to the previously described modified St. Jude total therapy studies XIII.", "question": "Subject.Gender in She", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": "She"}, {"id": "16816519_4_9799", "context": "She received chemotherapy according to the previously described modified St. Jude total therapy studies XIII.", "question": "Subject.Population in She", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "16816519_4_9800", "context": "She received chemotherapy according to the previously described modified St. Jude total therapy studies XIII.", "question": "Subject.Race in She", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "16816519_4_9801", "context": "She received chemotherapy according to the previously described modified St. Jude total therapy studies XIII.", "question": "Subject.Disorder in She", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "16816519_4_9802", "context": "She received chemotherapy according to the previously described modified St. Jude total therapy studies XIII.", "question": "Treatment.Drug in chemotherapy", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "16816519_4_9803", "context": "She received chemotherapy according to the previously described modified St. Jude total therapy studies XIII.", "question": "Treatment.Dosage in chemotherapy", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "16816519_4_9804", "context": "She received chemotherapy according to the previously described modified St. Jude total therapy studies XIII.", "question": "Treatment.Freq in chemotherapy", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "16816519_4_9805", "context": "She received chemotherapy according to the previously described modified St. Jude total therapy studies XIII.", "question": "Treatment.Route in chemotherapy", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": "chemotherapy"}, {"id": "16816519_4_9806", "context": "She received chemotherapy according to the previously described modified St. Jude total therapy studies XIII.", "question": "Treatment.Time_elapsed in chemotherapy", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16816519_4_9807", "context": "She received chemotherapy according to the previously described modified St. Jude total therapy studies XIII.", "question": "Treatment.Duration in chemotherapy", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "16816519_4_9808", "context": "She received chemotherapy according to the previously described modified St. Jude total therapy studies XIII.", "question": "Treatment.Disorder in chemotherapy", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "16816519_4_9809", "context": "She received chemotherapy according to the previously described modified St. Jude total therapy studies XIII.", "question": "Combination.Drug in chemotherapy", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "9039216_1_9810", "context": "A 17-year-old female patient who had been taking oral minocycline (50 mg twice daily) for 3 weeks for acne developed an eruption that progressed to an exfoliative dermatitis.", "question": "Subject.Age in A 17-year-old female patient", "question_type": "Adverse_event.Subject.Age", "answers": "17-year-old"}, {"id": "9039216_1_9811", "context": "A 17-year-old female patient who had been taking oral minocycline (50 mg twice daily) for 3 weeks for acne developed an eruption that progressed to an exfoliative dermatitis.", "question": "Subject.Gender in A 17-year-old female patient", "question_type": "Adverse_event.Subject.Gender", "answers": "female"}, {"id": "9039216_1_9812", "context": "A 17-year-old female patient who had been taking oral minocycline (50 mg twice daily) for 3 weeks for acne developed an eruption that progressed to an exfoliative dermatitis.", "question": "Subject.Population in A 17-year-old female patient", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "9039216_1_9813", "context": "A 17-year-old female patient who had been taking oral minocycline (50 mg twice daily) for 3 weeks for acne developed an eruption that progressed to an exfoliative dermatitis.", "question": "Subject.Race in A 17-year-old female patient", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "9039216_1_9814", "context": "A 17-year-old female patient who had been taking oral minocycline (50 mg twice daily) for 3 weeks for acne developed an eruption that progressed to an exfoliative dermatitis.", "question": "Subject.Disorder in A 17-year-old female patient", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "9039216_1_9815", "context": "A 17-year-old female patient who had been taking oral minocycline (50 mg twice daily) for 3 weeks for acne developed an eruption that progressed to an exfoliative dermatitis.", "question": "Treatment.Drug in oral minocycline (50 mg twice daily) for 3 weeks", "question_type": "Adverse_event.Treatment.Drug", "answers": "minocycline"}, {"id": "9039216_1_9816", "context": "A 17-year-old female patient who had been taking oral minocycline (50 mg twice daily) for 3 weeks for acne developed an eruption that progressed to an exfoliative dermatitis.", "question": "Treatment.Dosage in oral minocycline (50 mg twice daily) for 3 weeks", "question_type": "Adverse_event.Treatment.Dosage", "answers": "50 mg"}, {"id": "9039216_1_9817", "context": "A 17-year-old female patient who had been taking oral minocycline (50 mg twice daily) for 3 weeks for acne developed an eruption that progressed to an exfoliative dermatitis.", "question": "Treatment.Freq in oral minocycline (50 mg twice daily) for 3 weeks", "question_type": "Adverse_event.Treatment.Freq", "answers": "twice daily"}, {"id": "9039216_1_9818", "context": "A 17-year-old female patient who had been taking oral minocycline (50 mg twice daily) for 3 weeks for acne developed an eruption that progressed to an exfoliative dermatitis.", "question": "Treatment.Route in oral minocycline (50 mg twice daily) for 3 weeks", "question_type": "Adverse_event.Treatment.Route", "answers": "oral"}, {"id": "9039216_1_9819", "context": "A 17-year-old female patient who had been taking oral minocycline (50 mg twice daily) for 3 weeks for acne developed an eruption that progressed to an exfoliative dermatitis.", "question": "Treatment.Time_elapsed in oral minocycline (50 mg twice daily) for 3 weeks", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9039216_1_9820", "context": "A 17-year-old female patient who had been taking oral minocycline (50 mg twice daily) for 3 weeks for acne developed an eruption that progressed to an exfoliative dermatitis.", "question": "Treatment.Duration in oral minocycline (50 mg twice daily) for 3 weeks", "question_type": "Adverse_event.Treatment.Duration", "answers": "3 weeks"}, {"id": "9039216_1_9821", "context": "A 17-year-old female patient who had been taking oral minocycline (50 mg twice daily) for 3 weeks for acne developed an eruption that progressed to an exfoliative dermatitis.", "question": "Treatment.Disorder in oral minocycline (50 mg twice daily) for 3 weeks", "question_type": "Adverse_event.Treatment.Disorder", "answers": "acne"}, {"id": "9039216_1_9822", "context": "A 17-year-old female patient who had been taking oral minocycline (50 mg twice daily) for 3 weeks for acne developed an eruption that progressed to an exfoliative dermatitis.", "question": "Combination.Drug in oral minocycline (50 mg twice daily) for 3 weeks", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12880504_3_9823", "context": "Risperidone-induced obsessive-compulsive symptoms in two children.", "question": "Subject.Age in two children", "question_type": "Adverse_event.Subject.Age", "answers": "children"}, {"id": "12880504_3_9824", "context": "Risperidone-induced obsessive-compulsive symptoms in two children.", "question": "Subject.Gender in two children", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "12880504_3_9825", "context": "Risperidone-induced obsessive-compulsive symptoms in two children.", "question": "Subject.Population in two children", "question_type": "Adverse_event.Subject.Population", "answers": "two"}, {"id": "12880504_3_9826", "context": "Risperidone-induced obsessive-compulsive symptoms in two children.", "question": "Subject.Race in two children", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "12880504_3_9827", "context": "Risperidone-induced obsessive-compulsive symptoms in two children.", "question": "Subject.Disorder in two children", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "12880504_3_9828", "context": "Risperidone-induced obsessive-compulsive symptoms in two children.", "question": "Treatment.Drug in Risperidone", "question_type": "Adverse_event.Treatment.Drug", "answers": "Risperidone"}, {"id": "12880504_3_9829", "context": "Risperidone-induced obsessive-compulsive symptoms in two children.", "question": "Treatment.Dosage in Risperidone", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12880504_3_9830", "context": "Risperidone-induced obsessive-compulsive symptoms in two children.", "question": "Treatment.Freq in Risperidone", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12880504_3_9831", "context": "Risperidone-induced obsessive-compulsive symptoms in two children.", "question": "Treatment.Route in Risperidone", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12880504_3_9832", "context": "Risperidone-induced obsessive-compulsive symptoms in two children.", "question": "Treatment.Time_elapsed in Risperidone", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12880504_3_9833", "context": "Risperidone-induced obsessive-compulsive symptoms in two children.", "question": "Treatment.Duration in Risperidone", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12880504_3_9834", "context": "Risperidone-induced obsessive-compulsive symptoms in two children.", "question": "Treatment.Disorder in Risperidone", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12880504_3_9835", "context": "Risperidone-induced obsessive-compulsive symptoms in two children.", "question": "Combination.Drug in Risperidone", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11642488_2_9836", "context": "CONCLUSIONS: Cicatrization in the substantia propria of the conjunctiva by excessive lymphocytic infiltration after topically administered antiglaucoma drugs including dipivefrin is a possible mechanism of action for entropion.", "question": "Treatment.Drug in antiglaucoma drugs including dipivefrin", "question_type": "Adverse_event.Treatment.Drug", "answers": "dipivefrin; antiglaucoma drugs"}, {"id": "11642488_2_9837", "context": "CONCLUSIONS: Cicatrization in the substantia propria of the conjunctiva by excessive lymphocytic infiltration after topically administered antiglaucoma drugs including dipivefrin is a possible mechanism of action for entropion.", "question": "Treatment.Dosage in antiglaucoma drugs including dipivefrin", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11642488_2_9838", "context": "CONCLUSIONS: Cicatrization in the substantia propria of the conjunctiva by excessive lymphocytic infiltration after topically administered antiglaucoma drugs including dipivefrin is a possible mechanism of action for entropion.", "question": "Treatment.Freq in antiglaucoma drugs including dipivefrin", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11642488_2_9839", "context": "CONCLUSIONS: Cicatrization in the substantia propria of the conjunctiva by excessive lymphocytic infiltration after topically administered antiglaucoma drugs including dipivefrin is a possible mechanism of action for entropion.", "question": "Treatment.Route in antiglaucoma drugs including dipivefrin", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11642488_2_9840", "context": "CONCLUSIONS: Cicatrization in the substantia propria of the conjunctiva by excessive lymphocytic infiltration after topically administered antiglaucoma drugs including dipivefrin is a possible mechanism of action for entropion.", "question": "Treatment.Time_elapsed in antiglaucoma drugs including dipivefrin", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11642488_2_9841", "context": "CONCLUSIONS: Cicatrization in the substantia propria of the conjunctiva by excessive lymphocytic infiltration after topically administered antiglaucoma drugs including dipivefrin is a possible mechanism of action for entropion.", "question": "Treatment.Duration in antiglaucoma drugs including dipivefrin", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11642488_2_9842", "context": "CONCLUSIONS: Cicatrization in the substantia propria of the conjunctiva by excessive lymphocytic infiltration after topically administered antiglaucoma drugs including dipivefrin is a possible mechanism of action for entropion.", "question": "Treatment.Disorder in antiglaucoma drugs including dipivefrin", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11642488_2_9843", "context": "CONCLUSIONS: Cicatrization in the substantia propria of the conjunctiva by excessive lymphocytic infiltration after topically administered antiglaucoma drugs including dipivefrin is a possible mechanism of action for entropion.", "question": "Combination.Drug in antiglaucoma drugs including dipivefrin", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "2429270_1_9844", "context": "A patient with the Wolff-Parkinson-White syndrome presented with incessant orthodromic atrioventricular tachycardia following initiation of procainamide therapy.", "question": "Subject.Age in A patient with the Wolff-Parkinson-White syndrome", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "2429270_1_9845", "context": "A patient with the Wolff-Parkinson-White syndrome presented with incessant orthodromic atrioventricular tachycardia following initiation of procainamide therapy.", "question": "Subject.Gender in A patient with the Wolff-Parkinson-White syndrome", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "2429270_1_9846", "context": "A patient with the Wolff-Parkinson-White syndrome presented with incessant orthodromic atrioventricular tachycardia following initiation of procainamide therapy.", "question": "Subject.Population in A patient with the Wolff-Parkinson-White syndrome", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "2429270_1_9847", "context": "A patient with the Wolff-Parkinson-White syndrome presented with incessant orthodromic atrioventricular tachycardia following initiation of procainamide therapy.", "question": "Subject.Race in A patient with the Wolff-Parkinson-White syndrome", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "2429270_1_9848", "context": "A patient with the Wolff-Parkinson-White syndrome presented with incessant orthodromic atrioventricular tachycardia following initiation of procainamide therapy.", "question": "Subject.Disorder in A patient with the Wolff-Parkinson-White syndrome", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "2429270_1_9849", "context": "A patient with the Wolff-Parkinson-White syndrome presented with incessant orthodromic atrioventricular tachycardia following initiation of procainamide therapy.", "question": "Treatment.Drug in initiation of procainamide therapy", "question_type": "Adverse_event.Treatment.Drug", "answers": "procainamide"}, {"id": "2429270_1_9850", "context": "A patient with the Wolff-Parkinson-White syndrome presented with incessant orthodromic atrioventricular tachycardia following initiation of procainamide therapy.", "question": "Treatment.Dosage in initiation of procainamide therapy", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "2429270_1_9851", "context": "A patient with the Wolff-Parkinson-White syndrome presented with incessant orthodromic atrioventricular tachycardia following initiation of procainamide therapy.", "question": "Treatment.Freq in initiation of procainamide therapy", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2429270_1_9852", "context": "A patient with the Wolff-Parkinson-White syndrome presented with incessant orthodromic atrioventricular tachycardia following initiation of procainamide therapy.", "question": "Treatment.Route in initiation of procainamide therapy", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "2429270_1_9853", "context": "A patient with the Wolff-Parkinson-White syndrome presented with incessant orthodromic atrioventricular tachycardia following initiation of procainamide therapy.", "question": "Treatment.Time_elapsed in initiation of procainamide therapy", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2429270_1_9854", "context": "A patient with the Wolff-Parkinson-White syndrome presented with incessant orthodromic atrioventricular tachycardia following initiation of procainamide therapy.", "question": "Treatment.Duration in initiation of procainamide therapy", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2429270_1_9855", "context": "A patient with the Wolff-Parkinson-White syndrome presented with incessant orthodromic atrioventricular tachycardia following initiation of procainamide therapy.", "question": "Treatment.Disorder in initiation of procainamide therapy", "question_type": "Adverse_event.Treatment.Disorder", "answers": "Wolff-Parkinson-White syndrome"}, {"id": "2429270_1_9856", "context": "A patient with the Wolff-Parkinson-White syndrome presented with incessant orthodromic atrioventricular tachycardia following initiation of procainamide therapy.", "question": "Combination.Drug in initiation of procainamide therapy", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12439602_3_9857", "context": "Hypersensitivity to carboplatin is a rare but real complication of therapy and should be considered in patients presenting with hyperacute changes on ECG whilst receiving carboplatin therapy.", "question": "Subject.Age in patients presenting with hyperacute changes on ECG", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "12439602_3_9858", "context": "Hypersensitivity to carboplatin is a rare but real complication of therapy and should be considered in patients presenting with hyperacute changes on ECG whilst receiving carboplatin therapy.", "question": "Subject.Gender in patients presenting with hyperacute changes on ECG", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "12439602_3_9859", "context": "Hypersensitivity to carboplatin is a rare but real complication of therapy and should be considered in patients presenting with hyperacute changes on ECG whilst receiving carboplatin therapy.", "question": "Subject.Population in patients presenting with hyperacute changes on ECG", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "12439602_3_9860", "context": "Hypersensitivity to carboplatin is a rare but real complication of therapy and should be considered in patients presenting with hyperacute changes on ECG whilst receiving carboplatin therapy.", "question": "Subject.Race in patients presenting with hyperacute changes on ECG", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "12439602_3_9861", "context": "Hypersensitivity to carboplatin is a rare but real complication of therapy and should be considered in patients presenting with hyperacute changes on ECG whilst receiving carboplatin therapy.", "question": "Subject.Disorder in patients presenting with hyperacute changes on ECG", "question_type": "Adverse_event.Subject.Disorder", "answers": "hyperacute changes on ECG"}, {"id": "12439602_3_9862", "context": "Hypersensitivity to carboplatin is a rare but real complication of therapy and should be considered in patients presenting with hyperacute changes on ECG whilst receiving carboplatin therapy.", "question": "Treatment.Drug in carboplatin therapy", "question_type": "Adverse_event.Treatment.Drug", "answers": "carboplatin"}, {"id": "12439602_3_9863", "context": "Hypersensitivity to carboplatin is a rare but real complication of therapy and should be considered in patients presenting with hyperacute changes on ECG whilst receiving carboplatin therapy.", "question": "Treatment.Dosage in carboplatin therapy", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12439602_3_9864", "context": "Hypersensitivity to carboplatin is a rare but real complication of therapy and should be considered in patients presenting with hyperacute changes on ECG whilst receiving carboplatin therapy.", "question": "Treatment.Freq in carboplatin therapy", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12439602_3_9865", "context": "Hypersensitivity to carboplatin is a rare but real complication of therapy and should be considered in patients presenting with hyperacute changes on ECG whilst receiving carboplatin therapy.", "question": "Treatment.Route in carboplatin therapy", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12439602_3_9866", "context": "Hypersensitivity to carboplatin is a rare but real complication of therapy and should be considered in patients presenting with hyperacute changes on ECG whilst receiving carboplatin therapy.", "question": "Treatment.Time_elapsed in carboplatin therapy", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12439602_3_9867", "context": "Hypersensitivity to carboplatin is a rare but real complication of therapy and should be considered in patients presenting with hyperacute changes on ECG whilst receiving carboplatin therapy.", "question": "Treatment.Duration in carboplatin therapy", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12439602_3_9868", "context": "Hypersensitivity to carboplatin is a rare but real complication of therapy and should be considered in patients presenting with hyperacute changes on ECG whilst receiving carboplatin therapy.", "question": "Treatment.Disorder in carboplatin therapy", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12439602_3_9869", "context": "Hypersensitivity to carboplatin is a rare but real complication of therapy and should be considered in patients presenting with hyperacute changes on ECG whilst receiving carboplatin therapy.", "question": "Combination.Drug in carboplatin therapy", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3115809_2_9870", "context": "A well-recognized complication of ethambutol use is optic neuropathy, but the potential ocular toxicity of isoniazid is often overlooked.", "question": "Treatment.Drug in ethambutol", "question_type": "Adverse_event.Treatment.Drug", "answers": "ethambutol"}, {"id": "3115809_2_9871", "context": "A well-recognized complication of ethambutol use is optic neuropathy, but the potential ocular toxicity of isoniazid is often overlooked.", "question": "Treatment.Dosage in ethambutol", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3115809_2_9872", "context": "A well-recognized complication of ethambutol use is optic neuropathy, but the potential ocular toxicity of isoniazid is often overlooked.", "question": "Treatment.Freq in ethambutol", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3115809_2_9873", "context": "A well-recognized complication of ethambutol use is optic neuropathy, but the potential ocular toxicity of isoniazid is often overlooked.", "question": "Treatment.Route in ethambutol", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3115809_2_9874", "context": "A well-recognized complication of ethambutol use is optic neuropathy, but the potential ocular toxicity of isoniazid is often overlooked.", "question": "Treatment.Time_elapsed in ethambutol", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3115809_2_9875", "context": "A well-recognized complication of ethambutol use is optic neuropathy, but the potential ocular toxicity of isoniazid is often overlooked.", "question": "Treatment.Duration in ethambutol", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3115809_2_9876", "context": "A well-recognized complication of ethambutol use is optic neuropathy, but the potential ocular toxicity of isoniazid is often overlooked.", "question": "Treatment.Disorder in ethambutol", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3115809_2_9877", "context": "A well-recognized complication of ethambutol use is optic neuropathy, but the potential ocular toxicity of isoniazid is often overlooked.", "question": "Combination.Drug in ethambutol", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3115809_2_9878", "context": "A well-recognized complication of ethambutol use is optic neuropathy, but the potential ocular toxicity of isoniazid is often overlooked.", "question": "Treatment.Drug in isoniazid", "question_type": "Adverse_event.Treatment.Drug", "answers": "isoniazid"}, {"id": "3115809_2_9879", "context": "A well-recognized complication of ethambutol use is optic neuropathy, but the potential ocular toxicity of isoniazid is often overlooked.", "question": "Treatment.Dosage in isoniazid", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3115809_2_9880", "context": "A well-recognized complication of ethambutol use is optic neuropathy, but the potential ocular toxicity of isoniazid is often overlooked.", "question": "Treatment.Freq in isoniazid", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3115809_2_9881", "context": "A well-recognized complication of ethambutol use is optic neuropathy, but the potential ocular toxicity of isoniazid is often overlooked.", "question": "Treatment.Route in isoniazid", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3115809_2_9882", "context": "A well-recognized complication of ethambutol use is optic neuropathy, but the potential ocular toxicity of isoniazid is often overlooked.", "question": "Treatment.Time_elapsed in isoniazid", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3115809_2_9883", "context": "A well-recognized complication of ethambutol use is optic neuropathy, but the potential ocular toxicity of isoniazid is often overlooked.", "question": "Treatment.Duration in isoniazid", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3115809_2_9884", "context": "A well-recognized complication of ethambutol use is optic neuropathy, but the potential ocular toxicity of isoniazid is often overlooked.", "question": "Treatment.Disorder in isoniazid", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3115809_2_9885", "context": "A well-recognized complication of ethambutol use is optic neuropathy, but the potential ocular toxicity of isoniazid is often overlooked.", "question": "Combination.Drug in isoniazid", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11554897_4_9886", "context": "PURPOSE: To report that acute lamotrigine poisoning may result in severe encephalopathy.", "question": "Treatment.Drug in acute lamotrigine poisoning", "question_type": "Adverse_event.Treatment.Drug", "answers": "lamotrigine"}, {"id": "11554897_4_9887", "context": "PURPOSE: To report that acute lamotrigine poisoning may result in severe encephalopathy.", "question": "Treatment.Dosage in acute lamotrigine poisoning", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11554897_4_9888", "context": "PURPOSE: To report that acute lamotrigine poisoning may result in severe encephalopathy.", "question": "Treatment.Freq in acute lamotrigine poisoning", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11554897_4_9889", "context": "PURPOSE: To report that acute lamotrigine poisoning may result in severe encephalopathy.", "question": "Treatment.Route in acute lamotrigine poisoning", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11554897_4_9890", "context": "PURPOSE: To report that acute lamotrigine poisoning may result in severe encephalopathy.", "question": "Treatment.Time_elapsed in acute lamotrigine poisoning", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11554897_4_9891", "context": "PURPOSE: To report that acute lamotrigine poisoning may result in severe encephalopathy.", "question": "Treatment.Duration in acute lamotrigine poisoning", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11554897_4_9892", "context": "PURPOSE: To report that acute lamotrigine poisoning may result in severe encephalopathy.", "question": "Treatment.Disorder in acute lamotrigine poisoning", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11554897_4_9893", "context": "PURPOSE: To report that acute lamotrigine poisoning may result in severe encephalopathy.", "question": "Combination.Drug in acute lamotrigine poisoning", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6108450_1_9894", "context": "Reversal of ergotamine-induced arteriospasm by mechanical intra-arterial dilatation.", "question": "Treatment.Drug in ergotamine", "question_type": "Adverse_event.Treatment.Drug", "answers": "ergotamine"}, {"id": "6108450_1_9895", "context": "Reversal of ergotamine-induced arteriospasm by mechanical intra-arterial dilatation.", "question": "Treatment.Dosage in ergotamine", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6108450_1_9896", "context": "Reversal of ergotamine-induced arteriospasm by mechanical intra-arterial dilatation.", "question": "Treatment.Freq in ergotamine", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6108450_1_9897", "context": "Reversal of ergotamine-induced arteriospasm by mechanical intra-arterial dilatation.", "question": "Treatment.Route in ergotamine", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6108450_1_9898", "context": "Reversal of ergotamine-induced arteriospasm by mechanical intra-arterial dilatation.", "question": "Treatment.Time_elapsed in ergotamine", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6108450_1_9899", "context": "Reversal of ergotamine-induced arteriospasm by mechanical intra-arterial dilatation.", "question": "Treatment.Duration in ergotamine", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6108450_1_9900", "context": "Reversal of ergotamine-induced arteriospasm by mechanical intra-arterial dilatation.", "question": "Treatment.Disorder in ergotamine", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6108450_1_9901", "context": "Reversal of ergotamine-induced arteriospasm by mechanical intra-arterial dilatation.", "question": "Combination.Drug in ergotamine", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17667887_9_9902", "context": "There have been several case reports of serotonin syndrome from similar combinations of antidepressant and atypical antipsychotic treatment.", "question": "Treatment.Drug in combinations of antidepressant and atypical antipsychotic treatment", "question_type": "Adverse_event.Treatment.Drug", "answers": "antidepressant; antipsychotic"}, {"id": "17667887_9_9903", "context": "There have been several case reports of serotonin syndrome from similar combinations of antidepressant and atypical antipsychotic treatment.", "question": "Treatment.Dosage in combinations of antidepressant and atypical antipsychotic treatment", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17667887_9_9904", "context": "There have been several case reports of serotonin syndrome from similar combinations of antidepressant and atypical antipsychotic treatment.", "question": "Treatment.Freq in combinations of antidepressant and atypical antipsychotic treatment", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17667887_9_9905", "context": "There have been several case reports of serotonin syndrome from similar combinations of antidepressant and atypical antipsychotic treatment.", "question": "Treatment.Route in combinations of antidepressant and atypical antipsychotic treatment", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17667887_9_9906", "context": "There have been several case reports of serotonin syndrome from similar combinations of antidepressant and atypical antipsychotic treatment.", "question": "Treatment.Time_elapsed in combinations of antidepressant and atypical antipsychotic treatment", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17667887_9_9907", "context": "There have been several case reports of serotonin syndrome from similar combinations of antidepressant and atypical antipsychotic treatment.", "question": "Treatment.Duration in combinations of antidepressant and atypical antipsychotic treatment", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17667887_9_9908", "context": "There have been several case reports of serotonin syndrome from similar combinations of antidepressant and atypical antipsychotic treatment.", "question": "Treatment.Disorder in combinations of antidepressant and atypical antipsychotic treatment", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17667887_9_9909", "context": "There have been several case reports of serotonin syndrome from similar combinations of antidepressant and atypical antipsychotic treatment.", "question": "Combination.Drug in combinations of antidepressant and atypical antipsychotic treatment", "question_type": "Adverse_event.Combination.Drug", "answers": "antidepressant; antipsychotic"}, {"id": "18991509_2_9910", "context": "We report the first case of a human immunodeficiency virus type 1 (HIV-1)-infected individual receiving combination antiretroviral therapy, which included ritonavir, who developed Cushing syndrome with profound complications after epidural triamcinolone injections.", "question": "Subject.Age in a human immunodeficiency virus type 1 (HIV-1)-infected individual", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "18991509_2_9911", "context": "We report the first case of a human immunodeficiency virus type 1 (HIV-1)-infected individual receiving combination antiretroviral therapy, which included ritonavir, who developed Cushing syndrome with profound complications after epidural triamcinolone injections.", "question": "Subject.Gender in a human immunodeficiency virus type 1 (HIV-1)-infected individual", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "18991509_2_9912", "context": "We report the first case of a human immunodeficiency virus type 1 (HIV-1)-infected individual receiving combination antiretroviral therapy, which included ritonavir, who developed Cushing syndrome with profound complications after epidural triamcinolone injections.", "question": "Subject.Population in a human immunodeficiency virus type 1 (HIV-1)-infected individual", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "18991509_2_9913", "context": "We report the first case of a human immunodeficiency virus type 1 (HIV-1)-infected individual receiving combination antiretroviral therapy, which included ritonavir, who developed Cushing syndrome with profound complications after epidural triamcinolone injections.", "question": "Subject.Race in a human immunodeficiency virus type 1 (HIV-1)-infected individual", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "18991509_2_9914", "context": "We report the first case of a human immunodeficiency virus type 1 (HIV-1)-infected individual receiving combination antiretroviral therapy, which included ritonavir, who developed Cushing syndrome with profound complications after epidural triamcinolone injections.", "question": "Subject.Disorder in a human immunodeficiency virus type 1 (HIV-1)-infected individual", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "18991509_2_9915", "context": "We report the first case of a human immunodeficiency virus type 1 (HIV-1)-infected individual receiving combination antiretroviral therapy, which included ritonavir, who developed Cushing syndrome with profound complications after epidural triamcinolone injections.", "question": "Treatment.Drug in combination antiretroviral therapy, which included ritonavir; epidural triamcinolone injections", "question_type": "Adverse_event.Treatment.Drug", "answers": "triamcinolone; ritonavir"}, {"id": "18991509_2_9916", "context": "We report the first case of a human immunodeficiency virus type 1 (HIV-1)-infected individual receiving combination antiretroviral therapy, which included ritonavir, who developed Cushing syndrome with profound complications after epidural triamcinolone injections.", "question": "Treatment.Dosage in combination antiretroviral therapy, which included ritonavir; epidural triamcinolone injections", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18991509_2_9917", "context": "We report the first case of a human immunodeficiency virus type 1 (HIV-1)-infected individual receiving combination antiretroviral therapy, which included ritonavir, who developed Cushing syndrome with profound complications after epidural triamcinolone injections.", "question": "Treatment.Freq in combination antiretroviral therapy, which included ritonavir; epidural triamcinolone injections", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18991509_2_9918", "context": "We report the first case of a human immunodeficiency virus type 1 (HIV-1)-infected individual receiving combination antiretroviral therapy, which included ritonavir, who developed Cushing syndrome with profound complications after epidural triamcinolone injections.", "question": "Treatment.Route in combination antiretroviral therapy, which included ritonavir; epidural triamcinolone injections", "question_type": "Adverse_event.Treatment.Route", "answers": "epidural; injections"}, {"id": "18991509_2_9919", "context": "We report the first case of a human immunodeficiency virus type 1 (HIV-1)-infected individual receiving combination antiretroviral therapy, which included ritonavir, who developed Cushing syndrome with profound complications after epidural triamcinolone injections.", "question": "Treatment.Time_elapsed in combination antiretroviral therapy, which included ritonavir; epidural triamcinolone injections", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18991509_2_9920", "context": "We report the first case of a human immunodeficiency virus type 1 (HIV-1)-infected individual receiving combination antiretroviral therapy, which included ritonavir, who developed Cushing syndrome with profound complications after epidural triamcinolone injections.", "question": "Treatment.Duration in combination antiretroviral therapy, which included ritonavir; epidural triamcinolone injections", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18991509_2_9921", "context": "We report the first case of a human immunodeficiency virus type 1 (HIV-1)-infected individual receiving combination antiretroviral therapy, which included ritonavir, who developed Cushing syndrome with profound complications after epidural triamcinolone injections.", "question": "Treatment.Disorder in combination antiretroviral therapy, which included ritonavir; epidural triamcinolone injections", "question_type": "Adverse_event.Treatment.Disorder", "answers": "human immunodeficiency virus type 1"}, {"id": "18991509_2_9922", "context": "We report the first case of a human immunodeficiency virus type 1 (HIV-1)-infected individual receiving combination antiretroviral therapy, which included ritonavir, who developed Cushing syndrome with profound complications after epidural triamcinolone injections.", "question": "Combination.Drug in combination antiretroviral therapy, which included ritonavir; epidural triamcinolone injections", "question_type": "Adverse_event.Combination.Drug", "answers": "ritonavir; triamcinolone"}, {"id": "6324592_1_9923", "context": "Disulfiram-like reactions with newer cephalosporins: cefmenoxime.", "question": "Treatment.Drug in cefmenoxime", "question_type": "Adverse_event.Treatment.Drug", "answers": "cefmenoxime"}, {"id": "6324592_1_9924", "context": "Disulfiram-like reactions with newer cephalosporins: cefmenoxime.", "question": "Treatment.Dosage in cefmenoxime", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6324592_1_9925", "context": "Disulfiram-like reactions with newer cephalosporins: cefmenoxime.", "question": "Treatment.Freq in cefmenoxime", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6324592_1_9926", "context": "Disulfiram-like reactions with newer cephalosporins: cefmenoxime.", "question": "Treatment.Route in cefmenoxime", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6324592_1_9927", "context": "Disulfiram-like reactions with newer cephalosporins: cefmenoxime.", "question": "Treatment.Time_elapsed in cefmenoxime", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6324592_1_9928", "context": "Disulfiram-like reactions with newer cephalosporins: cefmenoxime.", "question": "Treatment.Duration in cefmenoxime", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6324592_1_9929", "context": "Disulfiram-like reactions with newer cephalosporins: cefmenoxime.", "question": "Treatment.Disorder in cefmenoxime", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6324592_1_9930", "context": "Disulfiram-like reactions with newer cephalosporins: cefmenoxime.", "question": "Combination.Drug in cefmenoxime", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11590881_4_9931", "context": "We recommend routine follow up by ECG of patients over the age of 50 treated with carbamazepine.", "question": "Subject.Age in patients over the age of 50", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": "over the age of 50"}, {"id": "11590881_4_9932", "context": "We recommend routine follow up by ECG of patients over the age of 50 treated with carbamazepine.", "question": "Subject.Gender in patients over the age of 50", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "11590881_4_9933", "context": "We recommend routine follow up by ECG of patients over the age of 50 treated with carbamazepine.", "question": "Subject.Population in patients over the age of 50", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "11590881_4_9934", "context": "We recommend routine follow up by ECG of patients over the age of 50 treated with carbamazepine.", "question": "Subject.Race in patients over the age of 50", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "11590881_4_9935", "context": "We recommend routine follow up by ECG of patients over the age of 50 treated with carbamazepine.", "question": "Subject.Disorder in patients over the age of 50", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "11590881_4_9936", "context": "We recommend routine follow up by ECG of patients over the age of 50 treated with carbamazepine.", "question": "Treatment.Drug in routine follow up by ECG", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "carbamazepine"}, {"id": "11590881_4_9937", "context": "We recommend routine follow up by ECG of patients over the age of 50 treated with carbamazepine.", "question": "Treatment.Dosage in routine follow up by ECG", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "11590881_4_9938", "context": "We recommend routine follow up by ECG of patients over the age of 50 treated with carbamazepine.", "question": "Treatment.Freq in routine follow up by ECG", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "11590881_4_9939", "context": "We recommend routine follow up by ECG of patients over the age of 50 treated with carbamazepine.", "question": "Treatment.Route in routine follow up by ECG", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "11590881_4_9940", "context": "We recommend routine follow up by ECG of patients over the age of 50 treated with carbamazepine.", "question": "Treatment.Time_elapsed in routine follow up by ECG", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11590881_4_9941", "context": "We recommend routine follow up by ECG of patients over the age of 50 treated with carbamazepine.", "question": "Treatment.Duration in routine follow up by ECG", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "11590881_4_9942", "context": "We recommend routine follow up by ECG of patients over the age of 50 treated with carbamazepine.", "question": "Treatment.Disorder in routine follow up by ECG", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "11590881_4_9943", "context": "We recommend routine follow up by ECG of patients over the age of 50 treated with carbamazepine.", "question": "Combination.Drug in routine follow up by ECG", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "3149484_1_9944", "context": "A 10-year-old girl with Lennox-Gastaut syndrome who received intravenous lorazepam for atypical absence status seizures is reported.", "question": "Subject.Age in A 10-year-old girl with Lennox-Gastaut syndrome", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": "10-year-old"}, {"id": "3149484_1_9945", "context": "A 10-year-old girl with Lennox-Gastaut syndrome who received intravenous lorazepam for atypical absence status seizures is reported.", "question": "Subject.Gender in A 10-year-old girl with Lennox-Gastaut syndrome", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": "girl"}, {"id": "3149484_1_9946", "context": "A 10-year-old girl with Lennox-Gastaut syndrome who received intravenous lorazepam for atypical absence status seizures is reported.", "question": "Subject.Population in A 10-year-old girl with Lennox-Gastaut syndrome", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "3149484_1_9947", "context": "A 10-year-old girl with Lennox-Gastaut syndrome who received intravenous lorazepam for atypical absence status seizures is reported.", "question": "Subject.Race in A 10-year-old girl with Lennox-Gastaut syndrome", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "3149484_1_9948", "context": "A 10-year-old girl with Lennox-Gastaut syndrome who received intravenous lorazepam for atypical absence status seizures is reported.", "question": "Subject.Disorder in A 10-year-old girl with Lennox-Gastaut syndrome", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": "Lennox-Gastaut syndrome"}, {"id": "3149484_1_9949", "context": "A 10-year-old girl with Lennox-Gastaut syndrome who received intravenous lorazepam for atypical absence status seizures is reported.", "question": "Treatment.Drug in intravenous lorazepam", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "lorazepam"}, {"id": "3149484_1_9950", "context": "A 10-year-old girl with Lennox-Gastaut syndrome who received intravenous lorazepam for atypical absence status seizures is reported.", "question": "Treatment.Dosage in intravenous lorazepam", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "3149484_1_9951", "context": "A 10-year-old girl with Lennox-Gastaut syndrome who received intravenous lorazepam for atypical absence status seizures is reported.", "question": "Treatment.Freq in intravenous lorazepam", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "3149484_1_9952", "context": "A 10-year-old girl with Lennox-Gastaut syndrome who received intravenous lorazepam for atypical absence status seizures is reported.", "question": "Treatment.Route in intravenous lorazepam", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": "intravenous"}, {"id": "3149484_1_9953", "context": "A 10-year-old girl with Lennox-Gastaut syndrome who received intravenous lorazepam for atypical absence status seizures is reported.", "question": "Treatment.Time_elapsed in intravenous lorazepam", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3149484_1_9954", "context": "A 10-year-old girl with Lennox-Gastaut syndrome who received intravenous lorazepam for atypical absence status seizures is reported.", "question": "Treatment.Duration in intravenous lorazepam", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "3149484_1_9955", "context": "A 10-year-old girl with Lennox-Gastaut syndrome who received intravenous lorazepam for atypical absence status seizures is reported.", "question": "Treatment.Disorder in intravenous lorazepam", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "atypical absence status seizures"}, {"id": "3149484_1_9956", "context": "A 10-year-old girl with Lennox-Gastaut syndrome who received intravenous lorazepam for atypical absence status seizures is reported.", "question": "Combination.Drug in intravenous lorazepam", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "10485779_10_9957", "context": "Ritonavir can inhibit the metabolism of fentanyl significantly, so caution should be exercised if fentanyl is given to patients receiving ritonavir medication.", "question": "Subject.Age in patients receiving ritonavir medication", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "10485779_10_9958", "context": "Ritonavir can inhibit the metabolism of fentanyl significantly, so caution should be exercised if fentanyl is given to patients receiving ritonavir medication.", "question": "Subject.Gender in patients receiving ritonavir medication", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "10485779_10_9959", "context": "Ritonavir can inhibit the metabolism of fentanyl significantly, so caution should be exercised if fentanyl is given to patients receiving ritonavir medication.", "question": "Subject.Population in patients receiving ritonavir medication", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "10485779_10_9960", "context": "Ritonavir can inhibit the metabolism of fentanyl significantly, so caution should be exercised if fentanyl is given to patients receiving ritonavir medication.", "question": "Subject.Race in patients receiving ritonavir medication", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "10485779_10_9961", "context": "Ritonavir can inhibit the metabolism of fentanyl significantly, so caution should be exercised if fentanyl is given to patients receiving ritonavir medication.", "question": "Subject.Disorder in patients receiving ritonavir medication", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "10485779_10_9962", "context": "Ritonavir can inhibit the metabolism of fentanyl significantly, so caution should be exercised if fentanyl is given to patients receiving ritonavir medication.", "question": "Treatment.Drug in fentanyl", "question_type": "Adverse_event.Treatment.Drug", "answers": "fentanyl; Ritonavir"}, {"id": "10485779_10_9963", "context": "Ritonavir can inhibit the metabolism of fentanyl significantly, so caution should be exercised if fentanyl is given to patients receiving ritonavir medication.", "question": "Treatment.Dosage in fentanyl", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10485779_10_9964", "context": "Ritonavir can inhibit the metabolism of fentanyl significantly, so caution should be exercised if fentanyl is given to patients receiving ritonavir medication.", "question": "Treatment.Freq in fentanyl", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10485779_10_9965", "context": "Ritonavir can inhibit the metabolism of fentanyl significantly, so caution should be exercised if fentanyl is given to patients receiving ritonavir medication.", "question": "Treatment.Route in fentanyl", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10485779_10_9966", "context": "Ritonavir can inhibit the metabolism of fentanyl significantly, so caution should be exercised if fentanyl is given to patients receiving ritonavir medication.", "question": "Treatment.Time_elapsed in fentanyl", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10485779_10_9967", "context": "Ritonavir can inhibit the metabolism of fentanyl significantly, so caution should be exercised if fentanyl is given to patients receiving ritonavir medication.", "question": "Treatment.Duration in fentanyl", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10485779_10_9968", "context": "Ritonavir can inhibit the metabolism of fentanyl significantly, so caution should be exercised if fentanyl is given to patients receiving ritonavir medication.", "question": "Treatment.Disorder in fentanyl", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10485779_10_9969", "context": "Ritonavir can inhibit the metabolism of fentanyl significantly, so caution should be exercised if fentanyl is given to patients receiving ritonavir medication.", "question": "Combination.Drug in fentanyl", "question_type": "Adverse_event.Combination.Drug", "answers": "fentanyl; Ritonavir"}, {"id": "8739289_7_9970", "context": "This case emphasizes the importance of the evaluation of lithium-associated polyuria with a direct measurement of plasma vasopressin, interpreted with simultaneous plasma and urine osmolality to secure the correct diagnosis and ensure appropriate therapeutic management.", "question": "Subject.Age in This case", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "8739289_7_9971", "context": "This case emphasizes the importance of the evaluation of lithium-associated polyuria with a direct measurement of plasma vasopressin, interpreted with simultaneous plasma and urine osmolality to secure the correct diagnosis and ensure appropriate therapeutic management.", "question": "Subject.Gender in This case", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "8739289_7_9972", "context": "This case emphasizes the importance of the evaluation of lithium-associated polyuria with a direct measurement of plasma vasopressin, interpreted with simultaneous plasma and urine osmolality to secure the correct diagnosis and ensure appropriate therapeutic management.", "question": "Subject.Population in This case", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "8739289_7_9973", "context": "This case emphasizes the importance of the evaluation of lithium-associated polyuria with a direct measurement of plasma vasopressin, interpreted with simultaneous plasma and urine osmolality to secure the correct diagnosis and ensure appropriate therapeutic management.", "question": "Subject.Race in This case", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "8739289_7_9974", "context": "This case emphasizes the importance of the evaluation of lithium-associated polyuria with a direct measurement of plasma vasopressin, interpreted with simultaneous plasma and urine osmolality to secure the correct diagnosis and ensure appropriate therapeutic management.", "question": "Subject.Disorder in This case", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "8739289_7_9975", "context": "This case emphasizes the importance of the evaluation of lithium-associated polyuria with a direct measurement of plasma vasopressin, interpreted with simultaneous plasma and urine osmolality to secure the correct diagnosis and ensure appropriate therapeutic management.", "question": "Treatment.Drug in lithium", "question_type": "Adverse_event.Treatment.Drug", "answers": "lithium"}, {"id": "8739289_7_9976", "context": "This case emphasizes the importance of the evaluation of lithium-associated polyuria with a direct measurement of plasma vasopressin, interpreted with simultaneous plasma and urine osmolality to secure the correct diagnosis and ensure appropriate therapeutic management.", "question": "Treatment.Dosage in lithium", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8739289_7_9977", "context": "This case emphasizes the importance of the evaluation of lithium-associated polyuria with a direct measurement of plasma vasopressin, interpreted with simultaneous plasma and urine osmolality to secure the correct diagnosis and ensure appropriate therapeutic management.", "question": "Treatment.Freq in lithium", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8739289_7_9978", "context": "This case emphasizes the importance of the evaluation of lithium-associated polyuria with a direct measurement of plasma vasopressin, interpreted with simultaneous plasma and urine osmolality to secure the correct diagnosis and ensure appropriate therapeutic management.", "question": "Treatment.Route in lithium", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8739289_7_9979", "context": "This case emphasizes the importance of the evaluation of lithium-associated polyuria with a direct measurement of plasma vasopressin, interpreted with simultaneous plasma and urine osmolality to secure the correct diagnosis and ensure appropriate therapeutic management.", "question": "Treatment.Time_elapsed in lithium", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8739289_7_9980", "context": "This case emphasizes the importance of the evaluation of lithium-associated polyuria with a direct measurement of plasma vasopressin, interpreted with simultaneous plasma and urine osmolality to secure the correct diagnosis and ensure appropriate therapeutic management.", "question": "Treatment.Duration in lithium", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8739289_7_9981", "context": "This case emphasizes the importance of the evaluation of lithium-associated polyuria with a direct measurement of plasma vasopressin, interpreted with simultaneous plasma and urine osmolality to secure the correct diagnosis and ensure appropriate therapeutic management.", "question": "Treatment.Disorder in lithium", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8739289_7_9982", "context": "This case emphasizes the importance of the evaluation of lithium-associated polyuria with a direct measurement of plasma vasopressin, interpreted with simultaneous plasma and urine osmolality to secure the correct diagnosis and ensure appropriate therapeutic management.", "question": "Combination.Drug in lithium", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17710018_1_9983", "context": "A patient with chronic myelomonocytic leukemia developed drug-induced pulmonary toxicity after using low dose oral etoposide.", "question": "Subject.Age in A patient with chronic myelomonocytic leukemia", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "17710018_1_9984", "context": "A patient with chronic myelomonocytic leukemia developed drug-induced pulmonary toxicity after using low dose oral etoposide.", "question": "Subject.Gender in A patient with chronic myelomonocytic leukemia", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "17710018_1_9985", "context": "A patient with chronic myelomonocytic leukemia developed drug-induced pulmonary toxicity after using low dose oral etoposide.", "question": "Subject.Population in A patient with chronic myelomonocytic leukemia", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "17710018_1_9986", "context": "A patient with chronic myelomonocytic leukemia developed drug-induced pulmonary toxicity after using low dose oral etoposide.", "question": "Subject.Race in A patient with chronic myelomonocytic leukemia", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "17710018_1_9987", "context": "A patient with chronic myelomonocytic leukemia developed drug-induced pulmonary toxicity after using low dose oral etoposide.", "question": "Subject.Disorder in A patient with chronic myelomonocytic leukemia", "question_type": "Adverse_event.Subject.Disorder", "answers": "chronic myelomonocytic leukemia"}, {"id": "17710018_1_9988", "context": "A patient with chronic myelomonocytic leukemia developed drug-induced pulmonary toxicity after using low dose oral etoposide.", "question": "Treatment.Drug in using low dose oral etoposide", "question_type": "Adverse_event.Treatment.Drug", "answers": "etoposide"}, {"id": "17710018_1_9989", "context": "A patient with chronic myelomonocytic leukemia developed drug-induced pulmonary toxicity after using low dose oral etoposide.", "question": "Treatment.Dosage in using low dose oral etoposide", "question_type": "Adverse_event.Treatment.Dosage", "answers": "low dose"}, {"id": "17710018_1_9990", "context": "A patient with chronic myelomonocytic leukemia developed drug-induced pulmonary toxicity after using low dose oral etoposide.", "question": "Treatment.Freq in using low dose oral etoposide", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17710018_1_9991", "context": "A patient with chronic myelomonocytic leukemia developed drug-induced pulmonary toxicity after using low dose oral etoposide.", "question": "Treatment.Route in using low dose oral etoposide", "question_type": "Adverse_event.Treatment.Route", "answers": "oral"}, {"id": "17710018_1_9992", "context": "A patient with chronic myelomonocytic leukemia developed drug-induced pulmonary toxicity after using low dose oral etoposide.", "question": "Treatment.Time_elapsed in using low dose oral etoposide", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17710018_1_9993", "context": "A patient with chronic myelomonocytic leukemia developed drug-induced pulmonary toxicity after using low dose oral etoposide.", "question": "Treatment.Duration in using low dose oral etoposide", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17710018_1_9994", "context": "A patient with chronic myelomonocytic leukemia developed drug-induced pulmonary toxicity after using low dose oral etoposide.", "question": "Treatment.Disorder in using low dose oral etoposide", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17710018_1_9995", "context": "A patient with chronic myelomonocytic leukemia developed drug-induced pulmonary toxicity after using low dose oral etoposide.", "question": "Combination.Drug in using low dose oral etoposide", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10442258_2_9996", "context": "Alopecia and hair loss are rare side effects of psychotropic drugs.", "question": "Treatment.Drug in psychotropic drugs", "question_type": "Adverse_event.Treatment.Drug", "answers": "psychotropic"}, {"id": "10442258_2_9997", "context": "Alopecia and hair loss are rare side effects of psychotropic drugs.", "question": "Treatment.Dosage in psychotropic drugs", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10442258_2_9998", "context": "Alopecia and hair loss are rare side effects of psychotropic drugs.", "question": "Treatment.Freq in psychotropic drugs", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10442258_2_9999", "context": "Alopecia and hair loss are rare side effects of psychotropic drugs.", "question": "Treatment.Route in psychotropic drugs", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10442258_2_10000", "context": "Alopecia and hair loss are rare side effects of psychotropic drugs.", "question": "Treatment.Time_elapsed in psychotropic drugs", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10442258_2_10001", "context": "Alopecia and hair loss are rare side effects of psychotropic drugs.", "question": "Treatment.Duration in psychotropic drugs", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10442258_2_10002", "context": "Alopecia and hair loss are rare side effects of psychotropic drugs.", "question": "Treatment.Disorder in psychotropic drugs", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10442258_2_10003", "context": "Alopecia and hair loss are rare side effects of psychotropic drugs.", "question": "Combination.Drug in psychotropic drugs", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11126885_1_10004", "context": "Occult quinine-induced thrombocytopenia.", "question": "Treatment.Drug in quinine", "question_type": "Adverse_event.Treatment.Drug", "answers": "quinine"}, {"id": "11126885_1_10005", "context": "Occult quinine-induced thrombocytopenia.", "question": "Treatment.Dosage in quinine", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11126885_1_10006", "context": "Occult quinine-induced thrombocytopenia.", "question": "Treatment.Freq in quinine", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11126885_1_10007", "context": "Occult quinine-induced thrombocytopenia.", "question": "Treatment.Route in quinine", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11126885_1_10008", "context": "Occult quinine-induced thrombocytopenia.", "question": "Treatment.Time_elapsed in quinine", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11126885_1_10009", "context": "Occult quinine-induced thrombocytopenia.", "question": "Treatment.Duration in quinine", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11126885_1_10010", "context": "Occult quinine-induced thrombocytopenia.", "question": "Treatment.Disorder in quinine", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11126885_1_10011", "context": "Occult quinine-induced thrombocytopenia.", "question": "Combination.Drug in quinine", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "19296063_3_10012", "context": "We report the case of a 17-year-old male who developed chest pain, elevated cardiac biomarkers, and acute left ventricular dysfunction following a single dose of methylphenidate.", "question": "Subject.Age in a 17-year-old male", "question_type": "Adverse_event.Subject.Age", "answers": "17-year-old"}, {"id": "19296063_3_10013", "context": "We report the case of a 17-year-old male who developed chest pain, elevated cardiac biomarkers, and acute left ventricular dysfunction following a single dose of methylphenidate.", "question": "Subject.Gender in a 17-year-old male", "question_type": "Adverse_event.Subject.Gender", "answers": "male"}, {"id": "19296063_3_10014", "context": "We report the case of a 17-year-old male who developed chest pain, elevated cardiac biomarkers, and acute left ventricular dysfunction following a single dose of methylphenidate.", "question": "Subject.Population in a 17-year-old male", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "19296063_3_10015", "context": "We report the case of a 17-year-old male who developed chest pain, elevated cardiac biomarkers, and acute left ventricular dysfunction following a single dose of methylphenidate.", "question": "Subject.Race in a 17-year-old male", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "19296063_3_10016", "context": "We report the case of a 17-year-old male who developed chest pain, elevated cardiac biomarkers, and acute left ventricular dysfunction following a single dose of methylphenidate.", "question": "Subject.Disorder in a 17-year-old male", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "19296063_3_10017", "context": "We report the case of a 17-year-old male who developed chest pain, elevated cardiac biomarkers, and acute left ventricular dysfunction following a single dose of methylphenidate.", "question": "Treatment.Drug in a single dose of methylphenidate", "question_type": "Adverse_event.Treatment.Drug", "answers": "methylphenidate"}, {"id": "19296063_3_10018", "context": "We report the case of a 17-year-old male who developed chest pain, elevated cardiac biomarkers, and acute left ventricular dysfunction following a single dose of methylphenidate.", "question": "Treatment.Dosage in a single dose of methylphenidate", "question_type": "Adverse_event.Treatment.Dosage", "answers": "a single dose"}, {"id": "19296063_3_10019", "context": "We report the case of a 17-year-old male who developed chest pain, elevated cardiac biomarkers, and acute left ventricular dysfunction following a single dose of methylphenidate.", "question": "Treatment.Freq in a single dose of methylphenidate", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "19296063_3_10020", "context": "We report the case of a 17-year-old male who developed chest pain, elevated cardiac biomarkers, and acute left ventricular dysfunction following a single dose of methylphenidate.", "question": "Treatment.Route in a single dose of methylphenidate", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "19296063_3_10021", "context": "We report the case of a 17-year-old male who developed chest pain, elevated cardiac biomarkers, and acute left ventricular dysfunction following a single dose of methylphenidate.", "question": "Treatment.Time_elapsed in a single dose of methylphenidate", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19296063_3_10022", "context": "We report the case of a 17-year-old male who developed chest pain, elevated cardiac biomarkers, and acute left ventricular dysfunction following a single dose of methylphenidate.", "question": "Treatment.Duration in a single dose of methylphenidate", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "19296063_3_10023", "context": "We report the case of a 17-year-old male who developed chest pain, elevated cardiac biomarkers, and acute left ventricular dysfunction following a single dose of methylphenidate.", "question": "Treatment.Disorder in a single dose of methylphenidate", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "19296063_3_10024", "context": "We report the case of a 17-year-old male who developed chest pain, elevated cardiac biomarkers, and acute left ventricular dysfunction following a single dose of methylphenidate.", "question": "Combination.Drug in a single dose of methylphenidate", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9925865_2_10025", "context": "In patients with swallowing dysfunction and pneumonia, a history of mineral oil use should be obtained and a diagnosis of ELP should be considered in the differential diagnoses if mineral oil use has occurred.", "question": "Subject.Age in In patients with swallowing dysfunction and pneumonia", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "9925865_2_10026", "context": "In patients with swallowing dysfunction and pneumonia, a history of mineral oil use should be obtained and a diagnosis of ELP should be considered in the differential diagnoses if mineral oil use has occurred.", "question": "Subject.Gender in In patients with swallowing dysfunction and pneumonia", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "9925865_2_10027", "context": "In patients with swallowing dysfunction and pneumonia, a history of mineral oil use should be obtained and a diagnosis of ELP should be considered in the differential diagnoses if mineral oil use has occurred.", "question": "Subject.Population in In patients with swallowing dysfunction and pneumonia", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "9925865_2_10028", "context": "In patients with swallowing dysfunction and pneumonia, a history of mineral oil use should be obtained and a diagnosis of ELP should be considered in the differential diagnoses if mineral oil use has occurred.", "question": "Subject.Race in In patients with swallowing dysfunction and pneumonia", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "9925865_2_10029", "context": "In patients with swallowing dysfunction and pneumonia, a history of mineral oil use should be obtained and a diagnosis of ELP should be considered in the differential diagnoses if mineral oil use has occurred.", "question": "Subject.Disorder in In patients with swallowing dysfunction and pneumonia", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "9925865_2_10030", "context": "In patients with swallowing dysfunction and pneumonia, a history of mineral oil use should be obtained and a diagnosis of ELP should be considered in the differential diagnoses if mineral oil use has occurred.", "question": "Treatment.Drug in a history of mineral oil use", "question_type": "Adverse_event.Treatment.Drug", "answers": "mineral oil"}, {"id": "9925865_2_10031", "context": "In patients with swallowing dysfunction and pneumonia, a history of mineral oil use should be obtained and a diagnosis of ELP should be considered in the differential diagnoses if mineral oil use has occurred.", "question": "Treatment.Dosage in a history of mineral oil use", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9925865_2_10032", "context": "In patients with swallowing dysfunction and pneumonia, a history of mineral oil use should be obtained and a diagnosis of ELP should be considered in the differential diagnoses if mineral oil use has occurred.", "question": "Treatment.Freq in a history of mineral oil use", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9925865_2_10033", "context": "In patients with swallowing dysfunction and pneumonia, a history of mineral oil use should be obtained and a diagnosis of ELP should be considered in the differential diagnoses if mineral oil use has occurred.", "question": "Treatment.Route in a history of mineral oil use", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9925865_2_10034", "context": "In patients with swallowing dysfunction and pneumonia, a history of mineral oil use should be obtained and a diagnosis of ELP should be considered in the differential diagnoses if mineral oil use has occurred.", "question": "Treatment.Time_elapsed in a history of mineral oil use", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9925865_2_10035", "context": "In patients with swallowing dysfunction and pneumonia, a history of mineral oil use should be obtained and a diagnosis of ELP should be considered in the differential diagnoses if mineral oil use has occurred.", "question": "Treatment.Duration in a history of mineral oil use", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9925865_2_10036", "context": "In patients with swallowing dysfunction and pneumonia, a history of mineral oil use should be obtained and a diagnosis of ELP should be considered in the differential diagnoses if mineral oil use has occurred.", "question": "Treatment.Disorder in a history of mineral oil use", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9925865_2_10037", "context": "In patients with swallowing dysfunction and pneumonia, a history of mineral oil use should be obtained and a diagnosis of ELP should be considered in the differential diagnoses if mineral oil use has occurred.", "question": "Combination.Drug in a history of mineral oil use", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15053046_1_10038", "context": "Agranulocytosis induced by vancomycin in an ESRD patient on CAPD.", "question": "Subject.Age in ESRD patient on CAPD", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "15053046_1_10039", "context": "Agranulocytosis induced by vancomycin in an ESRD patient on CAPD.", "question": "Subject.Gender in ESRD patient on CAPD", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15053046_1_10040", "context": "Agranulocytosis induced by vancomycin in an ESRD patient on CAPD.", "question": "Subject.Population in ESRD patient on CAPD", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "15053046_1_10041", "context": "Agranulocytosis induced by vancomycin in an ESRD patient on CAPD.", "question": "Subject.Race in ESRD patient on CAPD", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15053046_1_10042", "context": "Agranulocytosis induced by vancomycin in an ESRD patient on CAPD.", "question": "Subject.Disorder in ESRD patient on CAPD", "question_type": "Adverse_event.Subject.Disorder", "answers": "ESRD"}, {"id": "15053046_1_10043", "context": "Agranulocytosis induced by vancomycin in an ESRD patient on CAPD.", "question": "Treatment.Drug in vancomycin", "question_type": "Adverse_event.Treatment.Drug", "answers": "vancomycin"}, {"id": "15053046_1_10044", "context": "Agranulocytosis induced by vancomycin in an ESRD patient on CAPD.", "question": "Treatment.Dosage in vancomycin", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15053046_1_10045", "context": "Agranulocytosis induced by vancomycin in an ESRD patient on CAPD.", "question": "Treatment.Freq in vancomycin", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15053046_1_10046", "context": "Agranulocytosis induced by vancomycin in an ESRD patient on CAPD.", "question": "Treatment.Route in vancomycin", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15053046_1_10047", "context": "Agranulocytosis induced by vancomycin in an ESRD patient on CAPD.", "question": "Treatment.Time_elapsed in vancomycin", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15053046_1_10048", "context": "Agranulocytosis induced by vancomycin in an ESRD patient on CAPD.", "question": "Treatment.Duration in vancomycin", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15053046_1_10049", "context": "Agranulocytosis induced by vancomycin in an ESRD patient on CAPD.", "question": "Treatment.Disorder in vancomycin", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15053046_1_10050", "context": "Agranulocytosis induced by vancomycin in an ESRD patient on CAPD.", "question": "Combination.Drug in vancomycin", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16682062_1_10051", "context": "First case of ivermectin-induced severe hepatitis.", "question": "Treatment.Drug in ivermectin", "question_type": "Adverse_event.Treatment.Drug", "answers": "ivermectin"}, {"id": "16682062_1_10052", "context": "First case of ivermectin-induced severe hepatitis.", "question": "Treatment.Dosage in ivermectin", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16682062_1_10053", "context": "First case of ivermectin-induced severe hepatitis.", "question": "Treatment.Freq in ivermectin", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16682062_1_10054", "context": "First case of ivermectin-induced severe hepatitis.", "question": "Treatment.Route in ivermectin", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16682062_1_10055", "context": "First case of ivermectin-induced severe hepatitis.", "question": "Treatment.Time_elapsed in ivermectin", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16682062_1_10056", "context": "First case of ivermectin-induced severe hepatitis.", "question": "Treatment.Duration in ivermectin", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16682062_1_10057", "context": "First case of ivermectin-induced severe hepatitis.", "question": "Treatment.Disorder in ivermectin", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16682062_1_10058", "context": "First case of ivermectin-induced severe hepatitis.", "question": "Combination.Drug in ivermectin", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "2549018_4_10059", "context": "The authors suggest that fluoxetine-induced akathisia may be caused by serotonergically mediated inhibition of dopaminergic neurotransmission and that the pathophysiology of fluoxetine-induced akathisia and tricyclic antidepressant-induced \"jitteriness\" may be identical.", "question": "Treatment.Drug in fluoxetine", "question_type": "Adverse_event.Treatment.Drug", "answers": "fluoxetine"}, {"id": "2549018_4_10060", "context": "The authors suggest that fluoxetine-induced akathisia may be caused by serotonergically mediated inhibition of dopaminergic neurotransmission and that the pathophysiology of fluoxetine-induced akathisia and tricyclic antidepressant-induced \"jitteriness\" may be identical.", "question": "Treatment.Dosage in fluoxetine", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "2549018_4_10061", "context": "The authors suggest that fluoxetine-induced akathisia may be caused by serotonergically mediated inhibition of dopaminergic neurotransmission and that the pathophysiology of fluoxetine-induced akathisia and tricyclic antidepressant-induced \"jitteriness\" may be identical.", "question": "Treatment.Freq in fluoxetine", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2549018_4_10062", "context": "The authors suggest that fluoxetine-induced akathisia may be caused by serotonergically mediated inhibition of dopaminergic neurotransmission and that the pathophysiology of fluoxetine-induced akathisia and tricyclic antidepressant-induced \"jitteriness\" may be identical.", "question": "Treatment.Route in fluoxetine", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "2549018_4_10063", "context": "The authors suggest that fluoxetine-induced akathisia may be caused by serotonergically mediated inhibition of dopaminergic neurotransmission and that the pathophysiology of fluoxetine-induced akathisia and tricyclic antidepressant-induced \"jitteriness\" may be identical.", "question": "Treatment.Time_elapsed in fluoxetine", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2549018_4_10064", "context": "The authors suggest that fluoxetine-induced akathisia may be caused by serotonergically mediated inhibition of dopaminergic neurotransmission and that the pathophysiology of fluoxetine-induced akathisia and tricyclic antidepressant-induced \"jitteriness\" may be identical.", "question": "Treatment.Duration in fluoxetine", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2549018_4_10065", "context": "The authors suggest that fluoxetine-induced akathisia may be caused by serotonergically mediated inhibition of dopaminergic neurotransmission and that the pathophysiology of fluoxetine-induced akathisia and tricyclic antidepressant-induced \"jitteriness\" may be identical.", "question": "Treatment.Disorder in fluoxetine", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "2549018_4_10066", "context": "The authors suggest that fluoxetine-induced akathisia may be caused by serotonergically mediated inhibition of dopaminergic neurotransmission and that the pathophysiology of fluoxetine-induced akathisia and tricyclic antidepressant-induced \"jitteriness\" may be identical.", "question": "Combination.Drug in fluoxetine", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "19755414_10_10067", "context": "The use of telithromycin in patients receiving multiple doses of oxycodone for pain relief may increase the risk of opioid adverse effects.", "question": "Subject.Age in patients receiving multiple doses of oxycodone for pain relief", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "19755414_10_10068", "context": "The use of telithromycin in patients receiving multiple doses of oxycodone for pain relief may increase the risk of opioid adverse effects.", "question": "Subject.Gender in patients receiving multiple doses of oxycodone for pain relief", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "19755414_10_10069", "context": "The use of telithromycin in patients receiving multiple doses of oxycodone for pain relief may increase the risk of opioid adverse effects.", "question": "Subject.Population in patients receiving multiple doses of oxycodone for pain relief", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "19755414_10_10070", "context": "The use of telithromycin in patients receiving multiple doses of oxycodone for pain relief may increase the risk of opioid adverse effects.", "question": "Subject.Race in patients receiving multiple doses of oxycodone for pain relief", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "19755414_10_10071", "context": "The use of telithromycin in patients receiving multiple doses of oxycodone for pain relief may increase the risk of opioid adverse effects.", "question": "Subject.Disorder in patients receiving multiple doses of oxycodone for pain relief", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "19755414_10_10072", "context": "The use of telithromycin in patients receiving multiple doses of oxycodone for pain relief may increase the risk of opioid adverse effects.", "question": "Treatment.Drug in telithromycin", "question_type": "Adverse_event.Treatment.Drug", "answers": "telithromycin"}, {"id": "19755414_10_10073", "context": "The use of telithromycin in patients receiving multiple doses of oxycodone for pain relief may increase the risk of opioid adverse effects.", "question": "Treatment.Dosage in telithromycin", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "19755414_10_10074", "context": "The use of telithromycin in patients receiving multiple doses of oxycodone for pain relief may increase the risk of opioid adverse effects.", "question": "Treatment.Freq in telithromycin", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "19755414_10_10075", "context": "The use of telithromycin in patients receiving multiple doses of oxycodone for pain relief may increase the risk of opioid adverse effects.", "question": "Treatment.Route in telithromycin", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "19755414_10_10076", "context": "The use of telithromycin in patients receiving multiple doses of oxycodone for pain relief may increase the risk of opioid adverse effects.", "question": "Treatment.Time_elapsed in telithromycin", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19755414_10_10077", "context": "The use of telithromycin in patients receiving multiple doses of oxycodone for pain relief may increase the risk of opioid adverse effects.", "question": "Treatment.Duration in telithromycin", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "19755414_10_10078", "context": "The use of telithromycin in patients receiving multiple doses of oxycodone for pain relief may increase the risk of opioid adverse effects.", "question": "Treatment.Disorder in telithromycin", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "19755414_10_10079", "context": "The use of telithromycin in patients receiving multiple doses of oxycodone for pain relief may increase the risk of opioid adverse effects.", "question": "Combination.Drug in telithromycin", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17195428_1_10080", "context": "A case of metoclopramide-induced oculogyric crisis in a 16-year-old girl with cystic fibrosis.", "question": "Subject.Age in a 16-year-old girl with cystic fibrosis", "question_type": "Adverse_event.Subject.Age", "answers": "16-year-old"}, {"id": "17195428_1_10081", "context": "A case of metoclopramide-induced oculogyric crisis in a 16-year-old girl with cystic fibrosis.", "question": "Subject.Gender in a 16-year-old girl with cystic fibrosis", "question_type": "Adverse_event.Subject.Gender", "answers": "girl"}, {"id": "17195428_1_10082", "context": "A case of metoclopramide-induced oculogyric crisis in a 16-year-old girl with cystic fibrosis.", "question": "Subject.Population in a 16-year-old girl with cystic fibrosis", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "17195428_1_10083", "context": "A case of metoclopramide-induced oculogyric crisis in a 16-year-old girl with cystic fibrosis.", "question": "Subject.Race in a 16-year-old girl with cystic fibrosis", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "17195428_1_10084", "context": "A case of metoclopramide-induced oculogyric crisis in a 16-year-old girl with cystic fibrosis.", "question": "Subject.Disorder in a 16-year-old girl with cystic fibrosis", "question_type": "Adverse_event.Subject.Disorder", "answers": "cystic fibrosis"}, {"id": "17195428_1_10085", "context": "A case of metoclopramide-induced oculogyric crisis in a 16-year-old girl with cystic fibrosis.", "question": "Treatment.Drug in metoclopramide", "question_type": "Adverse_event.Treatment.Drug", "answers": "metoclopramide"}, {"id": "17195428_1_10086", "context": "A case of metoclopramide-induced oculogyric crisis in a 16-year-old girl with cystic fibrosis.", "question": "Treatment.Dosage in metoclopramide", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17195428_1_10087", "context": "A case of metoclopramide-induced oculogyric crisis in a 16-year-old girl with cystic fibrosis.", "question": "Treatment.Freq in metoclopramide", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17195428_1_10088", "context": "A case of metoclopramide-induced oculogyric crisis in a 16-year-old girl with cystic fibrosis.", "question": "Treatment.Route in metoclopramide", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17195428_1_10089", "context": "A case of metoclopramide-induced oculogyric crisis in a 16-year-old girl with cystic fibrosis.", "question": "Treatment.Time_elapsed in metoclopramide", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17195428_1_10090", "context": "A case of metoclopramide-induced oculogyric crisis in a 16-year-old girl with cystic fibrosis.", "question": "Treatment.Duration in metoclopramide", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17195428_1_10091", "context": "A case of metoclopramide-induced oculogyric crisis in a 16-year-old girl with cystic fibrosis.", "question": "Treatment.Disorder in metoclopramide", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17195428_1_10092", "context": "A case of metoclopramide-induced oculogyric crisis in a 16-year-old girl with cystic fibrosis.", "question": "Combination.Drug in metoclopramide", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16099004_4_10093", "context": "Supported by a subtherapeutic quinine level, we hypothesise that a drug interaction with phenytoin may compromise the efficacy of quinine in the treatment of malaria.", "question": "Treatment.Drug in phenytoin; quinine", "question_type": "Adverse_event.Treatment.Drug", "answers": "phenytoin; quinine"}, {"id": "16099004_4_10094", "context": "Supported by a subtherapeutic quinine level, we hypothesise that a drug interaction with phenytoin may compromise the efficacy of quinine in the treatment of malaria.", "question": "Treatment.Dosage in phenytoin; quinine", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16099004_4_10095", "context": "Supported by a subtherapeutic quinine level, we hypothesise that a drug interaction with phenytoin may compromise the efficacy of quinine in the treatment of malaria.", "question": "Treatment.Freq in phenytoin; quinine", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16099004_4_10096", "context": "Supported by a subtherapeutic quinine level, we hypothesise that a drug interaction with phenytoin may compromise the efficacy of quinine in the treatment of malaria.", "question": "Treatment.Route in phenytoin; quinine", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16099004_4_10097", "context": "Supported by a subtherapeutic quinine level, we hypothesise that a drug interaction with phenytoin may compromise the efficacy of quinine in the treatment of malaria.", "question": "Treatment.Time_elapsed in phenytoin; quinine", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16099004_4_10098", "context": "Supported by a subtherapeutic quinine level, we hypothesise that a drug interaction with phenytoin may compromise the efficacy of quinine in the treatment of malaria.", "question": "Treatment.Duration in phenytoin; quinine", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16099004_4_10099", "context": "Supported by a subtherapeutic quinine level, we hypothesise that a drug interaction with phenytoin may compromise the efficacy of quinine in the treatment of malaria.", "question": "Treatment.Disorder in phenytoin; quinine", "question_type": "Adverse_event.Treatment.Disorder", "answers": "malaria"}, {"id": "16099004_4_10100", "context": "Supported by a subtherapeutic quinine level, we hypothesise that a drug interaction with phenytoin may compromise the efficacy of quinine in the treatment of malaria.", "question": "Combination.Drug in phenytoin; quinine", "question_type": "Adverse_event.Combination.Drug", "answers": "phenytoin; quinine"}, {"id": "16688722_1_10101", "context": "Sporadic rippling muscle disease unmasked by simvastatin.", "question": "Treatment.Drug in simvastatin", "question_type": "Adverse_event.Treatment.Drug", "answers": "simvastatin"}, {"id": "16688722_1_10102", "context": "Sporadic rippling muscle disease unmasked by simvastatin.", "question": "Treatment.Dosage in simvastatin", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16688722_1_10103", "context": "Sporadic rippling muscle disease unmasked by simvastatin.", "question": "Treatment.Freq in simvastatin", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16688722_1_10104", "context": "Sporadic rippling muscle disease unmasked by simvastatin.", "question": "Treatment.Route in simvastatin", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16688722_1_10105", "context": "Sporadic rippling muscle disease unmasked by simvastatin.", "question": "Treatment.Time_elapsed in simvastatin", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16688722_1_10106", "context": "Sporadic rippling muscle disease unmasked by simvastatin.", "question": "Treatment.Duration in simvastatin", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16688722_1_10107", "context": "Sporadic rippling muscle disease unmasked by simvastatin.", "question": "Treatment.Disorder in simvastatin", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16688722_1_10108", "context": "Sporadic rippling muscle disease unmasked by simvastatin.", "question": "Combination.Drug in simvastatin", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16449538_1_10109", "context": "An objective causality assessment by use of the Naranjo probability scale revealed that NCSE due to ifosfamide was probable.", "question": "Treatment.Drug in ifosfamide", "question_type": "Adverse_event.Treatment.Drug", "answers": "ifosfamide"}, {"id": "16449538_1_10110", "context": "An objective causality assessment by use of the Naranjo probability scale revealed that NCSE due to ifosfamide was probable.", "question": "Treatment.Dosage in ifosfamide", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16449538_1_10111", "context": "An objective causality assessment by use of the Naranjo probability scale revealed that NCSE due to ifosfamide was probable.", "question": "Treatment.Freq in ifosfamide", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16449538_1_10112", "context": "An objective causality assessment by use of the Naranjo probability scale revealed that NCSE due to ifosfamide was probable.", "question": "Treatment.Route in ifosfamide", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16449538_1_10113", "context": "An objective causality assessment by use of the Naranjo probability scale revealed that NCSE due to ifosfamide was probable.", "question": "Treatment.Time_elapsed in ifosfamide", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16449538_1_10114", "context": "An objective causality assessment by use of the Naranjo probability scale revealed that NCSE due to ifosfamide was probable.", "question": "Treatment.Duration in ifosfamide", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16449538_1_10115", "context": "An objective causality assessment by use of the Naranjo probability scale revealed that NCSE due to ifosfamide was probable.", "question": "Treatment.Disorder in ifosfamide", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16449538_1_10116", "context": "An objective causality assessment by use of the Naranjo probability scale revealed that NCSE due to ifosfamide was probable.", "question": "Combination.Drug in ifosfamide", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15719254_1_10117", "context": "Cis-retinoic acid (RA) may further increase the risk of developing BMTN.", "question": "Treatment.Drug in Cis-retinoic acid (RA)", "question_type": "Adverse_event.Treatment.Drug", "answers": "Cis-retinoic acid"}, {"id": "15719254_1_10118", "context": "Cis-retinoic acid (RA) may further increase the risk of developing BMTN.", "question": "Treatment.Dosage in Cis-retinoic acid (RA)", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15719254_1_10119", "context": "Cis-retinoic acid (RA) may further increase the risk of developing BMTN.", "question": "Treatment.Freq in Cis-retinoic acid (RA)", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15719254_1_10120", "context": "Cis-retinoic acid (RA) may further increase the risk of developing BMTN.", "question": "Treatment.Route in Cis-retinoic acid (RA)", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15719254_1_10121", "context": "Cis-retinoic acid (RA) may further increase the risk of developing BMTN.", "question": "Treatment.Time_elapsed in Cis-retinoic acid (RA)", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15719254_1_10122", "context": "Cis-retinoic acid (RA) may further increase the risk of developing BMTN.", "question": "Treatment.Duration in Cis-retinoic acid (RA)", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15719254_1_10123", "context": "Cis-retinoic acid (RA) may further increase the risk of developing BMTN.", "question": "Treatment.Disorder in Cis-retinoic acid (RA)", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15719254_1_10124", "context": "Cis-retinoic acid (RA) may further increase the risk of developing BMTN.", "question": "Combination.Drug in Cis-retinoic acid (RA)", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12546343_3_10125", "context": "He was later skin tested to confirm allergy to MTX.", "question": "Subject.Age in He", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "12546343_3_10126", "context": "He was later skin tested to confirm allergy to MTX.", "question": "Subject.Gender in He", "question_type": "Adverse_event.Subject.Gender", "answers": "He"}, {"id": "12546343_3_10127", "context": "He was later skin tested to confirm allergy to MTX.", "question": "Subject.Population in He", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "12546343_3_10128", "context": "He was later skin tested to confirm allergy to MTX.", "question": "Subject.Race in He", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "12546343_3_10129", "context": "He was later skin tested to confirm allergy to MTX.", "question": "Subject.Disorder in He", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "12546343_3_10130", "context": "He was later skin tested to confirm allergy to MTX.", "question": "Treatment.Drug in MTX", "question_type": "Adverse_event.Treatment.Drug", "answers": "MTX"}, {"id": "12546343_3_10131", "context": "He was later skin tested to confirm allergy to MTX.", "question": "Treatment.Dosage in MTX", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12546343_3_10132", "context": "He was later skin tested to confirm allergy to MTX.", "question": "Treatment.Freq in MTX", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12546343_3_10133", "context": "He was later skin tested to confirm allergy to MTX.", "question": "Treatment.Route in MTX", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12546343_3_10134", "context": "He was later skin tested to confirm allergy to MTX.", "question": "Treatment.Time_elapsed in MTX", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12546343_3_10135", "context": "He was later skin tested to confirm allergy to MTX.", "question": "Treatment.Duration in MTX", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12546343_3_10136", "context": "He was later skin tested to confirm allergy to MTX.", "question": "Treatment.Disorder in MTX", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12546343_3_10137", "context": "He was later skin tested to confirm allergy to MTX.", "question": "Combination.Drug in MTX", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11319599_1_10138", "context": "Indolent aspergillus arthritis complicating fludarabine-based non-myeloablative stem cell transplantation.", "question": "Treatment.Drug in fludarabine", "question_type": "Adverse_event.Treatment.Drug", "answers": "fludarabine"}, {"id": "11319599_1_10139", "context": "Indolent aspergillus arthritis complicating fludarabine-based non-myeloablative stem cell transplantation.", "question": "Treatment.Dosage in fludarabine", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11319599_1_10140", "context": "Indolent aspergillus arthritis complicating fludarabine-based non-myeloablative stem cell transplantation.", "question": "Treatment.Freq in fludarabine", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11319599_1_10141", "context": "Indolent aspergillus arthritis complicating fludarabine-based non-myeloablative stem cell transplantation.", "question": "Treatment.Route in fludarabine", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11319599_1_10142", "context": "Indolent aspergillus arthritis complicating fludarabine-based non-myeloablative stem cell transplantation.", "question": "Treatment.Time_elapsed in fludarabine", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11319599_1_10143", "context": "Indolent aspergillus arthritis complicating fludarabine-based non-myeloablative stem cell transplantation.", "question": "Treatment.Duration in fludarabine", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11319599_1_10144", "context": "Indolent aspergillus arthritis complicating fludarabine-based non-myeloablative stem cell transplantation.", "question": "Treatment.Disorder in fludarabine", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11319599_1_10145", "context": "Indolent aspergillus arthritis complicating fludarabine-based non-myeloablative stem cell transplantation.", "question": "Combination.Drug in fludarabine", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "19296063_1_10146", "context": "A case of acute cardiomyopathy and pericarditis associated with methylphenidate.", "question": "Treatment.Drug in methylphenidate", "question_type": "Adverse_event.Treatment.Drug", "answers": "methylphenidate"}, {"id": "19296063_1_10147", "context": "A case of acute cardiomyopathy and pericarditis associated with methylphenidate.", "question": "Treatment.Dosage in methylphenidate", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "19296063_1_10148", "context": "A case of acute cardiomyopathy and pericarditis associated with methylphenidate.", "question": "Treatment.Freq in methylphenidate", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "19296063_1_10149", "context": "A case of acute cardiomyopathy and pericarditis associated with methylphenidate.", "question": "Treatment.Route in methylphenidate", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "19296063_1_10150", "context": "A case of acute cardiomyopathy and pericarditis associated with methylphenidate.", "question": "Treatment.Time_elapsed in methylphenidate", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19296063_1_10151", "context": "A case of acute cardiomyopathy and pericarditis associated with methylphenidate.", "question": "Treatment.Duration in methylphenidate", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "19296063_1_10152", "context": "A case of acute cardiomyopathy and pericarditis associated with methylphenidate.", "question": "Treatment.Disorder in methylphenidate", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "19296063_1_10153", "context": "A case of acute cardiomyopathy and pericarditis associated with methylphenidate.", "question": "Combination.Drug in methylphenidate", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9527943_3_10154", "context": "STUDY DESIGN: Case reports are presented of three premature infants (mean gestational age 27 weeks) cared for in the intensive care nursery in whom clinically significant septal hypertrophy and left ventricular outflow tract obstruction developed during dexamethasone treatment for bronchopulmonary dysplasia.", "question": "Subject.Age in three premature infants (mean gestational age 27 weeks) cared for in the intensive care nursery", "question_type": "Adverse_event.Subject.Age", "answers": "premature infants (mean gestational age 27 weeks)"}, {"id": "9527943_3_10155", "context": "STUDY DESIGN: Case reports are presented of three premature infants (mean gestational age 27 weeks) cared for in the intensive care nursery in whom clinically significant septal hypertrophy and left ventricular outflow tract obstruction developed during dexamethasone treatment for bronchopulmonary dysplasia.", "question": "Subject.Gender in three premature infants (mean gestational age 27 weeks) cared for in the intensive care nursery", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "9527943_3_10156", "context": "STUDY DESIGN: Case reports are presented of three premature infants (mean gestational age 27 weeks) cared for in the intensive care nursery in whom clinically significant septal hypertrophy and left ventricular outflow tract obstruction developed during dexamethasone treatment for bronchopulmonary dysplasia.", "question": "Subject.Population in three premature infants (mean gestational age 27 weeks) cared for in the intensive care nursery", "question_type": "Adverse_event.Subject.Population", "answers": "three"}, {"id": "9527943_3_10157", "context": "STUDY DESIGN: Case reports are presented of three premature infants (mean gestational age 27 weeks) cared for in the intensive care nursery in whom clinically significant septal hypertrophy and left ventricular outflow tract obstruction developed during dexamethasone treatment for bronchopulmonary dysplasia.", "question": "Subject.Race in three premature infants (mean gestational age 27 weeks) cared for in the intensive care nursery", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "9527943_3_10158", "context": "STUDY DESIGN: Case reports are presented of three premature infants (mean gestational age 27 weeks) cared for in the intensive care nursery in whom clinically significant septal hypertrophy and left ventricular outflow tract obstruction developed during dexamethasone treatment for bronchopulmonary dysplasia.", "question": "Subject.Disorder in three premature infants (mean gestational age 27 weeks) cared for in the intensive care nursery", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "9527943_3_10159", "context": "STUDY DESIGN: Case reports are presented of three premature infants (mean gestational age 27 weeks) cared for in the intensive care nursery in whom clinically significant septal hypertrophy and left ventricular outflow tract obstruction developed during dexamethasone treatment for bronchopulmonary dysplasia.", "question": "Treatment.Drug in during dexamethasone treatment for bronchopulmonary dysplasia", "question_type": "Adverse_event.Treatment.Drug", "answers": "dexamethasone"}, {"id": "9527943_3_10160", "context": "STUDY DESIGN: Case reports are presented of three premature infants (mean gestational age 27 weeks) cared for in the intensive care nursery in whom clinically significant septal hypertrophy and left ventricular outflow tract obstruction developed during dexamethasone treatment for bronchopulmonary dysplasia.", "question": "Treatment.Dosage in during dexamethasone treatment for bronchopulmonary dysplasia", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9527943_3_10161", "context": "STUDY DESIGN: Case reports are presented of three premature infants (mean gestational age 27 weeks) cared for in the intensive care nursery in whom clinically significant septal hypertrophy and left ventricular outflow tract obstruction developed during dexamethasone treatment for bronchopulmonary dysplasia.", "question": "Treatment.Freq in during dexamethasone treatment for bronchopulmonary dysplasia", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9527943_3_10162", "context": "STUDY DESIGN: Case reports are presented of three premature infants (mean gestational age 27 weeks) cared for in the intensive care nursery in whom clinically significant septal hypertrophy and left ventricular outflow tract obstruction developed during dexamethasone treatment for bronchopulmonary dysplasia.", "question": "Treatment.Route in during dexamethasone treatment for bronchopulmonary dysplasia", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9527943_3_10163", "context": "STUDY DESIGN: Case reports are presented of three premature infants (mean gestational age 27 weeks) cared for in the intensive care nursery in whom clinically significant septal hypertrophy and left ventricular outflow tract obstruction developed during dexamethasone treatment for bronchopulmonary dysplasia.", "question": "Treatment.Time_elapsed in during dexamethasone treatment for bronchopulmonary dysplasia", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9527943_3_10164", "context": "STUDY DESIGN: Case reports are presented of three premature infants (mean gestational age 27 weeks) cared for in the intensive care nursery in whom clinically significant septal hypertrophy and left ventricular outflow tract obstruction developed during dexamethasone treatment for bronchopulmonary dysplasia.", "question": "Treatment.Duration in during dexamethasone treatment for bronchopulmonary dysplasia", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9527943_3_10165", "context": "STUDY DESIGN: Case reports are presented of three premature infants (mean gestational age 27 weeks) cared for in the intensive care nursery in whom clinically significant septal hypertrophy and left ventricular outflow tract obstruction developed during dexamethasone treatment for bronchopulmonary dysplasia.", "question": "Treatment.Disorder in during dexamethasone treatment for bronchopulmonary dysplasia", "question_type": "Adverse_event.Treatment.Disorder", "answers": "bronchopulmonary dysplasia."}, {"id": "9527943_3_10166", "context": "STUDY DESIGN: Case reports are presented of three premature infants (mean gestational age 27 weeks) cared for in the intensive care nursery in whom clinically significant septal hypertrophy and left ventricular outflow tract obstruction developed during dexamethasone treatment for bronchopulmonary dysplasia.", "question": "Combination.Drug in during dexamethasone treatment for bronchopulmonary dysplasia", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "2063999_1_10167", "context": "A case of the Rett syndrome with acute encephalopathy induced during calcium hopantenate treatment.", "question": "Subject.Age in A case of the Rett syndrome", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "2063999_1_10168", "context": "A case of the Rett syndrome with acute encephalopathy induced during calcium hopantenate treatment.", "question": "Subject.Gender in A case of the Rett syndrome", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "2063999_1_10169", "context": "A case of the Rett syndrome with acute encephalopathy induced during calcium hopantenate treatment.", "question": "Subject.Population in A case of the Rett syndrome", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "2063999_1_10170", "context": "A case of the Rett syndrome with acute encephalopathy induced during calcium hopantenate treatment.", "question": "Subject.Race in A case of the Rett syndrome", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "2063999_1_10171", "context": "A case of the Rett syndrome with acute encephalopathy induced during calcium hopantenate treatment.", "question": "Subject.Disorder in A case of the Rett syndrome", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "2063999_1_10172", "context": "A case of the Rett syndrome with acute encephalopathy induced during calcium hopantenate treatment.", "question": "Treatment.Drug in calcium hopantenate treatment", "question_type": "Adverse_event.Treatment.Drug", "answers": "calcium hopantenate"}, {"id": "2063999_1_10173", "context": "A case of the Rett syndrome with acute encephalopathy induced during calcium hopantenate treatment.", "question": "Treatment.Dosage in calcium hopantenate treatment", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "2063999_1_10174", "context": "A case of the Rett syndrome with acute encephalopathy induced during calcium hopantenate treatment.", "question": "Treatment.Freq in calcium hopantenate treatment", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2063999_1_10175", "context": "A case of the Rett syndrome with acute encephalopathy induced during calcium hopantenate treatment.", "question": "Treatment.Route in calcium hopantenate treatment", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "2063999_1_10176", "context": "A case of the Rett syndrome with acute encephalopathy induced during calcium hopantenate treatment.", "question": "Treatment.Time_elapsed in calcium hopantenate treatment", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2063999_1_10177", "context": "A case of the Rett syndrome with acute encephalopathy induced during calcium hopantenate treatment.", "question": "Treatment.Duration in calcium hopantenate treatment", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2063999_1_10178", "context": "A case of the Rett syndrome with acute encephalopathy induced during calcium hopantenate treatment.", "question": "Treatment.Disorder in calcium hopantenate treatment", "question_type": "Adverse_event.Treatment.Disorder", "answers": "Rett syndrome"}, {"id": "2063999_1_10179", "context": "A case of the Rett syndrome with acute encephalopathy induced during calcium hopantenate treatment.", "question": "Combination.Drug in calcium hopantenate treatment", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "25540831_1_10180", "context": "Transient serotonin syndrome caused by concurrent use of tramadol and selective serotonin reuptake inhibitor.", "question": "Treatment.Drug in concurrent use of tramadol and selective serotonin reuptake inhibitor", "question_type": "Adverse_event.Treatment.Drug", "answers": "tramadol; selective serotonin reuptake inhibitor"}, {"id": "25540831_1_10181", "context": "Transient serotonin syndrome caused by concurrent use of tramadol and selective serotonin reuptake inhibitor.", "question": "Treatment.Dosage in concurrent use of tramadol and selective serotonin reuptake inhibitor", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "25540831_1_10182", "context": "Transient serotonin syndrome caused by concurrent use of tramadol and selective serotonin reuptake inhibitor.", "question": "Treatment.Freq in concurrent use of tramadol and selective serotonin reuptake inhibitor", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "25540831_1_10183", "context": "Transient serotonin syndrome caused by concurrent use of tramadol and selective serotonin reuptake inhibitor.", "question": "Treatment.Route in concurrent use of tramadol and selective serotonin reuptake inhibitor", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "25540831_1_10184", "context": "Transient serotonin syndrome caused by concurrent use of tramadol and selective serotonin reuptake inhibitor.", "question": "Treatment.Time_elapsed in concurrent use of tramadol and selective serotonin reuptake inhibitor", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "25540831_1_10185", "context": "Transient serotonin syndrome caused by concurrent use of tramadol and selective serotonin reuptake inhibitor.", "question": "Treatment.Duration in concurrent use of tramadol and selective serotonin reuptake inhibitor", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "25540831_1_10186", "context": "Transient serotonin syndrome caused by concurrent use of tramadol and selective serotonin reuptake inhibitor.", "question": "Treatment.Disorder in concurrent use of tramadol and selective serotonin reuptake inhibitor", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "25540831_1_10187", "context": "Transient serotonin syndrome caused by concurrent use of tramadol and selective serotonin reuptake inhibitor.", "question": "Combination.Drug in concurrent use of tramadol and selective serotonin reuptake inhibitor", "question_type": "Adverse_event.Combination.Drug", "answers": "tramadol; selective serotonin reuptake inhibitor"}, {"id": "16507380_3_10188", "context": "Adverse events associated with IFN alfa-2b use are primarily constitutional symptoms.", "question": "Treatment.Drug in IFN alfa-2b", "question_type": "Adverse_event.Treatment.Drug", "answers": "IFN alfa-2b"}, {"id": "16507380_3_10189", "context": "Adverse events associated with IFN alfa-2b use are primarily constitutional symptoms.", "question": "Treatment.Dosage in IFN alfa-2b", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16507380_3_10190", "context": "Adverse events associated with IFN alfa-2b use are primarily constitutional symptoms.", "question": "Treatment.Freq in IFN alfa-2b", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16507380_3_10191", "context": "Adverse events associated with IFN alfa-2b use are primarily constitutional symptoms.", "question": "Treatment.Route in IFN alfa-2b", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16507380_3_10192", "context": "Adverse events associated with IFN alfa-2b use are primarily constitutional symptoms.", "question": "Treatment.Time_elapsed in IFN alfa-2b", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16507380_3_10193", "context": "Adverse events associated with IFN alfa-2b use are primarily constitutional symptoms.", "question": "Treatment.Duration in IFN alfa-2b", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16507380_3_10194", "context": "Adverse events associated with IFN alfa-2b use are primarily constitutional symptoms.", "question": "Treatment.Disorder in IFN alfa-2b", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16507380_3_10195", "context": "Adverse events associated with IFN alfa-2b use are primarily constitutional symptoms.", "question": "Combination.Drug in IFN alfa-2b", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7474364_2_10196", "context": "Sustained-release procainamide-induced reversible granulocytopenia after myocardial infarction.", "question": "Treatment.Drug in Sustained-release procainamide", "question_type": "Adverse_event.Treatment.Drug", "answers": "procainamide"}, {"id": "7474364_2_10197", "context": "Sustained-release procainamide-induced reversible granulocytopenia after myocardial infarction.", "question": "Treatment.Dosage in Sustained-release procainamide", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7474364_2_10198", "context": "Sustained-release procainamide-induced reversible granulocytopenia after myocardial infarction.", "question": "Treatment.Freq in Sustained-release procainamide", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7474364_2_10199", "context": "Sustained-release procainamide-induced reversible granulocytopenia after myocardial infarction.", "question": "Treatment.Route in Sustained-release procainamide", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7474364_2_10200", "context": "Sustained-release procainamide-induced reversible granulocytopenia after myocardial infarction.", "question": "Treatment.Time_elapsed in Sustained-release procainamide", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7474364_2_10201", "context": "Sustained-release procainamide-induced reversible granulocytopenia after myocardial infarction.", "question": "Treatment.Duration in Sustained-release procainamide", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7474364_2_10202", "context": "Sustained-release procainamide-induced reversible granulocytopenia after myocardial infarction.", "question": "Treatment.Disorder in Sustained-release procainamide", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7474364_2_10203", "context": "Sustained-release procainamide-induced reversible granulocytopenia after myocardial infarction.", "question": "Combination.Drug in Sustained-release procainamide", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9681211_3_10204", "context": "We describe a patient with M4 AML treated with standard chemotherapy followed by G-CSF who developed marked monocytosis on day 8 of G-CSF therapy.", "question": "Subject.Age in a patient with M4 AML", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "9681211_3_10205", "context": "We describe a patient with M4 AML treated with standard chemotherapy followed by G-CSF who developed marked monocytosis on day 8 of G-CSF therapy.", "question": "Subject.Gender in a patient with M4 AML", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "9681211_3_10206", "context": "We describe a patient with M4 AML treated with standard chemotherapy followed by G-CSF who developed marked monocytosis on day 8 of G-CSF therapy.", "question": "Subject.Population in a patient with M4 AML", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "9681211_3_10207", "context": "We describe a patient with M4 AML treated with standard chemotherapy followed by G-CSF who developed marked monocytosis on day 8 of G-CSF therapy.", "question": "Subject.Race in a patient with M4 AML", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "9681211_3_10208", "context": "We describe a patient with M4 AML treated with standard chemotherapy followed by G-CSF who developed marked monocytosis on day 8 of G-CSF therapy.", "question": "Subject.Disorder in a patient with M4 AML", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "9681211_3_10209", "context": "We describe a patient with M4 AML treated with standard chemotherapy followed by G-CSF who developed marked monocytosis on day 8 of G-CSF therapy.", "question": "Treatment.Drug in standard chemotherapy followed by G-CSF", "question_type": "Adverse_event.Treatment.Drug", "answers": "chemotherapy; G-CSF"}, {"id": "9681211_3_10210", "context": "We describe a patient with M4 AML treated with standard chemotherapy followed by G-CSF who developed marked monocytosis on day 8 of G-CSF therapy.", "question": "Treatment.Dosage in standard chemotherapy followed by G-CSF", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9681211_3_10211", "context": "We describe a patient with M4 AML treated with standard chemotherapy followed by G-CSF who developed marked monocytosis on day 8 of G-CSF therapy.", "question": "Treatment.Freq in standard chemotherapy followed by G-CSF", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9681211_3_10212", "context": "We describe a patient with M4 AML treated with standard chemotherapy followed by G-CSF who developed marked monocytosis on day 8 of G-CSF therapy.", "question": "Treatment.Route in standard chemotherapy followed by G-CSF", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9681211_3_10213", "context": "We describe a patient with M4 AML treated with standard chemotherapy followed by G-CSF who developed marked monocytosis on day 8 of G-CSF therapy.", "question": "Treatment.Time_elapsed in standard chemotherapy followed by G-CSF", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "day 8"}, {"id": "9681211_3_10214", "context": "We describe a patient with M4 AML treated with standard chemotherapy followed by G-CSF who developed marked monocytosis on day 8 of G-CSF therapy.", "question": "Treatment.Duration in standard chemotherapy followed by G-CSF", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9681211_3_10215", "context": "We describe a patient with M4 AML treated with standard chemotherapy followed by G-CSF who developed marked monocytosis on day 8 of G-CSF therapy.", "question": "Treatment.Disorder in standard chemotherapy followed by G-CSF", "question_type": "Adverse_event.Treatment.Disorder", "answers": "M4 AML"}, {"id": "9681211_3_10216", "context": "We describe a patient with M4 AML treated with standard chemotherapy followed by G-CSF who developed marked monocytosis on day 8 of G-CSF therapy.", "question": "Combination.Drug in standard chemotherapy followed by G-CSF", "question_type": "Adverse_event.Combination.Drug", "answers": "chemotherapy; G-CSF"}, {"id": "7797283_2_10217", "context": "Esophageal candidiasis was diagnosed at endoscopy in two patients receiving omeprazole therapy.", "question": "Subject.Age in two patients", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "7797283_2_10218", "context": "Esophageal candidiasis was diagnosed at endoscopy in two patients receiving omeprazole therapy.", "question": "Subject.Gender in two patients", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "7797283_2_10219", "context": "Esophageal candidiasis was diagnosed at endoscopy in two patients receiving omeprazole therapy.", "question": "Subject.Population in two patients", "question_type": "Adverse_event.Subject.Population", "answers": "two"}, {"id": "7797283_2_10220", "context": "Esophageal candidiasis was diagnosed at endoscopy in two patients receiving omeprazole therapy.", "question": "Subject.Race in two patients", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "7797283_2_10221", "context": "Esophageal candidiasis was diagnosed at endoscopy in two patients receiving omeprazole therapy.", "question": "Subject.Disorder in two patients", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "7797283_2_10222", "context": "Esophageal candidiasis was diagnosed at endoscopy in two patients receiving omeprazole therapy.", "question": "Treatment.Drug in omeprazole therapy", "question_type": "Adverse_event.Treatment.Drug", "answers": "omeprazole"}, {"id": "7797283_2_10223", "context": "Esophageal candidiasis was diagnosed at endoscopy in two patients receiving omeprazole therapy.", "question": "Treatment.Dosage in omeprazole therapy", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7797283_2_10224", "context": "Esophageal candidiasis was diagnosed at endoscopy in two patients receiving omeprazole therapy.", "question": "Treatment.Freq in omeprazole therapy", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7797283_2_10225", "context": "Esophageal candidiasis was diagnosed at endoscopy in two patients receiving omeprazole therapy.", "question": "Treatment.Route in omeprazole therapy", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7797283_2_10226", "context": "Esophageal candidiasis was diagnosed at endoscopy in two patients receiving omeprazole therapy.", "question": "Treatment.Time_elapsed in omeprazole therapy", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7797283_2_10227", "context": "Esophageal candidiasis was diagnosed at endoscopy in two patients receiving omeprazole therapy.", "question": "Treatment.Duration in omeprazole therapy", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7797283_2_10228", "context": "Esophageal candidiasis was diagnosed at endoscopy in two patients receiving omeprazole therapy.", "question": "Treatment.Disorder in omeprazole therapy", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7797283_2_10229", "context": "Esophageal candidiasis was diagnosed at endoscopy in two patients receiving omeprazole therapy.", "question": "Combination.Drug in omeprazole therapy", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17660778_1_10230", "context": "Bisphosphonate induced osteochemonecrosis of the jaw mimicking a tumour.", "question": "Treatment.Drug in Bisphosphonate", "question_type": "Adverse_event.Treatment.Drug", "answers": "Bisphosphonate"}, {"id": "17660778_1_10231", "context": "Bisphosphonate induced osteochemonecrosis of the jaw mimicking a tumour.", "question": "Treatment.Dosage in Bisphosphonate", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17660778_1_10232", "context": "Bisphosphonate induced osteochemonecrosis of the jaw mimicking a tumour.", "question": "Treatment.Freq in Bisphosphonate", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17660778_1_10233", "context": "Bisphosphonate induced osteochemonecrosis of the jaw mimicking a tumour.", "question": "Treatment.Route in Bisphosphonate", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17660778_1_10234", "context": "Bisphosphonate induced osteochemonecrosis of the jaw mimicking a tumour.", "question": "Treatment.Time_elapsed in Bisphosphonate", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17660778_1_10235", "context": "Bisphosphonate induced osteochemonecrosis of the jaw mimicking a tumour.", "question": "Treatment.Duration in Bisphosphonate", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17660778_1_10236", "context": "Bisphosphonate induced osteochemonecrosis of the jaw mimicking a tumour.", "question": "Treatment.Disorder in Bisphosphonate", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17660778_1_10237", "context": "Bisphosphonate induced osteochemonecrosis of the jaw mimicking a tumour.", "question": "Combination.Drug in Bisphosphonate", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15338554_4_10238", "context": "OBJECTIVES: To describe the clinicopathologic features of 3 patients with CML who rapidly progressed from chronic phase to blast crisis while taking imatinib and to perform a review of the literature.", "question": "Subject.Age in 3 patients with CML", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "15338554_4_10239", "context": "OBJECTIVES: To describe the clinicopathologic features of 3 patients with CML who rapidly progressed from chronic phase to blast crisis while taking imatinib and to perform a review of the literature.", "question": "Subject.Gender in 3 patients with CML", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15338554_4_10240", "context": "OBJECTIVES: To describe the clinicopathologic features of 3 patients with CML who rapidly progressed from chronic phase to blast crisis while taking imatinib and to perform a review of the literature.", "question": "Subject.Population in 3 patients with CML", "question_type": "Adverse_event.Subject.Population", "answers": "3"}, {"id": "15338554_4_10241", "context": "OBJECTIVES: To describe the clinicopathologic features of 3 patients with CML who rapidly progressed from chronic phase to blast crisis while taking imatinib and to perform a review of the literature.", "question": "Subject.Race in 3 patients with CML", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15338554_4_10242", "context": "OBJECTIVES: To describe the clinicopathologic features of 3 patients with CML who rapidly progressed from chronic phase to blast crisis while taking imatinib and to perform a review of the literature.", "question": "Subject.Disorder in 3 patients with CML", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15338554_4_10243", "context": "OBJECTIVES: To describe the clinicopathologic features of 3 patients with CML who rapidly progressed from chronic phase to blast crisis while taking imatinib and to perform a review of the literature.", "question": "Treatment.Drug in imatinib", "question_type": "Adverse_event.Treatment.Drug", "answers": "imatinib"}, {"id": "15338554_4_10244", "context": "OBJECTIVES: To describe the clinicopathologic features of 3 patients with CML who rapidly progressed from chronic phase to blast crisis while taking imatinib and to perform a review of the literature.", "question": "Treatment.Dosage in imatinib", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15338554_4_10245", "context": "OBJECTIVES: To describe the clinicopathologic features of 3 patients with CML who rapidly progressed from chronic phase to blast crisis while taking imatinib and to perform a review of the literature.", "question": "Treatment.Freq in imatinib", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15338554_4_10246", "context": "OBJECTIVES: To describe the clinicopathologic features of 3 patients with CML who rapidly progressed from chronic phase to blast crisis while taking imatinib and to perform a review of the literature.", "question": "Treatment.Route in imatinib", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15338554_4_10247", "context": "OBJECTIVES: To describe the clinicopathologic features of 3 patients with CML who rapidly progressed from chronic phase to blast crisis while taking imatinib and to perform a review of the literature.", "question": "Treatment.Time_elapsed in imatinib", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15338554_4_10248", "context": "OBJECTIVES: To describe the clinicopathologic features of 3 patients with CML who rapidly progressed from chronic phase to blast crisis while taking imatinib and to perform a review of the literature.", "question": "Treatment.Duration in imatinib", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15338554_4_10249", "context": "OBJECTIVES: To describe the clinicopathologic features of 3 patients with CML who rapidly progressed from chronic phase to blast crisis while taking imatinib and to perform a review of the literature.", "question": "Treatment.Disorder in imatinib", "question_type": "Adverse_event.Treatment.Disorder", "answers": "CML"}, {"id": "15338554_4_10250", "context": "OBJECTIVES: To describe the clinicopathologic features of 3 patients with CML who rapidly progressed from chronic phase to blast crisis while taking imatinib and to perform a review of the literature.", "question": "Combination.Drug in imatinib", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8627446_3_10251", "context": "Although they had only a few nodules at diagnosis, the nodules increased in number and size 3 to 4 months after the start of methotrexate therapy in both patients.", "question": "Subject.Age in a few nodules at diagnosis", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "8627446_3_10252", "context": "Although they had only a few nodules at diagnosis, the nodules increased in number and size 3 to 4 months after the start of methotrexate therapy in both patients.", "question": "Subject.Gender in a few nodules at diagnosis", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "8627446_3_10253", "context": "Although they had only a few nodules at diagnosis, the nodules increased in number and size 3 to 4 months after the start of methotrexate therapy in both patients.", "question": "Subject.Population in a few nodules at diagnosis", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "8627446_3_10254", "context": "Although they had only a few nodules at diagnosis, the nodules increased in number and size 3 to 4 months after the start of methotrexate therapy in both patients.", "question": "Subject.Race in a few nodules at diagnosis", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "8627446_3_10255", "context": "Although they had only a few nodules at diagnosis, the nodules increased in number and size 3 to 4 months after the start of methotrexate therapy in both patients.", "question": "Subject.Disorder in a few nodules at diagnosis", "question_type": "Adverse_event.Subject.Disorder", "answers": "a few nodules"}, {"id": "8627446_3_10256", "context": "Although they had only a few nodules at diagnosis, the nodules increased in number and size 3 to 4 months after the start of methotrexate therapy in both patients.", "question": "Treatment.Drug in methotrexate therapy", "question_type": "Adverse_event.Treatment.Drug", "answers": "methotrexate"}, {"id": "8627446_3_10257", "context": "Although they had only a few nodules at diagnosis, the nodules increased in number and size 3 to 4 months after the start of methotrexate therapy in both patients.", "question": "Treatment.Dosage in methotrexate therapy", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8627446_3_10258", "context": "Although they had only a few nodules at diagnosis, the nodules increased in number and size 3 to 4 months after the start of methotrexate therapy in both patients.", "question": "Treatment.Freq in methotrexate therapy", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8627446_3_10259", "context": "Although they had only a few nodules at diagnosis, the nodules increased in number and size 3 to 4 months after the start of methotrexate therapy in both patients.", "question": "Treatment.Route in methotrexate therapy", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8627446_3_10260", "context": "Although they had only a few nodules at diagnosis, the nodules increased in number and size 3 to 4 months after the start of methotrexate therapy in both patients.", "question": "Treatment.Time_elapsed in methotrexate therapy", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "3 to 4 months"}, {"id": "8627446_3_10261", "context": "Although they had only a few nodules at diagnosis, the nodules increased in number and size 3 to 4 months after the start of methotrexate therapy in both patients.", "question": "Treatment.Duration in methotrexate therapy", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8627446_3_10262", "context": "Although they had only a few nodules at diagnosis, the nodules increased in number and size 3 to 4 months after the start of methotrexate therapy in both patients.", "question": "Treatment.Disorder in methotrexate therapy", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8627446_3_10263", "context": "Although they had only a few nodules at diagnosis, the nodules increased in number and size 3 to 4 months after the start of methotrexate therapy in both patients.", "question": "Combination.Drug in methotrexate therapy", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16449538_3_10264", "context": "CONCLUSIONS: Among the many presentations of ifosfamide neurotoxicity, clinicians should consider NCSE as a possible explanation for changes in consciousness in a patient receiving this agent.", "question": "Subject.Age in a patient", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "16449538_3_10265", "context": "CONCLUSIONS: Among the many presentations of ifosfamide neurotoxicity, clinicians should consider NCSE as a possible explanation for changes in consciousness in a patient receiving this agent.", "question": "Subject.Gender in a patient", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "16449538_3_10266", "context": "CONCLUSIONS: Among the many presentations of ifosfamide neurotoxicity, clinicians should consider NCSE as a possible explanation for changes in consciousness in a patient receiving this agent.", "question": "Subject.Population in a patient", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "16449538_3_10267", "context": "CONCLUSIONS: Among the many presentations of ifosfamide neurotoxicity, clinicians should consider NCSE as a possible explanation for changes in consciousness in a patient receiving this agent.", "question": "Subject.Race in a patient", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16449538_3_10268", "context": "CONCLUSIONS: Among the many presentations of ifosfamide neurotoxicity, clinicians should consider NCSE as a possible explanation for changes in consciousness in a patient receiving this agent.", "question": "Subject.Disorder in a patient", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "16449538_3_10269", "context": "CONCLUSIONS: Among the many presentations of ifosfamide neurotoxicity, clinicians should consider NCSE as a possible explanation for changes in consciousness in a patient receiving this agent.", "question": "Treatment.Drug in ifosfamide", "question_type": "Adverse_event.Treatment.Drug", "answers": "ifosfamide"}, {"id": "16449538_3_10270", "context": "CONCLUSIONS: Among the many presentations of ifosfamide neurotoxicity, clinicians should consider NCSE as a possible explanation for changes in consciousness in a patient receiving this agent.", "question": "Treatment.Dosage in ifosfamide", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16449538_3_10271", "context": "CONCLUSIONS: Among the many presentations of ifosfamide neurotoxicity, clinicians should consider NCSE as a possible explanation for changes in consciousness in a patient receiving this agent.", "question": "Treatment.Freq in ifosfamide", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16449538_3_10272", "context": "CONCLUSIONS: Among the many presentations of ifosfamide neurotoxicity, clinicians should consider NCSE as a possible explanation for changes in consciousness in a patient receiving this agent.", "question": "Treatment.Route in ifosfamide", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16449538_3_10273", "context": "CONCLUSIONS: Among the many presentations of ifosfamide neurotoxicity, clinicians should consider NCSE as a possible explanation for changes in consciousness in a patient receiving this agent.", "question": "Treatment.Time_elapsed in ifosfamide", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16449538_3_10274", "context": "CONCLUSIONS: Among the many presentations of ifosfamide neurotoxicity, clinicians should consider NCSE as a possible explanation for changes in consciousness in a patient receiving this agent.", "question": "Treatment.Duration in ifosfamide", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16449538_3_10275", "context": "CONCLUSIONS: Among the many presentations of ifosfamide neurotoxicity, clinicians should consider NCSE as a possible explanation for changes in consciousness in a patient receiving this agent.", "question": "Treatment.Disorder in ifosfamide", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16449538_3_10276", "context": "CONCLUSIONS: Among the many presentations of ifosfamide neurotoxicity, clinicians should consider NCSE as a possible explanation for changes in consciousness in a patient receiving this agent.", "question": "Combination.Drug in ifosfamide", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6507240_3_10277", "context": "It is concluded that SIADH is an important side effect of lorcainide therapy.", "question": "Treatment.Drug in lorcainide therapy", "question_type": "Adverse_event.Treatment.Drug", "answers": "lorcainide"}, {"id": "6507240_3_10278", "context": "It is concluded that SIADH is an important side effect of lorcainide therapy.", "question": "Treatment.Dosage in lorcainide therapy", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6507240_3_10279", "context": "It is concluded that SIADH is an important side effect of lorcainide therapy.", "question": "Treatment.Freq in lorcainide therapy", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6507240_3_10280", "context": "It is concluded that SIADH is an important side effect of lorcainide therapy.", "question": "Treatment.Route in lorcainide therapy", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6507240_3_10281", "context": "It is concluded that SIADH is an important side effect of lorcainide therapy.", "question": "Treatment.Time_elapsed in lorcainide therapy", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6507240_3_10282", "context": "It is concluded that SIADH is an important side effect of lorcainide therapy.", "question": "Treatment.Duration in lorcainide therapy", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6507240_3_10283", "context": "It is concluded that SIADH is an important side effect of lorcainide therapy.", "question": "Treatment.Disorder in lorcainide therapy", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6507240_3_10284", "context": "It is concluded that SIADH is an important side effect of lorcainide therapy.", "question": "Combination.Drug in lorcainide therapy", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16221163_8_10285", "context": "Hepatoxicity is a rare complication of SRL therapy and may be connected with some diagnostic and/or therapeutic problems.", "question": "Treatment.Drug in SRL therapy", "question_type": "Adverse_event.Treatment.Drug", "answers": "SRL"}, {"id": "16221163_8_10286", "context": "Hepatoxicity is a rare complication of SRL therapy and may be connected with some diagnostic and/or therapeutic problems.", "question": "Treatment.Dosage in SRL therapy", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16221163_8_10287", "context": "Hepatoxicity is a rare complication of SRL therapy and may be connected with some diagnostic and/or therapeutic problems.", "question": "Treatment.Freq in SRL therapy", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16221163_8_10288", "context": "Hepatoxicity is a rare complication of SRL therapy and may be connected with some diagnostic and/or therapeutic problems.", "question": "Treatment.Route in SRL therapy", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16221163_8_10289", "context": "Hepatoxicity is a rare complication of SRL therapy and may be connected with some diagnostic and/or therapeutic problems.", "question": "Treatment.Time_elapsed in SRL therapy", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16221163_8_10290", "context": "Hepatoxicity is a rare complication of SRL therapy and may be connected with some diagnostic and/or therapeutic problems.", "question": "Treatment.Duration in SRL therapy", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16221163_8_10291", "context": "Hepatoxicity is a rare complication of SRL therapy and may be connected with some diagnostic and/or therapeutic problems.", "question": "Treatment.Disorder in SRL therapy", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16221163_8_10292", "context": "Hepatoxicity is a rare complication of SRL therapy and may be connected with some diagnostic and/or therapeutic problems.", "question": "Combination.Drug in SRL therapy", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "19260037_1_10293", "context": "A previous study of patients with \"quinine-associated TTP/HUS\" found that ADAMTS13 activities were not abnormal in 12/12 patients.", "question": "Subject.Age in 12/12 patients", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "19260037_1_10294", "context": "A previous study of patients with \"quinine-associated TTP/HUS\" found that ADAMTS13 activities were not abnormal in 12/12 patients.", "question": "Subject.Gender in 12/12 patients", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "19260037_1_10295", "context": "A previous study of patients with \"quinine-associated TTP/HUS\" found that ADAMTS13 activities were not abnormal in 12/12 patients.", "question": "Subject.Population in 12/12 patients", "question_type": "Adverse_event.Subject.Population", "answers": "12/12"}, {"id": "19260037_1_10296", "context": "A previous study of patients with \"quinine-associated TTP/HUS\" found that ADAMTS13 activities were not abnormal in 12/12 patients.", "question": "Subject.Race in 12/12 patients", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "19260037_1_10297", "context": "A previous study of patients with \"quinine-associated TTP/HUS\" found that ADAMTS13 activities were not abnormal in 12/12 patients.", "question": "Subject.Disorder in 12/12 patients", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "19260037_1_10298", "context": "A previous study of patients with \"quinine-associated TTP/HUS\" found that ADAMTS13 activities were not abnormal in 12/12 patients.", "question": "Treatment.Drug in quinine", "question_type": "Adverse_event.Treatment.Drug", "answers": "quinine"}, {"id": "19260037_1_10299", "context": "A previous study of patients with \"quinine-associated TTP/HUS\" found that ADAMTS13 activities were not abnormal in 12/12 patients.", "question": "Treatment.Dosage in quinine", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "19260037_1_10300", "context": "A previous study of patients with \"quinine-associated TTP/HUS\" found that ADAMTS13 activities were not abnormal in 12/12 patients.", "question": "Treatment.Freq in quinine", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "19260037_1_10301", "context": "A previous study of patients with \"quinine-associated TTP/HUS\" found that ADAMTS13 activities were not abnormal in 12/12 patients.", "question": "Treatment.Route in quinine", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "19260037_1_10302", "context": "A previous study of patients with \"quinine-associated TTP/HUS\" found that ADAMTS13 activities were not abnormal in 12/12 patients.", "question": "Treatment.Time_elapsed in quinine", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19260037_1_10303", "context": "A previous study of patients with \"quinine-associated TTP/HUS\" found that ADAMTS13 activities were not abnormal in 12/12 patients.", "question": "Treatment.Duration in quinine", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "19260037_1_10304", "context": "A previous study of patients with \"quinine-associated TTP/HUS\" found that ADAMTS13 activities were not abnormal in 12/12 patients.", "question": "Treatment.Disorder in quinine", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "19260037_1_10305", "context": "A previous study of patients with \"quinine-associated TTP/HUS\" found that ADAMTS13 activities were not abnormal in 12/12 patients.", "question": "Combination.Drug in quinine", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9695308_3_10306", "context": "A teenage girl with crescentic glomerulonephritis had antineutrophil cytoplasmic antibody (ANCA) detected after she had received propylthiouracil (PTU) for hyperthyroidism without cutaneous vasculitis.", "question": "Subject.Age in A teenage girl with crescentic glomerulonephritis", "question_type": "Adverse_event.Subject.Age", "answers": "teenage"}, {"id": "9695308_3_10307", "context": "A teenage girl with crescentic glomerulonephritis had antineutrophil cytoplasmic antibody (ANCA) detected after she had received propylthiouracil (PTU) for hyperthyroidism without cutaneous vasculitis.", "question": "Subject.Gender in A teenage girl with crescentic glomerulonephritis", "question_type": "Adverse_event.Subject.Gender", "answers": "girl"}, {"id": "9695308_3_10308", "context": "A teenage girl with crescentic glomerulonephritis had antineutrophil cytoplasmic antibody (ANCA) detected after she had received propylthiouracil (PTU) for hyperthyroidism without cutaneous vasculitis.", "question": "Subject.Population in A teenage girl with crescentic glomerulonephritis", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "9695308_3_10309", "context": "A teenage girl with crescentic glomerulonephritis had antineutrophil cytoplasmic antibody (ANCA) detected after she had received propylthiouracil (PTU) for hyperthyroidism without cutaneous vasculitis.", "question": "Subject.Race in A teenage girl with crescentic glomerulonephritis", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "9695308_3_10310", "context": "A teenage girl with crescentic glomerulonephritis had antineutrophil cytoplasmic antibody (ANCA) detected after she had received propylthiouracil (PTU) for hyperthyroidism without cutaneous vasculitis.", "question": "Subject.Disorder in A teenage girl with crescentic glomerulonephritis", "question_type": "Adverse_event.Subject.Disorder", "answers": "crescentic glomerulonephritis"}, {"id": "9695308_3_10311", "context": "A teenage girl with crescentic glomerulonephritis had antineutrophil cytoplasmic antibody (ANCA) detected after she had received propylthiouracil (PTU) for hyperthyroidism without cutaneous vasculitis.", "question": "Treatment.Drug in propylthiouracil (PTU)", "question_type": "Adverse_event.Treatment.Drug", "answers": "propylthiouracil"}, {"id": "9695308_3_10312", "context": "A teenage girl with crescentic glomerulonephritis had antineutrophil cytoplasmic antibody (ANCA) detected after she had received propylthiouracil (PTU) for hyperthyroidism without cutaneous vasculitis.", "question": "Treatment.Dosage in propylthiouracil (PTU)", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9695308_3_10313", "context": "A teenage girl with crescentic glomerulonephritis had antineutrophil cytoplasmic antibody (ANCA) detected after she had received propylthiouracil (PTU) for hyperthyroidism without cutaneous vasculitis.", "question": "Treatment.Freq in propylthiouracil (PTU)", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9695308_3_10314", "context": "A teenage girl with crescentic glomerulonephritis had antineutrophil cytoplasmic antibody (ANCA) detected after she had received propylthiouracil (PTU) for hyperthyroidism without cutaneous vasculitis.", "question": "Treatment.Route in propylthiouracil (PTU)", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9695308_3_10315", "context": "A teenage girl with crescentic glomerulonephritis had antineutrophil cytoplasmic antibody (ANCA) detected after she had received propylthiouracil (PTU) for hyperthyroidism without cutaneous vasculitis.", "question": "Treatment.Time_elapsed in propylthiouracil (PTU)", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9695308_3_10316", "context": "A teenage girl with crescentic glomerulonephritis had antineutrophil cytoplasmic antibody (ANCA) detected after she had received propylthiouracil (PTU) for hyperthyroidism without cutaneous vasculitis.", "question": "Treatment.Duration in propylthiouracil (PTU)", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9695308_3_10317", "context": "A teenage girl with crescentic glomerulonephritis had antineutrophil cytoplasmic antibody (ANCA) detected after she had received propylthiouracil (PTU) for hyperthyroidism without cutaneous vasculitis.", "question": "Treatment.Disorder in propylthiouracil (PTU)", "question_type": "Adverse_event.Treatment.Disorder", "answers": "hyperthyroidism without cutaneous vasculitis"}, {"id": "9695308_3_10318", "context": "A teenage girl with crescentic glomerulonephritis had antineutrophil cytoplasmic antibody (ANCA) detected after she had received propylthiouracil (PTU) for hyperthyroidism without cutaneous vasculitis.", "question": "Combination.Drug in propylthiouracil (PTU)", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11468878_3_10319", "context": "Digestive hemorrhage caused by a Meckel's diverticulum in a metformin-treated patient: is there any connection?", "question": "Subject.Age in patient", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "11468878_3_10320", "context": "Digestive hemorrhage caused by a Meckel's diverticulum in a metformin-treated patient: is there any connection?", "question": "Subject.Gender in patient", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "11468878_3_10321", "context": "Digestive hemorrhage caused by a Meckel's diverticulum in a metformin-treated patient: is there any connection?", "question": "Subject.Population in patient", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "11468878_3_10322", "context": "Digestive hemorrhage caused by a Meckel's diverticulum in a metformin-treated patient: is there any connection?", "question": "Subject.Race in patient", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "11468878_3_10323", "context": "Digestive hemorrhage caused by a Meckel's diverticulum in a metformin-treated patient: is there any connection?", "question": "Subject.Disorder in patient", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "11468878_3_10324", "context": "Digestive hemorrhage caused by a Meckel's diverticulum in a metformin-treated patient: is there any connection?", "question": "Treatment.Drug in metformin", "question_type": "Adverse_event.Treatment.Drug", "answers": "metformin"}, {"id": "11468878_3_10325", "context": "Digestive hemorrhage caused by a Meckel's diverticulum in a metformin-treated patient: is there any connection?", "question": "Treatment.Dosage in metformin", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11468878_3_10326", "context": "Digestive hemorrhage caused by a Meckel's diverticulum in a metformin-treated patient: is there any connection?", "question": "Treatment.Freq in metformin", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11468878_3_10327", "context": "Digestive hemorrhage caused by a Meckel's diverticulum in a metformin-treated patient: is there any connection?", "question": "Treatment.Route in metformin", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11468878_3_10328", "context": "Digestive hemorrhage caused by a Meckel's diverticulum in a metformin-treated patient: is there any connection?", "question": "Treatment.Time_elapsed in metformin", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11468878_3_10329", "context": "Digestive hemorrhage caused by a Meckel's diverticulum in a metformin-treated patient: is there any connection?", "question": "Treatment.Duration in metformin", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11468878_3_10330", "context": "Digestive hemorrhage caused by a Meckel's diverticulum in a metformin-treated patient: is there any connection?", "question": "Treatment.Disorder in metformin", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11468878_3_10331", "context": "Digestive hemorrhage caused by a Meckel's diverticulum in a metformin-treated patient: is there any connection?", "question": "Combination.Drug in metformin", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18492617_1_10332", "context": "Our findings reveal that even in patients without a history of seizures, pregabalin can cause a cortical negative myoclonus.", "question": "Subject.Age in patients without a history of seizures", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "18492617_1_10333", "context": "Our findings reveal that even in patients without a history of seizures, pregabalin can cause a cortical negative myoclonus.", "question": "Subject.Gender in patients without a history of seizures", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "18492617_1_10334", "context": "Our findings reveal that even in patients without a history of seizures, pregabalin can cause a cortical negative myoclonus.", "question": "Subject.Population in patients without a history of seizures", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "18492617_1_10335", "context": "Our findings reveal that even in patients without a history of seizures, pregabalin can cause a cortical negative myoclonus.", "question": "Subject.Race in patients without a history of seizures", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "18492617_1_10336", "context": "Our findings reveal that even in patients without a history of seizures, pregabalin can cause a cortical negative myoclonus.", "question": "Subject.Disorder in patients without a history of seizures", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "18492617_1_10337", "context": "Our findings reveal that even in patients without a history of seizures, pregabalin can cause a cortical negative myoclonus.", "question": "Treatment.Drug in pregabalin", "question_type": "Adverse_event.Treatment.Drug", "answers": "pregabalin"}, {"id": "18492617_1_10338", "context": "Our findings reveal that even in patients without a history of seizures, pregabalin can cause a cortical negative myoclonus.", "question": "Treatment.Dosage in pregabalin", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18492617_1_10339", "context": "Our findings reveal that even in patients without a history of seizures, pregabalin can cause a cortical negative myoclonus.", "question": "Treatment.Freq in pregabalin", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18492617_1_10340", "context": "Our findings reveal that even in patients without a history of seizures, pregabalin can cause a cortical negative myoclonus.", "question": "Treatment.Route in pregabalin", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18492617_1_10341", "context": "Our findings reveal that even in patients without a history of seizures, pregabalin can cause a cortical negative myoclonus.", "question": "Treatment.Time_elapsed in pregabalin", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18492617_1_10342", "context": "Our findings reveal that even in patients without a history of seizures, pregabalin can cause a cortical negative myoclonus.", "question": "Treatment.Duration in pregabalin", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18492617_1_10343", "context": "Our findings reveal that even in patients without a history of seizures, pregabalin can cause a cortical negative myoclonus.", "question": "Treatment.Disorder in pregabalin", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18492617_1_10344", "context": "Our findings reveal that even in patients without a history of seizures, pregabalin can cause a cortical negative myoclonus.", "question": "Combination.Drug in pregabalin", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8551001_5_10345", "context": "We describe the first documented case of azathioprine-induced severe myelosuppression due to thiopurine methyltransferase deficiency in autoimmune liver disease.", "question": "Treatment.Drug in azathioprine", "question_type": "Adverse_event.Treatment.Drug", "answers": "azathioprine"}, {"id": "8551001_5_10346", "context": "We describe the first documented case of azathioprine-induced severe myelosuppression due to thiopurine methyltransferase deficiency in autoimmune liver disease.", "question": "Treatment.Dosage in azathioprine", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8551001_5_10347", "context": "We describe the first documented case of azathioprine-induced severe myelosuppression due to thiopurine methyltransferase deficiency in autoimmune liver disease.", "question": "Treatment.Freq in azathioprine", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8551001_5_10348", "context": "We describe the first documented case of azathioprine-induced severe myelosuppression due to thiopurine methyltransferase deficiency in autoimmune liver disease.", "question": "Treatment.Route in azathioprine", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8551001_5_10349", "context": "We describe the first documented case of azathioprine-induced severe myelosuppression due to thiopurine methyltransferase deficiency in autoimmune liver disease.", "question": "Treatment.Time_elapsed in azathioprine", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8551001_5_10350", "context": "We describe the first documented case of azathioprine-induced severe myelosuppression due to thiopurine methyltransferase deficiency in autoimmune liver disease.", "question": "Treatment.Duration in azathioprine", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8551001_5_10351", "context": "We describe the first documented case of azathioprine-induced severe myelosuppression due to thiopurine methyltransferase deficiency in autoimmune liver disease.", "question": "Treatment.Disorder in azathioprine", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8551001_5_10352", "context": "We describe the first documented case of azathioprine-induced severe myelosuppression due to thiopurine methyltransferase deficiency in autoimmune liver disease.", "question": "Combination.Drug in azathioprine", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15823103_4_10353", "context": "We report five cases of carboplatin (CBDCA) hypersensitivity after weekly low-dose paclitaxel (60 mg/m2)/CBDCA (area under the concentration curve = 2) therapy in patients with recurrent ovarian cancer receiving multiple platinum-based chemotherapy.", "question": "Subject.Age in patients with recurrent ovarian cancer", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "15823103_4_10354", "context": "We report five cases of carboplatin (CBDCA) hypersensitivity after weekly low-dose paclitaxel (60 mg/m2)/CBDCA (area under the concentration curve = 2) therapy in patients with recurrent ovarian cancer receiving multiple platinum-based chemotherapy.", "question": "Subject.Gender in patients with recurrent ovarian cancer", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15823103_4_10355", "context": "We report five cases of carboplatin (CBDCA) hypersensitivity after weekly low-dose paclitaxel (60 mg/m2)/CBDCA (area under the concentration curve = 2) therapy in patients with recurrent ovarian cancer receiving multiple platinum-based chemotherapy.", "question": "Subject.Population in patients with recurrent ovarian cancer", "question_type": "Adverse_event.Subject.Population", "answers": "five"}, {"id": "15823103_4_10356", "context": "We report five cases of carboplatin (CBDCA) hypersensitivity after weekly low-dose paclitaxel (60 mg/m2)/CBDCA (area under the concentration curve = 2) therapy in patients with recurrent ovarian cancer receiving multiple platinum-based chemotherapy.", "question": "Subject.Race in patients with recurrent ovarian cancer", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15823103_4_10357", "context": "We report five cases of carboplatin (CBDCA) hypersensitivity after weekly low-dose paclitaxel (60 mg/m2)/CBDCA (area under the concentration curve = 2) therapy in patients with recurrent ovarian cancer receiving multiple platinum-based chemotherapy.", "question": "Subject.Disorder in patients with recurrent ovarian cancer", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15823103_4_10358", "context": "We report five cases of carboplatin (CBDCA) hypersensitivity after weekly low-dose paclitaxel (60 mg/m2)/CBDCA (area under the concentration curve = 2) therapy in patients with recurrent ovarian cancer receiving multiple platinum-based chemotherapy.", "question": "Treatment.Drug in weekly low-dose paclitaxel (60 mg/m2)/CBDCA (area under the concentration curve = 2) therapy; multiple platinum-based chemotherapy", "question_type": "Adverse_event.Treatment.Drug", "answers": "paclitaxel; CBDCA; carboplatin; platinum"}, {"id": "15823103_4_10359", "context": "We report five cases of carboplatin (CBDCA) hypersensitivity after weekly low-dose paclitaxel (60 mg/m2)/CBDCA (area under the concentration curve = 2) therapy in patients with recurrent ovarian cancer receiving multiple platinum-based chemotherapy.", "question": "Treatment.Dosage in weekly low-dose paclitaxel (60 mg/m2)/CBDCA (area under the concentration curve = 2) therapy; multiple platinum-based chemotherapy", "question_type": "Adverse_event.Treatment.Dosage", "answers": "low-dose; 60 mg/m2"}, {"id": "15823103_4_10360", "context": "We report five cases of carboplatin (CBDCA) hypersensitivity after weekly low-dose paclitaxel (60 mg/m2)/CBDCA (area under the concentration curve = 2) therapy in patients with recurrent ovarian cancer receiving multiple platinum-based chemotherapy.", "question": "Treatment.Freq in weekly low-dose paclitaxel (60 mg/m2)/CBDCA (area under the concentration curve = 2) therapy; multiple platinum-based chemotherapy", "question_type": "Adverse_event.Treatment.Freq", "answers": "weekly"}, {"id": "15823103_4_10361", "context": "We report five cases of carboplatin (CBDCA) hypersensitivity after weekly low-dose paclitaxel (60 mg/m2)/CBDCA (area under the concentration curve = 2) therapy in patients with recurrent ovarian cancer receiving multiple platinum-based chemotherapy.", "question": "Treatment.Route in weekly low-dose paclitaxel (60 mg/m2)/CBDCA (area under the concentration curve = 2) therapy; multiple platinum-based chemotherapy", "question_type": "Adverse_event.Treatment.Route", "answers": "chemotherapy"}, {"id": "15823103_4_10362", "context": "We report five cases of carboplatin (CBDCA) hypersensitivity after weekly low-dose paclitaxel (60 mg/m2)/CBDCA (area under the concentration curve = 2) therapy in patients with recurrent ovarian cancer receiving multiple platinum-based chemotherapy.", "question": "Treatment.Time_elapsed in weekly low-dose paclitaxel (60 mg/m2)/CBDCA (area under the concentration curve = 2) therapy; multiple platinum-based chemotherapy", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15823103_4_10363", "context": "We report five cases of carboplatin (CBDCA) hypersensitivity after weekly low-dose paclitaxel (60 mg/m2)/CBDCA (area under the concentration curve = 2) therapy in patients with recurrent ovarian cancer receiving multiple platinum-based chemotherapy.", "question": "Treatment.Duration in weekly low-dose paclitaxel (60 mg/m2)/CBDCA (area under the concentration curve = 2) therapy; multiple platinum-based chemotherapy", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15823103_4_10364", "context": "We report five cases of carboplatin (CBDCA) hypersensitivity after weekly low-dose paclitaxel (60 mg/m2)/CBDCA (area under the concentration curve = 2) therapy in patients with recurrent ovarian cancer receiving multiple platinum-based chemotherapy.", "question": "Treatment.Disorder in weekly low-dose paclitaxel (60 mg/m2)/CBDCA (area under the concentration curve = 2) therapy; multiple platinum-based chemotherapy", "question_type": "Adverse_event.Treatment.Disorder", "answers": "recurrent ovarian cancer"}, {"id": "15823103_4_10365", "context": "We report five cases of carboplatin (CBDCA) hypersensitivity after weekly low-dose paclitaxel (60 mg/m2)/CBDCA (area under the concentration curve = 2) therapy in patients with recurrent ovarian cancer receiving multiple platinum-based chemotherapy.", "question": "Combination.Drug in weekly low-dose paclitaxel (60 mg/m2)/CBDCA (area under the concentration curve = 2) therapy; multiple platinum-based chemotherapy", "question_type": "Adverse_event.Combination.Drug", "answers": "paclitaxel; CBDCA; platinum"}, {"id": "22550162_3_10366", "context": "The patient was placed on omeprazole after his first cycle of high-dose methotrexate for stress ulcer prophylaxis, and it was discontinued before the start of the first day of the patient's second round of high-dose methotrexate.", "question": "Subject.Age in The patient", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "22550162_3_10367", "context": "The patient was placed on omeprazole after his first cycle of high-dose methotrexate for stress ulcer prophylaxis, and it was discontinued before the start of the first day of the patient's second round of high-dose methotrexate.", "question": "Subject.Gender in The patient", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "22550162_3_10368", "context": "The patient was placed on omeprazole after his first cycle of high-dose methotrexate for stress ulcer prophylaxis, and it was discontinued before the start of the first day of the patient's second round of high-dose methotrexate.", "question": "Subject.Population in The patient", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "22550162_3_10369", "context": "The patient was placed on omeprazole after his first cycle of high-dose methotrexate for stress ulcer prophylaxis, and it was discontinued before the start of the first day of the patient's second round of high-dose methotrexate.", "question": "Subject.Race in The patient", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "22550162_3_10370", "context": "The patient was placed on omeprazole after his first cycle of high-dose methotrexate for stress ulcer prophylaxis, and it was discontinued before the start of the first day of the patient's second round of high-dose methotrexate.", "question": "Subject.Disorder in The patient", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "22550162_3_10371", "context": "The patient was placed on omeprazole after his first cycle of high-dose methotrexate for stress ulcer prophylaxis, and it was discontinued before the start of the first day of the patient's second round of high-dose methotrexate.", "question": "Treatment.Drug in methotrexate", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "methotrexate; methotrexate; omeprazole"}, {"id": "22550162_3_10372", "context": "The patient was placed on omeprazole after his first cycle of high-dose methotrexate for stress ulcer prophylaxis, and it was discontinued before the start of the first day of the patient's second round of high-dose methotrexate.", "question": "Treatment.Dosage in methotrexate", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": "high-dose"}, {"id": "22550162_3_10373", "context": "The patient was placed on omeprazole after his first cycle of high-dose methotrexate for stress ulcer prophylaxis, and it was discontinued before the start of the first day of the patient's second round of high-dose methotrexate.", "question": "Treatment.Freq in methotrexate", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "22550162_3_10374", "context": "The patient was placed on omeprazole after his first cycle of high-dose methotrexate for stress ulcer prophylaxis, and it was discontinued before the start of the first day of the patient's second round of high-dose methotrexate.", "question": "Treatment.Route in methotrexate", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "22550162_3_10375", "context": "The patient was placed on omeprazole after his first cycle of high-dose methotrexate for stress ulcer prophylaxis, and it was discontinued before the start of the first day of the patient's second round of high-dose methotrexate.", "question": "Treatment.Time_elapsed in methotrexate", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "22550162_3_10376", "context": "The patient was placed on omeprazole after his first cycle of high-dose methotrexate for stress ulcer prophylaxis, and it was discontinued before the start of the first day of the patient's second round of high-dose methotrexate.", "question": "Treatment.Duration in methotrexate", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "22550162_3_10377", "context": "The patient was placed on omeprazole after his first cycle of high-dose methotrexate for stress ulcer prophylaxis, and it was discontinued before the start of the first day of the patient's second round of high-dose methotrexate.", "question": "Treatment.Disorder in methotrexate", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "stress ulcer"}, {"id": "22550162_3_10378", "context": "The patient was placed on omeprazole after his first cycle of high-dose methotrexate for stress ulcer prophylaxis, and it was discontinued before the start of the first day of the patient's second round of high-dose methotrexate.", "question": "Combination.Drug in methotrexate", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "19249953_6_10379", "context": "Because the patient had been taking lovastatin for the past 12 years, the possibility that the rhabdomyolysis may have been caused by a drug interaction between lovastatin and a concomitant drug was evaluated.", "question": "Subject.Age in the patient", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "19249953_6_10380", "context": "Because the patient had been taking lovastatin for the past 12 years, the possibility that the rhabdomyolysis may have been caused by a drug interaction between lovastatin and a concomitant drug was evaluated.", "question": "Subject.Gender in the patient", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "19249953_6_10381", "context": "Because the patient had been taking lovastatin for the past 12 years, the possibility that the rhabdomyolysis may have been caused by a drug interaction between lovastatin and a concomitant drug was evaluated.", "question": "Subject.Population in the patient", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "19249953_6_10382", "context": "Because the patient had been taking lovastatin for the past 12 years, the possibility that the rhabdomyolysis may have been caused by a drug interaction between lovastatin and a concomitant drug was evaluated.", "question": "Subject.Race in the patient", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "19249953_6_10383", "context": "Because the patient had been taking lovastatin for the past 12 years, the possibility that the rhabdomyolysis may have been caused by a drug interaction between lovastatin and a concomitant drug was evaluated.", "question": "Subject.Disorder in the patient", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "19249953_6_10384", "context": "Because the patient had been taking lovastatin for the past 12 years, the possibility that the rhabdomyolysis may have been caused by a drug interaction between lovastatin and a concomitant drug was evaluated.", "question": "Treatment.Drug in lovastatin", "question_type": "Adverse_event.Treatment.Drug", "answers": "lovastatin; lovastatin"}, {"id": "19249953_6_10385", "context": "Because the patient had been taking lovastatin for the past 12 years, the possibility that the rhabdomyolysis may have been caused by a drug interaction between lovastatin and a concomitant drug was evaluated.", "question": "Treatment.Dosage in lovastatin", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "19249953_6_10386", "context": "Because the patient had been taking lovastatin for the past 12 years, the possibility that the rhabdomyolysis may have been caused by a drug interaction between lovastatin and a concomitant drug was evaluated.", "question": "Treatment.Freq in lovastatin", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "19249953_6_10387", "context": "Because the patient had been taking lovastatin for the past 12 years, the possibility that the rhabdomyolysis may have been caused by a drug interaction between lovastatin and a concomitant drug was evaluated.", "question": "Treatment.Route in lovastatin", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "19249953_6_10388", "context": "Because the patient had been taking lovastatin for the past 12 years, the possibility that the rhabdomyolysis may have been caused by a drug interaction between lovastatin and a concomitant drug was evaluated.", "question": "Treatment.Time_elapsed in lovastatin", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19249953_6_10389", "context": "Because the patient had been taking lovastatin for the past 12 years, the possibility that the rhabdomyolysis may have been caused by a drug interaction between lovastatin and a concomitant drug was evaluated.", "question": "Treatment.Duration in lovastatin", "question_type": "Adverse_event.Treatment.Duration", "answers": "12 years"}, {"id": "19249953_6_10390", "context": "Because the patient had been taking lovastatin for the past 12 years, the possibility that the rhabdomyolysis may have been caused by a drug interaction between lovastatin and a concomitant drug was evaluated.", "question": "Treatment.Disorder in lovastatin", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "19249953_6_10391", "context": "Because the patient had been taking lovastatin for the past 12 years, the possibility that the rhabdomyolysis may have been caused by a drug interaction between lovastatin and a concomitant drug was evaluated.", "question": "Combination.Drug in lovastatin", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8104147_1_10392", "context": "Ibopamine-induced reversible leukopenia during treatment for congestive heart failure.", "question": "Treatment.Drug in Ibopamine", "question_type": "Adverse_event.Treatment.Drug", "answers": "Ibopamine"}, {"id": "8104147_1_10393", "context": "Ibopamine-induced reversible leukopenia during treatment for congestive heart failure.", "question": "Treatment.Dosage in Ibopamine", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8104147_1_10394", "context": "Ibopamine-induced reversible leukopenia during treatment for congestive heart failure.", "question": "Treatment.Freq in Ibopamine", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8104147_1_10395", "context": "Ibopamine-induced reversible leukopenia during treatment for congestive heart failure.", "question": "Treatment.Route in Ibopamine", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8104147_1_10396", "context": "Ibopamine-induced reversible leukopenia during treatment for congestive heart failure.", "question": "Treatment.Time_elapsed in Ibopamine", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8104147_1_10397", "context": "Ibopamine-induced reversible leukopenia during treatment for congestive heart failure.", "question": "Treatment.Duration in Ibopamine", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8104147_1_10398", "context": "Ibopamine-induced reversible leukopenia during treatment for congestive heart failure.", "question": "Treatment.Disorder in Ibopamine", "question_type": "Adverse_event.Treatment.Disorder", "answers": "congestive heart failure"}, {"id": "8104147_1_10399", "context": "Ibopamine-induced reversible leukopenia during treatment for congestive heart failure.", "question": "Combination.Drug in Ibopamine", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7474364_1_10400", "context": "A 71-year-old man with paroxysmal atrial fibrillation who had a previous anterior myocardial infarction exhibited granulocytopenia 8 days following the administration of oral sustained-release procainamide (750 mg/day).", "question": "Subject.Age in A 71-year-old man with paroxysmal atrial fibrillation who had a previous anterior myocardial infarction", "question_type": "Adverse_event.Subject.Age", "answers": "71-year-old"}, {"id": "7474364_1_10401", "context": "A 71-year-old man with paroxysmal atrial fibrillation who had a previous anterior myocardial infarction exhibited granulocytopenia 8 days following the administration of oral sustained-release procainamide (750 mg/day).", "question": "Subject.Gender in A 71-year-old man with paroxysmal atrial fibrillation who had a previous anterior myocardial infarction", "question_type": "Adverse_event.Subject.Gender", "answers": "man"}, {"id": "7474364_1_10402", "context": "A 71-year-old man with paroxysmal atrial fibrillation who had a previous anterior myocardial infarction exhibited granulocytopenia 8 days following the administration of oral sustained-release procainamide (750 mg/day).", "question": "Subject.Population in A 71-year-old man with paroxysmal atrial fibrillation who had a previous anterior myocardial infarction", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "7474364_1_10403", "context": "A 71-year-old man with paroxysmal atrial fibrillation who had a previous anterior myocardial infarction exhibited granulocytopenia 8 days following the administration of oral sustained-release procainamide (750 mg/day).", "question": "Subject.Race in A 71-year-old man with paroxysmal atrial fibrillation who had a previous anterior myocardial infarction", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "7474364_1_10404", "context": "A 71-year-old man with paroxysmal atrial fibrillation who had a previous anterior myocardial infarction exhibited granulocytopenia 8 days following the administration of oral sustained-release procainamide (750 mg/day).", "question": "Subject.Disorder in A 71-year-old man with paroxysmal atrial fibrillation who had a previous anterior myocardial infarction", "question_type": "Adverse_event.Subject.Disorder", "answers": "anterior myocardial infarction"}, {"id": "7474364_1_10405", "context": "A 71-year-old man with paroxysmal atrial fibrillation who had a previous anterior myocardial infarction exhibited granulocytopenia 8 days following the administration of oral sustained-release procainamide (750 mg/day).", "question": "Treatment.Drug in oral sustained-release procainamide (750 mg/day)", "question_type": "Adverse_event.Treatment.Drug", "answers": "sustained-release procainamide"}, {"id": "7474364_1_10406", "context": "A 71-year-old man with paroxysmal atrial fibrillation who had a previous anterior myocardial infarction exhibited granulocytopenia 8 days following the administration of oral sustained-release procainamide (750 mg/day).", "question": "Treatment.Dosage in oral sustained-release procainamide (750 mg/day)", "question_type": "Adverse_event.Treatment.Dosage", "answers": "750 mg/day"}, {"id": "7474364_1_10407", "context": "A 71-year-old man with paroxysmal atrial fibrillation who had a previous anterior myocardial infarction exhibited granulocytopenia 8 days following the administration of oral sustained-release procainamide (750 mg/day).", "question": "Treatment.Freq in oral sustained-release procainamide (750 mg/day)", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7474364_1_10408", "context": "A 71-year-old man with paroxysmal atrial fibrillation who had a previous anterior myocardial infarction exhibited granulocytopenia 8 days following the administration of oral sustained-release procainamide (750 mg/day).", "question": "Treatment.Route in oral sustained-release procainamide (750 mg/day)", "question_type": "Adverse_event.Treatment.Route", "answers": "oral"}, {"id": "7474364_1_10409", "context": "A 71-year-old man with paroxysmal atrial fibrillation who had a previous anterior myocardial infarction exhibited granulocytopenia 8 days following the administration of oral sustained-release procainamide (750 mg/day).", "question": "Treatment.Time_elapsed in oral sustained-release procainamide (750 mg/day)", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "8 days"}, {"id": "7474364_1_10410", "context": "A 71-year-old man with paroxysmal atrial fibrillation who had a previous anterior myocardial infarction exhibited granulocytopenia 8 days following the administration of oral sustained-release procainamide (750 mg/day).", "question": "Treatment.Duration in oral sustained-release procainamide (750 mg/day)", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7474364_1_10411", "context": "A 71-year-old man with paroxysmal atrial fibrillation who had a previous anterior myocardial infarction exhibited granulocytopenia 8 days following the administration of oral sustained-release procainamide (750 mg/day).", "question": "Treatment.Disorder in oral sustained-release procainamide (750 mg/day)", "question_type": "Adverse_event.Treatment.Disorder", "answers": "paroxysmal atrial fibrillation"}, {"id": "7474364_1_10412", "context": "A 71-year-old man with paroxysmal atrial fibrillation who had a previous anterior myocardial infarction exhibited granulocytopenia 8 days following the administration of oral sustained-release procainamide (750 mg/day).", "question": "Combination.Drug in oral sustained-release procainamide (750 mg/day)", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18957000_2_10413", "context": "Clinicians should be cognizant of this possibility and consider a diagnosis of HDAs in patients with ongoing thrombosis who are receiving heparin therapy.", "question": "Subject.Age in patients", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "18957000_2_10414", "context": "Clinicians should be cognizant of this possibility and consider a diagnosis of HDAs in patients with ongoing thrombosis who are receiving heparin therapy.", "question": "Subject.Gender in patients", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "18957000_2_10415", "context": "Clinicians should be cognizant of this possibility and consider a diagnosis of HDAs in patients with ongoing thrombosis who are receiving heparin therapy.", "question": "Subject.Population in patients", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "18957000_2_10416", "context": "Clinicians should be cognizant of this possibility and consider a diagnosis of HDAs in patients with ongoing thrombosis who are receiving heparin therapy.", "question": "Subject.Race in patients", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "18957000_2_10417", "context": "Clinicians should be cognizant of this possibility and consider a diagnosis of HDAs in patients with ongoing thrombosis who are receiving heparin therapy.", "question": "Subject.Disorder in patients", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "18957000_2_10418", "context": "Clinicians should be cognizant of this possibility and consider a diagnosis of HDAs in patients with ongoing thrombosis who are receiving heparin therapy.", "question": "Treatment.Drug in heparin", "question_type": "Adverse_event.Treatment.Drug", "answers": "heparin"}, {"id": "18957000_2_10419", "context": "Clinicians should be cognizant of this possibility and consider a diagnosis of HDAs in patients with ongoing thrombosis who are receiving heparin therapy.", "question": "Treatment.Dosage in heparin", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18957000_2_10420", "context": "Clinicians should be cognizant of this possibility and consider a diagnosis of HDAs in patients with ongoing thrombosis who are receiving heparin therapy.", "question": "Treatment.Freq in heparin", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18957000_2_10421", "context": "Clinicians should be cognizant of this possibility and consider a diagnosis of HDAs in patients with ongoing thrombosis who are receiving heparin therapy.", "question": "Treatment.Route in heparin", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18957000_2_10422", "context": "Clinicians should be cognizant of this possibility and consider a diagnosis of HDAs in patients with ongoing thrombosis who are receiving heparin therapy.", "question": "Treatment.Time_elapsed in heparin", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18957000_2_10423", "context": "Clinicians should be cognizant of this possibility and consider a diagnosis of HDAs in patients with ongoing thrombosis who are receiving heparin therapy.", "question": "Treatment.Duration in heparin", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18957000_2_10424", "context": "Clinicians should be cognizant of this possibility and consider a diagnosis of HDAs in patients with ongoing thrombosis who are receiving heparin therapy.", "question": "Treatment.Disorder in heparin", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18957000_2_10425", "context": "Clinicians should be cognizant of this possibility and consider a diagnosis of HDAs in patients with ongoing thrombosis who are receiving heparin therapy.", "question": "Combination.Drug in heparin", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17725438_2_10426", "context": "Rifampin-induced hypothyroidism without underlying thyroid disease.", "question": "Treatment.Drug in Rifampin", "question_type": "Adverse_event.Treatment.Drug", "answers": "Rifampin"}, {"id": "17725438_2_10427", "context": "Rifampin-induced hypothyroidism without underlying thyroid disease.", "question": "Treatment.Dosage in Rifampin", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17725438_2_10428", "context": "Rifampin-induced hypothyroidism without underlying thyroid disease.", "question": "Treatment.Freq in Rifampin", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17725438_2_10429", "context": "Rifampin-induced hypothyroidism without underlying thyroid disease.", "question": "Treatment.Route in Rifampin", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17725438_2_10430", "context": "Rifampin-induced hypothyroidism without underlying thyroid disease.", "question": "Treatment.Time_elapsed in Rifampin", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17725438_2_10431", "context": "Rifampin-induced hypothyroidism without underlying thyroid disease.", "question": "Treatment.Duration in Rifampin", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17725438_2_10432", "context": "Rifampin-induced hypothyroidism without underlying thyroid disease.", "question": "Treatment.Disorder in Rifampin", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17725438_2_10433", "context": "Rifampin-induced hypothyroidism without underlying thyroid disease.", "question": "Combination.Drug in Rifampin", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3149484_2_10434", "context": "Paradoxical precipitation of tonic seizures by lorazepam in a child with atypical absence seizures.", "question": "Subject.Age in child with atypical absence seizures", "question_type": "Adverse_event.Subject.Age", "answers": "child"}, {"id": "3149484_2_10435", "context": "Paradoxical precipitation of tonic seizures by lorazepam in a child with atypical absence seizures.", "question": "Subject.Gender in child with atypical absence seizures", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "3149484_2_10436", "context": "Paradoxical precipitation of tonic seizures by lorazepam in a child with atypical absence seizures.", "question": "Subject.Population in child with atypical absence seizures", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "3149484_2_10437", "context": "Paradoxical precipitation of tonic seizures by lorazepam in a child with atypical absence seizures.", "question": "Subject.Race in child with atypical absence seizures", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "3149484_2_10438", "context": "Paradoxical precipitation of tonic seizures by lorazepam in a child with atypical absence seizures.", "question": "Subject.Disorder in child with atypical absence seizures", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "3149484_2_10439", "context": "Paradoxical precipitation of tonic seizures by lorazepam in a child with atypical absence seizures.", "question": "Treatment.Drug in lorazepam", "question_type": "Adverse_event.Treatment.Drug", "answers": "lorazepam"}, {"id": "3149484_2_10440", "context": "Paradoxical precipitation of tonic seizures by lorazepam in a child with atypical absence seizures.", "question": "Treatment.Dosage in lorazepam", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3149484_2_10441", "context": "Paradoxical precipitation of tonic seizures by lorazepam in a child with atypical absence seizures.", "question": "Treatment.Freq in lorazepam", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3149484_2_10442", "context": "Paradoxical precipitation of tonic seizures by lorazepam in a child with atypical absence seizures.", "question": "Treatment.Route in lorazepam", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3149484_2_10443", "context": "Paradoxical precipitation of tonic seizures by lorazepam in a child with atypical absence seizures.", "question": "Treatment.Time_elapsed in lorazepam", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3149484_2_10444", "context": "Paradoxical precipitation of tonic seizures by lorazepam in a child with atypical absence seizures.", "question": "Treatment.Duration in lorazepam", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3149484_2_10445", "context": "Paradoxical precipitation of tonic seizures by lorazepam in a child with atypical absence seizures.", "question": "Treatment.Disorder in lorazepam", "question_type": "Adverse_event.Treatment.Disorder", "answers": "absence seizures"}, {"id": "3149484_2_10446", "context": "Paradoxical precipitation of tonic seizures by lorazepam in a child with atypical absence seizures.", "question": "Combination.Drug in lorazepam", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "2568058_2_10447", "context": "Peculiar nail-changes in a 70-year-old woman with rheumatoid arthritis occurring after approximately 1 year of penicillamine treatment are described.", "question": "Subject.Age in a 70-year-old woman with rheumatoid arthritis", "question_type": "Adverse_event.Subject.Age", "answers": "70-year-old"}, {"id": "2568058_2_10448", "context": "Peculiar nail-changes in a 70-year-old woman with rheumatoid arthritis occurring after approximately 1 year of penicillamine treatment are described.", "question": "Subject.Gender in a 70-year-old woman with rheumatoid arthritis", "question_type": "Adverse_event.Subject.Gender", "answers": "woman"}, {"id": "2568058_2_10449", "context": "Peculiar nail-changes in a 70-year-old woman with rheumatoid arthritis occurring after approximately 1 year of penicillamine treatment are described.", "question": "Subject.Population in a 70-year-old woman with rheumatoid arthritis", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "2568058_2_10450", "context": "Peculiar nail-changes in a 70-year-old woman with rheumatoid arthritis occurring after approximately 1 year of penicillamine treatment are described.", "question": "Subject.Race in a 70-year-old woman with rheumatoid arthritis", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "2568058_2_10451", "context": "Peculiar nail-changes in a 70-year-old woman with rheumatoid arthritis occurring after approximately 1 year of penicillamine treatment are described.", "question": "Subject.Disorder in a 70-year-old woman with rheumatoid arthritis", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "2568058_2_10452", "context": "Peculiar nail-changes in a 70-year-old woman with rheumatoid arthritis occurring after approximately 1 year of penicillamine treatment are described.", "question": "Treatment.Drug in penicillamine", "question_type": "Adverse_event.Treatment.Drug", "answers": "penicillamine"}, {"id": "2568058_2_10453", "context": "Peculiar nail-changes in a 70-year-old woman with rheumatoid arthritis occurring after approximately 1 year of penicillamine treatment are described.", "question": "Treatment.Dosage in penicillamine", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "2568058_2_10454", "context": "Peculiar nail-changes in a 70-year-old woman with rheumatoid arthritis occurring after approximately 1 year of penicillamine treatment are described.", "question": "Treatment.Freq in penicillamine", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2568058_2_10455", "context": "Peculiar nail-changes in a 70-year-old woman with rheumatoid arthritis occurring after approximately 1 year of penicillamine treatment are described.", "question": "Treatment.Route in penicillamine", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "2568058_2_10456", "context": "Peculiar nail-changes in a 70-year-old woman with rheumatoid arthritis occurring after approximately 1 year of penicillamine treatment are described.", "question": "Treatment.Time_elapsed in penicillamine", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "1 year"}, {"id": "2568058_2_10457", "context": "Peculiar nail-changes in a 70-year-old woman with rheumatoid arthritis occurring after approximately 1 year of penicillamine treatment are described.", "question": "Treatment.Duration in penicillamine", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2568058_2_10458", "context": "Peculiar nail-changes in a 70-year-old woman with rheumatoid arthritis occurring after approximately 1 year of penicillamine treatment are described.", "question": "Treatment.Disorder in penicillamine", "question_type": "Adverse_event.Treatment.Disorder", "answers": "rheumatoid arthritis"}, {"id": "2568058_2_10459", "context": "Peculiar nail-changes in a 70-year-old woman with rheumatoid arthritis occurring after approximately 1 year of penicillamine treatment are described.", "question": "Combination.Drug in penicillamine", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "14964753_1_10460", "context": "Cutaneous vasculitis secondary to ramipril.", "question": "Treatment.Drug in ramipril", "question_type": "Adverse_event.Treatment.Drug", "answers": "ramipril"}, {"id": "14964753_1_10461", "context": "Cutaneous vasculitis secondary to ramipril.", "question": "Treatment.Dosage in ramipril", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "14964753_1_10462", "context": "Cutaneous vasculitis secondary to ramipril.", "question": "Treatment.Freq in ramipril", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "14964753_1_10463", "context": "Cutaneous vasculitis secondary to ramipril.", "question": "Treatment.Route in ramipril", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "14964753_1_10464", "context": "Cutaneous vasculitis secondary to ramipril.", "question": "Treatment.Time_elapsed in ramipril", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "14964753_1_10465", "context": "Cutaneous vasculitis secondary to ramipril.", "question": "Treatment.Duration in ramipril", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "14964753_1_10466", "context": "Cutaneous vasculitis secondary to ramipril.", "question": "Treatment.Disorder in ramipril", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "14964753_1_10467", "context": "Cutaneous vasculitis secondary to ramipril.", "question": "Combination.Drug in ramipril", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15463865_5_10468", "context": "Multiple mechanisms for ciprofloxacin-induced nephrotoxicity have been proposed.", "question": "Treatment.Drug in ciprofloxacin", "question_type": "Adverse_event.Treatment.Drug", "answers": "ciprofloxacin"}, {"id": "15463865_5_10469", "context": "Multiple mechanisms for ciprofloxacin-induced nephrotoxicity have been proposed.", "question": "Treatment.Dosage in ciprofloxacin", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15463865_5_10470", "context": "Multiple mechanisms for ciprofloxacin-induced nephrotoxicity have been proposed.", "question": "Treatment.Freq in ciprofloxacin", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15463865_5_10471", "context": "Multiple mechanisms for ciprofloxacin-induced nephrotoxicity have been proposed.", "question": "Treatment.Route in ciprofloxacin", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15463865_5_10472", "context": "Multiple mechanisms for ciprofloxacin-induced nephrotoxicity have been proposed.", "question": "Treatment.Time_elapsed in ciprofloxacin", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15463865_5_10473", "context": "Multiple mechanisms for ciprofloxacin-induced nephrotoxicity have been proposed.", "question": "Treatment.Duration in ciprofloxacin", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15463865_5_10474", "context": "Multiple mechanisms for ciprofloxacin-induced nephrotoxicity have been proposed.", "question": "Treatment.Disorder in ciprofloxacin", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15463865_5_10475", "context": "Multiple mechanisms for ciprofloxacin-induced nephrotoxicity have been proposed.", "question": "Combination.Drug in ciprofloxacin", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "25295553_4_10476", "context": "Pregabalin was added to clozapine in 2 patients with schizophrenia, who both suffered from severe anxiety symptoms.", "question": "Subject.Age in 2 patients with schizophrenia, who both suffered from severe anxiety symptoms", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "25295553_4_10477", "context": "Pregabalin was added to clozapine in 2 patients with schizophrenia, who both suffered from severe anxiety symptoms.", "question": "Subject.Gender in 2 patients with schizophrenia, who both suffered from severe anxiety symptoms", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "25295553_4_10478", "context": "Pregabalin was added to clozapine in 2 patients with schizophrenia, who both suffered from severe anxiety symptoms.", "question": "Subject.Population in 2 patients with schizophrenia, who both suffered from severe anxiety symptoms", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": "2"}, {"id": "25295553_4_10479", "context": "Pregabalin was added to clozapine in 2 patients with schizophrenia, who both suffered from severe anxiety symptoms.", "question": "Subject.Race in 2 patients with schizophrenia, who both suffered from severe anxiety symptoms", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "25295553_4_10480", "context": "Pregabalin was added to clozapine in 2 patients with schizophrenia, who both suffered from severe anxiety symptoms.", "question": "Subject.Disorder in 2 patients with schizophrenia, who both suffered from severe anxiety symptoms", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "25295553_4_10481", "context": "Pregabalin was added to clozapine in 2 patients with schizophrenia, who both suffered from severe anxiety symptoms.", "question": "Treatment.Drug in Pregabalin was added to clozapine", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "clozapine; Pregabalin"}, {"id": "25295553_4_10482", "context": "Pregabalin was added to clozapine in 2 patients with schizophrenia, who both suffered from severe anxiety symptoms.", "question": "Treatment.Dosage in Pregabalin was added to clozapine", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "25295553_4_10483", "context": "Pregabalin was added to clozapine in 2 patients with schizophrenia, who both suffered from severe anxiety symptoms.", "question": "Treatment.Freq in Pregabalin was added to clozapine", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "25295553_4_10484", "context": "Pregabalin was added to clozapine in 2 patients with schizophrenia, who both suffered from severe anxiety symptoms.", "question": "Treatment.Route in Pregabalin was added to clozapine", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "25295553_4_10485", "context": "Pregabalin was added to clozapine in 2 patients with schizophrenia, who both suffered from severe anxiety symptoms.", "question": "Treatment.Time_elapsed in Pregabalin was added to clozapine", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "25295553_4_10486", "context": "Pregabalin was added to clozapine in 2 patients with schizophrenia, who both suffered from severe anxiety symptoms.", "question": "Treatment.Duration in Pregabalin was added to clozapine", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "25295553_4_10487", "context": "Pregabalin was added to clozapine in 2 patients with schizophrenia, who both suffered from severe anxiety symptoms.", "question": "Treatment.Disorder in Pregabalin was added to clozapine", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "anxiety symptoms; schizophrenia"}, {"id": "25295553_4_10488", "context": "Pregabalin was added to clozapine in 2 patients with schizophrenia, who both suffered from severe anxiety symptoms.", "question": "Combination.Drug in Pregabalin was added to clozapine", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": "Pregabalin; clozapine"}, {"id": "3718111_2_10489", "context": "Severe hyperkalemia as a complication of timolol, a topically applied beta-adrenergic antagonist.", "question": "Treatment.Drug in timolol; a topically applied beta-adrenergic antagonist", "question_type": "Adverse_event.Treatment.Drug", "answers": "timolol"}, {"id": "3718111_2_10490", "context": "Severe hyperkalemia as a complication of timolol, a topically applied beta-adrenergic antagonist.", "question": "Treatment.Dosage in timolol; a topically applied beta-adrenergic antagonist", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3718111_2_10491", "context": "Severe hyperkalemia as a complication of timolol, a topically applied beta-adrenergic antagonist.", "question": "Treatment.Freq in timolol; a topically applied beta-adrenergic antagonist", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3718111_2_10492", "context": "Severe hyperkalemia as a complication of timolol, a topically applied beta-adrenergic antagonist.", "question": "Treatment.Route in timolol; a topically applied beta-adrenergic antagonist", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3718111_2_10493", "context": "Severe hyperkalemia as a complication of timolol, a topically applied beta-adrenergic antagonist.", "question": "Treatment.Time_elapsed in timolol; a topically applied beta-adrenergic antagonist", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3718111_2_10494", "context": "Severe hyperkalemia as a complication of timolol, a topically applied beta-adrenergic antagonist.", "question": "Treatment.Duration in timolol; a topically applied beta-adrenergic antagonist", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3718111_2_10495", "context": "Severe hyperkalemia as a complication of timolol, a topically applied beta-adrenergic antagonist.", "question": "Treatment.Disorder in timolol; a topically applied beta-adrenergic antagonist", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3718111_2_10496", "context": "Severe hyperkalemia as a complication of timolol, a topically applied beta-adrenergic antagonist.", "question": "Combination.Drug in timolol; a topically applied beta-adrenergic antagonist", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8329789_1_10497", "context": "Amphotericin B overdose in pediatric patients with associated cardiac arrest.", "question": "Subject.Age in pediatric patients", "question_type": "Adverse_event.Subject.Age", "answers": "pediatric"}, {"id": "8329789_1_10498", "context": "Amphotericin B overdose in pediatric patients with associated cardiac arrest.", "question": "Subject.Gender in pediatric patients", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "8329789_1_10499", "context": "Amphotericin B overdose in pediatric patients with associated cardiac arrest.", "question": "Subject.Population in pediatric patients", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "8329789_1_10500", "context": "Amphotericin B overdose in pediatric patients with associated cardiac arrest.", "question": "Subject.Race in pediatric patients", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "8329789_1_10501", "context": "Amphotericin B overdose in pediatric patients with associated cardiac arrest.", "question": "Subject.Disorder in pediatric patients", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "8329789_1_10502", "context": "Amphotericin B overdose in pediatric patients with associated cardiac arrest.", "question": "Treatment.Drug in Amphotericin B overdose", "question_type": "Adverse_event.Treatment.Drug", "answers": "Amphotericin B"}, {"id": "8329789_1_10503", "context": "Amphotericin B overdose in pediatric patients with associated cardiac arrest.", "question": "Treatment.Dosage in Amphotericin B overdose", "question_type": "Adverse_event.Treatment.Dosage", "answers": "overdose"}, {"id": "8329789_1_10504", "context": "Amphotericin B overdose in pediatric patients with associated cardiac arrest.", "question": "Treatment.Freq in Amphotericin B overdose", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8329789_1_10505", "context": "Amphotericin B overdose in pediatric patients with associated cardiac arrest.", "question": "Treatment.Route in Amphotericin B overdose", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8329789_1_10506", "context": "Amphotericin B overdose in pediatric patients with associated cardiac arrest.", "question": "Treatment.Time_elapsed in Amphotericin B overdose", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8329789_1_10507", "context": "Amphotericin B overdose in pediatric patients with associated cardiac arrest.", "question": "Treatment.Duration in Amphotericin B overdose", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8329789_1_10508", "context": "Amphotericin B overdose in pediatric patients with associated cardiac arrest.", "question": "Treatment.Disorder in Amphotericin B overdose", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8329789_1_10509", "context": "Amphotericin B overdose in pediatric patients with associated cardiac arrest.", "question": "Combination.Drug in Amphotericin B overdose", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15279668_3_10510", "context": "Of particular interest is that toxicity only occurred during the second course of FLA and sixth course of Ara-C containing chemotherapy.", "question": "Treatment.Drug in second course of FLA and sixth course of Ara-C containing chemotherapy", "question_type": "Adverse_event.Treatment.Drug", "answers": "FLA; Ara-C"}, {"id": "15279668_3_10511", "context": "Of particular interest is that toxicity only occurred during the second course of FLA and sixth course of Ara-C containing chemotherapy.", "question": "Treatment.Dosage in second course of FLA and sixth course of Ara-C containing chemotherapy", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15279668_3_10512", "context": "Of particular interest is that toxicity only occurred during the second course of FLA and sixth course of Ara-C containing chemotherapy.", "question": "Treatment.Freq in second course of FLA and sixth course of Ara-C containing chemotherapy", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15279668_3_10513", "context": "Of particular interest is that toxicity only occurred during the second course of FLA and sixth course of Ara-C containing chemotherapy.", "question": "Treatment.Route in second course of FLA and sixth course of Ara-C containing chemotherapy", "question_type": "Adverse_event.Treatment.Route", "answers": "chemotherapy"}, {"id": "15279668_3_10514", "context": "Of particular interest is that toxicity only occurred during the second course of FLA and sixth course of Ara-C containing chemotherapy.", "question": "Treatment.Time_elapsed in second course of FLA and sixth course of Ara-C containing chemotherapy", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "sixth course"}, {"id": "15279668_3_10515", "context": "Of particular interest is that toxicity only occurred during the second course of FLA and sixth course of Ara-C containing chemotherapy.", "question": "Treatment.Duration in second course of FLA and sixth course of Ara-C containing chemotherapy", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15279668_3_10516", "context": "Of particular interest is that toxicity only occurred during the second course of FLA and sixth course of Ara-C containing chemotherapy.", "question": "Treatment.Disorder in second course of FLA and sixth course of Ara-C containing chemotherapy", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15279668_3_10517", "context": "Of particular interest is that toxicity only occurred during the second course of FLA and sixth course of Ara-C containing chemotherapy.", "question": "Combination.Drug in second course of FLA and sixth course of Ara-C containing chemotherapy", "question_type": "Adverse_event.Combination.Drug", "answers": "FLA; Ara-C"}, {"id": "15112258_8_10518", "context": "The literature search found 12 cases of radiation recall caused by gemcitabine.", "question": "Subject.Age in 12 cases", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "15112258_8_10519", "context": "The literature search found 12 cases of radiation recall caused by gemcitabine.", "question": "Subject.Gender in 12 cases", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15112258_8_10520", "context": "The literature search found 12 cases of radiation recall caused by gemcitabine.", "question": "Subject.Population in 12 cases", "question_type": "Adverse_event.Subject.Population", "answers": "12"}, {"id": "15112258_8_10521", "context": "The literature search found 12 cases of radiation recall caused by gemcitabine.", "question": "Subject.Race in 12 cases", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15112258_8_10522", "context": "The literature search found 12 cases of radiation recall caused by gemcitabine.", "question": "Subject.Disorder in 12 cases", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15112258_8_10523", "context": "The literature search found 12 cases of radiation recall caused by gemcitabine.", "question": "Treatment.Drug in gemcitabine", "question_type": "Adverse_event.Treatment.Drug", "answers": "gemcitabine"}, {"id": "15112258_8_10524", "context": "The literature search found 12 cases of radiation recall caused by gemcitabine.", "question": "Treatment.Dosage in gemcitabine", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15112258_8_10525", "context": "The literature search found 12 cases of radiation recall caused by gemcitabine.", "question": "Treatment.Freq in gemcitabine", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15112258_8_10526", "context": "The literature search found 12 cases of radiation recall caused by gemcitabine.", "question": "Treatment.Route in gemcitabine", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15112258_8_10527", "context": "The literature search found 12 cases of radiation recall caused by gemcitabine.", "question": "Treatment.Time_elapsed in gemcitabine", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15112258_8_10528", "context": "The literature search found 12 cases of radiation recall caused by gemcitabine.", "question": "Treatment.Duration in gemcitabine", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15112258_8_10529", "context": "The literature search found 12 cases of radiation recall caused by gemcitabine.", "question": "Treatment.Disorder in gemcitabine", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15112258_8_10530", "context": "The literature search found 12 cases of radiation recall caused by gemcitabine.", "question": "Combination.Drug in gemcitabine", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9491301_4_10531", "context": "Two heroin addicts, aged 34 and 19 years, developed ballistic movements after intravenous heroin overdose.", "question": "Subject.Age in Two heroin addicts, aged 34 and 19 years", "question_type": "Adverse_event.Subject.Age", "answers": "aged 34 and 19 years"}, {"id": "9491301_4_10532", "context": "Two heroin addicts, aged 34 and 19 years, developed ballistic movements after intravenous heroin overdose.", "question": "Subject.Gender in Two heroin addicts, aged 34 and 19 years", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "9491301_4_10533", "context": "Two heroin addicts, aged 34 and 19 years, developed ballistic movements after intravenous heroin overdose.", "question": "Subject.Population in Two heroin addicts, aged 34 and 19 years", "question_type": "Adverse_event.Subject.Population", "answers": "Two"}, {"id": "9491301_4_10534", "context": "Two heroin addicts, aged 34 and 19 years, developed ballistic movements after intravenous heroin overdose.", "question": "Subject.Race in Two heroin addicts, aged 34 and 19 years", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "9491301_4_10535", "context": "Two heroin addicts, aged 34 and 19 years, developed ballistic movements after intravenous heroin overdose.", "question": "Subject.Disorder in Two heroin addicts, aged 34 and 19 years", "question_type": "Adverse_event.Subject.Disorder", "answers": "heroin addicts"}, {"id": "9491301_4_10536", "context": "Two heroin addicts, aged 34 and 19 years, developed ballistic movements after intravenous heroin overdose.", "question": "Treatment.Drug in intravenous heroin overdose", "question_type": "Adverse_event.Treatment.Drug", "answers": "heroin"}, {"id": "9491301_4_10537", "context": "Two heroin addicts, aged 34 and 19 years, developed ballistic movements after intravenous heroin overdose.", "question": "Treatment.Dosage in intravenous heroin overdose", "question_type": "Adverse_event.Treatment.Dosage", "answers": "overdose"}, {"id": "9491301_4_10538", "context": "Two heroin addicts, aged 34 and 19 years, developed ballistic movements after intravenous heroin overdose.", "question": "Treatment.Freq in intravenous heroin overdose", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9491301_4_10539", "context": "Two heroin addicts, aged 34 and 19 years, developed ballistic movements after intravenous heroin overdose.", "question": "Treatment.Route in intravenous heroin overdose", "question_type": "Adverse_event.Treatment.Route", "answers": "intravenous"}, {"id": "9491301_4_10540", "context": "Two heroin addicts, aged 34 and 19 years, developed ballistic movements after intravenous heroin overdose.", "question": "Treatment.Time_elapsed in intravenous heroin overdose", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9491301_4_10541", "context": "Two heroin addicts, aged 34 and 19 years, developed ballistic movements after intravenous heroin overdose.", "question": "Treatment.Duration in intravenous heroin overdose", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9491301_4_10542", "context": "Two heroin addicts, aged 34 and 19 years, developed ballistic movements after intravenous heroin overdose.", "question": "Treatment.Disorder in intravenous heroin overdose", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9491301_4_10543", "context": "Two heroin addicts, aged 34 and 19 years, developed ballistic movements after intravenous heroin overdose.", "question": "Combination.Drug in intravenous heroin overdose", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9988365_3_10544", "context": "Successful challenge with clozapine in a history of eosinophilia.", "question": "Treatment.Drug in clozapine", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "clozapine"}, {"id": "9988365_3_10545", "context": "Successful challenge with clozapine in a history of eosinophilia.", "question": "Treatment.Dosage in clozapine", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "9988365_3_10546", "context": "Successful challenge with clozapine in a history of eosinophilia.", "question": "Treatment.Freq in clozapine", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "9988365_3_10547", "context": "Successful challenge with clozapine in a history of eosinophilia.", "question": "Treatment.Route in clozapine", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "9988365_3_10548", "context": "Successful challenge with clozapine in a history of eosinophilia.", "question": "Treatment.Time_elapsed in clozapine", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9988365_3_10549", "context": "Successful challenge with clozapine in a history of eosinophilia.", "question": "Treatment.Duration in clozapine", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "9988365_3_10550", "context": "Successful challenge with clozapine in a history of eosinophilia.", "question": "Treatment.Disorder in clozapine", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "eosinophilia"}, {"id": "9988365_3_10551", "context": "Successful challenge with clozapine in a history of eosinophilia.", "question": "Combination.Drug in clozapine", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "16352777_1_10552", "context": "CASE SUMMARY: A 57-year-old female with cardiomyopathy and \"sulfa\" (trimethoprim/sulfamethoxazole) allergy documented as pancreatitis presented with symptoms consistent with pancreatitis after use of furosemide.", "question": "Subject.Age in A 57-year-old female with cardiomyopathy and \"sulfa\" (trimethoprim/sulfamethoxazole) allergy", "question_type": "Adverse_event.Subject.Age", "answers": "57-year-old"}, {"id": "16352777_1_10553", "context": "CASE SUMMARY: A 57-year-old female with cardiomyopathy and \"sulfa\" (trimethoprim/sulfamethoxazole) allergy documented as pancreatitis presented with symptoms consistent with pancreatitis after use of furosemide.", "question": "Subject.Gender in A 57-year-old female with cardiomyopathy and \"sulfa\" (trimethoprim/sulfamethoxazole) allergy", "question_type": "Adverse_event.Subject.Gender", "answers": "female"}, {"id": "16352777_1_10554", "context": "CASE SUMMARY: A 57-year-old female with cardiomyopathy and \"sulfa\" (trimethoprim/sulfamethoxazole) allergy documented as pancreatitis presented with symptoms consistent with pancreatitis after use of furosemide.", "question": "Subject.Population in A 57-year-old female with cardiomyopathy and \"sulfa\" (trimethoprim/sulfamethoxazole) allergy", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "16352777_1_10555", "context": "CASE SUMMARY: A 57-year-old female with cardiomyopathy and \"sulfa\" (trimethoprim/sulfamethoxazole) allergy documented as pancreatitis presented with symptoms consistent with pancreatitis after use of furosemide.", "question": "Subject.Race in A 57-year-old female with cardiomyopathy and \"sulfa\" (trimethoprim/sulfamethoxazole) allergy", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16352777_1_10556", "context": "CASE SUMMARY: A 57-year-old female with cardiomyopathy and \"sulfa\" (trimethoprim/sulfamethoxazole) allergy documented as pancreatitis presented with symptoms consistent with pancreatitis after use of furosemide.", "question": "Subject.Disorder in A 57-year-old female with cardiomyopathy and \"sulfa\" (trimethoprim/sulfamethoxazole) allergy", "question_type": "Adverse_event.Subject.Disorder", "answers": "cardiomyopathy; \"sulfa\" (trimethoprim/sulfamethoxazole) allergy"}, {"id": "16352777_1_10557", "context": "CASE SUMMARY: A 57-year-old female with cardiomyopathy and \"sulfa\" (trimethoprim/sulfamethoxazole) allergy documented as pancreatitis presented with symptoms consistent with pancreatitis after use of furosemide.", "question": "Treatment.Drug in furosemide", "question_type": "Adverse_event.Treatment.Drug", "answers": "furosemide"}, {"id": "16352777_1_10558", "context": "CASE SUMMARY: A 57-year-old female with cardiomyopathy and \"sulfa\" (trimethoprim/sulfamethoxazole) allergy documented as pancreatitis presented with symptoms consistent with pancreatitis after use of furosemide.", "question": "Treatment.Dosage in furosemide", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16352777_1_10559", "context": "CASE SUMMARY: A 57-year-old female with cardiomyopathy and \"sulfa\" (trimethoprim/sulfamethoxazole) allergy documented as pancreatitis presented with symptoms consistent with pancreatitis after use of furosemide.", "question": "Treatment.Freq in furosemide", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16352777_1_10560", "context": "CASE SUMMARY: A 57-year-old female with cardiomyopathy and \"sulfa\" (trimethoprim/sulfamethoxazole) allergy documented as pancreatitis presented with symptoms consistent with pancreatitis after use of furosemide.", "question": "Treatment.Route in furosemide", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16352777_1_10561", "context": "CASE SUMMARY: A 57-year-old female with cardiomyopathy and \"sulfa\" (trimethoprim/sulfamethoxazole) allergy documented as pancreatitis presented with symptoms consistent with pancreatitis after use of furosemide.", "question": "Treatment.Time_elapsed in furosemide", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16352777_1_10562", "context": "CASE SUMMARY: A 57-year-old female with cardiomyopathy and \"sulfa\" (trimethoprim/sulfamethoxazole) allergy documented as pancreatitis presented with symptoms consistent with pancreatitis after use of furosemide.", "question": "Treatment.Duration in furosemide", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16352777_1_10563", "context": "CASE SUMMARY: A 57-year-old female with cardiomyopathy and \"sulfa\" (trimethoprim/sulfamethoxazole) allergy documented as pancreatitis presented with symptoms consistent with pancreatitis after use of furosemide.", "question": "Treatment.Disorder in furosemide", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16352777_1_10564", "context": "CASE SUMMARY: A 57-year-old female with cardiomyopathy and \"sulfa\" (trimethoprim/sulfamethoxazole) allergy documented as pancreatitis presented with symptoms consistent with pancreatitis after use of furosemide.", "question": "Combination.Drug in furosemide", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6510223_2_10565", "context": "Acute intravascular hemolysis developed when a diabetic patient, previously treated with glyburide, was started on another oral sulfonylurea drug, chlorpropamide.", "question": "Subject.Age in a diabetic patient", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "6510223_2_10566", "context": "Acute intravascular hemolysis developed when a diabetic patient, previously treated with glyburide, was started on another oral sulfonylurea drug, chlorpropamide.", "question": "Subject.Gender in a diabetic patient", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "6510223_2_10567", "context": "Acute intravascular hemolysis developed when a diabetic patient, previously treated with glyburide, was started on another oral sulfonylurea drug, chlorpropamide.", "question": "Subject.Population in a diabetic patient", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "6510223_2_10568", "context": "Acute intravascular hemolysis developed when a diabetic patient, previously treated with glyburide, was started on another oral sulfonylurea drug, chlorpropamide.", "question": "Subject.Race in a diabetic patient", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "6510223_2_10569", "context": "Acute intravascular hemolysis developed when a diabetic patient, previously treated with glyburide, was started on another oral sulfonylurea drug, chlorpropamide.", "question": "Subject.Disorder in a diabetic patient", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "6510223_2_10570", "context": "Acute intravascular hemolysis developed when a diabetic patient, previously treated with glyburide, was started on another oral sulfonylurea drug, chlorpropamide.", "question": "Treatment.Drug in chlorpropamide", "question_type": "Adverse_event.Treatment.Drug", "answers": "chlorpropamide"}, {"id": "6510223_2_10571", "context": "Acute intravascular hemolysis developed when a diabetic patient, previously treated with glyburide, was started on another oral sulfonylurea drug, chlorpropamide.", "question": "Treatment.Dosage in chlorpropamide", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6510223_2_10572", "context": "Acute intravascular hemolysis developed when a diabetic patient, previously treated with glyburide, was started on another oral sulfonylurea drug, chlorpropamide.", "question": "Treatment.Freq in chlorpropamide", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6510223_2_10573", "context": "Acute intravascular hemolysis developed when a diabetic patient, previously treated with glyburide, was started on another oral sulfonylurea drug, chlorpropamide.", "question": "Treatment.Route in chlorpropamide", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6510223_2_10574", "context": "Acute intravascular hemolysis developed when a diabetic patient, previously treated with glyburide, was started on another oral sulfonylurea drug, chlorpropamide.", "question": "Treatment.Time_elapsed in chlorpropamide", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6510223_2_10575", "context": "Acute intravascular hemolysis developed when a diabetic patient, previously treated with glyburide, was started on another oral sulfonylurea drug, chlorpropamide.", "question": "Treatment.Duration in chlorpropamide", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6510223_2_10576", "context": "Acute intravascular hemolysis developed when a diabetic patient, previously treated with glyburide, was started on another oral sulfonylurea drug, chlorpropamide.", "question": "Treatment.Disorder in chlorpropamide", "question_type": "Adverse_event.Treatment.Disorder", "answers": "diabetic"}, {"id": "6510223_2_10577", "context": "Acute intravascular hemolysis developed when a diabetic patient, previously treated with glyburide, was started on another oral sulfonylurea drug, chlorpropamide.", "question": "Combination.Drug in chlorpropamide", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17505739_1_10578", "context": "Intravitreal triamcinolone may have had an influence on the exacerbation of retinochoroiditis in the posterior pole of the patient.", "question": "Subject.Age in the patient", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "17505739_1_10579", "context": "Intravitreal triamcinolone may have had an influence on the exacerbation of retinochoroiditis in the posterior pole of the patient.", "question": "Subject.Gender in the patient", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "17505739_1_10580", "context": "Intravitreal triamcinolone may have had an influence on the exacerbation of retinochoroiditis in the posterior pole of the patient.", "question": "Subject.Population in the patient", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "17505739_1_10581", "context": "Intravitreal triamcinolone may have had an influence on the exacerbation of retinochoroiditis in the posterior pole of the patient.", "question": "Subject.Race in the patient", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "17505739_1_10582", "context": "Intravitreal triamcinolone may have had an influence on the exacerbation of retinochoroiditis in the posterior pole of the patient.", "question": "Subject.Disorder in the patient", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "17505739_1_10583", "context": "Intravitreal triamcinolone may have had an influence on the exacerbation of retinochoroiditis in the posterior pole of the patient.", "question": "Treatment.Drug in Intravitreal triamcinolone", "question_type": "Adverse_event.Treatment.Drug", "answers": "triamcinolone"}, {"id": "17505739_1_10584", "context": "Intravitreal triamcinolone may have had an influence on the exacerbation of retinochoroiditis in the posterior pole of the patient.", "question": "Treatment.Dosage in Intravitreal triamcinolone", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17505739_1_10585", "context": "Intravitreal triamcinolone may have had an influence on the exacerbation of retinochoroiditis in the posterior pole of the patient.", "question": "Treatment.Freq in Intravitreal triamcinolone", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17505739_1_10586", "context": "Intravitreal triamcinolone may have had an influence on the exacerbation of retinochoroiditis in the posterior pole of the patient.", "question": "Treatment.Route in Intravitreal triamcinolone", "question_type": "Adverse_event.Treatment.Route", "answers": "Intravitreal"}, {"id": "17505739_1_10587", "context": "Intravitreal triamcinolone may have had an influence on the exacerbation of retinochoroiditis in the posterior pole of the patient.", "question": "Treatment.Time_elapsed in Intravitreal triamcinolone", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17505739_1_10588", "context": "Intravitreal triamcinolone may have had an influence on the exacerbation of retinochoroiditis in the posterior pole of the patient.", "question": "Treatment.Duration in Intravitreal triamcinolone", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17505739_1_10589", "context": "Intravitreal triamcinolone may have had an influence on the exacerbation of retinochoroiditis in the posterior pole of the patient.", "question": "Treatment.Disorder in Intravitreal triamcinolone", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17505739_1_10590", "context": "Intravitreal triamcinolone may have had an influence on the exacerbation of retinochoroiditis in the posterior pole of the patient.", "question": "Combination.Drug in Intravitreal triamcinolone", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8961730_2_10591", "context": "We evaluated a patient who developed a psychotic disorder after 4 months of isoniazid prophylaxis for a positive tuberculosis tine test.", "question": "Subject.Age in patient", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "8961730_2_10592", "context": "We evaluated a patient who developed a psychotic disorder after 4 months of isoniazid prophylaxis for a positive tuberculosis tine test.", "question": "Subject.Gender in patient", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "8961730_2_10593", "context": "We evaluated a patient who developed a psychotic disorder after 4 months of isoniazid prophylaxis for a positive tuberculosis tine test.", "question": "Subject.Population in patient", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "8961730_2_10594", "context": "We evaluated a patient who developed a psychotic disorder after 4 months of isoniazid prophylaxis for a positive tuberculosis tine test.", "question": "Subject.Race in patient", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "8961730_2_10595", "context": "We evaluated a patient who developed a psychotic disorder after 4 months of isoniazid prophylaxis for a positive tuberculosis tine test.", "question": "Subject.Disorder in patient", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "8961730_2_10596", "context": "We evaluated a patient who developed a psychotic disorder after 4 months of isoniazid prophylaxis for a positive tuberculosis tine test.", "question": "Treatment.Drug in 4 months of isoniazid prophylaxis", "question_type": "Adverse_event.Treatment.Drug", "answers": "isoniazid"}, {"id": "8961730_2_10597", "context": "We evaluated a patient who developed a psychotic disorder after 4 months of isoniazid prophylaxis for a positive tuberculosis tine test.", "question": "Treatment.Dosage in 4 months of isoniazid prophylaxis", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8961730_2_10598", "context": "We evaluated a patient who developed a psychotic disorder after 4 months of isoniazid prophylaxis for a positive tuberculosis tine test.", "question": "Treatment.Freq in 4 months of isoniazid prophylaxis", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8961730_2_10599", "context": "We evaluated a patient who developed a psychotic disorder after 4 months of isoniazid prophylaxis for a positive tuberculosis tine test.", "question": "Treatment.Route in 4 months of isoniazid prophylaxis", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8961730_2_10600", "context": "We evaluated a patient who developed a psychotic disorder after 4 months of isoniazid prophylaxis for a positive tuberculosis tine test.", "question": "Treatment.Time_elapsed in 4 months of isoniazid prophylaxis", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "4 months"}, {"id": "8961730_2_10601", "context": "We evaluated a patient who developed a psychotic disorder after 4 months of isoniazid prophylaxis for a positive tuberculosis tine test.", "question": "Treatment.Duration in 4 months of isoniazid prophylaxis", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8961730_2_10602", "context": "We evaluated a patient who developed a psychotic disorder after 4 months of isoniazid prophylaxis for a positive tuberculosis tine test.", "question": "Treatment.Disorder in 4 months of isoniazid prophylaxis", "question_type": "Adverse_event.Treatment.Disorder", "answers": "tuberculosis"}, {"id": "8961730_2_10603", "context": "We evaluated a patient who developed a psychotic disorder after 4 months of isoniazid prophylaxis for a positive tuberculosis tine test.", "question": "Combination.Drug in 4 months of isoniazid prophylaxis", "question_type": "Adverse_event.Combination.Drug", "answers": ""}]}